PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Stranges, S; Marshall, JR; Natarajan, R; Donahue, RP; Trevisan, M; Combs, GF; Cappuccio, FP; Ceriello, A; Reid, ME				Stranges, Saverio; Marshall, James R.; Natarajan, Raj; Donahue, Richard P.; Trevisan, Maurizio; Combs, Gerald F.; Cappuccio, Francesco P.; Ceriello, Antonio; Reid, Mary E.			Effects of long-term selenium supplementation on the incidence of type 2 diabetes - A randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article							INSULIN-RESISTANCE; VITAMIN-E; CARDIOVASCULAR-DISEASE; GLUTATHIONE-PEROXIDASE; NUTRITIONAL PREVENTION; CANCER PREVENTION; CLINICAL-TRIAL; RISK; ANTIOXIDANT; MICE	Background: Findings from animal models suggest that selenium supplementation improves glucose metabolism. Objective: To examine the effect of long-term selenium supplementation on the incidence of type 2 diabetes. Design: Secondary analysis of a randomized, double-blind, placebo-controlled trial. Setting: Areas of low selenium consumption of the eastern United States. Patients: 1202 persons seen in dermatology clinics who did not have type 2 diabetes at baseline. Intervention: Oral administration of selenium, 200 mu g/d, or placebo. Measurements: Incidence of type 2 diabetes. Results: During an average follow-up of 7.7 years (SD, 2.7), type 2 diabetes developed in 58 selenium recipients and 39 placebo recipients (incidence, 12.6 cases per 1000 person-years vs. 8.4 cases per 1000 person-years, respectively; hazard ratio, 1.55 [95% Cl, 1.03 to 2.33]). The lack of benefit of selenium supplementation on the incidence of type 2 diabetes persisted in analyses stratified by age, sex, body mass index, and smoking status. An exposure-response gradient was found across tertiles of baseline plasma selenium level, with a statistically significantly increased risk for type 2 diabetes in the highest tertile of baseline plasma selenium level (hazard ratio, 2.70 [Cl, 1.30 to 5.61]). Limitations: Diabetes was a secondary outcome in the parent trial. Diagnoses of diabetes were self-reported but were validated in most participants. The sample was mostly older and white. Conclusions: Selenium supplementation does not seem to prevent type 2 diabetes, and it may increase risk for the disease.	Univ Hosp Coventry & Warwickshire, Warwick Med Sch, Inst Sci Res Inst, Coventry CV2 2DX, England; SUNY Coll Buffalo, Canc Prevent & Populat Sci, Roswell Pk Canc Inst, Buffalo, NY USA; Warwick Med Sch, Clin Scli Res Inst, Coventry, England; USDA ARS, Human Nutr Res Ctr, Grand Forks, ND 58202 USA	University of Warwick; Roswell Park Cancer Institute; State University of New York (SUNY) System; Buffalo State College; University of Warwick; United States Department of Agriculture (USDA)	Stranges, S (corresponding author), Univ Hosp Coventry & Warwickshire, Warwick Med Sch, Inst Sci Res Inst, Clifford Bridge Rd, Coventry CV2 2DX, England.	s.stranges@warwick.ac.uk	Cappuccio, Francesco Paolo/ABF-1094-2020; Cappuccio, Francesco/D-3028-2009; STRANGES, SAVERIO/F-3273-2010	Cappuccio, Francesco Paolo/0000-0002-7842-5493; Ceriello, Antonio/0000-0001-8122-3203; Stranges, Saverio/0000-0001-5226-8373				Bendich A, 2001, DIETARY REFERENCE IN, DOI [10.1016/s0899-9007(00)00596-7, DOI 10.1016/S0899-9007(00)00596-7]; Bleys J, 2007, DIABETES CARE, V30, P829, DOI 10.2337/dc06-1726; Bonora E, 2004, DIABETES, V53, P1782, DOI 10.2337/diabetes.53.7.1782; Carnethon MR, 2002, DIABETES CARE, V25, P1358, DOI 10.2337/diacare.25.8.1358; Centers for Disease Control and Prevention, NAT DIAB SURV SYST; Ceriello A, 2004, ARTERIOSCL THROM VAS, V24, P816, DOI 10.1161/01.ATV.0000122852.22604.78; Chen XH, 2003, J CLIN ENDOCR METAB, V88, P5963, DOI 10.1210/jc.2003-030544; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; Clemmons DR, 2006, CURR OPIN PHARMACOL, V6, P620, DOI 10.1016/j.coph.2006.08.006; COPELAND KT, 1977, AM J EPIDEMIOL, V105, P488, DOI 10.1093/oxfordjournals.aje.a112408; Czernichow S, 2006, AM J CLIN NUTR, V84, P395; Duffield-Lillico AJ, 2002, CANCER EPIDEM BIOMAR, V11, P630; Faure P, 2004, EUR J CLIN INVEST, V34, P475, DOI 10.1111/j.1365-2362.2004.01362.x; Flores-Mateo G, 2006, AM J CLIN NUTR, V84, P762, DOI 10.1093/ajcn/84.4.762; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Hawkes WC, 2003, J NUTR, V133, P3443, DOI 10.1093/jn/133.11.3443; Li XY, 2006, DIABETES, V55, P1592, DOI 10.2337/db05-1357; Lin DY, 1996, BIOMETRICS, V52, P1033, DOI 10.2307/2533064; Lippman SM, 2005, JNCI-J NATL CANCER I, V97, P94, DOI 10.1093/jnci/dji009; Liu SM, 1999, JAMA-J AM MED ASSOC, V282, P1073, DOI 10.1001/jama.282.11.1073; Lonn E, 2002, DIABETES CARE, V25, P1919, DOI 10.2337/diacare.25.11.1919; Mayer-Davis EJ, 2002, DIABETES CARE, V25, P2172, DOI 10.2337/diacare.25.12.2172; McClung JP, 2004, P NATL ACAD SCI USA, V101, P8852, DOI 10.1073/pnas.0308096101; MCSHANE LM, 1991, AM J CLIN NUTR, V53, P1354, DOI 10.1093/ajcn/53.6.1354; Montonen J, 2004, DIABETES CARE, V27, P362, DOI 10.2337/diacare.27.2.362; Mueller AS, 2006, J NUTR BIOCHEM, V17, P548, DOI 10.1016/j.jnutbio.2005.10.006; OLSON OE, 1975, J ASSOC OFF ANA CHEM, V58, P117; Rajpathak S, 2005, J AM COLL NUTR, V24, P250, DOI 10.1080/07315724.2005.10719472; Rayman MP, 2000, LANCET, V356, P233, DOI 10.1016/S0140-6736(00)02490-9; Reid ME, 2002, CANCER EPIDEM BIOMAR, V11, P1285; Sacco M, 2003, DIABETES CARE, V26, P3264, DOI 10.2337/diacare.26.12.3264; Satyanarayana S, 2006, MOL CELL BIOCHEM, V283, P123, DOI 10.1007/s11010-006-2387-2; Sheng XQ, 2004, BIOL TRACE ELEM RES, V99, P241, DOI 10.1385/BTER:99:1-3:241; Stapleton SR, 2000, CELL MOL LIFE SCI, V57, P1874, DOI 10.1007/PL00000669; Stranges S, 2006, AM J EPIDEMIOL, V163, P694, DOI 10.1093/aje/kwj097; Vinceti M, 2001, Rev Environ Health, V16, P233; Whanger P, 1996, ANN CLIN LAB SCI, V26, P99	38	492	515	5	90	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 21	2007	147	4					217	223		10.7326/0003-4819-147-4-200708210-00175	http://dx.doi.org/10.7326/0003-4819-147-4-200708210-00175			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	201AP	17620655				2022-12-28	WOS:000248804200001
J	Soda, M; Choi, YL; Enomoto, M; Takada, S; Yamashita, Y; Ishikawa, S; Fujiwara, SI; Watanabe, H; Kurashina, K; Hatanaka, H; Bando, M; Ohno, S; Ishikawa, Y; Aburatani, H; Niki, T; Sohara, Y; Sugiyama, Y; Mano, H				Soda, Manabu; Choi, Young Lim; Enomoto, Munehiro; Takada, Shuji; Yamashita, Yoshihiro; Ishikawa, Shunpei; Fujiwara, Shin-ichiro; Watanabe, Hideki; Kurashina, Kentaro; Hatanaka, Hisashi; Bando, Masashi; Ohno, Shoji; Ishikawa, Yuichi; Aburatani, Hiroyuki; Niki, Toshiro; Sohara, Yasunori; Sugiyama, Yukihiko; Mano, Hiroyuki			Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer	NATURE			English	Article							ANAPLASTIC LYMPHOMA KINASE; TYROSINE KINASE; FACTOR-RECEPTOR; ALK; MUTATIONS; GEFITINIB; TRANSLOCATIONS; PROLIFERATION; INHIBITOR; COMMON	Improvement in the clinical outcome of lung cancer is likely to be achieved by identification of the molecular events that underlie its pathogenesis. Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-associated protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells. Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase generated transformed foci in culture and subcutaneous tumours in nude mice. The EML4-ALK fusion transcript was detected in 6.7% (5 out of 75) of NSCLC patients examined; these individuals were distinct from those harbouring mutations in the epidermal growth factor receptor gene. Our data demonstrate that a subset of NSCLC patients may express a transforming fusion kinase that is a promising candidate for a therapeutic target as well as for a diagnostic molecular marker in NSCLC.	Jichi Med Univ, Div Funct Genom, Tochigi 3290498, Japan; Jichi Med Univ, Div Pulm Med, Tochigi 3290498, Japan; Jichi Med Univ, Dept Pathol, Tochigi 3290498, Japan; Jichi Med Univ, Div Gen Thorac Surg, Tochigi 3290498, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo 1538904, Japan; Japanese Fdn Canc Res, Inst Canc, Tokyo 1358550, Japan; Japan Sci & Technol Agcy, CREST, Saitama 3320012, Japan	Jichi Medical University; Jichi Medical University; Jichi Medical University; Jichi Medical University; University of Tokyo; Japanese Foundation for Cancer Research; Japan Science & Technology Agency (JST)	Mano, H (corresponding author), Jichi Med Univ, Div Funct Genom, Tochigi 3290498, Japan.	hmano@jichi.ac.jp	niki, toshiro/K-8917-2012; Fujiwara, Shin-ichiro/ABH-2030-2020	Fujiwara, Shin-ichiro/0000-0002-4523-2994; Takada, Shuji/0000-0002-9406-4683				Choi YL, 2007, LEUKEMIA RES, V31, P203, DOI 10.1016/j.leukres.2006.05.006; Donella-Deana A, 2005, BIOCHEMISTRY-US, V44, P8533, DOI 10.1021/bi0472954; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Duyster J, 2001, ONCOGENE, V20, P5623, DOI 10.1038/sj.onc.1204594; Eichenmuller B, 2002, J BIOL CHEM, V277, P1301, DOI 10.1074/jbc.M106628200; Fujiwara S, 2005, BIOCHEM BIOPH RES CO, V338, P1256, DOI 10.1016/j.bbrc.2005.10.080; Galkin AV, 2007, P NATL ACAD SCI USA, V104, P270, DOI 10.1073/pnas.0609412103; Hatanaka H, 2007, BIOCHEM BIOPH RES CO, V356, P723, DOI 10.1016/j.bbrc.2007.03.048; Hernandez L, 2002, AM J PATHOL, V160, P1487, DOI 10.1016/S0002-9440(10)62574-6; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Kaul KL, 2001, CLIN CHEM, V47, P1553; Li RS, 2006, J MED CHEM, V49, P1006, DOI 10.1021/jm050824x; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Marzec M, 2005, LAB INVEST, V85, P1544, DOI 10.1038/labinvest.3700348; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Onishi M, 1996, EXP HEMATOL, V24, P324; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Pollmann M, 2006, EXP CELL RES, V312, P3241, DOI 10.1016/j.yexcr.2006.06.035; Pulford K, 2004, J CELL PHYSIOL, V199, P330, DOI 10.1002/jcp.10472; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; SHIOTA M, 1994, ONCOGENE, V9, P1567; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; Yamashita Y, 2001, J BIOL CHEM, V276, P39012, DOI 10.1074/jbc.M106249200; Yoshizuka N, 2004, J BIOL CHEM, V279, P43998, DOI 10.1074/jbc.M406082200	27	3822	4158	12	354	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 2	2007	448	7153					561	U3		10.1038/nature05945	http://dx.doi.org/10.1038/nature05945			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	195XV	17625570				2022-12-28	WOS:000248446700036
J	Gudbjartsson, DF; Arnar, DO; Helgadottir, A; Gretarsdottir, S; Holm, H; Sigurdsson, A; Jonasdottir, A; Baker, A; Thorleifsson, G; Kristjansson, K; Palsson, A; Blondal, T; Sulem, P; Backman, VM; Hardarson, GA; Palsdottir, E; Helgason, A; Sigurjonsdottir, R; Sverrisson, JT; Kostulas, K; Ng, MCY; Baum, L; So, WY; Wong, KS; Chan, JCN; Furie, KL; Greenberg, SM; Sale, M; Kelly, P; MacRae, CA; Smith, EE; Rosand, J; Hillert, J; Ma, RCW; Ellinor, PT; Thorgeirsson, G; Gulcher, JR; Kong, A; Thorsteinsdottir, U; Stefansson, K				Gudbjartsson, Daniel F.; Arnar, David O.; Helgadottir, Anna; Gretarsdottir, Solveig; Holm, Hilma; Sigurdsson, Asgeir; Jonasdottir, Adalbjorg; Baker, Adam; Thorleifsson, Gudmar; Kristjansson, Kristleifur; Palsson, Arnar; Blondal, Thorarinn; Sulem, Patrick; Backman, Valgerdur M.; Hardarson, Gudmundur A.; Palsdottir, Ebba; Helgason, Agnar; Sigurjonsdottir, Runa; Sverrisson, Jon T.; Kostulas, Konstantinos; Ng, Maggie C. Y.; Baum, Larry; So, Wing Yee; Wong, Ka Sing; Chan, Juliana C. N.; Furie, Karen L.; Greenberg, Steven M.; Sale, Michelle; Kelly, Peter; MacRae, Calum A.; Smith, Eric E.; Rosand, Jonathan; Hillert, Jan; Ma, Ronald C. W.; Ellinor, Patrick T.; Thorgeirsson, Gudmundur; Gulcher, Jeffrey R.; Kong, Augustine; Thorsteinsdottir, Unnur; Stefansson, Kari			Variants conferring risk of atrial fibrillation on chromosome 4q25	NATURE			English	Article							OF-FUNCTION MUTATION; FAMILIAL AGGREGATION; ISCHEMIC-STROKE; GENE; PREVALENCE; KCNQ1	Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in humans and is characterized by chaotic electrical activity of the atria(1). It affects one in ten individuals over the age of 80 years, causes significant morbidity and is an independent predictor of mortality(2). Recent studies have provided evidence of a genetic contribution to AF(3-5). Mutations in potassium-channel genes have been associated with familial AF(6-10) but account for only a small fraction of all cases of AF(11,12). We have performed a genome-wide association scan, followed by replication studies in three populations of European descent and a Chinese population from Hong Kong and find a strong association between two sequence variants on chromosome 4q25 and AF. Here we show that about 35% of individuals of European descent have at least one of the variants and that the risk of AF increases by 1.72 and 1.39 per copy. The association with the stronger variant is replicated in the Chinese population, where it is carried by 75% of individuals and the risk of AF is increased by 1.42 per copy. A stronger association was observed in individuals with typical atrial flutter. Both variants are adjacent to PITX2, which is known to have a critical function in left-right asymmetry of the heart(13-15).	deCODE Genet, IS-101 Reykjavik, Iceland; Landspitali Univ, Div Cardiol, Dept Med, IS-101 Reykjavik, Iceland; Akureyri Reg Hosp, Dept Med, IS-600 Akureyri, Iceland; Karolinska Univ Hosp, Dept Neurol, S-14186 Huddinge, Sweden; Chinese Univ Hong Kong, Dept Med & Therapeut, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China; Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Karolinska Institutet; Karolinska University Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Gudbjartsson, DF (corresponding author), deCODE Genet, Sturlugata 8, IS-101 Reykjavik, Iceland.	daniel.gudbjartsson@decode.is; kstefans@decode.is	Smith, Eric E/C-5443-2012; Helgason, Agnar/K-1522-2015; Palsson, Arnar/M-2742-2015; Wong, Ka Sing Lawrence/N-3434-2015; Stefansson, Kari/AAE-7187-2019; Baum, Lawrence/B-1005-2013; Demchuk, Andrew M/E-1103-2012; Ma, Ronald/C-2788-2009; Chan, Juliana/B-7918-2016	Smith, Eric E/0000-0003-3956-1668; Palsson, Arnar/0000-0002-6525-8112; Wong, Ka Sing Lawrence/0000-0002-2031-9866; Baum, Lawrence/0000-0002-5345-9355; Demchuk, Andrew M/0000-0002-4930-7789; Ma, Ronald/0000-0002-1227-803X; Chan, Juliana/0000-0003-1325-1194; Kong, Augustine/0000-0001-8193-5438; Gudbjartsson, Daniel/0000-0002-5222-9857; Helgason, Agnar/0000-0002-8545-3767; Steinthorsdottir, Valgerdur/0000-0003-1846-6274; Ellinor, Patrick/0000-0002-2067-0533	NHLBI NIH HHS [R01 HL075431] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075431] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Arnar DO, 2006, EUR HEART J, V27, P708, DOI 10.1093/eurheartj/ehi727; Baum L, 2004, CLIN CHEM LAB MED, V42, P1370, DOI 10.1515/CCLM.2004.256; Chen YH, 2003, SCIENCE, V299, P251, DOI 10.1126/science.1077771; Ellinor PT, 2006, BMC MED GENET, V7, DOI 10.1186/1471-2350-7-70; Ellinor PT, 2005, HUM GENET, V118, P179, DOI 10.1007/s00439-005-0034-8; Ellinor PT, 2004, HEART, V90, P1487, DOI 10.1136/hrt.2003.027227; FALK CT, 1987, ANN HUM GENET, V51, P227, DOI 10.1111/j.1469-1809.1987.tb00875.x; Faucourt M, 2001, DEV BIOL, V229, P287, DOI 10.1006/dbio.2000.9950; Fox CS, 2004, JAMA-J AM MED ASSOC, V291, P2851, DOI 10.1001/jama.291.23.2851; Frank B, 2003, TAPPI J, V2, P13; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Grant SFA, 2006, NAT GENET, V38, P320, DOI 10.1038/ng1732; Gretarsdottir S, 2003, NAT GENET, V35, P131, DOI 10.1038/ng1245; Hong K, 2005, J CARDIOVASC ELECTR, V16, P394, DOI 10.1046/j.1540-8167.2005.40621.x; MANTEL N, 1959, J NATL CANCER I, V22, P719; Miyasaka Y, 2006, CIRCULATION, V114, P119, DOI 10.1161/CIRCULATIONAHA.105.595140; Mommersteeg MTM, 2007, CIRC RES, V100, P354, DOI 10.1161/01.RES.0000258019.74591.b3; Olson TM, 2006, HUM MOL GENET, V15, P2185, DOI 10.1093/hmg/ddl143; Waldo AL, 2005, PROG CARDIOVASC DIS, V48, P41, DOI 10.1016/j.pcad.2005.06.015; Xia M, 2005, BIOCHEM BIOPH RES CO, V332, P1012, DOI 10.1016/j.bbrc.2005.05.054; Yang RG, 2005, J COMPUT THEOR NANOS, V2, P75; Yang X, 2007, DIABETES CARE, V30, P65, DOI 10.2337/dc06-1273; Zini S, 1996, P NATL ACAD SCI USA, V93, P11968, DOI 10.1073/pnas.93.21.11968	24	659	685	1	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 19	2007	448	7151					353	357		10.1038/nature06007	http://dx.doi.org/10.1038/nature06007			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	191GC	17603472				2022-12-28	WOS:000248118300058
J	Bansal, S; Buring, JE; Rifai, N; Mora, S; Sacks, FM; Ridker, PM				Bansal, Sandeep; Buring, Julie E.; Rifai, Nader; Mora, Samia; Sacks, Frank M.; Ridker, Paul M.			Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-HEART-DISEASE; POSTPRANDIAL LIPOPROTEIN METABOLISM; DENSITY-LIPOPROTEIN; PLASMA-LIPOPROTEINS; SERUM TRIGLYCERIDE; INSULIN-RESISTANCE; PRIMARY PREVENTION; RICH LIPOPROTEINS; CHOLESTEROL; ATORVASTATIN	Context The association of triglycerides with incident cardiovascular disease remains controversial. Although triglyceride levels are typically obtained in the fasting state, postprandial hypertriglyceridemia may play an important role in atherosclerosis. Objective To determine the association of triglyceride levels (fasting vs nonfasting) and risk of future cardiovascular events. Design, Setting, and Participants Prospective study of 26 509 initially healthy US women (20 118 fasting and 6391 nonfasting) participating in the Women's Health Study, enrolled between November 1992 and July 1995 and undergoing follow-up for a median of 11.4 years. Triglyceride levels were measured in blood samples obtained at time of enrollment. Main Outcome Measure Hazard ratios for incident cardiovascular events (nonfatal myocardial infarction, nonfatal ischemic stroke, coronary revascularization, or cardiovascular death). Results At baseline, triglyceride levels in fasting as well as nonfasting women correlated with traditional cardiac risk factors and markers of insulin resistance. During a median follow-up of 11.4 years, 1001 participants experienced an incident cardiovascular event (including 276 nonfatal myocardial infarctions, 265 ischemic strokes, 628 coronary revascularizations, and 163 cardiovascular deaths), for an overall rate of 3.46 cardiovascular events per 1000 person-years of follow-up. After adjusting for age, blood pressure, smoking, and use of hormone therapy, both fasting and nonfasting triglyceride levels predicted cardiovascular events. Among fasting participants, further adjustment for levels of total and high-density lipoprotein cholesterol and measures of insulin resistance weakened this association (fully adjusted hazard ratio [95% confidence interval] for increasing tertiles of triglyceride levels: 1 [reference], 1.21 [0.96-1.52], and 1.09 [0.85-1.41] [P = .90 for trend]). In contrast, nonfasting triglyceride levels maintained a strong independent relationship with cardiovascular events in fully adjusted models (hazard ratio [95% confidence interval] for increasing tertiles of levels: 1 [reference], 1.44 [0.90-2.29], and 1.98 [1.21-3.25] [P = .006 for trend]). In secondary analyses stratified by time since participants' last meal, triglyceride levels measured 2 to 4 hours postprandially had the strongest association with cardiovascular events (fully adjusted hazard ratio [95% confidence interval] for highest vs lowest tertiles of levels, 4.48 [1.98-10.15] [P < .001 for trend]), and this association progressively decreased with longer periods of fasting. Conclusions In this cohort of initially healthy women, nonfasting triglyceride levels were associated with incident cardiovascular events, independent of traditional cardiac risk factors, levels of other lipids, and markers of insulin resistance; by contrast, fasting triglyceride levels showed little independent relationship.	Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Boston, MA 02215 USA; Brigham & Womens Hosp, Donald W Reynolds Ctr Cardiovasc Res, Boston, MA 02215 USA; Brigham & Womens Hosp, Leducq Ctr Mol & Genet Epidemiol, Boston, MA 02215 USA; Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02215 USA; Brigham & Womens Hosp, Div Cardiol, Boston, MA 02215 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Boston Children's Hospital; Harvard T.H. Chan School of Public Health	Ridker, PM (corresponding author), Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, 900 Commonwealth Ave E, Boston, MA 02215 USA.	pridker@partners.org	Adiels, Martin/C-9278-2011	Mora, Samia/0000-0001-6283-0980	NCI NIH HHS [CA-47988] Funding Source: Medline; NHLBI NIH HHS [T32 HL007575-21, HL-43851] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047988] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007575, R01HL043851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Avins AL, 2000, ARCH INTERN MED, V160, P1937, DOI 10.1001/archinte.160.13.1937; Bjorkegren J, 2000, CIRCULATION, V101, P227, DOI 10.1161/01.CIR.101.3.227; Boquist S, 1999, CIRCULATION, V100, P723, DOI 10.1161/01.CIR.100.7.723; Boquist S, 2002, ATHEROSCLEROSIS, V162, P163, DOI 10.1016/S0021-9150(01)00689-X; Braun D, 1997, J Cardiovasc Risk, V4, P143, DOI 10.1097/00043798-199704000-00011; Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P27; Campos H, 2005, ATHEROSCLEROSIS, V181, P345, DOI 10.1016/j.atherosclerosis.2004.12.045; CHEN YDI, 1993, J CLIN ENDOCR METAB, V76, P172, DOI 10.1210/jc.76.1.172; DAUGHERTY A, 1985, J LIPID RES, V26, P955; Eberly LE, 2003, ARCH INTERN MED, V163, P1077, DOI 10.1001/archinte.163.9.1077; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Gaziano JM, 1997, CIRCULATION, V96, P2520, DOI 10.1161/01.CIR.96.8.2520; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; Ginsberg HN, 2002, CIRCULATION, V106, P2137, DOI 10.1161/01.CIR.0000035280.64322.31; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Hsia J, 2006, ARCH INTERN MED, V166, P357, DOI 10.1001/archinte.166.3.357; Iso H, 2001, AM J EPIDEMIOL, V153, P490, DOI 10.1093/aje/153.5.490; Isomaa B, 2001, DIABETES CARE, V24, P683, DOI 10.2337/diacare.24.4.683; Karpe F, 1999, J INTERN MED, V246, P341, DOI 10.1046/j.1365-2796.1999.00548.x; Kim HS, 2001, AM J CLIN NUTR, V74, P592; Kolovou Genovefa D, 2005, Lipids Health Dis, V4, P21, DOI 10.1186/1476-511X-4-21; Lee IM, 2005, JAMA-J AM MED ASSOC, V294, P56, DOI 10.1001/jama.294.1.56; Malmstrom R, 1997, DIABETOLOGIA, V40, P454, DOI 10.1007/s001250050700; MANNINEN V, 1992, CIRCULATION, V85, P37, DOI 10.1161/01.CIR.85.1.37; Mohanlal N, 2004, DIABETES CARE, V27, P89, DOI 10.2337/diacare.27.1.89; Ooi TC, 2004, ATHEROSCLEROSIS, V172, P375, DOI 10.1016/j.atherosclerosis.2003.10.016; Parhofer KG, 2000, J CLIN ENDOCR METAB, V85, P4224, DOI 10.1210/jc.85.11.4224; PATSCH JR, 1992, ARTERIOSCLER THROMB, V12, P1336, DOI 10.1161/01.ATV.12.11.1336; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; Proctor SD, 1998, EUR J CLIN INVEST, V28, P497; RAPP JH, 1994, ARTERIOSCLER THROMB, V14, P1767, DOI 10.1161/01.ATV.14.11.1767; Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613; Sarwar N, 2007, CIRCULATION, V115, P450, DOI 10.1161/CIRCULATIONAHA.106.637793; Schaefer EJ, 2001, AM J CARDIOL, V88, P1129, DOI 10.1016/S0002-9149(01)02047-1; Schaefer EJ, 2002, AM J CARDIOL, V90, P689, DOI 10.1016/S0002-9149(02)02591-2; Stampfer MJ, 1996, JAMA-J AM MED ASSOC, V276, P882, DOI 10.1001/jama.276.11.882; STENSVOLD I, 1993, BMJ-BRIT MED J, V307, P1318, DOI 10.1136/bmj.307.6915.1318; STINSHOFF K, 1977, CLIN CHEM, V23, P1029; Teno S, 2000, DIABETES CARE, V23, P1401, DOI 10.2337/diacare.23.9.1401; Trevisan M, 1998, AM J EPIDEMIOL, V148, P958; Van Wijk JPH, 2005, DIABETES CARE, V28, P844, DOI 10.2337/diacare.28.4.844; Weintraub MS, 1996, BRIT MED J, V312, P935, DOI 10.1136/bmj.312.7036.935; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	43	1160	1248	1	55	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 18	2007	298	3					309	316		10.1001/jama.298.3.309	http://dx.doi.org/10.1001/jama.298.3.309			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	190US	17635891	Bronze			2022-12-28	WOS:000248086700025
J	Gregor, T; Wieschaus, EF; McGregor, AP; Bialek, W; Tank, DW				Gregor, Thomas; Wieschaus, Eric F.; McGregor, Alistair P.; Bialek, William; Tank, David W.			Stability and nuclear dynamics of the bicoid morphogen gradient	CELL			English	Article							DROSOPHILA; DIFFUSION; PROTEIN; CALCIUM; PATTERN; GFP	Patterning in multicellular organisms results from spatial gradients in morphogen concentration, but the dynamics of these gradients remain largely unexplored. We characterize, through in vivo optical imaging, the development and stability of the Bicoid morphogen gradient in Drosophila embryos that express a Bicoid- eGFP fusion protein. The gradient is established rapidly ( similar to 1 hr after fertilization), with nuclear Bicoid concentration rising and falling during mitosis. Interphase levels result from a rapid equilibrium between Bicoid uptake and removal. Initial interphase concentration in nuclei in successive cycles is constant ( +/- 10%), demonstrating a form of gradient stability, but it subsequently decays by approximately 30%. Both direct photobleaching measurements and indirect estimates of Bicoid- eGFP diffusion constants ( D <= 1 mu m(2)/s) provide a consistent picture of Bicoid transport on short ( similar to min) time scales but challenge traditional models of long- range gradient formation. A new model is presented emphasizing the possible role of nuclear dynamics in shaping and scaling the gradient.	Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA; Princeton Univ, Joseph Henry Labs Phys, Princeton, NJ 08544 USA; Princeton Univ, Dept Biol Mol, Princeton, NJ 08544 USA; Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA; Princeton Univ, Dept Ecol & Evolut Biol, Princeton, NJ 08544 USA	Princeton University; Princeton University; Princeton University; Howard Hughes Medical Institute; Princeton University; Princeton University	Gregor, T (corresponding author), Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA.	tg2@princeton.edu		Gregor, Thomas/0000-0001-9460-139X; McGregor, Alistair/0000-0002-2908-2420	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM071508, R01GM077599] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM077599-01, P50 GM071508-01, R01 GM077599-02, R01 GM077599, P50 GM071508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIIZUMI T, 1995, ZOOL SCI, V12, P509, DOI 10.2108/zsj.12.509; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; Barolo S, 2000, BIOTECHNIQUES, V29, P726, DOI 10.2144/00294bm10; BERG HC, 1977, BIOPHYS J, V20, P193, DOI 10.1016/S0006-3495(77)85544-6; Brown EB, 1999, BIOPHYS J, V77, P2837, DOI 10.1016/S0006-3495(99)77115-8; Collins GA, 2006, CURR OPIN GENET DEV, V16, P197, DOI 10.1016/j.gde.2006.02.009; CRICK F, 1970, NATURE, V225, P420, DOI 10.1038/225420a0; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Dhananjayan SC, 2005, ESSAYS BIOCHEM, V41, P69, DOI 10.1042/EB0410069; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; Ephrussi A, 2004, CELL, V116, P143, DOI 10.1016/S0092-8674(04)00037-6; Fersht A., 1985, ENZYME STRUCTURE MEC; Foe Victoria E., 1993, P149; Gregor T, 2005, P NATL ACAD SCI USA, V102, P18403, DOI 10.1073/pnas.0509483102; Hazelrigg T, 1998, DEV BIOL, V199, P245, DOI 10.1006/dbio.1998.8922; HODGKIN AL, 1957, J PHYSIOL-LONDON, V138, P253, DOI 10.1113/jphysiol.1957.sp005850; Houchmandzadeh B, 2002, NATURE, V415, P798, DOI 10.1038/415798a; Kiseleva E, 2001, J CELL SCI, V114, P3607; Kosman D, 1998, DEV GENES EVOL, V208, P290, DOI 10.1007/s004270050184; Kubitscheck U, 2005, J CELL BIOL, V168, P233, DOI 10.1083/jcb.200411005; Lacalli T.C., 1991, Seminars in Developmental Biology, V2, P107; LAWRENCE P, 1992, GENETICS ANIMAL DESI; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; Svoboda K, 1997, NATURE, V385, P161, DOI 10.1038/385161a0; Thummel CS, 1992, DROS INF SERV, V71, P150; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Wieschaus E., 1986, P199; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; ZECCA M, 1995, DEVELOPMENT, V121, P2265	31	348	352	0	34	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 13	2007	130	1					141	152		10.1016/j.cell.2007.05.026	http://dx.doi.org/10.1016/j.cell.2007.05.026			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	197WK	17632061	Green Accepted, Bronze, Green Submitted			2022-12-28	WOS:000248587000017
J	Fulweiler, RW; Nixon, SW; Buckley, BA; Granger, SL				Fulweiler, R. W.; Nixon, S. W.; Buckley, B. A.; Granger, S. L.			Reversal of the net dinitrogen gas flux in coastal marine sediments	NATURE			English	Article							SPRING PHYTOPLANKTON BLOOM; NARRAGANSETT-BAY; NITROGEN-FIXATION; CLIMATE-CHANGE; WATER; EUTROPHICATION; TEMPERATURE; ECOSYSTEMS; PHOSPHORUS; REDUCTION	The flux of nitrogen from land and atmosphere to estuaries and the coastal ocean has increased substantially in recent decades. The observed increase in nitrogen loading is caused by population growth, urbanization, expanding water and sewer infrastructure, fossil fuel combustion and synthetic fertilizer consumption(1,2). Most of the nitrogen is removed by denitrification in the sediments of estuaries and the continental shelf, leading to a reduction in both cultural eutrophication and nitrogen pollution of the open ocean(3,4). Nitrogen fixation, however, is thought to be a negligible process in sub-tidal heterotrophic marine systems(5). Here we report sediment core data from Narragansett Bay, USA, which demonstrate that heterotrophic marine sediments can switch from being a net sink to being a net source of nitrogen. Mesocosm and core incubation experiments, together with a historic data set of mean annual chlorophyll production(6,7), support the idea that a climate-induced decrease in primary production has led to a decrease in organic matter deposition to the benthos and the observed reversal of the net sediment nitrogen flux. Our results suggest that some estuaries may no longer remove nitrogen from the water column. Instead, nitrogen could be exported to the continental shelf and the open ocean and could shift the effect of anthropogenic nitrogen loading beyond the immediate coastal zone.	Univ Rhode Isl, Grad Sch Oceanog, Narragansett, RI 02882 USA	University of Rhode Island	Fulweiler, RW (corresponding author), Univ Rhode Isl, Grad Sch Oceanog, Narragansett, RI 02882 USA.	wally@gso.uri.edu	Fulweiler, Robinson W./A-3806-2010	Fulweiler, Robinson W./0000-0003-0871-4246				Borkman DG, 1998, ICES J MAR SCI, V55, P668, DOI 10.1006/jmsc.1998.0380; BORKMAN GD, 2002, THESIS U RHODE ISLAN; Brush MJ, 2002, MAR ECOL PROG SER, V238, P31, DOI 10.3354/meps238031; Edwards M, 2004, NATURE, V430, P881, DOI 10.1038/nature02808; Farnsworth EJ, 1995, J ECOL, V83, P967, DOI 10.2307/2261178; FULWEILER RW, IN PRESS HYDROBIOLOG; Furnas M.J., 1976, ESTUARINE PROCESSES, V1, P118; Galloway JN, 2004, BIOGEOCHEMISTRY, V70, P153, DOI 10.1007/s10533-004-0370-0; Galloway JN, 2002, AMBIO, V31, P64, DOI 10.1639/0044-7447(2002)031[0064:RNATWY]2.0.CO;2; Gardner WS, 2006, LIMNOL OCEANOGR, V51, P558, DOI 10.4319/lo.2006.51.1_part_2.0558; Howarth RW, 2006, LIMNOL OCEANOGR, V51, P364, DOI 10.4319/lo.2006.51.1_part_2.0364; HOWARTH RW, 1988, LIMNOL OCEANOGR, V33, P669, DOI 10.4319/lo.1988.33.4_part_2.0669; KANA TM, 1994, ANAL CHEM, V66, P4166, DOI 10.1021/ac00095a009; Keller AA, 1999, LIMNOL OCEANOGR, V44, P344, DOI 10.4319/lo.1999.44.2.0344; Kemp WM, 2005, MAR ECOL PROG SER, V303, P1, DOI 10.3354/meps303001; Li YQ, 1998, ICES J MAR SCI, V55, P661, DOI 10.1006/jmsc.1998.0383; Nixon SW, 1996, BIOGEOCHEMISTRY, V35, P141, DOI 10.1007/BF02179826; Nixon SW, 1995, BIOGEOCHEMISTRY, V31, P15; NIXON SW, ECOSYSTEM BASED ESTU; Nixon SW, 1980, MARINE BENTHIC DYNAM, P219; Nixon SX, 2004, ESTUARIES, V27, P397, DOI 10.1007/BF02803532; Nowicld B.L., 1991, THESIS U RHODE ISLAN; Oviatt C, 2002, ESTUAR COAST SHELF S, V54, P1013, DOI 10.1006/ecss.2001.0872; OVIATT C, 1995, MAR ECOL PROG SER, V116, P171, DOI 10.3354/meps116171; Pinckney JL, 2001, ORG GEOCHEM, V32, P585, DOI 10.1016/S0146-6380(00)00196-0; SEITZINGER S, 1982, THESIS U RHODE ISLAN; Seitzinger SP, 1996, BIOGEOCHEMISTRY, V35, P235, DOI 10.1007/BF02179829; SEITZINGER SP, 1987, MAR ECOL PROG SER, V37, P65, DOI 10.3354/meps037065; SISLER FD, 1951, SCIENCE, V113, P511, DOI 10.1126/science.113.2940.511; Townsend D.W., 1988, BIOL OCEANOGR, V5, P215, DOI DOI 10.1080/01965581.1987.10749514; Walther GR, 2002, NATURE, V416, P389, DOI 10.1038/416389a	31	151	154	2	117	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 12	2007	448	7150					180	182		10.1038/nature05963	http://dx.doi.org/10.1038/nature05963			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	188QN	17625562				2022-12-28	WOS:000247934500039
J	Robson, M; Offit, K				Robson, Mark; Offit, Kenneth			Management of an inherited predisposition to breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BRCA2 MUTATION CARRIERS; HIGH FAMILIAL RISK; SURGICAL ADJUVANT BREAST; SCREENING WOMEN; OVARIAN-CANCER; SALPINGO-OOPHORECTOMY; ORAL-CONTRACEPTIVES; COST-EFFECTIVENESS; HEREDITARY BREAST; MAMMOGRAPHY		Mem Sloan Kettering Canc Ctr, Clin Genet Serv, Dept Med, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Robson, M (corresponding author), Mem Sloan Kettering Canc Ctr, Clin Genet Serv, Dept Med, 1275 York Ave, New York, NY 10021 USA.	robsonm@mskcc.org	Pinheiro, Maísa/E-7424-2012; van Herwerden, Lynne/I-1087-2012	van Herwerden, Lynne/0000-0001-6717-8995; Robson, Mark/0000-0002-3109-1692				Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Bancej C, 2003, J MED SCREEN, V10, P16, DOI 10.1258/096914103321610761; Beral V, 2001, LANCET, V358, P1389, DOI 10.1016/S0140-6736(01)06524-2; Berg AO, 2005, ANN INTERN MED, V143, P355, DOI 10.7326/0003-4819-143-5-200509060-00011; Berg WA, 2004, RADIOL CLIN N AM, V42, P845, DOI 10.1016/j.rcl.2004.04.003; Berry DA, 2002, J CLIN ONCOL, V20, P2701, DOI 10.1200/JCO.2002.05.121; Brekelmans CTM, 2001, J CLIN ONCOL, V19, P924, DOI 10.1200/JCO.2001.19.4.924; Buist DSM, 2004, JNCI-J NATL CANCER I, V96, P1432, DOI 10.1093/jnci/djh269; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; Chart PL, 1997, CAN MED ASSOC J, V157, P1235; Chen SN, 2007, J CLIN ONCOL, V25, P1329, DOI 10.1200/JCO.2006.09.1066; CLAUS EB, 1994, CANCER, V73, P643, DOI 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5; Collett K, 2005, CANCER EPIDEM BIOMAR, V14, P1108, DOI 10.1158/1055-9965.EPI-04-0394; Domchek SM, 2006, LANCET ONCOL, V7, P223, DOI 10.1016/S1470-2045(06)70585-X; Eisen A, 2005, J CLIN ONCOL, V23, P7491, DOI 10.1200/JCO.2004.00.7138; Eisinger F, 1998, ANN ONCOL, V9, P939, DOI 10.1023/A:1008389021382; Evans DGR, 2004, J MED GENET, V41, P474, DOI 10.1136/jmg.2003.017996; Feigin KN, 2006, RADIOLOGY, V240, P650, DOI 10.1148/radiol.2403051377; Finch A, 2006, JAMA-J AM MED ASSOC, V296, P185, DOI 10.1001/jama.296.2.185; Fisher B, 2005, JNCI-J NATL CANCER I, V97, P1652, DOI 10.1093/jnci/dji372; Frank TS, 2002, J CLIN ONCOL, V20, P1480, DOI 10.1200/JCO.20.6.1480; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; Goldfrank D, 2006, CANCER EPIDEM BIOMAR, V15, P2311, DOI 10.1158/1055-9965.EPI-06-0176; Griebsch I, 2006, BRIT J CANCER, V95, P801, DOI 10.1038/sj.bjc.6603356; Gronwald J, 2006, INT J CANCER, V118, P2281, DOI 10.1002/ijc.21536; Gui GPH, 2006, EJSO-EUR J SURG ONC, V32, P719, DOI 10.1016/j.ejso.2006.05.002; Gui GPH, 2001, EUR J CANCER, V37, P1668, DOI 10.1016/S0959-8049(01)00207-6; Hackshaw AK, 2003, BRIT J CANCER, V88, P1047, DOI 10.1038/sj.bjc.6600847; Haile RW, 2006, CANCER EPIDEM BIOMAR, V15, P1863, DOI 10.1158/1055-9965.EPI-06-0258; Hermsen BBJ, 2007, BRIT J CANCER, V96, P1335, DOI 10.1038/sj.bjc.6603725; Humphrey LL, 2002, ANN INTERN MED, V137, P347, DOI 10.7326/0003-4819-137-5_Part_1-200209030-00012; Kauff ND, 2002, NEW ENGL J MED, V346, P1609, DOI 10.1056/NEJMoa020119; Kerlikowske K, 2000, ANN INTERN MED, V133, P855, DOI 10.7326/0003-4819-133-11-200012050-00009; Kerlikowske K, 1996, JAMA-J AM MED ASSOC, V276, P33, DOI 10.1001/jama.276.1.33; King MC, 2001, JAMA-J AM MED ASSOC, V286, P2251, DOI 10.1001/jama.286.18.2251; Kisch E, 2005, ANN INTERN MED, V143, P547, DOI 10.7326/0003-4819-143-7-200510040-00025; Kollias J, 1998, EUR J CANCER, V34, P878, DOI 10.1016/S0959-8049(97)00365-1; Kriege M, 2004, NEW ENGL J MED, V351, P427, DOI 10.1056/NEJMoa031759; Kuhl CK, 2005, J CLIN ONCOL, V23, P8469, DOI 10.1200/JCO.2004.00.4960; Lalloo F, 1998, EUR J CANCER, V34, P937, DOI 10.1016/S0959-8049(98)00005-7; Leach MO, 2005, LANCET, V365, P1769, DOI 10.1016/S0140-6736(05)66481-1; Lehman CD, 2005, CANCER, V103, P1898, DOI 10.1002/cncr.20971; Macmillan RD, 2000, EUR J SURG ONCOL, V26, P149, DOI 10.1053/ejso.1999.0759; McLaughlin JR, 2007, LANCET ONCOL, V8, P26, DOI 10.1016/S1470-2045(06)70983-4; Mitchell G, 2006, CANCER RES, V66, P1866, DOI 10.1158/0008-5472.CAN-05-3368; Moller P, 1999, DIS MARKERS, V15, P179, DOI 10.1155/1999/805420; Murday Victoria, 2004, Fam Cancer, V3, P29; Narod SA, 2002, JNCI-J NATL CANCER I, V94, P1773, DOI 10.1093/jnci/94.23.1773; Narod SA, 2006, LANCET ONCOL, V7, P453; Narod SA, 1998, NEW ENGL J MED, V339, P424, DOI 10.1056/NEJM199808133390702; Narod SA, 2006, LANCET ONCOL, V7, P402, DOI 10.1016/S1470-2045(06)70624-6; National Comprehensive Cancer Network, 2006, CLIN PRACT GUID ONC; Oestreicher N, 2005, AM J ROENTGENOL, V184, P428, DOI 10.2214/ajr.184.2.01840428; Offit K, 2004, JAMA-J AM MED ASSOC, V292, P1469, DOI 10.1001/jama.292.12.1469; Offit K, 2006, J NATL CANCER I, V98, P1675, DOI 10.1093/jnci/djj500; Offit K, 2006, JAMA-J AM MED ASSOC, V296, P2727, DOI 10.1001/jama.296.22.2727; Olivier RI, 2006, GYNECOL ONCOL, V100, P20, DOI 10.1016/j.ygyno.2005.08.038; Pisano ED, 2006, NEW ENGL J MED, V355, P1840; Plevritis SK, 2006, JAMA-J AM MED ASSOC, V295, P2374, DOI 10.1001/jama.295.20.2374; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; Rebbeck TR, 2004, J CLIN ONCOL, V22, P1055, DOI 10.1200/JCO.2004.04.188; Rennert G, 2007, NEW ENGL J MED, V357, P115, DOI 10.1056/NEJMoa070608; Robson ME, 2004, BREAST CANCER RES, V6, pR8, DOI 10.1186/bcr658; Sardanelli F, 2007, RADIOLOGY, V242, P698, DOI 10.1148/radiol.2423051965; Saslow D, 2007, CA-CANCER J CLIN, V57, P75, DOI 10.3322/canjclin.57.2.75; Scheuer L, 2002, J CLIN ONCOL, V20, P1260, DOI 10.1200/JCO.2002.20.5.1260; Tilanus-Linthorst MMA, 2005, EUR J CANCER, V41, P1610, DOI 10.1016/j.ejca.2005.02.034; Tilanus-Linthorst MMA, 2000, EUR J CANCER, V36, P514, DOI 10.1016/S0959-8049(99)00337-8; Tyrer J, 2005, STAT MED, V24, P156, DOI 10.1002/sim.1913; Vogel VG, 2006, JAMA-J AM MED ASSOC, V296, P2926; Vogel VG, 2006, JAMA-J AM MED ASSOC, V295, P2727, DOI 10.1001/jama.295.23.joc60074; Warner E, 2004, JAMA-J AM MED ASSOC, V292, P1317, DOI 10.1001/jama.292.11.1317; 2006, FAMILIAL BREAST CANC	73	177	180	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 12	2007	357	2					154	162		10.1056/NEJMcp071286	http://dx.doi.org/10.1056/NEJMcp071286			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188NX	17625127				2022-12-28	WOS:000247927700009
J	van Leer-Buter, C; Takes, RP; Hebeda, KM; Melchers, WJG; Verweij, PE				van Leer-Buter, Coretta; Takes, Robert P.; Hebeda, Konnie M.; Melchers, Wiliam J. G.; Verweij, Paul E.			Aspergillosis - and a misleading sensitivity result	LANCET			English	Editorial Material							FUMIGATUS		Univ Med Ctr St Radboud, Nijmegen, Netherlands	Radboud University Nijmegen	Verweij, PE (corresponding author), Univ Med Ctr St Radboud, Nijmegen, Netherlands.	p.verweij@mmb.umcn.nl	Verweij, P.E./H-8108-2014; Takes, R.P./L-4680-2015; Hebeda, K./L-4354-2015; Melchers, Willem/C-8819-2015	Verweij, P.E./0000-0002-8600-9860; Hebeda, K./0000-0002-4181-3302; Melchers, Willem/0000-0002-5446-2230; Van Leer, Coretta/0000-0002-4072-7373				Chazalet V, 1998, J CLIN MICROBIOL, V36, P1494, DOI 10.1128/JCM.36.6.1494-1500.1998; de Valk HA, 2005, J CLIN MICROBIOL, V43, P4112, DOI 10.1128/JCM.43.8.4112-4120.2005; Mellado E, 2007, ANTIMICROB AGENTS CH, V51, P1897, DOI 10.1128/AAC.01092-06; Radford SA, 1998, J CLIN MICROBIOL, V36, P1294, DOI 10.1128/JCM.36.5.1294-1299.1998; Verweij PE, 2007, NEW ENGL J MED, V356, P1481, DOI 10.1056/NEJMc061720	5	28	28	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 7	2007	370	9581					102	102		10.1016/S0140-6736(07)61055-1	http://dx.doi.org/10.1016/S0140-6736(07)61055-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187QE	17617278				2022-12-28	WOS:000247862300036
J	Dansinger, ML; Tatsioni, A; Wong, JB; Chung, M; Balk, EM				Dansinger, Michael L.; Tatsioni, Athina; Wong, John B.; Chung, Mei; Balk, Ethan M.			Meta-analysis: The effect of dietary counseling for weight loss	ANNALS OF INTERNAL MEDICINE			English	Review							RANDOMIZED CONTROLLED-TRIAL; CARDIOVASCULAR RISK-FACTORS; LIFE-STYLE INTERVENTION; ANTIHYPERTENSIVE MEDICATION REQUIREMENTS; INSULIN SENSITIVITY; REDUCTION PROGRAM; OVERWEIGHT MEN; EXERCISE; OBESE; HYPERTENSION	Background: Dietary and lifestyle modification efforts are the primary treatments for people who are obese or overweight. The effect of dietary counseling on long-term weight change is unclear. Purpose: To perform a meta-analysis of the effect of dietary counseling compared with usual care on body mass index (BMI) over time in adults. Data Sources: Early studies (1980 through 1997) from a previously published systematic review; MEDLINE and the Cochrane Central Register of Controlled Trials from 1997 through July 2006. Study Selection: English-language randomized, controlled trials ( 16 weeks in duration) in overweight adults that reported the effect of dietary counseling on weight. The authors included only weight loss studies with a dietaty component. Data Extraction: Single reviewers.; performed full data extraction; at least 1 additional reviewer reviewed the data. Data Synthesis: Random-effects, model meta-analyses of 46 trials of dietary counseling revealed a maximum net treatment effect of -1.9 (95% Cl, -2.3 to -1.5) BMI units (approximately -6%) at 12 months. Meta-analysis of changes in weight over time (slopes) and meta-regression suggest a change of approximately -0.1 BMI unit per month from 3 to 12 months of active programs and a regain of approximately 0.02 to 0.03 BMI unit per month during subsequent maintenance phases. Different analyses suggested that calorie recommendations, frequency of support meetings, inclusion of exercise, and diabetes may be independent predictors of weight change. Limitations: The interventions, study samples, and weight changes were heterogeneous. Studies were generally of moderate to poor methodological quality. They had high rates of missing data and failed to explain these losses. The meta-analytic techniques could not fully account for these limitations. Conclusions: Compared with usual care, dietary counseling interventions produce modest weight losses that diminish over time. In future studies, minimizing loss to follow-up and determining which factors result in more effective weight loss should be emphasized.	Tufts Univ, New England Med Ctr, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Dansinger, ML (corresponding author), Tufts Univ, New England Med Ctr, 750 Washington St,NEMC 216, Boston, MA 02111 USA.	mdansinger@tufts-nemc.org	Balk, Ethan/AAJ-2547-2020; Tatsioni, Athina/AAQ-5413-2020	Wong, John/0000-0003-4203-9010	NCRR NIH HHS [K23RR020709] Funding Source: Medline; PHS HHS [290-02-0022] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adams KF, 2006, NEW ENGL J MED, V355, P763, DOI 10.1056/NEJMoa055643; AgursCollins TD, 1997, DIABETES CARE, V20, P1503, DOI 10.2337/diacare.20.10.1503; Anderson JW, 2001, AM J CLIN NUTR, V74, P579; Anderssen Sigmund, 1995, Blood Pressure, V4, P343, DOI 10.3109/08037059509077619; [Anonymous], 1990, Arch Intern Med, V150, P153, DOI 10.1001/archinte.150.1.153; Appel LJ, 2003, JAMA-J AM MED ASSOC, V289, P2083, DOI 10.1001/jama.289.16.2083; Avenell A, 2004, J HUM NUTR DIET, V17, P293, DOI 10.1111/j.1365-277X.2004.00530.x; Avenell A, 2004, HEALTH TECHNOL ASSES, V8, P1; Ayyad C, 2000, Obes Rev, V1, P113, DOI 10.1046/j.1467-789x.2000.00019.x; Balk EM, 2002, JAMA-J AM MED ASSOC, V287, P2973, DOI 10.1001/jama.287.22.2973; Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032; BERKEY CS, 1995, STAT MED, V14, P395, DOI 10.1002/sim.4780140406; Clark M, 2004, BRIT J HEALTH PSYCH, V9, P365, DOI 10.1348/1359107041557066; CROFT PR, 1986, J ROY COLL GEN PRACT, V36, P445; Dalle Grave R, 2004, Eat Weight Disord, V9, P69; DAVIS BR, 1993, ARCH INTERN MED, V153, P1773, DOI 10.1001/archinte.153.15.1773; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DICKSON R, 1997, EFFECTIVE HLTH CARE, V3, P1; Djuric Z, 2002, OBES RES, V10, P657, DOI 10.1038/oby.2002.89; Douketis JD, 1999, THROMB HAEMOSTASIS, V82, P1028; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; Escalante-Pulido M, 2003, DIABETES NUTR METAB, V16, P277; Esposito K, 2004, JAMA-J AM MED ASSOC, V291, P2978, DOI 10.1001/jama.291.24.2978; Field AE, 2001, ARCH INTERN MED, V161, P1581, DOI 10.1001/archinte.161.13.1581; *FINN DIAB PREV ST, 2003, DIABETES CARE, V26, P3230; Flegal KM, 2005, JAMA-J AM MED ASSOC, V293, P1861, DOI 10.1001/jama.293.15.1861; Fontaine KR, 2003, JAMA-J AM MED ASSOC, V289, P187, DOI 10.1001/jama.289.2.187; Fontaine KR, 2000, INT J EAT DISORDER, V27, P101, DOI 10.1002/(SICI)1098-108X(200001)27:1&lt;101::AID-EAT12&gt;3.0.CO;2-D; Glasgow RE, 2003, AM J PUBLIC HEALTH, V93, P1261, DOI 10.2105/AJPH.93.8.1261; Glenny AM, 1997, INT J OBESITY, V21, P715, DOI 10.1038/sj.ijo.0800495; GUARE JC, 1995, OBES RES, V3, P329, DOI 10.1002/j.1550-8528.1995.tb00158.x; HAKALA P, 1989, EUR J CLIN NUTR, V43, P421; Hankey CR, 2002, J HUM NUTR DIET, V15, P439, DOI 10.1046/j.1365-277X.2002.00397.x; Haynes R B, 1984, J Hypertens, V2, P535, DOI 10.1097/00004872-198410000-00014; HELLENIUS ML, 1993, ATHEROSCLEROSIS, V103, P81, DOI 10.1016/0021-9150(93)90042-S; Heshka S, 2003, JAMA-J AM MED ASSOC, V289, P1792, DOI 10.1001/jama.289.14.1792; Hinderliter A, 2002, ARCH INTERN MED, V162, P1333, DOI 10.1001/archinte.162.12.1333; Hoeger KM, 2004, FERTIL STERIL, V82, P421, DOI 10.1016/j.fertnstert.2004.02.104; *ICAN STUD, 2004, DIABETES CARE, V27, P1570; JALKANEN L, 1991, SCAND J SOC MED, V19, P66, DOI 10.1177/140349489101900112; Jones DW, 1999, AM J HYPERTENS, V12, P1175, DOI 10.1016/S0895-7061(99)00123-5; KARVETTI RL, 1992, EUR J CLIN NUTR, V46, P743; Kastarinen MJ, 2002, J HYPERTENS, V20, P2505, DOI 10.1097/00004872-200212000-00031; KATZEL LI, 1995, JAMA-J AM MED ASSOC, V274, P1915, DOI 10.1001/jama.274.24.1915; Khan MA, 2000, OBES RES, V8, P43, DOI 10.1038/oby.2000.7; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; LANGFORD HG, 1985, JAMA-J AM MED ASSOC, V253, P657, DOI 10.1001/jama.253.5.657; Leermakers EA, 1998, INT J OBESITY, V22, P1103, DOI 10.1038/sj.ijo.0800734; MACMAHON SW, 1985, CLIN EXP PHARMACOL P, V12, P267, DOI 10.1111/j.1440-1681.1985.tb02645.x; MARKS BL, 1995, MED SCI SPORT EXER, V27, P1243; Mayer-Davis EJ, 2004, AM J PUBLIC HEALTH, V94, P1736, DOI 10.2105/AJPH.94.10.1736; McAuley KA, 2002, DIABETES CARE, V25, P445, DOI 10.2337/diacare.25.3.445; McTigue KM, 2003, ANN INTERN MED, V139, P933, DOI 10.7326/0003-4819-139-11-200312020-00013; Mensink M, 2003, OBES RES, V11, P1588, DOI 10.1038/oby.2003.211; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; MORRIS CN, 1983, J AM STAT ASSOC, V78, P47, DOI 10.2307/2287098; Must A, 1999, JAMA-J AM MED ASSOC, V282, P1523, DOI 10.1001/jama.282.16.1523; *NEDCOM, 2003, ANN INTERN MED, V138, P24; Nicklas BJ, 2004, AM J CLIN NUTR, V79, P544; Nordmann AJ, 2006, ARCH INTERN MED, V166, P285, DOI 10.1001/archinte.166.3.285; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Oldroyd JC, 2001, DIABETES RES CLIN PR, V52, P29, DOI 10.1016/S0168-8227(00)00244-8; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Simkin-Silverman LR, 2003, ANN BEHAV MED, V26, P212, DOI 10.1207/S15324796ABM2603_06; Southard Barbara H, 2003, J Cardiopulm Rehabil, V23, P341, DOI 10.1097/00008483-200309000-00003; STAMLER R, 1987, JAMA-J AM MED ASSOC, V257, P1484, DOI 10.1001/jama.257.11.1484; Swinburn BA, 2001, DIABETES CARE, V24, P619, DOI 10.2337/diacare.24.4.619; Tate DF, 2006, ARCH INTERN MED, V166, P1620, DOI 10.1001/archinte.166.15.1620; Tate DF, 2001, JAMA-J AM MED ASSOC, V285, P1172, DOI 10.1001/jama.285.9.1172; Toobert DJ, 2005, ANN BEHAV MED, V29, P128, DOI 10.1207/s15324796abm2902_7; Toobert DJ, 2000, ANN BEHAV MED, V22, P1, DOI 10.1007/BF02895162; U.S. Department of Health and Human Services, 2001, SURG GEN CALL ACT PR; Ware JH, 2003, NEW ENGL J MED, V348, P2136, DOI 10.1056/NEJMe030054; Whelton PK, 1998, JAMA-J AM MED ASSOC, V279, P839, DOI 10.1001/jama.279.11.839; Whelton PK, 1997, ARCH INTERN MED, V157, P657, DOI 10.1001/archinte.157.6.657; Wing RR, 1998, DIABETES CARE, V21, P350, DOI 10.2337/diacare.21.3.350; WOOD PD, 1988, NEW ENGL J MED, V319, P1173, DOI 10.1056/NEJM198811033191801; WOOD PD, 1991, NEW ENGL J MED, V325, P461, DOI 10.1056/NEJM199108153250703	80	328	332	0	53	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2007	147	1					41	50		10.7326/0003-4819-147-1-200707030-00007	http://dx.doi.org/10.7326/0003-4819-147-1-200707030-00007			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	186MN	17606960				2022-12-28	WOS:000247782900006
J	Landgraf, P; Rusu, M; Sheridan, R; Sewer, A; Iovino, N; Aravin, A; Pfeffer, S; Rice, A; Kamphorst, AO; Landthaler, M; Lin, C; Socci, ND; Hermida, L; Fulci, V; Chiaretti, S; Foa, R; Schliwka, J; Fuchs, U; Novosel, A; Muller, RU; Schermer, B; Bissels, U; Inman, J; Phan, Q; Chien, MC; Weir, DB; Choksi, R; De Vita, G; Frezzetti, D; Trompeter, HI; Hornung, V; Teng, G; Hartmann, G; Palkovits, M; Di Lauro, R; Wernet, P; Macino, G; Rogler, CE; Nagle, JW; Ju, JY; Papavasiliou, FN; Benzing, T; Lichter, P; Tam, W; Brownstein, MJ; Bosio, A; Borkhardt, A; Russo, JJ; Sander, C; Zavolan, M; Tuschl, T				Landgraf, Pablo; Rusu, Mirabela; Sheridan, Robert; Sewer, Alain; Iovino, Nicola; Aravin, Alexei; Pfeffer, Sebastien; Rice, Amanda; Kamphorst, Alice O.; Landthaler, Markus; Lin, Carolina; Socci, Nicholas D.; Hermida, Leandro; Fulci, Valerio; Chiaretti, Sabina; Foa, Robin; Schliwka, Julia; Fuchs, Uta; Novosel, Astrid; Mueller, Roman-Ulrich; Schermer, Bernhard; Bissels, Ute; Inman, Jason; Phan, Quang; Chien, Minchen; Weir, David B.; Choksi, Ruchi; De Vita, Gabriella; Frezzetti, Daniela; Trompeter, Hans-Ingo; Hornung, Veit; Teng, Grace; Hartmann, Gunther; Palkovits, Miklos; Di Lauro, Robert; Wernet, Peter; Macino, Giuseppe; Rogler, Charles E.; Nagle, James W.; Ju, Jingyue; Papavasiliou, F. Nina; Benzing, Thomas; Lichter, Peter; Tam, Wayne; Brownstein, Michael J.; Bosio, Andreas; Borkhardt, Arndt; Russo, James J.; Sander, Chris; Zavolan, Mihaela; Tuschl, Thomas			A mammalian microRNA expression atlas based on small RNA library sequencing	CELL			English	Article							MENTAL-RETARDATION PROTEIN; POSTTRANSCRIPTIONAL REGULATION; GENE-EXPRESSION; C-ELEGANS; IDENTIFICATION; CLONING; MODULATION; ZEBRAFISH; VIRUSES; TARGETS	MicroRNAs (miRNAs) are small noncoding regulatory RNAs that reduce stability and/or translation of fully or partially sequence-complementary target mRNAs. In order to identify miRNAs and to assess their expression patterns, we sequenced over 250 small RNA libraries from 26 different organ systems and cell types of human and rodents that were enriched in neuronal as well as normal and malignant hematopoietic cells and tissues. We present expression profiles derived from clone count data and provide computational tools for their analysis. Unexpectedly, a relatively small set of miRNAs, many of which are ubiquitously expressed, account for most of the differences in miRNA profiles between cell lineages and tissues. This broad survey also provides detailed and accurate information about mature sequences, precursors, genome locations, maturation processes, inferred transcriptional units, and conservation patterns. We also propose a subclassification scheme for miRNAs for assisting future experimental and computational functional analyses.	Univ Basel, Biozentrum, CH-4056 Basel, Switzerland; Rockefeller Univ, Howard Hughes Med Inst, Lab RNA Mol Biol, New York, NY 10021 USA; Univ Roma La Sapienza, Dipartimento Biotecnol Cellulari & Ematol, New York, NY 10021 USA; Deutsch Krebsforschungszentrum, Div Mol Genet, D-69120 Heidelberg, Germany; Univ Munich, Dr Von Haunerschen Kinderspital, Dept Hematol & Oncol, D-80337 Munich, Germany; Univ Hosp Freiburg, Div Renal, D-79106 Freiburg, Germany; Miltenyi Biotec GmbH, D-50829 Cologne, Germany; Inst Genom Res, Rockville, MD 20850 USA; J Craig Venter Inst, Funct Genom, Rockville, MD 20850 USA; Columbia Genome Ctr, Russ Berrie Pavilion, New York, NY 10032 USA; Univ Dusseldorf, Med Ctr, Inst Transplantat Diagnost & Cell Therapeut, D-40225 Dusseldorf, Germany; Rockefeller Univ, Lab Lymphocyte Biol, New York, NY 10021 USA; Hungarian Acad Sci Semmelweis Univ, Lab Neuromorphol, Budapest, Hungary; Albert Einstein Coll Med, Bronx, NY 10461 USA; Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Pathol & Lab Med, New York, NY 10021 USA; Univ Bonn, Univ Hosp, Div Clin Pharmacol, D-53105 Bonn, Germany; Swiss Inst Bioinformat, CH-1015 Lausanne, Switzerland; IRGS, Biogem Scarl, I-83031 Ariano Irpino, Italy; Columbia Univ, Dept Chem Engn, New York, NY 10027 USA; NIH, NINDS, DNA Sequencing Facil, Bethesda, MD 20892 USA; Univ Munich, Dept Internal Med, Div Clin Pharmacol, D-80366 Munich, Germany; Univ Massachusetts, Sch Med, Div Infect Dis & Immunol, Worcester, MA 01605 USA; IBM Corp, CNRS, F-678084 Strasbourg, France; Cold Spring Harbor Lab, Howard Hughes Med Inst, Sch Biol Sci, Cold Spring Harbor, NY 11724 USA; Rockefeller Univ, Lab Dev Neurogenet, New York, NY 10021 USA; Univ Dusseldorf, Med Ctr, Dept Pediat Oncol Hematol & Immunol, D-40225 Dusseldorf, Germany; Univ Lausanne, Dept Med Genet, Computat Biol Grp, CH-1005 Lausanne, Switzerland	University of Basel; Howard Hughes Medical Institute; Rockefeller University; Helmholtz Association; German Cancer Research Center (DKFZ); University of Munich; University of Freiburg; Miltenyi Biotec; J. Craig Venter Institute; J. Craig Venter Institute; Columbia University; Heinrich Heine University Dusseldorf; Rockefeller University; Semmelweis University; Yeshiva University; Albert Einstein College of Medicine; Cornell University; University of Bonn; Swiss Institute of Bioinformatics; Columbia University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Munich; University of Massachusetts System; University of Massachusetts Worcester; Centre National de la Recherche Scientifique (CNRS); International Business Machines (IBM); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; Rockefeller University; Heinrich Heine University Dusseldorf; University of Lausanne	Zavolan, M (corresponding author), Univ Basel, Biozentrum, CH-4056 Basel, Switzerland.	mihaela.zavolan@unibas.ch; ttuschl@rockefeller.edu	Müller, Roman-Ulrich/AAK-3493-2021; Palkovits, Miklos/F-2707-2013; Pfeffer, Sébastien/H-3212-2019; Pfeffer, Sebastien/A-6512-2010; Zavolan, Mihaela/S-3888-2016; Benzing, Thomas/X-5476-2019; Sander, Chris/H-1452-2011; Hartmann, Gunther/P-7492-2017; Fulci, Valerio/J-1963-2015; Schermer, Bernhard/E-9972-2014; Frezzetti, Daniela/AAI-2410-2019; Hornung, Veit/C-3565-2012; Di Lauro, Roberto/A-2746-2012; Landthaler, Markus/A-1427-2010; De Vita, Gabriella/H-4422-2011	Müller, Roman-Ulrich/0000-0001-6910-0745; Palkovits, Miklos/0000-0003-0578-0387; Pfeffer, Sébastien/0000-0002-8458-348X; Pfeffer, Sebastien/0000-0002-8458-348X; Sander, Chris/0000-0001-6059-6270; Hartmann, Gunther/0000-0003-1021-2018; Fulci, Valerio/0000-0002-1173-585X; Schermer, Bernhard/0000-0002-5194-9000; Frezzetti, Daniela/0000-0002-7500-5506; Hornung, Veit/0000-0002-4150-194X; Di Lauro, Roberto/0000-0001-9493-3036; Landthaler, Markus/0000-0002-1075-8734; De Vita, Gabriella/0000-0002-7302-1174; Zavolan, Mihaela/0000-0002-8832-2041; Hermida, Leandro Cruz/0000-0003-3887-518X; CHIARETTI, Sabina/0000-0001-8499-4492; Kamphorst, Alice/0000-0002-9230-9501; Bosio, Andreas/0000-0001-9776-2535; Rusu, Mirabela/0000-0002-0372-0367	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM073047] Funding Source: NIH RePORTER; NIGMS NIH HHS [P01 GM073047-03, P01 GM073047-01, P01 GM073047] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambros V, 2003, RNA, V9, P277, DOI 10.1261/rna.2183803; Aravin A, 2005, FEBS LETT, V579, P5830, DOI 10.1016/j.febslet.2005.08.009; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Baskerville S, 2005, RNA, V11, P241, DOI 10.1261/rna.7240905; Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590; Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031; Berezikov E, 2005, HUM MOL GENET, V14, pR183, DOI 10.1093/hmg/ddi271; Berezikov E, 2006, NAT GENET, V38, P1375, DOI 10.1038/ng1914; Berezikov E, 2006, GENOME RES, V16, P1289, DOI 10.1101/gr.5159906; Blow MJ, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-4-r27; Cao XW, 2006, ANNU REV NEUROSCI, V29, P77, DOI 10.1146/annurev.neuro.29.051605.112839; Caudy AA, 2002, GENE DEV, V16, P2491, DOI 10.1101/gad.1025202; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Cullen BR, 2006, NAT GENET, V38, pS25, DOI 10.1038/ng1793; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; De Vita G, 2005, MOL ENDOCRINOL, V19, P76, DOI 10.1210/me.2004-0172; Diederichs S, 2006, CANCER RES, V66, P6097, DOI 10.1158/0008-5472.CAN-06-0537; Eisenberg E, 2005, TRENDS GENET, V21, P77, DOI 10.1016/j.tig.2004.12.005; Farh KKH, 2005, SCIENCE, V310, P1817, DOI 10.1126/science.1121158; Gottwein E, 2006, J VIROL, V80, P5321, DOI 10.1128/JVI.02734-05; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Iwai N, 2005, BIOCHEM BIOPH RES CO, V331, P1439, DOI 10.1016/j.bbrc.2005.04.051; Jin P, 2004, NAT NEUROSCI, V7, P113, DOI 10.1038/nn1174; Kawahara Y, 2007, SCIENCE, V315, P1137, DOI 10.1126/science.1138050; Kim DDY, 2004, GENOME RES, V14, P1719, DOI 10.1101/gr.2855504; Kloosterman WP, 2006, NUCLEIC ACIDS RES, V34, P2558, DOI 10.1093/nar/gkl278; Kloosterman WP, 2006, NAT METHODS, V3, P27, DOI 10.1038/NMETH843; Kluiver J, 2006, LEUKEMIA, V20, P1931, DOI 10.1038/sj.leu.2404387; Kogler G, 2004, J EXP MED, V200, P123, DOI 10.1084/jem.20040440; Krutzfeldt J, 2006, NAT GENET, V38, pS14, DOI 10.1038/ng1799; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lagos-Quintana M, 2003, RNA, V9, P175, DOI 10.1261/rna.2146903; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Linsley PS, 2007, MOL CELL BIOL, V27, P2240, DOI 10.1128/MCB.02005-06; Luciano DJ, 2004, RNA, V10, P1174, DOI 10.1261/rna.7350304; Mallory AC, 2006, NAT GENET, V38, pS31, DOI 10.1038/ng1791; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; Murphy WJ, 2005, SCIENCE, V309, P613, DOI 10.1126/science.1111387; Nelson JM, 2006, J CORP FINANC, V12, P187, DOI 10.1016/j.jcorpfin.2005.07.002; Obernosterer G, 2006, RNA, V12, P1161, DOI 10.1261/rna.2322506; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Pfeffer S, 2005, NAT METHODS, V2, P269, DOI 10.1038/NMETH746; PFEFFER S, 2003, CURRENT PROTOCOLS MO; Plante I, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/64347; Plasterk RHA, 2006, CELL, V124, P877, DOI 10.1016/j.cell.2006.02.030; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Rajewsky N, 2006, NAT GENET, V38, pS8, DOI 10.1038/ng1798; Rigoutsos I, 2006, P NATL ACAD SCI USA, V103, P6605, DOI 10.1073/pnas.0601688103; Shivdasani Ramesh A, 2006, Blood, V108, P3646; Smalheiser NR, 2005, TRENDS GENET, V21, P322, DOI 10.1016/j.tig.2005.04.008; Sood P, 2006, P NATL ACAD SCI USA, V103, P2746, DOI 10.1073/pnas.0511045103; Stark A, 2005, CELL, V123, P1133, DOI 10.1016/j.cell.2005.11.023; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Takada S, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl653; Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.1444406; van Boxel-Dezaire AHH, 2006, IMMUNITY, V25, P361, DOI 10.1016/j.immuni.2006.08.014; Wienholds E, 2005, FEBS LETT, V579, P5911, DOI 10.1016/j.febslet.2005.07.070; Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Yang WD, 2006, NAT STRUCT MOL BIOL, V13, P13, DOI 10.1038/nsmb1041	69	2889	4169	6	342	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 29	2007	129	7					1401	1414		10.1016/j.cell.2007.04.040	http://dx.doi.org/10.1016/j.cell.2007.04.040			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188HQ	17604727	Green Accepted, Bronze			2022-12-28	WOS:000247911400024
J	Puthalakath, H; O'Reilly, LA; Gunn, P; Lee, L; Kelly, PN; Huntington, ND; Hughes, PD; Michalak, EM; McKimm-Breschkin, J; Motoyama, N; Gotoh, T; Akira, S; Bouillet, P; Strasser, A				Puthalakath, Hamsa; O'Reilly, Lorraine A.; Gunn, Priscilla; Lee, Lily; Kelly, Priscilla N.; Huntington, Nicholas D.; Hughes, Peter D.; Michalak, Ewa M.; McKimm-Breschkin, Jennifer; Motoyama, Noburo; Gotoh, Tomomi; Akira, Shizuo; Bouillet, Philippe; Strasser, Andreas			ER stress triggers apoptosis by activating BH3-only protein Bim	CELL			English	Article							ENDOPLASMIC-RETICULUM STRESS; FAMILY-MEMBER BIM; CELLS; PUMA; EXPRESSION; INHIBITOR; RESPONSES	Endoplasmic reticulum ( ER) stress caused by misfolded proteins or cytotoxic drugs can kill cells and although activation of this pathway has been implicated in the etiology of certain degenerative disorders its mechanism remains unresolved. Bim, a proapoptotic BH3-onlymember of the Bcl-2 family is required for initiation of apoptosis induced by cytokine deprivation or certain stress stimuli. Its proapoptotic activity can be regulated by several transcriptional or posttranslational mechanisms, such as ERK-mediated phosphorylation, promoting its ubiquitination and proteasomal degradation. We found that Bim is essential for ER stress-induced apoptosis in a diverse range of cell types both in culture and within the whole animal. ER stress activates Bim through two novel pathways, involving protein phosphatase 2A-mediated dephosphorylation, which prevents its ubiquitination and proteasomal degradation and CHOP-C/EBP alpha-mediated direct transcriptional induction. These results define the molecular mechanisms of ER stress-induced apoptosis and identify targets for therapeutic intervention in ER stress-related diseases.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia; CSIRO, Div Mol & Hlth Technol, Melbourne, Vic, Australia; Natl Ctr Geriatr & Gerontol, Natl Inst Longev Sci, Dept Geriatr Med, Aichi, Japan; Kumamoto Univ, Dept Mol Genet, Kumamoto 8608556, Japan; Osaka Univ, Dept Host Def, Suita, Osaka 5650871, Japan; Univ Melbourne, Dept Biochem, Bio21, Parkville, Vic 3052, Australia; Inst Pasteur, Dept Immunol, Cytokine & Lymphoid Dev Unit, F-75724 Paris, France	Walter & Eliza Hall Institute; University of Melbourne; Commonwealth Scientific & Industrial Research Organisation (CSIRO); National Center for Geriatrics & Gerontology; Kumamoto University; Osaka University; University of Melbourne; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Strasser, A (corresponding author), Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.	strasser@wehi.edu.au	Lee, Lily/GWZ-7968-2022; McKimm-Breschkin, Jennifer L/D-1880-2013; Puthalakath, Hamsa/B-8541-2011; Bouillet, Philippe/E-1241-2013; Huntington, NICHOLAS/AAV-4704-2020; Akira, Shizuo/C-3134-2009; Strasser, Andreas/C-7581-2013	Bouillet, Philippe/0000-0002-9012-6058; Huntington, NICHOLAS/0000-0002-5267-7211; Strasser, Andreas/0000-0002-5020-4891; Michalak, Ewa/0000-0002-5772-2122; McKimm-Breschkin, Jennifer/0000-0002-2345-6786	NATIONAL CANCER INSTITUTE [R01CA043540, R01CA080188] Funding Source: NIH RePORTER; NCI NIH HHS [CA 43540, CA 80188] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Becker EBE, 2006, NEURON, V49, P655, DOI 10.1016/j.neuron.2006.01.034; Bouillet P, 2005, CELL DEATH DIFFER, V12, P831, DOI 10.1038/sj.cdd.4401603; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Enders A, 2003, J EXP MED, V198, P1119, DOI 10.1084/jem.20030411; ETLINGER JD, 1977, P NATL ACAD SCI USA, V74, P54, DOI 10.1073/pnas.74.1.54; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Hildeman DA, 2002, IMMUNITY, V16, P759, DOI 10.1016/S1074-7613(02)00322-9; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kong M, 2004, SCIENCE, V306, P695, DOI 10.1126/science.1100537; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Ley R, 2005, CELL DEATH DIFFER, V12, P1008, DOI 10.1038/sj.cdd.4401688; Li JZ, 2006, J BIOL CHEM, V281, P7260, DOI 10.1074/jbc.M509868200; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Okada T, 2003, J BIOL CHEM, V278, P31024, DOI 10.1074/jbc.M300923200; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Rutishauser J, 2002, SWISS MED WKLY, V132, P211; Saleh M, 2006, NATURE, V440, P1064, DOI 10.1038/nature04656; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; Tsutsumi S, 2004, CELL DEATH DIFFER, V11, P1009, DOI 10.1038/sj.cdd.4401436; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108	35	1058	1097	1	92	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 29	2007	129	7					1337	1349		10.1016/j.cell.2007.04.027	http://dx.doi.org/10.1016/j.cell.2007.04.027			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188HQ	17604722	Bronze			2022-12-28	WOS:000247911400019
J	Jin, JP; Li, X; Gygi, SP; Harper, JW				Jin, Jianping; Li, Xue; Gygi, Steven P.; Harper, J. Wade			Dual E1 activation systems for ubiquitin differentially regulate E2 enzyme charging	NATURE			English	Article							CYCLE MUTANT TS85; AFFINITY PURIFICATION; PROTEIN-ACTIVATION; DEGRADATION; CONJUGATION; COMPLEX; TRANSCRIPTOMES; RECRUITMENT; RESOLUTION; MECHANISM	Modification of proteins with ubiquitin or ubiquitin-like proteins (UBLs) by means of an E1-E2-E3 cascade controls many signalling networks(1-3). Ubiquitin conjugation involves adenylation and thioesterification of the carboxy-terminal carboxylate of ubiquitin by the E1-activating enzyme Ube1 (Uba1 in yeast), followed by ubiquitin transfer to an E2-conjugating enzyme through a trans-thiolation reaction(4-7). Charged E2s function with E3s to ubiquitinate substrates(1). It is currently thought that Ube1/Uba1 is the sole E1 for charging of E2s with ubiquitin in animals and fungi(1,8). Here we identify a divergent E1 in vertebrates and sea urchin, Uba6, which specifically activates ubiquitin but not other UBLs in vitro and in vivo. Human Uba6 and Ube1 have distinct preferences for E2 charging in vitro, and their specificity depends in part on their C-terminal ubiquitin-fold domains, which recruit E2s. In tissue culture cells, Uba6 is required for charging a previously uncharacterized Uba6-specific E2 (Use1), whereas Ube1 is required for charging the cell-cycle E2s Cdc34A and Cdc34B. Our data reveal unexpected complexity in the pathways that control the conjugation of ubiquitin, in which dual E1s orchestrate the charging of distinct cohorts of E2s.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Harper, JW (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	wade_harper@hms.harvard.edu	Jin, Jianping/K-5002-2018	Jin, Jianping/0000-0003-4175-9104; Harper, Jeffrey/0000-0002-6944-7236	NIA NIH HHS [R01 AG011085] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bencsath KP, 2002, J BIOL CHEM, V277, P47938, DOI 10.1074/jbc.M207442200; Booth JW, 2002, EMBO J, V21, P251, DOI 10.1093/emboj/21.3.251; Chen XY, 2004, MOL CELL, V16, P839, DOI 10.1016/j.molcel.2004.11.011; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; Duda DM, 2005, J MOL BIOL, V349, P774, DOI 10.1016/j.jmb.2005.04.011; Eletr ZM, 2005, NAT STRUCT MOL BIOL, V12, P933, DOI 10.1038/nsmb984; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; GU X, IN PRESS MOL BIOL RE; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Huang DT, 2007, NATURE, V445, P394, DOI 10.1038/nature05490; Huang DT, 2005, MOL CELL, V17, P341, DOI 10.1016/j.molcel.2004.12.020; Huang DT, 2004, ONCOGENE, V23, P1958, DOI 10.1038/sj.onc.1207393; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Komatsu M, 2004, EMBO J, V23, P1977, DOI 10.1038/sj.emboj.7600205; Lake MW, 2001, NATURE, V414, P325, DOI 10.1038/35104586; Lehmann C, 2006, BIOCHEMISTRY-US, V45, P11, DOI 10.1021/bi051502y; Lois LM, 2005, EMBO J, V24, P439, DOI 10.1038/sj.emboj.7600552; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; Odorisio T, 1996, DEV BIOL, V180, P336, DOI 10.1006/dbio.1996.0305; PICKART CM, 1985, J BIOL CHEM, V260, P1573; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; Shringarpure R, 2003, J BIOL CHEM, V278, P311, DOI 10.1074/jbc.M206279200; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Walden H, 2003, MOL CELL, V12, P1427, DOI 10.1016/S1097-2765(03)00452-0; Walden H, 2003, NATURE, V422, P330, DOI 10.1038/nature01456	30	256	270	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 28	2007	447	7148					1135	U17		10.1038/nature05902	http://dx.doi.org/10.1038/nature05902			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183HT	17597759				2022-12-28	WOS:000247564600042
J	Lim, W; Eikelboom, JW; Ginsberg, JS				Lim, Wendy; Eikelboom, John W.; Ginsberg, Jeffrey S.			Pregnancy plus - Inherited thrombophilia and pregnancy associated venous thromboembolism	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FACTOR-V-LEIDEN; RISK; THROMBOSIS; COMPLICATIONS; MUTATION; MOTHER; WOMEN		McMaster Univ, HGH McMaster Clin, Dept Med, Hamilton, ON L9K 1H8, Canada; McMaster Univ, St Josephs Hosp, Dept Med, Hamilton, ON L9K 1H8, Canada; McMaster Univ, Med Ctr, Hamilton, ON L8S 4L8, Canada	McMaster University; McGill University; McMaster University; McMaster University	Eikelboom, JW (corresponding author), McMaster Univ, HGH McMaster Clin, Dept Med, Hamilton, ON L9K 1H8, Canada.	eikelbj@mcmaster.ca	Eikelboom, John/AAG-6117-2019; ginsberg, jeffrey s/ABC-1065-2020	Eikelboom, John/0000-0003-4126-1285; 				Bank I, 2004, ARCH INTERN MED, V164, P1932, DOI 10.1001/archinte.164.17.1932; Barbour LA, 1995, AM J OBSTET GYNECOL, V173, P1869, DOI 10.1016/0002-9378(95)90443-3; Chang Jeani, 2003, MMWR Surveill Summ, V52, P1; Dizon-Townson D, 2005, OBSTET GYNECOL, V106, P517, DOI 10.1097/01.AOG.0000173986.32528.ca; GINSBERG JS, 1992, THROMB HAEMOSTASIS, V67, P519; Greer IA, 1999, LANCET, V353, P1258, DOI 10.1016/S0140-6736(98)10265-9; HALL JG, 1980, AM J MED, V68, P122, DOI 10.1016/0002-9343(80)90181-3; Kupferminc MJ, 1999, NEW ENGL J MED, V340, P9, DOI 10.1056/NEJM199901073400102; Martinelli I, 2001, THROMB HAEMOSTASIS, V86, P800; MCKENNA R, 1983, J PEDIATR-US, V103, P325, DOI 10.1016/S0022-3476(83)80378-3; Middeldorp S, 2001, BRIT J HAEMATOL, V113, P553, DOI 10.1046/j.1365-2141.2001.02766.x; ORME ML, 1977, BRIT MED J, V1, P1564, DOI 10.1136/bmj.1.6076.1564; PABINGER I, 1994, THROMB HAEMOSTASIS, V71, P441; Pabinger I, 2000, Hematol J, V1, P37, DOI 10.1038/sj.thj.6200005; Ronsmans C, 2006, LANCET, V368, P1189, DOI 10.1016/S0140-6736(06)69380-X; Walker ID, 2001, BRIT J HAEMATOL, V114, P512, DOI 10.1046/j.1365-2141.2001.02981.x	16	31	32	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 23	2007	334	7607					1318	1321		10.1136/bmj.39205.484572.55	http://dx.doi.org/10.1136/bmj.39205.484572.55			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184MI	17585161	Green Published			2022-12-28	WOS:000247645400036
J	Montini, G; Toffolo, A; Zucchetta, P; Dall'Amico, R; Gobber, D; Calderan, A; Maschio, F; Pavanello, L; Molinari, PP; Scorrano, D; Zanchetta, S; Cassar, W; Brisotto, P; Corsini, A; Sartori, S; Da Dalt, L; Murer, L; Zacchello, G				Montini, Giovanni; Toffolo, Antonella; Zucchetta, Pietro; Dall'Amico, Roberto; Gobber, Daniela; Calderan, Alessandro; Maschio, Francesca; Pavanello, Luigi; Molinari, Pier Paolo; Scorrano, Dante; Zanchetta, Sergio; Cassar, Walburga; Brisotto, Paolo; Corsini, Andrea; Sartori, Stefano; Da Dalt, Liviana; Murer, Luisa; Zacchello, Graziella			Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non-inferiority trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							URINARY-TRACT-INFECTIONS; ATRIAL-FIBRILLATION; GENERAL-PRACTICE; PREVALENCE; MANAGEMENT	Objective To compare the efficacy of oral antibiotic treatment alone with treatment started parenterally and completed orally in children with a first episode of acute pyelonephritis. Design Multicentre, randomised controlled, open labelled, parallel group, non-inferiority trial. Setting 28 paediatric units in north east Italy. Participants 502 children aged 1 month to <7 years with clinical pyelonephritis. Intervention Oral co-amoxiclav (50 mg/kg/day in three doses for 10 days) or parenteral ceftriaxone (50 mg/kg/ day in a single parenteral dose) for three days, followed by oral co-amoxiclav (50 mg/kg/day in three divided doses for seven days). Main outcomes measures Primary outcome was the rate of renal scarring. Secondary measures of efficacy were time to defervescence ((37 C), reduction in inflammatory indices, and percentage with sterile urine after 72 hours. An exploratory subgroup analysis was conducted in the children in whom pyelonephritis was confirmed by dimercaptosuccinic acid (DMSA) scintigraphy within 10 days after study entry. Results Intention to treat analysis showed no significant differences between oral (n=244) and parenteral (n=258) treatment, both in the primary outcome (scarring scintigraphy at 12 months 27/197 (13.7%) v 36/203 (17.7%), difference in risk-4%, 95% confidence interval -11.1% to 3.1%) and secondary outcomes (time to defervescence 36.9 hours (SD 19.7) v34.3 hours (SD 20), mean difference 2.6 (-0.9 to 6.0); white cell count 9.8x10(9)/I (SD 3.5) v 9.5X10(9)/l(SD 3.1), mean difference 0.3 (-0.3 to 0.9); percentage with sterile urine 185/186 v 203/204, risk difference -0.05% (-1.5% to 1.4%)). Similar results were found in the subgroup of 278 children with confirmed acute pyelonephritis on scintigraphy at study entry. Conclusions Treatment with oral antibiotics is as effective as parenteral then oral treatment in the management of the first episode of clinical pyelonephritis in children.	Univ Padua, Azienda Osped, Dept Paediat, Nephrol Dialysis & Transplant Unit, I-35128 Padua, Italy; Univ Padua, Azienda Osped, Dept Nucl Med, I-35128 Padua, Italy; Univ Padua, Azienda Osped, Epidemiol Unit, I-35128 Padua, Italy; Bologna Hosp, Paediat Unit, Bologna, Italy; Belluno Hosp, Paediat Unit, Belluno, Italy; Soave Hosp, Paediat Unit, Verona, Italy; Bolzano Hosp, Paediat Unit, Bolzano, Italy; Montebelluna Hosp, Paediat Unit, Montebelluna, Italy; Paediat Unit, Bentivoglio, Italy; Univ Padua, Azienda Osped, Dept Paediat, Emergency Unit, I-35128 Padua, Italy	University of Padua; Azienda Ospedaliera - Universita di Padova; University of Padua; Azienda Ospedaliera - Universita di Padova; University of Padua; Azienda Ospedaliera - Universita di Padova; ULSS 1 Dolomiti; Ospedale di Belluno; Krankenhaus Bozen; ULSS 2 Marca TV; Ospedale Montebelluna; University of Padua; Azienda Ospedaliera - Universita di Padova	Montini, G (corresponding author), Univ Padua, Azienda Osped, Dept Paediat, Nephrol Dialysis & Transplant Unit, I-35128 Padua, Italy.	montini@pediatria.unipd.it	Montini, Giovanni/AAC-6612-2022; Sartori, Stefano/K-9498-2016; Zucchetta, Pietro/I-7102-2012; Murer, Luisa LM/I-8830-2018	Montini, Giovanni/0000-0002-7350-4475; Sartori, Stefano/0000-0002-0012-6848; Murer, Luisa LM/0000-0002-3010-2337				[Anonymous], 1991, J R Coll Physicians Lond, V25, P36; Benador D, 2001, ARCH DIS CHILD, V84, P241, DOI 10.1136/adc.84.3.241; Bloomfield P, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003772.pub2; Craig JC, 2004, BMJ-BRIT MED J, V328, P179, DOI 10.1136/bmj.328.7433.179; D'Agostino RB, 2003, STAT MED, V22, P169, DOI 10.1002/sim.1425; Davis RC, 2002, BRIT MED J, V325, P1156, DOI 10.1136/bmj.325.7373.1156; DORLANDS, 2003, ILLUSTRATED MED DICT; Downs SH, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.4.e54; Ghiro L, 2002, NEPHRON, V90, P8, DOI 10.1159/000046308; Hoberman A, 1999, PEDIATRICS, V104, P79, DOI 10.1542/peds.104.1.79; Jahnukainen T, 2005, PEDIATR NEPHROL, V20, P1043, DOI 10.1007/s00467-005-1898-5; JAKOBSSON B, 1994, ARCH DIS CHILD, V70, P111, DOI 10.1136/adc.70.2.111; Jungner Gunnar, 1968, PRINCIPLES PRACTICE, P34; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lip GYH, 1997, BRIT J GEN PRACT, V47, P285; Majeed A, 2001, HEART, V86, P284, DOI 10.1136/heart.86.3.284; Marjoram J, 1996, BRIT J GEN PRACT, V46, P283; Morgan S, 2002, BRIT J GEN PRACT, V52, P373; NATHAN DG, 1998, PEDIAT HEMATOLOGY; Onyeka B A, 2003, J Obstet Gynaecol, V23, P174; RUSHTON HG, 1992, J UROLOGY, V147, P1327, DOI 10.1016/S0022-5347(17)37555-9; SCHWARTZ GJ, 1976, PEDIATRICS, V58, P259; Somerville S, 2000, BRIT J GEN PRACT, V50, P727; Stewart S, 2001, HEART, V86, P516, DOI 10.1136/heart.86.5.516; Stokland E, 1996, J PEDIATR-US, V129, P815, DOI 10.1016/S0022-3476(96)70024-0; Sudlow M, 1998, BRIT MED J, V317, P327, DOI 10.1136/bmj.317.7154.327; TOLKOFFRUBIN NE, 2000, KIDNEY, P1449; Wald E, 2004, CURR OPIN PEDIATR, V16, P85, DOI 10.1097/00008480-200402000-00016; Wheeldon NM, 1998, HEART, V79, P50, DOI 10.1136/hrt.79.1.50; WINBERG J, 1974, Acta Paediatrica Scandinavica Supplement, P1; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; Zaki M, 2005, PEDIATR NEPHROL, V20, P1116, DOI 10.1007/s00467-005-1880-2	32	109	115	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 25	2007	335	7616					386	388A		10.1136/bmj.39244.692442.55	http://dx.doi.org/10.1136/bmj.39244.692442.55			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206VC	17611232	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000249210000028
J	Stefansson, H; Rye, DB; Hicks, A; Petursson, H; Ingason, A; Thorgeirsson, TE; Palsson, S; Sigmundsson, T; Sigurdsson, AP; Eiriksdottir, I; Soebech, E; Bliwise, D; Beck, JM; Rosen, A; Waddy, S; Trotti, LM; Iranzo, A; Thambisetty, M; Hardarson, GA; Kristjansson, K; Gudmundsson, LJ; Thorsteinsdottir, U; Kong, A; Gulcher, JR; Gudbjartsson, D; Stefansson, K				Stefansson, Hreinn; Rye, David B.; Hicks, Andrew; Petursson, Hjorvar; Ingason, Andres; Thorgeirsson, Thorgeir E.; Palsson, Stefan; Sigmundsson, Thordur; Sigurdsson, Albert P.; Eiriksdottir, Ingibjorg; Soebech, Emilia; Bliwise, Donald; Beck, Joseph M.; Rosen, Ami; Waddy, Salina; Trotti, Lynn M.; Iranzo, Alex; Thambisetty, Madhav; Hardarson, Gudmundur A.; Kristjansson, Kristleifur; Gudmundsson, Larus J.; Thorsteinsdottir, Unnur; Kong, Augustine; Gulcher, Jeffrey R.; Gudbjartsson, Daniel; Stefansson, Kari			A genetic risk factor for periodic limb movements in sleep	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESTLESS LEGS SYNDROME; GENERAL-POPULATION; PREVALENCE; SYMPTOMS; DISORDER; RLS; EPIDEMIOLOGY; ANTICIPATION; ASSOCIATION; VALIDATION	Background: The restless legs syndrome (RLS) is a common neurologic disorder characterized by an irresistible urge to move the legs. It is a major cause of sleep disruption. Periodic limb movements in sleep are detectable in most patients with RLS and represent an objective physiological metric. Methods: To search for sequence variants contributing to RLS, we performed a genomewide association study and two replication studies. To minimize phenotypic heterogeneity, we focused on patients with RLS who had objectively documented periodic limb movements in sleep. We measured serum ferritin levels, since iron depletion has been associated with the pathogenesis of RLS. Results: In an Icelandic discovery sample of patients with RLS and periodic limb movements in sleep, we observed a genomewide significant association with a common variant in an intron of BTBD9 on chromosome 6p21.2 (odds ratio, 1.8; P=2 x 10(sup -9)). This association was replicated in a second Icelandic sample (odds ratio, 1.8; P=4 x 10(sup -4)) and a U.S. sample (odds ratio, 1.5; P=4 x 10(sup -3)). With this variant, the population attributable risk of RLS with periodic limb movements was approximately 50%. An association between the variant and periodic limb movements in sleep without RLS (and the absence of such an association for RLS without periodic limb movements) suggests that we have identified a genetic determinant of periodic limb movements in sleep (odds ratio, 1.9; P=1 x 10(sup -17)). Serum ferritin levels were decreased by 13% per allele of the at-risk variant (95% confidence interval, 5 to 20; P=0.002). Conclusions: We have discovered a variant associated with susceptibility to periodic limb movements in sleep. The inverse correlation of the variant with iron stores is consistent with the suspected involvement of iron depletion in the pathogenesis of the disease.	deCODE Genet 1, IS-101 Reykjavik, Iceland; Landspitalinn Univ Hosp, Reykjavik, Iceland; Clin Res Ctr, Reykjavik, Iceland; Emory Univ, Dept Neurol, Atlanta, GA 30322 USA; Emory Univ, Program Sleep, Atlanta, GA 30322 USA; Hosp Clin Barcelona, Serv Neurol, Barcelona, Spain; Kings Coll London, Med Res Council Ctr Neurodegenerat Res, Inst Psychiat, London WC2R 2LS, England	Landspitali National University Hospital; Emory University; Emory University; University of Barcelona; Hospital Clinic de Barcelona; University of London; King's College London	Stefansson, K (corresponding author), deCODE Genet 1, Sturlugata 8, IS-101 Reykjavik, Iceland.	kstefans@decode.is	Stefansson, Kari/AAE-7187-2019; Hicks, Andrew/E-9518-2017	Thorgeirsson, Thorgeir/0000-0002-5149-7040; Hicks, Andrew/0000-0001-6320-0411; Stefansson, Hreinn/0000-0002-9331-6666; Gudbjartsson, Daniel/0000-0002-5222-9857; Kong, Augustine/0000-0001-8193-5438				Allen R, 2004, SLEEP MED, V5, P385, DOI 10.1016/j.sleep.2004.01.012; Allen Richard P, 2002, Sleep Med, V3, P467, DOI 10.1016/S1389-9457(02)00108-9; Allen RP, 1996, SLEEP, V19, P205, DOI 10.1093/sleep/19.3.205; Barrett JC, 2006, NAT GENET, V38, P659, DOI 10.1038/ng1801; Berger K, 2004, ARCH INTERN MED, V164, P196, DOI 10.1001/archinte.164.2.196; BONNET M, 1993, SLEEP, V16, P748; Devlin B, 2004, NAT GENET, V36, P1129, DOI 10.1038/ng1104-1129; Ekbom KA, 1960, NEUROLOGY, V10, P868, DOI 10.1212/WNL.10.9.868; Gretarsdottir S, 2005, NAT GENET, V37, P555, DOI 10.1038/ng0505-555a; Gretarsdottir S, 2003, NAT GENET, V35, P131, DOI 10.1038/ng1245; Gulcher JR, 2000, EUR J HUM GENET, V8, P739, DOI 10.1038/sj.ejhg.5200530; Hening WA, 2004, SLEEP MED, V5, P285, DOI 10.1016/j.sleep.2004.01.006; Hornyak M, 2006, SLEEP MED REV, V10, P169, DOI 10.1016/j.smrv.2005.12.003; Lazzarini A, 1999, MOVEMENT DISORD, V14, P111, DOI 10.1002/1531-8257(199901)14:1<111::AID-MDS1018>3.3.CO;2-0; Lee HB, 2006, SLEEP MED, V7, P642, DOI 10.1016/j.sleep.2006.03.015; MANTEL N, 1959, J NATL CANCER I, V22, P719; Merlino G, 2007, NEUROL SCI, V28, pS37, DOI 10.1007/s10072-007-0736-x; Mizuno S, 2005, PSYCHIAT CLIN NEUROS, V59, P461, DOI 10.1111/j.1440-1819.2005.01399.x; Montplaisir J, 1997, MOVEMENT DISORD, V12, P61, DOI 10.1002/mds.870120111; Ohayon MM, 2002, J PSYCHOSOM RES, V53, P547, DOI 10.1016/S0022-3999(02)00443-9; Ondo WG, 2000, NEUROLOGY, V55, P1404, DOI 10.1212/WNL.55.9.1404; Parker KP, 2002, NURS CLIN N AM, V37, P655, DOI 10.1016/S0029-6465(02)00031-2; Phillips B, 2006, CHEST, V129, P76, DOI 10.1378/chest.129.1.76; Phillips B, 2000, ARCH INTERN MED, V160, P2137, DOI 10.1001/archinte.160.14.2137; Rothdach AJ, 2000, NEUROLOGY, V54, P1064, DOI 10.1212/WNL.54.5.1064; Rye D, 2005, SLEEP, V28, pA270; Santamaria J, 2003, SLEEP MED, V4, P153, DOI 10.1016/S1389-9457(02)00153-3; Sforza E, 2005, SLEEP MED, V6, P407, DOI 10.1016/j.sleep.2005.01.004; Suominen P, 1998, BLOOD, V92, P2934, DOI 10.1182/blood.V92.8.2934.420k07_2934_2939; Trenkwalder C, 2005, LANCET NEUROL, V4, P465, DOI 10.1016/S1474-4422(05)70139-3; Trenkwalder C, 1996, MOVEMENT DISORD, V11, P389, DOI 10.1002/mds.870110407; Tuisku K, 2005, EUR J NEUROL, V12, P385, DOI 10.1111/j.1468-1331.2004.00960.x; Tuisku K, 2003, MOVEMENT DISORD, V18, P442, DOI 10.1002/mds.10381; Ulfberg J, 2001, EUR NEUROL, V46, P17, DOI 10.1159/000050750; Ulfberg J, 2001, MOVEMENT DISORD, V16, P1159, DOI 10.1002/mds.1209; Walters AS, 2003, SLEEP MED, V4, P121, DOI 10.1016/S1389-9457(02)00258-7; WALTERS AS, 1990, ARCH NEUROL-CHICAGO, V47, P1219, DOI 10.1001/archneur.1990.00530110079020; WALTERS AS, 1995, MOVEMENT DISORD, V10, P634, DOI 10.1002/mds.870100517; Walters AS, 1996, SLEEP, V19, P825; Winkelman JW, 2006, SLEEP MED, V7, P545, DOI 10.1016/j.sleep.2006.01.004; Woloshin S, 2006, PLOS MED, V3, P452, DOI 10.1371/journal.pmed.0030170	41	408	414	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 16	2007	357	7					639	647		10.1056/NEJMoa072743	http://dx.doi.org/10.1056/NEJMoa072743			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200EF	17634447				2022-12-28	WOS:000248746000003
J	Vickers, MR; MacLennan, AH; Lawton, B; Ford, D; Martin, J; Meredith, SK; DeStavola, BL; Rose, S; Dowell, A; Wikes, HC; Darbyshire, JH; Meade, TW				Vickers, Madge R.; MacLennan, Alastair H.; Lawton, Beverley; Ford, Deborah; Martin, Jeannett; Meredith, Sarah K.; DeStavola, Bianca L.; Rose, Sally; Dowell, Anthony; Wikes, Helen C.; Darbyshire, Janet H.; Meade, Tom W.		WISDOM Team	Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; PLUS PROGESTIN; BREAST-CANCER; YOUNGER; OLDER; RISK; HRT	Objective To assess the long term risks and benefits of hormone replacement therapy (combined hormone therapy versus placebo, and oestrogen alone versus combined hormone therapy). Design Multicentre, randomised, placebo controlled, double blind trial. Setting General practices in UK (384), Australia (91), and New Zealand (24). Participants Postmenopausal women aged 50-69 years at randomisation. At early closure of the trial, 56 583 had been screened, 8980 entered run-in, and 5692 (26% of target of 22 300) started treatment. Interventions Oestrogen only therapy (conjugated equine oestrogens 0.625 ring orally daily) or combined hormone therapy (conjugated equine oestrogens plus medroxyprogesterone acetate 2.5/5-0 ring orally daily). Ten years of treatment planned. Main outcome measures Primary outcomes: major cardiovascular disease, osteoporotic fractures, and breast cancer. Secondary outcomes: other cancers, death from all causes, venous thromboembolism, cerebrovascular disease, dementia, and quality of life. Results The trial was prematurely closed during recruitment, after a median follow-up of 11.9 months (interquartile range 7.1-19.6, total 6498 women years) in those enrolled, after the publication of early results from the women's health initiative study. The mean age of randomised women was 62.8 (SID 4.8) years. When combined hormone therapy (n=2196) was compared with placebo (n=2189), there was a significant increase in the number of major cardiovascular events (7 v 0, P=0.016) and venous thromboembolisms (22 v 3, hazard ratio 7.36 (95% CI 2.20 to 24.60)). There were no statistically significant differences in numbers of breast or other cancers (22 v 25, hazard ratio 0.88 (0.49 to 1.56)), cerebrovascular events (14 v 19, 0.73 (0.37 to 1.46)), fractures (40 v 58, 0.69 (0.46 to 1.03)), and overall deaths (8 v 5, 1.60 (0.52 to 4.89)). Comparison of combined hormone therapy (n=815) versus oestrogen therapy (n=826) outcomes revealed no significant differences. Conclusions Hormone replacement therapy increases cardiovascular and thromboembolic risk when started many years after the menopause. The results are consistent with the findings of the women's health initiative study and secondary prevention studies. Research is needed to assess the long term risks and benefits of starting hormone replacement therapy near the menopause, when the effect may be different.	Univ Adelaide, Womens & Childrens Hosp, Adelaide, SA 5006, Australia; MRC Gen Practice Res, London NW1 2ND, England; Wellington Sch Med & Hlth Sci, Dept Primary Hlth Care & Gen Practice, Wellington, New Zealand; MRC Clin Trials Unit, London NW1 2DA, England; Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England	University of Adelaide; Womens & Childrens Hospital Australia; University of Otago; Medical Research Council Clinical Trials Unit; University of London; London School of Hygiene & Tropical Medicine	MacLennan, AH (corresponding author), Univ Adelaide, Womens & Childrens Hosp, Adelaide, SA 5006, Australia.	alastair.maclennan@adelaide.edu.au	Golmohamad, Ramez/E-4848-2014	Golmohamad, Ramez/0000-0002-9958-7037; Lawton, Beverley/0000-0003-2447-8386	Medical Research Council [MC_U122797165] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Bajekal M, HLTH SURVEY ENGLAND; Cherry N, 2002, LANCET, V360, P2001; Clarke SC, 2002, BJOG-INT J OBSTET GY, V109, P1056, DOI 10.1111/j.1471-0528.2002.01544.x; Clarkson TB, 2005, MATURITAS, V51, P64, DOI 10.1016/j.maturitas.2005.02.016; Collett D, 1994, MODELLING SURVIVAL D; Cushman M, 2004, JAMA-J AM MED ASSOC, V292, P1573, DOI 10.1001/jama.292.13.1573; Grodstein F, 2006, J WOMENS HEALTH, V15, P35, DOI 10.1089/jwh.2006.15.35; Hoibraaten E, 2000, THROMB HAEMOSTASIS, V84, P961; Holmberg L, 2004, LANCET, V363, P453, DOI 10.1016/S0140-6736(04)15493-7; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Lawton B, 2003, BRIT MED J, V327, P845, DOI 10.1136/bmj.327.7419.845; MacLennan A, 2002, CLIMACTERIC, V5, P313, DOI 10.1080/713605308; Maclennan A H, 2004, Cochrane Database Syst Rev, pCD002978, DOI 10.1002/14651858.CD002978.pub2; MacLennan AH, 2006, MENOPAUSE, V13, P28, DOI 10.1097/01.gme.0000191204.38664.61; MacLennan AH, 2004, CLIMACTERIC, V7, P138, DOI 10.1080/13697130410001713733; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; Manson JE, 2007, NEW ENGL J MED, V356, P2591, DOI 10.1056/NEJMoa071513; MOEHRER B, 2003, COCHRANE DB SYST REV; Phillips LS, 2005, FERTIL STERIL, V83, P558, DOI 10.1016/j.fertnstert.2004.11.012; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Salpeter S, 2005, CLIMACTERIC, V8, P307, DOI 10.1080/13697130500345505; Salpeter SR, 2006, J GEN INTERN MED, V21, P363, DOI 10.1111/j.1525-1497.2006.00389.x; Salpeter SR, 2004, J GEN INTERN MED, V19, P791, DOI 10.1111/j.1525-1497.2004.30281.x; Stefanick ML, 2006, JAMA-J AM MED ASSOC, V295, P1647, DOI 10.1001/jama.295.14.1647; SUCKLING I, 2003, COCHRANE DB SYST REV; Tanko LB, 2006, CLIMACTERIC, V9, P169, DOI 10.1080/13697130600738765; VEENUS P, 2006, MATURITIAS, V55, P162; Vickers M, 2002, CLIMACTERIC, V5, P317, DOI 10.1080/713605309; VICKERS M, 1996, J BR MENOPAUSE SOC, V1, P9; Vickers Madge R, 2007, BMC Womens Health, V7, P2, DOI 10.1186/1472-6874-7-2; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Waters DD, 2002, JAMA-J AM MED ASSOC, V288, P2432, DOI 10.1001/jama.288.19.2432	33	166	170	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 4	2007	335	7613					239	+		10.1136/bmj.39266.425069.AD	http://dx.doi.org/10.1136/bmj.39266.425069.AD			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	201QC	17626056	Green Submitted, Green Published, Bronze, Green Accepted			2022-12-28	WOS:000248846700027
J	Einstein, AJ; Henzlova, MJ; Rajagopalan, S				Einstein, Andrew J.; Henzlova, Milena J.; Rajagopalan, Sanjay			Estimating risk of cancer associated with radiation exposure from 64-slice computed tomography coronary angiography	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ATOMIC-BOMB SURVIVORS; BREAST-CANCER; HEART; COMMITTEE; CARDIOLOGY; MORTALITY; DISEASE; COHORT; CT	Context Computed tomography coronary angiography (CTCA) has become a common diagnostic test, yet there are little data on its associated cancer risk. The recent Biological Effects of Ionizing Radiation (BEIR) VII Phase 2 report provides a framework for estimating lifetime attributable risk (LAR) of cancer incidence associated with radiation exposure from a CTCA study, using the most current data available on health effects of radiation. Objectives To determine the LAR of cancer incidence associated with radiation exposure from a 64-slice CTCA study and to evaluate the influence of age, sex, and scan protocol on cancer risk. Design, Setting, and Patients Organ doses from 64-slice CTCA to standardized phantom (computational model) male and female patients were estimated using Monte Carlo simulation methods, using standard spiral CT protocols. Age- and sex-specific LARs of individual cancers were estimated using the approach of BEIR VII and summed to obtain whole-body LARs. Main Outcome Measures Whole-body and organ LARs of cancer incidence. Results Organ doses ranged from 42 to 91 mSv for the lungs and 50 to 80 mSv for the female breast. Lifetime cancer risk estimates for standard cardiac scans varied from 1 in 143 for a 20-year-old woman to 1 in 3261 for an 80-year-old man. Use of simulated electrocardiographically controlled tube current modulation (ECTCM) decreased these risk estimates to 1 in 219 and 1 in 5017, respectively. Estimated cancer risks using ECTCM for a 60-year-old woman and a 60-year-old man were 1 in 715 and 1 in 1911, respectively. A combined scan of the heart and aorta had higher LARs, up to 1 in 114 for a 20-year-old woman. The highest organ LARs were for lung cancer and, in younger women, breast cancer. Conclusions These estimates derived from our simulation models suggest that use of 64-slice CTCA is associated with a nonnegligible LAR of cancer. This risk varies markedly and is considerably greater for women, younger patients, and for combined cardiac and aortic scans.	Columbia Univ, Med Ctr, Coll Phys & Surg, Dept Med,Div Cardiol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Radiol, New York, NY 10032 USA; Mt Sinai Med Ctr, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10029 USA; Mt Sinai Med Ctr, Marie Josee & Henry R Kravis Ctr Cardiovasc Hlth, New York, NY 10029 USA; Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA	Columbia University; Columbia University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University System of Ohio; Ohio State University	Einstein, AJ (corresponding author), Columbia Univ, Med Ctr, Coll Phys & Surg, Dept Med,Div Cardiol, 622 W 168th St,PH 10-408, New York, NY 10032 USA.	andrew.einstein@columbia.edu						ABRAMS HL, BEIR 7 VERY ERROR MO; American Nuclear Society, 2001, HLTH EFF LOW LEV RAD; [Anonymous], 1991, Ann ICRP, V21, P1; [Anonymous], 1995, Documents of the NRPB, V6, P1; Berman DS, 2006, J NUCL MED, V47, P74; Budoff MJ, 2006, CIRCULATION, V114, P1761, DOI 10.1161/CIRCULATIONAHA.106.178458; Carr ZA, 2002, RADIAT RES, V157, P668, DOI 10.1667/0033-7587(2002)157[0668:MNARTF]2.0.CO;2; Committee to Assess Health Risks From Exposure to Low Levels of Ionizing Radiation Board on Radiation Effects Research Division on Earth and Life Studies National Research Council of the National Academies, 2006, HLTH RISKS EXP LOW L; DAVIS FG, 1989, CANCER RES, V49, P6130; Elkind MM, 1999, RADIAT RES, V152, P567, DOI 10.2307/3580156; Gallagher MJ, 2007, ANN EMERG MED, V49, P125, DOI 10.1016/j.annemergmed.2006.06.043; Hamon M, 2006, J AM COLL CARDIOL, V48, P1896, DOI 10.1016/j.jacc.2006.08.028; Hausleiter J, 2006, CIRCULATION, V113, P1305, DOI 10.1161/CIRCULATIONAHA.105.602490; Health Physics Society, 1996, RAD RISK PERSP POS S RAD RISK PERSP POS S; HOWE GR, 1995, RADIAT RES, V142, P295, DOI 10.2307/3579139; *IMV MED INF DIV, 2005, 2004 CT CENS MARK SU; Jakobs TF, 2002, EUR RADIOL, V12, P1081, DOI 10.1007/s00330-001-1278-x; Kalender WA, 1999, EUR RADIOL, V9, P555, DOI 10.1007/s003300050709; Land CE, 2003, RADIAT RES, V160, P707, DOI 10.1667/RR3082; Mitka M, 2006, JAMA-J AM MED ASSOC, V295, P1989, DOI 10.1001/jama.295.17.1989; Preston DL, 2002, RADIAT RES, V158, P220, DOI 10.1667/0033-7587(2002)158[0220:REOBCR]2.0.CO;2; Scanlon PJ, 1999, J AM COLL CARDIOL, V33, P1756, DOI 10.1016/S0735-1097(99)00126-6; Stillman AE, 2007, INT J CARDIOVAS IMAG, V23, P415, DOI 10.1007/s10554-007-9226-8; Thom T, 2006, CIRCULATION, V113, pE85, DOI 10.1161/CIRCULATIONAHA.105.171600; THOMPSON DE, 1994, RADIAT RES, V137, pS17, DOI 10.2307/3578892; Tubiana M, 2005, DOSE EFFECT RELATION; United Nations, 2000, SOURC EFF ION RAD UN; Upton A. C., 2001, 136 NCRP; Valentin J., 2005, Annals of the ICRP, V35, pIII, DOI 10.1016/j.icrp.2005.01.001	29	1046	1116	1	50	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 18	2007	298	3					317	323		10.1001/jama.298.3.317	http://dx.doi.org/10.1001/jama.298.3.317			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	190US	17635892	Bronze			2022-12-28	WOS:000248086700026
J	Omichinski, JG				Omichinski, James G.			Biochemistry - Toward methylmercury bioremediation	SCIENCE			English	Editorial Material							BACTERIAL ORGANOMERCURIAL LYASE; MERCURY-RESISTANCE; MERB; CATALYSIS; TRANSPORT; REDUCTASE; PROTEIN; GENES		Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Omichinski, JG (corresponding author), Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada.	jg.omichinski@umontreal.ca						Barkay T, 2003, FEMS MICROBIOL REV, V27, P355, DOI 10.1016/S0168-6445(03)00046-9; BEGLEY TP, 1986, BIOCHEMISTRY-US, V25, P7192, DOI 10.1021/bi00370a064; Benison GC, 2004, BIOCHEMISTRY-US, V43, P8333, DOI 10.1021/bi049662h; Di Lello P, 2004, BIOCHEMISTRY-US, V43, P8322, DOI 10.1021/bi049669z; DITRI PA, 1978, ENVIRON MANAGE, V2, P3; GOPINATH E, 1987, J AM CHEM SOC, V109, P7903, DOI 10.1021/ja00259a061; Heaton ACP, 2005, WATER AIR SOIL POLL, V161, P137, DOI 10.1007/s11270-005-7111-4; Lyyra S, 2007, PLANT BIOTECHNOL J, V5, P254, DOI 10.1111/j.1467-7652.2006.00236.x; Meagher RB, 2000, CURR OPIN PLANT BIOL, V3, P153, DOI 10.1016/S1369-5266(99)00054-0; Melnick JG, 2007, SCIENCE, V317, P225, DOI 10.1126/science.1144314; MOORE MJ, 1990, ACCOUNTS CHEM RES, V23, P301, DOI 10.1021/ar00177a006; MORBY AP, 1995, MOL MICROBIOL, V17, P25, DOI 10.1111/j.1365-2958.1995.mmi_17010025.x; Pitts KE, 2002, BIOCHEMISTRY-US, V41, P10287, DOI 10.1021/bi0259148; Rossy E, 2004, FEBS LETT, V575, P86, DOI 10.1016/j.febslet.2004.08.041; SUMMERS AO, 1986, ANNU REV MICROBIOL, V40, P607, DOI 10.1146/annurev.mi.40.100186.003135	15	30	30	3	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 13	2007	317	5835					205	206		10.1126/science.1145810	http://dx.doi.org/10.1126/science.1145810			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189DC	17626871				2022-12-28	WOS:000247968600026
J	Dial, OE; Ashoori, RC; Pfeiffer, LN; West, KW				Dial, O. E.; Ashoori, R. C.; Pfeiffer, L. N.; West, K. W.			High-resolution spectroscopy of two-dimensional electron systems	NATURE			English	Article							DENSITY-OF-STATES; GAS; GAAS; LIQUID	Spectroscopic methods involving the sudden injection or ejection of electrons in materials are a powerful probe of electronic structure and interactions(1). These techniques, such as photoemission and tunnelling, yield measurements of the 'single-particle' density of states spectrum of a system(2). This density of states is proportional to the probability of successfully injecting or ejecting an electron in these experiments. It is equal to the number of electronic states in the system able to accept an injected electron as a function of its energy, and is among the most fundamental and directly calculable quantities in theories of highly interacting systems(3). However, the two-dimensional electron system (2DES), host to remarkable correlated electron states such as the fractional quantum Hall effect(4), has proved difficult to probe spectroscopically. Here we present an improved version of time-domain capacitance spectroscopy(5) that allows us to measure the single-particle density of states of a 2DES with unprecedented fidelity and resolution. Using the method, we perform measurements of a cold 2DES, providing direct measurements of interesting correlated electronic effects at energies that are difficult to reach with other techniques; these effects include the single-particle exchange-enhanced spin gap(6), single-particle lifetimes(7) in the quantum Hall system, and exchange splitting of Landau levels not at the Fermi surface.	MIT, Cambridge, MA 02139 USA; Bell Labs, Alcatel Lucent, Murray Hill, NJ 07974 USA	Massachusetts Institute of Technology (MIT); Alcatel-Lucent; AT&T	Ashoori, RC (corresponding author), MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	dial@alum.mit.edu; ashoori@mit.edu		/0000-0001-5031-1673				ALEINER IL, 1995, PHYS REV LETT, V74, P3435, DOI 10.1103/PhysRevLett.74.3435; ALEINER IL, 1995, PHYS REV B, V52, P11296, DOI 10.1103/PhysRevB.52.11296; ANDO T, 1974, J PHYS SOC JPN, V37, P1044, DOI 10.1143/JPSJ.37.1044; ASHOORI R, 1991, THEISS CORNELL U; ASHOORI RC, 1990, PHYS REV LETT, V64, P681, DOI 10.1103/PhysRevLett.64.681; BARDEEN J, 1961, PHYS REV LETT, V6, P57, DOI 10.1103/PhysRevLett.6.57; Chan HB, 1997, PHYS REV LETT, V79, P2867, DOI 10.1103/PhysRevLett.79.2867; CHAPLIK AV, 1971, SOV PHYS JETP-USSR, V33, P997; Dolgopolov VT, 1997, PHYS REV LETT, V79, P729, DOI 10.1103/PhysRevLett.79.729; EISENSTEIN JP, 1991, PHYS REV B, V44, P6511, DOI 10.1103/PhysRevB.44.6511; EISENSTEIN JP, 1992, PHYS REV LETT, V69, P3804, DOI 10.1103/PhysRevLett.69.3804; GIAEVER I, 1960, PHYS REV LETT, V5, P147, DOI 10.1103/PhysRevLett.5.147; HEDIN L, 1971, NBS SPEC PUBL, V323, P233; Iordanski SV, 2002, JETP LETT+, V75, P348, DOI 10.1134/1.1485265; Kukushkin IV, 1996, ADV PHYS, V45, P147, DOI 10.1080/00018739600101487; MACDONALD AH, 1986, PHYS REV B, V34, P2681, DOI 10.1103/PhysRevB.34.2681; Main PC, 2000, PHYS REV LETT, V84, P729, DOI 10.1103/PhysRevLett.84.729; MENDEZ EE, 1986, PHYS REV B, V33, P2893, DOI 10.1103/PhysRevB.33.2893; MURPHY SQ, 1995, PHYS REV B, V52, P14825, DOI 10.1103/PhysRevB.52.14825; PINCZUK A, 1988, PHYS REV LETT, V61, P2701, DOI 10.1103/PhysRevLett.61.2701; Popov VG, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.125310; SCHMELLER A, 1995, PHYS REV LETT, V75, P4290, DOI 10.1103/PhysRevLett.75.4290; SMITH AP, 1992, PHYS REV B, V45, P8829, DOI 10.1103/PhysRevB.45.8829; Stormer HL, 1999, REV MOD PHYS, V71, pS298, DOI 10.1103/RevModPhys.71.S298; USHER A, 1990, PHYS REV B, V41, P1129, DOI 10.1103/PhysRevB.41.1129; YACOBY A, 1991, PHYS REV LETT, V66, P1938, DOI 10.1103/PhysRevLett.66.1938	26	64	64	2	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 12	2007	448	7150					176	179		10.1038/nature05982	http://dx.doi.org/10.1038/nature05982			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	188QN	17625561	Green Submitted			2022-12-28	WOS:000247934500038
J	Mervis, J				Mervis, Jeffrey			Many voices, one message - Introduction	SCIENCE			English	Editorial Material																			0	3	3	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2007	317	5834					63	63		10.1126/science.317.5834.63	http://dx.doi.org/10.1126/science.317.5834.63			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186KD	17615334				2022-12-28	WOS:000247776700039
J	Putnam, NH; Srivastava, M; Hellsten, U; Dirks, B; Chapman, J; Salamov, A; Terry, A; Shapiro, H; Lindquist, E; Kapitonov, VV; Jurka, J; Genikhovich, G; Grigoriev, IV; Lucas, SM; Steele, RE; Finnerty, JR; Technau, U; Martindale, MQ; Rokhsar, DS				Putnam, Nicholas H.; Srivastava, Mansi; Hellsten, Uffe; Dirks, Bill; Chapman, Jarrod; Salamov, Asaf; Terry, Astrid; Shapiro, Harris; Lindquist, Erika; Kapitonov, Vladimir V.; Jurka, Jerzy; Genikhovich, Grigory; Grigoriev, Igor V.; Lucas, Susan M.; Steele, Robert E.; Finnerty, John R.; Technau, Ulrich; Martindale, Mark Q.; Rokhsar, Daniel S.			Sea anemone genome reveals ancestral eumetazoan gene repertoire and genomic organization	SCIENCE			English	Article							RELAXED MOLECULAR CLOCK; NEMATOSTELLA-VECTENSIS; EVOLUTION; EXPRESSION; ORIGINS; CNIDARIA; HOX; COMPLEXITY; JELLYFISH; DIVERSIFICATION	Sea anemones are seemingly primitive animals that, along with corals, jellyfish, and hydras, constitute the oldest eumetazoan phylum, the Cnidaria. Here, we report a comparative analysis of the draft genome of an emerging cnidarian model, the starlet sea anemone Nematostella vectensis. The sea anemone genome is complex, with a gene repertoire, exon-intron structure, and large-scale gene linkage more similar to vertebrates than to flies or nematodes, implying that the genome of the eumetazoan ancestor was similarly complex. Nearly one-fifth of the inferred genes of the ancestor are eumetazoan novelties, which are enriched for animal functions like cell signaling, adhesion, and synaptic transmission. Analysis of diverse pathways suggests that these gene "inventions" along the lineage leading to animals were likely already well integrated with preexisting eukaryotic genes in the eumetazoan progenitor.	Dept Energy Joint Genome Inst, Walnut Creek, CA 94598 USA; Univ Calif Berkeley, Ctr Integrat Genom, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Genet Informat Res Inst, Mountain View, CA 94043 USA; Univ Bergen, Sars Int Ctr Marine Mol Biol, N-5008 Bergen, Norway; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Ctr Dev Biol, Irvine, CA 92697 USA; Boston Univ, Dept Biol, Boston, MA 02215 USA; Univ Hawaii, Kewalo Marine Lab, Honolulu, HI 96813 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of Bergen; University of California System; University of California Irvine; University of California System; University of California Irvine; Boston University; University of Hawaii System	Rokhsar, DS (corresponding author), Dept Energy Joint Genome Inst, Walnut Creek, CA 94598 USA.	dsrokhsar@lbl.gov	Puigbò, Pere/A-2214-2008; Genikhovich, Grigory/AAU-9655-2021; Putnam, Nicholas/B-9968-2008; Terry, Astrid Y/A-2538-2011; Genikhovich, Grigory/AAV-2309-2020	Putnam, Nicholas/0000-0002-1315-782X; Terry, Astrid Y/0000-0002-5234-1224; Genikhovich, Grigory/0000-0003-4864-7770; Technau, Ulrich/0000-0003-4472-8258; Rokhsar, Daniel/0000-0002-8704-2224; Grigoriev, Igor/0000-0002-3136-8903	NLM NIH HHS [5 P41 LM006252-09] Funding Source: Medline; PHS HHS [THL007279F] Funding Source: Medline; NATIONAL LIBRARY OF MEDICINE [P41LM006252] Funding Source: NIH RePORTER	NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Adoutte A, 2000, P NATL ACAD SCI USA, V97, P4453, DOI 10.1073/pnas.97.9.4453; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; Bourque G, 2005, GENOME RES, V15, P98, DOI 10.1101/gr.3002305; BRIDGE D, 1992, P NATL ACAD SCI USA, V89, P8750, DOI 10.1073/pnas.89.18.8750; Byrum C.A., 2004, P33; Chen JY, 2002, DEV BIOL, V248, P182, DOI 10.1006/dbio.2002.0714; Chourrout D, 2006, NATURE, V442, P684, DOI 10.1038/nature04863; Ciccarelli FD, 2006, SCIENCE, V311, P1283, DOI 10.1126/science.1123061; Conery J S, 2001, Pac Symp Biocomput, P167; Darling JA, 2005, BIOESSAYS, V27, P211, DOI 10.1002/bies.20181; Dehal P, 2002, SCIENCE, V298, P2157, DOI 10.1126/science.1080049; Delsuc F, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-11; Douzery EJP, 2004, P NATL ACAD SCI USA, V101, P15386, DOI 10.1073/pnas.0403984101; Extavour CG, 2005, EVOL DEV, V7, P201, DOI 10.1111/j.1525-142X.2005.05023.x; Finnerty JR, 2004, SCIENCE, V304, P1335, DOI 10.1126/science.1091946; Finnerty JR, 1999, EVOL DEV, V1, P16, DOI 10.1046/j.1525-142x.1999.99010.x; Finnerty JR, 2003, EVOL DEV, V5, P331, DOI 10.1046/j.1525-142X.2003.03041.x; Fritzenwanker JH, 2004, DEV BIOL, V275, P389, DOI 10.1016/j.ydbio.2004.08.014; Fritzenwanker JH, 2002, DEV GENES EVOL, V212, P99, DOI 10.1007/s00427-002-0214-7; Galliot B, 2000, CURR OPIN GENET DEV, V10, P629, DOI 10.1016/S0959-437X(00)00141-6; Gauchat D, 2004, DEV BIOL, V275, P104, DOI 10.1016/j.ydbio.2004.07.037; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Haeckel E., 1866, GEN MORPHOLOGIE ORG, V1; Haeckel E., 1866, GEN MORPHOLOGIE ORG, V2; HAND C, 1994, ESTUARIES, V17, P501, DOI 10.2307/1352679; HAND C, 1992, BIOL BULL, V182, P169, DOI 10.2307/1542110; JACOB F, 1977, SCIENCE, V196, P1161, DOI 10.1126/science.860134; Jaillon O, 2004, NATURE, V431, P946, DOI 10.1038/nature03025; KAMM K, 2006, J EXP ZOOLOG B; Kamm K, 2006, CURR BIOL, V16, P920, DOI 10.1016/j.cub.2006.03.036; Kortschak RD, 2003, CURR BIOL, V13, P2190, DOI 10.1016/j.cub.2003.11.030; Kusserow A, 2005, NATURE, V433, P156, DOI 10.1038/nature03158; Lee PN, 2006, SEMIN CELL DEV BIOL, V17, P157, DOI 10.1016/j.semcdb.2006.05.002; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Long M, 2003, NAT REV GENET, V4, P865, DOI 10.1038/nrg1204; Lundin Lars-Gustav, 2003, Journal of Structural and Functional Genomics, V3, P53, DOI 10.1023/A:1022600813840; Martindale MQ, 2004, DEVELOPMENT, V131, P2463, DOI 10.1242/dev.01119; Martindale MQ, 2002, MOL PHYLOGENET EVOL, V24, P358, DOI 10.1016/S1055-7903(02)00208-7; Matus DQ, 2006, P NATL ACAD SCI USA, V103, P11195, DOI 10.1073/pnas.0601257103; Matus DQ, 2006, CURR BIOL, V16, P499, DOI 10.1016/j.cub.2006.01.052; Meaburn KJ, 2007, NATURE, V445, P379, DOI 10.1038/445379a; Miljkovic-Licina M, 2004, BIOSYSTEMS, V76, P75, DOI 10.1016/j.biosystems.2004.05.030; Miller DJ, 2005, TRENDS GENET, V21, P536, DOI 10.1016/j.tig.2005.08.002; Morris SC, 2006, PHILOS T R SOC B, V361, P1069, DOI 10.1098/rstb.2006.1846; Narbonne GM, 2005, ANNU REV EARTH PL SC, V33, P421, DOI 10.1146/annurev.earth.33.092203.122519; NIELSEN C, 2001, ANIMAL EVOLUTION, P51; Peterson KJ, 2004, P NATL ACAD SCI USA, V101, P6536, DOI 10.1073/pnas.0401670101; Pires-daSilva A, 2003, NAT REV GENET, V4, P39, DOI 10.1038/nrg977; Postlethwait JH, 2000, GENOME RES, V10, P1890, DOI 10.1101/gr.164800; Raible F, 2005, SCIENCE, V310, P1325, DOI 10.1126/science.1119089; Reber-Muller S, 2006, INT J DEV BIOL, V50, P377, DOI 10.1387/ijdb.052085sr; Rentzsch F, 2006, DEV BIOL, V296, P375, DOI 10.1016/j.ydbio.2006.06.003; Rogozin IB, 2003, CURR BIOL, V13, P1512, DOI 10.1016/S0960-9822(03)00558-X; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Ruvkun G, 1998, SCIENCE, V282, P2033, DOI 10.1126/science.282.5396.2033; Ryan JF, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-7-r64; Scholz CB, 2003, DEV GENES EVOL, V212, P563, DOI 10.1007/s00427-002-0272-x; Seipel K, 2005, DEV BIOL, V282, P14, DOI 10.1016/j.ydbio.2005.03.032; Seipel K, 2004, DEV DYNAM, V231, P303, DOI 10.1002/dvdy.20139; Seipel K, 2006, INT J DEV BIOL, V50, P589, DOI 10.1387/ijdb.062150ks; Sodergren E, 2006, SCIENCE, V314, P941, DOI 10.1126/science.1133609; Steele RE, 2002, DEV BIOL, V248, P199, DOI 10.1006/dbio.2002.0744; Sullivan James C, 2006, Genome Inform, V17, P219; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Technau U, 2005, TRENDS GENET, V21, P633, DOI 10.1016/j.tig.2005.09.007; Tyler S, 2003, INTEGR COMP BIOL, V43, P55, DOI 10.1093/icb/43.1.55; VALENTINE JW, 2004, ORIGIN PHYLA, P153; Weber JL, 1997, GENOME RES, V7, P401, DOI 10.1101/gr.7.5.401; Weinstock GM, 2006, NATURE, V443, P931, DOI 10.1038/nature05260; Wikramanayake AH, 2003, NATURE, V426, P446, DOI 10.1038/nature02113; Wolf YI, 2004, GENOME RES, V14, P29, DOI 10.1101/gr.1347404	71	1116	1280	6	188	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 6	2007	317	5834					86	94		10.1126/science.1139158	http://dx.doi.org/10.1126/science.1139158			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186KD	17615350	Green Submitted			2022-12-28	WOS:000247776700056
J	Sabbah, H; Biennier, L; Sims, IR; Georgievskii, Y; Klippenstein, SJ; Smith, IWM				Sabbah, Hassan; Biennier, Ludovic; Sims, Ian R.; Georgievskii, Yuri; Klippenstein, Stephen J.; Smith, Ian W. M.			Understanding reactivity at very low temperatures: The reactions of oxygen atoms with alkenes	SCIENCE			English	Article							NEUTRAL-NEUTRAL REACTIONS; KINETICS; O(P-3); OH	A remarkable number of reactions between neutral free radicals and neutral molecules have been shown to remain rapid down to temperatures as low as 20 kelvin. The rate coefficients generally increase as the temperature is lowered. We examined the reasons for this temperature dependence through a combined experimental and theoretical study of the reactions of O(P-3)atoms with a range of alkenes. The factors that control the rate coefficients were shown to be rather subtle, but excellent agreement was obtained between the experimental results and microcanonical transition state theory calculations based on ab initio representations of the potential energy surfaces describing the interaction between the reactants.	Univ Cambridge, Chem Lab, Cambridge CB2 1EW, England; Univ Rennes 1, CNRS,UMR 6627,Equipe Astrochim Expt, Inst Phys Rennes, Lab PALMS, F-35042 Rennes, France; Sandia Natl Labs, Combust Res Facil, Livermore, CA 94551 USA; Argonne Natl Lab, Div Chem, Argonne, IL 60439 USA	University of Cambridge; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes; United States Department of Energy (DOE); Sandia National Laboratories; United States Department of Energy (DOE); Argonne National Laboratory	Sims, IR (corresponding author), Univ Cambridge, Chem Lab, Lensfield Rd, Cambridge CB2 1EW, England.	ian.sims@univ-rennes1.fr; sjk@anl.gov; i.w.m.smith@bham.ac.uk	Biennier, Ludovic/O-1618-2014; Sabbah, Hassan/E-6202-2013; Sims, Ian R/F-8989-2014; Klippenstein, Stephen/AAF-1741-2021	Sims, Ian R/0000-0001-7870-1585; Biennier, Ludovic/0000-0001-7750-3042; Klippenstein, Stephen/0000-0001-6297-9187				Clarke JS, 1998, J PHYS CHEM A, V102, P9847, DOI 10.1021/jp982922i; CLARY DC, 1990, ANNU REV PHYS CHEM, V41, P61; CVETANOVIC RJ, 1987, J PHYS CHEM REF DATA, V16, P261, DOI 10.1063/1.555783; Georgievskii Y, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1899603; Georgievskii Y, 2007, J PHYS CHEM A, V111, P3802, DOI 10.1021/jp068430k; Greenwald EE, 2005, J PHYS CHEM A, V109, P6031, DOI 10.1021/jp058041a; Herbst E, 2005, J PHYS CHEM A, V109, P4017, DOI 10.1021/jp050461c; KLEMM RB, 1990, J PHYS CHEM-US, V94, P3354, DOI 10.1021/j100371a031; Nguyen TL, 2005, J PHYS CHEM A, V109, P7489, DOI 10.1021/jp052970k; ROWE BR, 1984, J CHEM PHYS, V80, P4915, DOI 10.1063/1.446513; SIMS IR, 1993, CHEM PHYS LETT, V211, P461, DOI 10.1016/0009-2614(93)87091-G; SIMS IR, 1994, J CHEM PHYS, V100, P4229, DOI 10.1063/1.467227; Smith IWM, 2006, FARADAY DISCUSS, V133, P137, DOI 10.1039/b600721j; Smith IWM, 2006, ANGEW CHEM INT EDIT, V45, P2842, DOI 10.1002/anie.200502747; Smith IWM, 2004, MON NOT R ASTRON SOC, V350, P323, DOI 10.1111/j.1365-2966.2004.07656.x; Troe J, 1997, ADV CHEM PHYS, V101, P819	16	112	113	2	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 6	2007	317	5834					102	105		10.1126/science.1142373	http://dx.doi.org/10.1126/science.1142373			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186KD	17615352				2022-12-28	WOS:000247776700059
J	Breen, DA; Breen, DP; Moore, JW; Breen, PA; O'Neill, D				Breen, David A.; Breen, David P.; Moore, John W.; Breen, Patricia A.; O'Neill, Desmond			Driving and dementia	BMJ-BRITISH MEDICAL JOURNAL			English	Review							MOTOR-VEHICLE CRASHES; OLDER DRIVERS; ALZHEIMER; ROAD		NHS Dumfries & Galloway, Dumfries, Scotland; Royal Infirm Edinburgh NHS Trust, Edinburgh, Midlothian, Scotland; Trinity Coll Dublin, Dublin, Ireland	Royal Infirmary of Edinburgh; University of Edinburgh; Trinity College Dublin	O'Neill, D (corresponding author), Adelaide & Meath Hosp, Dept Med Gerontol, Trinity Ctr Hlth Sci, Dublin 24, Ireland.	arhc@amnchi.ie	O'Neill, Desmond/D-1486-2013	O'Neill, Desmond/0000-0002-5542-9897				*ALZH SOC, DIAGN DRIV DEM; *AMA, 2004, PHYS GUID ASS COUNS; *BPS, 1999, FITN DRIV COGN; Carr DB, 2000, J AM GERIATR SOC, V48, P18, DOI 10.1111/j.1532-5415.2000.tb03023.x; COOPER PJ, 1993, J SAFETY RES, V24, P9, DOI 10.1016/0022-4375(93)90047-Q; DRACHMAN DA, 1993, NEUROLOGY, V43, P2448, DOI 10.1212/WNL.43.12.2448; DUBINSKY RM, 1993, J AM GERIATR SOC, V41, P890, DOI 10.1111/j.1532-5415.1993.tb06200.x; DUBINSKY RM, 1992, J AM GERIATR SOC, V40, P1112, DOI 10.1111/j.1532-5415.1992.tb01799.x; *DVLA, 2006, GLANC CURR MED STAND; FITTEN LJ, 1995, JAMA-J AM MED ASSOC, V273, P1360, DOI 10.1001/jama.273.17.1360; FRIEDLAND RP, 1988, ANN NEUROL, V24, P782, DOI 10.1002/ana.410240613; *GEN MED COUNC, 2004, CONF PROT PROV INF; GILLEY DW, 1991, ARCH INTERN MED, V151, P941, DOI 10.1001/archinte.151.5.941; HakamiesBlomqvist L, 1996, J AM GERIATR SOC, V44, P650, DOI 10.1111/j.1532-5415.1996.tb01826.x; Langford J, 2004, ACCIDENT ANAL PREV, V36, P993, DOI 10.1016/j.aap.2003.11.003; LUCASBLAUSTEIN MJ, 1988, J AM GERIATR SOC, V36, P1087, DOI 10.1111/j.1532-5415.1988.tb04394.x; McKenna P, 2004, BRIT J CLIN PSYCHOL, V43, P325, DOI 10.1348/0144665031752952; Molnar FJ, 2006, J AM GERIATR SOC, V54, P1809, DOI 10.1111/j.1532-5415.2006.00967.x; *ROYAL COLL PSYCH, 1996, PSYCHIAT B, V20, P631; Trobe JD, 1996, ARCH NEUROL-CHICAGO, V53, P411, DOI 10.1001/archneur.1996.00550050033021; TUOKKO H, 1995, J GERONTOL B-PSYCHOL, V50, pS173, DOI 10.1093/geronb/50B.3.S173; Viamonte Sarah M, 2006, Traffic Inj Prev, V7, P352, DOI 10.1080/15389580600791362; White S, 2000, GERONTOLOGY, V46, P146, DOI 10.1159/000022150; Zuin D, 2002, EUR J NEUROL, V9, P29, DOI 10.1046/j.1468-1331.2002.00296.x	24	50	52	1	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 30	2007	334	7608					1365	1369		10.1136/bmj.39233.585208.55	http://dx.doi.org/10.1136/bmj.39233.585208.55			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	185VX	17600026	Green Published			2022-12-28	WOS:000247739600035
J	Hawkes, N				Hawkes, Nigel			Collision, collusion, and confusion - Can choice, localisation, and other NHS agendas all be followed successfully at the same time?	BRITISH MEDICAL JOURNAL			English	Editorial Material												nigel.hawkes@thetimes.co.uk							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 30	2007	334	7608					1349	1349		10.1136/bmj.39255.707488.94	http://dx.doi.org/10.1136/bmj.39255.707488.94			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	185VX	17600021	Green Published			2022-12-28	WOS:000247739600028
J	Taylor, MW; Thacker, RW; Hentschel, U				Taylor, Michael W.; Thacker, Robert W.; Hentschel, Ute			Genetics - Evolutionary insights from sponges	SCIENCE			English	Editorial Material							CARBONIC-ANHYDRASE		Univ Auckland, Sch Biol Sci, Auckland, New Zealand; Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA; Univ Wurzburg, Res Ctr Infect Dis, D-97070 Wurzburg, Germany	University of Auckland; University of Alabama System; University of Alabama Birmingham; University of Wurzburg	Taylor, MW (corresponding author), Univ Auckland, Sch Biol Sci, Private Bag 92019, Auckland, New Zealand.	ute.hentschel@mail.uni-wuerzburg.de	Hentschel, Ute/ABD-6624-2021; Hentschel, Ute/H-8343-2013	Hentschel, Ute/0000-0003-0596-790X; Hentschel, Ute/0000-0003-0596-790X; Taylor, Michael/0000-0002-0463-7813				Aizenberg J, 2005, SCIENCE, V309, P275, DOI 10.1126/science.1112255; Dove PM, 2003, BIOMINERALISATION; Goodson MS, 2005, APPL ENVIRON MICROB, V71, P6934, DOI 10.1128/AEM.71.11.6934-6946.2005; Hallam SJ, 2006, P NATL ACAD SCI USA, V103, P18296, DOI 10.1073/pnas.0608549103; Henry RP, 1996, ANNU REV PHYSIOL, V58, P523, DOI 10.1146/annurev.ph.58.030196.002515; Jackson DJ, 2007, SCIENCE, V316, P1893, DOI 10.1126/science.1141560; Kumagai H, 2007, PLANT PHYSIOL, V143, P1293, DOI 10.1104/pp.106.095356; Larroux C, 2007, CURR BIOL, V17, P706, DOI 10.1016/j.cub.2007.03.008; Li CW, 1998, SCIENCE, V279, P879, DOI 10.1126/science.279.5352.879; Muller WEG, 2007, GENE, V395, P62, DOI 10.1016/j.gene.2007.02.014; Nichols SA, 2006, P NATL ACAD SCI USA, V103, P12451, DOI 10.1073/pnas.0604065103; Schmitt S, 2007, APPL ENVIRON MICROB, V73, P2067, DOI 10.1128/AEM.01944-06; Taylor MW, 2007, MICROBIOL MOL BIOL R, V71, P295, DOI 10.1128/MMBR.00040-06; Thacker RW, 2005, INTEGR COMP BIOL, V45, P369, DOI 10.1093/icb/45.2.369; Wiens M, 2007, MOL BIOL EVOL, V24, P792, DOI 10.1093/molbev/msl208	15	31	33	2	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 29	2007	316	5833					1854	1855		10.1126/science.1144387	http://dx.doi.org/10.1126/science.1144387			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183WI	17600204				2022-12-28	WOS:000247602700024
J	Ziurys, LM; Milam, SN; Apponi, AJ; Woolf, NJ				Ziurys, L. M.; Milam, S. N.; Apponi, A. J.; Woolf, N. J.			Chemical complexity in the winds of the oxygen-rich supergiant star VY Canis Majoris	NATURE			English	Article							MASS-LOSS; BEARING MOLECULES; RED GIANTS; CIRCUMSTELLAR; ABUNDANCES; ENVELOPES; CHEMISTRY; EMISSION; HCN; CONVECTION	The interstellar medium is enriched primarily by matter ejected from old, evolved stars(1,2). The outflows from these stars create spherical envelopes, which foster gas-phase chemistry(3-5). The chemical complexity in circumstellar shells was originally thought to be dominated by the elemental carbon to oxygen ratio(6). Observations have suggested that envelopes with more carbon than oxygen have a significantly greater abundance of molecules than their oxygen-rich analogues(7). Here we report observations of molecules in the oxygen-rich shell of the red supergiant star VY Canis Majoris (VY CMa). A variety of unexpected chemical compounds have been identified, including NaCl, PN, HNC and HCO+. From the spectral line profiles, the molecules can be distinguished as arising from three distinct kinematic regions: a spherical outflow, a tightly collimated, blue-shifted expansion, and a directed, red-shifted flow. Certain species (SiO, PN and NaCl) exclusively trace the spherical flow, whereas HNC and sulphur-bearing molecules (amongst others) are selectively created in the two expansions, perhaps arising from shock waves. CO, HCN, CS and HCO+ exist in all three components. Despite the oxygen-rich environment, HCN seems to be as abundant as CO. These results suggest that oxygen-rich shells may be as chemically diverse as their carbon counterparts.	Univ Arizona, Astrobiol Inst, NASA, Tucson, AZ 85721 USA; Univ Arizona, Dept Chem, Tucson, AZ 85721 USA; Univ Arizona, Arizona Radio Observ, Tucson, AZ 85721 USA; Univ Arizona, Dept Astron, Steward Observ, Tucson, AZ 85721 USA	National Aeronautics & Space Administration (NASA); University of Arizona; University of Arizona; National Radio Astronomy Observatory (NRAO); University of Arizona; University of Arizona	Ziurys, LM (corresponding author), Univ Arizona, Astrobiol Inst, NASA, 1306 E Univ Blvd, Tucson, AZ 85721 USA.	lziurys@as.arizona.edu	Milam, Stefanie/D-1092-2012	Milam, Stefanie/0000-0001-7694-4129				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BOWERS PF, 1983, ASTROPHYS J, V274, P733, DOI 10.1086/161485; BUJARRABAL V, 1994, ASTRON ASTROPHYS, V285, P247; Cernicharo J, 2000, ASTRON ASTROPHYS SUP, V142, P181, DOI 10.1051/aas:2000147; Cherchneff I, 2006, ASTRON ASTROPHYS, V456, P1001, DOI 10.1051/0004-6361:20064827; Duari D, 1999, ASTRON ASTROPHYS, V341, pL47; Glassgold AE, 1996, ANNU REV ASTRON ASTR, V34, P241, DOI 10.1146/annurev.astro.34.1.241; Highberger JL, 2003, ASTROPHYS J, V593, P393, DOI 10.1086/376446; Humphreys RM, 2005, ASTRON J, V129, P492, DOI 10.1086/426565; IBEN I, 1983, ANNU REV ASTRON ASTR, V21, P271, DOI 10.1146/annurev.aa.21.090183.001415; Kemper F, 2003, ASTRON ASTROPHYS, V407, P609, DOI 10.1051/0004-6361:20030701; LAURIA EF, 2006, 553 ALMA; Lim J, 1998, NATURE, V392, P575, DOI 10.1038/33352; Marvel KB, 2005, ASTRON J, V130, P261, DOI 10.1086/430746; MCCABE EM, 1979, NATURE, V281, P263, DOI 10.1038/281263a0; Monnier JD, 2000, ASTROPHYS J, V543, P868, DOI 10.1086/317127; Muller S, 2007, ASTROPHYS J, V656, P1109, DOI 10.1086/510513; NEJAD LAM, 1988, MON NOT R ASTRON SOC, V230, P79, DOI 10.1093/mnras/230.1.79; NERCESSIAN E, 1989, ASTRON ASTROPHYS, V210, P225; Olofsson H, 1997, ASTROPHYS SPACE SCI, V251, P31, DOI 10.1023/A:1000747630702; SAHAI R, 1992, ASTROPHYS J, V394, P320, DOI 10.1086/171585; SCHILKE P, 1992, ASTRON ASTROPHYS, V256, P595; SCHWARZSCHILD M, 1975, ASTROPHYS J, V195, P137, DOI 10.1086/153313; Smith N, 2004, MON NOT R ASTRON SOC, V349, pL31, DOI 10.1111/j.1365-2966.2004.07718.x; Smith N, 2001, ASTRON J, V121, P1111, DOI 10.1086/318748; Szczerba R, 2007, BALT ASTRON, V16, P134; Wallerstein G, 2001, PUBL ASTRON SOC PAC, V113, P954, DOI 10.1086/322920; Willson LA, 2000, ANNU REV ASTRON ASTR, V38, P573, DOI 10.1146/annurev.astro.38.1.573; Ziurys LM, 2006, P NATL ACAD SCI USA, V103, P12274, DOI 10.1073/pnas.0602277103; Zubko V, 2004, ASTROPHYS J, V610, P427, DOI 10.1086/421700	30	102	103	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 28	2007	447	7148					1094	1097		10.1038/nature05905	http://dx.doi.org/10.1038/nature05905			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183HT	17597755				2022-12-28	WOS:000247564600033
J	Robertson, CMT; Watt, MJ; Yasui, Y				Robertson, Charlene M. T.; Watt, Man-Joe; Yasui, Yutaka			Changes in the prevalence of cerebral palsy for children born very prematurely within a population-based program over 30 years	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BIRTH-WEIGHT INFANTS; GESTATIONAL-AGE; NEUROLOGIC DISABILITY; IMPROVED SURVIVAL; PRETERM INFANTS; TRENDS; GRAMS; MORTALITY; PROGNOSIS; PANORAMA	Context Although cerebral palsy (CP) among extremely premature infants has been reported as a major morbidity outcome, there are difficulties comparing published CP rates from many sites over various birth years. Objective To assess the changes in population-based, gestational age - specific prevalence rates of CP among extremely premature infants over 30 years. Design Prospective population-based longitudinal outcome study. Setting and Participants In Northern Alberta, 2318 infants 20 to 27 weeks' gestational age with birth weights of 500 to 1249 g were liveborn from 1974 through 2003. By 2 years of age, 1437 (62%) had died, 23 (1%) were lost to follow-up, and 858 (37%) had received multidisciplinary neurodevelopmental assessment. Main Outcome Measure Population-based prevalence rates of CP were determined. Logistic regression with linear spline was used to assess changes in CP prevalence over time. Results At age 2 years, 122 (14.2%) of 858 survivors had CP. This diagnosis was confirmed for each child by age 3 years or older. Among those whose gestational age was 20 to 25 weeks, population-based survival increased from 4% to 31% ( P <. 001), while CP prevalence per 1000 live births increased monotonically from 0 to 110 until the years 1992-1994 ( P <. 001) and decreased thereafter to 22 in the years 20012003 ( P <. 001). Among those whose gestational age was 26 to 27 weeks, population-based survival increased from 23% to between 75% and 80% ( P <. 001), while CP prevalence per 1000 live births increased monotonically from 15 to 155 until the years 1992-1994 ( P <. 001) and then decreased to 16 in the years 2001-2003 ( P <. 001). For all survivors born in the years 2001-2003, CP prevalence was 19 per 1000 live births. Conclusion Population-based CP prevalence rates for children whose gestational age was 20 to 27 weeks and whose birth weight ranged from 500 to 1249 g show steady reductions in the last decade with stable or reducing mortality, reversing trends prior to 1992-1994.	Glenrose Rehabil Hosp, Dept Pediat, Neonatal & Infant Follow Up Clin, Edmonton, AB T5G 0B7, Canada; Univ Alberta, Fac Med & Dent, Dept Pediat, Sect Neurosci, Edmonton, AB, Canada; Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada; Glenrose Rehabil Hosp, Dept Rehabil Med, Edmonton, AB T5G 0B7, Canada	University of Alberta; University of Alberta	Robertson, CMT (corresponding author), Glenrose Rehabil Hosp, Dept Pediat, Neonatal & Infant Follow Up Clin, Edmonton, AB T5G 0B7, Canada.	charlene.robertson@capitalhealth.ca	Yasui, Yutaka/E-2564-2015	Yasui, Yutaka/0000-0002-7717-8638				ALBERMAN E, 1984, EPIDEMIOLOGY CEREBRA, P172; ALLEN AC, 1994, CAN MED ASSOC J, V151, P547; Ancel PY, 2006, PEDIATRICS, V117, P828, DOI 10.1542/peds.2005-0091; AZIZ K, 1995, PEDIATRICS, V95, P837; Bax M, 2005, DEV MED CHILD NEUROL, V47, P571, DOI 10.1017/S001216220500112X; BAX M C, 1964, Dev Med Child Neurol, V6, P295; Bax M, 2006, JAMA-J AM MED ASSOC, V296, P1602, DOI 10.1001/jama.296.13.1602; BHUSHAN V, 1993, PEDIATRICS, V91, P1094; Blackmon LR, 2002, PEDIATRICS, V109, P330; Cans C, 2000, DEV MED CHILD NEUROL, V42, P816, DOI 10.1111/j.1469-8749.2000.tb00695.x; CASIRO O, 1995, J PEDIATR-US, V126, pS53, DOI 10.1016/S0022-3476(95)70008-0; Cooke RWI, 1999, ARCH DIS CHILD-FETAL, V80, pF115, DOI 10.1136/fn.80.2.F115; Dammann O, 2001, EARLY HUM DEV, V64, P79, DOI 10.1016/S0378-3782(01)00183-9; Doyle LW, 2001, PEDIATRICS, V108, P134, DOI 10.1542/peds.108.1.134; Emsley HCA, 1998, ARCH DIS CHILD-FETAL, V78, pF99, DOI 10.1136/fn.78.2.F99; Evans DJ, 2001, ARCH DIS CHILD-FETAL, V84, pF79, DOI 10.1136/fn.84.2.F79; *GOV SERV, ALB VIT STAT ANN REV; Grether JK, 2000, J PEDIATR-US, V136, P133, DOI 10.1016/S0022-3476(00)90071-4; Hagberg B, 2001, ACTA PAEDIATR, V90, P271, DOI 10.1080/080352501300067532; Harrell Jr FE, 2001, REGRESSION MODELING, P16; HENDSON L, 2005, 57 PED AC SOC ANN M; Himmelmann K, 2005, ACTA PAEDIATR, V94, P287, DOI 10.1111/j.1651-2227.2005.tb03071.x; Hintz SR, 2005, PEDIATRICS, V115, P1645, DOI 10.1542/peds.2004-2215; Jacobs SE, 2000, ACTA PAEDIATR, V89, P959; Lorenz JM, 2001, PEDIATRICS, V108, P1269, DOI 10.1542/peds.108.6.1269; Marlow N, 2004, ARCH DIS CHILD-FETAL, V89, pF224, DOI 10.1136/adc.2002.019752; Nelson KB, 2003, NEW ENGL J MED, V349, P1765, DOI 10.1056/NEJMsb035364; O'Shea TM, 1998, PEDIATRICS, V101, P642, DOI 10.1542/peds.101.4.642; PELIOWSKI A, 1998, PEDIATR RES, V43, P293; PHAROAH POD, 1990, ARCH DIS CHILD, V65, P602, DOI 10.1136/adc.65.6.602; PHAROAH POD, 1987, ARCH DIS CHILD, V62, P1035, DOI 10.1136/adc.62.10.1035; Pharoah POD, 1996, ARCH DIS CHILD-FETAL, V75, pF169, DOI 10.1136/fn.75.3.F169; Powell K, 2006, J MATERN-FETAL NEO M, V19, P43, DOI 10.1080/14767050500363519; R Development Core Team, 2005, LANG ENV STAT COMP; Robertson Charlene M T, 2002, J Obstet Gynaecol Can, V24, P138; ROBERTSON CMT, 1992, PEDIATRICS, V90, P750; Robertson CMT, 1998, CAN J NEUROL SCI, V25, P117, DOI 10.1017/S0317167100033710; Rosenbaum PL, 2002, JAMA-J AM MED ASSOC, V288, P1357, DOI 10.1001/jama.288.11.1357; ROSNER B, 2000, FUNDAMENTAL BIOSTATI, P296; Sauve RS, 1998, PEDIATRICS, V101, P438, DOI 10.1542/peds.101.3.438; SCHMIDT B, 2003, JAMA-J AM MED ASSOC, V289, P11142; STANLEY FJ, 1992, BRIT MED J, V304, P1658, DOI 10.1136/bmj.304.6843.1658; Surman G, 2003, DEV MED CHILD NEUROL, V45, P456, DOI 10.1017/S0012162203000859; Tommiska V, 2003, ARCH DIS CHILD-FETAL, V88, P29; Vincer MJ, 2006, PEDIATRICS, V118, pE1621, DOI 10.1542/peds.2006-1522; WATT JM, 1989, DEV MED CHILD NEUROL, V31, P766; Weber C, 2005, WIEN KLIN WOCHENSCHR, V117, P740, DOI 10.1007/s00508-005-0468-y; *WHO, 1997, INT CLASS DIS, P763; Wilson-Costello D, 2005, PEDIATRICS, V115, P997, DOI 10.1542/peds.2004-0221; Winter S, 2002, PEDIATRICS, V110, P1220, DOI 10.1542/peds.110.6.1220; Wood NS, 2000, NEW ENGL J MED, V343, P378, DOI 10.1056/NEJM200008103430601	51	111	117	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 27	2007	297	24					2733	2740		10.1001/jama.297.24.2733	http://dx.doi.org/10.1001/jama.297.24.2733			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	182UE	17595274	Bronze			2022-12-28	WOS:000247528700023
J	Burns, T; Catty, J; Dash, M; Roberts, C; Lockwood, A; Marshall, M				Burns, Tom; Catty, Jocelyn; Dash, Michael; Roberts, Chris; Lockwood, Austin; Marshall, Max			Use of intensive case management to reduce time in hospital in people with severe mental illness: systematic review and meta-regression	BRITISH MEDICAL JOURNAL			English	Article							SEVERE PSYCHOTIC ILLNESS; TRIAL	Objectives To explain why clinical trials of intensive case management for people with severe mental illness show such inconsistent effects on the use of hospital care. Design Systematic review with meta-regression techniques applied to data from randomised controlled trials. Data Sources Cochrane central register of controlled trials, CINAHL, Embase, Medline, and PsychINFO databases from inception to January 2007. Additional anonymised data on patients were obtained for multicentre trials. Review methods Included trials examined intensive case management compared with standard care or tow intensity case management for people with severe mental illness living in the community. We used a fidelity scale to rate adherence to the model of assertive community treatment. Multicentre trials were disaggregated into individual centres with fidelity data specific for each centre. A multivariate meta-regression used mean days per month in hospital as the dependent variable. Results We identified 1335 abstracts with a total of 5961 participants. Of these, 49 were eligible and 29 provided appropriate data. Trials with high hospital use at baseline (before the trial) or in the control group were more tikelyto find that intensive case management reduced the use of hospital care (coefficient -0.23, 95% confidence interval -0.36 to -0.09, for hospital use at baseline; -0.44, -0.57 to -0.31, for hospital use in control groups). Case management teams organised according to the model of assertive community treatment were more likely to reduce the use of hospital care (coefficient -0.31, -0.59 to -0.03), but this finding was less robust in sensitivity analyses and was not found for staffing levels recommended for assertive community treatment. Conclusions Intensive case management works best when participants tend to use a lot of hospital care and less well when they do not. When hospital use is high, intensive case management can reduce it, but it is less successful when hospital use is already low. The benefits of intensive case management might be marginal in settings that have already achieved low rates of bed use, and team Organisation is more important than the details of staffing. It might not be necessary to apply the full model of assertive community treatment to achieve reductions in inpatient care.	Univ Oxford, Warneford Hosp, Oxford OX3 7JX, England; St Georges Univ London, Div Mental Hlth, London SW17 0RE, England; Univ Manchester, Sch Epidemiol & Hlth Sci, Manchester, Lancs, England; Univ Manchester, Div Psychiat & Behav Sci, Preston, Lancs, England	University of Oxford; St Georges University London; University of Manchester; University of Manchester	Burns, T (corresponding author), Univ Oxford, Warneford Hosp, Oxford OX3 7JX, England.	Tom.burns@psych.ox.ac.uk						Burns T, 1999, LANCET, V353, P2185, DOI 10.1016/S0140-6736(98)12191-8; Burns T, 2001, Health Technol Assess, V5, P1; Burns T, 2000, BRIT J PSYCHIAT, V177, P427, DOI 10.1017/S0007125000227359; Catty J, 2002, PSYCHOL MED, V32, P383, DOI 10.1017/S0033291702005299; Department of Health, 1999, NAT SERV FRAM MENT H; Holloway F, 1991, Int J Soc Psychiatry, V37, P2, DOI 10.1177/002076409103700102; Killaspy H, 2006, BMJ-BRIT MED J, V332, P815, DOI 10.1136/bmj.38773.518322.7C; MCGREW JH, 1994, J CONSULT CLIN PSYCH, V62, P670, DOI 10.1037/0022-006X.62.4.670; RABEHESKETH S, 2001, GLLAMM MAN TECHN REP; Wright D, 2004, J COMMONW LIT, V39, P7, DOI 10.1177/0021989404044733	10	213	214	0	13	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	AUG 18	2007	335	7615					336	340		10.1136/bmj.39251.599259.55	http://dx.doi.org/10.1136/bmj.39251.599259.55			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	205LS	17631513	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000249115900028
J	Ding, M; Chao, D; Wang, G; Shen, K				Ding, Mei; Chao, Dan; Wang, George; Shen, Kang			Spatial regulation of an E3 ubiquitin ligase directs selective synapse elimination	SCIENCE			English	Article							VENTRAL NERVE CORD; C-ELEGANS; PROTEASOME SYSTEM; CAENORHABDITIS-ELEGANS; GLUTAMATE RECEPTORS; DIFFERENTIATION; DEGRADATION; SCF; NEUROTRANSMITTER; SYNAPTOGENESIS	Stereotyped synaptic connectivity can arise both by precise recognition between appropriate partners during synaptogenesis and by selective synapse elimination. The molecular mechanisms that underlie selective synapse removal are largely unknown. We found that stereotyped developmental elimination of synapses in the Caenorhabditis elegans hermaphrodite-specific motor neuron (HSNL) was mediated by an E3 ubiquitin ligase, a Skp1-cullin-F-box (SCF) complex composed of SKR-1 and the F-box protein SEL-10. SYG-1, a synaptic adhesion molecule, bound to SKR-1 and inhibited assembly of the SCF complex, thereby protecting nearby synapses. Thus, subcellular regulation of ubiquitin-mediated protein degradation contributes to precise synaptic connectivity through selective synapse elimination.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Stanford Univ, Program Neurosci, Stanford, CA 94305 USA	Stanford University; Stanford University	Shen, K (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.	kangshen@stanford.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048392] Funding Source: NIH RePORTER; NINDS NIH HHS [1R01NS048392] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bingol B, 2006, NATURE, V441, P1144, DOI 10.1038/nature04769; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Colledge M, 2003, NEURON, V40, P595, DOI 10.1016/S0896-6273(03)00687-1; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; DiAntonio A, 2004, ANNU REV NEUROSCI, V27, P223, DOI 10.1146/annurev.neuro.27.070203.144317; DiAntonio A, 2001, NATURE, V412, P449, DOI 10.1038/35086595; Dreier L, 2005, NEURON, V46, P51, DOI 10.1016/j.neuron.2004.12.058; Ehlers MD, 2003, NAT NEUROSCI, V6, P231, DOI 10.1038/nn1013; Hegde AN, 2002, NAT REV NEUROSCI, V3, P854, DOI 10.1038/nrn961; Hubbard EJA, 1997, GENE DEV, V11, P3182, DOI 10.1101/gad.11.23.3182; Jager S, 2004, P NATL ACAD SCI USA, V101, P12549, DOI 10.1073/pnas.0405087101; Juo P, 2004, CURR BIOL, V14, P2057, DOI 10.1016/j.cub.2004.11.010; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Liao EH, 2004, NATURE, V430, P345, DOI 10.1038/nature02647; Lichtman JW, 2000, NEURON, V25, P269, DOI 10.1016/S0896-6273(00)80893-4; Lin WC, 2005, NEURON, V46, P569, DOI 10.1016/j.neuron.2005.04.002; Misgeld T, 2005, P NATL ACAD SCI USA, V102, P11088, DOI 10.1073/pnas.0504806102; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Schaefer AM, 2000, NEURON, V26, P345, DOI 10.1016/S0896-6273(00)81168-X; Shen K, 2003, CELL, V112, P619, DOI 10.1016/S0092-8674(03)00113-2; Shen K, 2004, CELL, V116, P869, DOI 10.1016/S0092-8674(04)00251-X; Speese SD, 2003, CURR BIOL, V13, P899, DOI 10.1016/S0960-9822(03)00338-5; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; Waites CL, 2005, ANNU REV NEUROSCI, V28, P251, DOI 10.1146/annurev.neuro.27.070203.144336; Watts RJ, 2003, NEURON, V38, P871, DOI 10.1016/S0896-6273(03)00295-2; Zhen M, 2000, NEURON, V26, P331, DOI 10.1016/S0896-6273(00)81167-8; Zhen M, 1999, NATURE, V401, P371, DOI 10.1038/43886	27	84	98	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 17	2007	317	5840					947	951		10.1126/science.1145727	http://dx.doi.org/10.1126/science.1145727			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200RJ	17626846				2022-12-28	WOS:000248780200040
J	Molina, DM; Wetterholm, A; Kohl, A; McCarthy, AA; Niegowski, D; Ohlson, E; Hammarberg, T; Eshaghi, S; Haeggstrom, J; Nordlund, PR				Molina, Daniel Martinez; Wetterholm, Anders; Kohl, Andreas; McCarthy, Andrew A.; Niegowski, Damian; Ohlson, Eva; Hammarberg, Tove; Eshaghi, Said; Haeggstroem, Jesper Z.; Nordlund, Paer			Structural basis for synthesis of inflammatory mediators by human leukotriene C-4 synthase	NATURE			English	Article							GLUTATHIONE; REFINEMENT; ASTHMA	Cysteinyl leukotrienes are key mediators in inflammation and have an important role in acute and chronic inflammatory diseases of the cardiovascular and respiratory systems, in particular bronchial asthma. In the biosynthesis of cysteinyl leukotrienes, conversion of arachidonic acid forms the unstable epoxide leukotriene A(4) (LTA(4)). This intermediate is conjugated with glutathione (GSH) to produce leukotriene C-4 (LTC4) in a reaction catalysed by LTC4 synthase(1): this reaction is the key step in cysteinyl leukotriene formation. Here we present the crystal structure of the human LTC4 synthase in its apo and GSH- complexed forms to 2.00 and 2.15 angstrom resolution, respectively. The structure reveals a homotrimer, where each monomer is composed of four transmembrane segments. The structure of the enzyme in complex with substrate reveals that the active site enforces a horseshoe- shaped conformation on GSH, and effectively positions the thiol group for activation by a nearby arginine at the membrane - enzyme interface. In addition, the structure provides a model for how the omega- end of the lipophilic co- substrate is pinned at one end of a hydrophobic cleft, providing a molecular 'ruler' to align the reactive epoxide at the thiol of glutathione. This provides newstructural insights into themechanismof LTC4 formation, and also suggests that the observed binding and activation of GSHmight be common for a family of homologous proteins important for inflammatory and detoxification responses.	Karolinska Inst, Div Biophys, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Karolinska Inst, Div Chem, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Karolinska Inst, Struct Genom Consortium, S-17177 Stockholm, Sweden; Stockholm Univ, Dept Biochem & Biophys, S-10691 Stockholm, Sweden; European Mol Biol Lab, Grenoble Outstn, F-38042 Grenoble 9, France	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Stockholm University; European Molecular Biology Laboratory (EMBL)	Haeggstrom, J (corresponding author), Karolinska Inst, Div Biophys, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	said.eshaghi@ki.se; jesper.haeggstrom@ki.se; par.nordlund@ki.se	McCarthy, Andrew A/A-5926-2013	McCarthy, Andrew A/0000-0003-4478-0136				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bisgaard H, 2001, PEDIATRICS, V107, P381, DOI 10.1542/peds.107.2.381; COREY EJ, 1980, J AM CHEM SOC, V102, P1436, DOI 10.1021/ja00524a045; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DeLano W.L, PYMOL MOL GRAPHICS S; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; HANNA CJ, 1981, NATURE, V290, P343, DOI 10.1038/290343a0; Holm PJ, 2006, J MOL BIOL, V360, P934, DOI 10.1016/j.jmb.2006.05.056; IZUMI T, 1988, BIOCHIM BIOPHYS ACTA, V959, P305; Jakobsson PJ, 1999, PROTEIN SCI, V8, P689, DOI 10.1110/ps.8.3.689; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Lam BK, 2002, PROSTAG OTH LIPID M, V68-9, P511, DOI 10.1016/S0090-6980(02)00052-7; Leslie AGW, 1992, PROTEIN CRYSTALLOGR, V26, P27; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Morgenstern R, 2001, BIOCHEMISTRY-US, V40, P3378, DOI 10.1021/bi0023394; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Uson I, 1999, CURR OPIN STRUC BIOL, V9, P643, DOI 10.1016/S0959-440X(99)00020-2; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WEISS JW, 1982, SCIENCE, V216, P196, DOI 10.1126/science.7063880; YOSHIMOTO T, 1988, J CLIN INVEST, V81, P866, DOI 10.1172/JCI113396	28	155	159	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 2	2007	448	7153					613	U13		10.1038/nature06009	http://dx.doi.org/10.1038/nature06009			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	195XV	17632546				2022-12-28	WOS:000248446700048
J	Takaoka, A; Wang, Z; Choi, MK; Yanai, H; Negishi, H; Ban, T; Lu, Y; Miyagishi, M; Kodama, T; Honda, K; Ohba, Y; Taniguchi, T				Takaoka, Akinori; Wang, ZhiChao; Choi, Myoung Kwon; Yanai, Hideyuki; Negishi, Hideo; Ban, Tatsuma; Lu, Yan; Miyagishi, Makoto; Kodama, Tatsuhiko; Honda, Kenya; Ohba, Yusuke; Taniguchi, Tadatsugu			DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response	NATURE			English	Article							TOLL-LIKE RECEPTORS; PATTERN-RECOGNITION RECEPTORS; DOUBLE-STRANDED-RNA; RIG-I; ANTIVIRAL RESPONSES; GENE INDUCTION; HUMAN ZBP1; LOCALIZATION; VIRUSES; DOMAINS	Central to innate immunity is the sensing of pathogen-associated molecular patterns by cytosolic and membrane-associated receptors(1-4). In particular, DNA is a potent activator of immune responses during infection or tissue damage(5-7), and evidence indicates that, in addition to the membrane-associated Toll-like receptor 9, an unidentified cytosolic DNA sensor(s) can activate type I interferon (IFN) and other immune responses(8-10). Here we report on a candidate DNA sensor, previously named DLM-1 ( also called Z-DNA binding protein 1 (ZBP1))(11), for which biological function had remained unknown; we now propose the alternative name DAI (DNA-dependent activator of IFN-regulatory factors(12)). The artificial expression of otherwise IFN-inducible DAI (DLM-1/ ZBP1) in mouse fibroblasts selectively enhances the DNA-mediated induction of type I IFN and other genes involved in innate immunity. On the other hand, RNA interference of messenger RNA for DAI (DLM-1/ ZBP1) in cells inhibits this gene induction programme upon stimulation by DNA from various sources. Moreover, DAI (DLM-1/ZBP1) binds to double-stranded DNA and, by doing so, enhances its association with the IRF3 transcription factor and the TBK1 serine/threonine kinase. These observations underscore an integral role of DAI (DLM-1/ZBP1) in the DNA-mediated activation of innate immune responses, and may offer new insight into the signalling mechanisms underlying DNA- associated antimicrobial immunity and autoimmune disorders.	Univ Tokyo, Dept Immunol, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Dept 21st Century,Ctr Excellence Program, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Fac Med, Bunkyo Ku, Tokyo 1130033, Japan; Hokkaido Univ, Div Signaling Canc & Immunol, Inst Med Genet, Sapporo, Hokkaido 0600815, Japan; Hokkaido Univ, Dept Lab Med, Grad Sch Med, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Univ Tokyo, Dept Mol Biol & Med, Res Ctr Adv Sci & Technol, Meguro Ku, Tokyo 1538904, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Hokkaido University; Hokkaido University; University of Tokyo	Taniguchi, T (corresponding author), Univ Tokyo, Dept Immunol, Grad Sch Med, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.	tada@m.u-tokyo.ac.jp	Honda, Kenya/N-5297-2015; Ohba, Yusuke/E-7944-2011; Miyagishi, Makoto/L-8174-2016; Yanai, Hideyuki/AGK-5933-2022	Miyagishi, Makoto/0000-0001-7654-3616; Yanai, Hideyuki/0000-0002-0115-9000				Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Braun CS, 2003, BIOPHYS J, V84, P1114, DOI 10.1016/S0006-3495(03)74927-3; Creagh EM, 2006, TRENDS IMMUNOL, V27, P352, DOI 10.1016/j.it.2006.06.003; Deigendesch N, 2006, NUCLEIC ACIDS RES, V34, P5007, DOI 10.1093/nar/gkl575; Fu YN, 1999, GENE, V240, P157, DOI 10.1016/S0378-1119(99)00419-9; Ha SC, 2006, BBA-PROTEINS PROTEOM, V1764, P320, DOI 10.1016/j.bbapap.2005.12.012; Hochrein H, 2004, P NATL ACAD SCI USA, V101, P11416, DOI 10.1073/pnas.0403555101; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Honda K, 2006, NAT REV IMMUNOL, V6, P644, DOI 10.1038/nri1900; Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505; Ishii KJ, 2006, TRENDS IMMUNOL, V27, P525, DOI 10.1016/j.it.2006.09.002; Ishii KJ, 2006, NAT IMMUNOL, V7, P40, DOI 10.1038/ni1282; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Meylan E, 2006, NATURE, V442, P39, DOI 10.1038/nature04946; Napirei M, 2000, NAT GENET, V25, P177, DOI 10.1038/76032; Pham HT, 2006, BIOCHEM BIOPH RES CO, V348, P145, DOI 10.1016/j.bbrc.2006.07.061; Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998; Rich A, 2003, NAT REV GENET, V4, P566, DOI 10.1038/nrg1115; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Schwartz T, 2001, NAT STRUCT BIOL, V8, P761, DOI 10.1038/nsb0901-761; Stetson DB, 2006, IMMUNITY, V24, P93, DOI 10.1016/j.immuni.2005.12.003; SUGGS JW, 1986, NUCLEIC ACIDS RES, V14, P3703; Takaoka A, 2005, NATURE, V434, P243, DOI 10.1038/nature03308; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tokunaga T, 1999, JPN J INFECT DIS, V52, P1; Verthelyi D, 2003, TRENDS IMMUNOL, V24, P519, DOI 10.1016/S1471-4906(03)00243-6; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Yoshida H, 2005, NAT IMMUNOL, V6, P49, DOI 10.1038/ni1146	30	1212	1287	9	143	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 26	2007	448	7152					501	U14		10.1038/nature06013	http://dx.doi.org/10.1038/nature06013			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	193VG	17618271				2022-12-28	WOS:000248302700053
J	Goldacre, B				Goldacre, Ben			Medicine and the media - MMR: the scare stories are back	BRITISH MEDICAL JOURNAL			English	Editorial Material												ben@badscience.net		Goldacre, Ben/0000-0002-5127-4728					0	13	13	0	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 21	2007	335	7611					126	127		10.1136/bmj.39280.447419.59	http://dx.doi.org/10.1136/bmj.39280.447419.59			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195RA	17634177	Green Published			2022-12-28	WOS:000248428100030
J	Britton, J; McNeill, A; Arnott, D				Britton, John; McNeill, Ann; Arnott, Deborah			Tony Blair's 10 years of tobacco control	LANCET			English	Editorial Material									Univ Nottingham, Div Epidemiol & Publ Hlth, Nottingham NG5 1PB, England; Act Smoking & Hlth, London, England	University of Nottingham	Britton, J (corresponding author), Univ Nottingham, Div Epidemiol & Publ Hlth, Nottingham NG5 1PB, England.	j.britton@virgin.net		McNeill, Ann/0000-0002-6223-4000				*DEP HLTH, 2003, ANN REP CHIEF MED OF; Department of Health, 1998, SMOK KILLS WHIT PAP; Department of Health, 2004, CHOOS HLTH MAK HLTH; Fichtenberg CM, 2002, BMJ-BRIT MED J, V325, P188, DOI 10.1136/bmj.325.7357.188; Jarvis MJ., 2006, SOCIAL DETERMINANTS, P224; Joossens L, 2006, TOB CONTROL, V15, P247, DOI 10.1136/tc.2005.015347; *LAB PART, 1997, NEW LAB BEC BRIT DES; Wanless D., 2004, SECURING GOOD HLTH W	8	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 14	2007	370	9582					110	112		10.1016/s0140-6736(07)60985-4	http://dx.doi.org/10.1016/s0140-6736(07)60985-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	190WP	17604097				2022-12-28	WOS:000248091600007
J	Picchioni, MM; Murray, RM				Picchioni, Marco M.; Murray, Robin M.			Schizophrenia	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CANNABIS USE; ANTIPSYCHOTIC-DRUGS; ADULT PSYCHOSIS; METAANALYSIS; ENVIRONMENT; URBANICITY; ONSET; RISK		Kings Coll London, Inst Psychiat, Div Psychol Med, London SE5 8AF, England	University of London; King's College London	Picchioni, MM (corresponding author), Kings Coll London, Inst Psychiat, Div Psychol Med, London SE5 8AF, England.	m.picchioni@iop.kcl.ac.uk	Murray, Robin M/F-8658-2012; Picchioni, Marco M/E-3300-2010	Murray, Robin M/0000-0003-0829-0519; Picchioni, Marco M/0000-0001-6681-147X				ADAMS CE, 2003, SCHIZOPHRENIA FULL N; Arseneault L, 2002, BRIT MED J, V325, P1212, DOI 10.1136/bmj.325.7374.1212; Boydell J, 2004, SOC PSYCH PSYCH EPID, V39, P597, DOI 10.1007/s00127-004-0789-6; Boydell J, 2001, BMJ-BRIT MED J, V323, P1336, DOI 10.1136/bmj.323.7325.1336; Broome MR, 2005, SCHIZOPHR RES, V79, P23, DOI 10.1016/j.schres.2005.02.007; Cardno AG, 1999, ARCH GEN PSYCHIAT, V56, P162, DOI 10.1001/archpsyc.56.2.162; Caspi A, 2005, BIOL PSYCHIAT, V57, P1117, DOI 10.1016/j.biopsych.2005.01.026; Hanssen M, 2005, BRIT J CLIN PSYCHOL, V44, P181, DOI 10.1348/014466505X29611; Henquet C, 2005, SCHIZOPHRENIA BULL, V31, P608, DOI 10.1093/schbul/sbi027; Jablensky A, 2000, EUR ARCH PSY CLIN N, V250, P274, DOI 10.1007/s004060070002; Jones C, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000524.PUB2; Jones PB, 2006, ARCH GEN PSYCHIAT, V63, P1079, DOI 10.1001/archpsyc.63.10.1079; KENDLER KS, 1993, ARCH GEN PSYCHIAT, V50, P527; Lieberman JA, 2005, NEW ENGL J MED, V353, P1209, DOI 10.1056/NEJMoa051688; Marshall M, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004718.pub2; McGrath JJ, 2006, SCHIZOPHRENIA BULL, V32, P195, DOI 10.1093/schbul/sbi052; McGrath JJ, 2004, SCHIZOPHR RES, V67, P65; NICE, 2002, GUID US NEW AT ANT D; Pedersen CB, 2001, ARCH GEN PSYCHIAT, V58, P1039, DOI 10.1001/archpsyc.58.11.1039; Perkins DO, 2005, AM J PSYCHIAT, V162, P1785, DOI 10.1176/appi.ajp.162.10.1785; Robinson D, 1999, ARCH GEN PSYCHIAT, V56, P241, DOI 10.1001/archpsyc.56.3.241; Saha S, 2005, PLOS MED, V2, P413, DOI 10.1371/journal.pmed.0020141; Taylor D, 2005, MAUDSLEY 2005 2006 P; Wahlbeck K, 1999, AM J PSYCHIAT, V156, P990	24	176	180	2	72	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 14	2007	335	7610					91	95		10.1136/bmj.39227.616447.BE	http://dx.doi.org/10.1136/bmj.39227.616447.BE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	192JM	17626963	Green Published			2022-12-28	WOS:000248197500041
J	Stern, N; Taylor, C				Stern, Nicholas; Taylor, Chris			Climate change: Risk, ethics, and the Stern Review	SCIENCE			English	Editorial Material																		Hepburn C.J., 2007, WORKSH EC CLIM CHANG; Nordhaus W, 2007, SCIENCE, V317, P201, DOI 10.1126/science.1137316; Ramsey FP, 1928, ECON J, V38, P543, DOI 10.2307/2224098; STERN N, 2007, IN PRESS CASE ACTION; STERN N, 2007, IN PRESS VALUE JUDGM; Stern N., 2006, EC CLIMATE CHANGE ST; STERNER T, 2007, IN PRESS EVEN STERNE	7	78	79	2	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 13	2007	317	5835					203	204		10.1126/science.1142920	http://dx.doi.org/10.1126/science.1142920			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	189DC	17626870				2022-12-28	WOS:000247968600025
J	Campbell, S; Reeves, D; Kontopantelis, E; Middleton, E; Sibbald, B; Roland, M				Campbell, Stephen; Reeves, David; Kontopantelis, Evangelos; Middleton, Elizabeth; Sibbald, Bonnie; Roland, Martin			Quality of primary care in England with the introduction of pay for performance	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENGLISH GENERAL-PRACTICE; OF-CARE; UNINTENDED CONSEQUENCES; MEDICAL-PRACTICE; FOR-PERFORMANCE; UNITED-KINGDOM; MOTIVATION; PHYSICIANS; CRITERIA; ANGINA		Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England	University of Manchester	Campbell, S (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Oxford Rd, Manchester M13 9PL, Lancs, England.		Kontopantelis, Evangelos/H-2966-2019; Greiver, Michelle/N-8764-2015; Reeves, David/H-6203-2014	Kontopantelis, Evangelos/0000-0001-6450-5815; Greiver, Michelle/0000-0001-8957-0285; Reeves, David/0000-0001-6377-6859; Campbell, Stephen/0000-0002-2328-4136; Roland, Martin/0000-0002-8533-3060	Medical Research Council [MR/K006665/1, MC_PC_13042] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		[Anonymous], BBC NEWS HLTH; Asch SM, 2004, ANN INTERN MED, V141, P938, DOI 10.7326/0003-4819-141-12-200412210-00010; Baker D, 2003, J EPIDEMIOL COMMUN H, V57, P417, DOI 10.1136/jech.57.6.417; British Medical Association, QUAL OUTC FRAM GUID; Brook R H, 1986, Int J Technol Assess Health Care, V2, P53; Campbell S, 2003, BRIT J GEN PRACT, V53, P298; Campbell S, 2001, BRIT MED J, V322, P1580, DOI 10.1136/bmj.322.7302.1580; Campbell S, 2005, FAMILY MED DAWN 21ST, P391; CAMPBELL S, 2002, NATL TRACKER SURVEY; Campbell SM, 2005, BMJ-BRIT MED J, V331, P1121, DOI 10.1136/bmj.38632.611123.AE; Campbell SM, 2001, BMJ-BRIT MED J, V323, P784, DOI 10.1136/bmj.323.7316.784; Campbell SM, 2002, QUAL SAF HEALTH CARE, V11, P125, DOI 10.1136/qhc.11.2.125; Campbell SM, 1999, QUAL HEALTH CARE, V8, P6, DOI 10.1136/qshc.8.1.6; Campbell Stephen, 2005, J Health Serv Res Policy, V10, P31, DOI 10.1258/1355819052801813; Checkland K, 2004, QUAL SAF HEALTH CARE, V13, P130, DOI 10.1136/qshc.2003.009720; Collett D., 1991, MODELLING BINARY DAT; Committee on Redesigning Health Insurance Performance Measures PaPIP, 2007, REW PROV PERF AL INC; Deci EL, 1999, PSYCHOL BULL, V125, P627, DOI 10.1037/0033-2909.125.6.627; Doran T, 2006, NEW ENGL J MED, V355, P375, DOI 10.1056/NEJMsa055505; Epstein AM, 2004, NEW ENGL J MED, V350, P406, DOI 10.1056/NEJMsb035374; FISHER ES, 2006, N ENGL J MED; Gagne M, 2005, J ORGAN BEHAV, V26, P331, DOI 10.1002/job.322; Galvin R, 2006, HEALTH AFFAIR, V25, pW412, DOI 10.1377/hlthaff.25.w412; Ganz DA, 2007, MED CARE, V45, P8, DOI 10.1097/01.mlr.0000241115.31531.15; Gosden T, 2001, J Health Serv Res Policy, V6, P44, DOI 10.1258/1355819011927198; Marshall M, 2003, QUAL SAF HEALTH CARE, V12, P397, DOI 10.1136/qhc.12.6.397; McElduff P, 2004, QUAL SAF HEALTH CARE, V13, P191, DOI 10.1136/qshc.2003.007401; McGlynn EA, 2007, MED CARE, V45, P3, DOI 10.1097/01.mlr.0000252647.00688.d2; Middleton E, 2003, BMJ-BRIT MED J, V326, P854, DOI 10.1136/bmj.326.7394.854; Roland M, 2004, NEW ENGL J MED, V351, P1448, DOI 10.1056/NEJMhpr041294; Roland M, 2006, PRIM HEALTH CARE RES, V7, P18, DOI DOI 10.1191/1463423606PC2720A; Smith P., 1995, INT J PUBLIC ADMIN, V18, P277, DOI DOI 10.1080/01900699508525011; Spooner A, 2001, J Health Serv Res Policy, V6, P145, DOI 10.1258/1355819011927396; Whalley D, 2006, BRIT J GEN PRACT, V56, P87	34	282	283	2	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 12	2007	357	2					181	190		10.1056/NEJMsr065990	http://dx.doi.org/10.1056/NEJMsr065990			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	188NX	17625132				2022-12-28	WOS:000247927700016
J	Tinetti, G; Vidal-Madjar, A; Liang, MC; Beaulieu, JP; Yung, Y; Carey, S; Barber, RJ; Tennyson, J; Ribas, I; Allard, N; Ballester, GE; Sing, DK; Selsis, F				Tinetti, Giovanna; Vidal-Madjar, Alfred; Liang, Mao-Chang; Beaulieu, Jean-Philippe; Yung, Yuk; Carey, Sean; Barber, Robert J.; Tennyson, Jonathan; Ribas, Ignasi; Allard, Nicole; Ballester, Gilda E.; Sing, David K.; Selsis, Franck			Water vapour in the atmosphere of a transiting extrasolar planet	NATURE			English	Article							TRANSMISSION SPECTRA; THERMAL EMISSION; LIGHT CURVES; LINE; ABSORPTION; HYDROGEN	Water is predicted to be among the most abundant (if not the most abundant) molecular species after hydrogen in the atmospheres of close-in extrasolar giant planets ('hot Jupiters')(1,2). Several attempts have been made to detect water on such planets, but have either failed to find compelling evidence for it(3,4) or led to claims that should be taken with caution(5). Here we report an analysis of recent observations of the hot Jupiter HD 189733b (ref. 6) taken during the transit, when the planet passed in front of its parent star. We find that absorption by water vapour is the most likely cause of the wavelength-dependent variations in the effective radius of the planet at the infrared wavelengths 3.6 mu m, 5.8 mu m (both ref. 7) and 8 mu m (ref. 8). The larger effective radius observed at visible wavelengths(9) may arise from either stellar variability or the presence of clouds/hazes. We explain the report of a non-detection of water on HD 189733b (ref. 4) as being a consequence of the nearly isothermal vertical profile of the planet's atmosphere.	European Space Agcy, I-00044 Frascati, Italy; UCL, Dept Phys & Astron, London WC1E 6BT, England; Univ Paris 06, CNRS, Inst Astrophys Paris, F-75014 Paris, France; Acad Sinica, Res Ctr Environm Changes, Taipei 115, Taiwan; CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; CALTECH, IPAC Spitzer Sci Ctr, Pasadena, CA 91125 USA; CSIC, IEEC, Inst Ciencias Espai, Bellaterra 08193, Spain; Univ Arizona, Dept Planetary Sci, Lunar & Planetary Lab, Tucson, AZ 85721 USA; Ctr Natl Etud Spatiales, F-75001 Paris, France; CNRS, Ecole Normale Super, F-69364 Lyon, France	European Space Agency; University of London; University College London; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Academia Sinica - Taiwan; California Institute of Technology; California Institute of Technology; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Ciencias del Espacio (ICE); Institut d'Estudis Espacials de Catalunya (IEEC); University of Arizona; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)	Tinetti, G (corresponding author), European Space Agcy, I-00044 Frascati, Italy.	gio@gps.caltech.edu	Ribas, Ignasi/M-2134-2014; Liang, Mao-Chang/P-9796-2018; Tinetti, Giovanna/Q-4697-2019; Tennyson, Jonathan/I-2222-2012; Tinetti, Giovanna/G-7956-2017; Liang, Mao-Chang/AAG-4305-2021	Ribas, Ignasi/0000-0002-6689-0312; Liang, Mao-Chang/0000-0002-5294-9344; Tinetti, Giovanna/0000-0001-6058-6654; Tennyson, Jonathan/0000-0002-4994-5238; Tinetti, Giovanna/0000-0001-6058-6654; Beaulieu, Jean-Philippe/0000-0003-0014-3354; Carey, Sean/0000-0002-0221-6871; Selsis, Franck/0000-0001-9619-5356; Sing, David/0000-0001-6050-7645	Engineering and Physical Sciences Research Council [EP/E043674/1] Funding Source: researchfish; EPSRC [EP/E043674/1] Funding Source: UKRI	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Allard NF, 2007, ASTRON ASTROPHYS, V465, P1085, DOI 10.1051/0004-6361:20066616; Allard NF, 2003, ASTRON ASTROPHYS, V411, pL473, DOI 10.1051/0004-6361:20031299; Ballester GE, 2007, NATURE, V445, P511, DOI 10.1038/nature05525; Barber RJ, 2006, MON NOT R ASTRON SOC, V368, P1087, DOI 10.1111/j.1365-2966.2006.10184.x; Barman T, 2007, ASTROPHYS J, V661, pL191, DOI 10.1086/518736; BEAULIEU JP, UNPUB ASTROPHYS J; Borysow A, 2001, J QUANT SPECTROSC RA, V68, P235, DOI 10.1016/S0022-4073(00)00023-6; Bouchy F, 2005, ASTRON ASTROPHYS, V444, pL15, DOI 10.1051/0004-6361:200500201; Brown TM, 2001, ASTROPHYS J, V553, P1006, DOI 10.1086/320950; Burrows A, 2006, ASTROPHYS J, V650, P1140, DOI 10.1086/507269; Charbonneau D, 2005, ASTROPHYS J, V626, P523, DOI 10.1086/429991; Charbonneau D, 2002, ASTROPHYS J, V568, P377, DOI 10.1086/338770; Deming D, 2005, NATURE, V434, P740, DOI 10.1038/nature03507; Fortney JJ, 2006, ASTROPHYS J, V652, P746, DOI 10.1086/508442; FORTNEY JJ, UNPUB ASTROPHYS J; Grillmair CJ, 2007, ASTROPHYS J, V658, pL115, DOI 10.1086/513741; HANEL RA, 1972, J GEOPHYS RES, V77, P2629, DOI 10.1029/JC077i015p02629; Knutson HA, 2007, NATURE, V447, P183, DOI 10.1038/nature05782; Knutson HA, 2007, ASTROPHYS J, V655, P564, DOI 10.1086/510111; Liang MC, 2007, ASTROPHYS J, V661, pL199, DOI 10.1086/518785; Liang MC, 2003, ASTROPHYS J, V596, pL247, DOI 10.1086/379314; Richardson LJ, 2007, NATURE, V445, P892, DOI 10.1038/nature05636; Richardson LJ, 2006, ASTROPHYS J, V649, P1043, DOI 10.1086/506503; Rothman LS, 2005, J QUANT SPECTROSC RA, V96, P139, DOI 10.1016/j.jqsrt.2004.10.008; Seager S, 2000, ASTROPHYS J, V537, P916, DOI 10.1086/309088; Tinetti G, 2007, ASTROPHYS J, V654, pL99, DOI 10.1086/510716; Vidal-Madjar A, 2004, ASTROPHYS J, V604, pL69, DOI 10.1086/383347; Vidal-Madjar A, 2003, NATURE, V422, P143, DOI 10.1038/nature01448; Winn JN, 2007, ASTRON J, V133, P1828, DOI 10.1086/512159; Yung Y.L., 1989, ATMOSPHERIC RAD	30	392	394	3	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 12	2007	448	7150					169	171		10.1038/nature06002	http://dx.doi.org/10.1038/nature06002			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	188QN	17625559	Green Submitted, Green Accepted			2022-12-28	WOS:000247934500036
J	Conway, PH; Cnaan, A; Zaoutis, T; Henry, BV; Grundmeier, RW; Keren, R				Conway, Patrick H.; Cnaan, Avital; Zaoutis, Theoklis; Henry, Brandon V.; Grundmeier, Robert W.; Keren, Ron			Recurrent urinary tract infections in children - Risk factors and association with prophylactic antimicrobials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY VESICOURETERAL REFLUX; CONTROLLED-TRIAL; BACTERIURIA; MANAGEMENT; THERAPY	Context The evidence regarding risk factors for recurrent urinary tract infection ( UTI) and the risks and benefits of antimicrobial prophylaxis in children is scant. Objectives To identify risk factors for recurrent UTI in a pediatric primary care cohort, to determine the association between antimicrobial prophylaxis and recurrent UTI, and to identify the risk factors for resistance among recurrent UTIs. Design, Patients, and Setting From a network of 27 primary care pediatric practices in urban, suburban, and semirural areas spanning 3 states, a cohort of children aged 6 years or younger who were diagnosed with first UTI between July 1, 2001, and May 31, 2006, was assembled. Time-to-event analysis was used to determine risk factors for recurrent UTI and the association between antimicrobial prophylaxis and recurrent UTI, and a nested case-control study was performed among children with recurrent UTI to identify risk factors for resistant infections. Main Outcome Measures Time to recurrent UTI and antimicrobial resistance of recurrent UTI pathogens. Results Among 74 974 children in the network, 611 (0.007 per person-year) had a first UTI and 83 (0.12 per person-year after first UTI) had a recurrent UTI. In multivariable Cox time-to-event models, factors associated with increased risk of recurrent UTI included white race (0.17 per person-year; hazard ratio [HR], 1.97; 95% confidence interval [CI], 1.22-3.16), age 3 to 4 years (0.22 per person-year; HR, 2.75; 95% CI, 1.37-5.51), age 4 to 5 years (0.19 per person-year; HR, 2.47; 95% CI, 1.19-5.12), and grade 4 to 5 vesicoureteral reflux (0.60 per person-year; HR, 4.38; 95% CI, 1.26-15.29). Sex and grade 1 to 3 vesicoureteral reflux were not associated with risk of recurrence. Antimicrobial prophylaxis was not associated with decreased risk of recurrent UTI ( HR, 1.01; 95% CI, 0.50-2.02), even after adjusting for propensity to receive prophylaxis, but was a risk factor for antibimicrobial resistance among children with recurrent UTI ( HR, 7.50; 95% CI, 1.60-35.17). Conclusion Among the children in this study, antimicrobial prophylaxis was not associated with decreased risk of recurrent UTI, but was associated with increased risk of resistant infections.	Univ Penn, Robert Wood Johnson Clin Scholars Program, Philadelphia, PA 19104 USA; Univ Penn, Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Gen Pediat, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Biostat & Epidemiol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Ctr Biomed Informat, Philadelphia, PA 19104 USA; Cincinnati Childrens Hosp Med Ctr, Ctr Hlth Care Qual, Cincinnati, OH USA; Cincinnati Childrens Hosp Med Ctr, Div Gen Pediat, Cincinnati, OH USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center	Conway, PH (corresponding author), Univ Penn, Robert Wood Johnson Clin Scholars Program, 423 Guardian Dr,Bloddey Hall 1303A, Philadelphia, PA 19104 USA.	pconway2@mail.med.upenn.edu			NCRR NIH HHS [U54 RR023567-01] Funding Source: Medline; NICHD NIH HHS [K23 HD043179] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K23HD043179] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Austin PC, 2007, STAT MED, V26, P734, DOI 10.1002/sim.2580; Bergman DA, 1999, PEDIATRICS, V103, P843; BISSET GS, 1987, AM J ROENTGENOL, V148, P479, DOI 10.2214/ajr.148.3.479; Downs SH, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.4.e54; Elder JS, 1997, J UROLOGY, V157, P1846, DOI 10.1016/S0022-5347(01)64882-1; Garin EH, 2006, PEDIATRICS, V117, P626, DOI 10.1542/peds.2005-1362; GLEESON FV, 1991, ARCH DIS CHILD, V66, P1282, DOI 10.1136/adc.66.11.1282; Gorelick MH, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.5.e54; Hellerstein S, 2002, PEDIATR NEPHROL, V17, P506, DOI 10.1007/s00467-002-0899-x; HELLSTROM A, 1991, ARCH DIS CHILD, V66, P232, DOI 10.1136/adc.66.2.232; HOBERMAN A, 1994, J PEDIATR-US, V124, P513, DOI 10.1016/S0022-3476(05)83127-0; Kwok Wing-Yee, 2006, BMC Pediatr, V6, P10, DOI 10.1186/1471-2431-6-10; LEBOWITZ RL, 1985, PEDIATR RADIOL, V15, P105, DOI 10.1007/BF02388714; LOHR JA, 1977, PEDIATRICS, V59, P562; Lutter SA, 2005, ARCH PEDIAT ADOL MED, V159, P924, DOI 10.1001/archpedi.159.10.924; Mahant S, 2002, ARCH DIS CHILD, V86, P419, DOI 10.1136/adc.86.6.419; Mazzola BL, 2003, J NEPHROL, V16, P133; MCKERROW W, 1984, BRIT MED J, V289, P299, DOI 10.1136/bmj.289.6440.299; Panaretto KS, 1999, J PAEDIATR CHILD H, V35, P454, DOI 10.1046/j.1440-1754.1999.355417.x; Reddy PP, 1997, PEDIATRICS, V100, P555; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; SAVAGE DCL, 1975, LANCET, V1, P358; Shaikh N, 2003, PEDIATRICS, V112, P1134, DOI 10.1542/peds.112.5.1134; SMELLIE JM, 1988, PEDIATR NEPHROL, V2, P12, DOI 10.1007/BF00870372; SMELLIE JM, 1978, LANCET, V2, P175; SNODGRASS W, 1991, UROLOGY, V38, P341, DOI 10.1016/0090-4295(91)80148-Z; UHARI M, 1988, BRIT MED J, V297, P450, DOI 10.1136/bmj.297.6646.450; WAN JL, 1995, J UROLOGY, V154, P797, DOI 10.1016/S0022-5347(01)67167-2; WILLIAMS GJ, 2006, COCHRANE DB SYST REV, V3; WINBERG J, 1974, Acta Paediatrica Scandinavica Supplement, P1; WINBERG J, 1975, KIDNEY INT, V8, pS101	31	244	257	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2007	298	2					179	186		10.1001/jama.298.2.179	http://dx.doi.org/10.1001/jama.298.2.179			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188HI	17622599	Bronze			2022-12-28	WOS:000247910600023
J	Paavonen, J; Jenkins, D; Bosch, FX; Naud, P; Salmeron, J; Wheeler, CM; Chow, SN; Apter, DL; Kitchener, HC; Castellsague, X; de Carvalho, NS; Skinner, SR; Harper, DM; Hedrick, JA; Jaisamrarn, U; Limson, GAM; Dionne, M; Quint, W; Spiessens, B; Peeters, P; Struyf, F; Wieting, SL; Lehtinen, MO; Dubin, G				Paavonen, Jorma; Jenkins, David; Bosch, F. Xavier; Naud, Paulo; Salmeron, Jorge; Wheeler, Cosette M.; Chow, Song-Nan; Apter, Dan L.; Kitchener, Henry C.; Castellsague, Xavier; de Carvalho, Newton S.; Skinner, S. Rachel; Harper, Diane M.; Hedrick, James A.; Jaisamrarn, Unnop; Limson, Genara A. M.; Dionne, Marc; Quint, Wim; Spiessens, Bart; Peeters, Pascal; Struyf, Frank; Wieting, Susan L.; Lehtinen, Matti O.; Dubin, Gary		HPV PATRICIA study grp	Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial	LANCET			English	Article							MAJOR CAPSID PROTEIN; CERVICAL-CANCER; FOLLOW-UP; PERSISTENCE; DNA; HPV; IDENTIFICATION; CLASSIFICATION; PREVENTION; EPITOPES	Background The aim of this interim analysis of a large, international phase III study was to assess the efficacy of an AS04 adjuvanted L1 virus-like-particle prophylactic candidate vaccine against infection with human papillomavirus (HPV) types 16 and 18 in young women. Methods 18 644 women aged 15-25 years were randomly assigned to receive either HPV16/18 vaccine (n=9319) or hepatitis A vaccine (n=9325) at 0, 1, and 6 months. Of these women, 88 were excluded because of high-grade cytology and 31 for missing cytology results. Thus, 9258 women received the HPV16/18 vaccine and 9267 received the control vaccine in the total vaccinated cohort for efficacy, which included women who had prevalent oncogenic HPV infections, often with several HPV types, as well as low-grade cytological abnormalities at study entry and who received at least one vaccine dose. We assessed cervical cytology and subsequent biopsy for 14 oncogenic HPV types by PCR. The primary endpoint-vaccine efficacy against cervical intraepithelial neoplasia (CIN) 2+ associated with HPV16 or HPV18-was assessed in women who were seronegative and DNA negative for the corresponding vaccine type at baseline (month 0) and allowed inclusion of lesions with several oncogenic HPV types. This interim event-defined analysis was triggered when at least 23 cases of CIN2+ with HPV16 or HPV18 DNA in the lesion were detected in the total vaccinated cohort for efficacy. Analyses were done on a modified intention-to-treat basis. This trial is registered with the US National Institutes of Health clinical trial registry, number NCT00122681. Findings Mean length of follow-up for women in the primary analysis for efficacy at the time of the interim analysis was 14.8 (SD 4.9) months. Two cases of CIN2+ associated with HPV16 or HPV18 DNA were seen in the HPV16/18 vaccine group; 21 were recorded in the control group. Of the 23 cases, 14 (two in the HPV16/18 vaccine group, 12 in the control group) contained several oncogenic HPV types. Vaccine efficacy against CIN2+ containing HPV16/18 DNA was 90.4% (97.9% Cl 53.4-99.3; p < 0.0001). No clinically meaningful differences were noted in safety outcomes between the study groups. Interpretation The adjuvanted HPV16/18 vaccine showed prophylactic efficacy against CIN2+ associated with HPV16 or HPV18 and thus could be used for cervical cancer prevention.	Univ Helsinki, Dept Obstet & Gynaecol, FIN-00290 Helsinki, Finland; GlaxoSmithKline Biol, Rixensart, Belgium; Inst Catala Oncol, Epidemiol & Canc Registrat Unit, IDIBELL, Barcelona, Spain; Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil; Inst Mexicano Seguro Social, Unidad Invest Epidemiol & Serv Salud, Cuernavaca, Morelos, Mexico; Univ New Mexico, Hlth Sci Ctr, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA; Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan; Family Federat Finland, Sexual Hlth Clin, Helsinki, Finland; Univ Manchester, Acad Unit Obstet & Gynaecol, Manchester, Lancs, England; Univ Fed Parana, Dept Obstet & Gynaecol, BR-80060000 Curitiba, Parana, Brazil; Clin Hosp, Obstet Gynecol & Infect Dis Sector, Curitiba, Parana, Brazil; Univ Western Australia, TVWTelethon Inst Child Hlth Res, Perth, WA 6009, Australia; Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA 6009, Australia; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA; Kentucky Pediat & Adult Res, Bardstown, KY USA; Chulalongkorn Univ, Fac Med, Dept Obstet & Gynaecol, Bangkok 10330, Thailand; Univ Philippines, Coll Med, Philippine Gen Hosp, Makati Med Ctr, Makati, Philippines; Ctr Hosp Univ Quebec, Dept Publ Hlth, Beauport, PQ, Canada; DDL Diagnost Lab, Voorburg, Netherlands; Tampere Univ, Sch Publ Hlth, FIN-33101 Tampere, Finland; GlaxoSmithKline Biol, King Of Prussia, PA USA	University of Helsinki; GlaxoSmithKline; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Universidade Federal do Rio Grande do Sul; Instituto Mexicano del Seguro Social; University of New Mexico; University of New Mexico's Health Sciences Center; National Taiwan University; National Taiwan University Hospital; National Taiwan University; Family Federation of Finland; University of Manchester; Universidade Federal do Parana; University of Western Australia; University of Western Australia; Dartmouth College; Chulalongkorn University; Makati Medical Center; Laval University; DDL Diagnostic Laboratory; Tampere University; GlaxoSmithKline	Paavonen, J (corresponding author), Univ Helsinki, Dept Obstet & Gynaecol, Haartmaninkatu 2, FIN-00290 Helsinki, Finland.	Jorma.Paavonen@hus.fi	Skinner, Rachel S/J-8455-2017; de carvalho, newton/G-5045-2013; Wang, Jing/M-5607-2016; Pique, Xavier Castellsagué/N-5795-2014; Harper, Diane M./I-2180-2014; JOSÉ, FRANCESC XAVIER BOSCH/J-6339-2012; Apter, Dan/D-6269-2017	Skinner, Rachel S/0000-0003-1970-9792; Pique, Xavier Castellsagué/0000-0002-0802-3595; Harper, Diane M./0000-0001-7648-883X; JOSÉ, FRANCESC XAVIER BOSCH/0000-0002-7172-3412; Salmeron, Jorge/0000-0002-5113-299X; Paavonen, Jorma/0000-0003-4775-606X; Apter, Dan/0000-0002-5175-8845; Struyf, Frank/0000-0001-9988-0260; lehtinen, matti/0000-0002-9481-0535				Combita AL, 2002, J VIROL, V76, P6480, DOI 10.1128/JVI.76.13.6480-6486.2002; Cuschieri KS, 2004, J MED VIROL, V73, P65, DOI 10.1002/jmv.20062; de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033; Doorbar J, 1997, VIROLOGY, V238, P40, DOI 10.1006/viro.1997.8768; Dragalin V, 2002, STAT MED, V21, P877, DOI 10.1002/sim.1039; Fleiss J. L., 1981, STAT METHODS RATES P, V2; Fleury MJJ, 2006, ARCH VIROL, V151, P1511, DOI 10.1007/s00705-006-0734-y; Giroglou T, 2001, VACCINE, V19, P1783, DOI 10.1016/S0264-410X(00)00370-4; Harper DM, 2004, LANCET, V364, P1757, DOI 10.1016/S0140-6736(04)17398-4; Harper DM, 2006, LANCET, V367, P1247, DOI 10.1016/S0140-6736(06)68439-0; Hoyer H, 2005, INT J CANCER, V116, P136, DOI 10.1002/ijc.20955; Kjaer SK, 2016, BMJ-BRIT MED J, V353, DOI [10.1136/bmj.325.7364.572, 10.1136/bmj.i2820]; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Pagliusi SR, 2004, VACCINE, V23, P569, DOI 10.1016/j.vaccine.2004.07.046; Smith JS, 2007, INT J CANCER, V121, P621, DOI 10.1002/ijc.22527; Stanley M, 2007, BRIT J CANCER, V96, P1320, DOI 10.1038/sj.bjc.6603695; Trottier H, 2006, VACCINE, V24, P4, DOI 10.1016/j.vaccine.2005.09.054; van Doorn LJ, 2006, J CLIN MICROBIOL, V44, P3292, DOI 10.1128/JCM.00539-06; Van Herck K, 2005, EXPERT REV VACCINES, V4, P459, DOI 10.1586/14760584.4.4.459; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wallin KL, 1999, NEW ENGL J MED, V341, P1633, DOI 10.1056/NEJM199911253412201; WANG SK, 1987, BIOMETRICS, V43, P193, DOI 10.2307/2531959	22	938	989	1	84	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 30	2007	369	9580					2161	2170		10.1016/S0140-6736(07)60946-5	http://dx.doi.org/10.1016/S0140-6736(07)60946-5			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LX	17602732				2022-12-28	WOS:000247644200027
J	Kath, WL; Ottino, JM				Kath, William L.; Ottino, Julio M.			Chemistry - Rhythm engineering	SCIENCE			English	Editorial Material									Northwestern Univ, Robert R McCormick Sch Engn & Appl Sci, Evanston, IL 60208 USA; Northwestern Univ, Northwestern Inst Complex Syst, Evanston, IL 60208 USA	Northwestern University; Northwestern University	Kath, WL (corresponding author), Northwestern Univ, Robert R McCormick Sch Engn & Appl Sci, Evanston, IL 60208 USA.	kath@northwestern.edu; jm-ottino@northwestern.edu	Ottino, Julio/B-6682-2009; Kath, William/B-6771-2009	Kath, William/0000-0003-3867-4783				Benabid AL, 2003, CURR OPIN NEUROBIOL, V13, P696, DOI 10.1016/j.conb.2003.11.001; ERMENTROUT GB, 1991, J MATH BIOL, V29, P191; HOPPENSTEADT FC, 1976, SCIENCE, V194, P335, DOI 10.1126/science.987617; Kiss IZ, 2007, SCIENCE, V316, P1886, DOI 10.1126/science.1140858; Kuramoto Y., 1984, CHEM OSCILLATIONS WA; MAY RM, 1979, NATURE, V277, P347, DOI 10.1038/277347a0; Strogatz S.H., 1994, NONLINEAR DYNAMICS C; Strogatz SH, 2005, NATURE, V438, P43, DOI 10.1038/438043a; TAUBES G, 1997, GLOBAL POSITIONING S; Vanier J, 2005, METROLOGIA, V42, pS31, DOI 10.1088/0026-1394/42/3/S05	10	8	8	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 29	2007	316	5833					1857	1858		10.1126/science.1145111	http://dx.doi.org/10.1126/science.1145111			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183WI	17600206				2022-12-28	WOS:000247602700026
J	Geenen, MM; Cardous-Ubbink, MC; Kremer, LCM; van den Bos, C; van der Pal, HJH; Heinen, RC; Jaspers, MWM; Koning, CCE; Oldenburger, F; Langeveld, NE; Hart, AAM; Bakker, PJM; Caron, HN; van Leeuwen, FE				Geenen, Maud M.; Cardous-Ubbink, Mathilde C.; Kremer, Leontien C. M.; van den Bos, Cor; van der Pal, Helena J. H.; Heinen, Richard C.; Jaspers, Monique W. M.; Koning, Caro C. E.; Oldenburger, Foppe; Langeveld, Nelia E.; Hart, Augustinus A. M.; Bakker, Piet J. M.; Caron, Huib N.; van Leeuwen, Flora E.			Medical assessment of adverse health outcomes in long-term survivors of childhood cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; 2ND MALIGNANT NEOPLASMS; FOLLOW-UP; 5-YEAR SURVIVORS; ADULT SURVIVORS; ADOLESCENT CANCER; HODGKINS-DISEASE; HEART-FAILURE; CLINICAL CARE; BRAIN-TUMORS	Context Improved survival of children with cancer has been accompanied by multiple treatment-related complications. However, most studies in survivors of childhood cancer focused on only 1 late effect. Objective To assess the total burden of adverse health outcomes ( clinical or subclinical disorders ["adverse events"]) following childhood cancer in a large cohort of childhood cancer survivors with long-term and complete medical follow-up. Design, Setting, and Population Retrospective cohort study of 1362 five-year survivors of childhood cancer treated in a single institution in the Netherlands between 1966 and 1996. All survivors were invited to a late-effects clinic for medical assessment of adverse events. Adverse events occurring before January 2004 were graded for severity in a standardized manner. Main Outcome Measures Treatment-specific prevalence of adverse events ( according to severity) at end of follow-up and relative risk of high or severe burden of disease ( >= 2 severe or >= 1 life-threatening or disabling adverse events) associated with various treatments. Results Medical follow-up was complete for 94.3% of survivors ( median follow-up, 17.0 years). The median attained age at end of follow-up was 24.4 years. Almost 75% of survivors had 1 or more adverse events, and 24.6% had 5 or more adverse events. Furthermore, 40% of survivors had at least 1 severe or life-threatening or disabling adverse event. A high or severe burden of adverse events was observed in 55% of survivors who received radiotherapy only and 15% of survivors treated with chemotherapy only, compared with 25% of survivors who had surgery only ( adjusted relative risks, 2.18 [95% confidence interval, 1.62 - 2.95] and 0.65 [ 95% confidence interval, 0.46 - 0.90], respectively). A high or severe burden of adverse events was most often observed in survivors of bone tumors (64%) and least often in survivors of leukemia or Wilms tumor (12% each). Conclusions In young adulthood, a substantial proportion of childhood cancer survivors already has a high or severe burden of disease, particularly after radiotherapy. This underscores the need for lifelong risk-stratified medical surveillance of childhood cancer survivors.	Emma Childrens Hosp, Acad Med Ctr, Late Effects Study Grp, NL-1100 DD Amsterdam, Netherlands; Emma Childrens Hosp, Acad Med Ctr, Outpatient Clin, Poliklin Late Effecten Kindertumoren, NL-1100 DD Amsterdam, Netherlands; Emma Childrens Hosp, Acad Med Ctr, Dept Pediat Oncol, NL-1100 DD Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Med Oncol, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Med Informat, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Radiotherapy, NL-1105 AZ Amsterdam, Netherlands; Netherlands Canc Inst, Dept Radiotherapy, Amsterdam, Netherlands; Netherlands Canc Inst, Dept Epidemiol, Amsterdam, Netherlands	Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Netherlands Cancer Institute; Netherlands Cancer Institute	Caron, HN (corresponding author), Emma Childrens Hosp, Acad Med Ctr, Late Effects Study Grp, POB 22660, NL-1100 DD Amsterdam, Netherlands.	h.n.caron@amc.uva.nl	koning, caro/A-5339-2008	Kremer, Leontien/0000-0001-7422-3248				Adams MJ, 2004, J CLIN ONCOL, V22, P3139, DOI 10.1200/JCO.2004.09.109; Bhatia S, 2003, J CLIN ONCOL, V21, P4386, DOI 10.1200/JCO.2003.11.059; Bhatia S, 2006, PEDIATR BLOOD CANCER, V46, P143, DOI 10.1002/pbc.20613; Bhatia S, 2005, CANCER J, V11, P340, DOI 10.1097/00130404-200507000-00010; Cardous-Ubbink MC, 2004, PEDIATR BLOOD CANCER, V42, P563, DOI 10.1002/pbc.20028; Curry HL, 2006, EUR J CANCER, V42, P501, DOI 10.1016/j.ejca.2005.11.003; DONALDSON SS, 1993, INT J RADIAT ONCOL, V26, P739, DOI 10.1016/0360-3016(93)90487-G; Gleeson HK, 2004, ENDOCR-RELAT CANCER, V11, P589, DOI 10.1677/erc.1.00779; Green DM, 2001, J CLIN ONCOL, V19, P1926, DOI 10.1200/JCO.2001.19.7.1926; Gurney JG, 2003, CANCER-AM CANCER SOC, V97, P663, DOI 10.1002/cncr.11095; Hawkins MM, 2006, PEDIATR BLOOD CANCER, V46, P174, DOI 10.1002/pbc.20609; Hudson MM, 2003, JAMA-J AM MED ASSOC, V290, P1583, DOI 10.1001/jama.290.12.1583; Jenkinson HC, 2004, BRIT J CANCER, V91, P1905, DOI 10.1038/sj.bjc.6602226; JOFFE MM, 1995, STAT MED, V14, P2131, DOI 10.1002/sim.4780141907; Kenney LB, 2004, ANN INTERN MED, V141, P590, DOI 10.7326/0003-4819-141-8-200410190-00006; Kremer LCM, 2001, J CLIN ONCOL, V19, P191, DOI 10.1200/JCO.2001.19.1.191; Landier W, 2004, J CLIN ONCOL, V22, P4979, DOI 10.1200/JCO.2004.11.032; Langer T, 2002, MED PEDIATR ONCOL, V38, P320, DOI 10.1002/mpo.10055; LIPSHULTZ SE, 1991, NEW ENGL J MED, V324, P808, DOI 10.1056/NEJM199103213241205; Mackie E, 2000, LANCET, V355, P1310, DOI 10.1016/S0140-6736(00)02112-7; Marks LB, 2003, SEMIN RADIAT ONCOL, V13, P333, DOI 10.1016/S1053-4296(03)00034-1; Mertens AC, 2001, J CLIN ONCOL, V19, P3163, DOI 10.1200/JCO.2001.19.13.3163; Mulhern RK, 2005, J CLIN ONCOL, V23, P5511, DOI 10.1200/JCO.2005.00.703; Mulhern RK, 2004, LANCET ONCOL, V5, P399, DOI 10.1016/S1470-2045(04)01507-4; Neglia JP, 2006, J NATL CANCER I, V98, P1528, DOI 10.1093/jnci/djj411; Neglia JP, 2001, J NATL CANCER I, V93, P618, DOI 10.1093/jnci/93.8.618; Nicholson H S, 1993, Cancer Treat Res, V62, P45; Oeffinger KC, 2004, CA-CANCER J CLIN, V54, P208, DOI 10.3322/canjclin.54.4.208; Oeffinger KC, 2000, CANCER-AM CANCER SOC, V88, P1687, DOI 10.1002/(SICI)1097-0142(20000401)88:7<1687::AID-CNCR24>3.3.CO;2-D; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Simbre Valeriano C, 2005, Paediatr Drugs, V7, P187, DOI 10.2165/00148581-200507030-00005; Simone J.V., 2003, CHILDHOOD CANC SURVI; Skinner R, 1996, LANCET, V348, P578, DOI 10.1016/S0140-6736(96)03480-0; Skinner R, 2006, LANCET ONCOL, V7, P489, DOI 10.1016/S1470-2045(06)70724-0; SKLAR CA, 1995, INT J RADIAT ONCOL, V31, P1113, DOI 10.1016/0360-3016(94)00427-M; Sklar CA, 1999, ACTA PAEDIATR, V88, P1, DOI 10.1111/j.1651-2227.1999.tb14395.x; Speechley KN, 2006, J CLIN ONCOL, V24, P2536, DOI 10.1200/JCO.2005.03.9628; Stevens MCG, 1998, EUR J CANCER, V34, P694, DOI 10.1016/S0959-8049(98)00012-4; van Santen HM, 2005, EUR J CANCER, V41, P1767, DOI 10.1016/j.ejca.2005.02.036; Wallace WHB., 2004, LATE EFFECTS CHILDHO, P49; Zebrack BJ, 2004, J CLIN ONCOL, V22, P999, DOI 10.1200/JCO.2004.06.148	41	579	585	0	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 27	2007	297	24					2705	2715		10.1001/jama.297.24.2705	http://dx.doi.org/10.1001/jama.297.24.2705			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	182UE	17595271				2022-12-28	WOS:000247528700020
J	Darboe, MK; Thurnham, DI; Morgan, G; Adegbola, RA; Secka, O; Solon, JA; Jackson, SJ; Northrop-Clewes, C; Fulford, TJ; Doherty, CP; Prentice, AM				Darboe, Mornodou K.; Thurnham, David I.; Morgan, Gareth; Adegbola, Richard A.; Secka, Ousman; Solon, Juan A.; Jackson, Sarah J.; Northrop-Clewes, Christine; Fulford, Tony J.; Doherty, Conor P.; Prentice, Andrew M.			Effectiveness of an early supplementation scheme of high-dose vitamin A versus standard WHO protocol in Gambian mothers and infants: a randomised controlled	LANCET			English	Article							PLASMA RETINOL; BETA-CAROTENE; DEFICIENCY; MORBIDITY; MORTALITY; GROWTH	Background Most developing countries have adopted a standard WHO dosing schedule for vitamin A supplementation. However, in 2002 the International Vitamin A Consultative Group (IVACG) Annecy Accord recommended a new high-dose regimen for mothers and infants. Our aim was to test whether the new high-dose regimen of vitamin A supplementation would increase maternal and infant plasma vitamin A, reduce infant Helicobacter pylori infection and nasopharyngeal pneumococcal carriage, and improve infant gut epithelial integrity. Methods In an area of moderate vitamin A deficiency in rural Gambia, 220 mother-infant pairs were enrolled in a randomised double-blind trial between September, 2001, and October, 2004, that compared the IVACG high dose with the WHO dose. The primary endpoints were levels of maternal and infant plasma vitamin A, H pylori infection, pneumococcal carriage, and gut epithelial integrity. The trial is registered as ISRCTN 98554309. Findings 197 infants completed follow-up to 12 months (99 high dose and 98 WHO dose). There were no adverse events at dosing. No differences were found in the primary outcomes for high-dose versus WHO schedule: maternal vitamin A concentration at 2 months +0.02 mu mol/L (95% Cl -0.10 to 0.15); infant vitamin A at 5 months +0.01 mu mol/L (-0.06 to 0.08); H pylori infection at 12 months -0.3% (-14.7 to 14.2); maternal pneumococcal carriage at 12 months -2.0% (-13.7 to 9-7); infant pneumococcal. carriage at 12 months -4.1% (-15.8 to 7-6); infant gut mucosal damage at 12 months 5.2% (-8.7 to 19-2). There were more clinic attendances by the high-dose group in the first 6 months of life (p=0.018). Interpretation Our results do not lend support to the proposal to increase the existing WHO standard dosing schedule for vitamin A in areas of moderate vitamin A deficiency. Caution is urged for future studies because trials have shown possible adverse effects of higher doses of vitamin A, and potential negative interactions with the expanded programme on immunisation (EPI) vaccines.	Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1E 7HT, England; MRC Keneba, Keneba, Gambia; Univ Ulster, No Ireland Ctr Food & Hlth, Coleraine BT52 1SA, Londonderry, North Ireland; Univ Coll Swansea, Sch Med, Swansea, W Glam, Wales; MRC Labs, Banjul, Gambia; Univ Philippines Manila, Coll Publ Hlth, Manila, Philippines; MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge, England	University of London; London School of Hygiene & Tropical Medicine; Ulster University; Swansea University; MRC Laboratory Molecular Biology; University of the Philippines System; University of the Philippines Manila; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Prentice, AM (corresponding author), Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Keppel St, London WC1E 7HT, England.	Andrew.prentice@lshtm.ac.uk	Prentice, Andrew/AAG-1961-2019		MRC [MC_U105960396] Funding Source: UKRI; Medical Research Council [MC_U105960396] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ABDELJABER MH, 1999, AM J PUBLIC HEALTH, V81, P1654; BAH A, 2001, GAMBIA, P1; BATES CJ, 1984, T ROY SOC TROP MED H, V78, P814, DOI 10.1016/0035-9203(84)90028-2; Benn CS, 2007, VACCINE, V25, P777, DOI 10.1016/j.vaccine.2006.09.044; Benn CS, 2005, BMJ-BRIT MED J, V331, P1428, DOI 10.1136/bmj.38670.639340.55; Benn CS, 2003, INT J EPIDEMIOL, V32, P822, DOI 10.1093/ije/dyg208; Campbell DI, 2003, PEDIATR RES, V54, P306, DOI 10.1203/01.PDR.0000076666.16021.5E; COLE TJ, 1989, ANN HUM BIOL, V16, P407, DOI 10.1080/03014468900000532; DEFRANCISCO A, 1993, LANCET, V342, P526, DOI 10.1016/0140-6736(93)91648-6; FAWZI WW, 1993, JAMA-J AM MED ASSOC, V269, P898, DOI 10.1001/jama.269.7.898; Filteau SM, 1999, AM J CLIN NUTR, V69, P953; GLASZIOU PP, 1993, BMJ-BRIT MED J, V306, P366, DOI 10.1136/bmj.306.6874.366; Humphrey JH, 1998, AM J CLIN NUTR, V68, P109, DOI 10.1093/ajcn/68.1.109; Humphrey JH, 2000, LANCET, V356, P422, DOI 10.1016/S0140-6736(00)02541-1; Jewell VC, 2004, EUR J CLIN NUTR, V58, P90, DOI 10.1038/sj.ejcn.1601753; LUNN PG, 1991, T ROY SOC TROP MED H, V85, P8, DOI 10.1016/0035-9203(91)90137-N; LUNN PG, 1991, LANCET, V338, P907, DOI 10.1016/0140-6736(91)91772-M; Martines J, 1998, LANCET, V352, P1257, DOI 10.1016/S0140-6736(98)02487-8; McCullough FSW, 1999, P NUTR SOC, V58, P289, DOI 10.1017/S0029665199000403; O'Brien KL, 2003, PEDIATR INFECT DIS J, V22, P133, DOI [10.1097/00006454-200302000-00009, 10.1097/00006454-200302000-00010]; RAHMATHULLAH L, 1991, AM J CLIN NUTR, V54, P568, DOI 10.1093/ajcn/54.3.568; Rice AL, 1999, J NUTR, V129, P356, DOI 10.1093/jn/129.2.356; ROSS DA, 1993, LANCET, V342, P7, DOI 10.1016/0140-6736(93)91879-Q; Semba RD, 2001, ACTA PAEDIATR, V90, P1107, DOI 10.1080/080352501317061477; SOMMER A, 1986, LANCET, V1, P1169; Sommer A, 2002, J NUTR, V132, p2845S, DOI 10.1093/jn/132.9.2845S; Thurnham DI, 2003, LANCET, V362, P2052, DOI 10.1016/S0140-6736(03)15099-4; THURNHAM DI, 1988, CLIN CHEM, V34, P377; Thurnham DI, 2000, J INFECT DIS, V182, pS23, DOI 10.1086/315912; VILLARD L, 1987, HUM NUTR-APPL NUTR, V41A, P135; *WHO EPI, 1998, INT VIT A SUPPL IMM; *WHO NUT, 1996, IND ASS VIT A DEF TH; *WHO UNICEF IVACG, 1997, VIT A SUPPL GUID THE	33	58	60	1	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 23	2007	369	9579					2088	2096		10.1016/S0140-6736(07)60981-7	http://dx.doi.org/10.1016/S0140-6736(07)60981-7			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	182GM	17586304				2022-12-28	WOS:000247493100029
J	Haines, A; Sanders, D; Lehmann, U; Rowe, AK; Lawn, JE; Jan, S; Walker, DG; Bhutta, Z				Haines, Andy; Sanders, David; Lehmann, Uta; Rowe, Alexander K.; Lawn, Joy E.; Jan, Steve; Walker, Damian G.; Bhutta, Zuipqar			Achieving child survival goals: potential contribution of community health workers	LANCET			English	Review							INSECTICIDE-TREATED BEDNETS; INTEGRATED MANAGEMENT; DEVELOPING-COUNTRIES; MEASLES VACCINATION; HUMAN-RESOURCES; NEONATAL CARE; SCALING-UP; MORTALITY; FACILITIES; PNEUMONIA	There is renewed interest in the potential contribution of community health workers to child survival. Community health workers can undertake various tasks, including case management of childhood illnesses leg, pneumonia, malaria, and neonatal sepsis) and delivery of preventive interventions such as immunisation, promotion of healthy behaviour, and mobilisation of communities. Several trials show substantial reductions in child mortality, particularly through case management of ill children by these types of community interventions. However, community health workers are not a panacea for weak health systems and will need focussed tasks, adequate remuneration, training, supervision, and the active involvement of the communities in which they work. The introduction of large-scale programmes for community health workers requires evaluation to document the impact on child survival and cost effectiveness and to elucidate factors associated with success and sustainability.	Univ London London Sch Hyg & Trop Med, Directors Off, London WC1E 7HT, England; Univ Western Cape, Sch Publ Hlth, ZA-7535 Bellville, South Africa; Ctr Dis Control & Prevent, Malaria Branch, Natl Ctr Infect Dis, Atlanta, GA USA; MRC, Saving Newborn Lives Save Childrens US, Cape Town, South Africa; MRC, Hlth Syst Res Unit, Cape Town, South Africa; Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1E 7HT, England; George Inst Int Hlth, Sydney, NSW, Australia; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21218 USA; Aga Khan Univ, Dept Pediat & Child Hlth, Karachi, Pakistan	University of London; London School of Hygiene & Tropical Medicine; University of the Western Cape; Centers for Disease Control & Prevention - USA; Save the Children; University of London; London School of Hygiene & Tropical Medicine; University of Sydney; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Aga Khan University	Haines, A (corresponding author), Univ London London Sch Hyg & Trop Med, Directors Off, Keppel St, London WC1E 7HT, England.	andy.haines@lshtm.ac.uk	Jan, Stephen/AAG-3333-2021; Lawn, Joy/ABE-6382-2020	Lawn, Joy/0000-0002-4573-1443; Haines, Andy/0000-0002-8053-4605; Jan, Stephen/0000-0003-2839-1405; Walker, Damian/0000-0003-4568-0970; Lehmann-Grube, Uta/0000-0002-2627-8954				Aceng JR, 2005, BMJ-BRIT MED J, V330, P334, DOI 10.1136/bmj.330.7487.334; Adeniyi J D, 1987, Hygie, V6, P24; Anand S, 2004, LANCET, V364, P1603, DOI 10.1016/S0140-6736(04)17313-3; Arifeen SE, 2005, B WORLD HEALTH ORGAN, V83, P260; Bang Abhay T, 2005, J Perinatol, V25 Suppl 1, pS92, DOI 10.1038/sj.jp.7211277; Bang AT, 2005, PEDIATR INFECT DIS J, V24, P335, DOI 10.1097/01.inf.0000157094.43609.17; Bang AT, 1999, LANCET, V354, P1955, DOI 10.1016/S0140-6736(99)03046-9; Becerra-Posada F, 2004, LANCET, V364, P997, DOI 10.1016/S0140-6736(04)17026-8; BERMAN PA, 1987, SOC SCI MED, V25, P443, DOI 10.1016/0277-9536(87)90168-7; Bhattacharyya K, 2001, COMMUNITY HLTH WORKE; Bhutta ZA, 2005, PEDIATRICS, V115, P519, DOI 10.1542/peds.2004-1441; BHUTTA ZA, 2007, UNPUB LANCET; Borghi J, 2005, LANCET, V366, P1882, DOI 10.1016/S0140-6736(05)67758-6; BRIEGER WR, CATCHMENT AREA PLANN; Bryce J, 2005, HEALTH POLICY PLANN, V20, pI5, DOI 10.1093/heapol/czi055; Bryce J, 2005, LANCET, V365, P2193, DOI 10.1016/S0140-6736(05)66777-3; CalderonOrtiz R, 1996, SALUD PUBLICA MEXICO, V38, P243; Chen L, 2004, LANCET, V364, P1984, DOI 10.1016/S0140-6736(04)17482-5; CHOPRA M, 2004, 10 CHIP SAV CHILDR; Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; DAWSON P, PARTNERSHIPS INCREAS; DE ZOYSA I., 1983, World Health Forum, V4, P125; Diallo Khassoum, 2003, Hum Resour Health, V1, P3, DOI 10.1186/1478-4491-1-3; Dreesch N, 2005, HEALTH POLICY PLANN, V20, P267, DOI 10.1093/heapol/czi036; Garfield Richard, 1992, HLTH CARE NICARAGUA; Grabowsky M, 2005, TROP MED INT HEALTH, V10, P1151, DOI 10.1111/j.1365-3156.2005.01502.x; Grabowsky M, 2005, B WORLD HEALTH ORGAN, V83, P195; GRAY HH, 1988, SOCIO ECON PLAN SCI, V22, P39, DOI 10.1016/0038-0121(88)90033-X; GREENWOOD BM, 1990, J TROP MED HYG, V93, P87; Gupta Neeru, 2003, Int J Equity Health, V2, P11, DOI 10.1186/1475-9276-2-11; Gupta Neeru, 2003, Hum Resour Health, V1, P5, DOI 10.1186/1478-4491-1-5; Haines A, 2004, B WORLD HEALTH ORGAN, V82, P724; Huicho L, 2005, HEALTH POLICY PLANN, V20, P14, DOI 10.1093/heapol/czi002; *INT LAB ORG, 1990, ISCO88 INT LAB ORG; JAJU V, 1983, LENS; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; JONES G, 2005, COUNTD C LOND DEC; Kahssay H.M., 1998, COMMUNITY HLTH WORKE; Kallander K, 2006, T ROY SOC TROP MED H, V100, P956, DOI 10.1016/j.trstmh.2005.11.004; Kelly JM, 2001, AM J PUBLIC HEALTH, V91, P1617, DOI 10.2105/AJPH.91.10.1617; Kidane G, 2000, LANCET, V356, P550, DOI 10.1016/S0140-6736(00)02580-0; Knippenberg R, 2005, LANCET, V365, P1087, DOI 10.1016/S0140-6736(05)74233-1; KUROWSKI C, 2004, 0104 LOND SCH HYG TR; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; LEHMANN U, 2004, 41 JLI; LEHMANN U, 2005, AIDS B, V14, P1; Lewin SA, 2005, COCHRANE DB SYST REV, V1, P1, DOI DOI 10.1002/14651858.CD004015.PUB2; MAKAN B, EC ANAL COMMUNITY HL; Manandhar DS, 2004, LANCET, V364, P970, DOI 10.1016/S0140-6736(04)17021-9; Masanja H, 2005, HEALTH POLICY PLANN, V20, pI77, DOI 10.1093/heapol/czi054; MEHMOUD SA, 2005, COUNTD 2015 CHILD SU; Mumtaz Z, 2003, HEALTH POLICY PLANN, V18, P261, DOI 10.1093/heapol/czg032; Nathan R, 2004, TROP MED INT HEALTH, V9, P1121, DOI 10.1111/j.1365-3156.2004.01309.x; Newell KW., 1975, HLTH PEOPLE; Pegurri E, 2005, VACCINE, V23, P1624, DOI 10.1016/j.vaccine.2004.02.029; Quinn VJ, 2005, J HUM LACT, V21, P345, DOI 10.1177/0890334405278383; Rowe AK, 2005, LANCET, V366, P1026, DOI 10.1016/S0140-6736(05)67028-6; Rowe AK, 2003, INT J EPIDEMIOL, V32, P296, DOI 10.1093/ije/dyg063; Rowe AK, 2001, AM J PUBLIC HEALTH, V91, P1625, DOI 10.2105/AJPH.91.10.1625; Sadana R, 2000, GPE DISCUSSION PAPER; San Sebastian M, 2001, TROP DOCT, V31, P21; SANDERS D, 1992, COMMUNITY HLTH WORKE, P178; Sanders DM, 2005, BRIT MED J, V331, P755, DOI 10.1136/bmj.331.7519.755; Sanders F, 2001, S AFR MED J, V91, P108; SAUERBORN R, 1989, SOC SCI MED, V29, P1163, DOI 10.1016/0277-9536(89)90359-6; Sazawal S, 2003, LANCET INFECT DIS, V3, P547, DOI 10.1016/S1473-3099(03)00737-0; Schellenberg JA, 2003, LANCET, V361, P561, DOI 10.1016/S0140-6736(03)12515-9; Travis P, 2004, LANCET, V364, P900, DOI 10.1016/S0140-6736(04)16987-0; United Nations Development Program, 2003, HUM DEV REP 2003 MIL; Wagstaff A., 2004, MILLENNIUM DEVELOPME; Walker DG, 2005, J COMMUN HEALTH, V30, P221, DOI 10.1007/s10900-004-1960-4; WALT G, 1989, SOC SCI MED, V29, P599, DOI 10.1016/0277-9536(89)90179-2; Walt G., 1988, Health Policy and Planning, V3, P1, DOI 10.1093/heapol/3.1.1; WALT G, 1992, COMMUNITY HLTH WORKE; WANGOMBE JK, 1984, SOC SCI MED, V18, P375, DOI 10.1016/0277-9536(84)90055-8; WATERSTON T, 1987, MED EDUC, V21, P4, DOI 10.1111/j.1365-2923.1987.tb00506.x; WERNER D, VILLAGE HLTH WORKER; *WHO, 1990, STRENGTH PERF COMM H; WHO, 2006, WORK TOG HLTH WORLD; WHO, 1989, WHO TECHN REP SER, V780; Winch PJ, 2005, HEALTH POLICY PLANN, V20, P199, DOI 10.1093/heapol/czi027; World Bank, 1993, WORLD DEV REP INV HL; Zaba B, 2005, EPIDEMIOLOGY, V16, P275, DOI 10.1097/01.ede.0000155507.47884.43; Zeitz P S, 1993, Bull Pan Am Health Organ, V27, P109; 2005, BACKGROUND PAPER HIG; BASICS 2 CAPA HDB GU	86	621	629	1	37	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 23	2007	369	9579					2121	2131		10.1016/S0140-6736(07)60325-0	http://dx.doi.org/10.1016/S0140-6736(07)60325-0			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	182GM	17586307				2022-12-28	WOS:000247493100032
J	Pincock, S				Pincock, Stephen			Gaps exist in tsunami preparedness plans	LANCET			English	Editorial Material								In the wake of the 2004 Indian Ocean tsunami, the international community mobilised itself in an unprecedented way to strengthen tsunami early-warning systems. But, reports Stephen Pincock, high-tech buoys and international agreements will not be enough to protect people.						Pincock, Stephen/0000-0003-1655-2902					0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 23	2007	369	9579					2065	2065		10.1016/S0140-6736(07)60960-X	http://dx.doi.org/10.1016/S0140-6736(07)60960-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	182GM	17595702				2022-12-28	WOS:000247493100010
J	Crim, FF				Crim, F. Fleming			Making energy count	SCIENCE			English	Editorial Material							REACTIVITY; CH3D; BOND		Univ Wisconsin, Dept Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Crim, FF (corresponding author), Univ Wisconsin, Dept Chem, 1101 Univ Ave, Madison, WI 53706 USA.	fcrim@chem.wisc.edu						Bechtel HA, 2004, J CHEM PHYS, V120, P791, DOI 10.1063/1.1630961; Halonen L, 2001, J CHEM PHYS, V115, P5611, DOI 10.1063/1.1398075; POLANYI JC, 1972, ACCOUNTS CHEM RES, V5, P161, DOI 10.1021/ar50053a001; Rombauer I., 1973, JOY COOKING; Yan S, 2007, SCIENCE, V316, P1723, DOI 10.1126/science.1142313; Yoon S, 2003, J CHEM PHYS, V119, P9568, DOI 10.1063/1.1615755; Yoon S, 2003, J CHEM PHYS, V119, P4755, DOI 10.1063/1.1591176	7	16	16	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 22	2007	316	5832					1707	1708		10.1126/science.1144282	http://dx.doi.org/10.1126/science.1144282			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180XE	17588919				2022-12-28	WOS:000247400500033
J	Mueller, PS; Montori, VM; Bassler, D; Koenig, BA; Guyatt, GH				Mueller, Paul S.; Montori, Victor M.; Bassler, Dirk; Koenig, Barbara A.; Guyatt, Gordon H.			Ethical issues in stopping randomized trials early because of apparent benefit	ANNALS OF INTERNAL MEDICINE			English	Article							NONCARDIAC SURGERY; EQUIPOISE; MORTALITY; PLACEBO	Stopping randomized trials early because of an apparent benefit is becoming more common. To protect and promote the interests of trial participants, investigators may feel obligated to stop a trial early because of the apparent benefit of a study treatment (compared with placebo or other treatment). There are, however, serious ethical problems with doing so. Truncated trials systematically overestimate treatment effects; in cases where the number of accrued outcome events is small, the overestimation may be very large. Generating seriously inflated estimates of treatment effect violates the ethical research requirement of scientific validity. Subsequent use of inflated estimates to inform clinical decision making and practice guidelines violates the ethical requirements of social value and a favorable risk-benefit ratio. Researchers should ensure that a large number of outcome events accrues before stopping a trial and then continue recruitment to assess whether positive trends continue. This can balance the need to protect research participants with the ethical requirements of scientific validity, social value, and a favorable risk-benefit ratio.	Mayo Clin, Program Professionalism & Bioeth, Dept Med, Coll Med, Rochester, MN 55905 USA; Childrens Hosp, Tubingen, Germany; McMaster Univ, Hamilton, ON, Canada	Mayo Clinic; Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL; McMaster University	Mueller, PS (corresponding author), Mayo Clin, Program Professionalism & Bioeth, Dept Med, Coll Med, 200 1st St SW, Rochester, MN 55905 USA.	mueller.pauls@mayo.edu		Bassler, Dirk/0000-0003-2358-4419; Montori, Victor/0000-0003-0595-2898				ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; Brion LP., 2003, COCHRANE DB SYST REV, V(4), pCd003665, DOI [10.1002/14651858.CD003665, DOI 10.1002/14651858.CD003665]; Buchanan D, 2005, KENNEDY INST ETHIC J, V15, P161, DOI 10.1353/ken.2005.0010; Devereaux PJ, 2006, AM HEART J, V152, P223, DOI 10.1016/j.ahj.2006.05.019; Eagle KA, 2002, CIRCULATION, V105, P1257, DOI 10.1161/hc1002.104956; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701; FISH WH, 1990, PEDIATRICS, V85, P578; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; Juul AB, 2006, BMJ-BRIT MED J, V332, P1482, DOI 10.1136/bmj.332.7556.1482; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Lasser KE, 2002, JAMA-J AM MED ASSOC, V287, P2215, DOI 10.1001/jama.287.17.2215; Montori VM, 2005, JAMA-J AM MED ASSOC, V294, P2203, DOI 10.1001/jama.294.17.2203; Pan XR, 1997, DIABETES CARE, V20, P537, DOI 10.2337/diacare.20.4.537; Pocock SJ, 2005, JAMA-J AM MED ASSOC, V294, P2228, DOI 10.1001/jama.294.17.2228; Poldermans D, 1999, NEW ENGL J MED, V341, P1789, DOI 10.1056/NEJM199912093412402; Powell JT, 2005, J VASC SURG, V41, P602, DOI 10.1016/j.jvs.2005.01.048; Slutsky AS, 2004, NEW ENGL J MED, V350, P1143, DOI 10.1056/NEJMsb033476; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; Wheatley K, 2003, CONTROL CLIN TRIALS, V24, P66, DOI 10.1016/S0197-2456(02)00273-8	19	120	121	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 19	2007	146	12					878	881		10.7326/0003-4819-146-12-200706190-00009	http://dx.doi.org/10.7326/0003-4819-146-12-200706190-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180FF	17577007	Green Published			2022-12-28	WOS:000247347100006
J	Mant, J; Fitzmaurice, DA; Hobbs, FDR; Jowett, S; Murray, ET; Holder, R; Davies, M; Lip, GYH				Mant, Jonathan; Fitzmaurice, David A.; Hobbs, F. D. Richard; Jowett, Sue; Murray, Ellen T.; Holder, Roger; Davies, Michael; Lip, Gregory Y. H.			Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software: analysis of data from screening for atrial fibrillation in the elderly (SAFE) trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To assess the accuracy of general practitioners, practice nurses, and interpretative software in the use of different types of electrocardiogram to diagnose atrial fibrillation. Design Prospective comparison with reference standard of assessment of electrocardiograms by two independent specialists. Setting 49 general practices in central England. Participants 2595 patients aged 65 or over screened for atrial fibrillation as part of the screening for atrial fibrillation in the elderly (SAFE) study; 49 general practitioners and 49 practice nurses. Interventions All electrocardiograms were read with the Biolog interpretative software, and a random sample of 12 lead, limb lead, and single lead thoracic placement electrocardiograms were assessed by general practitioners and practice nurses independently of each other and of the Biolog assessment. Main outcome measures Sensitivity, specificity, and positive and negative predictive values. Results General practitioners detected 79 out of 99 cases of atria fibrillation on a 12 lead electrocardiogram (sensitivity 80%, 95% confidence interval 71% to 87%) and misinterpreted 114 out of 1355 cases of sinus rhythm as atria[ fibrillation (specificity 92%, 90% to 93%). Practice nurses detected a similar proportion of cases of atrial. fibrillation (sensitivity 77%, 67% to 85%), but had a lower specificity (85%, 83% to 87%). The interpretative software was significantly more accurate, with a specificity of 99%, but missed 36 of 215 cases of atrial fibrillation (sensitivity 83%). Combining general practitioners' interpretation with the interpretative software led to a sensitivity of 92% and a specificity of 91%. Use of limb lead or single lead thoracic placement electrocardiograms resulted in some loss of specificity. Conclusions Many primary care professionals cannot accurately detect atrial fibrillation on an electrocardiogram, and interpretative software is not sufficiently accurate to circumvent this problem, even when combined with interpretation by a general practitioner. Diagnosis of atrial fibrillation in the community needs to factor in the reading of electrocardiograms by appropriately trained people.	Univ Birmingham, Div Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Hlth Serv Management Ctr, Hlth Econ Facil, Birmingham B15 2RT, W Midlands, England; Queen Elizabeth Hosp, Dept Cardiol, Birmingham B15 2TH, W Midlands, England; City Hosp, Univ Dept Med, Birmingham B18 7QH, W Midlands, England	University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham	Fitzmaurice, DA (corresponding author), Univ Birmingham, Div Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England.	d.a.fitzmaurice@bham.ac.uk	Jowett, Sue/AAO-4198-2021	Jowett, Sue/0000-0001-8936-3745; hobbs, richard/0000-0001-7976-7172; Mant, Jonathan/0000-0002-9531-0268				*BMA NHS EMPL, REV GMS CONTR 2006 0; Department of Health, 2005, NAT SERV FRAM COR HE; Hobbs FDR, 2005, HEALTH TECHNOL ASSES, V9, P1, DOI 10.3310/hta9400; Houghton AR, 1997, INT J CARDIOL, V62, P31, DOI 10.1016/S0167-5273(97)00181-2; Lip GYH, 2006, THROMB RES, V118, P321, DOI 10.1016/j.thromres.2005.08.007; Lip GYH, 2006, HEART, V92, P155, DOI 10.1136/hrt.2005.066944; National Collaborating Centre for Chronic Conditions, 2006, ATR FIBR NAT CLIN GU; Poon K, 2005, J ELECTROCARDIOL, V38, P235, DOI 10.1016/j.jelectrocard.2005.01.008; Salerno SM, 2003, ANN INTERN MED, V138, P751, DOI 10.7326/0003-4819-138-9-200305060-00013; Somerville S, 2000, BRIT J GEN PRACT, V50, P727; Sudlow M, 1998, BRIT MED J, V317, P327, DOI 10.1136/bmj.317.7154.327; Sudlow M, 1998, LANCET, V352, P1167, DOI 10.1016/S0140-6736(98)01401-9; Sur DKC, 2000, FAM MED, V32, P315; Wheeldon NM, 1998, HEART, V79, P50, DOI 10.1136/hrt.79.1.50	14	104	105	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 25	2007	335	7616					380	382B		10.1136/bmj.39227.551713.AE	http://dx.doi.org/10.1136/bmj.39227.551713.AE			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206VC	17604299	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000249210000026
J	Hunter, DJ; Kraft, P				Hunter, David J.; Kraft, Peter			Statistics and medicine: Drinking from the fire hose - Statistical issues in genomewide association studies	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; NCI, Canc Genet Markers Susceptibil Project, Bethesda, MD 20892 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard T.H. Chan School of Public Health	Hunter, DJ (corresponding author), Harvard Univ, Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA.							Chanock SJ, 2007, NATURE, V447, P655, DOI 10.1038/447655a; Christensen K, 2007, NEW ENGL J MED, V356, P1094, DOI 10.1056/NEJMp068126; Thomas DC, 2004, JNCI-J NATL CANCER I, V96, P421, DOI 10.1093/jnci/djh094; Wacholder S, 2004, J NATL CANCER I, V96, P434, DOI 10.1093/jnci/djh075	4	133	136	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 2	2007	357	5					436	+		10.1056/NEJMp078120	http://dx.doi.org/10.1056/NEJMp078120			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195UB	17634446				2022-12-28	WOS:000248436300002
J	Coulter, A; Ellins, J				Coulter, Angela; Ellins, Jo			Effectiveness of strategies for informing, educating, and involving patients	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							INTERVENTIONS; CANCER		Picker Inst Europe, Oxford OX1 1RX, England; Univ Warwick, NHS Ctr Involvement, Vanguard Ctr, Coventry CV4 7AL, W Midlands, England	University of Warwick	Coulter, A (corresponding author), Picker Inst Europe, Kings Mead House, Oxford OX1 1RX, England.	coutter@pickereurope.ac.uk	Coulter, Angela/N-6998-2019	Coulter, Angela/0000-0002-6308-8375; Ellins, Jo/0000-0001-8138-9385				Berkman ND, 2004, 87 AG HEALTHC RES QU; Black ME, 2002, CAN J PUBLIC HEALTH, V93, P386, DOI 10.1007/BF03404575; Brown HC, 2004, COCHRANE DB SYST REV, V2, DOI [DOI 10.1002/14651858.CD002856.PUB2, 10.1002/14651858.CD002856.pub2]; Coulter A, 2006, PATIENT FOCUSED INTE; Deakin T, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003417.pub2; Eakin EG, 2002, DIABETES-METAB RES, V18, P26, DOI 10.1002/dmrr.266; Ford S, 2002, PATIENT EDUC COUNS, V47, P179, DOI 10.1016/S0738-3991(01)00198-7; Glueckauf RL, 2004, PROF PSYCHOL-RES PR, V35, P615, DOI 10.1037/0735-7028.35.6.615; Grilli R, 2002, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000389, DOI 10.1002/14651858.CD000389]; Gustafson DH, 2002, INT J MED INFORM, V65, P169, DOI 10.1016/S1386-5056(02)00048-5; HAYNES RB, 2005, COCHRANE DB SYST REV, V4, P11; Heneghan C, 2006, LANCET, V367, P404, DOI 10.1016/S0140-6736(06)68139-7; Hinkin J, 2002, EDTNA ERCA J, V28, P134; *I MED, 2004, HLTH LIT PRESCR END; Johansson K, 2005, J ADV NURS, V50, P212, DOI 10.1111/j.1365-2648.2005.03381.x; Kennedy ADM, 2002, JAMA-J AM MED ASSOC, V288, P2701, DOI 10.1001/jama.288.21.2701; McPherson CJ, 2001, J PUBLIC HEALTH MED, V23, P227, DOI 10.1093/pubmed/23.3.227; Murray E, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004274.pub4; O'Connor A, 2003, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD001431; Warsi A, 2004, ARCH INTERN MED, V164, P1641, DOI 10.1001/archinte.164.15.1641	20	620	637	1	42	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 7	2007	335	7609					24	27		10.1136/bmj.39246.581169.80	http://dx.doi.org/10.1136/bmj.39246.581169.80			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	191LY	17615222	Green Published			2022-12-28	WOS:000248133900030
J	Vernick, JS; Rutkow, L; Teret, SP				Vernick, Jon S.; Rutkow, Lainie; Teret, Stephen P.			Public health benefits of recent litigation against the tobacco industry	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Law & Publ Hlth, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Vernick, JS (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Law & Publ Hlth, 624 N Broadway, Baltimore, MD 21205 USA.	jvernick@jhsph.edu		Rutkow, Helaine/0000-0001-6423-7291				Alamar B, 2006, AM J PUBLIC HEALTH, V96, P1359, DOI 10.2105/AJPH.2005.069617; Daynard RA, 2001, AM J PUBLIC HEALTH, V91, P1967, DOI 10.2105/AJPH.91.12.1967; Glantz SA, 1997, JAMA-J AM MED ASSOC, V277, P751, DOI 10.1001/jama.277.9.751; Gross CP, 2002, NEW ENGL J MED, V347, P1080, DOI 10.1056/NEJMsa012743; Jacobson PD, 2002, J LAW MED ETHICS, V30, P224, DOI 10.1111/j.1748-720X.2002.tb00389.x; Kozlowski LT, 1998, AM J PREV MED, V15, P9, DOI 10.1016/S0749-3797(98)00004-X; KRANTZ M, 2006, US TODAY        0707, pB1; LaFrance AB, 2000, AM J LAW MED, V26, P187; Levin Myron, 2006, LOS ANGELES TIM 0707, pA; Office of the Surgeon General, 2004, HLTH CONS SMOK REP S; RABIN RL, 2001, REGULATING TOBACCO, P176; Schroeder SA, 2004, NEW ENGL J MED, V350, P293, DOI 10.1056/NEJMsr031421; SHENON P, 2006, NY TIMES        0818, pA13; Vernick JS, 2003, EPIDEMIOL REV, V25, P90, DOI 10.1093/epirev/mxg001; Warner KE, 2003, TOB CONTROL, V12, pI1, DOI 10.1136/tc.12.suppl_1.i1; WARNER M, 2006, N Y TIMES       0211, pC1; 2006, NY TIMES        0707, pC1	17	18	18	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 4	2007	298	1					86	89		10.1001/jama.298.1.86	http://dx.doi.org/10.1001/jama.298.1.86			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185OU	17609494				2022-12-28	WOS:000247721100025
J	Stephens, DS; Greenwood, B; Brandtzaeg, P				Stephens, David S.; Greenwood, Brian; Brandtzaeg, Petter			Epidemic meningitis, meningococcaemia, and Neisseria meningitidis	LANCET			English	Review							4G/5G PROMOTER POLYMORPHISM; TOLL-LIKE RECEPTOR-4; CASE-FATALITY RATE; BACTERIAL-MENINGITIS; PROTEIN-C; COMPLEMENT ACTIVATION; CEREBROSPINAL-FLUID; PURPURA FULMINANS; SEPTIC SHOCK; SEROGROUP-A	Meningococcus, an obligate human bacterial pathogen remains worldwide and devastating cause of epidemic meningitis and sepsis. However, advances have been made in our understanding of meningococcal biology and pathogenesis, global epidemiology, transmission and carriage, host susceptibility, pathophysiology, and clinical presentations. Approaches to diagnosis, treatment, and chemoprophylaxis are now in use on the basis of these advances. Importantly, the next generation of meningococcal conjugate vaccines for serogroups A, C, Y, W-135, and broadly effective serogroup B vaccines are on the horizon, which could eliminate the organism as a major threat to human health in industrialised countries in the next decade. The crucial challenge will be effective introduction of new meningococcal vaccines into developing countries, especially in sub-Saharan Africa, where they are urgently needed.	Emory Univ, Sch Med, Atlanta, GA 30322 USA; Atlanta VA Med Ctr, Res Serv 151I, Decatur, GA USA; London Sch Hyg & Trop Med, London WC1, England; Ullevaal Univ Hosp, Dept Paediat, Oslo, Norway; Ullevaal Univ Hosp, Dept Clin Chem, Oslo, Norway; Univ Oslo, Fac Med, Oslo, Norway	Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Atlanta VA Medical Center; University of London; London School of Hygiene & Tropical Medicine; University of Oslo; University of Oslo; University of Oslo	Stephens, DS (corresponding author), Emory Univ, Sch Med, 1440 Clifton Rd NE,Suite 313, Atlanta, GA 30322 USA.	dstep01@emory.edu	Stephens, David S/A-8788-2012	Brandtzaeg, Petter/0000-0002-0667-1097				Abramson JS, 2000, PEDIATRICS, V106, P1500, DOI 10.1542/peds.106.6.1500; Aguilera JF, 2002, EMERG INFECT DIS, V8, P761, DOI 10.3201/eid0808.010422; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Annane D, 2005, LANCET, V365, P63, DOI 10.1016/S0140-6736(04)17667-8; [Anonymous], 2006, Wkly Epidemiol Rec, V81, P119; Antignac A, 2003, CLIN INFECT DIS, V37, P912, DOI 10.1086/377739; APICELLA MA, 2005, PRINCIPLES PRACTICE, P2498; Arend SM, 2006, EUR J CLIN MICROBIOL, V25, P43, DOI 10.1007/s10096-005-0066-y; ARTENSTEIN MS, 1970, NEW ENGL J MED, V282, P417, DOI 10.1056/NEJM197002192820803; ARTENSTEIN MS, 1967, J AMER MED ASSOC, V201, P1004; Baines PB, 1999, CRIT CARE MED, V27, P1187, DOI 10.1097/00003246-199906000-00050; Batenburg WW, 2005, VASC PHARMACOL, V42, P109, DOI 10.1016/j.vph.2005.01.005; Bjerre A, 2000, CLIN INFECT DIS, V30, P643, DOI 10.1086/313754; Bjerre A, 2003, J ENDOTOXIN RES, V9, P155, DOI 10.1179/096805103125001559; Bjerre A, 2002, J INFECT DIS, V185, P220, DOI 10.1086/338269; BLACKWELL CC, 1992, EPIDEMIOL INFECT, V108, P441, DOI 10.1017/S0950268800049943; Block KI, 2006, INTEGR CANCER THER, V5, P3, DOI 10.1177/1534735405286005; Booy R, 2001, ARCH DIS CHILD, V85, P386, DOI 10.1136/adc.85.5.386; Borel T, 2006, T ROY SOC TROP MED H, V100, P964, DOI 10.1016/j.trstmh.2006.03.002; BRANDTZAEG P, 1991, PROG CLIN BIOL RES, V367, P25; BRANDTZAEG P, 1992, J INFECT DIS, V166, P650, DOI 10.1093/infdis/166.3.650; BRANDTZAEG P, 1990, THROMB RES, V57, P271, DOI 10.1016/0049-3848(90)90326-8; BRANDTZAEG P, 1983, NIPH (National Institute of Public Health) Annals (Oslo), V6, P183; Brandtzaeg P, 1996, J INFECT DIS, V173, P647, DOI 10.1093/infdis/173.3.647; Brandtzaeg P, 2001, J ENDOTOXIN RES, V7, P401, DOI 10.1177/09680519010070060401; BRANDTZAEG P, 1989, J INFECT DIS, V159, P195, DOI 10.1093/infdis/159.2.195; BRANDTZAEG P, 1989, J INFECT DIS, V160, P58, DOI 10.1093/infdis/160.1.58; BRANDTZAEG P, 1989, THROMB RES, V55, P459, DOI 10.1016/0049-3848(89)90054-6; Brandtzaeg P., 1992, BACTERIAL ENDOTOXIC, P327; Brandtzaeg P., 2006, HDB MENINGOCOCCAL DI, P427, DOI [10.1002/3527608508.ch21, DOI 10.1002/3527608508.CH21]; Brandtzaeg Petter, 2005, Adv Pediatr, V52, P129, DOI 10.1016/j.yapd.2005.03.005; Brooks R, 2006, CLIN INFECT DIS, V43, P49, DOI 10.1086/504804; CARTWRIGHT K, 1994, MENINGOCOCCAL DIS, P115; CARTWRIGHT K, BMJ, V305, P143; CARTWRIGHT KAV, 1987, EPIDEMIOL INFECT, V99, P591, DOI 10.1017/S0950268800066449; Caugant DA, 1998, APMIS, V106, P505, DOI 10.1111/j.1699-0463.1998.tb01379.x; Davidsen T, 2006, NAT REV MICROBIOL, V4, P11, DOI 10.1038/nrmicro1324; de Kleijn ED, 2003, CRIT CARE MED, V31, P1839, DOI 10.1097/01.CCM.0000072121.61120.D8; De Kleijn ED, 2002, PEDIATR INFECT DIS J, V21, P330, DOI 10.1097/00006454-200204000-00013; Delany I, 2006, J BACTERIOL, V188, P2483, DOI 10.1128/JB.188.7.2483-2492.2006; Derkx B, 1999, CLIN INFECT DIS, V28, P770, DOI 10.1086/515184; Diggle MA, 2006, EXPERT REV MOL DIAGN, V6, P79, DOI 10.1586/14737159.6.1.79; Djibo S, 2003, TROP MED INT HEALTH, V8, P1118, DOI 10.1046/j.1360-2276.2003.01126.x; Dolan-Livengood JM, 2003, J INFECT DIS, V187, P1616, DOI 10.1086/374740; Dyet KH, 2006, EPIDEMIOL INFECT, V134, P377, DOI 10.1017/S0950268805004954; Ellis-Pegler R, 2003, CLIN INFECT DIS, V37, P658, DOI 10.1086/377203; Emonts M, 2003, LANCET INFECT DIS, V3, P565, DOI 10.1016/S1473-3099(03)00740-0; Faber J, 2006, PEDIATR INFECT DIS J, V25, P80, DOI 10.1097/01.inf.0000195595.22547.fe; Faust SN, 2001, NEW ENGL J MED, V345, P408, DOI 10.1056/NEJM200108093450603; Fijen CAP, 2000, CLIN EXP IMMUNOL, V120, P338, DOI 10.1046/j.1365-2249.2000.01208.x; Fijen CAP, 1999, CLIN INFECT DIS, V28, P98, DOI 10.1086/515075; FIJNVANDRAAT K, 1995, THROMB HAEMOSTASIS, V73, P15; Fischer M, 2005, PEDIATR INFECT DIS J, V24, P177, DOI 10.1097/01.inf.0000154437.79398.ed; Flexner S, 1913, J EXP MED, V17, P553, DOI 10.1084/jem.17.5.553; FROSCH M, 1989, P NATL ACAD SCI USA, V86, P1669, DOI 10.1073/pnas.86.5.1669; GIRARDIN E, 1992, J INFECT DIS, V165, P695, DOI 10.1093/infdis/165.4.695; Giuliani MM, 2006, P NATL ACAD SCI USA, V103, P10834, DOI 10.1073/pnas.0603940103; GOLD R, 1975, J CLIN INVEST, V56, P1536, DOI 10.1172/JCI108235; Goldacre MJ, 2003, BRIT MED J, V327, P596, DOI 10.1136/bmj.327.7415.596; Goldman AP, 1997, LANCET, V349, P466, DOI 10.1016/S0140-6736(96)12106-1; GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1307, DOI 10.1084/jem.129.6.1307; GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1327, DOI 10.1084/jem.129.6.1327; Goldwater PN, 2005, INT J ANTIMICROB AG, V26, P408, DOI 10.1016/j.ijantimicag.2005.08.005; GOTSCHLICH EC, 1969, J EXP MED, V129, P1367, DOI 10.1084/jem.129.6.1367; Gray SJ, 2006, J MED MICROBIOL, V55, P887, DOI 10.1099/jmm.0.46288-0; Greenwood B, 1999, T ROY SOC TROP MED H, V93, P341, DOI 10.1016/S0035-9203(99)90106-2; GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P536, DOI 10.1016/0035-9203(87)90397-X; GREENWOOD BM, 1985, LANCET, V2, P829, DOI 10.1016/S0140-6736(85)90812-8; Guarner J, 2004, AM J CLIN PATHOL, V122, P754, DOI 10.1309/3489075U03LMK9AE; Gupta S, 2004, ARCH DIS CHILD, V89, P82; Hackett SJ, 2002, ARCH DIS CHILD, V86, P44, DOI 10.1136/adc.86.1.44; Hackett SJ, 2001, J MED MICROBIOL, V50, P847, DOI 10.1099/0022-1317-50-10-847; HAHNE SJM, 2006, BMJ-BRIT MED J, V332, P1283, DOI DOI 10.1136/BMJ.332.7553.1299; HANEBERG B, 1983, NIPH (National Institute of Public Health) Annals (Oslo), V6, P43; Haralambous E, 2003, CRIT CARE MED, V31, P2788, DOI 10.1097/01.CCM.0000100122.57249.5D; Harnden A, 2006, BRIT MED J, V332, P1295, DOI 10.1136/bmj.38789.723611.55; Harrison LH, 2001, JAMA-J AM MED ASSOC, V286, P694, DOI 10.1001/jama.286.6.694; Harrison OB, 2002, INFECT IMMUN, V70, P5193, DOI 10.1128/IAI.70.9.5193-5201.2002; Harwood CA, 2005, BRIT J DERMATOL, V153, P669, DOI 10.1111/j.1365-2133.2005.06771.x; Hazelzet JA, 1996, THROMB HAEMOSTASIS, V76, P932; Hazelzet JA, 1998, INFECT IMMUN, V66, P5350, DOI 10.1128/IAI.66.11.5350-5356.1998; Hermans PWM, 1999, LANCET, V354, P556, DOI 10.1016/S0140-6736(99)02220-5; Hibberd ML, 1999, LANCET, V353, P1049, DOI 10.1016/S0140-6736(98)08350-0; Hilse R, 1996, J BACTERIOL, V178, P2527, DOI 10.1128/jb.178.9.2527-2532.1996; Ingalls RR, 2001, INFECT IMMUN, V69, P2230, DOI 10.1128/IAI.69.4.2230-2236.2001; JACKSON LA, 1995, JAMA-J AM MED ASSOC, V273, P383, DOI 10.1001/jama.273.5.383; Janda WM, 2003, MANUAL CLIN MICROBIO, V8th, P585; Jorgensen JH, 2005, J CLIN MICROBIOL, V43, P3162, DOI 10.1128/JCM.43.7.3162-3171.2005; Kahler CM, 1998, CRIT REV MICROBIOL, V24, P281, DOI 10.1080/10408419891294216; Kanegaye JT, 2001, PEDIATRICS, V108, P1169; LaForce FM, 2003, LANCET, V362, P251, DOI 10.1016/S0140-6736(03)13930-X; Larrauri A, 2005, VACCINE, V23, P4097, DOI 10.1016/j.vaccine.2005.03.045; Levin M, 2000, LANCET, V356, P961, DOI 10.1016/S0140-6736(00)02712-4; Lewis R, 2001, LANCET, V358, P287, DOI 10.1016/S0140-6736(01)05484-8; Linz B, 2000, MOL MICROBIOL, V36, P1049, DOI 10.1046/j.1365-2958.2000.01932.x; Lodder MC, 1996, J MED MICROBIOL, V45, P16, DOI 10.1099/00222615-45-1-16; Luyt DK, 2004, ACTA PAEDIATR, V93, P1608, DOI 10.1080/08035250410022549; MacLennan J, 2006, EMERG INFECT DIS, V12, P950; Maiden MCJ, 2002, LANCET, V359, P1829, DOI 10.1016/S0140-6736(02)08679-8; Maiden MCJ, 1998, P NATL ACAD SCI USA, V95, P3140, DOI 10.1073/pnas.95.6.3140; MANDRELL RE, 1988, J EXP MED, V168, P107, DOI 10.1084/jem.168.1.107; MARZOUK O, 1991, ARCH DIS CHILD, V66, P485, DOI 10.1136/adc.66.4.485; Massari P, 2003, TRENDS MICROBIOL, V11, P87, DOI 10.1016/S0966-842X(02)00037-9; Melendez E, 2006, CURR OPIN PEDIATR, V18, P245, DOI 10.1097/01.mop.0000193305.55635.ff; Merz AJ, 2000, ANNU REV CELL DEV BI, V16, P423, DOI 10.1146/annurev.cellbio.16.1.423; Moe GR, 2006, MOL IMMUNOL, V43, P1424, DOI 10.1016/j.molimm.2005.07.033; Mogensen TH, 2006, J LEUKOCYTE BIOL, V80, P267, DOI 10.1189/jlb.1105626; Molesworth AM, 2003, EMERG INFECT DIS, V9, P1287; Molesworth AM, 2002, T ROY SOC TROP MED H, V96, P242, DOI 10.1016/S0035-9203(02)90089-1; Moller ASW, 2005, J INFECT DIS, V191, P768, DOI 10.1086/427514; Molyneux EM, 2002, LANCET, V360, P211, DOI 10.1016/S0140-6736(02)09458-8; MOORE PS, 1990, JAMA-J AM MED ASSOC, V264, P1271, DOI 10.1001/jama.264.10.1271; Morelli G, 1997, MOL MICROBIOL, V25, P1047, DOI 10.1046/j.1365-2958.1997.5211882.x; Mueller JE, 2006, J INFECT DIS, V193, P812, DOI 10.1086/500511; Nadel S, 2007, LANCET, V369, P836, DOI 10.1016/S0140-6736(07)60411-5; Namork E, 2002, LANCET, V360, P1741, DOI 10.1016/S0140-6736(02)11721-1; Nathan N, 2005, LANCET, V366, P308, DOI 10.1016/S0140-6736(05)66792-X; National Association of State Public Health Veterinarians Inc. (NASPHV), 2005, MMWR Recomm Rep, V54, P1; Nielsen HE, 2001, ARCH DIS CHILD, V85, P160, DOI 10.1136/adc.85.2.160; Nieuwland R, 2000, BLOOD, V95, P930, DOI 10.1182/blood.V95.3.930.003k46_930_935; Olesch CA, 1999, J PAEDIATR CHILD H, V35, P42, DOI 10.1046/j.1440-1754.1999.t01-1-00337.x; OSTERUD B, 1983, THROMB HAEMOSTASIS, V49, P5; Ovstebo R, 2004, J CLIN MICROBIOL, V42, P2980, DOI 10.1128/JCM.42.7.2980-2987.2004; Parker Margaret M, 2004, Crit Care Med, V32, pS591, DOI 10.1097/01.CCM.0000145904.97821.0D; Parkhill J, 2000, NATURE, V404, P502, DOI 10.1038/35006655; PELTOLA H, 1982, LANCET, V2, P595; Pizza M, 2000, SCIENCE, V287, P1816, DOI 10.1126/science.287.5459.1816; Pollard AJ, 1999, ARCH DIS CHILD, V80, P290, DOI 10.1136/adc.80.3.290; Pollard AJ, 2006, HDB MENINGOCOCCAL DI, P481; Post DMB, 2005, J BIOL CHEM, V280, P38383, DOI 10.1074/jbc.M508063200; Prins JM, 1997, J ANTIMICROB CHEMOTH, V39, P13, DOI 10.1093/jac/39.1.13; Racoosin JA, 1998, JAMA-J AM MED ASSOC, V280, P2094, DOI 10.1001/jama.280.24.2094; Raghunathan PL, 2006, J INFECT DIS, V193, P607, DOI 10.1086/499822; RAMSAY ME, 2003, BMJ-BRIT MED J, V326, P36566; Raymond NJ, 1997, J INFECT DIS, V176, P1277, DOI 10.1086/514123; Read RC, 2001, J INFECT DIS, V184, P640, DOI 10.1086/322798; Riordan FAI, 1999, CRIT CARE MED, V27, P2257, DOI 10.1097/00003246-199910000-00032; Riordan FAI, 2001, EMERG MED J, V18, P162, DOI 10.1136/emj.18.3.162; Rosenstein NE, 1999, J INFECT DIS, V180, P1894, DOI 10.1086/315158; Rosenstein NE, 2001, NEW ENGL J MED, V344, P1378, DOI 10.1056/NEJM200105033441807; Russell JA, 2006, NEW ENGL J MED, V355, P1699, DOI 10.1056/NEJMra043632; Saez-Llorens X, 2003, LANCET, V361, P2139, DOI 10.1016/S0140-6736(03)13693-8; SCHOEN C, 2006, HDB MENINGOCOCCAL DI, P77; SJOHOLM AG, 1982, CLIN EXP IMMUNOL, V50, P291; Smirnova I, 2003, P NATL ACAD SCI USA, V100, P6075, DOI 10.1073/pnas.1031605100; Snape MD, 2005, LANCET INFECT DIS, V5, P21, DOI 10.1016/S1473-3099(04)01251-4; Soriano-Gabarro M, 2004, J HEALTH POPUL NUTR, V22, P275; Steeghs L, 1998, NATURE, V392, P449, DOI 10.1038/33046; STEPHENS DS, 1982, J INFECT DIS, V146, P568, DOI 10.1093/infdis/146.4.568; STEPHENS DS, 1983, J INFECT DIS, V148, P369, DOI 10.1093/infdis/148.3.369; STEPHENS DS, 1995, ANN INTERN MED, V123, P937, DOI 10.7326/0003-4819-123-12-199512150-00007; Stephens DS, 1999, LANCET, V353, P941, DOI 10.1016/S0140-6736(98)00279-7; Swartley JS, 1997, P NATL ACAD SCI USA, V94, P271, DOI 10.1073/pnas.94.1.271; Tettelin H, 2000, SCIENCE, V287, P1809, DOI 10.1126/science.287.5459.1809; Thompson MJ, 2006, LANCET, V367, P397, DOI 10.1016/S0140-6736(06)67932-4; Thomson MC, 2006, TROP MED INT HEALTH, V11, P781, DOI 10.1111/j.1365-3156.2006.01630.x; Trotter CL, 2006, HUM VACCINES, V2, P68, DOI 10.4161/hv.2.2.2611; Trotter CL, 2004, LANCET, V364, P365, DOI 10.1016/S0140-6736(04)16725-1; Trotter CL, 2002, J MED MICROBIOL, V51, P855, DOI 10.1099/0022-1317-51-10-855; Tully J, 2006, BMJ-BRIT MED J, V332, P445, DOI 10.1136/bmj.38725.728472.BE; Tzeng YL, 2000, MICROBES INFECT, V2, P687, DOI 10.1016/S1286-4579(00)00356-7; van de Beek D, 2006, NEW ENGL J MED, V354, P44, DOI 10.1056/NEJMra052116; van Deuren L, 2000, LANCET, V356, P954, DOI 10.1016/S0140-6736(00)02705-7; van Deuren M, 2000, CLIN MICROBIOL REV, V13, P144, DOI 10.1128/CMR.13.1.144-166.2000; van Deuren M, 1998, CLIN INFECT DIS, V26, P918, DOI 10.1086/513933; VANDEUREN M, 1993, BMJ-BRIT MED J, V306, P1229, DOI 10.1136/bmj.306.6887.1229; VANDEUREN M, 1992, CLIN INFECT DIS, V15, P424, DOI 10.1093/clind/15.3.424; VANDEUREN M, 1995, J INFECT DIS, V172, P433, DOI 10.1093/infdis/172.2.433; VILADRICH PF, 1986, ARCH INTERN MED, V146, P2380, DOI 10.1001/archinte.146.12.2380; Vincent Jean-Louis, 2004, Crit Care Med, V32, pS451, DOI 10.1097/01.CCM.0000142984.44321.A4; WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333; WANG JF, 1992, INFECT IMMUN, V60, P5267, DOI 10.1128/IAI.60.12.5267-5282.1992; Weichselbaum A, 1887, FORTSCHR MED, V5, P573; Welch SB, 2003, ARCH DIS CHILD, V88, P608, DOI 10.1136/adc.88.7.608; Wells LC, 2001, ARCH DIS CHILD, V85, P218, DOI 10.1136/adc.85.3.218; White B, 2000, BLOOD, V96, P3719, DOI 10.1182/blood.V96.12.3719.h8003719_3719_3724; *WHO WORK GROUP, 1995, CONTR MEN DIS WHO PR; Yazdankhah SP, 2004, J MED MICROBIOL, V53, P821, DOI 10.1099/jmm.0.45529-0; YOUNG LS, 1972, NEW ENGL J MED, V287, P5, DOI 10.1056/NEJM197207062870102; Zenz W, 2004, CRIT CARE MED, V32, P1777, DOI 10.1097/01.CCM.0000133667.86429.5D; Zerouali K, 2002, EUR J CLIN MICROBIOL, V21, P483, DOI 10.1007/s10096-002-0736-y; Zimmer SM, 2006, CURR OPIN INVEST DR, V7, P733; Zughaier SM, 2005, INFECT IMMUN, V73, P2940, DOI 10.1128/IAI.73.5.2940-2950.2005; Zughaier SM, 2004, INFECT IMMUN, V72, P371, DOI 10.1128/IAI.72.1.371-380.2004	184	639	686	2	124	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 30	2007	369	9580					2196	2210		10.1016/S0140-6736(07)61016-2	http://dx.doi.org/10.1016/S0140-6736(07)61016-2			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LX	17604802				2022-12-28	WOS:000247644200031
J	Manning, BD; Cantley, LC				Manning, Brendan D.; Cantley, Lewis C.			AKT/PKB signaling: Navigating downstream	CELL			English	Review							PROTEIN-KINASE-B; INSULIN-STIMULATED PHOSPHORYLATION; GLYCOGEN-SYNTHASE KINASE-3; TUMOR-SUPPRESSOR GENE; IN-VIVO ROLE; NF-KAPPA-B; MAMMALIAN TARGET; NITRIC-OXIDE; MEDIATED PHOSPHORYLATION; TRANSCRIPTION FACTORS	The serine/threonine kinase Akt, also known as protein kinase B (PKB), is a central node in cell signaling downstream of growth factors, cytokines, and other cellular stimuli. Aberrant loss or gain of Akt activation underlies the pathophysiological properties of a variety of complex diseases, including type-2 diabetes and cancer. Here, we review the molecular properties of Akt and the approaches used to characterize its true cellular targets. In addition, we discuss those Akt substrates that are most likely to contribute to the diverse cellular roles of Akt, which include cell survival, growth, proliferation, angiogenesis, metabolism, and migration.	Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Syst Biol, Beth Israel Deaconess Med Ctr,Div Signal T, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Manning, BD (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave,SPH2-117, Boston, MA 02115 USA.	bmanning@hsph.harvard.edu	Li, Chia Cheng/D-9906-2015; Manning, Brendan/ABD-6528-2021; Peng, Chunwei/F-6788-2010; Cantley, Lewis C/D-1800-2014	Manning, Brendan/0000-0003-3895-5956; Cantley, Lewis C/0000-0002-1298-7653	NCI NIH HHS [P01 CA120964-01A1, P01-CA120964, CA122617, P01-CA089021, R01 CA122617, P01 CA089021, R01 CA122617-02, P01 CA120964] Funding Source: Medline; NIGMS NIH HHS [R37 GM041890, R01 GM041890, R01 GM056203, GM41890] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA122617, P01CA120964, P01CA089021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890, R37GM041890, R01GM056203] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Ackah E, 2005, J CLIN INVEST, V115, P2119, DOI 10.1172/JCI24726; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Arboleda MJ, 2003, CANCER RES, V63, P196; Bai L, 2007, CELL METAB, V5, P47, DOI 10.1016/j.cmet.2006.11.013; Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Berwick DC, 2004, J CELL SCI, V117, P5985, DOI 10.1242/jcs.01517; Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cai SL, 2006, J CELL BIOL, V173, P279, DOI 10.1083/jcb.200507119; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chiang GG, 2005, J BIOL CHEM, V280, P25485, DOI 10.1074/jbc.M501707200; Collins BJ, 2003, EMBO J, V22, P4202, DOI 10.1093/emboj/cdg407; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dong JX, 2004, GENE DEV, V18, P2479, DOI 10.1101/gad.1240504; Dummler B, 2007, BIOCHEM SOC T, V35, P231, DOI 10.1042/BST0350231; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Eguez L, 2005, CELL METAB, V2, P263, DOI 10.1016/j.cmet.2005.09.005; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Gordan JD, 2007, CURR OPIN GENET DEV, V17, P71, DOI 10.1016/j.gde.2006.12.006; Goswami A, 2005, MOL CELL, V20, P33, DOI 10.1016/j.molcel.2005.08.016; Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007; Harthill JE, 2002, BIOCHEM J, V368, P565, DOI 10.1042/BJ20020838; Heron-Milhavet L, 2006, MOL CELL BIOL, V26, P8267, DOI 10.1128/MCB.00201-06; Holz MK, 2005, J BIOL CHEM, V280, P26089, DOI 10.1074/jbc.M504045200; Hutchinson JN, 2004, CANCER RES, V64, P3171, DOI 10.1158/0008-5472.CAN-03-3465; Hutti JE, 2004, NAT METHODS, V1, P27, DOI 10.1038/NMETH708; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; JACINTO PF, 2006, P NATL ACAD SCI USA, V127, P125; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; King FW, 2004, CELL CYCLE, V3, P634; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kovacina KS, 2003, J BIOL CHEM, V278, P10189, DOI 10.1074/jbc.M210837200; LI X, 2007, IN PRESS NATURE 0606, DOI DOI 10.1038/NATURE05861; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Lum JJ, 2007, GENE DEV, V21, P1037, DOI 10.1101/gad.1529107; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; McManus EJ, 2004, EMBO J, V23, P2071, DOI 10.1038/sj.emboj.7600218; McManus EJ, 2005, EMBO J, V24, P1571, DOI 10.1038/sj.emboj.7600633; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Morbidelli L, 2003, CURR PHARM DESIGN, V9, P521, DOI 10.2174/1381612033391405; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Ozes ON, 1999, NATURE, V401, P82; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Plas DR, 2005, ONCOGENE, V24, P7435, DOI 10.1038/sj.onc.1209097; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; Robey RB, 2006, ONCOGENE, V25, P4683, DOI 10.1038/sj.onc.1209595; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sano H, 2003, J BIOL CHEM, V278, P14599, DOI 10.1074/jbc.C300063200; Sapkota GP, 2007, BIOCHEM J, V401, P29, DOI 10.1042/BJ20061088; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sekimoto T, 2004, EMBO J, V23, P1934, DOI 10.1038/sj.emboj.7600198; Sekulic A, 2000, CANCER RES, V60, P3504; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shtivelman E, 2002, CURR BIOL, V12, P919, DOI 10.1016/S0960-9822(02)00843-6; Skeen JE, 2006, CANCER CELL, V10, P269, DOI 10.1016/j.ccr.2006.08.022; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Sundqvist A, 2005, CELL METAB, V1, P379, DOI 10.1016/j.cmet.2005.04.010; Taha C, 1999, J BIOL CHEM, V274, P33085, DOI 10.1074/jbc.274.46.33085; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; TRAN H, 2003, SCI STKE, pRE5, DOI DOI 10.1126/STKE.2003.172.RE5; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhang H, 2003, CARCINOGENESIS, V24, P185, DOI 10.1093/carcin/24.2.185; Zhang H, 2002, J BIOL CHEM, V277, P39379, DOI 10.1074/jbc.M206399200; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou GL, 2006, J BIOL CHEM, V281, P36443, DOI 10.1074/jbc.M600788200; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	113	4493	4710	20	590	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 29	2007	129	7					1261	1274		10.1016/j.cell.2007.06.009	http://dx.doi.org/10.1016/j.cell.2007.06.009			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188HQ	17604717	Bronze, Green Accepted			2022-12-28	WOS:000247911400013
J	Pfleiderer, C; Boni, P; Keller, T; Rossler, UK; Rosch, A				Pfleiderer, C.; Boeni, P.; Keller, T.; Roessler, U. K.; Rosch, A.			Non-Fermi liquid metal without quantum criticality	SCIENCE			English	Article							PHASE-TRANSITION; MNSI; ELECTRON; SUPERCONDUCTIVITY; SUPPRESSION; DEPENDENCE; PRESSURE; STATE	A key question in condensed matter physics concerns whether pure three-dimensional metals can always be described as Fermi liquids. Using neutron Larmor diffraction to overcome the traditional resolution limit of diffraction experiments, we studied the lattice constants of the cubic itinerant-electron magnet manganese silicide (MnSi) at low temperatures and high pressures. We were able to resolve the nature of the phase diagram of MnSi and to establish that a stable, extended non-Fermi liquid state emerges under applied pressure without quantum criticality. This suggests that new forms of quantum order may be expected even far from quantum phase transitions.	Tech Univ Munich, Phys Dept E21, D-85748 Garching, Germany; Max Planck Inst Festkorperforsch, D-70569 Stuttgart, Germany; Tech Univ Munich, Forsch Neutronenquelle Heinz Maier Leibnitz, FRM II, D-85748 Garching, Germany; Leibniz Inst Festkorper & Werkstoffforsch IFW Dre, D-01171 Dresden, Germany; Univ Cologne, Inst Theoret Phys, D-50937 Cologne, Germany	Technical University of Munich; Max Planck Society; Technical University of Munich; Leibniz Institute for Solid State & Materials Research Dresden; University of Cologne	Pfleiderer, C (corresponding author), Tech Univ Munich, Phys Dept E21, D-85748 Garching, Germany.	christian.pfleiderer@frm2.tum.de	Pfleiderer, Christian/P-3575-2014; Rosch, Achim/AAY-7730-2020; Rosch, Achim/A-2962-2009	Pfleiderer, Christian/0000-0001-7749-7965; Rosch, Achim/0000-0002-6586-5721; Rosch, Achim/0000-0002-6586-5721				Binz B, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.207202; Borzi RA, 2007, SCIENCE, V315, P214, DOI 10.1126/science.1134796; Doiron-Leyraud N, 2003, NATURE, V425, P595, DOI 10.1038/nature01968; Fak B, 2005, J PHYS-CONDENS MAT, V17, P1635, DOI 10.1088/0953-8984/17/10/018; Fawcett E., 1970, International Journal of Magnetism, V1, P29; Garst M, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.205129; Grube K, 1999, PHYS REV B, V60, P11947, DOI 10.1103/PhysRevB.60.11947; Keller T, 2002, APPL PHYS A-MATER, V74, pS332, DOI 10.1007/s003390201612; KELLER T, 2002, SCATTERING, P1264; KROEGER FR, 1977, J APPL PHYS, V48, P853, DOI 10.1063/1.323746; LONZARICH GG, 1985, J PHYS C SOLID STATE, V18, P4339, DOI 10.1088/0022-3719/18/22/017; Mathur ND, 1998, NATURE, V394, P39, DOI 10.1038/27838; MATSUNAGA M, 1982, J PHYS SOC JPN, V51, P1153, DOI 10.1143/JPSJ.51.1153; Moriya T., 1985, SOLID STATE SCI, V56; Motoyama G, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.166402; Pedrazzini P, 2006, PHYSICA B, V378-80, P165, DOI 10.1016/j.physb.2006.01.062; Pfleiderer C, 2004, NATURE, V427, P227, DOI 10.1038/nature02232; Pfleiderer C, 1997, PHYS REV B, V55, P8330, DOI 10.1103/PhysRevB.55.8330; Pfleiderer C, 2003, PHYSICA B, V328, P100, DOI 10.1016/S0921-4526(02)01818-5; Pfleiderer C, 2001, NATURE, V414, P427, DOI 10.1038/35106527; Rossler UK, 2006, NATURE, V442, P797, DOI 10.1038/nature05056; Saxena SS, 2000, NATURE, V406, P587, DOI 10.1038/35020500; Schofield AJ, 1999, CONTEMP PHYS, V40, P95, DOI 10.1080/001075199181602; Tewari S, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.047207; Thessieu C, 1997, J PHYS-CONDENS MAT, V9, P6677, DOI 10.1088/0953-8984/9/31/019; Uemura YJ, 2007, NAT PHYS, V3, P29, DOI 10.1038/nphys488; Yu W, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.086403	28	106	106	0	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 29	2007	316	5833					1871	1874		10.1126/science.1142644	http://dx.doi.org/10.1126/science.1142644			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183WI	17600211				2022-12-28	WOS:000247602700031
J	Zhang, K; Guo, JZ; Peng, YQ; Xi, W; Guo, AK				Zhang, Ke; Guo, JianZeng; Peng, Yueqing; Xi, Wang; Guo, Aike			Dopamine-mushroom body circuit regulates saliency-based decision-making in Drosophila	SCIENCE			English	Article							EXPRESSION; NEURONS; BEHAVIOR; MEMORY; BRAIN; MELANOGASTER; VALUATION; BODIES; SYSTEM; REWARD	Drosophila melanogaster can make appropriate choices among alternative flight options on the basis of the relative salience of competing visual cues. We show that this choice behavior consists of early and late phases; the former requires activation of the dopaminergic system and mushroom bodies, whereas the latter is independent of these activities. Immunohistological analysis showed that mushroom bodies are densely innervated by dopaminergic axons. Thus, the circuit from the dopamine system to mushroom bodies is crucial for choice behavior in Drosophila.	Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Neurobiol, Inst Neurosci, Shanghai 200031, Peoples R China; Chinese Acad Sci, Grad Sch, Beijing, Peoples R China; Chinese Acad Sci, Inst Biophys, State Key Lab Brain & Cognit Sci, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; Institute of Biophysics, CAS	Guo, AK (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Neurobiol, Inst Neurosci, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	akguo@ion.ac.cn						Andretic R, 2005, CURR BIOL, V15, P1165, DOI 10.1016/j.cub.2005.05.025; Crittenden JR, 1998, LEARN MEMORY, V5, P38; Davis RL, 2005, ANNU REV NEUROSCI, V28, P275, DOI 10.1146/annurev.neuro.28.061604.135651; Dubnau J, 2001, NATURE, V411, P476, DOI 10.1038/35078077; Friggi-Grelin F, 2003, J NEUROBIOL, V54, P618, DOI 10.1002/neu.10185; Guo FZ, 2005, SCIENCE, V309, P307, DOI 10.1126/science.1111280; Han KA, 1996, NEURON, V16, P1127, DOI 10.1016/S0896-6273(00)80139-7; Heekeren HR, 2004, NATURE, V431, P859, DOI 10.1038/nature02966; HEISENBERG M, 1985, J NEUROGENET, V2, P1, DOI 10.3109/01677068509100140; Kim YC, 2003, GENE EXPR PATTERNS, V3, P237, DOI 10.1016/S1567-133X(02)00098-4; Kitamoto T, 2001, J NEUROBIOL, V47, P81, DOI 10.1002/neu.1018; Li H, 2000, CURR BIOL, V10, P211, DOI 10.1016/S0960-9822(00)00340-7; Liu G, 2006, NATURE, V439, P551, DOI 10.1038/nature04381; McGuire SE, 2001, SCIENCE, V293, P1330, DOI 10.1126/science.1062622; Padoa-Schioppa C, 2006, NATURE, V441, P223, DOI 10.1038/nature04676; Riemensperger T, 2005, CURR BIOL, V15, P1953, DOI 10.1016/j.cub.2005.09.042; Salzman CD, 2005, CURR OPIN NEUROBIOL, V15, P721, DOI 10.1016/j.conb.2005.10.016; Schultz W, 2006, ANNU REV PSYCHOL, V57, P87, DOI 10.1146/annurev.psych.56.091103.070229; Schwaerzel M, 2003, J NEUROSCI, V23, P10495, DOI 10.1523/jneurosci.23-33-10495.2003; Strauss R, 2002, CURR OPIN NEUROBIOL, V12, P633, DOI 10.1016/S0959-4388(02)00385-9; Sugrue LP, 2005, NAT REV NEUROSCI, V6, P363, DOI 10.1038/nrn1666; Tang SM, 2001, SCIENCE, V294, P1543, DOI 10.1126/science.1058237; Unoki S, 2005, EUR J NEUROSCI, V22, P1409, DOI 10.1111/j.1460-9568.2005.04318.x; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; Wang J, 2004, NEURON, V43, P663, DOI 10.1016/j.neuron.2004.06.033; Wise RA, 2004, NAT REV NEUROSCI, V5, P483, DOI 10.1038/nrn1406; Wolf R, 1998, LEARN MEMORY, V5, P166; Zhang YQ, 2002, GENESIS, V34, P142, DOI 10.1002/gene.10144	28	147	159	2	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 29	2007	316	5833					1901	1904		10.1126/science.1137357	http://dx.doi.org/10.1126/science.1137357			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183WI	17600217				2022-12-28	WOS:000247602700041
J	Foerster, K; Coulson, T; Sheldon, BC; Pemberton, JM; Clutton-Brock, TH; Kruuk, LEB				Foerster, Katharina; Coulson, Tim; Sheldon, Ben C.; Pemberton, Josephine M.; Clutton-Brock, Tim H.; Kruuk, Loeske E. B.			Sexually antagonistic genetic variation for fitness in red deer	NATURE			English	Article							NATURAL-POPULATIONS; ONTOGENIC CONFLICT; MATE CHOICE; SELECTION; HERITABILITY; DIMORPHISM; PLEIOTROPY; EVOLUTION; SEXES; WILD	Evolutionary theory predicts the depletion of genetic variation in natural populations as a result of the effects of selection, but genetic variation is nevertheless abundant for many traits that are under directional or stabilizing selection(1). Evolutionary geneticists commonly try to explain this paradox with mechanisms that lead to a balance between mutation and selection(2). However, theoretical predictions of equilibrium genetic variance under mutation-selection balance are usually lower than the observed values, and the reason for this is unknown(3). The potential role of sexually antagonistic selection in maintaining genetic variation has received little attention in this debate, surprisingly given its potential ubiquity in dioecious organisms. At fitness-related loci, a given genotype may be selected in opposite directions in the two sexes. Such sexually antagonistic selection will reduce the otherwise-expected positive genetic correlation between male and female fitness(4). Both theory(5-7) and experimental data(8-12) suggest that males and females of the same species may have divergent genetic optima, but supporting data from wild populations are still scarce(13-15). Here we present evidence for sexually antagonistic fitness variation in a natural population, using data from a long-term study of red deer (Cervus elaphus). We show that male red deer with relatively high fitness fathered, on average, daughters with relatively low fitness. This was due to a negative genetic correlation between estimates of fitness in males and females. In particular, we show that selection favours males that carry low breeding values for female fitness. Our results demonstrate that sexually antagonistic selection can lead to a trade-off between the optimal genotypes for males and females; this mechanism will have profound effects on the operation of selection and the maintenance of genetic variation in natural populations.	Univ Edinburgh, Inst Evolutionary Biol, Edinburgh EH9 3JT, Midlothian, Scotland; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Univ Oxford, Dept Zool, Edward Grey Inst, Oxford OX1 3PS, England; Univ London Imperial Coll Sci Technol & Med, Ctr Populat Biol, Ascot SL5 7PY, Berks, England; Univ London Imperial Coll Sci Technol & Med, Div Biol, Ascot SL5 7PY, Berks, England	University of Edinburgh; University of Cambridge; University of Oxford; Imperial College London; Imperial College London	Foerster, K (corresponding author), Univ Edinburgh, Inst Evolutionary Biol, Edinburgh EH9 3JT, Midlothian, Scotland.	foerster@orn.mpg.de; loeske.kruuk@ed.ac.uk	Coulson, Tim/AAL-8148-2021; Kruuk, Loeske E. B./J-3295-2012; Foerster, Katharina/AAX-3894-2020; Kruuk, Loeske/AAB-8714-2019; Sheldon, Ben C/A-8056-2010; Pemberton, Josephine M/F-3100-2010	Coulson, Tim/0000-0001-9371-9003; Kruuk, Loeske E. B./0000-0001-8588-1123; Kruuk, Loeske/0000-0001-8588-1123; Sheldon, Ben C/0000-0002-5240-7828; 	NERC [cpb010001] Funding Source: UKRI; Natural Environment Research Council [cpb010001, NE/B504314/1] Funding Source: researchfish	NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Barton NH, 2002, NAT REV GENET, V3, P11, DOI 10.1038/nrg700; Calsbeek R, 2004, J EVOLUTION BIOL, V17, P464, DOI 10.1046/j.1420-9101.2003.00665.x; Chippindale AK, 2001, P NATL ACAD SCI USA, V98, P1671, DOI 10.1073/pnas.041378098; Clutton-Brock TH., 1982, RED DEER BEHAV ECOLO; CLUTTONBROCK TH, 1983, J ANIM ECOL, V52, P367, DOI 10.2307/4560; Coulson T, 2006, P ROY SOC B-BIOL SCI, V273, P547, DOI 10.1098/rspb.2005.3357; Coulson T, 1997, ECOLOGY, V78, P852, DOI 10.1890/0012-9658(1997)078[0852:PSLDAC]2.0.CO;2; Fedorka KM, 2004, NATURE, V429, P65, DOI 10.1038/nature02492; FORSMAN A, 1995, J EVOLUTION BIOL, V8, P53, DOI 10.1046/j.1420-9101.1995.8010053.x; Gibson JR, 2002, P ROY SOC B-BIOL SCI, V269, P499, DOI 10.1098/rspb.2001.1863; GILMOUR AW, 2002, ASREML USER GUIDE 1; Hedrick PW, 1999, HEREDITY, V82, P126, DOI 10.1038/sj.hdy.6884400; HOULE D, 1992, GENETICS, V130, P195; Kokko H, 2001, ECOL LETT, V4, P322, DOI 10.1046/j.1461-0248.2001.00224.x; Kruuk LEB, 1999, P ROY SOC B-BIOL SCI, V266, P1655, DOI 10.1098/rspb.1999.0828; Kruuk LEB, 2002, EVOLUTION, V56, P1683, DOI 10.1111/j.0014-3820.2002.tb01480.x; Kruuk LEB, 2004, PHILOS T R SOC B, V359, P873, DOI 10.1098/rstb.2003.1437; Kruuk LEB, 2000, P NATL ACAD SCI USA, V97, P698, DOI 10.1073/pnas.97.2.698; Lynch M., 1998, GENETICS ANAL QUANTI; Marshall TC, 2002, P ROY SOC B-BIOL SCI, V269, P1533, DOI 10.1098/rspb.2002.2035; MEAGHER TR, 1992, EVOLUTION, V46, P445, DOI 10.1111/j.1558-5646.1992.tb02050.x; Merila J, 2001, GENETICA, V112, P199, DOI 10.1023/A:1013391806317; Metcalf CJE, 2007, TRENDS ECOL EVOL, V22, P205, DOI 10.1016/j.tree.2006.12.001; Pischedda A, 2006, PLOS BIOL, V4, P2099, DOI 10.1371/journal.pbio.0040356; Rice WR, 2000, P NATL ACAD SCI USA, V97, P12953, DOI 10.1073/pnas.97.24.12953; RICE WR, 1992, SCIENCE, V256, P1436, DOI 10.1126/science.1604317; RICE WR, 1984, EVOLUTION, V38, P735, DOI 10.1111/j.1558-5646.1984.tb00346.x; Rice WR, 2001, J EVOLUTION BIOL, V14, P685, DOI 10.1046/j.1420-9101.2001.00319.x; Robinson MR, 2006, EVOLUTION, V60, P2168, DOI 10.1111/j.0014-3820.2006.tb01854.x; Sokal RR, 1995, BIOMETRY; Turelli M, 2004, GENETICS, V166, P1053, DOI 10.1534/genetics.166.2.1053	31	280	283	0	169	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 28	2007	447	7148					1107	U9		10.1038/nature05912	http://dx.doi.org/10.1038/nature05912			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183HT	17597758				2022-12-28	WOS:000247564600036
J	Cole, TJ; Flegal, KM; Nicholls, D; Jackson, AA				Cole, Tim J.; Flegal, Katherine M.; Nicholls, Dasha; Jackson, Alan A.			Body mass index cut offs to define thinness in children and adolescents: international survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FOR-DISEASE-CONTROL; T-CELL COUNTS; NUTRITIONAL-STATUS; ANTIRETROVIRAL TREATMENT; QUALITY ASSESSMENT; ANOREXIA-NERVOSA; GROWTH STANDARDS; REFERENCE CURVES; UNITED-STATES; HIV-INFECTION	Objective To determine cut offs to define thinness in children and adolescents, based on body mass index at age 18 years. Design International survey of six large nationally representative cross sectional studies on growth. Setting Brazil, Great Britain, Hong Kong, the Netherlands, Singapore, and the United States. Subjects 97 876 mates and 94 851 females from birth to 25 years. Main outcome measure Body mass index (BMI, weight/ height2). Results The World Health Organization defines grade 2 thinness in adults as BMI <17. This same cut off, applied to the six datasets at age 18 years, gave mean BMI close to a z score of -2 and 80% of the median. Thus it matches existing criteria forwasting in children based on weight for height. For each dataset, centile curves were drawn to pass through the cut off of BMI 17 at 18 years. The resulting curves were averaged to provide age and sex specific cut-off points from 2-18 years. Similar cut offs were derived based on BMI 16 and 18.5 at 18 years, together providing definitions of thinness grades 1, 2, and 3 in children and adolescents consistent with the WHO adult definitions. Conclusions The proposed cut-off points should help to provide internationally comparable prevalence rates of thinness in children and adolescents.	UCL, Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London WC1N 1EH, England; Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA; Great Ormond St Hosp Sick Children, Dept Child & Adolescent Mental Hlth, London WC1N 3JH, England; Univ Southampton, Inst Human Nutr, Southampton, Hants, England	University of London; University College London; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Southampton	Cole, TJ (corresponding author), UCL, Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London WC1N 1EH, England.	tim.cote@ich.uct.ac.uk	Flegal, Katherine M/A-4608-2013; Yates, Emma/C-7318-2009; Cole, Tim J/B-7883-2008	Cole, Tim J/0000-0001-5711-8200; Nicholls, Dasha/0000-0001-7257-6605; Flegal, Katherine/0000-0002-0838-469X	MRC [G9827821] Funding Source: UKRI; Medical Research Council [G9827821(62595), G9827821] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		American Psychiatric Association, 2000, DIAGN STAT MAN MENT; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Brando B, 2000, CYTOMETRY, V42, P327, DOI 10.1002/1097-0320(20001215)42:6<327::AID-CYTO1000>3.0.CO;2-F; Chinn S, 2002, ANN HUM BIOL, V29, P306, DOI 10.1080/03014460110085340; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; COLE TJ, 1985, HUM BIOL, V57, P183; Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240; COLE TJ, 1992, STAT MED, V11, P1305, DOI 10.1002/sim.4780111005; Cole TJ, 1998, STAT MED, V17, P407, DOI 10.1002/(SICI)1097-0258(19980228)17:4&lt;407::AID-SIM742&gt;3.0.CO;2-L; COLE TJ, 1979, ANN HUM BIOL, V6, P249, DOI 10.1080/03014467900007252; Cole TJ, 1999, ANN HUM BIOL, V26, P303, DOI 10.1080/030144699282633; COLE TJ, 1986, ANN HUM BIOL, V13, P433, DOI 10.1080/03014468600008621; COLE TJ, 1994, BMJ-BRIT MED J, V308, P641, DOI 10.1136/bmj.308.6929.641; Cole TJ, 1991, ANTHROPOMETRIC ASSES, P83; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; de Onis M, 2000, B WORLD HEALTH ORGAN, V78, P1271; de Onis M, 2006, ACTA PAEDIATR, V95, P76, DOI 10.1080/08035320500495548; Diagbouga S, 2003, AIDS, V17, P2201, DOI 10.1097/00002030-200310170-00008; Dietz WH, 1998, J PEDIATR-US, V132, P191; El-Ghannam Ashraf Ragab, 2003, J Health Soc Policy, V16, P1, DOI 10.1300/J045v16n04_01; Flegal KM, 2002, AM J CLIN NUTR, V75, P761, DOI 10.1093/ajcn/75.4.761; Fredriks AM, 2000, ARCH DIS CHILD, V82, P107, DOI 10.1136/adc.82.2.107; Freedman DS, 2005, INT J OBESITY, V29, P1, DOI 10.1038/sj.ijo.0802735; GARROW JS, 1985, INT J OBESITY, V9, P147; Gelman R, 2000, CYTOMETRY, V42, P1, DOI 10.1002/(SICI)1097-0320(20000215)42:1<1::AID-CYTO1>3.0.CO;2-A; Glencross D, 2002, CYTOMETRY, V50, P69, DOI 10.1002/cyto.10068; GOLDEN MHN, 2000, HUMAN NUTR DIET, P517; Gomez Federico, 1956, J Trop Pediatr (Lond), V2, P77; Hamill P.V., 1977, NCHS GROWTH CURVES C; Harries AD, 2006, LANCET, V367, P1870, DOI 10.1016/S0140-6736(06)68809-0; Hattori K, 2002, AM J HUM BIOL, V14, P275, DOI 10.1002/ajhb.10037; Hebebrand J, 1996, INT J EAT DISORDER, V19, P359, DOI 10.1002/(SICI)1098-108X(199605)19:4&lt;359::AID-EAT4&gt;3.0.CO;2-K; JAMES WPT, 1988, EUR J CLIN NUTR, V42, P969; Jani IV, 2001, J IMMUNOL METHODS, V257, P145; Janossy G, 2004, LANCET, V363, P1074, DOI 10.1016/S0140-6736(04)15849-2; Janossy G, 2000, BRIT J HAEMATOL, V111, P1198, DOI 10.1046/j.1365-2141.2000.02433.x; Jelliffe D.B., 1966, ASSESSMENT NUTR STAT; Kassa E, 1999, AIDS, V13, P381, DOI 10.1097/00002030-199902250-00011; KEYS A, 1972, J CHRON DIS, V25, P329, DOI 10.1016/0021-9681(72)90027-6; LAVOIPIERRE GJ, 1983, MEASURING CHANGE NUT; Leung SSF, 1998, ANN HUM BIOL, V25, P169, DOI 10.1080/03014469800005542; Lobstein T., 2004, OBES REV S1, V5, P4, DOI [https://doi.org/10.1111/j.1467-789X.2004.00133.x, DOI 10.1111/J.1467-789X.2004.00133.X]; Lopez A, 1999, CYTOMETRY, V38, P231, DOI 10.1002/(SICI)1097-0320(19991015)38:5<231::AID-CYTO5>3.0.CO;2-Y; LOUA A, 1994, ANN SOC BELG MED TR, V74, P61; LUCAS AR, 1991, AM J PSYCHIAT, V148, P917; Mandy F, 2002, CYTOMETRY, V50, P111, DOI 10.1002/cyto.10088; *MIN HLTH, 2007, HIV UN ART Q REP MAR; MONTEIRO CA, 1992, B WORLD HEALTH ORGAN, V70, P657; MUST A, 1991, AM J CLIN NUTR, V53, P839, DOI 10.1093/ajcn/53.4.839; Mwaba P, 2003, LANCET, V362, P1459, DOI 10.1016/S0140-6736(03)14693-4; *NAT AIDS COMM, 2003, NAT EST HIV AIDS MAL; Nicholls D, 2005, ACTA PAEDIATR, V94, P1356, DOI 10.1080/08035250500251460; Nouanthong P, 2006, CLIN VACCINE IMMUNOL, V13, P598, DOI 10.1128/CVI.13.5.598-601.2006; *NSO ORC MACR, 2005, MAL DEM HLTH SURV 20; Ogden CL, 2002, PEDIATRICS, V109, P45, DOI 10.1542/peds.109.1.45; Onyango AW, 2007, J NUTR, V137, P149, DOI 10.1093/jn/137.1.149; PAN H, 2007, IMSGROWTH MICROSOFT; PAN H, 2007, IM5GROWTH MICROSOFT; PELLETIER DL, 1994, J NUTR, V124, pS2047; Pelletier DL, 2003, J NUTR, V133, P107, DOI 10.1093/jn/133.1.107; Poskitt EME, 2000, ACTA PAEDIATR, V89, P507, DOI 10.1080/080352500750027745; Rajan U., 1994, International Journal of Obesity, V18, P27; ROLLANDCACHERA MF, 1982, AM J CLIN NUTR, V36, P178, DOI 10.1093/ajcn/36.1.178; Sandhu J, 2006, INT J OBESITY, V30, P14, DOI 10.1038/sj.ijo.0803156; Schnizlein-Bick CT, 2000, CLIN DIAGN LAB IMMUN, V7, P336, DOI 10.1128/CDLI.7.3.336-343.2000; Schnizlein-Bick CT, 2002, CYTOMETRY, V50, P46, DOI 10.1002/cyto.10073; SCHOOF M, 2004, WALL STREET J   0114; Seal A, 2007, BMJ-BRIT MED J, V334, P733, DOI 10.1136/bmj.39101.664109.AE; SELZER R, 1995, AM J PSYCHIAT, V152, P813; SEOANE N, 1971, Journal of Tropical Pediatrics and Environmental Child Health, V17, P98; Sherman GG, 1999, J IMMUNOL METHODS, V222, P209, DOI 10.1016/S0022-1759(98)00172-0; Staton DM, 2004, PEDIATR ANN, V33, P647, DOI 10.3928/0090-4481-20041001-08; Stratton RJ, 2004, BRIT J NUTR, V92, P799, DOI 10.1079/BJN20041258; Troiano RP, 1998, PEDIATRICS, V101, P497; *UNICEF UNAIDS MSF, SOURC PRIC SEL MED D; WATERLOW JC, 1972, BRIT MED J, V3, P566, DOI 10.1136/bmj.3.5826.566; WATERLOW JC, 1977, B WORLD HEALTH ORGAN, V55, P489; Whitby L, 2002, CYTOMETRY, V50, P102, DOI 10.1002/cyto.10094; WHO, 2012, ICD 10 CLASS MENT BE; *WHO, 2005, CD4 T CELL EN TECHN; Woodruff BA, 2002, EUR J CLIN NUTR, V56, P1108, DOI 10.1038/sj.ejcn.1601456; World Health Organisation, 2006, ANT THER HIV INF INF; World Health Organization, 1995, PHYS STAT US INT ANT; World Health Organization, 2005, INT WHO CLIN STAG HI; Zachariah R, 2006, T ROY SOC TROP MED H, V100, P24, DOI 10.1016/j.trstmh.2005.06.018	85	1797	1858	5	129	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 28	2007	335	7612					194	197		10.1136/bmj.39238.399444.55	http://dx.doi.org/10.1136/bmj.39238.399444.55			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198YA	17591624	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000248662200031
J	Ledford, H				Ledford, Heidi			Patent examiners call in the jury	NATURE			English	News Item																		Marris E, 2005, NATURE, V437, P1230, DOI 10.1038/4371230a	1	1	1	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 19	2007	448	7151					239	239		10.1038/448239a	http://dx.doi.org/10.1038/448239a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	191GC	17637629	Bronze			2022-12-28	WOS:000248118300011
J	Jayachandran, R; Sundaramurthy, V; Combaluzier, B; Mueller, P; Korf, H; Huygen, K; Miyazaki, T; Albrecht, I; Massner, J; Pieters, J				Jayachandran, Rajesh; Sundaramurthy, Varadharajan; Combaluzier, Benoit; Mueller, Philipp; Korf, Hannelie; Huygen, Kris; Miyazaki, Toru; Albrecht, Imke; Massner, Jan; Pieters, Jean			Survival of mycobacteria in macrophages is mediated by coronin 1-dependent activation of calcineurin	CELL			English	Article							GREEN FLUORESCENT PROTEIN; ACTIN-BINDING PROTEIN; ENDOPLASMIC-RETICULUM; INTRACELLULAR SURVIVAL; TUBERCULOSIS; PHAGOCYTOSIS; CHOLESTEROL; INHIBITION; MEMBRANE; DYNAMICS	Pathogenic mycobacteria survive within macrophages by avoiding lysosomal delivery, instead residing in mycobacterial phagosomes. Upon infection, the leukocyte- specific protein coronin 1 is actively recruited to mycobacterial phagosomes, where it blocks lysosomal delivery by an unknown mechanism. Analysis of macrophages from coronin 1- deficient mice showed that coronin 1 is dispensable for Factindependent processes such as phagocytosis, motility, and membrane ruffling. However, upon mycobacterial infection, coronin 1 was required for activation of the Ca2+- dependent phosphatase calcineurin, thereby blocking lysosomal delivery of mycobacteria. In the absence of coronin 1, calcineurin activity did not occur, resulting in lysosomal delivery and killing of mycobacteria. Furthermore, blocking calcineurin activation with cyclosporin A or FK506 led to lysosomal delivery and intracellular mycobacterial killing. These results demonstrate a role for coronin 1 in activating Ca2+ dependent signaling processes in macrophages and reveal a function for calcineurin in the regulation of phagosome- lysosome fusion upon mycobacterial infection.	Univ Basel, Bioctr, CH-4056 Basel, Switzerland; WIV Pasteur Inst Brussels, Brussels, Belgium; Univ Tokyo, Tokyo 106, Japan	University of Basel; University of Tokyo	Pieters, J (corresponding author), Univ Basel, Bioctr, Klingelbergstr 50, CH-4056 Basel, Switzerland.	jean.pieters@unibas.ch	Sundaramurthy, Varadharajan/AGK-2349-2022	Sundaramurthy, Varadharajan/0000-0003-2562-8518; Korf, Hannelie/0000-0003-3540-0138; Huygen, Kris/0000-0001-7808-0512; Pieters, Jean/0000-0002-5284-9757; Miyazaki, Toru/0000-0003-3842-4362				Albrecht I, 2006, INT IMMUNOL, V18, P755, DOI 10.1093/intimm/dxl013; ARMSTRONG JA, 1971, J EXP MED, V134, P713, DOI 10.1084/jem.134.3.713; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; BOSLOVER S, 2001, BIOCHEM J, V356, P345; BUBB MR, 1994, J BIOL CHEM, V269, P14869; Butcher SP, 1997, J NEUROSCI, V17, P6939; DEHOSTOS EL, 1993, J CELL BIOL, V120, P163, DOI 10.1083/jcb.120.1.163; DHANDAYUTHAPANI S, 1995, MOL MICROBIOL, V17, P901, DOI 10.1111/j.1365-2958.1995.mmi_17050901.x; Ferrari G, 1997, J CELL BIOL, V139, P1433, DOI 10.1083/jcb.139.6.1433; Ferrari G, 1999, CELL, V97, P435, DOI 10.1016/S0092-8674(00)80754-0; Foger N, 2006, SCIENCE, V313, P839, DOI 10.1126/science.1130563; Fukui Y, 1999, CELL MOTIL CYTOSKEL, V42, P204, DOI 10.1002/(SICI)1097-0169(1999)42:3<204::AID-CM4>3.0.CO;2-L; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; Gallo EM, 2006, NAT IMMUNOL, V7, P25, DOI 10.1038/ni1295; Gatfield J, 2000, SCIENCE, V288, P1647, DOI 10.1126/science.288.5471.1647; Gatfield J, 2005, MOL BIOL CELL, V16, P2786, DOI 10.1091/mbc.E05-01-0042; Hasan Z, 1997, MOL MICROBIOL, V24, P545, DOI 10.1046/j.1365-2958.1997.3591731.x; Heil-Chapdelaine RA, 1998, CURR BIOL, V8, P1281, DOI 10.1016/S0960-9822(07)00539-8; Hippenmeyer S, 2005, PLOS BIOL, V3, P878, DOI 10.1371/journal.pbio.0030159; Humphries CL, 2002, J CELL BIOL, V159, P993, DOI 10.1083/jcb.200206113; Itoh S, 2002, BIOL PHARM BULL, V25, P837, DOI 10.1248/bpb.25.837; Le Cabec V, 2002, J IMMUNOL, V169, P2003, DOI 10.4049/jimmunol.169.4.2003; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MacMicking JD, 2005, CURR OPIN MICROBIOL, V8, P74, DOI 10.1016/j.mib.2004.12.012; Malik ZA, 2000, J EXP MED, V191, P287, DOI 10.1084/jem.191.2.287; Malik ZA, 2003, J IMMUNOL, V170, P2811, DOI 10.4049/jimmunol.170.6.2811; MANIAK M, 1995, CELL, V83, P915, DOI 10.1016/0092-8674(95)90207-4; Muller-Taubenberger A, 2001, EMBO J, V20, P6772, DOI 10.1093/emboj/20.23.6772; Nguyen L, 2005, TRENDS CELL BIOL, V15, P269, DOI 10.1016/j.tcb.2005.03.009; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Peyron P, 2000, J IMMUNOL, V165, P5186, DOI 10.4049/jimmunol.165.9.5186; Rodal AA, 2005, NAT STRUCT MOL BIOL, V12, P26, DOI 10.1038/nsmb870; Rubart M, 2004, J CLIN INVEST, V114, P775, DOI 10.1172/JCI200421589; Russell DG, 2001, NAT REV MOL CELL BIO, V2, P569, DOI 10.1038/35085034; Rybakin V, 2005, BIOESSAYS, V27, P625, DOI 10.1002/bies.20235; Schuller S, 2001, CELL MICROBIOL, V3, P785, DOI 10.1046/j.1462-5822.2001.00155.x; Singh SB, 2006, SCIENCE, V313, P1438, DOI 10.1126/science.1129577; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; STEINMAN RM, 1995, J EXP MED, V182, P283, DOI 10.1084/jem.182.2.283; Tailleux L, 2003, J IMMUNOL, V170, P1939, DOI 10.4049/jimmunol.170.4.1939; Tanghe A, 2001, INFECT IMMUN, V69, P3041, DOI 10.1128/IAI.69.5.3041-3047.2001; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; Velasco-Velazquez MA, 2003, MICROB PATHOGENESIS, V35, P125, DOI 10.1016/S0882-4010(03)00099-8; Vergne I, 2005, P NATL ACAD SCI USA, V102, P4033, DOI 10.1073/pnas.0409716102; Walburger A, 2004, SCIENCE, V304, P1800, DOI 10.1126/science.1099384; Winslow MM, 2003, CURR OPIN IMMUNOL, V15, P299, DOI 10.1016/S0952-7915(03)00050-5; Yan M, 2005, MOL BIOL CELL, V16, P3077, DOI 10.1091/mbc.E04-11-0989; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147	49	213	227	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 13	2007	130	1					37	50		10.1016/j.cell.2007.04.043	http://dx.doi.org/10.1016/j.cell.2007.04.043			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	197WK	17632055	Bronze			2022-12-28	WOS:000248587000009
J	Rennert, G; Bisland-Naggan, S; Barnett-Griness, O; Bar-Joseph, N; Zhang, SY; Rennert, HS; Narod, SA				Rennert, Gad; Bisland-Naggan, Shantih; Barnett-Griness, Ofra; Bar-Joseph, Naomi; Zhang, Shiyu; Rennert, Hedy S.; Narod, Steven A.			Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SURVIVAL; CARCINOMA; FREQUENCY	BACKGROUND: Some features of breast cancer in women with a BRCA1 mutation suggest that hereditary breast cancer has a poor outcome. We conducted a national population-based study of Israeli women to determine the influence, if any, of a BRCA1 or a BRCA2 mutation on the prognosis in breast cancer. METHODS: We obtained data on all incident cases of invasive breast cancer that were diagnosed from January 1, 1987, to December 31, 1988, and recorded in the Israel National Cancer Registry. We requested a paraffin-embedded tumor block or an unstained slide and the corresponding pathological and clinical records for all such cases. DNA extracted from the tumor specimens was analyzed for the three founder mutations in BRCA1 and BRCA2. For each subject, available pathological and oncologic records were reviewed. RESULTS: We were able to retrieve a pathological sample from 1794 of 2514 subjects (71%). Among those women, we obtained medical records for 1545 (86%). A BRCA1 or BRCA2 mutation was identified in 10% of the women who were of Ashkenazi Jewish ancestry. The adjusted hazard ratios for death from breast cancer were not significantly different among mutation carriers and noncarriers (hazard ratio among BRCA1 carriers, 0.76; 95% confidence interval [CI], 0.45 to 1.30; P=0.31; hazard ratio among BRCA2 carriers, 1.31; 95% CI, 0.80 to 2.15; P=0.28). Among women who were treated with chemotherapy, the hazard ratio for death among BRCA1 carriers was 0.48 (95% CI, 0.19 to 1.21; P=0.12). CONCLUSIONS: Breast cancer-specific rates of death among Israeli women are similar for carriers of a BRCA founder mutation and noncarriers.	Carmel Hosp, Natl Canc Control Ctr, Clalit Hlth Serv, IL-34362 Haifa, Israel; Carmel Hosp, Dept Community Med & Epidemiol, IL-34362 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel; Univ Toronto, Womens Coll Res Inst, Toronto, ON, Canada	Clalit Health Services; Carmel Medical Center; Clalit Health Services; Carmel Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; University of Toronto; University Toronto Affiliates; Womens College Hospital	Rennert, G (corresponding author), Carmel Hosp, Natl Canc Control Ctr, Clalit Hlth Serv, IL-34362 Haifa, Israel.	rennert@tx.technion.ac.il	Narod, Steven A/AAA-6112-2022	Rennert, Gad/0000-0002-8512-068X	NCI NIH HHS [CA8097] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brekelmans CTM, 2006, ANN ONCOL, V17, P391, DOI 10.1093/annonc/mdj095; Eerola H, 2001, INT J CANCER, V93, P368, DOI 10.1002/ijc.1341; El-Tamer M, 2004, ANN SURG ONCOL, V11, P157, DOI 10.1245/ASO.2004.05.018; Goffin JR, 2003, CANCER-AM CANCER SOC, V97, P527, DOI 10.1002/cncr.11080; Goode EL, 2002, CANCER RES, V62, P3052; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; Karp SE, 1997, CANCER-AM CANCER SOC, V80, P435, DOI 10.1002/(SICI)1097-0142(19970801)80:3<435::AID-CNCR11>3.0.CO;2-Y; Kauff ND, 2002, J MED GENET, V39, P611, DOI 10.1136/jmg.39.8.611; Kuperstein G, 2000, CLIN GENET, V57, P213, DOI 10.1034/j.1399-0004.2000.570307.x; *MIN HLTH, 1997, ISR CANC REG 1997; Moller P, 2002, INT J CANCER, V101, P555, DOI 10.1002/ijc.10641; Oddoux C, 1996, NAT GENET, V14, P188, DOI 10.1038/ng1096-188; PARKIN DM, 2000, IARC SCI PUBLICATION, V155; Phelan CM, 2002, HUM MUTAT, V20, P352, DOI 10.1002/humu.10123; RENNERT G, 1999, BREAST CANC SCREENIN; RENNERT G, 1999, INT EP ASS M FLOR IT; Robson ME, 2004, BREAST CANCER RES, V6, pR8, DOI 10.1186/bcr658; Stoppa-Lyonnet D, 2000, J CLIN ONCOL, V18, P4053, DOI 10.1200/JCO.2000.18.24.4053; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Warner E, 1999, J NATL CANCER I, V91, P1241, DOI 10.1093/jnci/91.14.1241	20	234	239	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 12	2007	357	2					115	123		10.1056/NEJMoa070608	http://dx.doi.org/10.1056/NEJMoa070608			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188NX	17625123				2022-12-28	WOS:000247927700005
J	Timmins, N				Timmins, Nick			What's next for the NHS	BRITISH MEDICAL JOURNAL			English	Editorial Material												Nick.Timmins@FT.com							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUL 7	2007	335	7609					18	19		10.1136/bmj.39261.449097.AD	http://dx.doi.org/10.1136/bmj.39261.449097.AD			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	191LY	17599975	Green Published			2022-12-28	WOS:000248133900026
J	Chevrier, V; Poulet, F; Bibring, JP				Chevrier, Vincent; Poulet, Francois; Bibring, Jean-Pierre			Early geochemical environment of Mars as determined from thermodynamics of phyllosilicates	NATURE			English	Article							MERIDIANI; CLIMATE	Images of geomorphological features that seem to have been produced by the action of liquid water have been considered evidence for wet surface conditions on early Mars(1). Moreover, the recent identification of large deposits of phyllosilicates, associated with the ancient Noachian terrains(2,3) suggests long-timescale weathering(4) of the primary basaltic crust by liquid water(2,5). It has been proposed that a greenhouse effect resulting from a carbon-dioxide-rich atmosphere sustained the temperate climate required to maintain liquid water on the martian surface during the Noachian(6,7). The apparent absence of carbonates and the low escape rates of carbon dioxide(8), however, are indicative of an early martian atmosphere with low levels of carbon dioxide. Here we investigate the geochemical conditions prevailing on the surface of Mars during the Noachian period using calculations of the aqueous equilibria of phyllosilicates. Our results show that Fe3+-rich phyllosilicates probably precipitated under weakly acidic to alkaline pH, an environment different from that of the following period, which was dominated by strongly acid weathering(9) that led to the sulphate deposits identified on Mars(10-12). Thermodynamic calculations demonstrate that the oxidation state of the martian surface was already high, supporting early escape of hydrogen. Finally, equilibrium with carbonates implies that phyllosilicate precipitation occurs preferentially at a very low partial pressure of carbon dioxide. We suggest that the possible absence of Noachian carbonates more probably resulted from low levels of atmospheric carbon dioxide, rather than primary acidic conditions(13). Other greenhouse gases may therefore have played a part in sustaining a warm and wet climate on the early Mars.	Univ Arkansas, WM Keck Lab Space Simulat, Arkansas Ctr Space & Planetary Sci, Fayetteville, AR 72701 USA; Univ Paris Sud, Inst Astrophys Spatiale, F-91405 Orsay, France; CNRS, UMR 8617, F-91405 Orsay, France	University of Arkansas System; University of Arkansas Fayetteville; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universite Paris Saclay	Chevrier, V (corresponding author), Univ Arkansas, WM Keck Lab Space Simulat, Arkansas Ctr Space & Planetary Sci, MUSE 202, Fayetteville, AR 72701 USA.	vchevrie@uark.edu						Arvidson RE, 2005, SCIENCE, V307, P1591, DOI 10.1126/science.1109509; Barabash S, 2007, SCIENCE, V315, P501, DOI 10.1126/science.1134358; Bibring JP, 2005, SCIENCE, V307, P1576, DOI 10.1126/science.1108806; Bibring JP, 2006, SCIENCE, V312, P400, DOI 10.1126/science.1122659; Catling DC, 2003, ICARUS, V165, P277, DOI 10.1016/S0019-1035(03)00173-8; Chevrier V, 2004, GEOLOGY, V32, P1033, DOI 10.1130/G21078.1; EGGLETON RA, 1987, CLAY CLAY MINER, V35, P161, DOI 10.1346/CCMN.1987.0350301; Encrenaz T, 2004, ICARUS, V170, P424, DOI 10.1016/j.icarus.2004.05.008; Fairen AG, 2004, NATURE, V431, P423, DOI 10.1038/nature02911; Gendrin A, 2005, SCIENCE, V307, P1587, DOI 10.1126/science.1109087; Glotch TD, 2006, J GEOPHYS RES-PLANET, V111, DOI 10.1029/2005JE002672; GOODING JL, 1978, ICARUS, V33, P483, DOI 10.1016/0019-1035(78)90186-0; Jakosky BM, 2001, NATURE, V412, P237, DOI 10.1038/35084184; KASTING JF, 1993, SCIENCE, V259, P920, DOI 10.1126/science.11536547; Lammer H, 2003, ICARUS, V165, P9, DOI 10.1016/S0019-1035(03)00170-2; Madden MEE, 2004, NATURE, V431, P821, DOI 10.1038/nature02971; Malin MC, 2003, SCIENCE, V302, P1931, DOI 10.1126/science.1090544; Meunier A, 2007, TERRA NOVA, V19, P95, DOI 10.1111/j.1365-3121.2006.00719.x; Naumov MV, 2005, GEOFLUIDS, V5, P165, DOI 10.1111/j.1468-8123.2005.00092.x; Phillips RJ, 2001, SCIENCE, V291, P2587, DOI 10.1126/science.1058701; POLLACK JB, 1987, ICARUS, V71, P203, DOI 10.1016/0019-1035(87)90147-3; Poulet F, 2005, NATURE, V438, P623, DOI 10.1038/nature04274; Sagan C, 1997, SCIENCE, V276, P1217, DOI 10.1126/science.276.5316.1217; Sheldon ND, 2006, PRECAMBRIAN RES, V147, P148, DOI 10.1016/j.precamres.2006.02.004; Sheldon ND, 2002, GEOLOGY, V30, P919, DOI 10.1130/0091-7613(2002)030<0919:LOLIET>2.0.CO;2; Solomon SC, 2005, SCIENCE, V307, P1214, DOI 10.1126/science.1101812; Squyres SW, 2004, SCIENCE, V306, P1709, DOI 10.1126/science.1104559; Tosca NJ, 2005, EARTH PLANET SC LETT, V240, P122, DOI 10.1016/j.epsl.2005.09.042; Wang A, 2006, J GEOPHYS RES-PLANET, V111, DOI 10.1029/2005JE002516	29	151	151	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 5	2007	448	7149					60	63		10.1038/nature05961	http://dx.doi.org/10.1038/nature05961			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185OS	17611538				2022-12-28	WOS:000247720900037
J	Ng, SS; Kavanagh, KL; McDonough, MA; Butler, D; Pilka, ES; Lienard, BMR; Bray, JE; Savitsky, P; Gileadi, O; von Delft, F; Rose, NR; Offer, J; Scheinost, JC; Borowski, T; Sundstrom, M; Schofield, CJ; Oppermann, U				Ng, Stanley S.; Kavanagh, Kathryn L.; McDonough, Michael A.; Butler, Danica; Pilka, Ewa S.; Lienard, Benoit M. R.; Bray, James E.; Savitsky, Pavel; Gileadi, Opher; von Delft, Frank; Rose, Nathan R.; Offer, John; Scheinost, Johanna C.; Borowski, Tomasz; Sundstrom, Michael; Schofield, Christopher J.; Oppermann, Udo			Crystal structures of histone demethylase JMJD2A reveal basis for substrate specificity	NATURE			English	Article							DOMAIN-CONTAINING PROTEINS; KETOGLUTARATE DIOXYGENASE; LYSINE METHYLATION; FAMILY; TRANSCRIPTION; INTERMEDIATE	Post-translational histone modification has a fundamental role in chromatin biology and is proposed to constitute a 'histone code' in epigenetic regulation(1,2). Differential methylation of histone H3 and H4 lysyl residues regulates processes including heterochromatin formation, X-chromosome inactivation, genome imprinting, DNA repair and transcriptional regulation(3). The discovery of lysyl demethylases using flavin (amine oxidases)(4) or Fe( II) and 2-oxoglutarate as cofactors (2OG oxygenases)(5-7) has changed the view of methylation as a stable epigenetic marker. However, little is known about how the demethylases are selective for particular lysyl-containing sequences in specific methylation states, a key to understanding their functions. Here we reveal how human JMJD2A ( jumonji domain containing 2A), which is selective towards tri- and dimethylated histone H3 lysyl residues 9 and 36 (H3K9me3/me2 and H3K36me3/me2), discriminates between methylation states and achieves sequence selectivity for H3K9. We report structures of JMJD2A - Ni( II) - Zn( II) inhibitor complexes bound to tri-, di- and monomethyl forms of H3K9 and the trimethyl form of H3K36. The structures reveal a lysyl-binding pocket in which substrates are bound in distinct bent conformations involving the Zn-binding site. We propose a mechanism for achieving methylation state selectivity involving the orientation of the substrate methyl groups towards a ferryl intermediate. The results suggest distinct recognition mechanisms in different demethylase subfamilies and provide a starting point to develop chemical tools for drug discovery and to study and dissect the complexity of reversible histone methylation and its role in chromatin biology.	Univ Oxford, Struct Genom Consortium, Botnar Res Ctr, Oxford OX3 7LD, England; Univ Oxford, Dept Chem, Oxford OX1 3TA, England; Univ Oxford, Oxford Ctr Integrated Syst Biol, Oxford OX1 3TA, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; PAS Univ, Inst Catalysis & Surface Chem, PL-830239 Krakow, Poland	University of Oxford; University of Oxford; University of Oxford; University of Oxford; Polish Academy of Sciences; Jerzy Haber Institute of Catalysis & Surface Chemistry	Schofield, CJ (corresponding author), Univ Oxford, Struct Genom Consortium, Botnar Res Ctr, Oxford OX3 7LD, England.	christopher.schofield@chemistry.oxford.ac.uk	McDonough, Michael/N-8913-2019; Gileadi, Opher/F-1105-2013; McDonough, Michael A/G-2744-2013; Rose, Nathan R/A-9270-2013; Borowski, Tomasz/E-8569-2016	McDonough, Michael/0000-0003-4664-6942; Gileadi, Opher/0000-0001-6886-898X; McDonough, Michael A/0000-0003-4664-6942; Rose, Nathan R/0000-0002-1871-1156; Borowski, Tomasz/0000-0002-3450-3576; BRAY, JAMES/0000-0003-3554-4254; von Delft, Frank/0000-0003-0378-0017; offer, john/0000-0002-2471-1216; Schofield, Christopher/0000-0002-0290-6565; Savitsky, Pavel/0000-0001-8584-7750	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Chen ZZ, 2006, CELL, V125, P691, DOI 10.1016/j.cell.2006.04.024; Clifton IJ, 2006, J INORG BIOCHEM, V100, P644, DOI 10.1016/j.jinorgbio.2006.01.024; Elkins JM, 2003, J BIOL CHEM, V278, P1802, DOI 10.1074/jbc.C200644200; Flashman E, 2007, NAT CHEM BIOL, V3, P86, DOI 10.1038/nchembio0207-86; Grzyska PK, 2005, BIOCHEMISTRY-US, V44, P3845, DOI 10.1021/bi048746n; Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945; Liang G, 2007, NAT STRUCT MOL BIOL, V14, P243, DOI 10.1038/nsmb1204; Lo WS, 2001, SCIENCE, V293, P1142, DOI 10.1126/science.1062322; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Nelson CJ, 2006, CELL, V126, P905, DOI 10.1016/j.cell.2006.07.026; Price JC, 2003, BIOCHEMISTRY-US, V42, P7497, DOI 10.1021/bi030011f; Seward DJ, 2007, NAT STRUCT MOL BIOL, V14, P240, DOI 10.1038/nsmb1200; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	17	255	260	3	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 5	2007	448	7149					87	91		10.1038/nature05971	http://dx.doi.org/10.1038/nature05971			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185OS	17589501				2022-12-28	WOS:000247720900043
J	Arnesen, H; Lunde, K; Aakhus, S; Forfang, K				Arnesen, Harald; Lunde, Ketil; Aakhus, Svend; Forfang, Kolbjorn			Cell therapy in myocardial infarction	LANCET			English	Editorial Material							LEFT-VENTRICULAR VOLUME; PROGENITOR CELLS; MARROW; REPAIR; TRIAL		Ullevaal Univ Hosp, Dept Cardiol, N-0407 Oslo, Norway; Rikshosp Radiumhosp Univ Hosp, Dept Cardiol, Oslo, Norway	University of Oslo; University of Oslo	Arnesen, H (corresponding author), Ullevaal Univ Hosp, Dept Cardiol, N-0407 Oslo, Norway.	harald.arnesen@ulleval.no						DODGE HT, 1960, AM HEART J, V60, P762, DOI 10.1016/0002-8703(60)90359-8; Grebe O, 2004, Z KARDIOL, V93, P686; Janssens S, 2006, LANCET, V367, P113, DOI 10.1016/S0140-6736(05)67861-0; Korbling M, 2003, NEW ENGL J MED, V349, P570, DOI 10.1056/NEJMra022361; LUNDE K, 2006, NO LONG TERM EFFECTS; Lunde K, 2006, NEW ENGL J MED, V355, P1199, DOI 10.1056/NEJMoa055706; Meyer GP, 2006, CIRCULATION, V113, P1287, DOI 10.1161/CIRCULATIONAHA.105.575118; Schachinger V, 2006, EUR HEART J, V27, P2775, DOI 10.1093/eurheartj/ehl388; Schachinger V, 2006, NEW ENGL J MED, V355, P1210, DOI 10.1056/NEJMoa060186; SHEEHAN FH, 1989, AM J CARDIOL, V64, P661, DOI 10.1016/0002-9149(89)90498-0; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C	11	39	46	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 30	2007	369	9580					2142	2143		10.1016/S0140-6736(07)60992-1	http://dx.doi.org/10.1016/S0140-6736(07)60992-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LX	17604783				2022-12-28	WOS:000247644200008
J	Delpierre, C; Cuzin, L; Lert, F				Delpierre, Cyrille; Cuzin, Lise; Lert, France			Routine testing to reduce late HIV diagnosis in France	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; VIRAL LOAD; COST; TRANSMISSION; CARE; ERA		Hop Purpan, Unit Infect & Trop Dis, Toulouse, France; INSERM, U687, F-94410 St Maurice, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Delpierre, C (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Landmark Ctr, 401 Park Dr, Boston, MA 02115 USA.	cdelpier@hsph.harvard.edu		delpierre, cyrille/0000-0002-0831-080X				BELTZER N, 2005, CONNAISSANCES ATTITU; Celentano DD, 1998, SCIENCE, V280, P1889, DOI 10.1126/science.280.5371.1889; Centers for Disease Control and Prevention, 2003, MMWR MORB MORTAL WKL, V52, P581; Chadborn TR, 2005, AIDS, V19, P513, DOI 10.1097/01.aids.0000162340.43310.08; Cook J, 1999, AIDS RES HUM RETROV, V15, P499, DOI 10.1089/088922299311024; Delpierre C, 2007, INT J STD AIDS, V18, P312, DOI 10.1258/095646207780749709; Delpierre C, 2006, AIDS PATIENT CARE ST, V20, P838, DOI 10.1089/apc.2006.20.838; DEVINCENZI I, 1994, NEW ENGL J MED, V331, P341, DOI 10.1056/NEJM199408113310601; *I VEILL SAN, 2006, SURV VIH SIDA FRANC; Kamb ML, 1998, JAMA-J AM MED ASSOC, V280, P1161, DOI 10.1001/jama.280.13.1161; Krentz HB, 2004, HIV MED, V5, P93, DOI 10.1111/j.1468-1293.2004.00193.x; LEWDEN C, 2006, EPIDEMIOL INFECT, P1; Marks G, 2006, AIDS, V20, P1447, DOI 10.1097/01.aids.0000233579.79714.8d; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Paltiel AD, 2005, NEW ENGL J MED, V352, P586, DOI 10.1056/NEJMsa042088; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Sabin CA, 2006, AIDS, V20, P67, DOI 10.1097/01.aids.0000196178.73174.24; Sanders GD, 2005, NEW ENGL J MED, V352, P570, DOI 10.1056/NEJMsa042657; Yazdanpanah Y, 2002, ANTIVIR THER, V7, P257; YENI R, 2006, PRISE CHARGE THERAPE	20	32	40	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 30	2007	334	7608					1354	1356		10.1136/bmj.39225.458218.94	http://dx.doi.org/10.1136/bmj.39225.458218.94			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	185VX	17600025	Green Submitted, Green Published			2022-12-28	WOS:000247739600032
J	Takashima, Y; Era, T; Nakao, K; Kondo, S; Kasuga, M; Smith, AG; Nishikawa, SI				Takashima, Yasuhiro; Era, Takumi; Nakao, Kazuki; Kondo, Saki; Kasuga, Masato; Smith, Austin G.; Nishikawa, Shin-Ichi			Neuroepithelial cells supply an initial transient wave of MSC differentiation	CELL			English	Article							MESENCHYMAL STEM-CELLS; MARROW STROMAL CELLS; NEURAL CREST; BONE-MARROW; MOUSE; EXPRESSION; ORIGIN; GROWTH; MESODERM; LINEAGE	Mesenchymal stem cells (MSCs) are defined as cells that undergo sustained in vitro growth and are able to give rise to multiple mesenchymal lineages. Although MSCs are already used in regenerative medicine little is known about their in vivo behavior and developmental derivation. Here, we show that the earliest wave of MSC in the embryonic trunk is generated from Sox1(+) neuroepithelium but not from mesoderm. Using lineage marking by direct gfp knock- in and Cre-recombinase mediated lineage tracing, we provide evidence that Sox1(+) neuroepithelium gives rise to MSCs in part through a neural crest intermediate stage. This pathway can be distinguished from the pathway through which Sox1(+) cells give rise to oligodendrocytes by expression of PDGFR beta and A2B5. MSC recruitment from this pathway, however, is transient and is replaced by MSCs from unknown sources. We conclude that MSC can be defined as a definite in vivo entity recruited from multiple developmental origins.	Riken Ctr Dev Biol, Lab Stem Cell Biol, Chuo Ku, Kobe, Hyogo 6500047, Japan; Riken Ctr Dev Biol, Lab Anim Resources & Genet Engn, Chuo Ku, Kobe, Hyogo 6500047, Japan; Kobe Univ, Grad Sch Med, Div Diabet & Digest & Kidney Dis, Dept Clin Mol Med,Chuo Ku, Kobe, Hyogo 6500017, Japan; Univ Tokyo, Inst Med Sci, Mol Genet Lab, Tokyo 1088639, Japan; Univ Cambridge, Inst Stem Cell Biol, Cambridge CB2 1QT, England	RIKEN; RIKEN; Kobe University; University of Tokyo; University of Cambridge	Era, T (corresponding author), Riken Ctr Dev Biol, Lab Stem Cell Biol, Chuo Ku, 2-2-3 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.	tera@cdb.riken.jp		Takashima, Yasuhiro/0000-0003-0126-7260; zhong wei, he gui/0000-0002-3066-3564; Smith, Austin/0000-0002-3029-4682	MRC [G9806702] Funding Source: UKRI; Medical Research Council [G9806702, G0800784] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aubert J, 2003, P NATL ACAD SCI USA, V100, P11836, DOI 10.1073/pnas.1734197100; Bailey P, 2001, CURR OPIN CELL BIOL, V13, P679, DOI 10.1016/S0955-0674(00)00271-4; Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19-3-180; Dani C, 1997, J CELL SCI, V110, P1279; Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301-472X(00)00482-3; Dennis JE, 2002, STEM CELLS, V20, P205, DOI 10.1634/stemcells.20-3-205; Dezawa M, 2001, EUR J NEUROSCI, V14, P1771, DOI 10.1046/j.0953-816x.2001.01814.x; DROZDOFF V, 1991, J BIOL CHEM, V266, P17165; Fernandes KJL, 2004, NAT CELL BIOL, V6, P1082, DOI 10.1038/ncb1181; FRIEDENSTEIN AJ, 1970, CELL TISSUE KINET, V3, P393, DOI 10.1111/j.1365-2184.1970.tb00347.x; GRONTHOS S, 1994, BLOOD, V84, P4164, DOI 10.1182/blood.V84.12.4164.bloodjournal84124164; Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399; Javazon EH, 2004, EXP HEMATOL, V32, P414, DOI 10.1016/j.exphem.2004.02.004; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Joseph NM, 2004, DEVELOPMENT, V131, P5599, DOI 10.1242/dev.01429; Kawaguchi J, 2005, BONE, V36, P758, DOI 10.1016/j.bone.2004.07.019; KILBY NJ, 1993, TRENDS GENET, V9, P413, DOI 10.1016/0168-9525(93)90104-P; Kondo S, 2006, MICROBIOL IMMUNOL, V50, P831, DOI 10.1111/j.1348-0421.2006.tb03850.x; Kondo T, 2000, SCIENCE, V289, P1754, DOI 10.1126/science.289.5485.1754; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; LaBonne C, 1999, ANNU REV CELL DEV BI, V15, P81, DOI 10.1146/annurev.cellbio.15.1.81; Le Douarin NM, 2004, DEVELOPMENT, V131, P4637, DOI 10.1242/dev.01350; Li M, 2002, Methods Mol Biol, V185, P205; Matsuoka T, 2005, NATURE, V436, P347, DOI 10.1038/nature03837; McCormick MB, 1996, MOL CELL BIOL, V16, P5792; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Ogawa M, 2006, BLOOD, V108, P2893, DOI 10.1182/blood-2006-04-016600; PARR BA, 1993, DEVELOPMENT, V119, P247; Pevny LH, 1998, DEVELOPMENT, V125, P1967; Pietri T, 2003, DEV BIOL, V259, P176, DOI 10.1016/S0012-1606(03)00175-1; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Sakurai H, 2006, STEM CELLS, V24, P575, DOI 10.1634/stemcells.2005-0256; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Stolt CC, 2006, DEV CELL, V11, P697, DOI 10.1016/j.devcel.2006.08.011; Tada S, 2005, DEVELOPMENT, V132, P4363, DOI 10.1242/dev.02005; Takakura N, 1997, J HISTOCHEM CYTOCHEM, V45, P883, DOI 10.1177/002215549704500613; Weston JA, 2004, DEV DYNAM, V229, P118, DOI 10.1002/dvdy.10478; Wilson YM, 2004, DEVELOPMENT, V131, P6153, DOI 10.1242/dev.01533; Wobus A M, 2002, Methods Mol Biol, V185, P127; Yamauchi Y, 1999, DEV BIOL, V212, P191, DOI 10.1006/dbio.1999.9323; ZON LI, 1995, BLOOD, V86, P2876	45	389	411	3	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 29	2007	129	7					1377	1388		10.1016/j.cell.2007.04.028	http://dx.doi.org/10.1016/j.cell.2007.04.028			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188HQ	17604725	Bronze			2022-12-28	WOS:000247911400022
J	Nakayama, Y; Pauzauskie, PJ; Radenovic, A; Onorato, RM; Saykally, RJ; Liphardt, J; Yang, PD				Nakayama, Yuri; Pauzauskie, Peter J.; Radenovic, Aleksandra; Onorato, Robert M.; Saykally, Richard J.; Liphardt, Jan; Yang, Peidong			Tunable nanowire nonlinear optical probe	NATURE			English	Article							2-PHOTON EXCITATION; ORTHORHOMBIC KNBO3; REFRACTIVE-INDEXES; MICROSCOPY; RESOLUTION; MANIPULATION; SCALE	One crucial challenge for subwavelength optics has been the development of a tunable source of coherent laser radiation for use in the physical, information and biological sciences that is stable at room temperature and physiological conditions. Current advanced near-field imaging techniques using fibre-optic scattering probes(1,2) have already achieved spatial resolution down to the 20-nm range. Recently reported far-field approaches for optical microscopy, including stimulated emission depletion(3), structured illumination(4), and photoactivated localization microscopy(5), have enabled impressive, theoretically unlimited spatial resolution of fluorescent bio-molecular complexes. Previous work with laser tweezers(6-8) has suggested that optical traps could be used to create novel spatial probes and sensors. Inorganic nanowires have diameters substantially below the wavelength of visible light and have electronic and optical properties(9,10) that make them ideal for subwavelength laser and imaging technology. Here we report the development of an electrode-free, continuously tunable coherent visible light source compatible with physiological environments, from individual potassium niobate (KNbO3) nanowires. These wires exhibit efficient second harmonic generation, and act as frequency converters, allowing the local synthesis of a wide range of colours via sum and difference frequency generation. We use this tunable nanometric light source to implement a novel form of subwavelength microscopy, in which an infrared laser is used to optically trap and scan a nanowire over a sample, suggesting a wide range of potential applications in physics, chemistry, materials science and biology.	Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Biophys Grad Grp, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA; Sony Corp, Mat Labs, Kanagawa 2430021, Japan	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Sony Corporation	Liphardt, J (corresponding author), Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA.	liphardt@physics.berkeley.edu; p_yang@berkeley.edu	Radenovic, Aleksandra/C-5350-2011; Pauzauskie, Peter J/A-1316-2014; Liphardt, Jan/A-5906-2012; Radenovic, Aleksandra/AAZ-5582-2021	Radenovic, Aleksandra/0000-0001-8194-2785; Liphardt, Jan/0000-0003-2835-5025; Nakayama, Yuri/0000-0003-1705-5078; SAYKALLY, RICHARD/0000-0001-8942-3656				Agarwal R, 2005, OPT EXPRESS, V13, P8906, DOI 10.1364/OPEX.13.008906; ASHKIN A, 1987, NATURE, V330, P769, DOI 10.1038/330769a0; BETZIG E, 1991, SCIENCE, V251, P1468, DOI 10.1126/science.251.5000.1468; Betzig E, 2006, SCIENCE, V313, P1642, DOI 10.1126/science.1127344; BIAGGIO I, 1992, J OPT SOC AM B, V9, P507, DOI 10.1364/JOSAB.9.000507; Donnert G, 2006, P NATL ACAD SCI USA, V103, P11440, DOI 10.1073/pnas.0604965103; Duan XF, 2003, NATURE, V421, P241, DOI 10.1038/nature01353; Florin EL, 1998, APPL PHYS A-MATER, V66, pS75, DOI 10.1007/s003390051103; Florin EL, 1997, J STRUCT BIOL, V119, P202, DOI 10.1006/jsbi.1997.3880; GHISLAIN LP, 1993, OPT LETT, V18, P1678, DOI 10.1364/OL.18.001678; Grier DG, 2003, NATURE, V424, P810, DOI 10.1038/nature01935; Gustafsson MGL, 2005, P NATL ACAD SCI USA, V102, P13081, DOI 10.1073/pnas.0406877102; Huang Y, 2001, SCIENCE, V291, P630, DOI 10.1126/science.291.5504.630; INOUYE Y, 1994, OPT LETT, V19, P159, DOI 10.1364/OL.19.000159; Johnson JC, 2002, NANO LETT, V2, P279, DOI 10.1021/nl015686n; Johnson JC, 2003, J PHYS CHEM B, V107, P8816, DOI 10.1021/jp034482n; Kind H, 2002, ADV MATER, V14, P158, DOI 10.1002/1521-4095(20020116)14:2<158::AID-ADMA158>3.0.CO;2-W; Knutsen KP, 2006, J PHYS CHEM B, V110, P5854, DOI 10.1021/jp052416a; Kudo K, 2003, JPN J APPL PHYS 1, V42, P6099, DOI 10.1143/JJAP.42.6099; Law M, 2004, SCIENCE, V305, P1269, DOI 10.1126/science.1100999; Magrez A, 2006, J PHYS CHEM B, V110, P58, DOI 10.1021/jp053800a; Pauzauskie PJ, 2006, NAT MATER, V5, P97, DOI 10.1038/nmat1563; Pauzauskie PJ, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.143903; POHL DW, 1984, APPL PHYS LETT, V44, P651, DOI 10.1063/1.94865; Qian F, 2004, NANO LETT, V4, P1975, DOI 10.1021/nl0487774; Sanchez EJ, 1999, PHYS REV LETT, V82, P4014, DOI 10.1103/PhysRevLett.82.4014; Shoji I, 1997, J OPT SOC AM B, V14, P2268, DOI 10.1364/JOSAB.14.002268; Sirbuly DJ, 2005, J PHYS CHEM B, V109, P15190, DOI 10.1021/jp051813i; Yang PD, 2005, MRS BULL, V30, P85, DOI 10.1557/mrs2005.26; ZYSSET B, 1992, J OPT SOC AM B, V9, P380, DOI 10.1364/JOSAB.9.000380	30	485	492	6	427	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 28	2007	447	7148					1098	U8		10.1038/nature05921	http://dx.doi.org/10.1038/nature05921			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183HT	17597756	Green Published, Green Submitted			2022-12-28	WOS:000247564600034
J	Watts, G				Watts, Geoff			In search of fat profits	BRITISH MEDICAL JOURNAL			English	Editorial Material							FOOD-INTAKE; OBESITY					geoff@scileg.freeserve.co.uk						Batterham RL, 2002, NATURE, V418, P650, DOI 10.1038/nature00887; Batterham RL, 2003, J CLIN ENDOCR METAB, V88, P3989, DOI 10.1210/jc.2003-030630; Cawthorne MA, 2007, OBES REV, V8, P131, DOI 10.1111/j.1467-789X.2007.00332.x; Farooqi IS, 2002, J CLIN INVEST, V110, P1093, DOI 10.1172/JCI200215693; *FED AM SOC EXP BI, EX PILL SWITCH GEN T; Flier JS, 2004, CELL, V116, P337, DOI 10.1016/S0092-8674(03)01081-X; Stocker CJ, 2007, AM J PHYSIOL-REG I, V292, pR1810, DOI 10.1152/ajpregu.00676.2006; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; *WHO, 2006, 311 WHO; ZHANG Y, 1994, NATURE, V372, P42	10	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 23	2007	334	7607					1298	1299		10.1136/bmj.39241.483681.AD	http://dx.doi.org/10.1136/bmj.39241.483681.AD			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184MI	17585156	Green Published			2022-12-28	WOS:000247645400026
J	Rock, FL; Mao, WM; Yaremchuk, A; Tukalo, M; Crepin, T; Zhou, HC; Zhang, YK; Hernandez, V; Akama, T; Baker, SJ; Plattner, JJ; Shapiro, L; Martinis, SA; Benkovic, SJ; Cusack, S; Alley, MRK				Rock, Fernando L.; Mao, Weimin; Yaremchuk, Anya; Tukalo, Mikhail; Crepin, Thibaut; Zhou, Huchen; Zhang, Yong-Kang; Hernandez, Vincent; Akama, Tsutomu; Baker, Stephen J.; Plattner, Jacob J.; Shapiro, Lucy; Martinis, Susan A.; Benkovic, Stephen J.; Cusack, Stephen; Alley, M. R. K.			An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site	SCIENCE			English	Article							CRYSTAL-STRUCTURE	Aminoacyl-transfer RNA (tRNA) synthetases, which catalyze the attachment of the correct amino acid to its corresponding tRNA during translation of the genetic code, are proven antimicrobial drug targets. We show that the broad-spectrum antifungal 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690), in development for the treatment of onychomycosis, inhibits yeast cytoplasmic leucyl-tRNA synthetase by formation of a stable tRNA(Leu)-AN2690 adduct in the editing site of the enzyme. Adduct formation is mediated through the boron atom of AN2690 and the 2'- and 3'-oxygen atoms of tRNA's 3'-terminal adenosine. The trapping of enzyme-bound tRNALeu in the editing site prevents catalytic turnover, thus inhibiting synthesis of leucyl-tRNA(Leu) and consequentially blocking protein synthesis. This result establishes the editing site as a bona fide target for aminoacyl-tRNA synthetase inhibitors.	Anacor Pharmaceut Inc, Palo Alto, CA 94303 USA; European Mol Biol Lab, Grenoble Outstn, F-38042 Grenoble 9, France; Ukrainian Acad Sci, Inst Mol Biol & Genet, UA-252627 Kiev, Ukraine; Shanghai Jiao Tong Univ, Sch Pharm, Shanghai 200240, Peoples R China; Stanford Univ, Sch Med, Dept Dev Biol, Beckman Ctr, Stanford, CA 94305 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Penn State Univ, Dept Chem, University Pk, PA 16802 USA	European Molecular Biology Laboratory (EMBL); National Academy of Sciences Ukraine; Institute of Molecular Biology & Genetics of NASU; Shanghai Jiao Tong University; Stanford University; University of Illinois System; University of Illinois Urbana-Champaign; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Alley, MRK (corresponding author), Anacor Pharmaceut Inc, 1060 E Meadow Circle, Palo Alto, CA 94303 USA.	dalley@anacor.com		CREPIN, Thibaut/0000-0003-2663-1794; Martinis, Susan/0000-0001-5730-8346; Cusack, Stephen/0000-0002-9324-0796; Tukalo, Michael/0000-0002-0982-2372	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE016835] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01 DE16835] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Baker SJ, 2006, J MED CHEM, V49, P4447, DOI 10.1021/jm0603724; Cusack S, 2000, EMBO J, V19, P2351, DOI 10.1093/emboj/19.10.2351; Fukunaga R, 2005, J MOL BIOL, V346, P57, DOI 10.1016/j.jmb.2004.11.060; Hendrickson T.L., 2003, TRANSLATION MECH, P34; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; Lincecum TL, 2003, MOL CELL, V11, P951, DOI 10.1016/S1097-2765(03)00098-4; MCCUTCHAN TF, 1975, NUCLEIC ACIDS RES, V2, P853, DOI 10.1093/nar/2.6.853; SCHIMMEL P, 1995, TRENDS BIOCHEM SCI, V20, P1, DOI 10.1016/S0968-0004(00)88937-9; Zhai YX, 2005, BIOCHEMISTRY-US, V44, P15437, DOI 10.1021/bi0514461	9	464	521	3	118	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 22	2007	316	5832					1759	1761		10.1126/science.1142189	http://dx.doi.org/10.1126/science.1142189			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180XE	17588934				2022-12-28	WOS:000247400500051
J	Carpten, JD; Faber, AL; Horn, C; Donoho, GP; Briggs, SL; Robbins, CM; Hostetter, G; Boguslawski, S; Moses, TY; Savage, S; Uhlik, M; Lin, AM; Du, J; Qian, YW; Zeckner, DJ; Tucker-Kellogg, G; Touchman, J; Patel, K; Mousses, S; Bittner, M; Schevitz, R; Lai, MHT; Blanchard, KL; Thomas, JE				Carpten, John D.; Faber, Andrew L.; Horn, Candice; Donoho, Gregory P.; Briggs, Stephen L.; Robbins, Christiane M.; Hostetter, Galen; Boguslawski, Sophie; Moses, Tracy Y.; Savage, Stephanie; Uhlik, Mark; Lin, Aimin; Du, Jian; Qian, Yue-Wei; Zeckner, Douglas J.; Tucker-Kellogg, Greg; Touchman, Jeffrey; Patel, Ketan; Mousses, Spyro; Bittner, Michael; Schevitz, Richard; Lai, Mei-Huei T.; Blanchard, Kerry L.; Thomas, James E.			A transforming mutation in the pleckstrin homology domain of AKT1 in cancer	NATURE			English	Article							PROTEIN-KINASE-B; PIK3CA GENE; BREAST CANCERS; PHOSPHATIDYLINOSITOL 3-KINASE; ONCOGENIC TRANSFORMATION; SIGNALING PATHWAY; HIGH-FREQUENCY; ACTIVATION; AKT/PKB; PROTOONCOGENE	Although AKT1 (v-akt murine thymoma viral oncogene homologue 1) kinase is a central member of possibly the most frequently activated proliferation and survival pathway in cancer, mutation of AKT1 has not been widely reported. Here we report the identification of a somatic mutation in human breast, colorectal and ovarian cancers that results in a glutamic acid to lysine substitution at amino acid 17 (E17K) in the lipid-binding pocket of AKT1. Lys 17 alters the electrostatic interactions of the pocket and forms new hydrogen bonds with a phosphoinositide ligand. This mutation activates AKT1 by means of pathological localization to the plasma membrane, stimulates downstream signalling, transforms cells and induces leukaemia in mice. This mechanism indicates a direct role of AKT1 in human cancer, and adds to the known genetic alterations that promote oncogenesis through the phosphatidylinositol-3-OH kinase/AKT pathway. Furthermore, the E17K substitution decreases the sensitivity to an allosteric kinase inhibitor, so this mutation may have important clinical utility for AKT drug development.	Lilly Corp Ctr, Lilly Res Labs, Canc Discovery Res, Indianapolis, IN 46285 USA; Translat Genom Res Inst, Div Integrated Canc Genom, Phoenix, AZ 85004 USA; Lilly Corp Ctr, Lilly Res Labs, Global Struct Biol, Indianapolis, IN 46285 USA; Lilly Corp Ctr, Lilly Res Labs, Integrat Biol, Indianapolis, IN 46285 USA; Lilly Singapore, Ctr Drug Discovery, Singapore 117528, Singapore; Translat Genom Res Inst, Scottsdale, AZ 85259 USA	Eli Lilly; Translational Genomics Research Institute; Eli Lilly; Eli Lilly; Translational Genomics Research Institute	Blanchard, KL (corresponding author), Lilly Corp Ctr, Lilly Res Labs, Canc Discovery Res, Indianapolis, IN 46285 USA.	kblanc@lilly.com; thomas_james_e@lilly.com	Tucker-Kellogg, Greg/G-3344-2012	Tucker-Kellogg, Greg/0000-0001-8407-9251				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; AHMED NN, 1993, ONCOGENE, V8, P1957; Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; Barnett SF, 2005, BIOCHEM J, V385, P399, DOI 10.1042/BJ20041140; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; HAWLEY RG, 1994, GENE THER, V1, P136; Khan S, 2004, INT J CANCER, V112, P407, DOI 10.1002/ijc.20447; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Knobbe CB, 2003, BRAIN PATHOL, V13, P507; Komander D, 2004, EMBO J, V23, P3918, DOI 10.1038/sj.emboj.7600379; Lee JW, 2005, ONCOGENE, V24, P1477, DOI 10.1038/sj.onc.1208304; Levine DA, 2005, CLIN CANCER RES, V11, P2875, DOI 10.1158/1078-0432.CCR-04-2142; Li WQ, 2004, J BIOL CHEM, V279, P37398, DOI 10.1074/jbc.M405730200; Milburn CC, 2003, BIOCHEM J, V375, P531, DOI 10.1042/BJ20031229; Mirza AM, 2000, CELL GROWTH DIFFER, V11, P279; Parsons DW, 2005, NATURE, V436, P792, DOI 10.1038/436792a; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Scheid MP, 2002, MOL CELL BIOL, V22, P6247, DOI 10.1128/MCB.22.17.6247-6260.2002; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Soung YH, 2006, ONCOLOGY-BASEL, V70, P285, DOI 10.1159/000096289; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stocker H, 2002, SCIENCE, V295, P2088, DOI 10.1126/science. 1068094; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369	37	945	982	1	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 26	2007	448	7152					439	U1		10.1038/nature05933	http://dx.doi.org/10.1038/nature05933			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	193VG	17611497				2022-12-28	WOS:000248302700040
J	Moffatt, MF; Kabesch, M; Liang, LM; Dixon, AL; Strachan, D; Heath, S; Depner, M; von Berg, A; Bufe, A; Rietschel, E; Heinzmann, A; Simma, B; Frischer, T; Willis-Owen, SAG; Wong, KCC; Illig, T; Vogelberg, C; Weiland, SK; von Mutius, E; Abecasis, GR; Farrall, M; Gut, IG; Lathrop, GM; Cookson, WOC				Moffatt, Miriam F.; Kabesch, Michael; Liang, Liming; Dixon, Anna L.; Strachan, David; Heath, Simon; Depner, Martin; von Berg, Andrea; Bufe, Albrecht; Rietschel, Ernst; Heinzmann, Andrea; Simma, Burkard; Frischer, Thomas; Willis-Owen, Saffron A. G.; Wong, Kenny C. C.; Illig, Thomas; Vogelberg, Christian; Weiland, Stephan K.; von Mutius, Erika; Abecasis, Goncalo R.; Farrall, Martin; Gut, Ivo G.; Lathrop, G. Mark; Cookson, William O. C.			Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma	NATURE			English	Article							NORMALIZATION	Asthma is caused by a combination of poorly understood genetic and environmental factors(1,2). We have systematically mapped the effects of single nucleotide polymorphisms ( SNPs) on the presence of childhood onset asthma by genome-wide association. We characterized more than 317,000 SNPs in DNA from 994 patients with childhood onset asthma and 1,243 non-asthmatics, using family and case-referent panels. Here we show multiple markers on chromosome 17q21 to be strongly and reproducibly associated with childhood onset asthma in family and case-referent panels with a combined P value of P < 10(-12). In independent replication studies the 17q21 locus showed strong association with diagnosis of childhood asthma in 2,320 subjects from a cohort of German children (P=0.0003) and in 3,301 subjects from the British 1958 Birth Cohort (P=0.0005). We systematically evaluated the relationships between markers of the 17q21 locus and transcript levels of genes in Epstein - Barr virus (EBV)-transformed lymphoblastoid cell lines from children in the asthma family panel used in our association study. The SNPs associated with childhood asthma were consistently and strongly associated (P < 10(-22)) in cis with transcript levels of ORMDL3, a member of a gene family that encodes transmembrane proteins anchored in the endoplasmic reticulum(3). The results indicate that genetic variants regulating ORMDL3 expression are determinants of susceptibility to childhood asthma.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England; Univ Munich, Childrens Hosp, D-80337 Munich, Germany; Univ Michigan, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA; Univ Oxford, Wellcome Trust, Ctr Human Genet, Oxford OX3 7BN, England; Univ London, Div Community Hlth Sci, London SW17 0RE, England; CEA, Ctr Natl Genotypage, Inst Genom, F-91057 Evry, France; Marien Hosp, Res Inst Prevent Allerg Dis, Childrens Dept, D-46483 Wesel, Germany; Ruhr Univ Bochum, Dept Expt Pneumol, D-44789 Bochum, Germany; Univ Cologne, Childrens Hosp, D-50924 Cologne, Germany; Univ Freiburg, Childrens Hosp, D-79106 Freiburg, Germany; Feldkirch Hosp, Childrens Dept, A-6800 Feldkirch, Austria; Univ Vienna, Childrens Hosp, A-1090 Vienna, Austria; GSF, Res Ctr Environm & Hlth, Inst Epidemiol, D-85764 Neuherberg, Germany; Tech Univ Dresden, Childrens Hosp, S-01307 Dresden, Germany; Univ Ulm, Inst Epidemiol, D-89081 Ulm, Germany	Imperial College London; University of Munich; University of Michigan System; University of Michigan; University of Oxford; Wellcome Centre for Human Genetics; University of London; CEA; UDICE-French Research Universities; Universite Paris Saclay; St. Marien Hospital; Ruhr University Bochum; University of Cologne; University of Freiburg; University of Vienna; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technische Universitat Dresden; Ulm University	Cookson, WOC (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England.	w.cookson@imperial.ac.uk	Heath, Simon C/J-4138-2012; Abecasis, Goncalo R/B-7840-2010; Kabesch, Michael/GZM-1583-2022; Cookson, William/HHC-1790-2022; Kabesch, Michael/AAB-5701-2020; Gut, Ivo/ABF-3188-2020	Heath, Simon C/0000-0002-9550-0897; Gut, Ivo/0000-0001-7219-632X; Abecasis, Goncalo/0000-0003-1509-1825; Willis-Owen, Saffron/0000-0003-2633-1150; von Mutius, Erika/0000-0002-8893-4515; Bufe, Albrecht/0000-0001-7335-9362	MRC [G0000934] Funding Source: UKRI; Medical Research Council [G0000934] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786; Abecasis GR, 2000, BIOINFORMATICS, V16, P182, DOI 10.1093/bioinformatics/16.2.182; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Buetow KH, 2001, P NATL ACAD SCI USA, V98, P581, DOI 10.1073/pnas.021506298; Burdick JT, 2006, NAT GENET, V38, P1002, DOI 10.1038/ng1863; Cardon LR, 1999, AM J HUM GENET, V65, pA245; Clayton D, 1999, AM J HUM GENET, V65, P1170, DOI 10.1086/302577; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Gunderson KL, 2005, NAT GENET, V37, P549, DOI 10.1038/ng1547; Hjelmqvist L, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-6-research0027; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Morley M, 2004, NATURE, V430, P743, DOI 10.1038/nature02797; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434; Setakis E, 2006, GENOME RES, V16, P290, DOI 10.1101/gr.4346306; Steemers FJ, 2006, NAT METHODS, V3, P31, DOI 10.1038/NMETH842; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Wedzicha JA, 2003, THORAX, V58, P1, DOI 10.1136/thorax.58.1.1; Weiland SK, 2004, EUR RESPIR J, V24, P406, DOI 10.1183/09031936.04.00090303; Williams RL, 2000, BIOMETRICS, V56, P645, DOI 10.1111/j.0006-341X.2000.00645.x; 1987, AM REV RESPIR DIS, V136, P225, DOI 10.1164/ajrccm/136.1.225	22	1153	1217	2	87	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 26	2007	448	7152					470	U5		10.1038/nature06014	http://dx.doi.org/10.1038/nature06014			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	193VG	17611496	Green Published			2022-12-28	WOS:000248302700046
J	Sandborn, WJ; Feagan, BG; Stoinov, S; Honiball, PJ; Rutgeerts, P; Mason, D; Bloomfield, R; Schreiber, S				Sandborn, William J.; Feagan, Brian G.; Stoinov, Simeon; Honiball, Pieter J.; Rutgeerts, Paul; Mason, David; Bloomfield, Ralph; Schreiber, Stefan		PRECISE 1 Study Investigators	Certolizumab pegol for the treatment of Crohn's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MAINTENANCE THERAPY; CLINICAL-TRIALS; INFLIXIMAB; ADALIMUMAB; EFFICACY; CDP870; REMISSION	Background: Certolizumab pegol is a pegylated humanized Fab' fragment that binds tumor necrosis factor (alpha). Methods: In a randomized, double-blind, placebo-controlled trial, we evaluated the efficacy of certolizumab pegol in 662 adults with moderate-to-severe Crohn's disease. Patients were stratified according to baseline levels of C-reactive protein (CRP) and were randomly assigned to receive either 400 mg of certolizumab pegol or placebo subcutaneously at weeks 0, 2, and 4 and then every 4 weeks. Primary end points were the induction of a response at week 6 and a response at both weeks 6 and 26. Results: Among patients with a baseline CRP level of at least 10 mg per liter, 37% of patients in the certolizumab group had a response at week 6, as compared with 26% in the placebo group (P=0.04). At both weeks 6 and 26, the corresponding values were 22% and 12%, respectively (P=0.05). In the overall population, response rates at week 6 were 35% in the certolizumab group and 27% in the placebo group (P=0.02); at both weeks 6 and 26, the response rates were 23% and 16%, respectively (P=0.02). At weeks 6 and 26, the rates of remission in the two groups did not differ significantly (P=0.17). Serious adverse events were reported in 10% of patients in the certolizumab group and 7% of those in the placebo group; serious infections were reported in 2% and less than 1%, respectively. In the certolizumab group, antibodies to the drug developed in 8% of patients, and antinuclear antibodies developed in 2%. Conclusions: In patients with moderate-to-severe Crohn's disease, induction and maintenance therapy with certolizumab pegol was associated with a modest improvement in response rates, as compared with placebo, but with no significant improvement in remission rates.	Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA; Univ Western Ontario, London, ON, Canada; Multiprofile Hosp Act Treatment Queen Ioanna, Gastroenterol Clin, Sofia, Bulgaria; Arcadia, Pretoria, South Africa; Univ Hosp, Div Gastroenterol, Louvain, Belgium; UCB Pharma, Slough, Berks, England; Univ Kiel, Dept Gen Internal Med, Kiel, Germany	Mayo Clinic; Western University (University of Western Ontario); Medical University Sofia; UCB Pharma SA; University of Kiel	Sandborn, WJ (corresponding author), Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol, 200 1st St SW, Rochester, MN 55905 USA.	sandborn.william@mayo.edu	Sandborn, William/ABE-8342-2020; Feagan, Brian G/M-4283-2015; Feagan, Brian/G-3292-2011; Marakhouski, Yury/M-7128-2015; Lukas, Milan/J-6382-2017	Marakhouski, Yury/0000-0001-7327-7762; Leong, Rupert/0000-0001-5944-3488; Vermeire, Severine/0000-0001-9942-3019; Varabei, Aliaksandr/0000-0002-9765-2755; Zadorova, Zdena/0000-0002-9187-2466; Rydzewska, Grazyna/0000-0002-1267-7620; Babak, Oleg/0000-0002-8319-8731; Lukas, Milan/0000-0002-1463-3840; Pimanov, Sergei Ivanovic/0000-0001-6067-3600	NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024150] Funding Source: NIH RePORTER; NCRR NIH HHS [1-UL1-RR024150-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BEST WR, 1976, GASTROENTEROLOGY, V70, P439; Choy EHS, 2002, RHEUMATOLOGY, V41, P1133, DOI 10.1093/rheumatology/41.10.1133; Colombel JF, 2007, GASTROENTEROLOGY, V132, P52, DOI 10.1053/j.gastro.2006.11.041; Cominelli F, 2004, NEW ENGL J MED, V351, P2045, DOI 10.1056/NEJMp048253; Fossati G, 2005, AM J GASTROENTEROL, V100, pS299, DOI 10.14309/00000434-200509001-00807; Hanauer SB, 2006, GASTROENTEROLOGY, V130, P323, DOI 10.1053/j.gastro.2005.11.030; Hanauer SB, 2002, LANCET, V359, P1541, DOI 10.1016/S0140-6736(02)08512-4; IRVINE EJ, 1994, GASTROENTEROLOGY, V106, P287, DOI 10.1016/0016-5085(94)90585-1; Koch G, 1996, DRUG INF J, V30, P523, DOI DOI 10.1177/009286159603000228; NESBITT A, IN PRESS INFLAMM BOW; Present DH, 1999, NEW ENGL J MED, V340, P1398, DOI 10.1056/NEJM199905063401804; Sandborn WJ, 2007, ANN INTERN MED, V146, P829, DOI 10.7326/0003-4819-146-12-200706190-00159; Sandborn WJ, 2005, NEW ENGL J MED, V353, P1912, DOI 10.1056/NEJMoa043335; Sandborn WJ, 2002, GASTROENTEROLOGY, V122, P512, DOI 10.1053/gast.2002.31072; Sands BE, 2004, NEW ENGL J MED, V350, P876, DOI 10.1056/NEJMoa030815; Schreiber S, 2005, GASTROENTEROLOGY, V129, P807, DOI 10.1053/j.gastro.2005.06.064; Schreiber S, 2005, GASTROENTEROLOGY, V129, P1808; Schreiber S, 2007, NEW ENGL J MED, V357, P239, DOI 10.1056/NEJMoa062897; Su CY, 2004, GASTROENTEROLOGY, V126, P1257, DOI 10.1053/j.gastro.2004.01.024; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502	20	838	859	0	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 19	2007	357	3					228	238		10.1056/NEJMoa067594	http://dx.doi.org/10.1056/NEJMoa067594			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191FH	17634458				2022-12-28	WOS:000248115100004
J	Nordestgaard, BG; Benn, M; Schnohr, P; Tybjaerg-Hansen, A				Nordestgaard, Borge G.; Benn, Marianne; Schnohr, Peter; Tybjaerg-Hansen, Anne			Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY-ARTERY-DISEASE; CARDIOVASCULAR-DISEASE; HDL CHOLESTEROL; LIPASE GENE; FOLLOW-UP; MUTATIONS; PLASMA; RABBITS; ATHEROGENESIS	Context Elevated nonfasting triglycerides indicate the presence of remnant lipoproteins, which may promote atherosclerosis. Objective To test the hypothesis that very high levels of nonfasting triglycerides predict myocardial infarction (MI), ischemic heart disease (IHD), and death. Design, Setting, and Participants A prospective cohort study of 7587 women and 6394 men from the general population of Copenhagen, Denmark, aged 20 to 93 years, followed up from baseline (1976-1978) until 2004. Main Outcome Measures Hazard ratios (HRs) for incident MI, IHD, and total death according to baseline nonfasting triglyceride level categories of 1 to 1.99 mmol/L (88.5-176.1 mg/dL), 2 to 2.99 mmol/L (177.0-264.6 mg/dL), 3 to 3.99 mmol/L (265.5-353.0 mg/dL), 4 to 4.99 mmol/L (354.0-441.6 mg/dL), and 5 mmol/L or more (>= 442.5 mg/dL) vs triglyceride levels of less than 1 mmol/L (<88.5 mg/dL). Results With increasing levels of nonfasting triglycerides, levels of remnant lipoprotein cholesterol increased. During a mean follow-up of 26 years, 1793 participants (691 women and 1102 men) developed MI, 3479 (1567 women and 1912 men) developed IHD, and 7818 (3731 women and 4087 men) died. For MI, among women, the age-adjusted HRs and multifactorially adjusted HRs (aHRs) for each respective category per 1-mmol/L increase in nonfasting triglyceride levels were 2.2 (aHR, 1.7), 4.4 (aHR, 2.5), 3.9 (aHR, 2.1), 5.1 (aHR, 2.4), and 16.8 (aHR, 5.4); for both, P for trend < .001. For MI, among men, the values were 1.6 (aHR, 1.4), 2.3 (aHR, 1.6), 3.6 (aHR, 2.3), 3.3 (aHR, 1.9), and 4.6 (aHR, 2.4); for both, P for trend < .001. For IHD, among women, the values were 1.7 (aHR, 1.4), 2.8 (aHR, 1.8), 3.0 (aHR, 1.8), 2.1 (aHR, 1.2), and 5.9 (aHR, 2.6); for both, P for trend < .001. For IHD, among men, the values were 1.3 (aHR, 1.1), 1.7 (aHR, 1.3), 2.1 (aHR, 1.3), 2.0 (aHR, 1.2), and 2.9 (aHR, 1.5); P for trend < .001 for age-adjusted and P for trend = .03 for multifactorially adjusted. For total death, among women, the values were 1.3 (aHR, 1.3), 1.7 (aHR, 1.6), 2.2 (aHR, 2.2), 2.2 (aHR, 1.9), and 4.3 (aHR, 3.3); for both, P for trend < .001. For total death, among men, the values were 1.3 (aHR, 1.2), 1.4 (aHR, 1.4), 1.7 (aHR, 1.5), 1.8 (aHR, 1.6), and 2.0 (aHR, 1.8); for both, P for trend < .001. Conclusion In this general population cohort, elevated nonfasting triglyceride levels were associated with increased risk of MI, IHD, and death in men and women.	Herlev Univ Hosp, Dept Clin Biochem, DK-2730 Herlev, Denmark; Bispebjerg Hosp, Copenhagen City Heart Study, Copenhagen, Denmark; Univ Copenhagen, Copenhagen Univ Hosp, Rigshosp, Dept Clin Biochem, Copenhagen, Denmark	University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Bispebjerg Hospital; Rigshospitalet; University of Copenhagen	Nordestgaard, BG (corresponding author), Herlev Univ Hosp, Dept Clin Biochem, Herlev Ringvej 75, DK-2730 Herlev, Denmark.	brno@heh.regionh.dk	Nordestgaard, Borge Gronne/ABF-1310-2020; Adiels, Martin/C-9278-2011; Benn, Marianne/O-4164-2019; Gonzalez, Javier T/K-6910-2014	Benn, Marianne/0000-0002-1701-595X; Gonzalez, Javier T/0000-0002-9939-0074; Nordestgaard, Borge/0000-0002-1954-7220				Agerholm-Larsen B, 2000, CIRCULATION, V102, P2197; Agerholm-Larsen B, 2000, CIRCULATION, V101, P1907, DOI 10.1161/01.CIR.101.16.1907; Andersen RV, 2003, J AM COLL CARDIOL, V41, P1972, DOI 10.1016/S0735-1097(03)00407-8; Austin MA, 2000, CIRCULATION, V101, P2777, DOI 10.1161/01.CIR.101.24.2777; AUSTIN MA, 1991, ARTERIOSCLER THROMB, V11, P2, DOI 10.1161/01.ATV.11.1.2; Benlian P, 1996, NEW ENGL J MED, V335, P848, DOI 10.1056/NEJM199609193351203; Benn M, 2007, ARTERIOSCL THROM VAS, V27, P661, DOI 10.1161/01.ATV.0000255580.73689.8e; Berneis KK, 2002, J LIPID RES, V43, P1363, DOI 10.1194/jlr.R200004-JLR200; BRUNZELL JD, 2001, METABOLIC MOL BASES, P2789; Clarke R, 1999, AM J EPIDEMIOL, V150, P341; COHN JS, 1988, J LIPID RES, V29, P925; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; Hokanson J E, 1996, J Cardiovasc Risk, V3, P213, DOI 10.1097/00043798-199604000-00014; Hokanson JE, 1999, CURR OPIN LIPIDOL, V10, P393, DOI 10.1097/00041433-199910000-00003; Hokanson JE, 2002, DIABETES, V51, P1208, DOI 10.2337/diabetes.51.4.1208; Julian DG, 1997, EUR HEART J, V18, P394; Kofoed SC, 2002, J VASC SURG, V36, P783, DOI 10.1067/mva.2002.126552; Kolovou GD, 2005, CURR MED CHEM, V12, P1931, DOI 10.2174/0929867054546609; Mahley RW., 2001, METABOLIC MOL BASES, V8th ed, P2835; MANNINEN V, 1988, JAMA-J AM MED ASSOC, V260, P641, DOI 10.1001/jama.260.5.641; NORDESTGAARD BG, 1988, J LIPID RES, V29, P1491; NORDESTGAARD BG, 1995, ARTERIOSCL THROM VAS, V15, P534, DOI 10.1161/01.ATV.15.4.534; NORDESTGAARD BG, 1988, ARTERIOSCLEROSIS, V8, P421, DOI 10.1161/01.ATV.8.4.421; PATSCH JR, 1992, ARTERIOSCLER THROMB, V12, P1336, DOI 10.1161/01.ATV.12.11.1336; Robins SJ, 2001, JAMA-J AM MED ASSOC, V285, P1585, DOI 10.1001/jama.285.12.1585; Rutledge JC, 2000, CIRC RES, V86, P768, DOI 10.1161/01.RES.86.7.768; Sarti C, 2006, J DIABETES COMPLICAT, V20, P121, DOI 10.1016/j.jdiacomp.2005.06.014; Sarwar N, 2007, CIRCULATION, V115, P450, DOI 10.1161/CIRCULATIONAHA.106.637793; Schlesinger Z, 2000, CIRCULATION, V102, P21, DOI 10.1161/01.CIR.102.1.21; Schnohr P, 2002, EUR HEART J, V23, P620, DOI 10.1053/euhj.2001.2842; SHAIKH M, 1991, ARTERIOSCLER THROMB, V11, P569, DOI 10.1161/01.ATV.11.3.569; Stampfer MJ, 1996, JAMA-J AM MED ASSOC, V276, P882, DOI 10.1001/jama.276.11.882; STENSVOLD I, 1993, BMJ-BRIT MED J, V307, P1318, DOI 10.1136/bmj.307.6915.1318; Wittrup HH, 1997, J CLIN INVEST, V99, P1606, DOI 10.1172/JCI119323; Wittrup HH, 1999, CIRCULATION, V99, P2901, DOI 10.1161/01.CIR.99.22.2901; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	36	1507	1560	3	74	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 18	2007	298	3					299	308		10.1001/jama.298.3.299	http://dx.doi.org/10.1001/jama.298.3.299			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	190US	17635890				2022-12-28	WOS:000248086700024
J	Koopman, M; Antonini, NF; Douma, J; Wals, J; Honkoop, AH; Erdkamp, FLG; de Jong, RS; Rodenburg, CJ; Vreugdenhil, G; Loosveld, OJL; van Bochove, A; Sinnige, HAM; Creemers, GJM; Tesselaar, MET; Slee, PHTJ; Werter, MJBP; Mol, L; Dalesio, O; Punt, CJA				Koopman, Miriam; Antonini, Ninja F.; Douma, Joep; Wals, Jaap; Honkoop, Aafke H.; Erdkamp, Frans L. G.; de Jong, Robert S.; Rodenburg, Cees J.; Vreugdenhil, Gerard; Loosveld, Olaf J. L.; van Bochove, Aart; Sinnige, Harm A. M.; Creemers, Geert-Jan M.; Tesselaar, Margot E. T.; Slee, Peter H. Th J.; Werter, Marjon J. B. P.; Mol, Linda; Dalesio, Otilia; Punt, Cornelis J. A.			Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial	LANCET			English	Article							FLUOROURACIL PLUS LEUCOVORIN; 2 DIFFERENT SCHEDULES; 1ST-LINE TREATMENT; ORAL CAPECITABINE; MULTICENTER; CELECOXIB; THERAPY; FOLFIRI	Background The optimum use of cytotoxic drugs for advanced colorectal cancer has not been defined. Our aim was to investigate whether combination treatment is better than sequential administration of the same drugs in patients with advanced colorectal cancer. Methods We randomly assigned 820 patients with advanced colorectal cancer to receive either first-line treatment with capecitabine, second-line irinotecan, and third-line capecitabine plus oxaliplatin (sequential treatment; n=410) or first-line treatment capecitabine plus irinotecan and second-line capecitabine plus oxaliplatin (combination treatment; n=410). The primary endpoint was overall survival. Analyses were done by intention to treat. This trial is registered with ClinicalTrials.gov with the number NCT00312000. Findings 17 patients (nine in the sequential treatment group, eight in the combination group) were found to be ineligible and were excluded from the analysis. 675 (84%) patients died during the study: 336 in the sequential group and 339 in the combination group. Median overall survival was 16.3 (95% Cl 14.3-18.1) months for sequential treatment and 17.4 (15.2-19.2) months for combination treatment (p=0.3281). The hazard ratio for combination versus sequential treatment was 0.92 (95% Cl 0-79-1.08; p=0.3281). The frequency of grade 3-4 toxicity over all lines of treatment did not differ significantly between the two groups, except for grade 3 hand-foot syndrome, which occurred more often with sequential treatment than with combination treatment (13% vs 7%; p=0.004). Interpretation Combination treatment does not significantly improve overall survival compared with the sequential use of cytotoxic drugs in advanced colorectal cancer. Thus sequential treatment remains a valid option for patients with advanced colorectal cancer.	Radboud Univ Nijmegen Med Ctr, Dept Med Oncol, NL-6500 HB Nijmegen, Netherlands; Netherlands Canc Inst, Biometr Dept, Amsterdam, Netherlands; Rijnstate Hosp, Arnhem, Netherlands; Atrium Med Ctr, Heerlen, Netherlands; Isala Hosp, Zwolle, Netherlands; Maasland Hosp, Sittard, Netherlands; Martini Hosp, Groningen, Netherlands; Meander Med Ctr, Amersfoort, Netherlands; Maxima Med Ctr, Veldhoven, Netherlands; Amphia Hosp, Breda, Netherlands; Zaans Med Ctr, Zaandam, Netherlands; Jeroen Bosch Hosp, Den Bosch, Netherlands; Catharina Hosp, Eindhoven, Netherlands; Leiden Univ, Med Ctr, Leiden, Netherlands; St Antonius Hosp, Nieuwegein, Netherlands; Viecuri Hosp, Venlo, Netherlands; Comprehens Canc Ctr E, Nijmegen, Netherlands	Radboud University Nijmegen; Netherlands Cancer Institute; Rijnstate Hospital; Atrium Medical Center; Maasland Hospital; Martini Hospital; Meander Medisch Centrum; Maxima Medical Center; Amphia Hospital; Jeroen Bosch Ziekenhuis; Catharina Hospital; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; St. Antonius Hospital Utrecht; VieCuri Medical Center	Punt, CJA (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Med Oncol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	c.punt@onco.umcn.nl		Mol, Linda/0000-0002-4155-1605				Bajetta E, 2004, CANCER-AM CANCER SOC, V100, P279, DOI 10.1002/cncr.11910; Borner MM, 2005, ANN ONCOL, V16, P282, DOI 10.1093/annonc/mdi047; Borner MM, 2002, J CLIN ONCOL, V20, P1759, DOI 10.1200/JCO.2002.07.087; Colucci G, 2005, J CLIN ONCOL, V23, P4866, DOI 10.1200/JCO.2005.07.113; Cunningham D, 1998, LANCET, V352, P1413, DOI 10.1016/S0140-6736(98)02309-5; de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Fuchs C, 2006, J CLIN ONCOL, V24, p147S; Grothey A, 2004, J CLIN ONCOL, V22, P1209, DOI 10.1200/JCO.2004.11.037; Haller DG, 2006, J CLIN ONCOL, V24, p149S; Hoff PM, 2001, J CLIN ONCOL, V19, P2282, DOI 10.1200/JCO.2001.19.8.2282; Kohne CH, 2005, J CLIN ONCOL, V23, p252S; Koopman M, 2006, ANN ONCOL, V17, P1523, DOI 10.1093/annonc/mdl179; Punt CJA, 2005, ANN ONCOL, V16, P845, DOI 10.1093/annonc/mdi196; Punt CJA, 2004, ANN ONCOL, V15, P1453, DOI 10.1093/annonc/mdh383; Rea DW, 2005, ANN ONCOL, V16, P1123, DOI 10.1093/annonc/mdi227; Rothenberg ML, 2003, J CLIN ONCOL, V21, P2059, DOI 10.1200/JCO.2003.11.126; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; Seymour MT, 2007, LANCET, V370, P143, DOI 10.1016/S0140-6736(07)61087-3; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113; Van Cutsem E, 2001, J CLIN ONCOL, V19, P4097, DOI 10.1200/JCO.2001.19.21.4097	22	511	518	0	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 14	2007	370	9582					135	142		10.1016/S0140-6736(07)61086-1	http://dx.doi.org/10.1016/S0140-6736(07)61086-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	190WP	17630036				2022-12-28	WOS:000248091600027
J	Ameres, SL; Martinez, J; Schroeder, R				Ameres, Stefan Ludwig; Martinez, Javier; Schroeder, Renee			Molecular basis for target RNA recognition and cleavage by human RISC	CELL			English	Article							INFLUENCES SIRNA EFFICACY; DOUBLE-STRANDED-RNA; MESSENGER-RNA; CRYSTAL-STRUCTURE; PASSENGER-STRAND; INTERFERENCE; ARGONAUTE2; MICRORNA; PROTEIN; GENE	The RNA- Induced Silencing Complex ( RISC) is a ribonucleoprotein particle composed of a single- stranded short interfering RNA ( siRNA) and an endonucleolytically active Argonaute protein, capable of cleaving mRNAs complementary to the siRNA. The mechanism by which RISC cleaves a target RNA is well understood, however it remains enigmatic how RISC finds its target RNA. Here, we show, both in vitro and in vivo, that the accessibility of the target site correlates directly with the efficiency of cleavage, demonstrating that RISC is unable to unfold structured RNA. In the course of target recognition, RISC transiently contacts single-stranded RNA nonspecifically and promotes siRNA- target RNA annealing. Furthermore, the 50 part of the siRNA within RISC creates a thermodynamic threshold that determines the stable association of RISC and the target RNA. We therefore provide mechanistic insights by revealing features of RISC and target RNAs that are crucial to achieve efficiency and specificity in RNA interference.	Austrian Acad Sci, Inst Mol Biotechnol, IMBA, A-1030 Vienna, Austria; Univ Vienna, Max F Perutz Labs, A-1030 Vienna, Austria	Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Martinez, J (corresponding author), Austrian Acad Sci, Inst Mol Biotechnol, IMBA, Dr Bohr Gasse 3-5, A-1030 Vienna, Austria.	javier.martinez@imba.oeaw.ac.at; renee.schroeder@univie.ac.at	Ameres, Stefan Ludwig/B-4046-2012; Ameres, Stefan/G-3775-2010	Ameres, Stefan Ludwig/0000-0002-8248-3098; Martinez, Javier/0000-0001-9152-7323				Ameres SL, 2005, EMBO J, V24, P358, DOI 10.1038/sj.emboj.7600531; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Boese Q, 2005, METHOD ENZYMOL, V392, P73, DOI 10.1016/S0076-6879(04)92005-8; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Brown KM, 2005, NAT STRUCT MOL BIOL, V12, P469, DOI 10.1038/nsmb931; Caudy AA, 2003, NATURE, V425, P411, DOI 10.1038/nature01956; Caudy AA, 2002, GENE DEV, V16, P2491, DOI 10.1101/gad.1025202; Didiano D, 2006, NAT STRUCT MOL BIOL, V13, P849, DOI 10.1038/nsmb1138; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Filipowicz W, 2005, CELL, V122, P17, DOI 10.1016/j.cell.2005.06.023; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gu S, 2005, RNA, V11, P38, DOI 10.1261/rna.7158605; Haley B, 2004, NAT STRUCT MOL BIOL, V11, P599, DOI 10.1038/nsmb780; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Heale BSE, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni026; Humphreys DT, 2005, P NATL ACAD SCI USA, V102, P16961, DOI 10.1073/pnas.0506482102; Hutvagner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Ishizuka A, 2002, GENE DEV, V16, P2497, DOI 10.1101/gad.1022002; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Leuschner PJF, 2006, EMBO REP, V7, P314, DOI 10.1038/sj.embor.7400637; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Long D, 2007, NAT STRUCT MOL BIOL, V14, P287, DOI 10.1038/nsmb1226; Luo KQ, 2004, BIOCHEM BIOPH RES CO, V318, P303, DOI 10.1016/j.bbrc.2004.04.027; Ma JB, 2005, NATURE, V434, P666, DOI 10.1038/nature03514; Martinez J, 2004, GENE DEV, V18, P975, DOI 10.1101/gad.1187904; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Matranga C, 2005, CELL, V123, P607, DOI 10.1016/j.cell.2005.08.044; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Miyoshi K, 2005, GENE DEV, V19, P2837, DOI 10.1101/gad.1370605; Moller T, 2002, MOL CELL, V9, P23, DOI 10.1016/S1097-2765(01)00436-1; NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Overhoff M, 2005, J MOL BIOL, V348, P871, DOI 10.1016/j.jmb.2005.03.012; Pham JW, 2004, CELL, V117, P83, DOI 10.1016/S0092-8674(04)00258-2; Pillai RS, 2005, SCIENCE, V309, P1573, DOI 10.1126/science.1115079; Pillai RS, 2004, RNA, V10, P1518, DOI 10.1261/rna.7131604; Rand TA, 2005, CELL, V123, P621, DOI 10.1016/j.cell.2005.10.020; Rivas FV, 2005, NAT STRUCT MOL BIOL, V12, P340, DOI 10.1038/nsmb918; Sasaki T, 2003, GENOMICS, V82, P323, DOI 10.1016/S0888-7543(03)00129-0; Schubert S, 2005, J MOL BIOL, V348, P883, DOI 10.1016/j.jmb.2005.03.011; Schwarz DS, 2006, PLOS GENET, V2, P1307, DOI 10.1371/journal.pgen.0020140; Schwarz DS, 2004, CURR BIOL, V14, P787, DOI 10.1016/j.cub.2004.03.008; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Sen GL, 2005, DIFFERENTIATION, V73, P287, DOI 10.1111/j.1432-0436.2005.00029.x; Song JJ, 2004, SCIENCE, V305, P1434, DOI 10.1126/science.1102514; Tomari Y, 2005, GENE DEV, V19, P517, DOI 10.1101/gad.1284105; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; Wang BB, 2006, MOL CELL, V22, P553, DOI 10.1016/j.molcel.2006.03.034; Wassarman KM, 2002, CELL, V109, P141, DOI 10.1016/S0092-8674(02)00717-1; Yuan YR, 2005, MOL CELL, V19, P405, DOI 10.1016/j.molcel.2005.07.011; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zhang AX, 2002, MOL CELL, V9, P11, DOI 10.1016/S1097-2765(01)00437-3; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	62	379	416	4	48	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 13	2007	130	1					101	112		10.1016/j.cell.2007.04.037	http://dx.doi.org/10.1016/j.cell.2007.04.037			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	197WK	17632058	Bronze			2022-12-28	WOS:000248587000014
J	Callen, E; Jankovic, M; Difilippantonio, S; Daniel, JA; Chen, HT; Celeste, A; Pellegrini, M; McBride, K; Wangsa, D; Bredemeyer, AL; Sleckman, BP; Ried, T; Nussenzweig, M; Nussenzweig, A				Callen, Elsa; Jankovic, Mila; Difilippantonio, Simone; Daniel, Jeremy A.; Chen, Hua-Tang; Celeste, Arkady; Pellegrini, Manuela; McBride, Kevin; Wangsa, Danny; Bredemeyer, Andrea L.; Sleckman, Barry P.; Ried, Thomas; Nussenzweig, Michel; Nussenzweig, Andre			ATM prevents the persistence and propagation of chromosome breaks in lymphocytes	CELL			English	Article							CLASS-SWITCH RECOMBINATION; DOUBLE-STRAND BREAKS; CYTIDINE DEAMINASE AID; B-CELL DEVELOPMENT; HEAVY-CHAIN LOCUS; GENOMIC INSTABILITY; V(D)J RECOMBINATION; DEFICIENT MICE; IONIZING-RADIATION; GENE AMPLIFICATION	DNA double- strand breaks ( DSBs) induce a signal transmitted by the ataxia- telangiectasia mutated ( ATM) kinase, which suppresses illegitimate joining of DSBs and activates cell- cycle checkpoints. Here we show that a significant fraction of mature ATM- deficient lymphocytes contain telomere- deleted ends produced by failed end joining during V( D) J recombination. These RAG- 1/ 2 endonuclease- dependent, terminally deleted chromosomes persist in peripheral lymphocytes for at least 2 weeks in vivo and are stable over several generations in vitro. Restoration of ATM kinase activity in mature lymphocytes that have transiently lostATM function leads to loss of cells with terminally deleted chromosomes. Thus, maintenance of genomic stability in lymphocytes requires faithful end joining as well a checkpoint that prevents the long- term persistence and transmission of DSBs. Silencing this checkpoint permits DNA ends produced by V( D) J recombination in a lymphoid precursor to serve as substrates for translocations with chromosomes subsequently damaged by other means in mature cells.	Rockefeller Univ, Lab Mol Immunol, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA; NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; NCI, Sect Canc Genom, NIH, Genet Branch, Bethesda, MD 20892 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Rockefeller University; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Washington University (WUSTL)	Nussenzweig, M (corresponding author), Rockefeller Univ, Lab Mol Immunol, New York, NY 10021 USA.	andre_nussenzweig@nih.gov; nussen@mail.rockefeller.edu	Nussenzweig, Michel/AAE-7292-2019; Daniel, Jeremy/S-4729-2016; Pellegrini, manuela/AAC-1423-2022; mcbride, kevin/E-8230-2011	Daniel, Jeremy/0000-0002-1981-5571; Bredemeyer, Andrea/0000-0003-2970-5998; pellegrini, manuela/0000-0001-6387-5187	NATIONAL CANCER INSTITUTE [ZIABC010837, Z01BC010837, Z01BC010283, ZICBC009255, ZIABC010283, Z01BC009255] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Arlt MF, 2006, DNA REPAIR, V5, P1126, DOI 10.1016/j.dnarep.2006.05.010; Aten JA, 2004, SCIENCE, V303, P92, DOI 10.1126/science.1088845; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Boursalian TE, 2004, NAT IMMUNOL, V5, P418, DOI 10.1038/ni1049; Bredemeyer AL, 2006, NATURE, V442, P466, DOI 10.1038/nature04866; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Cuadrado M, 2006, J EXP MED, V203, P297, DOI 10.1084/jem.20051923; Difilippantonio MJ, 2002, J EXP MED, V196, P469, DOI 10.1084/jem.20020851; Franco S, 2006, MOL CELL, V21, P201, DOI 10.1016/j.molcel.2006.01.005; Gladdy RA, 2003, CANCER CELL, V3, P37, DOI 10.1016/S1535-6108(02)00236-2; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HUANG CY, 2007, J EXP MED, V334, P676; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Jung D, 2006, ANNU REV IMMUNOL, V24, P541, DOI 10.1146/annurev.immunol.23.021704.115830; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; Kracker S, 2005, P NATL ACAD SCI USA, V102, P1584, DOI 10.1073/pnas.0409191102; Liyanage M, 2000, BLOOD, V96, P1940, DOI 10.1182/blood.V96.5.1940.h8001940_1940_1946; Lumsden JM, 2004, J EXP MED, V200, P1111, DOI 10.1084/jem.20041074; Manis JP, 2004, NAT IMMUNOL, V5, P481, DOI 10.1038/ni1067; Matei IR, 2007, BLOOD, V109, P1887, DOI 10.1182/blood-2006-05-020917; McBride KM, 2006, P NATL ACAD SCI USA, V103, P8798, DOI 10.1073/pnas.0603272103; Meffre E, 2000, NAT IMMUNOL, V1, P379, DOI 10.1038/80816; MIYAKE K, 1995, J IMMUNOL, V154, P3333; Mochan TA, 2004, DNA REPAIR, V3, P945, DOI 10.1016/j.dnarep.2004.03.017; Monroe RJ, 1999, IMMUNITY, V11, P201, DOI 10.1016/S1074-7613(00)80095-3; Morales JC, 2006, P NATL ACAD SCI USA, V103, P3310, DOI 10.1073/pnas.0511259103; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Myers JS, 2006, J BIOL CHEM, V281, P9346, DOI 10.1074/jbc.M513265200; Perkins EJ, 2002, GENE DEV, V16, P159, DOI 10.1101/gad.956902; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Petiniot LK, 2002, MOL CELL BIOL, V22, P3174, DOI 10.1128/MCB.22.9.3174-3177.2002; Ramiro AR, 2006, CANCER RES, V66, P7837, DOI 10.1158/0008-5472.CAN-06-0863; Ramiro AR, 2006, NATURE, V440, P105, DOI 10.1038/nature04495; Reina-San-Martin B, 2005, P NATL ACAD SCI USA, V102, P1590, DOI 10.1073/pnas.0406289102; Reina-San-Martin B, 2004, J EXP MED, V200, P1103, DOI 10.1084/jem.20041162; Reina-San-Martin B, 2007, EUR J IMMUNOL, V37, P235, DOI 10.1002/eji.200636789; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Rolink AG, 2000, J EXP MED, V191, P23, DOI 10.1084/jem.191.1.23; Rosenwald A, 2003, CANCER CELL, V3, P185, DOI 10.1016/S1535-6108(03)00028-X; Sayegh C, 2005, GENE DEV, V19, P322, DOI 10.1101/gad.1254305; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SPRENT J, 1994, SCIENCE, V265, P1395, DOI 10.1126/science.8073282; Takao N, 1999, ONCOGENE, V18, P7002, DOI 10.1038/sj.onc.1203172; Vacchio MS, 2007, P NATL ACAD SCI USA, V104, P6323, DOI 10.1073/pnas.0611222104; Ward IM, 2005, MOL CELL BIOL, V25, P10079, DOI 10.1128/MCB.25.22.10079-10086.2005; Ward IM, 2004, J CELL BIOL, V165, P459, DOI 10.1083/jcb.200403021; Yu W, 1999, NATURE, V400, P682, DOI 10.1038/23287; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5	52	151	153	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 13	2007	130	1					63	75		10.1016/j.cell.2007.06.016	http://dx.doi.org/10.1016/j.cell.2007.06.016			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	197WK	17599403	Bronze			2022-12-28	WOS:000248587000011
J	Lee, JY; Engelman, JA; Cantley, LC				Lee, Jennifer Y.; Engelman, Jeffrey A.; Cantley, Lewis C.			Biochemistry - PI3K charges ahead	SCIENCE			English	Editorial Material							PHOSPHATIDYLINOSITOL 3'-KINASE; 3-KINASES		Harvard Univ, Sch Med, Dept Biol Syst Engn, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA; Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital	Lee, JY (corresponding author), Harvard Univ, Sch Med, Dept Biol Syst Engn, Boston, MA 02115 USA.	lewis_cantley@hms.harvard.edu	Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NIGMS NIH HHS [R01 GM041890] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Miled N, 2007, SCIENCE, V317, P239, DOI 10.1126/science.1135394; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; VOGT PK, 2007, TRENDS BIOCH SCI; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Yu JH, 1998, J BIOL CHEM, V273, P30199, DOI 10.1074/jbc.273.46.30199	9	28	30	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 13	2007	317	5835					206	207		10.1126/science.1146073	http://dx.doi.org/10.1126/science.1146073			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189DC	17626872				2022-12-28	WOS:000247968600027
J	Tokmakoff, A				Tokmakoff, Andrei			Shining light on the rapidly evolving structure of water	SCIENCE			English	Editorial Material							ULTRAFAST INFRARED-SPECTROSCOPY; HYDROGEN-BOND DYNAMICS; LIQUID WATER; RELAXATION; NETWORK; ENERGY; H2O		MIT, Dept Chem, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Tokmakoff, A (corresponding author), MIT, Dept Chem, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	tokmakof@mit.edu						Asbury JB, 2004, J CHEM PHYS, V121, P12431, DOI 10.1063/1.1818107; Ashihara S, 2007, J PHYS CHEM A, V111, P743, DOI 10.1021/jp0676538; Corcelli SA, 2004, J CHEM PHYS, V120, P8107, DOI 10.1063/1.1683072; Cowan ML, 2005, NATURE, V434, P199, DOI 10.1038/nature03383; Eaves JD, 2005, P NATL ACAD SCI USA, V102, P13019, DOI 10.1073/pnas.0505125102; Eisenberg D. S., 2005, STRUCTURE PROPERTIES; Fecko CJ, 2003, SCIENCE, V301, P1698, DOI 10.1126/science.1087251; Laage D, 2006, SCIENCE, V311, P832, DOI 10.1126/science.1122154; Lindner J, 2006, CHEM PHYS LETT, V421, P329, DOI 10.1016/j.cplett.2006.01.081; Ohmine I, 1999, ACCOUNTS CHEM RES, V32, P741, DOI 10.1021/ar970161g; Rey R, 2002, J PHYS CHEM A, V106, P11993, DOI 10.1021/jp026419o; STILLINGER FH, 1980, SCIENCE, V209, P451, DOI 10.1126/science.209.4455.451	12	55	55	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2007	317	5834					54	55		10.1126/science.1144515	http://dx.doi.org/10.1126/science.1144515			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186KD	17615330				2022-12-28	WOS:000247776700035
J	Mastenbroek, S; Twisk, M; van Echten-Arends, J; Sikkema-Raddatz, B; Korevaar, JC; Verhoeve, HR; Vogel, NEA; Arts, EGJM; de Vries, JWA; Bossuyt, PM; Buys, CHCM; Heineman, MJ; Repping, S; van der Veen, F				Mastenbroek, Sebastiaan; Twisk, Moniek; van Echten-Arends, Jannie; Sikkema-Raddatz, Birgit; Korevaar, Johanna C.; Verhoeve, Harold R.; Vogel, Niels E. A.; Arts, Eus G. J. M.; de Vries, Jan W. A.; Bossuyt, Patrick M.; Buys, Charles H. C. M.; Heineman, Maas Jan; Repping, Sjoerd; van der Veen, Fulco			In vitro fertilization with preimplantation genetic screening	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MATERNAL AGE; DIAGNOSIS; ANEUPLOIDY; BIOPSY	BACKGROUND: Pregnancy rates in women of advanced maternal age undergoing in vitro fertilization (IVF) are disappointingly low. It has been suggested that the use of preimplantation genetic screening of cleavage-stage embryos for aneuploidies may improve the effectiveness of IVF in these women. METHODS: We conducted a multicenter, randomized, double-blind, controlled trial comparing three cycles of IVF with and without preimplantation genetic screening in women 35 through 41 years of age. The primary outcome measure was ongoing pregnancy at 12 weeks of gestation. The secondary outcome measures were biochemical pregnancy, clinical pregnancy, miscarriage, and live birth. RESULTS: Four hundred eight women (206 assigned to preimplantation genetic screening and 202 assigned to the control group) underwent 836 cycles of IVF (434 cycles with and 402 cycles without preimplantation genetic screening). The ongoing-pregnancy rate was significantly lower in the women assigned to preimplantation genetic screening (52 of 206 women [25%]) than in those not assigned to preimplantation genetic screening (74 of 202 women [37%]; rate ratio, 0.69; 95% confidence interval [CI], 0.51 to 0.93). The women assigned to preimplantation genetic screening also had a significantly lower live-birth rate (49 of 206 women [24%] vs. 71 of 202 women [35%]; rate ratio, 0.68; 95% CI, 0.50 to 0.92). CONCLUSIONS: Preimplantation genetic screening did not increase but instead significantly reduced the rates of ongoing pregnancies and live births after IVF in women of advanced maternal age.	Univ Amsterdam, Acad Med Ctr, Ctr Reprod Med, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1100 DE Amsterdam, Netherlands; Univ Groningen, Sect Reprod Med, Dept Obstet & Gynecol, Groningen, Netherlands; Univ Groningen, Dept Genet, Univ Med Ctr Groningen, Groningen, Netherlands; Onze Lieve Vrouw Hosp, Dept Obstet & Gynecol, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Groningen; University of Groningen; Onze Lieve Vrouwe Gasthuis Hospital	Repping, S (corresponding author), Univ Amsterdam, Acad Med Ctr, Ctr Reprod Med, POB 22700, NL-1100 DE Amsterdam, Netherlands.	s.repping@amc.uva.nl	Bossuyt, Patrick M/AAR-1183-2021; Bossuyt, Patrick M./B-4557-2016	Bossuyt, Patrick M/0000-0003-4427-0128; Bossuyt, Patrick M./0000-0003-4427-0128; Mastenbroek, Sebastiaan/0000-0002-7550-2924; Repping, Sjoerd/0000-0002-6959-149X				Baird DT, 2005, HUM REPROD UPDATE, V11, P261, DOI 10.1093/humupd/dmi006; Coonen E, 2004, HUM REPROD, V19, P316, DOI 10.1093/humrep/deh077; De Vos A, 2001, PRENATAL DIAG, V21, P767, DOI 10.1002/pd.172; Dozortsev DI, 2001, FERTIL STERIL, V76, P186, DOI 10.1016/S0015-0282(01)01836-2; EIM, 2006, HUM REPROD, V21, P1680, DOI 10.1093/humrep/del075; Gianaroli L, 1999, FERTIL STERIL, V72, P837, DOI 10.1016/S0015-0282(99)00377-5; Le Caignec C, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl336; Mastenbroek S, 2005, HUM REPROD, V20, P2362, DOI 10.1093/humrep/deh879; Montag M, 2004, REPROD BIOMED ONLINE, V9, P425, DOI 10.1016/S1472-6483(10)61278-3; Munne S, 1999, HUM REPROD, V14, P2191, DOI 10.1093/humrep/14.9.2191; MUNNE S, 1995, FERTIL STERIL, V64, P382, DOI 10.1016/S0015-0282(16)57739-5; Munne Santiago, 2003, Reprod Biomed Online, V7, P91; Obasaju Michael, 2001, Reprod Biomed Online, V2, P98; PUISSANT F, 1987, HUM REPROD, V2, P705, DOI 10.1093/oxfordjournals.humrep.a136618; Sermon KD, 2007, HUM REPROD, V22, P323, DOI 10.1093/humrep/del402; Staessen C, 2004, HUM REPROD, V19, P2849, DOI 10.1093/humrep/deh536; Twisk M, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005291.pub2; Velilla Esther, 2002, Reprod Biomed Online, V4, P210; Verlinsky Y, 2004, FERTIL STERIL, V82, P292, DOI 10.1016/j.fertnstert.2003.09.082; Wilton L, 2002, PRENATAL DIAG, V22, P512, DOI 10.1002/pd.388; Wright Victoria Clay, 2005, Morbidity and Mortality Weekly Report, V54, P1	21	471	508	0	121	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 5	2007	357	1					9	17		10.1056/NEJMoa067744	http://dx.doi.org/10.1056/NEJMoa067744			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185OR	17611204				2022-12-28	WOS:000247720800004
J	Gibbon, W				Gibbon, Wayne			Medical schools for the health-care needs of the 21st century	LANCET			English	Article							FAMILY PHYSICIANS; CHOICE; UNDERGRADUATE; SPECIALTY		Bond Univ, Fac Med & Hlth Sci, Gold Coast, Qld 4229, Australia	Bond University	Gibbon, W (corresponding author), Bond Univ, Fac Med & Hlth Sci, Gold Coast, Qld 4229, Australia.	wgibbon@bond.edu.au						Campbell RJ, 2003, FAM MED, V35, P60; Campos-Outcalt D, 2004, FAM MED, V36, P260; ENGEL CE, 1995, CAPABILITY, V1; Ferrante JM, 2000, J AM BOARD FAM PRACT, V13, P408, DOI DOI 10.3122/15572625-13-6-408; Goldacre MJ, 2004, MED EDUC, V38, P249, DOI 10.1046/j.1365-2923.2004.01763.x; Harris MG, 2005, MED J AUSTRALIA, V183, P295, DOI 10.5694/j.1326-5377.2005.tb07058.x; Howe A, 2001, MED EDUC, V35, P391, DOI 10.1046/j.1365-2923.2001.00866.x; Jamrozik K, 2005, MED J AUSTRALIA, V182, P152, DOI 10.5694/j.1326-5377.2005.tb06642.x; Joyce CM, 2006, MED J AUSTRALIA, V185, P102, DOI 10.5694/j.1326-5377.2006.tb00484.x; Leeder S, 2004, RACE TIME CHALLENGE; LINDBLOM CE, 1959, PUBLIC ADMIN REV, V19, P79, DOI 10.2307/973677; Macinko J, 2003, HEALTH SERV RES, V38, P831, DOI 10.1111/1475-6773.00149; MARTINI CJM, 1994, JAMA-J AM MED ASSOC, V272, P661, DOI 10.1001/jama.272.9.661; Organisation for Economic Co-Operation and Development, 2005, HLTH GLANC OECD IND; Roetzheim RG, 2001, J FAM PRACTICE, V50, P1027; Roetzheim RG, 2000, J AM ACAD DERMATOL, V43, P211, DOI 10.1067/mjd.2000.106242; Schwarz MR, 2002, MED TEACH, V24, P125, DOI 10.1080/01421590220120740; Senf JH, 2003, J AM BOARD FAM PRACT, V16, P502, DOI 10.3122/jabfm.16.6.502; Shanley Brian C, 2002, Aust Fam Physician, V31, P49; *U SOUTH, NEW GEN PROJ; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; Wilkinson D, 2003, MED EDUC, V37, P809, DOI 10.1046/j.1365-2923.2003.01596.x; World Health Organization (WHO), 2006, WORLD HLTH REP 2006; Wright B, 2004, CAN MED ASSOC J, V170, P1920, DOI 10.1503/cmaj.1031111; Yach D, 2004, JAMA-J AM MED ASSOC, V291, P2616, DOI 10.1001/jama.291.21.2616; 2006, LANCET, V367, P1029	26	14	16	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 30	2007	369	9580					2211	2213		10.1016/S0140-6736(07)61017-4	http://dx.doi.org/10.1016/S0140-6736(07)61017-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	184LX	17604803				2022-12-28	WOS:000247644200032
J	Teklehaimanot, A; Sachs, JD; Curtis, C				Teklehaimanot, Awash; Sachs, Jeffrey D.; Curtis, Chris			Malaria control needs mass distribution of insecticidal bednets	LANCET			English	Editorial Material							TREATED BEDNETS; CHILD-MORTALITY; NETS; TRANSMISSION; INFECTION; MORBIDITY; MOSQUITOS; COVERAGE; DISTRICT; IMPACT		Columbia Univ, Earth Inst, Ctr Global Hlth & Econ Dev, New York, NY 10025 USA; London Sch Hyg & Trop Med, London WC1, England	Columbia University; University of London; London School of Hygiene & Tropical Medicine	Teklehaimanot, A (corresponding author), Columbia Univ, Earth Inst, Ctr Global Hlth & Econ Dev, New York, NY 10025 USA.	at2076@columbia.edu						[Anonymous], 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000363.PUB2; Binka FN, 1996, TROP MED INT HEALTH, V1, P147; Cham MK, 1997, HEALTH POLICY PLANN, V12, P240, DOI 10.1093/heapol/12.3.240; Curtis C, 2003, LANCET INFECT DIS, V3, P304, DOI 10.1016/S1473-3099(03)00612-1; Curtis CF, 1996, MED VET ENTOMOL, V10, P1, DOI 10.1111/j.1365-2915.1996.tb00075.x; Curtis CF, 1998, TROP MED INT HEALTH, V3, P619, DOI 10.1046/j.1365-3156.1998.00281.x; Grabowsky M, 2005, B WORLD HEALTH ORGAN, V83, P195; Guyatt HL, 2002, TROP MED INT HEALTH, V7, P846, DOI 10.1046/j.1365-3156.2002.00929.x; Hawley WA, 2003, AM J TROP MED HYG, V68, P121, DOI 10.4269/ajtmh.2003.68.121; Hay SI, 2005, NAT REV MICROBIOL, V3, P81, DOI 10.1038/nrmicro1069; Howard SC, 2000, T ROY SOC TROP MED H, V94, P357, DOI 10.1016/S0035-9203(00)90103-2; Le Menach A, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-10; MAGESA SM, 1991, ACTA TROP, V49, P97, DOI 10.1016/0001-706X(91)90057-Q; Maxwell CA, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-44; Maxwell CA, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-28; Sachs JD, 2005, NEW ENGL J MED, V352, P115, DOI 10.1056/NEJMp048319; Smith DL, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-13; Snow RW, 1999, HEALTH POLICY PLANN, V14, P18, DOI 10.1093/heapol/14.1.18; Soremekun S, 2004, TROP MED INT HEALTH, V9, P664, DOI 10.1111/j.1365-3156.2004.01250.x; TEKLEHAIMANOT A, IN PRESS AM J TROP M; WABWIREMANGEN F, 1989, AM J TROP MED HYG, V41, P504, DOI 10.4269/ajtmh.1989.41.504; Whitworth JAG, 2005, LANCET, V365, P196; *WORK GROUP MAL, 2005, COM GRIPS MAL NEW MI	23	86	88	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 30	2007	369	9580					2143	2146		10.1016/S0140-6736(07)60951-9	http://dx.doi.org/10.1016/S0140-6736(07)60951-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LX	17597200				2022-12-28	WOS:000247644200009
J	Tonks, A				Tonks, Alison			The quest for the AIDS vaccine	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												atonks@bmj.com						*AVAC, 2006, AIDS VACC NEXT FRONT; Bhan MK, 2005, PLOS MED, V2, P111, DOI 10.1371/journal.pmed.0020025; Day M, 2007, BRIT MED J, V334, P1133, DOI 10.1136/bmj.39227.629803.DB; FISHER K, 2006, ADDING IT ALL FUNDIN; Flynn MN, 2005, J INFECT DIS, V191, P654, DOI 10.1086/428404; Gallo RC, 2005, LANCET, V366, P1894, DOI 10.1016/S0140-6736(05)67395-3; *GLOB HIV VACC ENT, ENT; HORTON R, 2004, NEW YORK REV BOOKS, V51; *IAVI, 2006, AIDS VACC BLUEPR 200; Johnston MI, 2007, NEW ENGL J MED, V356, P2073, DOI 10.1056/NEJMra066267; Markel H, 2005, NEW ENGL J MED, V353, P753, DOI 10.1056/NEJMp058146; Pitisuttithum P, 2006, J INFECT DIS, V194, P1661, DOI 10.1086/508748; STOVER J, 2005, ESTIMATING GLOBAL IM; *THAIL MIN PUBL HL, PRIM BOOST HIV VACC; Wadman M, 2007, NAT MED, V13, P518, DOI 10.1038/nm1594	15	12	13	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 30	2007	334	7608					1346	1348		10.1136/bmj.39240.416968.AD	http://dx.doi.org/10.1136/bmj.39240.416968.AD			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	185VX	17600020	Green Published			2022-12-28	WOS:000247739600027
J	Baker, DF				Baker, David F.			Reassessing carbon sinks	SCIENCE			English	Editorial Material									Natl Ctr Atmospher Res, Climate & Global Dynam Div, Boulder, CO 80307 USA	National Center Atmospheric Research (NCAR) - USA	Baker, DF (corresponding author), Natl Ctr Atmospher Res, Climate & Global Dynam Div, POB 3000, Boulder, CO 80307 USA.	dfb@cgd.ucar.edu						Arblaster JM, 2006, J CLIMATE, V19, P2896, DOI 10.1175/JCLI3774.1; Baker DF, 2006, GLOBAL BIOGEOCHEM CY, V20, DOI 10.1029/2004GB002439; Fletcher SEM, 2007, GLOBAL BIOGEOCHEM CY, V21, DOI 10.1029/2006GB002751; Fletcher SEM, 2006, GLOBAL BIOGEOCHEM CY, V20, DOI 10.1029/2005GB002530; GRUBER N, 2005, 7 INT CARB DIOX C; Jacobson AR, 2007, GLOBAL BIOGEOCHEM CY, V21, DOI 10.1029/2006GB002703; Le Quere C, 2007, SCIENCE, V316, P1735, DOI 10.1126/science.1136188; Lenton A, 2007, GLOBAL BIOGEOCHEM CY, V21, DOI 10.1029/2006GB002714; Stephens BB, 2007, SCIENCE, V316, P1732, DOI 10.1126/science.1137004; TAKAHASHI T, 1999, P 2 INT S CO2 OC CTR, P9; Wetzel P, 2005, GLOBAL BIOGEOCHEM CY, V19, DOI 10.1029/2004GB002339	11	13	16	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 22	2007	316	5832					1708	1709		10.1126/science.1144863	http://dx.doi.org/10.1126/science.1144863			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180XE	17588920				2022-12-28	WOS:000247400500034
J	Merkel, S; McNamara, AK; Kubo, A; Speziale, S; Miyagi, L; Meng, Y; Duffy, TS; Wenk, HR				Merkel, Sebastien; McNamara, Allen K.; Kubo, Atsushi; Speziale, Sergio; Miyagi, Lowell; Meng, Yue; Duffy, Thomas S.; Wenk, Hans-Rudolf			Deformation of (Mg,Fe) SiO(3) post-perovskite and D anisotropy	SCIENCE			English	Article							EARTHS D''-LAYER; SEISMIC ANISOTROPY; LOWERMOST-MANTLE; PHASE-TRANSITION; PLASTIC-DEFORMATION; CENTRAL PACIFIC; DEEP MANTLE; MGSIO3; BENEATH; FLOW	Polycrystalline (Mg(0.9),Fe(0.1))SiO(3) post-perovskite was plastically deformed in the diamond anvil cell between 145 and 157 gigapascals. The lattice-preferred orientations obtained in the sample suggest that slip on planes near (100) and (110) dominate plastic deformation under these conditions. Assuming similar behavior at lower mantle conditions, we simulated plastic strains and the contribution of post-perovskite to anisotropy in the D '' region at the Earth core-mantle boundary using numerical convection and viscoplastic polycrystal plasticity models. We find a significant depth dependence of the anisotropy that only develops near and beyond the turning point of a downwelling slab. Our calculated anisotropies are strongly dependent on the choice of elastic moduli and remain hard to reconcile with seismic observations.	Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA; Univ Sci & Technol Lille, CNRS, UMR 8008, Lab Struct & Proprietes Etat Solide, F-59655 Villeneuve Dascq, France; Arizona State Univ, Sch Earth & Space Explorat, Tempe, AZ 85287 USA; Princeton Univ, Dept Geosci, Princeton, NJ 08544 USA; Carnegie Inst Washington, High Pressure Collaborat Access Team, Argonne, IL 60439 USA	University of California System; University of California Berkeley; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; Arizona State University; Arizona State University-Tempe; Princeton University; Carnegie Institution for Science	Merkel, S (corresponding author), Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA.	sebastien.merkel@univ-lille1.fr	Merkel, Sébastien/E-5501-2011; McNamara, Allen/P-3144-2014; Duffy, Thomas S/C-9140-2017	Merkel, Sébastien/0000-0003-2767-581X; McNamara, Allen/0000-0003-3866-9503; Duffy, Thomas S/0000-0002-5357-1259				Carrez P, 2007, NATURE, V446, P68, DOI 10.1038/nature05593; Garnero EJ, 2004, SCIENCE, V306, P259, DOI 10.1126/science.1103411; Helmberger D, 2005, P NATL ACAD SCI USA, V102, P17257, DOI 10.1073/pnas.0502504102; Hirose K, 2006, REV GEOPHYS, V44, DOI 10.1029/2005RG000186; Kendall JM, 1998, GEODYNAMICS, V28, P97; Lay T, 1998, NATURE, V392, P461, DOI 10.1038/33083; Lay T, 2006, SCIENCE, V314, P1272, DOI 10.1126/science.1133280; LEBENSOHN RA, 1993, ACTA METALL MATER, V41, P2611, DOI 10.1016/0956-7151(93)90130-K; Mao WL, 2006, SCIENCE, V312, P564, DOI 10.1126/science.1123442; McNamara AK, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB001970; McNamara AK, 2004, EARTH PLANET SC LETT, V222, P485, DOI 10.1016/j.epsl.2004.03.008; McNamara AK, 2002, NATURE, V416, P310, DOI 10.1038/416310a; Merkel S, 2006, SCIENCE, V311, P644, DOI 10.1126/science.1121808; Moore MM, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002546; Moresi L, 1996, EARTH PLANET SC LETT, V138, P15, DOI 10.1016/0012-821X(95)00221-W; Murakami M, 2004, SCIENCE, V304, P855, DOI 10.1126/science.1095932; Oganov AR, 2005, NATURE, V438, P1142, DOI 10.1038/nature04439; Oganov AR, 2004, NATURE, V430, P445, DOI 10.1038/nature02701; Panning M, 2004, SCIENCE, V303, P351, DOI 10.1126/science.1091524; Rokosky JM, 2006, EARTH PLANET SC LETT, V248, P411, DOI 10.1016/j.epsl.2006.06.005; Russell SA, 1998, NATURE, V396, P255, DOI 10.1038/24364; Russell SA, 1999, J GEOPHYS RES-SOL EA, V104, P13183, DOI 10.1029/1999JB900114; Santillan J, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL026423; Stackhouse S, 2005, EARTH PLANET SC LETT, V230, P1, DOI 10.1016/j.epsl.2004.11.021; van der Hilst RD, 2007, SCIENCE, V315, P1813, DOI 10.1126/science.1137867; Wentzcovitch RM, 2006, P NATL ACAD SCI USA, V103, P543, DOI 10.1073/pnas.0506879103; Williams Q, 1996, SCIENCE, V273, P1528, DOI 10.1126/science.273.5281.1528; Wookey J, 2005, NATURE, V438, P1004, DOI 10.1038/nature04345; Wookey J, 2005, GEOPHYS J INT, V161, P829, DOI 10.1111/j.1365-246X.2005.02623.x; Yamazaki D, 2006, EARTH PLANET SC LETT, V252, P372, DOI 10.1016/j.epsl.2006.10.004	30	117	117	2	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 22	2007	316	5832					1729	1732		10.1126/science.1140609	http://dx.doi.org/10.1126/science.1140609			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180XE	17588926				2022-12-28	WOS:000247400500042
J	Davidson, EA; de Carvalho, CJR; Figueira, AM; Ishida, FY; Ometto, JPHB; Nardoto, GB; Saba, RT; Hayashi, SN; Leal, EC; Vieira, ICG; Martinelli, LA				Davidson, Eric A.; de Carvalho, Claudio J. Reis; Figueira, Adelaine Michela; Ishida, Francoise Yoko; Ometto, Jean Pierre H. B.; Nardoto, Gabriela B.; Saba, Renata Tuma; Hayashi, Sanae N.; Leal, Eliane C.; Vieira, Ima Celia G.; Martinelli, Luiz A.			Recuperation of nitrogen cycling in Amazonian forests following agricultural abandonment	NATURE			English	Article							LAND-USE CHANGE; EASTERN AMAZONIA; BRAZILIAN AMAZON; ISOTOPIC COMPOSITION; OXIDE EMISSIONS; GLOBAL PATTERNS; COSTA-RICA; SOIL; REGROWTH; ECOSYSTEMS	Phosphorus ( P) is generally considered the most common limiting nutrient for productivity of mature tropical lowland forests growing on highly weathered soils(1-5). It is often assumed that P limitation also applies to young tropical forests, but nitrogen (N) losses during land-use change may alter the stoichiometric balance of nutrient cycling processes. In the Amazon basin, about 16% of the original forest area has been cleared(6), and about 30 - 50% of cleared land is estimated now to be in some stage of secondary forest succession following agricultural abandonment(7). Here we use forest age chronosequences to demonstrate that young successional forests growing after agricultural abandonment on highly weathered lowland tropical soils exhibit conservative N-cycling properties much like those of N-limited forests on younger soils in temperate latitudes. As secondary succession progresses, N-cycling properties recover and the dominance of a conservative P cycle typical of mature lowland tropical forests re-emerges. These successional shifts in N: P cycling ratios with forest age provide a mechanistic explanation for initially lower and then gradually increasing soil emissions of the greenhouse gas nitrous oxide (N2O). The patterns of N and P cycling during secondary forest succession, demonstrated here over decadal timescales, are similar to N- and P-cycling patterns during primary succession as soils age over thousands and millions of years, thus revealing that N availability in terrestrial ecosystems is ephemeral and can be disrupted by either natural or anthropogenic disturbances at several timescales.	EMBRAPA Amazonia Oriental, BR-66095100 Belem, Para, Brazil; Woods Hole Res Ctr, Falmouth, MA 02540 USA; Univ Sao Paulo, CENA, BR-13416000 Piracicaba, SP, Brazil; Museu Paraensr Emilio Goeldi, Dept Bot, BR-66040179 Belem, Para, Brazil	Empresa Brasileira de Pesquisa Agropecuaria (EMBRAPA); Woods Hole Research Center; Universidade de Sao Paulo; Museu Paraense Emilio Goeldi	Davidson, EA (corresponding author), Woods Hole Res Ctr, 149 Woods Hole Rd, Falmouth, MA 02540 USA.	edavidson@whrc.org	Vieira, Ima C.G./H-6897-2012; Martinelli, Luiz Antonio/F-7870-2011; Nardoto, Gabriela Bielefeld/J-7459-2012; Ometto, Jean Pierre/B-3351-2013; Davidson, Eric A/K-4984-2013	Vieira, Ima C.G./0000-0003-1233-318X; Martinelli, Luiz Antonio/0000-0002-7103-7551; Nardoto, Gabriela Bielefeld/0000-0001-8062-7417; Ometto, Jean Pierre/0000-0002-4221-1039; Davidson, Eric A/0000-0002-8525-8697; E SILVA FIGUEIRA, ADELAINE MICHELA/0000-0002-3702-3180				Amundson R, 2003, GLOBAL BIOGEOCHEM CY, V17, DOI 10.1029/2002GB001903; [Anonymous], 2001, BIOGEOCHEMISTRY AMAZ; Davidson EA, 2000, BIOSCIENCE, V50, P667, DOI 10.1641/0006-3568(2000)050[0667:TACMOS]2.0.CO;2; Davidson EA, 2004, GEOPHYS MONOGR SER, V153, P147, DOI 10.1029/153GM12; Davidson EA, 2004, ECOL APPL, V14, pS150; Dias-Filho M.B., 2001, BIOGEOCHEM AMAZ BASI, P84; Erickson H, 2001, ECOSYSTEMS, V4, P67, DOI 10.1007/s100210000060; Gehring C, 2005, AGR ECOSYST ENVIRON, V111, P237, DOI 10.1016/j.agee.2005.06.009; Gehring C, 1999, BIOGEOCHEMISTRY, V45, P223, DOI 10.1023/A:1006138815453; Hedin LO, 2003, ECOLOGY, V84, P2231, DOI 10.1890/02-4066; Hirsch AI, 2004, GLOBAL CHANGE BIOL, V10, P908, DOI 10.1111/j.1529-8817.2003.00765.x; *INPE, 2004, MON AMB AM SAT; KAUFFMAN JB, 1995, OECOLOGIA, V104, P397, DOI 10.1007/BF00341336; KELLER M, 1994, GLOBAL BIOGEOCHEM CY, V8, P399, DOI 10.1029/94GB01660; KELLER M, 1993, NATURE, V365, P244, DOI 10.1038/365244a0; Markewitz D, 2004, ECOL APPL, V14, pS177; Martinelli LA, 1999, BIOGEOCHEMISTRY, V46, P45, DOI 10.1023/A:1006100128782; McGrath DA, 2001, ECOSYSTEMS, V4, P625, DOI 10.1007/s10021-001-0033-0; McGroddy ME, 2004, ECOLOGY, V85, P2390, DOI 10.1890/03-0351; Melillo JM, 2001, J GEOPHYS RES-ATMOS, V106, P34179, DOI 10.1029/2000JD000036; Reich PB, 2004, P NATL ACAD SCI USA, V101, P11001, DOI 10.1073/pnas.0403588101; Verchot LV, 1999, GLOBAL BIOGEOCHEM CY, V13, P31, DOI 10.1029/1998GB900019; Vieira ICG, 2003, REMOTE SENS ENVIRON, V87, P470, DOI 10.1016/j.rse.2002.09.002; VIEIRA ICG, 1996, CIENCIA HOJE, V20, P38; VITOUSEK PM, 1982, ECOL MONOGR, V52, P155, DOI 10.2307/1942609; Vitousek PM, 2002, BIOGEOCHEMISTRY, V57, P1, DOI 10.1023/A:1015798428743; VITOUSEK PM, 1984, ECOLOGY, V65, P285, DOI 10.2307/1939481; WALKER TW, 1976, GEODERMA, V15, P1, DOI 10.1016/0016-7061(76)90066-5; Zarin DJ, 2005, FRONT ECOL ENVIRON, V3, P365, DOI 10.2307/3868585	29	320	341	11	240	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 21	2007	447	7147					995	U6		10.1038/nature05900	http://dx.doi.org/10.1038/nature05900			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180NU	17581583				2022-12-28	WOS:000247373100045
J	Downs, JA; Nussenzweig, MC; Nussenzweig, A				Downs, Jessica A.; Nussenzweig, Michel C.; Nussenzweig, Andre			Chromatin dynamics and the preservation of genetic information	NATURE			English	Review							DOUBLE-STRAND BREAKS; CLASS-SWITCH RECOMBINATION; DNA-DAMAGE-RESPONSE; CEREVISIAE HISTONE H2A; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; REMODELING COMPLEX; ATM ACTIVATION; MRE11-RAD50-NBS1 COMPLEX; HOMOLOGOUS RECOMBINATION	The integrity of the genome is frequently challenged by double-strand breaks in the DNA. Defects in the cellular response to double-strand breaks are a major cause of cancer and other age-related pathologies; therefore, much effort has been directed at understanding the enzymatic mechanisms involved in recognizing, signalling and repairing double-strand breaks. Recent work indicates that chromatin - the fibres into which DNA is packaged with a proteinaceous structural polymer - has an important role in initiating, propagating and terminating this cellular response to DNA damage.	Univ Sussex, MRC, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA	University of Sussex; Howard Hughes Medical Institute; Rockefeller University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Downs, JA (corresponding author), Univ Sussex, MRC, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England.	j.a.downs@sussex.ac.uk; andre_nussenzweig@nih.gov	Nussenzweig, Michel/AAE-7292-2019	Downs, Jessica/0000-0002-6600-849X	NATIONAL CANCER INSTITUTE [Z01BC010283, ZIABC010283] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Ahn SH, 2005, CELL CYCLE, V4, P780, DOI 10.4161/cc.4.6.1745; Ahn SH, 2005, CELL, V120, P25, DOI 10.1016/j.cell.2004.11.016; Angus-Hill ML, 2001, MOL CELL, V7, P741, DOI 10.1016/S1097-2765(01)00219-2; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bekker-Jensen S, 2006, J CELL BIOL, V173, P195, DOI 10.1083/jcb.200510130; Bekker-Jensen S, 2005, J CELL BIOL, V170, P201, DOI 10.1083/jcb.200503043; Bennett CB, 2001, NAT GENET, V29, P426, DOI 10.1038/ng778; Bird AW, 2002, NATURE, V419, P411, DOI 10.1038/nature01035; Birger Y, 2005, CANCER RES, V65, P6711, DOI 10.1158/0008-5472.CAN-05-0310; Botuyan MV, 2006, CELL, V127, P1361, DOI 10.1016/j.cell.2006.10.043; Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214; Cairns BR, 1999, MOL CELL, V4, P715, DOI 10.1016/S1097-2765(00)80382-2; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celic I, 2006, CURR BIOL, V16, P1280, DOI 10.1016/j.cub.2006.06.023; Chai B, 2005, GENE DEV, V19, P1656, DOI 10.1101/gad.1273105; Cheung WL, 2005, CURR BIOL, V15, P656, DOI 10.1016/j.cub.2005.02.049; Collins SR, 2007, NATURE, V446, P806, DOI 10.1038/nature05649; Dirksen EHC, 2006, CANCER RES, V66, P1473, DOI 10.1158/0008-5472.CAN-05-2129; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Downs JA, 2003, MOL CELL, V11, P1685, DOI 10.1016/S1097-2765(03)00197-7; Downs JA, 2004, MOL CELL, V16, P979, DOI 10.1016/j.molcel.2004.12.003; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Driscoll R, 2007, SCIENCE, V315, P649, DOI 10.1126/science.1135862; Du LL, 2006, GENE DEV, V20, P1583, DOI 10.1101/gad.1422606; Dupre A, 2006, NAT STRUCT MOL BIOL, V13, P451, DOI 10.1038/nsmb1090; FALZON M, 1993, J BIOL CHEM, V268, P10546; Fernandez-Capetillo O, 2004, J EXP MED, V199, P1671, DOI 10.1084/jem.20032247; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Fernandez-Capetillo O, 2003, CELL CYCLE, V2, P426, DOI 10.4161/cc.2.5.509; Flaus A, 2006, NUCLEIC ACIDS RES, V34, P2887, DOI 10.1093/nar/gkl295; Franco S, 2006, MOL CELL, V21, P201, DOI 10.1016/j.molcel.2006.01.005; Giannattasio M, 2005, J BIOL CHEM, V280, P9879, DOI 10.1074/jbc.M414453200; Gupta A, 2005, MOL CELL BIOL, V25, P5292, DOI 10.1128/MCB.25.12.5292-5305.2005; Harvey AC, 2005, GENETICS, V170, P543, DOI 10.1534/genetics.104.038570; Hill DA, 2000, BIOCHEMISTRY-US, V39, P11649, DOI 10.1021/bi001330z; Honjo T, 2005, NAT IMMUNOL, V6, P655, DOI 10.1038/ni1218; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Javaheri A, 2006, P NATL ACAD SCI USA, V103, P13771, DOI 10.1073/pnas.0511192103; Jazayeri A, 2004, P NATL ACAD SCI USA, V101, P1644, DOI 10.1073/pnas.0304797101; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Keogh MC, 2006, NATURE, V439, P497, DOI 10.1038/nature04384; Kruhlak MJ, 2006, CELL CYCLE, V5, P1910, DOI 10.4161/cc.5.17.3169; Kruhlak MJ, 2006, J CELL BIOL, V172, P823, DOI 10.1083/jcb.200510015; Kumagai A, 2006, CELL, V124, P943, DOI 10.1016/j.cell.2005.12.041; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lou ZK, 2006, MOL CELL, V21, P187, DOI 10.1016/j.molcel.2005.11.025; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Maas NL, 2006, MOL CELL, V23, P109, DOI 10.1016/j.molcel.2006.06.006; Manis JP, 2004, NAT IMMUNOL, V5, P481, DOI 10.1038/ni1067; Masumoto H, 2005, NATURE, V436, P294, DOI 10.1038/nature03714; Meek K, 2004, IMMUNOL REV, V200, P132, DOI 10.1111/j.0105-2896.2004.00162.x; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; Morrison AJ, 2004, CELL, V119, P767, DOI 10.1016/j.cell.2004.11.037; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Nakamura TM, 2004, MOL CELL BIOL, V24, P6215, DOI 10.1128/MCB.24.14.6215-6230.2004; Nussenzweig A, 2006, NATURE, V439, P406, DOI 10.1038/439406a; Odegard VH, 2005, IMMUNITY, V23, P101, DOI 10.1016/j.immuni.2005.05.007; Ozdemir A, 2005, J BIOL CHEM, V280, P25949, DOI 10.1074/jbc.C500181200; Papamichos-Chronakis M, 2006, GENE DEV, V20, P2437, DOI 10.1101/gad.1440206; Park JH, 2006, EMBO J, V25, P3986, DOI 10.1038/sj.emboj.7601291; Pellegrini M, 2006, NATURE, V443, P222, DOI 10.1038/nature05112; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Qin S, 2006, MOL CELL BIOL, V26, P3649, DOI 10.1128/MCB.26.9.3649-3658.2006; Ramiro AR, 2006, NATURE, V440, P105, DOI 10.1038/nature04495; Reina-San-Martin B, 2005, P NATL ACAD SCI USA, V102, P1590, DOI 10.1073/pnas.0406289102; Reina-San-Martin B, 2003, J EXP MED, V197, P1767, DOI 10.1084/jem.20030569; Reina-San-Martin B, 2007, EUR J IMMUNOL, V37, P235, DOI 10.1002/eji.200636789; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Ryan MP, 1998, MOL CELL BIOL, V18, P1774, DOI 10.1128/MCB.18.4.1774; Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Shim EY, 2007, MOL CELL BIOL, V27, P1602, DOI 10.1128/MCB.01956-06; Shim EY, 2005, MOL CELL BIOL, V25, P3934, DOI 10.1128/MCB.25.10.3934-3944.2005; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Strom L, 2004, MOL CELL, V16, P1003, DOI 10.1016/j.molcel.2004.11.026; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; TAKAHASHI K, 1985, INT J RADIAT BIOL, V48, P389, DOI 10.1080/09553008514551391; Tamburini BA, 2005, MOL CELL BIOL, V25, P4903, DOI 10.1128/MCB.25.12.4903-4913.2005; Toh GWL, 2006, DNA REPAIR, V5, P693, DOI 10.1016/j.dnarep.2006.03.005; Tsukuda T, 2005, NATURE, V438, P379, DOI 10.1038/nature04148; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Unal E, 2004, MOL CELL, V16, P991, DOI 10.1016/j.molcel.2004.11.027; Utley RT, 2005, MOL CELL BIOL, V25, P8179, DOI 10.1128/MCB.25.18.8179-8190.2005; van Attikum H, 2004, CELL, V119, P777, DOI 10.1016/j.cell.2004.11.033; Ward IM, 2004, J CELL BIOL, V165, P459, DOI 10.1083/jcb.200403021; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Wyatt HR, 2003, GENETICS, V164, P47; Wysocki R, 2005, MOL CELL BIOL, V25, P8430, DOI 10.1128/MCB.25.19.8430-8443.2005; Xie AY, 2004, MOL CELL, V16, P1017, DOI 10.1016/j.molcel.2004.12.007; You ZS, 2005, MOL CELL BIOL, V25, P5363, DOI 10.1128/MCB.25.13.5363-5379.2005; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	98	236	242	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 21	2007	447	7147					951	958		10.1038/nature05980	http://dx.doi.org/10.1038/nature05980			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180NU	17581578				2022-12-28	WOS:000247373100037
J	Steinbrook, R				Steinbrook, Robert			Organ donation after cardiac death	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material												rsteinbrook@attglobal.net						Bernat JL, 2006, AM J TRANSPLANT, V6, P281, DOI 10.1111/j.1600-6143.2005.01194.x; DeVita M A, 2001, Prog Transplant, V11, P58; DuBois JM, 2006, CRIT CARE MED, V34, P3045, DOI 10.1097/01.CCM.0000248525.53130.57; *I MED, 2006, ORG DON OPP ACT; Mandell MS, 2006, CRIT CARE MED, V34, P2952, DOI 10.1097/01.CCM.0000247718.27324.65	5	149	158	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 19	2007	357	3					209	213		10.1056/NEJMp078066	http://dx.doi.org/10.1056/NEJMp078066			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191FH	17634455				2022-12-28	WOS:000248115100001
J	Burton, M; Allard, P; Mure, F; La Spina, A				Burton, Mike; Allard, Patrick; Mure, Filippo; La Spina, Alessandro			Magmatic gas composition reveals the source depth of slug-driven Strombolian explosive activity	SCIENCE			English	Article							ACOUSTIC OBSERVATIONS; AEOLIAN ARCHIPELAGO; BASALTIC MAGMA; VOLCANO; DYNAMICS; MECHANISMS; ERUPTION; ASCENT; TREMOR; RATES	Strombolian-type eruptive activity, common at many volcanoes, consists of regular explosions driven by the bursting of gas slugs that rise faster than surrounding magma. Explosion quakes associated with this activity are usually localized at shallow depth; however, where and how slugs actually form remain poorly constrained. We used spectroscopic measurements performed during both quiescent degassing and explosions on Stromboli volcano ( Italy) to demonstrate that gas slugs originate from as deep as the volcano-crust interface (similar to 3 kilometers), where both structural discontinuities and differential bubble-rise speed can promote slug coalescence. The observed decoupling between deep slug genesis and shallow (similar to 250-meter) explosion quakes may be a common feature of strombolian activity, determined by the geometry of plumbing systems.	Ist Nazl Geofis & Vulcanol, Catania, Italy; CEA, CNRS, Grp Sci Terre, Lab Pierre Sue, F-91198 Gif Sur Yvette, France; Univ Palermo, Dipartimento Chim & Fis Terra & Applicaz, Palermo, Italy	Istituto Nazionale Geofisica e Vulcanologia (INGV); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Palermo	Burton, M (corresponding author), Ist Nazl Geofis & Vulcanol, Catania, Italy.	burton@ct.ingv.it	ALLARD, Patrick/H-9480-2017; Burton, Mike/B-5716-2014	ALLARD, Patrick/0000-0001-7836-3117; Burton, Mike/0000-0003-3779-4812; La Spina, Alessandro/0000-0002-5007-613X				Aiuppa A, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020458; Allard P, 2005, NATURE, V433, P407, DOI 10.1038/nature03246; ALLARD P, 1994, NATURE, V368, P326, DOI 10.1038/368326a0; Allard P, 2000, GEOPHYS RES LETT, V27, P1207, DOI 10.1029/1999GL008413; Barberi F, 1993, ACTA VULCANOL, V3, P173; Bertagnini A, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB002146; BURTON M, 2005, EOS S, V86, P52; Carapezza ML, 2000, J VOLCANOL GEOTH RES, V95, P227, DOI 10.1016/S0377-0273(99)00128-6; CHAIGNEA.M, 1965, CR HEBD ACAD SCI, V261, P2241; Chouet B, 1997, J GEOPHYS RES-SOL EA, V102, P15129, DOI 10.1029/97JB00953; Chouet B, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB001919; Francis P, 1998, NATURE, V396, P567, DOI 10.1038/25115; Hagerty MT, 2000, J VOLCANOL GEOTH RES, V101, P27, DOI 10.1016/S0377-0273(00)00162-1; James MR, 2006, J GEOPHYS RES-SOL EA, V111, DOI 10.1029/2005JB003718; JAUPART C, 1988, NATURE, V331, P58, DOI 10.1038/331058a0; JAUPART C, 1989, J FLUID MECH, V203, P347, DOI 10.1017/S0022112089001497; Landi P, 2004, CONTRIB MINERAL PETR, V147, P213, DOI 10.1007/s00410-004-0555-5; Langer H, 1996, PURE APPL GEOPHYS, V147, P57, DOI 10.1007/BF00876436; Metrich N, 1996, GEOCHIM COSMOCHIM AC, V60, P4151, DOI 10.1016/S0016-7037(96)00229-3; Metrich N, 2001, J PETROL, V42, P1471, DOI 10.1093/petrology/42.8.1471; MORI T, 1995, EARTH PLANET SC LETT, V134, P219, DOI 10.1016/0012-821X(95)00119-W; Newman S, 2002, COMPUT GEOSCI-UK, V28, P597, DOI 10.1016/S0098-3004(01)00081-4; Oppenheimer C, 2006, APPL PHYS B-LASERS O, V85, P453, DOI 10.1007/s00340-006-2353-4; Parfitt EA, 2004, J VOLCANOL GEOTH RES, V134, P77, DOI 10.1016/j.jvolgeores.2004.01.002; Ripepe M, 2005, GEOLOGY, V33, P341, DOI 10.1130/G21173.1; Ripepe M, 2002, J VOLCANOL GEOTH RES, V118, P285, DOI 10.1016/S0377-0273(02)00298-6; Ripepe M, 2001, J GEOPHYS RES-SOL EA, V106, P8713, DOI 10.1029/2000JB900374; Rowe CA, 2000, J VOLCANOL GEOTH RES, V101, P105, DOI 10.1016/S0377-0273(00)00170-0; SPARKS RSJ, 1978, J VOLCANOL GEOTH RES, V3, P1, DOI 10.1016/0377-0273(78)90002-1; Vergniolle S, 1996, J GEOPHYS RES-SOL EA, V101, P20449, DOI 10.1029/96JB01925; WILSON L, 1981, J GEOPHYS RES, V86, P2971, DOI 10.1029/JB086iB04p02971	31	257	259	1	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 13	2007	317	5835					227	230		10.1126/science.1141900	http://dx.doi.org/10.1126/science.1141900			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189DC	17626881				2022-12-28	WOS:000247968600037
J	Clifford, G; Fronceschi, S				Clifford, Gary; Fronceschi, Silvia			Immunity, infection, and cancer	LANCET			English	Editorial Material							HUMAN-PAPILLOMAVIRUS; HIV; IMMUNODEFICIENCY; COHORT; VIRUS; RISK		Int Agcy Res Canc, F-69372 Lyon 08, France	World Health Organization; International Agency for Research on Cancer (IARC)	Clifford, G (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	clifford@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071				Biggar RJ, 2006, BLOOD, V108, P3786, DOI 10.1182/blood-2006-05-024109; Clifford GM, 2006, AIDS, V20, P2337, DOI 10.1097/01.aids.0000253361.63578.14; Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072; Darby SC, 1997, LANCET, V350, P1425, DOI 10.1016/S0140-6736(97)05413-5; Frisch M, 2001, JAMA-J AM MED ASSOC, V285, P1736, DOI 10.1001/jama.285.13.1736; Galceran J, 2007, EUR J CANCER, V43, P1085, DOI 10.1016/j.ejca.2007.01.028; Giordano TP, 2004, ARCH INTERN MED, V164, P2349, DOI 10.1001/archinte.164.21.2349; Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2; International Agency for Research on Cancer (IARC), 1996, MON EV CARC RISKS HU, V67; Mbulaiteye SM, 2006, INT J CANCER, V118, P985, DOI 10.1002/ijc.21443; Serraino D, 2005, BRIT J CANCER, V92, P572, DOI 10.1038/sj.bjc.6602346; Strickler HD, 2005, J NATL CANCER I, V97, P577, DOI 10.1093/jnci/dji073	12	7	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 7	2007	370	9581					6	7		10.1016/S0140-6736(07)61023-X	http://dx.doi.org/10.1016/S0140-6736(07)61023-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187QE	17617251				2022-12-28	WOS:000247862300005
J	Lazzarin, A; Campbell, T; Clotet, B; Johnson, M; Katlama, C; Moll, A; Towner, W; Trortier, B; Peeters, M; Vingerhoets, J; de Smedt, G; Baeten, B; Beets, G; Sinha, R; Woodfall, B				Lazzarin, Adriano; Campbell, Thomas; Clotet, Bonaventura; Johnson, Margaret; Katlama, Christine; Moll, Arend; Towner, William; Trortier, Benoit; Peeters, Monika; Vingerhoets, Johan; de Smedt, Goedele; Baeten, Benny; Beets, Greet; Sinha, Rekha; Woodfall, Brian		DUET-2 Study Grp	Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial	LANCET			English	Article							4-DRUG ANTIRETROVIRAL REGIMENS; SEQUENTIAL 3-DRUG REGIMENS; HIV-1 INFECTION; NAIVE PATIENTS; COMBINATION THERAPY; PROTEASE INHIBITOR; DRUG-RESISTANCE; INITIAL THERAPY; TENOFOVIR DF; EFAVIRENZ	Background TMC125 (etravirine) is a non-nucleoside reverse-transcriptase inhibitor (NNRTI) with activity against NNRTI-resistant HfV-1 in phase IIb trials. The aim of DUET-2 is to examine the efficacy, tolerability, and safety of TMC125 in treatment-experienced patients. Methods In this continuing randomised, double-blind, placebo-controlled, phase III trial, HIV-1-infected patients on failing antiretroviral therapy with evidence of resistance to currently available NNRTIs and at least three primary protease inhibitor muta:ions were eligible for enrolment if on stable (8 weeks unchanged) antiretroviral therapy with plasma HIV-1 RNA greater than 5000 copies per mL. Patients were randomly assigned to receive either TMC125 (200 mg) or placebo, each given twice daily with darunavir-ritonavir, investigator-selected nucleoside/nucleotide reverse transcriptase inhibitors, and optional enfuvirtide. The primary endpornt was the proportion of patients with confirmed viral load below 50 copies per mL at week 24 (FDA time-to-loss of virological response algorithm). Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00255099. Findings 591 patients were randomised and treated (295 patients in the TMC125 group and 296 in the placebo group). By week 24, 51 (17%) patients in the TMC125 group and 73 (25%) in the placebo group had discontinued, mainly because of virological failure. 183 (62%) patients in the TMC125 group and 129 (44%) in the placebo group achieved confirmed viral load below 50 copies per mL at week 24 (difference 18%, 95% CI 11-26; p = 0.0003). The type and frequency of adverse events were: much the same in the two groups. Interpretation In treatment-experienced patients, treatment with TMC125 led to better virological suppression at week 24 than did placebo. The safety and tolerability profile of TMC125 was generally comparable with placebo.	San Raffaele Univ, I-20132 Milan, Italy; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; UAB, Hosp Germans Trias & Pujol, Barcelona, Spain; UAB, IrsiCaixa Fdn, Barcelona, Spain; Royal Free Hosp, London NW3 2QG, England; Hop La Pitie Salpetriere, Paris, France; Praxiszentrum Kaiserdamm, EPIMED, Berlin, Germany; Kaiser Permanente, Los Angeles, CA USA; Clin Med Actuel, Montreal, PQ, Canada; Tibotec BVBA, Mechelen, Belgium	Vita-Salute San Raffaele University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Autonomous University of Barcelona; Hospital Germans Trias i Pujol; Autonomous University of Barcelona; Institut de Recerca de la Sida - IrsiCaixa; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Kaiser Permanente; Johnson & Johnson	Lazzarin, A (corresponding author), San Raffaele Univ, Via Olgettina 58, I-20132 Milan, Italy.	lazzarin.adriano@hsr.it	LAZZARIN, Adriano/K-3607-2018	LAZZARIN, Adriano/0000-0003-2551-7754				Andries K, 2004, ANTIMICROB AGENTS CH, V48, P4680, DOI 10.1128/AAC.48.12.4680-4686.2004; Bacheler L, 2001, J VIROL, V75, P4999, DOI 10.1128/JVI.75.11.4999-5008.2001; Center for Drug Evaluation and Research (CDER), 2002, GUID IND ANT DRUGS U; Clotet B, 2004, AIDS REV, V6, P123; Clotet B, 2007, LANCET, V369, P1169, DOI 10.1016/S0140-6736(07)60497-8; COHEN C, 2006, 16 INT AIDS C TOR CA; Delaugerre C, 2001, J MED VIROL, V65, P445, DOI 10.1002/jmv.2055; Demeter LM, 2000, ANTIMICROB AGENTS CH, V44, P794, DOI 10.1128/AAC.44.3.794-797.2000; Fischl MA, 2003, J INFECT DIS, V188, P625, DOI 10.1086/377311; Gallant JE, 2006, NEW ENGL J MED, V354, P251, DOI 10.1056/NEJMoa051871; Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191; Gazzard B, 2006, HIV MED, V7, P487, DOI 10.1111/j.1468-1293.2006.00424.x; Geretti AM, 2007, CURR OPIN INFECT DIS, V20, P22, DOI 10.1097/QCO.0b013e328013caff; Gulick RM, 2006, JAMA-J AM MED ASSOC, V296, P769, DOI 10.1001/jama.296.7.769; Hammer SM, 2006, JAMA-J AM MED ASSOC, V296, P827, DOI 10.1001/jama.296.7.827; Hammer SM, 2002, JAMA-J AM MED ASSOC, V288, P169, DOI 10.1001/jama.288.2.169; Haubrich R, 2007, AIDS, V21, pF11, DOI 10.1097/QAD.0b013e3280b07b47; Johnson Victoria A, 2005, Top HIV Med, V13, P125; KATLAMA C, 2005, 12 C RETR OPP INF BO; Katlama C, 2007, AIDS, V21, P395, DOI 10.1097/QAD.0b013e328013d9d7; Madruga JV, 2007, LANCET, V370, P29, DOI 10.1016/S0140-6736(07)61047-2; MCCOLL D, 2005, 3 INT AIDS C HIV PAT; MELLORS JW, 1992, MOL PHARMACOL, V41, P446; MONTANER J, 2005, 10 EUR AIDS C DUBL I; Podzamczer D, 2002, ANTIVIR THER, V7, P81; Pozniak AL, 2006, JAIDS-J ACQ IMM DEF, V43, P535; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; Richman DD, 2004, AIDS, V18, P1393, DOI 10.1097/01.aids.0000131310.52526.c7; Robbins GK, 2003, NEW ENGL J MED, V349, P2293, DOI 10.1056/NEJMoa030264; SCHOLLER M, 2005, 3 INT AIDS SOC C HIV; SCHOLLER M, 2006, 13 C RETR OPP INF DE; SCHOLLERGYURE M, IN PRESS ANTIVIR THE; Shafer RW, 2003, NEW ENGL J MED, V349, P2304, DOI 10.1056/NEJMoa030265; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; TAMBUYZER L, 2007, 5 EUR HIV DRUG RES W; van Leeuwen R, 2003, AIDS, V17, P987, DOI 10.1097/00002030-200305020-00007; VANLETH F, 2003, 10 C RETR OPP INF BO; Vingerhoets J, 2005, J VIROL, V79, P12773, DOI 10.1128/JVI.79.20.12773-12782.2005; VINGERHOETS J, 2007, 16 INT HIV DRUG RES; Yeni P, 2006, LANCET, V368, P287, DOI 10.1016/S0140-6736(06)69074-0; Youle M, 2004, LANCET, V364, P1036, DOI 10.1016/S0140-6736(04)17055-4; Zhang H, 2004, CHINESE CHEM LETT, V15, P121	42	359	374	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 7	2007	370	9581					39	48		10.1016/S0140-6736(07)61048-4	http://dx.doi.org/10.1016/S0140-6736(07)61048-4			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187QE	17617271				2022-12-28	WOS:000247862300029
J	Hauert, C; Traulsen, A; Brandt, H; Nowak, MA; Sigmund, K				Hauert, Christoph; Traulsen, Arne; Brandt, Hannelore; Nowak, Martin A.; Sigmund, Karl			Via freedom to coercion: The emergence of costly punishment	SCIENCE			English	Article							ALTRUISTIC PUNISHMENT; PUBLIC-GOODS; INDIRECT RECIPROCITY; HUMAN COOPERATION; EVOLUTION; DYNAMICS; TRAGEDY; COMMONS; HUMANS; GAMES	In human societies, cooperative behavior in joint enterprises is often enforced through institutions that impose sanctions on defectors. Many experiments on so-called public goods games have shown that in the absence of such institutions, individuals are willing to punish defectors, even at a cost to themselves. Theoretical models confirm that social norms prescribing the punishment of uncooperative behavior are stable-once established, they prevent dissident minorities from spreading. But how can such costly punishing behavior gain a foothold in the population? A surprisingly simple model shows that if individuals have the option to stand aside and abstain from the joint endeavor, this paves the way for the emergence and establishment of cooperative behavior based on the punishment of defectors. Paradoxically, the freedom to withdraw from the common enterprise leads to enforcement of social norms. Joint enterprises that are compulsory rather than voluntary are less likely to lead to cooperation.	Harvard Univ, Dept Math, Dept Organism & Evolutionary Biol, Program Evolutionary Dynam, Cambridge, MA 02138 USA; Vienna Univ Econ & Business Adm, A-1090 Vienna, Austria; Univ Vienna, Fac Math, A-1090 Vienna, Austria; Int Inst Appl Syst Anal, A-2361 Laxenburg, Austria	Harvard University; Vienna University of Economics & Business; University of Vienna; International Institute for Applied Systems Analysis (IIASA)	Sigmund, K (corresponding author), Harvard Univ, Dept Math, Dept Organism & Evolutionary Biol, Program Evolutionary Dynam, Cambridge, MA 02138 USA.	karl.sigmund@univie.ac.at	Hauert, Christoph/E-5369-2011; Traulsen, Arne/A-4955-2009; Nowak, Martin A/A-6977-2008	Hauert, Christoph/0000-0002-1239-281X; Traulsen, Arne/0000-0002-0669-5267; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078986] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM078986, R01 GM078986, R01 GM078986-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1987, EVOLUTION HUMAN SOC; Boyd R, 2003, P NATL ACAD SCI USA, V100, P3531, DOI 10.1073/pnas.0630443100; BOYD R, 1992, ETHOL SOCIOBIOL, V13, P171, DOI 10.1016/0162-3095(92)90032-Y; Brandt H, 2006, P NATL ACAD SCI USA, V103, P495, DOI 10.1073/pnas.0507229103; Camerer CF, 2006, SCIENCE, V311, P47, DOI 10.1126/science.1110600; Colman AM, 2006, NATURE, V440, P744, DOI 10.1038/440744b; de Quervain DJF, 2004, SCIENCE, V305, P1254, DOI 10.1126/science.1100735; Fehr E, 2002, NATURE, V415, P137, DOI 10.1038/415137a; Fehr E, 2003, NATURE, V425, P785, DOI 10.1038/nature02043; Fehr E, 2003, NATURE, V422, P137, DOI 10.1038/nature01474; Fowler JH, 2005, NATURE, V437, pE8, DOI 10.1038/nature04201; Fowler JH, 2005, P NATL ACAD SCI USA, V102, P7047, DOI 10.1073/pnas.0500938102; Fudenberg D, 2006, J ECON THEORY, V131, P251, DOI 10.1016/j.jet.2005.04.006; Gintis H., 2005, MORAL SENTIMENTS MAT; Gurerk O, 2006, SCIENCE, V312, P108, DOI 10.1126/science.1123633; Hammerstein P., 2003, GENETIC CULTURAL EVO; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; Hauert C, 2002, J THEOR BIOL, V218, P187, DOI 10.1006/jtbi.2002.3067; Hauert C, 2002, SCIENCE, V296, P1129, DOI 10.1126/science.1070582; Henrich J, 2001, J THEOR BIOL, V208, P79, DOI 10.1006/jtbi.2000.2202; Henrich J, 2006, SCIENCE, V312, P1767, DOI 10.1126/science.1127333; KIYONARI T, 2006, ANN M HUM BEH EV SOC; Milinski M, 2006, P NATL ACAD SCI USA, V103, P3994, DOI 10.1073/pnas.0504902103; Milinski M, 2002, NATURE, V415, P424, DOI 10.1038/415424a; Nakamaru M, 2006, J THEOR BIOL, V240, P475, DOI 10.1016/j.jtbi.2005.10.011; Nowak MA, 2004, NATURE, V428, P646, DOI 10.1038/nature02414; Panchanathan K, 2005, NATURE, V437, pE8, DOI 10.1038/nature04202; Panchanathan K, 2004, NATURE, V432, P499, DOI 10.1038/nature02978; Price ME, 2002, EVOL HUM BEHAV, V23, P203, DOI 10.1016/S1090-5138(01)00093-9; Rockenbach B, 2006, NATURE, V444, P718, DOI 10.1038/nature05229; Semmann D, 2003, NATURE, V425, P390, DOI 10.1038/nature01986; Wedekind C, 2000, SCIENCE, V288, P850, DOI 10.1126/science.288.5467.850	32	494	502	3	128	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 29	2007	316	5833					1905	1907		10.1126/science.1141588	http://dx.doi.org/10.1126/science.1141588			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183WI	17600218	Green Accepted, Green Submitted			2022-12-28	WOS:000247602700042
J	Pugacheva, EN; Jablonski, SA; Hartman, TR; Henske, EP; Golemis, EA				Pugacheva, Elena N.; Jablonski, Sandra A.; Hartman, Tiffiney R.; Henske, Elizabeth P.; Golemis, Erica A.			HEF1-Dependent aurora a activation induces disassembly of the primary cilium	CELL			English	Article							HISTONE DEACETYLASE INHIBITORS; INTRAFLAGELLAR TRANSPORT; FLAGELLAR LENGTH; CELL-CYCLE; KINASE; PROTEIN; MICROTUBULES; TUBULIN; HEF1; OVEREXPRESSION	The mammalian cilium protrudes from the apical/lumenal surface of polarized cells and acts as a sensor of environmental cues. Numerous developmental disorders and pathological conditions have been shown to arise from defects in cilia-associated signaling proteins. Despite mounting evidence that cilia are essential sites for coordination of cell signaling, little is known about the cellular mechanisms controlling their formation and disassembly. Here, we show that interactions between the prometastatic scaffolding protein HEF1/Cas-L/NEDD9 and the oncogenic Aurora A (AurA) kinase at the basal body of cilia causes phosphorylation and activation of HDAC6, a tubulin deacetylase, promoting ciliary disassembly. We show that this pathway is both necessary and sufficient for ciliary resorption and that it constitutes an unexpected nonmitotic activity of AurA in vertebrates. Moreover, we demonstrate that small molecule inhibitors of AurA and HDAC6 selectively stabilize cilia from regulated resorption cues, suggesting a novel mode of action for these clinical agents.	Fox Chase Canc Ctr, Div Basic Sci, Philadelphia, PA 19111 USA; Fox Chase Canc Ctr, Div Med Sci, Philadelphia, PA 19111 USA	Fox Chase Cancer Center; Fox Chase Cancer Center	Golemis, EA (corresponding author), Fox Chase Canc Ctr, Div Basic Sci, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	ea_golemis@fccc.edu		Jablonski, Sandra/0000-0001-7220-8159; Golemis, Erica/0000-0003-3618-3673; Pugacheva, Elena/0000-0001-9814-7446	NCI NIH HHS [R01 CA63366, P30 CA006927, CA-06927, R01 CA063366, R01 CA063366-11, P30 CA006927-44] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, R01CA063366] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Andrews PD, 2005, ONCOGENE, V24, P5005, DOI 10.1038/sj.onc.1208752; Benzing T, 2001, P NATL ACAD SCI USA, V98, P9784, DOI 10.1073/pnas.171269898; Benzing T, 2006, CURR OPIN NEPHROL HY, V15, P245, DOI 10.1097/01.mnh.0000222690.53970.ca; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Blagosklonny MV, 2002, MOL CANCER THER, V1, P937; Bradley BA, 2005, J CELL SCI, V118, P3317, DOI 10.1242/jcs.02455; Brush MH, 2004, J BIOL CHEM, V279, P7685, DOI 10.1074/jbc.M310997200; Cano DA, 2004, DEVELOPMENT, V131, P3457, DOI 10.1242/dev.01189; Ezratty EJ, 2005, NAT CELL BIOL, V7, P581, DOI 10.1038/ncb1262; Follit JA, 2006, MOL BIOL CELL, V17, P3781, DOI 10.1091/mbc.E06-02-0133; Fukushige T, 1999, J CELL SCI, V112, P395; Goepfert TM, 2002, CANCER RES, V62, P4115; Gritsko TM, 2003, CLIN CANCER RES, V9, P1420; Hideshima T, 2005, P NATL ACAD SCI USA, V102, P8567, DOI 10.1073/pnas.0503221102; Huangfu D, 2005, P NATL ACAD SCI USA, V102, P11325, DOI 10.1073/pnas.0505328102; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Iomini C, 2004, J CELL BIOL, V164, P811, DOI 10.1083/jcb.200312133; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Kostic A, 2006, MOL BIOL CELL, V17, P2684, DOI 10.1091/mbc.E05-12-1161; Law SF, 1998, MOL CELL BIOL, V18, P3540, DOI 10.1128/MCB.18.6.3540; Law SF, 1996, MOL CELL BIOL, V16, P3327; Liao H, 1998, J BIOL CHEM, V273, P21901, DOI 10.1074/jbc.273.34.21901; Liu AM, 2005, DEVELOPMENT, V132, P3103, DOI 10.1242/dev.01894; Marshall WF, 2005, MOL BIOL CELL, V16, P270, DOI 10.1091/mbc.E04-07-0586; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Natarajan M, 2006, ONCOGENE, V25, P1721, DOI 10.1038/sj.onc.1209199; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Pan JM, 2005, LAB INVEST, V85, P452, DOI 10.1038/labinvest.3700253; Pan JM, 2005, DEV CELL, V9, P431, DOI 10.1016/j.devcel.2005.07.010; Pan JM, 2004, DEV CELL, V6, P445, DOI 10.1016/S1534-5807(04)00064-4; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; Pugacheva EN, 2006, CELL CYCLE, V5, P384, DOI 10.4161/cc.5.4.2439; Pugacheva EN, 2005, NAT CELL BIOL, V7, P937, DOI 10.1038/ncb1309; Quarmby LM, 2005, J CELL BIOL, V169, P707, DOI 10.1083/jcb.200503053; Quarmby LM, 2004, INT REV CYTOL, V233, P47, DOI 10.1016/S0074-7696(04)33002-0; RIEDER CL, 1979, J ULTRA MOL STRUCT R, V68, P173, DOI 10.1016/S0022-5320(79)90152-7; Satinover DL, 2004, P NATL ACAD SCI USA, V101, P8625, DOI 10.1073/pnas.0402966101; Schneider L, 2005, CURR BIOL, V15, P1861, DOI 10.1016/j.cub.2005.09.012; Simons M, 2005, NAT GENET, V37, P537, DOI 10.1038/ng1552; Singla V, 2006, SCIENCE, V313, P629, DOI 10.1126/science.1124534; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Sloboda RD, 2005, J CELL BIOCHEM, V94, P266, DOI 10.1002/jcb.20323; Soncini C, 2006, CLIN CANCER RES, V12, P4080, DOI 10.1158/1078-0432.CCR-05-1964; Strickland LI, 2005, CURR BIOL, V15, P2249, DOI 10.1016/j.cub.2005.10.073; Tanaka Y, 2005, NATURE, V435, P172, DOI 10.1038/nature03494; TUCKER RW, 1979, CELL, V17, P527, DOI 10.1016/0092-8674(79)90261-7; Vanhaecke T, 2004, CURR MED CHEM, V11, P1629, DOI 10.2174/0929867043365099; Wilson PD, 2001, J AM SOC NEPHROL, V12, P834, DOI 10.1681/ASN.V124834; Zhang Y, 2003, EMBO J, V22, P1168, DOI 10.1093/emboj/cdg115	52	603	627	3	34	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 29	2007	129	7					1351	1363		10.1016/j.cell.2007.04.035	http://dx.doi.org/10.1016/j.cell.2007.04.035			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188HQ	17604723	Green Accepted, Bronze			2022-12-28	WOS:000247911400020
J	Chipman, A				Chipman, Andrea			Contest puts brakes on carbon capture	NATURE			English	News Item																			0	0	0	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 28	2007	447	7148					1044	1045		10.1038/4471044a	http://dx.doi.org/10.1038/4471044a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183HT	17597731				2022-12-28	WOS:000247564600012
J	Savoye, M; Shaw, M; Dziura, J; Tamborlane, WV; Rose, P; Guandalini, C; Goldberg-Gell, R; Burgert, TS; Cali, AMG; Weiss, R; Caprio, S				Savoye, Mary; Shaw, Melissa; Dziura, James; Tamborlane, William V.; Rose, Paulina; Guandalini, Cindy; Goldberg-Gell, Rachel; Burgert, Tania S.; Cali, Anna M. G.; Weiss, Ram; Caprio, Sonia			Effects of a weight management program on body composition and metabolic parameters in overweight children - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHILDHOOD OBESITY; INSULIN-RESISTANCE; GLUCOSE-TOLERANCE; ADOLESCENTS; PREVALENCE; YOUTH; LIFE	Context Pediatric obesity has escalated to epidemic proportions, leading to an array of comorbidities, including type 2 diabetes in youth. Since most overweight children become overweight adults, this chronic condition results in serious metabolic complications by early adulthood. To curtail this major health issue, effective pediatric interventions are essential. Objective To compare effects of a weight management program, Bright Bodies, on adiposity and metabolic complications of overweight children with a control group. Design One-year randomized controlled trial conducted May 2002-September 2005. Setting Recruitment and follow-up conducted at Yale Pediatric Obesity Clinic in New Haven, Conn, and intervention at nearby school. Participants Random sample of 209 overweight children ( body mass index [BMI] > 95th percentile for age and sex), ages 8 to 16 years of mixed ethnic groups were recruited. A total of 135 participants (60%) completed 6 months of study, 119 (53%) completed 12 months. Intervention Participants were randomly assigned to either a control or weight management group. The control group (n= 69) received traditional clinical weight management counseling every 6 months, and the weight management group ( n= 105) received an intensive family-based program including exercise, nutrition, and behavior modification. Intervention occurred biweekly the first 6 months, bimonthly thereafter. The second randomization within the weight management group assigned participants ( n= 35) to a structured meal plan approach ( dieting), but this arm of the study was discontinued while enrollment was ongoing due to a high dropout rate. Main Outcome Measures Change in weight, BMI, body fat, and homeostasis model assessment of insulin resistance (HOMA-IR) at 6 and 12 months. Results Six-month improvements were sustained at 12 months in weight management vs control, including changes in the following ( mean [95% confidence interval]): weight ( + 0.3 kg [- 1.4 to 2.0] vs + 7.7 kg [5.3 to 10.0]); BMI (- 1.7 [- 2.3 to - 1.1] vs = 1.6 [0.8 to 2.3]); body fat (- 3.7 kg [- 5.4 to - 2.1] vs + 5.5 kg [3.2 to 7.8]); and HOMA-IR (- 1.52 [- 1.93 to - 1.01] vs +0.90 [- 0.07 to 2.05]). Conclusion The Bright Bodies weight management program had beneficial effects on body composition and insulin resistance in overweight children that were sustained up to 12 months.	Yale Univ, Sch Med, Yale Ctr Clin Invest, New Haven, CT 06520 USA; Yale Univ, Dept Pediat Endocrinol, New Haven, CT 06520 USA; Hadassah Hebrew Univ Sch Med, Ctr Diabet, Jerusalem, Israel; Hadassah Hebrew Univ Sch Med, Dept Pediat, Jerusalem, Israel	Yale University; Yale University; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Savoye, M (corresponding author), Yale Univ, Sch Med, Yale Ctr Clin Invest, 333 Cedar St,LMP3103, New Haven, CT 06520 USA.	mary.savoye@yale.edu	Weiss, Ram/AAC-3964-2020		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD028016, R01HD040787] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000125] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00125] Funding Source: Medline; NICHD NIH HHS [R01-HD28016, R01-HD40787] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], 2001, MISSING DATA; BERRY D, IN PRESS NURS RES; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Caprio S, 2002, J PEDIATR ENDOCR MET, V15, P487; DeStefano R A, 2000, Pediatr Diabetes, V1, P61, DOI 10.1034/j.1399-5448.2000.010202.x; Duncan GE, 2004, DIABETES CARE, V27, P2438, DOI 10.2337/diacare.27.10.2438; EPSTEIN LH, 1990, J CONSULT CLIN PSYCH, V58, P661, DOI 10.1037/0022-006X.58.5.661; EPSTEIN LH, 1994, HEALTH PSYCHOL, V13, P373, DOI 10.1037/0278-6133.13.5.373; Field AE, 2003, PEDIATRICS, V112, P900, DOI 10.1542/peds.112.4.900; Golan M, 2004, OBES RES, V12, P357, DOI 10.1038/oby.2004.45; Grey M, 2000, J PEDIATR-US, V137, P107, DOI 10.1067/mpd.2000.106568; Guo SS, 2002, AM J CLIN NUTR, V76, P653, DOI 10.1093/ajcn/76.3.653; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Kuczmarski RJ, 2000, ADV DATA, V314, P1; Lee JM, 2006, DIABETES CARE, V29, P2427, DOI 10.2337/dc06-0709; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Neumark-Sztainer D, 2006, J AM DIET ASSOC, V106, P559, DOI 10.1016/j.jada.2006.01.003; NUNEZ C, 1999, APPL LEG TO LEG BIOI; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Palamara Kerri L, 2006, Cardiol Rev, V14, P238, DOI 10.1097/01.crd.0000233903.57946.fd; Quattrin T, 2005, PEDIATRICS, V115, P348, DOI 10.1542/peds.2004-1452; Rosenbloom AL, 1999, DIABETES CARE, V22, P345, DOI 10.2337/diacare.22.2.345; Savoye M, 2005, J AM DIET ASSOC, V105, P364, DOI 10.1016/j.jada.2004.12.009; Sinha R, 2002, NEW ENGL J MED, V346, P802, DOI 10.1056/NEJMoa012578; Sinha R, 2002, NEW ENGL J MED, V346, P1756; Sothern MS, 1999, SOUTH MED J, V92, P577, DOI 10.1097/00007611-199906000-00006; *STAT AN SYST, 1988, SAS US GUID STAT; Weiss R, 2005, DIABETES CARE, V28, P902, DOI 10.2337/diacare.28.4.902; Weiss R, 2004, NEW ENGL J MED, V350, P2362, DOI 10.1056/NEJMoa031049; Wrotniak BH, 2005, OBES RES, V13, P1089, DOI 10.1038/oby.2005.127	31	363	374	0	44	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 27	2007	297	24					2697	2704		10.1001/jama.297.24.2697	http://dx.doi.org/10.1001/jama.297.24.2697			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	182UE	17595270	Bronze			2022-12-28	WOS:000247528700019
J	Arroll, B; Falloon, K				Arroll, Bruce; Falloon, Karen			Should doctors go to patients funerals?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Auckland, Dept Gen Practice & Primary Hlth Care, Auckland 1, New Zealand	University of Auckland	Arroll, B (corresponding author), Univ Auckland, Dept Gen Practice & Primary Hlth Care, Auckland 1, New Zealand.	b.arroll@auckland.ac.nz							0	15	15	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 23	2007	334	7607					1322	1322		10.1136/bmj.39251.616678.47	http://dx.doi.org/10.1136/bmj.39251.616678.47			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184MI	17585162	Green Published			2022-12-28	WOS:000247645400037
J	Kumar, P				Kumar, Pooja			Providing the providers - Remedying Africa's shortage of health care workers	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Harvard Affiliated Emergency Med Residency, Boston, MA USA	Harvard University; Harvard Medical School	Kumar, P (corresponding author), Harvard Affiliated Emergency Med Residency, Boston, MA USA.							World Health Organization, WORLD HLTH REP 2006	1	44	45	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 21	2007	356	25					2564	2567		10.1056/NEJMp078091	http://dx.doi.org/10.1056/NEJMp078091			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	180GN	17582065				2022-12-28	WOS:000247351200002
J	McMahon, MA; Jilek, BL; Brennan, TP; Shen, L; Zhou, Y; Wind-Rotolo, M; Xing, SF; Bhat, S; Hale, B; Hegarty, R; Chong, CR; Liu, JO; Siliciano, RF; Thio, CL				McMahon, Moira A.; Jilek, Benjamin L.; Brennan, Timothy P.; Shen, Lin; Zhou, Yan; Wind-Rotolo, Megan; Xing, Sifei; Bhat, Shridhar; Hale, Braden; Hegarty, Robert; Chong, Curtis R.; Liu, Jun O.; Siliciano, Robert F.; Thio, Chloe L.			Brief report - The HBV drug entecavir - Effects on HIV-1 replication and resistance	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HEPATITIS-B-VIRUS; REVERSE-TRANSCRIPTASE; IN-VITRO; REDUCED REPLICATION; LAMIVUDINE; INFECTION; MUTATION; ASSAY; SUSCEPTIBILITY	Entecavir, a drug approved by the Food and Drug Administration for the treatment of chronic hepatitis B virus (HBV) infection, is not believed to inhibit replication of human immunodeficiency virus type 1 (HIV-1) at clinically relevant doses. We observed that entecavir led to a consistent 1-log(10) decrease in HIV-1 RNA in three persons with HIV-1 HBV coinfection, and we obtained supportive in vitro evidence that entecavir is a potent partial inhibitor of HIV-1 replication. Detailed analysis showed that in one of these patients, entecavir monotherapy led to an accumulation of HIV-1 variants with the lamivudine-resistant mutation, M184V. In vitro experiments showed that M184V confers resistance to entecavir. Until more is known about HIV-1-resistance patterns and their selection by entecavir, caution is needed with the use of entecavir in persons with HIV-1 and HBV coinfection who are not receiving fully suppressive antiretroviral regimens.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Natl Naval Med Ctr, Div Infect Dis, San Diego, CA USA	Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; United States Department of Defense; United States Navy; Naval Medical Center San Diego	Thio, CL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, 1503 E Jefferson St, Baltimore, MD 21231 USA.	cthio@jhmi.edu	Bhat, Shridhar/C-5412-2012	McMahon, Moira/0000-0001-9810-8623	Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [R01 AI043222-08, R01AI060449, R01 AI043222, R37 AI051178-06A1, R01 AI060449, R01 AI051178-04, R01 AI043222-07, R01 AI051178, R01 AI043222-09, R37 AI051178, R01 AI051178-05] Funding Source: Medline; PHS HHS [A151178, A143222] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051178, R01AI060449, R01AI043222, R37AI051178] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; Bailey JR, 2006, J VIROL, V80, P6441, DOI 10.1128/JVI.00591-06; Bartholomeusz A, 2004, ANTIVIR THER, V9, P149; Boyer PL, 2002, J VIROL, V76, P3248, DOI 10.1128/JVI.76.7.3248-3256.2002; *DEP HLTH HUM SERV, 2006, GUID US ANT AG HIV 1; DOONG SL, 1991, P NATL ACAD SCI USA, V88, P8495, DOI 10.1073/pnas.88.19.8495; Gallant JE, 2003, ANTIVIR THER, V8, P489; GAO Q, 1993, ANTIMICROB AGENTS CH, V37, P1390, DOI 10.1128/AAC.37.6.1390; HEIJTINK RA, 1993, ANTIVIR RES, V21, P141, DOI 10.1016/0166-3542(93)90050-S; Innaimo SF, 1997, ANTIMICROB AGENTS CH, V41, P1444, DOI 10.1128/AAC.41.7.1444; Karayiannis P, 2003, J ANTIMICROB CHEMOTH, V51, P761, DOI 10.1093/jac/dkg163; Levine S, 2002, ANTIMICROB AGENTS CH, V46, P2525, DOI 10.1128/AAC.46.8.2525-2532.2002; Marion PL, 2002, ANTIMICROB AGENTS CH, V46, P82, DOI 10.1128/AAC.46.1.82-88.2002; *NIH INF DIS SOC A, 2005, MMWR RECOMM REP, V54, P311; *NIH INF DIS SOC A, 2004, MMWR RECOMM REP, V53, P1; Petropoulos CJ, 2000, ANTIMICROB AGENTS CH, V44, P920, DOI 10.1128/AAC.44.4.920-928.2000; Rathbun RC, 2006, CURR PHARM DESIGN, V12, P1045, DOI 10.2174/138161206776055840; Ruff CT, 2002, J VIROL, V76, P9481, DOI 10.1128/JVI.76.18.9481-9492.2002; SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; Sheldon JA, 2005, AIDS, V19, P2036, DOI 10.1097/01.aids.0000189563.79976.05; Sims KA, 2006, PHARMACOTHERAPY, V26, P1745, DOI 10.1592/phco.26.12.1745; Soriano V, 2004, J VIRAL HEPATITIS, V11, P2, DOI 10.1046/j.1365-2893.2003.00491.x; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; WEISLOW OS, 1989, JNCI-J NATL CANCER I, V81, P963; WEISLOW OS, 1989, JNCI-J NATL CANCER I, V81, P577, DOI 10.1093/jnci/81.8.577; Yamanaka G, 1999, ANTIMICROB AGENTS CH, V43, P190, DOI 10.1128/AAC.43.1.190; Ying C, 2000, J VIRAL HEPATITIS, V7, P79; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zhang HL, 2004, J VIROL, V78, P1718, DOI 10.1128/JVI.78.4.1718-1729.2004	30	175	187	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 21	2007	356	25					2614	2621		10.1056/NEJMoa067710	http://dx.doi.org/10.1056/NEJMoa067710			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180GN	17582071	Green Accepted			2022-12-28	WOS:000247351200008
J	Poole, A; Penny, D				Poole, Anthony; Penny, David			Engulfed by speculation	NATURE			English	Editorial Material							EUKARYOTES; ORIGIN		Stockholm Univ, Dept Mol Biol & Funct Genom, SE-10691 Stockholm, Sweden; Massey Univ, Inst Mol Biosci, Allan Wilson Ctr Mol Ecol & Evolut, Palmerston North, New Zealand	Stockholm University; Massey University	Poole, A (corresponding author), Stockholm Univ, Dept Mol Biol & Funct Genom, SE-10691 Stockholm, Sweden.		Penny, David/E-9410-2011	Poole, Anthony/0000-0001-9940-2824				Cavalier-Smith T, 2002, INT J SYST EVOL MICR, V52, P297, DOI 10.1099/00207713-52-2-297; de Duve C, 2007, NAT REV GENET, V8, P395, DOI 10.1038/nrg2071; Pace NR, 2006, NATURE, V441, P289, DOI 10.1038/441289a; Poole AM, 2007, BIOESSAYS, V29, P74, DOI 10.1002/bies.20516; van der Giezen M, 2005, EMBO REP, V6, P525, DOI 10.1038/sj.embor.7400440	5	47	50	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 21	2007	447	7147					913	913		10.1038/447913a	http://dx.doi.org/10.1038/447913a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180NU	17581566				2022-12-28	WOS:000247373100026
J	Wadman, M				Wadman, Meredith			Anaemic outlook for Amgen	NATURE			English	News Item																			0	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 21	2007	447	7147					899	899		10.1038/447899a	http://dx.doi.org/10.1038/447899a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180NU	17581554	Bronze			2022-12-28	WOS:000247373100012
J	Himmelfarb, J				Himmelfarb, Jonathan			Chronic kidney disease and the public health - Gaps in evidence from interventional trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							STAGE RENAL-DISEASE; RANDOMIZED CONTROLLED-TRIALS; CARDIOVASCULAR-DISEASE; CLINICAL-TRIALS; PERITONEAL-DIALYSIS; UNITED-STATES; HEMODIALYSIS; ASSOCIATION; OUTCOMES; MORTALITY		Maine Med Ctr, Div Nephrol, Portland, ME 04102 USA	Maine Medical Center	Himmelfarb, J (corresponding author), Maine Med Ctr, Div Nephrol, 22 Bramhall St, Portland, ME 04102 USA.	himmej@mmc.org						Anavekar NS, 2004, NEW ENGL J MED, V351, P1285, DOI 10.1056/NEJMoa041365; Califf RM, 2007, HEALTH AFFAIR, V26, P62, DOI 10.1377/hlthaff.26.1.62; Charytan D, 2006, KIDNEY INT, V70, P2021, DOI 10.1038/sj.ki.5001934; Churchill DN, 1996, J AM SOC NEPHROL, V7, P198; Coca SG, 2006, JAMA-J AM MED ASSOC, V296, P1377, DOI 10.1001/jama.296.11.1377; Coyne DW, 2007, JAMA-J AM MED ASSOC, V297, P1713, DOI 10.1001/jama.297.15.1713; Drueke TB, 2006, NEW ENGL J MED, V355, P2071, DOI 10.1056/NEJMoa062276; Eknoyan G, 2002, NEW ENGL J MED, V347, P2010, DOI 10.1056/NEJMoa021583; Gilbertson DT, 2005, J AM SOC NEPHROL, V16, P3736, DOI 10.1681/ASN.2005010112; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Greene T, 2005, J AM SOC NEPHROL, V16, P3371, DOI 10.1681/ASN.2005030321; Himmelfarb J, 2007, ANNU REV MED, V58, P387, DOI 10.1146/annurev.med.58.061705.151442; Ioannidis JPA, 2005, JAMA-J AM MED ASSOC, V294, P218, DOI 10.1001/jama.294.2.218; Johnston SC, 2006, LANCET, V367, P1319, DOI 10.1016/S0140-6736(06)68578-4; McClellan W, 2007, J AM SOC NEPHROL, V18, P1344, DOI 10.1681/ASN.2006090952; Paniagua R, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1351307; Porter ME, 2007, JAMA-J AM MED ASSOC, V297, P1103, DOI 10.1001/jama.297.10.1103; Rocco MV, 2006, ANN INTERN MED, V145, P512, DOI 10.7326/0003-4819-145-7-200610030-00009; Sarnak MJ, 2003, CIRCULATION, V108, P2154, DOI 10.1161/01.CIR.0000095676.90936.80; Schoolwerth Anton C, 2006, Prev Chronic Dis, V3, pA57; Shlipak M, 2005, J AM SOC NEPHROL, V16, P3477, DOI 10.1681/ASN.2005080806; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Strippoli GFM, 2004, J AM SOC NEPHROL, V15, P411, DOI 10.1097/01.ASN.0000100125.21491.46; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; White CA, 2007, KIDNEY INT, V71, P312, DOI 10.1038/sj.ki.5002037	25	45	47	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 20	2007	297	23					2630	2633		10.1001/jama.297.23.2630	http://dx.doi.org/10.1001/jama.297.23.2630			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180HB	17579231				2022-12-28	WOS:000247352600026
J	Airan, RD; Meltzer, LA; Roy, M; Gong, YQ; Chen, H; Deisseroth, K				Airan, Raag D.; Meltzer, Leslie A.; Roy, Madhuri; Gong, Yuqing; Chen, Han; Deisseroth, Karl			High-speed Imaging reveals neurophysiological links to behavior in an animal model of depression	SCIENCE			English	Article							HIPPOCAMPAL NEUROGENESIS; MAJOR DEPRESSION; STRESS; CELLS	The hippocampus is one of several brain areas thought to play a central role in affective behaviors, but the underlying local network dynamics are not understood. We used quantitative voltage-sensitive dye imaging to probe hippocampal dynamics with millisecond resolution in brain slices after bidirectional modulation of affective state in rat models of depression. We found that a simple measure of real-time activity-stimulus-evoked percolation of activity through the dentate gyrus relative to the hippocampal output subfield-accounted for induced changes in animal behavior independent of the underlying mechanism of action of the treatments. Our results define a circuit-level neurophysiological endophenotype for affective behavior and suggest an approach to understanding circuit-level substrates underlying psychiatric disease symptoms.	Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; Stanford Univ, Program Neurosci, Stanford, CA 94305 USA; Stanford Univ, Dept Elect Engn, Stanford, CA 94305 USA; Stanford Univ, Dept Stat, Stanford, CA 94305 USA; Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University; Stanford University	Deisseroth, K (corresponding author), Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA.	deissero@stanford.edu	Yan, Shuo/B-8381-2009	Airan, Raag/0000-0001-5259-5606				Bannerman DM, 2004, NEUROSCI BIOBEHAV R, V28, P273, DOI 10.1016/j.neubiorev.2004.03.004; BIRNSTIEL S, 1995, SYNAPSE, V20, P117, DOI 10.1002/syn.890200204; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Campbell S, 2004, J PSYCHIATR NEUROSCI, V29, P417; Cowan WM, 2000, ANNU REV NEUROSCI, V23, P343, DOI 10.1146/annurev.neuro.23.1.343; Cryan JF, 2005, NAT REV DRUG DISCOV, V4, P775, DOI 10.1038/nrd1825; Cryan JF, 2005, NEUROSCI BIOBEHAV R, V29, P547, DOI 10.1016/j.neubiorev.2005.03.008; Drevets WC, 2001, CURR OPIN NEUROBIOL, V11, P240, DOI 10.1016/S0959-4388(00)00203-8; Grinvald A, 2004, NAT REV NEUROSCI, V5, P874, DOI 10.1038/nrn1536; Hasselmo ME, 2005, NEURAL NETWORKS, V18, P1172, DOI 10.1016/j.neunet.2005.08.007; Henn FA, 2004, BIOL PSYCHIAT, V56, P146, DOI 10.1016/j.biopsych.2004.04.011; Lisman JE, 2005, NEURON, V46, P703, DOI 10.1016/j.neuron.2005.05.002; Lopez-Rubalcava C, 2000, NEUROPSYCHOPHARMACOL, V22, P191, DOI 10.1016/S0893-133X(99)00100-1; Mayberg HS, 2005, NEURON, V45, P651, DOI 10.1016/j.neuron.2005.02.014; Mayberg HS, 1999, AM J PSYCHIAT, V156, P675; Mayberg HS, 2000, BIOL PSYCHIAT, V48, P830, DOI 10.1016/S0006-3223(00)01036-2; McEwen BS, 1999, ANNU REV NEUROSCI, V22, P105, DOI 10.1146/annurev.neuro.22.1.105; Mirescu C, 2006, HIPPOCAMPUS, V16, P233, DOI 10.1002/hipo.20155; Nestler EJ, 2002, NEURON, V34, P13, DOI 10.1016/S0896-6273(02)00653-0; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Sapolsky RM, 2000, ARCH GEN PSYCHIAT, V57, P925, DOI 10.1001/archpsyc.57.10.925; Seminowicz DA, 2004, NEUROIMAGE, V22, P409, DOI 10.1016/j.neuroimage.2004.01.015; Tecott LH, 2004, NAT NEUROSCI, V7, P462, DOI 10.1038/nn1225; Walling SG, 2004, J NEUROSCI, V24, P598, DOI 10.1523/JNEUROSCI.4426-03.2004; Warner-Schmidt JL, 2006, HIPPOCAMPUS, V16, P239, DOI 10.1002/hipo.20156; Willner P, 2005, NEUROPSYCHOBIOLOGY, V52, P90, DOI 10.1159/000087097	26	306	312	3	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 10	2007	317	5839					819	823		10.1126/science.1144400	http://dx.doi.org/10.1126/science.1144400			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198JN	17615305				2022-12-28	WOS:000248624500045
J	Sato, T; Mushiake, S; Kato, Y; Sato, K; Sato, M; Takeda, N; Ozono, K; Miki, K; Kubo, Y; Tsuji, A; Harada, R; Harada, A				Sato, Takashi; Mushiake, Sotaro; Kato, Yukio; Sato, Ken; Sato, Miyuki; Takeda, Naoki; Ozono, Keiichi; Miki, Kazunori; Kubo, Yoshiyuki; Tsuji, Akira; Harada, Reiko; Harada, Akihiro			The Rab8 GTPase regulates apical protein localization in intestinal cells	NATURE			English	Article							CONGENITAL MICROVILLOUS ATROPHY; BETA-LACTAM ANTIBIOTICS; EPITHELIAL-CELLS; MEMBRANE; MICE; ABSORPTION; MECHANISMS; TRANSPORT; POLARITY; NEURONS	A number of proteins are known to be involved in apical/basolateral transport of proteins in polarized epithelial cells(1-7). The small GTP-binding protein Rab(8) was thought to regulate basolateral transport in polarized kidney epithelial cells through the AP1B-complex-mediated pathway(8,9). However, the role of Rab8 (Rab8A) in cell polarity in vivo remains unknown. Here we show that Rab8 is responsible for the localization of apical proteins in intestinal epithelial cells. We found that apical peptidases and transporters localized to lysosomes in the small intestine of Rab8-deficient mice. Their mislocalization and degradation in lysosomes led to a marked reduction in the absorption rate of nutrients in the small intestine, and ultimately to death. Ultrastructurally, a shortening of apical microvilli, an increased number of enlarged lysosomes, and microvillus inclusions in the enterocytes were also observed. One microvillus inclusion disease patient who shows an identical phenotype to Rab8-deficient mice expresses a reduced amount of RAB8 (RAB8A; NM_005370). Our results demonstrate that Rab8 is necessary for the proper localization of apical proteins and the absorption and digestion of various nutrients in the small intestine.	Osaka Univ, Grad Sch Med, Dept Pediat, Suita, Osaka 5650871, Japan; Kanazawa Univ, Div Pharmaceut Sci, Grad Sch Nat Sci & Technol, Kanazawa, Ishikawa 9201192, Japan; Kumamoto Univ, Div Transgen Technol, CARD, IRDA, Kumamoto 8600811, Japan; Itami Municipal Hosp, Dept Pediat, Itami, Hyogo 6648540, Japan	Osaka University; Kanazawa University; Kumamoto University	Harada, A (corresponding author), Gunma Univ, Lab Mol Traff, Dept Mol & Cellular Biol, Inst Mol & Cellular Regulat, Gunma 3718512, Japan.	aharada@showa.gunma-u.ac.jp	KATO, Yukio/D-8396-2015; Sato, Miyuki/S-5112-2018; Kubo, Yoshiyuki/Q-6069-2019	Sato, Miyuki/0000-0002-1944-4918; Kubo, Yoshiyuki/0000-0002-7905-5666				Ang AL, 2003, J CELL BIOL, V163, P339, DOI 10.1083/jcb.200307046; DAVIDSON GP, 1978, GASTROENTEROLOGY, V75, P783; Harada A, 2002, J CELL BIOL, V158, P541, DOI 10.1083/jcb.200110134; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; HARADA A, 1990, CELL STRUCT FUNCT, V15, P329, DOI 10.1247/csf.15.329; HOMAREDA H, 1993, FEBS LETT, V327, P99, DOI 10.1016/0014-5793(93)81048-5; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; Ishida Y, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.24.e35; Kagitani K, 1998, J BONE MINER RES, V13, P1946, DOI 10.1359/jbmr.1998.13.12.1946; Koike M, 2005, AM J PATHOL, V167, P1713, DOI 10.1016/S0002-9440(10)61253-9; LOUVARD D, 1992, ANNU REV CELL BIOL, V8, P157, DOI 10.1146/annurev.cb.08.110192.001105; Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; Nakamura N, 2001, J BIOCHEM-TOKYO, V130, P765, DOI 10.1093/oxfordjournals.jbchem.a003047; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; PHILLIPS AD, 1985, ARCH DIS CHILD, V60, P135, DOI 10.1136/adc.60.2.135; Rodriguez CI, 2000, NAT GENET, V25, P139, DOI 10.1038/75973; Rodriguez-Boulan E, 2004, CURR OPIN CELL BIOL, V16, P436, DOI 10.1016/j.ceb.2004.06.013; Sabatini DD, 2005, ANNU REV CELL DEV BI, V21, P1, DOI 10.1146/annurev.cellbio.21.020904.151711; Saito H, 1995, J PHARMACOL EXP THER, V275, P1631; Sakai K, 1997, BIOCHEM BIOPH RES CO, V237, P318, DOI 10.1006/bbrc.1997.7111; Sasaki T, 2002, TRANSPLANTATION, V73, P560, DOI 10.1097/00007890-200202270-00013; Sato M, 2005, NAT CELL BIOL, V7, P559, DOI 10.1038/ncb1261; Schuck S, 2004, J CELL SCI, V117, P5955, DOI 10.1242/jcs.01596; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Tamai I, 1997, J PHARM PHARMACOL, V49, P796, DOI 10.1111/j.2042-7158.1997.tb06115.x; UMESAKI Y, 1982, J BIOCHEM-TOKYO, V92, P373, DOI 10.1093/oxfordjournals.jbchem.a133943; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	28	240	246	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 19	2007	448	7151					366	369		10.1038/nature05929	http://dx.doi.org/10.1038/nature05929			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	191GC	17597763				2022-12-28	WOS:000248118300061
J	Fountain, SJ; Parkinson, K; Young, MT; Cao, LS; Thompson, CRL; North, RA				Fountain, Samuel J.; Parkinson, Katie; Young, Mark T.; Cao, Lishuang; Thompson, Christopher R. L.; North, R. Alan			An intracellular P2X receptor required for osmoregulation in Dictyostelium discoideum	NATURE			English	Article							CONTRACTILE VACUOLE; ION CHANNELS; MOLECULAR-PROPERTIES; MEMBRANE; TRIMERS; PROTEIN; MOTIF; LVSA	P2X receptors are membrane ion channels gated by extracellular ATP(1,2) that are found widely in vertebrates, but not previously in microbes. Here we identify a weakly related gene in the genome of the social amoeba Dictyostelium discoideum, and show, with the use of heterologous expression in human embryonic kidney cells, that it encodes a membrane ion channel activated by ATP (30-100 mu M). Site-directed mutagenesis revealed essential conservation of structure-function relations with P2X receptors of higher organisms. The receptor was insensitive to the usual P2X antagonists(3) but was blocked by nanomolar concentrations of Cu2+ ions. In D. discoideum, the receptor was found on intracellular membranes, with prominent localization to an osmoregulatory organelle, the contractile vacuole. Targeted disruption of the gene in D. discoideum resulted in cells that were unable to regulate cell volume in hypotonic conditions. Cell swelling in these mutant cells was accompanied by a marked inhibition of contractile vacuole emptying. These findings demonstrate a new functional role for P2X receptors on intracellular organelles, in this case in osmoregulation.	Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Thompson, CRL (corresponding author), Univ Manchester, Fac Life Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	christopher.thompson@manchester.ac.uk; r.a.north@manchester.ac.uk	North, Richard/GQA-6156-2022; Young, Mark T/E-8928-2010; Fountain, Samuel J/C-2142-2011	Young, Mark T/0000-0002-9615-9002; 	Medical Research Council [G0400103, G0400103(70396)] Funding Source: Medline; Wellcome Trust [074950] Funding Source: Medline; MRC [G0400103] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Allen RD, 2000, BIOESSAYS, V22, P1035; Allen RD, 2002, INT REV CYTOL, V215, P351; Barrera NP, 2005, J BIOL CHEM, V280, P10759, DOI 10.1074/jbc.M412265200; Chaumont S, 2004, J BIOL CHEM, V279, P29628, DOI 10.1074/jbc.M403940200; Coddou C, 2003, J BIOL CHEM, V278, P36777, DOI 10.1074/jbc.M305177200; Gerald NJ, 2002, TRAFFIC, V3, P50, DOI 10.1034/j.1600-0854.2002.30107.x; Gever JR, 2006, PFLUG ARCH EUR J PHY, V452, P513, DOI 10.1007/s00424-006-0070-9; Heuser J, 2006, EUR J CELL BIOL, V85, P859, DOI 10.1016/j.ejcb.2006.05.011; Jentsch TJ, 2004, NAT CELL BIOL, V6, P1039, DOI 10.1038/ncb1104-1039; Khakh BS, 2006, NATURE, V442, P527, DOI 10.1038/nature04886; Masse K, 2006, GENOMICS, V87, P366, DOI 10.1016/j.ygeno.2005.11.003; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Ramjeesingh M, 1999, BIOCHEM J, V342, P119, DOI 10.1042/0264-6021:3420119; Roberts JA, 2006, PFLUG ARCH EUR J PHY, V452, P486, DOI 10.1007/s00424-006-0073-6; Vial C, 2004, TRENDS PHARMACOL SCI, V25, P487, DOI 10.1016/j.tips.2004.07.008; Virginio C, 1997, NEUROPHARMACOLOGY, V36, P1285, DOI 10.1016/S0028-3908(97)00141-X; Wu WI, 2004, TRAFFIC, V5, P346, DOI 10.1111/j.1600-0854.2004.00177.x; ZHU QL, 1992, J CELL BIOL, V118, P347, DOI 10.1083/jcb.118.2.347	19	115	118	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 12	2007	448	7150					200	203		10.1038/nature05926	http://dx.doi.org/10.1038/nature05926			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	188QN	17625565	Green Accepted			2022-12-28	WOS:000247934500044
J	Berkley, SF; Koff, WC				Berkley, Seth Franklin; Koff, Wayne Chester			Scientific and policy challenges to development of an AIDS vaccine	LANCET			English	Article							SIMIAN-IMMUNODEFICIENCY-VIRUS; CELLULAR IMMUNE-RESPONSES; CD4(+) T-CELLS; NEUTRALIZING ANTIBODIES; ATTENUATED SIV; HIV-1; INFECTION; LIVE; MACAQUES; VECTORS		Int AIDS Vaccine Initiat, New York, NY 10038 USA	International AIDS Vaccine Initiative	Berkley, SF (corresponding author), Int AIDS Vaccine Initiat, 110 William St, New York, NY 10038 USA.	SBerkley@IAVI.org						Addo MM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000321; Anderson R, 2005, J INFECT DIS, V191, pS85, DOI 10.1086/425267; BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; Barnet SW, 2001, J VIROL, V75, P5526, DOI 10.1128/JVI.75.12.5526-5540.2001; Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; Bhan MK, 2005, PLOS MED, V2, P111, DOI 10.1371/journal.pmed.0020025; Burton DR, 2004, SCIENCE, V303, P316, DOI 10.1126/science.1094620; Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233; Calarese DA, 2005, P NATL ACAD SCI USA, V102, P13372, DOI 10.1073/pnas.0505763102; Cardoso RMF, 2005, IMMUNITY, V22, P163, DOI 10.1016/j.immuni.2004.12.011; Casimiro DR, 2005, J VIROL, V79, P15547, DOI 10.1128/JVI.79.24.15547-15555.2005; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; Evans DT, 2005, J VIROL, V79, P7707, DOI 10.1128/JVI.79.12.7707-7720.2005; EXCLER JL, IN PRESS AIDS; Fischer W, 2007, NAT MED, V13, P100, DOI 10.1038/nm1461; Flynn MN, 2005, J INFECT DIS, V191, P654, DOI 10.1086/428404; Fouts T, 2002, P NATL ACAD SCI USA, V99, P11842, DOI 10.1073/pnas.182412199; Fu TM, 2007, AIDS RES HUM RETROV, V23, P67, DOI 10.1089/aid.2006.0114; *G8 GLEN, 2005, G8 AFR; Gauduin MC, 2006, J EXP MED, V203, P2661, DOI 10.1084/jem.20060134; Golding H, 2002, J VIROL, V76, P6780, DOI 10.1128/JVI.76.13.6780-6790.2002; Gorny MK, 2002, J VIROL, V76, P9035, DOI 10.1128/JVI.76.18.9035-9045.2002; Grundner C, 2005, VIROLOGY, V331, P33, DOI 10.1016/j.virol.2004.09.022; Haase AT, 2005, NAT REV IMMUNOL, V5, P783, DOI 10.1038/nri1706; *HIV VACC MICR RES, ADD IT ALL FUND HIV; Horton R, 2004, NEW YORK REV BOOKS, V51, P53; Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520; Kijak Gustavo H, 2005, Curr Infect Dis Rep, V7, P480, DOI 10.1007/s11908-005-0051-8; Koff WC, 2006, NAT IMMUNOL, V7, P19, DOI 10.1038/ni1296; Korber B, 2001, BRIT MED BULL, V58, P19, DOI 10.1093/bmb/58.1.19; Kostense S, 2004, AIDS, V18, P1213, DOI 10.1097/00002030-200405210-00019; Lee D, 2004, J INFECT DIS, V190, P903, DOI 10.1086/423284; Letvin NL, 2006, SCIENCE, V312, P1530, DOI 10.1126/science.1124226; Lifson JD, 2004, AIDS RES HUM RETROV, V20, P772, DOI 10.1089/0889222041524661; Lifson JD, 2003, J MED PRIMATOL, V32, P201, DOI 10.1034/j.1600-0684.2003.00026.x; Mascola JR, 2003, CURR MOL MED, V3, P209, DOI 10.2174/1566524033479799; Mascola JR, 1999, J VIROL, V73, P4009, DOI 10.1128/JVI.73.5.4009-4018.1999; Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501; Nitayaphan S, 2004, J INFECT DIS, V190, P702, DOI 10.1086/422258; Ofek G, 2004, J VIROL, V78, P10724, DOI 10.1128/JVI.78.19.10724-10737.2004; Pantophlet R, 2003, J VIROL, V77, P5889, DOI 10.1128/JVI.77.10.5889-5901.2003; Pantophlet R, 2006, ANNU REV IMMUNOL, V24, P739, DOI 10.1146/annurev.immunol.24.021605.090557; Parren PWHI, 2001, J VIROL, V75, P8340, DOI 10.1128/JVI.75.17.8340-8347.2001; Peng Y, 2007, J VIROL, V81, P2187, DOI 10.1128/JVI.01879-06; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Rhodes DI, 2000, J VIROL, V74, P10581, DOI 10.1128/JVI.74.22.10581-10588.2000; Roberts DM, 2006, NATURE, V441, P239, DOI 10.1038/nature04721; Salomon JA, 2005, PLOS MED, V2, P50, DOI 10.1371/journal.pmed.0020016; Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002; Saphire EO, 2001, SCIENCE, V293, P1155, DOI 10.1126/science.1061692; SATTENTAU QJ, 1995, J EXP MED, V182, P185, DOI 10.1084/jem.182.1.185; Schmitz JE, 2005, J VIROL, V79, P8131, DOI 10.1128/JVI.79.13.8131-8141.2005; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Shiver JW, 2004, ANNU REV MED, V55, P355, DOI 10.1146/annurev.med.55.091902.104344; Stover J, 2007, HEALTH AFFAIR, V26, P1147, DOI 10.1377/hlthaff.26.4.1147; *UNAIDS WHO, 2006, AIDS EP UPD; Veazey RS, 2003, NAT MED, V9, P343, DOI 10.1038/nm833; Vogels R, 2003, J VIROL, V77, P8263, DOI 10.1128/JVI.77.15.8263-8271.2003; WHATMORE AM, 1995, J VIROL, V69, P5117, DOI 10.1128/JVI.69.8.5117-5123.1995; Wilson NA, 2006, J VIROL, V80, P5875, DOI 10.1128/JVI.00171-06; Wyand MS, 1999, J VIROL, V73, P8356, DOI 10.1128/JVI.73.10.8356-8363.1999; Wyand MS, 1997, NAT MED, V3, P32, DOI 10.1038/nm0197-32; Yang XZ, 2002, J VIROL, V76, P4634, DOI 10.1128/JVI.76.9.4634-4642.2002; Zhou TQ, 2007, NATURE, V445, P732, DOI 10.1038/nature05580; Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001	65	30	35	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 7	2007	370	9581					94	101		10.1016/S0140-6736(07)61054-X	http://dx.doi.org/10.1016/S0140-6736(07)61054-X			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	187QE	17617277				2022-12-28	WOS:000247862300035
J	Madruga, JV; Cahn, P; Grinsztejn, B; Haubrich, R; Lalezari, J; Mills, A; Pialoux, G; Wilkin, T; Peeters, M; Vingerhoets, J; de Smedt, G; Leopold, L; Trefiglio, R; Woodfall, B				Madruga, Jose Valdez; Cahn, Pedro; Grinsztejn, Beatriz; Haubrich, Richard; Lalezari, Jacob; Mills, Anthony; Pialoux, Gilles; Wilkin, Timothy; Peeters, Monika; Vingerhoets, Johan; de Smedt, Goedele; Leopold, Lorant; Trefiglio, Roberto; Woodfall, Brion		DUET-1 Study Grp	Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial	LANCET			English	Article; Proceedings Paper	4th International-AIDS-Society Conference on HIV Pathogenesis, Treatment and Prevention	JUL 22-25, 2007	Sydney, AUSTRALIA	Int AIDS Soc			RESISTANCE; INFECTION; HIV-1	Background Antiretroviral agent; active against drug-resistant HIV-1 are needed for treatment-experienced patients. The aim of this trial was to assess the efficacy, safety; and tolerability of TMC125 (etravirine), a non-nucleoside reverse transcriptase inhibitor (NNRTI). Methods DUET-1 is a continuing, multinational randomised, double-blind, placebo-controlled, phase III trial. Treatment-experienced adult patients with virological failure on stable antiretroviral therapy, documented genotypic evidence of NNRTI resistance, Aral load over 5000 copies per mL, and three or more primary protease inhibitor mutations were randomly assigned to receive 200 mg TMC125 or placebo twice daily. All patients also received darunavir with low-dose ritonavir and investigator-selected nucleoside reverse transcriptase inhibitors. Enfuvirtide use was optional. The primary endpoint was a confirmed viral load below 50 copies per mL at week 24 (FDA time-to-loss of virological response algorithm). Analyses were done by intention to treat. This trial is registered with ClinicalTrials.gov, with the number NCT00254046. Findings 612 patients were randomised and treated (304 in the TMC125 group, 308 in the placebo group). By week 24, 42 (14%) patients in the TMC125 group and 56 (18%) in the placebo group had discontinued, mainly due to virological failure. At week 24, 170 (56%) patients in the TMC125 group and 119 (39%) patients in the placebo group achieved a confirmed viral load of less than 50 copies per mL (difference in response rates 17%; 95% CI 9-25; p = 0.005). Most adverse events were mild or moderate in severity. The type and incidence of adverse events, including neuropsychiatric events, seen with TMC125 were generally comparable with placebo, with the exception of rash (61 [20%] patients on TMC125 vs 30 [10%] on placebo) and diarrhoea (36 [12%] patients on TMC125 vs 63 [20%] on placebo). Interpretation In treatment-experienced patients with NNRTI resistance, treatment with TMC125 achieved better virological suppression at week 24 than did placebo. The safety and tolerability profile of TMC125 was generally comparable with placebo.	DST AIDS, Ctr Referencia & Treinamento, BR-04121000 Sao Paulo, Brazil; Hosp Juan A Fernandez & Fdn Huesped, Buenos Aires, DF, Argentina; Univ Calif San Diego, San Diego, CA 92103 USA; Quest Clin Res, San Francisco, CA USA; Hop Tenon, Serv Malad Infect, APHP, F-75970 Paris, France; Cornell Univ, Weill Med Coll, New York, NY USA; Tibotec BVBA, Mechelen, Belgium; Tibotec Inc, Yardley, PA USA	University of California System; University of California San Diego; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Cornell University; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson USA	Madruga, JV (corresponding author), DST AIDS, Ctr Referencia & Treinamento, Rua Santa Cruz 81,Vila Mariana, BR-04121000 Sao Paulo, Brazil.	vaidezmr@uol.com.br		Mills, Anthony/0000-0002-6997-5581				Andries K, 2004, ANTIMICROB AGENTS CH, V48, P4680, DOI 10.1128/AAC.48.12.4680-4686.2004; [Anonymous], 14 C RETR OPP INF LO; [Anonymous], 2007, EFFICACY SAFETY MARA; Bacheler L, 2001, J VIROL, V75, P4999, DOI 10.1128/JVI.75.11.4999-5008.2001; Clotet B, 2007, LANCET, V369, P1169, DOI 10.1016/S0140-6736(07)60497-8; COHEN C, 2006, 16 INT AIDS C TOR CA; COOPER D, 2007, 14 C RETR OPP INF LO; Delaugerre C, 2001, J MED VIROL, V65, P445, DOI 10.1002/jmv.2055; DEMEYER S, 2006, 15 INT HIV DRUG RES; DEMEYER S, 2006, 8 INT C DRUG THER HI; Gazzard B, 2006, HIV MED, V7, P487, DOI 10.1111/j.1468-1293.2006.00424.x; Hammer SM, 2006, JAMA-J AM MED ASSOC, V296, P827, DOI 10.1001/jama.296.7.827; Johnson Victoria A, 2005, Top HIV Med, V13, P125; KATLAMA C, 2005, 12 C RETR OPP INF BO; Lazzarin A, 2007, LANCET, V370, P39, DOI 10.1016/S0140-6736(07)61048-4; MONTANER J, 2005, 10 EUR AIDS C DUBL I; Nadler JP, 2007, AIDS, V21, pF1, DOI 10.1097/01.aids.0000299404.99033.bf; PISCITELLI S, 2002, 42 INT C ANT AG CHEM; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; SCHOLLER M, 2006, 13 C RETR OPP INF DE; SCHOLLER M, 2005, 3 IAS C HIV PATH TRE; STEIGBIGEL R, 2007, 14 C RETR OPP INF LO; TAMBUYZER L, 2007, 5 EUR HIV DRUG RES W; *US DEP HHS, 2006, GUID US ANT AG HIV 1; *US DEP HHS FDA CD, 2002, GUID IND ANT DRUGS U; Vingerhoets J, 2005, J VIROL, V79, P12773, DOI 10.1128/JVI.79.20.12773-12782.2005; VINGERHOETS J, 2007, 16 INT HIV DRUG RES; Youle M, 2004, LANCET, V364, P1036, DOI 10.1016/S0140-6736(04)17055-4	28	360	377	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 7	2007	370	9581					29	38		10.1016/S0140-6736(07)61047-2	http://dx.doi.org/10.1016/S0140-6736(07)61047-2			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	187QE	17617270				2022-12-28	WOS:000247862300028
J	Lyerly, AD; Faden, RR				Lyerly, Anne Drapkin; Faden, Ruth R.			Embryonic stem cells - Willingness to donate frozen embryos for stem cell research	SCIENCE			English	Editorial Material							COUPLES DECISIONS; ATTITUDES		Duke Univ, Med Ctr, Durham, NC 27710 USA; Johns Hopkins Berman Inst Bioeth, Baltimore, MD 21205 USA	Duke University; Johns Hopkins University	Lyerly, AD (corresponding author), Duke Univ, Med Ctr, Durham, NC 27710 USA.	lyerl003@mc.duke.edu		Lyerly, Anne/0000-0003-2211-6920	NHLBI NIH HHS [K01 HL79517-01] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRIDGES A, 2007, WASHINGTON POST 0319; Burton PJ, 2004, MED J AUSTRALIA, V180, P559, DOI 10.5694/j.1326-5377.2004.tb06091.x; Choudhary M, 2004, HUM REPROD, V19, P2091, DOI 10.1093/humrep/deh401; de Lacey S, 2005, HUM REPROD, V20, P1661, DOI 10.1093/humrep/deh831; Hammarberg K, 2006, FERTIL STERIL, V86, P86, DOI 10.1016/j.fertnstert.2005.11.071; Hoffman DI, 2003, FERTIL STERIL, V79, P1063, DOI 10.1016/S0015-0282(03)00172-9; HUDSON K, 2005, VALUES CONFLICT PUBL; LARUELLE C, 1995, FERTIL STERIL, V63, P1047, DOI 10.1016/S0015-0282(16)57546-3; Lyerly AD, 2006, FERTIL STERIL, V85, P1623, DOI 10.1016/j.fertnstert.2005.11.056; McMahon CA, 2003, HUM REPROD, V18, P871, DOI 10.1093/humrep/deg167; Van Voorhis BJ, 1999, FERTIL STERIL, V71, P604, DOI 10.1016/S0015-0282(98)00545-7; 2006, PRESIDENT DISCUSSES	12	39	39	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2007	317	5834					46	47		10.1126/science.1145067	http://dx.doi.org/10.1126/science.1145067			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186KD	17588897				2022-12-28	WOS:000247776700030
J	Srivastava, R				Srivastava, Ranjana			The art of letting go	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 5	2007	357	1					3	5		10.1056/NEJMp068278	http://dx.doi.org/10.1056/NEJMp068278			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185OR	17611202				2022-12-28	WOS:000247720800002
J	Jewkes, R				Jewkes, Rachel			Comprehensive response to rape needed in conflict settings	LANCET			English	Editorial Material									MRC, Gender & Hlth Res Unit, ZA-0001 Pretoria, South Africa		Jewkes, R (corresponding author), MRC, Gender & Hlth Res Unit, ZA-0001 Pretoria, South Africa.	rjewkes@mrc.ac.za		Jewkes, Rachel/0000-0002-4330-6267				Biason L., 2005, WOMEN INSECURE WORLD; Inter-Agency Standing Committee, 2005, GUID GEND BAS VIOL I; JEWKES R, 2002, SOC SCI MED, V55, P153; Jewkes R, 2006, SOC SCI MED, V63, P2949, DOI 10.1016/j.socscimed.2006.07.027; NDUNA S, 1997, PAIN TOO DEEP TEARS; *OFF COORD HUM AFF, 2007, SHAM WAR SEX VIOL WO; Spiegel PB, 2007, LANCET, V369, P2187, DOI 10.1016/S0140-6736(07)61015-0	7	19	19	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 30	2007	369	9580					2140	2141		10.1016/S0140-6736(07)60991-X	http://dx.doi.org/10.1016/S0140-6736(07)60991-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	184LX	17604782				2022-12-28	WOS:000247644200007
J	Friedlander, RM				Friedlander, Robert M.			Arteriovenous malformations of the brain	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRACRANIAL VASCULAR MALFORMATIONS; NATURAL-HISTORY; ENDOVASCULAR TREATMENT; OLMSTED COUNTY; GRADING SYSTEM; HEMORRHAGE; RISK; RADIOSURGERY; COMPLICATIONS; FREQUENCY		Brigham & Womens Hosp, Dept Neurosurg, Div Cerebrovasc Surg, Boston, MA 02115 USA; Harvard Med Sch, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Friedlander, RM (corresponding author), Brigham & Womens Hosp, Dept Neurosurg, Div Cerebrovasc Surg, 75 Francis St, Boston, MA 02115 USA.	rfriedlander@rics.bwh.harvard.edu	Friedlander, Robert M/A-2845-2016	Friedlander, Robert M/0000-0003-4423-9219				Al-Shahi R, 2002, J NEUROL NEUROSUR PS, V73, P547, DOI 10.1136/jnnp.73.5.547; Al-Shahi R, 2001, BRAIN, V124, P1900, DOI 10.1093/brain/124.10.1900; ApSimon HT, 2002, STROKE, V33, P2794, DOI 10.1161/01.STR.0000043674.99741.9B; Barker FG, 2003, J NEUROSURG, V99, P254, DOI 10.3171/jns.2003.99.2.0254; BATJER H, 1986, NEUROSURGERY, V18, P29, DOI 10.1227/00006123-198601000-00006; Brown RD, 1996, J NEUROSURG, V85, P29, DOI 10.3171/jns.1996.85.1.0029; BROWN RD, 1990, J NEUROSURG, V73, P859, DOI 10.3171/jns.1990.73.6.0859; Brown RD, 1996, NEUROLOGY, V46, P949, DOI 10.1212/WNL.46.4.949; CRAWFORD PM, 1986, J NEUROL NEUROSUR PS, V49, P1, DOI 10.1136/jnnp.49.1.1; Fleetwood IG, 2002, LANCET, V359, P863, DOI 10.1016/S0140-6736(02)07946-1; Flickinger JC, 2002, RADIOTHER ONCOL, V63, P347, DOI 10.1016/S0167-8140(02)00103-2; FRIEDMAN WA, 1995, J NEUROSURG, V82, P180, DOI 10.3171/jns.1995.82.2.0180; GRAF CJ, 1983, J NEUROSURG, V58, P331, DOI 10.3171/jns.1983.58.3.0331; GROSS CR, 1984, STROKE, V15, P249, DOI 10.1161/01.STR.15.2.249; HAMILTON MG, 1994, NEUROSURGERY, V34, P2; Hartmann A, 1998, STROKE, V29, P931, DOI 10.1161/01.STR.29.5.931; Hartmann A, 2002, STROKE, V33, P1816, DOI 10.1161/01.STR.0000020123.80940.B2; HEISERMAN JE, 1994, AM J NEURORADIOL, V15, P1401; Heros R C, 1993, Clin Neurosurg, V40, P139; HORTON JC, 1990, NEUROSURGERY, V27, P867, DOI 10.1227/00006123-199012000-00002; KIKUCHI K, 1994, SURG NEUROL, V41, P374, DOI 10.1016/0090-3019(94)90030-2; LASJAUNIAS P, 1988, ACTA NEUROCHIR, V91, P29, DOI 10.1007/BF01400524; LAUFER L, 1994, PEDIATR RADIOL, V24, P272, DOI 10.1007/BF02015455; MANDYBUR TI, 1990, ARCH PATHOL LAB MED, V114, P970; Maruyama K, 2005, NEW ENGL J MED, V352, P146, DOI 10.1056/NEJMoa040907; Mast H, 1997, LANCET, V350, P1065, DOI 10.1016/S0140-6736(97)05390-7; McCormick W., 1984, INTRACRANIAL ARTERIO, P44, DOI 10.1016/S1042-3680(18)30174-8; McCormick WF., 1978, WKLY UPDATE NEUROL N, V14, P2; MONTEIRO JMP, 1993, HEADACHE, V33, P563, DOI 10.1111/j.1526-4610.1993.hed3310563.x; Ogilvy CS, 2001, STROKE, V32, P1458, DOI 10.1161/01.STR.32.6.1458; ONDRA SL, 1990, J NEUROSURG, V73, P387, DOI 10.3171/jns.1990.73.3.0387; PERRET G, 1966, J NEUROSURG, V25, P467, DOI 10.3171/jns.1966.25.4.0467; Pikus HJ, 1998, J NEUROSURG, V88, P641, DOI 10.3171/jns.1998.88.4.0641; PRITZ MB, 1994, ACTA NEUROCHIR, V131, P314, DOI 10.1007/BF01808635; PRITZ MB, 1994, ACTA NEUROCHIR, V128, P150, DOI 10.1007/BF01400666; Redekop G, 1998, J NEUROSURG, V89, P539, DOI 10.3171/jns.1998.89.4.0539; SADASIVAN B, 1990, SURG NEUROL, V33, P305, DOI 10.1016/0090-3019(90)90197-W; Sirin S, 2006, NEUROSURGERY, V58, P17, DOI 10.1227/01.NEU.0000190653.42970.6B; Soderman M, 2003, EUR J RADIOL, V46, P195, DOI 10.1016/S0720-048X(03)00091-3; SPETZLER RF, 1992, J NEUROSURG, V76, P918, DOI 10.3171/jns.1992.76.6.0918; SPETZLER RF, 1986, J NEUROSURG, V65, P476, DOI 10.3171/jns.1986.65.4.0476; Stapf C, 2006, NEUROLOGY, V66, P1350, DOI 10.1212/01.wnl.0000210524.68507.87; Stapf C, 2006, CURR OPIN NEUROL, V19, P63, DOI 10.1097/01.wco.0000200546.14668.78; Stapf C, 2003, STROKE, V34, pE29, DOI 10.1161/01.STR.0000068784.36838.19; Stefani MA, 2002, STROKE, V33, P1220, DOI 10.1161/01.STR.0000013738.53113.33; Stieg P, 2007, INTRACRANIAL ARTERIO; Taylor CL, 2004, J NEUROSURG, V100, P810, DOI 10.3171/jns.2004.100.5.0810; Trivedi R A, 2003, J Obstet Gynaecol, V23, P484; TURJMAN F, 1995, NEUROSURGERY, V37, P856, DOI 10.1227/00006123-199511000-00002; Weber W, 2007, AM J NEURORADIOL, V28, P371; WILKINS RH, 1985, NEUROSURGERY, V16, P421, DOI 10.1227/00006123-198503000-00026	51	216	224	1	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 28	2007	356	26					2704	2712		10.1056/NEJMcp067192	http://dx.doi.org/10.1056/NEJMcp067192			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	183HS	17596605				2022-12-28	WOS:000247564500008
J	Perrin, JM; Bloom, SR; Gortmaker, SL				Perrin, James M.; Bloom, Sheila R.; Gortmaker, Steven L.			The increase of childhood chronic conditions in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							YOUNG ADULTHOOD; CHILDREN; OBESITY; PREVALENCE; OVERWEIGHT; ASTHMA; ADOLESCENTS; DISABILITY; DISORDERS; TRENDS		MassGen Hosp Children, Ctr Child & Adolescent Hlth Policy, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Perrin, JM (corresponding author), MassGen Hosp Children, Ctr Child & Adolescent Hlth Policy, 50 Staniford St,Suite 901, Boston, MA 02114 USA.	jperrin@partners.org		Perrin, James/0000-0002-1810-3708	PHS HHS [U 53 MC 04473, U48/CCU115807] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Akinbami, 2006, STATE CHILDHOOD ASTH, V381; American Psychiatric Association, 1968, DIAGN STAT MAN MENT; Biederman J, 2005, LANCET, V366, P237, DOI 10.1016/S0140-6736(05)66915-2; Christakis DA, 2004, PEDIATRICS, V113, P708, DOI 10.1542/peds.113.4.708; Costello EJ, 2006, J CHILD PSYCHOL PSYC, V47, P1263, DOI 10.1111/j.1469-7610.2006.01682.x; Dietz WH, 2001, ANNU REV PUBL HEALTH, V22, P337, DOI 10.1146/annurev.publhealth.22.1.337; Fischer M, 2002, J ABNORM CHILD PSYCH, V30, P463, DOI 10.1023/A:1019864813776; Freedman DS, 1999, PEDIATRICS, V103, P1175, DOI 10.1542/peds.103.6.1175; Gold DR, 2005, ANNU REV PUBL HEALTH, V26, P89, DOI 10.1146/annurev.publhealth.26.021304.144528; GORTMAKER SL, 1993, NEW ENGL J MED, V329, P1008, DOI 10.1056/NEJM199309303291406; GORTMAKER SL, 1984, PEDIATR CLIN N AM, V31, P3; GREEN M, 1999, DIAGNOSIS ATTENTION, V3; Koplan J., 2005, PREVENTING CHILDHOOD; *NAT COMM CHILDH D, 1995, SUPPL SEC INC CHILDR; National Center for Health Statistics, 2006, HLTH US CHARTB TREND; NEWACHECK PW, 1984, AM J PUBLIC HEALTH, V74, P232, DOI 10.2105/AJPH.74.3.232; Newacheck PW, 2000, ARCH PEDIAT ADOL MED, V154, P287, DOI 10.1001/archpedi.154.3.287; Newacheck PW, 1998, PEDIATRICS, V102, P117, DOI 10.1542/peds.102.1.117; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; *SOC SEC ADM, 2005, CHILDR REC SSI; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; von Kries R, 2002, AM J EPIDEMIOL, V156, P954, DOI 10.1093/aje/kwf128; Whitaker RC, 1997, NEW ENGL J MED, V337, P869, DOI 10.1056/NEJM199709253371301; World Health Organization, INT CLASS FUNCT DIS	25	338	346	1	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 27	2007	297	24					2755	2759		10.1001/jama.297.24.2755	http://dx.doi.org/10.1001/jama.297.24.2755			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	182UE	17595277				2022-12-28	WOS:000247528700026
J	David, SS; O'Shea, VL; Kundu, S				David, Sheila S.; O'Shea, Valerie L.; Kundu, Sucharita			Base-excision repair of oxidative DNA damage	NATURE			English	Review							ONE-ELECTRON OXIDATION; GUANOSINE LESIONS SPIROIMINODIHYDANTOIN; ESCHERICHIA-COLI; COLORECTAL-CANCER; HYDANTOIN PRODUCTS; FUNCTIONAL-CHARACTERIZATION; INHERITED MUTATIONS; GLYCOSYLASES NEIL1; STRUCTURAL BASIS; MAJOR PRODUCT	Maintaining the chemical integrity of DNA in the face of assault by oxidizing agents is a constant challenge for living organisms. Base-excision repair has an important role in preventing mutations associated with a common product of oxidative damage to DNA, 8-oxoguanine. Recent structural studies have shown that 8-oxoguanine DNA glycosylases use an intricate series of steps to locate and excise 8-oxoguanine lesions efficiently against a high background of undamaged bases. The importance of preventing mutations associated with 8-oxoguanine is shown by a direct association between defects in the DNA glycosylase MUTYH and colorectal cancer. The properties of other guanine oxidation products and the associated DNA glycosylases that remove them are now also being revealed.	Univ Calif Davis, Dept Chem, 1 Shields Ave, Davis, CA 95616 USA; Univ Utah, Dept Chem, Salt Lake City, UT 84112 USA	University of California System; University of California Davis; Utah System of Higher Education; University of Utah	David, SS (corresponding author), Univ Calif Davis, Dept Chem, 1 Shields Ave, Davis, CA 95616 USA.	david@chem.ucdavis.edu	Kundu, Sucharita/AAC-6847-2020	Kundu, Sucharita/0000-0003-0970-5528	NCI NIH HHS [R01 CA067985-14, R01 CA067985, R01 CA090689-07, R01 CA090689, T32 CA093247, R01 CA090689-08, R01 CA067985-13] Funding Source: Medline; NIGMS NIH HHS [T32 GM008537] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067985, R01CA090689, T32CA093247] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008537] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam W, 2002, ORG LETT, V4, P537, DOI 10.1021/ol017138m; Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828; Alhopuro Pia, 2005, Hum Mutat, V26, P393, DOI 10.1002/humu.9368; Bai HB, 2007, CANCER LETT, V250, P74, DOI 10.1016/j.canlet.2006.09.016; Bai HB, 2005, NUCLEIC ACIDS RES, V33, P597, DOI 10.1093/nar/gki209; Bandaru V, 2002, DNA REPAIR, V1, P517, DOI 10.1016/S1568-7864(02)00036-8; Banerjee A, 2006, SCIENCE, V311, P1153, DOI 10.1126/science.1120288; Banerjee A, 2005, NATURE, V434, P612, DOI 10.1038/nature03458; Banerjee A, 2006, P NATL ACAD SCI USA, V103, P15020, DOI 10.1073/pnas.0603644103; Barnes DE, 2004, ANNU REV GENET, V38, P445, DOI 10.1146/annurev.genet.38.072902.092448; Bernards AS, 2002, J BIOL CHEM, V277, P20960, DOI 10.1074/jbc.C200181200; Blainey PC, 2006, P NATL ACAD SCI USA, V103, P5752, DOI 10.1073/pnas.0509723103; Bodmer WF, 2006, J HUM GENET, V51, P391, DOI 10.1007/s10038-006-0373-x; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; Burrows CJ, 1998, CHEM REV, V98, P1109, DOI 10.1021/cr960421s; Burrows CJ, 2002, ENVIRON HEALTH PERSP, V110, P713, DOI 10.1289/ehp.02110s5713; CADET J, 1983, ISRAEL J CHEM, V23, P420; Cheadle JP, 2007, DNA REPAIR, V6, P274, DOI 10.1016/j.dnarep.2006.11.001; Chmiel NH, 2003, J MOL BIOL, V327, P431, DOI 10.1016/S0022-2836(03)00124-4; Chmiel NH, 2001, NUCLEIC ACIDS RES, V29, P553, DOI 10.1093/nar/29.2.553; Chow E, 2004, LANCET ONCOL, V5, P600, DOI 10.1016/S1470-2045(04)01595-5; Das A, 2005, J BIOL CHEM, V280, P35272, DOI 10.1074/jbc.M505526200; David SS, 1998, CHEM REV, V98, P1221, DOI 10.1021/cr980321h; Delaney S, 2007, BIOCHEMISTRY-US, V46, P1448, DOI 10.1021/bi061174h; Dou H, 2003, J BIOL CHEM, V278, P49679, DOI 10.1074/jbc.M308658200; Doublie S, 2004, P NATL ACAD SCI USA, V101, P10284, DOI 10.1073/pnas.0402051101; Farrington SM, 2005, AM J HUM GENET, V77, P112, DOI 10.1086/431213; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Fleischmann C, 2004, INT J CANCER, V109, P554, DOI 10.1002/ijc.20020; Friedberg EC, 2003, NATURE, V421, P436, DOI 10.1038/nature01408; Friedberg EC, 2004, DNA REPAIR, V3, P1531, DOI 10.1016/j.dnarep.2004.05.014; Fromme JC, 2004, ADV PROTEIN CHEM, V69, P1; Fromme JC, 2004, CURR OPIN STRUC BIOL, V14, P43, DOI 10.1016/j.sbi.2004.01.003; Fromme JC, 2004, NATURE, V427, P652, DOI 10.1038/nature02306; Fromme JC, 2003, J BIOL CHEM, V278, P51543, DOI 10.1074/jbc.M307768200; Gedik CM, 2005, FASEB J, V19, P82, DOI 10.1096/fj.04-1767fje; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; Hailer MK, 2005, CHEM RES TOXICOL, V18, P1378, DOI 10.1021/tx0501379; Hailer MK, 2005, DNA REPAIR, V4, P41, DOI 10.1016/j.dnarep.2004.07.006; Hazra TK, 2002, J BIOL CHEM, V277, P30417, DOI 10.1074/jbc.C200355200; Hazra TK, 2002, P NATL ACAD SCI USA, V99, P3523, DOI 10.1073/pnas.062053799; Hazra TK, 2001, NUCLEIC ACIDS RES, V29, P1967, DOI 10.1093/nar/29.9.1967; Henderson PT, 2003, BIOCHEMISTRY-US, V42, P9257, DOI 10.1021/bi0347252; Hirano S, 2003, J BIOL CHEM, V278, P38121, DOI 10.1074/jbc.C300316200; Hitomi K, 2007, DNA REPAIR, V6, P410, DOI 10.1016/j.dnarep.2006.10.004; Hsu GW, 2004, NATURE, V431, P217, DOI 10.1038/nature02908; Huffman JL, 2005, MUTAT RES-FUND MOL M, V577, P55, DOI 10.1016/j.mrfmmm.2005.03.012; Jo WS, 2005, SEMIN ONCOL, V32, P11, DOI 10.1053/j.seminoncol.2004.09.034; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Klaunig JE, 2004, ANNU REV PHARMACOL, V44, P239, DOI 10.1146/annurev.pharmtox.44.101802.121851; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Kornyushyna O, 2003, BIOCHEMISTRY-US, V42, P13008, DOI 10.1021/bi0350755; Kornyushyna O, 2002, BIOCHEMISTRY-US, V41, P15304, DOI 10.1021/bi0264925; Krahn JM, 2003, STRUCTURE, V11, P121, DOI 10.1016/S0969-2126(02)00930-9; Leipold MD, 2003, BIOCHEMISTRY-US, V42, P11373, DOI 10.1021/bi034951b; Leipold MD, 2000, BIOCHEMISTRY-US, V39, P14984, DOI 10.1021/bi0017982; Leite JS, 2005, COLORECTAL DIS, V7, P327, DOI 10.1111/j.1463-1318.2005.00811.x; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Lindor NM, 2006, JAMA-J AM MED ASSOC, V296, P1507, DOI 10.1001/jama.296.12.1507; Lipton L, 2003, CANCER RES, V63, P7595; Lipton L, 2006, FAM CANCER, V5, P221, DOI 10.1007/s10689-005-5673-3; Lipton L, 2004, CLIN GASTROENTEROL H, V2, P633, DOI 10.1016/S1542-3565(04)00286-1; Livingston AL, 2005, BIOCHEMISTRY-US, V44, P14179, DOI 10.1021/bi050976u; Lukianova OA, 2005, CURR OPIN CHEM BIOL, V9, P145, DOI 10.1016/j.cbpa.2005.02.006; Luo WC, 2001, CHEM RES TOXICOL, V14, P927, DOI 10.1021/tx010072j; Luo WC, 2000, ORG LETT, V2, P613, DOI 10.1021/ol9913643; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Morland I, 2002, NUCLEIC ACIDS RES, V30, P4926, DOI 10.1093/nar/gkf618; Neeley WL, 2006, CHEM RES TOXICOL, V19, P491, DOI 10.1021/tx0600043; Niles JC, 2001, ORG LETT, V3, P963, DOI 10.1021/ol006993n; Noll DM, 1999, BIOCHEMISTRY-US, V38, P6374, DOI 10.1021/bi990335x; Osterod M, 2002, ONCOGENE, V21, P8232, DOI 10.1038/sj.onc.1206027; Osterod M, 2001, CARCINOGENESIS, V22, P1459, DOI 10.1093/carcin/22.9.1459; Parikh SS, 2000, MUTAT RES-DNA REPAIR, V460, P183, DOI 10.1016/S0921-8777(00)00026-4; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; Pope MA, 2005, DNA REPAIR, V4, P315, DOI 10.1016/j.dnarep.2004.10.003; Radom CT, 2007, J BIOL CHEM, V282, P9182, DOI 10.1074/jbc.M608989200; RAVANAT JL, 1995, CHEM RES TOXICOL, V8, P379, DOI 10.1021/tx00045a009; RAVANAT JL, 1992, PHOTOCHEM PHOTOBIOL, V55, P809, DOI 10.1111/j.1751-1097.1992.tb08528.x; Rosenquist TA, 2003, DNA REPAIR, V2, P581, DOI 10.1016/S1568-7864(03)00025-9; Russo MT, 2004, CANCER RES, V64, P4411, DOI 10.1158/0008-5472.CAN-04-0355; Sampson JR, 2005, BIOCHEM SOC T, V33, P679, DOI 10.1042/BST0330679; Sampson JR, 2003, LANCET, V362, P39, DOI 10.1016/S0140-6736(03)13805-6; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Shinmura K, 2004, CARCINOGENESIS, V25, P2311, DOI 10.1093/carcin/bgh267; Sieber OM, 2004, CANCER RES, V64, P8876, DOI 10.1158/0008-5472.CAN-04-2958; Soreide K, 2006, BRIT J SURG, V93, P395, DOI 10.1002/bjs.5328; Stivers JT, 2004, PROG NUCLEIC ACID RE, V77, P37, DOI 10.1016/S0079-6603(04)77002-6; Strate LL, 2005, CANCER CAUSE CONTROL, V16, P201, DOI 10.1007/s10552-004-3488-4; Sunesen M, 2002, ONCOGENE, V21, P3571, DOI 10.1038/sj.onc.1205443; Sung JS, 2006, FEBS J, V273, P1620, DOI 10.1111/j.1742-4658.2006.05192.x; Tenesa A, 2006, BRIT J CANCER, V95, P239, DOI 10.1038/sj.bjc.6603239; Tominaga Y, 2004, NUCLEIC ACIDS RES, V32, P3198, DOI 10.1093/nar/gkh642; Vartanian V, 2006, P NATL ACAD SCI USA, V103, P1864, DOI 10.1073/pnas.0507444103; Venesio T, 2004, GASTROENTEROLOGY, V126, P1681, DOI 10.1053/j.gastro.2004.02.022; Wallace SS, 2003, DNA REPAIR, V2, P441, DOI 10.1016/S1568-7864(02)00182-9; Wiederholt CJ, 2003, BIOCHEMISTRY-US, V42, P9755, DOI 10.1021/bi034844h; Wooden SH, 2004, CANCER LETT, V205, P89, DOI 10.1016/j.canlet.2003.10.006; Xie YL, 2004, CANCER RES, V64, P3096, DOI 10.1158/0008-5472.CAN-03-3834; Yu LJ, 2004, BIOCHEMISTRY-US, V43, P15429, DOI 10.1021/bi0483864	100	849	868	9	203	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 21	2007	447	7147					941	950		10.1038/nature05978	http://dx.doi.org/10.1038/nature05978			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180NU	17581577	Green Accepted			2022-12-28	WOS:000247373100036
J	Mann, DL				Mann, Douglas L.			MicroRNAs and the failing heart	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							FAILURE		Baylor Coll Med, Winters Ctr Heart Failure Res, Houston, TX 77030 USA; St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX USA	Baylor College of Medicine; Saint Lukes Episcopal Hospital; Texas Heart Institute	Mann, DL (corresponding author), Baylor Coll Med, Winters Ctr Heart Failure Res, Houston, TX 77030 USA.		Mann, Douglas Lowell/AAQ-3524-2021	Mann, Douglas/0000-0002-2516-0145				JACKSON RJ, 2007, SCI STKE, V367, pRE1, DOI DOI 10.1126/STKE.3672007RE1; Mann DL, 2005, CIRCULATION, V111, P2837, DOI 10.1161/CIRCULATIONAHA.104.500546; MANN DL, 2005, CIRCULATION, V112, pE75; van Rooij E, 2007, SCIENCE, V316, P575, DOI 10.1126/science.1139089; van Rooij E, 2006, P NATL ACAD SCI USA, V103, P18255, DOI 10.1073/pnas.0608791103	5	42	46	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 21	2007	356	25					2644	2645		10.1056/NEJMcibr072068	http://dx.doi.org/10.1056/NEJMcibr072068			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180GN	17582077				2022-12-28	WOS:000247351200014
J	Mirkin, SM				Mirkin, Sergei M.			Expandable DNA repeats and human disease	NATURE			English	Review							FRAGILE-X-SYNDROME; FMR1 MESSENGER-RNA; DOT-CAG REPEATS; MYOTONIC-DYSTROPHY; TRINUCLEOTIDE REPEATS; CTG REPEAT; SACCHAROMYCES-CEREVISIAE; FRIEDREICHS-ATAXIA; IN-VIVO; SOMATIC INSTABILITY	Nearly 30 hereditary disorders in humans result from an increase in the number of copies of simple repeats in genomic DNA. These DNA repeats seem to be predisposed to such expansion because they have unusual structural features, which disrupt the cellular replication, repair and recombination machineries. The presence of expanded DNA repeats alters gene expression in human cells, leading to disease. Surprisingly, many of these debilitating diseases are caused by repeat expansions in the non-coding regions of their resident genes. It is becoming clear that the peculiar structures of repeat-containing transcripts are at the heart of the pathogenesis of these diseases.	Tufts Univ, Dept Biol, Medford, MA 02155 USA	Tufts University	Mirkin, SM (corresponding author), Tufts Univ, Dept Biol, Medford, MA 02155 USA.	sergei.mirkin@tufts.edu	Mirkin, Sergei/AAR-7226-2020; Mirkin, Sergei/A-7310-2010	Mirkin, Sergei/0000-0003-4576-7582; 				Abu-Baker A, 2006, GENETIC INSTABILITIE, P487; Amack JD, 2001, HUM MOL GENET, V10, P1879, DOI 10.1093/hmg/10.18.1879; ANVRET M, 1993, HUM MOL GENET, V2, P1397, DOI 10.1093/hmg/2.9.1397; Bacolla A, 2006, DNA REPAIR, V5, P1161, DOI 10.1016/j.dnarep.2006.05.032; Bhattacharyya S, 2004, MOL CELL BIOL, V24, P7324, DOI 10.1128/MCB.24.17.7324-7330.2004; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; Brown LY, 2004, TRENDS GENET, V20, P51, DOI 10.1016/j.tig.2003.11.002; Cho DH, 2005, MOL CELL, V20, P483, DOI 10.1016/j.molcel.2005.09.002; Cleary JD, 2005, TRENDS GENET, V21, P272, DOI 10.1016/j.tig.2005.03.008; Cleary JD, 2002, NAT GENET, V31, P37, DOI 10.1038/ng870; Daee DL, 2007, MOL CELL BIOL, V27, P102, DOI 10.1128/MCB.01167-06; Davis BM, 1997, P NATL ACAD SCI USA, V94, P7388, DOI 10.1073/pnas.94.14.7388; Dere R, 2004, J BIOL CHEM, V279, P41715, DOI 10.1074/jbc.M406415200; Dere R, 2006, J MOL BIOL, V360, P21, DOI 10.1016/j.jmb.2006.05.012; Fardaei M, 2002, HUM MOL GENET, V11, P805, DOI 10.1093/hmg/11.7.805; Fleiseher B., 1918, ALBRECHT GRAEFES ARC, V96, P91, DOI DOI 10.1007/BF02018704; Fortune MT, 2000, HUM MOL GENET, V9, P439, DOI 10.1093/hmg/9.3.439; Fouche N, 2006, NUCLEIC ACIDS RES, V34, P6044, DOI 10.1093/nar/gkl757; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; Gacy AM, 1998, MOL CELL, V1, P583, DOI 10.1016/S1097-2765(00)80058-1; GACY AM, 1995, CELL, V81, P533; Gray SJ, 2007, MOL CELL BIOL, V27, P426, DOI 10.1128/MCB.01382-06; Handa V, 2005, J BIOL CHEM, V280, P29340, DOI 10.1074/jbc.M503495200; Handa V, 2003, NUCLEIC ACIDS RES, V31, P6243, DOI 10.1093/nar/gkg818; Henricksen LA, 2000, J BIOL CHEM, V275, P16420, DOI 10.1074/jbc.M909635199; Ho TH, 2004, EMBO J, V23, P3103, DOI 10.1038/sj.emboj.7600300; Iwahashi CK, 2006, BRAIN, V129, P256, DOI 10.1093/brain/awh650; Jakupciak JP, 1999, J BIOL CHEM, V274, P23468, DOI 10.1074/jbc.274.33.23468; Jin P, 2003, NEURON, V39, P739, DOI 10.1016/S0896-6273(03)00533-6; JODICE C, 1994, AM J HUM GENET, V54, P959; Kanadia RN, 2006, P NATL ACAD SCI USA, V103, P11748, DOI 10.1073/pnas.0604970103; Kanadia RN, 2003, SCIENCE, V302, P1978, DOI 10.1126/science.1088583; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; Kennedy L, 2003, HUM MOL GENET, V12, P3359, DOI 10.1093/hmg/ddg352; Kino Y, 2004, HUM MOL GENET, V13, P495, DOI 10.1093/hmg/ddh056; Kovtun IV, 2007, NATURE, V447, P447, DOI 10.1038/nature05778; Kovtun IV, 2001, NAT GENET, V27, P407, DOI 10.1038/86906; Krasilnikova MM, 2004, MOL CELL BIOL, V24, P2286, DOI 10.1128/MCB.24.6.2286-2295.2004; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; Krol J, 2007, MOL CELL, V25, P575, DOI 10.1016/j.molcel.2007.01.031; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1; LA SA, 1991, NATURE, V352, P77; Lia AS, 1998, HUM MOL GENET, V7, P1285, DOI 10.1093/hmg/7.8.1285; Lin X, 2005, CEREBELLUM, V4, P37, DOI 10.1080/14734220510007897; Liu Y, 2004, MOL CELL BIOL, V24, P4049, DOI 10.1128/MCB.24.9.4049-4064.2004; Lu XH, 1999, HUM MOL GENET, V8, P53, DOI 10.1093/hmg/8.1.53; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; Malinina L, 2005, J BIOMOL STRUCT DYN, V23, P233, DOI 10.1080/07391102.2005.10531230; Mankodi A, 2000, SCIENCE, V289, P1769, DOI 10.1126/science.289.5485.1769; Manley K, 1999, NAT GENET, V23, P471, DOI 10.1038/70598; McMurray CT, 1999, P NATL ACAD SCI USA, V96, P1823, DOI 10.1073/pnas.96.5.1823; Meservy JL, 2003, MOL CELL BIOL, V23, P3152, DOI 10.1128/MCB.23.9.3152-3162.2003; Miller JW, 2000, EMBO J, V19, P4439, DOI 10.1093/emboj/19.17.4439; Miret JJ, 1998, P NATL ACAD SCI USA, V95, P12438, DOI 10.1073/pnas.95.21.12438; Mirkin S. M, 2004, CHEMTRACTS BIOCH MOL, V17, P639; Mirkin SM, 2006, CURR OPIN STRUC BIOL, V16, P351, DOI 10.1016/j.sbi.2006.05.004; Mirkin SM, 2002, NAT GENET, V31, P5, DOI 10.1038/ng0502-5; Moore H, 1999, P NATL ACAD SCI USA, V96, P1504, DOI 10.1073/pnas.96.4.1504; Moseley ML, 2006, NAT GENET, V38, P758, DOI 10.1038/ng1827; Mutsuddi M, 2004, CURR BIOL, V14, P302, DOI 10.1016/j.cub.2004.01.034; Nag DK, 2004, NUCLEIC ACIDS RES, V32, P5677, DOI 10.1093/nar/gkh901; Napierala M, 1997, J BIOL CHEM, V272, P31079, DOI 10.1074/jbc.272.49.31079; Napierala M, 2005, NUCLEIC ACIDS RES, V33, P451, DOI 10.1093/nar/gki186; Napierala M, 2004, J BIOL CHEM, V279, P6444, DOI 10.1074/jbc.M309596200; Ohshima K, 1997, J BIOL CHEM, V272, P16798, DOI 10.1074/jbc.272.27.16798; Owen BAL, 2005, NAT STRUCT MOL BIOL, V12, P663, DOI 10.1038/nsmb965; Panigrahi GB, 2005, NAT STRUCT MOL BIOL, V12, P654, DOI 10.1038/nsmb959; Pearson CE, 2002, NUCLEIC ACIDS RES, V30, P4534, DOI 10.1093/nar/gkf572; Pearson CE, 1996, BIOCHEMISTRY-US, V35, P5041, DOI 10.1021/bi9601013; Pearson CE, 2005, NAT REV GENET, V6, P729, DOI 10.1038/nrg1689; Pelletier R, 2003, MOL CELL BIOL, V23, P1349, DOI 10.1128/MCB.23.4.1349-1357.2003; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Potaman VN, 2003, J MOL BIOL, V326, P1095, DOI 10.1016/S0022-2836(03)00037-8; Ranum LPW, 2006, ANNU REV NEUROSCI, V29, P259, DOI 10.1146/annurev.neuro.29.051605.113014; Richard GF, 2000, EMBO J, V19, P2381, DOI 10.1093/emboj/19.10.2381; Richard GF, 2003, J MOL BIOL, V326, P769, DOI 10.1016/S0022-2836(02)01405-5; RICHARDS RI, 1992, NAT GENET, V1, P257, DOI 10.1038/ng0792-257; Rindler PM, 2006, NUCLEIC ACIDS RES, V34, P6352, DOI 10.1093/nar/gkl846; Rolfsmeier ML, 2000, MOL CELL, V6, P1501, DOI 10.1016/S1097-2765(00)00146-5; Sakamoto N, 1999, MOL CELL, V3, P465, DOI 10.1016/S1097-2765(00)80474-8; Sakamoto N, 2001, J BIOL CHEM, V276, P27178, DOI 10.1074/jbc.M101852200; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Savouret C, 2003, EMBO J, V22, P2264, DOI 10.1093/emboj/cdg202; Savouret C, 2004, MOL CELL BIOL, V24, P629, DOI 10.1128/MCB.24.2.629-637.2004; SHERMAN SL, 1985, HUM GENET, V69, P289, DOI 10.1007/BF00291644; Sobczak K, 2003, NUCLEIC ACIDS RES, V31, P5469, DOI 10.1093/nar/gkg766; Spiro C, 1999, MOL CELL, V4, P1079, DOI 10.1016/S1097-2765(00)80236-1; Tassone F, 2000, AM J HUM GENET, V66, P6, DOI 10.1086/302720; THORNTON CA, 2006, GENETIC INSTABILITIE, P37; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; van den Broek WJAA, 2006, FEBS LETT, V580, P5208, DOI 10.1016/j.febslet.2006.08.059; van den Broek WJAA, 2002, HUM MOL GENET, V11, P191, DOI 10.1093/hmg/11.2.191; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; Vetcher AA, 2002, J BIOL CHEM, V277, P39217, DOI 10.1074/jbc.M205209200; Warren ST, 1997, SCIENCE, V275, P408, DOI 10.1126/science.275.5298.408; Wells RD, 2005, NUCLEIC ACIDS RES, V33, P3785, DOI 10.1093/nar/gki697; Yoon SR, 2003, P NATL ACAD SCI USA, V100, P8834, DOI 10.1073/pnas.1331390100	100	644	657	0	86	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 21	2007	447	7147					932	940		10.1038/nature05977	http://dx.doi.org/10.1038/nature05977			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180NU	17581576				2022-12-28	WOS:000247373100035
J	North, TE; Goessling, W; Walkley, CR; Lengerke, C; Kopani, KR; Lord, AM; Weber, GJ; Bowman, TV; Jang, IH; Grosser, T; FitzGerald, GA; Daley, GQ; Orkin, SH; Zon, LI				North, Trista E.; Goessling, Wolfram; Walkley, Carl R.; Lengerke, Claudia; Kopani, Kamden R.; Lord, Allegra M.; Weber, Gerhard J.; Bowman, Teresa V.; Jang, Il-Ho; Grosser, Tilo; FitzGerald, Garret A.; Daley, George Q.; Orkin, Stuart H.; Zon, Leonard I.			Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis	NATURE			English	Article							ZEBRAFISH; EXPRESSION; MICE; CYCLOOXYGENASE-2; TRANSPLANTATION; EMBRYO; BLOOD; STAT5; RUNX1	Haematopoietic stem cell (HSC) homeostasis is tightly controlled by growth factors, signalling molecules and transcription factors. Definitive HSCs derived during embryogenesis in the aorta gonad - mesonephros region subsequently colonize fetal and adult haematopoietic organs(1,2). To identify new modulators of HSC formation and homeostasis, a panel of biologically active compounds was screened for effects on stem cell induction in the zebrafish aorta - gonad - mesonephros region. Here, we show that chemicals that enhance prostaglandin ( PG) E2 synthesis increased HSC numbers, and those that block prostaglandin synthesis decreased stem cell numbers. The cyclooxygenases responsible for PGE2 synthesis were required for HSC formation. A stable derivative of PGE2 improved kidney marrow recovery following irradiation injury in the adult zebrafish. In murine embryonic stem cell differentiation assays, PGE2 caused amplification of multipotent progenitors. Furthermore, ex vivo exposure to stabilized PGE2 enhanced spleen colony forming units at day 12 post transplant and increased the frequency of long-term repopulating HSCs present in murine bone marrow after limiting dilution competitive transplantation. The conserved role for PGE2 in the regulation of vertebrate HSC homeostasis indicates that modulation of the prostaglandin pathway may facilitate expansion of HSC number for therapeutic purposes.	Harvard Univ, Sch Med, Childrens Hosp, Div Hematol Oncol,Harvard Stem Cell Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Stem Cell Program, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Univ Penn, Sch Med, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; University of Pennsylvania; Pennsylvania Medicine	Zon, LI (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Div Hematol Oncol,Harvard Stem Cell Inst, Boston, MA 02115 USA.	zon@enders.tch.harvard.edu	FitzGerald, Garret A/A-4222-2010; Walkley, Carl/AAO-6021-2020; Grosser, Tilo/A-1057-2007; North, Trista/ABG-4789-2020; Lengerke, Claudia/AAV-8745-2021	Walkley, Carl/0000-0002-4784-9031; Grosser, Tilo/0000-0001-8569-8396; North, Trista/0000-0003-1249-563X; Lengerke, Claudia/0000-0001-5442-2805; Goessling, Wolfram/0000-0001-9972-1569; Jang, Il Ho/0000-0002-0820-3035	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048801] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL048801-16, R01 HL048801] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akashi K, 2003, BLOOD, V101, P383, DOI 10.1182/blood-2002-06-1780; Boer AK, 2002, BLOOD, V100, P467, DOI 10.1182/blood.V100.2.467; Burns CE, 2005, GENE DEV, V19, P2331, DOI 10.1101/gad.1337005; CAYEUX SJ, 1993, BONE MARROW TRANSPL, V12, P603; Cha YI, 2006, GENE DEV, V20, P77, DOI 10.1101/gad.1374506; Cha YI, 2005, DEV BIOL, V282, P274, DOI 10.1016/j.ydbio.2005.03.014; Dzierzak E, 2005, CURR OPIN HEMATOL, V12, P197, DOI 10.1097/01.moh.0000160736.44726.0e; FEHER I, 1974, NATURE, V247, P550, DOI 10.1038/247550a0; Galloway JL, 2003, CURR TOP DEV BIOL, V53, P139, DOI 10.1016/S0070-2153(03)53004-6; Grosser T, 2002, P NATL ACAD SCI USA, V99, P8418, DOI 10.1073/pnas.112217799; HERTELENDY F, 1973, PROSTAG OTH LIPID M, V3, P223, DOI 10.1016/0090-6980(73)90090-7; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Kalev-Zylinska ML, 2002, DEVELOPMENT, V129, P2015; Kyba M, 2003, P NATL ACAD SCI USA, V100, P11904, DOI 10.1073/pnas.1734140100; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Langenbach R, 1999, BIOCHEM PHARMACOL, V58, P1237, DOI 10.1016/S0006-2952(99)00158-6; Lorenz M, 1999, EXP HEMATOL, V27, P1494, DOI 10.1016/S0301-472X(99)00087-9; Mukouyama YS, 1999, CURR BIOL, V9, P833, DOI 10.1016/S0960-9822(99)80368-6; Nakano T, 1996, SCIENCE, V272, P722, DOI 10.1126/science.272.5262.722; North TE, 2002, IMMUNITY, V16, P661, DOI 10.1016/S1074-7613(02)00296-0; Pini B, 2005, ARTERIOSCL THROM VAS, V25, P315, DOI 10.1161/01.ATV.0000152355.97808.10; Rocca B, 2002, P NATL ACAD SCI USA, V99, P7634, DOI 10.1073/pnas.112202999; Talosi G, 2004, J PERINAT MED, V32, P368, DOI 10.1515/JPM.2004.069; THANOPOULOS BD, 1987, EUR J PEDIATR, V146, P279, DOI 10.1007/BF00716473; Traver D, 2004, BLOOD, V104, P1298, DOI 10.1182/blood-2004-01-0100; Venezia TA, 2004, PLOS BIOL, V2, P1640, DOI 10.1371/journal.pbio.0020301; Wang Y, 2005, P NATL ACAD SCI USA, V102, P19081, DOI 10.1073/pnas.0506127102; Weber GJ, 2005, BLOOD, V106, P521, DOI 10.1182/blood-2004-11-4541; Zhang CC, 2004, BLOOD, V103, P2513, DOI 10.1182/blood-2003-08-2955; Zhu H, 2005, DEV BIOL, V281, P256, DOI 10.1016/j.ydbio.2005.01.034	30	846	912	3	97	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 21	2007	447	7147					1007	U7		10.1038/nature05883	http://dx.doi.org/10.1038/nature05883			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180NU	17581586	Green Accepted			2022-12-28	WOS:000247373100048
J	Yool, A; Martin, AP; Fernandez, C; Clark, DR				Yool, Andrew; Martin, Adrian P.; Fernandez, Camila; Clark, Darren R.			The significance of nitrification for oceanic new production	NATURE			English	Article							MARINE NITRIFYING BACTERIA; ORGANIC NITROGEN; NITRATE; NITRITE; RATES; PHOTOINHIBITION; AMMONIUM; PACIFIC; CARBON; CYCLE	The flux of organic material sinking to depth is a major control on the inventory of carbon in the ocean(1). To first order, the oceanic system is at equilibrium such that what goes down must come up(2). Because the export flux is difficult to measure directly, it is routinely estimated indirectly by quantifying the amount of phytoplankton growth, or primary production, fuelled by the upward flux of nitrate(3). To do so it is necessary to take into account other sources of biologically available nitrogen. However, the generation of nitrate by nitrification in surface waters has only recently received attention. Here we perform the first synthesis of open-ocean measurements of the specific rate of surface nitrification(4-12) and use these to configure a global biogeochemical model(13,14) to quantify the global role of nitrification. We show that for much of the world ocean a substantial fraction of the nitrate taken up is generated through recent nitrification near the surface. At the global scale, nitrification accounts for about half of the nitrate consumed by growing phytoplankton. A consequence is that many previous attempts to quantify marine carbon export, particularly those based on inappropriate use of the f-ratio ( a measure of the efficiency of the 'biological pump'), are significant overestimates.	Natl Oceanog Ctr, Southampton SO14 3ZH, Hants, England; Ctr Oceanol Marseille, Lab Oceanog & Biogeochim, F-13288 Marseille, France; Univ Concepcion, Dept Oceanog, Lab Proc Oceanog & Clima, Concepcion, Chile; Univ Concepcion, Ctr Invest Oceanog Pacifico Sur Oriental, Concepcion, Chile; Plymouth Marine Lab, Plymouth PL1 3DH, Devon, England	NERC National Oceanography Centre; Universidad de Concepcion; Universidad de Concepcion; Plymouth Marine Laboratory	Yool, A (corresponding author), Natl Oceanog Ctr, European Way, Southampton SO14 3ZH, Hants, England.	axy@noc.soton.ac.uk	Yool, Andrew/B-4799-2012; Fernandez, Camila/F-6938-2010	Yool, Andrew/0000-0002-9879-2776; /0000-0002-8492-5881	Natural Environment Research Council [NER/O/S/2001/00680, soc010008, NE/C00387X/1, pml010001, pml010002] Funding Source: researchfish; NERC [pml010001, pml010002, soc010008] Funding Source: UKRI	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Allen AE, 2002, J MARINE SYST, V38, P93, DOI 10.1016/S0924-7963(02)00171-9; Armstrong RA, 2001, DEEP-SEA RES PT II, V49, P219, DOI 10.1016/S0967-0645(01)00101-1; Bianchi M, 1997, DEEP-SEA RES PT II, V44, P1017, DOI 10.1016/S0967-0645(96)00109-9; Clark DR, 2007, MAR CHEM, V103, P84, DOI 10.1016/j.marchem.2006.06.005; Cox PM, 2000, NATURE, V408, P184, DOI 10.1038/35041539; Diaz F, 2000, MAR ECOL PROG SER, V197, P51, DOI 10.3354/meps197051; Dore JE, 1996, LIMNOL OCEANOGR, V41, P1619, DOI 10.4319/lo.1996.41.8.1619; DUGDALE RC, 1967, LIMNOL OCEANOGR, V12, P196, DOI 10.4319/lo.1967.12.2.0196; EPPLEY RW, 1979, NATURE, V282, P677, DOI 10.1038/282677a0; Fernandez C, 2005, J GEOPHYS RES-OCEANS, V110, DOI 10.1029/2004JC002616; FERNANDEZ C, 2003, THESIS U MEDITERRANE; Field CB, 1998, SCIENCE, V281, P237, DOI 10.1126/science.281.5374.237; Guerrero MA, 1996, MAR ECOL PROG SER, V141, P183, DOI 10.3354/meps141183; Key RM, 2004, GLOBAL BIOGEOCHEM CY, V18, DOI 10.1029/2004GB002247; Lipschultz F, 2001, DEEP-SEA RES PT II, V48, P1897, DOI 10.1016/S0967-0645(00)00168-5; Marsh R, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL022281; Martin AP, 2006, GLOBAL BIOGEOCHEM CY, V20, DOI 10.1029/2005GB002608; MIYAZAKI T, 1975, MAR SCI COMMUN, V1, P381; OLSON RJ, 1981, J MAR RES, V39, P203; OLSON RJ, 1981, J MAR RES, V39, P227; Orr JC, 2005, NATURE, V437, P681, DOI 10.1038/nature04095; Oschlies A, 2001, GEOPHYS RES LETT, V28, P1751, DOI 10.1029/2000GL012328; Raimbault P, 1999, J GEOPHYS RES-OCEANS, V104, P3341, DOI 10.1029/1998JC900004; Raven JA, 1999, PLANT CELL ENVIRON, V22, P741, DOI 10.1046/j.1365-3040.1999.00419.x; SLAWYK G, 1995, MAR ECOL PROG SER, V124, P289, DOI 10.3354/meps124289; Sutka RL, 2004, GEOCHIM COSMOCHIM AC, V68, P517, DOI 10.1016/S0016-7037(03)00483-6; Takahashi T, 2002, DEEP-SEA RES PT II, V49, P1601, DOI 10.1016/S0967-0645(02)00003-6; WARD BB, 1989, LIMNOL OCEANOGR, V34, P493, DOI 10.4319/lo.1989.34.3.0493; Ward BB, 2005, MAR ECOL PROG SER, V292, P97, DOI 10.3354/meps292097; Wuchter C, 2006, P NATL ACAD SCI USA, V103, P12317, DOI 10.1073/pnas.0600756103	30	293	301	3	152	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 21	2007	447	7147					999	1002		10.1038/nature05885	http://dx.doi.org/10.1038/nature05885			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180NU	17581584				2022-12-28	WOS:000247373100046
J	Goodman, SN				Goodman, Steven N.			Stopping at nothing? Some dilemmas of data monitoring in clinical trials	ANNALS OF INTERNAL MEDICINE			English	Article							MULTIPLE END-POINTS; RANDOMIZED-TRIALS; INTERIM ANALYSES; SAFETY; ISSUES; STATISTICS; BENEFIT	This commentary reviews the argument that clinical trials with data monitoring committees that use statistical stopping guidelines should generally not be stopped early for large observed efficacy differences because efficacy estimates may be exaggerated and there is minimal information on treatment harms. Overall, the average of estimates from trials that use these boundaries differs minimally from the true value. Estimates from a given trial that seem implausibly high can be moderated by using Bayesian methods. Data monitoring committees are not ethically required to precisely estimate a large efficacy difference if that difference differs convincingly from zero, and the requirement to detect harms and balance efficacy against harm depends on whether the nature of the harm is known or unknown before the trial.	Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Goodman, SN (corresponding author), Johns Hopkins Univ, Sch Med, 550 N Broadway,Suite 1103, Baltimore, MD 21205 USA.	sgoodman@jhmi.edu		Goodman, Steven/0000-0002-3872-5723				ARMITAGE P, 1993, STAT MED, V12, P1395; Ashby D, 2005, CLIN TRIALS, V2, P197, DOI 10.1191/1740774505cn088oa; Ashby D, 2005, CLIN TRIALS, V2, P208; BATHER JA, 1985, INT STAT REV, V53, P1, DOI 10.2307/1402870; BERRY DA, 1993, STAT MED, V12, P1377, DOI 10.1002/sim.4780121504; Carlin C, 1996, BAYES EMPIRICAL BAYE; CHANG MN, 1989, STAT MED, V8, P563, DOI 10.1002/sim.4780080505; Ellenberg SS, 2003, DATA MONITORING COMM; EMERSON SS, 1990, BIOMETRIKA, V77, P875, DOI 10.2307/2337110; ENAS GG, 1995, STAT MED, V14, P1099, DOI 10.1002/sim.4780140930; Fan Xiaoyin Frank, 2004, J Biopharm Stat, V14, P505, DOI 10.1081/BIP-120037195; FLEMING TR, 1993, CONTROL CLIN TRIALS, V14, P183, DOI 10.1016/0197-2456(93)90002-U; Freedman L, 1996, CONTROL CLIN TRIALS, V17, P509, DOI 10.1016/S0197-2456(96)00016-5; Furberg, 2005, DATA MONITORING CLIN; Gong JJ, 2000, CONTROL CLIN TRIALS, V21, P313, DOI 10.1016/S0197-2456(00)00049-0; Goodman SN, 1999, ANN INTERN MED, V130, P995, DOI 10.7326/0003-4819-130-12-199906150-00008; Grant AM, 2005, HEALTH TECHNOL ASSES, V9, P1; Greenberg DS, 2001, LANCET, V358, P393, DOI 10.1016/S0140-6736(01)05596-9; Greenland S, 2006, INT J EPIDEMIOL, V35, P765, DOI 10.1093/ije/dyi312; HELLMAN S, 1991, NEW ENGL J MED, V324, P1585, DOI 10.1056/NEJM199105303242208; Ioannidis JPA, 2006, ANN INTERN MED, V144, P298, DOI 10.7326/0003-4819-144-4-200602210-00013; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V285, P437, DOI 10.1001/jama.285.4.437; Ioannidis JPA, 2004, ANN INTERN MED, V141, P781, DOI 10.7326/0003-4819-141-10-200411160-00009; JENNISON C, 1984, CONTROL CLIN TRIALS, V5, P33, DOI 10.1016/0197-2456(84)90148-X; JENNISON C, 1993, BIOMETRICS, V49, P741, DOI 10.2307/2532195; JENNISON C, 1999, STAT SCI, V5, P299; JONAS H, 1969, EXPT HUMAN SUBJECTS, P304; MEIER P, 1975, BIOMETRICS, V31, P511, DOI 10.2307/2529434; Montori VM, 2005, JAMA-J AM MED ASSOC, V294, P2203, DOI 10.1001/jama.294.17.2203; Mueller PS, 2007, ANN INTERN MED, V146, P878, DOI 10.7326/0003-4819-146-12-200706190-00009; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Palmer CR, 1999, CONTROL CLIN TRIALS, V20, P172, DOI 10.1016/S0197-2456(98)00056-7; PASSAMANI E, 1991, NEW ENGL J MED, V324, P1589, DOI 10.1056/NEJM199105303242209; POCOCK SJ, 1989, CONTROL CLIN TRIALS, V10, pS209; Pocock SJ, 2006, CLIN TRIALS, V3, P513, DOI 10.1177/1740774506073467; Sedrakyan A, 2006, LANCET, V367, P1376, DOI 10.1016/S0140-6736(06)68590-5; Slutsky AS, 2004, NEW ENGL J MED, V350, P1143, DOI 10.1056/NEJMsb033476; SPIEGELHALTER DJ, 1994, J R STAT SOC A STAT, V157, P357, DOI 10.2307/2983527; Spiegelhalter DJ, 2004, BAYESIAN APPROACHES, DOI DOI 10.1002/0470092602; TANG DI, 1993, BIOMETRICS, V49, P23, DOI 10.2307/2532599; Walker Anne E, 2004, Clin Trials, V1, P282, DOI 10.1191/1740774504cn023oa; Wheatley K, 2003, CONTROL CLIN TRIALS, V24, P66, DOI 10.1016/S0197-2456(02)00273-8; WITTES J, 1993, STAT MED, V12, P419, DOI 10.1002/sim.4780120504; WITTES J, 2007, IN PRESS CLIN TRIALS, P10054; Zhao Y, 2007, CLIN TRIALS, V4, P140, DOI 10.1177/1740774507076936; 1981, CONTROL CLIN TRIALS, V1, P363	46	55	55	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 19	2007	146	12					882	887		10.7326/0003-4819-146-12-200706190-00010	http://dx.doi.org/10.7326/0003-4819-146-12-200706190-00010			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180FF	17577008				2022-12-28	WOS:000247347100007
J	Wessely, S				Wessely, Simon			When doctors become terroists	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Kings Coll London, Inst Psychiat, London WC2R 2LS, England; Kings Ctr Mil Hlth Res, London, England	University of London; King's College London; University of London; King's College London	Wessely, S (corresponding author), Kings Coll London, Inst Psychiat, London WC2R 2LS, England.		Wessely, Simon C/A-8713-2008	Wessely, Simon Charles/0000-0002-6743-9929				Brunnh?lzl Karl., 2007, PRAISE DHARMADHATU N; Burleigh M., 1997, ETHICS EXTERMINATION, P113; LANDER M, 2007, INT HERALD TRIB 0703; Proctor Robert N., 1988, RACIAL HYGIENE MED N; Sedgwick M, 2004, TERROR POLIT VIOLENC, V16, P795, DOI 10.1080/09546550590906098	5	7	7	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 16	2007	357	7					635	637		10.1056/NEJMp078149	http://dx.doi.org/10.1056/NEJMp078149			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200EF	17636057				2022-12-28	WOS:000248746000002
J	Driscoll, CA; Menotti-Raymond, M; Roca, AL; Hupe, K; Johnson, WE; Geffen, E; Harley, EH; Delibes, M; Pontier, D; Kitchener, AC; Yamaguchi, N; O'Brien, SJ; Macdonald, DW				Driscoll, Carlos A.; Menotti-Raymond, Marilyn; Roca, Alfred L.; Hupe, Karsten; Johnson, Warren E.; Geffen, Eli; Harley, Eric H.; Delibes, Miguel; Pontier, Dominique; Kitchener, Andrew C.; Yamaguchi, Nobuyuki; O'Brien, Stephen J.; Macdonald, David W.			The Near Eastern origin of cat domestication	SCIENCE			English	Article							FELIS-SILVESTRIS; WILD; POPULATIONS; RADIATION	The world's domestic cats carry patterns of sequence variation in their genome that reflect a history of domestication and breed development. A genetic assessment of 979 domestic cats and their wild progenitors-Felis silvestris silvestris ( European wildcat), F. s. lybica ( Near Eastern wildcat), F. s. ornata ( central Asian wildcat), F. s. cafra ( southern African wildcat), and F. s. bieti ( Chinese desert cat)indicated that each wild group represents a distinctive subspecies of Felis silvestris. Further analysis revealed that cats were domesticated in the Near East, probably coincident with agricultural village development in the Fertile Crescent. Domestic cats derive from at least five founders from across this region, whose descendants were transported across the world by human assistance.	NCI, Lab Genom Divers, Frederick, MD 21702 USA; Univ Oxford, Dept Zool, Wildlife Conservat Res Unit, Oxford OX1 3PS, England; NCI, Lab Genom Divers, SAIC Frederick Inc, Frederick, MD 21702 USA; JagdEinrichtungsBuro, D-37170 Furstenhagen, Germany; Tel Aviv Univ, Dept Zool, IL-69978 Tel Aviv, Israel; Univ Cape Town, Div Chem Pathol, Observ, ZA-7925 Cape Town, South Africa; CSIC, Dept Appl Biol, Estac Biol Donana, Seville 41013, Spain; Univ Lyon 1, CNRS, Biometrie & Biol Evolut UMR 5558, F-69622 Villeurbanne, France; Natl Museums Scotland, Dept Nat Sci, Edinburgh EH1 1JF, Midlothian, Scotland; Univ Edinburgh, Inst Geog, Sch Geosci, Edinburgh EH8 9XP, Midlothian, Scotland	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Oxford; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Tel Aviv University; University of Cape Town; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Biologica de Donana (EBD); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of Edinburgh	Macdonald, DW (corresponding author), NCI, Lab Genom Divers, Frederick, MD 21702 USA.	driscoll@ncifcrf.gov; obrien@ncifcrf.gov; david.macdonald@zoology.oxford.ac.uk	OBRIEN, STEPHEN/ABD-1346-2020; Yamaguchi, Nobuyuki/AAN-4884-2020; Johnson, Warren/D-4149-2016; Delibes, Miguel/K-2744-2014	Yamaguchi, Nobuyuki/0000-0002-6492-6588; Johnson, Warren/0000-0002-5954-186X; Delibes, Miguel/0000-0002-3569-567X; Pontier, Dominique/0000-0003-4700-3543; Driscoll, Carlos/0000-0003-2392-505X; OBRIEN, STEPHEN/0000-0001-7857-0757; Roca, Alfred/0000-0001-9217-5593; Kitchener, Andrew/0000-0003-2594-0827	NATIONAL CANCER INSTITUTE [Z01BC005367, Z01BC005385] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 AA999999] Funding Source: Medline; NCI NIH HHS [N01CO12400, N01-CO-12400] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beaumont M, 2001, MOL ECOL, V10, P319, DOI 10.1046/j.1365-294x.2001.01196.x; BUDIANSKY S, 1999, COVENANT WILD WHY AN; Clutton-Brock J., 1999, NATURAL HIST DOMESTI; Donalson M.D., 1999, DOMESTIC CAT ROMAN C; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Johnson WE, 2006, SCIENCE, V311, P73, DOI 10.1126/science.1122277; KITCHENER A., 1991, NATURAL HIST WILD CA; KURTEN BJORN, 1965, ACTA ZOOL FENNICA, V111, P3; Lecis R, 2006, MOL ECOL, V15, P119, DOI 10.1111/j.1365-294X.2005.02812.x; LEGAY JM, 1986, CR ACAD SCI III-VIE, V303, P709; Lopez JV, 1997, MOL BIOL EVOL, V14, P277, DOI 10.1093/oxfordjournals.molbev.a025763; Macdonald D.W., 2004, SCOTTISH WILDCAT ANA; Macdonald DW, 1987, ADV ETHOL, V28, P1, DOI DOI 10.1016/0168-1591(88)90058-5; Menotti-Raymond M, 2003, CYTOGENET GENOME RES, V102, P272, DOI 10.1159/000075762; Morrell PL, 2007, P NATL ACAD SCI USA, V104, P3289, DOI 10.1073/pnas.0611377104; Nowell K., 1996, WILD CATS STATUS SUR; O'Brien SJ, 2005, ANNU REV GENOM HUM G, V6, P407, DOI 10.1146/annurev.genom.6.080604.162151; Pocock R.I., 1951, CATALOGUE GENUS FELI; Pocock RI, 1907, P ZOOL SOC LOND, V1907, P656; Pritchard JK, 2001, THEOR POPUL BIOL, V60, P227, DOI 10.1006/tpbi.2001.1543; Randi E, 2001, MOL BIOL EVOL, V18, P1679, DOI 10.1093/oxfordjournals.molbev.a003956; RANDI E, 1991, J MAMMAL, V72, P79, DOI 10.2307/1381981; STEPHENS G, 2001, LEGACY CAT ULTIMATE; Sunquist ME, 2002, WILD CATS WORLD; SWOFFORD D. L., 1985, PHYLOGENETIC ANAL US; TAKEZAKI N, 1995, MOL BIOL EVOL, V12, P828; Tanno K, 2006, SCIENCE, V311, P1886, DOI 10.1126/science.311.5769.1866a; Vella CM, 2003, ROBINSONS GENETICS C; Vigne JD, 2004, SCIENCE, V304, P259, DOI 10.1126/science.1095335; WILLCOX G, 2005, 13 IWGP S, P534; Yamaguchi N, 2004, ANIM CONSERV, V7, P339, DOI 10.1017/S1367943004001520	31	317	334	21	302	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 27	2007	317	5837					519	523		10.1126/science.1139518	http://dx.doi.org/10.1126/science.1139518			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194JD	17600185	Green Submitted, Green Accepted			2022-12-28	WOS:000248339800047
J	Outeiro, TF; Kontopoulos, E; Altmann, SM; Kufareva, I; Strathearn, KE; Amore, AM; Volk, CB; Maxwell, MM; Rochet, JC; McLean, PJ; Young, AB; Abagyan, R; Feany, MB; Hyman, BT; Kazantsev, AG				Outeiro, Tiago Fleming; Kontopoulos, Eirene; Altmann, Stephen M.; Kufareva, Irina; Strathearn, Katherine E.; Amore, Allison M.; Volk, Catherine B.; Maxwell, Michele M.; Rochet, Jean-Christophe; McLean, Pamela J.; Young, Anne B.; Abagyan, Ruben; Feany, Mel B.; Hyman, Bradley T.; Kazantsev, Aleksey G.			Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease	SCIENCE			English	Article							DROSOPHILA MODEL; LEWY BODIES; PROTEIN; AGGREGATION; DEACETYLASE; ACETYLATION; SUPPRESSION; HUNTINGTONS; SIRT2; HDAC6	The sirtuins are members of the histone deacetylase family of proteins that participate in a variety of cellular functions and play a role in aging. We identified a potent inhibitor of sirtuin 2 ( SIRT2) and found that inhibition of SIRT2 rescued alpha-synuclein toxicity and modified inclusion morphology in a cellular model of Parkinson's disease. Genetic inhibition of SIRT2 via small interfering RNA similarly rescued alpha-synuclein toxicity. Furthermore, the inhibitors protected against dopaminergic cell death both in vitro and in a Drosophila model of Parkinson's disease. The results suggest a link between neurodegeneration and aging.	Harvard Univ, Sch Med, MassGen Inst Neurodegenerat Dis, MGH, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Alzheimers Res Unit, MGH, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA	Harvard University; Harvard University; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Scripps Research Institute; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Kontopoulos, E (corresponding author), Harvard Univ, Sch Med, MassGen Inst Neurodegenerat Dis, MGH, CNY 114,16th St, Charlestown, MA 02129 USA.	akazantsev@partners.org	Outeiro, Tiago/L-7351-2019; Outeiro, Tiago F/C-1067-2008; Outeiro, Tiago/M-8106-2019; Young, Anne/AAF-4283-2020	Outeiro, Tiago/0000-0003-1679-1727; Outeiro, Tiago F/0000-0003-1679-1727; Rochet, Jean-Christophe/0000-0002-6484-1541; McLean, Pamela/0000-0003-4870-5715; Kufareva, Irina/0000-0001-9083-7039; Feany, Mel/0000-0003-0315-7970	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS049221, P50NS038372] Funding Source: NIH RePORTER; NINDS NIH HHS [5P50-NS38372A-06, R01-NS049221] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; Alim MA, 2004, J ALZHEIMERS DIS, V6, P435; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Avalos JL, 2005, MOL CELL, V17, P855, DOI 10.1016/j.molcel.2005.02.022; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Bodner RA, 2006, P NATL ACAD SCI USA, V103, P4246, DOI 10.1073/pnas.0511256103; Cohen E, 2006, SCIENCE, V313, P1604, DOI 10.1126/science.1124646; Dompierre JP, 2007, J NEUROSCI, V27, P3571, DOI 10.1523/JNEUROSCI.0037-07.2007; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Heltweg B, 2006, CANCER RES, V66, P4368, DOI 10.1158/0008-5472.CAN-05-3617; Iwata A, 2005, J BIOL CHEM, V280, P40282, DOI 10.1074/jbc.M508786200; Jensen PH, 2000, J BIOL CHEM, V275, P21500, DOI 10.1074/jbc.M000099200; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Klucken J, 2004, J BIOL CHEM, V279, P25497, DOI 10.1074/jbc.M400255200; Kontopoulos E, 2006, HUM MOL GENET, V15, P3012, DOI 10.1093/hmg/ddl243; Langley B, 2005, CNS NEUROL DISORD-DR, V4, P41, DOI 10.2174/1568007053005091; McLean PJ, 2002, J NEUROCHEM, V83, P846, DOI 10.1046/j.1471-4159.2002.01190.x; McLean PJ, 2001, NEUROSCIENCE, V104, P901, DOI 10.1016/S0306-4522(01)00113-0; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Outeiro TF, 2006, BIOCHEM BIOPH RES CO, V351, P631, DOI 10.1016/j.bbrc.2006.10.085; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Tanaka M, 2004, J BIOL CHEM, V279, P4625, DOI 10.1074/jbc.M310994200; Vaquero A, 2006, GENE DEV, V20, P1256, DOI 10.1101/gad.1412706; Zhou WB, 2000, BRAIN RES, V866, P33, DOI 10.1016/S0006-8993(00)02215-0	25	824	858	2	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 27	2007	317	5837					516	519		10.1126/science.1143780	http://dx.doi.org/10.1126/science.1143780			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194JD	17588900				2022-12-28	WOS:000248339800046
J	Cox, P; Stephenson, D				Cox, Peter; Stephenson, David			Climate change - A changing climate for prediction	SCIENCE			English	Editorial Material									Univ Exeter, Sch Engn Comp & Math, Exeter EX4 4QF, Devon, England	University of Exeter	Cox, P (corresponding author), Univ Exeter, Sch Engn Comp & Math, Exeter EX4 4QF, Devon, England.	p.m.cox@exeter.ac.uk	Cox, Peter Michae;/B-3299-2012	Cox, Peter Michae;/0000-0002-0679-2219				Andreae MO, 2005, NATURE, V435, P1187, DOI 10.1038/nature03671; Friedlingstein P, 2006, J CLIMATE, V19, P3337, DOI 10.1175/JCLI3800.1; Ganachaud A, 2003, J CLIMATE, V16, P696, DOI 10.1175/1520-0442(2003)016<0696:LSOHAF>2.0.CO;2; Hibbard K. A., 2007, EOS T, V88, P217, DOI DOI 10.1029/2007EO200002; Jones CD, 2006, TELLUS B, V58, P603, DOI 10.1111/j.1600-0889.2006.00215.x; Lee TCK, 2006, J CLIMATE, V19, P5305, DOI 10.1175/JCLI3912.1; Liniger MA, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2006GL028335; Murphy JM, 2004, NATURE, V430, P768, DOI 10.1038/nature02771; Rayner PJ, 2005, GLOBAL BIOGEOCHEM CY, V19, DOI 10.1029/2004GB002254; Stainforth DA, 2005, NATURE, V433, P403, DOI 10.1038/nature03301	10	119	122	8	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 13	2007	317	5835					207	208		10.1126/science.1145956	http://dx.doi.org/10.1126/science.1145956			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	189DC	17626873				2022-12-28	WOS:000247968600028
J	Guenther, MG; Levine, SS; Boyer, LA; Jaenisch, R; Young, RA				Guenther, Matthew G.; Levine, Stuart S.; Boyer, Laurie A.; Jaenisch, Rudolf; Young, Richard A.			A chromatin landmark and transcription initiation at most promoters in human cells	CELL			English	Article							RNA-POLYMERASE-II; EMBRYONIC STEM-CELLS; HISTONE H3; SACCHAROMYCES-CEREVISIAE; ACTIVE GENES; HIV-1 TAT; IN-VIVO; METHYLATION; ELONGATION; METHYLTRANSFERASE	We describe the results of a genome- wide analysis of human cells that suggests that most protein- coding genes, including most genes thought to be transcriptionally inactive, experience transcription initiation. We found that nucleosomes with H3K4me3 and H3K9,14Ac modifications, together with RNA polymerase II, occupy the promoters of most protein- coding genes in human embryonic stem cells. Only a subset of these genes produce detectable full- length transcripts and are occupied by nucleosomes with H3K36me3 modifications, a hallmark of elongation. The other genes experience transcription initiation but show no evidence of elongation, suggesting that they are predominantly regulated at post-initiation steps. Genes encoding most developmental regulators fall into this group. Our results also identify a class of genes that are excluded from experiencing transcription initiation, at which mechanisms that prevent initiation must predominate. These observations extend to differentiated cells, suggesting that transcription initiation at most genes is a general phenomenon in human cells.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Young, RA (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	young@wi.mit.edu	Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Levine, Stuart/0000-0001-7363-562X	NHGRI NIH HHS [HG002668, R01 HG002668, R01 HG002668-04A1] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002668] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Abeyta MJ, 2004, HUM MOL GENET, V13, P601, DOI 10.1093/hmg/ddh068; Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403; Bannister AJ, 2005, J BIOL CHEM, V280, P17732, DOI 10.1074/jbc.M500796200; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Brandenberger R, 2004, NAT BIOTECHNOL, V22, P707, DOI 10.1038/nbt971; Brandenberger Ralph, 2004, BMC Developmental Biology, V4, P1; Brinkman AB, 2006, EMBO REP, V7, P628, DOI 10.1038/sj.embor.7400686; Buhler M, 2006, CELL, V125, P873, DOI 10.1016/j.cell.2006.04.025; Cheng J, 2005, SCIENCE, V308, P1149, DOI 10.1126/science.1108625; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; Dvir A, 2002, BBA-GENE STRUCT EXPR, V1577, P208, DOI 10.1016/S0167-4781(02)00453-0; Farh KKH, 2005, SCIENCE, V310, P1817, DOI 10.1126/science.1121158; Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kato H, 2005, SCIENCE, V309, P467, DOI 10.1126/science.1114955; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; KRUMM A, 1993, BIOESSAYS, V15, P659, DOI 10.1002/bies.950151005; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Laribee RN, 2005, CURR BIOL, V15, P1487, DOI 10.1016/j.cub.2005.07.028; LASPIA MF, 1993, J MOL BIOL, V232, P732, DOI 10.1006/jmbi.1993.1427; Law A, 1998, NUCLEIC ACIDS RES, V26, P919, DOI 10.1093/nar/26.4.919; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Li B, 2003, J BIOL CHEM, V278, P8897, DOI 10.1074/jbc.M212134200; Li JX, 2002, J BIOL CHEM, V277, P49383, DOI 10.1074/jbc.M209294200; Liang GN, 2004, P NATL ACAD SCI USA, V101, P7357, DOI 10.1073/pnas.0401866101; Lis J, 1998, COLD SPRING HARB SYM, V63, P347, DOI 10.1101/sqb.1998.63.347; Lomvardas S, 2006, CELL, V126, P403, DOI 10.1016/j.cell.2006.06.035; Mayhall EA, 2004, CURR OPIN CELL BIOL, V16, P713, DOI 10.1016/j.ceb.2004.09.007; Meshorer E, 2006, DEV CELL, V10, P105, DOI 10.1016/j.devcel.2005.10.017; Meshorer E, 2006, NAT REV MOL CELL BIO, V7, P540, DOI 10.1038/nrm1938; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; Morillon A, 2005, MOL CELL, V18, P723, DOI 10.1016/j.molcel.2005.05.009; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Parada CA, 1999, EMBO J, V18, P3688, DOI 10.1093/emboj/18.13.3688; Pera MF, 2004, DEVELOPMENT, V131, P5515, DOI 10.1242/dev.01451; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; Ptashne M, 1986, GENETIC SWITCH; Radonjic M, 2005, MOL CELL, V18, P171, DOI 10.1016/j.molcel.2005.03.010; Roh TY, 2006, P NATL ACAD SCI USA, V103, P15782, DOI 10.1073/pnas.0607617103; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Sato N, 2003, DEV BIOL, V260, P404, DOI 10.1016/S0012-1606(03)00256-2; Saunders A, 2006, NAT REV MOL CELL BIO, V7, P557, DOI 10.1038/nrm1981; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; Soutoglou E, 2002, SCIENCE, V295, P1901, DOI 10.1126/science.1068356; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Tenney K, 2005, J CELL BIOCHEM, V95, P429, DOI 10.1002/jcb.20421; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Wei CL, 2005, STEM CELLS, V23, P166, DOI 10.1634/stemcells.2004-0162; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Xiao TJ, 2003, GENE DEV, V17, P654, DOI 10.1101/gad.1055503	61	1457	1498	1	103	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 13	2007	130	1					77	88		10.1016/j.cell.2007.05.042	http://dx.doi.org/10.1016/j.cell.2007.05.042			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	197WK	17632057	Green Accepted, Bronze			2022-12-28	WOS:000248587000012
J	Burgess, EH; Vieira, LFM				Burgess, Elizabeth H.; Mora Vieira, Luis Fernando			Endogenous endophthalmitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Emory Univ, Sch Med, Atlanta, GA 30333 USA	Emory University	Burgess, EH (corresponding author), Emory Univ, Sch Med, Atlanta, GA 30333 USA.	luismora71@hotmail.com							0	4	4	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 12	2007	357	2					163	163		10.1056/NEJMicm064352	http://dx.doi.org/10.1056/NEJMicm064352			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188NX	17625128				2022-12-28	WOS:000247927700010
J	De Wals, P; Tairou, F; Van Allen, MI; Uh, S; Lowry, R B; Sibbald, B; Evans, JA; Van den Hof, MC; Zimmer, P; Crowley, M; Fernandez, B; Lee, NS; Niyonsenga, T				De Wals, Philippe; Tairou, Fassiatou; Van Allen, Margot I.; Uh, Soo-Hong; Lowry, R. Brian; Sibbald, Barbara; Evans, Jane A.; Van den Hof, Michiel C.; Zimmer, Pamela; Crowley, Marian; Fernandez, Bridget; Lee, Nora S.; Niyonsenga, Theophile			Reduction in neural-tube defects after folic acid fortification in Canada	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOOD FORTIFICATION; AFFECTED PREGNANCIES; FOLATE; WOMEN; PREVALENCE; DIAGNOSIS; RISK; AGE	BACKGROUND: In 1998, folic acid fortification of a large variety of cereal products became mandatory in Canada, a country where the prevalence of neural-tube defects was historically higher in the eastern provinces than in the western provinces. We assessed changes in the prevalence of neural-tube defects in Canada before and after food fortification with folic acid was implemented. METHODS: The study population included live births, stillbirths, and terminations of pregnancies because of fetal anomalies among women residing in seven Canadian provinces from 1993 to 2002. On the basis of published results of testing of red-cell folate levels, the study period was divided into prefortification, partial-fortification, and full-fortification periods. We evaluated the relationship between baseline rates of neural-tube defects in each province and the magnitude of the decrease after fortification was implemented. RESULTS: A total of 2446 subjects with neural-tube defects were recorded among 1.9 million births. The prevalence of neural-tube defects decreased from 1.58 per 1000 births before fortification to 0.86 per 1000 births during the full-fortification period, a 46% reduction (95% confidence interval, 40 to 51). The magnitude of the decrease was proportional to the prefortification baseline rate in each province, and geographical differences almost disappeared after fortification began. The observed reduction in rate was greater for spina bifida (a decrease of 53%) than for anencephaly and encephalocele (decreases of 38% and 31%, respectively). CONCLUSIONS: Food fortification with folic acid was associated with a significant reduction in the rate of neural-tube defects in Canada. The decrease was greatest in areas in which the baseline rate was high.	Univ Laval, Dept Med Sociale & Prevent, Quebec City, PQ G1K 7P4, Canada; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; British Columbia Minist Hlth, Victoria, BC, Canada; Alberta Hlth & Wellness, Calgary, AB, Canada; Univ Manitoba, Winnipeg, MB, Canada; Dalhousie Univ, Halifax, NS, Canada; IWK Hlth Ctr, Halifax, NS, Canada; Hlth Sci Ctr, St John, NF, Canada; Hlth Canada, Food Directorate, Ottawa, ON K1A 0L2, Canada; Florida Int Univ, Robert Stempel Sch Publ Hlth, Miami, FL 33199 USA	Laval University; University of British Columbia; Alberta Health Services (AHS); University of Manitoba; Dalhousie University; Dalhousie University; Memorial University Newfoundland; University of Manitoba; Children's Hospital Research Institute of Manitoba; Health Canada; State University System of Florida; Florida International University	De Wals, P (corresponding author), Univ Laval, Dept Med Sociale & Prevent, Pavillon Est,Local 1110,2180 Chemin St Foy, Quebec City, PQ G1K 7P4, Canada.	dewals@msp.ulaval.ca	Niyonsenga, Theo/C-3759-2014	Niyonsenga, Theo/0000-0002-6723-0316; , Fassiatou O./0000-0002-9410-4278				Berry RJ, 1999, NEW ENGL J MED, V341, P1485, DOI 10.1056/NEJM199911113412001; Botto LD, 1999, NEW ENGL J MED, V341, P1509, DOI 10.1056/NEJM199911113412006; Caudill MA, 1997, J NUTR, V127, P2363, DOI 10.1093/jn/127.12.2363; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P362; CRANE JMG, 2001, J SOC OBSTET GYNAECO, V23, P510; De Wals P, 1999, CAN J PUBLIC HEALTH, V90, P237, DOI 10.1007/BF03404123; De Wals P, 2003, BIRTH DEFECTS RES A, V67, P919, DOI 10.1002/bdra.10124; Food and Nutrition Board, 1998, DIET REF INT THIAM R, P196; French MR, 2003, J AM DIET ASSOC, V103, P181, DOI 10.1053/jada.2003.50062; House JD, 2006, CAN J PUBLIC HEALTH, V97, P132, DOI 10.1007/BF03405331; LEMIRE RJ, 1988, JAMA-J AM MED ASSOC, V259, P558, DOI 10.1001/jama.259.4.558; LITTLE J, 1992, EPIDEMIOLOGY CONTROL, P92; Liu Shiliang, 2004, BMC Pregnancy Childbirth, V4, P20, DOI 10.1186/1471-2393-4-20; Morin P, 2002, PREV MED, V35, P143, DOI 10.1006/pmed.2002.1041; Morin P, 2002, CAN J PUBLIC HEALTH, V93, P259, DOI 10.1007/BF03405012; NEVIN NC, 1983, ILLUSTRATED GUIDE MA; Pacheco-Jacome E, 2003, NEUROIMAG CLIN N AM, V13, P327, DOI 10.1016/S1052-5149(03)00028-5; Persad VL, 2002, CAN MED ASSOC J, V167, P241; Quinlivan EP, 2003, AM J CLIN NUTR, V77, P221, DOI 10.1093/ajcn/77.1.221; Ray JG, 2002, LANCET, V360, P2047, DOI 10.1016/S0140-6736(02)11994-5; Ray JG, 2002, EPIDEMIOLOGY, V13, P238, DOI 10.1097/00001648-200203000-00026; Ray JG, 2002, CAN J PUBLIC HEALTH, V93, P249, DOI 10.1007/BF03405010; Morris MS, 2007, AM J CLIN NUTR, V85, P193, DOI 10.1093/ajcn/85.1.193; Shaw GM, 1996, JAMA-J AM MED ASSOC, V275, P1093, DOI 10.1001/jama.275.14.1093; Tairou Fassiatou, 2006, Chronic Dis Can, V27, P120; Van Allen MI, 2006, J APPL GENET, V47, P151, DOI 10.1007/BF03194615; Velie EM, 2006, PAEDIATR PERINAT EP, V20, P219, DOI 10.1111/j.1365-3016.2006.00722.x	27	558	571	2	54	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 12	2007	357	2					135	142		10.1056/NEJMoa067103	http://dx.doi.org/10.1056/NEJMoa067103			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188NX	17625125				2022-12-28	WOS:000247927700007
J	Dello Russo, N; Vervack, RJ; Weaver, HA; Biver, N; Bockelee-Morvan, D; Crovisier, J; Lisse, CM				Dello Russo, N.; Vervack, R. J., Jr.; Weaver, H. A.; Biver, N.; Bockelee-Morvan, D.; Crovisier, J.; Lisse, C. M.			Compositional homogeneity in the fragmented comet 73P/Schwassmann-Wachmann 3	NATURE			English	Article							ECHELLE SPECTROGRAPH; ORGANIC COMPOSITION; DEEP IMPACT; COMETS; 73P/SCHWASSMANN-WACHMANN-3; NIRSPEC; RELEASE; SEARCH	The remarkable compositional diversity of volatile ices within comets(1-3) can plausibly be attributed to several factors, including differences in the chemical, thermal and radiation environments in comet-forming regions, chemical evolution during their long storage in reservoirs far from the Sun(4), and thermal processing by the Sun after removal from these reservoirs. To determine the relevance of these factors, measurements of the chemistry as a function of depth in cometary nuclei are critical. Fragmenting comets expose formerly buried material, but observational constraints have in the past limited the ability to assess the importance of formative conditions and the effects of evolutionary processes on measured composition(5-8). Here we report the chemical composition of two distinct fragments of 73P/Schwassmann-Wachmann 3. The fragments are remarkably similar in composition, in marked contrast to the chemical diversity within the overall comet population and contrary to the expectation that short-period comets should show strong compositional variation with depth in the nucleus owing to evolutionary processing from numerous close passages to the Sun. Comet 73P/Schwassmann-Wachmann 3 is also depleted in the most volatile ices compared to other comets, suggesting that the depleted carbon-chain chemistry seen in some comets from the Kuiper belt reservoir is primordial and not evolutionary(1).	Johns Hopkins Univ, Appl Phys Lab, Dept Space, Laurel, MD 20723 USA; Observ Meudon Paris, LESIA, F-92190 Meudon, France	Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris	Dello Russo, N (corresponding author), Johns Hopkins Univ, Appl Phys Lab, Dept Space, 11100 Johns Hopkins Rd, Laurel, MD 20723 USA.	neil.dello.russo@jhuapl.edu	Weaver, Harold A/D-9188-2016; Lisse, Carey M/B-7772-2016; Russo, Neil Dello/G-2727-2015; Vervack, Ronald J/C-2702-2016	Weaver, Harold A/0000-0003-0951-7762; Lisse, Carey M/0000-0002-9548-1526; Russo, Neil Dello/0000-0002-8379-7304; Vervack, Ronald J/0000-0002-8227-9564				A'Hearn MF, 2005, SCIENCE, V310, P258, DOI 10.1126/science.1118923; AHearn MF, 1995, ICARUS, V118, P223, DOI 10.1006/icar.1995.1190; AHEARN MF, 1977, ASTRON J, V82, P518, DOI 10.1086/112085; Biver N, 2002, EARTH MOON PLANETS, V90, P323, DOI 10.1023/A:1021530316352; Bockelee-Morvan D, 2002, ASTRON ASTROPHYS, V384, P1107, DOI 10.1051/0004-6361:20020086; Bockelee-Morvan D, 2001, SCIENCE, V292, P1339, DOI 10.1126/science.1058512; Bocklelee-Morvan D., 2004, COMETS, P391; Boehnhardt H, 2002, EARTH MOON PLANETS, V90, P131, DOI 10.1023/A:1021524720470; Crovisier J, 1996, ASTRON ASTROPHYS, V310, pL17; Dello Russo N, 1998, ICARUS, V135, P377, DOI 10.1006/icar.1998.5990; Dello Russo N, 2004, ICARUS, V168, P186, DOI 10.1016/j.icarus.2003.11.004; Dello Russo N, 2001, ICARUS, V153, P162, DOI 10.1006/icar.2001.6678; Fink U, 1996, ASTROPHYS J, V459, P729, DOI 10.1086/176938; Gibb EL, 2007, ICARUS, V188, P224, DOI 10.1016/j.icarus.2006.11.009; GREENE TP, 1993, P SOC PHOTO-OPT INS, V1946, P313, DOI 10.1117/12.158684; Levison HF, 2003, NATURE, V426, P419, DOI 10.1038/nature02120; Lisse CM, 2006, SCIENCE, V313, P635, DOI 10.1126/science.1124694; McLean IS, 1998, P SOC PHOTO-OPT INS, V3354, P566, DOI 10.1117/12.317283; MORFILL GE, 1983, ICARUS, V53, P41, DOI 10.1016/0019-1035(83)90019-2; Mumma MJ, 2001, ASTROPHYS J, V546, P1183, DOI 10.1086/318314; Mumma MJ, 2005, SCIENCE, V310, P270, DOI 10.1126/science.1119337; Mumma MJ, 2001, SCIENCE, V292, P1334, DOI 10.1126/science.1058929; Nolan M. C., 2006, BAAS, V38, P504; Nuth JA, 2000, NATURE, V406, P275, DOI 10.1038/35018516; Prialnik D., 2004, COMETS, P359; REUTER DC, 1989, ASTROPHYS J, V341, P1045, DOI 10.1086/167562; SCHLEICHER DG, 2006, BAAS, V38, P485; Stern SA, 2003, NATURE, V424, P639, DOI 10.1038/nature01725; Villanueva GL, 2006, ASTROPHYS J, V650, pL87, DOI 10.1086/508806; Weaver H. A., 2006, BAAS, V38, P490	30	80	81	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 12	2007	448	7150					172	175		10.1038/nature05908	http://dx.doi.org/10.1038/nature05908			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	188QN	17625560				2022-12-28	WOS:000247934500037
J	Gregg, PM; Lin, J; Behn, MD; Montesi, LGJ				Gregg, Patricia M.; Lin, Jian; Behn, Mark D.; Montesi, Laurent G. J.			Spreading rate dependence of gravity anomalies along oceanic transform faults	NATURE			English	Article							MID-ATLANTIC-RIDGE; EAST-PACIFIC-RISE; SOUTHWEST INDIAN RIDGE; DE-FUCA RIDGE; FRACTURE-ZONE; CRUSTAL THICKNESS; SEISMIC STRUCTURE; BOTTOM GRAVITY; ACCRETION; DEFORMATION	Mid-ocean ridge morphology and crustal accretion are known to depend on the spreading rate of the ridge. Slow-spreading mid-ocean-ridge segments exhibit significant crustal thinning towards transform and non-transform offsets(1-12), which is thought to arise from a three-dimensional process of buoyant mantle upwelling and melt migration focused beneath the centres of ridge segments(1,2,4-7,9,10,12). In contrast, fast-spreading mid-ocean ridges are characterized by smaller, segment-scale variations in crustal thickness, which reflect more uniform mantle upwelling beneath the ridge axis(13-15). Here we present a systematic study of the residual mantle Bouguer gravity anomaly of 19 oceanic transform faults that reveals a strong correlation between gravity signature and spreading rate. Previous studies have shown that slow-slipping transform faults are marked by more positive gravity anomalies than their adjacent ridge segments(1,2,4,6), but our analysis reveals that intermediate and fast-slipping transform faults exhibit more negative gravity anomalies than their adjacent ridge segments. This finding indicates that there is a mass deficit at intermediate- and fast-slipping transform faults, which could reflect increased rock porosity, serpentinization of mantle peridotite, and/or crustal thickening. The most negative anomalies correspond to topographic highs flanking the transform faults, rather than to transform troughs (where deformation is probably focused and porosity and alteration are expected to be greatest), indicating that crustal thickening could be an important contributor to the negative gravity anomalies observed. This finding in turn suggests that three-dimensional magma accretion may occur near intermediate- and fast-slipping transform faults.	MIT, Woods Hole Oceanog Inst Joint Program, Dept Geol & Geophys, Cambridge, MA 02139 USA; Woods Hole Oceanog Inst, Dept Geol & Geophys, Woods Hole, MA 02543 USA	Massachusetts Institute of Technology (MIT); Woods Hole Oceanographic Institution	Gregg, PM (corresponding author), MIT, Woods Hole Oceanog Inst Joint Program, Dept Geol & Geophys, Cambridge, MA 02139 USA.	pgregg@whoi.edu	Montesi, Laurent G. J./C-5216-2009; Behn, Mark D/F-5813-2012	Montesi, Laurent G. J./0000-0002-3519-1412; Behn, Mark D/0000-0002-2001-1335; Lin, Jian/0000-0002-6831-2014				Abercrombie RE, 2001, NATURE, V410, P74, DOI 10.1038/35065064; Begnaud ML, 1997, J GEOPHYS RES-SOL EA, V102, P7803, DOI 10.1029/96JB03393; Behn MD, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2002GC000393; Blackman DK, 1998, J GEOPHYS RES-SOL EA, V103, P21315, DOI 10.1029/98JB01756; BLACKMAN DK, 1991, J GEOPHYS RES-SOLID, V96, P11741, DOI 10.1029/91JB00602; BLAKELY RJ, 1996, POTENTIAL THEORY GRA, P378; Bruguier NJ, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB001172; Canales JP, 2000, J GEOPHYS RES-SOL EA, V105, P2699, DOI 10.1029/1999JB900379; Canales JP, 2003, GEOPHYS J INT, V152, P766, DOI 10.1046/j.1365-246X.2003.01885.x; Cochran JR, 1999, J GEOPHYS RES-SOL EA, V104, P10841, DOI 10.1029/1999JB900049; DEMARTIN B, 2004, MIDOCEAN RIDGES HYDR, P318; DETRICK RS, 1995, J GEOPHYS RES-SOL EA, V100, P3767, DOI 10.1029/94JB02649; Escartin J, 1997, J GEOPHYS RES-SOL EA, V102, P2897, DOI 10.1029/96JB02792; ESCARTIN J, 1995, J GEOPHYS RES-SOL EA, V100, P6163, DOI 10.1029/94JB03267; Fialko YA, 1998, J GEOPHYS RES-SOL EA, V103, P2501, DOI 10.1029/97JB03105; FORNARI DJ, 1989, MAR GEOPHYS RES, V11, P263, DOI 10.1007/BF00282579; FOX PJ, 1984, TECTONOPHYSICS, V104, P205, DOI 10.1016/0040-1951(84)90124-0; Fujiwara T, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2002GC000364; Georgen JE, 2001, EARTH PLANET SC LETT, V187, P283, DOI 10.1016/S0012-821X(01)00293-X; Gregg PM, 2006, GEOLOGY, V34, P289, DOI 10.1130/G22212.1; Hooft EEE, 2000, J GEOPHYS RES-SOL EA, V105, P8205, DOI 10.1029/1999JB900442; Johnson HP, 2000, GEOPHYS RES LETT, V27, P1053, DOI 10.1029/1999GL011130; Karson JA, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2000JB000051; KUO BY, 1988, MAR GEOPHYS RES, V10, P205, DOI 10.1007/BF00310065; LIN J, 1992, GEOPHYS RES LETT, V19, P13, DOI 10.1029/91GL03041; LIN J, 1990, NATURE, V344, P627, DOI 10.1038/344627a0; MACDONALD KC, 1988, NATURE, V335, P217, DOI 10.1038/335217a0; MENARD HW, 1969, NATURE, V222, P1037, DOI 10.1038/2221037a0; Minshull TA, 1996, GEOPHYS RES LETT, V23, P849, DOI 10.1029/96GL00730; Muller MR, 2000, J GEOPHYS RES-SOL EA, V105, P25809, DOI 10.1029/2000JB900262; Perfit MR, 1996, EARTH PLANET SC LETT, V141, P91, DOI 10.1016/0012-821X(96)00052-0; Smith W. H. F., 1997, Science, V277, P1956, DOI 10.1126/science.277.5334.1956; Sohn RA, 2005, GEOLOGY, V33, P93, DOI 10.1130/G21116.1; STEVENSON JM, 1994, J GEOPHYS RES-SOL EA, V99, P4875, DOI 10.1029/93JB02076; TOLSTOY M, 1993, SCIENCE, V262, P726, DOI 10.1126/science.262.5134.726; ULMER P, 1995, SCIENCE, V268, P858, DOI 10.1126/science.268.5212.858; Van Avendonk HJA, 2001, J GEOPHYS RES-SOL EA, V106, P10961, DOI 10.1029/2000JB900459; WILKENS RH, 1991, J GEOPHYS RES-SOL EA, V96, P17981, DOI 10.1029/91JB01454	38	57	59	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 12	2007	448	7150					183	U5		10.1038/nature05962	http://dx.doi.org/10.1038/nature05962			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	188QN	17625563				2022-12-28	WOS:000247934500040
J	Mitsumoto, H; Rabkin, JG				Mitsumoto, Hiroshi; Rabkin, Judith G.			Palliative care for patients with amyotrophic lateral sclerosis - "Prepare for the worst and hope for the best"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; TERM MECHANICAL VENTILATION; SERIOUSLY ILL PATIENTS; ALS PATIENTS; NONINVASIVE VENTILATION; ASSISTED SUICIDE; CANCER-PATIENTS; STAGE ALS; CAREGIVERS	Amyotrophic lateral sclerosis (ALS) is a devastating terminal neurodegenerative disease with a highly predictable clinical course such that palliative care should begin at or soon after diagnosis. The outcome is certain in most cases. The only medication approved for treatment in the United States, riluzole, extends life by about 2 months. Virtually all skeletal muscles eventually are affected. Multiple problems require a multidisciplinary approach including aggressive symptomatic management, rehabilitation to maintain motor function, nutritional and respiratory support, augmentative communication devices, and psychological support for both patients and families because family members so often play a central role in management and care. Social, bioethical, and financial issues as well as advance directives should be addressed long before enteral feeding or assistive ventilatory support might be considered. Goals of care should be assessed on an ongoing basis. Presenting the unusual case of a patient with ALS who is also a prominent neurologist specializing in ALS, we enumerate issues in management and palliative care applicable to ALS but also to other fatal, progressive neurologic diseases such as Huntington's chorea and late-stage Parkinson disease.	Columbia Univ, Coll Phys & Surg, Dept Psychiat, Eleanor & Lou Gehrig ALS MDA Ctr, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Neurol Inst, Dept Psychiat, New York, NY 10032 USA; New York State Psychiat Inst & Hosp, New York, NY 10032 USA	Columbia University; Columbia University; New York State Psychiatry Institute	Rabkin, JG (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Psychiat, Eleanor & Lou Gehrig ALS MDA Ctr, 1051 Riverside Dr, New York, NY 10032 USA.	jgr1@columbia.edu						Albert SM, 1999, NEUROLOGY, V53, P278, DOI 10.1212/WNL.53.2.278; Albert SM, 2005, NEUROLOGY, V65, P68, DOI 10.1212/01.wnl.0000168161.54833.bb; Albert SM, 2001, J NEUROL SCI, V191, P115, DOI 10.1016/S0022-510X(01)00614-1; Andersen PM, 2006, CURR NEUROL NEUROSCI, V6, P37, DOI 10.1007/s11910-996-0008-9; Bascom PB, 2002, JAMA-J AM MED ASSOC, V288, P91, DOI 10.1001/jama.288.1.91; Belsh JM, 1999, NEUROLOGY, V53, pS26; Borasio GD, 1998, J NEUROL, V245, P717, DOI 10.1007/s004150050273; Bourke SC, 2006, LANCET NEUROL, V5, P140, DOI 10.1016/S1474-4422(05)70326-4; Brooks BR, 2000, AMYOTROPH LATERAL SC, V1, P293, DOI 10.1080/146608200300079536; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; CHAD DA, 2006, AMYOTROPH LATERAL SC, P201; Chen ML, 2004, SUPPORT CARE CANCER, V12, P469, DOI 10.1007/s00520-004-0636-z; Chio A, 2005, NEUROLOGY, V64, P1780, DOI 10.1212/01.WNL.0000162034.06268.37; Cummings JL, 2006, CNS SPECTRUMS, V11, P1; CWIK VA, 2006, AMYOTROPHIC LATERAL, P99; DELBENE ML, 2003, AMYOTROPH LATERAL S1, V4, P64; Desport JC, 1999, NEUROLOGY, V53, P1059, DOI 10.1212/WNL.53.5.1059; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Ganzini L, 1998, NEW ENGL J MED, V339, P967, DOI 10.1056/NEJM199810013391406; GANZINI L, 2005, AMYOTROPHIC LATERAL, P811; GELINAS D, 2001, AMYOTROPHIC LATERAL, P47; Gelinas DF, 1998, J NEUROL SCI, V160, pS134, DOI 10.1016/S0022-510X(98)00212-3; GIRGIS A, 1995, J CLIN ONCOL, V13, P2449, DOI 10.1200/JCO.1995.13.9.2449; Goldstein LH, 2006, PSYCHOL MED, V36, P865, DOI 10.1017/S0033291706007124; Goldstein LH, 2000, J NEUROL SCI, V180, P101, DOI 10.1016/S0022-510X(00)00416-0; Gordon PH, 2006, AMYOTROPHIC LATERAL, P227; Hayase T, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-25; Hayashi H, 2003, NEUROLOGY, V61, P135, DOI 10.1212/01.WNL.0000069925.02052.1F; HOERTH CL, 2006, AMYOTROPHIC LATERAL, P117; *I MED, 1997, APPR DEATH IMPR CAR, P31; Jackson CE, 2006, AMYOTROPH LATERAL SC, P649; Kaub-Wittemer D, 2003, J PAIN SYMPTOM MANAG, V26, P890, DOI 10.1016/S0885-3924(03)00323-3; Krivickas LS, 1997, J NEUROL SCI, V152, pS82, DOI 10.1016/S0022-510X(97)00251-7; KRIVIKAS LS, 2006, AMYOTROPHIC LATERAL, P691; Lamont EB, 2003, JAMA-J AM MED ASSOC, V290, P98, DOI 10.1001/jama.290.1.98; Larson AM, 2006, JAMA-J AM MED ASSOC, V295, P2168, DOI 10.1001/jama.295.18.2168; LI TM, 1990, J NEUROL NEUROSUR PS, V53, P1043, DOI 10.1136/jnnp.53.12.1043; Lo B, 2005, JAMA-J AM MED ASSOC, V294, P1810, DOI 10.1001/jama.294.14.1810; Lomen-Hoerth C, 2002, NEUROLOGY, V59, P1077, DOI 10.1212/WNL.59.7.1077; Lyall RA, 2001, NEUROLOGY, V57, P153, DOI 10.1212/WNL.57.1.153; Lyall RA, 2001, BRAIN, V124, P2000, DOI 10.1093/brain/124.10.2000; Lynn J, 2001, JAMA-J AM MED ASSOC, V285, P925, DOI 10.1001/jama.285.7.925; MAZZINI L, 1995, J NEUROL, V242, P695, DOI 10.1007/BF00866922; McCluskey L, 2004, AMYOTROPH LATERAL SC, V5, P131, DOI 10.1080/14660820410020772; McGuire V, 2006, AMYOTROPHIC LATERAL, P17; Meier DE, 2002, NEW ENGL J MED, V346, P1087, DOI 10.1056/NEJM200204043461413; Miller RG, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001447.pub2; Miller RG, 1999, NEUROLOGY, V52, P1311, DOI 10.1212/WNL.52.7.1311; Miller RG, 2000, NEUROLOGY, V54, P53, DOI 10.1212/WNL.54.1.53; Miller RG, 2006, AMYOTROPH LATERAL SC, V7, P56; MILLER RG, 2006, AMYOTROPHIC LATERAL, P633; Mitsumoto H, 2005, AMYOTROPH LATERAL SC, V6, P145, DOI 10.1080/14660820510028647; Mitsumoto H, 2003, AMYOTROPH LATERAL SC, V4, P177, DOI 10.1080/14660820310011728; MITSUMOTO H, 2001, AMYOTROPHIC LATERAL, P27; Mitsumoto HM, 2006, AMYOTROPHIC LATERAL, P605; MONTGOMERY GK, 1987, NEUROL CLIN, V5, P61, DOI 10.1016/S0733-8619(18)30935-6; MOSS AH, 1993, NEUROLOGY, V43, P438, DOI 10.1212/WNL.43.2.438; Moss AH, 1996, CHEST, V110, P249, DOI 10.1378/chest.110.1.249; Mustfa N, 2006, NEUROLOGY, V66, P1211, DOI 10.1212/01.wnl.0000208957.88534.11; Nagai M, 2007, NAT NEUROSCI, V10, P615, DOI 10.1038/nn1876; NAKAJIMA T, 2006, AMYOTROPH LATERAL S1, V7, P45; Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546; Neudert C, 2001, J NEUROL, V248, P612, DOI 10.1007/s004150170140; Nijboer C, 1999, CANCER, V86, P577, DOI 10.1002/(SICI)1097-0142(19990815)86:4<577::AID-CNCR6>3.0.CO;2-S; Olney RK, 2005, NEUROLOGY, V65, P1774, DOI 10.1212/01.wnl.0000188759.87240.8b; Olney RK, 2005, NEUROLOGY, V65, P9, DOI 10.1212/01.wnl.0000171741.00711.b5; Pasinelli P, 2006, NAT REV NEUROSCI, V7, P710, DOI 10.1038/nrn1971; Patrick DL, 1997, ANN INTERN MED, V127, P509, DOI 10.7326/0003-4819-127-7-199710010-00002; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; Rabkin JG, 2005, NEUROLOGY, V65, P62, DOI 10.1212/01.wnl.0000167187.14501.0c; Rabkin JG, 2000, PSYCHOSOM MED, V62, P271, DOI 10.1097/00006842-200003000-00020; RABKIN JG, 1995, GOOD DOCTORS GOOD PA; Rabkin JG, 2006, AMYOTROPH LATERAL SC, V7, P86, DOI 10.1080/14660820500515021; Rabow MW, 2004, JAMA-J AM MED ASSOC, V291, P483, DOI 10.1001/jama.291.4.483; Ringholz GM, 2005, NEUROLOGY, V65, P586, DOI 10.1212/01.wnl.0000172911.39167.b6; Rowland L. P., 2005, MERRITTS NEUROLOGY, P861; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; SHOESMITH CL, 2006, AMYOTROPH LATERAL S1, V7, P101; Silani V, 1999, NEUROLOGY, V53, pS37; SIMPSON EP, 2006, AMYOTROPH LATERAL S1, V7, P64; Smyth A, 1997, J NEUROL SCI, V152, pS93, DOI 10.1016/S0022-510X(97)00253-0; Srinivasan J, 2006, MUSCLE NERVE, V34, P359, DOI 10.1002/mus.20555; STILLMAN MJ, 2001, AMYTROPHIC LATERAL S, P359; SYKES NP, 2006, AMYOTROPHIC LATERAL, P783; Traynor BJ, 2003, J NEUROL NEUROSUR PS, V74, P1258, DOI 10.1136/jnnp.74.9.1258; VACHON ML, HDB PSYCHIAT PALLIAT, P303; Van den Berg JP, 2005, NEUROLOGY, V65, P1264, DOI 10.1212/01.wnl.0000180717.29273.12; Verma A, 2006, MUSCLE NERVE, V34, P235, DOI 10.1002/mus.20545; Wood JD, 2003, NEUROPATH APPL NEURO, V29, P529, DOI 10.1046/j.0305-1846.2003.00518.x; Yoshor D, 2005, NEUROSURGERY, V57, P984, DOI 10.1227/01.NEU.0000180028.64385.d3; ZOCCOLELLA S, 2006, AMYOTROPH LATERAL S1, V7, P100	91	72	74	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2007	298	2					207	216		10.1001/jama.298.2.207	http://dx.doi.org/10.1001/jama.298.2.207			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188HI	17622602				2022-12-28	WOS:000247910600026
J	Bannerman, DM; Sprengel, R				Bannerman, David M.; Sprengel, Rolf			Remembering the subtle differences	SCIENCE			English	Editorial Material							NMDA RECEPTORS; DENTATE GYRUS; MEMORY; HIPPOCAMPUS; CA3; CODES		Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England; Max Planck Inst Med Res, Heidelberg, Germany	University of Oxford; Max Planck Society	Bannerman, DM (corresponding author), Univ Oxford, Dept Expt Psychol, S Parks Rd, Oxford OX1 3UD, England.	david.bannerman@psy.ox.ac.u; rolf.sprengel@mpimf-heidelberg.mpg.de		Bannerman, David/0000-0002-3024-7595	Wellcome Trust [087736] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Fortin NJ, 2002, NAT NEUROSCI, V5, P458, DOI 10.1038/nn834; HIRSH R, 1974, BEHAV BIOL, V12, P421, DOI 10.1016/S0091-6773(74)92231-7; Leutgeb JK, 2007, SCIENCE, V315, P961, DOI 10.1126/science.1135801; Leutgeb S, 2005, SCIENCE, V309, P619, DOI 10.1126/science.1114037; Leutgeb S, 2004, SCIENCE, V305, P1295, DOI 10.1126/science.1100265; McHugh TJ, 2007, SCIENCE, V317, P94, DOI 10.1126/science.1140263; Nakazawa K, 2002, SCIENCE, V297, P211, DOI 10.1126/science.1071795; Niewoehner B, 2007, EUR J NEUROSCI, V25, P837, DOI 10.1111/j.1460-9568.2007.05312.x; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; Wood ER, 1999, NATURE, V397, P613, DOI 10.1038/17605	11	3	3	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2007	317	5834					50	51		10.1126/science.1145811	http://dx.doi.org/10.1126/science.1145811			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186KD	17615327				2022-12-28	WOS:000247776700032
J	Pomeranz, MK; Karen, JK				Pomeranz, Miriam Keltz; Karen, Julie K.			Images in clinical medicine - Phytophotodermatitis and limes	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NYU, Sch Med, New York, NY 10016 USA	New York University	Pomeranz, MK (corresponding author), NYU, Sch Med, New York, NY 10016 USA.	miriam.pomeranz@med.nyu.edu		Pomeranz, Miriam Keltz/0000-0002-6959-9280					0	11	11	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 5	2007	357	1					E1	E1		10.1056/NEJMicm053778	http://dx.doi.org/10.1056/NEJMicm053778			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185OR	17611200				2022-12-28	WOS:000247720800009
J	Rowland, HM; Ihalainen, E; Lindstrom, L; Mappes, J; Speed, MP				Rowland, Hannah M.; Ihalainen, Eira; Lindstrom, Leena; Mappes, Johanna; Speed, Michael P.			Co-mimics have a mutualistic relationship despite unequal defences	NATURE			English	Article							MULLERIAN MIMICRY; NATURAL-SELECTION; PHYLOGENETIC EVIDENCE; ALTERNATIVE PREY; WARNING-COLOR; EVOLUTION; PREDATION; DYNAMICS; MODEL	In the first clear mathematical treatment of natural selection, Muller(1) proposed that a shared warning signal ( mimicry) would benefit defended prey species by sharing out the per capita mortality incurred during predator education. Although mimicry is a mainstay of adaptationist thinking, there has been repeated debate on whether there is a mutualistic or a parasitic relationship between unequally defended co-mimic species(2-5). Here we show that the relationship between unequally defended species is mutualistic. We examined this in a 'novel world'(6) of artificial prey with wild predators ( great tit, Parus major). We kept the abundance of a highly defended prey ('model') constant and increased the density of a moderately defended prey ('defended mimic') of either perfect or imperfect mimetic resemblance to the model. Both model and defended mimic showed a net benefit from a density-dependent decrease in their per capita mortality. Even when the effect of dilution through density was controlled for, defended mimics did not induce additional attacks on the model, but we found selection for accurate signal mimicry. In comparison, the addition of fully edible (batesian) mimics did increase additional attacks on the model, but as a result of dilution this resulted in no overall increase in per capita mortality. By ignoring the effects of density, current theories may have overestimated the parasitic costs imposed by less defended mimics on highly defended models.	Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England; Univ Jyvaskyla, Dept Biol & Environm Sci, FI-40014 Jyvaskyla, Finland	University of Liverpool; University of Jyvaskyla	Rowland, HM (corresponding author), Univ Liverpool, Sch Biol Sci, Biosci Bldg,Crown St, Liverpool L69 7ZB, Merseyside, England.	h.m.rowland@liv.ac.uk	Lindstrom, Leena/B-2326-2012; Rowland, Hannah/D-8114-2012; Mappes, Johanna/AAZ-3627-2021	Lindstrom, Leena/0000-0002-6452-4538; Rowland, Hannah/0000-0002-1040-555X; Mappes, Johanna/0000-0002-1117-5629				Alatalo RV, 1996, NATURE, V382, P708, DOI 10.1038/382708a0; Bates H.W., 1862, T LINN SOC LOND, V23, P495; BENSON WW, 1972, SCIENCE, V176, P936, DOI 10.1126/science.176.4037.936; DIXEY FA, 1919, REP BR ASS ADVMT SCI, P199; Dumbacher JP, 2001, P ROY SOC B-BIOL SCI, V268, P1971, DOI 10.1098/rspb.2001.1717; Fisher, 1958, GENETICAL THEORY NAT; HUHEEY J E, 1988, American Naturalist, V131, pS22, DOI 10.1086/284765; HUHEEY JE, 1980, J HERPETOL, V14, P223, DOI 10.2307/1563543; Ihalainen E, 2007, J EVOLUTION BIOL, V20, P780, DOI 10.1111/j.1420-9101.2006.01234.x; Kapan DD, 2001, NATURE, V409, P338, DOI 10.1038/35053066; Kokko H, 2003, ECOL LETT, V6, P1068, DOI 10.1046/j.1461-0248.2003.00532.x; Lindstrom L, 2001, P NATL ACAD SCI USA, V98, P9181, DOI 10.1073/pnas.161071598; Lindstrom L, 2006, ANIM BEHAV, V72, P323, DOI 10.1016/j.anbehav.2005.10.015; Lindstrom L, 2004, EVOLUTION, V58, P1294, DOI 10.1554/03-271; Mallet J, 1999, ANNU REV ECOL SYST, V30, P201, DOI 10.1146/annurev.ecolsys.30.1.201; Mallet J, 1999, EVOL ECOL, V13, P777, DOI 10.1023/A:1011060330515; MALLET J, 1989, EVOLUTION, V43, P421, DOI 10.1111/j.1558-5646.1989.tb04237.x; Marshall G. A. K., 1908, T ENTOMOLOGICAL SOC, V1908, P93; Muller F., 1878, ZOOL ANZ, V1, P54; NONACS P, 1985, AM NAT, V126, P165, DOI 10.1086/284407; OWEN RE, 1984, J THEOR BIOL, V109, P217, DOI 10.1016/S0022-5193(84)80004-1; Rowe C, 2004, P ROY SOC B-BIOL SCI, V271, P407, DOI 10.1098/rspb.2003.2615; SHEPPARD PM, 1959, COLD SPRING HARB SYM, V24, P131, DOI 10.1101/SQB.1959.024.01.013; SHEPPARD PM, 1975, NATURAL SELECTION HE; Sherratt TN, 2004, J THEOR BIOL, V228, P217, DOI 10.1016/j.jtbi.2003.12.009; Sherratt TN, 2003, OIKOS, V103, P93, DOI 10.1034/j.1600-0706.2003.12576.x; SPEED MP, 1993, ANIM BEHAV, V45, P571, DOI 10.1006/anbe.1993.1067; Speed MP, 2000, P ROY SOC B-BIOL SCI, V267, P725, DOI 10.1098/rspb.2000.1063; Speed MP, 1999, EVOL ECOL, V13, P755, DOI 10.1023/A:1010871106763; Symula R, 2001, P ROY SOC B-BIOL SCI, V268, P2415, DOI 10.1098/rspb.2001.1812	30	114	114	0	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 5	2007	448	7149					64	67		10.1038/nature05899	http://dx.doi.org/10.1038/nature05899			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185OS	17611539				2022-12-28	WOS:000247720900038
J	Chen, Z; Odstrcil, EA; Tu, BP; McKnight, SL				Chen, Zheng; Odstrcil, Elizabeth A.; Tu, Benjamin P.; McKnight, Steven L.			Restriction of DNA replication to the reductive phase of the metabolic cycle protects genome integrity	SCIENCE			English	Article							CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; CANCER-CELLS; YEAST; INSTABILITY; INHIBITOR; MUTATIONS; MECHANISM; STRESS; DAMAGE	When prototrophic yeast cells are cultured under nutrient-limited conditions that mimic growth in the wild, rather than in the high-glucose solutions used in most laboratory studies, they exhibit a robustly periodic metabolic cycle. Over a cycle of 4 to 5 hours, yeast cells rhythmically alternate between glycolysis and respiration. The cell division cycle is tightly constrained to the reductive phase of this yeast metabolic cycle, with DNA replication taking place only during the glycolytic phase. We show that cell cycle mutants impeded in metabolic cycle-directed restriction of cell division exhibit substantial increases in spontaneous mutation rate. In addition, disruption of the gene encoding a DNA checkpoint kinase that couples the cell division cycle to the circadian cycle abolishes synchrony of the metabolic and cell cycles. Thus, circadian, metabolic, and cell division cycles may be coordinated similarly as an evolutionarily conserved means of preserving genome integrity.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Baylor Univ, Med Ctr, Dallas, TX 75246 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Baylor University; Baylor University Medical Center	McKnight, SL (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Steven.McKnight@UTSouthwestern.edu		Chen, Jake/0000-0001-8829-7504				Canaple L, 2003, CANCER RES, V63, P7545; Chen JH, 2005, DNA REPAIR, V4, P1140, DOI 10.1016/j.dnarep.2005.06.003; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Futcher B, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-4-107; Gery S, 2006, MOL CELL, V22, P375, DOI 10.1016/j.molcel.2006.03.038; Gillette MU, 2005, SCIENCE, V309, P1196, DOI 10.1126/science.1111420; HESS B, 1971, ANNU REV BIOCHEM, V40, P237, DOI 10.1146/annurev.bi.40.070171.001321; Huang GC, 2006, EMBO J, V25, P5349, DOI 10.1038/sj.emboj.7601397; Huang ME, 2003, P NATL ACAD SCI USA, V100, P11529, DOI 10.1073/pnas.2035018100; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; Klevecz RR, 2004, P NATL ACAD SCI USA, V101, P1200, DOI 10.1073/pnas.0306490101; Lengronne A, 2002, MOL CELL, V9, P1067, DOI 10.1016/S1097-2765(02)00513-0; Leroy C, 2001, EMBO J, V20, P2896, DOI 10.1093/emboj/20.11.2896; Lloyd D, 2005, TRENDS BIOCHEM SCI, V30, P373, DOI 10.1016/j.tibs.2005.05.005; Lowrey PL, 2004, ANNU REV GENOM HUM G, V5, P407, DOI 10.1146/annurev.genom.5.061903.175925; Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094; Matsuo T, 2003, SCIENCE, V302, P255, DOI 10.1126/science.1086271; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; Pregueiro AM, 2006, SCIENCE, V313, P644, DOI 10.1126/science.1121716; Richard P, 2003, FEMS MICROBIOL REV, V27, P547, DOI 10.1016/S0168-6445(03)00065-2; Schibler U, 2005, CURR OPIN CELL BIOL, V17, P223, DOI 10.1016/j.ceb.2005.01.007; Shcherbakova PV, 1999, MOL CELL BIOL, V19, P3177; Sidorova JM, 2003, MUTAT RES-FUND MOL M, V532, P5, DOI 10.1016/j.mrfmmm.2003.08.006; Tu BP, 2006, NAT REV MOL CELL BIO, V7, P696, DOI 10.1038/nrm1980; Tu BP, 2005, SCIENCE, V310, P1152, DOI 10.1126/science.1120499; WHELAN WL, 1979, GENETICS, V91, P35	26	169	172	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 29	2007	316	5833					1916	1919		10.1126/science.1140958	http://dx.doi.org/10.1126/science.1140958			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183WI	17600220				2022-12-28	WOS:000247602700045
J	Alwan, S; Reefhuis, J; Rasmussen, SA; Olney, RS; Friedman, JM				Alwan, Sura; Reefhuis, Jennita; Rasmussen, Sonja A.; Olney, Richard S.; Friedman, Jan M.		Natl Birth Defects Prevention Stud	Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MATERNAL OBESITY; 1ST-TRIMESTER EXPOSURE; CARDIAC-MALFORMATIONS; DEPRESSIVE SYMPTOMS; MORPHOGENESIS; ASSOCIATION; OUTCOMES; DRUGS; WOMEN	BACKGROUND: Information regarding the safety of selective serotonin-reuptake inhibitors (SSRIs) in human pregnancy is sparse. Concern has been raised about the risk of congenital heart defects associated with the use of SSRIs in pregnancy. METHODS: We obtained data on 9622 case infants with major birth defects and 4092 control infants born from 1997 through 2002 from the National Birth Defects Prevention Study. Case infants were ascertained through birth-defects surveillance systems in eight U.S. states; controls were selected randomly from the same geographic areas. Mothers completed a standardized telephone interview regarding exposure to potential risk factors, including medications, before and during pregnancy. Exposure to SSRIs was defined as treatment with any SSRI from 1 month before to 3 months after conception. Birth defects were assigned to 26 categories and subcategories. RESULTS: There were no significant associations between maternal use of SSRIs overall during early pregnancy and congenital heart defects or most other categories or subcategories of birth defects. Maternal SSRI use was associated with anencephaly (214 infants, 9 exposed; adjusted odds ratio, 2.4; 95% confidence interval [CI], 1.1 to 5.1), craniosynostosis (432 infants, 24 exposed; adjusted odds ratio, 2.5; 95% CI, 1.5 to 4.0), and omphalocele (181 infants, 11 exposed; adjusted odds ratio, 2.8; 95% CI, 1.3 to 5.7). CONCLUSIONS: Maternal use of SSRIs during early pregnancy was not associated with significantly increased risks of congenital heart defects or of most other categories of birth defects. Associations were observed between SSRI use and three types of birth defects, but the absolute risks were small, and these observations require confirmation by other studies.	Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA; Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada	Centers for Disease Control & Prevention - USA; University of British Columbia	Reefhuis, J (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS E-86, Atlanta, GA 30333 USA.	JReefhuis@cdc.gov	Reefhuis, Jennita/E-1793-2011	Reefhuis, Jennita/0000-0002-4747-4831; Friedman, Jan/0000-0002-7482-9570				Allister L, 2001, DEV NEUROPSYCHOL, V20, P639, DOI 10.1207/S15326942DN2003_6; Anderson JL, 2005, EPIDEMIOLOGY, V16, P87, DOI 10.1097/01.ede.0000147122.97061.bb; Berard A, 2007, BIRTH DEFECTS RES B, V80, P18, DOI 10.1002/bdrb.20099; BYRD RA, 1994, FUND APPL TOXICOL, V22, P511, DOI 10.1006/faat.1994.1058; Carey J C, 1978, Birth Defects Orig Artic Ser, V14, P253; Chambers CD, 1996, NEW ENGL J MED, V335, P1010, DOI 10.1056/NEJM199610033351402; Daniel WA, 2003, PROG NEURO-PSYCHOPH, V27, P65, DOI 10.1016/S0278-5846(02)00317-2; Ericson A, 1999, EUR J CLIN PHARMACOL, V55, P503, DOI 10.1007/s002280050664; Garbis H, 2005, REPROD TOXICOL, V19, P453, DOI 10.1016/j.reprotox.2004.09.002; *GLAXOSMITHKLINE, EP STUD PREL REP BUP; HOSMER DW, 1992, EPIDEMIOLOGY, V3, P452, DOI 10.1097/00001648-199209000-00012; Kallen B, 2006, REPROD TOXICOL, V21, P221, DOI 10.1016/j.reprotox.2005.11.006; Kallen BAJ, 2007, BIRTH DEFECTS RES A, V79, P301, DOI 10.1002/bdra.20327; Kulin NA, 1998, JAMA-J AM MED ASSOC, V279, P609, DOI 10.1001/jama.279.8.609; Louik C, 2007, NEW ENGL J MED, V356, P2675, DOI 10.1056/NEJMoa067407; Malm H, 2005, OBSTET GYNECOL, V106, P1289, DOI 10.1097/01.AOG.0000187302.61812.53; Mann JJ, 2005, NEW ENGL J MED, V353, P1819, DOI 10.1056/NEJMra050730; Marcus SM, 2003, J WOMEN HEALTH GEN-B, V12, P373, DOI 10.1089/154099903765448880; Mikhail LN, 2002, J NATL MED ASSOC, V94, P695; Moore LL, 2000, EPIDEMIOLOGY, V11, P689, DOI 10.1097/00001648-200011000-00013; ORR ST, 1995, EPIDEMIOL REV, V17, P165, DOI 10.1093/oxfordjournals.epirev.a036172; PASTUSZAK A, 1993, JAMA-J AM MED ASSOC, V269, P2246, DOI 10.1001/jama.269.17.2246; Rasmussen SA, 2003, BIRTH DEFECTS RES A, V67, P193, DOI 10.1002/bdra.10012; Reefhuis J, 2006, NEW ENGL J MED, V354, P2188; Sari Y, 2003, INT J DEV NEUROSCI, V21, P417, DOI 10.1016/j.ijdevneu.2003.10.002; SHUEY DL, 1993, ANAT EMBRYOL, V187, P75; Simon GE, 2002, AM J PSYCHIAT, V159, P2055, DOI 10.1176/appi.ajp.159.12.2055; Stewart J. D., 1998, Neurotoxicology and Teratology, V20, P365, DOI 10.1016/S0892-0362(98)80616-8; WADHWA PD, 1993, AM J OBSTET GYNECOL, V169, P858, DOI 10.1016/0002-9378(93)90016-C; Watkins ML, 2003, PEDIATRICS, V111, P1152; Wisner KL, 1999, JAMA-J AM MED ASSOC, V282, P1264, DOI 10.1001/jama.282.13.1264; Wogelius P, 2006, EPIDEMIOLOGY, V17, P701, DOI 10.1097/01.ede.0000239581.76793.ae; YAVARONE MS, 1993, TERATOLOGY, V47, P573, DOI 10.1002/tera.1420470609; Yoon PW, 2001, PUBLIC HEALTH REP, V116, P32, DOI 10.1093/phr/116.S1.32	34	340	347	2	40	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 28	2007	356	26					2684	2692		10.1056/NEJMoa066584	http://dx.doi.org/10.1056/NEJMoa066584			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	183HS	17596602				2022-12-28	WOS:000247564500005
J	Gallagher, TH; Studdert, D; Levinson, W				Gallagher, Thomas H.; Studdert, David; Levinson, Wendy			Disclosing harmful medical errors to patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ADVERSE EVENTS; HOSPITALIZED-PATIENTS; PHYSICIANS ATTITUDES; MALPRACTICE CLAIMS; RISK-MANAGEMENT; CARE; SAFETY; VIEWS		Univ Washington, Dept Med, Seattle, WA 98105 USA; Univ Washington, Dept Med Hist & Eth, Seattle, WA 98195 USA; Univ Melbourne, Sch Populat Hlth, Melbourne, Vic, Australia; Univ Melbourne, Melbourne Law Sch, Melbourne, Vic, Australia; Univ Toronto, Toronto, ON, Canada	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Melbourne; University of Melbourne; University of Toronto	Gallagher, TH (corresponding author), Univ Washington, Dept Med, POB 354981, Seattle, WA 98105 USA.	thomasg@u.washington.edu	Studdert, David/AAF-3116-2021	Studdert, David/0000-0003-0585-5537	AHRQ HHS [1K08HS01401201] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AHA MAN ADV, 1992, ETH COND HLTH CAR I; *AM MED ASS COUNC, 2004, COD MED ETH ANN CURR; AMORI G, 2006, PEARLS DISCLOSURE AD; [Anonymous], 2004, NAT SURV CONS EXP PA; [Anonymous], 2006, WHEN THINGS GO WRONG; Australian Council for Safety and Quality in Health Care, 2003, OP DISCL STAND NAT S; Baker GR, 2004, CAN MED ASSOC J, V170, P1678, DOI 10.1503/cmaj.1040498; Bismark M, 2006, CAN MED ASSOC J, V175, P889, DOI 10.1503/cmaj.060429; Blendon RJ, 2002, NEW ENGL J MED, V347, P1933, DOI 10.1056/NEJMsa022151; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Canadian Patient Safety Institute, 2006, BACKGR PAP DEV NAT G; Clinton HR, 2006, NEW ENGL J MED, V354, P2205, DOI 10.1056/NEJMp068100; Davis P., 2002, NEW ZEAL MED J, V115, P271; FLYNN E, 2002, SHINING LIGHT ERRORS; GALLAGHER T, 2006, ASHRM J, V26, P11, DOI DOI 10.1002/JHRM.5600260305; Gallagher TH, 2005, ARCH INTERN MED, V165, P1819, DOI 10.1001/archinte.165.16.1819; Gallagher TH, 2003, JAMA-J AM MED ASSOC, V289, P1001, DOI 10.1001/jama.289.8.1001; GALLAGHER TH, 2006, MED LIABILITY HLTH C; Gallagher TH, 2006, ARCH INTERN MED, V166, P1585, DOI 10.1001/archinte.166.15.1585; Gallagher TH, 2006, ARCH INTERN MED, V166, P1605, DOI 10.1001/archinte.166.15.1605; Gibson R., 2003, WALL SILENCE UNTOLD; HICKSON GB, 1992, JAMA-J AM MED ASSOC, V267, P1359, DOI 10.1001/jama.267.10.1359; Joint Commission on Accreditation of Healthcare Organizations, 2005, HLTH CAR CROSSR STRA; Kraman SS, 1999, ANN INTERN MED, V131, P963, DOI 10.7326/0003-4819-131-12-199912210-00010; Lamb RM, 2003, HEALTH AFFAIR, V22, P73, DOI 10.1377/hlthaff.22.2.73; Lazare A, 2006, JAMA-J AM MED ASSOC, V296, P1401, DOI 10.1001/jama.296.11.1401; *LEAPFR GROUP, 2007, WELC LEAPFR HOSP QUA; *LEAPFR GROUP, 2007, NAT QUAL FOR SAF PR; Levinson W, 1997, JAMA-J AM MED ASSOC, V277, P553, DOI 10.1001/jama.277.7.553; Mazor KM, 2004, ANN INTERN MED, V140, P409, DOI 10.7326/0003-4819-140-6-200403160-00006; *NAT PAT SAF AG, 2005, SAF PRACT NOT BEING; Schioler T, 2001, Ugeskr Laeger, V163, P5370; Snyder L, 2005, ANN INTERN MED, V142, P560, DOI 10.7326/0003-4819-142-7-200504050-00014; Studdert DM, 2007, HEALTH AFFAIR, V26, P215, DOI 10.1377/hlthaff.26.1.215; The Joint Commission, 2007, HOSP ACCR STAND; Thomas EJ, 2000, MED CARE, V38, P261, DOI 10.1097/00005650-200003000-00003; VINCENT C, 1994, LANCET, V343, P1609, DOI 10.1016/S0140-6736(94)93062-7; Vincent C, 2001, BMJ-BRIT MED J, V322, P1395; WEI M, 2007, J HLTH LAW; Wilson RM, 1995, MED J AUSTRALIA, V163, P458, DOI 10.5694/j.1326-5377.1995.tb124691.x; Witman AB, 1996, ARCH INTERN MED, V156, P2565, DOI 10.1001/archinte.156.22.2565; 2007, NATL QUAL FOR	42	252	253	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 28	2007	356	26					2713	2719		10.1056/NEJMra070568	http://dx.doi.org/10.1056/NEJMra070568			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	183HS	17596606				2022-12-28	WOS:000247564500009
J	Elwy, AR				Elwy, A. Rani			Extended family	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												relwy@bu.edu		Elwy, A. Rani/0000-0001-7088-3118					0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 27	2007	297	24					2675	2676		10.1001/jama.297.24.2675	http://dx.doi.org/10.1001/jama.297.24.2675			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	182UE	17595261				2022-12-28	WOS:000247528700001
J	Pao, M; Ballard, ED; Rosenstein, DL				Pao, Maryland; Ballard, Elizabeth D.; Rosenstein, Donald L.			Growing up in the hospital	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CHILDREN; DEPRESSION; ADOLESCENT; PREVALENCE; CARE		NIMH, NIH, Clin Res Ctr, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Pao, M (corresponding author), NIMH, NIH, Clin Res Ctr, 6-5340, Bethesda, MD 20892 USA.	paom@mail.nih.gov	Ballard, Elizabeth/O-6856-2017	Ballard, Elizabeth/0000-0001-5304-0127				Anderson GM, 2000, CHILD ADOL PSYCH CL, V9, P23; Armstrong FD, 2006, MENT RETARD DEV D R, V12, P168, DOI 10.1002/mrdd.20114; BENNETT DS, 1994, J PEDIATR PSYCHOL, V19, P149, DOI 10.1093/jpepsy/19.2.149; Bhutta AT, 2002, CLIN PERINATOL, V29, P357, DOI 10.1016/S0095-5108(02)00011-8; Dejong M, 2006, PSYCHO-ONCOLOGY, V15, P553, DOI 10.1002/pon.1002; Drotar D, 2006, CHILD HEALTH CARE, V35, P91, DOI 10.1207/s15326888chc3501_8; Erikson E.H., 1968, IDENTITY YOUTH CRISI; Jellinek M., 2002, BRIGHT FUTURES PRACT; Kanner L, 1937, J PEDIATR-US, V11, P418, DOI 10.1016/S0022-3476(37)80027-X; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Mahan, 2005, M CHILDRENS PSYCHOSO; Mayes LC, 2003, CHILD ADOL PSYCH CL, V12, P401, DOI 10.1016/S1056-4993(03)00022-1; Newacheck PW, 1998, AM J PUBLIC HEALTH, V88, P610, DOI 10.2105/AJPH.88.4.610; OWENS PL, 2003, CARE CHILDEN ADOLESC; Peebles-Kleiger MJ, 2000, B MENNINGER CLIN, V64, P257; PERRIN JM, 1993, PEDIATRICS, V92, P876; Schechter NL, 1997, PEDIATRICS, V99, P890, DOI 10.1542/peds.99.6.890; Stuber ML, 2006, CHILD ADOL PSYCH CL, V15, P597, DOI 10.1016/j.chc.2006.02.006; Stuber ML, 2006, CNS SPECTRUMS, V11, P137, DOI 10.1017/S1092852900010671; Suris JC, 2004, ARCH DIS CHILD, V89, P938, DOI 10.1136/adc.2003.045369; THOMASGARD M, 1995, J DEV BEHAV PEDIATR, V16, P47; Uman LS, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005179; Yoshida K, 2005, NEUROPSYCHOBIOLOGY, V52, P55, DOI 10.1159/000086605; Zielinski Tanya A., 2000, Prim Care Companion J Clin Psychiatry, V2, P153	24	19	19	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 27	2007	297	24					2752	2755		10.1001/jama.297.24.2752	http://dx.doi.org/10.1001/jama.297.24.2752			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	182UE	17595276				2022-12-28	WOS:000247528700025
J	Wible, JR; Rougier, GW; Novacek, MJ; Asher, RJ				Wible, J. R.; Rougier, G. W.; Novacek, M. J.; Asher, R. J.			Cretaceous eutherians and Laurasian origin for placental mammals near the K/T boundary	NATURE			English	Article							ANTIQUITY; RODENTS	Estimates of the time of origin for placental mammals from DNA studies span nearly the duration of the Cretaceous period ( 145 to 65 million years ago), with a maximum of 129 million years ago(1) and a minimum of 78 million years ago(2). Palaeontologists too are divided on the timing. Some(3-5) support a deep Cretaceous origin by allying certain middle Cretaceous fossils ( 97 90 million years old) from Uzbekistan with modern placental lineages, whereas others(6,7) support the origin of crown group Placentalia near the close of the Cretaceous. This controversy has yet to be addressed by a comprehensive phylogenetic analysis that includes all well-known Cretaceous fossils and a wide sample of morphology among Tertiary and recent placentals(6). Here we report the discovery of a new well-preserved mammal from the Late Cretaceous of Mongolia and a broad-scale phylogenetic analysis. Our results exclude Cretaceous fossils from Placentalia, place the origin of Placentalia near the Cretaceous/Tertiary (K/T) boundary in Laurasia rather than much earlier within the Cretaceous in the Southern Hemisphere(8,9), and place afrotherians and xenarthrans in a nested rather than a basal position(8,9) within Placentalia.	Museum Hist Nat, Carnegie Museum, Sect Mammals, Pittsburgh, PA 15206 USA; Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA; Amer Museum Nat Hist, Div Paleontol, New York, NY 10024 USA; Univ Cambridge, Museum Zool, Cambridge CB2 3EJ, England	University of Louisville; American Museum of Natural History (AMNH); University of Cambridge	Wible, JR (corresponding author), Museum Hist Nat, Carnegie Museum, Sect Mammals, Pittsburgh, PA 15206 USA.	wiblej@carnegiemnh.org						Archibald JD, 2006, ACTA PALAEONTOL POL, V51, P351; Archibald J. David, 2001, Journal of Mammalian Evolution, V8, P107, DOI 10.1023/A:1011317930838; Archibald JD, 2001, NATURE, V414, P62, DOI 10.1038/35102048; Arnason U, 2002, P NATL ACAD SCI USA, V99, P8151, DOI 10.1073/pnas.102164299; Asher RJ, 2005, SCIENCE, V307, P1091, DOI 10.1126/science.1107808; ASHER RJ, 2003, J MAMM EVOL, V19, P131; Averianov A, 2005, CRETACEOUS RES, V26, P593, DOI 10.1016/j.cretres.2005.03.007; Benton MJ, 2007, MOL BIOL EVOL, V24, P26, DOI 10.1093/molbev/msl150; Bininda-Emonds ORP, 2007, NATURE, V446, P507, DOI 10.1038/nature05634; Clemens W.A. Jr., 1973, University of California Publications in Geological Sciences, V94, P1; Dashzeveg D, 2005, AM MUS NOVIT, P1, DOI 10.1206/0003-0082(2005)498[0001:NSSDEA]2.0.CO;2; Douzery EJP, 2003, J MOL EVOL, V57, pS201, DOI 10.1007/s00239-003-0028-x; Horovitz I, 2003, J VERTEBR PALEONTOL, V23, P857, DOI 10.1671/2399-10; Hunter John P., 2006, Journal of Mammalian Evolution, V13, P89, DOI 10.1007/s10914-006-9006-6; Kielan-Jaworowska Z., 2004, MAMALS AGE DINOSAURS; Kielan-Jaworowska Z, 1981, PALAEONTOLOGIA POLON, V42, P25; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Lillegraven J. A., 1969, U KANSAS PALEONTOLOG, V50, P1; McKenna MC, 1997, CLASSIFICATION MAMMA; Murphy WJ, 2001, SCIENCE, V294, P2348, DOI 10.1126/science.1067179; Nessov Lev A., 1998, Bulletin of Carnegie Museum of Natural History, V34, P40; Novacek MJ, 1997, NATURE, V389, P483, DOI 10.1038/39020; PRASAD GVR, 1994, J VERTEBR PALEONTOL, V14, P260, DOI 10.1080/02724634.1994.10011556; Rougier GW, 2007, AM MUS NOVIT, P1, DOI 10.1206/0003-0082(2007)507[1:NJMFPA]2.0.CO;2; Springer Mark S., 2005, P37; Wible John R., 2005, P15; Wible JR, 2004, B AM MUS NAT HIST, P1, DOI 10.1206/0003-0090(2004)281<0001:NDOTSA>2.0.CO;2; Wilson D. E., 2005, MAMMAL SPECIES WORLD; Woodburne MO, 2003, MOL PHYLOGENET EVOL, V28, P360, DOI 10.1016/S1055-7903(03)00113-1; Zack SP, 2005, NATURE, V434, P497, DOI 10.1038/nature03351	30	217	226	1	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 21	2007	447	7147					1003	1006		10.1038/nature05854	http://dx.doi.org/10.1038/nature05854			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180NU	17581585				2022-12-28	WOS:000247373100047
J	Armani, AM; Kulkarni, RP; Fraser, SE; Flagan, RC; Vahala, KJ				Armani, Andrea M.; Kulkarni, Rajan P.; Fraser, Scott E.; Flagan, Richard C.; Vahala, Kerry J.			Label-free, single-molecule detection with optical microcavities	SCIENCE			English	Article							FLUORESCENCE SPECTROSCOPY; PROTEIN; SURFACE; DNA; CELL; NANOPARTICLES; RESONANCE; DYNAMICS; ARRAYS	Current single-molecule detection techniques require labeling the target molecule. We report a highly specific and sensitive optical sensor based on an ultrahigh quality (Q) factor (Q > 10(8)) whispering-gallery microcavity. The silica surface is functionalized to bind the target molecule; binding is detected by a resonant wavelength shift. Single-molecule detection is confirmed by observation of single-molecule binding events that shift the resonant frequency, as well as by the statistics for these shifts over many binding events. These shifts result from a thermo-optic mechanism. Additionally, label-free, single-molecule detection of interleukin-2 was demonstrated in serum. These experiments demonstrate a dynamic range of 10(12) in concentration, establishing the microcavity as a sensitive and versatile detector.	CALTECH, Dept Appl Phys, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology; California Institute of Technology	Fraser, SE (corresponding author), CALTECH, Dept Appl Phys, MC 128-95, Pasadena, CA 91125 USA.	sefraser@caltech.edu; flagan@caltech.edu	Armani, Andrea/A-8132-2010; Armani, Andrea/A-1216-2007; Armani, Andrea/X-7611-2019; Fraser, Scott/Y-3406-2019	Armani, Andrea/0000-0001-9890-5104; Armani, Andrea/0000-0001-9890-5104; Fraser, Scott/0000-0002-5377-0223				Ambrose WP, 1999, CHEM REV, V99, P2929, DOI 10.1021/cr980132z; Armani AM, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2099529; Armani DK, 2003, NATURE, V421, P925, DOI 10.1038/nature01371; Arnold S, 2003, OPT LETT, V28, P272, DOI 10.1364/OL.28.000272; Burg TP, 2007, NATURE, V446, P1066, DOI 10.1038/nature05741; Cao YWC, 2002, SCIENCE, V297, P1536, DOI 10.1126/science.297.5586.1536; Elf J, 2007, SCIENCE, V316, P1191, DOI 10.1126/science.1141967; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; Fureder-Kitzmuller E, 2005, CHEM PHYS LETT, V404, P13, DOI 10.1016/j.cplett.2005.01.053; Huang B, 2007, SCIENCE, V315, P81, DOI 10.1126/science.1133992; HUGHES RC, 1991, SCIENCE, V254, P74, DOI 10.1126/science.254.5028.74; Jaiswal JK, 2007, NAT CHEM BIOL, V3, P92, DOI 10.1038/nchembio855; Krioukov E, 2002, OPT LETT, V27, P512, DOI 10.1364/OL.27.000512; Ksendzov A, 2005, OPT LETT, V30, P3344, DOI 10.1364/OL.30.003344; Kulkarni RP, 2006, BIOPHYS J, V90, pL42, DOI 10.1529/biophysj.105.077941; Lang MJ, 2004, NAT METHODS, V1, P133, DOI 10.1038/NMETH714; Mazur B, 2004, HEMATOL ONCOL, V22, P27, DOI 10.1002/hon.725; Moore BD, 2004, NAT BIOTECHNOL, V22, P1133, DOI 10.1038/nbt1003; Myong S, 2005, NATURE, V437, P1321, DOI 10.1038/nature04049; Nakatani K, 2001, NAT BIOTECHNOL, V19, P51, DOI 10.1038/83505; Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755; Sako Y, 2000, NAT CELL BIOL, V2, P168, DOI 10.1038/35004044; Schuler B, 2002, NATURE, V419, P743, DOI 10.1038/nature01060; Vijayendran RA, 2001, ANAL CHEM, V73, P471, DOI 10.1021/ac000523p; Wu GH, 2001, NAT BIOTECHNOL, V19, P856, DOI 10.1038/nbt0901-856; Yeo WS, 2005, ANGEW CHEM INT EDIT, V44, P5480, DOI 10.1002/anie.200501363; Zheng GF, 2005, NAT BIOTECHNOL, V23, P1294, DOI 10.1038/nbt1138; Zhong ZH, 2003, SCIENCE, V302, P1377, DOI 10.1126/science.1090899	29	939	985	13	435	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 10	2007	317	5839					783	787		10.1126/science.1145002	http://dx.doi.org/10.1126/science.1145002			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198JN	17615303				2022-12-28	WOS:000248624500034
J	Jouzel, J; Masson-Delmotte, V; Cattani, O; Dreyfus, G; Falourd, S; Hoffmann, G; Minster, B; Nouet, J; Barnola, JM; Chappellaz, J; Fischer, H; Gallet, JC; Johnsen, S; Leuenberger, M; Loulergue, L; Luethi, D; Oerter, H; Parrenin, F; Raisbeck, G; Raynaud, D; Schilt, A; Schwander, J; Selmo, E; Souchez, R; Spahni, R; Stauffer, B; Steffensen, JP; Stenni, B; Stocker, TF; Tison, JL; Werner, M; Wolff, EW				Jouzel, J.; Masson-Delmotte, V.; Cattani, O.; Dreyfus, G.; Falourd, S.; Hoffmann, G.; Minster, B.; Nouet, J.; Barnola, J. M.; Chappellaz, J.; Fischer, H.; Gallet, J. C.; Johnsen, S.; Leuenberger, M.; Loulergue, L.; Luethi, D.; Oerter, H.; Parrenin, F.; Raisbeck, G.; Raynaud, D.; Schilt, A.; Schwander, J.; Selmo, E.; Souchez, R.; Spahni, R.; Stauffer, B.; Steffensen, J. P.; Stenni, B.; Stocker, T. F.; Tison, J. L.; Werner, M.; Wolff, E. W.			Orbital and millennial Antarctic climate variability over the past 800,000 years	SCIENCE			English	Article							PLEISTOCENE GLACIAL TERMINATIONS; SEA-ICE EXTENT; EPICA DOME-C; EAST ANTARCTICA; TEMPERATURE RECORD; TROPICAL PACIFIC; ISOTOPE RECORDS; GREENLAND; CYCLES; CORE	A high-resolution deuterium profile is now available along the entire European Project for Ice Coring in Antarctica Dome C ice core, extending this climate record back to marine isotope stage 20.2, similar to 800,000 years ago. Experiments performed with an atmospheric general circulation model including water isotopes support its temperature interpretation. We assessed the general correspondence between Dansgaard-Oeschger events and their smoothed Antarctic counterparts for this Dome C record, which reveals the presence of such features with similar amplitudes during previous glacial periods. We suggest that the interplay between obliquity and precession accounts for the variable intensity of interglacial periods in ice core records.	Univ Versailles St Quentin Yvelines, CE Saclay, Lab Sci Climat & Environn, Inst Pierre Simon Laplace,CEA,CNRS, F-91191 Gif Sur Yvette, France; Univ Grenoble 1, Lab Glaciol & Geophys Environm, CNRS, F-38402 St Martin Dheres, France; Alfred Wegener Inst Polar & Marine Res, D-27568 Bremerhaven, Germany; Univ Copenhagen, Dept Geophys, DK-2100 Copenhagen, Denmark; Univ Reykjavik, Inst Sci, IS-107 Reykjavik, Iceland; Univ Bern, Inst Phys, CH-3012 Bern, Switzerland; CNRS, Ctr Spectrometrie Nucl & Spectrometrie Masse, F-91405 Orsay, France; Univ Parma, Dept Earth Sci, I-43100 Parma, Italy; Univ Libre Bruxelles, Dept Sci Terre & Environm, Brussels, Belgium; Univ Trieste, Dept Geol Environm & Marine Sci, I-34127 Trieste, Italy; Max Planck Inst Biogeochem, D-7701 Jena, Germany; British Antarctic Survey, Cambridge CB3 0ET, England	UDICE-French Research Universities; Universite Paris Cite; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Helmholtz Association; Alfred Wegener Institute, Helmholtz Centre for Polar & Marine Research; University of Copenhagen; University of Iceland; University of Bern; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Parma; Universite Libre de Bruxelles; University of Trieste; Max Planck Society; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Antarctic Survey	Jouzel, J (corresponding author), Univ Versailles St Quentin Yvelines, CE Saclay, Lab Sci Climat & Environn, Inst Pierre Simon Laplace,CEA,CNRS, F-91191 Gif Sur Yvette, France.	jean.jouzel@lsce.ipsl.fr	raynaud, dominique/ABG-4718-2020; Chappellaz, Jérôme A./A-4872-2011; Werner, Martin/C-8067-2014; Leuenberger, Markus C/K-9655-2016; Wolff, Eric/AAB-1097-2021; Stocker, Thomas/B-1273-2013; Masson-Delmotte, Valerie L/G-1995-2011; Raynaud, Dominique/H-9626-2016; Wolff, Eric W/D-7925-2014; Parrenin, Frédéric/H-3054-2014; Fischer, Hubertus/A-1211-2014; Tison, Jean-Louis/F-4065-2015	Werner, Martin/0000-0002-6473-0243; Leuenberger, Markus C/0000-0003-4299-6793; Wolff, Eric/0000-0002-5914-8531; Masson-Delmotte, Valerie L/0000-0001-8296-381X; Wolff, Eric W/0000-0002-5914-8531; Parrenin, Frédéric/0000-0002-9489-3991; Fischer, Hubertus/0000-0002-2787-4221; Stenni, Barbara/0000-0003-4950-3664; Gallet, Jean-Charles/0000-0002-6153-1361; Schilt, Adrian/0000-0001-6312-7947; Nouet, Julius/0000-0001-5435-542X; Tison, Jean-Louis/0000-0002-9758-3454; Steffensen, Jorgen Peder/0000-0002-5516-1093	NERC [bas010016] Funding Source: UKRI; Natural Environment Research Council [bas010016] Funding Source: researchfish	NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Andersen KK, 2004, NATURE, V431, P147, DOI 10.1038/nature02805; Augustin L, 2004, NATURE, V429, P623, DOI 10.1038/nature02599; Barbante C, 2006, NATURE, V444, P195, DOI 10.1038/nature05301; Bender ML, 1999, GEOPH MONOG SERIES, V112, P149; BERGER AL, 1978, J ATMOS SCI, V35, P2362, DOI 10.1016/0033-5894(78)90064-9; Blunier T, 2001, SCIENCE, V291, P109, DOI 10.1126/science.291.5501.109; Caillon N, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017838; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; Delmotte M, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD004417; Dreyfus GB, 2007, CLIM PAST, V3, P341, DOI 10.5194/cp-3-341-2007; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; Hoffmann G, 1998, J GEOPHYS RES-ATMOS, V103, P16871, DOI 10.1029/98JD00423; Huber C, 2006, EARTH PLANET SC LETT, V243, P504, DOI 10.1016/j.epsl.2006.01.002; Huybers P, 2005, NATURE, V434, P491, DOI 10.1038/nature03401; Huybers P, 2006, SCIENCE, V313, P508, DOI 10.1126/science.1125249; JOOS F, 2005, PAGES NEWS, V13, P11; Jouzel J, 2001, GEOPHYS RES LETT, V28, P3199, DOI 10.1029/2000GL012243; LANDAIS A, 2005, CR HEBD ACAD SCI, V377, P947; Lee SY, 2006, EARTH PLANET SC LETT, V248, P253, DOI 10.1016/j.epsl.2006.05.030; Lisiecki LE, 2005, PALEOCEANOGRAPHY, V20, DOI 10.1029/2005PA001164; Masson-Delmotte V, 2006, CLIM PAST, V2, P145, DOI 10.5194/cp-2-145-2006; McManus JF, 1999, SCIENCE, V283, P971, DOI 10.1126/science.283.5404.971; Medina-Elizalde M, 2005, SCIENCE, V310, P1009, DOI 10.1126/science.1115933; Paillard D., 1996, EOS T AM GEOPHYS UN, V77, P379, DOI 10.1029/96EO00259; Palike H, 2001, EARTH PLANET SC LETT, V193, P589, DOI 10.1016/S0012-821X(01)00501-5; Parrenin F, 2007, CLIM PAST, V3, P243, DOI 10.5194/cp-3-243-2007; Parrenin F, 2003, EARTH PLANET SC LETT, V214, P243, DOI 10.1016/S0012-821X(03)00363-7; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Raymo ME, 2006, SCIENCE, V313, P492, DOI 10.1126/science.1123296; Raynaud D, 2005, NATURE, V436, P39, DOI 10.1038/43639b; Schulz KG, 2006, EARTH PLANET SC LETT, V249, P326, DOI 10.1016/j.epsl.2006.07.004; Siegenthaler U, 2005, SCIENCE, V310, P1313, DOI 10.1126/science.1120130; Spahni R, 2005, SCIENCE, V310, P1317, DOI 10.1126/science.1120132; Stenni B, 2004, EARTH PLANET SC LETT, V217, P183, DOI 10.1016/S0012-821X(03)00574-0; Stocker TF, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2003PA000920; Watanabe O, 2003, NATURE, V422, P509, DOI 10.1038/nature01525; Wolff EW, 2006, NATURE, V440, P491, DOI 10.1038/nature04614; Yiou F, 1997, J GEOPHYS RES-OCEANS, V102, P26783, DOI 10.1029/97JC01265; Yuan XJ, 2000, J CLIMATE, V13, P1697, DOI 10.1175/1520-0442(2000)013<1697:ASIEVA>2.0.CO;2	39	1419	1480	18	532	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 10	2007	317	5839					793	796		10.1126/science.1141038	http://dx.doi.org/10.1126/science.1141038			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198JN	17615306	Green Published			2022-12-28	WOS:000248624500037
J	Schreiber, S; Khaliq-Kareemi, M; Lawrance, IC; Thomsen, OO; Hanauer, SB; McColm, J; Bloomfield, R; Sandborn, WJ				Schreiber, Stefan; Khaliq-Kareemi, Mani; Lawrance, Ian C.; Thomsen, Ole Ostergaard; Hanauer, Stephen B.; McColm, Juliet; Bloomfield, Ralph; Sandborn, William J.		PRECISE 2 Study Investigators	Maintenance therapy with certolizumab pegol for Crohn's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; ANTI-TNF AGENTS; PEGYLATED FAB FRAGMENT; FACTOR-ALPHA; RHEUMATOID-ARTHRITIS; CDP870; INFLIXIMAB; TRIAL; ETANERCEPT; ADALIMUMAB	Background: Certolizumab pegol is a pegylated humanized Fab' fragment with a high binding affinity for tumor necrosis factor (alpha) that does not induce apoptosis of T cells or monocytes. Methods: In our randomized, double-blind, placebo-controlled trial, we evaluated the efficacy of certolizumab pegol maintenance therapy in adults with moderate-to-severe Crohn's disease. As induction therapy, 400 mg of certolizumab pegol was administered subcutaneously at weeks 0, 2, and 4. Patients with a clinical response (defined as reduction of at least 100 from the baseline score on the Crohn's Disease Activity Index [CDAI]) at week 6 were stratified according to their baseline C-reactive protein level and were randomly assigned to receive 400 mg of certolizumab pegol or placebo every 4 weeks through week 24, with follow-up through week 26. Results: Among patients with a response to induction therapy at week 6 (428 of 668 [64%]), the response was maintained through week 26 in 62% of patients with a baseline C-reactive protein level of at least 10 mg per liter (the primary end point) who were receiving certolizumab pegol (vs. 34% of those receiving placebo, P<0.001) and in 63% of patients in the intention-to-treat population who were receiving certolizumab pegol (vs. 36% receiving placebo, P<0.001). Among patients with a response to induction therapy at week 6, remission (defined by a CDAI score of lessthan/equal 150) at week 26 was achieved in 48% of patients in the certolizumab group and 29% of those in the placebo group (P<0.001). The efficacy of certolizumab pegol was also shown in patients taking and those not taking glucocorticoids or immunosuppressants and in patients who had and those who had not previously taken infliximab. Infectious serious adverse events (including one case of pulmonary tuberculosis) occurred in 3% of patients receiving certolizumab pegol and in less than 1% of patients receiving placebo. Antinuclear antibodies developed in 8% of the patients in the certolizumab group; antibodies against certolizumab pegol developed in 9% of all patients who entered the induction phase. Conclusions: Patients with moderate-to-severe Crohn's disease who had a response to induction therapy with 400 mg of certolizumab pegol were more likely to have a maintained response and a remission at 26 weeks with continued certolizumab pegol treatment than with a switch to placebo.	Univ Kiel, Hosp Gen Internal Med, Kiel, Germany; Dalhousie Univ, Halifax, NS, Canada; Univ Western Australia, Fremantle Hosp, Sch Med & Pharmacol, Fremantle, Australia; Univ Copenhagen, Herlev Hosp, Dept Gastroenterol, DK-2730 Herlev, Denmark; Univ Chicago, Med Ctr, Sect Gastroenterol & Nutr, Chicago, IL 60637 USA; UCB Pharma, Slough, Berks, England; Mayo Clin, Div Gastroenterol, Rochester, MN USA	University of Kiel; Dalhousie University; University of Western Australia; University of Copenhagen; Herlev & Gentofte Hospital; University of Chicago; University of Chicago Medical Center; UCB Pharma SA; Mayo Clinic	Schreiber, S (corresponding author), Univ Klinikum Schleswig Holstein, Klin Allgemeine Innere Med, Schittenhelmstr 122, D-24105 Kiel, Germany.	s.schreiber@mucosa.de	Pavli, Paul/GZL-0607-2022; Lawrance, Ian C/H-5252-2014; Sandborn, William/ABE-8342-2020					BEST WR, 1976, GASTROENTEROLOGY, V70, P439; BRAEGGER CP, 1992, LANCET, V339, P89, DOI 10.1016/0140-6736(92)90999-J; Choy EHS, 2002, RHEUMATOLOGY, V41, P1133, DOI 10.1093/rheumatology/41.10.1133; Colombel JF, 2007, GASTROENTEROLOGY, V132, P52, DOI 10.1053/j.gastro.2006.11.041; Fossati G, 2005, AM J GASTROENTEROL, V100, pS298, DOI 10.14309/00000434-200509001-00806; Fossati G, 2005, AM J GASTROENTEROL, V100, pS299, DOI 10.14309/00000434-200509001-00807; Hanauer SB, 2002, LANCET, V359, P1541, DOI 10.1016/S0140-6736(02)08512-4; IRVINE EJ, 1994, GASTROENTEROLOGY, V106, P287, DOI 10.1016/0016-5085(94)90585-1; Keystone E, 2001, ARTHRITIS RHEUM, V44, P2946; Koch G, 1996, DRUG INF J, V30, P523, DOI DOI 10.1177/009286159603000228; Lugering A, 2001, GASTROENTEROLOGY, V121, P1145, DOI 10.1053/gast.2001.28702; MACDONALD TT, 1990, CLIN EXP IMMUNOL, V81, P301; MURCH SH, 1991, GUT, V32, P913, DOI 10.1136/gut.32.8.913; Nesbitt AM, 2004, AM J GASTROENTEROL, V99, pS253, DOI 10.14309/00000434-200410001-00777; Sandborn WJ, 2007, NEW ENGL J MED, V357, P228, DOI 10.1056/NEJMoa067594; SCALLON BJ, 1995, CYTOKINE, V7, P251, DOI 10.1006/cyto.1995.0029; Schreiber S, 2005, GASTROENTEROLOGY, V129, P807, DOI 10.1053/j.gastro.2005.06.064; Schreiber S, 2005, GASTROENTEROLOGY, V129, P1808; Schreiber S, 1999, LANCET, V353, P459, DOI 10.1016/S0140-6736(98)03339-X; Tan EM, 1997, ARTHRITIS RHEUM-US, V40, P1601, DOI 10.1002/art.1780400909; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; Van Den Brande JMH, 2003, GASTROENTEROLOGY, V124, P1774, DOI 10.1016/S0016-5085(03)00382-2; Winter TA, 2004, ALIMENT PHARM THER, V20, P1337, DOI 10.1111/j.1365-2036.2004.02285.x	23	801	828	0	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 19	2007	357	3					239	250		10.1056/NEJMoa062897	http://dx.doi.org/10.1056/NEJMoa062897			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191FH	17634459				2022-12-28	WOS:000248115100005
J	Pierce, JP; Natarajan, L; Caan, BJ; Parker, BA; Greenberg, ER; Flatt, SW; Rock, CL; Kealey, S; Al-Delaimy, WK; Bardwell, WA; Carlson, RW; Emond, JA; Faerber, S; Gold, EB; Hajek, RA; Hollenbach, K; Jones, LA; Karanja, N; Madlensky, L; Marshall, J; Newman, VA; Ritenbaugh, C; Thomson, CA; Wasserman, L; Stefanick, ML				Pierce, John P.; Natarajan, Loki; Caan, Bette J.; Parker, Barbara A.; Greenberg, E. Robert; Flatt, Shirley W.; Rock, Cheryl L.; Kealey, Sheila; Al-Delaimy, Wael K.; Bardwell, Wayne A.; Carlson, Robert W.; Emond, Jennifer A.; Faerber, Susan; Gold, Ellen B.; Hajek, Richard A.; Hollenbach, Kathryn; Jones, Lovell A.; Karanja, Njeri; Madlensky, Lisa; Marshall, James; Newman, Vicky A.; Ritenbaugh, Cheryl; Thomson, Cynthia A.; Wasserman, Linda; Stefanick, Marcia L.			Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer - The Women's Healthy Eating and Living (WHEL) Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTMENOPAUSAL WOMEN; UNITED-STATES; SURVIVAL; DIAGNOSIS; MORTALITY; NUTRITION; COHORT	Context Evidence is lacking that a dietary pattern high in vegetables, fruit, and fiber and low in total fat can influence breast cancer recurrence or survival. Objective To assess whether a major increase in vegetable, fruit, and fiber intake and a decrease in dietary fat intake reduces the risk of recurrent and new primary breast cancer and all-cause mortality among women with previously treated early stage breast cancer. Design, Setting, and Participants Multi-institutional randomized controlled trial of dietary change in 3088 women previously treated for early stage breast cancer who were 18 to 70 years old at diagnosis. Women were enrolled between 1995 and 2000 and followed up through June 1, 2006. Intervention The intervention group (n = 1537) was randomly assigned to receive a telephone counseling program supplemented with cooking classes and newsletters that promoted daily targets of 5 vegetable servings plus 16 oz of vegetable juice; 3 fruit servings; 30 g of fiber; and 15% to 20% of energy intake from fat. The comparison group (n = 1551) was provided with print materials describing the "5-A-Day" dietary guidelines. Main Outcome Measures Invasive breast cancer event (recurrence or new primary) or death from any cause. Results From comparable dietary patterns at baseline, a conservative imputation analysis showed that the intervention group achieved and maintained the following statistically significant differences vs the comparison group through 4 years: servings of vegetables, +65%; fruit, +25%; fiber, +30%, and energy intake from fat, -13%. Plasma carotenoid concentrations validated changes in fruit and vegetable intake. Throughout the study, women in both groups received similar clinical care. Over the mean 7.3-year follow-up, 256 women in the intervention group (16.7%) vs 262 in the comparison group (16.9%) experienced an invasive breast cancer event (adjusted hazard ratio, 0.96; 95% confidence interval, 0.80-1.14; P =.63), and 155 intervention group women (10.1%) vs 160 comparison group women (10.3%) died (adjusted hazard ratio, 0.91; 95% confidence interval, 0.72-1.15; P =.43). No significant interactions were observed between diet group and baseline demographics, characteristics of the original tumor, baseline dietary pattern, or breast cancer treatment. Conclusion Among survivors of early stage breast cancer, adoption of a diet that was very high in vegetables, fruit, and fiber and low in fat did not reduce additional breast cancer events or mortality during a 7.3-year follow-up period.	Univ Calif San Diego, Moores UCSD Canc Ctr, Canc Prevent & Control Program, La Jolla, CA 92093 USA; Kaiser Permanente No Calif, Div Res, Oakland, CA USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Stanford Univ, Stanford Comprehens Canc Ctr, Stanford, CA 94305 USA; Stanford Univ, Stanford Prevnet Res Ctr, Stanford, CA 94305 USA; Univ Calif San Diego, Dept Family & Prevent Med, Div Biostat, San Diego, CA 92103 USA; Univ Calif Davis, Dept Publ Hlth Sci, Davis, CA 95616 USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Ctr Hlth Res, Portland, OR USA; Roswell Pk Canc Inst, Buffalo, NY USA; Univ Arizona, Dept Family & Community Med, Tucson, AZ USA; Univ Arizona, Arizona Canc Ctr, Dept Nutr Sci, Tucson, AZ USA	University of California System; University of California San Diego; Kaiser Permanente; Fred Hutchinson Cancer Center; Stanford University; Stanford University; University of California System; University of California San Diego; University of California System; University of California Davis; University of Texas System; UTMD Anderson Cancer Center; Roswell Park Cancer Institute; University of Arizona; Arizona Center Cancer Care; University of Arizona	Pierce, JP (corresponding author), Univ Calif San Diego, Moores UCSD Canc Ctr, Canc Prevent & Control Program, La Jolla, CA 92093 USA.	jppierce@ucsd.edu	Al-Delaimy, Wael/AFK-1530-2022; Al-Delaimy, Wael/AAF-8821-2022; Carlson, Robert/AAQ-8098-2020	Al-Delaimy, Wael/0000-0001-8292-0510; Caan, Bette/0000-0002-5803-310X; Pierce, John/0000-0002-0075-7471; Ritenbaugh, Cheryl/0000-0002-3307-2727	NCI NIH HHS [R01 CA069375-05, R01 CA069375-09, R01 CA069375-04S3, R01 CA069375-04, R01 CA069375-05S3, R01 CA069375-04S4, R01 CA069375-05S5, R01 CA069375-08, R01 CA069375-06, R01 CA069375-06S2, R01 CA069375, R01 CA069375-02S1, R01 CA069375-04S1, R01 CA069375-05S2, R01 CA069375-07, R01 CA069375-03, R01 CA069375-05S1, R01 CA069375-05S4, R01 CA069375-10, R01 CA069375-06S1, R01 CA069375-02, R01 CA069375-03S1, CA 69375, R01 CA069375-04S2] Funding Source: Medline; NCRR NIH HHS [M01 RR000827, M01-RR00070, M01 RR000070, M01-RR00079, M01-RR00827, M01 RR000079] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069375] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000070, M01RR000079, M01RR000827] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BANDURA A, 1986, SOCIAL FDN THOUGHT A; BARDWELL W, 2003, ANN BEHAV MED, V25, P52; Caan B, 2005, CANCER CAUSE CONTROL, V16, P545, DOI 10.1007/s10552-004-8340-3; Chlebowski RT, 2006, JNCI-J NATL CANCER I, V98, P1767, DOI 10.1093/jnci/djj494; CLARK C, 1998, SAN DIEGO UNION 0311, pA1; Davies AA, 2006, JNCI-J NATL CANCER I, V98, P961, DOI 10.1093/jnci/djj263; GREGORIO DI, 1985, JNCI-J NATL CANCER I, V75, P37; Harashima E, 2007, ASIA PAC J CLIN NUTR, V16, P193; HOLM LE, 1993, J NATL CANCER I, V85, P32, DOI 10.1093/jnci/85.1.32; Hong S, 2007, BREAST CANCER RES TR, V101, P225, DOI 10.1007/s10549-006-9284-y; INGRAM D, 1994, BRIT J CANCER, V69, P592, DOI 10.1038/bjc.1994.108; JAIN M, 1994, J NATL CANCER I, V86, P1390, DOI 10.1093/jnci/86.18.1390; Jatoi I, 2007, J CLIN ONCOL, V25, P1683, DOI 10.1200/JCO.2006.09.2106; Johnson-Kozlow M, 2007, AM J HEALTH BEHAV, V31, P193, DOI 10.5993/AJHB.31.2.8; Kroenke CH, 2005, J CLIN ONCOL, V23, P9295, DOI 10.1200/JCO.2005.02.0198; LACHIN JM, 1986, BIOMETRICS, V42, P507, DOI 10.2307/2531201; Little R. J. A., 1987, STAT ANAL MISSING DA; Mai V, 2005, INT J EPIDEMIOL, V34, P54, DOI 10.1093/ije/dyh388; McEligot AJ, 2006, NUTR CANCER, V55, P132, DOI 10.1207/s15327914nc5502_3; *MYR GEN LAB, BRCA RISK CALC MUT P; *NAT CANC I, 1995, ACT GUID HLTH EAT; *NAT CANC I, 1995, EAT 5 FRUITS VEG DAY; NOMURA AMY, 1991, BREAST CANCER RES TR, V18, pS135, DOI 10.1007/BF02633546; Pierce JP, 2007, J NATL CANCER I, V99, P900, DOI 10.1093/jnci/djk206; Pierce JP, 2007, J CLIN ONCOL, V25, P2345, DOI 10.1200/JCO.2006.08.6819; Pierce JP, 2004, J NUTR, V134, P452; Pierce JP, 2002, CONTROL CLIN TRIALS, V23, P728, DOI 10.1016/S0197-2456(02)00241-6; Rock CL, 2005, J CLIN ONCOL, V23, P6631, DOI 10.1200/JCO.2005.19.505; Rock CL, 2004, J NUTR, V134, P342; Rock CL, 2002, J CLIN ONCOL, V20, P3302, DOI 10.1200/JCO.2002.03.008; ROHAN TE, 1993, NUTR CANCER, V20, P167, DOI 10.1080/01635589309514283; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P427, DOI 10.1007/BF00054304; Thiebaut ACM, 2006, JNCI-J NATL CANCER I, V98, P1753, DOI 10.1093/jnci/djj504; Thomson CA, 2002, J AM DIET ASSOC, V102, P801, DOI 10.1016/S0002-8223(02)90180-X; TM Therneau., 2000, MODELING SURVIVAL DA, DOI DOI 10.1007/978; *USDA US DEP HHS, 1995, HOME HLTH GARDEN B U, V232; Wayne SJ, 2004, J AM DIET ASSOC, V104, P1561, DOI 10.1016/j.jada.2004.07.028; *WOM HLTH IN, WHI THOUGHTS FEEL QU; *WOM HLTH IN, WHI PERS HAB QUEST; [World Cancer Research Fund American Institute for Cancer Research], 1997, FOOD NUTR PREV CANC; ZHANG SM, 1995, CANCER, V76, P275, DOI 10.1002/1097-0142(19950715)76:2<275::AID-CNCR2820760218>3.0.CO;2-6	41	488	502	3	52	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 18	2007	298	3					289	298		10.1001/jama.298.3.289	http://dx.doi.org/10.1001/jama.298.3.289			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	190US	17635889	Green Accepted, Bronze			2022-12-28	WOS:000248086700023
J	Schmoll, HJ; Sargent, D				Schmoll, Hans-Joachim; Sargent, Daniel			Single agent fluorouracil for-first-line treatment of advanced colorectal cancer as standard?	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; COMBINATION CHEMOTHERAPY; OXALIPLATIN; IRINOTECAN; LEUCOVORIN		Univ Halle Wittenberg, Dept Haematol Oncol, Internal Med Clin, D-06120 Halle, Germany; Mayo Clin, Rochester, MN USA	Martin Luther University Halle Wittenberg; Mayo Clinic	Schmoll, HJ (corresponding author), Univ Halle Wittenberg, Dept Haematol Oncol, Internal Med Clin, D-06120 Halle, Germany.		Schmoll, Hans-Joachim/AAG-5888-2019; schmoll, hans-joachim/AAO-5219-2021	schmoll, hans-joachim/0000-0001-8705-0593; Sargent, Daniel/0000-0002-2684-4741				BOUCHE O, 2007, J CLIN ONCOL S, V18, P4069; Falcone A, 2007, J CLIN ONCOL, V25, P1670, DOI 10.1200/JCO.2006.09.0928; FUCHS C, 2007, J CLIN ONCOL S, V18, P4027; Grothey A, 2004, J CLIN ONCOL, V22, P1209, DOI 10.1200/JCO.2004.11.037; Koopman M, 2007, LANCET, V370, P135, DOI 10.1016/S0140-6736(07)61086-1; SALTZ L, 2007, J CLIN ONCOL S, V18, P4028; Saunders M, 2006, BRIT J CANCER, V95, P131, DOI 10.1038/sj.bjc.6603233; Schrag D, 2004, NEW ENGL J MED, V351, P317, DOI 10.1056/NEJMp048143; Seymour MT, 2007, LANCET, V370, P143, DOI 10.1016/S0140-6736(07)61087-3; Souglakos J, 2006, BRIT J CANCER, V94, P798, DOI 10.1038/sj.bjc.6603011; VANCUTSEM E, 2007, J CLIN ONCOL S, V18, P4000	11	29	30	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 14	2007	370	9582					105	107		10.1016/S0140-6736(07)61062-9	http://dx.doi.org/10.1016/S0140-6736(07)61062-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	190WP	17630019				2022-12-28	WOS:000248091600004
J	Dietzl, G; Chen, D; Schnorrer, F; Su, KC; Barinova, Y; Fellner, M; Gasser, B; Kinsey, K; Oppel, S; Scheiblauer, S; Couto, A; Marra, V; Keleman, K; Dickson, BJ				Dietzl, Georg; Chen, Doris; Schnorrer, Frank; Su, Kuan-Chung; Barinova, Yulia; Fellner, Michaela; Gasser, Beate; Kinsey, Kaolin; Oppel, Silvia; Scheiblauer, Susanne; Couto, Africa; Marra, Vincent; Keleman, Krystyna; Dickson, Barry J.			A genome-wide transgenic RNAi library for conditional gene inactivation in Drosophila	NATURE			English	Article							DOUBLE-STRANDED-RNA; CAENORHABDITIS-ELEGANS; INTERFERENCE; EXPRESSION; MELANOGASTER; IDENTIFICATION; INITIATION; PATHWAYS; SCREENS; VECTOR	Forward genetic screens in model organisms have provided important insights into numerous aspects of development, physiology and pathology. With the availability of complete genome sequences and the introduction of RNA-mediated gene interference (RNAi), systematic reverse genetic screens are now also possible. Until now, such genome-wide RNAi screens have mostly been restricted to cultured cells and ubiquitous gene inactivation in Caenorhabditis elegans. This powerful approach has not yet been applied in a tissue-specific manner. Here we report the generation and validation of a genome-wide library of Drosophila melanogaster RNAi transgenes, enabling the conditional inactivation of gene function in specific tissues of the intact organism. Our RNAi transgenes consist of short gene fragments cloned as inverted repeats and expressed using the binary GAL4/UAS system. We generated 22,270 transgenic lines, covering 88% of the predicted protein-coding genes in the Drosophila genome. Molecular and phenotypic assays indicate that the majority of these transgenes are functional. Our transgenic RNAi library thus opens up the prospect of systematically analysing gene functions in any tissue and at any stage of the Drosophila lifespan.	Austrian Acad Sci, Inst Mol Biotechnol, A-1030 Vienna, Austria; Res Inst Mol Pathol, A-1030 Vienna, Austria	Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Dickson, BJ (corresponding author), Austrian Acad Sci, Inst Mol Biotechnol, Dr Bohr Gasse 3-5, A-1030 Vienna, Austria.	dickson@imp.ac.at	Dickson, Barry/AAE-7632-2019; Schnorrer, Frank/AIE-3578-2022	Dickson, Barry/0000-0003-0715-892X; Schnorrer, Frank/0000-0002-9518-7263; Couto, Africa/0000-0002-3868-5637; Chen, Doris/0000-0001-8835-0280				Arbeitman MN, 2002, SCIENCE, V297, P2270, DOI 10.1126/science.1072152; Beall EL, 2002, GENETICS, V162, P217; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Boutros M, 2004, SCIENCE, V303, P832, DOI 10.1126/science.1091266; BRAND AH, 1993, DEVELOPMENT, V118, P401; Caudy AA, 2003, NATURE, V425, P411, DOI 10.1038/nature01956; Duffy JB, 2002, GENESIS, V34, P1, DOI 10.1002/gene.10150; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fortier E, 2000, GENESIS, V26, P240, DOI 10.1002/(SICI)1526-968X(200004)26:4<240::AID-GENE40>3.0.CO;2-P; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Kalidas S, 2002, NEURON, V33, P177, DOI 10.1016/S0896-6273(02)00560-3; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kennerdell JR, 2000, NAT BIOTECHNOL, V18, P896, DOI 10.1038/78531; Kulkarni MM, 2006, NAT METHODS, V3, P833, DOI 10.1038/nmeth935; Lam G, 2000, CURR BIOL, V10, P957, DOI 10.1016/S0960-9822(00)00631-X; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Lee YS, 2003, METHODS, V30, P322, DOI 10.1016/S1046-2023(03)00051-3; Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Ma Y, 2006, NATURE, V443, P359, DOI 10.1038/nature05179; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Martinek S, 2000, GENETICS, V156, P1717; McGuire SE, 2003, SCIENCE, V302, P1765, DOI 10.1126/science.1089035; Newmark PA, 2003, P NATL ACAD SCI USA, V100, P11861, DOI 10.1073/pnas.1834205100; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; Ranganayakulu G, 1996, DEV BIOL, V176, P143, DOI 10.1006/dbio.1996.9987; Reddien PW, 2005, DEV CELL, V8, P635, DOI 10.1016/j.devcel.2005.02.014; Reichhart JM, 2002, GENESIS, V34, P160, DOI 10.1002/gene.10122; Roignant JY, 2003, RNA, V9, P299, DOI 10.1261/rna.2154103; Roman G, 2001, P NATL ACAD SCI USA, V98, P12602, DOI 10.1073/pnas.221303998; Rozen S, 2000, Methods Mol Biol, V132, P365; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Ryder E, 2004, GENETICS, V167, P797, DOI 10.1534/genetics.104.026658; Schuler GD, 1997, GENOME RES, V7, P541, DOI 10.1101/gr.7.5.541; Sonnichsen B, 2005, NATURE, V434, P462, DOI 10.1038/nature03353; Stebbins MJ, 2001, P NATL ACAD SCI USA, V98, P10775, DOI 10.1073/pnas.121186498; TOMANCAK P, 2002, GENOME BIOL, V3; Van Roessel P, 2002, GENESIS, V34, P170, DOI 10.1002/gene.10146; Williams RW, 2002, P NATL ACAD SCI USA, V99, P6889, DOI 10.1073/pnas.072190799; Wong ML, 2005, BIOTECHNIQUES, V39, P75, DOI 10.2144/05391RV01	43	1904	1950	4	223	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 12	2007	448	7150					151	U1		10.1038/nature05954	http://dx.doi.org/10.1038/nature05954			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	188QN	17625558				2022-12-28	WOS:000247934500033
J	Vassylyev, DG; Vassylyeva, MN; Perederina, A; Tahirov, TH; Artsimovitch, I				Vassylyev, Dmitry G.; Vassylyeva, Marina N.; Perederina, Anna; Tahirov, Tahir H.; Artsimovitch, Irina			Structural basis for transcription elongation by bacterial RNA polymerase	NATURE			English	Article							3.3 ANGSTROM RESOLUTION; ELECTRON-DENSITY MAPS; THERMUS-THERMOPHILUS; CRYSTAL-STRUCTURE; LID ELEMENT; DNA HYBRID; COMPLEX; MECHANISM; TRANSLOCATION; INITIATION	The RNA polymerase elongation complex (EC) is both highly stable and processive, rapidly extending RNA chains for thousands of nucleotides. Understanding the mechanisms of elongation and its regulation requires detailed information about the structural organization of the EC. Here we report the 2.5-angstrom resolution structure of the Thermus thermophilus EC; the structure reveals the post-translocated intermediate with the DNA template in the active site available for pairing with the substrate. DNA strand separation occurs one position downstream of the active site, implying that only one substrate at a time can specifically bind to the EC. The upstream edge of the RNA/DNA hybrid stacks on the beta'-subunit 'lid' loop, whereas the first displaced RNA base is trapped within a protein pocket, suggesting a mechanism for RNA displacement. The RNA is threaded through the RNA exit channel, where it adopts a conformation mimicking that of a single strand within a double helix, providing insight into a mechanism for hairpin-dependent pausing and termination.	Univ Alabama Birmingham, Sch Med, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Sch Dent, Birmingham, AL 35294 USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Lied Transplant Ctr, Omaha, NE 68198 USA; Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Nebraska System; University of Nebraska Medical Center; University System of Ohio; Ohio State University	Vassylyev, DG (corresponding author), Univ Alabama Birmingham, Sch Med, Dept Biochem & Mol Genet, 402B Kaul Genet Bldg,720 20th St S, Birmingham, AL 35294 USA.	dmitry@uab.edu	Vassylyev, Dmitry/A-9005-2008; Artsimovitch, Irina/L-3467-2019; Ganesh, Dunna Sai/AGX-5170-2022	Tahirov, Tahir/0000-0002-1238-0069				Abbondanzieri EA, 2005, NATURE, V438, P460, DOI 10.1038/nature04268; Afonine PV, 2005, ACTA CRYSTALLOGR D, V61, P850, DOI 10.1107/S0907444905007894; ARCHAMBAULT J, 1993, MICROBIOL REV, V57, P703, DOI 10.1128/MMBR.57.3.703-724.1993; Artsimovitch I, 1998, GENE DEV, V12, P3110, DOI 10.1101/gad.12.19.3110; BAKER D, 1993, ACTA CRYSTALLOGR D, V49, P429, DOI 10.1107/S0907444993004032; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Chlenov M, 2005, J MOL BIOL, V353, P138, DOI 10.1016/j.jmb.2005.07.073; Cramer P, 2002, CURR OPIN STRUC BIOL, V12, P89, DOI 10.1016/S0959-440X(02)00294-4; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Foster JE, 2001, CELL, V106, P243, DOI 10.1016/S0092-8674(01)00420-2; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Gong XQ, 2005, MOL CELL, V18, P461, DOI 10.1016/j.molcel.2005.04.011; Gusarov I, 1999, MOL CELL, V3, P495, DOI 10.1016/S1097-2765(00)80477-3; Huang JB, 2000, BIOCHEMISTRY-US, V39, P11571, DOI 10.1021/bi000579d; Jiang ML, 2004, MOL CELL, V15, P777, DOI 10.1016/j.molcel.2004.07.019; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kapanidis AN, 2006, SCIENCE, V314, P1144, DOI 10.1126/science.1131399; Kashkina E, 2006, NUCLEIC ACIDS RES, V34, P4036, DOI 10.1093/nar/gkl559; Kettenberger H, 2004, MOL CELL, V16, P955, DOI 10.1016/j.molcel.2004.11.040; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuznedelov K, 2002, EMBO J, V21, P1369, DOI 10.1093/emboj/21.6.1369; Landick R, 2005, TRENDS BIOCHEM SCI, V30, P651, DOI 10.1016/j.tibs.2005.10.001; MATTHEWS BW, 1975, ACTA CRYSTALLOGR A, V31, P480, DOI 10.1107/S0567739475001040; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mooney RA, 2005, MOL CELL, V20, P335, DOI 10.1016/j.molcel.2005.10.015; Naryshkin N, 2000, CELL, V101, P601, DOI 10.1016/S0092-8674(00)80872-7; Naryshkina T, 2006, J MOL BIOL, V361, P634, DOI 10.1016/j.jmb.2006.05.034; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Revyakin A, 2006, SCIENCE, V314, P1139, DOI 10.1126/science.1131398; Santangelo TJ, 2004, MOL CELL, V14, P117, DOI 10.1016/S1097-2765(04)00154-6; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Tahirov TH, 2002, NATURE, V420, P43, DOI 10.1038/nature01129; Temiakov D, 2004, CELL, V116, P381, DOI 10.1016/S0092-8674(04)00059-5; Toulokhonov I, 2006, J MOL BIOL, V361, P644, DOI 10.1016/j.jmb.2006.06.071; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; Vassylyeva MN, 2002, ACTA CRYSTALLOGR D, V58, P1497, DOI 10.1107/S0907444902011770; Wang D, 2006, CELL, V127, P941, DOI 10.1016/j.cell.2006.11.023; Wang JH, 1996, ACTA CRYSTALLOGR D, V52, P369, DOI 10.1107/S0907444995012352; Weeks CM, 1999, ACTA CRYSTALLOGR D, V55, P492, DOI 10.1107/S0907444998012633; Westover KD, 2004, CELL, V119, P481, DOI 10.1016/j.cell.2004.10.016; Westover KD, 2004, SCIENCE, V303, P1014, DOI 10.1126/science.1090839; Yarnell WS, 1999, SCIENCE, V284, P611, DOI 10.1126/science.284.5414.611; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3; Yin YW, 2004, CELL, V116, P393, DOI 10.1016/S0092-8674(04)00120-5; Yin YW, 2002, SCIENCE, V298, P1387, DOI 10.1126/science.1077464; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	50	318	330	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 12	2007	448	7150					157	U3		10.1038/nature05932	http://dx.doi.org/10.1038/nature05932			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	188QN	17581590				2022-12-28	WOS:000247934500034
J	Cooper, D; Cahn, P; Lewin, S; Kaldor, J; McClure, C; Kort, R; Boyd, M				Cooper, David; Cahn, Pedro; Lewin, Sharon; Kaldor, John; McClure, Craig; Kort, Rodney; Boyd, Mark			The Sydney Declaration: a call to scale up research	LANCET			English	Editorial Material									Int AIDS Soc, CH-1216 Geneva, Switzerland; Univ New S Wales, Sydney, NSW, Australia; Fdn Huesped, Buenos Aires, DF, Argentina; Monash Univ, Clayton, Vic 3168, Australia; Alfred Hosp, Prahran, Vic 3181, Australia	University of New South Wales Sydney; Monash University; Florey Institute of Neuroscience & Mental Health	Kort, R (corresponding author), Int AIDS Soc, CH-1216 Geneva, Switzerland.	Rodney.Kort@iasociety.org	Kaldor, John M/D-4545-2011; Lewin, Sharon/Z-3297-2019	Lewin, Sharon Ruth/0000-0002-0330-8241					0	12	12	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 7	2007	370	9581					7	8		10.1016/S0140-6736(07)61024-1	http://dx.doi.org/10.1016/S0140-6736(07)61024-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187QE	17617252				2022-12-28	WOS:000247862300006
J	Gatrad, R; Gatrad, A; Sheikh, A				Gatrad, Rashid; Gatrad, Adam; Sheikh, Aziz			One last puff	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Edinburgh, Div Community Hlth Sci, Allergy & Resp Res Grp, Edinburgh EH8 9YL, Midlothian, Scotland; Univ Cent England, Birmingham, W Midlands, England; Manor Hosp, Walsall, W Midlands, England	University of Edinburgh; Birmingham City University	Sheikh, A (corresponding author), Univ Edinburgh, Div Community Hlth Sci, Allergy & Resp Res Grp, Edinburgh EH8 9YL, Midlothian, Scotland.	Aziz.Sheikh@ed.ac.uk	Sheikh, Aziz/D-2818-2009	Sheikh, Aziz/0000-0001-7022-3056					0	32	36	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 7	2007	335	7609					20	20		10.1136/bmj.39227.409641.AD	http://dx.doi.org/10.1136/bmj.39227.409641.AD			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	191LY	17615218	Green Published, Green Submitted			2022-12-28	WOS:000248133900027
J	Stewart, W				Stewart, Will			The power to set you free	SCIENCE			English	Editorial Material									Univ Southampton, Optoelect Res Ctr, Southampton SO17 1BJ, Hants, England	University of Southampton	Stewart, W (corresponding author), Univ Southampton, Optoelect Res Ctr, Southampton SO17 1BJ, Hants, England.	w.stewart@ieee.org						Kurs A, 2007, SCIENCE, V317, P83, DOI 10.1126/science.1143254; PENDRY JP, COMMUNICATION	2	8	47	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2007	317	5834					55	56		10.1126/science.1145008	http://dx.doi.org/10.1126/science.1145008			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186KD	17615331				2022-12-28	WOS:000247776700036
J	Ruby, JG; Jan, CH; Bartel, DP				Ruby, J. Graham; Jan, Calvin H.; Bartel, David P.			Intronic microRNA precursors that bypass Drosha processing	NATURE			English	Article							GENOME; RNAS; MATURATION; SEQUENCE; GENE	MicroRNAs ( miRNAs) are similar to 22-nucleotide endogenous RNAs that often repress the expression of complementary messenger RNAs1. In animals, miRNAs derive from characteristic hairpins in primary transcripts through two sequential RNase III-mediated cleavages; Drosha cleaves near the base of the stem to liberate a similar to 60-nucleotide pre-miRNA hairpin, then Dicer cleaves near the loop to generate a miRNA: miRNA* duplex(2,3). From that duplex, the mature miRNA is incorporated into the silencing complex. Here we identify an alternative pathway for miRNA biogenesis, in which certain debranched introns mimic the structural features of pre-miRNAs to enter the miRNA-processing pathway without Drosha-mediated cleavage. We call these pre-miRNAs/introns 'mirtrons', and have identified 14 mirtrons in Drosophila melanogaster and another four in Caenorhabditis elegans ( including the reclassification of mir-62). Some of these have been selectively maintained during evolution with patterns of sequence conservation suggesting important regulatory functions in the animal. The abundance of introns comparable in size to pre-miRNAs appears to have created a context favourable for the emergence of mirtrons in flies and nematodes. This suggests that other lineages with many similarly sized introns probably also have mirtrons, and that the mirtron pathway could have provided an early avenue for the emergence of miRNAs before the advent of Drosha.	MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Bartel, DP (corresponding author), MIT, Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	dbartel@wi.mit.edu			NIGMS NIH HHS [R01 GM067031-04, R01 GM067031] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067031] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Blanchette M, 2004, GENOME RES, V14, P708, DOI 10.1101/gr.1933104; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Dorner S, 2006, P NATL ACAD SCI USA, V103, P11880, DOI 10.1073/pnas.0605210103; Forstemann K, 2005, PLOS BIOL, V3, P1187, DOI 10.1371/journal.pbio.0030236; Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023; Grumbling G, 2006, NUCLEIC ACIDS RES, V34, pD484, DOI 10.1093/nar/gkj068; Han J, 2001, DRUG DELIV, V8, P125; HOFACKER IL, 1994, MONATSH CHEM, V125, P167, DOI 10.1007/BF00818163; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; Kim YK, 2007, EMBO J, V26, P775, DOI 10.1038/sj.emboj.7601512; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; LEVERETTE RD, 1992, CELL, V71, P1215, DOI 10.1016/S0092-8674(05)80069-8; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lim LP, 2001, P NATL ACAD SCI USA, V98, P11193, DOI 10.1073/pnas.201407298; Lim LP, 2003, GENE DEV, V17, P991, DOI 10.1101/gad.1074403; LO PCH, 1994, GENETICS, V138, P365; PADGETT RA, 1984, SCIENCE, V225, P898, DOI 10.1126/science.6206566; Pruitt KD, 2005, NUCLEIC ACIDS RES, V33, pD501, DOI 10.1093/nar/gki025; Richards S, 2005, GENOME RES, V15, P1, DOI 10.1101/gr.3059305; Ruby JG, 2006, CELL, V127, P1193, DOI 10.1016/j.cell.2006.10.040; RUBY JG, IN PRESS GENOME RES; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; Stein L, 2001, NUCLEIC ACIDS RES, V29, P82, DOI 10.1093/nar/29.1.82; Tomari Y, 2005, GENE DEV, V19, P517, DOI 10.1101/gad.1284105; Yandell M, 2006, PLOS COMPUT BIOL, V2, P113, DOI 10.1371/journal.pcbi.0020015	30	1028	1124	1	86	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 5	2007	448	7149					83	86		10.1038/nature05983	http://dx.doi.org/10.1038/nature05983			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185OS	17589500	Green Accepted			2022-12-28	WOS:000247720900042
J	Hamill, M; Burgoine, K; Farrell, F; Hemelaar, J; Patel, G; Welchew, DE; Jaffe, HW				Hamill, M.; Burgoine, K.; Farrell, F.; Hemelaar, J.; Patel, G.; Welchew, D. E.; Jaffe, H. W.			Time to move towards opt-out testing for HIV in the UK	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							UNITED-STATES		Univ Oxford, Dept Publ Hlth, Oxford OX3 7LF, England; Camden Primary Care Trust, Dept Genitourinary Med, Mortimer Market Ctr, London, England; Univ Oxford, Sch Clin, Oxford OX3 7LF, England	University of Oxford; University of Oxford	Jaffe, HW (corresponding author), Univ Oxford, Dept Publ Hlth, Oxford OX3 7LF, England.	Harold.jaffe@dphpc.ox.ac.uk		Burgoine, Kathy/0000-0001-7975-745X; Hemelaar, Joris/0000-0003-3523-7457; Hamill, Matthew M/0000-0002-1277-819X				Brandt PT, 2006, POLIT ANAL, V14, P1, DOI 10.1093/pan/mpi035; *BRIT HIV ASS, 2005, GUID TREATM HIV INF; De Cock KM, 1998, BMJ-BRIT MED J, V316, P290, DOI 10.1136/bmj.316.7127.290; Greenwald Jeffrey L, 2006, Curr Infect Dis Rep, V8, P125, DOI 10.1007/s11908-006-0008-6; *HLTH PROT AG, MIGR HLTH INF DIS NO; LYSS SB, IN PRESS J ACQUIRE I; Marks G, 2005, JAIDS-J ACQ IMM DEF, V39, P446, DOI 10.1097/01.qai.0000151079.33935.79; *NAT I HLTH CLIN E, 2005, SOC VAL JUDGM PRINC; *NHS, 199183 NHS; Paltiel AD, 2006, ANN INTERN MED, V145, P797, DOI 10.7326/0003-4819-145-11-200612050-00004; Poznansky MC, 1996, J ACCID EMERG MED, V13, P424; ROGSTAD KE, 2006, UK NATL GUIDELINES H; The UK Collaborative Group for HIV and STI Surveillance, 2006, COMPL PICT HIV OTH S; *UN GEN ASS, SCAL HIV PREV TREATM; *UNAIDS REF GROUP, 2007, PROV IN TEST COUNS H; Walensky RP, 2005, AM J PUBLIC HEALTH, V95, P71, DOI 10.2105/AJPH.2003.031310; World Health Organization, 2007, GUID PROV IN HIV TES	17	36	36	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 30	2007	334	7608					1352	1354		10.1136/bmj.39218.404201.94	http://dx.doi.org/10.1136/bmj.39218.404201.94			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	185VX	17600024	Green Published			2022-12-28	WOS:000247739600031
J	Tessmar-Raible, K; Raible, F; Christodoulou, F; Guy, K; Rembold, M; Hausen, H; Arendt, D				Tessmar-Raible, Kristin; Raible, Florian; Christodoulou, Foteini; Guy, Keren; Rembold, Martina; Hausen, Harald; Arendt, Detlev			Conserved sensory-neurosecretory cell types in annelid and fish forebrain: Insights into hypothalamus evolution	CELL			English	Article							VASOPRESSIN OXYTOCIN SUPERFAMILY; CENTRAL-NERVOUS-SYSTEM; PLATYNEREIS-DUMERILII; MICRORNA EXPRESSION; ARGININE VASOTOCIN; LOCUSTA-MIGRATORIA; AMPHIOXUS LARVAE; MESSENGER-RNA; EYE-FIELD; BRAIN	Neurosecretory control centers form part of the forebrain in many animal phyla, including vertebrates, insects, and annelids. The evolutionary origin of these centers is largely unknown. To identify conserved, and thus phylogenetically ancient, components of neurosecretory brain centers, we characterize and compare neurons that express the prohormone vasotocin (vasopressin/oxytocin)-neurophysin in the developing forebrain of the annelid Platynereis dumerilii and of the zebrafish. These neurons express the same tissue-restricted microRNA, miR-7, and conserved, cell-type-specific combinations of transcription factors (nk2.1, rx, and otp) that specify their identity, as evidenced by the specific requirement of zebrafish rx3 for vasotocin-neurophysin expression. MiR-7 also labels another shared population of neurons containing RF amides. Since the vasotocinergic and RF amidergic neurons appear to be directly sensory in annelid and fish, we propose that cell types with dual sensory-neurosecretory properties were the starting point for the evolution of neurosecretory brain centers in Bilateria.	European Mol Biol Lab, Dev Biol Unit, D-69012 Heidelberg, Germany; European Mol Biol Lab, Computat Biol Unit, D-69012 Heidelberg, Germany; Free Univ Berlin, Inst Biol, D-14195 Berlin, Germany	European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL); Free University of Berlin	Tessmar-Raible, K (corresponding author), European Mol Biol Lab, Dev Biol Unit, Meyerhofstr 1, D-69012 Heidelberg, Germany.	kristin.tessmar@embl.de; detlev.arendt@embl.de	Tessmar-Raible, Kristin/F-9642-2011; Raible, Florian/G-6019-2011	Tessmar-Raible, Kristin/0000-0002-8038-1741; Raible, Florian/0000-0002-4515-6485				Acampora D, 1999, GENE DEV, V13, P2787, DOI 10.1101/gad.13.21.2787; ADASHI EY, 1981, NATURE, V293, P650, DOI 10.1038/293650a0; [Anonymous], NEUROENDOCRINOLOGY I; Arendt D, 2004, SCIENCE, V306, P869, DOI 10.1126/science.1099955; Arendt D, 2002, DEVELOPMENT, V129, P1143; Ason B, 2006, P NATL ACAD SCI USA, V103, P14385, DOI 10.1073/pnas.0603529103; Castro A, 2001, J COMP NEUROL, V440, P43, DOI 10.1002/cne.1369; Chuang JC, 1999, MECH DEVELOP, V84, P195, DOI 10.1016/S0925-4773(99)00077-5; Corbin JG, 2003, DEVELOPMENT, V130, P4895, DOI 10.1242/dev.00717; Corbin JG, 2001, NAT NEUROSCI, V4, P1177, DOI 10.1038/nn749; de Velasco B, 2007, DEV BIOL, V302, P309, DOI 10.1016/j.ydbio.2006.09.035; Del Giacco L, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-50; Dickmeis T, 2007, PLOS BIOL, V5, P854, DOI 10.1371/journal.pbio.0050078; DUBE L, 1990, BRAIN BEHAV EVOLUT, V35, P212, DOI 10.1159/000115868; Fujino Y, 1999, J EXP ZOOL, V284, P401, DOI 10.1002/(SICI)1097-010X(19990901)284:4<401::AID-JEZ6>3.0.CO;2-U; Goodson JL, 2000, NATURE, V403, P769, DOI 10.1038/35001581; Gozdowska M, 2006, COMP BIOCHEM PHYS B, V143, P330, DOI 10.1016/j.cbpb.2005.12.004; Hartenstein V, 2006, J ENDOCRINOL, V190, P555, DOI 10.1677/joe.1.06964; HAUENSCHILD C, 1955, NATURWISSENSCHAFTEN, V42, P611, DOI 10.1007/BF00601014; Hausen H, 1998, ACTA ZOOL-STOCKHOLM, V79, P149, DOI 10.1111/j.1463-6395.1998.tb01154.x; Hewes RS, 2001, GENOME RES, V11, P1126, DOI 10.1101/gr.169901; HOFMANN DK, 1976, DEV GENES EVOL, V180, P47; Ishikawa Y, 2001, BRAIN BEHAV EVOLUT, V58, P173, DOI 10.1159/000047271; Iwakoshi E, 2002, BIOCHEM BIOPH RES CO, V291, P1187, DOI 10.1006/bbrc.2002.6594; Jekely G, 2007, BIOTECHNIQUES, V42, P751, DOI 10.2144/000112462; JOWETT T, 1994, TRENDS GENET, V10, P73, DOI 10.1016/0168-9525(94)90220-8; Kempf SC, 1997, J COMP NEUROL, V386, P507, DOI 10.1002/(SICI)1096-9861(19970929)386:3<507::AID-CNE12>3.0.CO;2-7; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; LACALLI TC, 1984, PHILOS T ROY SOC B, V306, P79, DOI 10.1098/rstb.1984.0082; Lacalli TC, 2000, ACTA ZOOL-STOCKHOLM, V81, P37, DOI 10.1046/j.1463-6395.2000.00036.x; Lacalli TC, 1996, PHILOS T ROY SOC B, V351, P243, DOI 10.1098/rstb.1996.0022; LEONHARDT H, 1980, HDB MIKROSKOPISCHEN, V4; Loosli F, 2003, EMBO REP, V4, P894, DOI 10.1038/sj.embor.embor919; Lowe CJ, 2003, CELL, V113, P853, DOI 10.1016/S0092-8674(03)00469-0; Matsumoto A., 1992, ATLAS ENDOCRINE ORGA; Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682; Murakami Y, 2001, DEVELOPMENT, V128, P3521; Norris D. O., 1997, VERTEBRATE ENDOCRINO; Oliveira RF, 2005, HORM BEHAV, V48, P430, DOI 10.1016/j.yhbeh.2005.06.002; Ota Y, 1999, GEN COMP ENDOCR, V116, P40, DOI [10.1006/gcen.1999.7344, 10.1006/gcen.1999.7343]; OUMI T, 1994, BIOCHEM BIOPH RES CO, V198, P393, DOI 10.1006/bbrc.1994.1055; Pinelli C, 2000, DEV BRAIN RES, V119, P195, DOI 10.1016/S0165-3806(99)00172-8; Plickert G, 2004, HYDROBIOLOGIA, V530, P49, DOI 10.1007/s10750-004-2689-x; Prochnik SE, 2007, DEV GENES EVOL, V217, P73, DOI 10.1007/s00427-006-0116-1; PROUX JP, 1987, BIOCHEM BIOPH RES CO, V149, P180, DOI 10.1016/0006-291X(87)91621-4; Raible F, 2005, SCIENCE, V310, P1325, DOI 10.1126/science.1119089; Rembold M, 2006, SCIENCE, V313, P1130, DOI 10.1126/science.1127144; RODRIGUEZ M, 1991, GEN COMP ENDOCR, V83, P249, DOI 10.1016/0016-6480(91)90028-5; Rogers C, 2003, NAT NEUROSCI, V6, P1178, DOI 10.1038/nn1140; Rohr KB, 2001, NEURON, V29, P341, DOI 10.1016/S0896-6273(01)00210-0; Rojas-Munoz A, 2005, DEV BIOL, V288, P348, DOI 10.1016/j.ydbio.2005.08.046; Salzet M, 1997, J IMMUNOL, V159, P5400; Sood P, 2006, P NATL ACAD SCI USA, V103, P2746, DOI 10.1073/pnas.0511045103; Stigloher C, 2006, DEVELOPMENT, V133, P2925, DOI 10.1242/dev.02450; Take-uchi M, 2003, DEVELOPMENT, V130, P955, DOI 10.1242/dev.00305; Takuwa-Kuroda K, 2003, REGUL PEPTIDES, V115, P139, DOI 10.1016/S0167-0115(03)00151-4; TAYLOR MH, 1986, AM ZOOL, V26, P159; Tessmar-Raible K, 2005, BIOTECHNIQUES, V39, P460, DOI 10.2144/000112023; THOMPSON KSJ, 1991, J COMP PHYSIOL A, V168, P619, DOI 10.1007/BF00215084; THORNDYKE M, 1998, NEUROHORMONES INVERT; Thornton JW, 2003, SCIENCE, V301, P1714, DOI 10.1126/science.1086185; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; Twan WH, 2006, ENDOCRINOLOGY, V147, P397, DOI 10.1210/en.2005-0584; UEMURA H, 1994, CELL TISSUE RES, V277, P279, DOI 10.1007/s004410050154; Unger JL, 2003, GENE EXPR PATTERNS, V3, P105, DOI 10.1016/S1567-133X(02)00064-9; VANKESTEREN RE, 1995, J NEUROSCI, V15, P5989; VANKESTEREN RE, 1992, P NATL ACAD SCI USA, V89, P4593, DOI 10.1073/pnas.89.10.4593; Varga ZM, 1999, DEVELOPMENT, V126, P5533; Vigh B, 2004, HISTOL HISTOPATHOL, V19, P607, DOI 10.14670/HH-19.607; Voronezhskaya EE, 2002, J COMP NEUROL, V444, P25, DOI 10.1002/cne.10130; Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519; Wilson SW, 2002, RES PRO CEL, V40, P181; Wullimann MF, 1996, NEUROANATOMY ZEBRAFI, DOI 10.1007/978-3-0348-8979-7_6	73	251	255	1	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 29	2007	129	7					1389	1400		10.1016/j.cell.2007.04.041	http://dx.doi.org/10.1016/j.cell.2007.04.041			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188HQ	17604726	Bronze			2022-12-28	WOS:000247911400023
J	Draine, BT; Ostriker, JP				Draine, Bruce T.; Ostriker, Jeremiah P.			Bohdan Paczynski (1940-2007) - Obituary	NATURE			English	Biographical-Item									Princeton Univ, Dept Astrophys Sci, Princeton, NJ 08544 USA	Princeton University	Draine, BT (corresponding author), Princeton Univ, Dept Astrophys Sci, Princeton, NJ 08544 USA.	draine@astro.princeton.edu							0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 28	2007	447	7148					1065	1065		10.1038/4471064a	http://dx.doi.org/10.1038/4471064a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183HT	17597752	Bronze			2022-12-28	WOS:000247564600027
J	May, R				May, Robert			Tony Blair's era: good news, bad news	NATURE			English	Editorial Material																		Blair T, 1998, SCIENCE, V281, P1141, DOI 10.1126/science.281.5380.1141; Goodall AH, 2006, J DOC, V62, P388, DOI 10.1108/00220410610666529; 1997, SCI WATCH, V8, P1	3	2	2	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 28	2007	447	7148					1053	1053		10.1038/4471053a	http://dx.doi.org/10.1038/4471053a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183HT	17597740				2022-12-28	WOS:000247564600019
J	Meyzen, CM; Blichert-Toft, J; Ludden, JN; Humler, E; Mevel, C; Albarede, F				Meyzen, Christine M.; Blichert-Toft, Janne; Ludden, John N.; Humler, Eric; Mevel, Catherine; Albarede, Francis			Isotopic portrayal of the Earth's upper mantle flow field	NATURE			English	Article							SOUTHWEST INDIAN RIDGE; MID-ATLANTIC RIDGE; AUSTRALIAN-ANTARCTIC DISCORDANCE; CONTINENTAL LITHOSPHERE; HETEROGENEITY BENEATH; TRIPLE JUNCTION; OCEANIC MANTLE; BASALTS; PLUME; CONVECTION	It is now well established that oceanic plates sink into the lower mantle at subduction zones, but the reverse process of replacing lost upper-mantle material is not well constrained. Even whether the return flow is strongly localized as narrow upwellings or more broadly distributed remains uncertain. Here we show that the distribution of long-lived radiogenic isotopes along the world's mid-ocean ridges can be used to map geochemical domains, which reflect contrasting refilling modes of the upper mantle. New hafnium isotopic data along the Southwest Indian Ridge delineate a sharp transition between an Indian province with a strong lower-mantle isotopic flavour and a South Atlantic province contaminated by advection of upper-mantle material beneath the lithospheric roots of the Archaean African craton. The uppermantle of both domains appears to be refilled through the seismically defined anomaly underlying South Africa and the Afar plume. Because of the viscous drag exerted by the continental keels, refilling of the upper mantle in the Atlantic and Indian domains appears to be slow and confined to localized upwellings. By contrast, in the unencumbered Pacific domain, upwellings seem comparatively much wider and more rapid.	Univ Lyon 1, Ecole Normale Super Lyon, CNRS UMR 5570, Lab Sci Terre, F-69364 Lyon 07, France; British Geol Survey, Keyworth NG12 5GG, Notts, England; Univ Nantes, CNRS UMR 6112, Lab Planetol & Geodynam, F-44322 Nantes 03, France; Inst Phys Globe, Lab Geosci Marines, CNRS UMR 7154, F-75252 Paris 05, France	Ecole Normale Superieure de Lyon (ENS de LYON); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Geological Survey; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); Nantes Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universite Paris Cite	Meyzen, CM (corresponding author), Univ Lyon 1, Ecole Normale Super Lyon, CNRS UMR 5570, Lab Sci Terre, 46 Allee Italie, F-69364 Lyon 07, France.	christine.meyzen@ens-lyon.fr	Blichert-Toft, Janne/C-8280-2012; Albarede, Francis/A-8871-2011; lgm, ipgp/F-8820-2010; Meyzen, Christine/L-1941-2015	Blichert-Toft, Janne/0000-0002-4932-4079; Albarede, Francis/0000-0003-1994-1428; Meyzen, Christine/0000-0002-7529-5347				Agranier A, 2005, EARTH PLANET SC LETT, V238, P96, DOI 10.1016/j.epsl.2005.07.011; Andres M, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2002GC000324; Andres M, 2004, EARTH PLANET SC LETT, V225, P89, DOI 10.1016/j.epsl.2004.05.041; Behn MD, 2004, EARTH PLANET SC LETT, V224, P259, DOI 10.1016/j.epsl.2004.05.026; Blichert-Toft J, 1999, SCIENCE, V285, P879, DOI 10.1126/science.285.5429.879; Blichert-Toft J, 2005, GEOCHEM GEOPHY GEOSY, V6, DOI 10.1029/2004GC000788; Bryce JG, 2005, GEOCHEM GEOPHY GEOSY, V6, DOI 10.1029/2004GC000809; Carlson RW, 2000, GSA TODAY, V10, P1; CASTILLO P, 1988, NATURE, V336, P667, DOI 10.1038/336667a0; Class C, 2006, GEOLOGY, V34, P129, DOI 10.1130/G21943.1; Collins WJ, 2003, EARTH PLANET SC LETT, V205, P225, DOI 10.1016/S0012-821X(02)01043-9; Douglass J, 1999, J GEOPHYS RES-SOL EA, V104, P2941, DOI 10.1029/98JB02642; DUPRE B, 1983, NATURE, V303, P142, DOI 10.1038/303142a0; Escrig S, 2004, NATURE, V431, P59, DOI 10.1038/nature02904; Gasperini D, 2000, NATURE, V408, P701, DOI 10.1038/35047049; Gautheron C, 2002, EARTH PLANET SC LETT, V199, P39, DOI 10.1016/S0012-821X(02)00563-0; GORDON RG, 1995, PRESENT PLATE MOTION, P66; Graham DW, 2002, REV MINERAL GEOCHEM, V47, P247, DOI 10.2138/rmg.2002.47.8; Grand SP., 1997, GSA TODAY, V7, P1; GURNIS M, 1988, NATURE, V332, P695, DOI 10.1038/332695a0; Gurnis M, 1998, SCIENCE, V279, P1499, DOI 10.1126/science.279.5356.1499; HAMELIN B, 1986, EARTH PLANET SC LETT, V76, P288, DOI 10.1016/0012-821X(86)90080-4; Hanan BB, 2004, NATURE, V432, P91, DOI 10.1038/nature03026; Hanan BB, 1996, SCIENCE, V272, P991, DOI 10.1126/science.272.5264.991; HART SR, 1992, SCIENCE, V256, P517, DOI 10.1126/science.256.5056.517; HART SR, 1984, NATURE, V309, P753, DOI 10.1038/309753a0; Helmberger D, 2000, J GEOPHYS RES-SOL EA, V105, P23865, DOI 10.1029/2000JB900143; Hofmann A.W., 2003, TREAT GEOCHEM, V2, P61, DOI DOI 10.1016/B0-08-043751-6/02123-X; Horner-Johnson BC, 2005, GEOPHYS J INT, V162, P221, DOI [10.1111/j.1365-246X.2005.02608.x, 10.1111/j.1365-246X.2005-02608.x]; James DE, 2001, GEOPHYS RES LETT, V28, P2485, DOI 10.1029/2000GL012578; Janney PE, 2005, J PETROL, V46, P2427, DOI 10.1093/petrology/egi060; Kamenetsky VS, 2001, GEOLOGY, V29, P243, DOI 10.1130/0091-7613(2001)029<0243:ROGCLI>2.0.CO;2; KEMPTON PD, 2002, GEOCHEM GEOPHYS GEOS, V3, DOI DOI 10.1029/2002GC000320; KLEIN EM, 1988, NATURE, V333, P623, DOI 10.1038/333623a0; Kurz MD, 1998, GEOCHIM COSMOCHIM AC, V62, P841, DOI 10.1016/S0016-7037(97)00383-9; le Roux PJ, 2002, EARTH PLANET SC LETT, V203, P479, DOI 10.1016/S0012-821X(02)00832-4; LEROEX AP, 1989, J PETROL, V30, P947, DOI 10.1093/petrology/30.4.947; MAHONEY J, 1992, J GEOPHYS RES-SOL EA, V97, P19771, DOI 10.1029/92JB01424; MAHONEY JJ, 1989, J GEOPHYS RES-SOLID, V94, P4033, DOI 10.1029/JB094iB04p04033; Meyzen CM, 2005, GEOCHEM GEOPHY GEOSY, V6, DOI 10.1029/2005GC000979; Meyzen CM, 2003, NATURE, V421, P731, DOI 10.1038/nature01424; Nolet G, 2006, EARTH PLANET SC LETT, V248, P685, DOI 10.1016/j.epsl.2006.06.011; PRESS WH, 1992, NUMERICAL RECIPES FO, P569; Rehkamper M, 1997, EARTH PLANET SC LETT, V147, P93, DOI 10.1016/S0012-821X(97)00009-5; Ritsema J, 1998, GEOPHYS RES LETT, V25, P4245, DOI 10.1029/1998GL900127; Ritsema J, 1998, J GEOPHYS RES-SOL EA, V103, P21201, DOI 10.1029/98JB01274; SCHILLING JG, 1992, J GEOPHYS RES-SOL EA, V97, P10927, DOI 10.1029/92JB00415; STOREY M, 1989, NATURE, V338, P574, DOI 10.1038/338574a0; TACKLEY PJ, 1995, J GEOPHYS RES-SOL EA, V100, P15477, DOI 10.1029/95JB00318; TACKLEY PJ, 1994, J GEOPHYS RES-SOL EA, V99, P15877, DOI 10.1029/94JB00853; Zhang SQ, 2005, J PETROL, V46, P829, DOI 10.1093/petrology/egi002; ZHONG SJ, 1993, J GEOPHYS RES-SOL EA, V98, P12219, DOI 10.1029/93JB00193	52	94	98	1	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 28	2007	447	7148					1069	1074		10.1038/nature05920	http://dx.doi.org/10.1038/nature05920			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183HT	17597754				2022-12-28	WOS:000247564600029
J	Yan, S; Wu, YT; Zhang, BL; Yue, XF; Liu, KP				Yan, Shannon; Wu, Yen-Tien; Zhang, Bailin; Yue, Xian-Fang; Liu, Kopin			Do vibrational excitations of CHD3 preferentially promote reactivity toward the chlorine atom?	SCIENCE			English	Article							BIMOLECULAR REACTIONS; RELATIVE REACTIVITY; REACTION DYNAMICS; GROUND-STATE; METHANE; RESONANCE; CL+CH4; CH3D; BOND; CH4	The influence of vibrational excitation on chemical reaction dynamics is well understood in triatomic reactions, but the multiple modes in larger systems complicate efforts toward the validation of a predictive framework. Although recent experiments support selective vibrational enhancements of reactivities, such studies generally do not properly account for the differing amounts of total energy deposited by the excitation of different modes. By precise tuning of translational energies, we measured the relative efficiencies of vibration and translation in promoting the gas-phase reaction of CHD3 with the Cl atom to form HCl and CD3. Unexpectedly, we observed that C-H stretch excitation is no more effective than an equivalent amount of translational energy in raising the overall reaction efficiency; CD3 bend excitation is only slightly more effective. However, vibrational excitation does have a strong impact on product state and angular distributions, with C-H stretch-excited reactants leading to predominantly forward-scattered, vibrationally excited HCl.	Acad Sinica, Inst Atom & Mol Sci, Taipei 10617, Taiwan; Natl Taiwan Univ, Dept Chem, Taipei 10617, Taiwan	Academia Sinica - Taiwan; National Taiwan University	Liu, KP (corresponding author), Acad Sinica, Inst Atom & Mol Sci, POB 23-166, Taipei 10617, Taiwan.	kliu@po.iams.sinica.edu.tw	Liu, Kopin/F-7929-2012	Liu, Kopin/0000-0001-7499-2397; Yan, Shannon/0000-0001-7994-9427				Bechtel HA, 2005, ANGEW CHEM INT EDIT, V44, P2382, DOI 10.1002/anie.200462837; Bechtel HA, 2004, J CHEM PHYS, V120, P5096, DOI 10.1063/1.1647533; Bechtel HA, 2004, J CHEM PHYS, V120, P791, DOI 10.1063/1.1630961; Castillo JF, 2006, J CHEM PHYS, V125, DOI 10.1063/1.2357741; Corchado JC, 2000, J CHEM PHYS, V112, P9375, DOI 10.1063/1.481602; Crim FF, 1999, ACCOUNTS CHEM RES, V32, P877, DOI 10.1021/ar950046a; DUNCAN WT, 1995, J CHEM PHYS, V103, P9642, DOI 10.1063/1.470731; Holiday RJ, 2006, J CHEM PHYS, V125, DOI 10.1063/1.2352742; Kandel SA, 1998, J CHEM PHYS, V109, P9719, DOI 10.1063/1.477642; Kim ZH, 2001, J AM CHEM SOC, V123, P12714, DOI 10.1021/ja017180c; Kim ZH, 2001, J CHEM PHYS, V115, P179, DOI 10.1063/1.1378042; Lee SH, 2006, J CHEM PHYS, V125, DOI 10.1063/1.2217374; Lin JJ, 2003, SCIENCE, V300, P966, DOI 10.1126/science.1083672; Lin JJ, 2003, REV SCI INSTRUM, V74, P2495, DOI 10.1063/1.1561604; Liu KP, 2006, J CHEM PHYS, V125, DOI 10.1063/1.2216706; Liu KP, 2007, PHYS CHEM CHEM PHYS, V9, P17, DOI 10.1039/b614801h; POLANYI JC, 1972, ACCOUNTS CHEM RES, V5, P161, DOI 10.1021/ar50053a001; Sanson J, 2006, J PHYS CHEM A, V110, P9568, DOI 10.1021/jp062826e; Simpson WR, 1996, J PHYS CHEM-US, V100, P7938, DOI 10.1021/jp952627n; SIMPSON WR, 1995, J CHEM PHYS, V103, P7313, DOI 10.1063/1.470305; Skodje RT, 2000, J CHEM PHYS, V112, P4536, DOI 10.1063/1.481041; Skodje RT, 2000, PHYS REV LETT, V85, P1206, DOI 10.1103/PhysRevLett.85.1206; Yan S, 2007, PHYS CHEM CHEM PHYS, V9, P250, DOI 10.1039/b614307e; Yoon S, 2003, J CHEM PHYS, V119, P9568, DOI 10.1063/1.1615755; Yoon S, 2003, J CHEM PHYS, V119, P4755, DOI 10.1063/1.1591176; Yoon S, 2002, J CHEM PHYS, V116, P10744, DOI 10.1063/1.1476318; Zare RN, 1998, SCIENCE, V279, P1875, DOI 10.1126/science.279.5358.1875; Zhang BL, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1871894; Zhou J, 2005, MOL PHYS, V103, P1757, DOI 10.1080/00268970500064838; Zhou JG, 2004, J PHYS CHEM A, V108, P7832, DOI 10.1021/jp040128t	30	236	236	0	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 22	2007	316	5832					1723	1726		10.1126/science.1142313	http://dx.doi.org/10.1126/science.1142313			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180XE	17588925				2022-12-28	WOS:000247400500040
J	Wilson, JF				Wilson, Jennifer Fisher			Strategies to stop abuse of prescribed opioid drugs	ANNALS OF INTERNAL MEDICINE			English	News Item							CHRONIC PAIN; ASSOCIATION; DISORDERS					jenwilson@acponline.org	Wilson, Jennifer/Q-3623-2019	Wilson, Jennifer/0000-0003-4025-3136				Gourlay DL, 2005, PAIN MED, V6, P107, DOI 10.1111/j.1526-4637.2005.05031.x; GOURLAY DL, 2004, DRUG TESTING CLIN PR, P4349; Hariharan J, 2007, J GEN INTERN MED, V22, P485, DOI 10.1007/s11606-006-0084-1; Ives TJ, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-46; Martell BA, 2007, ANN INTERN MED, V146, P116, DOI 10.7326/0003-4819-146-2-200701160-00006; Sullivan MD, 2006, ARCH INTERN MED, V166, P2087, DOI 10.1001/archinte.166.19.2087; Sullivan MD, 2005, PAIN, V119, P95, DOI 10.1016/j.pain.2005.09.020; Turk DC, 2002, CLIN J PAIN, V18, P355, DOI 10.1097/00002508-200211000-00003; Webster LR, 2005, PAIN MED, V6, P432, DOI 10.1111/j.1526-4637.2005.00072.x	9	10	10	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 19	2007	146	12					897	900		10.7326/0003-4819-146-12-200706190-00017	http://dx.doi.org/10.7326/0003-4819-146-12-200706190-00017			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180FF	17577013				2022-12-28	WOS:000247347100013
J	Cowan, J				Cowan, John			A constant surprise	NATURE			English	Editorial Material									Univ Oklahoma, Homer L Dodge Dept Phys & Astron, Norman, OK 73019 USA	University of Oklahoma System; University of Oklahoma - Norman	Cowan, J (corresponding author), Univ Oklahoma, Homer L Dodge Dept Phys & Astron, Norman, OK 73019 USA.							Cowan JJ, 2006, NATURE, V440, P1151, DOI 10.1038/nature04807; Prochaska JX, 2003, NATURE, V423, P57, DOI 10.1038/nature01524; Shetrone M, 2003, ASTRON J, V125, P684, DOI 10.1086/345966	3	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 5	2007	448	7149					29	29		10.1038/448029a	http://dx.doi.org/10.1038/448029a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185OS	17611528	Bronze			2022-12-28	WOS:000247720900025
J	Dickinson, HO; Parkinson, KN; Ravens-Sieberer, U; Schirripa, G; Thyen, U; Arnaud, C; Beckung, E; Fauconnier, J; McManus, V; Michelsen, SI; Parkes, J; Colver, AF				Dickinson, Heather O.; Parkinson, Kathryn N.; Ravens-Sieberer, Ulrike; Schirripa, Giorgio; Thyen, Ute; Arnaud, Catherine; Beckung, Eva; Fauconnier, Jerome; McManus, Vicki; Michelsen, Susan I.; Parkes, Jackie; Colver, Allan F.			Self-reported quality of life of 8-12-year-old children with cerebral palsy: a cross-sectional European study	LANCET			English	Article							SCHOOL-AGE-CHILDREN; HEALTH-STATUS; PAIN; ADOLESCENTS; SCHOOLCHILDREN; PARTICIPATION; RELIABILITY; INSTRUMENTS; IMPAIRMENT; PREVALENCE	Background Little is known about the quality of life (QoL) of disabled children. We describe self-reported QoL of children with cerebral palsy, factors that influence it, and how it compares with QoL of the general population. Methods 1174 children aged 8-12 years were randomly selected from eight population-based registers of children with cerebral palsy in six European countries and 743 (63%) agreed to participate; one further region recruited 75 children from multiple sources. Researchers visited these 818 children. 318 (39%) with severe intellectual impairment could not self-report; 500 (61%) reported their QoL using KIDSCREEN, an instrument with scores in ten domains, each with SD=10. Multivariable regression was used to relate QoL to impairments, pain, and sociodemographic characteristics. Comparisons were made with QoL data from the general population. Findings Impairments were not significantly associated with six KIDSCREEN domains. Comparison of least and most able groups showed that severely limited self-mobility was significantly associated with reduced mean score for physical wellbeing (7.6, 95% CI 2.7-12.4); intellectual impairment with reduced mean for moods and emotions (3.7, 1.5-5.9) and autonomy (3.3, 0.9-5.7); and speech difficulties with reduced mean for relationships with parents (4.5,1.9-7.1). Pain was common and associated with lower QoL on all domains. Impairments and pain explained up to 3% and 7%, respectively, of variation in QoL. Children with cerebral palsy had similar QoL to children in the general population in all domains except schooling, in which evidence was equivocal, and physical wellbeing, in which comparison was not possible. Interpretation Parents can be reassured that most children aged 8-12 years with cerebral palsy will have similar QoL to other children. This finding should guide social and educational policy to ensure that disabled children participate fully in society. Because of its association with QoL, children's pain should be carefully assessed.	Newcastle Univ, Royal Victoria Infirm, Sir James Spence Inst, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Newcastle Univ, Sch Clin Med Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Robert Koch Inst, Forsch Grp Psychosoziale Gesundheit, D-1000 Berlin, Germany; Azienda Sanit Locale Viterbo, Viterbo, Italy; Univ Klinikum Schleswig Holstein, Klin Kinder & Jugendmed, Lubeck, Germany; Univ Toulouse 3, Fac Med, INSERM, F-31062 Toulouse, France; Univ Gothenburg, Queen Silvia Childrens Hosp, Gothenburg, Sweden; Univ Grenoble 1, SIIM Pole Exploitat, Grenoble, France; Enable Ireland, Lavanagh Ctr, Cork, Ireland; Natl Inst Publ Hlth, Copenhagen, Denmark; Queens Univ Belfast, Sch Nursing & Midwifery, Belfast, Antrim, North Ireland	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Robert Koch Institute; University of Kiel; Schleswig Holstein University Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Queen Silvia Children's Hospital; University of Gothenburg; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Queens University Belfast	Colver, AF (corresponding author), Newcastle Univ, Royal Victoria Infirm, Sir James Spence Inst, Queen Victoria Rd, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.	allan.colver@ncl.ac.uk	Fauconnier, Jerome/M-6720-2014; ARNAUD, Catherine/AAC-5646-2019	ARNAUD, Catherine/0000-0002-4002-802X; Michelsen, Susan I/0000-0002-6291-8031				Albrecht GL, 1999, SOC SCI MED, V48, P977, DOI 10.1016/S0277-9536(98)00411-0; APPLETON PL, 1994, DEV MED CHILD NEUROL, V36, P198; ARNOLD P, 1992, DEV MED CHILD NEUROL, V34, P97; Bakoula C, 2006, ACTA PAEDIATR, V95, P947, DOI 10.1080/08035250600684453; Beaton DE, 2000, SPINE, V25, P3186, DOI 10.1097/00007632-200012150-00014; Beckung E, 2002, DEV MED CHILD NEUROL, V44, P309; Bisegger C, 2005, SOZ PRAVENTIV MED, V50, P281, DOI 10.1007/s00038-005-4094-2; Brunner HI, 2004, ARTHRIT RHEUM-ARTHR, V51, P763, DOI 10.1002/art.20689; Colver A, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-105; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; Cummins RA, 1993, COMPREHENSIVE QUALIT; DALES LG, 1978, INT J EPIDEMIOL, V7, P373, DOI 10.1093/ije/7.4.373; Davis E, 2006, DEV MED CHILD NEUROL, V48, P311, DOI 10.1017/S0012162206000673; Detmar SB, 2006, QUAL LIFE RES, V15, P1345, DOI 10.1007/s11136-006-0022-z; Dickinson H, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-273; Eiser C, 2001, Health Technol Assess, V5, P1; GRUE L, 2003, DEV MED CHILD NEUR S, V45, P8; Houlihan CM, 2004, DEV MED CHILD NEUROL, V46, P305, DOI 10.1017/S0012162204000507; Jemta L, 2005, ACTA PAEDIATR, V94, P616, DOI 10.1080/08035250410022152; Kennes J, 2002, DEV MED CHILD NEUROL, V44, P240, DOI 10.1017/S0012162201002018; KING GA, 1993, AM J OCCUP THER, V47, P132, DOI 10.5014/ajot.47.2.132; Kristjansdottir G, 1997, SCAND J SOC MED, V25, P58, DOI 10.1177/140349489702500112; Kucynski E, 2003, AN PEDIATR, V58, P550; KUYKEN W, 1995, SOC SCI MED, V41, P1403, DOI 10.1016/0277-9536(95)00112-k; Landgraf JM, 1999, CHILD HLTH QUESTIONN; Liptak GS, 2001, DEV MED CHILD NEUROL, V43, P364, DOI 10.1017/S001216220100069X; Marks D, 1997, DISABIL REHABIL, V19, P85, DOI 10.3109/09638289709166831; McCarthy ML, 2002, DEV MED CHILD NEUROL, V44, P468; Oliver Michael, 1990, POLITICS DISABLEMENT; Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x; Petersen S, 2006, PAIN, V121, P145, DOI 10.1016/j.pain.2005.12.017; Pirpiris M, 2006, J PEDIATR ORTHOPED, V26, P119, DOI 10.1097/01.bpo.0000191553.26574.27; Ravens-Sieberer Ulrike, 2005, Expert Rev Pharmacoecon Outcomes Res, V5, P353, DOI 10.1586/14737167.5.3.353; Rendeli C, 2005, SPINAL CORD, V43, P230, DOI 10.1038/sj.sc.3101707; Riley AW, 2004, AMBUL PEDIATR, V4, P371, DOI 10.1367/A03-178R.1; ROYALL RM, 1986, INT STAT REV, V54, P221, DOI 10.2307/1403146; Sallfors C, 2004, CLIN EXP RHEUMATOL, V22, P125; Sawyer MG, 2004, RHEUMATOLOGY, V43, P325, DOI 10.1093/rheumatology/keh030; Shields N, 2006, DEV MED CHILD NEUROL, V48, P151, DOI 10.1017/S0012162206000326; The KIDSCREEN Group Europe, 2006, KIDSCREEN QUEST QUAL; *UN, 2006, 60232 UN; UN, 1989, CONV RIGHTS CHILD; Vargus-Adams J, 2005, ARCH PHYS MED REHAB, V86, P940, DOI 10.1016/j.apmr.2004.10.036; Varni JW, 2005, DEV MED CHILD NEUROL, V47, P592, DOI 10.1017/S0012162205001179; Wake M, 2003, DEV MED CHILD NEUROL, V45, P194, DOI 10.1017/S0012162203000379; Watson SMR, 2002, MENT RETARD, V40, P304, DOI 10.1352/0047-6765(2002)040<0304:CTQOLO>2.0.CO;2; White-Koning M, 2005, DEV MED CHILD NEUROL, V47, P281, DOI 10.1017/S0012162205000526	47	295	303	3	40	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 30	2007	369	9580					2171	2178		10.1016/S0140-6736(07)61013-7	http://dx.doi.org/10.1016/S0140-6736(07)61013-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	184LX	17604799	Green Submitted			2022-12-28	WOS:000247644200028
J	Dubcovsky, J; Dvorak, J				Dubcovsky, Jorge; Dvorak, Jan			Genome plasticity a key factor in the success of polyploid wheat under domestication	SCIENCE			English	Review							HEXAPLOID WHEAT; MOLECULAR CHARACTERIZATION; ARABIDOPSIS POLYPLOIDS; TETRAPLOID WHEATS; GENE-EXPRESSION; GRAIN PROTEIN; EVOLUTION; SEQUENCE; WILD; LOCUS	Wheat was domesticated about 10,000 years ago and has since spread worldwide to become one of the major crops. Its adaptability to diverse environments and end uses is surprising given the diversity bottlenecks expected from recent domestication and polyploid speciation events. Wheat compensates for these bottlenecks by capturing part of the genetic diversity of its progenitors and by generating new diversity at a relatively fast pace. Frequent gene deletions and disruptions generated by a fast replacement rate of repetitive sequences are buffered by the polyploid nature of wheat, resulting in subtle dosage effects on which selection can operate.	Univ Calif Davis, Dept Plant Sci, Davis, CA 95616 USA	University of California System; University of California Davis	Dubcovsky, J (corresponding author), Univ Calif Davis, Dept Plant Sci, Shields Ave, Davis, CA 95616 USA.	jdubcovsky@ucdavis.edu	Dubcovsky, Jorge/T-5214-2019; Dubcovsky, Jorge/A-4969-2008	Dubcovsky, Jorge/0000-0002-7571-4345	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Akhunov ED, 2007, MOL BIOL EVOL, V24, P539, DOI 10.1093/molbev/msl183; Buckler ES, 2001, GENET RES, V77, P213, DOI 10.1017/S0016672301005158; Chantret N, 2005, PLANT CELL, V17, P1033, DOI 10.1105/tpc.104.029181; Chen ZJ, 2006, BIOESSAYS, V28, P240, DOI 10.1002/bies.20374; *CHIMP SEQ AN CONS, 2005, NATURE, V0437; Doebley J, 2006, SCIENCE, V312, P1318, DOI 10.1126/science.1128836; Dvorak J, 1998, THEOR APPL GENET, V97, P657, DOI 10.1007/s001220050942; Dvorak J, 2005, GENETICS, V171, P323, DOI 10.1534/genetics.105.041632; Dvorak J, 2004, GENETICS, V168, P1665, DOI 10.1534/genetics.103.024927; Dvorak J, 1998, ORIGINS AGR CROP DOM, P235; Dvorak J, 2006, MOL BIOL EVOL, V23, P1386, DOI 10.1093/molbev/msl004; FAURE S, 2007, PLANT ANIMAL GENOME, V15; FLAVELL RB, 1974, BIOCHEM GENET, V12, P257, DOI 10.1007/BF00485947; Fu DL, 2005, MOL GENET GENOMICS, V273, P54, DOI 10.1007/s00438-004-1095-4; GAUT BS, 1993, GENETICS, V135, P1091; Giroux MJ, 1998, P NATL ACAD SCI USA, V95, P6262, DOI 10.1073/pnas.95.11.6262; Gu YQ, 2006, GENETICS, V174, P1493, DOI 10.1534/genetics.106.060756; HAMMER K, 1984, Kulturpflanze, V32, P11; HARBERD NP, 1987, MOL GEN GENET, V209, P326, DOI 10.1007/BF00329661; HARLAN JR, 1966, SCIENCE, V153, P1074, DOI 10.1126/science.153.3740.1074; HAUDRY A, IN PRESS MOL BIOL EV; Heller J, 1996, HULLED WHEATS; Heun M, 1997, SCIENCE, V278, P1312, DOI 10.1126/science.278.5341.1312; Jantasuriyarat C, 2004, THEOR APPL GENET, V108, P261, DOI 10.1007/s00122-003-1432-8; Kashkush K, 2003, NAT GENET, V33, P102, DOI 10.1038/ng1063; Kidwell MG, 1997, P NATL ACAD SCI USA, V94, P7704, DOI 10.1073/pnas.94.15.7704; KIHARA H, 1944, AGR HORTIC, V19, P889, DOI DOI 10.1016/J.JGG.2011.07.002; Kong XY, 2004, PLANT MOL BIOL, V54, P55, DOI 10.1023/B:PLAN.0000028768.21587.dc; Lantican M.A., 2005, IMPACTS INT WHEAT BR; Loukoianov A, 2005, PLANT PHYSIOL, V138, P2364, DOI 10.1104/pp.105.064287; Luo MC, 2007, THEOR APPL GENET, V114, P947, DOI 10.1007/s00122-006-0474-0; Madlung A, 2005, PLANT J, V41, P221, DOI 10.1111/j.1365-313X.2004.02297.x; Morgante M, 2006, CURR OPIN BIOTECH, V17, P168, DOI 10.1016/j.copbio.2006.03.001; Nalam VJ, 2006, THEOR APPL GENET, V112, P373, DOI 10.1007/s00122-005-0140-y; Ozkan H, 2005, THEOR APPL GENET, V110, P1052, DOI 10.1007/s00122-005-1925-8; Ramakrishna W, 2002, GENETICS, V162, P1389; Salamini F, 2002, NAT REV GENET, V3, P429, DOI 10.1038/nrg817; SanMiguel PJ, 2002, FUNCT INTEGR GENOMIC, V2, P70, DOI 10.1007/s10142-002-0056-4; Shaked H, 2001, PLANT CELL, V13, P1749, DOI 10.1105/tpc.13.8.1749; Simons KJ, 2006, GENETICS, V172, P547, DOI 10.1534/genetics.105.044727; Slade AJ, 2005, NAT BIOTECHNOL, V23, P75, DOI 10.1038/nbt1043; *STAT DIV, 2006, STAT YB 2005 2006 FO; STEBBINS GL, 1950, VARIATION EVOLUTION; Talbert LE, 1998, GENOME, V41, P402, DOI 10.1139/gen-41-3-402; Tanno K, 2006, SCIENCE, V311, P1886, DOI 10.1126/science.311.5769.1866a; Uauy C, 2006, SCIENCE, V314, P1298, DOI 10.1126/science.1133649; Uauy C, 2006, J EXP BOT, V57, P2785, DOI 10.1093/jxb/erl047; Wang JL, 2004, GENETICS, V167, P1961, DOI 10.1534/genetics.104.027896; Warburton ML, 2006, EUPHYTICA, V149, P289, DOI 10.1007/s10681-005-9077-0; Wendel JF, 2000, PLANT MOL BIOL, V42, P225, DOI 10.1023/A:1006392424384; Wicker T, 2003, PLANT CELL, V15, P1186, DOI 10.1105/tpc.011023; Wright SI, 2005, SCIENCE, V308, P1310, DOI 10.1126/science.1107891; Yan L, 2006, P NATL ACAD SCI USA, V103, P19581, DOI 10.1073/pnas.0607142103; Yan L, 2004, THEOR APPL GENET, V109, P1677, DOI 10.1007/s00122-004-1796-4; Yan LL, 2004, SCIENCE, V303, P1640, DOI 10.1126/science.1094305; ZOHARY D., 1961, Wheat Information Service, P6; Zohary D, 2000, DOMESTICATION PLANTS, DOI DOI 10.1006/ANBO.2001.1505	57	633	660	9	176	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 29	2007	316	5833					1862	1866		10.1126/science.1143986	http://dx.doi.org/10.1126/science.1143986			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183WI	17600208	Green Accepted			2022-12-28	WOS:000247602700028
J	Dabelea, D; Bell, RA; D'Agostino, RB; Imperatore, G; Johansen, JM; Linder, B; Liu, LL; Loots, B; Marcovina, S; Mayer-Davis, EJ; Pettitt, DJ; Waitzfelder, B				Dabelea, Dana; Bell, Ronny A.; D'Agostino, Ralph B., Jr.; Imperatore, Giuseppina; Johansen, Judith M.; Linder, Barbara; Liu, Lenna L.; Loots, Beth; Marcovina, Santica; Mayer-Davis, Elizabeth J.; Pettitt, David J.; Waitzfelder, Beth		Writing Grp SEARCH Diabet Youth St	Incidence of diabetes in youth in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACID DECARBOXYLASE GAD65; ALLEGHENY-COUNTY; AFRICAN-AMERICAN; MELLITUS; CHILDREN; ADOLESCENTS; TYPE-2; PREVALENCE; EPIDEMIC; TRENDS	Context Data on the incidence of diabetes mellitus (DM) among US youth according to racial/ethnic background and DM type are limited. Objective To estimate DM incidence in youth aged younger than 20 years according to race/ethnicity and DM type. Design, Setting, and Participants A multiethnic, population-based study (The SEARCH for Diabetes in Youth Study) of 2435 youth with newly diagnosed, nonsecondary DM in 2002 and 2003, ascertained at 10 study locations in the United States, covering a population of more than 10 million person-years. Main Outcome Measure Incidence rates by age group, sex, race/ethnicity, and DM type were calculated per 100 000 person-years at risk. Diabetes mellitus type ( type 1/type 2) was based on health care professional assignment and, in a subset, further characterized with glutamicacid decarboxylase( GAD65) autoantibody and fasting C peptide measures. Results The incidence of DM ( per 100 000 person-years) was 24.3 (95% confidence interval [CI], 23.3-25.3). Among children younger than 10 years, most had type 1 DM, regardless of race/ethnicity. The highest rates of type 1 DM were observed in non-Hispanic white youth (18.6, 28.1, and 32.9 for age groups 0-4, 5-9, and 10-14 years, respectively). Even among older youth ( >= 10 years), type 1 DM was frequent among non-Hispanic white, Hispanic, and African American adolescents. Overall, type 2 DM was still relatively infrequent, but the highest rates (17.0 to 49.4 per 100 000 person-years) were documented among 15- to 19-year-old minority groups. Conclusions Our data document the incidence rates of type 1 DM among youth of all racial/ethnic groups, with the highest rates in non-Hispanic white youth. Overall, type 2 DM is still relatively infrequent; however, the highest rates were observed among adolescent minority populations.	Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA; Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA; Ctr Dis Control & Prevent, Atlanta, GA USA; Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA; NIDDK, Bethesda, MD USA; Univ Washington, Inst Child Hlth, Seattle, WA 98195 USA; Childrens Hosp & Reg Med Ctr, Seattle, WA USA; Univ S Carolina, Columbia, SC 29208 USA; Sansum Diabet Res Inst, Santa Barbara, CA USA; Pacific Hlth Res Inst, Honolulu, HI USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Wake Forest University; Wake Forest Baptist Medical Center; Centers for Disease Control & Prevention - USA; Cincinnati Children's Hospital Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Washington; University of Washington Seattle; Seattle Children's Hospital; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; William Sansum Diabetes Center; Pacific Health Research & Education Institute	Dabelea, D (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, 4200 E 9th Ave,Box C245, Denver, CO 80262 USA.	dana.dabelea@uchsc.edu	Dagostino, Ralph/C-4060-2017	Dagostino, Ralph/0000-0002-3550-8395	NCRR NIH HHS [M01RR00037, M01 RR08084, M01 RR01070, M01 RR00069, M01RR001271] Funding Source: Medline; PHS HHS [00097] Funding Source: Medline; NCCDPHP CDC HHS [U01 DP000254, U01 DP000250, U01 DP000248, U01 DP000247, U01 DP000246, U01 DP000245, DP-05-069, U01 DP000244] Funding Source: Medline; NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMO [U01DP000248, U01DP000245, U01DP000244, U01DP000250, U01DP000254, U01DP000247, U01DP000246] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR008084, M01RR001070, M01RR000037, M01RR001271, M01RR000069] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NCCDPHP CDC HHS; NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMO(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Agresti A, 1998, AM STAT, V52, P119, DOI 10.2307/2685469; BISHOP YMM, 1975, FSHPW DISCRETE MULTI; Brooks-Worrell BM, 2004, J CLIN ENDOCR METAB, V89, P2222, DOI 10.1210/jc.2003-031360; Chen WS, 2004, ANN EPIDEMIOL, V14, P339, DOI 10.1016/j.annepidem.2003.07.002; Dabelea D, 1998, DIABETOLOGIA, V41, P904, DOI 10.1007/s001250051006; Dabelea D, 1999, ENDOCRIN METAB CLIN, V28, P709, DOI 10.1016/S0889-8529(05)70098-0; Dean HJ, 1998, LANCET, V352, P1523, DOI 10.1016/S0140-6736(05)60329-7; DOKHEEL TM, 1993, DIABETES CARE, V16, P1606, DOI 10.2337/diacare.16.12.1606; Dolan LM, 2005, J PEDIATR-US, V146, P751, DOI 10.1016/j.jpeds.2005.01.045; ESPELAND MA, 1986, COMMUN STAT SIMULAT, V15, P405, DOI 10.1080/03610918608812515; FALORNI A, 1995, J IMMUNOL METHODS, V186, P89, DOI 10.1016/0022-1759(95)00139-2; Feltbower RG, 2003, ARCH DIS CHILD, V88, P676, DOI 10.1136/adc.88.8.676; Gale EAM, 2001, DIABETOLOGIA, V44, P3, DOI 10.1007/s001250051573; Gavin JR, 1997, DIABETES CARE, V20, P1183; GREEN A, 1992, LANCET, V339, P905, DOI 10.1016/0140-6736(92)90938-Y; Green A, 2000, LANCET, V355, P873; Green A, 2001, DIABETOLOGIA, V44, pB3, DOI 10.1007/PL00002950; Harris SB, 1997, DIABETES CARE, V20, P185, DOI 10.2337/diacare.20.2.185; Hathout EH, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.6.e102; HEDING LG, 1975, DIABETOLOGIA, V11, P541, DOI 10.1007/BF01222104; Ingram DD., 2003, VITAL HLTH STAT SERI, V2; Karvonen M, 2000, DIABETES CARE, V23, P1516, DOI 10.2337/diacare.23.10.1516; KITAGAWA T, 1983, Tohoku Journal of Experimental Medicine, V141, P171; KNOWLER WC, 1978, AM J EPIDEMIOL, V108, P497, DOI 10.1093/oxfordjournals.aje.a112648; KOSTRABA JN, 1992, EPIDEMIOLOGY, V3, P232, DOI 10.1097/00001648-199205000-00008; LAPORTE RE, 1981, DIABETES, V30, P279, DOI 10.2337/diabetes.30.4.279; Libman IM, 1998, DIABETES CARE, V21, P1278, DOI 10.2337/diacare.21.8.1278; Liese AD, 2006, PEDIATRICS, V118, P1510, DOI 10.1542/peds.2006-0690; Lipman TH, 2006, DIABETES CARE, V29, P2391, DOI 10.2337/dc06-0517; Lipman TH, 2002, DIABETES CARE, V25, P1969, DOI 10.2337/diacare.25.11.1969; Lipton R, 2002, DIABETES-METAB RES, V18, P135, DOI 10.1002/dmrr.265; Macaluso CJ, 2002, PUBLIC HEALTH REP, V117, P373, DOI 10.1016/S0033-3549(04)50174-7; Marcovina SM, 2000, INT J CLIN LAB RES, V30, P21, DOI 10.1007/s005990070029; Onkamo P, 1999, DIABETOLOGIA, V42, P1395, DOI 10.1007/s001250051309; Ortega-Rodriguez E, 2001, DIABETES METAB, V27, P574; Petitti DB, 2007, ARCH PEDIAT ADOL MED, V161, P159, DOI 10.1001/archpedi.161.2.159; Pettitt DJ, 2004, CONTROL CLIN TRIALS, V25, P458, DOI 10.1016/j.cct.2004.08.002; Pihoker C, 1998, CLIN PEDIATR, V37, P97, DOI 10.1177/000992289803700206; PinhasHamiel O, 1996, J PEDIATR-US, V128, P608, DOI 10.1016/S0022-3476(96)80124-7; Rewers M, 2004, ADV EXP MED BIOL, V552, P219; REWERS M, 1987, DIABETES, V36, P106, DOI 10.2337/diabetes.36.1.106; SCHOBER E, 1988, ACTA PAEDIATR SCAND, V77, P299, DOI 10.1111/j.1651-2227.1988.tb10646.x; Scott CR, 1997, PEDIATRICS, V100, P84, DOI 10.1542/peds.100.1.84; STONE RA, 1990, DIABETES, V39, P858; TUOMILEHTO J, 1995, INT J EPIDEMIOL, V24, P984, DOI 10.1093/ije/24.5.984; Verlato G, 2000, DIABETES CARE, V23, P759, DOI 10.2337/diacare.23.6.759	46	671	683	1	31	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 27	2007	297	24					2716	2724						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	182UE	17595272				2022-12-28	WOS:000247528700021
J	Brabin, B				Brabin, Bernard			Infant vitamin A supplementation: consensus and controversy	LANCET			English	Editorial Material									Univ Liverpool, Liverpool Sch Trop Med, Child & Reprod Hlth Grp, Liverpool L3 5QA, Merseyside, England; Univ Amsterdam, Acad Med Ctr, Emma Kinderziekenhuis, NL-1105 AZ Amsterdam, Netherlands	Liverpool School of Tropical Medicine; University of Liverpool; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam	Brabin, B (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Child & Reprod Hlth Grp, Liverpool L3 5QA, Merseyside, England.	b.j.brabin@liv.ac.uk	Brabin, Bernard/AAJ-7389-2020	Brabin, Bernard/0000-0001-6860-2508				BEATON GH, 1993, ACC SCN STATE ART SE, V13; Benn CS, 2007, VACCINE, V25, P777, DOI 10.1016/j.vaccine.2006.09.044; Benn CS, 2005, BMJ-BRIT MED J, V331, P1428, DOI 10.1136/bmj.38670.639340.55; Darboe MK, 2007, LANCET, V369, P2088, DOI 10.1016/S0140-6736(07)60981-7; Humphrey JH, 2000, LANCET, V356, P422, DOI 10.1016/S0140-6736(00)02541-1; Idindili B, 2007, AM J CLIN NUTR, V85, P1312, DOI 10.1093/ajcn/85.5.1312; Martines J, 1998, LANCET, V352, P1257, DOI 10.1016/S0140-6736(98)02487-8; Newton S, 2007, J NUTR, V137, P1272, DOI 10.1093/jn/137.5.1272; Sommer A, 2002, J NUTR, V132, p2845S, DOI 10.1093/jn/132.9.2845S; West KP, 2002, J NUTR, V132, p2857S, DOI 10.1093/jn/132.9.2857S; *WHO UNICEF IVACG, 1997, VIT A SUPPL GUID THE	11	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 23	2007	369	9579					2054	2056		10.1016/S0140-6736(07)60956-8	http://dx.doi.org/10.1016/S0140-6736(07)60956-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	182GM	17586285				2022-12-28	WOS:000247493100005
J	Stearns, V				Stearns, Vered			Clinical update: new treatments for hot flushes	LANCET			English	Editorial Material							VASOMOTOR SYMPTOMS; POSTMENOPAUSAL WOMEN; BREAST-CANCER; FLASHES; MENOPAUSE; TRIAL; ESTROGEN; VENLAFAXINE; MANAGEMENT; THERAPIES		Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Stearns, V (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.	vstearn1@jhmi.edu						*AM COLL OBST GYN, 2004, OBSTET GYNECOL S, V104, pS106; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Butt DA, 2007, MENOPAUSE, V14, P203, DOI 10.1097/01.gme.0000235370.32103.4c; Deecher DC, 2005, EXPERT OPIN INV DRUG, V14, P435, DOI 10.1517/13543784.14.4.435; Fabre A, 2007, BRIT J CANCER, V96, P841, DOI 10.1038/sj.bjc.6603618; Freedman RR, 2005, MENOPAUSE, V12, P156, DOI 10.1097/00042192-200512020-00009; Freedman RR, 2002, FERTIL STERIL, V77, P487, DOI 10.1016/S0015-0282(01)03009-6; Gold EB, 2006, AM J PUBLIC HEALTH, V96, P1226, DOI 10.2105/AJPH.2005.066936; Loibl S, 2007, ANN ONCOL, V18, P689, DOI 10.1093/annonc/mdl478; Loprinzi CL, 2007, J CLIN ONCOL, V25, P308, DOI 10.1200/JCO.2006.07.5390; Loprinzi CL, 2006, J CLIN ONCOL, V24, P1409, DOI 10.1200/JCO.2005.04.7324; LOPRINZI CL, 1994, NEW ENGL J MED, V331, P347, DOI 10.1056/NEJM199408113310602; Nedrow A, 2006, ARCH INTERN MED, V166, P1453, DOI 10.1001/archinte.166.14.1453; Nelson HD, 2004, JAMA-J AM MED ASSOC, V291, P1610, DOI 10.1001/jama.291.13.1610; Nelson HD, 2006, JAMA-J AM MED ASSOC, V295, P2057, DOI 10.1001/jama.295.17.2057; Newton KM, 2006, ANN INTERN MED, V145, P869, DOI 10.7326/0003-4819-145-12-200612190-00003; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Santoro NF, 2004, MENOPAUSE, V11, P11; Sloan JA, 2001, J CLIN ONCOL, V19, P4280, DOI 10.1200/JCO.2001.19.23.4280; Stearns V, 2002, LANCET, V360, P1851, DOI 10.1016/S0140-6736(02)11774-0	20	25	28	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 23	2007	369	9579					2062	2064		10.1016/S0140-6736(07)60959-3	http://dx.doi.org/10.1016/S0140-6736(07)60959-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	182GM	17586289				2022-12-28	WOS:000247493100009
J	Stoessl, AJ				Stoessl, A. Jon			Gene therapy for Parkinson's disease: early data	LANCET			English	Editorial Material							RAT MODEL; TRIAL; TRANSPLANTATION; DEGENERATION; DELIVERY		Univ British Columbia, Pacific Parkinsons Res Ctr, Vancouver, BC V6T 2B5, Canada	University of British Columbia	Stoessl, AJ (corresponding author), Univ British Columbia, Pacific Parkinsons Res Ctr, Vancouver, BC V6T 2B5, Canada.	jstoessl@interchange.ubc.ca	Stoessl, A Jon/J-9661-2015	Stoessl, A Jon/0000-0002-9778-7246				Bankiewicz KS, 2006, MOL THER, V14, P564, DOI 10.1016/j.ymthe.2006.05.005; Berns GS, 1998, J COGNITIVE NEUROSCI, V10, P108, DOI 10.1162/089892998563815; de la Fuente-Fernandez R, 2004, BIOL PSYCHIAT, V56, P67, DOI 10.1016/j.biopsych.2003.11.019; Deuschl G, 2006, NEW ENGL J MED, V355, P896, DOI 10.1056/NEJMoa060281; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Kaplitt MG, 2007, LANCET, V369, P2097, DOI 10.1016/S0140-6736(07)60982-9; Kordower JH, 2006, ANN NEUROL, V60, P706, DOI 10.1002/ana.21032; Lang AE, 2004, ANN NEUROL, V55, P761, DOI 10.1002/ana.20102; Lo Bianco C, 2004, P NATL ACAD SCI USA, V101, P17510, DOI 10.1073/pnas.0405313101; Luo J, 2002, SCIENCE, V298, P425, DOI 10.1126/science.1074549; McRae C, 2004, ARCH GEN PSYCHIAT, V61, P412, DOI 10.1001/archpsyc.61.4.412; Mochizuki H, 2006, PARKINSONISM RELAT D, V12, pS107, DOI 10.1016/j.parkreldis.2006.05.014; Olanow CW, 2003, ANN NEUROL, V54, P403, DOI 10.1002/ana.10720; Pardridge William M, 2005, NeuroRx, V2, P129, DOI 10.1007/BF03206649; Piallat B, 1996, EUR J NEUROSCI, V8, P1408, DOI 10.1111/j.1460-9568.1996.tb01603.x	15	7	7	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 23	2007	369	9579					2056	2058		10.1016/S0140-6736(07)60957-X	http://dx.doi.org/10.1016/S0140-6736(07)60957-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	182GM	17586286				2022-12-28	WOS:000247493100006
J	Zimmet, P; Alberti, G; Kaufman, F; Tajima, N; Silink, M; Arslanian, S; Wong, G; Bennett, P; Shaw, J; Caprio, S				Zimmet, Paul; Alberti, George; Kaufman, Francine; Tajima, Naoko; Silink, Martin; Arslanian, Silva; Wong, Gary; Bennett, Peter; Shaw, Jonathan; Caprio, Sonia		Int Diabet Federation Task Force E	The metabolic syndrome in children and adolescents	LANCET			English	Editorial Material							3RD NATIONAL-HEALTH; CARDIOVASCULAR RISK-FACTORS; WAIST CIRCUMFERENCE; PREVALENCE; AMERICAN		St Marys Hosp, Dept Endocrinol & Metab Med, London W2 1NY, England; Int Diabet Inst, Melbourne, Vic, Australia; Univ London Imperial Coll Sci Technol & Med, London, England; Childrens Hosp, Los Angeles, CA USA; Jikei Univ, Sch Med, Tokyo, Japan; Westmead Hosp, Sydney, NSW, Australia; Childrens Hosp, Pittsburgh, PA 15213 USA; Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China; NIDDK, Phoenix Epidemiol & Clin Res Branch, Phoenix, AZ USA; Yale Univ, Sch Med, New Haven, CT USA	Imperial College London; Imperial College London; Children's Hospital Los Angeles; Jikei University; University of Sydney; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Chinese University of Hong Kong; Prince of Wales Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Yale University	Alberti, G (corresponding author), St Marys Hosp, Dept Endocrinol & Metab Med, Praed St, London W2 1NY, England.	George.alberti@ncl.ac.uk	Wong, Gary WK/AAY-9207-2020; Bennett, Peter/AAH-9605-2021; Shaw, Jonathan/E-7388-2010; Zimmet, Paul/O-8486-2019	Wong, Gary WK/0000-0001-5939-812X; Shaw, Jonathan/0000-0002-6187-2203; Zimmet, Paul/0000-0003-0627-0776				Alberti G, 2004, DIABETES CARE, V27, P1798, DOI 10.2337/diacare.27.7.1798; Alberti KGMM, 2005, LANCET, V366, P1059, DOI 10.1016/S0140-6736(05)67402-8; Bacha F, 2006, DIABETES CARE, V29, P1599, DOI 10.2337/dc06-0581; Burke V, 2005, INT J OBESITY, V29, P15, DOI 10.1038/sj.ijo.0802750; Cook S, 2003, ARCH PEDIAT ADOL MED, V157, P821, DOI 10.1001/archpedi.157.8.821; de Ferranti SD, 2004, CIRCULATION, V110, P2494, DOI 10.1161/01.CIR.0000145117.40114.C7; Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7; Fernandez JR, 2004, J PEDIATR-US, V145, P439, DOI 10.1016/j.jpeds.2004.06.044; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; Gungor N, 2004, PEDIATR RES, V55, p145A; Jolliffe CJ, 2007, J AM COLL CARDIOL, V49, P891, DOI 10.1016/j.jacc.2006.08.065; Lee SJ, 2006, J PEDIATR-US, V149, P809, DOI 10.1016/j.jpeds.2006.08.075; Maffeis C, 2001, OBES RES, V9, P179, DOI 10.1038/oby.2001.19; Singh R, 2004, PEDIATR DIABETES, V5, P154, DOI 10.1111/j.1399-543X.2004.00060.x	14	652	731	0	27	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 23	2007	369	9579					2059	2061		10.1016/S0140-6736(07)60958-1	http://dx.doi.org/10.1016/S0140-6736(07)60958-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	182GM	17586288				2022-12-28	WOS:000247493100008
J	Bakal, C; Aach, J; Church, G; Perrimon, N				Bakal, Chris; Aach, John; Church, George; Perrimon, Norbert			Quantitative morphological signatures define local signaling networks regulating cell morphology	SCIENCE			English	Article							MEMBRANE PROTRUSION; LEADING-EDGE; DROSOPHILA; ADHESION; COMPLEX; LOCALIZATION; ACTIVATION; RESTRICTS; PAXILLIN; BEHAVIOR	Although classical genetic and biochemical approaches have identified hundreds of proteins that function in the dynamic remodeling of cell shape in response to upstream signals, there is currently little systems-level understanding of the organization and composition of signaling networks that regulate cell morphology. We have developed quantitative morphological profiling methods to systematically investigate the role of individual genes in the regulation of cell morphology in a fast, robust, and cost-efficient manner. We analyzed a compendium of quantitative morphological signatures and described the existence of local signaling networks that act to regulate cell protrusion, adhesion, and tension.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02215 USA; MIT, Comp Sci & Technol Lab, Cambridge, MA 02139 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Bakal, C (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.			Perrimon, Norbert/0000-0001-7542-472X; Bakal, Chris/0000-0002-0413-6744; church, george/0000-0001-6232-9969				Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Biyasheva A, 2004, J CELL SCI, V117, P837, DOI 10.1242/jcs.00921; Brown MC, 2005, MOL BIOL CELL, V16, P4316, DOI 10.1091/mbc.E05-02-0131; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; Gunsalus KC, 2005, NATURE, V436, P861, DOI 10.1038/nature03876; Hall A, 2005, BIOCHEM SOC T, V33, P891, DOI 10.1042/BST0330891; Huelsmann S, 2006, DEVELOPMENT, V133, P2915, DOI 10.1242/dev.02449; Knox AL, 2002, SCIENCE, V295, P1285, DOI 10.1126/science.1067549; Kunda P, 2003, CURR BIOL, V13, P1867, DOI 10.1016/j.cub.2003.10.005; Mayhew MW, 2006, J PROTEOME RES, V5, P2417, DOI 10.1021/pr060140t; MURAYAMA K, 2006, J BIOL CHEM     1226; Nishita M, 2004, J BIOL CHEM, V279, P7193, DOI 10.1074/jbc.M312591200; Nishiya N, 2005, NAT CELL BIOL, V7, P343, DOI 10.1038/ncb1234; Perlman ZE, 2004, SCIENCE, V306, P1194, DOI 10.1126/science.1100709; Rogers SL, 2003, J CELL BIOL, V162, P1079, DOI 10.1083/jcb.200303023; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Singh SR, 2006, DEV GROWTH DIFFER, V48, P169, DOI 10.1111/j.1440-169x.2006.00854.x; Sone M, 1997, SCIENCE, V275, P543, DOI 10.1126/science.275.5299.543; Takagi Y, 1998, NEUROSCI LETT, V244, P149, DOI 10.1016/S0304-3940(98)00145-1; Wang H, 2006, DEV CELL, V10, P117, DOI 10.1016/j.devcel.2005.11.004; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Welch MD, 1997, J CELL BIOL, V138, P375, DOI 10.1083/jcb.138.2.375; Zallen JA, 2002, J CELL BIOL, V156, P689, DOI 10.1083/jcb.200109057; Zebda N, 2000, J CELL BIOL, V151, P1119, DOI 10.1083/jcb.151.5.1119	25	224	232	3	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 22	2007	316	5832					1753	1756		10.1126/science.1140324	http://dx.doi.org/10.1126/science.1140324			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180XE	17588932				2022-12-28	WOS:000247400500049
J	King, DA; Thomas, SM				King, David A.; Thomas, Sandy M.			Taking science out of the box - Foresight recast	SCIENCE			English	Editorial Material							MOUTH EPIDEMIC; FOOT					sandy.thomas@dti.gsi.gov.uk						Barker I., 2006, FORESIGHT INFECT DIS; CURRY A, 2006, FORESIGHT INTELLIGEN; Ferguson NM, 2001, SCIENCE, V292, P1155, DOI 10.1126/science.1061020; Keeling MJ, 2001, SCIENCE, V294, P813, DOI 10.1126/science.1065973; King DA, 2004, SCIENCE, V303, P176, DOI 10.1126/science.1094329; WOOLHOUSE MEJ, 2006, SCIENCE, V313, P1392	6	27	30	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 22	2007	316	5832					1701	1702		10.1126/science.1146051	http://dx.doi.org/10.1126/science.1146051			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180XE	17588916				2022-12-28	WOS:000247400500029
J	Barry, M				Barry, Michele			The tail end of guinea worm - Global eradication without a drug or a vaccine	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Yale Univ, Sch Med, New Haven, CT 06520 USA	Yale University	Barry, M (corresponding author), Yale Univ, Sch Med, New Haven, CT 06520 USA.							[Anonymous], 2004, Wkly Epidemiol Rec, V79, P234; Hopkins DR, 2005, AM J TROP MED HYG, V73, P669, DOI 10.4269/ajtmh.2005.73.669; Rwakimari JB, 2006, AM J TROP MED HYG, V75, P3, DOI 10.4269/ajtmh.2006.75.3; 2007, WKLY EPIDEMIOL REC, V82, P133	4	36	37	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 21	2007	356	25					2561	2564		10.1056/NEJMp078089	http://dx.doi.org/10.1056/NEJMp078089			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	180GN	17582064				2022-12-28	WOS:000247351200001
J	Roman-Leshkov, Y; Barrett, CJ; Liu, ZY; Dumesic, JA				Roman-Leshkov, Yuriy; Barrett, Christopher J.; Liu, Zhen Y.; Dumesic, James A.			Production of dimethylfuran for liquid fuels from biomass-derived carbohydrates	NATURE			English	Article							SUPPORTED COPPER; HYDROGENATION; CATALYSTS; FRUCTOSE; 2-METHYLFURAN; EQUILIBRIA; MEDIA	Diminishing fossil fuel reserves and growing concerns about global warming indicate that sustainable sources of energy are needed in the near future. For fuels to be useful in the transportation sector, they must have specific physical properties that allow for efficient distribution, storage and combustion; these properties are currently fulfilled by non-renewable petroleum-derived liquid fuels. Ethanol, the only renewable liquid fuel currently produced in large quantities, suffers from several limitations, including low energy density, high volatility, and contamination by the absorption of water from the atmosphere. Here we present a catalytic strategy for the production of 2,5-dimethylfuran from fructose ( a carbohydrate obtained directly from biomass or by the isomerization of glucose) for use as a liquid transportation fuel. Compared to ethanol, 2,5-dimethylfuran has a higher energy density ( by 40 per cent), a higher boiling point ( by 20 K), and is not soluble in water. This catalytic strategy creates a route for transforming abundant renewable biomass resources(1,2) into a liquid fuel suitable for the transportation sector, and may diminish our reliance on petroleum.	Univ Wisconsin, Dept Biol & Chem Engn, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Dumesic, JA (corresponding author), Univ Wisconsin, Dept Biol & Chem Engn, Madison, WI 53706 USA.	dumesic@engr.wisc.edu	Barrett, Christopher J/B-7474-2008; Knafo-Noam, Ariel/E-8067-2011; Roman-Leshkov, Yuriy/E-1387-2014	Barrett, Christopher J/0000-0001-6194-9066; Knafo-Noam, Ariel/0000-0003-0613-1960; Roman-Leshkov, Yuriy/0000-0002-0025-4233				Barlow M. T., 1983, Fuel composition. Eur. Pat., Patent No. [EP0082689, 0082689]; Broughton D.B., 1961, Patent No. [US2985589A, 2985589, 2,985,589]; BROWN DW, 1982, J CHEM TECHNOL BIOT, V32, P920, DOI 10.1002/jctb.5030320730; EISEN EO, 1966, J CHEM ENG DATA, V11, P480, DOI 10.1021/je60031a007; GRABOSKI M, 2003, ANAL ALTERNATIVES UN; Hashimoto K., 1993, PREPARATIVE PRODUCTI, P395; HELMS CR, 1978, SURF SCI, V72, P229, DOI 10.1016/0039-6028(78)90292-3; JONES DT, 1986, MICROBIOL REV, V50, P484, DOI 10.1128/MMBR.50.4.484-524.1986; JONES JH, 2001, IND ENG CHEM PROD RD, V10, P57; KUSTER BFM, 1990, STARCH-STARKE, V42, P314, DOI 10.1002/star.19900420808; MANLY DG, 1958, J ORG CHEM, V23, P1093, DOI 10.1021/jo01102a002; Moreau C, 2004, TOP CATAL, V27, P11, DOI 10.1023/B:TOCA.0000013537.13540.0e; NEIER W, 1982, Patent No. 3040997; Parikka M, 2004, BIOMASS BIOENERG, V27, P613, DOI 10.1016/j.biombioe.2003.07.005; Ragauskas AJ, 2006, SCIENCE, V311, P484, DOI 10.1126/science.1114736; Ramey D. E., 1998, US Patent, Patent No. [5753474, 5,753,474]; Rao RS, 1999, CATAL LETT, V60, P51, DOI 10.1023/A:1019090520407; Roman-Leshkov Y, 2006, SCIENCE, V312, P1933, DOI 10.1126/science.1126337; SINFELT JH, 1976, J CATAL, V42, P227, DOI 10.1016/0021-9517(76)90257-8; SINFELT JH, 1973, J CATAL, V29, P308, DOI 10.1016/0021-9517(73)90234-0; SZMANT HH, 1981, J CHEM TECHNOL BIOT, V31, P135, DOI 10.1002/jctb.280310119; Tan TC, 1999, FLUID PHASE EQUILIBR, V163, P243, DOI 10.1016/S0378-3812(99)00231-9; Twigg MV, 2001, APPL CATAL A-GEN, V212, P161, DOI 10.1016/S0926-860X(00)00854-1; VANDAM HE, 1986, STARCH-STARKE, V38, P95, DOI 10.1002/star.19860380308; Zheng HY, 2006, J MOL CATAL A-CHEM, V246, P18, DOI 10.1016/j.molcata.2005.10.003	25	1757	1887	24	1050	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 21	2007	447	7147					982	U5		10.1038/nature05923	http://dx.doi.org/10.1038/nature05923			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	180NU	17581580				2022-12-28	WOS:000247373100042
J	Gray, RH; Wawer, MJ				Gray, Ronald H.; Wawer, Maria J.			Randomised trials of HIV prevention	LANCET			English	Editorial Material							MALE CIRCUMCISION; VACCINE		Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Populat & Family Hlth Sci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Gray, RH (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Populat & Family Hlth Sci, Baltimore, MD 21205 USA.	rgray@jhsph.edu						Auvert B, 2005, PLOS MED, V2, P1112, DOI 10.1371/journal.pmed.0020298; Bailey RC, 2007, LANCET, V369, P643, DOI 10.1016/S0140-6736(07)60312-2; Burton DR, 2004, SCIENCE, V303, P316, DOI 10.1126/science.1094620; CHECK E, 2007, NATURE, V446, P12; Gray RH, 2007, LANCET, V369, P657, DOI 10.1016/S0140-6736(07)60313-4; Gregson S, 2007, PLOS MED, V4, P545, DOI 10.1371/journal.pmed.0040102; Johnston MI, 2007, NEW ENGL J MED, V356, P2073, DOI 10.1056/NEJMra066267; PADIAN NS, 2007, LANCET          0713, DOI DOI 10.1016/S0140-6736(07)60950-7; Peterson Leigh, 2007, PLoS Clin Trials, V2, pe27, DOI 10.1371/journal.pctr.0020027; Pitisuttithum P, 2006, J INFECT DIS, V194, P1661, DOI 10.1086/508748; TRUSSELL J, 2004, CONTRACEPTIVE TECHNO, P773; WASSERHEIT J, 2007, 14 C RETR OPP INF LO, P56; WHO, 2006, AIR QUAL GUID GLOB U, DOI DOI 10.1016/0004-6981(88)90109-6	13	24	27	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 21	2007	370	9583					200	201		10.1016/S0140-6736(07)61058-7	http://dx.doi.org/10.1016/S0140-6736(07)61058-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	194MG	17631388				2022-12-28	WOS:000248347900007
J	Chung, DC; Yoon, SS; Lauwers, GY; Patel, D				Chung, Daniel C.; Yoon, Sam S.; Lauwers, Gregory Y.; Patel, Devanshi			A woman with a family history of gastric and breast cancer - Hereditary diffuse gastric cancer syndrome due to germ-line E-cadherin mutation, with gastric intramucosal signet-ring-cell carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; PROPHYLACTIC TOTAL GASTRECTOMY; CARRIERS; MANAGEMENT; RECONSTRUCTION; GENETICS; BRCA1; RISK		Massachusetts Gen Hosp, Gastroenterol Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Canc Risk Anal, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Surg, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University	Chung, DC (corresponding author), Massachusetts Gen Hosp, Gastroenterol Unit, Boston, MA 02114 USA.							Blair V, 2006, CLIN GASTROENTEROL H, V4, P262, DOI 10.1016/j.cgh.2005.12.003; Brooks-Wilson AR, 2004, J MED GENET, V41, P508, DOI 10.1136/jmg.2004.018275; Brown Linda Morris, 2002, Surg Oncol Clin N Am, V11, P235, DOI 10.1016/S1055-3207(02)00002-9; Caldas C, 1999, J MED GENET, V36, P873; Carneiro F, 2004, J PATHOL, V203, P681, DOI 10.1002/path.1564; CHO S, 2001, GAS WE PASS STORY FA; Chun YS, 2001, CANCER, V92, P181, DOI 10.1002/1097-0142(20010701)92:1<181::AID-CNCR1307>3.0.CO;2-J; Chung DC, 2003, ANN INTERN MED, V138, P560, DOI 10.7326/0003-4819-138-7-200304010-00012; Claus EB, 1996, CANCER, V77, P2318, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z; DONOVAN IA, 1982, BRIT J SURG, V69, P389, DOI 10.1002/bjs.1800690711; Dulucq JL, 2005, J AM COLL SURGEONS, V200, P191, DOI 10.1016/j.jamcollsurg.2004.10.004; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Hartgrink HH, 2004, J CLIN ONCOL, V22, P2069, DOI 10.1200/JCO.2004.08.026; Huntsman DG, 2001, NEW ENGL J MED, V344, P1904, DOI 10.1056/NEJM200106213442504; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jo WS, 2005, SEMIN ONCOL, V32, P11, DOI 10.1053/j.seminoncol.2004.09.034; Johannsson O, 1999, EUR J CANCER, V35, P1248, DOI 10.1016/S0959-8049(99)00135-5; Kaurah P, 2007, JAMA-J AM MED ASSOC, V297, P2360, DOI 10.1001/jama.297.21.2360; Lehnert T, 2004, BRIT J SURG, V91, P528, DOI 10.1002/bjs.4512; Lewis FR, 2001, SURGERY, V130, P612, DOI 10.1067/msy.2001.117099; Lynch HT, 2005, J SURG ONCOL, V90, P114, DOI 10.1002/jso.20214; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; MADURA JA, 2001, CURRENT SURG THERAPY, P89; MIHOLIC J, 1990, SURGERY, V108, P488; Oliveira C, 2005, VIRCHOWS ARCH, V446, P181, DOI 10.1007/s00428-004-1156-4; Park DJ, 2005, BRIT J SURG, V92, P1099, DOI 10.1002/bjs.4952; Park YJ, 2000, CLIN CANCER RES, V6, P2994; Pharoah PDP, 2001, GASTROENTEROLOGY, V121, P1348, DOI 10.1053/gast.2001.29611; RUBINSTEIN WS, IN PRESS FAM CANC; Shaw D, 2005, GUT, V54, P461, DOI 10.1136/gut.2004.049171; Suriano G, 2005, CLIN CANCER RES, V11, P5401, DOI 10.1158/1078-0432.CCR-05-0247; Usui S, 2005, SURG LAPARO ENDO PER, V15, P309, DOI 10.1097/01.sle.0000191589.84485.4a; van Kouwen MCA, 2004, CLIN CANCER RES, V10, P6456, DOI 10.1158/1078-0432.CCR-04-0599; WANEBO HJ, 1993, ANN SURG, V218, P583, DOI 10.1097/00000658-199321850-00002	34	33	33	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 19	2007	357	3					283	291		10.1056/NEJMcpc079016	http://dx.doi.org/10.1056/NEJMcpc079016			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191FH	17634464				2022-12-28	WOS:000248115100011
J	Ford, R; Spafford, EH				Ford, Richard; Spafford, Eugene H.			Computer science - Happy birthday, dear viruses	SCIENCE			English	Editorial Material									Florida Inst Technol, Coll Engn & Comp Sci, Melbourne, FL 32901 USA; Purdue Univ, Ctr Educ & Res Informat Assurance & Secur, W Lafayette, IN 47907 USA	Florida Institute of Technology; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Ford, R (corresponding author), Florida Inst Technol, Coll Engn & Comp Sci, Melbourne, FL 32901 USA.	rford@se.fit.edu; spaf@cerias.purdue.edu	Spafford, Eugene H/Q-1244-2015	Spafford, Eugene H/0000-0002-5555-8330				Cohen F. B., 1994, SHORT COURSE COMPUTE; FERBRACHE D, 1991, PATHOLOGY COMPUTER V; SPAFFORD EUGENE H., 1994, ENCY SOFTWARE ENG	4	17	19	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 13	2007	317	5835					210	211		10.1126/science.1140909	http://dx.doi.org/10.1126/science.1140909			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189DC	17626875				2022-12-28	WOS:000247968600030
J	Strom, L; Karlsson, C; Lindroos, HB; Wedahl, S; Katou, Y; Shirahige, K; Sjogren, C				Stroem, Lena; Karlsson, Charlotte; Betts Lindroos, Hanna; Wedahl, Sara; Katou, Yuki; Shirahige, Katsuhiko; Sjoegren, Camilla			Postreplicative formation of cohesion is required for repair and induced by a single DNA break	SCIENCE			English	Article							SISTER-CHROMATID COHESION; DOUBLE-STRAND BREAKS; DAMAGE-RESPONSE; BUDDING YEAST; COMPLEX; PROTEIN; CHECKPOINT; ANAPHASE; RECOMBINATION; ESTABLISHMENT	Sister-chromatid cohesion, established during replication by the protein complex cohesin, is essential for both chromosome segregation and double-strand break (DSB) repair. Normally, cohesion formation is strictly limited to the S phase of the cell cycle, but DSBs can trigger cohesion also after DNA replication has been completed. The function of this damage-induced cohesion remains unknown. In this investigation, we show that damage-induced cohesion is essential for repair in postreplicative cells in yeast. Furthermore, it is established genome-wide after induction of a single DSB, and it is controlled by the DNA damage response and cohesin-regulating factors. We thus define a cohesion establishment pathway that is independent of DNA duplication and acts together with cohesion formed during replication in sister chromatid-based DSB repair.	Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden; Tokyo Inst Technol, Ctr Gene Res, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Karolinska Institutet; Tokyo Institute of Technology	Sjogren, C (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden.	camilla.sjogren@ki.se	Ström, Lena/AAJ-9025-2020	Shirahige, Katsuhiko/0000-0002-7862-1144; Lindroos, Hanna/0000-0002-8455-8452; Bjorkegren, Camilla/0000-0001-7354-9270; Strom, Lena/0000-0002-8898-3675				Blankley RT, 2004, J CELL SCI, V117, P601, DOI 10.1242/jcs.00907; Ciosk R, 2000, MOL CELL, V5, P243, DOI 10.1016/S1097-2765(00)80420-7; Cohen-Fix O, 1999, GENE DEV, V13, P1950, DOI 10.1101/gad.13.15.1950; De Piccoli G, 2006, NAT CELL BIOL, V8, P1032, DOI 10.1038/ncb1466; Kenna MA, 2003, MOL CELL BIOL, V23, P2999, DOI 10.1128/MCB.23.8.2999-3007.2003; Kim JS, 2002, J BIOL CHEM, V277, P45149, DOI 10.1074/jbc.M209123200; Krejci L, 2002, J BIOL CHEM, V277, P40132, DOI 10.1074/jbc.M206511200; Lengronne A, 2006, MOL CELL, V23, P787, DOI 10.1016/j.molcel.2006.08.018; Lindroos HB, 2006, MOL CELL, V22, P755, DOI 10.1016/j.molcel.2006.05.014; Lisby M, 2004, CELL, V118, P699, DOI 10.1016/j.cell.2004.08.015; Moldovan GL, 2006, MOL CELL, V23, P723, DOI 10.1016/j.molcel.2006.07.007; Nasmyth K, 2005, ANNU REV BIOCHEM, V74, P595, DOI 10.1146/annurev.biochem.74.082803.133219; Potts PR, 2006, EMBO J, V25, P3377, DOI 10.1038/sj.emboj.7601218; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Shroff R, 2004, CURR BIOL, V14, P1703, DOI 10.1016/j.cub.2004.09.047; Sjogren C, 2001, CURR BIOL, V11, P991, DOI 10.1016/S0960-9822(01)00271-8; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; Strom L, 2004, MOL CELL, V16, P1003, DOI 10.1016/j.molcel.2004.11.026; Strom L, 2005, CELL CYCLE, V4, P536, DOI 10.4161/cc.4.4.1613; Stucki M, 2006, DNA REPAIR, V5, P534, DOI 10.1016/j.dnarep.2006.01.012; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Unal E, 2007, SCIENCE, V317, P245, DOI 10.1126/science.1140637; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Unal E, 2004, MOL CELL, V16, P991, DOI 10.1016/j.molcel.2004.11.027; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679	28	234	238	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 13	2007	317	5835					242	245		10.1126/science.1140649	http://dx.doi.org/10.1126/science.1140649			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189DC	17626884				2022-12-28	WOS:000247968600042
J	Lee, TH; Torchiana, DF; Lock, JE				Lee, Thomas H.; Torchiana, David F.; Lock, James E.			Is zero the ideal death rate?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Partners Healthcare Syst, Boston, MA 02199 USA; Massachusetts Gen Phys Org, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; Childrens Hosp, Boston, MA 02115 USA	Partners Healthcare System; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Lee, TH (corresponding author), Partners Healthcare Syst, Boston, MA 02199 USA.							*AG HEALTHC RES QU, NAT QUAL MEAS CLEAR; Guru V, 2006, AM HEART J, V152, P573, DOI 10.1016/j.ahj.2005.10.026; Hochman JS, 2006, JAMA-J AM MED ASSOC, V295, P2511, DOI 10.1001/jama.295.21.2511; Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115	4	24	24	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 12	2007	357	2					111	113		10.1056/NEJMp078025	http://dx.doi.org/10.1056/NEJMp078025			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188NX	17625122				2022-12-28	WOS:000247927700004
J	Shiffman, ML; Suter, F; Bacon, BR; Nelson, D; Harley, H; Sola, R; Shafran, SD; Barange, K; Lin, A; Soman, A; Zeuzem, S; Crawford, D; Leggett, L; Roberts, S; Weltman, M; Greenbloom, S; Menon, K; Bourliere, M; Brissot, P; Bronowicki, JP; Doffoel, M; Hezode, C; Marcellin, P; Tran, A; Zarski, JP; Avci, O; Berg, T; Potthoff, O; Rasenack, J; Ross, O; von Wagner, M; Ascione, A; Brillanti, S; Brunetto, M; Bruno, R; Bruno, S; Cane, E; Aguilar, J; Barcena, R; Diago, M; Enriquez, J; Garcia-Samaniego, J; Moreno, R; Planas, R; Rincon, D; Sola, R; Testillano, M; Anand, B; Bilir, BB; Balan, V; Bank, L; Barranco, E; Berg, C; Bernstein, D; Bloom, J; Bonkovsky, H; Box, T; Brau, N; Bzowej, N; Cassidy, W; Clain, D; Corasanti, J; Davis, M; DeJesus, E; Delich, P; Esposito, S; Etzkorn, K; Flora, K; Fried, M; Fromm, H; Ghalib, R; Gibas, A; Godofsky, E; Gompf, S; Gordon, S; Gordon, F; Hammond, G; Harrison, S; Herrera, J; Ho, S; Howell, C; Joshi, S; Keeffe, E; Kranz, K; Kwo, P; Lake-Bakaar, G; Larson, A; Levin, A; Lok, A; Lucey, M; Lyons, M; Malet, P; Malik, P; Manch, R; Mehra, S; Mihas, A; Mikolich, D; Morgan, T; Muir, A; Nguyen, R; Nunes, D; Nyberg, L; O'Brien, C; Pappas, S; Pauly, M; Pedrosa, M; Perkel, M; Person, J; Pockros, P; Post, A; Poulos, J; Powell, R; Raj, V; Reed, A; Reindollar, R; Riley, T; Rodriguez-Torres, M; Rubin, R; Sahagun, G; Schmidt, W; Sepe, T; Shaw-Stiffel, T; Sheikh, A; Sherman, K; Smith, C; Stevens, D; Sulkowski, M; Toro, D; Torres, E; Tran, T; Tsai, N; Wohlman, R; Wright, W; Wruble, L; Younossi, Z				Shiffman, Mitchell L.; Suter, Fredy; Bacon, Bruce R.; Nelson, David; Harley, Hugh; Sola, Ricard; Shafran, Stephen D.; Barange, Karl; Lin, Amy; Soman, Ash; Zeuzem, Stefan; Crawford, D.; Leggett, L.; Roberts, S.; Weltman, M.; Greenbloom, S.; Menon, K.; Bourliere, M.; Brissot, P.; Bronowicki, J.-P.; Doffoel, M.; Hezode, C.; Marcellin, P.; Tran, A.; Zarski, J.-P.; Avci, O.; Berg, T.; Potthoff, O.; Rasenack, J.; Ross, O.; von Wagner, M.; Ascione, A.; Brillanti, S.; Brunetto, M.; Bruno, R.; Bruno, S.; Cane, E.; Aguilar, J.; Barcena, R.; Diago, M.; Enriquez, J.; Garcia-Samaniego, J.; Moreno, R.; Planas, R.; Rincon, D.; Sola, R.; Testillano, M.; Anand, B.; Bilir, B. Bahri; Balan, V.; Bank, L.; Barranco, E.; Berg, C.; Bernstein, D.; Bloom, J.; Bonkovsky, H.; Box, T.; Brau, N.; Bzowej, N.; Cassidy, W.; Clain, D.; Corasanti, J.; Davis, M.; DeJesus, E.; Delich, P.; Esposito, S.; Etzkorn, K.; Flora, K.; Fried, M.; Fromm, H.; Ghalib, R.; Gibas, A.; Godofsky, E.; Gompf, S.; Gordon, S.; Gordon, F.; Hammond, G.; Harrison, S.; Herrera, J.; Ho, S.; Howell, C.; Joshi, S.; Keeffe, E.; Kranz, K.; Kwo, P.; Lake-Bakaar, G.; Larson, A.; Levin, A.; Lok, A.; Lucey, M.; Lyons, M.; Malet, P.; Malik, P.; Manch, R.; Mehra, S.; Mihas, A.; Mikolich, D.; Morgan, T.; Muir, A.; Nguyen, R.; Nunes, D.; Nyberg, L.; O'Brien, C.; Pappas, S.; Pauly, M.; Pedrosa, M.; Perkel, M.; Person, J.; Pockros, P.; Post, A.; Poulos, J.; Powell, R.; Raj, V.; Reed, A.; Reindollar, R.; Riley, T.; Rodriguez-Torres, M.; Rubin, R.; Sahagun, G.; Schmidt, W.; Sepe, T.; Shaw-Stiffel, T.; Sheikh, A.; Sherman, K.; Smith, C.; Stevens, D.; Sulkowski, M.; Toro, D.; Torres, E.; Tran, T.; Tsai, N.; Wohlman, R.; Wright, W.; Wruble, L.; Younossi, Z.		ACCELERATE Investigators	Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC HEPATITIS-C; ALPHA-2B PLUS RIBAVIRIN; 40KD	BACKGROUND: Patients infected with hepatitis C virus (HCV) genotype 2 or 3 have sustained virologic response rates of approximately 80% after receiving treatment with peginterferon and ribavirin for 24 weeks. We conducted a large, randomized, multinational, noninferiority trial to determine whether similar efficacy could be achieved with only 16 weeks of treatment with peginterferon alfa-2a and ribavirin. METHODS: We randomly assigned 1469 patients with HCV genotype 2 or 3 to receive 180 microg of peginterferon alfa-2a weekly, plus 800 < mg of ribavirin daily, for either 16 or 24 weeks. A sustained virologic response was defined as an undetectable serum HCV RNA level (50 IU per milliliter) 24 weeks after the end of treatment. RESULTS: The study failed to demonstrate that the 16-week regimen was noninferior to the 24-week regimen. The sustained virologic response rate was significantly lower in patients treated for 16 weeks than in patients treated for 24 weeks (62% vs. 70%; odds ratio for 16 weeks vs. 24 weeks, 0.67; 95% confidence interval, 0.54 to 0.84; P < 0.001). In addition, the rate of relapse (a detectable HCV RNA level during follow-up in patients who had undetectable HCV RNA at the end of treatment) was significantly greater in the 16-week group (31%, vs. 18% in the 24-week group; P < 0.001). The sustained virologic response rates in patients with a pretreatment serum HCV RNA level of 400,000 IU per milliliter or less was 82% with the 16-week regimen and 81% with the 24-week regimen. Among patients with a rapid virologic response (an undetectable HCV RNA level by week 4), sustained virologic response rates were 79% in the 16-week group and 85% in the 24-week group (P=0.02). CONCLUSIONS: Treatment with peginterferon and ribavirin for 16 weeks in patients infected with HCV genotype 2 or 3 results in a lower overall sustained virologic response rate than treatment with the standard 24-week regimen.	Virginia Commonwealth Univ, Med Ctr, Liver Transplant Program, Richmond, VA 23298 USA; Osped Riuniti Bergamo, I-24100 Bergamo, Italy; St Louis Univ, St Louis, MO 63103 USA; Univ Florida, Gainesville, FL USA; Royal Adelaide Hosp, Adelaide, SA 5000, Australia; Univ Autonoma Barcelona, E-08193 Barcelona, Spain; Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada; Hop Purpan, Toulouse, France; Roche, Nutley, NJ USA; Roche, Welwyn Garden City, England; Saarland Univ Hosp, Homburg, Germany	Virginia Commonwealth University; Ospedali Riuniti di Bergamo; Saint Louis University; State University System of Florida; University of Florida; Royal Adelaide Hospital; Autonomous University of Barcelona; University of Alberta; CHU de Toulouse; Roche Holding; Roche Holding; Universitatsklinikum des Saarlandes	Shiffman, ML (corresponding author), Virginia Commonwealth Univ, Med Ctr, Liver Transplant Program, 1251 E Marshall St,Box 663, Richmond, VA 23298 USA.	mshiffma@vcu.edu	Hezode, Christophe/U-4659-2018; Esposito, Susanna/AAA-8275-2022; Lok, Anna/B-8292-2009; DIAGO, MOISES/AAH-5364-2019; Zeuzem, Stefan/AAE-7435-2019; Rubin, Rita/AAD-1259-2020; Rincon-Valenzuela, David A/HGC-0532-2022; Brillanti, Stefano/E-8970-2010	Brillanti, Stefano/0000-0003-4181-795X				Dalgard O, 2004, HEPATOLOGY, V40, P1260, DOI 10.1002/hep.20467; Ferenci P, 2006, J HEPATOL, V44, pS37, DOI 10.1016/S0168-8278(06)80083-8; Ferenci R, 2006, J HEPATOL, V44, pS6; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Hadziyannis SJ, 2004, ANN INTERN MED, V140, P346, DOI 10.7326/0003-4819-140-5-200403020-00010; Henry MJ, 2005, NEW ENGL J MED, V353, P1183; Jacobson IM, 2005, HEPATOLOGY, V42, p749A; Jensen, 2006, HEPATOLOGY, V43, P1410, DOI 10.1002/hep.21245; Jensen DM, 2006, HEPATOLOGY, V43, P954, DOI 10.1002/hep.21159; Mangia A, 2005, NEW ENGL J MED, V352, P2609, DOI 10.1056/NEJMoa042608; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Strader DB, 2004, HEPATOLOGY, V40, P269, DOI 10.1002/hep.20316; von Wagner M, 2005, GASTROENTEROLOGY, V129, P522, DOI 10.1053/j.gastro.2005.05.008; Yu ML, 2007, GUT, V56, P553, DOI 10.1136/gut.2006.102558; Zeuzem S, 2006, J HEPATOL, V44, P97, DOI 10.1016/j.jhep.2005.10.003	15	441	465	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 12	2007	357	2					124	134		10.1056/NEJMoa066403	http://dx.doi.org/10.1056/NEJMoa066403			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188NX	17625124	Green Published			2022-12-28	WOS:000247927700006
J	Shuchman, M				Shuchman, Miriam			Falling throuch the cracks - Virginia Tech and the restructuring of college mental health service	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SUICIDE											Appleby L, 1999, BRIT MED J, V318, P1235; *COMM VIRG OFF INS, 2007, 14007 COMM VIRG OFF; Knox KL, 2003, BMJ-BRIT MED J, V327, P1376, DOI 10.1136/bmj.327.7428.1376; *MIT, 2001, MIT MENT HLTH TASK F; SUTPHIN M, 2005, COLL TIMES      0812	5	21	21	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 12	2007	357	2					105	110		10.1056/NEJMp078096	http://dx.doi.org/10.1056/NEJMp078096			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	188NX	17625121				2022-12-28	WOS:000247927700001
J	Este, JA; Telenti, A				Este, Jose A.; Telenti, Amalio			HIV entry inhibitors	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; TREATMENT-EXPERIENCED PATIENTS; PLACEBO-CONTROLLED TRIAL; CHEMOKINE RECEPTOR CCR5; SHORT-TERM MONOTHERAPY; HIV-1-INFECTED PATIENTS; ANTIVIRAL ACTIVITY; CORECEPTOR USE; SMALL-MOLECULE; VIRAL ENTRY	The need for new classes of antiretroviral drugs has become apparent because of increasing concern about the long-term toxic effects of existing drugs, the need to combat HIV-1 variants that are resistant to treatment, and the frequency of treatment change in drug-experienced patients. Currently, most regimens are combinations of inhibitors of two viral enzymes-reverse transcriptase and protease. Nevertheless, several steps in the HIV replication cycle are potential targets for intervention. These steps can be divided into entry steps, in which viral envelope glycoproteins and their receptors are involved, and postentry steps, involving viral accessory gene products and the cellular proteins with which they interact. New treatment options target viral entry into the cell. These treatments include the HIV fusion inhibitor enfuvirtide, and new HIV coreceptor antagonists in advanced stages of clinical development or in different stages of preclinical development. Here, we review the development of new HIV entry inhibitors, their performance in clinical trials, and their possible role in anti-HIV therapy.	Univ Autonoma Barcelona, Fdn IrsiCaixa, Lab Retrovirol, Hosp Germans Trias & Pujol, Badalona 08916, Spain; Univ Lausanne, Inst Microbiol, Univ Hosp Ctr, Lausanne, Switzerland	Autonomous University of Barcelona; Hospital Germans Trias i Pujol; Institut de Recerca de la Sida - IrsiCaixa; University of Lausanne	Este, JA (corresponding author), Univ Autonoma Barcelona, Fdn IrsiCaixa, Lab Retrovirol, Hosp Germans Trias & Pujol, Ctra Del Canyet S-N, Badalona 08916, Spain.	jaeste@irsicaixa.es	Este, Jose/B-5509-2008; Telenti, Amalio/AAY-1674-2021	Este, Jose/0000-0002-1436-5823; 				Ank N, 2005, J VIROL, V79, P9831, DOI 10.1128/JVI.79.15.9831-9841.2005; Aquaro S, 2006, J ANTIMICROB CHEMOTH, V58, P714, DOI 10.1093/jac/dkl306; Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698; Belnoue E, 2003, BLOOD, V101, P4253, DOI 10.1182/blood-2002-05-1493; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Brumme ZL, 2005, J INFECT DIS, V192, P466, DOI 10.1086/431519; Cahn P, 2006, CLIN INFECT DIS, V43, P1347, DOI 10.1086/508352; Chan SY, 1999, J VIROL, V73, P2350, DOI 10.1128/JVI.73.3.2350-2358.1999; Clotet B, 2007, LANCET, V369, P1169, DOI 10.1016/S0140-6736(07)60497-8; Coakley E, 2005, CURR OPIN INFECT DIS, V18, P9, DOI 10.1097/00001432-200502000-00003; Cohen J, 2007, SCIENCE, V315, P1357, DOI 10.1126/science.315.5817.1357; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; COOPER D, 2007, PATIENTS TRIPLE CLAS; Crabb C, 2006, AIDS, V20, P641, DOI 10.1097/01.aids.0000216362.59657.96; Dai SJ, 2005, ACTA PHARMACOL SIN, V26, P1274, DOI 10.1111/j.1745-7254.2005.00163.x; De Clercq E, 2003, NAT REV DRUG DISCOV, V2, P581, DOI 10.1038/nrd1134; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deeks SG, 2007, J INFECT DIS, V195, P387, DOI 10.1086/510531; Dorr P, 2005, ANTIMICROB AGENTS CH, V49, P4721, DOI 10.1128/AAC.49.11.4721-4732.2005; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Este JA, 2003, CURR MED CHEM, V10, P1617, DOI 10.2174/0929867033457098; Este JA, 2006, J EXP MED, V203, P35; Fatkenheuer G, 2005, NAT MED, V11, P1170, DOI 10.1038/nm1319; Fischereder M, 2001, LANCET, V357, P1758, DOI 10.1016/S0140-6736(00)04898-4; Fletcher CV, 2003, LANCET, V361, P1577, DOI 10.1016/S0140-6736(03)13323-5; Floto RA, 2006, SCIENCE, V314, P454, DOI 10.1126/science.1133515; Gardam MA, 2003, LANCET INFECT DIS, V3, P148, DOI 10.1016/S1473-3099(03)00545-0; Glass WG, 2005, J EXP MED, V202, P1087, DOI 10.1084/jem.20042530; Glass WG, 2006, J EXP MED, V203, P35, DOI 10.1084/jem.20051970; GREAVES W, 2006, 13 C RETR OPP INF; Grinsztejn B, 2007, LANCET, V369, P1261, DOI 10.1016/S0140-6736(07)60597-2; Gulick RM, 2007, J INFECT DIS, V196, P304, DOI 10.1086/518797; Hammer SM, 2006, JAMA-J AM MED ASSOC, V296, P827, DOI 10.1001/jama.296.7.827; HANNA G, 2004, HIV U INFECT PATIENT; Harris M, 2006, AIDS, V20, P719, DOI 10.1097/01.aids.0000216372.53819.db; Hendrix CW, 2004, JAIDS-J ACQ IMM DEF, V37, P1253, DOI 10.1097/01.qai.0000137371.80695.ef; Hicks CB, 2006, LANCET, V368, P466, DOI 10.1016/S0140-6736(06)69154-X; Hunt PW, 2006, J INFECT DIS, V194, P926, DOI 10.1086/507312; Jensen MA, 2003, J VIROL, V77, P13376, DOI 10.1128/JVI.77.24.13376-13388.2003; Johnson Victoria A, 2006, Top HIV Med, V14, P125; Katlama C, 2007, AIDS, V21, P395, DOI 10.1097/QAD.0b013e328013d9d7; Khan IA, 2006, PLOS PATHOG, V2, P484, DOI 10.1371/journal.ppat.0020049; Kilby JM, 2003, NEW ENGL J MED, V348, P2228, DOI 10.1056/NEJMra022812; Kiselyeva Y, 2007, J VIROL, V81, P3657, DOI 10.1128/JVI.02310-06; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; Lalezari J, 2005, AIDS, V19, P1443, DOI 10.1097/01.aids.0000183633.06580.8a; Lalezari J., 2007, 14 C RETR OPP INF; Lazzarin A, 2007, LANCET, V370, P39, DOI 10.1016/S0140-6736(07)61048-4; Lederman MM, 2006, JAMA-J AM MED ASSOC, V296, P815, DOI 10.1001/jama.296.7.815; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Machado ES, 2006, AIDS, V20, P2130, DOI 10.1097/01.aids.0000247570.11128.ab; Machado FS, 2005, J INFECT DIS, V191, P627, DOI 10.1086/427515; Madruga JV, 2007, LANCET, V370, P29, DOI 10.1016/S0140-6736(07)61047-2; Margolis L, 2006, NAT REV MICROBIOL, V4, P312, DOI 10.1038/nrmicro1387; Matthews T, 2004, NAT REV DRUG DISCOV, V3, P215, DOI 10.1038/nrd1331; Melby T, 2006, J INFECT DIS, V194, P238, DOI 10.1086/504693; Menendez-Arias L, 2004, CURR PHARM DESIGN, V10, P1845, DOI 10.2174/1381612043384574; Morse C, 2007, J INFECT DIS, V195, P318, DOI 10.1086/510539; Moyle G., 2007, 14 C RETR OPP INF; Moyle GJ, 2005, J INFECT DIS, V191, P866, DOI 10.1086/428096; NELSON M, 2007, 14 C RETR OPP INF; Norris D, 2006, 16 INT AIDS C; Pastore C, 2006, J VIROL, V80, P750, DOI 10.1128/JVI.80.2.750-758.2006; Pierson TC, 2003, CURR TOP MICROBIOL, V281, P1; Prahalad S, 2006, GENES IMMUN, V7, P264, DOI 10.1038/sj.gene.6364298; *PROG PHARM, FORM 8 K; Pugach P, 2007, VIROLOGY, V361, P212, DOI 10.1016/j.virol.2006.11.004; Rahbar R, 2006, J VIROL, V80, P7245, DOI 10.1128/JVI.00463-06; Ray N, 2007, J VIROL, V81, P3240, DOI 10.1128/JVI.02413-06; Sabeti PC, 2005, PLOS BIOL, V3, P1963, DOI 10.1371/journal.pbio.0030378; Schols D, 2006, ANTIVIR RES, V71, P216, DOI 10.1016/j.antiviral.2006.04.009; Schuiling GA, 2003, J PSYCHOSOM OBST GYN, V24, P205, DOI 10.3109/01674820309039674; Shalit P, 2007, HIV CLIN TRIALS, V8, P24, DOI 10.1310/hct0801-24; STARCICH BR, 1986, CELL, V45, P637, DOI 10.1016/0092-8674(86)90778-6; Strizki JM, 2005, ANTIMICROB AGENTS CH, V49, P4911, DOI 10.1128/AAC.49.12.4911-4919.2005; Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016; Telenti A, 2007, ANTIVIR THER, V12, P147; Trkola A, 2002, P NATL ACAD SCI USA, V99, P395, DOI 10.1073/pnas.012519099; VANTWOUT AB, 1994, J CLIN INVEST, V94, P2060, DOI 10.1172/JCI117560; Walker DK, 2005, DRUG METAB DISPOS, V33, P587, DOI 10.1124/dmd.104.002626; Watson C, 2005, MOL PHARMACOL, V67, P1268, DOI 10.1124/mol.104.008565; Weber J, 2006, AIDS REV, V8, P60; Westby M, 2006, J VIROL, V80, P4909, DOI 10.1128/JVI.80.10.4909-4920.2006; Westby M, 2007, J VIROL, V81, P2359, DOI 10.1128/JVI.02006-06; Wheeler J, 2007, ANTIVIR THER, V12, P233; Whitcomb JM, 2007, ANTIMICROB AGENTS CH, V51, P566, DOI 10.1128/AAC.00853-06; Wilkin TJ, 2007, CLIN INFECT DIS, V44, P591, DOI 10.1086/511035; Xu J, 2003, J PHARMACOL EXP THER, V307, P1148, DOI 10.1124/jpet.103.055178; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	89	219	230	1	30	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 7	2007	370	9581					81	88		10.1016/S0140-6736(07)61052-6	http://dx.doi.org/10.1016/S0140-6736(07)61052-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187QE	17617275				2022-12-28	WOS:000247862300033
J	Lawrence, T; Hagemann, T; Balkwill, F				Lawrence, Toby; Hagemann, Thorsten; Balkwill, Frances			Sex, cytokines, and cancer	SCIENCE			English	Editorial Material							TUMORIGENESIS; INFLAMMATION		Barts & London Queen Marys Sch Med & Dent, Ctr Translat Oncol, Inst Canc, London EC1M 6BQ, England	Royal Marsden NHS Foundation Trust; University of London; Queen Mary University London	Lawrence, T (corresponding author), Barts & London Queen Marys Sch Med & Dent, Ctr Translat Oncol, Inst Canc, Charterhouse Sq, London EC1M 6BQ, England.	frances.balkwill@cancer.org.uk	Lawrence, Toby/F-4461-2015; Lawrence, Toby/GLU-3895-2022	Lawrence, Toby/0000-0003-0967-6122; Lawrence, Toby/0000-0003-0967-6122; Balkwill, Frances/0000-0002-5587-9759	MRC [G0501974, G0601867] Funding Source: UKRI; Medical Research Council [G0601867, G0501974] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Choy EHS, 2002, ARTHRITIS RHEUM-US, V46, P3143, DOI 10.1002/art.10623; Farquhar CM, 2005, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004143.pub2, 10.1002/14651858.CD003139.pub2, 10.1002/14651858.CD001122.pub2, 10.1002/14651858.CD003142.pub2]; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488; Yan L, 2006, EUR J CANCER, V42, P793, DOI 10.1016/j.ejca.2006.01.013	12	36	39	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 6	2007	317	5834					51	52		10.1126/science.1146052	http://dx.doi.org/10.1126/science.1146052			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186KD	17615328				2022-12-28	WOS:000247776700033
J	Petraglia, M; Korisettar, R; Boivin, N; Clarkson, C; Ditchfield, P; Jones, S; Koshy, J; Lahr, MM; Oppenheimer, C; Pyle, D; Roberts, R; Schwenninger, JL; Arnold, L; White, K				Petraglia, Michael; Korisettar, Ravi; Boivin, Nicole; Clarkson, Christopher; Ditchfield, Peter; Jones, Sacha; Koshy, Jinu; Lahr, Marta Mirazon; Oppenheimer, Clive; Pyle, David; Roberts, Richard; Schwenninger, Jean-Luc; Arnold, Lee; White, Kevin			Middle paleolithic assemblages from the Indian subcontinent before and after the Toba super-eruption	SCIENCE			English	Article							MODERN HUMAN ORIGINS; VOLCANIC WINTER; ASH; DISPERSAL; EVOLUTION; BEHAVIOR; SOUTH	The Youngest Toba Tuff (YTT) eruption, which occurred in Indonesia 74,000 years ago, is one of Earth's largest known volcanic events. The effect of the YTT eruption on existing populations of humans, and accordingly on the course of human evolution, is debated. Here we associate the YTT with archaeological assemblages at Jwalapuram, in the Jurreru River valley of southern India. Broad continuity of Middle Paleolithic technology across the YTT event suggests that hominins persisted regionally across this major eruptive event.	Univ Cambridge, Leverhulme Ctr Human Evolutionary Studies, Cambridge CB2 1QH, England; Smithsonian Inst, Natl Museum Nat Hist, Human Origins Program, Washington, DC 20560 USA; Karnatak Univ, Dept Hist & Archaeol, Dharwad 580003, Karnataka, India; Univ Queensland, Sch Social Sci, St Lucia, Qld, Australia; Univ Oxford, Archaeol & Hist Art Res Lab, Oxford OX1 3QY, England; Univ Cambridge, Dept Geog, Cambridge CB2 3EN, England; Univ Oxford, Dept Earth Sci, Oxford OX1 3PR, England; Univ Wollongong, GeoQUEST Res Ctr, Sch Earth & Environm Sci, Wollongong, NSW 2522, Australia; Univ Reading, Dept Geog, Reading RG6 6AB, Berks, England	University of Cambridge; Smithsonian Institution; Smithsonian National Museum of Natural History; Karnatak University; University of Queensland; University of Oxford; University of Cambridge; University of Oxford; University of Wollongong; University of Reading	Petraglia, M (corresponding author), Univ Cambridge, Leverhulme Ctr Human Evolutionary Studies, Cambridge CB2 1QH, England.	m.petraglia@human-evol.cam.ac.uk	Pyle, David M/C-5707-2009; Oppenheimer, Clive/G-9881-2013; Arnold, Lee J/J-4356-2018; Petraglia, Michael/ABA-9748-2021; Roberts, Richard Graham/B-8245-2013	Pyle, David M/0000-0002-2663-9940; Oppenheimer, Clive/0000-0003-4506-7260; Arnold, Lee J/0000-0001-9603-3824; Roberts, Richard Graham/0000-0002-0128-4119; BOIVIN, NICOLE/0000-0002-7783-4199; Jones, Sacha/0000-0003-0492-2662; Petraglia, Michael/0000-0003-2522-5727; Koshy, Jinu/0000-0003-3246-0485; Mirazon Lahr, Marta/0000-0001-5752-5770; Clarkson, Chris/0000-0002-8938-8974	Natural Environment Research Council [NER/T/S/2002/00468] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		ACHARYYA SK, 1993, QUATERNARY RES, V40, P10, DOI 10.1006/qres.1993.1051; Ambrose SH, 2003, J HUM EVOL, V45, P231, DOI 10.1016/j.jhevol.2003.08.001; Ambrose SH, 1998, J HUM EVOL, V34, P623, DOI 10.1006/jhev.1998.0219; CHESNER CA, 1991, GEOLOGY, V19, P200, DOI 10.1130/0091-7613(1991)019<0200:EHOESL>2.3.CO;2; Gathorne-Hardy FJ, 2003, J HUM EVOL, V45, P227, DOI 10.1016/S0047-2484(03)00105-2; James HVA, 2005, CURR ANTHROPOL, V46, pS3, DOI 10.1086/444365; Jones GS, 2005, CLIM DYNAM, V25, P725, DOI 10.1007/s00382-005-0066-8; Jones SC, 2007, VERTEBR PALEOBIOL PA, P173, DOI 10.1007/1-4020-5562-5_8; Kivisild T, 2003, AM J HUM GENET, V72, P313, DOI 10.1086/346068; Lahr Marta Mirazon, 1994, Evolutionary Anthropology, V3, P48, DOI 10.1002/evan.1360030206; Macaulay V, 2005, SCIENCE, V308, P1034, DOI 10.1126/science.1109792; Mason BG, 2004, B VOLCANOL, V66, P735, DOI 10.1007/s00445-004-0355-9; Metspalu M, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-26; MISRA VN, 1989, MAN ENV, V14, P1764; MURTY MLK, 1974, P AM PHILOS SOC, V118, P196; Oppenheimer C, 2002, QUATERNARY SCI REV, V21, P1593, DOI 10.1016/S0277-3791(01)00154-8; Petraglia MD, 2003, ANTIQUITY, V77, P671, DOI 10.1017/S0003598X00061639; RAMPINO MR, 1993, QUATERNARY RES, V40, P269, DOI 10.1006/qres.1993.1081; RAMPINO MR, 1992, NATURE, V359, P50, DOI 10.1038/359050a0; RAMPINO MR, 1993, SCIENCE, V262, P1955, DOI 10.1126/science.8266085; Reddy K. T., 1977, ASIAN PERSPECT, V20, P206; ROSE WI, 1990, GLOBAL PLANET CHANGE, V89, P269, DOI 10.1016/0921-8181(90)90023-6; ROSE WI, 1987, GEOLOGY, V15, P913, DOI 10.1130/0091-7613(1987)15<913:DOAITG>2.0.CO;2; SHANE P, 1995, QUATERNARY RES, V44, P200, DOI 10.1006/qres.1995.1064; Westgate JA, 1998, QUATERNARY RES, V50, P107, DOI 10.1006/qres.1998.1974	25	208	216	1	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 6	2007	317	5834					114	116		10.1126/science.1141564	http://dx.doi.org/10.1126/science.1141564			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186KD	17615356				2022-12-28	WOS:000247776700063
J	Check, E				Check, Erika			Abbott's AIDS fight-back	NATURE			English	News Item								In March 2007, Abbott Laboratories withdrew its application to register the AIDS drug Aluvia in Thailand because since November 2006, the Thai government has issued a series of compulsory licences to enable it to manufacture or purchase generic copies of patented medicines from third parties without the consent of the patent holder. In May, the company sued the French activist group Act Up-Paris in a Paris court after it had launched an attack on the company's website. Abbott's hardball tactics reflect the high stakes of the latest round of disputes to break out between the industry and governments over drug pricing and access.											0	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 5	2007	448	7149					14	14		10.1038/448014a	http://dx.doi.org/10.1038/448014a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185OS	17611514	Bronze			2022-12-28	WOS:000247720900012
J	Lindholm, P; Voutilainen, MH; Lauren, J; Peranen, J; Leppanen, VM; Andressoo, JO; Lindahl, M; Janhunen, S; Kalkkinen, N; Timmusk, T; Tuominen, RK; Saarma, M				Lindholm, Pivi; Voutilainen, Merja H.; Lauren, Juha; Peranen, Johan; Leppanen, Veli-Matti; Andressoo, Jaan-Olle; Lindahl, Maria; Janhunen, Sanna; Kalkkinen, Nisse; Timmusk, Tonis; Tuominen, Raimo K.; Saarma, Mart			Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo	NATURE			English	Article							MICE LACKING GDNF; PARTIAL LESION MODEL; PARKINSONS-DISEASE; INFUSION; RAT; 6-HYDROXYDOPAMINE; EXPRESSION; DEGENERATION; RECOVERY; 6-OHDA	In Parkinson's disease, brain dopamine neurons degenerate most prominently in the substantia nigra(1). Neurotrophic factors promote survival, differentiation and maintenance of neurons in developing and adult vertebrate nervous system(2,3). The most potent neurotrophic factor for dopamine neurons described so far is the glial-cell-line-derived neurotrophic factor (GDNF)(4). Here we have identified a conserved dopamine neurotrophic factor (CDNF) as a trophic factor for dopamine neurons. CDNF, together with its previously described vertebrate and invertebrate homologue the mesencephalic-astrocyte-derived neurotrophic factor(5), is a secreted protein with eight conserved cysteine residues, predicting a unique protein fold and defining a new, evolutionarily conserved protein family. CDNF (Armetl1) is expressed in several tissues of mouse and human, including the mouse embryonic and postnatal brain. In vivo, CDNF prevented the 6-hydroxydopamine (6-OHDA)-induced degeneration of dopaminergic neurons in a rat experimental model of Parkinson's disease. A single injection of CDNF before 6-OHDA delivery into the striatum significantly reduced amphetamine-induced ipsilateral turning behaviour and almost completely rescued dopaminergic tyrosine-hydroxylase-positive cells in the substantia nigra. When administered four weeks after 6-OHDA, intrastriatal injection of CDNF was able to restore the dopaminergic function and prevent the degeneration of dopaminergic neurons in substantia nigra. Thus, CDNF was at least as efficient as GDNF in both experimental settings. Our results suggest that CDNF might be beneficial for the treatment of Parkinson's disease.	Univ Helsinki, Inst Biotechnol, Viikki Bioctr, FIN-00014 Helsinki, Finland; Univ Helsinki, Div Pharmacol & Toxicol, Viikki Bioctr, Fac Pharm, FIN-00014 Helsinki, Finland; Tallinn Univ Technol, Dept Gene Technol, EE-19086 Tallinn, Estonia	University of Helsinki; University of Helsinki; Tallinn University of Technology	Saarma, M (corresponding author), Univ Helsinki, Inst Biotechnol, Viikki Bioctr, POB 56, FIN-00014 Helsinki, Finland.	mart.saarma@helsinki.fi	Voutilainen, Merja/D-9601-2014; Kalkkinen, Nisse EJ/B-3923-2010; Lindahl, Maria/AHE-1252-2022; Andressoo, Jaan-Olle/AAA-1216-2021; Andressoo, Jaan-Olle/AFU-7846-2022; Timmusk, Tonis/H-4889-2015	Andressoo, Jaan-Olle/0000-0002-0271-3157; Voutilainen, Merja/0000-0002-9832-7655; Timmusk, Tonis/0000-0002-1015-3348; Leppanen, Veli-Matti/0000-0001-7100-965X; Pulkkila, Paivi/0000-0003-3022-5035; Lindahl, Maria/0000-0002-5674-8830				Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Akerud P, 2001, J NEUROSCI, V21, P8108, DOI 10.1523/JNEUROSCI.21-20-08108.2001; Aoi M, 2000, NEUROSCI RES, V36, P319, DOI 10.1016/S0168-0102(00)00097-3; BOWENKAMP KE, 1995, J COMP NEUROL, V355, P479, DOI 10.1002/cne.903550402; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Gill SS, 2003, NAT MED, V9, P589, DOI 10.1038/nm850; Granholm ACE, 1997, J NEUROSCI, V17, P1168; Hidalgo A, 2006, BRAIN BEHAV EVOLUT, V68, P173, DOI 10.1159/000094086; HOFFER BJ, 1994, NEUROSCI LETT, V182, P107, DOI 10.1016/0304-3940(94)90218-6; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Jaaro H, 2001, TRENDS NEUROSCI, V24, P79, DOI 10.1016/S0166-2236(00)01690-8; Janhunen S, 2005, NEUROSCI LETT, V381, P314, DOI 10.1016/j.neulet.2005.02.038; Kearns CM, 1997, J NEUROSCI, V17, P7111; KEARNS CM, 1995, BRAIN RES, V672, P104, DOI 10.1016/0006-8993(94)01366-P; Keinanen K, 1998, BIOCHEM J, V330, P1461, DOI 10.1042/bj3301461; Kirik D, 2000, EUR J NEUROSCI, V12, P3871, DOI 10.1046/j.1460-9568.2000.00274.x; Kirik D, 2001, EUR J NEUROSCI, V13, P1589, DOI 10.1046/j.0953-816x.2001.01534.x; Kramer ER, 2007, PLOS BIOL, V5, P616, DOI 10.1371/journal.pbio.0050039; Lang AE, 2006, ANN NEUROL, V59, P459, DOI 10.1002/ana.20737; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Patel NK, 2005, ANN NEUROL, V57, P298, DOI 10.1002/ana.20374; Paxinos G., 1998, RAT BRAIN STEROTAXIC; Peranen J, 1996, ANAL BIOCHEM, V236, P371, DOI 10.1006/abio.1996.0187; Peranen J, 2001, METHOD ENZYMOL, V329, P188; Petrova PS, 2003, J MOL NEUROSCI, V20, P173, DOI 10.1385/JMN:20:2:173; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Rosenblad C, 1999, EUR J NEUROSCI, V11, P1554, DOI 10.1046/j.1460-9568.1999.00566.x; Rosenblad C, 1998, NEUROSCIENCE, V82, P129; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SAUER H, 1994, NEUROSCIENCE, V59, P401, DOI 10.1016/0306-4522(94)90605-X; SAUER H, 1995, P NATL ACAD SCI USA, V92, P8935, DOI 10.1073/pnas.92.19.8935; TIMMUSK T, 1993, EUR J NEUROSCI, V5, P605, DOI 10.1111/j.1460-9568.1993.tb00526.x; UNGERSTEDT U, 1970, Brain Research, V24, P485, DOI 10.1016/0006-8993(70)90187-3; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411	35	320	349	0	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 5	2007	448	7149					73	77		10.1038/nature05957	http://dx.doi.org/10.1038/nature05957			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185OS	17611540				2022-12-28	WOS:000247720900040
J	Markel, H; Gostin, LO; Fidler, DP				Markel, Howard; Gostin, Lawrence O.; Fidler, David P.			Extensively drug-resistant tuberculosis - An isolation order, public health powers, and a global crisis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ACT		Univ Michigan, Sch Med, Ctr Hist Med, Ann Arbor, MI 48109 USA; Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, Washington, DC USA; Indiana Univ, Sch Law, Bloomington, IN 47401 USA	University of Michigan System; University of Michigan; Georgetown University; Indiana University System; Indiana University Bloomington	Markel, H (corresponding author), Univ Michigan, Sch Med, Ctr Hist Med, 102 Observ,0725,100 SMI, Ann Arbor, MI 48109 USA.	howard@umich.edu						BROWN D, 2007, WASHINGTON POST 0607, pA6; *CDC, 2007, EXT DRUG RES TUB XDR; *CDC, 1996, MMWR-MORBID MORTAL W, V45, P538; *COMM MEAS ENH EFF, 2006, QUAR STAT PORTS ENTR; Gostin LO, 2002, JAMA-J AM MED ASSOC, V288, P622, DOI 10.1001/jama.288.5.622; Hodge JG, 2006, J LAW MED ETHICS, V34, P77, DOI 10.1111/j.1748-720X.2006.00010.x; Markel H., 1999, QUARANTINE E EUROPEA; Markel Howard, 2005, GERMS TRAVEL 6 MAJOR; SCHARTZ J, 2007, NY TIMES        0602, pA1; Singh JA, 2007, PLOS MED, V4, P19, DOI 10.1371/journal.pmed.0040050; SPEAKER A, 2007, GOOD MORNING AM 0601; SPEAKER A, 2007, GOOD MORNING AM 0604; WORLD HEALTH ORGANIZATION, 2007, WHO GUID HUM RIGHTS; 2005, FED REG, V70, P71891	14	27	28	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 4	2007	298	1					83	86		10.1001/jama.298.1.83	http://dx.doi.org/10.1001/jama.298.1.83			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185OU	17609493				2022-12-28	WOS:000247721100024
J	Taubert, D; Roesen, R; Lehmann, C; Jung, N; Schomig, E				Taubert, Dirk; Roesen, Renate; Lehmann, Clara; Jung, Norma; Schoemig, Edgar			Effects of low habitual cocoa intake on blood pressure and bioactive nitric oxide - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GUIDELINES-FOR-AMERICANS; MAJOR CHRONIC DISEASE; FLAVANOL-RICH COCOA; DEPENDENT VASODILATION; THEOBROMA-CACAO; S-NITROSOTHIOLS; CHOCOLATE; RISK; HYPERTENSION; CONSUMPTION	Context Regular intake of cocoa-containing foods is linked to lower cardiovascular mortality in observational studies. Short-term interventions of at most 2 weeks indicate that high doses of cocoa can improve endothelial function and reduce blood pressure (BP) due to the action of the cocoa polyphenols, but the clinical effect of low habitual cocoa intake on BP and the underlying BP-lowering mechanisms are unclear. Objective To determine effects of low doses of polyphenol-rich dark chocolate on BP. Design, Setting, and Participants Randomized, controlled, investigator-blinded, parallel-group trial involving 44 adults aged 56 through 73 years (24 women, 20 men) with untreated upper-range prehypertension or stage 1 hypertension without concomitant risk factors. The trial was conducted at a primary care clinic in Germany between January 2005 and December 2006. Intervention Participants were randomly assigned to receive for 18 weeks either 6.3 g (30 kcal) per day of dark chocolate containing 30 mg of polyphenols or matching polyphenol-free white chocolate. Main Outcome Measures Primary outcome measure was the change in BP after 18 weeks. Secondary outcome measures were changes in plasma markers of vasodilative nitric oxide (S-nitrosoglutathione) and oxidative stress (8-isoprostane), and bioavailability of cocoa polyphenols. Results From baseline to 18 weeks, dark chocolate intake reduced mean (SD) systolic BP by -2.9 (1.6) mm Hg (P < .001) and diastolic BP by -1.9 (1.0) mm Hg (P < .001) without changes in body weight, plasma levels of lipids, glucose, and 8-isoprostane. Hypertension prevalence declined from 86% to 68%. The BP decrease was accompanied by a sustained increase of S-nitrosoglutathione by 0.23 (0.12) nmol/L (P < .001), and a dark chocolate dose resulted in the appearance of cocoa phenols in plasma. White chocolate intake caused no changes in BP or plasma biomarkers. Conclusions Data in this relatively small sample of otherwise healthy individuals with above-optimal BP indicate that inclusion of small amounts of polyphenol-rich dark chocolate as part of a usual diet efficiently reduced BP and improved formation of vasodilative nitric oxide.	Univ Hosp Cologne, Dept Pharmacol, D-50931 Cologne, Germany; Univ Hosp Cologne, Dept Internal Med, D-50931 Cologne, Germany	University of Cologne; University of Cologne	Taubert, D (corresponding author), Univ Hosp Cologne, Dept Pharmacol, Gleueler Str 24, D-50931 Cologne, Germany.	dirk.taubert@medizin.uni-koeln.de	Lehmann, Clara/F-9671-2016	Lehmann, Clara/0000-0002-7042-1578				Actis-Goretta L, 2006, J AGR FOOD CHEM, V54, P229, DOI 10.1021/jf052263o; Ainsworth BE, 2000, MED SCI SPORT EXER, V32, pS498, DOI 10.1097/00005768-200009001-00009; Appel LJ, 2003, JAMA-J AM MED ASSOC, V289, P2083, DOI 10.1001/jama.289.16.2083; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Arts ICW, 1999, LANCET, V354, P488, DOI 10.1016/S0140-6736(99)02267-9; Baron AM, 1999, AM J CARDIOL, V84, P370, DOI 10.1016/S0002-9149(99)00301-X; Bingham S. A., 1987, Nutrition Abstracts and Reviews. Series A-Human and Experimental, V57, P705; Bortolotto L A, 1999, Blood Press Monit, V4, P21, DOI 10.1097/00126097-199904010-00004; Buijsse B, 2006, ARCH INTERN MED, V166, P411, DOI 10.1001/.411; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; Fisher NDL, 2003, J HYPERTENS, V21, P2281, DOI 10.1097/00004872-200312000-00016; Foster MW, 2005, HYPERTENSION, V45, P15, DOI 10.1161/01.HYP.0000150160.41992.71; Fraga Cesar G, 2005, Clin Dev Immunol, V12, P11, DOI 10.1080/10446670410001722159; Gandley RE, 2005, HYPERTENSION, V45, P21, DOI 10.1161/01.HYP.0000150158.42620.3e; Gleim GW, 2006, CLIN THER, V28, P1639, DOI 10.1016/j.clinthera.2006.10.014; Grassi D, 2005, HYPERTENSION, V46, P398, DOI 10.1161/01.HYP.0000174990.46027.70; Grassi D, 2005, AM J CLIN NUTR, V81, P611; Halliwell B, 2005, AM J CLIN NUTR, V81, p268S, DOI 10.1093/ajcn/81.1.268S; Hammerstone JF, 1999, J AGR FOOD CHEM, V47, P490, DOI 10.1021/jf980760h; He FJ, 2006, LANCET, V367, P320, DOI 10.1016/S0140-6736(06)68069-0; Heiss C, 2006, J CARDIOVASC PHARM, V47, pS128, DOI 10.1097/00005344-200606001-00007; Himmelmann A, 2001, BLOOD PRESSURE, V10, P43, DOI 10.1080/080370501750183381; Hollenberg N.K., 2004, BRIT J CARDIOLOGY, V11, P379; HOLM S, 1979, SCAND J STAT, V6, P65; Huxley RR, 2003, EUR J CLIN NUTR, V57, P904, DOI 10.1038/sj.ejcn.1601624; Joshipura KJ, 2001, ANN INTERN MED, V134, P1106, DOI 10.7326/0003-4819-134-12-200106190-00010; Kelly CJ, 2005, AM J CLIN NUTR, V82, P486, DOI 10.1093/ajcn/82.2.486a; Leikert JF, 2002, CIRCULATION, V106, P1614, DOI 10.1161/01.CIR.0000034445.31543.43; Lillegaard ITL, 2007, EUR J CLIN NUTR, V61, P61, DOI 10.1038/sj.ejcn.1602487; Marchei E, 2005, J PHARMACEUT BIOMED, V37, P499, DOI 10.1016/j.jpba.2004.11.013; McCullough ML, 2000, AM J CLIN NUTR, V72, P1223; McCullough ML, 2000, AM J CLIN NUTR, V72, P1214; McInnes GT, 2005, J HYPERTENS, V23, pS3, DOI 10.1097/01.hjh.0000165622.34192.fd; O'Reilly JD, 2001, AM J CLIN NUTR, V73, P1040; Pepine CJ, 2003, AM J CARDIOL, V91, P274, DOI 10.1016/S0002-9149(02)03154-5; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; Roberts LJ, 1997, BBA-LIPID LIPID MET, V1345, P121, DOI 10.1016/S0005-2760(96)00162-2; Schroeter H, 2006, P NATL ACAD SCI USA, V103, P1024, DOI 10.1073/pnas.0510168103; Shoji T, 2006, J AGR FOOD CHEM, V54, P884, DOI 10.1021/jf052260b; Stamler JS, 2004, CIRC RES, V94, P414, DOI 10.1161/01.RES.0000122071.55721.BC; Stark T, 2005, J AGR FOOD CHEM, V53, P5407, DOI 10.1021/jf050457y; Stevens VJ, 2001, ANN INTERN MED, V134, P1, DOI 10.7326/0003-4819-134-1-200101020-00007; Taubert D, 2003, JAMA-J AM MED ASSOC, V290, P1029, DOI 10.1001/jama.290.8.1029; Taubert D, 2007, ARCH INTERN MED, V167, P626, DOI 10.1001/archinte.167.7.626; *USDA AGR RES SERV, 2005, USDA NAT NUTR DAT ST; Vinson JA, 2006, J AGR FOOD CHEM, V54, P8071, DOI 10.1021/jf062175j; Wang JF, 2000, J NUTR, V130, p2115S, DOI 10.1093/jn/130.8.2115S	50	376	384	4	125	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 4	2007	298	1					49	60		10.1001/jama.298.1.49	http://dx.doi.org/10.1001/jama.298.1.49			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185OU	17609490	Bronze			2022-12-28	WOS:000247721100021
J	van der Wel, N; Hava, D; Houben, D; Fluitsma, D; van Zon, M; Pierson, J; Brenner, M; Peters, PJ				van der Wel, Nicole; Hava, David; Houben, Diane; Fluitsma, Donna; van Zon, Maaike; Pierson, Jason; Brenner, Michael; Peters, Peter J.			M-tuberculosis and M-leprae translocate from the phagolysosome to the cytosol in myeloid cells	CELL			English	Article							CROSS-PRESENTATION; CALMETTE-GUERIN; BOVIS BCG; ALVEOLAR MACROPHAGES; PHAGOSOMAL MEMBRANES; DENDRITIC CELLS; II MOLECULES; HOST-CELLS; INFECTION; VIRULENCE	M. tuberculosis and M. leprae are considered to be prototypical intracellular pathogens that have evolved strategies to enable growth in the intracellular phagosomes. In contrast, we show that lysosomes rapidly fuse with the virulent M. tuberculosis- and M. leprae-containing phagosomes of human monocyte-derived dendritic cells and macrophages. After 2 days, M. tuberculosis progressively translocates from phagolysosomes into the cytosol in nonapoptotic cells. Cytosolic entry is also observed for M. leprae but not for vaccine strains such as M. bovis BCG or in heat-killed mycobacteria and is dependent upon secretion of the mycobacterial gene products CFP-10 and ESAT-6. The cytosolic bacterial localization and replication are pathogenic features of virulent mycobacteria, causing significant cell death within a week. This may also reveal a mechanism for MHC-based antigen presentation that is lacking in current vaccine strains.	Netherlands Canc Inst, Antoni Van Leeuwenhoek Hosp, NL-1066 CX Amsterdam, Netherlands; Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA; VU Med Ctr, Dept Mol Cell Biol & Immunol, Amsterdam, Netherlands; VU Med Ctr, Dept Med Microbiol & Infect Control, Amsterdam, Netherlands	Netherlands Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Peters, PJ (corresponding author), Netherlands Canc Inst, Antoni Van Leeuwenhoek Hosp, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	p.peters@nki.nl	Van Der Wel, Nicole/AAE-7569-2020	van der Wel, Nicole/0000-0001-6392-3417				Ackerman AL, 2003, P NATL ACAD SCI USA, V100, P12889, DOI 10.1073/pnas.1735556100; Adams LB, 2002, J INFECT DIS, V185, pS1, DOI 10.1086/338002; ARMSTRONG JA, 1971, J EXP MED, V134, P713, DOI 10.1084/jem.134.3.713; Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Berthet FX, 1998, MICROBIOL-UK, V144, P3195, DOI 10.1099/00221287-144-11-3195; Brodin P, 2006, INFECT IMMUN, V74, P88, DOI 10.1128/IAI.74.1.88-98.2006; Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299; Derrick SC, 2007, CELL MICROBIOL, V9, P1547, DOI 10.1111/j.1462-5822.2007.00892.x; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Fortune SM, 2005, P NATL ACAD SCI USA, V102, P10676, DOI 10.1073/pnas.0504922102; Gao LY, 2006, INFECT IMMUN, V74, P1757, DOI 10.1128/IAI.74.3.1757-1767.2006; Glomski IJ, 2002, J CELL BIOL, V156, P1029, DOI 10.1083/jcb.200201081; Gordon SV, 1999, MOL MICROBIOL, V32, P643, DOI 10.1046/j.1365-2958.1999.01383.x; Grode L, 2005, J CLIN INVEST, V115, P2472, DOI 10.1172/JCI24617; Guermonprez P, 2003, NATURE, V425, P397, DOI 10.1038/nature01911; Guinn KM, 2004, MOL MICROBIOL, V51, P359, DOI 10.1046/j.1365-2958.2003.03844.x; Harboe M, 1996, INFECT IMMUN, V64, P16, DOI 10.1128/IAI.64.1.16-22.1996; Houde M, 2003, NATURE, V425, P402, DOI 10.1038/nature01912; Hsu T, 2003, P NATL ACAD SCI USA, V100, P12420, DOI 10.1073/pnas.1635213100; Kang PB, 2005, J EXP MED, V202, P987, DOI 10.1084/jem.20051239; Keane J, 1997, INFECT IMMUN, V65, P298, DOI 10.1128/IAI.65.1.298-304.1997; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kremer JR, 1996, J STRUCT BIOL, V116, P71, DOI 10.1006/jsbi.1996.0013; Lazarevic V, 2005, J IMMUNOL, V175, P1107, DOI 10.4049/jimmunol.175.2.1107; LEAKE ES, 1984, INFECT IMMUN, V45, P443, DOI 10.1128/IAI.45.2.443-446.1984; Lee J, 2006, J IMMUNOL, V176, P4267, DOI 10.4049/jimmunol.176.7.4267; Lewis KN, 2003, J INFECT DIS, V187, P117, DOI 10.1086/345862; Majlessi L, 2005, J IMMUNOL, V174, P3570, DOI 10.4049/jimmunol.174.6.3570; Margolin W, 2005, NAT REV MOL CELL BIO, V6, P862, DOI 10.1038/nrm1745; MCDONOUGH KA, 1993, INFECT IMMUN, V61, P2763, DOI 10.1128/IAI.61.7.2763-2773.1993; Mostowy S, 2002, J INFECT DIS, V186, P74, DOI 10.1086/341068; MYRVIK QN, 1984, AM REV RESPIR DIS, V129, P322; Orme I, 2004, CURR OPIN MICROBIOL, V7, P58, DOI 10.1016/j.mib.2003.11.002; Peters P. J., 2006, CURRENT PROTOCOLS CE; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; Philipp WJ, 1996, MICROBIOL-UK, V142, P3135, DOI 10.1099/13500872-142-11-3135; Pizarro-Cerda J, 2006, CELL, V124, P715, DOI 10.1016/j.cell.2006.02.012; Placido R, 1997, J PATHOL, V181, P31, DOI 10.1002/(SICI)1096-9896(199701)181:1<31::AID-PATH722>3.0.CO;2-G; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; Ramakrishnan L, 2000, SCIENCE, V288, P1436, DOI 10.1126/science.288.5470.1436; Riendeau CJ, 2003, INFECT IMMUN, V71, P254, DOI 10.1128/IAI.71.1.254-259.2003; Russell DG, 2002, J CELL BIOL, V158, P421, DOI 10.1083/jcb.200205034; Russell DG, 2001, NAT REV MOL CELL BIO, V2, P569, DOI 10.1038/35085034; Schuerch DW, 2005, P NATL ACAD SCI USA, V102, P12537, DOI 10.1073/pnas.0500558102; Stamm LM, 2005, P NATL ACAD SCI USA, V102, P14837, DOI 10.1073/pnas.0504663102; Stamm LM, 2003, J EXP MED, V198, P1361, DOI 10.1084/jem.20031072; Stanley SA, 2003, P NATL ACAD SCI USA, V100, P13001, DOI 10.1073/pnas.2235593100; Stevens JM, 2006, NAT REV MICROBIOL, V4, P91, DOI 10.1038/nrmicro1320; Tekaia F., 1999, Tubercle and Lung Disease, V79, P329, DOI 10.1054/tuld.1999.0220; Touret N, 2005, CELL, V123, P157, DOI 10.1016/j.cell.2005.08.018; van der Wel NN, 2005, CURR OPIN MICROBIOL, V8, P323, DOI 10.1016/j.mib.2005.04.014; van der Wel NN, 2003, MOL BIOL CELL, V14, P3378, DOI 10.1091/mbc.e02-11-0744; Vergne I, 2004, ANNU REV CELL DEV BI, V20, P367, DOI 10.1146/annurev.cellbio.20.010403.114015	53	686	697	0	34	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 29	2007	129	7					1287	1298		10.1016/j.cell.2007.05.059	http://dx.doi.org/10.1016/j.cell.2007.05.059			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188HQ	17604718	Bronze			2022-12-28	WOS:000247911400015
J	Cuevas-Ramos, D; Perez-Enriquez, B				Cuevas-Ramos, Daniel; Perez-Enriquez, Bernardo			Endemic multinodular goiter	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico	Cuevas-Ramos, D (corresponding author), Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico.	shiverqks@hotmail.com							0	1	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 28	2007	356	26					E27	E27		10.1056/NEJMicm065299	http://dx.doi.org/10.1056/NEJMicm065299			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	183HS	17596597				2022-12-28	WOS:000247564500012
J	Okie, S				Okie, Susan			An elusive balance - Residents' work hours and the continuity of care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ADVERSE EVENTS											Barger LK, 2006, PLOS MED, V3, P2440, DOI 10.1371/journal.pmed.0030487; Petersen L A, 1998, Jt Comm J Qual Improv, V24, P77; PETERSEN LA, 1994, ANN INTERN MED, V121, P866, DOI 10.7326/0003-4819-121-11-199412010-00008; Vidyarthi AR, 2006, J HOSP MED, V1, P257, DOI 10.1002/jhm.103	4	67	68	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 28	2007	356	26					2665	2667		10.1056/NEJMp078085	http://dx.doi.org/10.1056/NEJMp078085			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	183HS	17596598				2022-12-28	WOS:000247564500001
J	Bradford, CR; Levine, PA				Bradford, Carol R.; Levine, Paul A.			Incidence and prognosis of cutaneous melanoma involving the head and neck	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							AMERICAN JOINT COMMITTEE; EARLY-STAGE MELANOMA; NODE BIOPSY; VALIDATION		Univ Michigan, Dept Otolaryngol Head & Neck Surg, Ann Arbor, MI 48109 USA; Univ Virginia Hlth Syst, Dept Otolaryngol Head & Neck Surg, Charlottesville, VA USA	University of Michigan System; University of Michigan; University of Virginia	Bradford, CR (corresponding author), Univ Michigan, Dept Otolaryngol Head & Neck Surg, 1904 Taubman,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	cbradfor@med.umich.edu						Balch CM, 2001, J CLIN ONCOL, V19, P3622, DOI 10.1200/JCO.2001.19.16.3622; Balch CM, 2001, J CLIN ONCOL, V19, P3635, DOI 10.1200/JCO.2001.19.16.3635; Golger A, 2007, ARCH OTOLARYNGOL, V133, P442, DOI 10.1001/archotol.133.5.442; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Morton DL, 1999, ANN SURG, V230, P453, DOI 10.1097/00000658-199910000-00001; MORTON DL, 1992, ARCH SURG-CHICAGO, V127, P392; Morton DL, 2006, NEW ENGL J MED, V355, P1307, DOI 10.1056/NEJMoa060992; Patel SG, 2002, ARCH OTOLARYNGOL, V128, P285, DOI 10.1001/archotol.128.3.285; Rigel DS, 2000, CA-CANCER J CLIN, V50, P215, DOI 10.3322/canjclin.50.4.215; Schmalbach CE, 2003, ARCH OTOLARYNGOL, V129, P61, DOI 10.1001/archotol.129.1.61; Tsao H, 2004, NEW ENGL J MED, V351, P998, DOI 10.1056/NEJMra041245	11	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 20	2007	297	23					2628	2629		10.1001/jama.297.23.2628	http://dx.doi.org/10.1001/jama.297.23.2628			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180HB	17582845				2022-12-28	WOS:000247352600025
J	Patat, F; Chandra, P; Chevalier, R; Justham, S; Podsiadlowski, P; Wolf, C; Gal-Yam, A; Pasquini, L; Crawford, IA; Mazzali, PA; Pauldrach, AWA; Nomoto, K; Benetti, S; Cappellaro, E; Elias-Rosa, N; Hillebrandt, W; Leonard, DC; Pastorello, A; Renzini, A; Sabbadin, F; Simon, JD; Turatto, M				Patat, F.; Chandra, P.; Chevalier, R.; Justham, S.; Podsiadlowski, Ph.; Wolf, C.; Gal-Yam, A.; Pasquini, L.; Crawford, I. A.; Mazzali, P. A.; Pauldrach, A. W. A.; Nomoto, K.; Benetti, S.; Cappellaro, E.; Elias-Rosa, N.; Hillebrandt, W.; Leonard, D. C.; Pastorello, A.; Renzini, A.; Sabbadin, F.; Simon, J. D.; Turatto, M.			Detection of circumstellar material in a normal type Ia supernova	SCIENCE			English	Article							PROGENITOR SYSTEM; 2006 OUTBURST; RS-OPHIUCHI; EVOLUTION; SPECTRA; NOVAE; SWIFT; STAR; MASS	Type Ia supernovae are important cosmological distance indicators. Each of these bright supernovae supposedly results from the thermonuclear explosion of a white dwarf star that, after accreting material from a companion star, exceeds some mass limit, but the true nature of the progenitor star system remains controversial. Here we report the spectroscopic detection of circumstellar material in a normal type Ia supernova explosion. The expansion velocities, densities, and dimensions of the circumstellar envelope indicate that this material was ejected from the progenitor system. In particular, the relatively low expansion velocities suggest that the white dwarf was accreting material from a companion star that was in the red-giant phase at the time of the explosion. Normalized Flux	European So Observ, D-85748 Garching, Germany; Univ Virginia, Dept Astron, Charlottesville, VA 22904 USA; Univ Oxford, Dept Astrophys, Oxford OX1 3RH, England; CALTECH, Dept Astron, Pasadena, CA 91125 USA; Univ London Birkbeck Coll, Sch Earth Sci, London WC1E 7HX, England; Max Planck Inst Astrophys, D-85748 Garching, Germany; Osserv Astron Trieste, INAF, I-34131 Trieste, Italy; Univ Munich, Inst Astron & Astrophys, D-81679 Munich, Germany; Univ Tokyo, Dept Astron, Bunkyo Ku, Tokyo 1130033, Japan; Osserv Astron Padova, INAF, I-35122 Padua, Italy; Univ La Laguna, E-38206 Tenerife, Spain; San Diego State Univ, Dept Astron, San Diego, CA 92182 USA; Queens Univ Belfast, Astrophys Res Ctr, Belfast BT7 1NN, Antrim, North Ireland	European Southern Observatory; University of Virginia; University of Oxford; California Institute of Technology; University of London; Birkbeck University London; Max Planck Society; Istituto Nazionale Astrofisica (INAF); University of Munich; University of Tokyo; Istituto Nazionale Astrofisica (INAF); University of Padua; Universidad de la Laguna; California State University System; San Diego State University; Queens University Belfast	Patat, F (corresponding author), European So Observ, Karl Schwarzschild Str 2, D-85748 Garching, Germany.	fpatat@eso.org	Crawford, Ian/H-7510-2012; Elias-Rosa, Nancy/D-3759-2014; Simon, Joshua D/AAX-7117-2021	Crawford, Ian/0000-0001-5661-7403; Elias-Rosa, Nancy/0000-0002-1381-9125; Chandra, Poonam/0000-0002-0844-6563; Renzini, Alvio/0000-0002-7093-7355; Patat, Ferdinando/0000-0002-0537-3573; Benetti, Stefano/0000-0002-3256-0016; Wolf, Christian/0000-0002-4569-016X; Turatto, Massimo/0000-0002-9719-3157; Mazzali, Paolo/0000-0001-6876-8284; Cappellaro, Enrico/0000-0001-5008-8619				Aldering G, 2006, ASTROPHYS J, V650, P510, DOI 10.1086/507020; Benetti S, 2006, ASTROPHYS J, V653, pL129, DOI 10.1086/510667; Bode MF, 2006, ASTROPHYS J, V652, P629, DOI 10.1086/507980; BODE MF, IN PRESS ASTROPHYS; BRANCH D, 1995, PUBL ASTRON SOC PAC, V107, P1019, DOI 10.1086/133657; Chevalier RA, 2003, LECT NOTES PHYS, V598, P171; Hachisu I, 1999, ASTROPHYS J, V522, P487, DOI 10.1086/307608; Hachisu I, 2001, ASTROPHYS J, V558, P323, DOI 10.1086/321601; Hamuy M, 2003, NATURE, V424, P651, DOI 10.1038/nature01854; Hao H, 2007, ASTROPHYS J, V659, pL99, DOI 10.1086/518032; Hillebrandt W, 2000, ANNU REV ASTRON ASTR, V38, P191, DOI 10.1146/annurev.astro.38.1.191; Immler S, 2006, ASTROPHYS J, V648, pL119, DOI 10.1086/507947; JUDGE PG, 1991, ASTROPHYS J, V371, P357, DOI 10.1086/169897; Mattila S, 2005, ASTRON ASTROPHYS, V443, P649, DOI 10.1051/0004-6361:20052731; O'Brien TJ, 2006, NATURE, V442, P279, DOI 10.1038/nature04949; PANAGIA N, 2007, SUP 1987A 20 YEARS S; Panagia N, 2006, ASTROPHYS J, V646, P369, DOI 10.1086/504710; Pauldrach AWA, 1996, ASTRON ASTROPHYS, V312, P525; Perlmutter S, 1999, ASTROPHYS J, V517, P565, DOI 10.1086/307221; QUIMBY R, 2006, CENT BUR ELECT TELEG, V421; RAND RJ, 1995, ASTRON J, V109, P2444, DOI 10.1086/117462; Riess AG, 1998, ASTRON J, V116, P1009, DOI 10.1086/300499; STOCKDALE CJ, 2006, CENT BUR ELECT TELEG, V396; Suzuki S., 2006, 8667 IAU; WHELAN J, 1973, ASTROPHYS J, V186, P1007, DOI 10.1086/152565; Willson LA, 2000, ANNU REV ASTRON ASTR, V38, P573, DOI 10.1146/annurev.astro.38.1.573; Wood-Vasey WM, 2006, ASTROPHYS J, V645, pL53, DOI 10.1086/506179	27	302	305	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 17	2007	317	5840					924	926		10.1126/science.1143005	http://dx.doi.org/10.1126/science.1143005			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200RJ	17626848	Green Submitted, Green Accepted			2022-12-28	WOS:000248780200032
J	Timmins, N				Timmins, Nicholas			Alan Johnson - Can the ex-postman deliver?	BRITISH MEDICAL JOURNAL			English	Biographical-Item												Nicholas.Timmins@FT.com							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUL 14	2007	335	7610					71	71		10.1136/bmj.39269.426134.AD	http://dx.doi.org/10.1136/bmj.39269.426134.AD			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192JM	17626957	Green Published			2022-12-28	WOS:000248197500027
J	Gibson, MC				Gibson, Matthew C.			Bicoid by the numbers: Quantifying a morphogen gradient	CELL			English	Editorial Material							EARLY DROSOPHILA EMBRYO; PROTEIN		Stowers Inst Med Res, Kansas City, MO 64110 USA	Stowers Institute for Medical Research	Gibson, MC (corresponding author), Stowers Inst Med Res, 1000 E 50th St, Kansas City, MO 64110 USA.	mg2@stowers-institute.org		Gibson, Matthew/0000-0001-5588-8842				CRICK F, 1970, NATURE, V225, P420, DOI 10.1038/225420a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; Ephrussi A, 2004, CELL, V116, P143, DOI 10.1016/S0092-8674(04)00037-6; Houchmandzadeh B, 2002, NATURE, V415, P798, DOI 10.1038/415798a; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0	8	6	6	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 13	2007	130	1					14	16		10.1016/j.cell.2007.06.036	http://dx.doi.org/10.1016/j.cell.2007.06.036			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	197WK	17632050	Bronze, Green Published			2022-12-28	WOS:000248587000004
J	Nordhaus, W				Nordhaus, William			Critical assumptions in the stern review on climate change	SCIENCE			English	Editorial Material									Yale Univ, Dept Econ, New Haven, CT 06511 USA	Yale University	Nordhaus, W (corresponding author), Yale Univ, Dept Econ, New Haven, CT 06511 USA.	william.nordhaus@yale.edu	van Lent, Laurence/G-5298-2010	van Lent, Laurence/0000-0002-9354-0932				ARROW KJ, CLIMATE CHANGE 1995; Koopmans T. C., 1965, ACADEMIAE SCIENTIARU, V28, P1; Nordhaus W, 2007, CHALLENGE GLOBAL WAR; Nordhaus W. D, 2000, WARMING WORLD EC MOD; NORDHAUS WD, IN PRESS J EC LIT; Ramsey FP, 1928, ECON J, V38, P543, DOI 10.2307/2224098; Stern Nicholas, 2006, STERN REV EC CLIMATE; Tol RSJ, 2005, ENERG POLICY, V33, P2064, DOI 10.1016/j.enpol.2004.04.002; Weyant JP, 2004, ENERG ECON, V26, P501, DOI 10.1016/j.eneco.2004.04.019	9	166	171	5	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 13	2007	317	5835					201	202		10.1126/science.1137316	http://dx.doi.org/10.1126/science.1137316			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	189DC	17626869				2022-12-28	WOS:000247968600024
J	Davey, E; d'Assuncao, J; Irwig, L; Macaskill, P; Chan, SF; Richards, A; Farnsworth, A				Davey, Elizabeth; d'Assuncao, Jefferson; Irwig, Les; Macaskill, Petra; Chan, Siew F.; Richards, Adele; Farnsworth, Annabelle			Accuracy of reading liquid based cytology slides using the ThinPrep Imager compared with conventional cytology: prospective study	BRITISH MEDICAL JOURNAL			English	Article							SQUAMOUS INTRAEPITHELIAL LESIONS; CERVICAL CYTOLOGY; IMAGING-SYSTEM; PAP-SMEAR; PERFORMANCE	Objective To compare the accuracy of liquid based cytology using the computerised Thin Prep Imager with that of manually read conventional cytology. Design Prospective study. Setting Pathology laboratory in Sydney, Australia. Participants 55 164 split sample pairs (liquid based sample collected after conventional sample from one collection) from consecutive samples of women choosing both types of cytology and whose specimens were examined between August 2004 and June 2005. Main outcome measures Primary outcome was accuracy of slides for detecting squamous lesions. Secondary outcomes were rate of unsatisfactory slides, distribution of squarrous cytological classifications, and accuracy of detecting glandular lesions. Results Fewer unsatisfactory slides were found for imager read cytology than for conventional cytology (1.8% v 3.1%; P<0.001). More slides were classified as abnormal by imager read cytology (7.4% v 6.0% overall and 2.8% v 2.2% for cervical intraepithelial neoplasia of grade 1 or higher). Among 550 patients in whom imager read cytology was cervical intraepithelial neoplasia grade 1 or higher and conventional cytology was less severe than grade 1, 133 of 380 biopsy samples taken were high grade histology. Among 294 patients in whom imager read cytology was less severe than cervical intraepithelial neoplasia grade 1 and conventional cytology was grade I or higher, 62 of 210 biopsy samples taken were high grade histology. Imager read cytology therefore detected 71 more cases of high grade histology than did conventional cytology, resulting from 170 more biopsies. Similar results were found when one pathologist reread the slides, masked to cytology results. Conclusion The ThinPrep Imager detects 1.29 more cases of histological high grade squamous disease per 1000 women screened than conventional cytology, with cervical intraepithelial neoplasia grade 1 as the threshold for referral to colposcopy. More imager read slides than conventional slides were satisfactory for examination and more contained low grade cytological abnormalities.	Univ Sydney, Sch Publ Hlth, Screening & Test Evaluat Program, Sydney, NSW 2006, Australia; Douglass Hanly Moir Pathol, Cytol Dept, N Ryde, NSW, Australia	University of Sydney	Davey, E (corresponding author), Univ Sydney, Sch Publ Hlth, Screening & Test Evaluat Program, Sydney, NSW 2006, Australia.	daveye@health.usyd.edu.au		Macaskill, Petra/0000-0001-5879-6193				*AUSTR I HLTH WELF, 2005, CANC SER AUSTR I HLT, V31; Bergeron C, 2001, ACTA CYTOL, V45, P519, DOI 10.1159/000327858; Biscotti CV, 2005, AM J CLIN PATHOL, V123, P281, DOI 10.1309/AGB1MJ9H5N43MEGX; Chock C, 1997, J CLIN EPIDEMIOL, V50, P1211, DOI 10.1016/S0895-4356(97)00122-4; *COMM DEP HUM SERV, 1994, GUID MAN WOM SCREEN; Davey E, 2006, LANCET, V367, P122, DOI 10.1016/S0140-6736(06)67961-0; DAVEY E, 2007, IN PRESS CERVICAL CY; Dziura B, 2006, ACTA CYTOL, V50, P309, DOI 10.1159/000325959; Ferris DG, 2000, J FAM PRACTICE, V49, P1005; Irwig L, 2004, J CLIN EPIDEMIOL, V57, P75, DOI 10.1016/S0895-4356(03)00259-2; Laverty CR, 1997, ANAL QUANT CYTOL, V19, P239; Medical Services Advisory Committee, 2002, LIQ BAS CYT CERV SCR; Melnikow J, 1998, OBSTET GYNECOL, V92, P727, DOI 10.1016/S0029-7844(98)00245-2; Roberts JM, 1997, MED J AUSTRALIA, V167, P466, DOI 10.5694/j.1326-5377.1997.tb126672.x; Roberts JM, 1999, ACTA CYTOL, V43, P74, DOI 10.1159/000330871; Sherman ME, 1998, MODERN PATHOL, V11, P837; Wilbur DC, 1997, ACTA CYTOL, V41, P24, DOI 10.1159/000332300	17	110	115	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUL 7	2007	335	7609					31	35		10.1136/bmj.39219.645475.55	http://dx.doi.org/10.1136/bmj.39219.645475.55			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191LY	17604301	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000248133900032
J	Prendergast, A; Tudor-Williams, G; Jeena, P; Burchett, S; Goulder, P				Prendergast, Andrew; Tudor-Williams, Gareth; Jeena, Prakash; Burchett, Sandra; Goulder, Philip			International perspectives, progress, and future challenges of paediatric HIV infection	LANCET			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; MOTHER-TO-CHILD; ACTIVE ANTIRETROVIRAL THERAPY; PNEUMOCYSTIS-CARINII-PNEUMONIA; LATE POSTNATAL TRANSMISSION; MATERNAL VIRAL LOAD; BREAST-FED CHILDREN; HIV-1-INFECTED CHILDREN; DISEASE PROGRESSION; LYMPHOCYTE RESPONSE	Paediatric HIV infection is a growing health challenge worldwide, with an estimated 1500 new infections every day. in developed countries, well established prevention programmes keep mother-to-child transmission rates at less than 2%. However, in developing countries, where transmission rates are 25-40%, interventions are available to only 5-10% of women. Children with untreated natural infection progress rapidly to disease, especially in resource-poor settings where mortality is greater than 50% by 2 years of age. As in adult infection, antiretroviral therapy has the potential to rewrite the natural history of HIV, but is accessible only to a small number of children needing therapy. We focus on the clinical and immunological features of HIV that are specific to paediatric infection, and the formidable challenges ahead to ensure that all children worldwide have access to interventions that have proved successful in developed countries.	Univ Oxford, Dept Paediat, Oxford OX1 3SY, England; Univ London Imperial Coll Sci Technol & Med, Dept Paediat, Div Med, London, England; Univ Kwazulu Natal, Dept Child Life & Hlth, HIV Pathogenesis Programme, Durban, South Africa; Harvard Univ, Sch Med, Div Infect Dis, Childrens Hosp Boston, Boston, MA USA; Harvard Univ, Sch Med, Partners AIDS Res Ctr, Massachusetts Gen Hosp, Charlestown, MA USA	University of Oxford; Imperial College London; University of Kwazulu Natal; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Massachusetts General Hospital	Goulder, P (corresponding author), Univ Oxford, Dept Paediat, Peter Medawar Bldg Pathogen Res, Oxford OX1 3SY, England.	philip.goulder@ndm.ox.ac.uk		Prendergast, Andrew/0000-0001-7904-7992	Medical Research Council [G0500384] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G0500384] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aboulker JP, 2004, AIDS, V18, P237, DOI [10.1097/01.aids.0000111388.02002.6b, 10.1097/00002030-200401230-00013]; Aboulker JP, 2001, ARCH DIS CHILD, V84, P230, DOI 10.1136/adc.84.3.230; ABOUYA YL, 1992, AM REV RESPIR DIS, V145, P617, DOI 10.1164/ajrccm/145.3.617; Abrams EJ, 1998, J INFECT DIS, V178, P101, DOI 10.1086/515596; ADJORLOLOJOHNSON G, 1994, JAMA-J AM MED ASSOC, V272, P462, DOI 10.1001/jama.272.6.462; Alimenti A, 2003, PEDIATR INFECT DIS J, V22, P782, DOI 10.1097/01.inf.0000086400.93257.74; Allen TM, 2005, J VIROL, V79, P12952, DOI 10.1128/JVI.79.20.12952-12960.2005; ANDIMAN WA, 1985, LANCET, V2, P1390; [Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1; [Anonymous], 2006, Lancet, V368, P424; BARLOWMOSHA L, 2005, 3 INT AIDS SOC C HIV; Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a; BENTWICH Z, 1995, IMMUNOL TODAY, V16, P187, DOI 10.1016/0167-5699(95)80119-7; Berhane R, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.1.e7; BLANCHE S, 1990, AM J DIS CHILD, V144, P1210, DOI 10.1001/archpedi.1990.02150350042021; Boerma JT, 2006, B WORLD HEALTH ORGAN, V84, P145, DOI 10.2471/BLT.05.025189; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Brahmbhatt H, 2003, AIDS, V17, P2539, DOI 10.1097/00002030-200311210-00020; Brambilla P, 2001, AIDS, V15, P2415, DOI 10.1097/00002030-200112070-00009; BWAYO J, 1995, AM J OBSTET GYNECOL, V172, P700, DOI 10.1016/0002-9378(95)90597-9; CASSOL S, 1991, J CLIN MICROBIOL, V29, P667, DOI 10.1128/JCM.29.4.667-671.1991; *CDCP, 2004, CAS HIV INF AIDS US; Centers for Disease Control and Prevention (CDC), 2006, MMWR Morb Mortal Wkly Rep, V55, P592; Chiappini E, 2006, AIDS, V20, P207, DOI 10.1097/01.aids.0000200529.64113.3e; Chiappini E, 2003, J MED VIROL, V70, P506, DOI 10.1002/jmv.10424; *CHILDR HIV ASS UK, 2004, GUID PREV OPP INF OI; Chintu C, 2004, LANCET, V364, P1865, DOI 10.1016/S0140-6736(04)17442-4; Chintu C, 2002, LANCET, V360, P985, DOI 10.1016/S0140-6736(02)11082-8; Chokephaibulkit K, 2005, AIDS, V19, P1495, DOI 10.1097/01.aids.0000183625.97170.59; Chouquet C, 1999, STAT MED, V18, P815, DOI 10.1002/(SICI)1097-0258(19990415)18:7&lt;815::AID-SIM74&gt;3.0.CO;2-G; Colebunders R, 2006, LANCET INFECT DIS, V6, P53, DOI 10.1016/S1473-3099(05)70327-3; Coovadia HM, 2007, LANCET, V369, P1107, DOI 10.1016/S0140-6736(07)60283-9; CORBETT A, 2005, INT C ANT AG CHEM; Coutsoudis A, 2004, J INFECT DIS, V189, P2154, DOI 10.1086/420834; CREEK T, 2007, 14 C RETR OPP INF LO; Dabis F, 2003, LANCET, V362, P1597, DOI 10.1016/S0140-6736(03)14839-8; Dabis F, 2001, AIDS, V15, P771, DOI 10.1097/00002030-200104130-00013; DATTA P, 1994, J INFECT DIS, V170, P1134, DOI 10.1093/infdis/170.5.1134; De Cock KM, 2002, LANCET, V360, P67, DOI 10.1016/S0140-6736(02)09337-6; de Martino M, 2000, JAMA-J AM MED ASSOC, V284, P190, DOI 10.1001/jama.284.2.190; De Rossi A, 2005, ANTIVIR THER, V10, P63; Dunn DT, 2003, LANCET, V362, P1605, DOI 10.1016/S0140-6736(03)14793-9; Elenga N, 2005, PEDIATR INFECT DIS J, V24, P1077, DOI 10.1097/01.inf.0000190008.91534.b7; Eley B, 2006, T ROY SOC TROP MED H, V100, P19, DOI 10.1016/j.trstmh.2005.04.015; Eshleman SH, 2001, AIDS, V15, P1951, DOI 10.1097/00002030-200110190-00006; ESHLEMAN SH, 2005, 12 C RETR OPP INF; *EUR COLL STUD, 1992, LANCET, V335, P1007; Fassinou P, 2004, AIDS, V18, P1905, DOI 10.1097/00002030-200409240-00006; Fawzi WW, 1999, PEDIATR INFECT DIS J, V18, P127, DOI 10.1097/00006454-199902000-00009; Feeney ME, 2005, J IMMUNOL, V174, P7524, DOI 10.4049/jimmunol.174.12.7524; Feeney ME, 2004, J VIROL, V78, P8927, DOI 10.1128/JVI.78.16.8927-8930.2004; Ferrantelli F, 2004, J INFECT DIS, V189, P2167, DOI 10.1086/420833; Fiscus SA, 2007, J CLIN MICROBIOL, V45, P2274, DOI 10.1128/JCM.00813-07; Florence E, 2004, INT J STD AIDS, V15, P538, DOI 10.1258/0956462041558159; Fraaij PLA, 2005, CLIN INFECT DIS, V40, P604, DOI 10.1086/427696; French MA, 2004, AIDS, V18, P1615, DOI 10.1097/01.aids.0000131375.21070.06; Geffin R, 2003, VIROLOGY, V310, P207, DOI 10.1016/S0042-6822(03)00137-5; Giaquinto C, 2005, CLIN INFECT DIS, V40, P458, DOI 10.1086/427287; Gibb DM, 2003, BMJ-BRIT MED J, V327, P1019, DOI 10.1136/bmj.327.7422.1019; Gibb DM, 1997, ARCH DIS CHILD, V77, P478, DOI 10.1136/adc.77.6.478; Gortmaker SL, 2001, NEW ENGL J MED, V345, P1522, DOI 10.1056/NEJMoa011157; Goulder PJR, 2004, NEW ENGL J MED, V351, P2013; Goulder PJR, 2004, NAT REV IMMUNOL, V4, P630, DOI 10.1038/nri1417; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576; Graham SM, 2004, INT J TUBERC LUNG D, V8, P648; Hartmann SU, 2006, J HUM LACT, V22, P75, DOI 10.1177/0890334405280650; Hawkins D, 2005, HIV MED, V6, P107, DOI 10.1111/j.1468-1293.2005.00302.x; Heymann J, 2007, AIDS CARE, V19, P337, DOI 10.1080/09540120600763225; *HLTH PROT AG CTR, UNPUB Q SURV TABL NU; Hoffman IF, 1999, AIDS, V13, P487, DOI 10.1097/00002030-199903110-00007; Iliff PJ, 2005, AIDS, V19, P699, DOI 10.1097/01.aids.0000166093.16446.c9; Ioannidis JPA, 2004, AIDS, V18, P99, DOI 10.1097/00002030-200401020-00012; *IT MULT STUD, 1988, LANCET, V332, P1043; Jeena PM, 1996, TUBERCLE LUNG DIS, V77, P437, DOI 10.1016/S0962-8479(96)90117-3; Jeena PM, 1996, ANN TROP PAEDIATR, V16, P361, DOI 10.1080/02724936.1996.11747852; Jeena PM, 2002, INT J TUBERC LUNG D, V6, P672; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; John GC, 2001, J INFECT DIS, V183, P206, DOI 10.1086/317918; John-Stewart GC, 2007, J INFECT DIS, V196, P1, DOI 10.1086/518516; Kiepiela P, 2004, NATURE, V432, P769, DOI 10.1038/nature03113; KLINE M, 2007, 14 C RETR OPP INF LO; Kline MW, 2006, PEDIATRICS, V117, P1388, DOI 10.1542/peds.2005-1348; Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Kourtis AP, 1996, NEW ENGL J MED, V335, P1431, DOI 10.1056/NEJM199611073351904; Kuhn L, 2004, AIDS, V18, P1281, DOI 10.1097/00002030-200406180-00006; Kuhn L, 1999, J INFECT DIS, V179, P52, DOI 10.1086/314551; Lackritz E M, 1998, AIDS, V12 Suppl A, pS81; LEPAGE P, 1989, AIDS, V3, P221, DOI 10.1097/00002030-198904000-00005; Leslie AJ, 2004, NAT MED, V10, P282, DOI 10.1038/nm992; Lichterfeld M, 2004, J EXP MED, V200, P701, DOI 10.1084/jem.20041270; LIDINJANSSON G, 1994, PEDIATRICS, V94, P815; Lindegren ML, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.4.e46; Little K, 2007, INT J EPIDEMIOL, V36, P679, DOI 10.1093/ije/dym019; Lockman S, 2007, NEW ENGL J MED, V356, P135, DOI 10.1056/NEJMoa062876; Lucas SB, 1996, BRIT MED J, V312, P335, DOI 10.1136/bmj.312.7027.335; Luzuriaga K, 2000, J VIROL, V74, P6984, DOI 10.1128/JVI.74.15.6984-6991.2000; Luzuriaga K, 2006, LANCET, V368, P511, DOI 10.1016/S0140-6736(06)69159-9; Madhi SA, 2000, INT J TUBERC LUNG D, V4, P448; Madhi SA, 2000, CLIN INFECT DIS, V31, P170, DOI 10.1086/313925; MALIN AS, 1995, LANCET, V346, P1258, DOI 10.1016/S0140-6736(95)91862-0; Martinez-Picado J, 2006, J VIROL, V80, P3617, DOI 10.1128/JVI.80.7.3617-3623.2006; Matano T, 1998, J VIROL, V72, P164, DOI 10.1128/JVI.72.1.164-169.1998; Mayaux MJ, 1996, JAMA-J AM MED ASSOC, V275, P606, DOI 10.1001/jama.275.8.606; McIntyre J, 2006, CURR OPIN INFECT DIS, V19, P33, DOI 10.1097/01.qco.0000200290.99790.72; MCKINNEY RE, 1991, NEW ENGL J MED, V324, P1018, DOI 10.1056/NEJM199104113241503; Melvin AJ, 2001, AIDS RES HUM RETROV, V17, P1117, DOI 10.1089/088922201316912727; Menson EN, 2006, BMJ-BRIT MED J, V332, P1183, DOI 10.1136/bmj.332.7551.1183; Mofenson LM, 2003, LANCET, V362, P1625, DOI 10.1016/S0140-6736(03)14825-8; Moodley D, 2003, J INFECT DIS, V187, P725, DOI 10.1086/367898; Moss WJ, 2003, B WORLD HEALTH ORGAN, V81, P61; Mphatswe W, 2007, AIDS, V21, P1253, DOI 10.1097/QAD.0b013e3281a3bec2; Mukadi YD, 1997, AIDS, V11, P1151, DOI 10.1097/00002030-199709000-00011; Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167; NESHEIM SR, 1994, AIDS, V8, P1293, DOI 10.1097/00002030-199409000-00012; Newell ML, 2006, T ROY SOC TROP MED H, V100, P1, DOI 10.1016/j.trstmh.2005.05.012; Newell ML, 2004, LANCET, V364, P1236, DOI 10.1016/S0140-6736(04)17140-7; Newell ML, 2004, AIDS, V18, pS27, DOI 10.1097/00002030-200406002-00004; Nightingale S, 2006, J TROP PEDIATRICS, V52, P235, DOI 10.1093/tropej/fml033; Nolan ML, 2002, AIDS, V16, P1991, DOI 10.1097/00002030-200210180-00003; Nyandiko WM, 2006, JAIDS-J ACQ IMM DEF, V43, P418, DOI 10.1097/01.qai.0000243122.52282.89; O'Brien DP, 2007, CLIN INFECT DIS, V44, P1245, DOI 10.1086/513433; Oberdorfer P, 2006, J PAEDIATR CHILD H, V42, P283, DOI 10.1111/j.1440-1754.2006.00855.x; Obimbo EM, 2004, PEDIATR INFECT DIS J, V23, P536, DOI 10.1097/01.inf.0000129692.42964.30; ONYANGO C, 2007, 14 C RETR OPP INF LO; Otieno F A, 2002, East Afr Med J, V79, P111; Otieno RO, 2006, AIDS, V20, P275, DOI 10.1097/01.aids.0000200533.56490.b7; Owens DK, 1996, JAMA-J AM MED ASSOC, V275, P1342, DOI 10.1001/jama.275.17.1342; *PAED EUR NETW TRE, PENPACT 1; Palumbo PE, 1998, JAMA-J AM MED ASSOC, V279, P756, DOI 10.1001/jama.279.10.756; Pillay T, 2005, J VIROL, V79, P12100, DOI 10.1128/JVI.79.18.12100-12105.2005; Rabkin M, 2002, LANCET, V360, P1503, DOI 10.1016/S0140-6736(02)11478-4; Reddi Anand, 2007, BMC Pediatr, V7, P13, DOI 10.1186/1471-2431-7-13; Resino S, 2003, CLIN INFECT DIS, V37, P1216, DOI 10.1086/378804; Rhoads MP, 2006, HIV MED, V7, P16, DOI 10.1111/j.1468-1293.2005.00337.x; Rich JD, 1999, ANN INTERN MED, V130, P37, DOI 10.7326/0003-4819-130-1-199901050-00007; Rodriguez WR, 2005, PLOS MED, V2, P663, DOI 10.1371/journal.pmed.0020182; Rogerson SR, 2004, T ROY SOC TROP MED H, V98, P544, DOI 10.1016/j.trstmh.2003.12.011; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Rouet F, 2005, J CLIN MICROBIOL, V43, P2709, DOI 10.1128/JCM.43.6.2709-2717.2005; Rouet F, 2001, AIDS, V15, P1849, DOI 10.1097/00002030-200109280-00015; Rouet F, 2006, J TROP PEDIATRICS, V52, P346, DOI 10.1093/tropej/fml024; Rouet F, 2006, AIDS, V20, P2315, DOI 10.1097/QAD.0b013e328010943b; Schmid GP, 2004, LANCET, V363, P482, DOI 10.1016/S0140-6736(04)15497-4; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Schreibman T, 2004, CLIN INFECT DIS, V38, P257, DOI 10.1086/380792; Sharland M, 2004, HIV MED, V5, P61, DOI 10.1111/j.1468-1293.2004.00227.x; Shearer WT, 1997, NEW ENGL J MED, V336, P1337, DOI 10.1056/NEJM199705083361901; Shingadia D, 2000, PEDIATRICS, V105, part. no., DOI 10.1542/peds.105.6.e80; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; Spira R, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.5.e56; Steinmann G G, 1986, Curr Top Pathol, V75, P43; Taha TE, 2007, J INFECT DIS, V196, P10, DOI 10.1086/518511; THEA DM, 1993, NEW ENGL J MED, V329, P1696, DOI 10.1056/NEJM199312023292304; Tindyebwa D., 2004, HDB PAEDIAT AIDS AFR; UNAIDS, 2008, REP GLOB AIDS EP; *UNAIDS UNICEF USA, 2004, CHILDR BRINK 2004 JO; *UNAIDS WHO, 2006, AIDS EP UPD; *US PHS INF DIS SO, 2002, GUID PREV OPP INF HI; Van Dyke RB, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.4.e61; WADE AM, 1992, PEDIATR INFECT DIS J, V11, P1018, DOI 10.1097/00006454-199211120-00006; Walters S, 2006, ADV EXP MED BIOL, V582, P221; Watson DC, 1999, PEDIATR INFECT DIS J, V18, P682, DOI 10.1097/00006454-199908000-00006; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; WEMIN L, 2006, PEPFAR ANN M; Whitworth J, 2000, LANCET, V356, P1051, DOI 10.1016/S0140-6736(00)02727-6; WHO, 2006, ANT DRUGS TREAT PREG; *WHO, 2000, NEW DAT PREV MOTH CH; *WHO, 2007, M IMM STRAT ADV GROU; WHO/UNAIDS, 2003, TREAT 3 MILL 2005 MA; Wilfert CM, 2007, J INFECT DIS, V195, P165, DOI 10.1086/510255; Williams AJ, 2001, AIDS, V15, P335, DOI 10.1097/00002030-200102160-00006; *WORK GROUP ANT TH, 2006, GUID US ANT AG PED H; World Health Organisation, 2006, ANT THER HIV INF INF; World Health Organisation, 2005, WORLD HLTH REP MAK E; World Health Organization, 2006, CONS STAT WHO HIV IN; World Health Organization, 2006, WHO CAS DEF HIV SURV; World Health Organization, 2003, SCAL ANT THER RES LT; World Health Organization (WHO), 2006, GUID COTR PROPH HIV; Wu XL, 2006, J VIROL, V80, P835, DOI 10.1128/JVI.80.2.835-844.2006	181	80	82	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 7	2007	370	9581					68	80		10.1016/S0140-6736(07)61051-4	http://dx.doi.org/10.1016/S0140-6736(07)61051-4			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187QE	17617274				2022-12-28	WOS:000247862300032
J	Ives, AR; Carpenter, SR				Ives, Anthony R.; Carpenter, Stephen R.			Stability and diversity of ecosystems	SCIENCE			English	Review							BIODIVERSITY; COMPLEXITY; CONSEQUENCES; RESISTANCE; DYNAMICS; ECOLOGY	Understanding the relationship between diversity and stability requires a knowledge of how species interact with each other and how each is affected by the environment. The relationship is also complex, because the concept of stability is multifaceted; different types of stability describing different properties of ecosystems lead to multiple diversity-stability relationships. A growing number of empirical studies demonstrate positive diversity-stability relationships. These studies, however, have emphasized only a few types of stability, and they rarely uncover the mechanisms responsible for stability. Because anthropogenic changes often affect stability and diversity simultaneously, diversity-stability relationships cannot be understood outside the context of the environmental drivers affecting both. This shifts attention away from diversity-stability relationships toward the multiple factors, including diversity, that dictate the stability of ecosystems.	Univ Wisconsin, Dept Zool, Madison, WI 53706 USA; Univ Wisconsin, Ctr Limnol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ives, AR (corresponding author), Univ Wisconsin, Dept Zool, Madison, WI 53706 USA.	arives@wisc.edu; srcarpen@wisc.edu	Carpenter, Stephen/AAQ-6404-2020; Ives, Anthony/A-5698-2008	Ives, Anthony/0000-0001-9375-9523				[Anonymous], 2006, ALASKAS CHANGING BOR; Carpenter S R, 2003, REGIME SHIFTS LAKE E; Chapin III F.S., 2001, GLOBAL BIODIVERSITY; Dennis B, 2001, ECOL MONOGR, V71, P277, DOI 10.1890/0012-9615(2001)071[0277:ECACDI]2.0.CO;2; Dukes JS, 2001, OECOLOGIA, V126, P563, DOI 10.1007/s004420000549; Elton C., 1927, ANIMAL ECOLOGY; Foley JA, 2005, SCIENCE, V309, P570, DOI 10.1126/science.1111772; FROST TM, 1995, LINKING SPECIES & ECOSYSTEMS, P224; Grimm V, 1997, OECOLOGIA, V109, P323, DOI 10.1007/s004420050090; HASTINGS A, 1993, ANNU REV ECOL SYST, V24, P1, DOI 10.1146/annurev.es.24.110193.000245; Holling C.S., 1973, Annual Rev Ecol Syst, V4, P1, DOI 10.1146/annurev.es.04.110173.000245; Hooper DU, 2005, ECOL MONOGR, V75, P3, DOI 10.1890/04-0922; Ives AR, 2004, NATURE, V429, P174, DOI 10.1038/nature02515; Ives AR, 2003, ECOL MONOGR, V73, P301, DOI 10.1890/0012-9615(2003)073[0301:ECSAEI]2.0.CO;2; Kendall BE, 1999, ECOLOGY, V80, P1789, DOI 10.1890/0012-9658(1999)080[1789:WDPCAS]2.0.CO;2; Klug JL, 2000, ECOLOGY, V81, P387; Loreau M, 2002, BIODIVERSITY AND ECOSYSTEM FUNCTIONING: SYNTHESIS AND PERSPECTIVES, P79; Loreau M, 2001, SCIENCE, V294, P804, DOI 10.1126/science.1064088; May R.M., 1974, STABILITY COMPLEXITY; MAY RM, 1976, AM NAT, V110, P573, DOI 10.1086/283092; MAY RM, 1977, NATURE, V269, P471, DOI 10.1038/269471a0; McCann KS, 2000, NATURE, V405, P228, DOI 10.1038/35012234; Millenium Ecosystem Assessment, 2005, EC HUM WELLB GEN SYN; PAINE RT, 1966, AM NAT, V100, P65, DOI 10.1086/282400; PIMM SL, 1984, NATURE, V307, P321, DOI 10.1038/307321a0; PIMM SL, 1979, THEOR POPUL BIOL, V16, P144, DOI 10.1016/0040-5809(79)90010-8; Scheffer M, 2001, NATURE, V413, P591, DOI 10.1038/35098000; Scheffer M, 1997, ECOLOGY, V78, P272; Stachowicz JJ, 2002, ECOLOGY, V83, P2575; Terborgh J, 2001, SCIENCE, V294, P1923, DOI 10.1126/science.1064397; Tilman D, 1996, ECOLOGY, V77, P350, DOI 10.2307/2265614; Wootton JT, 2004, ECOL LETT, V7, P653, DOI 10.1111/j.1461-0248.2004.00621.x; Worm B, 2003, TRENDS ECOL EVOL, V18, P628, DOI 10.1016/j.tree.2003.09.003; Yodzis P., 1989, INTRO THEORETICAL EC	36	889	968	45	790	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 6	2007	317	5834					58	62		10.1126/science.1133258	http://dx.doi.org/10.1126/science.1133258			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186KD	17615333				2022-12-28	WOS:000247776700038
J	van Hecke, M				van Hecke, Martin			Shape matters	SCIENCE			English	Editorial Material							TRANSITION		Leiden Univ, Kamerlingh Onnes Lab, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	van Hecke, M (corresponding author), Leiden Univ, Kamerlingh Onnes Lab, POB 9506, NL-2300 RA Leiden, Netherlands.	mvhecke@physics.leidenuniv.nl		van Hecke, Martin/0000-0002-9550-6607				Aranson IS, 2007, PHYS REV E, V75, DOI 10.1103/PhysRevE.75.051301; Chate H, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.180602; Couzin ID, 2005, NATURE, V433, P513, DOI 10.1038/nature03236; Dauchot O, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.265701; Donev A, 2004, SCIENCE, V303, P990, DOI 10.1126/science.1093010; Ellenbroek WG, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.258001; Keys AS, 2007, NAT PHYS, V3, P260, DOI 10.1038/nphys572; Liu AJ, 1998, NATURE, V396, P21, DOI 10.1038/23819; Narayan V, 2006, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2006/01/P01005; Narayan V, 2007, SCIENCE, V317, P105, DOI 10.1126/science.1140414; Ramaswamy S, 2003, EUROPHYS LETT, V62, P196, DOI 10.1209/epl/i2003-00346-7; Toner J, 1998, PHYS REV E, V58, P4828, DOI 10.1103/PhysRevE.58.4828; VICSEK T, 1995, PHYS REV LETT, V75, P1226, DOI 10.1103/PhysRevLett.75.1226	13	11	11	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 6	2007	317	5834					49	50		10.1126/science.1145113	http://dx.doi.org/10.1126/science.1145113			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186KD	17615326				2022-12-28	WOS:000247776700031
J	Woo, CJ; Kingston, RE				Woo, Caroline J.; Kingston, Robert E.			HOTAIR lifts noncoding RNAs to new levels	CELL			English	Editorial Material							EMBRYONIC STEM-CELLS; DEVELOPMENTAL REGULATORS; POLYCOMB; TRANSCRIPTION; TRITHORAX	It is not clear to what extent noncoding RNAs regulate the homeobox (HOX) genes that encode key regulators of development in the embryo. In this issue, Rinn et al. (2007) characterize noncoding RNAs that regulate HOX genes and discover one, HOTAIR, that unexpectedly regulates a HOX gene cluster on a different chromosome than the HOX cluster that encodes it.	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Kingston, RE (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.	kingston@molbio.mgh.harvard.edu						Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Klymenko T, 2004, EMBO REP, V5, P373, DOI 10.1038/sj.embor.7400111; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lemons D, 2006, SCIENCE, V313, P1918, DOI 10.1126/science.1132040; Mainguy G, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000356; Petruk S, 2006, CELL, V127, P1209, DOI 10.1016/j.cell.2006.10.039; Rank G, 2002, MOL CELL BIOL, V22, P8026, DOI 10.1128/MCB.22.22.8026-8034.2002; Sessa L, 2007, RNA, V13, P223, DOI 10.1261/rna.266707	9	110	123	1	28	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 29	2007	129	7					1257	1259		10.1016/j.cell.2007.06.014	http://dx.doi.org/10.1016/j.cell.2007.06.014			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188HQ	17604716	Bronze			2022-12-28	WOS:000247911400012
J	Beddington, JR; Agnew, DJ; Clark, CW				Beddington, J. R.; Agnew, D. J.; Clark, C. W.			Current problems in the management of marine fisheries	SCIENCE			English	Review							SUSTAINABLE FISHERIES; RECOVERY; RESERVES; FUTURE	The public perception of fisheries is that they are in crisis and have been for some time. Numerous scientific and popular articles have pointed to the failures of fisheries management that have caused this crisis. These are widely accepted to be overcapacity in fishing fleets, a failure to take the ecosystem effects of fishing into account, and a failure to enforce unpalatable but necessary reductions in fishing effort on fishing fleets and communities. However, the claims of some analysts that there is an inevitable decline in the status of fisheries is, we believe, incorrect. There have been successes in fisheries management, and we argue that the tools for appropriate management exist. Unfortunately, they have not been implemented widely. Our analysis suggests that management authorities need to develop legally enforceable and tested harvest strategies, coupled with appropriate rights-based incentives to the fishing community, for the future of fisheries to be better than their past.	Univ London Imperial Coll Sci Technol & Med, Dept Biol, London SW7 2BP, England; Univ British Columbia, Dept Math, Vancouver, BC V7E 1Y5, Canada	Imperial College London; University of British Columbia	Beddington, JR (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol, London SW7 2BP, England.	j.beddington@imperial.ac.uk						AGNEW DJ, 2006, 3 REG SESS COMM CONS; Barton A. John, 2004, P202, DOI 10.1002/9780470999936.ch12; Beddington John R., 2007, P148; Beverton R.J.H., 1957, FISH INVEST LONDON S, V19; Caddy JF, 2004, REV FISH BIOL FISHER, V14, P43, DOI 10.1007/s11160-004-3770-2; Clark C.W., 1990, MATH BIOECONOMICS OP, V2nd; Clark CW, 2005, J ENVIRON ECON MANAG, V50, P47, DOI 10.1016/j.jeem.2004.11.002; Clark CW., 2007, WORLDWIDE CRISIS FIS, DOI 10.1017/CBO9780511617966; Cunningham S., 2005, SUCCESSFUL FISHERIES; del Valle I, 2006, DEV AQUAC FISH SCI, V36, P55; FAO, 2007, STAT WORLD FISH AQ 2; Fisheries Policy Council,, 2006, INT DISC PAP REV BAS; Garcia SM, 2005, PHILOS T R SOC B, V360, P21, DOI 10.1098/rstb.2004.1580; Gordon HS, 1954, J POLIT ECON, V62, P124, DOI 10.1086/257497; Grafton RQ, 2006, CAN J FISH AQUAT SCI, V63, P699, DOI 10.1139/f05-247; *HIGH SEAS TASK FO, 2006, CLOS NET STOP ILL FI; Hilborn R, 2005, PHILOS T R SOC B, V360, P47, DOI 10.1098/rstb.2004.1569; Hilborn R, 2007, AMBIO, V36, P296, DOI 10.1579/0044-7447(2007)36[296:MTSBLF]2.0.CO;2; *ICES, 2006, 2006ACFM24 CM ICES; Kirby DS, 2006, 2 REG SESS SCI COMM; MACE PM, 1994, CAN J FISH AQUAT SCI, V51, P110, DOI 10.1139/f94-013; McLoughlin K., 2007, FISHERY STATUS REPOR; MEES CC, 2006, REBUILDING FISHERIES; Ministry of Fisheries, 2006, REP FISH ASS PLEN MA; MOONEYSEUS M, 0703 EEDP BP CHATH H; *NOAA FISH OFF SUS, STAT US FISH 2006; *OECD, 2003, COST MAN FISH; Pauly D., 2003, PERFECT OCEAN STATE; *PEW OC COMM, 2003, AM LIV OC CHART COUR; Roberts CM, 2005, PHILOS T R SOC B, V360, P123, DOI 10.1098/rstb.2004.1578; Rosenberg AA, 2006, FRONT ECOL ENVIRON, V4, P303, DOI 10.1890/1540-9295(2006)4[303:RUFPAP]2.0.CO;2; Safina C, 2005, SCIENCE, V309, P707, DOI 10.1126/science.1113725; Shepherd JG, 2003, FISH RES, V63, P149, DOI 10.1016/S0165-7836(03)00125-5; Shertzer KW, 2007, ICES J MAR SCI, V64, P149, DOI 10.1093/icesjms/fsl005; Stefansson G, 2005, PHILOS T R SOC B, V360, P133, DOI 10.1098/rstb.2004.1579; Tupper MH, 2002, SCIENCE, V295, P1233; [No title captured]	37	412	424	0	202	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 22	2007	316	5832					1713	1716		10.1126/science.1137362	http://dx.doi.org/10.1126/science.1137362			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180XE	17588923				2022-12-28	WOS:000247400500037
J	Kristensen, P; Bjerkedal, T				Kristensen, Petter; Bjerkedal, Tor			Explaining the relation between birth order and intelligence	SCIENCE			English	Article							FAMILY-SIZE		Natl Inst Occupat Hlth, N-0033 Oslo, Norway; Univ Oslo, Prevent Med & Epidemiol Sect, N-0318 Oslo, Norway; Norwegian Armed Forces Med Serv, Inst Epidemiol, N-0015 Oslo, Norway	University of Oslo	Kristensen, P (corresponding author), Natl Inst Occupat Hlth, N-0033 Oslo, Norway.	petter.kristensen@stami.no						BELMONT L, 1973, SCIENCE, V182, P1096, DOI 10.1126/science.182.4117.1096; BJERKEDAL T, 2007, INTELLIGENCE, V35; Galton F., 1874, ENGLISH MEN SCI; GUALTIERI T, 1985, BEHAV BRAIN SCI, V8, P427, DOI 10.1017/S0140525X00001023; RECORD RG, 1969, ANN HUM GENET, V33, P61, DOI 10.1111/j.1469-1809.1969.tb01630.x; Rodgers JL, 2000, AM PSYCHOL, V55, P599, DOI 10.1037//0003-066X.55.6.599; Ross G, 2003, ARCH PEDIAT ADOL MED, V157, P397, DOI 10.1001/archpedi.157.4.397	7	134	135	4	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 22	2007	316	5832					1717	1717		10.1126/science.1141493	http://dx.doi.org/10.1126/science.1141493			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	180XE	17588924				2022-12-28	WOS:000247400500038
J	Klempner, MS; Unnasch, TR; Hu, LT				Klempner, Mark S.; Unnasch, Thomas R.; Hu, Linden T.			Focus on research: Taking a bite out of vector-transmitted infectious diseases	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MOSQUITOS		Boston Univ, Sch Med, Boston, MA 02118 USA; Univ S Florida, Coll Publ Hlth, Dept Global Hlth, Tampa, FL USA; Tufts Univ, Sch Med, Boston, MA 02111 USA	Boston University; State University System of Florida; University of South Florida; Tufts University	Klempner, MS (corresponding author), Boston Univ, Sch Med, Boston, MA 02118 USA.				NIAID NIH HHS [R01 AI050043, R01 AI049724-08, R01 AI050043-03, R01 AI050043-04, U01 AI058266-04, R01 AI049724, U01 AI058266-03, R01 AI050043-05, R01 AI050043-01A1, U01 AI058266-02, U01 AI058266, R01 AI050043-02, U01 AI058266-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049724, U01AI058266, R01AI050043] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		GARRETTJONES C, 1964, NATURE, V204, P1173, DOI 10.1038/2041173a0; Labuda M, 2006, PLOS PATHOG, V2, P251, DOI 10.1371/journal.ppat.0020027; Marrelli MT, 2007, P NATL ACAD SCI USA, V104, P5580, DOI 10.1073/pnas.0609809104; Tsao JI, 2004, P NATL ACAD SCI USA, V101, P18159, DOI 10.1073/pnas.0405763102; Valenzuela JG, 2001, J EXP MED, V194, P331, DOI 10.1084/jem.194.3.331	5	41	45	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 21	2007	356	25					2567	2569		10.1056/NEJMp078081	http://dx.doi.org/10.1056/NEJMp078081			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180GN	17582066	Green Accepted			2022-12-28	WOS:000247351200003
J	Hermann, JC; Marti-Arbona, R; Fedorov, AA; Fedorov, E; Almo, SC; Shoichet, BK; Raushel, FM				Hermann, Johannes C.; Marti-Arbona, Ricardo; Fedorov, Alexander A.; Fedorov, Elena; Almo, Steven C.; Shoichet, Brian K.; Raushel, Frank M.			Structure-based activity prediction for an enzyme of unknown function	NATURE			English	Article							DOCKING; INHIBITORS; CATALYSIS; ERRORS	With many genomes sequenced, a pressing challenge in biology is predicting the function of the proteins that the genes encode. When proteins are unrelated to others of known activity, bioinformatics inference for function becomes problematic. It would thus be useful to interrogate protein structures for function directly. Here, we predict the function of an enzyme of unknown activity, Tm0936 from Thermotoga maritima, by docking high- energy intermediate forms of thousands of candidate metabolites. The docking hit list was dominated by adenine analogues, which appeared to undergo C6- deamination. Four of these, including 5- methylthioadenosine and S- adenosylhomocysteine ( SAH), were tested as substrates, and three had substantial catalytic rate constants ( 10(5) M-1 s(-1)). The X- ray crystal structure of the complex between Tm0936 and the product resulting from the deamination of SAH, S- inosylhomocysteine, was determined, and it corresponded closely to the predicted structure. The deaminated products can be further metabolized by T. maritima in a previously uncharacterized SAH degradation pathway. Structure- based docking with high- energy forms of potential substrates may be a useful tool to annotate enzymes for function.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77842 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	University of California System; University of California San Francisco; Texas A&M University System; Texas A&M University College Station; Yeshiva University; Albert Einstein College of Medicine	Shoichet, BK (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, MC 2550 1700 4th St, San Francisco, CA 94158 USA.	shoichet@cgl.ucsf.edu	Raushel, Frank/B-7125-2015	Raushel, Frank/0000-0002-5918-3089	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059957, R01GM071896] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM059957, R01 GM071896-04, R01 GM071896, R01 GM059957-09] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brenner SE, 1999, TRENDS GENET, V15, P132, DOI 10.1016/S0168-9525(99)01706-0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cleland W W, 1979, Methods Enzymol, V63, P103; Cleland W W, 1979, Methods Enzymol, V63, P500; Devos D, 2001, TRENDS GENET, V17, P429, DOI 10.1016/S0168-9525(01)02348-4; ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6; Gerlt JA, 2000, GENOME BIOL, V1; GILSON MK, 1987, NATURE, V330, P84, DOI 10.1038/330084a0; Gschwend DA, 1996, J COMPUT AID MOL DES, V10, P123, DOI 10.1007/BF00402820; Hermann JC, 2006, ORG BIOMOL CHEM, V4, P206, DOI 10.1039/b512969a; Hermann JC, 2006, J AM CHEM SOC, V128, P15882, DOI 10.1021/ja065860f; Holm L, 1997, PROTEINS, V28, P72, DOI 10.1002/(SICI)1097-0134(199705)28:1<72::AID-PROT7>3.0.CO;2-L; Irwin JJ, 2005, BIOCHEMISTRY-US, V44, P12316, DOI 10.1021/bi050801k; Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+; JONES TA, 1985, METHOD ENZYMOL, V115, P157; Jorgensen WL, 2004, SCIENCE, V303, P1813, DOI 10.1126/science.1096361; Kairys V, 2006, J CHEM INF MODEL, V46, P365, DOI 10.1021/ci050238c; Kalyanaraman C, 2005, BIOCHEMISTRY-US, V44, P2059, DOI 10.1021/bi0481186; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Klebe G, 2006, DRUG DISCOV TODAY, V11, P580, DOI 10.1016/j.drudis.2006.05.012; KUNTZ ID, 1982, J MOL BIOL, V161, P269, DOI 10.1016/0022-2836(82)90153-X; Lorber DM, 2005, CURR TOP MED CHEM, V5, P739, DOI 10.2174/1568026054637683; Macchiarulo A, 2004, NAT BIOTECHNOL, V22, P1039, DOI 10.1038/nbt999; MENG EC, 1992, J COMPUT CHEM, V13, P505, DOI 10.1002/jcc.540130412; Mohan V, 2005, CURR PHARM DESIGN, V11, P323, DOI 10.2174/1381612053382106; MUSZBEK L, 1985, CLIN CHEM, V31, P35; Nowlan C, 2006, J AM CHEM SOC, V128, P15892, DOI 10.1021/ja0658618; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pegg SCH, 2006, BIOCHEMISTRY-US, V45, P2545, DOI 10.1021/bi052101l; RADZICKA A, 1995, SCIENCE, V267, P90, DOI 10.1126/science.7809611; Rao MS, 1999, PROTEINS, V34, P173, DOI 10.1002/(SICI)1097-0134(19990201)34:2<173::AID-PROT3>3.0.CO;2-F; Schapira M, 2003, J MED CHEM, V46, P3045, DOI 10.1021/jm0300173; Schramm VL, 2005, CURR OPIN STRUC BIOL, V15, P604, DOI 10.1016/j.sbi.2005.10.017; Seibert CM, 2005, BIOCHEMISTRY-US, V44, P6383, DOI 10.1021/bi047326v; Shoichet BK, 2004, NATURE, V432, P862, DOI 10.1038/nature03197; SPEEDIE MK, 1988, J BACTERIOL, V170, P4376, DOI 10.1128/jb.170.9.4376-4378.1988; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Sukuru SCK, 2006, J COMPUT AID MOL DES, V20, P159, DOI 10.1007/s10822-006-9043-5; Tantillo DJ, 2002, J COMPUT CHEM, V23, P84, DOI 10.1002/jcc.10019; Tyler PC, 2007, J AM CHEM SOC, V129, P6872, DOI 10.1021/ja0708363; Warshel A, 1998, P NATL ACAD SCI USA, V95, P5950, DOI 10.1073/pnas.95.11.5950; Wei BQQ, 2002, J MOL BIOL, V322, P339, DOI 10.1016/S0022-2836(02)00777-5; Whisstock JC, 2003, Q REV BIOPHYS, V36, P307, DOI 10.1017/S0033583503003901	43	202	215	1	49	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 16	2007	448	7155					775	U2		10.1038/nature05981	http://dx.doi.org/10.1038/nature05981			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200HJ	17603473	Green Accepted			2022-12-28	WOS:000248754200032
J	Ago, H; Kanaoka, Y; Irikura, D; Lam, BK; Shimamura, T; Austen, KF; Miyano, M				Ago, Hideo; Kanaoka, Yoshihide; Irikura, Daisuke; Lam, Bing K.; Shimamura, Tatsuro; Austen, K. Frank; Miyano, Masashi			Crystal structure of a human membrane protein involved in cysteinyl leukotriene biosynthesis	NATURE			English	Article							C-4 SYNTHASE; GLUTATHIONE; IDENTIFICATION; TRANSFERASE; EXPRESSION; SUBSTANCE; CLONING; ENZYME	The cysteinyl leukotrienes, namely leukotriene (LT)C-4 and its metabolites LTD4 and LTE4, the components of slow-reacting substance of anaphylaxis(1,2), are lipid mediators of smooth muscle constriction(3-5) and inflammation(6,7), particularly implicated in bronchial asthma(8,9). LTC4 synthase (LTC4S), the pivotal enzyme for the biosynthesis of LTC4 (ref. 10), is an 18-kDa integral nuclear membrane protein(11,12) that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase- activating protein, microsomal glutathione S-transferases (MGSTs), and microsomal prostaglandin E synthase 1 (ref. 13). LTC4S conjugates glutathione to LTA(4), the endogenous substrate derived from arachidonic acid through the 5-lipoxygenase pathway(14). In contrast with MGST2 and MGST3 (refs 15, 16), LTC4S does not conjugate glutathione to xenobiotics(17). Here we show the atomic structure of human LTC4S in a complex with glutathione at 3.3 angstrom resolution by X-ray crystallography and provide insights into the high substrate specificity for glutathione and LTA(4) that distinguishes LTC4S from other MGSTs. The LTC4S monomer has four transmembrane alpha-helices and forms a threefold symmetric trimer as a unit with functional domains across each interface. Glutathione resides in a U-shaped conformation within an interface between adjacent monomers, and this binding is stabilized by a loop structure at the top of the interface. LTA(4) would fit into the interface so that Arg 104 of one monomer activates glutathione to provide the thiolate anion that attacks C6 of LTA(4) to form a thioether bond, and Arg 31 in the neighbouring monomer donates a proton to form a hydroxyl group at C5, resulting in 5(S)-hydroxy-6(R)-S-glutathionyl-7,9-trans-11,14-cis-eicosatetraenoic acid (LTC4). These findings provide a structural basis for the development of LTC4S inhibitors for a proinflammatory pathway mediated by three cysteinyl leukotriene ligands whose stability and potency are different and by multiple cysteinyl leukotriene receptors whose functions may be non-redundant.	Harima Inst, Struct Biophys Lab, RIKEN SPring Ctr 8, Sayo, Hyogo 6795148, Japan; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA	RIKEN; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Miyano, M (corresponding author), Harima Inst, Struct Biophys Lab, RIKEN SPring Ctr 8, 1-1-1 Kouto, Sayo, Hyogo 6795148, Japan.	fausten@rics.bwh.harvard.edu; miyano@spring8.or.jp	Miyano, Masashi/R-2785-2016	Miyano, Masashi/0000-0003-2253-6175; Ago, Hideo/0000-0002-9040-488X				Adachi S, 2001, NUCL INSTRUM METH A, V467, P711, DOI 10.1016/S0168-9002(01)00472-7; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beller TC, 2004, P NATL ACAD SCI USA, V101, P3047, DOI 10.1073/pnas.0400235101; Bresell A, 2005, FEBS J, V272, P1688, DOI 10.1111/j.1742-4658.2005.04596.x; BROCKLEHURST WE, 1960, J PHYSIOL-LONDON, V151, P416, DOI 10.1113/jphysiol.1960.sp006449; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Christmas P, 2002, J BIOL CHEM, V277, P28902, DOI 10.1074/jbc.M203074200; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; Holm PJ, 2006, J MOL BIOL, V360, P934, DOI 10.1016/j.jmb.2006.05.056; Jakobsson PJ, 1997, J BIOL CHEM, V272, P22934, DOI 10.1074/jbc.272.36.22934; Jakobsson PJ, 1996, J BIOL CHEM, V271, P22203, DOI 10.1074/jbc.271.36.22203; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kanaoka Y, 2001, J BIOL CHEM, V276, P22608, DOI 10.1074/jbc.M103562200; Kellaway CH, 1940, Q J EXP PHYSIOL CMS, V30, P121; Kim DC, 2006, J IMMUNOL, V176, P4440, DOI 10.4049/jimmunol.176.7.4440; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; Lam BK, 1997, J BIOL CHEM, V272, P13923, DOI 10.1074/jbc.272.21.13923; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; MARFAT A, 1985, ADV PROSTAG THROMB L, V14, P155; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Schlippe YVG, 2005, ARCH BIOCHEM BIOPHYS, V433, P266, DOI 10.1016/j.abb.2004.09.018; Schmidt- Krey I, 2004, STRUCTURE, V12, P2009, DOI 10.1016/j.str.2004.08.008; Sheldrick GM, 2002, Z KRISTALLOGR, V217, P644, DOI 10.1524/zkri.217.12.644.20662; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; Thoren S, 2003, J BIOL CHEM, V278, P22199, DOI 10.1074/jbc.M303227200; WEISS JW, 1982, SCIENCE, V216, P196, DOI 10.1126/science.7063880; WELSCH DJ, 1994, P NATL ACAD SCI USA, V91, P9745, DOI 10.1073/pnas.91.21.9745; YOSHIMOTO T, 1988, J CLIN INVEST, V81, P866, DOI 10.1172/JCI113396; Zimmer JSD, 2004, J LIPID RES, V45, P2138, DOI 10.1194/jlr.M400240-JLR200	31	122	127	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 2	2007	448	7153					609	U12		10.1038/nature05936	http://dx.doi.org/10.1038/nature05936			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	195XV	17632548				2022-12-28	WOS:000248446700047
J	Nurieva, R; Yang, XXO; Martinez, G; Zhang, YL; Panopoulos, AD; Ma, L; Schluns, K; Tian, Q; Watowich, SS; Jetten, AM; Dong, C				Nurieva, Roza; Yang, Xuexian O.; Martinez, Gustavo; Zhang, Yongliang; Panopoulos, Athanasia D.; Ma, Li; Schluns, Kimberly; Tian, Qiang; Watowich, Stephanie S.; Jetten, Anton M.; Dong, Chen			Essential autocrine regulation by IL-21 in the generation of inflammatory T cells	NATURE			English	Article							MYELIN OLIGODENDROCYTE GLYCOPROTEIN; AUTOIMMUNE INFLAMMATION; ROR-GAMMA; TH1 CELLS; DIFFERENTIATION; CYTOKINE; EXPRESSION; LINEAGE; T(H)17; ENCEPHALOMYELITIS	After activation, CD4(+) helper T (T-H) cells differentiate into distinct effector subsets that are characterized by their unique cytokine expression and immunoregulatory function(1,2). During this differentiation, T(H)1 and T(H)2 cells produce interferon-gamma and interleukin (IL)-4, respectively, as autocrine factors necessary for selective lineage commitment. A distinct T-H subset, termed THIL-17, T(H)17 or inflammatory T-H (T(H)i), has been recently identified as a distinct T-H lineage mediating tissue inflammation(3,4). T(H)17 differentiation is initiated by transforming growth factor-beta and IL-6 (refs 5 - 7) and reinforced by IL-23 ( ref. 8), in which signal transduction and activators of transcription ( STAT) 3 and retinoic acid receptor-related orphan receptor (ROR)-gamma mediate the lineage specification(8-10). T(H)17 cells produce IL-17, IL-17F and IL-22, all of which regulate inflammatory responses by tissue cells but have no importance in T(H)17 differentiation(11-14). Here we show that IL-21 is another cytokine highly expressed by mouse T(H)17 cells. IL-21 is induced by IL-6 in activated T cells, a process that is dependent on STAT3 but not ROR-gamma. IL-21 potently induces T(H)17 differentiation and suppresses Foxp3 expression, which requires STAT3 and ROR-gamma, which is encoded by Rorc. IL-21 deficiency impairs the generation of T(H)17 cells and results in protection against experimental autoimmune encephalomyelitis. IL-21 is therefore an autocrine cytokine that is sufficient and necessary for T(H)17 differentiation, and serves as a target for treating inflammatory diseases.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Inst Syst Engn, Seattle, WA 98103 USA; NIEHS, Cell Biol Sect, LRB, NIH, Res Triangle Pk, NC 27709 USA	University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Nurieva, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rnurieva@mdanderson.org; cdong@mdanderson.org	dong, chen/B-3181-2009; Yang, Xuexian/Y-2472-2019; Jetten, Anton/C-3736-2019	dong, chen/0000-0002-0084-9130; Yang, Xuexian/0000-0001-6816-7024; Jetten, Anton/0000-0003-0954-4445; Panopoulos, Athanasia/0000-0002-9610-2604; Watowich, Stephanie/0000-0003-1969-659X; Martinez, Gustavo/0000-0003-0178-3329	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES101586, Z01ES101586] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Afkarian M, 2002, NAT IMMUNOL, V3, P549, DOI 10.1038/ni794; Akimzhanov AM, 2007, J BIOL CHEM, V282, P5969, DOI 10.1074/jbc.C600322200; ANGKASEKWINAI P, IN PRESS J EXP MED; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Chen Z, 2006, P NATL ACAD SCI USA, V103, P8137, DOI 10.1073/pnas.0600666103; Chung YS, 2006, CELL RES, V16, P902, DOI 10.1038/sj.cr.7310106; Dong C, 2006, NAT REV IMMUNOL, V6, P329, DOI 10.1038/nri1807; Dong C, 2000, ARTHRITIS RES, V2, P179, DOI 10.1186/ar85; Glimcher LH, 2000, GENE DEV, V14, P1693; Hjelmstrom P, 1998, J IMMUNOL, V161, P4480; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Kleinschek MA, 2007, J EXP MED, V204, P161, DOI 10.1084/jem.20061738; Kurebayashi S, 2000, P NATL ACAD SCI USA, V97, P10132, DOI 10.1073/pnas.97.18.10132; Laky K, 1997, J IMMUNOL, V158, P1417; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Leonard WJ, 2005, NAT REV IMMUNOL, V5, P688, DOI 10.1038/nri1688; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Okuda Y, 1999, J NEUROIMMUNOL, V101, P188, DOI 10.1016/S0165-5728(99)00139-3; Okuda Y, 2000, J NEUROIMMUNOL, V105, P120, DOI 10.1016/S0165-5728(00)00192-2; Ozaki K, 2002, SCIENCE, V298, P1630, DOI 10.1126/science.1077002; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Suto A, 2006, J IMMUNOL, V177, P3721, DOI 10.4049/jimmunol.177.6.3721; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Weaver CT, 2006, IMMUNITY, V24, P677, DOI 10.1016/j.immuni.2006.06.002; Wurster AL, 2002, J EXP MED, V196, P969, DOI 10.1084/jem.20020620; Yang XXO, 2007, J BIOL CHEM, V282, P9358, DOI 10.1074/jbc.C600321200; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505	28	1170	1269	0	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 26	2007	448	7152					480	U8		10.1038/nature05969	http://dx.doi.org/10.1038/nature05969			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	193VG	17581589				2022-12-28	WOS:000248302700048
J	Ziegelstein, RC				Ziegelstein, Roy C.			Acute emotional stress and cardiac arrhythmias	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY-DISEASE; PAROXYSMAL ATRIAL-FIBRILLATION; LIFE-THREATENING ARRHYTHMIAS; LEFT-VENTRICULAR DYSFUNCTION; ACUTE MYOCARDIAL-INFARCTION; ISCHEMIC-HEART-DISEASE; MENTAL STRESS; PSYCHOLOGICAL STRESS; SOCIAL SUPPORT; SYMPATHETIC HYPERACTIVITY	Episodes of acute emotional stress can have significant adverse effects on the heart. Acute emotional stress can produce left ventricular contractile dysfunction, myocardial ischemia, or disturbances of cardiac rhythm. Although these abnormalities are often only transient, their consequences can be gravely damaging and sometimes fatal. Despite the many descriptions of catastrophic cardiovascular events in the setting of acute emotional stress, the anatomical substrate and physiological pathways by which emotional stress triggers cardiovascular events are only now being characterized, aided by the advent of functional neuroimaging. Recent evidence indicates that asymmetric brain activity is particularly important in making the heart more susceptible to ventricular arrhythmias. Lateralization of cerebral activity during emotional stress may stimulate the heart asymmetrically and produce areas of inhomogeneous repolarization that create electrical instability and facilitate the development of cardiac arrhythmias. Patients with ischemic heart disease who survive an episode of sudden cardiac death in the setting of acute emotional stress should receive a beta-blocker. Nonpharmacological approaches to manage emotional stress in patients with and without coronary artery disease, including social support, relaxation therapy, yoga, meditation, controlled slow breathing, and biofeedback, are also appropriate to consider and merit additional investigation in randomized trials.	Johns Hopkins Bayview Med Ctr, Dept Med, Div Cardiol, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Ziegelstein, RC (corresponding author), Johns Hopkins Bayview Med Ctr, Dept Med, Div Cardiol, 4940 eastern Ave, Baltimore, MD 21224 USA.	rziegel@jhmi.edu						Becker LC, 1996, CIRCULATION, V94, P2768, DOI 10.1161/01.CIR.94.11.2768; Bettoni M, 2002, CIRCULATION, V105, P2753, DOI 10.1161/01.CIR.0000018443.44005.D8; BRODSKY MA, 1987, JAMA-J AM MED ASSOC, V257, P2064, DOI 10.1001/jama.257.15.2064; Cannon Walter Bradford, 2002, American Journal of Public Health, V92, P1593, DOI 10.2105/AJPH.92.10.1593; Christian LM, 2006, PSYCHOSOM MED, V68, P914, DOI 10.1097/01.psy.0000244023.20755.cf; Critchley HD, 2005, BRAIN, V128, P75, DOI 10.1093/brain/awh324; Del Pozo JM, 2004, AM HEART J, V147, pG1, DOI 10.1016/j.ahj.2003.08.013; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; ENGEL GL, 1971, ANN INTERN MED, V74, P771, DOI 10.7326/0003-4819-74-5-771; Gullette ECD, 1997, JAMA-J AM MED ASSOC, V277, P1521, DOI 10.1001/jama.277.19.1521; Hansson Anders, 2004, BMC Cardiovasc Disord, V4, P13, DOI 10.1186/1471-2261-4-13; HOCKMAN CH, 1966, AM HEART J, V71, P695, DOI 10.1016/0002-8703(66)90322-X; Joseph CN, 2005, HYPERTENSION, V46, P714, DOI 10.1161/01.HYP.0000179581.68566.7d; KAMARCK TW, 1990, PSYCHOSOM MED, V52, P42, DOI 10.1097/00006842-199001000-00004; Kies P, 2005, J CARDIOVASC ELECTR, V16, P1049, DOI 10.1111/j.1540-8167.2005.50006.x; Kume T, 2005, CIRC J, V69, P934, DOI 10.1253/circj.69.934; KUO CS, 1983, CIRCULATION, V67, P1356, DOI 10.1161/01.CIR.67.6.1356; Kurisu S, 2002, AM HEART J, V143, P448, DOI 10.1067/mhj.2002.120403; Lampert R, 2000, CIRCULATION, V101, P158, DOI 10.1161/01.CIR.101.2.158; Lampert R, 2002, CIRCULATION, V106, P1800, DOI 10.1161/01.CIR.0000031733.51374.C1; Lane RD, 2005, PSYCHOSOM MED, V67, P359, DOI 10.1097/01.psy.0000160476.67536.41; LEPORE SJ, 1993, PSYCHOSOM MED, V55, P518, DOI 10.1097/00006842-199311000-00007; LOWN B, 1976, NEW ENGL J MED, V294, P623, DOI 10.1056/NEJM197603182941201; LOWN B, 1987, CIRCULATION, V76, P186; LOWN B, 1973, SCIENCE, V182, P834, DOI 10.1126/science.182.4114.834; LOWN B, 1977, AM J CARDIOL, V39, P890, DOI 10.1016/S0002-9149(77)80044-1; MORI H, 1993, CARDIOVASC RES, V27, P192, DOI 10.1093/cvr/27.2.192; MYERS A, 1975, BRIT HEART J, V37, P1133; Nolan RP, 2005, AM HEART J, V149, DOI 10.1016/j.ahj.2005.03.015; PATEL C, 1975, LANCET, V2, P93; Patterson E, 2005, HEART RHYTHM, V2, P624, DOI 10.1016/j.hrthm.2005.02.012; Po SS, 2006, HEART RHYTHM, V3, P201, DOI 10.1016/j.hrthm.2005.11.008; Ramachandruni S, 2006, J AM COLL CARDIOL, V47, P987, DOI 10.1016/j.jacc.2005.10.051; REICH P, 1985, ANNU REV MED, V36, P397; REICH P, 1981, JAMA-J AM MED ASSOC, V246, P233, DOI 10.1001/jama.246.3.233; ROZANSKI A, 1988, NEW ENGL J MED, V318, P1005, DOI 10.1056/NEJM198804213181601; Scherlag BJ, 2005, J AM COLL CARDIOL, V45, P1878, DOI 10.1016/j.jacc.2005.01.057; SCHWARTZ PJ, 1981, J CARDIOVASC PHARM, V3, P1251, DOI 10.1097/00005344-198111000-00012; SCHWARTZ PJ, 1985, AM HEART J, V109, P937, DOI 10.1016/0002-8703(85)90233-9; Selvamurthy W., 1998, Indian Journal of Physiology and Pharmacology, V42, P205; Sharkey SW, 2005, CIRCULATION, V111, P472, DOI 10.1161/01.CIR.0000153801.51470.EB; Soufer R, 1998, P NATL ACAD SCI USA, V95, P6454, DOI 10.1073/pnas.95.11.6454; Soufer R, 2004, CIRCULATION, V110, P1710, DOI 10.1161/01.CIR.0000144841.84987.50; Taggart P, 2005, PSYCHOSOM MED, V67, P376, DOI 10.1097/01.psy.0000160463.10583.88; Tsuchihashi K, 2001, J AM COLL CARDIOL, V38, P11, DOI 10.1016/S0735-1097(01)01316-X; van Dixhoorn J, 2005, EUR J CARDIOV PREV R, V12, P193, DOI 10.1097/00149831-200506000-00002; van Dixhoorn J J, 1999, J Cardiopulm Rehabil, V19, P178, DOI 10.1097/00008483-199905000-00005; VERRIER RL, 1975, AM J PHYSIOL, V228, P923, DOI 10.1152/ajplegacy.1975.228.3.923; VERRIER RL, 1987, CIRCULATION, V75, P249, DOI 10.1161/01.CIR.75.1.249; Wen ZC, 1998, J AM COLL CARDIOL, V31, P602, DOI 10.1016/S0735-1097(97)00555-X; Wittstein IS, 2005, NEW ENGL J MED, V352, P539, DOI 10.1056/NEJMoa043046	51	82	91	1	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 18	2007	298	3					324	329		10.1001/jama.298.3.324	http://dx.doi.org/10.1001/jama.298.3.324			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	190US	17635893				2022-12-28	WOS:000248086700027
J	Fletcher, J				Fletcher, John			Clinical epidemiology notes - Subgroup analyses: how to avoid being misted	BRITISH MEDICAL JOURNAL			English	Article												jfletcher@bmj.com						Bech BH, 2007, BMJ-BRIT MED J, V334, P409, DOI 10.1136/bmj.39062.520648.BE; CHAN EY, 2004, BMJ, V334; Gohel MS, 2007, BMJ-BRIT MED J, V335, P83, DOI 10.1136/bmj.39216.542442.BE	3	34	34	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUL 14	2007	335	7610					96	97		10.1136/bmj.39265.596262.AD	http://dx.doi.org/10.1136/bmj.39265.596262.AD			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192JM	17626964	Green Published			2022-12-28	WOS:000248197500042
J	Hardy, WR; Li, LY; Wang, Z; Sedy, J; Fawcett, J; Frank, E; Kucera, J; Pawson, T				Hardy, W. Rod; Li, Lingying; Wang, Zhi; Sedy, Jiri; Fawcett, James; Frank, Eric; Kucera, Jan; Pawson, Tony			Combinatorial ShcA docking interactions support diversity in tissue morphogenesis	SCIENCE			English	Article							MUSCLE-SPINDLE; SIGNAL TRANSDUCTION; ADAPTER PROTEIN; SENSORY NEURONS; CRE RECOMBINASE; IN-VIVO; RECEPTOR; EXPRESSION; PHOSPHOTYROSINE; PATHWAY	Changes in protein-protein interactions may allow polypeptides to perform unexpected regulatory functions. Mammalian ShcA docking proteins have amino-terminal phosphotyrosine (pTyr) binding (PTB) and carboxyl-terminal Src homology 2 (SH2) domains, which recognize specific pTyr sites on activated receptors, and a central region with two phosphorylated tyrosine-X-asparagine (pYXN) motifs ( where X represents any amino acid) that each bind the growth factor receptor-bound protein 2 (Grb2) adaptor. Phylogenetic analysis indicates that ShcA may signal through both pYXN-dependent and - independent pathways. We show that, in mice, cardiomyocyte-expressed ShcA directs mid-gestational heart development by a PTB-dependent mechanism that does not require the pYXN motifs. In contrast, the pYXN motifs are required with PTB and SH2 domains in the same ShcA molecule for the formation of muscle spindles, skeletal muscle sensory organs that regulate motor behavior. Thus, combinatorial differences in ShcA docking interactions may yield multiple signaling mechanisms to support diversity in tissue morphogenesis.	Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Vet Adm Med Ctr, Boston, MA 02130 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA; Charles Univ Prague, Inst Anat, Fac Med 1, Prague 12000, Czech Republic; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Vet Adm Med Ctr, Boston, MA 02130 USA	Boston University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Tufts University; Charles University Prague; Boston University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Kucera, J (corresponding author), Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.	jfkucera@bu.edu; pawson@mshri.on.ca	Pawson, Tony J/E-4578-2013	Fawcett, Jim/0000-0003-0043-2164	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024373] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS024373-19, R01 NS024373-18, R01 NS024373, R01 NS024373-20] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agah R, 1997, J CLIN INVEST, V100, P169, DOI 10.1172/JCI119509; Altiok N, 1997, EMBO J, V16, P717, DOI 10.1093/emboj/16.4.717; Andrechek ER, 2002, MOL CELL BIOL, V22, P4714, DOI 10.1128/MCB.22.13.4714-4722.2002; Bothe GWM, 2000, GENESIS, V26, P165, DOI 10.1002/(SICI)1526-968X(200002)26:2<165::AID-GENE22>3.0.CO;2-F; Chen HH, 2003, CURR OPIN NEUROBIOL, V13, P96, DOI 10.1016/S0959-4388(03)00006-0; Chen HH, 2002, J NEUROSCI, V22, P3512; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Ganju P, 1998, EUR J NEUROSCI, V10, P1995, DOI 10.1046/j.1460-9568.1998.00209.x; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Hippenmeyer S, 2002, NEURON, V36, P1035, DOI 10.1016/S0896-6273(02)01101-7; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; Klinghoffer RA, 2002, DEV CELL, V2, P103, DOI 10.1016/S1534-5807(01)00103-4; Lai KMV, 2000, GENE DEV, V14, P1132; Leu M, 2003, DEVELOPMENT, V130, P2291, DOI 10.1242/dev.00447; Luschnig S, 2000, MOL CELL, V5, P231, DOI 10.1016/S1097-2765(00)80419-0; Luzi L, 2000, CURR OPIN GENET DEV, V10, P668, DOI 10.1016/S0959-437X(00)00146-5; MAEDA N, 1983, NATURE, V302, P61, DOI 10.1038/302061a0; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Nakamura T, 2002, ONCOGENE, V21, P22, DOI 10.1038/sj.onc.1205019; Patel TD, 2003, NEURON, V38, P403, DOI 10.1016/S0896-6273(03)00261-7; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Postigo A, 2002, GENE DEV, V16, P633, DOI 10.1101/gad.217902; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Schlessinger Joseph, 2003, Sci STKE, V2003, pRE12, DOI 10.1126/stke.2003.191.re12; Tourtellotte WG, 2001, DEV BIOL, V232, P388, DOI 10.1006/dbio.2001.0202; True JR, 2002, ANNU REV CELL DEV BI, V18, P53, DOI 10.1146/annurev.cellbio.18.020402.140619; Yang L, 2006, DEVELOPMENT, V133, P1575, DOI 10.1242/dev.02322	31	47	47	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 13	2007	317	5835					251	256		10.1126/science.1140114	http://dx.doi.org/10.1126/science.1140114			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189DC	17626887	Green Accepted			2022-12-28	WOS:000247968600045
J	Kelly, BC; Ikonomou, MG; Blair, JD; Morin, AE; Gobas, FAPC				Kelly, Barry C.; Ikonomou, Michael G.; Blair, Joel D.; Morin, Anne E.; Gobas, Frank A. P. C.			Food web-specific biomagnification of persistent organic pollutants	SCIENCE			English	Article							TROUT ONCORHYNCHUS-MYKISS; DECABROMODIPHENYL ETHER; PERFLUOROOCTANE SULFONATE; DIETARY ACCUMULATION; AQUATIC ORGANISMS; TROPHIC TRANSFER; BIOACCUMULATION; MAGNIFICATION; MECHANISM; CHEMICALS	Substances that accumulate to hazardous levels in living organisms pose environmental and human-health risks, which governments seek to reduce or eliminate. Regulatory authorities identify bioaccumulative substances as hydrophobic, fat-soluble chemicals having high octanol-water partition coefficients (K-OW) (>= 100,000). Here we show that poorly metabolizable, moderately hydrophobic substances with a K-OW between 100 and 100,000, which do not biomagnify ( that is, increase in chemical concentration in organisms with increasing trophic level) in aquatic food webs, can biomagnify to a high degree in food webs containing air-breathing animals ( including humans) because of their high octanol-air partition coefficient (K-OA) and corresponding low rate of respiratory elimination to air. These low K-OW-high K-OA chemicals, representing a third of organic chemicals in commercial use, constitute an unidentified class of potentially bioaccumulative substances that require regulatory assessment to prevent possible ecosystem and human-health consequences.	Simon Fraser Univ, Sch Resource & Environm Management, Burnaby, BC V5A 1S6, Canada; Fisheries & Oceans Canada, Inst Ocean Sci, Ocean Sci Div, Sidney, BC V8L 4B2, Canada	Simon Fraser University; Fisheries & Oceans Canada	Gobas, FAPC (corresponding author), Simon Fraser Univ, Sch Resource & Environm Management, 8888 Univ Dr, Burnaby, BC V5A 1S6, Canada.	gobas@sfu.ca		Kelly, Barry/0000-0002-3449-6310				Arnot JA, 2006, ENVIRON REV, V14, P257, DOI 10.1139/a06-005; CHEN YCJ, 1992, JAMA-J AM MED ASSOC, V268, P3213, DOI 10.1001/jama.268.22.3213; CONNOLLY JP, 1988, ENVIRON SCI TECHNOL, V22, P99, DOI 10.1021/es00166a011; Cook PM, 2003, ENVIRON SCI TECHNOL, V37, P3864, DOI 10.1021/es034045m; Fisk AT, 1998, ENVIRON TOXICOL CHEM, V17, P951, DOI [10.1002/etc.5620170526, 10.1897/1551-5028(1998)017&lt;0951:DAADOH&gt;2.3.CO;2]; Fisk AT, 2001, ENVIRON SCI TECHNOL, V35, P732, DOI 10.1021/es001459w; Giesy JP, 2001, ENVIRON SCI TECHNOL, V35, P1339, DOI 10.1021/es001834k; GLADEN BC, 1988, J PEDIATR-US, V113, P991, DOI 10.1016/S0022-3476(88)80569-9; Gobas FAPC, 1999, ENVIRON SCI TECHNOL, V33, P133, DOI 10.1021/es980681m; Gobas FAPC, 2003, QSAR COMB SCI, V22, P329, DOI 10.1002/qsar.200390022; GOBAS FAPC, 1993, ENVIRON SCI TECHNOL, V27, P2855, DOI 10.1021/es00049a028; Hoekstra PF, 2003, ENVIRON POLLUT, V124, P509, DOI 10.1016/S0269-7491(02)00482-7; Hop H, 2002, ENVIRON SCI TECHNOL, V36, P2589, DOI 10.1021/es010231l; Ikonomou MG, 2002, ENVIRON SCI TECHNOL, V36, P1886, DOI 10.1021/es011401x; Kannan K, 2001, ENVIRON SCI TECHNOL, V35, P1593, DOI 10.1021/es001873w; Kelly BC, 2001, ENVIRON SCI TECHNOL, V35, P325, DOI 10.1021/es0011966; Kelly BC, 2003, ENVIRON SCI TECHNOL, V37, P2966, DOI 10.1021/es021035x; Kierkegaard A, 1999, ENVIRON SCI TECHNOL, V33, P1612, DOI 10.1021/es9807082; MACKAY D, 1982, ENVIRON SCI TECHNOL, V16, P274, DOI 10.1021/es00099a008; Martin JW, 2003, ENVIRON TOXICOL CHEM, V22, P189, DOI [10.1002/etc.5620220125, 10.1897/1551-5028(2003)022&lt;0189:DAOPAI&gt;2.0.CO;2]; Morck A, 2003, DRUG METAB DISPOS, V31, P900, DOI 10.1124/dmd.31.7.900; RATCLIFF.DA, 1967, NATURE, V215, P208, DOI 10.1038/215208a0; Stapleton HM, 2004, ENVIRON SCI TECHNOL, V38, P112, DOI 10.1021/es034746j; Tomy GT, 2004, ENVIRON SCI TECHNOL, V38, P6475, DOI 10.1021/es049620g; UNEP, 2001, C PLEN STOCKH CONV P; WOODWELL GM, 1967, SCI AM, V216, P24, DOI 10.1038/scientificamerican0367-24	26	646	693	24	622	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 13	2007	317	5835					236	239		10.1126/science.1138275	http://dx.doi.org/10.1126/science.1138275			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189DC	17626882				2022-12-28	WOS:000247968600040
J	Lucassen, A; Clarke, A				Lucassen, Anneke; Clarke, Angus			Should families own genetic information?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Princess Anne Hosp, Wessex Clin Genet Serv, Southampton SO16 5YA, Hants, England; Univ Wales Hosp, Inst Med Genet, Cardiff CF14 4XN, S Glam, Wales	Cardiff University	Lucassen, A (corresponding author), Princess Anne Hosp, Wessex Clin Genet Serv, Southampton SO16 5YA, Hants, England.	annekel@soton.ac.uk; clarkeaj@cardiff.ac.uk	Lucassen, Anneke/D-7764-2017	Lucassen, Anneke/0000-0003-3324-4338					0	13	13	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUL 7	2007	335	7609					22	23		10.1136/bmj.39252.386030.AD	http://dx.doi.org/10.1136/bmj.39252.386030.AD			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191LY	17615220	Green Published			2022-12-28	WOS:000248133900029
J	Paxton, LA; Hope, T; Jaffe, HW				Paxton, Lynn A.; Hope, Tony; Jaffe, Harold W.			Pre-exposure prophylaxis for HIV infection: what if it works?	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RANDOMIZED CONTROLLED-TRIAL; SEXUAL RISK BEHAVIOR; INJECTION-DRUG USERS; MALE CIRCUMCISION; ANTIRETROVIRAL THERAPY; EFFICACY TRIAL; PREVENTION; VACCINE; TRANSMISSION		Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Coordinating Ctr Infect Dis, Atlanta, GA 30333 USA; Univ Oxford, Ethox Ctr, Oxford, England; Univ Oxford, Dept Publ Hlth, Oxford, England	Centers for Disease Control & Prevention - USA; University of Oxford; University of Oxford	Paxton, LA (corresponding author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Coordinating Ctr Infect Dis, 1600 Clifton Rd,Mailstop E45, Atlanta, GA 30333 USA.	lap5@cdc.gov						ABBAS U, 2007, 14 C RETR OPP INF FE; [Anonymous], COMMUNICATION; [Anonymous], 2004, INVESTIGATORS BROCHU; Auvert B, 2005, PLOS MED, V2, P1112, DOI 10.1371/journal.pmed.0020298; Baggaley RF, 2006, PLOS MED, V3, P493, DOI 10.1371/journal.pmed.0030124; Bailey RC, 2007, LANCET, V369, P643, DOI 10.1016/S0140-6736(07)60312-2; Bartholow BN, 2005, JAIDS-J ACQ IMM DEF, V39, P90, DOI 10.1097/01.qai.0000143600.41363.78; Blower SM, 2000, SCIENCE, V287, P650, DOI 10.1126/science.287.5453.650; Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101; COHEN J, 2006, NY TIMES MAGAZI 0122; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; *CONRAD, 2007, PHAS III TRIALS CELL; Crepaz N, 2004, JAMA-J AM MED ASSOC, V292, P224, DOI 10.1001/jama.292.2.224; DOBSON J, COMPLETE MARRIAGE FA; Flynn MN, 2005, J INFECT DIS, V191, P654, DOI 10.1086/428404; Foss AM, 2003, AIDS, V17, P1227, DOI 10.1097/00002030-200305230-00015; GARCIALERMA J, 2006, 13 C RETR OPP INF FE; *GLOB HIV PREV WOR, 2006, ACC RES ENS FUT ACC; Gray RH, 2007, LANCET, V369, P657, DOI 10.1016/S0140-6736(07)60313-4; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; JOHNSON J, 2006, 13 C RETR OPP INF FE; Martin JN, 2004, AIDS, V18, P787, DOI 10.1097/00002030-200403260-00010; OKWEMBA A, 2006, DAILY NATION KE 0615; Peterson Leigh, 2007, PLoS Clin Trials, V2, pe27, DOI 10.1371/journal.pctr.0020027; Pitisuttithum P, 2006, J INFECT DIS, V194, P1661, DOI 10.1086/508748; *PUBL HLTH WORK GR, 2002, PUBL HLTH BEN MICR L; ROSENBERG Z, 2006, MICROBICIDE RES PROM; Schechter M, 2004, JAIDS-J ACQ IMM DEF, V35, P519, DOI 10.1097/00126334-200404150-00010; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; Smith RJ, 2005, AIDS, V19, P413, DOI 10.1097/01.aids.0000161771.44276.92; Subbarao S, 2006, J INFECT DIS, V194, P904, DOI 10.1086/507306; Tsai CC, 1998, J VIROL, V72, P4265, DOI 10.1128/JVI.72.5.4265-4273.1998; UNAIDS, 2006, REP GLOB AIDS EP; van de Wijgert Janneke, 2002, BETA, V15, P23; van Griensven F, 2004, AIDS, V18, P295, DOI 10.1097/00002030-200401230-00020; Van Rompay KKA, 2001, J INFECT DIS, V184, P429, DOI 10.1086/322781; Whitcomb JM, 2003, J INFECT DIS, V188, P992, DOI 10.1086/378281; 2006, MED LETT, V4, P67; 2005, INVESTIGATORS BROCHU	39	74	78	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 7	2007	370	9581					89	93		10.1016/S0140-6736(07)61053-8	http://dx.doi.org/10.1016/S0140-6736(07)61053-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	187QE	17617276				2022-12-28	WOS:000247862300034
J	Pursell, ZF; Isoz, I; Lundstrom, EB; Johansson, E; Kunkel, TA				Pursell, Zachary F.; Isoz, Isabelle; Lundstroem, Else-Britt; Johansson, Erik; Kunkel, Thomas A.			Yeast DNA polymerase epsilon participates in leading-strand DNA replication	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; S-PHASE; POL EPSILON; CHECKPOINT; REPAIR; ERRORS; FORK	Multiple DNA polymerases participate in replicating the leading and lagging strands of the eukaryotic nuclear genome. Although 50 years have passed since the first DNA polymerase was discovered, the identity of the major polymerase used for leading-strand replication is uncertain. We constructed a derivative of yeast DNA polymerase e that retains high replication activity but has strongly reduced replication fidelity, particularly for thymine-deoxythymidine 5'-monophosphate (T-dTMP) but not adenine-deoxyadenosine 5'-monophosphate (A-dAMP) mismatches. Yeast strains with this DNA polymerase e allele have elevated rates of T to A substitution mutations. The position and rate of these substitutions depend on the orientation of the mutational reporter and its location relative to origins of DNA replication and reveal a pattern indicating that DNA polymerase e participates in leading-strand DNA replication.	NIEHS, Mol Genet Lab, NIH, US Dept HHS, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, NIH, US Dept HHS, Res Triangle Pk, NC 27709 USA; Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Umea University	Kunkel, TA (corresponding author), NIEHS, Mol Genet Lab, NIH, US Dept HHS, Res Triangle Pk, NC 27709 USA.	kunkel@niehs.nih.gov	Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788; Johansson, Erik/0000-0002-8526-6224	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES065070] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 ES065070-17] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Dua R, 2000, J BIOL CHEM, V275, P28816, DOI 10.1074/jbc.M002376200; Dua R, 1999, J BIOL CHEM, V274, P22283, DOI 10.1074/jbc.274.32.22283; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; Fuss J, 2002, J BIOL CHEM, V277, P8658, DOI 10.1074/jbc.M110615200; Garg P, 2005, CRIT REV BIOCHEM MOL, V40, P115, DOI 10.1080/10409230590935433; Harrison JC, 2006, ANNU REV GENET, V40, P209, DOI 10.1146/annurev.genet.40.051206.105231; Johnson A, 2005, ANNU REV BIOCHEM, V74, P283, DOI 10.1146/annurev.biochem.73.011303.073859; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; Pavlov YI, 2003, CURR BIOL, V13, P744, DOI 10.1016/S0960-9822(03)00284-7; Pavlov YI, 2002, MOL CELL, V10, P207, DOI 10.1016/S1097-2765(02)00567-1; Poloumienko A, 2001, MOL BIOL CELL, V12, P3317, DOI 10.1091/mbc.12.11.3317; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shcherbakova PV, 1996, GENETICS, V142, P717; Shcherbakova PV, 1999, MOL CELL BIOL, V19, P3177	14	399	410	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2007	317	5834					127	130		10.1126/science.1144067	http://dx.doi.org/10.1126/science.1144067			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186KD	17615360	Green Accepted			2022-12-28	WOS:000247776700068
J	Steinbrook, R				Steinbrook, Robert			The age of teleradiology	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material												rsteinbrook@attglobal.net						Ebbert TL, 2007, AM J ROENTGENOL, V188, pW103, DOI 10.2214/AJR.06.1310; LEVY F, 2006, MILKEN I REV, P64; Sunshine JH, 2006, AM J ROENTGENOL, V187, P1160, DOI 10.2214/AJR.06.0559; Van Moore Arl, 2005, J Am Coll Radiol, V2, P121, DOI 10.1016/j.jacr.2004.08.003; Wachter RM, 2006, NEW ENGL J MED, V354, P662, DOI 10.1056/NEJMp058286	5	36	36	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 5	2007	357	1					5	7		10.1056/NEJMp078059	http://dx.doi.org/10.1056/NEJMp078059			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185OR	17611203				2022-12-28	WOS:000247720800003
J	Tegmark, M				Tegmark, Max			Many lives in many worlds	NATURE			English	Editorial Material									MIT, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Tegmark, M (corresponding author), MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA.							SHIKHOVTSEV EB, 2003, BIOGRAPHICAL SKETCH, V3; TEGMARK M, 2001, ARXIVORGPDFQUANTPH01	2	23	23	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 5	2007	448	7149					23	24		10.1038/448023a	http://dx.doi.org/10.1038/448023a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185OS	17611522				2022-12-28	WOS:000247720900020
J	Asfaw, N; Licence, P; Engida, T; Poliakoff, M				Asfaw, Nigist; Licence, Peter; Engida, Temechegn; Poliakoff, Martyn			Collaborations - Empowering green chemists in Ethiopia	SCIENCE			English	Editorial Material									Univ Addis Ababa, Dept Chem, Addis Ababa, Ethiopia; Univ Nottingham, Sch Chem, Nottingham NG7 2RD, England; Univ Addis Ababa, Federat African Soc Chem, Addis Ababa, Ethiopia	Addis Ababa University; University of Nottingham; Addis Ababa University	Asfaw, N (corresponding author), Univ Addis Ababa, Dept Chem, Addis Ababa, Ethiopia.	nigista@chem.aau.edu.et; martyn.poliakoff@nottingham.ac.uk	Licence, Peter/A-7918-2008; Licence, Peter/AAF-2327-2019	Licence, Peter/0000-0003-2992-0153; Licence, Peter/0000-0003-2992-0153	Engineering and Physical Sciences Research Council [GR/S87409/01, EP/D501229/1] Funding Source: researchfish; EPSRC [EP/D501229/1] Funding Source: UKRI	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Asfaw N, 2005, GREEN CHEM, V7, P352, DOI 10.1039/b417961g; CARMICHAEL H, 2006, CHEM WORLD       DEC, P54; FREEMANTLE M, 2006, CHEM ENG NEWS    MAY, P44; Licence P, 2005, GREEN CHEM, V7, P401, DOI 10.1039/b501367b; LICENCE P, 2005, RSC ESEF NEWSL, V5, P3; Poliakoff M, 2004, GREEN CHEM, V6, pG37, DOI 10.1039/b404259j; Poliakoff M, 2002, SCIENCE, V297, P807, DOI 10.1126/science.297.5582.807; Poliakoff M, 2001, NATURE, V413, P257, DOI 10.1038/35095133; Tang SLY, 2005, GREEN CHEM, V7, P761, DOI 10.1039/b513020b; 2006, RSC NEWS         APR, P1	10	4	4	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 29	2007	316	5833					1849	1850		10.1126/science.1144439	http://dx.doi.org/10.1126/science.1144439			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183WI	17588898				2022-12-28	WOS:000247602700021
J	Kirchhausen, T				Kirchhausen, Tomas			Making COPII coats	CELL			English	Editorial Material							VESICLE; FISSION; SEC23A	Newly synthesized proteins en route to the Golgi apparatus are exported from the endoplasmic reticulum by COPII coated vesicles. Fath et al. (2007) now reveal the structure of a large portion of the yeast Sec13/31 complex, which comprises the coat framework of COPII- coated vesicles. Their findings suggest a mechanism by which the COPII cage assembles and accommodates cargo of different sizes.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Kirchhausen, T (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.	kirchhausen@crystal.harvard.edu						BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bi XP, 2002, NATURE, V419, P271, DOI 10.1038/nature01040; Bielli A, 2005, J CELL BIOL, V171, P919, DOI 10.1083/jcb.200509095; Boyadjiev SA, 2006, NAT GENET, V38, P1192, DOI 10.1038/ng1876; Fotin A, 2004, NATURE, V432, P573, DOI 10.1038/nature03079; Lang MR, 2006, NAT GENET, V38, P1198, DOI 10.1038/ng1880; Lee MCS, 2005, CELL, V122, P605, DOI 10.1016/j.cell.2005.07.025; Stagg SM, 2006, NATURE, V439, P234, DOI 10.1038/nature04339	8	6	6	0	8	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 29	2007	129	7					1251	1252		10.1016/j.cell.2007.06.015	http://dx.doi.org/10.1016/j.cell.2007.06.015			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188HQ	17604713	Bronze			2022-12-28	WOS:000247911400009
J	Makary, MA; Al-Attar, A; Holzmueller, CG; Sexton, JB; Syin, D; Gilson, MM; Sulkowski, MS; Pronovost, PJ				Makary, Martin A.; Al-Attar, Ali; Holzmueller, Christine G.; Sexton, J. Bryan; Syin, Dora; Gilson, Marta M.; Sulkowski, Mark S.; Pronovost, Peter J.			Needlestick injuries among surgeons in training	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-CARE WORKERS; POSTTRAUMATIC-STRESS-DISORDER; HUMAN-IMMUNODEFICIENCY-VIRUS; OCCUPATIONAL EXPOSURES; PERCUTANEOUS INJURY; SHARPS INJURIES; HIV; BLOOD; PREVALENCE; URBAN	BACKGROUND: Surgeons in training are at high risk for needlestick injuries. The reporting of such injuries is a critical step in initiating early prophylaxis or treatment. METHODS: We surveyed surgeons in training at 17 medical centers about previous needlestick injuries. Survey items inquired about whether the most recent injury was reported to an employee health service or involved a ``high-risk'' patient (i.e., one with a history of infection with human immunodeficiency virus, hepatitis B or hepatitis C, or injection-drug use); we also asked about the perceived cause of the injury and the surrounding circumstances. RESULTS: The overall response rate was 95%. Of 699 respondents, 582 (83%) had had a needlestick injury during training; the mean number of needlestick injuries during residency increased according to the postgraduate year (PGY): PGY-1, 1.5 injuries; PGY-2, 3.7; PGY-3, 4.1; PGY-4, 5.3; and PGY-5, 7.7. By their final year of training, 99% of residents had had a needlestick injury; for 53%, the injury had involved a high-risk patient. Of the most recent injuries, 297 of 578 (51%) were not reported to an employee health service, and 15 of 91 of those involving high-risk patients (16%) were not reported. Lack of time was the most common reason given for not reporting such injuries among 126 of 297 respondents (42%). If someone other than the respondent knew about an unreported injury, that person was most frequently the attending physician (51%) and least frequently a ``significant other'' (13%). CONCLUSIONS: Needlestick injuries are common among surgeons in training and are often not reported. Improved prevention and reporting strategies are needed to increase occupational safety for surgical providers.	Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Qual & Safety Res Grp, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Surg, Ctr Outcomes Res, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21205 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; Georgetown Univ, Sch Med, Dept Plast Surg, Washington, DC USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Georgetown University	Makary, MA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Qual & Safety Res Grp, 1909 Thames St,2nd Fl, Baltimore, MD 21231 USA.	mmakary1@jhmi.edu						Babcock HM, 2003, INFECT CONT HOSP EP, V24, P731, DOI 10.1086/502121; Bakaeen Faisal, 2006, Am J Surg, V192, pe18, DOI 10.1016/j.amjsurg.2006.08.013; Berguer R, 2005, SURG CLIN N AM, V85, P1299, DOI 10.1016/j.suc.2005.09.012; Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101; *CDC, 2001, MMWR RECOMM REP, V50, P47; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P25; Do AN, 2003, INFECT CONT HOSP EP, V24, P86, DOI 10.1086/502178; Doebbeling BN, 2003, CLIN INFECT DIS, V37, P1006, DOI 10.1086/377535; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; HEALD AE, 1990, J GEN INTERN MED, V5, P389, DOI 10.1007/BF02599422; Howsepian AA, 1998, GEN HOSP PSYCHIAT, V20, P123; Jaeckel E, 2001, NEW ENGL J MED, V345, P1452, DOI 10.1056/NEJMoa011232; Jagger J, 1998, AORN J, V67, P979, DOI 10.1016/S0001-2092(06)62623-9; JAGGER J, 1995, ADV EXPOSURE PREV, V1, P1; Jagger J, 1998, ADV EXPOSURE PREVENT, V3, P1; Jagger J, 1998, AORN J, V67, P983; Jagger J, 1998, AORN J, V67, P986; Makary MA, 2006, ANN SURG, V243, P628, DOI 10.1097/01.sla.0000216410.74062.0f; Makary MA, 2006, WORLD J SURG, V30, P1224, DOI 10.1007/s00268-005-0605-9; Makary MA, 2006, JT COMM J QUAL PATIE, V32, P351, DOI 10.1016/S1553-7250(06)32045-4; Mingoli A, 1999, ANN SURG, V230, P737, DOI 10.1097/00000658-199911000-00022; *NIOSH, 1999, PUBL NIOSH; ONEILL TM, 1992, ARCH INTERN MED, V152, P1451, DOI 10.1001/archinte.152.7.1451; Osborn EHS, 1999, ANN INTERN MED, V130, P45, DOI 10.7326/0003-4819-130-1-199901050-00009; Patterson JMM, 1998, ANN SURG, V228, P266, DOI 10.1097/00000658-199808000-00017; PERRY J, 2005, ADV EXPOSURE PREV, V7, P42; Perry Jane, 2002, Bull Am Coll Surg, V87, P8; Pruss-Ustun A, 2005, AM J IND MED, V48, P482, DOI 10.1002/ajim.20230; QUEBBEMAN EJ, 1992, ARCH SURG-CHICAGO, V127, P213; Shiao JSC, 1999, AM J INFECT CONTROL, V27, P254, DOI 10.1053/ic.1999.v27.a97006; Sohn JW, 2006, J OCCUP HEALTH, V48, P474, DOI 10.1539/joh.48.474; Stringer B, 2002, OCCUP ENVIRON MED, V59, P703, DOI 10.1136/oem.59.10.703; Sulkowski MS, 2002, JAMA-J AM MED ASSOC, V287, P2406, DOI 10.1001/jama.287.18.2406; TANNER J, 2002, COCHRANE DB SYST REV, V3; Tereskerz PM, 1997, AM J PUBLIC HEALTH, V87, P1558, DOI 10.2105/AJPH.87.9.1558; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V267, P2899, DOI 10.1001/jama.267.21.2899; Weiss ES, 2007, AM J SURG, V193, P55, DOI 10.1016/j.amjsurg.2006.07.008; Weiss ES, 2005, ANN SURG, V241, P803, DOI 10.1097/01.sla.0000161174.71460.1f; Worthington MG, 2006, INFECT CONT HOSP EP, V27, P215, DOI 10.1086/501155	39	195	206	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 28	2007	356	26					2693	2699		10.1056/NEJMoa070378	http://dx.doi.org/10.1056/NEJMoa070378			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	183HS	17596603				2022-12-28	WOS:000247564500006
J	Mello, MM; Joffe, S				Mello, Michelle M.; Joffe, Steven			Compact versus contract - Industry sponsors' obligations to their research subjects	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CLINICAL-TRIAL AGREEMENTS; LITIGATION; ETHICS		Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Med Sch, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Mello, MM (corresponding author), Harvard Univ, Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA.		Joffe, Steven/H-3941-2019	Joffe, Steven/0000-0002-0667-7384; Mello, Michelle/0000-0003-2877-4270	NCI NIH HHS [CA96872] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA096872] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		6World Medical Association, 2000, DECL HELS; Armstrong David, 2006, Wall St J (East Ed), pA9; Coleman C.H., 2005, VANDERBILT LAW REV, V58, P387; DeAngelis CD, 2006, JAMA-J AM MED ASSOC, V296, P996, DOI 10.1001/jama.296.8.jed60051; DuVal G, 2004, J MED ETHICS, V30, P30, DOI 10.1136/jme.2003.005199; Gunsalus CK, 2006, SCIENCE, V312, P1441, DOI 10.1126/science.1121479; Haavi Morreim E., HOUS J HLTH L POLY, V4, P1; Lang AE, 2006, ANN NEUROL, V59, P459, DOI 10.1002/ana.20737; Mello Michelle M, 2005, Account Res, V12, P163, DOI 10.1080/08989620500216380; Mello MM, 2005, NEW ENGL J MED, V352, P2202, DOI 10.1056/NEJMsa044115; Mello MM, 2003, ANN INTERN MED, V139, P40, DOI 10.7326/0003-4819-139-1-200307010-00011; MELO MM, 2005, NEW ENGL J MED, V12, P163; Miller FG, 2003, HASTINGS CENT REP, V33, P19, DOI 10.2307/3528434; Morreim EH, 2005, J LAW MED ETHICS, V33, P586, DOI 10.1111/j.1748-720X.2005.tb00521.x; Morreim EH, 2004, J LAW MED ETHICS, V32, P474, DOI 10.1111/j.1748-720X.2004.tb00160.x; Resnik DB, 2004, J LEGAL MED, V25, P131, DOI 10.1080/01947640490457451; Saver RS, 2006, U CINCI LAW REV, V74, P941; Schulman KA, 2002, NEW ENGL J MED, V347, P1335, DOI 10.1056/NEJMsa020349; Steinbrook R, 2005, NEW ENGL J MED, V352, P2160, DOI 10.1056/NEJMp048353; WANERMAN RE, 2006, MED RES LAW POLICY R, V5, P439; WASHBURN J, 2005, RENT A RES DID BRIT; 2006, NY TIMES        0713, pA19; 2006, ANN NEUROL, V59, pA5	23	14	14	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 28	2007	356	26					2737	2743		10.1056/NEJMhle067499	http://dx.doi.org/10.1056/NEJMhle067499			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	183HS	17596610				2022-12-28	WOS:000247564500016
J	Vartiainen, MK; Guettler, S; Larijani, B; Treisman, R				Vartiainen, Maria K.; Guettler, Sebastian; Larijani, Banafshe; Treisman, Richard			Nuclear actin regulates dynamic subcellular localization and activity of the SRF cofactor MAL	SCIENCE			English	Article							SERUM RESPONSE FACTOR; MUTANT ACTINS; COACTIVATOR; TRANSCRIPTION; GROWTH; CELLS	Actin, which is best known as a cytoskeletal component, also participates in the control of gene expression. We report a function of nuclear actin in the regulation of MAL, a coactivator of the transcription factor serum response factor (SRF). MAL, which binds monomeric actin, is cytoplasmic in many cells but accumulates in the nucleus upon serum-induced actin polymerization. MAL rapidly shuttles between cytoplasm and nucleus in unstimulated cells. Serum stimulation effectively blocks MAL nuclear export, which requires MAL-actin interaction. Nuclear MAL binds SRF target genes but remains inactive unless actin binding is disrupted. Fluorescence resonance energy transfer analysis demonstrates that the MAL-actin interaction responds to extracellular signals. Serum-induced signaling is thus communicated to nuclear actin to control a transcriptional regulator.	Canc Res UK, London Res Inst, Transcript Lab, Lincolns Inn Fields Labs, London WC2A 3PX, England; Canc Res UK, London Res Inst, Cell Biophys Lab, Lincolns Inn Fields Labs, London WC2A 3PX, England	Cancer Research UK; Cancer Research UK	Treisman, R (corresponding author), Canc Res UK, London Res Inst, Transcript Lab, Lincolns Inn Fields Labs, 44 Lincolns Inn Fields, London WC2A 3PX, England.	Richard.Treisman@cancer.org.uk	Vartiainen, Maria/P-7043-2019; Larijani, Banafshe/H-3909-2015; Vartiainen, Maria K/F-4767-2013	Vartiainen, Maria/0000-0002-2017-0475; Larijani, Banafshe/0000-0003-4735-1169; Vartiainen, Maria K/0000-0002-2017-0475; Treisman, Richard/0000-0002-9658-0067; Guettler, Sebastian/0000-0002-3135-1546				Cen B, 2003, MOL CELL BIOL, V23, P6597, DOI 10.1128/MCB.23.18.6597-6608.2003; Engelsma D, 2004, EMBO J, V23, P3643, DOI 10.1038/sj.emboj.7600370; Lippincott-Schwartz J, 2003, SCIENCE, V300, P87, DOI 10.1126/science.1082520; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Miralles F, 2006, CURR OPIN CELL BIOL, V18, P261, DOI 10.1016/j.ceb.2006.04.009; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; Pederson T, 2005, MOL BIOL CELL, V16, P5055, DOI 10.1091/mbc.E05-07-0656; Pipes GCT, 2006, GENE DEV, V20, P1545, DOI 10.1101/gad.1428006; Posern G, 2004, EMBO J, V23, P3973, DOI 10.1038/sj.emboj.7600404; Posern G, 2002, MOL BIOL CELL, V13, P4167, DOI 10.1091/mbc.02-05-0068; Schmierer B, 2005, MOL CELL BIOL, V25, P9845, DOI 10.1128/MCB.25.22.9845-9858.2005; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Stuven T, 2003, EMBO J, V22, P5928, DOI 10.1093/emboj/cdg565; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134	14	471	485	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 22	2007	316	5832					1749	1752		10.1126/science.1141084	http://dx.doi.org/10.1126/science.1141084			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180XE	17588931				2022-12-28	WOS:000247400500048
J	Wu, JI; Crabtree, GR				Wu, Jiang I.; Crabtree, Gerald R.			Nuclear actin as choreographer of cell morphology and transcription	SCIENCE			English	Editorial Material							SERUM RESPONSE FACTOR; MIGRATION; CHROMATIN; COMPLEX; GROWTH		Stanford Univ, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA	Stanford University; Howard Hughes Medical Institute; Stanford University	Wu, JI (corresponding author), Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA.	crabtree@cmgm.stanford.edu						Alberti S, 2005, P NATL ACAD SCI USA, V102, P6148, DOI 10.1073/pnas.0501191102; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Knoll B, 2006, NAT NEUROSCI, V9, P195, DOI 10.1038/nn1627; Li SJ, 2006, MOL CELL BIOL, V26, P5797, DOI 10.1128/MCB.00211-06; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Olave IA, 2002, ANNU REV BIOCHEM, V71, P755, DOI 10.1146/annurev.biochem.71.110601.135507; Pipes GCT, 2006, GENE DEV, V20, P1545, DOI 10.1101/gad.1428006; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Vartiainen MK, 2007, SCIENCE, V316, P1749, DOI 10.1126/science.1141084; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	10	12	13	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 22	2007	316	5832					1710	1711		10.1126/science.1145014	http://dx.doi.org/10.1126/science.1145014			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180XE	17588921				2022-12-28	WOS:000247400500035
J	Jakobsson, M; Backman, J; Rudels, B; Nycander, J; Frank, M; Mayer, L; Jokat, W; Sangiorgi, F; O'Regan, M; Brinkhuis, H; King, J; Moran, K				Jakobsson, Martin; Backman, Jan; Rudels, Bert; Nycander, Jonas; Frank, Martin; Mayer, Larry; Jokat, Wilfried; Sangiorgi, Francesca; O'Regan, Matthew; Brinkhuis, Henk; King, John; Moran, Kathryn			The early Miocene onset of a ventilated circulation regime in the Arctic Ocean	NATURE			English	Article							LOMONOSOV RIDGE; FRAM STRAIT; BASIN	Deep-water formation in the northern North Atlantic Ocean and the Arctic Ocean is a key driver of the global thermohaline circulation and hence also of global climate(1). Deciphering the history of the circulation regime in the Arctic Ocean has long been prevented by the lack of data from cores of Cenozoic sediments from the Arctic's deep-sea floor. Similarly, the timing of the opening of a connection between the northern North Atlantic and the Arctic Ocean, permitting deep-water exchange, has been poorly constrained. This situation changed when the first drill cores were recovered from the central Arctic Ocean(2). Here we use these cores to show that the transition from poorly oxygenated to fully oxygenated ('ventilated') conditions in the Arctic Ocean occurred during the later part of early Miocene times. We attribute this pronounced change in ventilation regime to the opening of the Fram Strait. A palaeo-geographic and palaeo-bathymetric reconstruction of the Arctic Ocean, together with a physical oceanographic analysis of the evolving strait and sill conditions in the Fram Strait, suggests that the Arctic Ocean went from an oxygen-poor 'lake stage', to a transitional 'estuarine sea' phase with variable ventilation, and finally to the fully ventilated 'ocean' phase 17.5 Myr ago. The timing of this palaeo-oceanographic change coincides with the onset of the middle Miocene climatic optimum(3), although it remains unclear if there is a causal relationship between these two events.	Stockholm Univ, Dept Geol & Geochem, SE-10691 Stockholm, Sweden; Stockholm Univ, Dept Meteorol, SE-10691 Stockholm, Sweden; Finnish Inst Marine Res, FI-00561 Helsinki, Finland; Univ Kiel, IFM GEOMAR, Leibniz Inst MArine Sci, DE-24148 Kiel, Germany; Univ New Hampshire, Ctr Coastal & Ocean Mapping, Durham, NH 03824 USA; Alfred Wegener Inst Polar Res, DE-27570 Bremerhaven, Germany; Univ Utrecht, Palaeobot & Palynol Lab, NL-3584 Utrecht, Netherlands; Univ Rhode Isl, Grad Sch Oceanog, Narragansett, RI 02882 USA	Stockholm University; Stockholm University; Helmholtz Association; GEOMAR Helmholtz Center for Ocean Research Kiel; University of Kiel; University System Of New Hampshire; University of New Hampshire; Helmholtz Association; Alfred Wegener Institute, Helmholtz Centre for Polar & Marine Research; Utrecht University; University of Rhode Island	Jakobsson, M (corresponding author), Stockholm Univ, Dept Geol & Geochem, SE-10691 Stockholm, Sweden.	martin.jakobsson@geo.su.se	Brinkhuis, Henk/B-4223-2009; Nycander, Jonas/E-1334-2011; O'Regan, Matt/B-2157-2010; Jakobsson, Martin/F-6214-2010; O'Regan, Matt/P-6277-2019	Nycander, Jonas/0000-0002-4414-6859; O'Regan, Matt/0000-0002-6046-1488; Mayer, Larry/0000-0003-1846-5140; Brinkhuis, Henk/0000-0003-0253-6610; Frank, Martin/0000-0002-8606-4421; Jakobsson, Martin/0000-0002-9033-3559; Jokat, Wilfried/0000-0002-7793-5854				AAGAARD K, 1994, POLAR OCEANS THEIR R, P5, DOI DOI 10.1029/GM085P0005; BACKMAN J, 2006, P IODP, V302, DOI DOI 10.2204/IODP.2006; BATTEN DJ, 1996, PALYNOLOGY PRINCIPLE, V3, P1021; Brozena JM, 2003, GEOLOGY, V31, P825, DOI 10.1130/G19528.1; CANDE SC, 1995, J GEOPHYS RES-SOL EA, V100, P6093, DOI 10.1029/94JB03098; Dixon J, 1992, GEOL SURV CAN B, V407, P1, DOI DOI 10.4095/133237; ENGEN O, 2005, THESIS U OSLO; Fahrbach E, 2001, POLAR RES, V20, P217, DOI 10.1111/j.1751-8369.2001.tb00059.x; Jakobsson M, 2000, EOS T AGU, V81, P93, DOI DOI 10.1029/00E000059; JOKAT W, 1995, GEOPHYS J INT, V122, P378; JOKAT W, UNPUB GEOPHYS J INT; Klenke M, 2002, MAR GEOPHYS RES, V23, P367, DOI 10.1023/A:1025764206736; Lane-Serff GF, 2004, DEEP-SEA RES PT II, V51, P321, DOI 10.1016/j.dsr2.2003.07.019; LANGINEN AE, 2006, 4 INT C ARCT MARG IC; LAWVER LA, 1990, ARCTIC OCEAN REGION, VL, P593; LOURENS L, 2004, GEOLOGIC TIME SCALE, P409, DOI DOI 10.1017/CBO9780511536045.022; Miller KG, 2005, SCIENCE, V310, P1293, DOI 10.1126/science.1116412; Moran K, 2006, NATURE, V441, P601, DOI 10.1038/nature04800; MULLER RD, 1993, GEOLOGY, V21, P275, DOI 10.1130/0091-7613(1993)021<0275:RPMRTT>2.3.CO;2; Palike H, 2006, SCIENCE, V314, P1894, DOI 10.1126/science.1133822; Pratt LJ, 2004, DEEP-SEA RES PT II, V51, P351, DOI 10.1016/j.dsr2.2003.06.005; RUDELS B, 1994, GEOPHYS MONOGR SER, V85, P33, DOI DOI 10.1029/GM085P0033; Schauer U, 2004, J GEOPHYS RES-OCEANS, V109, DOI 10.1029/2003JC001823; Stanev E.V., 2005, OCEANOGRAPHY, V18, P56, DOI [10.5670/oceanog.2005.42, DOI 10.5670/0CEAN0G.2005.42]; Stein R, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL026776; VOGT P, 1989, J GEOPHYS RES, V84, P1071; Whitehead J. A., 1974, Geophysical Fluid Dynamics, V6, P101, DOI 10.1080/03091927409365790; Williams Graham L., 1999, Proceedings of the Ocean Drilling Program Scientific Results, V162, P99; Zachos J, 2001, SCIENCE, V292, P686, DOI 10.1126/science.1059412	29	176	182	0	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 21	2007	447	7147					986	990		10.1038/nature05924	http://dx.doi.org/10.1038/nature05924			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180NU	17581581				2022-12-28	WOS:000247373100043
J	Cassenaer, S; Laurent, G				Cassenaer, Stijn; Laurent, Gilles			Hebbian STDP in mushroom bodies facilitates the synchronous flow of olfactory information in locusts	NATURE			English	Article							ODOR REPRESENTATIONS; TEMPORAL INFORMATION; ANTENNAL LOBE; SYNCHRONIZATION; OSCILLATIONS; PROPAGATION; PLASTICITY; RECEPTORS; NEURONS; MEMORY	Odour representations in insects undergo progressive transformations and decorrelation(1-3) from the receptor array to the presumed site of odour learning, the mushroom body(4-7). There, odours are represented by sparse assemblies of Kenyon cells in a large population(2). Using intracellular recordings in vivo, we examined transmission and plasticity at the synapse made by Kenyon cells onto downstream targets in locusts. We find that these individual synapses are excitatory and undergo hebbian spike-timing dependent plasticity (STDP)(8-10) on a+/-25 ms timescale. When placed in the context of odour-evoked Kenyon cell activity (a 20-Hz oscillatory population discharge), this form of STDP enhances the synchronization of the Kenyon cells' targets and thus helps preserve the propagation of the odour-specific codes through the olfactory system.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Laurent, G (corresponding author), CALTECH, Div Biol, 139-74, Pasadena, CA 91125 USA.	laurentg@caltech.edu	Laurent, Gilles/A-4583-2012	Laurent, Gilles/0000-0002-2296-114X				[Anonymous], 2006, ADV NEURAL INFORM PR; Bi GQ, 1998, J NEUROSCI, V18, P10464, DOI 10.1523/jneurosci.18-24-10464.1998; Blum KI, 1996, NEURAL COMPUT, V8, P85, DOI 10.1162/neco.1996.8.1.85; Clyne PJ, 1999, NEURON, V22, P327, DOI 10.1016/S0896-6273(00)81093-4; DEBELLE JS, 1994, SCIENCE, V263, P692, DOI 10.1126/science.8303280; Diesmann M, 1999, NATURE, V402, P529, DOI 10.1038/990101; Drew PJ, 2006, P NATL ACAD SCI USA, V103, P8876, DOI 10.1073/pnas.0600676103; Dubnau J, 2001, NATURE, V411, P476, DOI 10.1038/35078077; Frey U, 1998, TRENDS NEUROSCI, V21, P181, DOI 10.1016/S0166-2236(97)01189-2; Jortner RA, 2007, J NEUROSCI, V27, P1659, DOI 10.1523/JNEUROSCI.4171-06.2007; Leitch B, 1996, J COMP NEUROL, V372, P487; MacLeod K, 1996, SCIENCE, V274, P976, DOI 10.1126/science.274.5289.976; MacLeod K, 1998, NATURE, V395, P693, DOI 10.1038/27201; MAKRAM H, 1997, SCIENCE, V275, P213; Mazor O, 2005, NEURON, V48, P661, DOI 10.1016/j.neuron.2005.09.032; Mehta MR, 2002, NATURE, V417, P741, DOI 10.1038/nature00807; Nowotny T, 2003, J COMPUT NEUROSCI, V15, P271, DOI 10.1023/A:1025825111088; Perez-Orive J, 2004, J NEUROSCI, V24, P6037, DOI 10.1523/JNEUROSCI.1084-04.2004; Perez-Orive J, 2002, SCIENCE, V297, P359, DOI 10.1126/science.1070502; Roberts PD, 2002, BIOL CYBERN, V87, P392, DOI 10.1007/s00422-002-0361-y; Suri RE, 2002, BIOL CYBERN, V87, P440, DOI 10.1007/s00422-002-0355-9; Tanimoto H, 2004, NATURE, V430, P983, DOI 10.1038/430983a; ULTSCH A, 1993, FEBS LETT, V324, P171, DOI 10.1016/0014-5793(93)81387-F; Vogels TP, 2005, ANNU REV NEUROSCI, V28, P357, DOI 10.1146/annurev.neuro.28.061604.135637; Vosshall LB, 2000, CELL, V102, P147, DOI 10.1016/S0092-8674(00)00021-0; Wehr M, 1996, NATURE, V384, P162, DOI 10.1038/384162a0; Weinstock GM, 2006, NATURE, V443, P931, DOI 10.1038/nature05260; Wilson RI, 2004, SCIENCE, V303, P366, DOI 10.1126/science.1090782; Yu DH, 2005, CELL, V123, P945, DOI 10.1016/j.cell.2005.09.037; Zars T., 2000, Science (Washington D C), V288, P672, DOI 10.1126/science.288.5466.672; Zhigulin VP, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.021901	31	202	203	3	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 9	2007	448	7154					709	U12		10.1038/nature05973	http://dx.doi.org/10.1038/nature05973			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197ZY	17581587				2022-12-28	WOS:000248598000048
J	Ferguson, AD; McKeever, BM; Xu, SH; Wisniewski, D; Miller, DK; Yamin, TT; Spencer, RH; Chu, L; Ujjainwalla, F; Cunningham, BR; Evans, JF; Becker, JW				Ferguson, Andrew D.; McKeever, Brian M.; Xu, Shihua; Wisniewski, Douglas; Miller, Douglas K.; Yamin, Ting-Ting; Spencer, Robert H.; Chu, Lin; Ujjainwalla, Feroze; Cunningham, Barry R.; Evans, Jilly F.; Becker, Joseph W.			Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein	SCIENCE			English	Article							LEUKOTRIENE BIOSYNTHESIS INHIBITORS; MICROSOMAL GLUTATHIONE TRANSFERASE; AMINO-ACID-RESIDUES; ACTIVATING PROTEIN; C-4 SYNTHASE; IN-VIVO; BINDING; IDENTIFICATION; LEUKOCYTES; PROJECTION	Leukotrienes are proinflammatory products of arachidonic acid oxidation by 5-lipoxygenase that have been shown to be involved in respiratory and cardiovascular diseases. The integral membrane protein FLAP is essential for leukotriene biosynthesis. We describe the x-ray crystal structures of human FLAP in complex with two leukotriene biosynthesis inhibitors at 4.0 and 4.2 angstrom resolution, respectively. The structures show that inhibitors bind in membrane-embedded pockets of FLAP, which suggests how these inhibitors prevent arachidonic acid from binding to FLAP and subsequently being transferred to 5-lipoxygenase, thereby preventing leukotriene biosynthesis. This structural information provides a platform for the development of therapeutics for respiratory and cardiovascular diseases.	Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA; Merck Res Labs, Dept Infect Dis, Rahway, NJ 07065 USA; Merck Res Labs, Dept Cardiovasc Dis, Rahway, NJ 07065 USA; Merck Res Labs, Dept Pain Res, West Point, PA 19486 USA; Vitae Pharmaceut, Ft Washington, PA 19034 USA; Wyeth Ayerst Res, Collegeville, PA 19426 USA; Cara Therapeut, Tarrytown, NY 10591 USA; Amira Pharmaceut, San Diego, CA 92121 USA	Merck & Company; Merck & Company; Merck & Company; Merck & Company; Pfizer	Becker, JW (corresponding author), Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA.	joseph_becker@merck.com	Wisniewski, Douglas/AAT-9198-2021					ANDERSSON C, 1994, BBA-PROTEIN STRUCT M, V1204, P298, DOI 10.1016/0167-4838(94)90021-3; Binkowski TA, 2003, J MOL BIOL, V332, P505, DOI 10.1016/S0022-2836(03)00882-9; Bresell A, 2005, FEBS J, V272, P1688, DOI 10.1111/j.1742-4658.2005.04596.x; Cordes FS, 2002, J MOL BIOL, V323, P951, DOI 10.1016/S0022-2836(02)01006-9; DIAMANT Z, 1995, J ALLERGY CLIN IMMUN, V95, P42, DOI 10.1016/S0091-6749(95)70151-6; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; Folco G, 2006, PHARMACOL REV, V58, P375, DOI 10.1124/pr.58.3.8; Funk CD, 2005, NAT REV DRUG DISCOV, V4, P664, DOI 10.1038/nrd1796; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Helgadottir A, 2004, NAT GENET, V36, P233, DOI 10.1038/ng1311; Holm PJ, 2006, J MOL BIOL, V360, P934, DOI 10.1016/j.jmb.2006.05.056; Lam BK, 1997, J BIOL CHEM, V272, P13923, DOI 10.1074/jbc.272.21.13923; MANCINI JA, 1993, FEBS LETT, V318, P277, DOI 10.1016/0014-5793(93)80528-3; MANCINI JA, 1994, LIFE SCI, V54, P137; Mandal AK, 2004, P NATL ACAD SCI USA, V101, P6587, DOI 10.1073/pnas.0308523101; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; Plante H, 2006, BIOCHEM J, V393, P211, DOI 10.1042/BJ20060669; Radmark O, 2005, BIOCHEM BIOPH RES CO, V338, P102, DOI 10.1016/j.bbrc.2005.08.013; ROUZER CA, 1990, J BIOL CHEM, V265, P1436; Schmidt- Krey I, 2004, STRUCTURE, V12, P2009, DOI 10.1016/j.str.2004.08.008; Smart OS, 1996, J MOL GRAPH MODEL, V14, P354, DOI 10.1016/S0263-7855(97)00009-X; Thoren S, 2003, J BIOL CHEM, V278, P22199, DOI 10.1074/jbc.M303227200; VICKERS PJ, 1993, J LIPID MEDIATOR, V6, P31; VICKERS PJ, 1992, MOL PHARMACOL, V42, P94; Weinander R, 1997, J BIOL CHEM, V272, P8871; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; YOUNG RN, 1993, J LIPID MEDIATOR, V6, P233; Young RN, 1999, EUR J MED CHEM, V34, P671, DOI 10.1016/S0223-5234(99)00225-1	28	182	190	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 27	2007	317	5837					510	512		10.1126/science.1144346	http://dx.doi.org/10.1126/science.1144346			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194JD	17600184				2022-12-28	WOS:000248339800044
J	Horton, WA; Hall, JG; Hecht, JT				Horton, William A.; Hall, Judith G.; Hecht, Jacqueline T.			Achondroplasia	LANCET			English	Review							FIBROBLAST-GROWTH-FACTOR; CERVICOMEDULLARY-JUNCTION COMPRESSION; SOMATOSENSORY-EVOKED POTENTIALS; SIGNAL-TRANSDUCTION PATHWAYS; UPPER AIRWAY-OBSTRUCTION; BIRTH PREVALENCE RATES; TYROSINE KINASE DOMAIN; FACTOR RECEPTOR 3; QUALITY-OF-LIFE; CHONDROCYTE PROLIFERATION	Achondroplasia is the most common form of short limb dwarfism in human beings, affecting more than 250000 individuals worldwide. More than 95% of patients have the same point mutation in the gene for fibroblast growth factor receptor 3 (FGFR3) and more than 80% of these are new mutations. The mutation, which causes gain of FGFR3 function, affects many tissues, most strikingly the cartilaginous growth plate in the growing skeleton, leading to a variety of manifestations and complications. The biology of FGFR3 and the molecular and cellular consequences of the achondroplasia, mutation are being elucidated, providing a more complete understanding of the disorder and a basis for future treatments targeted directly at relevant pathogenetic pathways. Furthermore, the natural history of the condition, which has been well delineated in childhood and adolescence, is being defined more fully in adults with achondroplasia; most of the serious complications can be modified favourably or prevented by anticipation and early treatment. Possible future treatments include chemical inhibition of receptor signalling, antibody blockade of receptor activation, and alteration of pathways that modulate the downstream propagation of FGFR3 signals.	Shriners Hosp Children, Res Ctr, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; Univ British Columbia, Dept Pediat, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC V5Z 1M9, Canada; British Columbia Childrens Hosp, Dept Pediat, Vancouver, BC V6H 3V4, Canada; Univ Texas, Med Sch Houston, Dept Pediat, Houston, TX USA	Oregon Health & Science University; University of British Columbia; University of British Columbia; BC Childrens Hospital; University of British Columbia; University of Texas System; University of Texas Health Science Center Houston	Horton, WA (corresponding author), Shriners Hosp Children, Res Ctr, 3101 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	wah@shcc.org		Hall, Judith G./0000-0001-5062-491X				Adar R, 2002, J BONE MINER RES, V17, P860, DOI 10.1359/jbmr.2002.17.5.860; ALDEGHERI R, 1988, J BONE JOINT SURG BR, V70, P69, DOI 10.1302/0301-620X.70B1.3339063; Aldegheri R, 2001, J PEDIATR ORTHOP B, V10, P238, DOI 10.1097/00009957-200107000-00015; ALLANSON JE, 1986, OBSTET GYNECOL, V67, P74; Aviezer D, 2003, CURR DRUG TARGETS, V4, P353, DOI 10.2174/1389450033490993; Bartels CF, 2004, AM J HUM GENET, V75, P27, DOI 10.1086/422013; BEIGHTON P, 1981, J BONE JOINT SURG BR, V63, P328, DOI 10.1302/0301-620X.63B3.7263742; Belluardo N, 1997, J COMP NEUROL, V379, P226; Bellus GA, 2000, AM J HUM GENET, V67, P1411, DOI 10.1086/316892; BELLUS GA, 1995, NAT GENET, V10, P357, DOI 10.1038/ng0795-357; BELLUS GA, 1995, AM J HUM GENET, V56, P368; BELLUS GA, 1994, LANCET, V344, P1511, DOI 10.1016/S0140-6736(94)90332-8; Ben-Zvi T, 2006, J CELL SCI, V119, P380, DOI 10.1242/jcs.02740; BERKOWITZ ID, 1990, ANESTHESIOLOGY, V73, P739, DOI 10.1097/00000542-199010000-00021; BERKOWITZ R G, 1991, Ear Nose and Throat Journal, V70, P305; Boor R, 1999, EUR J PEDIATR, V158, P662, DOI 10.1007/s004310051172; BRINKMANN G, 1993, AM J MED GENET, V47, P800, DOI 10.1002/ajmg.1320470540; Bruhl K, 2001, EUR J PEDIATR, V160, P10, DOI 10.1007/PL00008410; Chen L, 1999, J CLIN INVEST, V104, P1517, DOI 10.1172/JCI6690; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; Cho JY, 2004, P NATL ACAD SCI USA, V101, P609, DOI 10.1073/pnas.2237184100; Choi DY, 2001, J BIOL CHEM, V276, P5116, DOI 10.1074/jbc.M002959200; Claus P, 2001, HISTOCHEM CELL BIOL, V115, P147; COHEN MM, 1985, J CRAN GENET DEV BIO, P139; COLAMARIA V, 1991, BRAIN DEV-JPN, V13, P270, DOI 10.1016/S0387-7604(12)80062-3; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; CORDONE M, 1993, PRENATAL DIAG, V13, P395, DOI 10.1002/pd.1970130512; Dailey L, 2003, J CELL BIOL, V161, P1053, DOI 10.1083/jcb.200302075; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DENNIS JP, 1961, BRAIN, V84, P427, DOI 10.1093/brain/84.3.427; Elwood ET, 2003, CLEFT PALATE-CRAN J, V40, P100, DOI 10.1597/1545-1569(2003)040<0100:MDTAUA>2.0.CO;2; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Fowler ES, 1997, J DEV BEHAV PEDIATR, V18, P143, DOI 10.1097/00004703-199706000-00001; FRANCOMANO CA, GENEREVIEWS ACHONDRO; Ganel A, 1996, CLIN ORTHOP RELAT R, P179; Garofalo S, 1999, J BONE MINER RES, V14, P1909, DOI 10.1359/jbmr.1999.14.11.1909; Gollust SE, 2003, AM J MED GENET A, V120A, P447, DOI 10.1002/ajmg.a.20127; Gooding HC, 2002, PRENATAL DIAG, V22, P933, DOI 10.1002/pd.437; Goriely A, 2005, P NATL ACAD SCI USA, V102, P6051, DOI 10.1073/pnas.0500267102; Goriely A, 2003, SCIENCE, V301, P643, DOI 10.1126/science.1085710; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Hafner C, 2006, J INVEST DERMATOL, V126, P2404, DOI 10.1038/sj.jid.5700422; HALL JG, 1982, AM J MED GENET, V13, P105, DOI 10.1002/ajmg.1320130116; HALL JG, 1988, J PEDIATR-US, V112, P166, DOI 10.1016/S0022-3476(88)80157-4; HALL JG, 1988, HUMAN ACHONDROPLASIA, P3; HAMAMCI N, 1993, PARAPLEGIA, V31, P375, DOI 10.1038/sc.1993.62; Hart KC, 2000, ONCOGENE, V19, P3309, DOI 10.1038/sj.onc.1203650; Hart KC, 2001, MOL BIOL CELL, V12, P931, DOI 10.1091/mbc.12.4.931; HECHT JT, 1985, AM J MED GENET, V20, P355, DOI 10.1002/ajmg.1320200219; HECHT JT, 1987, AM J HUM GENET, V41, P454; HECHT JT, 1988, AM J MED GENET, V31, P597, DOI 10.1002/ajmg.1320310314; HECHT JT, 1984, EUR J PEDIATR, V143, P58, DOI 10.1007/BF00442750; HECHT JT, 1991, AM J MED GENET, V41, P208, DOI 10.1002/ajmg.1320410215; HECHT JT, 1989, AM J MED GENET, V32, P528, DOI 10.1002/ajmg.1320320421; Hehr U, 1999, MOL GENET METAB, V68, P139, DOI 10.1006/mgme.1999.2915; Ho NC, 2004, AM J MED GENET A, V131A, P163, DOI 10.1002/ajmg.a.30342; HORTON WA, 1978, J PEDIATR-US, V93, P435, DOI 10.1016/S0022-3476(78)81152-4; Horton WA, 2006, AM J MED GENET A, V140A, P166, DOI 10.1002/ajmg.a.31029; HORTON WA, 1992, AM J MED GENET, V42, P667, DOI 10.1002/ajmg.1320420508; Horton WA, 2006, GROWTH GENETICS HORM, V22, P49; Horton William A, 2002, Rev Endocr Metab Disord, V3, P381, DOI 10.1023/A:1020914026829; Horton William A., 1997, Current Opinion in Pediatrics, V9, P437, DOI 10.1097/00008480-199708000-00021; Hughes SE, 1997, J HISTOCHEM CYTOCHEM, V45, P1005, DOI 10.1177/002215549704500710; Hunter AGW, 1996, AM J MED GENET, V62, P255, DOI 10.1002/(SICI)1096-8628(19960329)62:3<255::AID-AJMG10>3.0.CO;2-J; Hunter AGW, 1996, AM J MED GENET, V62, P91, DOI 10.1002/(SICI)1096-8628(19960301)62:1<91::AID-AJMG18>3.3.CO;2-H; Hunter AGW, 1998, J MED GENET, V35, P705, DOI 10.1136/jmg.35.9.705; Jang JH, 2001, CANCER RES, V61, P3541; Kanai M, 1997, J BIOL CHEM, V272, P6621, DOI 10.1074/jbc.272.10.6621; Kanaka-Gantenbein C, 2001, J PEDIATR ENDOCR MET, V14, P17; KAO SCS, 1989, AM J ROENTGENOL, V153, P565, DOI 10.2214/ajr.153.3.565; Keiper GL, 1999, PEDIATR NEUROSURG, V31, P78, DOI 10.1159/000028838; KODAMA H, 1990, Acta Paediatrica Japonica, V32, P323; Kopits S E, 1988, Basic Life Sci, V48, P241; KOPITS SE, 1980, JOHNS HOPKINS MED J, V146, P206; Kozma C, 2006, AM J MED GENET A, V140A, P303, DOI 10.1002/ajmg.a.31068; Krejci P, 2005, J CELL SCI, V118, P5089, DOI 10.1242/jcs.02618; KURTZ AB, 1986, J ULTRAS MED, V5, P137, DOI 10.7863/jum.1986.5.3.137; Lachman RS, 1997, AM J MED GENET, V69, P33, DOI 10.1002/(SICI)1096-8628(19970303)69:1<33::AID-AJMG7>3.0.CO;2-U; LANGER LO, 1968, CLIN PEDIATR, V7, P474, DOI 10.1177/000992286800700809; LAVINI F, 1990, CLIN ORTHOP RELAT R, P138; Legeai-Mallet L, 1998, J BIOL CHEM, V273, P13007, DOI 10.1074/jbc.273.21.13007; Lievens PMJ, 2006, J MOL BIOL, V357, P783, DOI 10.1016/j.jmb.2006.01.058; Liu ZH, 2002, GENE DEV, V16, P859, DOI 10.1101/gad.965602; Mahomed NN, 1998, AM J MED GENET, V78, P30, DOI 10.1002/(SICI)1096-8628(19980616)78:1<30::AID-AJMG7>3.0.CO;2-P; MARTINEZFRIAS ML, 1991, AM J MED GENET, V38, P622, DOI 10.1002/ajmg.1320380424; Mesoraca A, 1996, PRENATAL DIAG, V16, P764, DOI 10.1002/(SICI)1097-0223(199608)16:8<764::AID-PD941>3.0.CO;2-M; Minina E, 2002, DEV CELL, V3, P439, DOI 10.1016/S1534-5807(02)00261-7; Miyazawa T, 2002, ENDOCRINOLOGY, V143, P3604, DOI 10.1210/en.2002-220307; Mogayzel PJ, 1998, J PEDIATR-US, V132, P667, DOI 10.1016/S0022-3476(98)70358-0; Mohammadi M, 2005, CURR OPIN STRUC BIOL, V15, P506, DOI 10.1016/j.sbi.2005.09.002; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Monsonego-Ornan E, 2000, MOL CELL BIOL, V20, P516, DOI 10.1128/MCB.20.2.516-522.2000; Muenke M, 1997, AM J HUM GENET, V60, P555; Murakami S, 2004, GENE DEV, V18, P290, DOI 10.1101/gad.1179104; MURDOCH JL, 1970, ANN HUM GENET, V33, P227, DOI 10.1111/j.1469-1809.1970.tb01648.x; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; Naski MC, 1998, DEVELOPMENT, V125, P4977; NELSON FW, 1988, ANN NEUROL, V24, P89, DOI 10.1002/ana.410240117; Nicoletti B., 1988, HUMAN ACHONDROPLASIA; NISHI Y, 1993, ACTA ENDOCRINOL-COP, V128, P394, DOI 10.1530/acta.0.1280394; OBERKLAID F, 1979, J MED GENET, V16, P140, DOI 10.1136/jmg.16.2.140; Ohbayashi N, 2002, GENE DEV, V16, P870, DOI 10.1101/gad.965702; OKABA T, 1991, Acta Paediatrica Japonica, V33, P357; ORIOLI IM, 1986, J MED GENET, V23, P328, DOI 10.1136/jmg.23.4.328; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Ornitz DM, 2005, CYTOKINE GROWTH F R, V16, P205, DOI 10.1016/j.cytogfr.2005.02.003; PATEL MD, 1995, RADIOLOGY, V196, P541, DOI 10.1148/radiology.196.2.7617874; PAULI RM, 1995, AM J HUM GENET, V56, P732; Pauli RM, 1997, J PEDIATR ORTHOPED, V17, P726, DOI 10.1097/00004694-199711000-00006; PAULI RM, 1984, J PEDIATR-US, V104, P342, DOI 10.1016/S0022-3476(84)81092-6; PAULI RM, 2005, MANAGEMENT GENETIC S, P13; PIERREKAHN A, 1980, CHILD BRAIN, V7, P205; Potter LR, 2006, ENDOCR REV, V27, P47, DOI 10.1210/er.2005-0014; PYERITZ RE, 1987, AM J MED GENET, V28, P433, DOI 10.1002/ajmg.1320280221; Rauchenberger R, 2003, J BIOL CHEM, V278, P38194, DOI 10.1074/jbc.M303164200; REID CS, 1987, J PEDIATR-US, V110, P522, DOI 10.1016/S0022-3476(87)80542-5; Reynolds KK, 2001, AM J MED GENET, V101, P40, DOI 10.1002/ajmg.1307; RIMOIN DL, 1975, ADV HUM GENET, V5, P1; RIMOIN DL, 1995, AM J HUM GENET, V56, P824; ROIZEN N, 1990, AM J MED GENET, V35, P257, DOI 10.1002/ajmg.1320350222; Rousseau F, 1996, HUM MOL GENET, V5, P509, DOI 10.1093/hmg/5.4.509; ROUSSEAU F, 1995, NAT GENET, V10, P11, DOI 10.1038/ng0595-11; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; RuizGarcia M, 1997, CHILD NERV SYST, V13, P208, DOI 10.1007/s003819770001; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; SALEH M, 1991, ORTHOP CLIN N AM, V22, P589; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schulz S, 2005, PEPTIDES, V26, P1024, DOI 10.1016/j.peptides.2004.08.027; Seino Y, 2000, HORM RES, V53, P53, DOI 10.1159/000023534; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; Shimizu A, 2001, J BIOL CHEM, V276, P11031, DOI 10.1074/jbc.M003535200; Shohat M, 1996, J CLIN ENDOCR METAB, V81, P4033, DOI 10.1210/jc.81.11.4033; SIEBENS AA, 1978, JOHNS HOPKINS MED J, V142, P205; Simsic Janet M, 2006, J Intensive Care Med, V21, P22, DOI 10.1177/0885066605282532; Sisk EA, 1999, OTOLARYNG HEAD NECK, V120, P248, DOI 10.1016/S0194-5998(99)70414-6; Spranger J, 2002, BONE DYSPLASIAS ATLA, V2nd; Stamoyannou L, 1997, AM J MED GENET, V72, P71, DOI 10.1002/(SICI)1096-8628(19971003)72:1<71::AID-AJMG15>3.0.CO;2-R; Stanley G, 2002, J PEDIATR ORTHOPED, V22, P112, DOI 10.1097/00004694-200201000-00023; Steger K, 1998, HISTOCHEM CELL BIOL, V110, P57, DOI 10.1007/s004180050265; STEINBOK P, 1989, J NEUROSURG, V71, P42, DOI 10.3171/jns.1989.71.1.0042; STOKES DC, 1988, CHEST, V93, P364, DOI 10.1378/chest.93.2.364; STOKES DC, 1990, CHEST, V98, P145, DOI 10.1378/chest.98.1.145; STOKES DC, 1983, J PEDIATR-US, V102, P534, DOI 10.1016/S0022-3476(83)80180-2; STOLL C, 1989, CLIN GENET, V35, P88; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Superti-Furga A, 2007, AM J MED GENET A, V143A, P1, DOI 10.1002/ajmg.a.31483; SUPERTIFURGA A, 1995, EUR J PEDIATR, V154, P215, DOI 10.1007/BF01954274; Tasker RC, 1998, ARCH DIS CHILD, V79, P99, DOI 10.1136/adc.79.2.99; Tavormina PL, 1999, AM J HUM GENET, V64, P722, DOI 10.1086/302275; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; THOMAS IT, 1988, AM J DIS CHILD, V142, P989; Thompson NM, 1999, AM J MED GENET, V88, P145, DOI 10.1002/(SICI)1096-8628(19990416)88:2<145::AID-AJMG10>3.0.CO;2-B; Tiemann-Boege I, 2002, P NATL ACAD SCI USA, V99, P14952, DOI 10.1073/pnas.232568699; TODOROV AB, 1981, AM J MED GENET, V9, P19, DOI 10.1002/ajmg.1320090105; Trotter TL, 2005, PEDIATRICS, V116, P771, DOI 10.1542/peds.2005-1440; van Rhijn BWG, 2001, CANCER RES, V61, P1265; Vidrich A, 2004, DEV DYNAM, V230, P114, DOI 10.1002/dvdy.20018; VILARRUBIAS JM, 1990, CLIN ORTHOP RELAT R, P143; WANG H, 1987, RADIOLOGY, V164, P515, DOI 10.1148/radiology.164.2.3602395; Wang YC, 1999, P NATL ACAD SCI USA, V96, P4455, DOI 10.1073/pnas.96.8.4455; WATERS KA, 1993, ARCH DIS CHILD, V69, P191, DOI 10.1136/adc.69.2.191; WATERS KA, 1995, AM J MED GENET, V59, P460, DOI 10.1002/ajmg.1320590412; Weber G, 1996, AM J MED GENET, V61, P396, DOI 10.1002/(SICI)1096-8628(19960202)61:4<396::AID-AJMG17>3.0.CO;2-N; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; Wilkin DJ, 1998, AM J HUM GENET, V63, P711, DOI 10.1086/302000; Yasoda A, 2004, NAT MED, V10, P80, DOI 10.1038/nm971; YAZAKI N, 1994, J NEUROSCI RES, V37, P445, DOI 10.1002/jnr.490370403; You M, 2006, BIOCHEMISTRY-US, V45, P5551, DOI 10.1021/bi060113g; Zhang R, 2006, P NATL ACAD SCI USA, V103, P365, DOI 10.1073/pnas.0507979103; Zucconi M, 1996, J PEDIATR-US, V129, P743, DOI 10.1016/S0022-3476(96)70159-2	171	324	357	2	68	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 14	2007	370	9582					162	172		10.1016/S0140-6736(07)61090-3	http://dx.doi.org/10.1016/S0140-6736(07)61090-3			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	190WP	17630040				2022-12-28	WOS:000248091600031
J	Richards, T				Richards, Tessa			Who is at the helm on patient journeys?	BRITISH MEDICAL JOURNAL			English	Editorial Material												trichards@bmj.com						2007, BRIT MED J, V334, P1130	1	3	3	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUL 14	2007	335	7610					76	76		10.1136/bmj.39272.484248.59	http://dx.doi.org/10.1136/bmj.39272.484248.59			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192JM	17626961	Green Published			2022-12-28	WOS:000248197500031
J	Spinewine, A; Schmader, KE; Barber, N; Hughes, C; Lapane, KL; Swine, C; Hanlon, JT				Spinewine, Anne; Schmader, Kenneth E.; Barber, Nick; Hughes, Carmel; Lapane, Kate L.; Swine, Christian; Hanlon, Joseph T.			Prescribing in elderly people 1 - Appropriate prescribing in elderly people: how well can it be measured and optimised?	LANCET			English	Review							RANDOMIZED CONTROLLED-TRIAL; INAPPROPRIATE MEDICATION USE; DRUG-RELATED MORBIDITY; NURSING-HOME RESIDENTS; QUALITY-OF-CARE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CLINICAL PHARMACIST INTERVENTION; HOSPITALIZED OLDER-ADULTS; LONG-TERM-CARE; POTENTIALLY INAPPROPRIATE	Prescription of medicines is a fundamental component of the care of elderly people, and optimisation of drug prescribing for this group of patients has become an important public-health issue worldwide. Several characteristics of ageing and geriatric medicine affect medication prescribing for elderly people and render the selection of appropriate pharmacotherapy a challenging and complex process. In the first paper in this series we aim to define and categorise appropriate prescribing in elderly people, critically review the instruments that are available to measure it and discuss their predictive validity, critically review recent randomised controlled intervention studies that assessed the effect of optimisation strategies on the appropriateness of prescribing in elderly people, and suggest directions for future research and practice.	Catholic Univ Louvain, Ctr Clin Pharm, Sch Pharm, B-1200 Brussels, Belgium; Duke Univ, Med Ctr, Sch Med, Dept Geriatr Med, Durham, England; Duke Univ, Med Ctr, Aging Ctr, Durham, England; Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Durham, NC USA; Univ London, Sch Pharm, Dept Practice & Policy, London, England; Queens Univ, Sch Pharm, Belfast, Antrim, North Ireland; Brown Med Sch, Dept Community Hlth, Providence, RI USA; Catholic Univ Louvain, Mt Godinne Univ Hosp, Dept Geriatr Med, B-1200 Brussels, Belgium; Univ Pittsburgh, Inst Aging, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Geriatr Med, Pittsburgh, PA USA; Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA USA; Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res, Pittsburgh, PA USA; Vet Affairs Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA	Universite Catholique Louvain; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of London; University College London; University of London School of Pharmacy; Queens University Belfast; Brown University; Universite Catholique Louvain; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System	Spinewine, A (corresponding author), Catholic Univ Louvain, Ctr Clin Pharm, Sch Pharm, UCL 73-70,Ave E Mounier 73, B-1200 Brussels, Belgium.	anne.spinewine@facm.ucl.ac.be			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS016394] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K12HD049109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI051324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG024827, R01AG027017, R01AG014158] Funding Source: NIH RePORTER; AHRQ HHS [U18HS016394] Funding Source: Medline; NIAID NIH HHS [K24AI051324-01] Funding Source: Medline; NIA NIH HHS [P30 AG024827, R01AG14158, R01 AG027017] Funding Source: Medline; NICHD NIH HHS [K12HD049109] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Allard J, 2001, CAN MED ASSOC J, V164, P1291; Anderson G M, 1997, J Eval Clin Pract, V3, P283, DOI 10.1046/j.1365-2753.1997.t01-1-00005.x; Andrade SE, 2003, ARCH INTERN MED, V163, P2052, DOI 10.1001/archinte.163.17.2052; [Anonymous], CONSULT PHARM; [Anonymous], 2003, PRINCIPLES GERIATRIC; Aparasu Rajender R, 2004, Am J Geriatr Pharmacother, V2, P102, DOI 10.1016/S1543-5946(04)90015-3; Barber N, 2005, J CLIN PHARM THER, V30, P533, DOI 10.1111/j.1365-2710.2005.00681.x; BEERS MH, 1991, ARCH INTERN MED, V151, P1825; Beers MH, 1997, ARCH INTERN MED, V157, P1531, DOI 10.1001/archinte.157.14.1531; BEERS MH, 1993, J AM GERIATR SOC, V41, P802, DOI 10.1111/j.1532-5415.1993.tb06173.x; Bernabei R, 1999, J GERONTOL A-BIOL, V54, pM25, DOI 10.1093/gerona/54.1.M25; Blakey SA, 2000, PHARMACOTHERAPY, V20, P1198, DOI 10.1592/phco.20.15.1198.34581; Bogardus ST, 2004, J AM GERIATR SOC, V52, P99, DOI 10.1111/j.1532-5415.2004.52017.x; Boyd CM, 2005, JAMA-J AM MED ASSOC, V294, P716, DOI 10.1001/jama.294.6.716; BRADLEY CP, 1992, BRIT MED J, V304, P294, DOI 10.1136/bmj.304.6822.294; BRADLEY EH, 2004, ISSUE BRIEF COMMONW, V724, P1; Bregnhoj L, 2005, EUR J CLIN PHARMACOL, V61, P769, DOI 10.1007/s00228-005-0963-0; Briesacher BA, 2005, ARCH INTERN MED, V165, P1280, DOI 10.1001/archinte.165.11.1280; Britten N, 2003, QUAL SAF HEALTH CARE, V12, P246, DOI 10.1136/qhc.12.4.246; BROOK RH, 1977, NEW ENGL J MED, V296, P170, DOI 10.1056/NEJM197701202960311; Buetow SA, 1997, SOC SCI MED, V45, P261, DOI 10.1016/S0277-9536(96)00342-5; Bungard TJ, 2001, DRUGS, V61, P2021, DOI 10.2165/00003495-200161140-00002; Campbell SM, 2001, J CLIN PHARM THER, V26, P5, DOI 10.1046/j.1365-2710.2001.00331.x; Carder PC, 2003, J CLIN PHARM THER, V28, P409, DOI 10.1046/j.0269-4727.2003.00511.x; Chang CM, 2005, PHARMACOTHERAPY, V25, P831, DOI 10.1592/phco.2005.25.6.831; Chin MH, 1999, ACAD EMERG MED, V6, P1232, DOI 10.1111/j.1553-2712.1999.tb00139.x; Chutka DS, 2004, MAYO CLIN PROC, V79, P122, DOI 10.4065/79.1.122; Coleman EA, 1999, J AM GERIATR SOC, V47, P775, DOI 10.1111/j.1532-5415.1999.tb03832.x; Cowper PA, 1998, PHARMACOTHERAPY, V18, P327; Cribb A, 1997, HEALTH CARE ANAL, V5, P292, DOI 10.1002/(SICI)1099-1042(199712)5:4<292::AID-HCA238>3.0.CO;2-J; Crotty M, 2004, AGE AGEING, V33, P612, DOI 10.1093/ageing/afh213; Crotty Maria, 2004, Am J Geriatr Pharmacother, V2, P257, DOI 10.1016/j.amjopharm.2005.01.001; *DEP HLTH, 1999, CROWN REP REV PRESCR; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; ELLIOTT A, 2001, AUST J HOSP PHARM, V31, P19; Elliott RA, 2001, INTERN MED J, V31, P529, DOI 10.1046/j.1445-5994.2001.00139.x; Feinstein AR, 1997, AM J MED, V103, P529, DOI 10.1016/S0002-9343(97)00244-1; Feldstein A, 2006, J AM GERIATR SOC, V54, P450, DOI 10.1111/j.1532-5415.2005.00618.x; Fialova D, 2005, JAMA-J AM MED ASSOC, V293, P1348, DOI 10.1001/jama.293.11.1348; Fick D, 2001, J MANAGE CARE PHARM, V7, P407, DOI [10.18553/jmcp.2001.7.5.407, DOI 10.18553/JMCP.2001.7.5.407]; Fick DM, 2004, AM J MANAG CARE, V10, P761; Fick DM, 2003, ARCH INTERN MED, V163, P2716, DOI 10.1001/archinte.163.22.2716; Fillenbaum Gerda G, 2004, Am J Geriatr Pharmacother, V2, P92, DOI 10.1016/S1543-5946(04)90014-1; Fitzgerald LS, 1997, ANN PHARMACOTHER, V31, P543, DOI 10.1177/106002809703100503; Flanagan PS, 2004, ANN PHARMACOTHER, V38, P20, DOI 10.1345/aph.1D295; Fossey J, 2006, BMJ-BRIT MED J, V332, P756, DOI 10.1136/bmj.38782.575868.7C; Franic DM, 2006, PHARMACOTHERAPY, V26, P768, DOI 10.1592/phco.26.6.768; Fu AZ, 2004, J AM GERIATR SOC, V52, P1934, DOI 10.1111/j.1532-5415.2004.52522.x; Fuat A, 2003, BRIT MED J, V326, P196, DOI 10.1136/bmj.326.7382.196; Furniss L, 2000, BRIT J PSYCHIAT, V176, P563, DOI 10.1192/bjp.176.6.563; GARRARD J, 1995, AM J PUBLIC HEALTH, V85, P771, DOI 10.2105/AJPH.85.6.771; GOSNEY M, 1984, LANCET, V2, P564; Grymonpre RE, 2001, INT J PHARM PRACT, V9, P235, DOI DOI 10.1111/j.2042-7174.2001.tb01054.x; Gupta S, 1996, CLIN THER, V18, P183, DOI 10.1016/S0149-2918(96)80189-5; Gurwitz JH, 2002, ARCH INTERN MED, V162, P1670, DOI 10.1001/archinte.162.15.1670; GURWITZ JH, 1990, J AM GERIATR SOC, V38, P542, DOI 10.1111/j.1532-5415.1990.tb02406.x; Hajjar ER, 2005, J AM GERIATR SOC, V53, P1518, DOI 10.1111/j.1532-5415.2005.53523.x; Hammersley VS, 2006, J CLIN PHARM THER, V31, P223, DOI 10.1111/j.1365-2710.2006.00723.x; Hanlon Joseph T, 2004, Am J Geriatr Pharmacother, V2, P3, DOI 10.1016/S1543-5946(04)90002-5; Hanlon JT, 2001, J AM GERIATR SOC, V49, P200, DOI 10.1046/j.1532-5415.2001.49042.x; Hanlon JT, 2004, ANN PHARMACOTHER, V38, P9, DOI 10.1345/aph.1D313; Hanlon JT, 2002, MED CARE, V40, P166, DOI 10.1097/00005650-200202000-00011; Hanlon JT, 2002, J AM GERIATR SOC, V50, P26, DOI 10.1046/j.1532-5415.2002.50004.x; Hanlon JT, 1996, AM J MED, V100, P428, DOI 10.1016/S0002-9343(97)89519-8; HANLON JT, 1992, J CLIN EPIDEMIOL, V45, P1045, DOI 10.1016/0895-4356(92)90144-C; Heisler M, 2004, MED CARE, V42, P626, DOI 10.1097/01.mlr.0000129352.36733.cc; Higashi T, 2005, ANN INTERN MED, V143, P274, DOI 10.7326/0003-4819-143-4-200508160-00008; Higashi T, 2004, ANN INTERN MED, V140, P714, DOI 10.7326/0003-4819-140-9-200405040-00011; Holland R, 2005, BMJ-BRIT MED J, V330, P293, DOI 10.1136/bmj.38338.674583.AE; Holmes HM, 2006, ARCH INTERN MED, V166, P605, DOI 10.1001/archinte.166.6.605; Hughes CM, 1999, BRIT MED J, V319, P1060, DOI 10.1136/bmj.319.7216.1060; Hughes CM, 2000, MED CARE, V38, P1164, DOI 10.1097/00005650-200012000-00003; Judge J, 2006, J AM MED INFORM ASSN, V13, P385, DOI 10.1197/jamia.M1945; Juurlink DN, 2003, JAMA-J AM MED ASSOC, V289, P1652, DOI 10.1001/jama.289.13.1652; Kassam R, 2003, ANN PHARMACOTHER, V37, P40; Klarin I, 2005, DRUG AGING, V22, P69, DOI 10.2165/00002512-200522010-00005; Ko DT, 2005, ARCH INTERN MED, V165, P2486, DOI 10.1001/archinte.165.21.2486; Krska J, 2001, AGE AGEING, V30, P205, DOI 10.1093/ageing/30.3.205; Kunin CM, 2004, ARCH INTERN MED, V164, P1701, DOI 10.1001/archinte.164.15.1701-a; Kuzuya M, 2006, J AM GERIATR SOC, V54, P598, DOI 10.1111/j.1532-5415.2006.00659.x; Laroche ML, 2007, BRIT J CLIN PHARMACO, V63, P177, DOI 10.1111/j.1365-2125.2006.02831.x; Laroche ML, 2006, DRUG AGING, V23, P49, DOI 10.2165/00002512-200623010-00005; Larson EB, 2001, ANN INTERN MED, V134, P997, DOI 10.7326/0003-4819-134-10-200105150-00013; Lau DT, 2005, ARCH INTERN MED, V165, P68, DOI 10.1001/archinte.165.1.68; Lilford R, 2004, LANCET, V363, P1147, DOI 10.1016/S0140-6736(04)15901-1; Lloyd F., 2007, INT J PHARM PRACT, V15, P31, DOI [10.1211/ijpp.15.1.0006, DOI 10.1211/ijpp.15.1.0006]; LUISI AF, 1995, PHARMACOTHERAPY, V15, P124; Mackinnon Neil J, 2002, J Manag Care Pharm, V8, P365; Majumdar SR, 2004, ANN INTERN MED, V141, P366, DOI 10.7326/0003-4819-141-5-200409070-00011; Mangoni AA, 2004, BRIT J CLIN PHARMACO, V57, P6, DOI 10.1046/j.1365-2125.2003.02007.x; Marshall MN, 2003, QUAL SAF HEALTH CARE, V12, P8, DOI 10.1136/qhc.12.1.8; Masoudi FA, 2004, CIRCULATION, V110, P724, DOI 10.1161/01.CIR.0000138934.28340.ED; McLeod PJ, 1997, CAN MED ASSOC J, V156, P385; Mendelson G, 1998, J AM GERIATR SOC, V46, P1423, DOI 10.1111/j.1532-5415.1998.tb06011.x; Meredith S, 2002, J AM GERIATR SOC, V50, P1484, DOI 10.1046/j.1532-5415.2002.50402.x; Morris CJ, 2003, J CLIN PHARM THER, V28, P295, DOI 10.1046/j.1365-2710.2003.00496.x; Morris CJ, 2002, INT J QUAL HEALTH C, V14, P183, DOI 10.1093/oxfordjournals.intqhc.a002610; Naugler C T, 2000, Can J Clin Pharmacol, V7, P103; NELSON EA, 1992, GERONTOLOGIST, V32, P17, DOI 10.1093/geront/32.1.17; Oborne CA, 1997, BRIT J CLIN PHARMACO, V43, P91, DOI 10.1111/j.1365-2125.1997.tb00038.x; Oborne CA, 2003, AGE AGEING, V32, P102; Oborne CA, 2002, AGE AGEING, V31, P435, DOI 10.1093/ageing/31.6.435; Onder G, 2003, EUR J CLIN PHARMACOL, V59, P157, DOI 10.1007/s00228-003-0600-8; Onder G, 2005, EUR J CLIN PHARMACOL, V61, P453, DOI 10.1007/s00228-005-0928-3; Page Robert L 2nd, 2006, Am J Geriatr Pharmacother, V4, P297; PATTERSON SP, IN PRESS PHARM WORLD; Perri M, 2005, ANN PHARMACOTHER, V39, P405, DOI 10.1345/aph.1E230; Peterson JF, 2005, ARCH INTERN MED, V165, P802, DOI 10.1001/archinte.165.7.802; Pimlott NJG, 2003, CAN MED ASSOC J, V168, P835; Pitkala KH, 2001, DRUG AGING, V18, P143, DOI 10.2165/00002512-200118020-00007; Pronovost PJ, 2004, LANCET, V363, P1061, DOI 10.1016/S0140-6736(04)15843-1; Rahme E, 2005, AM J MED, V118, P1262, DOI 10.1016/j.amjmed.2005.03.026; Raivio MM, 2006, DRUG AGING, V23, P333, DOI 10.2165/00002512-200623040-00006; Rask KJ, 2005, AM J MANAG CARE, V11, P145; Ray WA, 2001, MED CARE, V39, P425, DOI 10.1097/00005650-200105000-00003; Roberts MS, 2001, BRIT J CLIN PHARMACO, V51, P257, DOI 10.1046/j.1365-2125.2001.00347.x; Robertson HA, 2002, CLIN THER, V24, P1595, DOI 10.1016/S0149-2918(02)80063-7; Rollnick S, 2005, BMJ-BRIT MED J, V331, P961, DOI 10.1136/bmj.331.7522.961; Saltvedt I, 2005, EUR J CLIN PHARMACOL, V61, P921, DOI 10.1007/s00228-005-0046-2; SAMSA GP, 1994, J CLIN EPIDEMIOL, V47, P891, DOI 10.1016/0895-4356(94)90192-9; Schiff GD, 1998, JAMA-J AM MED ASSOC, V279, P1024, DOI 10.1001/jama.279.13.1024; Schmader KE, 2004, AM J MED, V116, P394, DOI 10.1016/j.amjmed.2003.10.031; Schmader KE, 1997, ANN PHARMACOTHER, V31, P529, DOI 10.1177/106002809703100501; Sellors J, 2003, CAN MED ASSOC J, V169, P17; Shekelle PG, 2001, ANN INTERN MED, V135, P647, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00003; Simon SR, 2005, J AM GERIATR SOC, V53, P2165, DOI 10.1111/j.1532-5415.2005.00498.x; Simon SR, 2006, J AM GERIATR SOC, V54, P963, DOI 10.1111/j.1532-5415.2006.00734.x; Simonson W, 2005, DRUG AGING, V22, P559, DOI 10.2165/00002512-200522070-00002; Sloane PD, 2004, ARCH INTERN MED, V164, P2031, DOI 10.1001/archinte.164.18.2031; Solomon DH, 2003, J AM GERIATR SOC, V51, P902, DOI 10.1046/j.1365-2389.2003.513331.x; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; Spinewine A, 2006, J AM GERIATR SOC, V54, P720, DOI 10.1111/j.1532-5415.2006.00668_8.x; Spinewine A, 2005, BMJ-BRIT MED J, V331, P935, DOI 10.1136/bmj.38551.410012.06; Spinewine A, 2007, J AM GERIATR SOC, V55, P658, DOI 10.1111/j.1532-5415.2007.01132.x; Steel N, 2004, QUAL SAF HEALTH CARE, V13, P260, DOI 10.1136/qshc.2004.010280; Stein CM, 2001, MED CARE, V39, P436; Steinman MA, 2006, J AM GERIATR SOC, V54, P1516, DOI 10.1111/j.1532-5415.2006.00889.x; Strandberg TE, 2006, AM HEART J, V152, P585, DOI 10.1016/j.ahj.2006.02.006; Strothers HS, 2005, J AM GERIATR SOC, V53, P456, DOI 10.1111/j.1532-5415.2005.53164.x; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; Tamblyn R, 2003, CAN MED ASSOC J, V169, P549; Tinetti ME, 2004, NEW ENGL J MED, V351, P2870, DOI 10.1056/NEJMsb042458; *UN DIV SOC POL DE, 2002, 2 WORLD ASS AG MADR; Unutzer J, 2004, J AM GERIATR SOC, V52, P1916, DOI 10.1111/j.1532-5415.2004.52519.x; van Eijk MEC, 2001, BRIT MED J, V322, P654, DOI 10.1136/bmj.322.7287.654; Viktil KK, 2004, ANN PHARMACOTHER, V38, P942, DOI 10.1345/aph.1D531; Wenger NS, 2001, ANN INTERN MED, V135, P642, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00002; Williams ME, 2004, J AM GERIATR SOC, V52, P93, DOI 10.1111/j.1532-5415.2004.52016.x; Woodhouse KW, 1997, AGE AGEING, V26, P245, DOI 10.1093/ageing/26.4.245; Zermansky AG, 2001, BRIT MED J, V323, P1340, DOI 10.1136/bmj.323.7325.1340; Zermansky AG, 2006, AGE AGEING, V35, P586, DOI 10.1093/ageing/afl075; Zuckerman IH, 2006, MED CARE, V44, P722, DOI 10.1097/01.mlr.0000215849.15769.be	152	684	706	3	78	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 14	2007	370	9582					173	184		10.1016/S0140-6736(07)61091-5	http://dx.doi.org/10.1016/S0140-6736(07)61091-5			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	190WP	17630041				2022-12-28	WOS:000248091600032
J	Williams, G				Williams, Gareth			Should medical journals carry drug advertising? No	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Bristol, Fac Med & Dent, Bristol BS2 8DZ, Avon, England	University of Bristol		Gareth.Williams@bris.ac.uk							0	4	4	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUL 14	2007	335	7610					75	75		10.1136/bmj.39259.481134.AD	http://dx.doi.org/10.1136/bmj.39259.481134.AD			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	192JM	17626960	Green Published			2022-12-28	WOS:000248197500030
J	Depue, BE; Curran, T; Banich, MT				Depue, Brendan E.; Curran, Tim; Banich, Marie T.			Prefrontal regions orchestrate suppression of emotional memories via a two-phase process	SCIENCE			English	Article							CORTEX; FMRI; AMYGDALA; MECHANISMS	Whether memories can be suppressed has been a controversial issue in psychology and cognitive neuroscience for decades. We found evidence that emotional memories are suppressed via two time-differentiated neural mechanisms: (i) an initial suppression by the right inferior frontal gyrus over regions supporting sensory components of the memory representation ( visual cortex, thalamus), followed by (ii) right medial frontal gyrus control over regions supporting multimodal and emotional components of the memory representation ( hippocampus, amygdala), both of which are influenced by fronto-polar regions. These results indicate that memory suppression does occur and, at least in nonpsychiatric populations, is under the control of prefrontal regions.	Univ Colorado, Dept Psychol, Boulder, CO 80309 USA; Univ Colorado, Ctr Neurosci, Boulder, CO 80309 USA; Univ Colorado, Inst Cognit Sci, Boulder, CO 80309 USA; Univ Denver Hlth Sci, Dept Psychiat, Denver, CO 80208 USA	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus	Depue, BE (corresponding author), Univ Colorado, Dept Psychol, Campus Box 345, Boulder, CO 80309 USA.	depue@colorado.edu		BANICH, MARIE/0000-0001-9373-9194				Anderson MC, 2004, SCIENCE, V303, P232, DOI 10.1126/science.1089504; Anderson MC, 2001, NATURE, V410, P366, DOI 10.1038/35066572; Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; Beauregard M, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-18-j0001.2001; Depue BE, 2006, PSYCHOL SCI, V17, P441, DOI 10.1111/j.1467-9280.2006.01725.x; Eisenberger NI, 2003, SCIENCE, V302, P290, DOI 10.1126/science.1089134; Garavan H, 1999, P NATL ACAD SCI USA, V96, P8301, DOI 10.1073/pnas.96.14.8301; Gauthier I, 2000, NAT NEUROSCI, V3, P191, DOI 10.1038/72140; Hamann S, 2001, TRENDS COGN SCI, V5, P394, DOI 10.1016/S1364-6613(00)01707-1; Hertel PT, 2005, PSYCHON B REV, V12, P484, DOI 10.3758/BF03193792; Jacoby LL, 1999, DUAL-PROCESS THEORIES IN SOCIAL PSYCHOLOGY, P383; Kastner S, 2004, J NEUROPHYSIOL, V91, P438, DOI 10.1152/jn.00553.2003; Kastner S, 1998, SCIENCE, V282, P108, DOI 10.1126/science.282.5386.108; Kihlstrom JF, 2002, TRENDS COGN SCI, V6, P502, DOI 10.1016/S1364-6613(02)02006-5; Knoch D, 2006, SCIENCE, V314, P829, DOI 10.1126/science.1129156; Lang PJ, 1998, PSYCHOPHYSIOLOGY, V35, P199, DOI 10.1017/S0048577298001991; Loftus E, 2003, NAT REV NEUROSCI, V4, P231, DOI 10.1038/nrn1054; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; O'Reilly RC, 2006, SCIENCE, V314, P91, DOI 10.1126/science.1127242; Ochsner KN, 2002, J COGNITIVE NEUROSCI, V14, P1215, DOI 10.1162/089892902760807212; Phelps EA, 2004, CURR OPIN NEUROBIOL, V14, P198, DOI 10.1016/j.conb.2004.03.015; Purdon C, 1999, BEHAV RES THER, V37, P1029, DOI 10.1016/S0005-7967(98)00200-9; Ramnani N, 2004, NAT REV NEUROSCI, V5, P184, DOI 10.1038/nrn1343; Raye CL, 2007, CORTEX, V43, P135, DOI 10.1016/S0010-9452(08)70451-9; ROLLS ET, 1984, HUM NEUROBIOL, V3, P209; Sakai K, 2006, J NEUROSCI, V26, P1211, DOI 10.1523/JNEUROSCI.3887-05.2006; Urry HL, 2006, J NEUROSCI, V26, P4415, DOI 10.1523/JNEUROSCI.3215-05.2006; vanderKolk BA, 1996, AM J PSYCHIAT, V153, P83; vanderKolk BA, 1997, ANN NY ACAD SCI, V821, P99; Wagner AD, 2001, NEUROIMAGE, V14, P1337, DOI 10.1006/nimg.2001.0936; Wraga M, 2000, J COGNITIVE NEUROSCI, P75	31	301	319	1	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 13	2007	317	5835					215	219		10.1126/science.1139560	http://dx.doi.org/10.1126/science.1139560			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189DC	17626877	Green Submitted			2022-12-28	WOS:000247968600033
J	Giorgi, C; Yeo, GW; Stone, ME; Katz, DB; Burge, C; Turrigiano, G; Moore, MJ				Giorgi, Corinna; Yeo, Gene W.; Stone, Martha E.; Katz, Donald B.; Burge, Christopher; Turrigiano, Gina; Moore, Melissa J.			The EJC factor eIF4AIII modulates synaptic strength and neuronal protein expression	CELL			English	Article							MESSENGER-RNA LOCALIZATION; MAMMALIAN-CELLS; ABERRANT TERMINATION; STAUFEN; TRANSLATION; ARC/ARG3.1; NUCLEAR; AMPA; PLASTICITY; COMPLEX	tProper neuronal function and several forms of synaptic plasticity are highly dependent on precise control of mRNA translation, particularly in dendrites. We find that eIF4AIII, a core exon junction complex ( EJC) component loaded onto mRNAs by pre- mRNA splicing, is associated with neuronal mRNA granules and dendritic mRNAs. eIF4AIII knockdown markedly increases both synaptic strength and GLUR1 AMPA receptor abundance at synapses. eIF4AIII depletion also increases ARC, a protein required for maintenance of long- term potentiation; arc mRNA, one of the most abundant in dendrites, is a natural target for nonsense-mediated decay ( NMD). Numerous new NMD candidates, some with potential to affect synaptic activity, were also identified computationally. Two models are presented for how translation- dependent decay pathways such as NMD might advantageously function as critical brakes for protein synthesis in cells such as neurons that are highly dependent on spatially and temporally restricted protein expression.	Brandeis Univ, Howard Hughes Med Inst, Dept Biochem, Waltham, MA 02454 USA; Brandeis Univ, Dept Psychol, Waltham, MA 02454 USA; Brandeis Univ, Volen Ctr Complex Syst, Waltham, MA 02454 USA; Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; Salk Inst Biol Studies, Crick Jacobs Ctr Computat & Theoret Biol, La Jolla, CA 92037 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Brandeis University; Howard Hughes Medical Institute; Brandeis University; Brandeis University; Brandeis University; Salk Institute; Massachusetts Institute of Technology (MIT)	Moore, MJ (corresponding author), Brandeis Univ, Howard Hughes Med Inst, Dept Biochem, Waltham, MA 02454 USA.	mmoore@brandeis.edu	giorgi, corinna/G-7794-2011; Burge, Christopher B./AAH-2177-2020; Yeo, Gene/AAE-7676-2019	Yeo, Gene/0000-0002-0799-6037; Stone, Martha/0000-0001-6771-994X; giorgi, corinna/0000-0003-1065-369X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036853] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amrani N, 2006, BIOCHEM SOC T, V34, P39, DOI 10.1042/BST0340039; Amrani N, 2004, NATURE, V432, P112, DOI 10.1038/nature03060; Ashraf SI, 2006, CELL, V124, P191, DOI 10.1016/j.cell.2005.12.017; Ballut L, 2005, NAT STRUCT MOL BIOL, V12, P861, DOI 10.1038/nsmb990; Barbee SA, 2006, NEURON, V52, P997, DOI 10.1016/j.neuron.2006.10.028; Bingol B, 2005, CURR OPIN NEUROBIOL, V15, P536, DOI 10.1016/j.conb.2005.08.016; Bingol B, 2006, NATURE, V441, P1144, DOI 10.1038/nature04769; Buhler M, 2006, NAT STRUCT MOL BIOL, V13, P462, DOI 10.1038/nsmb1081; Chowdhury S, 2006, NEURON, V52, P445, DOI 10.1016/j.neuron.2006.08.033; Conti E, 2005, CURR OPIN CELL BIOL, V17, P316, DOI 10.1016/j.ceb.2005.04.005; Czaplinski K, 2006, TRENDS BIOCHEM SCI, V31, P687, DOI 10.1016/j.tibs.2006.10.007; Dostie J, 2002, CURR BIOL, V12, P1060, DOI 10.1016/S0960-9822(02)00902-8; Du TG, 2007, SEMIN CELL DEV BIOL, V18, P171, DOI 10.1016/j.semcdb.2007.01.010; Farina KL, 2002, TRENDS CELL BIOL, V12, P466, DOI 10.1016/S0962-8924(02)02357-7; Giorgi C, 2007, SEMIN CELL DEV BIOL, V18, P186, DOI 10.1016/j.semcdb.2007.01.002; Glanzer J, 2005, P NATL ACAD SCI USA, V102, P16859, DOI 10.1073/pnas.0503783102; Guzowski JF, 2000, J NEUROSCI, V20, P3993; Hachet O, 2004, NATURE, V428, P959, DOI 10.1038/nature02521; Hillman RT, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-2-r8; Ichikawa H, 2003, J PHARMACOL SCI, V91, P247; Ishigaki Y, 2001, CELL, V106, P607, DOI 10.1016/S0092-8674(01)00475-5; Ju W, 2004, NAT NEUROSCI, V7, P244, DOI 10.1038/nn1189; Kanai Y, 2004, NEURON, V43, P513, DOI 10.1016/j.neuron.2004.07.022; Kiebler MA, 2005, TRENDS BIOCHEM SCI, V30, P228, DOI 10.1016/j.tibs.2005.03.005; Kiebler MA, 1999, J NEUROSCI, V19, P288, DOI 10.1523/JNEUROSCI.19-01-00288.1999; Kim YK, 2005, CELL, V120, P195, DOI 10.1016/j.cell.2004.11.050; Kindler S, 2005, ANNU REV CELL DEV BI, V21, P223, DOI 10.1146/annurev.cellbio.21.122303.120653; Klann E, 2004, NAT REV NEUROSCI, V5, P931, DOI 10.1038/nrn1557; Lai DM, 2006, RNA, V12, P1446, DOI 10.1261/rna.94306; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Li P, 1997, CELL, V90, P437, DOI 10.1016/S0092-8674(00)80504-8; Macchi P, 2003, J NEUROSCI, V23, P5778; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; Mendell JT, 2004, NAT GENET, V36, P1073, DOI 10.1038/ng1429; Micklem DR, 2000, EMBO J, V19, P1366, DOI 10.1093/emboj/19.6.1366; Monshausen M, 2004, NEUROMOL MED, V6, P127, DOI 10.1385/NMM:6:2-3:127; Moore MJ, 2005, SCIENCE, V309, P1514, DOI 10.1126/science.1111443; Nott A, 2004, GENE DEV, V18, P210, DOI 10.1101/gad.1163204; Palacios IM, 2004, NATURE, V427, P753, DOI 10.1038/nature02351; Plath N, 2006, NEURON, V52, P437, DOI 10.1016/j.neuron.2006.08.024; Schratt GM, 2006, NATURE, V439, P283, DOI 10.1038/nature04367; Shepherd JD, 2006, NEURON, V52, P475, DOI 10.1016/j.neuron.2006.08.034; Shibuya T, 2004, NAT STRUCT MOL BIOL, V11, P346, DOI 10.1038/nsmb750; St Johnston D, 2005, NAT REV MOL CELL BIO, V6, P363, DOI 10.1038/nrm1643; Steward O, 2001, NEURON, V30, P227, DOI 10.1016/S0896-6273(01)00275-6; Steward O, 2003, NEURON, V40, P347, DOI 10.1016/S0896-6273(03)00635-4; Steward O, 1998, NEURON, V21, P741, DOI 10.1016/S0896-6273(00)80591-7; Steward O, 2002, NEUROBIOL LEARN MEM, V78, P508, DOI 10.1006/nlme.2002.4102; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Sutton MA, 2005, J NEUROBIOL, V64, P116, DOI 10.1002/neu.20152; Sutton MA, 2006, CELL, V125, P785, DOI 10.1016/j.cell.2006.03.040; Tang SJ, 2001, NEURON, V32, P463, DOI 10.1016/S0896-6273(01)00493-7; Tange TO, 2005, RNA, V11, P1869, DOI 10.1261/rna.2155905; Tange TO, 2004, CURR OPIN CELL BIOL, V16, P279, DOI 10.1016/j.ceb.2004.03.012; Turrigiano GG, 2004, NAT REV NEUROSCI, V5, P97, DOI 10.1038/nrn1327; Turrigiano GG, 1998, NATURE, V391, P892, DOI 10.1038/36103; Tzingounis AV, 2006, NEURON, V52, P403, DOI 10.1016/j.neuron.2006.10.016; Ule J, 2006, CURR OPIN NEUROBIOL, V16, P102, DOI 10.1016/j.conb.2006.01.003; Vanderklish PW, 2005, GENES BRAIN BEHAV, V4, P360, DOI 10.1111/j.1601-183X.2005.00134.x; Verde EMR, 2006, NEURON, V52, P461, DOI 10.1016/j.neuron.2006.09.031; Wallace CS, 1998, J NEUROSCI, V18, P26; Waltereit R, 2001, J NEUROSCI, V21, P5484, DOI 10.1523/JNEUROSCI.21-15-05484.2001; Watt AJ, 2000, NEURON, V26, P659, DOI 10.1016/S0896-6273(00)81202-7; Weil JE, 2006, RNA, V12, P102, DOI 10.1261/rna.2129806; Wittmann J, 2006, MOL CELL BIOL, V26, P1272, DOI 10.1128/MCB.26.4.1272-1287.2006; [No title captured]	67	219	223	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 13	2007	130	1					179	191		10.1016/j.cell.2007.05.028	http://dx.doi.org/10.1016/j.cell.2007.05.028			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	197WK	17632064	Bronze			2022-12-28	WOS:000248587000020
J	Goodnow, CC				Goodnow, Christopher C.			Multistep pathogenesis of autoimmune disease	CELL			English	Review							FAS-MEDIATED APOPTOSIS; NF-KAPPA-B; T-CELLS; LYMPHOPROLIFERATIVE SYNDROME; CD28 COSTIMULATION; SYSTEMIC AUTOIMMUNITY; SOMATIC MUTATION; SELF-TOLERANCE; MICE DEFICIENT; RARE VARIANTS		Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia; Australian Natl Univ, Australian Phenom Facil, Canberra, ACT 2601, Australia	Australian National University; John Curtin School of Medical Research; Australian National University	Goodnow, CC (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Garran Rd,POB 334, Canberra, ACT 2601, Australia.	chris.goodnow@anu.edu.au	Goodnow, Christopher C/V-8108-2018	Goodnow, Christopher C/0000-0001-5296-6155	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Araten DJ, 2005, CANCER RES, V65, P8111, DOI 10.1158/0008-5472.CAN-04-1198; Araten DJ, 1999, P NATL ACAD SCI USA, V96, P5209, DOI 10.1073/pnas.96.9.5209; Bende RJ, 2005, J EXP MED, V201, P1229, DOI 10.1084/jem.20050068; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bernatsky S, 2005, ARTHRITIS RHEUM-US, V52, P1481, DOI 10.1002/art.21029; BERNATSKY S, 2006, NONHODGKINS LYMPHOMA; Betterle C, 1998, J CLIN ENDOCR METAB, V83, P1049, DOI 10.1210/jc.83.4.1049; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Buckler JL, 2006, J IMMUNOL, V177, P4262, DOI 10.4049/jimmunol.177.7.4262; Burnet F.M., 1972, AUTOIMMUNITY AUTOIMM; Cappione A, 2005, J CLIN INVEST, V115, P3205, DOI 10.1172/JCI24179; Casola S, 2004, NAT IMMUNOL, V5, P317, DOI 10.1038/ni1036; Cellier C, 2000, LANCET, V356, P203, DOI 10.1016/S0140-6736(00)02481-8; Chan OTM, 1999, IMMUNOL REV, V169, P107, DOI 10.1111/j.1600-065X.1999.tb01310.x; Chapman CJ, 1996, BLOOD, V88, P3562, DOI 10.1182/blood.V88.9.3562.bloodjournal8893562; Chen C, 2006, J IMMUNOL, V176, P5183, DOI 10.4049/jimmunol.176.9.5183; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; Corcos D, 2001, J IMMUNOL, V166, P3083, DOI 10.4049/jimmunol.166.5.3083; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Egle A, 2004, BLOOD, V103, P2276, DOI 10.1182/blood-2003-07-2469; Erickson RP, 2003, MUTAT RES-REV MUTAT, V543, P125, DOI 10.1016/S1383-5742(03)00010-3; Fairhurst AM, 2006, ADV IMMUNOL, V92, P1, DOI 10.1016/S0065-2776(06)92001-X; Fearnhead NS, 2004, P NATL ACAD SCI USA, V101, P15992, DOI 10.1073/pnas.0407187101; Fearon DT, 2000, ANNU REV IMMUNOL, V18, P393, DOI 10.1146/annurev.immunol.18.1.393; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543; Glynne R, 2000, NATURE, V403, P672, DOI 10.1038/35001102; Goodnow CC, 2006, SCIENCE, V312, P1606, DOI 10.1126/science.1129797; Goodnow CC, 2005, NATURE, V435, P590, DOI 10.1038/nature03724; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; Gregersen PK, 2006, SEMIN IMMUNOL, V18, P214, DOI 10.1016/j.smim.2006.03.009; Gronbaek K, 1998, BLOOD, V92, P3018; Grumont RJ, 2002, MOL CELL, V10, P1283, DOI 10.1016/S1097-2765(02)00779-7; Haag-Liautard C, 2007, NATURE, V445, P82, DOI 10.1038/nature05388; Heissmeyer V, 2004, NAT IMMUNOL, V5, P255, DOI 10.1038/ni1047; Holzelova E, 2004, NEW ENGL J MED, V351, P1409, DOI 10.1056/NEJMoa040036; Hussell T, 1996, J PATHOL, V178, P122, DOI 10.1002/(SICI)1096-9896(199602)178:2<122::AID-PATH486>3.0.CO;2-D; Ignatowicz L, 1996, CELL, V84, P521, DOI 10.1016/S0092-8674(00)81028-4; JEVNIKAR AM, 1994, J EXP MED, V179, P1137, DOI 10.1084/jem.179.4.1137; Jiang WY, 2005, J EXP MED, V202, P805, DOI 10.1084/jem.20050693; Jones RG, 2002, J EXP MED, V196, P335, DOI 10.1084/jem.20020307; Kane LP, 2002, TRENDS IMMUNOL, V23, P413, DOI 10.1016/S1471-4906(02)02264-0; Kim JM, 2007, NAT IMMUNOL, V8, P191, DOI 10.1038/ni1428; KOH DR, 1995, EUR J IMMUNOL, V25, P2558, DOI 10.1002/eji.1830250923; Komori H, 2006, J IMMUNOL, V176, P395, DOI 10.4049/jimmunol.176.1.395; Kovanen PE, 2004, IMMUNOL REV, V202, P67, DOI 10.1111/j.0105-2896.2004.00203.x; Kramer D, 1999, SCHWEIZ ARCH VOLKSKU, V95, P1; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; Li MO, 2006, IMMUNITY, V25, P455, DOI 10.1016/j.immuni.2006.07.011; Liston A, 2005, IMMUNOL REV, V204, P87, DOI 10.1111/j.0105-2896.2005.00253.x; Liston A, 2004, IMMUNITY, V21, P817, DOI 10.1016/S1074-7613(04)00313-9; Liston A, 2003, NAT IMMUNOL, V4, P350, DOI 10.1038/ni906; Ma J, 1996, J IMMUNOL, V157, P417; Maldonado MA, 1999, J IMMUNOL, V162, P6322; Marie JC, 2006, IMMUNITY, V25, P441, DOI 10.1016/j.immuni.2006.07.012; Marsh DJ, 1999, HUM MOL GENET, V8, P1461, DOI 10.1093/hmg/8.8.1461; Marshak-Rothstein A, 2006, NAT REV IMMUNOL, V6, P823, DOI 10.1038/nri1957; MERINO R, 1989, EUR J IMMUNOL, V19, P2131, DOI 10.1002/eji.1830191124; Muschen M, 2000, J EXP MED, V192, P1833, DOI 10.1084/jem.192.12.1833; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Narayan P, 2006, MOL CELL BIOL, V26, P2327, DOI 10.1128/MCB.26.6.2327-2336.2006; Pisitkun P, 2006, SCIENCE, V312, P1669, DOI 10.1126/science.1124978; Pritchard JK, 2001, AM J HUM GENET, V69, P124, DOI 10.1086/321272; RATHMELL JC, 1994, J IMMUNOL, V153, P2831; Rieux-Laucat F, 2006, NEW ENGL J MED, V354, P1913, DOI 10.1056/NEJMoa053750; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Santulli-Marotto S, 2001, J IMMUNOL, V166, P5292, DOI 10.4049/jimmunol.166.8.5292; Schattner EJ, 2002, AUTOIMMUNITY, V35, P283, DOI 10.1080/0891693021000002072; SHLOMCHIK M, 1990, J EXP MED, V171, P265, DOI 10.1084/jem.171.1.265; SILBERSTEIN LE, 1991, BLOOD, V78, P2372; Smedby KE, 2006, JNCI-J NATL CANCER I, V98, P51, DOI 10.1093/jnci/djj004; Smith K, 2001, J EXP MED, V194, P1253, DOI 10.1084/jem.194.9.1253; Soderberg KC, 2006, EUR J CANCER, V42, P3028, DOI 10.1016/j.ejca.2006.04.021; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Straus SE, 2001, BLOOD, V98, P194, DOI 10.1182/blood.V98.1.194; Suarez F, 2006, BLOOD, V107, P3034, DOI 10.1182/blood-2005-09-3679; Subramanian S, 2006, P NATL ACAD SCI USA, V103, P9970, DOI 10.1073/pnas.0603912103; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; Tada Y, 1999, J IMMUNOL, V163, P3153; TIGHE H, 1995, J EXP MED, V181, P599, DOI 10.1084/jem.181.2.599; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; Ueda H, 2003, NATURE, V423, P506, DOI 10.1038/nature01621; Vyse TJ, 1996, CELL, V85, P311, DOI 10.1016/S0092-8674(00)81110-1; Wan YSY, 2007, NATURE, V445, P766, DOI 10.1038/nature05479; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Williams LM, 2007, NAT IMMUNOL, V8, P277, DOI 10.1038/ni1437; Winandy S, 1999, J EXP MED, V190, P1039, DOI 10.1084/jem.190.8.1039; Wong P, 2001, J EXP MED, V193, P1179, DOI 10.1084/jem.193.10.1179; Wright AF, 1999, NAT GENET, V23, P397, DOI 10.1038/70501; Wu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042; Yokoi N, 2002, NAT GENET, V31, P391, DOI 10.1038/ng927; Zerrahn J, 1997, CELL, V88, P627, DOI 10.1016/S0092-8674(00)81905-4; Zhang JQ, 2004, J EXP MED, V200, P1467, DOI 10.1084/jem.20041575; Zheng Y, 2007, NATURE, V445, P936, DOI 10.1038/nature05563; Zintzaras E, 2005, ARCH INTERN MED, V165, P2337, DOI 10.1001/archinte.165.20.2337	101	292	298	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 13	2007	130	1					25	35		10.1016/j.cell.2007.06.033	http://dx.doi.org/10.1016/j.cell.2007.06.033			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	197WK	17632054	Bronze			2022-12-28	WOS:000248587000008
J	Miled, N; Yan, Y; Hon, WC; Perisic, O; Zvelebil, M; Inbar, Y; Schneidman-Duhovny, D; Wolfson, HJ; Backer, JM; Williams, RL				Miled, Nabil; Yan, Ying; Hon, Wai-Ching; Perisic, Olga; Zvelebil, Marketa; Inbar, Yuval; Schneidman-Duhovny, Dina; Wolfson, Haim J.; Backer, Jonathan M.; Williams, Roger L.			Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit	SCIENCE			English	Article							PHOSPHATIDYLINOSITOL 3'-KINASE; FUNCTIONAL-ANALYSIS; REGULATORY SUBUNIT; PIK3CA MUTATIONS; INTER-SH2 DOMAIN; PI 3-KINASE; ACTIVATION; PATHWAY; TARGETS; GENE	Many human cancers involve up-regulation of the phosphoinositide 3-kinase PI3K alpha, with oncogenic mutations identified in both the p110 alpha catalytic and the p85 alpha regulatory subunits. We used crystallographic and biochemical approaches to gain insight into activating mutations in two noncatalytic p110 alpha domains-the adaptor-binding and the helical domains. A structure of the adaptor-binding domain of p110 alpha in a complex with the p85 alpha inter-Src homology 2 (inter-SH2) domain shows that oncogenic mutations in the adaptor-binding domain are not at the inter-SH2 interface but in a polar surface patch that is a plausible docking site for other domains in the holo p110/p85 complex. We also examined helical domain mutations and found that the Glu(545) to Lys(545) (E545K) oncogenic mutant disrupts an inhibitory charge-charge interaction with the p85 N-terminal SH2 domain. These studies extend our understanding of the architecture of PI3Ks and provide insight into how two classes of mutations that cause a gain in function can lead to cancer.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; UCL, Ludwig Inst Canc Res, London, England; Tel Aviv Univ, Sch Comp Sci, Raymond & Beverly Sackler Fac Exact Sci, IL-69978 Tel Aviv, Israel	MRC Laboratory Molecular Biology; Yeshiva University; Albert Einstein College of Medicine; Ludwig Institute for Cancer Research; University of London; University College London; Tel Aviv University	Backer, JM (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	backer@aecom.yu.edu; rlw@mrc-lmb.cam.ac.uk	Wolfson, Haim/A-1837-2011; Miled, Nabil/ABC-6773-2020; Schneidman, Dina/ABH-6654-2020	Wolfson, Haim/0000-0002-7600-2702; Miled, Nabil/0000-0001-7445-6324; Schneidman, Dina/0000-0003-0480-0438; Williams, Roger/0000-0001-7754-4207; Zvelebil, Marketa/0000-0001-8018-5591; Perisic, Olga/0000-0002-3842-2896	MRC [MC_U105184308] Funding Source: UKRI; Medical Research Council [MC_U105184308] Funding Source: Medline; NIGMS NIH HHS [GM55692] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Elis W, 2006, BIOL CHEM, V387, P1567, DOI 10.1515/BC.2006.195; Fu Z, 2003, P NATL ACAD SCI USA, V100, P3275, DOI 10.1073/pnas.0535975100; Geering B, 2007, P NATL ACAD SCI USA, V104, P7809, DOI 10.1073/pnas.0700373104; Gymnopoulos M, 2007, P NATL ACAD SCI USA, V104, P5569, DOI 10.1073/pnas.0701005104; Ikenoue T, 2005, CANCER RES, V65, P4562, DOI 10.1158/0008-5472.CAN-04-4114; Isakoff SJ, 2005, CANCER RES, V65, P10992, DOI 10.1158/0008-5472.CAN-05-2612; Jimenez C, 2002, J BIOL CHEM, V277, P41556, DOI 10.1074/jbc.M205893200; Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102; Landau M, 2005, NUCLEIC ACIDS RES, V33, pW299, DOI 10.1093/nar/gki370; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Nolte RT, 1996, NAT STRUCT BIOL, V3, P364, DOI 10.1038/nsb0496-364; Okkenhaug K, 2001, Sci STKE, V2001, ppe1; Pirola L, 2001, J BIOL CHEM, V276, P21544, DOI 10.1074/jbc.M011330200; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Shekar SC, 2005, J BIOL CHEM, V280, P27850, DOI 10.1074/jbc.M506005200; Stephens L, 2005, CURR OPIN PHARMACOL, V5, P357, DOI 10.1016/j.coph.2005.03.002; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; Wetzker R, 2004, CURR PHARM DESIGN, V10, P1915, DOI 10.2174/1381612043384402; Workman P, 2004, BIOCHEM SOC T, V32, P393, DOI 10.1042/BST0320393; Wymann MP, 2005, CURR OPIN CELL BIOL, V17, P141, DOI 10.1016/j.ceb.2005.02.011; Wymann MP, 2003, TRENDS PHARMACOL SCI, V24, P366, DOI 10.1016/S0165-6147(03)00163-9; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Yu JH, 1998, J BIOL CHEM, V273, P30199, DOI 10.1074/jbc.273.46.30199	29	307	325	3	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 13	2007	317	5835					239	242		10.1126/science.1135394	http://dx.doi.org/10.1126/science.1135394			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189DC	17626883				2022-12-28	WOS:000247968600041
J	Donath, J				Donath, Judith			Virtually trustworthy	SCIENCE			English	Editorial Material									MIT, Media Lab, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Donath, J (corresponding author), MIT, Media Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	judith@media.mit.edu	Donath, Judith/AAB-6397-2022					Bailenson JN, 2006, COMP SUPP COMP W SER, V34, P1; Cassell J., 1999, Autonomous Agents and Multi-Agent Systems, V2, P45, DOI 10.1023/A:1010027123541; DePaulo BM, 2003, PSYCHOL BULL, V129, P74, DOI 10.1037//0033-2909.129.1.74; DONATH J, IN PRESS SIGNALS TRU; Nowak K, 2006, J COMPUTERMEDIATED C, V11, P153, DOI [10.1111/j.1083-6101.2006.tb00308, DOI 10.1111/J.1083-6101.2006.TB00308.X]	5	26	27	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 6	2007	317	5834					53	54		10.1126/science.1142770	http://dx.doi.org/10.1126/science.1142770			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186KD	17615329				2022-12-28	WOS:000247776700034
J	Lai, CL; Yuen, MF				Lai, Ching-Lung; Yuen, Man-Fung			The natural history and evaluation of standard treatment of chronic hepatitis B: A critical treatment criteria and end points	ANNALS OF INTERNAL MEDICINE			English	Article							HBV-DNA LEVELS; LAMIVUDINE THERAPY; CONSENSUS STATEMENT; UNITED-STATES; INFECTION; MANAGEMENT; CHINESE; CIRRHOSIS; UPDATE; LIVER	The definite indications for the treatment of chronic hepatitis B are serum hepatitis B virus (HBV) DNA levels greater than 10(5) copies/mL and alanine aminotransferase (ALT) levels more than 2 times the upper limit of normal. if cirrhosis is present, an HBV DNA level greater than 105 copies/mL is the sole criterion for treatment. Treatment end points include hepatitis B e antigen (HEeAg) seroconversion for HBeAg-positive patients, reduction of HEV DNA levels to less than 105 copies/mL, and normalization of ALT values. These guidelines may apply to patients who acquire the hepatitis B infection during adolescence or adulthood but are less suitable for most hepatitis B carriers, who are infected in early life. Cirrhosis complications, including hepatocellular carcinoma, often occur in this latter group despite HBeAg seroconversion, HBV DNA levels less than 10(4) copies/mL, or ALT levels between 0.5 and 2 times the upper limit of normal. Therefore, HBeAg seroconversion may not be an adequate end point for these patients; the ideal treatment end points are permanent suppression of HBV DNA to levels undetectable by polymerase chain reaction and reduction of ALT levels to less than 0.5 times the upper limit of normal.	Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Lai, CL (corresponding author), Queen Mary Hosp, Dept Med, 102 Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	hrmelcl@hkucc.hku.hk	Lai, Ching Lung/C-4298-2009; Yuen, Man-Fung/C-4466-2009	Yuen, Man-Fung/0000-0001-7985-7725; Lai, Ching-Lung/0000-0002-5927-2436				Chen CJ, 2006, JAMA-J AM MED ASSOC, V295, P65, DOI 10.1001/jama.295.1.65; Chu CJ, 2002, HEPATOLOGY, V36, P1408, DOI 10.1053/jhep.2002.36949; de Franchis R, 2003, J HEPATOL, V39, pS3, DOI 10.1016/S0168-8278(03)00378-7; DIBISCEGLIE AM, 1987, GASTROENTEROLOGY, V93, P1236, DOI 10.1016/0016-5085(87)90250-2; Dienstag JL, 2003, GASTROENTEROLOGY, V124, P105, DOI 10.1053/gast.2003.50013; Hadziyannis SJ, 2005, NEW ENGL J MED, V352, P2673, DOI 10.1056/NEJMoa042957; Keeffe EB, 2006, CLIN GASTROENTEROL H, V4, P936, DOI 10.1016/j.cgh.2006.05.016; Kim HC, 2004, BMJ-BRIT MED J, V328, P983, DOI 10.1136/bmj.38050.593634.63; Lee TA, 2004, J CLIN GASTROENTEROL, V38, pS144, DOI 10.1097/00004836-200411003-00005; LIAW YF, 1988, HEPATOLOGY, V8, P493, DOI 10.1002/hep.1840080310; Liaw YF, 2005, LIVER INT, V25, P472, DOI 10.1111/j.1478-3231.2005.01134.x; Liaw YF, 2004, NEW ENGL J MED, V351, P1521, DOI 10.1056/NEJMoa033364; Lok ASF, 2007, HEPATOLOGY, V45, P507, DOI 10.1002/hep.21513; Lok AS, 2001, GASTROENTEROLOGY, V120, P1828, DOI 10.1053/gast.2001.24839; Manno M, 2004, GASTROENTEROLOGY, V127, P756, DOI 10.1053/j.gastro.2004.06.021; Newman TB, 1996, JAMA-J AM MED ASSOC, V275, P55, DOI 10.1001/jama.275.1.55; Nguyen MH, 2005, HEPATOLOGY, V42, p593A; Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202; Sherman M, 2005, GUT, V54, P1521, DOI 10.1136/gut.2005.071332; *TAIW COMM BAS CAN, 2002, NEW ENGL J MED, V347, P168; Wong DKH, 2006, ANTIVIR THER, V11, P909; Yuan HJ, 2005, J VIRAL HEPATITIS, V12, P373, DOI 10.1111/j.1365-2893.2005.00603.x; Yuen MF, 2005, AM J GASTROENTEROL, V100, P1099, DOI 10.1111/j.1572-0241.2005.41530.x; Yuen MF, 2004, HEPATOLOGY, V39, P1694, DOI 10.1002/hep.20240; Yuen MF, 2005, HEPATOLOGY, V42, p583A; Yuen MF, 2005, GUT, V54, P1610, DOI 10.1136/gut.2005.065136	26	144	150	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2007	147	1					58	61		10.7326/0003-4819-147-1-200707030-00010	http://dx.doi.org/10.7326/0003-4819-147-1-200707030-00010			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186MN	17606962				2022-12-28	WOS:000247782900008
J	Rando, TA				Rando, Thomas A.			The immortal strand hypothesis: Segregation and reconstruction	CELL			English	Article							SISTER CHROMATIDS; DNA STRANDS; STEM-CELLS; ESCHERICHIA COLI; MAMMALIAN-CELLS; MITOSIS; CANCER; COSEGREGATION; REPLICATION; KINETICS	The immortal strand hypothesis posits that the propensity of stem cell compartments to give rise to cancer in later life can be minimized if stem cells, during the process of self-renewal, retain those DNA strands with the fewest mutations acquired during DNA replication. In this Essay, I explore evidence in support of the hypothesis, the biological implications, and the key questions that remain to be answered experimentally to address the fundamental tenets of the hypothesis.	Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, GRECC & Neurol Serv, Palo Alto, CA 94304 USA	Stanford University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Rando, TA (corresponding author), Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.	rando@stanford.edu		Rando, Thomas/0000-0001-5843-8564	NIH HHS [DP1 OD000392] Funding Source: Medline; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD000392] Funding Source: NIH RePORTER	NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BICKENBACH JR, 1981, J DENT RES, V60, P1611, DOI 10.1177/002203458106000311011; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; Cairns J, 2002, P NATL ACAD SCI USA, V99, P10567, DOI 10.1073/pnas.162369899; Cairns J, 2006, GENETICS, V174, P1069, DOI 10.1534/genetics.104.66886; COMINGS DE, 1970, CHROMOSOMA, V29, P428; Conboy MJ, 2007, PLOS BIOL, V5, P1120, DOI 10.1371/journal.pbio.0050102; Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075; CUZIN F, 1965, CR HEBD ACAD SCI, V260, P5411; FERNANDEZGOMEZ ME, 1975, EXP CELL RES, V96, P156, DOI 10.1016/S0014-4827(75)80048-6; GEARD CR, 1973, CHROMOSOMA, V44, P301, DOI 10.1007/BF00291024; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; ITO K, 1987, CELL, V49, P329, DOI 10.1016/0092-8674(87)90285-6; JACKSON V, 1988, BIOCHEMISTRY-US, V27, P2109, DOI 10.1021/bi00406a044; KUROKI T, 1989, JPN J CANCER RES, V80, P637, DOI 10.1111/j.1349-7006.1989.tb01690.x; LARK KG, 1965, P NATL ACAD SCI USA, V54, P1444, DOI 10.1073/pnas.54.5.1444; LARK KG, 1966, BACTERIOL REV, V30, P3, DOI 10.1128/MMBR.30.1.3-32.1966; LARK KG, 1967, P NATL ACAD SCI USA, V58, P352, DOI 10.1073/pnas.58.1.352; LARK KG, 1966, SCIENCE, V154, P1202, DOI 10.1126/science.154.3753.1202; LEFFAK IM, 1977, CELL, V12, P837, DOI 10.1016/0092-8674(77)90282-3; Merok JR, 2002, CANCER RES, V62, P6791; MORRIS VB, 1977, CHROMOSOMA, V60, P139, DOI 10.1007/BF00288461; NEFF MW, 1991, GENETICS, V127, P463; Potten CS, 2002, J CELL SCI, V115, P2381; POTTEN CS, 1978, CELL, V15, P899, DOI 10.1016/0092-8674(78)90274-X; Rambhatla L, 2005, CANCER RES, V65, P3155, DOI 10.1158/0008-5472.CAN-04-3161; Rando TA, 2006, NATURE, V441, P1080, DOI 10.1038/nature04958; ROSENBERGER RF, 1968, J BACTERIOL, V96, P1208, DOI 10.1128/JB.96.4.1208-1213.1968; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; von Zglinicki T, 2002, TRENDS BIOCHEM SCI, V27, P339, DOI 10.1016/S0968-0004(02)02110-2; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Williamson DH, 1981, A BENZON S, V16, P89	31	126	134	0	20	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 29	2007	129	7					1239	1243		10.1016/j.cell.2007.06.019	http://dx.doi.org/10.1016/j.cell.2007.06.019			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188HQ	17604710	Bronze			2022-12-28	WOS:000247911400006
J	Anderson, PW				Anderson, Philip W.			Is there glue in cuprate superconductors?	SCIENCE			English	Editorial Material							HIGH-TEMPERATURE SUPERCONDUCTIVITY; LIQUID HE-3; DENSITY; OXIDES; MODEL; STATE		Princeton Univ, Dept Phys, Princeton, NJ 08544 USA	Princeton University	Anderson, PW (corresponding author), Princeton Univ, Dept Phys, Princeton, NJ 08544 USA.	pwa@princeton.edu						Anderson PW, 2006, NAT PHYS, V2, P626, DOI 10.1038/nphys388; Anderson PW, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.017001; BRUECKNER KA, 1960, PHYS REV, V118, P1442, DOI 10.1103/PhysRev.118.1442; DAVIS JC, 2006, NATURE, V452, P546; Demler E, 1998, NATURE, V396, P733, DOI 10.1038/25482; MILLIS AJ, 1990, PHYS REV B, V42, P167, DOI 10.1103/PhysRevB.42.167; MONTHOUX P, 1991, PHYS REV LETT, V67, P3448, DOI 10.1103/PhysRevLett.67.3448; MORIYA T, 1990, J PHYS SOC JPN, V59, P2905, DOI 10.1143/JPSJ.59.2905; Norman MR, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.140501; PITAEVSKII LP, 1960, SOV PHYS JETP-USSR, V10, P1267; Scalapino D. J., 1969, Superconductivity vol 1, P449; SCALAPINO DJ, 1986, PHYS REV B, V34, P8190, DOI 10.1103/PhysRevB.34.8190	14	178	180	2	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 22	2007	316	5832					1705	1707		10.1126/science.1140970	http://dx.doi.org/10.1126/science.1140970			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180XE	17588918				2022-12-28	WOS:000247400500032
J	Sundar, S; Jha, TK; Thakur, CP; Sinha, PK; Bhattacharya, SK; Nguyen, B; Kwan, E; Oudin, A; Valcke, K; Mathie, S; Ley, C; Rosenberg, M; Gaithersburg, EL; Muenz, L; He, D; Wei, LJ; Ballanchanda, B; Wrone, E; Mahmoud, E; Davidson, R; Sweetow, R; Ballanchanda, B; Valente, M; Sheiner, L; Beal, S; Lin, E; Gee, W; Huang, Y; Chang, H; Li, X				Sundar, Shyam; Jha, T. K.; Thakur, Chandreshwar P.; Sinha, Prabhat K.; Bhattacharya, Sujit K.; Nguyen, B.; Kwan, E.; Oudin, A.; Valcke, K.; Mathie, S.; Ley, C.; Rosenberg, M.; Gaithersburg, E. L.; Muenz, L.; He, D.; Wei, L. J.; Ballanchanda, B.; Wrone, E.; Mahmoud, E.; Davidson, R.; Sweetow, R.; Ballanchanda, B.; Valente, M.; Sheiner, L.; Beal, S.; Lin, E.; Gee, W.; Huang, Y.; Chang, H.; Li, X.			Injectable paromomycin for visceral leishmaniasis in India	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SODIUM STIBOGLUCONATE; KALA-AZAR; PENTAVALENT ANTIMONY; AMPHOTERICIN-B; AMINOSIDINE; BIHAR; MILTEFOSINE; EFFICACY; TRIAL	Background: Visceral leishmaniasis (kala-azar) affects large, rural, resource-poor populations in South Asia, Africa, and Brazil. Safe, effective, and affordable new therapies are needed. We conducted a randomized, controlled, phase 3 open-label study comparing paromomycin, an aminoglycoside, with amphotericin B, the present standard of care in Bihar, India. Methods: In four treatment centers for visceral leishmaniasis, 667 patients between 5 and 55 years of age who were negative for the human immunodeficiency virus and had parasitologically confirmed visceral leishmaniasis were randomly assigned in a 3:1 ratio to receive paromomycin (502 patients) at a dose of 11 mg per kilogram of body weight intramuscularly daily for 21 days or amphotericin B (165 patients) at a dose of 1 mg per kilogram intravenously every other day for 30 days. Final cure was assessed 6 months after the end of treatment; safety assessments included daily clinical evaluations and weekly laboratory and audiometric evaluations. Noninferiority testing was used to compare 6-month cure rates, with a chosen margin of noninferiority of 10 percentage points. Results: Paromomycin was shown to be noninferior to amphotericin B (final cure rate, 94.6% vs. 98.8%; difference, 4.2 percentage points; upper bound of the 97.5% confidence interval, 6.9; P<0.001). Mortality rates in the two groups were less than 1%. Adverse events, which were more common among patients receiving paromomycin than among those receiving amphotericin B (6% vs. 2%, P=0.02), included transient elevation of aspartate aminotransferase levels (>3 times the upper limit of the normal range); transient reversible ototoxicity (2% vs. 0, P=0.20); and injection-site pain (55% vs. 0, P<0.001); and in patients receiving amphotericin B, as compared with those receiving paromomycin, nephrotoxicity (4% vs. 0, P<0.001), fevers (57% vs. 3%), rigors (24% vs. 0, P<0.001), and vomiting (10% vs. <1%, P<0.001). Conclusions: Paromomycin was shown to be noninferior to amphotericin B for the treatment of visceral leishmaniasis in India.	Banaras Hindu Univ, Inst Med Sci, Varanasi 221005, Uttar Pradesh, India; Kala Azar Res Ctr, Muzaffarpur, Bihar, India; Balaji Utthan Sansthan, Patna, Bihar, India; Rajendra Mem Res Inst Med Sci, Patna, Bihar, India	Banaras Hindu University (BHU); Indian Council of Medical Research (ICMR); ICMR - Rajendra Memorial Research Institute of Medical Sciences (RMRI)	Sundar, S (corresponding author), Banaras Hindu Univ, Inst Med Sci, Varanasi 221005, Uttar Pradesh, India.	drshyamsundar@hotmail.com	Wei, Lee-Jen/CAI-0175-2022					Aggarwal P, 1990, Indian J Gastroenterol, V9, P135; Ahasan H A, 1996, Med J Malaysia, V51, P29; CHUNGE CN, 1990, T ROY SOC TROP MED H, V84, P221, DOI 10.1016/0035-9203(90)90263-E; Collin S, 2004, CLIN INFECT DIS, V38, P612, DOI 10.1086/381203; Czeizel AE, 2000, SCAND J INFECT DIS, V32, P309; Das VNR, 2005, NATL MED J INDIA, V18, P131; Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004; ELHAG IA, 1994, J CLIN PATHOL, V47, P547, DOI 10.1136/jcp.47.6.547; Hardman J, 2006, AMINOGLYCOSIDES GOOD, V11; Jha TK, 1999, NEW ENGL J MED, V341, P1795, DOI 10.1056/NEJM199912093412403; Jha TK, 1998, BRIT MED J, V316, P1200, DOI 10.1136/bmj.316.7139.1200; Lira R, 1999, J INFECT DIS, V180, P564, DOI 10.1086/314896; National Cancer Institute, 1998, CANC THER EV PROGR C; Rosenthal E, 2003, J Postgrad Med, V49, P61; Singh Utpal Kant, 1995, Indian Journal of Pediatrics, V62, P571, DOI 10.1007/BF02761879; Sinha PK, 2006, INDIAN J MED RES, V123, P197; Sundar S, 2006, J CLIN MICROBIOL, V44, P251, DOI 10.1128/JCM.44.1.251-253.2006; Sundar S, 2005, B WORLD HEALTH ORGAN, V83, P394; Sundar S, 2002, CURR OPIN INFECT DIS, V15, P593, DOI 10.1097/00001432-200212000-00007; Sundar S, 2002, NEW ENGL J MED, V347, P1739, DOI 10.1056/NEJMoa021556; Sundar S, 1997, J INFECT DIS, V176, P1117, DOI 10.1086/516526; Sundar S, 2000, CLIN INFECT DIS, V31, P1104, DOI 10.1086/318121; Thakur CP, 2000, T ROY SOC TROP MED H, V94, P429, DOI 10.1016/S0035-9203(00)90130-5; Thakur CP, 2000, T ROY SOC TROP MED H, V94, P432, DOI 10.1016/S0035-9203(00)90131-7; Thakur CP, 1998, ANN TROP MED PARASIT, V92, P561, DOI 10.1080/00034989859258; Thakur CP, 2004, INDIAN J MED RES, V120, P166; Walsh TJ, 2007, NEW ENGL J MED, V356, P760; Walsh TJ, 2002, NEW ENGL J MED, V346, P225, DOI 10.1056/NEJM200201243460403; Wingard JR, 1999, CLIN INFECT DIS, V29, P1402, DOI 10.1086/313498; Zijistra EE, 2003, LANCET INFECT DIS, V3, P87, DOI 10.1016/S1473-3099(03)00517-6	30	304	309	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 21	2007	356	25					2571	2581		10.1056/NEJMoa066536	http://dx.doi.org/10.1056/NEJMoa066536			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180GN	17582067	Bronze			2022-12-28	WOS:000247351200004
J	Taqueti, VR				Taqueti, Viviany R.			Leaving against medical advice	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Taqueti, VR (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.								0	7	7	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 19	2007	357	3					213	215		10.1056/NEJMp078046	http://dx.doi.org/10.1056/NEJMp078046			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191FH	17634456				2022-12-28	WOS:000248115100002
J	Charlat, S; Hornett, EA; Fullard, JH; Davies, N; Roderick, GK; Wedell, N; Hurst, GDD				Charlat, Sylvain; Hornett, Emily A.; Fullard, James H.; Davies, Neil; Roderick, George K.; Wedell, Nina; Hurst, Gregory D. D.			Extraordinary flux in sex ratio	SCIENCE			English	Article									UCL, Dept Biol, 4 Stephenson Way, London NW1 2HE, England; Univ Calif Berkeley, Gump S Pacific Res Stn, F-98728 Moorea, France; Univ Toronto, Dept Biol, Mississauga, ON L5L 1C6, Canada; Univ Calif Berkeley, ESPM, Berkeley, CA 94720 USA; Univ Exeter, Sch Biosci, Tremough TR10 9EZ, Penryn, England	University of London; University College London; University of California System; University of California Berkeley; University of Toronto; University Toronto Mississauga; University of California System; University of California Berkeley; University of Exeter	Charlat, S (corresponding author), UCL, Dept Biol, 4 Stephenson Way, London NW1 2HE, England.	s.charlat@ucl.ac.uk	Hurst, Gregory D D/C-2723-2008; Davies, Neil/E-5863-2012	Hurst, Gregory D D/0000-0002-7163-7784; Davies, Neil/0000-0001-8085-5014; Charlat, Sylvain/0000-0003-0760-0087; Roderick, George/0000-0001-7557-2415	Natural Environment Research Council [NE/B503292/1] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Charlat S, 2007, CURR BIOL, V17, P273, DOI 10.1016/j.cub.2006.11.068; Dyson EA, 2004, P NATL ACAD SCI USA, V101, P6520, DOI 10.1073/pnas.0304068101; HAMILTON WD, 1967, SCIENCE, V156, P477, DOI 10.1126/science.156.3774.477; Hornett EA, 2006, PLOS BIOL, V4, P1643, DOI 10.1371/journal.pbio.0040283	4	90	96	0	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 13	2007	317	5835					214	214		10.1126/science.1143369	http://dx.doi.org/10.1126/science.1143369			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189DC	17626876				2022-12-28	WOS:000247968600032
J	Junttila, MR; Puustinen, P; Niemela, M; Ahola, R; Arnold, H; Bottzauw, T; Ala-Aho, R; Nielsen, C; Ivaska, J; Taya, Y; Lu, SL; Lin, SJ; Chan, EKL; Wang, XJ; Grenman, R; Kast, J; Kallunki, T; Sears, R; Kahari, VM; Westermarck, J				Junttila, Melissa R.; Puustinen, Pietri; Niemela, Minna; Ahola, Raija; Arnold, Hugh; Bottzauw, Trine; Ala-aho, Risto; Nielsen, Christina; Ivaska, Johanna; Taya, Yoichi; Lu, Shi-Long; Lin, Shujun; Chan, Edward K. L.; Wang, Xiao-Jing; Grenman, Reidar; Kast, Juergen; Kallunki, Tuula; Sears, Rosalie; Kahari, Veli-Matti; Westermarck, Jukka			CIP2A inhibits PP2A in human malignancies	CELL			English	Article							PROTEIN PHOSPHATASE 2A; HUMAN CELL-TRANSFORMATION; C-MYC; COLON-CANCER; SUBUNIT; ALPHA; SERINE/THREONINE; DEGRADATION; HOLOENZYME; ELEMENTS	Inhibition of protein phosphatase 2A ( PP2A) activity has been identified as a prerequisite for the transformation of human cells. However, the molecular mechanisms by which PP2A activity is inhibited in human cancers are currently unclear. In this study, we describe a cellular inhibitor of PP2A with oncogenic activity. The protein, designated Cancerous Inhibitor of PP2A ( CIP2A), interacts directly with the oncogenic transcription factor c- Myc, inhibits PP2A activity toward c- Myc serine 62 ( S62), and thereby prevents c- Myc proteolytic degradation. In addition to its function in cMyc stabilization, CIP2A promotes anchorage-independent cell growth and in vivo tumor formation. The oncogenic activity of CIP2A is demonstrated by transformation of human cells by overexpression of CIP2A. Importantly, CIP2A is overexpressed in two common human malignancies, head and neck squamous cell carcinoma ( HNSCC) and colon cancer. Thus, our data show that CIP2A is a human oncoprotein that inhibits PP2A and stabilizes c- Myc in human malignancies.	Univ Turku, Ctr Biotechnol, FIN-20520 Turku, Finland; Abo Akad Univ, FIN-20520 Turku, Finland; Univ Turku, Turku Grad Sch Biomed Sci, FIN-20520 Turku, Finland; Univ Turku, Dept Med Biochem & Mol Biol, FIN-20520 Turku, Finland; Univ Turku, Medic Res Lab, FIN-20520 Turku, Finland; Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; Danish Canc Soc, Inst Canc Biol, Apoptosis Lab, DK-2100 Copenhagen, Denmark; VTT Tech Res Ctr Finland, Med Biotechnol, FIN-20520 Turku, Finland; Natl Canc Ctr, Res Inst, Tokyo 1040045, Japan; OHSU, Dept Otolaryngol, Portland, OR 97239 USA; OHSU, Dept Dermatol, Portland, OR 97239 USA; OHSU, Dept Cell & Dev Biol, Portland, OR 97239 USA; Univ British Columbia, Biomed Res Ctr, Vancouver, BC V5Z 1M9, Canada; Univ Florida, Dept Oral Biol, Gainesville, FL 32610 USA; Turku Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, FIN-20520 Turku, Finland; Turku Univ Hosp, Dept Dermatol, FIN-20520 Turku, Finland; Univ Tampere, Inst Med Technol, FIN-33520 Tampere, Finland; Tampere Univ Hosp, FIN-33520 Tampere, Finland	University of Turku; Abo Akademi University; University of Turku; University of Turku; University of Turku; Oregon Health & Science University; Danish Cancer Society; VTT Technical Research Center Finland; National Cancer Center - Japan; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; University of British Columbia; State University System of Florida; University of Florida; University of Turku; University of Turku; Tampere University; Tampere University; Tampere University Hospital	Westermarck, J (corresponding author), Univ Turku, Ctr Biotechnol, FIN-20520 Turku, Finland.	ltjuwe@uta.fi	Kahari, Veli-Matti/T-4925-2019; Kähäri, Veli-Matti/E-5144-2011; Westermarck, Jukka/AAL-6464-2020; Chan, Edward K. L./B-5671-2009; Pope, Janet/G-3342-2011	Kahari, Veli-Matti/0000-0003-2421-9368; Kähäri, Veli-Matti/0000-0003-2421-9368; Westermarck, Jukka/0000-0001-7478-3018; Chan, Edward K. L./0000-0003-3938-9503; Pope, Janet/0000-0003-1479-5302; Ivaska, Johanna/0000-0002-6295-6556; Kallunki, Tuula/0000-0002-8571-383X	NCI NIH HHS [R01-CA100855] Funding Source: Medline; NIDCR NIH HHS [DE15953] Funding Source: Medline; NIGMS NIH HHS [T32-GM08617] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008617] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen W, 2005, CANCER RES, V65, P8183, DOI 10.1158/0008-5472.CAN-05-1103; Cho US, 2007, NATURE, V445, P53, DOI 10.1038/nature05351; Dietrich N, 2004, CELL DEATH DIFFER, V11, P301, DOI 10.1038/sj.cdd.4401353; Escamilia-Powers JR, 2007, J BIOL CHEM, V282, P5432, DOI 10.1074/jbc.M611437200; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gotz J, 1998, P NATL ACAD SCI USA, V95, P12370, DOI 10.1073/pnas.95.21.12370; Grady WM, 2002, ANNU REV GENOM HUM G, V3, P101, DOI 10.1146/annurev.genom.3.022502.103043; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Honeycutt KA, 2004, J DERMATOL, V31, P368, DOI 10.1111/j.1346-8138.2004.tb00687.x; Hoo LS, 2002, ONCOGENE, V21, P5006, DOI 10.1038/sj.onc.1205625; Janssens IA, 2005, BIOGEOSCIENCES, V2, P15, DOI 10.5194/bg-2-15-2005; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; LANSFORD CD, 1999, HUMAN CELL CULTURE, V2, P185; Lu SL, 2006, GENE DEV, V20, P1331, DOI 10.1101/gad.1413306; Moreno CS, 2004, CANCER RES, V64, P6978, DOI 10.1158/0008-5472.CAN-04-1150; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Moule MG, 2004, P NATL ACAD SCI USA, V101, P14063, DOI 10.1073/pnas.0405533101; Neviani P, 2005, CANCER CELL, V8, P355, DOI 10.1016/j.ccr.2005.10.015; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Pastula C, 2003, COMB CHEM HIGH T SCR, V6, P341; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Xu YH, 2006, CELL, V127, P1239, DOI 10.1016/j.cell.2006.11.033; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Zhao JJ, 2004, TRENDS MOL MED, V10, P344, DOI 10.1016/j.molmed.2004.05.005	33	475	517	0	61	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 13	2007	130	1					51	62		10.1016/j.cell.2007.04.044	http://dx.doi.org/10.1016/j.cell.2007.04.044			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	197WK	17632056	Bronze			2022-12-28	WOS:000248587000010
J	Subramani, S; Farre, JC				Subramani, Suresh; Farre, Jean-Claude			A ubiquitin-like protein involved in membrane fusion	CELL			English	Editorial Material							AUTOPHAGY		Univ Calif San Diego, Div Biol Sci, Sect Mol Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Subramani, S (corresponding author), Univ Calif San Diego, Div Biol Sci, Sect Mol Biol, La Jolla, CA 92093 USA.	ssubramani@ucsd.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069373] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM069373, R01 GM069373-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chernomordik LV, 2005, CELL, V123, P375, DOI 10.1016/j.cell.2005.10.015; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Ichimura Y, 2004, J BIOL CHEM, V279, P40584, DOI 10.1074/jbc.M405860200; Jahn R, 2006, NAT REV MOL CELL BIO, V7, P631, DOI 10.1038/nrm2002; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Langosch D, 2007, CELL MOL LIFE SCI, V64, P850, DOI 10.1007/s00018-007-6439-x; Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765	9	11	11	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 13	2007	130	1					18	20		10.1016/j.cell.2007.06.041	http://dx.doi.org/10.1016/j.cell.2007.06.041			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	197WK	17632052	Bronze			2022-12-28	WOS:000248587000006
J	Goldston, D				Goldston, David			Technical advice	NATURE			English	Editorial Material											Goldston, D (corresponding author), Princeton Univ, Woodrow Wilson Sch Publ & Int Affairs, Princeton, NJ 08544 USA.								0	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 12	2007	448	7150					119	119		10.1038/448119a	http://dx.doi.org/10.1038/448119a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	188QN	17625534	Bronze			2022-12-28	WOS:000247934500010
J	Seidel, HM				Seidel, Henry M.			On retirement	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												hseidel@jhmi.edu						FEINSTEIN AR, 1967, CLINICAL JUDGEMENT, P144	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2007	298	2					147	148		10.1001/jama.298.2.147	http://dx.doi.org/10.1001/jama.298.2.147			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188HI	17622587				2022-12-28	WOS:000247910600001
J	Hirschel, B; Perneger, T				Hirschel, Bernard; Perneger, Thomas			No patient left behind - better treatments for resistant HIV infection	LANCET			English	Editorial Material							SELECTION; EFFICACY; TMC125; SAFETY		Univ Hosp Geneva, Div Infect Dis, CH-1211 Geneva, Switzerland; Univ Hosp Geneva, Clin Epidemiol Serv, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Hirschel, B (corresponding author), Univ Hosp Geneva, Div Infect Dis, CH-1211 Geneva, Switzerland.	Bernard.hirschel@hcuge.ch						[Anonymous], 14 C RETR OPP INF LO; [Anonymous], 2007, EFFICACY SAFETY MARA; Boffito M, 2007, AIDS, V21, P1449, DOI 10.1097/QAD.0b013e3282170ab1; Clotet B, 2007, LANCET, V369, P1169, DOI 10.1016/S0140-6736(07)60497-8; COOPER D, 2007, 14 C RETR OPP INF LO; *FDA, 1989, GUID IND PROV CLIN E; Klein CE, 2007, JAIDS-J ACQ IMM DEF, V44, P401, DOI 10.1097/QAI.0b013e31803133c5; Lazzarin A, 2007, LANCET, V370, P39, DOI 10.1016/S0140-6736(07)61048-4; Madruga JV, 2007, LANCET, V370, P29, DOI 10.1016/S0140-6736(07)61047-2; Madruga JV, 2007, LANCET, V370, P49, DOI 10.1016/S0140-6736(07)61049-6; Nadler JP, 2007, AIDS, V21, pF1, DOI 10.1097/01.aids.0000299404.99033.bf; STEIGBIGEL R, 2007, 14 C RETR OPP INF LO; Surleraux DLNG, 2005, J MED CHEM, V48, P1813, DOI 10.1021/jm049560p; Vingerhoets J, 2007, ANTIVIR THER, V12, pS34; Vingerhoets J, 2005, J VIROL, V79, P12773, DOI 10.1128/JVI.79.20.12773-12782.2005; WOODFALL B, 2006, 8 INT C DRUG THER HI	16	12	12	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 7	2007	370	9581					3	5		10.1016/S0140-6736(07)61022-8	http://dx.doi.org/10.1016/S0140-6736(07)61022-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	187QE	17617250				2022-12-28	WOS:000247862300004
J	Watts, G				Watts, Geoff			Commentary: Liquid automation refreshes Dr Papanicolaou	BRITISH MEDICAL JOURNAL			English	Editorial Material												geoff@scileg.freeserve.co.uk						DAVEY E, 2007, BMJ; DAWSON AE, 2004, CANC CYTOPATHOLOGY; Henstock E., 2002, EVALUATION HPV LBC C; LINDER J, 2004, EUR INT EXP M NIC OC; RONCO G, 2007, BMJ	5	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUL 7	2007	335	7609					35	36		10.1136/bmj.39260.482616.DE	http://dx.doi.org/10.1136/bmj.39260.482616.DE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191LY	17615223	Green Published			2022-12-28	WOS:000248133900033
J	Gilbert, SJ; Dumontheil, I; Simons, JS; Frith, CD; Burgess, PW				Gilbert, Sam J.; Dumontheil, Iroise; Simons, Jon S.; Frith, Chris D.; Burgess, Paul W.			Comment on "Wandering minds: The default network and stimulus-independent thought"	SCIENCE			English	Editorial Material							PREFRONTAL CORTEX AREA-10; POSTERIOR CINGULATE; BRAIN-FUNCTION; MODE; SELF	Mason et al. (Reports, 19 January 2007, p. 393) attributed activity in certain regions of the "resting" brain to the occurrence of mind-wandering. However, previous research has demonstrated the difficulty of distinguishing this type of stimulus-independent thought from stimulus-oriented thought (e.g., watchfulness). Consideration of both possibilities is required to resolve this ambiguity.	UCL, Inst Cognit Neurosci, London, England; UCL, Dept Psychol, London, England; MRC, Cognit & Brain Sci Unit, Cambridge, England; Univ Cambridge, Behav & Clin Neurosci Inst, Dept Expt Psychol, Cambridge, England; UCL, Wellcome Dept Imaging Neurosci, Neurol Inst, London, England	University of London; University College London; University of London; University College London; University of Cambridge; University of London; University College London	Gilbert, SJ (corresponding author), UCL, Inst Cognit Neurosci, London, England.	sam.gilbert@ucl.ac.uk	Simons, Jon/A-1619-2009; Dumontheil, Iroise/AAU-3395-2021; Frith, Chris D/A-2171-2009; Gilbert, Sam/V-2503-2019; Burgess, Paul W/A-1811-2010; Simons, Jon/AAG-7104-2020; Gilbert, Sam J./C-1909-2008	Dumontheil, Iroise/0000-0001-5236-7849; Frith, Chris D/0000-0002-8665-0690; Gilbert, Sam/0000-0002-3839-7045; Simons, Jon/0000-0002-7508-9084; Gilbert, Sam J./0000-0002-3839-7045	Wellcome Trust [061171] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BURGESS PW, 2007, IN PRESS TRENDS 0604, DOI DOI 10.1016/J.TICS.2007.05.004; Christoff K, 2004, CORTEX, V40, P623, DOI 10.1016/S0010-9452(08)70158-8; Gilbert SJ, 2006, J COGNITIVE NEUROSCI, V18, P932, DOI 10.1162/jocn.2006.18.6.932; Gilbert SJ, 2006, CEREB CORTEX, V16, P1783, DOI 10.1093/cercor/bhj113; Gilbert SJ, 2006, J EXP PSYCHOL HUMAN, V32, P45, DOI 10.1037/0096-1523.32.1.45; Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098; Hahn B, 2007, CEREB CORTEX, V17, P1664, DOI 10.1093/cercor/bhl075; Mason MF, 2007, SCIENCE, V315, P393, DOI 10.1126/science.1131295; MORCOM AM, 2006, IN PRESS NEUROI 1017, DOI DOI 10.1016/J.NEUROIMAGE.2006.09.013; Olson CR, 1996, J NEUROPHYSIOL, V76, P3285, DOI 10.1152/jn.1996.76.5.3285; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Singer J. L., 1972, FUNCTION NATURE IMAG, P175; Small DM, 2003, NEUROIMAGE, V18, P633, DOI 10.1016/S1053-8119(02)00012-5; Wicker B, 2003, BRAIN RES REV, V43, P224, DOI 10.1016/j.brainresrev.2003.08.003	15	153	156	2	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2007	317	5834					43	+		10.1126/science.1140801	http://dx.doi.org/10.1126/science.1140801			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186KD	17615325	Green Submitted			2022-12-28	WOS:000247776700026
J	Dai, SD; Friemann, R; Glauser, DA; Bourquin, F; Manieri, W; Schurmann, P; Eklund, H				Dai, Shaodong; Friemann, Rosmarie; Glauser, Dominique A.; Bourquin, Florence; Manieri, Wanda; Schuermann, Peter; Eklund, Hans			Structural snapshots along the reaction pathway of ferredoxin-thioredoxin reductase	NATURE			English	Article							CRYSTAL-STRUCTURE; S-ADENOSYLMETHIONINE; 4FE-4S CLUSTER; FERREDOXINTHIOREDOXIN REDUCTASE; DISULFIDE REDUCTION; SPINACH FERREDOXIN; ACTIVE-SITE; CHLOROPLAST; PROTEIN; CHEMISTRY	Oxygen-evolving photosynthetic organisms regulate carbon metabolism through a light-dependent redox signalling pathway(1). Electrons are shuttled from photosystem I by means of ferredoxin (Fdx) to ferredoxin - thioredoxin reductase (FTR), which catalyses the two-electron-reduction of chloroplast thioredoxins (Trxs). These modify target enzyme activities by reduction, regulating carbon flow(2). FTR is unique in its use of a [4Fe - 4S] cluster and a proximal disulphide bridge in the conversion of a light signal into a thiol signal(2). We determined the structures of FTR in both its one- and its two-electron-reduced intermediate states and of four complexes in the pathway, including the ternary Fdx - FTR - Trx complex. Here we show that, in the first complex ( Fdx - FTR) of the pathway, the Fdx [2Fe - 2S] cluster is positioned suitably for electron transfer to the FTR [ 4Fe - 4S] centre. After the transfer of one electron, an intermediate is formed in which one sulphur atom of the FTR active site is free to attack a disulphide bridge in Trx and the other sulphur atom forms a fifth ligand for an iron atomin the FTR [ 4Fe - 4S] centre - a unique structure in biology. Fdx then delivers a second electron that cleaves the FTR - Trx heterodisulphide bond, which occurs in the Fdx - FTR - Trx complex. In this structure, the redox centres of the three proteins are aligned to maximize the efficiency of electron transfer from the Fdx [2Fe - 2S] cluster to the active-site disulphide of Trxs. These results provide a structural framework for understanding the mechanism of disulphide reduction by an iron - sulphur enzyme(3) and describe previously unknown interaction networks for both Fdx and Trx ( refs 4 - 6).	Natl Jewish Med & Res Ctr, Howard Hughes Med Inst, Integrated Dept Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO 80206 USA; Swedish Univ Agr Sci, Ctr Biomed, Dept Mol Biol, S-75124 Uppsala, Sweden; Univ Neuchatel, Mol & Cellular Biol Lab, CH-2009 Neuchatel, Switzerland	Howard Hughes Medical Institute; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Swedish University of Agricultural Sciences; University of Neuchatel	Dai, SD (corresponding author), Natl Jewish Med & Res Ctr, Howard Hughes Med Inst, Integrated Dept Immunol, 1400 Jackson St, Denver, CO 80206 USA.	dais@njc.org	Glauser, Dominique/B-3918-2012; Friemann, Rosmarie/C-1018-2008	Glauser, Dominique/0000-0002-3228-7304; Friemann, Rosmarie/0000-0002-5633-2894				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Balmer Y, 2003, P NATL ACAD SCI USA, V100, P370, DOI 10.1073/pnas.232703799; Balmer Y, 2001, FEBS LETT, V492, P58, DOI 10.1016/S0014-5793(01)02229-3; Berkovitch F, 2004, SCIENCE, V303, P76, DOI 10.1126/science.1088493; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buchanan BB, 2005, ANNU REV PLANT BIOL, V56, P187, DOI 10.1146/annurev.arplant.56.032604.144246; BUCHANAN BB, 1994, ARCH BIOCHEM BIOPHYS, V314, P257, DOI 10.1006/abbi.1994.1439; Chen DW, 2003, J AM CHEM SOC, V125, P11788, DOI 10.1021/ja036120z; Chen KS, 2002, NAT STRUCT BIOL, V9, P188, DOI 10.1038/nsb751; Dai SD, 2000, Q REV BIOPHYS, V33, P67, DOI 10.1017/S0033583500003607; Dai SD, 2000, SCIENCE, V287, P655, DOI 10.1126/science.287.5453.655; DeLano W.L, PYMOL MOL GRAPHICS S; Duin EC, 2002, FEBS LETT, V512, P263, DOI 10.1016/S0014-5793(02)02281-0; Giastas P, 2006, J BIOL INORG CHEM, V11, P445, DOI 10.1007/s00775-006-0094-9; Glauser DA, 2004, J BIOL CHEM, V279, P16662, DOI 10.1074/jbc.M313851200; Hanzelmann P, 2004, P NATL ACAD SCI USA, V101, P12870, DOI 10.1073/pnas.0404624101; Hirasawa M, 1999, BIOCHEMISTRY-US, V38, P5200, DOI 10.1021/bi982783v; Jameson GNL, 2003, J AM CHEM SOC, V125, P1146, DOI 10.1021/ja029338e; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 2003, STRUCTURE, V11, P1051, DOI 10.1016/S0969-2126(03)00186-2; Knaff D. B., 1996, ADV PHOTOSYNTHESIS O, P333; Kurisu G, 2001, NAT STRUCT BIOL, V8, P117, DOI 10.1038/84097; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAUBLE H, 1994, J MOL BIOL, V237, P437, DOI 10.1006/jmbi.1994.1246; Layer G, 2003, EMBO J, V22, P6214, DOI 10.1093/emboj/cdg598; LELONG C, 1995, BIOCHEMISTRY-US, V34, P14462, DOI 10.1021/bi00044a024; Lennon BW, 2000, SCIENCE, V289, P1190, DOI 10.1126/science.289.5482.1190; Lepore BW, 2005, P NATL ACAD SCI USA, V102, P13819, DOI 10.1073/pnas.0505726102; Manieri W, 2003, FEBS LETT, V549, P167, DOI 10.1016/S0014-5793(03)00811-1; Morales R, 2000, EMBO REP, V1, P271, DOI 10.1093/embo-reports/kvd057; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; ONUCHIC JN, 1992, ANNU REV BIOPH BIOM, V21, P349, DOI 10.1146/annurev.biophys.21.1.349; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Powell HR, 1999, ACTA CRYSTALLOGR D, V55, P1690, DOI 10.1107/S0907444999009506; SCHURMANN P, 1993, CHIMIA, V47, P245; Schurmann P, 2003, ANTIOXID REDOX SIGN, V5, P69, DOI 10.1089/152308603321223559; Schurmann P, 1995, PHOTOSYNTH RES, V46, P309, DOI 10.1007/BF00020445; SCHURMANN P, 1995, METHOD ENZYMOL, V252, P274; Staples CR, 1996, BIOCHEMISTRY-US, V35, P11425, DOI 10.1021/bi961007p; Staples CR, 1998, BIOCHEMISTRY-US, V37, P4612, DOI 10.1021/bi9729763; STURA EA, 1999, CRYSTALLIZATION NUCL, P99; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; van den Heuvel RHH, 2003, J MOL BIOL, V330, P113, DOI 10.1016/S0022-2836(03)00522-9; Walters EM, 2005, J AM CHEM SOC, V127, P9612, DOI 10.1021/ja051909q; Walters EM, 2004, PHOTOSYNTH RES, V79, P249, DOI 10.1023/B:PRES.0000017195.05870.61; WEDEL N, 1992, PLANT MOL BIOL, V18, P527, DOI 10.1007/BF00040668; Xu XF, 2006, FEBS LETT, V580, P6714, DOI 10.1016/j.febslet.2006.11.027	51	103	111	1	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 5	2007	448	7149					92	102		10.1038/nature05937	http://dx.doi.org/10.1038/nature05937			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185OS	17611542				2022-12-28	WOS:000247720900044
J	Thomas, PC; Armstrong, JW; Asmar, SW; Burns, JA; Denk, T; Giese, B; Helfenstein, P; Iess, L; Johnson, TV; McEwen, A; Nicolaisen, L; Porco, C; Rappaport, N; Richardson, J; Somenzi, L; Tortora, P; Turtle, EP; Veverka, J				Thomas, P. C.; Armstrong, J. W.; Asmar, S. W.; Burns, J. A.; Denk, T.; Giese, B.; Helfenstein, P.; Iess, L.; Johnson, T. V.; McEwen, A.; Nicolaisen, L.; Porco, C.; Rappaport, N.; Richardson, J.; Somenzi, L.; Tortora, P.; Turtle, E. P.; Veverka, J.			Hyperion's sponge-like appearance	NATURE			English	Article							CHAOTIC ROTATION; SMALL SATELLITES; IMPACT; GEOLOGY; ASTEROIDS; DYNAMICS; IAPETUS; IMAGES; PHOEBE; SATURN	Hyperion is Saturn's largest known irregularly shaped satellite and the only moon observed to undergo chaotic rotation(1-3). Previous work has identified Hyperion's surface as distinct from other small icy objects(4,5) but left the causes unsettled. Here we report high-resolution images that reveal a unique sponge-like appearance at scales of a few kilometres. Mapping shows a high surface density of relatively well-preserved craters two to ten kilometres across. We have also determined Hyperion's size and mass, and calculated the mean density as 544 +/- 50 kg m(-3), which indicates a porosity of > 40 per cent. The high porosity may enhance preservation of craters by minimizing the amount of ejecta produced or retained(6,7), and accordingly may be the crucial factor in crafting this unusual surface.	Cornell Univ, Ctr Radiophys & Space Res, Ithaca, NY 14853 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Free Univ Berlin, Inst Geol Wissenschaft, D-12249 Berlin, Germany; German Aerosp Ctr, Inst Planetary Res, D-12489 Berlin, Germany; Univ Roma La Sapienza, Dipartimento Ingn Aerosp & Astronaut, I-00184 Rome, Italy; Univ Arizona, Dept Planetary Sci, Tucson, AZ 85721 USA; Univ Calif Los Angeles, Dept Phys & Astron, Los Angeles, CA 90095 USA; Space Sci Inst, Boulder, CO 80301 USA; Univ Bologna, DIEM II Fac Ingn, Forli, Italy; Johns Hopkins Univ, Appl Phys Lab, Laurel, MD 20723 USA	Cornell University; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Free University of Berlin; Helmholtz Association; German Aerospace Centre (DLR); Sapienza University Rome; University of Arizona; University of California System; University of California Los Angeles; University of Bologna; Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory	Thomas, PC (corresponding author), Cornell Univ, Ctr Radiophys & Space Res, Ithaca, NY 14853 USA.	pct2@cornell.edu	IESS, Luciano/F-4902-2011; Turtle, Elizabeth/K-8673-2012; Tortora, Paolo/J-6191-2012	IESS, Luciano/0000-0002-6230-5825; Turtle, Elizabeth/0000-0003-1423-5751; Tortora, Paolo/0000-0001-9259-7673				[Anonymous], 1989, OXFORD MONOGRAPHS GE; Armstrong JW, 2003, ASTROPHYS J, V599, P806, DOI 10.1086/379505; Asphaug E, 2002, ASTEROIDS, P463; BINZEL RP, 1986, NATURE, V320, P511, DOI 10.1038/320511a0; BLACK GJ, 1995, ICARUS, V117, P149, DOI 10.1006/icar.1995.1148; Buratti BJ, 2005, ICARUS, V175, P490, DOI 10.1016/j.icarus.2004.11.024; CARR MH, 1994, ICARUS, V107, P61, DOI 10.1006/icar.1994.1006; Chapman CR, 2002, ICARUS, V155, P104, DOI 10.1006/icar.2001.6744; Clark R. N., 1986, SATELLITES, P437; CRIDDLE KE, 2006, 29 ANN AAS GUID CONT; CRUIKSHANK DP, 1983, ICARUS, V53, P90, DOI 10.1016/0019-1035(83)90023-4; FANALE FP, 1989, ICARUS, V82, P97, DOI 10.1016/0019-1035(89)90026-2; Housen KR, 2003, ICARUS, V163, P102, DOI 10.1016/S0019-1035(03)00024-1; KLAVETTER JJ, 1989, ASTRON J, V97, P570, DOI 10.1086/115006; KLAVETTER JJ, 1989, ASTRON J, V98, P1855, DOI 10.1086/115264; Moore JM, 1999, ICARUS, V140, P294, DOI 10.1006/icar.1999.6132; PIKE RJ, 1977, IMPACT EXPLOSION CRA, P484; Porco CC, 2005, SCIENCE, V307, P1237, DOI 10.1126/science.1107981; PORCO CC, 2006, ANN LUN PLAN SCI C, V37, P2289; Richardson JE, 2005, ICARUS, V179, P325, DOI 10.1016/j.icarus.2005.07.005; RICHARDSON JE, UNPUB ICARUS; SCHENK PM, 1991, J GEOPHYS RES-PLANET, V96, P15635, DOI 10.1029/91JE00932; SMITH BA, 1982, SCIENCE, V215, P504, DOI 10.1126/science.215.4532.504; Sugita S, 2005, SCIENCE, V310, P274, DOI 10.1126/science.1119091; THOMAS PC, 1995, ICARUS, V117, P128, DOI 10.1006/icar.1995.1147; THOMAS PC, 1993, ICARUS, V105, P326, DOI 10.1006/icar.1993.1130; Thomas PC, 1999, ICARUS, V140, P17, DOI 10.1006/icar.1999.6121; Wilkening L. L, 1982, IAU C 61 COMET DISCO, P85; WISDOM J, 1984, ICARUS, V58, P137, DOI 10.1016/0019-1035(84)90032-0	29	46	46	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 5	2007	448	7149					50	53		10.1038/nature05779	http://dx.doi.org/10.1038/nature05779			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185OS	17611535				2022-12-28	WOS:000247720900034
J	Yoon, HH				Yoon, Harry H.			Adapting to duty-hour limits - Four years on	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Johns Hopkins Sch Med, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins Medicine	Yoon, HH (corresponding author), Johns Hopkins Sch Med, Baltimore, MD 21218 USA.								0	18	19	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 28	2007	356	26					2668	2670		10.1056/NEJMp078070	http://dx.doi.org/10.1056/NEJMp078070			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	183HS	17596599				2022-12-28	WOS:000247564500002
J	Koes, BW; van Tulder, MW; Peul, WC				Koes, B. W.; van Tulder, M. W.; Peul, W. C.			Diagnosis and treatment of sciatica	BMJ-BRITISH MEDICAL JOURNAL			English	Review							LOW-BACK-PAIN; LUMBAR-DISK HERNIATION; RESEARCH TRIAL SPORT; NONOPERATIVE TREATMENT; SPINE; PATHOPHYSIOLOGY; RADICULOPATHY		Erasmus MC, Univ Med Ctr Rotterdam, Dept Gen Practice, NL-3000 CA Rotterdam, Netherlands; Vrije Univ Amsterdam Med Ctr, EMGO Inst, Amsterdam, Netherlands; Leiden Univ, Med Ctr, Dept Neurosurg, Leiden, Netherlands	Erasmus University Rotterdam; Erasmus MC; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Koes, BW (corresponding author), Erasmus MC, Univ Med Ctr Rotterdam, Dept Gen Practice, POB 2040, NL-3000 CA Rotterdam, Netherlands.	b.koes@erasmusmc.nl	van Tulder, Maurits/AAB-9785-2022; Koes, Bart w/K-4614-2016	van Tulder, Maurits/0000-0002-7589-8471; Koes, Bart w/0000-0002-0450-9969				Awad JN, 2006, CLIN ORTHOP RELAT R, P183, DOI 10.1097/01.blo.0000198724.54891.3a; Deville WLJM, 2000, SPINE, V25, P1140, DOI 10.1097/00007632-200005010-00016; GIBSON JN, 2007, COCHRANE DATABA 0124; Govind Jay, 2004, Aust Fam Physician, V33, P409; Hagen KB, 2005, SPINE, V30, P542, DOI 10.1097/01.brs.0000154625.02586.95; Jarvik JG, 2002, ANN INTERN MED, V137, P586, DOI 10.7326/0003-4819-137-7-200210010-00010; JENSEN MC, 1994, NEW ENGL J MED, V331, P69, DOI 10.1056/NEJM199407143310201; Koes BW, 2001, SPINE, V26, P2504, DOI 10.1097/00007632-200111150-00022; Korhonen T, 2006, SPINE, V31, P2759, DOI 10.1097/01.brs.0000245873.23876.1e; LUIJSTERBURG PAJ, 2007, EUR SPINE J     0406; Miranda H, 2002, SPINE, V27, P1102, DOI 10.1097/00007632-200205150-00017; MODIC MT, 1995, RADIOLOGY, V195, P429, DOI 10.1148/radiology.195.2.7724762; Modic MT, 2005, RADIOLOGY, V237, P597, DOI 10.1148/radiol.2372041509; Mulleman D, 2006, JOINT BONE SPINE, V73, P270, DOI 10.1016/j.jbspin.2005.03.004; Mulleman D, 2006, JOINT BONE SPINE, V73, P151, DOI 10.1016/j.jbspin.2005.03.003; Osterman H, 2006, SPINE, V31, P2409; van Tulder MW, 2006, EUR SPINE J, V15, pS82, DOI 10.1007/s00586-005-1049-5; Vroomen PCAJ, 1999, J NEUROL, V246, P899, DOI 10.1007/s004150050480; Vroomen PCAJ, 2000, J SPINAL DISORD, V13, P463, DOI 10.1097/00002517-200012000-00001; WEBER H, 1993, SPINE, V18, P1433, DOI 10.1097/00007632-199309010-00006; WEBER H, 1983, SPINE, V8, P131, DOI 10.1097/00007632-198303000-00003; Weinstein JN, 2006, JAMA-J AM MED ASSOC, V296, P2451, DOI 10.1001/jama.296.20.2451; Weinstein JN, 2006, JAMA-J AM MED ASSOC, V296, P2441, DOI 10.1001/jama.296.20.2441; Weinstein JN, 2006, SPINE, V31, P2707, DOI 10.1097/01.brs.0000248132.15231.fe; Younes M, 2006, JOINT BONE SPINE, V73, P538, DOI 10.1016/j.jbspin.2005.10.022	25	262	273	0	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 23	2007	334	7607					1313	1317		10.1136/bmj.39223.428495.BE	http://dx.doi.org/10.1136/bmj.39223.428495.BE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184MI	17585160	Green Accepted, Green Published			2022-12-28	WOS:000247645400032
J	Verdun, RE; Karlseder, J				Verdun, Ramiro E.; Karlseder, Jan			Replication and protection of telomeres	NATURE			English	Review							OXYTRICHA MACRONUCLEAR DNA; END-BINDING-PROTEIN; NORMAL HUMAN-CELLS; HUMAN ALT CELLS; HOMOLOGOUS RECOMBINATION; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; IN-VIVO; MAMMALIAN TELOMERES; HUMAN-CHROMOSOMES	During the evolution of linear genomes, it became essential to protect the natural chromosome ends to prevent triggering of the DNA-damage repair machinery and enzymatic attack. Telomeres - tightly regulated complexes consisting of repetitive G-rich DNA and specialized proteins - accomplish this task. Telomeres not only conceal linear chromosome ends from detection and inappropriate repair but also provide a buffer to counteract replication-associated shortening. Lessons from many model organisms have taught us about the complications of maintaining these specialized structures. Here, we discuss how telomeres interact and cooperate with the DNA replication and DNA-damage repair machineries.	Salk Inst Biol Studies, La Jolla, CA 92037 USA	Salk Institute	Karlseder, J (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	karlseder@salk.edu						Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Bailey SM, 2004, NUCLEIC ACIDS RES, V32, P3743, DOI 10.1093/nar/gkh691; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Bechter OE, 2004, CELL CYCLE, V3, P547; Bianchi A, 2004, MOL CELL, V16, P139, DOI 10.1016/j.molcel.2004.09.009; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Booth C, 2001, NUCLEIC ACIDS RES, V29, P4414, DOI 10.1093/nar/29.21.4414; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Celli GB, 2005, NAT CELL BIOL, V7, P712, DOI 10.1038/ncb1275; Cesare AJ, 2004, MOL CELL BIOL, V24, P9948, DOI 10.1128/MCB.24.22.9948-9957.2004; Chai WH, 2006, MOL CELL, V21, P427, DOI 10.1016/j.molcel.2005.12.004; Chan SWL, 2003, MOL CELL, V11, P1379, DOI 10.1016/S1097-2765(03)00174-6; Chan SWL, 2001, CURR BIOL, V11, P1240, DOI 10.1016/S0960-9822(01)00391-8; Chandra A, 2001, GENE DEV, V15, P404, DOI 10.1101/gad.861001; Chang S, 2004, NAT GENET, V36, P877, DOI 10.1038/ng1389; Colgin LM, 2003, CURR BIOL, V13, P942, DOI 10.1016/S0960-9822(03)00339-7; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Crabbe L, 2004, SCIENCE, V306, P1951, DOI 10.1126/science.1103619; Cristofari G, 2006, EMBO J, V25, P565, DOI 10.1038/sj.emboj.7600952; DADDA DF, 2003, NATURE, V426, P194, DOI DOI 10.1038/NATURE02118; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; de Lange T, 2004, NAT REV MOL CELL BIO, V5, P323, DOI 10.1038/nrm1359; de Lange T, 1999, CELL, V98, P273, DOI 10.1016/S0092-8674(00)81955-8; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Diede SJ, 1999, CELL, V99, P723, DOI 10.1016/S0092-8674(00)81670-0; Dionne I, 1996, P NATL ACAD SCI USA, V93, P13902, DOI 10.1073/pnas.93.24.13902; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Fan XQ, 1997, MOL BIOL CELL, V8, P2145, DOI 10.1091/mbc.8.11.2145; Ferreira MG, 2001, MOL CELL, V7, P55, DOI 10.1016/S1097-2765(01)00154-X; Fisher TS, 2005, DNA REPAIR, V4, P1215, DOI 10.1016/j.dnarep.2005.04.021; Fisher TS, 2004, NAT STRUCT MOL BIOL, V11, P1198, DOI 10.1038/nsmb854; Garvik B, 1996, MOL CELL BIOL, V16, P457; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; Grandin N, 1997, GENE DEV, V11, P512, DOI 10.1101/gad.11.4.512; Grandin N, 2001, EMBO J, V20, P1173, DOI 10.1093/emboj/20.5.1173; GRAY JT, 1991, CELL, V67, P807, DOI 10.1016/0092-8674(91)90075-A; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Grossi S, 2004, GENE DEV, V18, P992, DOI 10.1101/gad.300004; Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Herbig U, 2006, SCIENCE, V311, P1257, DOI 10.1126/science.1122446; Hockemeyer D, 2005, EMBO J, V24, P2667, DOI 10.1038/sj.emboj.7600733; Hockemeyer D, 2006, CELL, V126, P63, DOI 10.1016/j.cell.2006.04.044; Horvath MP, 1998, CELL, V95, P963, DOI 10.1016/S0092-8674(00)81720-1; Jacob NK, 2003, MOL CELL, V11, P1021, DOI 10.1016/S1097-2765(03)00131-X; Jacob NK, 2001, EMBO J, V20, P4299, DOI 10.1093/emboj/20.15.4299; Joeng KS, 2004, NAT GENET, V36, P607, DOI 10.1038/ng1356; Karlseder J, 2003, MOL CELL BIOL, V23, P6533, DOI 10.1128/MCB.23.18.6533-6541.2003; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lendvay TS, 1996, GENETICS, V144, P1399; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Liu Y, 2000, CURR BIOL, V10, P1459, DOI 10.1016/S0960-9822(00)00805-8; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; Lundblad V, 2002, ONCOGENE, V21, P522, DOI 10.1038/sj.onc.1205079; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; McEachern MJ, 2006, ANNU REV BIOCHEM, V75, P111, DOI 10.1146/annurev.biochem.74.082803.133234; Mieczkowski PA, 2003, P NATL ACAD SCI USA, V100, P10854, DOI 10.1073/pnas.1934561100; Miller KM, 2006, NATURE, V440, P824, DOI 10.1038/nature04638; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Nakamura M, 2005, MOL CELL BIOL, V25, P11073, DOI 10.1128/MCB.25.24.11073-11088.2005; Nakamura TM, 2002, GENETICS, V161, P1437; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Pennock E, 2001, CELL, V104, P387, DOI 10.1016/S0092-8674(01)00226-4; PRICE CM, 1987, GENE DEV, V1, P783, DOI 10.1101/gad.1.8.783; Raices M, 2005, PLOS GENET, V1, P295, DOI 10.1371/journal.pgen.0010030; Ranganathan V, 2001, CURR BIOL, V11, P962, DOI 10.1016/S0960-9822(01)00267-6; Reddel RR, 2003, LANCET, V361, P1840, DOI 10.1016/S0140-6736(03)13538-6; RHODES D, 1995, CURR OPIN STRUC BIOL, V5, P311, DOI 10.1016/0959-440X(95)80092-1; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Seger YR, 2002, CANCER CELL, V2, P401, DOI 10.1016/S1535-6108(02)00183-6; Sfeir AJ, 2005, MOL CELL, V18, P131, DOI 10.1016/j.molcel.2005.02.035; Shay JW, 2000, NAT REV MOL CELL BIO, V1, P72, DOI 10.1038/35036093; SINGH D, 1994, INDIAN J CHEM TECHN, V1, P266; Smogorzewska A, 2002, CURR BIOL, V12, P1635, DOI 10.1016/S0960-9822(02)01179-X; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Takata H, 2005, MOL CELL, V17, P573, DOI 10.1016/j.molcel.2005.01.014; Takata H, 2004, MOL CELL, V14, P515, DOI 10.1016/S1097-2765(04)00262-X; Teixeira MT, 2004, CELL, V117, P323, DOI 10.1016/S0092-8674(04)00334-4; Tsukamoto Y, 2001, CURR BIOL, V11, P1328, DOI 10.1016/S0960-9822(01)00372-4; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Varley H, 2002, NAT GENET, V30, P301, DOI 10.1038/ng834; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Verdun RE, 2006, CELL, V127, P709, DOI 10.1016/j.cell.2006.09.034; Verdun RE, 2005, MOL CELL, V20, P551, DOI 10.1016/j.molcel.2005.09.024; Wang RC, 2004, CELL, V119, P355, DOI 10.1016/j.cell.2004.10.011; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Wellinger RJ, 1996, CELL, V85, P423, DOI 10.1016/S0092-8674(00)81120-4; Wu L, 2006, CELL, V126, P49, DOI 10.1016/j.cell.2006.05.037; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	100	370	388	0	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 21	2007	447	7147					924	931		10.1038/nature05976	http://dx.doi.org/10.1038/nature05976			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180NU	17581575				2022-12-28	WOS:000247373100034
J	Tseng, CW; Mangione, CM; Brook, RH; Keeler, E; Dudley, RA				Tseng, Chien-Wen; Mangione, Carol M.; Brook, Robert H.; Keeler, Emmett; Dudley, R. Adams			Identifying widely covered drugs and drug coverage variation among Medicare Part D formularies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BENEFICIARIES; BENEFIT; ADULTS; CAPS	Context Clinicians can find it difficult to know which drugs are covered for their Medicare patients because formularies vary widely among Medicare Part D plans and many states have 50 or more such plans. Objective To determine whether Part D formularies in California ( the state with the most Medicare beneficiaries) and Hawaii have at least 1 drug within each of 8 treatment classes for hypertension, hyperlipidemia, and depression that can be identified for clinicians as "widely covered" by the vast majority of Part D plans. Design and Setting Use of the medicare. gov Web site ( March 1-April 15, 2006) to examine 72 California and 43 Hawaii Part D formularies' coverage of 8 treatment classes (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, calcium channel blockers, loop diuretics, selective serotonin reuptake inhibitors, statins, and thiazide diuretics), with evaluation of how often drugs were widely covered ( defined as inclusion in >= 90% of formularies at co-payments of <=$35 without prior authorization). Main Outcome Measure Identification of treatment classes with at least 1 widely covered drug. Results For California, coverage for the 75 drugs examined ranged from 7% to 100%. Despite this variation, 7 of 8 classes ( excluding angiotensin II receptor blockers) had at least 1 widely covered drug. Of the 34 widely covered drugs (45%), all but 2 were generic. Restricting widely covered to include 95% or more of formularies at co-payments of $15 or less still resulted in 7 of 8 classes with at least 1 widely covered drug. Overall, 73% of generic drugs and 6% of brand-name drugs were widely covered. Findings were similar for Hawaii. Conclusions Formularies varied substantially; however, all but 1 treatment class examined had 1 or more widely covered drugs at low co-payments. Knowing which drugs are widely covered would assist clinicians in prescribing, since not all generic drugs were widely covered. Clinicians should know that few brand-name drugs are widely covered and check coverage before prescribing.	Univ Hawaii, John A Burns Sch Med, Dept Family & Community Hlth, Honolulu, HI 96822 USA; RAND Corp, Santa Monica, CA USA; Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA; Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of Hawaii System; RAND Corporation; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Tseng, CW (corresponding author), Pacific Hlth Res Inst, 846 Hotel St,Suite 303, Honolulu, HI 96813 USA.	cwtseng@hawaii.edu			NIA NIH HHS [AG21684] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG021684] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*CA HEALTHC FDN, 2006, MED DRUG BEN GOOD AR; *CA HEALTHC FDN, 2006, MED DRUG BEN CAL FAC; Federman AD, 2001, JAMA-J AM MED ASSOC, V286, P1732, DOI 10.1001/jama.286.14.1732; Gibson TB, 2005, AM J MANAG CARE, V11, P730; Goldman DP, 2004, JAMA-J AM MED ASSOC, V291, P2344, DOI 10.1001/jama.291.19.2344; Haas JS, 2005, ANN INTERN MED, V142, P891, DOI 10.7326/0003-4819-142-11-200506070-00006; Hsu J, 2006, NEW ENGL J MED, V354, P2349, DOI 10.1056/NEJMsa054436; Huskamp HA, 2005, J GEN INTERN MED, V20, P662, DOI 10.1007/s11606-005-0115-3; *KAIS FAM FDN, 2005, MED GLANC; *KAIS FAM FDN, 2006, SEN EARL EXP THEIR N; *KAIS FAM FDN, 2006, BEN DES FORM MED DRU; *KAIS FAM FDN, 2006, IN DEPTH EX FORM OTH; *KAIS FAM FDN, 2006, MED PRESCR DRUG BEN; *KAIS FAM FDN, 2006, NAT SURV PHYS; *KAIS FAM FDN, 2003, PUBL KAIS FAM FDN; Kaiser Family Foundation, STAT HLTH FACTS; Kaiser Family Foundation, 2007, MED PRIM; Landon BE, 2004, HEALTH AFFAIR, V23, P218, DOI 10.1377/hlthaff.23.1.218; *MED LETT, TREATM GUID; *MED LETT, MED LETT; *NAT AMB MED CAR S, HLTH US 2005; *OR HLTH SCI U, DRUG EFF REV PROJ; PETERSON S, 2007, TRACKING MEDICARE HL; Piette JD, 2004, AM J PUBLIC HEALTH, V94, P1782, DOI 10.2105/AJPH.94.10.1782; Piette JD, 2004, DIABETES CARE, V27, P384, DOI 10.2337/diacare.27.2.384; Shrank WH, 2004, J AM BOARD FAM PRACT, V17, P401, DOI 10.3122/jabfm.17.6.401; Soumerai SB, 2006, ARCH INTERN MED, V166, P1829, DOI 10.1001/archinte.166.17.1829; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; The Cochrane Collaboration, COCHR LIB; Tseng CW, 2004, JAMA-J AM MED ASSOC, V292, P952, DOI 10.1001/jama.292.8.952; Wilson IB, 2005, J GEN INTERN MED, V20, P715, DOI 10.1111/j.1525-1497.2005.0128.x; 2006, MED NEWS TODAY  0214	32	14	14	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 20	2007	297	23					2596	2602		10.1001/jama.297.23.2596	http://dx.doi.org/10.1001/jama.297.23.2596			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180HB	17579228	Green Submitted			2022-12-28	WOS:000247352600022
J	Bendall, SC; Stewart, MH; Menendez, P; George, D; Vijayaragavan, K; Werbowetski-Ogilvie, T; Ramos-Mejia, V; Rouleau, A; Yang, JB; Bosse, M; Lajoie, G; Bhatia, M				Bendall, Sean C.; Stewart, Morag H.; Menendez, Pablo; George, Dustin; Vijayaragavan, Kausalia; Werbowetski-Ogilvie, Tamra; Ramos-Mejia, Veronica; Rouleau, Anne; Yang, Jiabi; Bosse, Marc; Lajoie, Gilles; Bhatia, Mickie			IGF and FGF cooperatively establish the regulatory stem cell niche of pluripotent human cells in vitro	NATURE			English	Article							MOUSE EMBRYONIC FIBROBLASTS; SELF-RENEWAL; GROWTH; RECEPTOR; EXPRESSION; DIFFERENTIATION; SB-431542; INHIBITOR; SUPPORT; CULTURE	Distinctive properties of stem cells are not autonomously achieved, and recent evidence points to a level of external control from the microenvironment. Here, we demonstrate that self-renewal and pluripotent properties of human embryonic stem (ES) cells depend on a dynamic interplay between human ES cells and autologously derived human ES cell fibroblast-like cells (hdFs). Human ES cells and hdFs are uniquely defined by insulin-like growth factor (IGF)- and fibroblast growth factor (FGF)-dependence. IGF 1 receptor (IGF1R) expression was exclusive to the human ES cells, whereas FGF receptor 1 (FGFR1) expression was restricted to surrounding hdFs. Blocking the IGF-II/IGF1R pathway reduced survival and clonogenicity of human ES cells, whereas inhibition of the FGF pathway indirectly caused differentiation. IGF-II is expressed by hdFs in response to FGF, and alone was sufficient in maintaining human ES cell cultures. Our study demonstrates a direct role of the IGF-II/IGF1R axis on human ES cell physiology and establishes that hdFs produced by human ES cells themselves define the stem cell niche of pluripotent human stem cells.	McMaster Univ, Michael G DeGroote Sch Med, McMaster Stem Cell & Canc Res Inst, Hamilton, ON L8N 3Z5, Canada; Univ Western Ontario, Don Rix Prot Identificat Facil, Dept Biochem, Schulich Sch Med & Dent, London, ON N6A 5C1, Canada	McMaster University; Western University (University of Western Ontario)	Bhatia, M (corresponding author), McMaster Univ, Michael G DeGroote Sch Med, McMaster Stem Cell & Canc Res Inst, Hamilton, ON L8N 3Z5, Canada.	mbhatia@mcmaster.ca	Vijayaragavan, Kausalia/AAM-8590-2021; Bujan, Pablo Menendez/W-3736-2017; Bendall, Sean/AGG-0126-2022; Bosse, Marc/AAM-8593-2021; Ramos-Mejia, Veronica/C-4338-2017	Bujan, Pablo Menendez/0000-0001-9372-1007; Ramos-Mejia, Veronica/0000-0002-8013-4273; Werbowetski-Ogilvie, Tamra/0000-0002-5469-0559; Bendall, Sean/0000-0003-1341-2453				Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Chi MMY, 2000, ENDOCRINOLOGY, V141, P4784, DOI 10.1210/en.141.12.4784; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; Dvorak P, 2005, STEM CELLS, V23, P1200, DOI 10.1634/stemcells.2004-0303; Greber B, 2007, STEM CELLS, V25, P455, DOI 10.1634/stemcells.2006-0476; Heyner S, 1997, Early Pregnancy, V3, P153; Hoffman LM, 2005, NAT BIOTECHNOL, V23, P699, DOI 10.1038/nbt1102; Hofmann F, 2005, DRUG DISCOV TODAY, V10, P1041, DOI 10.1016/S1359-6446(05)03512-9; HUANG S, 1992, NATURE, V360, P745, DOI 10.1038/360745a0; HUANG S, 1994, NATURE, V368, P664, DOI 10.1038/368664a0; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Kauma SW, 2000, J REPROD FERTIL, P31; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; Levenstein ME, 2006, STEM CELLS, V24, P568, DOI 10.1634/stemcells.2005-0247; Lighten AD, 1997, MOL REPROD DEV, V47, P134, DOI 10.1002/(SICI)1098-2795(199706)47:2<134::AID-MRD2>3.0.CO;2-N; Ludwig TE, 2006, NAT BIOTECHNOL, V24, P185, DOI 10.1038/nbt1177; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; ORFAO A, 1995, SCAND J CLIN LAB INV, V55, P145, DOI 10.3109/00365519509090577; ORFAO A, 1995, HAEMATOLOGICA, V80, P69; Rosler ES, 2004, DEV DYNAM, V229, P259, DOI 10.1002/dvdy.10430; Scadden DT, 2006, NATURE, V441, P1075, DOI 10.1038/nature04957; Sperger JM, 2003, P NATL ACAD SCI USA, V100, P13350, DOI 10.1073/pnas.2235735100; Stewart MH, 2006, NAT METHODS, V3, P807, DOI 10.1038/nmeth939; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tropepe V, 2001, NEURON, V30, P65, DOI 10.1016/S0896-6273(01)00263-X; Vallier L, 2004, DEV BIOL, V275, P403, DOI 10.1016/j.ydbio.2004.08.031; Wang LS, 2005, BLOOD, V105, P4598, DOI 10.1182/blood-2004-10-4065; Xu CH, 2005, STEM CELLS, V23, P315, DOI 10.1634/stemcells.2004-0211; Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971; Xu RH, 2005, NAT METHODS, V2, P185, DOI 10.1038/NMETH744; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X	31	475	537	1	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 30	2007	448	7157					1015	U3		10.1038/nature06027	http://dx.doi.org/10.1038/nature06027			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	205EU	17625568				2022-12-28	WOS:000249097600030
J	Loh, KY; Yushak, AW				Loh, Keng Yin; Yushak, Abd Wahab			Virchow's node (Troisier's sign)	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Int Med Univ, Seremban 70300, Malaysia	International Medical University Malaysia	Loh, KY (corresponding author), Int Med Univ, Seremban 70300, Malaysia.								0	3	4	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 19	2007	357	3					282	282		10.1056/NEJMicm063871	http://dx.doi.org/10.1056/NEJMicm063871			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191FH	17634463				2022-12-28	WOS:000248115100009
J	Mazzone, T				Mazzone, Theodore			HDL cholesterol and atherosclerosis	LANCET			English	Editorial Material							INTIMA-MEDIA THICKNESS; RANDOMIZED CONTROLLED-TRIAL; SECONDARY PREVENTION; EVENTS; GEMFIBROZIL; NIACIN		Univ Illinois, Chicago, IL 61612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Mazzone, T (corresponding author), Univ Illinois, 1819 W Polk St, Chicago, IL 61612 USA.	tmazzone@uic.edu						CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; Dormandy JA, 2005, LANCET, V366, P1279, DOI 10.1016/S0140-6736(05)67528-9; KASTELEIN JJP, 2007, LANCET, V370, P153; KASTELEIN JJP, 2007, NEW ENGL J MED, V356, P1; Lorenz MW, 2007, CIRCULATION, V115, P459, DOI 10.1161/CIRCULATIONAHA.106.628875; Mazzone T, 2006, JAMA-J AM MED ASSOC, V296, P2572, DOI 10.1001/jama.296.21.joc60158; Nissen SE, 2007, NEW ENGL J MED, V356, P1304, DOI 10.1056/NEJMoa070635; Rader DJ, 2006, J CLIN INVEST, V116, P3090, DOI 10.1172/JCI30163; Robins SJ, 2001, JAMA-J AM MED ASSOC, V285, P1585, DOI 10.1001/jama.285.12.1585; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Taylor AJ, 2006, CURR MED RES OPIN, V22, P2243, DOI 10.1185/030079906X148508; Vaisar T, 2007, J CLIN INVEST, V117, P746, DOI 10.1172/JCI26206	12	7	8	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 14	2007	370	9582					107	108		10.1016/S0140-6736(07)61063-0	http://dx.doi.org/10.1016/S0140-6736(07)61063-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	190WP	17630020				2022-12-28	WOS:000248091600005
J	Melnick, JG; Parkin, G				Melnick, Jonathan G.; Parkin, Gerard			Cleaving mercury-alkyl bonds: A functional model for mercury detoxification by MerB	SCIENCE			English	Article							ORGANOMERCURIAL LYASE MERB; HG-C BOND; CRYSTAL-STRUCTURE; COMPLEXES; COORDINATION; PROTEINS; PROTONOLYSIS; RESISTANCE; MECHANISM; CATALYSIS	The extreme toxicity of organomercury compounds that are found in the environment has focused attention on the mechanisms of action of bacterial remediating enzymes. We describe facile room-temperature protolytic cleavage by a thiol of the Hg-C bond in mercury-alkyl compounds that emulate the structure and function of the organomercurial lyase MerB. Specifically, the tris( 2-mercapto-1-t-butylimidazolyl) hydroborato ligand [Tm-But], which features three sulfur donors, has been used to synthesize [Tm-But] HgR alkyl compounds (R = methyl or ethyl) that react with phenylthiol (PhSH) to yield [Tm-But] HgSPh and RH. Although [Tm-But] HgR compounds exist as linear two-coordinate complexes in the solid state, H-1 nuclear magnetic resonance spectroscopy indicates that the complexes exist in rapid equilibrium with their higher-coordinate [kappa(2)-Tm-But] HgR and [kappa(3)-Tm-But] HgR isomers in solution. Facile access to a higher-coordinate species is proposed to account for the exceptional reactivity of [ TmBut] HgR relative to that of other two-coordinate mercury-alkyl compounds.	Columbia Univ, Dept Chem, New York, NY 10027 USA	Columbia University	Parkin, G (corresponding author), Columbia Univ, Dept Chem, New York, NY 10027 USA.	parkin@columbia.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046502] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM046502] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBARO P, 1994, INORG CHEM, V33, P6163, DOI 10.1021/ic00104a029; Barkay T, 2003, FEMS MICROBIOL REV, V27, P355, DOI 10.1016/S0168-6445(03)00046-9; Benison GC, 2004, BIOCHEMISTRY-US, V43, P8333, DOI 10.1021/bi049662h; CANTY AJ, 1987, AUST J CHEM, V40, P1609, DOI 10.1071/CH9871609; Cassidy I, 2002, EUR J INORG CHEM, P1235; Clarkson TW, 2006, CRIT REV TOXICOL, V36, P609, DOI 10.1080/10408440600845619; Di Lello P, 2004, BIOCHEMISTRY-US, V43, P8322, DOI 10.1021/bi049669z; Fitzgerald WF, 2007, CHEM REV, V107, P641, DOI 10.1021/cr050353m; GOPINATH E, 1987, J AM CHEM SOC, V109, P7903, DOI 10.1021/ja00259a061; Hartwig A, 2002, FOOD CHEM TOXICOL, V40, P1179, DOI 10.1016/S0278-6915(02)00043-1; HOLLOWAY CE, 1995, J ORGANOMET CHEM, V495, P1, DOI 10.1016/0022-328X(95)05395-6; KREEVOY MM, 1957, J AM CHEM SOC, V79, P5927, DOI 10.1021/ja01579a025; Lobbia GG, 1998, J ORGANOMET CHEM, V552, P31; MOORE MJ, 1990, ACCOUNTS CHEM RES, V23, P301, DOI 10.1021/ar00177a006; Ni B, 2006, J PHYS CHEM A, V110, P9451, DOI 10.1021/jp061852+; NORRIS AR, 1983, CAN J CHEM, V61, P1536, DOI 10.1139/v83-267; Parkin G, 2004, CHEM REV, V104, P699, DOI 10.1021/cr0206263; Pitts KE, 2002, BIOCHEMISTRY-US, V41, P10287, DOI 10.1021/bi0259148; Rabinovich D, 2006, STRUCT BOND, V120, P143, DOI 10.1007/430_031; Razmiafshari M, 2001, TOXICOL APPL PHARM, V172, P1, DOI 10.1006/taap.2001.9132; Strasdeit H, 2000, ANGEW CHEM INT EDIT, V39, P784, DOI 10.1002/(SICI)1521-3773(20000218)39:4<784::AID-ANIE784>3.3.CO;2-Q; Tai HC, 2006, J PHYS CHEM A, V110, P452, DOI 10.1021/jp0529826; White JL, 2002, J CHEM SOC DALTON, P2987, DOI 10.1039/b111558h; Wilhelm M, 2004, EUR J INORG CHEM, P2301, DOI 10.1002/ejic.200300907; Witkiewicz-Kucharczyk A, 2006, TOXICOL LETT, V162, P29, DOI 10.1016/j.toxlet.2005.10.018; WRIGHT JG, 1990, PROG INORG CHEM, V38, P323	26	83	85	1	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 13	2007	317	5835					225	227		10.1126/science.1144314	http://dx.doi.org/10.1126/science.1144314			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	189DC	17626880				2022-12-28	WOS:000247968600036
J	Medema, RH; Burgering, BMT				Medema, Rene H.; Burgering, Boudewijn M. Th			The X factor: Skewing X inactivation towards cancer	CELL			English	Editorial Material							FOXP3; MUTATION; TUMOR	Increased expression of the epidermal growth factor receptor HER-2/ErbB2 is frequently observed in breast cancer and is targeted by the anticancer drug Herceptin. Now, Zuo et al. (2007) reveal that an X-linked gene encoding the transcription factor FOXP3 is a breast cancer tumor suppressor that represses expression of HER2/ErbB2.	Univ Med Ctr Utrecht, Dept Med Oncol, NL-3584 CG Utrecht, Netherlands; Univ Med Ctr Utrecht, Physiol Chem Lab, NL-3584 CG Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Medema, RH (corresponding author), Univ Med Ctr Utrecht, Dept Med Oncol, Univ Weg 100,Stratenum, NL-3584 CG Utrecht, Netherlands.	r.h.medema@umcutrecht.nl; b.m.t.burgering@umcutrecht.nl	Medema, Rene H/E-2981-2013; Medema, Rene H/G-5415-2011	Medema, Rene/0000-0002-6754-0381				Chang X, 2005, J EXP MED, V202, P1141, DOI 10.1084/jem.20050157; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Levine Arnold J., 2004, Cell, VS116, pS67, DOI 10.1016/S0092-8674(04)00036-4; Rivera MN, 2007, SCIENCE, V315, P642, DOI 10.1126/science.1137509; Santarosa M, 2004, BBA-REV CANCER, V1654, P105, DOI 10.1016/j.bbcan.2004.01.001; Wu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042; Zheng Y, 2007, NAT IMMUNOL, V8, P457, DOI 10.1038/ni1455	9	23	24	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 29	2007	129	7					1253	1254		10.1016/j.cell.2007.06.008	http://dx.doi.org/10.1016/j.cell.2007.06.008			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188HQ	17604714	Bronze			2022-12-28	WOS:000247911400010
J	Sandrelli, F; Tauber, E; Pegoraro, M; Mazzotta, G; Cisotto, P; Landskron, J; Stanewsky, R; Piccin, A; Rosato, E; Zordan, M; Costa, R; Kyriacou, CP				Sandrelli, Federica; Tauber, Eran; Pegoraro, Mirko; Mazzotta, Gabriella; Cisotto, Paola; Landskron, Johannes; Stanewsky, Ralf; Piccin, Alberto; Rosato, Ezio; Zordan, Mauro; Costa, Rodolfo; Kyriacou, Charalambos P.			A molecular basis for natural selection at the timeless locus in Drosophila melanogaster	SCIENCE			English	Article							CIRCADIAN CLOCK; LATITUDINAL CLINES; CRYPTOCHROME; PHOTORECEPTOR; ENTRAINMENT; PACEMAKER; PROTEIN	Diapause is a protective response to unfavorable environments that results in a suspension of insect development and is most often associated with the onset of winter. The ls-tim mutation in the Drosophila melanogaster clock gene timeless has spread in Europe over the past 10,000 years, possibly because it enhances diapause. We show that the mutant allele attenuates the photosensitivity of the circadian clock and causes decreased dimerization of the mutant TIMELESS protein isoform to CRYPTOCHROME, the circadian photoreceptor. This interaction results in a more stable TIMELESS product. These findings reveal a molecular link between diapause and circadian photoreception.	Univ Padua, Dept Biol, I-35131 Padua, Italy; Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England; Univ Regensburg, Lehrstuhl Entwicklungsbiol, Inst Zool, D-93040 Regensburg, Germany; Univ London Queen Mary Coll, Sch Biol & Chem Sci, London E1 4NS, England	University of Padua; University of Leicester; University of Regensburg; University of London; Queen Mary University London	Costa, R (corresponding author), Univ Padua, Dept Biol, I-35131 Padua, Italy.	rodolfo.costa@unipd.it	Tauber, Eran/F-9826-2011; Stanewsky, Ralf/ABB-9193-2021; Tauber, Eran/AAA-1562-2022	Tauber, Eran/0000-0003-4018-6535; Tauber, Eran/0000-0003-4018-6535; SANDRELLI, FEDERICA/0000-0002-5631-7467; Rosato, Ezio/0000-0001-7297-4697; Pegoraro, Mirko/0000-0001-9381-5249; MAZZOTTA, GABRIELLA MARGHERITA/0000-0001-5461-6837; Stanewsky, Ralf/0000-0001-8238-6864	Natural Environment Research Council [NE/D012058/1] Funding Source: researchfish; NERC [NE/D012058/1] Funding Source: UKRI	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Ashmore LJ, 2003, J BIOL RHYTHM, V18, P206, DOI [10.1177/0748730403018003003, 10.1177/0748730403253385]; Busza A, 2004, SCIENCE, V304, P1503, DOI 10.1126/science.1096973; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; Dissel S, 2004, NAT NEUROSCI, V7, P834, DOI 10.1038/nn1285; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Emery P, 2000, NATURE, V404, P456, DOI 10.1038/35006558; Helfrich-Forster C, 2001, NEURON, V30, P249, DOI 10.1016/S0896-6273(01)00277-X; Lin FJ, 2001, MOL CELL BIOL, V21, P7287, DOI 10.1128/MCB.21.21.7287-7294.2001; Martinek S, 2001, CELL, V105, P769, DOI 10.1016/S0092-8674(01)00383-X; Peschel N, 2006, P NATL ACAD SCI USA, V103, P17313, DOI 10.1073/pnas.0606675103; PITTENDRIGH CS, 1989, J BIOL RHYTHM, V4, P217; PITTENDRIGH CS, 1991, J BIOL RHYTHM, V6, P299, DOI 10.1177/074873049100600402; Rosato E, 1997, NUCLEIC ACIDS RES, V25, P455, DOI 10.1093/nar/25.3.455; Rosato E, 2001, CURR BIOL, V11, P909, DOI 10.1016/S0960-9822(01)00259-7; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Tauber E, 2007, SCIENCE, V316, P1895, DOI 10.1126/science.1138412; Young MW, 1996, COLD SPRING HARB SYM, V61, P279; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0	18	129	130	2	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 29	2007	316	5833					1898	1900		10.1126/science.1138426	http://dx.doi.org/10.1126/science.1138426			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183WI	17600216				2022-12-28	WOS:000247602700040
J	Chauhan, S; D'Cruz, S				Chauhan, Sandeep; D'Cruz, Sanjay			Saddle nose deformity	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Govt Med Coll & Hosp, Chandigarh 160030, India		Chauhan, S (corresponding author), Govt Med Coll & Hosp, Chandigarh 160030, India.	drsc88@rediffmail.com							0	2	2	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 28	2007	356	26					2720	2720		10.1056/NEJMicm063822	http://dx.doi.org/10.1056/NEJMicm063822			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	183HS	17596607				2022-12-28	WOS:000247564500011
J	Manson, JE; Allison, MA; Rossouw, JE; Carr, JJ; Langer, RD; Hsia, J; Kuller, LH; Cochrane, BB; Hunt, JR; Ludlam, SE; Pettinger, MB; Gass, M; Margolis, KL; Nathan, L; Ockene, JK; Prentice, RL; Robbins, J; Stefanick, ML; Rossouw, JE; Ludlam, S; Cochrane, BB; Hunt, JR; Lund, B; Prentice, R; Carr, JJ; O'Rourke, C; Du, L; Pillsbury, S; Hightower, C; Ellison, R; Tan, J; Wassertheil-Smoller, S; Magnani, M; Noble, DH; Dellicarpini, T; Manson, JE; Bueche, M; McGinnis, AD; Rybicki, FJ; Assaf, AR; Sloane, G; Phillips, LS; Butler, V; Huber, M; Vitali, J; Hsia, J; LeBrun, C; Palm, R; Embersit, D; Whitlock, E; Arnold, K; Sidney, S; Cantrell, V; Kotchen, JM; Feltz, C; Howard, BV; Thomas-Geevarghese, A; Boggs, G; Jelinick, JS; Greenland, P; Neuman, A; Carlson-Lund, G; Giovanazzi, SM; Stefanick, ML; Swope, S; Jackson, R; Toussant, K; Lewis, CE; Pierce, P; Stallings, C; Wactawski-Wende, J; Goel, S; Laughlin, R; Robbins, J; Zaragoza, S; Macias, D; Belisle, D; Nathan, L; Voigt, B; Goldin, J; Woo, M; Langer, RD; Allison, MA; Lien, X; Wright, CM; Gass, M; Sheridan, S; Robinson, JG; Feddersen, D; Kelly-Brake, K; Carroll, J; Ockene, J; Churchill, L; Lasser, NL; Miller, B; Maldjian, PD; Pierre-Louis, J; Fishman, J; O'Sullivan, MJ; Fernandez, D; Margolis, KL; Bjerk, CL; Truwit, C; Hearity, JA; Hyslop, WB; Darroch, K; Murphy, C; Heiss, G; Kuller, LH; Edmundowicz, D; Ives, D; Johnson, KC; Satterfield, S; Connelly, SA; Jones, EL; Brzyski, R; Nashawati, MA; Torchia, S; Rodriguez, A; Garza, R; Nentwich, P; Sarto, GE; Broderick, L; Sweitzer, NK; Nabel, E; Rossouw, JE; Ludlam, SE; Pottern, L; McGowan, J; Ford, L; Geller, N; Prentice, RL; Anderson, G; LaCroix, A; Kooperberg, CL; Patterson, RE; McTiernan, A; Shumaker, S; Stein, E; Cummings, S; Wassertheil-Smoller, S; Hays, J; Manson, JE; Assaf, AR; Phillips, L; Beresford, S; Hsia, J; Chlebowski, R; Whitlock, E; Caan, B; Kotchen, JM; Howard, BV; Van Horn, L; Black, H; Stefanick, ML; Lane, D; Jackson, R; Lewis, CE; Bassford, T; Wactawski-Wende, J; Robbins, J; Hubbell, FA; Judd, H; Langer, RD; Gass, M; Limacher, M; Curb, D; Wallace, R; Ockene, J; Lasser, N; O'Sullivan, MJ; Margolis, KL; Brunner, R; Heiss, G; Kuller, LH; Johnson, KC; Brzyski, R; Sarto, GE; Bonds, D; Hendrix, S				Manson, JoAnn E.; Allison, Matthew A.; Rossouw, Jacques E.; Carr, J. Jeffrey; Langer, Robert D.; Hsia, Judith; Kuller, Lewis H.; Cochrane, Barbara B.; Hunt, Julie R.; Ludlam, Shari E.; Pettinger, Mary B.; Gass, Margery; Margolis, Karen L.; Nathan, Lauren; Ockene, Judith K.; Prentice, Ross L.; Robbins, John; Stefanick, Marcia L.; Rossouw, J. E.; Ludlam, S.; Cochrane, B. B.; Hunt, J. R.; Lund, B.; Prentice, R.; Carr, J. J.; O'Rourke, C.; Du, L.; Pillsbury, S.; Hightower, C.; Ellison, R.; Tan, J.; Wassertheil-Smoller, S.; Magnani, M.; Noble, D. H.; Dellicarpini, T.; Manson, J. E.; Bueche, M.; McGinnis, A. D.; Rybicki, F. J.; Assaf, A. R.; Sloane, G.; Phillips, L. S.; Butler, V.; Huber, M.; Vitali, J.; Hsia, J.; LeBrun, C.; Palm, R.; Embersit, D.; Whitlock, E.; Arnold, K.; Sidney, S.; Cantrell, V.; Kotchen, J. M.; Feltz, C.; Howard, B. V.; Thomas-Geevarghese, A.; Boggs, G.; Jelinick, J. S.; Greenland, P.; Neuman, A.; Carlson-Lund, G.; Giovanazzi, S. M.; Stefanick, M. L.; Swope, S.; Jackson, R.; Toussant, K.; Lewis, C. E.; Pierce, P.; Stallings, C.; Wactawski-Wende, J.; Goel, S.; Laughlin, R.; Robbins, J.; Zaragoza, S.; Macias, D.; Belisle, D.; Nathan, L.; Voigt, B.; Goldin, J.; Woo, M.; Langer, R. D.; Allison, M. A.; Lien, X.; Wright, C. M.; Gass, M.; Sheridan, S.; Robinson, J. G.; Feddersen, D.; Kelly-Brake, K.; Carroll, J.; Ockene, J.; Churchill, L.; Lasser, N. L.; Miller, B.; Maldjian, P. D.; Pierre-Louis, J.; Fishman, J.; O'Sullivan, M. J.; Fernandez, D.; Margolis, K. L.; Bjerk, C. L.; Truwit, C.; Hearity, J. A.; Hyslop, W. B.; Darroch, K.; Murphy, C.; Heiss, G.; Kuller, L. H.; Edmundowicz, D.; Ives, D.; Johnson, K. C.; Satterfield, S.; Connelly, S. A.; Jones, E. L.; Brzyski, R.; Nashawati, M. A.; Torchia, S.; Rodriguez, A.; Garza, R.; Nentwich, P.; Sarto, G. E.; Broderick, L.; Sweitzer, N. K.; Nabel, E.; Rossouw, J. E.; Ludlam, S. E.; Pottern, L.; McGowan, J.; Ford, L.; Geller, N.; Prentice, R. L.; Anderson, G.; LaCroix, A.; Kooperberg, C. L.; Patterson, R. E.; McTiernan, A.; Shumaker, S.; Stein, E.; Cummings, S.; Wassertheil-Smoller, S.; Hays, J.; Manson, J. E.; Assaf, A. R.; Phillips, L.; Beresford, S.; Hsia, J.; Chlebowski, R.; Whitlock, E.; Caan, B.; Kotchen, J. M.; Howard, B. V.; Van Horn, L.; Black, H.; Stefanick, M. L.; Lane, D.; Jackson, R.; Lewis, C. E.; Bassford, T.; Wactawski-Wende, J.; Robbins, J.; Hubbell, F. A.; Judd, H.; Langer, R. D.; Gass, M.; Limacher, M.; Curb, D.; Wallace, R.; Ockene, J.; Lasser, N.; O'Sullivan, M. J.; Margolis, K. L.; Brunner, R.; Heiss, G.; Kuller, L. H.; Johnson, K. C.; Brzyski, R.; Sarto, G. E.; Bonds, D.; Hendrix, S.		WHI WHI-CACS Investigators	Estrogen therapy and coronary-artery calcification	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSTMENOPAUSAL HORMONE-THERAPY; REPLACEMENT THERAPY; COMPUTED-TOMOGRAPHY; HEART-DISEASE; CALCIUM; WOMEN; CT; ATHEROSCLEROSIS; QUANTIFICATION; ASSOCIATION	Background: Calcified plaque in the coronary arteries is a marker for atheromatous-plaque burden and is predictive of future risk of cardiovascular events. We examined the relationship between estrogen therapy and coronary-artery calcium in the context of a randomized clinical trial. Methods: In our ancillary substudy of the Women's Health Initiative trial of conjugated equine estrogens (0.625 mg per day) as compared with placebo in women who had undergone hysterectomy, we performed computed tomography of the heart in 1064 women aged 50 to 59 years at randomization. Imaging was conducted at 28 of 40 centers after a mean of 7.4 years of treatment and 1.3 years after the trial was completed (8.7 years after randomization). Coronary-artery calcium (or Agatston) scores were measured at a central reading center without knowledge of randomization status. Results: The mean coronary-artery calcium score after trial completion was lower among women receiving estrogen (83.1) than among those receiving placebo (123.1) (P=0.02 by rank test). After adjustment for coronary risk factors, the multivariate odds ratios for coronary-artery calcium scores of more than 0, 10 or more, and 100 or more in the group receiving estrogen as compared with placebo were 0.78 (95% confidence interval, 0.58 to 1.04), 0.74 (0.55 to 0.99), and 0.69 (0.48 to 0.98), respectively. The corresponding odds ratios among women with at least 80% adherence to the study estrogen or placebo were 0.64 (P=0.01), 0.55 (P<0.001), and 0.46 (P=0.001). For coronary-artery calcium scores of more than 300 (vs. <10), the multivariate odds ratio was 0.58 (P=0.03) in an intention-to-treat analysis and 0.39 (P=0.004) among women with at least 80% adherence. Conclusions: Among women 50 to 59 years old at enrollment, the calcified-plaque burden in the coronary arteries after trial completion was lower in women assigned to estrogen than in those assigned to placebo. However, estrogen has complex biologic effects and may influence the risk of cardiovascular events and other outcomes through multiple pathways. (ClinicalTrials.gov number, NCT00000611.).	Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02215 USA; Univ Calif San Diego, San Diego, CA 92103 USA; NHLBI, NIH, Bethesda, MD 20892 USA; Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA; Geisinger Hlth Syst, Danville, PA USA; George Washington Univ, Washington, DC USA; Univ Pittsburgh, Pittsburgh, PA USA; Univ Washington, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Univ Cincinnati, Cincinnati, OH USA; Healthpartners Res Fdn, Minneapolis, MN USA; Univ Minnesota, Minneapolis, MN USA; Univ Calif Los Angeles, Los Angeles, CA USA; Univ Massachusetts, Sch Med, Worcester, MA USA; Univ Calif Davis, Sacramento, CA 95817 USA; Stanford Univ, Palo Alto, CA 94304 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Wake Forest University; Geisinger Health System; George Washington University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University System of Ohio; University of Cincinnati; HealthPartners Institute for Education & Research; University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California Los Angeles; University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California Davis; Stanford University	Manson, JE (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Prevent Med, 900 Commonwealth Ave E,3rd Fl, Boston, MA 02215 USA.	jmanson@rics.bwh.harvard.edu	Carr, John/AAN-7531-2021; Greenland, Philip/ABD-5528-2021; Wactawski-Wende, Jean/AGH-5457-2022; Truwit, Charles/AAL-7140-2021	Carr, John/0000-0002-4398-8237; Wactawski-Wende, Jean/0000-0003-3096-9595; Truwit, Charles/0000-0001-8598-9812; Margolis, Karen/0000-0003-1862-7402; Allison, Matthew/0000-0003-0777-8272				AGATSTON AS, 1990, J AM COLL CARDIOL, V15, P827, DOI 10.1016/0735-1097(90)90282-T; Akhrass F, 2003, J CLIN ENDOCR METAB, V88, P5611, DOI 10.1210/jc.2003-031008; Allison MA, 2004, ARTERIOSCL THROM VAS, V24, P331, DOI 10.1161/01.ATV.0000110786.02097.0c; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Anderson GL, 2003, ANN EPIDEMIOL, V13, pS5, DOI 10.1016/S1047-2797(03)00043-7; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Arad Y, 2000, J AM COLL CARDIOL, V36, P1253, DOI 10.1016/S0735-1097(00)00872-X; Barrett-Connor E, 2005, MENOPAUSE, V12, P40, DOI 10.1097/00042192-200512010-00009; Budoff MJ, 2006, CIRCULATION, V114, P1761, DOI 10.1161/CIRCULATIONAHA.106.178458; Budoff MJ, 2005, J WOMENS HEALTH, V14, P410, DOI 10.1089/jwh.2005.14.410; Carr JJ, 2005, RADIOLOGY, V234, P35, DOI 10.1148/radiol.2341040439; Carr JJ, 2000, AM J ROENTGENOL, V174, P915, DOI 10.2214/ajr.174.4.1740915; Chae CU, 2004, CLIN TRIALS HEART DI, P349; Cheng YLJ, 2003, AM J CARDIOL, V92, P498, DOI 10.1016/S0002-9149(03)00714-8; Detrano RC, 2005, RADIOLOGY, V236, P477, DOI 10.1148/radiol.2362040513; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Greenland P, 2004, JAMA-J AM MED ASSOC, V291, P210, DOI 10.1001/jama.291.2.210; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Grodstein F, 2003, NEW ENGL J MED, V348, P645, DOI 10.1056/NEJMsb022365; Han C, 2004, STAT MED, V23, P3671, DOI 10.1002/sim.1925; Harman SM, 2005, CLIMACTERIC, V8, P3, DOI 10.1080/13697130500042417; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Hsia, 2006, ARCH INTERN MED, V166, P759; Hsia J, 2006, ARCH INTERN MED, V166, P357, DOI 10.1001/archinte.166.3.357; Manson JE, 2006, MENOPAUSE, V13, P139, DOI 10.1097/01.gme.0000177906.94515.ff; MAUTNER GC, 1994, RADIOLOGY, V192, P619, DOI 10.1148/radiology.192.3.8058924; Mendelsohn ME, 2005, SCIENCE, V308, P1583, DOI 10.1126/science.1112062; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Mikkola TS, 2002, CARDIOVASC RES, V53, P605, DOI 10.1016/S0008-6363(01)00466-7; *NAT I AG, 2007, ELITE EARL VERS LAT; Phillips LS, 2005, FERTIL STERIL, V83, P558, DOI 10.1016/j.fertnstert.2004.11.012; Raggi P, 2004, J AM COLL CARDIOL, V43, P1663, DOI 10.1016/j.jacc.2003.09.068; Robins JM, 2000, BIOMETRICS, V56, P779, DOI 10.1111/j.0006-341X.2000.00779.x; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rumberger JA, 1996, MAYO CLIN PROC, V71, P369, DOI 10.4065/71.4.369; Sangiorgi G, 1998, J AM COLL CARDIOL, V31, P126, DOI 10.1016/S0735-1097(97)00443-9; Schisterman EF, 2002, J WOMEN HEALTH GEN-B, V11, P631, DOI 10.1089/152460902760360577; Stary HC, 2001, AM J CARDIOL, V88, p16E; Stefanick ML, 2003, ANN EPIDEMIOL, V13, pS78, DOI 10.1016/S1047-2797(03)00045-0; Waters DD, 2002, JAMA-J AM MED ASSOC, V288, P2432, DOI 10.1001/jama.288.19.2432	40	519	547	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 21	2007	356	25					2591	2602		10.1056/NEJMoa071513	http://dx.doi.org/10.1056/NEJMoa071513			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180GN	17582069				2022-12-28	WOS:000247351200006
J	Bishop, M				Bishop, Marion			Life math	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												mcbishop@unmc.edu						BRADSTREET A, 1969, WORKS A BRADSTREET	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 18	2007	298	3					266	268		10.1001/jama.298.3.266	http://dx.doi.org/10.1001/jama.298.3.266			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	190US	17635878				2022-12-28	WOS:000248086700001
J	Carbillon, L				Carbillon, Lionel			Comment on "Maternal oxytocin triggers a transient inhibitory switch in GABA signaling in the fetal brain during delivery"	SCIENCE			English	Editorial Material							RAT; VASOPRESSIN; LABOR		Univ Paris 13, Hop Jean Verdier, Dept Obstet & Gynecol, Assistance Publ Hop Paris, F-93143 Bondy, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris 13	Carbillon, L (corresponding author), Univ Paris 13, Hop Jean Verdier, Dept Obstet & Gynecol, Assistance Publ Hop Paris, Ave 14 Juillet, F-93143 Bondy, France.	lionel.carbillon@jvr.aphp.fr						ALTSTEIN M, 1988, J NEUROSCI, V8, P3967; BOER K, 1980, J ENDOCRINOL, V86, P221, DOI 10.1677/joe.0.0860221; Chen Xue-Qun, 1999, Neuro Endocrinol Lett, V20, P373; Kovacs KJ, 2004, ANN NY ACAD SCI, V1018, P466, DOI 10.1196/annals.1296.057; Mastorakos G, 2003, ANN NY ACAD SCI, V997, P136, DOI 10.1196/annals.1290.016; SCHRIEFER JA, 1982, BIOL REPROD, V27, P362, DOI 10.1095/biolreprod27.2.362; Tyzio R, 2006, SCIENCE, V314, P1788, DOI 10.1126/science.1133212; VANDERSLUIS PJ, 1986, DEV BRAIN RES, V26, P85, DOI 10.1016/0165-3806(86)90010-6; VASICKA A, 1978, AM J OBSTET GYNECOL, V130, P263	9	6	7	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 13	2007	317	5835								10.1126/science.1141090	http://dx.doi.org/10.1126/science.1141090			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189DC	17626868				2022-12-28	WOS:000247968600020
J	Mumby, M				Mumby, Marc			PP2A: Unveiling a reluctant tumor suppressor	CELL			English	Review							PROTEIN PHOSPHATASE 2A; IDENTIFICATION; RAIA		Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mumby, M (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA.	marc.mumby@utsouthwestern.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031107] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen W, 2005, CANCER RES, V65, P8183, DOI 10.1158/0008-5472.CAN-05-1103; Cho US, 2007, NATURE, V445, P53, DOI 10.1038/nature05351; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hoo LS, 2002, ONCOGENE, V21, P5006, DOI 10.1038/sj.onc.1205625; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Lim KH, 2005, CANCER CELL, V7, P533, DOI 10.1016/j.ccr.2005.04.030; Neviani P, 2005, CANCER CELL, V8, P355, DOI 10.1016/j.ccr.2005.10.015; Ruediger R, 2001, ONCOGENE, V20, P1892, DOI 10.1038/sj.onc.1204279; Sablina AA, 2007, CELL, V129, P969, DOI 10.1016/j.cell.2007.03.047; Wu JC, 2005, J BIOL CHEM, V280, P9013, DOI 10.1074/jbc.M411068200; Xing Y, 2006, CELL, V127, P341, DOI 10.1016/j.cell.2006.09.025; Xu YH, 2006, CELL, V127, P1239, DOI 10.1016/j.cell.2006.11.033; Yu J, 2001, VIROLOGY, V290, P192, DOI 10.1006/viro.2001.1204	17	230	245	4	28	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 13	2007	130	1					21	24		10.1016/j.cell.2007.06.034	http://dx.doi.org/10.1016/j.cell.2007.06.034			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	197WK	17632053	Bronze			2022-12-28	WOS:000248587000007
J	Kleiner, K				Kleiner, Kurt			Civil aviation faces green challenge	NATURE			English	News Item																			0	6	6	4	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 12	2007	448	7150					120	121		10.1038/448120a	http://dx.doi.org/10.1038/448120a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	188QN	17625535				2022-12-28	WOS:000247934500011
J	Narayan, V; Ramaswamy, S; Menon, N				Narayan, Vijay; Ramaswamy, Sriram; Menon, Narayanan			Long-lived giant number fluctuations in a swarming granular nematic	SCIENCE			English	Article							TRANSITION; FLOCKS; ORDER	Coherently moving flocks of birds, beasts, or bacteria are examples of living matter with spontaneous orientational order. How do these systems differ from thermal equilibrium systems with such liquid crystalline order? Working with a fluidized monolayer of macroscopic rods in the nematic liquid crystalline phase, we find giant number fluctuations consistent with a standard deviation growing linearly with the mean, in contrast to any situation where the central limit theorem applies. These fluctuations are long-lived, decaying only as a logarithmic function of time. This shows that flocking, coherent motion, and large-scale inhomogeneity can appear in a system in which particles do not communicate except by contact.	Indian Inst Sci, Dept Phys, Ctr Condensed Matter Theory, Bangalore 560012, Karnataka, India; Jawaharlal Nehru Ctr Adv Sci Res, Condensed Matter Theory Unit, Bangalore 560064, Karnataka, India; Univ Massachusetts, Dept Phys, Amherst, MA 01003 USA	Indian Institute of Science (IISC) - Bangalore; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR); University of Massachusetts System; University of Massachusetts Amherst	Narayan, V (corresponding author), Indian Inst Sci, Dept Phys, Ctr Condensed Matter Theory, Bangalore 560012, Karnataka, India.	vj@physics.iisc.ernet.in						Aranson IS, 2007, PHYS REV E, V75, DOI 10.1103/PhysRevE.75.051301; Becco C, 2006, PHYSICA A, V367, P487, DOI 10.1016/j.physa.2005.11.041; Blair DL, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.031303; Bray D, 2001, CELL MOVEMENTS MOL M; Buhl J, 2006, SCIENCE, V312, P1402, DOI 10.1126/science.1125142; Chate H, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.180602; Feller W., 2000, INTRO PROBABILITY TH, VI; Galanis J, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.028002; Gruler H, 1999, EUR PHYS J B, V11, P187, DOI 10.1007/s100510050928; Holden C, 2006, SCIENCE, V313, P779, DOI 10.1126/science.313.5788.779; Makris NC, 2006, SCIENCE, V311, P660, DOI 10.1126/science.1121756; Narayan V, 2006, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2006/01/P01005; Nedelec FJ, 1997, NATURE, V389, P305, DOI 10.1038/38532; Prevost A, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.084301; Ramaswamy S, 2003, EUROPHYS LETT, V62, P196, DOI 10.1209/epl/i2003-00346-7; Reis PM, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.258001; Szabo B, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.061908; Toner J, 2005, ANN PHYS-NEW YORK, V318, P170, DOI 10.1016/j.aop.2005.04.011; TONER J, 1995, PHYS REV LETT, V75, P4326, DOI 10.1103/PhysRevLett.75.4326; Toner J, 1998, PHYS REV E, V58, P4828, DOI 10.1103/PhysRevE.58.4828; VICSEK T, 1995, PHYS REV LETT, V75, P1226, DOI 10.1103/PhysRevLett.75.1226	22	571	572	5	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 6	2007	317	5834					105	108		10.1126/science.1140414	http://dx.doi.org/10.1126/science.1140414			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186KD	17615353	Green Submitted			2022-12-28	WOS:000247776700060
J	Cires, RS; Maya, SV				Cires, Rafael S.; Maya, Susana V.			Images in clinical medicine - Severe digital ischemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Alcivars Hosp, Guayaquil, Ecuador		Cires, RS (corresponding author), Alcivars Hosp, Guayaquil, Ecuador.	rafaelcires@yahoo.com							0	0	0	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 5	2007	357	1					52	52		10.1056/NEJMicm065845	http://dx.doi.org/10.1056/NEJMicm065845			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185OR	17611207				2022-12-28	WOS:000247720800008
J	Truog, RD				Truog, Robert D.			Tackling medical futility in Texas	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							INTENSIVE-CARE		Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Social Med, Boston, MA 02115 USA; Childrens Hosp, Div Crit Care Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Truog, RD (corresponding author), Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA.							Fine RL, 2003, ANN INTERN MED, V138, P743, DOI 10.7326/0003-4819-138-9-200305060-00011; Halevy A, 1996, ARCH INTERN MED, V156, P100, DOI 10.1001/archinte.156.1.100; Luce JM, 2002, AM J RESP CRIT CARE, V165, P750, DOI 10.1164/ajrccm.165.6.2109045; Meltzer LS, 2004, AM J CRIT CARE, V13, P202, DOI 10.4037/ajcc2004.13.3.202; Okhuysen-Cawley R, 2007, PEDIATR CRIT CARE ME, V8, P225, DOI 10.1097/01.PCC.0000264317.83788.ED	5	55	57	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 5	2007	357	1					1	3		10.1056/NEJMp078109	http://dx.doi.org/10.1056/NEJMp078109			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185OR	17611201				2022-12-28	WOS:000247720800001
J	Butman, JA; Kim, HJ; Baggenstos, M; Ammerman, JM; Dambrosia, J; Patsalides, A; Patronas, NJ; Oldfield, EH; Lonser, RR				Butman, John A.; Kim, H. Jeffrey; Baggenstos, Martin; Ammerman, Joshua M.; Dambrosia, James; Patsalides, Athos; Patronas, Nicholas J.; Oldfield, Edward H.; Lonser, Russell R.			Mechanisms of morbid hearing loss associated with tumors of the endolymphatic sac in von Hippel-Lindau disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CENTRAL-NERVOUS-SYSTEM; NATURAL-HISTORY; VHL GENE; HEMANGIOBLASTOMAS; IDENTIFICATION; ADENOCARCINOMA; MANAGEMENT	Context Endolymphatic sac tumors (ELSTs) are associated with von Hippel-Lindau disease and cause irreversible sensorineural hearing loss (SNHL) and vestibulopathy. The underlying mechanisms of audiovestibular morbidity remain unclear and optimal timing of treatment is not known. Objective To define the mechanisms underlying audiovestibular pathophysiology associated with ELSTs. Design, Setting, and Patients Prospective and serial evaluation of patients with von Hippel-Lindau disease and ELSTs at the National Institutes of Health between May 1990 and December 2006. Main Outcome Measures Clinical findings and audiologic data were correlated with serial magnetic resonance imaging and computed tomography imaging studies to determine mechanisms underlying audiovestibular dysfunction. Results Thirty-five patients with von Hippel-Lindau disease and ELSTs in 38 ears (3 bilateral ELSTs) were identified. Tumor invasion of the otic capsule was associated with larger tumors (P = .01) and occurred in 7 ears (18%) causing SNHL (100%). No evidence of otic capsule invasion was present in the remaining 31 ears (82%). SNHL developed in 27 of these 31 ears (87%) either suddenly (14 ears; 52%) or gradually (13 ears; 48%) and 4 ears had normal hearing. Intralabyrinthine hemorrhage was found in 11 of 14 ears with sudden SNHL (79%; P < .001) but occurred in none of the 17 ears with gradual SNHL or normal hearing. Tumor size was not related to SNHL (P = .23) or vestibulopathy (P = .83). Conclusions ELST-associated SNHL and vestibulopathy may occur suddenly due to tumor-associated intralabyrinthine hemorrhage, or insidiously, consistent with endolymphatic hydrops. Both of these pathophysiologic mechanisms occur with small tumors that are not associated with otic capsule invasion.	NIH, Dept Diagnost Radiol, Ctr Clin, Bethesda, MD 20892 USA; Natl Inst Hlth & Other Commun Disorders, Neurootol Branch, NIH, Bethesda, MD USA; NINDS, Biostat Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Butman, JA (corresponding author), NIH, Dept Diagnost Radiol, Ctr Clin, Bldg 10,Room 1C365, Bethesda, MD 20892 USA.	jbutman@nih.gov	Butman, John/J-2780-2013; Butman, John A/A-2694-2008	Butman, John/0000-0002-1547-9195; 	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS003053, Z01NS002855, Z01NS003053] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000064, Z01DC000064] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Choo D, 2004, J NEUROSURG, V100, P480, DOI 10.3171/jns.2004.100.3.0480; Gaeta M, 1999, NEURORADIOLOGY, V41, P799, DOI 10.1007/s002340050845; Hansen MR, 2004, LARYNGOSCOPE, V114, P1470, DOI 10.1097/00005537-200408000-00028; HEFFNER DK, 1989, CANCER, V64, P2292, DOI 10.1002/1097-0142(19891201)64:11<2292::AID-CNCR2820641119>3.0.CO;2-#; Kim HJ, 2005, J NEUROSURG, V102, P503, DOI 10.3171/jns.2005.102.3.0503; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Libutti SK, 1998, SURGERY, V124, P1153, DOI 10.1067/msy.1998.91823; Libutti SK, 2000, SURGERY, V128, P1022, DOI 10.1067/msy.2000.110239; LINEHAN WM, 1995, JAMA-J AM MED ASSOC, V273, P564; Lonser RR, 2005, ANN NEUROL, V58, P392, DOI 10.1002/ana.20584; Lonser RR, 2004, NEW ENGL J MED, V350, P2481, DOI 10.1056/NEJMoa040666; Lonser RR, 2003, J NEUROSURG, V98, P106, DOI 10.3171/jns.2003.98.1.0106; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Manski TJ, 1997, JAMA-J AM MED ASSOC, V277, P1461, DOI 10.1001/jama.277.18.1461; Megerian CA, 2002, OTOL NEUROTOL, V23, P378, DOI 10.1097/00129492-200205000-00026; MEGERIAN CA, 1995, LARYNGOSCOPE, V105, P801, DOI 10.1288/00005537-199508000-00006; NEUMANN HPH, 1991, LANCET, V337, P1052, DOI 10.1016/0140-6736(91)91705-Y; Richard S, 1998, J INTERN MED, V243, P547; Rodrigues S, 2004, OTOL NEUROTOL, V25, P599, DOI 10.1097/00129492-200407000-00030; SCHUKNECHT HF, 1975, J LARYNGOL OTOL, V89, P985, DOI 10.1017/S0022215100081305; Thomassin J M, 2000, Ann Otolaryngol Chir Cervicofac, V117, P274; Vortmeyer AO, 1997, JNCI-J NATL CANCER I, V89, P970, DOI 10.1093/jnci/89.13.970-a; Vortmeyer AO, 2000, NEUROLOGY, V55, P460, DOI 10.1212/WNL.55.3.460; Wait SD, 2004, ANN NEUROL, V55, P236, DOI 10.1002/ana.10807; WALTHER MM, 1995, J UROLOGY, V154, P2010, DOI 10.1016/S0022-5347(01)66674-6; Wanebo JE, 2003, J NEUROSURG, V98, P82, DOI 10.3171/jns.2003.98.1.0082	26	54	56	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 4	2007	298	1					41	48		10.1001/jama.298.1.41	http://dx.doi.org/10.1001/jama.298.1.41			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185OU	17609489				2022-12-28	WOS:000247721100020
J	Strasser, H; Marksteiner, R; Margreiter, E; Pinggera, GM; Mitterberger, M; Frauscher, F; Ulmer, H; Fussenegger, M; Kofler, K; Bartsch, G				Strasser, Hannes; Marksteiner, Rainer; Margreiter, Eva; Pinggera, Germar Michael; Mitterberger, Michael; Frauscher, Ferdinand; Ulmer, Hanno; Fussenegger, Martin; Kofler, Kurt; Bartsch, Georg			RETRACTED: Autologous myoblasts and fibroblasts versus collagen for treatment of stress urinary incontinence in women: a randomised controlled trial (Retracted Article. See vol 372, pg 789, 2008)	LANCET			English	Article; Retracted Publication							AGE-DEPENDENT APOPTOSIS; URETHRAL SPHINCTER; MUSCLE; RHABDOSPHINCTER; CELLS; COMPLICATIONS; MANAGEMENT; INJECTION	Background Preclinical studies have suggested that transurethral injections of autologous myoblasts can aid in regeneration of the rhabdosphincter, and fibroblasts in reconstruction of the urethral submucosa. We aimed to compare the effectiveness and tolerability of ultrasonography-guided injections of aultologous cells with those of endoscopic injections of Collagen for stress incontinence. Methods Between 2002 and 2004, we recruited 63 eligible women with urinary stress incontinence. 42 of these women were randomly assigned to receive transurethral ultrasonography-guided injections of autologous myoblasts and fibroblasts, and 21 to receive conventional endoscopic injections of collagen. The first primary outcome measure was an incontinence score (range 0-6) based on a 24-hour voiding diary, a 24-hour pad test, and a patient questionnaire. The other primary outcome measures were contractility of the rhabdosphincter and thickness of both the urethra and rhabdosphincter. Analysis was by intention to treat. This trial is registered with Controlled-Trials.com, number CCTNAPN-16630. Findings At 12-months' follow-tip, 38 of the 42 women injected with autologous cells were completely continent, compared with two of the 21 patients given conventional treatment with Collagen. The median incontinence score decreased from a baseline of 6.0 (IQR 6.0-6.0; where 6 represents complete incontinence), to 0 (0-0) for patients treated with autologous cells, and 6.0 (3.5-6.0) for patients treated with Collagen (p < 0.0001). Ultrasonographic measurements showed that the mean thickness of the rhabdosphincter increased from a baseline of 2.13 mm (SD 0.39) for all patients to 3.38 mm (0.26) for patients treated with autologous cells and 2.32 mm (0.44) for patients treated with Collagen (p < 0.0001). Contractility of the rhabdosphincter increased from a baseline of 0.58 mm (SD 0.32) to 1.56 mm (0.28) for patients treated with autologous cells and 0.67 min (0.51) for controls (p < 0.0001). The change in the thickness of the urethra after treatment was not significantly different between treatment groups. No adverse effects were recorded in any of the 63 patients. Interpretation Long-term postoperative results and data from multicentre trials with larger numbers of patients are needed to assess whether injection of autologous cells into the rhabdosphincter and the urethra could become a standard treatment for urinary incontinence.	Univ Innsbruck, Dept Urol, A-6020 Innsbruck, Austria; Univ Innsbruck, Inst Biochem Pharmacol, A-6020 Innsbruck, Austria; Univ Innsbruck, Dept Radiol 2, A-6020 Innsbruck, Austria; Univ Innsbruck, Dept Med Stat Informat & Hlth Econ, A-6020 Innsbruck, Austria; Sisters Charity Hosp, Dept Otolaryngol, Wels, Austria	University of Innsbruck; University of Innsbruck; University of Innsbruck; University of Innsbruck	Strasser, H (corresponding author), Med Univ Innsbruck, Dept Urol, Anichstr 35, A-6020 Innsbruck, Austria.	hannes.strasser@uibk.ac.at	Pinggera, Germar/AAE-1084-2022; Mitterberger, Michael/C-6113-2009; Pinggera, Germar/ABD-5689-2021; Ulmer, Hanno/S-6615-2019	Ulmer, Hanno/0000-0001-5911-1002; PINGGERA, Germar-Michael/0000-0001-6463-2494				Arcila ME, 1997, J NEUROBIOL, V33, P185, DOI 10.1002/(SICI)1097-4695(199708)33:2<185::AID-NEU7>3.0.CO;2-Z; Berjukow S, 2004, PROSTATE, V58, P238, DOI 10.1002/pros.10334; Chancellor MB, 2000, NEUROUROL URODYNAM, V19, P279, DOI 10.1002/(SICI)1520-6777(2000)19:3<279::AID-NAU9>3.0.CO;2-M; Chou ECL, 2003, J UROLOGY, V170, P494, DOI 10.1097/01.ju.0000069432.60521.6f; Colleselli K, 1998, J UROLOGY, V160, P49, DOI 10.1016/S0022-5347(01)63025-8; Deng DY, 2007, NEUROUROL URODYNAM, V26, P46, DOI 10.1002/nau.20357; Falconer C, 2001, INT UROGYNECOL J, V12, pS19, DOI 10.1007/s001920170007; Frauscher F, 1998, EUR RADIOL, V8, P50, DOI 10.1007/s003300050336; Fritsch H, 2006, NEUROUROL URODYNAM, V25, P128, DOI 10.1002/nau.20133; Griffiths D, 2005, INCONTINENCE, VOLS 1 AND 2, P585; Guys JM, 2001, J UROLOGY, V165, P2389, DOI 10.1016/S0022-5347(05)66211-8; Hunskaar S, 2005, INCONTINENCE, VOLS 1 AND 2, P255; Irintchev A, 1997, J PHYSIOL-LONDON, V500, P775, DOI 10.1113/jphysiol.1997.sp022057; Klutke C, 2001, UROLOGY, V58, P697, DOI 10.1016/S0090-4295(01)01366-8; Law PK, 1997, CELL TRANSPLANT, V6, P95, DOI 10.1016/S0963-6897(96)00138-8; Leach GE, 1997, J UROLOGY, V158, P875, DOI 10.1016/S0022-5347(01)64346-5; Liu JB, 2002, J ULTRAS MED, V21, P323, DOI 10.7863/jum.2002.21.3.323; MCKINNEY CD, 1995, J UROLOGY, V153, P149, DOI 10.1097/00005392-199501000-00053; MITTERBERGER M, 2007, EUR UROL        0522; Mostwin J, 2005, INCONTINENCE, VOLS 1 AND 2, P423; NOE HN, 1994, UROLOGY, V43, P852, DOI 10.1016/0090-4295(94)90149-X; Pannek J, 2001, J UROLOGY, V166, P1350, DOI 10.1016/S0022-5347(05)65767-9; Patrick DL, 1999, UROLOGY, V53, P71, DOI 10.1016/S0090-4295(98)00454-3; PETROS PEP, 1994, AM J OBSTET GYNECOL, V171, P1159, DOI 10.1016/0002-9378(94)90056-6; Prasad SR, 2005, RADIOGRAPHICS, V25, P749, DOI 10.1148/rg.253045067; Shi XZ, 2006, GENE DEV, V20, P1692, DOI 10.1101/gad.1419406; Smith ARB, 2005, INCONTINENCE, VOLS 1 AND 2, P1297; Strasser H, 2000, J UROLOGY, V164, P1781, DOI 10.1016/S0022-5347(05)67106-6; Strasser H, 1999, LANCET, V354, P918, DOI 10.1016/S0140-6736(99)02588-X; Sweat SD, 1999, J UROLOGY, V161, P93, DOI 10.1016/S0022-5347(01)62074-3; Taylor DA, 1998, NAT MED, V4, P929, DOI 10.1038/nm0898-929; von Heimburg D, 2004, CELLS TISSUES ORGANS, V178, P87, DOI 10.1159/000081719; Watson D, 1999, Arch Facial Plast Surg, V1, P165, DOI 10.1001/archfaci.1.3.165; Yiou R, 2003, TRANSPLANTATION, V76, P1053, DOI 10.1097/01.TP.0000090396.71097.C2; Yokoyama T, 2001, J UROLOGY, V165, P271, DOI 10.1097/00005392-200101000-00077; Yonneau L, 2000, PROG UROL, V10, P1238	36	107	117	0	25	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 30	2007	369	9580					2179	2186		10.1016/S0140-6736(07)61014-9	http://dx.doi.org/10.1016/S0140-6736(07)61014-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LX	17604800				2022-12-28	WOS:000247644200029
J	Dubrovinsky, L; Dubrovinskaia, N; Narygina, O; Kantor, I; Kuznetzov, A; Prakapenka, VB; Vitos, L; Johansson, B; Mikhaylushkin, AS; Simak, SI; Abrikosov, IA				Dubrovinsky, L.; Dubrovinskaia, N.; Narygina, O.; Kantor, I.; Kuznetzov, A.; Prakapenka, V. B.; Vitos, L.; Johansson, B.; Mikhaylushkin, A. S.; Simak, S. I.; Abrikosov, I. A.			Body-centered cubic iron-nickel alloy in Earth's core	SCIENCE			English	Article							SITU X-RAY; HIGH-PRESSURE; INNER-CORE; IN-SITU; DIFFERENTIAL ROTATION; PHASE-DIAGRAM; GPA; PLANET	Cosmochemical, geochemical, and geophysical studies provide evidence that Earth's core contains iron with substantial (5 to 15%) amounts of nickel. The iron-nickel alloy Fe0.9Ni0.1 has been studied in situ by means of angle-dispersive x-ray diffraction in internally heated diamond anvil cells (DACs), and its resistance has been measured as a function of pressure and temperature. At pressures above 225 gigapascals and temperatures over 3400 kelvin, Fe0.9Ni0.1 adopts a body-centered cubic structure. Our experimental and theoretical results not only support the interpretation of shockwave data on pure iron as showing a solid-solid phase transition above about 200 gigapascals but also suggest that iron alloys with geochemically reasonable compositions (that is, with substantial nickel, sulfur, or silicon content) adopt the bcc structure in Earth's inner core.	Univ Bayreuth, Bayer Geoinst, D-95440 Bayreuth, Germany; Heidelberg Univ, Inst Mineral, D-69120 Heidelberg, Germany; Univ Chicago, Ctr Adv Radiat Sources, Chicago, IL 60637 USA; Royal Inst Technol, Dept Mat Sci & Engn, SE-10044 Stockholm, Sweden; Uppsala Univ, Dept Phys, Condensed Matter Theory Grp, SE-75121 Uppsala, Sweden; Res Inst Solid State Phys & Opt, H-1525 Budapest, Hungary; Linkoping Univ, Dept Phys Chem & Biol, Linkoping, Sweden	University of Bayreuth; Ruprecht Karls University Heidelberg; University of Chicago; Royal Institute of Technology; Uppsala University; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Wigner Research Centre for Physics; Linkoping University	Dubrovinsky, L (corresponding author), Univ Bayreuth, Bayer Geoinst, POB 101251, D-95440 Bayreuth, Germany.		Simak, Sergei/N-3205-2019; Dubrovinskaia, Natalia/A-8013-2015; Simak, Sergei/AAN-7125-2021; Kantor, Innokenty/E-7326-2018; Simak, Sergei I./C-3030-2014; Vitos, Levente/AAW-5606-2021; Abrikosov, Igor A/I-7328-2013; Kuznetsov, Alexei/C-2274-2008	Simak, Sergei/0000-0002-1320-389X; Dubrovinskaia, Natalia/0000-0002-8256-5675; Kantor, Innokenty/0000-0001-5132-8354; Simak, Sergei I./0000-0002-1320-389X; Dubrovinsky, Leonid/0000-0002-3717-7585				ANDERSON DL, 1989, THEORY EARTH; Andrault D, 1997, SCIENCE, V278, P831, DOI 10.1126/science.278.5339.831; Belonoshko AB, 2003, NATURE, V424, P1032, DOI 10.1038/nature01954; BOEHLER R, 1993, NATURE, V363, P534, DOI 10.1038/363534a0; Bottke WF, 2006, NATURE, V439, P821, DOI 10.1038/nature04536; Brown JM, 2001, GEOPHYS RES LETT, V28, P4339, DOI 10.1029/2001GL013759; BROWN JM, 1986, J GEOPHYS RES-SOLID, V91, P7485, DOI 10.1029/JB091iB07p07485; CREAGER KC, 1992, NATURE, V356, P309, DOI 10.1038/356309a0; Dewaele A, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.215504; Dubrovinskaia N, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.245502; Dubrovinsky L, 2004, NATO SCI SER II MATH, V140, P393; Dubrovinsky L, 2001, PHYS REV LETT, V86, P4851, DOI 10.1103/PhysRevLett.86.4851; Dubrovinsky LS, 2000, PHYS REV LETT, V84, P1720, DOI 10.1103/PhysRevLett.84.1720; HUANG E, 1992, J GEOPHYS RES-SOL EA, V97, P4497, DOI 10.1029/92JB00020; Lin JF, 2002, SCIENCE, V295, P313, DOI 10.1126/science.1066932; LIN JF, 2003, GEOPHYS RES LETT, V29, P109; Loubeyre P, 2002, NATURE, V416, P613, DOI 10.1038/416613a; MAO HK, 1990, J GEOPHYS RES-SOLID, V95, P21737, DOI 10.1029/JB095iB13p21737; Mao WL, 2006, PHYS EARTH PLANET IN, V155, P146, DOI 10.1016/j.pepi.2005.11.002; RAMDOHR P, 1976, FORTSCHR MINERAL, V53, P165; Shen GY, 2005, J SYNCHROTRON RADIAT, V12, P642, DOI 10.1107/S0909049505022442; Shen GY, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.185701; Song XD, 1996, NATURE, V382, P221, DOI 10.1038/382221a0; Su WJ, 1996, SCIENCE, V274, P1883, DOI 10.1126/science.274.5294.1883; Vidale JE, 2000, NATURE, V405, P445, DOI 10.1038/35013039; Vocadlo L, 2003, NATURE, V424, P536, DOI 10.1038/nature01829; YOO CS, 1995, SCIENCE, V270, P1473, DOI 10.1126/science.270.5241.1473	27	171	177	2	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 29	2007	316	5833					1880	1883		10.1126/science.1142105	http://dx.doi.org/10.1126/science.1142105			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183WI	17600212				2022-12-28	WOS:000247602700034
J	Anand, S; Yusuf, S; Xie, CC; Pogue, J; Eikelboom, J; Budaj, A; Sussex, B; Liu, LS; Guzman, R; Cina, C; Crowell, R; Keltai, M; Gosselin, G				Anand, Sonia; Yusuf, Salim; Xie, Changchun; Pogue, Janice; Eikelboom, John; Budaj, Andrzej; Sussex, Bruce; Liu, Lisheng; Guzman, Randy; Cina, Claudio; Crowell, Richard; Keltai, Matyas; Gosselin, Gilbert		Warfarin Antiplatelet Vascular Eva	Oral anticoagulant and antiplatelet therapy and peripheral arterial disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE CORONARY SYNDROMES; MYOCARDIAL-INFARCTION; LONG-TERM; ASPIRIN; WARFARIN; TRIAL; METAANALYSIS; INTENSITY; MORTALITY; EVENTS	Background: Atherosclerotic peripheral arterial disease is associated with an increased risk of myocardial infarction, stroke, and death from cardiovascular causes. Antiplatelet drugs reduce this risk, but the role of oral anticoagulant agents in the prevention of cardiovascular complications in patients with peripheral arterial disease is unclear. Methods: We assigned patients with peripheral arterial disease to combination therapy with an antiplatelet agent and an oral anticoagulant agent (target international normalized ratio [INR], 2.0 to 3.0) or to antiplatelet therapy alone. The first coprimary outcome was myocardial infarction, stroke, or death from cardiovascular causes; the second coprimary outcome was myocardial infarction, stroke, severe ischemia of the peripheral or coronary arteries leading to urgent intervention, or death from cardiovascular causes. Results: A total of 2161 patients were randomly assigned to therapy. The mean follow-up time was 35 months. Myocardial infarction, stroke, or death from cardiovascular causes occurred in 132 of 1080 patients receiving combination therapy (12.2%) and in 144 of 1081 patients receiving antiplatelet therapy alone (13.3%) (relative risk, 0.92; 95% confidence interval [CI], 0.73 to 1.16; P=0.48). Myocardial infarction, stroke, severe ischemia, or death from cardiovascular causes occurred in 172 patients receiving combination therapy (15.9%) as compared with 188 patients receiving antiplatelet therapy alone (17.4%) (relative risk, 0.91; 95% CI, 0.74 to 1.12; P=0.37). Life-threatening bleeding occurred in 43 patients receiving combination therapy (4.0%) as compared with 13 patients receiving antiplatelet therapy alone (1.2%) (relative risk, 3.41; 95% CI, 1.84 to 6.35; P<0.001). Conclusions: In patients with peripheral arterial disease, the combination of an oral anticoagulant and antiplatelet therapy was not more effective than antiplatelet therapy alone in preventing major cardiovascular complications and was associated with an increase in life-threatening bleeding.	McMaster Univ, Hamilton, ON, Canada; Grochowski Hosp, Warsaw, Poland; Mem Univ Newfoundland, St John, NF, Canada; Natl Canc Ctr Cardiovasc Dis, Beijing, Peoples R China; Univ Manitoba, Winnipeg, MB, Canada; Hamilton Hlth Sci, Hamilton, ON, Canada; St Josephs Hosp, Hamilton, ON, Canada; Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada; Semmelweis Univ, Hungarian Inst Cardiol, Budapest, Hungary; Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada	McMaster University; Centre of Postgraduate Medical Education - Poland; Memorial University Newfoundland; University of Manitoba; McMaster University; McGill University; McMaster University; Queen Elizabeth II Health Sciences Centre; Semmelweis University; Universite de Montreal	Anand, S (corresponding author), Hamilton Gen Hosp, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.	anands@mcmaster.ca	Eikelboom, John/AAG-6117-2019	Eikelboom, John/0000-0003-4126-1285; Guzman, Randolph/0000-0003-3675-4771; Yusuf, Salim/0000-0003-4776-5601				Anand S, 2006, AM HEART J, V151, P1, DOI 10.1016/j.ahj.2005.03.021; ANAND SS, 2000, JAMA-J AM MED ASSOC, V284, P45; Andreotti F, 2006, EUR HEART J, V27, P519, DOI 10.1093/eurheartj/ehi485; Antithrombotic Trialists' Collaboration, 2002, BMJ-BRIT MED J, V324, P141, DOI DOI 10.1136/BMJ.324.7330.141; Antman Elliott M, 2004, J Am Coll Cardiol, V44, P671, DOI 10.1016/j.jacc.2004.07.002; ANTMAN EM, 2005, J AM COLL CARDIOL, V45, P1376; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Bauer KA, 2006, J THROMB THROMBOLYS, V21, P67, DOI 10.1007/s11239-006-5579-4; Butch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group, 2000, LANCET, V355, P1104; CRIQUI MH, 1992, NEW ENGL J MED, V326, P381, DOI 10.1056/NEJM199202063260605; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Hurlen M, 2002, NEW ENGL J MED, V347, P969, DOI 10.1056/NEJMoa020496; Johnson WC, 2002, J VASC SURG, V35, P413, DOI 10.1067/mva.2002.121847; Leng GC, 1996, INT J EPIDEMIOL, V25, P1172, DOI 10.1093/ije/25.6.1172; Levine MN, 2004, CHEST, V126, p287S, DOI 10.1378/chest.126.3_suppl.287S; ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236; Saw J, 2006, J AM COLL CARDIOL, V48, P1567, DOI 10.1016/j.jacc.2006.03.067; Tangelder MJD, 2000, LANCET, V355, P346; van Es RF, 2002, LANCET, V360, P109, DOI 10.1016/S0140-6736(02)09409-6; You JHS, 2005, BRIT J CLIN PHARMACO, V59, P582, DOI 10.1111/j.1365-2125.2005.02361.x; Yusuf S, 2001, J AM COLL CARDIOL, V37, P475	21	276	293	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 19	2007	357	3					217	227						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191FH	17634457				2022-12-28	WOS:000248115100003
J	Ramaswamy, S				Ramaswamy, Sridhar			Rational design of cancer-drug combinations	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Cambridge, MA 02138 USA; MIT, Broad Inst, Cambridge, MA 02139 USA; Harvard Univ, Stem Cell Inst, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University	Ramaswamy, S (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.				NATIONAL CANCER INSTITUTE [K08CA100339] Funding Source: NIH RePORTER; NCI NIH HHS [K08 CA100339-05, K08 CA100339] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Whitehurst AW, 2007, NATURE, V446, P815, DOI 10.1038/nature05697	1	38	41	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 19	2007	357	3					299	300		10.1056/NEJMcibr072593	http://dx.doi.org/10.1056/NEJMcibr072593			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191FH	17634467				2022-12-28	WOS:000248115100014
J	Schiffer, CA				Schiffer, Charles A.			BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC MYELOID-LEUKEMIA; PATIENTS RECEIVING IMATINIB; HIGH-DOSE IMATINIB; CYTOGENETIC RESPONSES; MESYLATE THERAPY; DOMAIN MUTATIONS; BLAST CRISIS; CHROMOSOME; DASATINIB; RESISTANT		Wayne State Univ, Barbara Ann Karmanos Canc Inst, Div Hematol Oncol, Sch Med, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Schiffer, CA (corresponding author), Wayne State Univ, Barbara Ann Karmanos Canc Inst, Div Hematol Oncol, Sch Med, HWCRB 4th Fl,4100 John R, Detroit, MI 48201 USA.	schiffer@karmanos.org						ATALLAH E, IN PRESS BLOOD; Ault P, 2006, J CLIN ONCOL, V24, P1204, DOI 10.1200/JCO.2005.04.6557; Baccarani M, 2006, BLOOD, V108, P1809, DOI 10.1182/blood-2006-02-005686; Berman E, 2006, NEW ENGL J MED, V354, P2006, DOI 10.1056/NEJMoa051140; Copland M, 2006, BLOOD, V107, P4532, DOI 10.1182/blood-2005-07-2947; Cortes J, 2004, HEMATOL ONCOL CLIN N, V18, P569, DOI 10.1016/j.hoc.2004.03.011; DALEY GQ, 1991, P NATL ACAD SCI USA, V88, P11335, DOI 10.1073/pnas.88.24.11335; Deininger MWN, 2003, J CLIN ONCOL, V21, P1637, DOI 10.1200/JCO.2003.11.143; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Gambacorti-Passerini C, 2003, LANCET, V361, P1954, DOI 10.1016/S0140-6736(03)13554-4; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; Goldman JM, 2003, NEW ENGL J MED, V349, P1451, DOI 10.1056/NEJMra020777; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gratwohl A, 2006, HAEMATOLOGICA, V91, P513; Guilhot F, 1997, NEW ENGL J MED, V337, P223, DOI 10.1056/NEJM199707243370402; Guilhot F, 2007, BLOOD, V109, P4143, DOI 10.1182/blood-2006-09-046839; Hochhaus A, 2007, BLOOD, V109, P2303, DOI 10.1182/blood-2006-09-047266; Hughes T, 2006, BLOOD, V108, P28, DOI 10.1182/blood-2006-01-0092; Kantarjian H, 2004, BLOOD, V103, P2873, DOI 10.1182/blood-2003-11-3800; Kantarjian H, 2007, BLOOD, V109, P5143, DOI 10.1182/blood-2006-11-056028; Kantarjian H, 2006, NEW ENGL J MED, V354, P2542, DOI 10.1056/NEJMoa055104; Kerkela R, 2006, NAT MED, V12, P908, DOI 10.1038/nm1446; Kovitz C, 2006, BLOOD, V108, P2811, DOI 10.1182/blood-2006-04-017400; Le Gouill S, 2000, J CLIN ONCOL, V18, P1533, DOI 10.1200/JCO.2000.18.7.1533; Lin YL, 2006, CANCER GENET CYTOGEN, V170, P16, DOI 10.1016/j.cancergencyto.2006.04.012; *NAT CANC I, CHRON MYEL LEUK PDQ; *NAT COMPRE CANC N, 2007, NCCN CLIN PRACT GUID; NOWELL PC, 1960, SCIENCE, V132, P1497; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; O'Hare T, 2005, CANCER RES, V65, P4500, DOI 10.1158/0008-5472.CAN-05-0259; Ottmann OG, 2002, BLOOD, V100, P1965, DOI 10.1182/blood-2001-12-0181; OZER H, 1993, BLOOD, V82, P2975; Passweg JR, 2004, BRIT J HAEMATOL, V125, P613, DOI 10.1111/j.1365-2141.2004.04955.x; Peng B, 2005, CLIN PHARMACOKINET, V44, P879, DOI 10.2165/00003088-200544090-00001; Quintas-Cardama A, 2006, MAYO CLIN PROC, V81, P973, DOI 10.4065/81.7.973; ROSTI G, 2007, J CLIN ONCOL S, V25, pS18; Rosti G, 2007, NAT MED, V13, P15, DOI 10.1038/nm0107-15a; Rousselot P, 2007, BLOOD, V109, P58, DOI 10.1182/blood-2006-03-011239; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182/blood.V99.10.3530; Schoemans H, 2006, BONE MARROW TRANSPL, V38, P83, DOI 10.1038/sj.bmt.1705403; Silver RT, 2004, BLOOD, V104, p11A; Soverini S, 2006, CLIN CANCER RES, V12, P7374, DOI 10.1158/1078-0432.CCR-06-1516; Talpaz M, 2002, BLOOD, V99, P1928, DOI 10.1182/blood.V99.6.1928; TALPAZ M, 1986, NEW ENGL J MED, V314, P1065, DOI 10.1056/NEJM198604243141701; Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229; Terre C, 2004, LEUKEMIA, V18, P1340, DOI 10.1038/sj.leu.2403399; TURA S, 1994, NEW ENGL J MED, V330, P820	48	134	150	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 19	2007	357	3					258	265		10.1056/NEJMct071828	http://dx.doi.org/10.1056/NEJMct071828			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191FH	17634461				2022-12-28	WOS:000248115100007
J	Akkersdijk, GP; Prins, HA				Akkersdijk, George P.; Prins, Hubert A.			Lower abdominal pain in a pregnant woman	LANCET			English	Editorial Material									Erasmus MC, Dept Surg, NL-3015 GD Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Akkersdijk, GP (corresponding author), Erasmus MC, Dept Surg, Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands.	g_p_akkersdijk@hotmail.com							0	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 14	2007	370	9582					161	161		10.1016/S0140-6736(07)61089-7	http://dx.doi.org/10.1016/S0140-6736(07)61089-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	190WP	17630039				2022-12-28	WOS:000248091600030
J	Rodrigo-Brenni, MC; Morgan, DO				Rodrigo-Brenni, Monica C.; Morgan, David O.			Sequential E2s drive polyubiquitin chain assembly on APC targets	CELL			English	Article							UBIQUITIN-CONJUGATING ENZYME; ANAPHASE-PROMOTING COMPLEX; MITOTIC CYCLIN; BUDDING YEAST; SACCHAROMYCES-CEREVISIAE; DEPENDENT PROTEOLYSIS; DEGRADATION; DESTRUCTION; SYSTEM; TRANSLOCATION	The anaphase- promoting complex ( APC), or cyclosome, is an E3 ubiquitin- protein ligase that collaborates with E2 ubiquitin- conjugating enzymes to assemble polyubiquitin chains on proteins important for cell- cycle progression. It remains unclear how the APC - or many other E3s - promotes the multiple distinct reactions necessary for chain assembly. We addressed this problem by analyzing APC interactions with different E2s. We screened all budding yeast E2s as APC coenzymes in vitro and found that two, Ubc4 and Ubc1, are the key E2 partners for the APC. These proteins display strikingly different but complementary enzymatic behaviors: Ubc4 supports the rapid monoubiquitination of multiple lysines on APC targets, while Ubc1 catalyzes K48- linked polyubiquitin chain assembly on preattached ubiquitins. Mitotic APC function is lost in yeast strains lacking both Ubc1 and Ubc4. E2- 25K, a human homolog of Ubc1, also promotes APC- dependent chain extension on preattached ubiquitins. We propose that sequential E2 proteins catalyze K48- linked polyubiquitination and thus proteasomal destruction of APC targets.	Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Morgan, DO (corresponding author), Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94158 USA.	david.morgan@ucsf.edu		Morgan, David/0000-0001-8753-4416	NIGMS NIH HHS [R01 GM053270, GM53270] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053270, R37GM053270] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aristarkhov A, 1996, P NATL ACAD SCI USA, V93, P4294, DOI 10.1073/pnas.93.9.4294; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Carroll CW, 2005, METHOD ENZYMOL, V398, P219, DOI 10.1016/S0076-6879(05)98018-X; Carroll CW, 2002, NAT CELL BIOL, V4, P880, DOI 10.1038/ncb871; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CHEN ZJ, 1991, J BIOL CHEM, V266, P15698; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Eddins MJ, 2006, NAT STRUCT MOL BIOL, V13, P915, DOI 10.1038/nsmb1148; Flierman D, 2006, P NATL ACAD SCI USA, V103, P11589, DOI 10.1073/pnas.0605215103; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Haldeman MT, 1997, BIOCHEMISTRY-US, V36, P10526, DOI 10.1021/bi970750u; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; Hicke L, 2005, NAT REV MOL CELL BIO, V6, P610, DOI 10.1038/nrm1701; Hochstrasser M, 2006, CELL, V124, P27, DOI 10.1016/j.cell.2005.12.025; Hodgins R, 1996, J BIOL CHEM, V271, P28766, DOI 10.1074/jbc.271.46.28766; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hoppe T, 2005, TRENDS BIOCHEM SCI, V30, P183, DOI 10.1016/j.tibs.2005.02.004; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Kirkpatrick DS, 2006, NAT CELL BIOL, V8, P700, DOI 10.1038/ncb1436; Kraft C, 2006, METHODS, V38, P39, DOI 10.1016/j.ymeth.2005.07.005; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mathe E, 2004, CURR BIOL, V14, P1723, DOI 10.1016/j.cub.2004.09.023; Merkley N, 2004, J BIOL CHEM, V279, P47139, DOI 10.1074/jbc.M409576200; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Morgan D. O., 2007, CELL CYCLE PRINCIPLE; Ozkan E, 2005, P NATL ACAD SCI USA, V102, P18890, DOI 10.1073/pnas.0509418102; Passmore LA, 2005, METHOD ENZYMOL, V398, P195, DOI 10.1016/S0076-6879(05)98017-8; Passmore LA, 2004, BIOCHEM J, V379, P513, DOI 10.1042/BJ20040198; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Petroski MD, 2005, CELL, V123, P1107, DOI 10.1016/j.cell.2005.09.033; Petroski MD, 2003, MOL CELL, V11, P1435, DOI 10.1016/S1097-2765(03)00221-1; Pickart CM, 2004, CURR OPIN CHEM BIOL, V8, P610, DOI 10.1016/j.cbpa.2004.09.009; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Rape M, 2006, CELL, V124, P89, DOI 10.1016/j.cell.2005.10.032; Rape M, 2004, NATURE, V432, P588, DOI 10.1038/nature03023; Seino H, 2003, MOL CELL BIOL, V23, P3497, DOI 10.1128/MCB.23.10.3497-3505.2003; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; Thornton BR, 2006, GENE DEV, V20, P3069, DOI 10.1101/gad.1478306; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Townsley FM, 1998, YEAST, V14, P747, DOI 10.1002/(SICI)1097-0061(19980615)14:8<747::AID-YEA271>3.0.CO;2-T; Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362; Wasch R, 2002, NATURE, V418, P556, DOI 10.1038/nature00856; Wu PY, 2003, EMBO J, V22, P5241, DOI 10.1093/emboj/cdg501; Yu HT, 1996, CURR BIOL, V6, P455, DOI 10.1016/S0960-9822(02)00513-4	50	199	205	0	3	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 13	2007	130	1					127	139		10.1016/j.cell.2007.05.027	http://dx.doi.org/10.1016/j.cell.2007.05.027			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	197WK	17632060	Bronze			2022-12-28	WOS:000248587000016
J	[Anonymous]				[Anonymous]			Linnaeus and taxonomy in Japan	NATURE			English	Editorial Material													P., Akihito/M-1268-2015						0	0	0	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 12	2007	448	7150					139	140		10.1038/448139a	http://dx.doi.org/10.1038/448139a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	188QN	17632886	Bronze			2022-12-28	WOS:000247934500025
J	Behn, MD; Hirth, G; Kelemen, PB				Behn, Mark D.; Hirth, Greg; Kelemen, Peter B.			Trench-parallel anisotropy produced by foundering of arc lower crust	SCIENCE			English	Article							MANTLE FLOW; B-TYPE; BENEATH; PATTERN; WEDGE	Many volcanic arcs display fast seismic shear-wave velocities parallel to the strike of the trench. This pattern of anisotropy is inconsistent with simple models of corner flow in the mantle wedge. Although several models, including slab rollback, oblique subduction, and deformation of water-rich olivine, have been proposed to explain trench-parallel anisotropy, none of these mechanisms are consistent with all observations. Instead, small-scale convection driven by the foundering of dense arc lower crust provides an explanation for the trench-parallel anisotropy, even in settings with orthogonal convergence and no slab rollback.	Woods Hole Oceanog Inst, Dept Geol & Geophys, Woods Hole, MA 02543 USA; Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA	Woods Hole Oceanographic Institution; Columbia University	Behn, MD (corresponding author), Woods Hole Oceanog Inst, Dept Geol & Geophys, Woods Hole, MA 02543 USA.	mbehn@whoi.edu	Kelemen, Peter B./D-6813-2013; Behn, Mark D/F-5813-2012; Hofreiter, Michael/A-3996-2017; Cappellini, Enrico/F-9346-2013; Collins, Matthew James/O-1095-2019; Boomsma, Wouter/K-2903-2014; Armitage, Simon J/K-7471-2015; Alfimov, Vasily/B-3629-2010; Collins, Matthew J/A-7534-2008; Bennike, Ole/G-7070-2018; Nielsen, Rasmus/D-4405-2009; casoli, antonella/H-6953-2016; Christl, Marcus/J-4769-2016; De Hoog, Jan CM/C-1354-2010; Taberlet, Pierre/D-1178-2010	Kelemen, Peter B./0000-0003-4757-0855; Behn, Mark D/0000-0002-2001-1335; Cappellini, Enrico/0000-0001-7885-7811; Collins, Matthew James/0000-0003-4226-5501; Boomsma, Wouter/0000-0002-8257-3827; Armitage, Simon J/0000-0003-1480-9188; Collins, Matthew J/0000-0003-4226-5501; Bennike, Ole/0000-0002-5486-9946; Nielsen, Rasmus/0000-0003-0513-6591; casoli, antonella/0000-0002-9212-9463; Christl, Marcus/0000-0002-3131-6652; De Hoog, Jan CM/0000-0002-5930-3597; Taberlet, Pierre/0000-0002-3554-5954	NERC [NE/C511148/1] Funding Source: UKRI	NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		ABT DL, 2005, EOS S, V86; Behn MD, 2006, J GEOPHYS RES-SOL EA, V111, DOI 10.1029/2006JB004327; Behn MD, 2004, EARTH PLANET SC LETT, V224, P259, DOI 10.1016/j.epsl.2004.05.026; Blackman DK, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2001GC000247; Gerya TV, 2003, EARTH PLANET SC LETT, V212, P47, DOI 10.1016/S0012-821X(03)00265-6; HALL C.E., 2000, J GEOPHYS RES, V105, P009; Hirth G., 2003, INSIDE SUBDUCTION FA, V138, P83, DOI [10.1029/138GM06, DOI 10.1029/138GM06]; Jicha BR, 2006, GEOLOGY, V34, P661, DOI 10.1130/G22433.1; Jull M, 2001, J GEOPHYS RES-SOL EA, V106, P6423, DOI 10.1029/2000JB900357; Katayama I, 2004, GEOLOGY, V32, P1045, DOI 10.1130/G20805.1; Katayama I, 2006, PHYS EARTH PLANET IN, V157, P33, DOI 10.1016/j.pepi.2006.03.005; KAY RW, 1991, GEOL RUNDSCH, V80, P259, DOI 10.1007/BF01829365; Kelemen P., 2003, GEOPHYS MONOGR SER, V138, P293, DOI DOI 10.1029/138GM13; Kelemen P.B., 2007, TREATISE GEOCHEMISTR, V3, P1, DOI [10.1016/B0-08-043751-6/03035-8, DOI 10.1016/B0-08-043751-6/03035-8]; Kincaid C, 2003, NATURE, V425, P58, DOI 10.1038/nature01923; Kneller EA, 2005, EARTH PLANET SC LETT, V237, P781, DOI 10.1016/j.epsl.2005.06.049; Lee CTA, 2006, CONTRIB MINERAL PETR, V151, P222, DOI 10.1007/s00410-005-0056-1; Long MD, 2006, PHYS EARTH PLANET IN, V155, P300, DOI 10.1016/j.pepi.2006.01.003; Long MD, 2005, PHYS EARTH PLANET IN, V151, P206, DOI 10.1016/j.pepi.2005.03.003; Mehl L, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB002233; Nakajima J, 2004, EARTH PLANET SC LETT, V225, P365, DOI 10.1016/j.epsl.2004.06.011; Nicolas A., 1987, FORMATION ANISOTROPY, DOI DOI 10.1029/GD016P0111; POZGAY SH, 2005, EOS, V86; RUSSO RM, 1994, SCIENCE, V263, P1105, DOI 10.1126/science.263.5150.1105; Smith GP, 2001, SCIENCE, V292, P713, DOI 10.1126/science.1058763; van Keken PE, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2001GC000256; Wolfe CJ, 1998, SCIENCE, V280, P1230, DOI 10.1126/science.280.5367.1230	27	83	85	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 6	2007	317	5834					108	111		10.1126/science.1141269	http://dx.doi.org/10.1126/science.1141269			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186KD	17615354				2022-12-28	WOS:000247776700061
J	Sipahi, I; Tuzcu, EM; Wolski, KE; Nicholls, SJ; Schoenhagen, P; Hu, B; Balog, C; Shishehbor, M; Magyar, WA; Crowe, TD; Kapadia, S; Nissen, SE				Sipahi, Iike; Tuzcu, E. Murat; Wolski, Katherine E.; Nicholls, Stephen J.; Schoenhagen, Paul; Hu, Bo; Balog, Craig; Shishehbor, Mehdi; Magyar, William A.; Crowe, Timothy D.; Kapadia, Samir; Nissen, Steven E.			beta-blockers and progression of coronary atherosclerosis: Pooled analysis of 4 intravascular ultrasonography trials	ANNALS OF INTERNAL MEDICINE			English	Article							EXPERT CONSENSUS DOCUMENT; INTIMA-MEDIA THICKNESS; MYOCARDIAL-INFARCTION; STATIN THERAPY; CARDIOVASCULAR-DISEASE; TASK-FORCE; HEART-RATE; METOPROLOL; PROPRANOLOL; CHOLESTEROL	Background: In patients with myocardial infarction, beta-adrenergic blockers reduce recurrent myocardial infarction and total mortality rates. However, whether a direct influence of beta-blockers on coronary atherosclerosis contributes to reduced recurrent myocardial infarction and total mortality rates is not known. Objective: To assess whether P-blocker therapy is associated with reduced atheroma progression in adults with known coronary artery disease. Design: Post hoc, pooled analysis of individual patient data from 4 intravascular ultrasonography (IVUS) trials. Setting: Four IVUS trials conducted in the United States, Europe, and Australia. Patients: 1515 patients with coronary artery disease. Intervention: The original trials used 3 different statins, a calcium-channel blocker, an angiotensin-converting enzyme inhibitor, or an acyl coenzyme A-cholesterol acyltransferase inhibitor. Measurements: Changes in atheroma volume, as determined by IVUS after adjustment for possible confounders by using linear mixed-effects models, were compared in patients who did and did not receive concomitant beta-blocker treatment. Results: Patients who received beta-blockers (n = 1154) were more likely to have histories of myocardial infarction, angina, and hyper-tension than were patients who did not receive beta-blockers (n = 361). The estimated annual change in atheroma volume was statistically significantly less in patients who received beta-blockers. This was true for univariate and multivariable analyses that controlled for history of myocardial infarction, angina, and hypertension (mean [+/- SE] atheroma volume, -2.4 +/- 0.5 mm(3)/y in treated patients vs. -0.4 +/- 0.8 mm(3)/y in untreated patients; P = 0.034). Accordingly, atheroma volume statistically significantly decreased at follow-up IVUS in patients who received beta-blockers (P < 0.001) and did not change in patients who did not receive beta-blockers (P = 0.86). Additional adjustments for low-density lipoprotein cholesterol level, concomitant medications, and clinical trial did not change the results. Limitations: Patients were not randomly assigned to p-blocker therapy, and interventions other than beta-blocker therapy could have influenced the changes in atheroma volume. Whether progression rate of atherosclerosis as detected by IVUS predicts cardiovascular outcomes is unknown. Conclusions: The analysis demonstrates that beta-blockers can slow progression of coronary atherosclerosis. The findings provide additional support for the current clinical guidelines advocating long-term use of beta-blockers to treat most forms of coronary artery disease.	Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Nissen, SE (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, 9500 Euclid Ave,Desk F15, Cleveland, OH 44195 USA.	nissens@ccf.org	SIPAHI, ILKE/K-9745-2013; Schoenhagen, Paul/A-2808-2012	SIPAHI, ILKE/0000-0001-8581-9557; Schoenhagen, Paul/0000-0002-7751-5243; Nicholls, Stephen/0000-0002-9668-4368	NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR024990] Funding Source: NIH RePORTER; NCRR NIH HHS [KL2 RR024990] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		[Anonymous], 1986, LANCET, V2, P57; CAMEJO G, 1991, CIRCULATION, V84, P17; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; Chen ZM, 2005, LANCET, V366, P1622; CHOBANIAN AV, 1985, CIRC RES, V56, P755, DOI 10.1161/01.RES.56.5.755; CRUICKSHANK JM, 1990, CIRCULATION, V82, P60; CURB JD, 1983, JAMA-J AM MED ASSOC, V250, P2814; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Dargie HJ, 2001, LANCET, V357, P1385, DOI 10.1016/s0140-6736(00)04560-8; De Backer G, 2003, EUR HEART J, V24, P1601, DOI 10.1016/S0195-668X(03)00347-6; Di Mario C, 1998, EUR HEART J, V19, P207, DOI 10.1053/euhj.1996.0433; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; Hedblad B, 2001, CIRCULATION, V103, P1721, DOI 10.1161/01.CIR.103.13.1721; Heidland UE, 2001, CIRCULATION, V104, P1477, DOI 10.1161/hc3801.096325; JULIAN DG, 1982, LANCET, V1, P1142; KANNEL WB, 1987, AM HEART J, V113, P1489, DOI 10.1016/0002-8703(87)90666-1; KAPLAN JR, 1994, AM HEART J, V128, P1316, DOI 10.1016/0002-8703(94)90254-2; KAPLAN JR, 1987, CIRCULATION, V76, P1364, DOI 10.1161/01.CIR.76.6.1364; KASISKE BL, 1995, ANN INTERN MED, V122, P133, DOI 10.7326/0003-4819-122-2-199501150-00010; LINDQVIST P, 1988, ATHEROSCLEROSIS, V72, P163, DOI 10.1016/0021-9150(88)90077-9; LOALDI A, 1991, CHEST, V99, P1238, DOI 10.1378/chest.99.5.1238; LOALDI A, 1989, AM J CARDIOL, V64, P433, DOI 10.1016/0002-9149(89)90417-7; Lopez-Sendon J, 2004, EUR HEART J, V25, P1341, DOI 10.1016/j.ehj.2004.06.002; Mintz GS, 2001, J AM COLL CARDIOL, V37, P1478, DOI 10.1016/S0735-1097(01)01175-5; Nissen SE, 2006, NEW ENGL J MED, V354, P1253, DOI 10.1056/NEJMoa054699; Nissen SE, 2005, NEW ENGL J MED, V352, P29, DOI 10.1056/NEJMoa042000; Nissen SE, 2004, JAMA-J AM MED ASSOC, V292, P2217, DOI 10.1001/jama.292.18.2217; Nissen SE, 2006, JAMA-J AM MED ASSOC, V295, P1556, DOI 10.1001/jama.295.13.jpc60002; Nissen SE, 2004, JAMA-J AM MED ASSOC, V291, P1071, DOI 10.1001/jama.291.9.1071; OLSSON G, 1985, J AM COLL CARDIOL, V5, P1428, DOI 10.1016/S0735-1097(85)80360-0; OSTLUNDLINDQVIST AM, 1988, ARTERIOSCLEROSIS, V8, P40, DOI 10.1161/01.ATV.8.1.40; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; Pepine CJ, 2003, JAMA-J AM MED ASSOC, V290, P2805, DOI 10.1001/jama.290.21.2805; PETTERSSON K, 1990, CIRC RES, V67, P1027, DOI 10.1161/01.RES.67.4.1027; Sipahi I, 2006, ATHEROSCLEROSIS, V189, P229, DOI 10.1016/j.atherosclerosis.2005.12.006; Smith SC, 2001, CIRCULATION, V104, P1577, DOI 10.1161/hc3801.097475; Topol EJ, 2004, NEW ENGL J MED, V350, P1562, DOI 10.1056/NEJMe048061; Wiklund O, 2002, STROKE, V33, P572, DOI 10.1161/hs0202.102332	39	70	75	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2007	147	1					10	18		10.7326/0003-4819-147-1-200707030-00003	http://dx.doi.org/10.7326/0003-4819-147-1-200707030-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186MN	17606956				2022-12-28	WOS:000247782900002
J	Fimia, GM; Stoykova, A; Romagnoli, A; Giunta, L; Di Bartolomeo, S; Nardacci, R; Corazzari, M; Fuoco, C; Ucar, A; Schwartz, P; Gruss, P; Piacentini, M; Chowdhury, K; Cecconi, F				Fimia, Gian Maria; Stoykova, Anastassia; Romagnoli, Alessandra; Giunta, Luigi; Di Bartolomeo, Sabrina; Nardacci, Roberta; Corazzari, Marco; Fuoco, Claudia; Ucar, Ahmet; Schwartz, Peter; Gruss, Peter; Piacentini, Mauro; Chowdhury, Kamal; Cecconi, Francesco			Ambra1 regulates autophagy and development of the nervous system	NATURE			English	Article							CELL-DEATH; EMBRYONIC-DEVELOPMENT; MOLECULAR MACHINERY; TUMOR-SUPPRESSOR; GENE; APOPTOSIS; MICE; PROTEINS; BECLIN-1; TUMORIGENESIS	Autophagy is a self-degradative process involved both in basal turnover of cellular components and in response to nutrient starvation or organelle damage in a wide range of eukaryotes(1-3). During autophagy, portions of the cytoplasm are sequestered by double-membraned vesicles called autophagosomes, and are degraded after fusion with lysosomes for subsequent recycling(4). In vertebrates, this process acts as a pro-survival or pro-death mechanism in different physiological and pathological conditions, such as neurodegeneration and cancer(2,5-7); however, the roles of autophagy during embryonic development are still largely uncharacterized(3). Beclin1 (Becn1; coiled-coil, myosin-like BCL2-interacting protein) is a principal regulator in autophagosome formation, and its deficiency results in early embryonic lethality(8,9). Here we show that Ambra1 (activating molecule in Beclin1-regulated autophagy), a large, previously unknown protein bearing a WD40 domain at its amino terminus, regulates autophagy and has a crucial role in embryogenesis. We found that Ambra1 is a positive regulator of the Becn1-dependent programme of autophagy, as revealed by its overexpression and by RNA interference experiments in vitro. Notably, Ambra1 functional deficiency in mouse embryos leads to severe neural tube defects associated with autophagy impairment, accumulation of ubiquitinated proteins, unbalanced cell proliferation and excessive apoptotic cell death. In addition to identifying a new and essential element regulating the autophagy programme, our results provide in vivo evidence supporting the existence of a complex interplay between autophagy, cell growth and cell death required for neural development in mammals.	Univ Roma Tor Vergata, Dept Biol, Dulbecco Telethon Inst, I-00133 Rome, Italy; Max Planck Inst Biophys Chem, Dept Mol Cell Biol, D-37077 Gottingen, Germany; IRCCS L Spallanzani, Natl Inst Infect Dis, I-00149 Rome, Italy; IRCCS, Fdn St Lucia, Lab Mol Neuroembryol, I-00143 Rome, Italy; Univ Gottingen, Dept Anat & Embryol, D-37085 Gottingen, Germany	Fondazione Telethon; Dulbecco Telethon Institute (DTI); University of Rome Tor Vergata; Max Planck Society; IRCCS Lazzaro Spallanzani; IRCCS Santa Lucia; University of Gottingen	Cecconi, F (corresponding author), Univ Roma Tor Vergata, Dept Biol, Dulbecco Telethon Inst, I-00133 Rome, Italy.	kchowdh@gwdg.de; francesco.cecconi@uniroma2.it	Nardacci, Roberta/K-6555-2016; Corazzari, Marco/B-4631-2019; Ucar, Ahmet/E-8981-2012; Piacentini, Mauro/I-2411-2016; Fuoco, Claudia/AAB-2268-2019; Fimia, Gian Maria/K-3232-2016; Cecconi, Francesco/K-3969-2016; Romagnoli, Alessandra/B-5779-2017; Corazzari, Marco/J-5825-2019; Corazzari, Marco/K-6422-2016; Di+Bartolomeo, Sabrina/AAB-9791-2019	Nardacci, Roberta/0000-0002-9209-1207; Corazzari, Marco/0000-0002-6246-5968; Piacentini, Mauro/0000-0003-2919-1296; Fimia, Gian Maria/0000-0003-4438-3325; Cecconi, Francesco/0000-0002-5614-4359; Corazzari, Marco/0000-0002-6246-5968; Corazzari, Marco/0000-0002-6246-5968; DI BARTOLOMEO, Sabrina/0000-0002-5748-1541; Fuoco, Claudia/0000-0001-8372-305X; romagnoli, alessandra/0000-0003-4946-6138; Ucar, Ahmet/0000-0002-6551-3486	Telethon [TCR04004] Funding Source: Medline	Telethon(Fondazione Telethon)		Baehrecke EH, 2002, NAT REV MOL CELL BIO, V3, P779, DOI 10.1038/nrm931; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Chowdhury K, 1997, NUCLEIC ACIDS RES, V25, P1531, DOI 10.1093/nar/25.8.1531; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Copp AJ, 2005, J ANAT, V207, P623, DOI 10.1111/j.1469-7580.2005.00476.x; Edinger AL, 2003, CANCER CELL, V4, P422, DOI 10.1016/S1535-6108(03)00306-4; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; Huang WP, 2002, CELL STRUCT FUNCT, V27, P409, DOI 10.1247/csf.27.409; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lockshin RA, 2004, INT J BIOCHEM CELL B, V36, P2405, DOI 10.1016/j.biocel.2004.04.011; Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Paglin S, 2001, CANCER RES, V61, P439; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Qu XP, 2007, CELL, V128, P931, DOI 10.1016/j.cell.2006.12.044; Ranga U, 1997, J VIROL, V71, P7020, DOI 10.1128/JVI.71.9.7020-7029.1997; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; Somia NV, 1999, P NATL ACAD SCI USA, V96, P12667, DOI 10.1073/pnas.96.22.12667; Stoykova A, 1998, DEV DYNAM, V212, P198; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	34	752	788	1	86	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 28	2007	447	7148					1121	U14		10.1038/nature05925	http://dx.doi.org/10.1038/nature05925			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183HT	17589504	Green Published			2022-12-28	WOS:000247564600039
J	van der Lee, JH; Mokkink, LB; Grootenhuis, MA; Heymans, HS; Offringa, M				van der Lee, Johanna H.; Mokkink, Lidwine B.; Grootenhuis, Martha A.; Heymans, Hugo S.; Offringa, Martin			Definitions and measurement of chronic health conditions in childhood - A systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							SCHOOL-AGED CHILDREN; LIMITING CHRONIC CONDITIONS; COMPLEX CHRONIC CONDITIONS; CHRONIC ILLNESS; CARE NEEDS; IDENTIFYING CHILDREN; CHRONIC DISEASE; WASHINGTON-STATE; ISRAELI CHILDREN; NATIONAL SAMPLE	Context Changes in the prevalence of chronic health conditions in childhood have considerable societal consequences for health care planning and for employment. To obtain valid and reliable estimates of the prevalence of chronic health conditions, a clear definition is needed. Objective To present an overview of all definitions and operationalizations that have been applied to measure the prevalence of chronic health conditions in childhood. Data Sources PubMed and the Web of Science were searched for articles published up to December 2006. Also, references were searched by hand for related articles. Study Selection Non - English- and non - Dutch-language articles were excluded. Of 7252 articles found, 64 articles that stated a conceptual definition and/or operationalization of chronic health conditions in children ( aged 0-18 years) were included. Data Extraction Data on the ( 1) definition; ( 2) operationalization in terms of source of information, method of information retrieval, and study population; and ( 3) resulting prevalence rate were extracted by 2 independent reviewers. Data Synthesis A large range of definitions were in use, of which 4 were cited by many authors. Various operationalizations of the concepts that were measured were identified. Chronic health conditions in childhood prevalence estimates ranged from 0.22% to 44%, depending on these operationalizations. Conclusions The wide variability in reported prevalence rates of chronic health conditions in childhood can be explained by considerable diversity in the concepts and operationalizations used. International consensus about the conceptual definition of chronic health conditions in childhood is needed.	Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Pediat Clin Epidemiol, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Pediat Psychosocial Dept, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Pediat, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Neonatol, NL-1105 AZ Amsterdam, Netherlands	Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	van der Lee, JH (corresponding author), Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Pediat Clin Epidemiol, Room H3-144,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	j.h.vanderlee@amc.uva.nl		Mokkink, Lidwine/0000-0001-6489-2827; Offringa, Martin/0000-0002-4402-5299				Al-Eissa EI, 2000, SAUDI MED J, V21, P934; Barlow JH, 2006, CHILD CARE HLTH DEV, V32, P19, DOI 10.1111/j.1365-2214.2006.00591.x; Beers NS, 2003, PUBLIC HEALTH REP, V118, P434, DOI 10.1016/S0033-3549(04)50275-3; BENDEL J, 1989, ISRAEL J MED SCI, V25, P264; Bloom Barbara, 2006, Vital Health Stat 10, P1; Boekaerts M, 1999, DISABIL REHABIL, V21, P311; Buescher PA, 2006, MATERN CHILD HLTH J, V10, P461, DOI 10.1007/s10995-006-0081-3; CADMAN D, 1986, CAN MED ASSOC J, V135, P761; Cooper WO, 1999, ARCH PEDIAT ADOL MED, V153, P1145, DOI 10.1001/archpedi.153.11.1145; Dosa NP, 2001, PEDIATRICS, V107, P499, DOI 10.1542/peds.107.3.499; EISER C, 1990, CHRONIC CHILDHOOD DI; Enriquez R, 2007, PEDIATRICS, V119, P222, DOI 10.1542/peds.2006-2757; Farooqi A, 2006, PEDIATRICS, V118, pE1466, DOI 10.1542/peds.2006-1070; Feudtner C, 2000, PEDIATRICS, V106, P205; Feudtner C, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.6.e99; Gallaher MM, 2002, ARCH PEDIAT ADOL MED, V156, P246, DOI 10.1001/archpedi.156.3.246; Garwick AW, 1998, ARCH PEDIAT ADOL MED, V152, P665; Geist R, 2003, BEST PRACT RES CL GA, V17, P141, DOI 10.1016/S1521-6918(02)00142-7; GORTMAKER SL, 1990, PEDIATRICS, V85, P267; HOBBS N, 1984, REHABIL LIT, V45, P206; JANSON S, 1994, ANN TROP PAEDIATR, V14, P137, DOI 10.1080/02724936.1994.11747706; Jee SH, 2006, J HEALTH CARE POOR U, V17, P328, DOI 10.1353/hpu.2006.0062; JESSOP DJ, 1995, ARCH PEDIAT ADOL MED, V149, P1105, DOI 10.1001/archpedi.1995.02170230059008; KAPLAN SL, 1986, J ADOLESCENT HEALTH, V7, P107, DOI 10.1016/S0197-0070(86)80005-5; Knafl K, 1996, J Pediatr Nurs, V11, P315, DOI 10.1016/S0882-5963(05)80065-X; Kuhlthau KA, 2002, AMBUL PEDIATR, V2, P58, DOI 10.1367/1539-4409(2002)002<0058:CADLWA>2.0.CO;2; Martin C, 1996, Aust Fam Physician, V25, P1273; McDougall J, 2004, DISABIL REHABIL, V26, P35, DOI 10.1080/09638280410001645076; McDougall J, 2003, DISABIL REHABIL, V25, P922, DOI 10.1080/0963828031000122249; McPherson M, 1998, PEDIATRICS, V102, P137, DOI 10.1542/peds.102.1.137; Miauton L, 2003, EUR J PEDIATR, V162, P682, DOI 10.1007/s00431-003-1179-x; MOKKINK LB, 2006, EXTENT CONSEQUENCES; Neff JM, 2002, ARCH PEDIAT ADOL MED, V156, P703, DOI 10.1001/archpedi.156.7.703; Neff JM, 2002, AMBUL PEDIATR, V2, P71, DOI 10.1367/1539-4409(2002)002<0071:IACCWC>2.0.CO;2; Newacheck PW, 2006, PEDIATRICS, V118, P334, DOI 10.1542/peds.2005-2238; NEWACHECK PW, 1994, J PEDIATR-US, V124, P40, DOI 10.1016/S0022-3476(94)70252-7; NEWACHECK PW, 1986, AM J PUBLIC HEALTH, V76, P178, DOI 10.2105/AJPH.76.2.178; NEWACHECK PW, 1986, J CHRON DIS, V39, P63, DOI 10.1016/0021-9681(86)90062-7; Newacheck PW, 1998, AM J PUBLIC HEALTH, V88, P610, DOI 10.2105/AJPH.88.4.610; Newacheck PW, 1998, PEDIATRICS, V102, P117, DOI 10.1542/peds.102.1.117; NEWACHECK PW, 1992, AM J PUBLIC HEALTH, V82, P364, DOI 10.2105/AJPH.82.3.364; NEWACHECK PW, 1991, AM J DIS CHILD, V145, P1367, DOI 10.1001/archpedi.1991.02160120035015; PALTI H, 1992, ISRAEL J MED SCI, V28, P435; Partington Susan N, 2006, WMJ, V105, P30; PERRIN EC, 1993, PEDIATRICS, V91, P787; Perrin JM, 2002, MILBANK Q, V80, P303, DOI 10.1111/1468-0009.t01-1-00005; Perrin JM, 1999, ARCH PEDIAT ADOL MED, V153, P80; PERRIN JM, 1993, PEDIATRICS, V92, P876; PLESS IB, 1971, PEDIATRICS, V47, P405; PLESS IB, 1993, PEDIATRICS, V91, P1131; PLESS IB, 1975, CHRONIC CHILDHOOD DI; Reilly JJ, 1999, LANCET, V354, P1874, DOI 10.1016/S0140-6736(99)04555-9; Rolnick SJ, 2003, ARCH PEDIAT ADOL MED, V157, P273, DOI 10.1001/archpedi.157.3.273; Seguin L, 2003, CAN MED ASSOC J, V168, P1533; Silver EJ, 1999, ARCH PEDIAT ADOL MED, V153, P815, DOI 10.1001/archpedi.153.8.815; Simeonsson RJ, 2006, J CLIN EPIDEMIOL, V59, P365, DOI 10.1016/j.jclinepi.2005.09.009; Spaite D W, 2001, Prehosp Disaster Med, V16, P96; Spencer N, 2003, ARCH DIS CHILD, V88, P570, DOI 10.1136/adc.88.7.570; Stein REK, 1999, ARCH PEDIAT ADOL MED, V153, P68; Stein REK, 1997, PEDIATRICS, V99, P513, DOI 10.1542/peds.99.4.513; Stein REK, 2000, ARCH PEDIAT ADOL MED, V154, P447, DOI 10.1001/archpedi.154.5.447; Stein REK, 2002, AMBUL PEDIATR, V2, P63, DOI 10.1367/1539-4409(2002)002<0063:CDDOCC>2.0.CO;2; Stein REK, 2001, PEDIATRICS, V107, part. no., DOI 10.1542/peds.107.4.e61; STEIN REK, 1982, PUBLIC HEALTH REP, V97, P354; Stein REK, 2001, AMBUL PEDIATR, V1, P280, DOI 10.1367/1539-4409(2001)001<0280:CILTHC>2.0.CO;2; STEIN REK, 1993, J PEDIATR-US, V122, P342, DOI 10.1016/S0022-3476(05)83414-6; Stein REK, 2006, PEDIATRICS, V118, P217, DOI 10.1542/peds.2005-2836; Stiller C, 2002, MED PEDIATR ONCOL, V39, P149, DOI 10.1002/mpo.10142; Suris JC, 2003, J PEDIATR ENDOCR MET, V16, P247; URPONEN H, 1978, INT J REHABIL RES, V1, P309, DOI 10.1097/00004356-197807000-00002; van der Veen W J, 2003, Ned Tijdschr Geneeskd, V147, P378; Vogel AM, 1996, J PAEDIATR CHILD H, V32, P484, DOI 10.1111/j.1440-1754.1996.tb00959.x; VUORI H, 1978, PUBLIC HEALTH, V92, P272, DOI 10.1016/S0033-3506(78)80079-1; VUORINEN HS, 1991, SOC SCI MED, V33, P1023, DOI 10.1016/0277-9536(91)90007-Y; WEALE J, 1980, J EPIDEMIOL COMMUN H, V34, P111, DOI 10.1136/jech.34.2.111; WESTBOM L, 1987, SCAND J SOC MED, V15, P87, DOI 10.1177/140349488701500206; Youngblade LM, 2003, J PEDIATR PSYCHOL, V28, P393, DOI 10.1093/jpepsy/jsg029	77	268	269	0	26	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 27	2007	297	24					2741	2751		10.1001/jama.297.24.2741	http://dx.doi.org/10.1001/jama.297.24.2741			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	182UE	17595275				2022-12-28	WOS:000247528700024
J	Tibbles, CD; Edlow, JA				Tibbles, Carrie D.; Edlow, Jonathan A.			Does this patient have erythema migrans?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EARLY LYME-DISEASE; POLYMERASE CHAIN-REACTION; BURGDORFERI SENSU-LATO; CENTRAL-NERVOUS-SYSTEM; BORRELIA-BURGDORFERI; CHRONICUM MIGRANS; AMBLYOMMA-AMERICANUM; SKIN-LESIONS; CEFUROXIME AXETIL; CLINICAL CHARACTERISTICS	Context Erythema migrans, while not pathognomonic, is the most common manifestation of early Lyme disease. Accurate diagnosis of this rash is essential to initiating appropriate antibiotic therapy. Objective To determine the sensitivity of history and physical examination characteristics for the diagnosis of erythema migrans. Data Sources Structured MEDLINE searches of articles written only in English, 1966 through March 2007. Study Selection Studies were included if they enrolled at least 15 consecutive patients with the diagnosis of erythema migrans and reported original data regarding the history and physical examination characteristics of the patients. Data Extraction One author abstracted data from the studies. Results We separately analyzed the studies from Europe and analyzed both Lyme-endemic and nonendemic areas of the United States to search for potential differences in the clinical presentation. Thirty-two studies from Europe, 20 studies from the United States, and 1 from Europe and the United States met inclusion criteria for a total of 8493 patients. Sensitivity was calculated for each of the variables. No studies included patients without erythema migrans, so specificity data and likelihood ratios could not be determined. Many patients do not recall a tick bite. Associated systemic symptoms, such as fever and headache, are frequently reported. Nausea and vomiting are rare. A solitary lesion is the most frequent presentation in both US (81%; 95% confidence interval [CI], 72%-87%) and European patients (88%; 95% CI, 81%-93%). Central clearing is less common in the endemic United States (19%; 95% CI, 11%-32%) vs Europe (79%; 95% CI, 69%-86%) and the nonendemic United States (80%; 95% CI, 63%-90%). Conclusions Our analysis of the current available literature suggests that there is no single element in the history or physical examination that is highly sensitive by itself for the diagnosis of erythema migrans. Clinicians should be aware of the wide variability in the clinical presentation of erythema migrans and the need to factor in multiple components of the clinical examination and epidemiological context.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Tibbles, CD (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Emergency Med, W Clin Ctr 2,1 Deaconess Rd, Boston, MA 02215 USA.	ctibbles@bidmc.harvard.edu	Edlow, Jonathan A/F-7128-2016					Aguero-Rosenfeld ME, 2005, CLIN MICROBIOL REV, V18, P484, DOI 10.1128/CMR.18.3.484-509.2005; AgueroRosenfeld ME, 1996, J CLIN MICROBIOL, V34, P1; Amez M, 1999, WIEN KLIN WOCHENSCHR, V111, P916; Armstrong PM, 2001, B WORLD HEALTH ORGAN, V79, P916; Arnez M, 2003, INFECTION, V31, P404, DOI 10.1007/s15010-003-4007-3; Arnez M, 2002, WIEN KLIN WOCHENSCHR, V114, P498; Arnez M, 2001, PEDIATR INFECT DIS J, V20, P251, DOI 10.1097/00006454-200103000-00007; Arnez M, 2001, WIEN KLIN WOCHENSCHR, V113, P98; ASBRINK E, 1985, ACTA DERM-VENEREOL, V65, P43; ASBRINK E, 1986, ZBL BAKT-INT J MED M, V263, P229; Barsic B, 2000, INFECTION, V28, P153, DOI 10.1007/s150100050069; Bennet L, 2006, WIEN KLIN WOCHENSCHR, V118, P531, DOI 10.1007/s00508-006-0659-1; BERGER BW, 1989, REV INFECT DIS, V11, pS1475; BERGER BW, 1992, J CLIN MICROBIOL, V30, P359, DOI 10.1128/JCM.30.2.359-361.1992; BERGER BW, 1984, ARCH DERMATOL, V120, P1017, DOI 10.1001/archderm.120.8.1017; Breier F, 1996, INFECTION, V24, P69, DOI 10.1007/BF01780662; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; CAMPBELL GL, 1995, J INFECT DIS, V172, P470, DOI 10.1093/infdis/172.2.470; Carlsson SA, 2003, SCAND J INFECT DIS, V35, P31, DOI 10.1080/0036554021000026978; Christova I, 2004, WIEN KLIN WOCHENSCHR, V116, P42, DOI 10.1007/BF03040423; Coyle BS, 1996, J INFECT DIS, V173, P1260, DOI 10.1093/infdis/173.5.1260; DATTWYLER RJ, 1990, LANCET, V336, P1404, DOI 10.1016/0140-6736(90)93103-V; Dattwyler RJ, 1996, ANTIMICROB AGENTS CH, V40, P468, DOI 10.1128/AAC.40.2.468; Dhote R, 2000, EUR J CLIN MICROBIOL, V19, P809, DOI 10.1007/s100960000391; EDLOW J, 2003, B EYE UNRAVELING MED; Edlow JA, 2002, MED CLIN N AM, V86, P239, DOI 10.1016/S0025-7125(03)00085-3; Eppes SC, 2002, PEDIATRICS, V109, P1173, DOI 10.1542/peds.109.6.1173; FEDER HM, 1995, AM J MED, V99, P412, DOI 10.1016/S0002-9343(99)80190-9; Felz MW, 1999, ARCH DERMATOL, V135, P1317, DOI 10.1001/archderm.135.11.1317; FLISIAK LI, 1996, ROCZNIKI AKAD MED BI, V41, P78; Gerber MA, 1996, NEW ENGL J MED, V335, P1270, DOI 10.1056/NEJM199610243351703; GOODMAN JL, 1995, AM J MED, V99, P6, DOI 10.1016/S0002-9343(99)80097-7; James AM, 2001, J INFECT DIS, V183, P1810, DOI 10.1086/320721; Jurca T, 1998, CLIN INFECT DIS, V27, P636, DOI 10.1086/514715; Keirans JE, 1998, J PARASITOL, V84, P629, DOI 10.2307/3284739; Kirkland KB, 1997, ARCH INTERN MED, V157, P2635, DOI 10.1001/archinte.157.22.2635; KUIPER H, 1994, EUR J CLIN MICROBIOL, V13, P379, DOI 10.1007/BF01971994; KUIPER H, 1994, BRIT J DERMATOL, V130, P466, DOI 10.1111/j.1365-2133.1994.tb03379.x; Lipsker D, 2004, ARCH DERMATOL, V140, P620, DOI 10.1001/archderm.140.5.620; Lipsker D, 2002, BRIT J DERMATOL, V146, P872, DOI 10.1046/j.1365-2133.2002.04628.x; Logar M, 2004, INFECTION, V32, P15, DOI 10.1007/s15010-004-3042-z; Logar M, 1999, WIEN KLIN WOCHENSCHR, V111, P945; Luft BJ, 1996, ANN INTERN MED, V124, P785, DOI 10.7326/0003-4819-124-9-199605010-00002; LUFT BJ, 1992, JAMA-J AM MED ASSOC, V267, P1364, DOI 10.1001/jama.267.10.1364; LUGER SW, 1995, ANTIMICROB AGENTS CH, V39, P661, DOI 10.1128/AAC.39.3.661; MASSAROTTI EM, 1992, AM J MED, V92, P396, DOI 10.1016/0002-9343(92)90270-L; Masters E, 1998, ARCH DERMATOL, V134, P955, DOI 10.1001/archderm.134.8.955; Masters EJ, 1998, ARCH INTERN MED, V158, P2162, DOI 10.1001/archinte.158.19.2162; MELSKI JW, 1993, ARCH DERMATOL, V129, P709, DOI 10.1001/archderm.129.6.709; NADELMAN RB, 1990, AM J MED, V88, P21, DOI 10.1016/0002-9343(90)90122-T; Nadelman RB, 1996, AM J MED, V100, P502, DOI 10.1016/S0002-9343(95)99915-9; NADELMAN RB, 1992, ANN INTERN MED, V117, P273, DOI 10.7326/0003-4819-117-4-273; NADELMAN RB, 1995, AM J MED, V98, pS15, DOI 10.1016/S0002-9343(99)80040-0; NEUMANN R, 1987, ZBL BAKT-INT J MED M, V263, P372; Nichol G, 1998, ANN INTERN MED, V128, P37, DOI 10.7326/0003-4819-128-1-199801010-00007; Nowakowski J, 2001, CLIN INFECT DIS, V33, P2023, DOI 10.1086/324490; Oksi J, 2001, APMIS, V109, P581, DOI 10.1034/j.1600-0463.2001.d01-178.x; Orloski K A, 2000, MMWR CDC Surveill Summ, V49, P1; Philipp MT, 2006, CLIN VACCINE IMMUNOL, V13, P1170, DOI 10.1128/CVI.00238-06; Picken MM, 1997, J CLIN PATHOL-MOL PA, V50, P186, DOI 10.1136/mp.50.4.186; SCHULZE TL, 1984, SCIENCE, V224, P601, DOI 10.1126/science.6710158; Seltzer EG, 2000, JAMA-J AM MED ASSOC, V283, P609, DOI 10.1001/jama.283.5.609; Smith RP, 2002, ANN INTERN MED, V136, P421, DOI 10.7326/0003-4819-136-6-200203190-00005; Snyder SB, 2005, ANN EMERG MED, V46, P224, DOI 10.1016/j.annemergmed.2004.11.035; Sood SK, 1997, J INFECT DIS, V175, P996, DOI 10.1086/514009; Stanek G, 2003, LANCET, V362, P1639, DOI 10.1016/S0140-6736(03)14798-8; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1980, ANN INTERN MED, V93, P1, DOI 10.7326/0003-4819-93-1-1; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; STEERE AC, 1977, ARTHRITIS RHEUM, V20, P7, DOI 10.1002/art.1780200102; Steere AC, 2001, NEW ENGL J MED, V345, P115, DOI 10.1056/NEJM200107123450207; STRLE F, 1992, J ANTIMICROB CHEMOTH, V30, P543, DOI 10.1093/jac/30.4.543; Strle F, 2002, WIEN KLIN WOCHENSCHR, V114, P493; Strle F, 1996, CLIN INFECT DIS, V23, P61, DOI 10.1093/clinids/23.1.61; Strle F, 1996, EUR J EPIDEMIOL, V12, P503, DOI 10.1007/BF00144004; Strle F, 1999, ANN INTERN MED, V130, P32, DOI 10.7326/0003-4819-130-1-199901050-00006; Strle F, 1996, INFECTION, V24, P64, DOI 10.1007/BF01780661; STRLE F, 1993, INFECTION, V21, P83, DOI 10.1007/BF01710737; Stromdahl EY, 2003, J CLIN MICROBIOL, V41, P5557, DOI 10.1128/JCM.41.12.5557-5562.2003; Taft SC, 2005, VECTOR-BORNE ZOONOT, V5, P383, DOI 10.1089/vbz.2005.5.383; Varela AS, 2004, J CLIN MICROBIOL, V42, P1163, DOI 10.1128/JCM.42.3.1163-1169.2004; VONSTEDINGK LT, 1995, EUR J CLIN MICROBIOL, V14, P1, DOI 10.1007/BF02112610; WEBER K, 1986, ZBL BAKT-INT J MED M, V263, P209; WEBER K, 1993, INFECTION, V21, P367, DOI 10.1007/BF01728915; WEBER K, 1990, INFECTION, V18, P91, DOI 10.1007/BF01641422; WEBERK, 1987, ZENTRALBL BAKTERIO A, V263, P377; Wormser GP, 2006, NEW ENGL J MED, V354, P2794, DOI 10.1056/NEJMcp061181; Wormser GP, 2005, ANN INTERN MED, V142, P751, DOI 10.7326/0003-4819-142-9-200505030-00011; Wormser GP, 2005, CLIN INFECT DIS, V40, P423, DOI 10.1086/427289; Wormser GP, 2003, ANN INTERN MED, V138, P697, DOI 10.7326/0003-4819-138-9-200305060-00005; Wormser GP, 2005, CLIN INFECT DIS, V41, P958, DOI 10.1086/432935; Zajkowska Joanna, 2002, Med Sci Monit, V8, pCR37; 1997, MMWR MORB MORTAL WKL, V46, P531	93	97	101	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 20	2007	297	23					2617	2627		10.1001/jama.297.23.2617	http://dx.doi.org/10.1001/jama.297.23.2617			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180HB	17579230				2022-12-28	WOS:000247352600024
J	Mikkelsen, TS; Ku, MC; Jaffe, DB; Issac, B; Lieberman, E; Giannoukos, G; Alvarez, P; Brockman, W; Kim, TK; Koche, RP; Lee, W; Mendenhall, E; O'Donovan, A; Presser, A; Russ, C; Xie, XH; Meissner, A; Wernig, M; Jaenisch, R; Nusbaum, C; Lander, ES; Bernstein, BE				Mikkelsen, Tarjei S.; Ku, Manching; Jaffe, David B.; Issac, Biju; Lieberman, Erez; Giannoukos, Georgia; Alvarez, Pablo; Brockman, William; Kim, Tae-Kyung; Koche, Richard P.; Lee, William; Mendenhall, Eric; O'Donovan, Aisling; Presser, Aviva; Russ, Carsten; Xie, Xiaohui; Meissner, Alexander; Wernig, Marius; Jaenisch, Rudolf; Nusbaum, Chad; Lander, Eric S.; Bernstein, Bradley E.			Genome-wide maps of chromatin state in pluripotent and lineage-committed cells	NATURE			English	Article							EMBRYONIC STEM-CELLS; HISTONE LYSINE METHYLATION; DEVELOPMENTAL REGULATORS; DNA METHYLATION; GENE-EXPRESSION; NONCODING RNAS; MOUSE; POLYCOMB; TRANSCRIPTION; DIFFERENTIATION	We report the application of single-molecule-based sequencing technology for high-throughput profiling of histone modifications in mammalian cells. By obtaining over four billion bases of sequence from chromatin immunoprecipitated DNA, we generated genome-wide chromatin-state maps of mouse embryonic stem cells, neural progenitor cells and embryonic fibroblasts. We find that lysine 4 and lysine 27 trimethylation effectively discriminates genes that are expressed, poised for expression, or stably repressed, and therefore reflect cell state and lineage potential. Lysine 36 trimethylation marks primary coding and non-coding transcripts, facilitating gene annotation. Trimethylation of lysine 9 and lysine 20 is detected at satellite, telomeric and active long-terminal repeats, and can spread into proximal unique sequences. Lysine 4 and lysine 9 trimethylation marks imprinting control regions. Finally, we show that chromatin state can be read in an allele-specific manner by using single nucleotide polymorphisms. This study provides a framework for the application of comprehensive chromatin profiling towards characterization of diverse mammalian cell populations.	Harvard Univ, Broad Inst, Cambridge, MA 02142 USA; MIT, Div Hlth Sci & Technol, Cambridge, MA 02142 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Neurol, Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Lander, ES (corresponding author), Harvard Univ, Broad Inst, Cambridge, MA 02142 USA.	lander@broad.mit.edu; bbernstein@partners.org	Kim, Tae-Kyung/AAX-4230-2020; Mikkelsen, Tarjei S/A-1306-2007; Aiden, Erez Lieberman/A-2908-2010	Kim, Tae-Kyung/0000-0001-5161-9864; Mikkelsen, Tarjei S/0000-0002-8133-3135; Xie, Xiaohui/0000-0002-5479-6345; Issac, Biju/0000-0002-7311-678X; Koche, Richard/0000-0002-6820-5083; Mendenhall, Eric/0000-0002-7395-6295	NCI NIH HHS [T32 CA009216] Funding Source: Medline; NIGMS NIH HHS [R01 GM078986, R01 GM078986-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009216] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078986] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexander DL, 1998, J CELL SCI, V111, P3311; Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403; Bannister AJ, 2005, J BIOL CHEM, V280, P17732, DOI 10.1074/jbc.M500796200; Baust C, 2003, J VIROL, V77, P11448, DOI 10.1128/JVI.77.21.11448-11458.2003; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Buck MJ, 2004, GENOMICS, V83, P349, DOI 10.1016/j.ygeno.2003.11.004; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; Cho DH, 2005, MOL CELL, V20, P483, DOI 10.1016/j.molcel.2005.09.002; Conti L, 2005, PLOS BIOL, V3, P1594, DOI 10.1371/journal.pbio.0030283; Cullen BR, 2004, MOL CELL, V16, P861, DOI 10.1016/j.molcel.2004.12.002; Delaval K, 2007, EMBO J, V26, P720, DOI 10.1038/sj.emboj.7601513; Doetsch F, 2003, NAT NEUROSCI, V6, P1127, DOI 10.1038/nn1144; Edwards CA, 2007, CURR OPIN CELL BIOL, V19, P281, DOI 10.1016/j.ceb.2007.04.013; Fantes J, 2003, NAT GENET, V33, P461, DOI 10.1038/ng1120; Feil R, 2007, TRENDS GENET, V23, P192, DOI 10.1016/j.tig.2007.02.004; Feng YQ, 2005, MOL CELL BIOL, V25, P3864, DOI 10.1128/MCB.25.10.3864-3874.2005; Garreta E, 2006, TISSUE ENG, V12, P2215, DOI 10.1089/ten.2006.12.2215; Hutchinson JN, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-39; Kim A, 2007, MOL CELL BIOL, V27, P1271, DOI 10.1128/MCB.01684-06; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Krichevsky AM, 2006, STEM CELLS, V24, P857, DOI 10.1634/stemcells.2005-0441; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lengner CJ, 2004, J CELL PHYSIOL, V200, P327, DOI 10.1002/jcp.20118; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Martens JHA, 2005, EMBO J, V24, P800, DOI 10.1038/sj.emboj.7600545; Mockler TC, 2005, GENOMICS, V85, P1, DOI 10.1016/j.ygeno.2004.10.005; Pasini D, 2007, MOL CELL BIOL, V27, P3769, DOI 10.1128/MCB.01432-06; Rao B, 2005, MOL CELL BIOL, V25, P9447, DOI 10.1128/MCB.25.21.9447-9459.2005; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Roh TY, 2005, GENE DEV, V19, P542, DOI 10.1101/gad.1272505; Saxonov S, 2006, P NATL ACAD SCI USA, V103, P1412, DOI 10.1073/pnas.0510310103; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Seitz H, 2004, GENOME RES, V14, P1741, DOI 10.1101/gr.2743304; Service RF, 2006, SCIENCE, V311, P1544, DOI 10.1126/science.311.5767.1544; Squazzo SL, 2006, GENOME RES, V16, P890, DOI 10.1101/gr.5306606; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Surani MA, 2007, CELL, V128, P747, DOI 10.1016/j.cell.2007.02.010; Svoboda P, 2004, DEV BIOL, V269, P276, DOI 10.1016/j.ydbio.2004.01.028; Vakoc CR, 2006, MOL CELL BIOL, V26, P9185, DOI 10.1128/MCB.01529-06; Verdel A, 2005, FEBS LETT, V579, P5872, DOI 10.1016/j.febslet.2005.08.083; Wang XZ, 2002, GENE DEV, V16, P1890, DOI 10.1101/gad.1004802; Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990; Zaratiegui M, 2007, CELL, V128, P763, DOI 10.1016/j.cell.2007.02.016	48	3058	3191	3	316	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 2	2007	448	7153					553	U2		10.1038/nature06008	http://dx.doi.org/10.1038/nature06008			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	195XV	17603471	Green Accepted			2022-12-28	WOS:000248446700035
J	Chinchilla, D; Zipfel, C; Robatzek, S; Kemmerling, B; Nurnberger, T; Jones, JDG; Felix, G; Boller, T				Chinchilla, Delphine; Zipfel, Cyril; Robatzek, Silke; Kemmerling, Birgit; Nuernberger, Thorsten; Jones, Jonathan D. G.; Felix, Georg; Boller, Thomas			A flagellin-induced complex of the receptor FLS2 and BAK1 initiates plant defence	NATURE			English	Article							INNATE IMMUNITY; ARABIDOPSIS-THALIANA; KINASE; PERCEPTION; BRASSINOSTEROIDS; PHOSPHORYLATION; ENDOCYTOSIS; DOMAIN; SIGNAL; GENE	Plants sense potential microbial invaders by using pattern-recognition receptors to recognize pathogen-associated molecular patterns (PAMPs)(1). In Arabidopsis thaliana, the leucine-rich repeat receptor kinases flagellin-sensitive 2 (FLS2) (ref. 2) and elongation factor Tu receptor (EFR) ( ref. 3) act as pattern-recognition receptors for the bacterial PAMPs flagellin(4) and elongation factor Tu (EF-Tu) ( ref. 5) and contribute to resistance against bacterial pathogens. Little is known about the molecular mechanisms that link receptor activation to intracellular signal transduction. Here we show that BAK1 (BRI1-associated receptor kinase 1), a leucine-rich repeat receptor-like kinase that has been reported to regulate the brassinosteroid receptor BRI1 (refs 6,7), is involved in signalling by FLS2 and EFR. Plants carrying bak1 mutations show normal flagellin binding but abnormal early and late flagellin-triggered responses, indicating that BAK1 acts as a positive regulator in signalling. The bak1-mutant plants also show a reduction in early, but not late, EF-Tu-triggered responses. The decrease in responses to PAMPs is not due to reduced sensitivity to brassino-steroids. We provide evidence that FLS2 and BAK1 form a complex in vivo, in a specific ligand-dependent manner, within the first minutes of stimulation with flagellin. Thus, BAK1 is not only associated with developmental regulation through the plant hormone receptor BRI1 ( refs 6,7), but also has a functional role in PRR-dependent signalling, which initiates innate immunity.	Univ Basel, Zurich Basel Plant Sci Ctr, Inst Bot, CH-4056 Basel, Switzerland; Sainsbury Lab, Norwich NR4 7UH, Norfolk, England; Max Planck Inst Plant Breeding Res, D-50829 Cologne, Germany; Univ Tubingen, Inst Plant Biochem, ZMBP, D-72076 Tubingen, Germany	University of Basel; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Max Planck Society; Eberhard Karls University of Tubingen	Chinchilla, D (corresponding author), Univ Basel, Zurich Basel Plant Sci Ctr, Inst Bot, Hebelstr 1, CH-4056 Basel, Switzerland.	delphine.chinchilla@unibas.ch; thomas.boller@unibas.ch	ZIPFEL, CYRIL/ABD-5076-2021; Robatzek, Silke/B-6844-2013; Boller, Thomas/G-3500-2012; ZIPFEL, CYRIL B/D-7103-2011; Jones, Jonathan DG/J-5129-2012	ZIPFEL, CYRIL/0000-0003-4935-8583; Boller, Thomas/0000-0001-6768-7503; ZIPFEL, CYRIL B/0000-0003-4935-8583; Jones, Jonathan DG/0000-0002-4953-261X; Kemmerling, Birgit/0000-0003-1174-0189				Albrecht C, 2005, PLANT CELL, V17, P3337, DOI 10.1105/tpc.105.036814; Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Chinchilla D, 2006, PLANT CELL, V18, P465, DOI 10.1105/tpc.105.036574; Colcombet J, 2005, PLANT CELL, V17, P3350, DOI 10.1105/tpc.105.036731; Dardick C, 2006, PLOS PATHOG, V2, P14, DOI 10.1371/journal.ppat.0020002; Felix G, 1999, PLANT J, V18, P265, DOI 10.1046/j.1365-313X.1999.00265.x; FELIX G, 1991, P NATL ACAD SCI USA, V88, P8831, DOI 10.1073/pnas.88.19.8831; Gomez-Gomez L, 2000, MOL CELL, V5, P1003, DOI 10.1016/S1097-2765(00)80265-8; Gomez-Gomez L, 2001, PLANT CELL, V13, P1155, DOI 10.1105/tpc.13.5.1155; Hecht V, 2001, PLANT PHYSIOL, V127, P803, DOI 10.1104/pp.010324; Hellens RP, 2000, PLANT MOL BIOL, V42, P819, DOI 10.1023/A:1006496308160; Karlova R, 2006, PLANT CELL, V18, P626, DOI 10.1105/tpc.105.039412; Kauschmann A, 1996, PLANT J, V9, P701, DOI 10.1046/j.1365-313X.1996.9050701.x; Kemmerling B, 2007, CURR BIOL, V17, P1116, DOI 10.1016/j.cub.2007.05.046; Kinoshita T, 2005, NATURE, V433, P167, DOI 10.1038/nature03227; Kunze G, 2004, PLANT CELL, V16, P3496, DOI 10.1105/tpc.104.026765; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Li J, 2002, CELL, V110, P213, DOI 10.1016/S0092-8674(02)00812-7; Li JM, 2007, TRENDS PLANT SCI, V12, P37, DOI 10.1016/j.tplants.2006.11.002; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nam KH, 2002, CELL, V110, P203, DOI 10.1016/S0092-8674(02)00814-0; Nurnberger T, 2004, IMMUNOL REV, V198, P249, DOI 10.1111/j.0105-2896.2004.0119.x; Robatzek S, 2006, GENE DEV, V20, P537, DOI 10.1101/gad.366506; Russinova E, 2004, PLANT CELL, V16, P3216, DOI 10.1105/tpc.104.025387; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Vert G, 2005, ANNU REV CELL DEV BI, V21, P177, DOI 10.1146/annurev.cellbio.21.090704.151241; Wang XF, 2005, PLANT CELL, V17, P1685, DOI 10.1105/tpc.105.031393; Zeidler D, 2004, P NATL ACAD SCI USA, V101, P15811, DOI 10.1073/pnas.0404536101; Zipfel C, 2004, NATURE, V428, P764, DOI 10.1038/nature02485; Zipfel C, 2006, CELL, V125, P749, DOI 10.1016/j.cell.2006.03.037	31	1199	1272	15	369	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 26	2007	448	7152					497	U12		10.1038/nature05999	http://dx.doi.org/10.1038/nature05999			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	193VG	17625569	Green Published			2022-12-28	WOS:000248302700052
J	Dominguez-Sola, D; Ying, CY; Grandori, C; Ruggiero, L; Chen, B; Li, MY; Galloway, DA; Gu, W; Gautier, J; Dalla-Favera, R				Dominguez-Sola, David; Ying, Carol Y.; Grandori, Carla; Ruggiero, Luca; Chen, Brenden; Li, Muyang; Galloway, Denise A.; Gu, Wei; Gautier, Jean; Dalla-Favera, Riccardo			Non-transcriptional control of DNA replication by c-Myc	NATURE			English	Article							LEUKEMIA-CELL-LINE; NEGATIVE AUTOREGULATION; GENOMIC INSTABILITY; BURKITT-LYMPHOMA; DAMAGE RESPONSE; ONC GENE; TUMORIGENESIS; PROTEIN; ACTIVATION; CHECKPOINT	The c-Myc proto-oncogene encodes a transcription factor that is essential for cell growth and proliferation and is broadly implicated in tumorigenesis. However, the biological functions required by c-Myc to induce oncogenesis remain elusive. Here we show that c-Myc has a direct role in the control of DNA replication. c-Myc interacts with the pre-replicative complex and localizes to early sites of DNA synthesis. Depletion of c-Myc from mammalian ( human and mouse) cells as well as from Xenopus cell-free extracts, which are devoid of RNA transcription, demonstrates a non-transcriptional role for c-Myc in the initiation of DNA replication. Overexpression of c-Myc causes increased replication origin activity with subsequent DNA damage and checkpoint activation. These findings identify a critical function of c-Myc in DNA replication and suggest a novel mechanism for its normal and oncogenic functions.	Columbia Univ, Med Ctr, Inst Canc Genet, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ, Med Ctr, Herbert Irving Ctr Comprehens Canc, New York, NY 10032 USA; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA	Columbia University; Columbia University; Fred Hutchinson Cancer Center	Gautier, J (corresponding author), Columbia Univ, Med Ctr, Inst Canc Genet, Dept Genet & Dev, New York, NY 10032 USA.	jg130@columbia.edu; rd10@columbia.edu	Gautier, jean/A-2774-2008	Dominguez-Sola, David/0000-0001-9569-8402				Abdurashidova G, 2000, SCIENCE, V287, P2023, DOI 10.1126/science.287.5460.2023; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; Cobb JA, 2005, GENE DEV, V19, P3055, DOI 10.1101/gad.361805; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; Costanzo V, 2001, MOL CELL, V8, P137, DOI 10.1016/S1097-2765(01)00294-5; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DALLAFAVERA R, 1982, NATURE, V299, P61; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; Felsher DW, 2000, P NATL ACAD SCI USA, V97, P10544, DOI 10.1073/pnas.190327097; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Gilbert DM, 2004, NAT REV MOL CELL BIO, V5, P848, DOI 10.1038/nrm1495; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Grandori C, 2005, NAT CELL BIOL, V7, P311, DOI 10.1038/ncb1224; Grandori C, 2003, GENE DEV, V17, P1569, DOI 10.1101/gad.1100303; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; Jackson JR, 2000, CANCER RES, V60, P566; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; Koch HB, 2007, CELL CYCLE, V6, P205, DOI 10.4161/cc.6.2.3742; Kovalchuk AL, 2000, J EXP MED, V192, P1183, DOI 10.1084/jem.192.8.1183; Machida YJ, 2005, CELL, V123, P13, DOI 10.1016/j.cell.2005.09.019; Mai Sabine, 2003, Journal of Environmental Pathology Toxicology and Oncology, V22, P179; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Michael WM, 2000, SCIENCE, V289, P2133, DOI 10.1126/science.289.5487.2133; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Norio P, 2006, EMBO REP, V7, P779, DOI 10.1038/sj.embor.7400766; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Prathapam T, 2006, P NATL ACAD SCI USA, V103, P2695, DOI 10.1073/pnas.0511186103; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Shechter D, 2004, NAT CELL BIOL, V6, P648, DOI 10.1038/ncb1145; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; Tao L, 2000, J CELL BIOCHEM, V78, P442, DOI 10.1002/1097-4644(20000901)78:3<442::AID-JCB9>3.0.CO;2-1; VENNSTROM B, 1982, J VIROL, V42, P773, DOI 10.1128/JVI.42.3.773-779.1982; Wade M, 2006, CURR TOP MICROBIOL, V302, P169; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; Wang X, 2004, MOL CELL BIOL, V24, P6891, DOI 10.1128/MCB.24.16.6891-6899.2004; Woodward AM, 2006, J CELL BIOL, V173, P673, DOI 10.1083/jcb.200602108; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963	51	489	503	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 26	2007	448	7152					445	U3		10.1038/nature05953	http://dx.doi.org/10.1038/nature05953			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	193VG	17597761				2022-12-28	WOS:000248302700041
J	Jain, T; Gupta, RS				Jain, Tarun; Gupta, Ruchi S.			Trends in the use of intracytoplasmic sperm injection in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IN-VITRO FERTILIZATION; MALE-FACTOR INFERTILITY; UNEXPLAINED INFERTILITY; INTRAUTERINE INSEMINATION; ICSI; CONCEPTION; IVF; OUTCOMES; FAILURE; EMBRYO	Background: Intracytoplasmic sperm injection (ICSI) was initially developed as part of in vitro fertilization (IVF) to treat male-factor infertility. However, despite the added cost, uncertain efficacy, and potential risks of ICSI, its use has been extended to include some patients without documented male-factor infertility. Methods: We analyzed national data on assisted reproductive technology reported to the Centers for Disease Control and Prevention, to determine temporal trends in the use of ICSI and IVF in the United States, and we examined differences in the use of ICSI between states with and those without mandated insurance coverage. Results: From 1995 to 2004, the number of fertility clinics and fresh-embryo cycles and the rates of IVF-related pregnancies and live births increased. The percentage of IVF cycles with the use of ICSI also increased dramatically (from 11.0% to 57.5%), while the percentage of diagnoses of infertility attributed to male-factor conditions remained stable. The ratio of ICSI procedures to diagnoses of male-factor infertility steadily increased each year, suggesting an increasing use of ICSI for conditions other than male-factor infertility. From 1999 to 2004, there was an increasing use of ICSI relative to the percentage of patients with male-factor infertility in states with and those without mandated insurance coverage. For any given year, however, states with insurance coverage had a higher ratio of ICSI use to diagnoses of male-factor infertility than did states without insurance coverage (P<0.001). Conclusions: Since 1995, the use of ICSI in the United States has increased dramatically, while the proportion of patients receiving treatment for male-factor infertility has remained stable. State-mandated health insurance coverage for IVF services is associated with greater use of ICSI for infertility that is not attributed to male-factor conditions.	Univ Illinois, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, Coll Med, Chicago, IL 60612 USA; Northwestern Univ, Feinberg Sch Med, Inst Healthcare Studies, Chicago, IL 60611 USA; Childrens Mem Hosp, Childrens Mem Res Ctr, Chicago, IL 60614 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago	Jain, T (corresponding author), Univ Illinois, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, Coll Med, 820 S Wood St,Rm 285, Chicago, IL 60612 USA.	tjain@uic.edu	Jain, Tarun/ABF-7304-2020	Jain, Tarun/0000-0002-8889-084X				Aboulghar MA, 1996, FERTIL STERIL, V66, P753, DOI 10.1016/S0015-0282(16)58630-0; Abu-Hassan D, 2003, HUM REPROD, V18, P893, DOI 10.1093/humrep/deg159; [Anonymous], FREQ ASK QUEST INF; *ASRM, 2006, GEN CONS REL INTR SP; *ASRM, 1994, INTR SPERM INJ ICSI; Bhattacharya S, 2001, LANCET, V357, P2075, DOI 10.1016/S0140-6736(00)05179-5; Bonduelle M, 2005, HUM REPROD, V20, P413, DOI 10.1093/humrep/deh592; Bonduelle M, 2002, HUM REPROD, V17, P2600, DOI 10.1093/humrep/17.10.2600; Bungum L, 2004, REPROD BIOMED ONLINE, V8, P584, DOI 10.1016/S1472-6483(10)61107-8; Collins JA, 2002, HUM REPROD UPDATE, V8, P265, DOI 10.1093/humupd/8.3.265; Cox GF, 2002, AM J HUM GENET, V71, P162, DOI 10.1086/341096; Devroey P, 2004, HUM REPROD UPDATE, V10, P19, DOI 10.1093/humupd/dmh004; Fishel S, 2000, HUM REPROD, V15, P1278, DOI 10.1093/humrep/15.6.1278; Foong SC, 2006, J ASSIST REPROD GEN, V23, P137, DOI 10.1007/s10815-005-9008-y; Hamberger L, 1998, HUM REPROD, V13, P128, DOI 10.1093/humrep/13.suppl_1.128; Hansen M, 2002, NEW ENGL J MED, V346, P725, DOI 10.1056/NEJMoa010035; Jain T, 2004, NEW ENGL J MED, V350, P1639, DOI 10.1056/NEJMsa032073; Jain T, 2002, NEW ENGL J MED, V347, P661, DOI 10.1056/NEJMsa013491; Karpman E, 2005, THESCIENTIFICWORLDJO, V5, P922, DOI 10.1100/tsw.2005.117; Kassirer JP, 1998, NEW ENGL J MED, V339, P397, DOI 10.1056/NEJM199808063390608; Kastrop PMM, 1999, HUM REPROD, V14, P65, DOI 10.1093/humrep/14.1.65; MOLLOY D, 1991, FERTIL STERIL, V56, P285; Moreno C, 1998, HUM REPROD, V13, P2126, DOI 10.1093/humrep/13.8.2126; Nikolettos N, 2006, J SOC GYNECOL INVEST, V13, P317, DOI 10.1016/j.jsgi.2006.04.002; Oehninger S, 2002, HUM REPROD, V17, P2237, DOI 10.1093/humrep/17.9.2237; Ola B, 2001, HUM REPROD, V16, P2485, DOI 10.1093/humrep/16.12.2485; Orief Y, 2004, REPROD BIOMED ONLINE, V9, P348, DOI 10.1016/S1472-6483(10)62152-9; PALERMO G, 1992, LANCET, V340, P17, DOI 10.1016/0140-6736(92)92425-F; Reschovsky JD, 2006, HEALTH SERV RES, V41, P1200, DOI 10.1111/j.1475-6773.2006.00531.x; Roest J, 1998, J ASSIST REPROD GEN, V15, P18, DOI 10.1023/A:1022570120207; Ruiz A, 1997, FERTIL STERIL, V68, P171, DOI 10.1016/S0015-0282(97)81497-5; Saito H, 2000, FERTIL STERIL, V73, P465, DOI 10.1016/S0015-0282(99)00547-6; Shen J, 2004, MED CARE, V42, P297, DOI 10.1097/01.mlr.0000114918.50088.1c; STEPTOE PC, 1978, LANCET, V2, P366; Tucker M, 2001, LANCET, V358, P1645, DOI 10.1016/S0140-6736(01)06679-X; van der Westerlaken L, 2005, FERTIL STERIL, V83, P612, DOI 10.1016/j.fertnstert.2004.08.029; van Rumste MM, 2003, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD001301; Withers R, 2000, ARTFORUM, V38, P42	38	94	96	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 19	2007	357	3					251	257		10.1056/NEJMsa070707	http://dx.doi.org/10.1056/NEJMsa070707			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191FH	17634460				2022-12-28	WOS:000248115100006
J	Bots, ML; Visseren, FL; Evans, GW; Riley, WA; Revkin, JH; Tegeler, CH; Shear, CL; Duggan, WT; Vicari, RM; Grobbee, DE; Kastelein, JJ				Bots, Michiel L.; Visseren, Frank L.; Evans, Gregory W.; Riley, Ward A.; Revkin, James H.; Tegeler, Charles H.; Shear, Charles L.; Duggan, William T.; Vicari, Ralph M.; Grobbee, Diederick E.; Kastelein, John J.		RADIANCE 2 Investigators	Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial	LANCET			English	Article							HIGH-DENSITY-LIPOPROTEIN; ESTER TRANSFER PROTEIN; CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASE; SECONDARY PREVENTION; CHOLESTEROL LEVELS; ATHEROSCLEROSIS; PROGRESSION; HDL; GEMFIBROZIL	Background Patients with mixed dyslipidaemia have raised triglycerides, low high-density lipoprotein (HDL) cholesterol, and high low-density lipoprotein (LDL) cholesterol. Augmentation of HDL cholesterol by inhibition of the cholesteryl ester transfer protein (CETP) could benefit these patients. We aimed to investigate the effect of the CETP inhibitor, torcetrapil), on carotid atherosclerosis progression in patients with mixed dyslipidaemia. Methods We did a randomised double-blind trial at 64 centres in North America and Europe. 752 eligible participants completed an atorvastatin-only run-in period for dose titration, after which they all continued to receive atorvastatin at the titrated dose. 377 of these patients were randomly assigned to receive 60 mg of torcetrapib per day and 375 to placebo. We made carotid ultrasound images at baseline and at 6-month intervals for 24 months. The primary endpoint was the yearly rate of change in the maximum intima-media. thickness of 12 carotid segments. Analysis was restricted to 683 patients who had at least one dose of treatment and had at least one follow-up carotid intima-media measurement; they were analysed as randomised. Mean follow-up for these patients was 22 (SD 4.8) months. This trial is registered with ClinicalTrials.gov, number NCT00134238. Findings The change in maximum carotid intima-media thickness was 0.025 (SD 0.005) mm per year in patients given torcetrapib with atorvastatin and 0.030 (0.005) mm per year in those given atorvastatin alone (difference -0.005 mm per year, 95% CI -0.018 to 0.008, p = 0.46). Patients in the combined-treatment group had a 63.4% relative increase in H-DL cholesterol (p < 0.0001) and an 17.7% relative decrease in LDL cholesterol (p < 0.0001), compared with controls. Systolic blood pressure increased by 6.6 mm Hg in the combined-treatment group and 1.5 mm Hg in the atorvastatin-only group (difference 5.4 mm Hg, 95% CI 4.3-6.4, p < 0.0001). Interpretation Although torcetrapib substantially raised HDL cholesterol and lowered LDL cholesterol, it also increased systolic blood pressure, and did not affect the yearly rate of change in the maximum intima-media thickness of 12 carotid segments. Torcetrapib showed no clinical benefit in this or other studies, and will not be developed further.	Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3584 CX Utrecht, Netherlands; Univ Med Ctr Utrecht, Dept Vasc Med, NL-3584 CX Utrecht, Netherlands; Acad Med Ctr, Amsterdam, Netherlands; Wake Forest Univ, Winston Salem, NC 27109 USA; MIMA Century Res Associates, Melbourne, FL USA; Pfizer Inc, New London, CT USA	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Amsterdam; Academic Medical Center Amsterdam; Wake Forest University; Pfizer	Bots, ML (corresponding author), Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Str 6-131,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	M.L.Bots@umcutrecht.nl	Tegeler, Charles/R-3623-2019; Kastelein, John/AAF-7950-2020; Grobbee, Diederick/C-7651-2014; Visseren, Frank LJ/I-4855-2013	Grobbee, Diederick/0000-0003-4472-4468; Visseren, Frank/0000-0003-3951-5223				Anderssen SA, 2005, ATHEROSCLEROSIS, V178, P387, DOI 10.1016/j.atherosclerosis.2004.08.033; Ashen MD, 2005, NEW ENGL J MED, V353, P1252, DOI 10.1056/NEJMcp044370; ASSMANN G, 1992, AM J CARDIOL, V70, P733, DOI 10.1016/0002-9149(92)90550-I; Bonow RO, 2002, CIRCULATION, V106, P1602, DOI 10.1161/01.CIR.0000035036.22612.2B; Bots ML, 2003, STROKE, V34, P2985, DOI 10.1161/01.STR.0000102044.27905.B5; BROWN ML, 1989, NATURE, V342, P448, DOI 10.1038/342448a0; Costa J, 2006, BMJ-BRIT MED J, V332, P1115, DOI 10.1136/bmj.38793.468449.AE; Crouse JR, 2007, JAMA-J AM MED ASSOC, V297, P1344, DOI 10.1001/jama.297.12.1344; CROUSE JR, 1995, AM J CARDIOL, V75, P455, DOI 10.1016/S0002-9149(99)80580-3; de Grooth GJ, 2002, CIRCULATION, V105, P2159, DOI 10.1161/01.CIR.0000015857.31889.7B; Dullaart RPF, 2007, EUR J CLIN INVEST, V37, P90, DOI 10.1111/j.1365-2362.2007.01756.x; Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7; Espeland MA, 2005, CURR CONTR TRIALS C, V6, DOI 10.1186/1468-6708-6-3; Espeland MA, 1999, ANN EPIDEMIOL, V9, P196, DOI 10.1016/S1047-2797(98)00069-6; ESPELAND MA, 1992, STAT MED, V11, P1041, DOI 10.1002/sim.4780110806; Frick MH, 1997, CIRCULATION, V96, P2137; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Grundy SM, 2005, CIRCULATION, V112, P2735, DOI 10.1161/CIRCULATIONAHA.105.169404; Guerin M, 1996, EUR J CLIN INVEST, V26, P485, DOI 10.1046/j.1365-2362.1996.168318.x; Hedblad B, 2001, CIRCULATION, V103, P1721, DOI 10.1161/01.CIR.103.13.1721; INAZU A, 1990, NEW ENGL J MED, V323, P1234, DOI 10.1056/NEJM199011013231803; Kastelein JJP, 2007, CURR MED RES OPIN, V23, P885, DOI 10.1185/030079907X182121; Kastelein JJP, 2007, NEW ENGL J MED, V356, P1620, DOI 10.1056/NEJMoa071359; Lewis GF, 2005, CIRC RES, V96, P1221, DOI 10.1161/01.RES.0000170946.56981.5c; Liang Q, 2000, IEEE T MED IMAGING, V19, P127, DOI 10.1109/42.836372; Linsel-Nitschke P, 2005, NAT REV DRUG DISCOV, V4, P193, DOI 10.1038/nrd1658; McKenney JM, 2006, J AM COLL CARDIOL, V48, P1782, DOI 10.1016/j.jacc.2006.06.066; MCPHERSON R, 1991, ARTERIOSCLER THROMB, V11, P797, DOI 10.1161/01.ATV.11.4.797; MEINDERS AE, 2004, DIABETES CARE, V27, P2887; Mercuri M, 1996, AM J MED, V101, P627, DOI 10.1016/S0002-9343(96)00333-6; Morehouse LA, 2007, J LIPID RES, V48, P1263, DOI 10.1194/jlr.M600332-JLR200; Nagano Makoto, 2004, J Atheroscler Thromb, V11, P110; Nissen SE, 2007, NEW ENGL J MED, V356, P1304, DOI 10.1056/NEJMoa070635; *PFIZ, PHAS 3 MULT CTR DOUB; Robins SJ, 2001, JAMA-J AM MED ASSOC, V285, P1585, DOI 10.1001/jama.285.12.1585; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; SALONEN R, 1995, CIRCULATION, V92, P1758, DOI 10.1161/01.CIR.92.7.1758; Tall AR, 2007, ARTERIOSCL THROM VAS, V27, P257, DOI 10.1161/01.ATV.0000256728.60226.77; TATO F, 1995, ARTERIOSCL THROM VAS, V15, P112, DOI 10.1161/01.ATV.15.1.112; Taylor AJ, 2004, CIRCULATION, V110, P3512, DOI 10.1161/01.CIR.0000148955.19792.8D; Wang JG, 2006, STROKE, V37, P1933, DOI 10.1161/01.STR.0000227223.90239.13; Whitney EJ, 2005, ANN INTERN MED, V142, P95, DOI 10.7326/0003-4819-142-2-200501180-00008; Williams CL, 2002, CIRCULATION, V106, P143, DOI 10.1161/01.CIR.0000019555.61092.9E; Zanchetti A, 2004, STROKE, V35, P2807, DOI 10.1161/01.STR.0000147041.00840.59	46	381	388	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 14	2007	370	9582					153	160		10.1016/S0140-6736(07)61088-5	http://dx.doi.org/10.1016/S0140-6736(07)61088-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	190WP	17630038				2022-12-28	WOS:000248091600029
J	Christensen, H				Christensen, Helen			Computerised therapy for psychiatric disorders	LANCET			English	Editorial Material							HEALTH; BURDEN		Australian Natl Univ, Mental Hlth Res Ctr, Canberra, ACT, Australia	Australian National University	Christensen, H (corresponding author), Australian Natl Univ, Mental Hlth Res Ctr, Canberra, ACT, Australia.	Helen.Christensen@anu.edu.au	Christensen, Helen/F-5053-2012	Christensen, Helen/0000-0003-0435-2065				Adler KG, 2006, J MED INTERNET RES, V8, DOI 10.2196/jmir.8.4.e26; Coiera E, 2004, BRIT MED J, V328, P1197, DOI 10.1136/bmj.328.7449.1197; Department of Health, 2007, IMPR ACC PSYCH THER; EYSENBACH G, 2005, J MED INTERNET  0331, DOI DOI 10.2196/JMIR.7.1.E117:E11; Griffiths K, 2007, AUSTRALAS PSYCHIATRY, V15, P100, DOI 10.1080/10398560601123716; Jorm AF, 2003, PSYCHOL MED, V33, P1071, DOI 10.1017/S0033291703008079; Kaltenthaler E, 2006, HEALTH TECHNOL ASSES, V10, P1, DOI 10.3310/hta10330; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; National Institute for Clinical Excellence, 2004, DEPR MAN DEPR PRIM S; Wittchen HU, 2005, EUR NEUROPSYCHOPHARM, V15, P357, DOI 10.1016/j.euroneuro.2005.04.012	10	11	15	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 14	2007	370	9582					112	113		10.1016/S0140-6736(07)61065-4	http://dx.doi.org/10.1016/S0140-6736(07)61065-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	190WP	17630022	Green Submitted			2022-12-28	WOS:000248091600008
J	Unal, E; Heidinger-Pauli, JM; Koshland, D				Uenal, Elcin; Heidinger-Pauli, Jill M.; Koshland, Douglas			DNA double-strand breaks trigger genome-wide sister-chromatid cohesion through Eco1 (Ctf7)	SCIENCE			English	Article							ESTABLISHMENT; REPLICATION; PROTEINS; DAMAGE; RECRUITMENT; PATHWAY; COMPLEX; REPAIR	Faithful chromosome segregation and repair of DNA double-strand breaks (DSBs) require cohesin, the protein complex that mediates sister-chromatid cohesion. Cohesion between sister chromatids is thought to be generated only during ongoing DNA replication by an obligate coupling between cohesion establishment factors such as Eco1 (Ctf7) and the replisome. Using budding yeast, we challenge this model by showing that cohesion is generated by an Eco1-dependent but replication-independent mechanism in response to DSBs in G(2)/M. Furthermore, our studies reveal that Eco1 has two functions: a cohesive activity and a conserved acetyltransferase activity, which triggers the generation of cohesion in response to the DSB and the DNA damage checkpoint. Finally, the DSB-induced cohesion is not limited to broken chromosomes but occurs also on unbroken chromosomes, suggesting that the DNA damage checkpoint through Eco1 provides genome-wide protection of chromosome integrity.	Howard Hughes Med Inst, Carnegie Inst, Dept Embryol, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Carnegie Institution for Science; Howard Hughes Medical Institute; Johns Hopkins University	Koshland, D (corresponding author), Howard Hughes Med Inst, Carnegie Inst, Dept Embryol, 3520 San Martin Dr, Baltimore, MD 21218 USA.	koshland@ciwemb.edu		Unal, Elcin/0000-0002-6768-609X				Brands A, 2005, CURR BIOL, V15, pR50, DOI 10.1016/j.cub.2004.12.052; Ciosk R, 2000, MOL CELL, V5, P243, DOI 10.1016/S1097-2765(00)80420-7; Haering CH, 2004, MOL CELL, V15, P951, DOI 10.1016/j.molcel.2004.08.030; Huang CE, 2005, PHILOS T ROY SOC B, V360, P537, DOI 10.1098/rstb.2004.1609; Ivanov D, 2002, CURR BIOL, V12, P323, DOI 10.1016/S0960-9822(02)00681-4; Kim JS, 2002, J BIOL CHEM, V277, P45149, DOI 10.1074/jbc.M209123200; Koshland DE, 2000, CURR OPIN CELL BIOL, V12, P297, DOI 10.1016/S0955-0674(00)00092-2; Lengronne A, 2006, MOL CELL, V23, P787, DOI 10.1016/j.molcel.2006.08.018; Meluh PB, 2002, EUR J BIOCHEM, V269, P2300, DOI 10.1046/j.1432-1033.2002.02886.x; Milutinovich M, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030012; Moldovan GL, 2006, MOL CELL, V23, P723, DOI 10.1016/j.molcel.2006.07.007; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; Strom L, 2007, SCIENCE, V317, P242, DOI 10.1126/science.1140649; Strom L, 2004, MOL CELL, V16, P1003, DOI 10.1016/j.molcel.2004.11.026; STROM L, 2007, CURR OPIN CELL BIOL; Sugawara N, 2003, MOL CELL, V12, P209, DOI 10.1016/S1097-2765(03)00269-7; Unal E, 2004, MOL CELL, V16, P991, DOI 10.1016/j.molcel.2004.11.027; Watrin E, 2006, EXP CELL RES, V312, P2687, DOI 10.1016/j.yexcr.2006.06.024	19	244	247	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 13	2007	317	5835					245	248		10.1126/science.1140637	http://dx.doi.org/10.1126/science.1140637			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189DC	17626885				2022-12-28	WOS:000247968600043
J	Brons, IGM; Smithers, LE; Trotter, MWB; Rugg-Gunn, P; Sun, BW; Lopes, SMCD; Howlett, SK; Clarkson, A; Ahrlund-Richter, L; Pedersen, RA; Vallier, L				Brons, I. Gabrielle M.; Smithers, Lucy E.; Trotter, Matthew W. B.; Rugg-Gunn, Peter; Sun, Bowen; de Sousa Lopes, Susana M. Chuva; Howlett, Sarah K.; Clarkson, Amanda; Ahrlund-Richter, Lars; Pedersen, Roger A.; Vallier, Ludovic			Derivation of pluripotent epiblast stem cells from mammalian embryos	NATURE			English	Article							PRIMORDIAL GERM-CELLS; MOUSE EMBRYO; ES CELLS; DIFFERENTIATION; CULTURE; LINE; GASTRULATION; BLASTOCYSTS; EXPRESSION	Although the first mouse embryonic stem (ES) cell lines were derived 25 years ago(1,2) using feeder-layer-based blastocyst cultures, subsequent efforts to extend the approach to other mammals, including both laboratory and domestic species, have been relatively unsuccessful. The most notable exceptions were the derivation of non-human primate ES cell lines(3) followed shortly thereafter by their derivation of human ES cells(4). Despite the apparent common origin and the similar pluripotency of mouse and human embryonic stem cells, recent studies have revealed that they use different signalling pathways to maintain their pluripotent status. Mouse ES cells depend on leukaemia inhibitory factor and bone morphogenetic protein, whereas their human counterparts rely on activin (INHBA)/nodal (NODAL) and fibroblast growth factor (FGF). Here we show that pluripotent stem cells can be derived from the late epiblast layer of post-implantation mouse and rat embryos using chemically defined, activin-containing culture medium that is sufficient for long-term maintenance of human embryonic stem cells. Our results demonstrate that activin/Nodal signalling has an evolutionarily conserved role in the derivation and the maintenance of pluripotency in these novel stem cells. Epiblast stem cells provide a valuable experimental system for determining whether distinctions between mouse and human embryonic stem cells reflect species differences or diverse temporal origins.	Univ Cambridge, Addenbrookes Hosp, Dept Surg, Cambridge CB2 0XY, England; Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Med Res, Cambridge CB2 0XY, England; UCL, Wolfson Inst Biomed Res, CR UK Viral Oncol Grp, London WC1E 6BT, England; Univ Cambridge, Wellcome Trust Canc Res UK, Gurdon Inst Canc & Dev Biol, Cambridge CB2 1QR, England; Univ Cambridge, Dept Physiol, Cambridge CB2 1QR, England; Univ Cambridge, Juvenile Diabet Res Fdn, Wellcome Trust Diabet & Inflammat Lab, Cambridge CB2 0XY, England; Univ Cambridge, Hosp NHS Fdn Trust, Dept Med Genet, Cambridge CB2 2FF, England; Karolinska Inst, Karolinska Univ Hosp, Clin Res Ctr, Dept Lab Med, S-14157 Stockholm, Sweden	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of London; University College London; Cancer Research UK; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Karolinska Institutet; Karolinska University Hospital	Vallier, L (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Surg, Cambridge CB2 0XY, England.	lv225@cam.ac.uk	Ahrlund-Richter, Lars/C-6226-2012; vallier, ludovic/C-6368-2011	Vallier, Ludovic/0000-0002-3848-2602; Trotter, Matthew/0000-0003-3702-915X; Rugg-Gunn, Peter/0000-0002-9601-5949	MRC [G0600275, G0300723] Funding Source: UKRI; Medical Research Council [G0300723B] Funding Source: researchfish; Medical Research Council [G0300723, G0600275] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Brook FA, 2003, DIABETES, V52, P205, DOI 10.2337/diabetes.52.1.205; Camus A, 2006, DEV BIOL, V295, P743, DOI 10.1016/j.ydbio.2006.03.047; CONLON FL, 1994, DEVELOPMENT, V120, P1919; DEFELICI M, 1982, EXP CELL RES, V142, P476, DOI 10.1016/0014-4827(82)90393-7; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Gu ZY, 1999, DEVELOPMENT, V126, P2551; James D, 2006, DEV BIOL, V295, P90, DOI 10.1016/j.ydbio.2006.03.026; JOHANSSON MW, 1995, TECHNIQUES FISH IMMU, V4, P141; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MATSUI Y, 1992, CELL, V70, P841, DOI 10.1016/0092-8674(92)90317-6; Mesnard D, 2006, DEVELOPMENT, V133, P2497, DOI 10.1242/dev.02413; Nichols J, 2001, DEVELOPMENT, V128, P2333; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Pelton TA, 2002, J CELL SCI, V115, P329; Rathjen J, 1999, J CELL SCI, V112, P601; RESNICK JL, 1992, NATURE, V359, P550, DOI 10.1038/359550a0; Rugg-Gunn PJ, 2005, NAT GENET, V37, P585, DOI 10.1038/ng1556; Song JW, 1999, DEV BIOL, V213, P157, DOI 10.1006/dbio.1999.9370; Sun BW, 2006, HUM MOL GENET, V15, P65, DOI 10.1093/hmg/ddi427; THOMSON JA, 1995, P NATL ACAD SCI USA, V92, P7844, DOI 10.1073/pnas.92.17.7844; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Vallier L, 2005, J CELL SCI, V118, P4495, DOI 10.1242/jcs.02553; Xu RH, 2002, NAT BIOTECHNOL, V20, P1261, DOI 10.1038/nbt761	26	1429	1499	4	158	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 12	2007	448	7150					191	U7		10.1038/nature05950	http://dx.doi.org/10.1038/nature05950			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	188QN	17597762				2022-12-28	WOS:000247934500042
J	Fredenburgh, LE; Campion, EW; Drazen, JM				Fredenburgh, Laura E.; Campion, Edward W.; Drazen, Jeffrey M.			Mild persistent asthma - Polling results	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Brigham & Womens Hosp, Div Pulm, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Fredenburgh, LE (corresponding author), Brigham & Womens Hosp, Div Pulm, 75 Francis St, Boston, MA 02115 USA.		Drazen, Jeffrey M/E-5841-2012					Kraft M, 2007, NEW ENGL J MED, V356, P2096; Papi A, 2007, NEW ENGL J MED, V356, P2040, DOI 10.1056/NEJMoa063861; Peters SP, 2007, NEW ENGL J MED, V356, P2027	3	4	5	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 12	2007	357	2					179	180		10.1056/NEJMclde078123	http://dx.doi.org/10.1056/NEJMclde078123			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188NX	17582063				2022-12-28	WOS:000247927700015
J	Garovic, VD; Helgen, KE				Garovic, Vesna D.; Helgen, Katherine E.			Nephrogenic fibrosing dermopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Mayo Clin, Rochester, MN 55905 USA	Mayo Clinic	Garovic, VD (corresponding author), Mayo Clin, Rochester, MN 55905 USA.	garovic.vesna@mayo.edu		Garovic, Vesna/0000-0001-6891-0578					0	4	4	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 12	2007	357	2					E2	E2		10.1056/NEJMicm066185	http://dx.doi.org/10.1056/NEJMicm066185			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188NX	17625120				2022-12-28	WOS:000247927700011
J	Payne, JH				Payne, John H.			A patient's journey - Tethered spinal cord syndrome	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												jhpayne777@pop3.poptel.org.uk							0	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 7	2007	335	7609					42	43		10.1136/bmj.39216.436713.BE	http://dx.doi.org/10.1136/bmj.39216.436713.BE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191LY	17615225	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000248133900035
J	Jaramillo, TF; Jorgensen, KP; Bonde, J; Nielsen, JH; Horch, S; Chorkendorff, I				Jaramillo, Thomas F.; Jorgensen, Kristina P.; Bonde, Jacob; Nielsen, Jane H.; Horch, Sebastian; Chorkendorff, Ib			Identification of active edge sites for electrochemical H-2 evolution from MoS2 nanocatalysts	SCIENCE			English	Article							HYDROGEN EVOLUTION; ACID-SOLUTIONS; SURFACE SCIENCE; NANOCLUSTERS; CATALYST; LAYER	The identification of the active sites in heterogeneous catalysis requires a combination of surface sensitive methods and reactivity studies. We determined the active site for hydrogen evolution, a reaction catalyzed by precious metals, on nanoparticulate molybdenum disulfide (MoS2) by atomically resolving the surface of this catalyst before measuring electrochemical activity in solution. By preparing MoS2 nanoparticles of different sizes, we systematically varied the distribution of surface sites on MoS2 nanoparticles on Au(111), which we quantified with scanning tunneling microscopy. Electrocatalytic activity measurements for hydrogen evolution correlate linearly with the number of edge sites on the MoS2 catalyst.	Tech Univ Denmark, Ctr Individual Nanoparticle Funct, Dept Phys, Nano DTU, DK-2800 Lyngby, Denmark; Tech Univ Denmark, Ctr Atom Scale Mat Design, Dept Phys, Nano DTU, DK-2800 Lyngby, Denmark	Technical University of Denmark; Technical University of Denmark	Chorkendorff, I (corresponding author), Tech Univ Denmark, Ctr Individual Nanoparticle Funct, Dept Phys, Nano DTU, DK-2800 Lyngby, Denmark.	ibchork@fysik.dtu.dk	Chorkendorff, Ib/C-7282-2008; Horch, Sebastian/A-7748-2011; Jaramillo, Thomas F/C-4174-2014; Nielsen, Jane Hvolbaek/A-9089-2011	Chorkendorff, Ib/0000-0003-2738-0325; Horch, Sebastian/0000-0001-7601-9224; Jaramillo, Thomas F/0000-0001-9900-0622; Bonde, Jacob Lindner/0000-0002-8432-6555; Nielsen, Jane Hvolbaek/0000-0002-5211-948X				Bockris J.O., 1993, SURFACE ELECTROCHEMI, DOI [10.1007/978-1-4615-3040-4, DOI 10.1007/978-1-4615-3040-4]; Bollinger MV, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.085410; BOLLINGER MV, 2001, PHYS REV LETT, V87, P19; Campbell CT, 2001, SCIENCE, V294, P1471, DOI 10.1126/science.1066253; Chianelli RR, 2006, CATAL REV, V48, P1, DOI 10.1080/01614940500439776; Clausen B.S., 1996, CATAL SCI TECHNOL, V11; Conway BE, 2002, ELECTROCHIM ACTA, V47, P3571, DOI 10.1016/S0013-4686(02)00329-8; Dahl S, 1999, PHYS REV LETT, V83, P1814, DOI 10.1103/PhysRevLett.83.1814; Helveg S, 2000, PHYS REV LETT, V84, P951, DOI 10.1103/PhysRevLett.84.951; Hinnemann B, 2005, J AM CHEM SOC, V127, P5308, DOI 10.1021/ja0504690; Jaeger NI, 2001, SCIENCE, V293, P1601, DOI 10.1126/science.1064595; JAEGERMANN W, 1988, PROG SURF SCI, V29, P1, DOI 10.1016/0079-6816(88)90015-9; Kibsgaard J, 2006, J AM CHEM SOC, V128, P13950, DOI 10.1021/ja0651106; Lauritsen JV, 2007, NAT NANOTECHNOL, V2, P53, DOI 10.1038/nnano.2006.171; Lauritsen JV, 2004, J CATAL, V224, P94, DOI 10.1016/j.jcat.2004.02.009; Markovic NM, 1997, J PHYS CHEM B, V101, P5405, DOI 10.1021/jp970930d; Norskov JK, 2005, J ELECTROCHEM SOC, V152, pJ23, DOI 10.1149/1.1856988; Perez J, 1998, J PHYS CHEM B, V102, P10931, DOI 10.1021/jp9831987; PRINS R, 1989, CATAL REV, V31, P1, DOI 10.1080/01614948909351347; Skulason E, 2007, PHYS CHEM CHEM PHYS, V9, P3241, DOI 10.1039/b700099e; Somorjai G.A., 2010, INTRO SURFACE CHEM C; TRASATTI S, 1972, J ELECTROANAL CHEM, V39, P163, DOI 10.1016/0368-1874(72)85118-9; Zambelli T, 1996, SCIENCE, V273, P1688, DOI 10.1126/science.273.5282.1688	23	4424	4494	131	3178	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 6	2007	317	5834					100	102		10.1126/science.1141483	http://dx.doi.org/10.1126/science.1141483			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186KD	17615351				2022-12-28	WOS:000247776700058
J	Bradshaw, W; Holzapfel, C				Bradshaw, William; Holzapfel, Christina			Evolution - Tantalizing timeless	SCIENCE			English	Editorial Material							DROSOPHILA CIRCADIAN CLOCK; ENTRAINMENT; EXPRESSION; MECHANISM; PERIOD; GENE		Univ Oregon, Ctr Ecol & Evolut Biol, Eugene, OR 97403 USA	University of Oregon	Bradshaw, W (corresponding author), Univ Oregon, Ctr Ecol & Evolut Biol, Eugene, OR 97403 USA.	mosquito@uoregon.edu						Bradshaw WE, 2006, SCIENCE, V312, P1477, DOI 10.1126/science.1127000; Bunning E., 1936, BER DEUT BOT GES, V54, P590, DOI DOI 10.1038/424033A; Danilevskii A.S., 1965, PHOTOPERIODISM SEASO; Dunlap J.C., 2004, CHRONOBIOLOGY BIOL T; Goto SG, 2002, J INSECT PHYSIOL, V48, P803, DOI 10.1016/S0022-1910(02)00108-7; Mathias D, 2005, J INSECT PHYSIOL, V51, P661, DOI 10.1016/j.jinsphys.2005.03.011; Mathias D, 2007, GENETICS, V176, P391, DOI 10.1534/genetics.106.068726; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; Pavelka J, 2003, EUR J ENTOMOL, V100, P255, DOI 10.14411/eje.2003.041; PRICE JL, 2004, MOL BIOL CIRCADIAN R, pCH3; Sandrelli F, 2007, SCIENCE, V316, P1898, DOI 10.1126/science.1138426; SAUNDERS DS, 1990, J BIOL RHYTHM, V5, P315, DOI 10.1177/074873049000500404; Tauber E, 2007, SCIENCE, V316, P1895, DOI 10.1126/science.1138412; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0	14	27	27	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 29	2007	316	5833					1851	1852		10.1126/science.1145053	http://dx.doi.org/10.1126/science.1145053			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183WI	17600202				2022-12-28	WOS:000247602700022
J	Fath, S; Mancias, JD; Bi, XP; Goldberg, J				Fath, Stephan; Mancias, Joseph D.; Bi, Xiping; Goldberg, Jonathan			Structure and organization of coat proteins in the COPII cage	CELL			English	Article							MEMBRANE DEFORMATION; VESICLE FORMATION; CLATHRIN COAT; HYDROLYSIS; TRANSPORT; SOFTWARE; BINDING	COPII-coated vesicles export newly synthesized proteins from the endoplasmic reticulum. The COPII coat consists of the Sec23/24-Sar1 complex that selects cargo and the Sec13/31 assembly unit that can polymerize into an octahedral cage and deform the membrane into a bud. Crystallographic analysis of the assembly unit reveals a 28 nm long rod comprising a central alpha-solenoid dimer capped by two beta-propeller domains at each end. We construct a molecular model of the COPII cage by fitting Sec13/31 crystal structures into a recently determined electron microscopy density map. The vertex geometry involves four copies of the Sec31 beta-propeller that converge through their axial ends; there is no interdigitation of assembly units of the kind seen in clathrin cages. We also propose that the assembly unit has a central hinge-an arrangement of interlocked alpha-solenoids-about which it can bend to adapt to cages of variable curvature.	Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Struct Biol Program, New York, NY 10021 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Goldberg, J (corresponding author), Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, 1275 York Ave, New York, NY 10021 USA.	jonathan@ximpact4.ski.mskcc.org						Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; Antonny B, 2006, CURR OPIN CELL BIOL, V18, P386, DOI 10.1016/j.ceb.2006.06.003; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bi XP, 2002, NATURE, V419, P271, DOI 10.1038/nature01040; Bielli A, 2005, J CELL BIOL, V171, P919, DOI 10.1083/jcb.200509095; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cheng YF, 2007, J MOL BIOL, V365, P892, DOI 10.1016/j.jmb.2006.10.036; CROWTHER RA, 1976, J MOL BIOL, V103, P785, DOI 10.1016/0022-2836(76)90209-6; Devos D, 2004, PLOS BIOL, V2, P2085, DOI 10.1371/journal.pbio.0020380; Dokudovskaya S, 2006, STRUCTURE, V14, P653, DOI 10.1016/j.str.2006.02.006; Ehrlich M, 2004, CELL, V118, P591, DOI 10.1016/j.cell.2004.08.017; Fotin A, 2004, NATURE, V432, P649, DOI 10.1038/nature03078; Fotin A, 2004, NATURE, V432, P573, DOI 10.1038/nature03079; Fromme JC, 2005, CURR OPIN CELL BIOL, V17, P345, DOI 10.1016/j.ceb.2005.06.004; HEUSER J, 1980, J CELL BIOL, V84, P560, DOI 10.1083/jcb.84.3.560; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kajava AV, 2002, J BIOL CHEM, V277, P49791, DOI 10.1074/jbc.M204982200; Kirchhausen T, 2000, NAT REV MOL CELL BIO, V1, P187, DOI 10.1038/35043117; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P941, DOI 10.1107/S0907444999001031; Lederkremer GZ, 2001, P NATL ACAD SCI USA, V98, P10704, DOI 10.1073/pnas.191359398; Lee MCS, 2005, CELL, V122, P605, DOI 10.1016/j.cell.2005.07.025; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Matsuoka K, 2001, P NATL ACAD SCI USA, V98, P13705, DOI 10.1073/pnas.241522198; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Miller EA, 2003, CELL, V114, P497, DOI 10.1016/S0092-8674(03)00609-3; Mossessova E, 2003, CELL, V114, P483, DOI 10.1016/S0092-8674(03)00608-1; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pearse BMF, 2000, CURR OPIN STRUC BIOL, V10, P220, DOI 10.1016/S0959-440X(00)00071-3; Shaywitz DA, 1997, J BIOL CHEM, V272, P25413, DOI 10.1074/jbc.272.41.25413; Shugrue CA, 1999, J CELL SCI, V112, P4547; Stagg SM, 2006, NATURE, V439, P234, DOI 10.1038/nature04339; Takamori S, 2006, CELL, V127, P831, DOI 10.1016/j.cell.2006.10.030; ter Haar E, 1998, CELL, V95, P563, DOI 10.1016/S0092-8674(00)81623-2; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Ybe JA, 1999, NATURE, V399, P371, DOI 10.1038/20708	39	210	219	1	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 29	2007	129	7					1325	1336		10.1016/j.cell.2007.05.036	http://dx.doi.org/10.1016/j.cell.2007.05.036			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188HQ	17604721	Bronze			2022-12-28	WOS:000247911400018
J	Rinn, JL; Kertesz, M; Wang, JK; Squazzo, SL; Xu, X; Brugmann, SA; Goodnough, LH; Helms, JA; Farnham, PJ; Segal, E; Chang, HY				Rinn, John L.; Kertesz, Michael; Wang, Jordon K.; Squazzo, Sharon L.; Xu, Xiao; Brugmann, Samantha A.; Goodnough, L. Henry; Helms, Jill A.; Farnham, Peggy J.; Segal, Eran; Chang, Howard Y.			Functional demarcation of active and silent chromatin domains in human HOX loci by Noncoding RNAs	CELL			English	Article							DEVELOPMENTAL REGULATORS; RESPONSE ELEMENTS; GENE-EXPRESSION; HISTONE H3; CELL FATE; POLYCOMB; TRANSCRIPTION; GENOME; ROLES; EVOLUTION	Noncoding RNAs (ncRNA) participate in epigenetic regulation but are poorly understood. Here we characterize the transcriptional landscape of the four human HOX loci at five base pair resolution in 11 anatomic sites and identify 231 HOX ncRNAs that extend known transcribed regions by more than 30 kilobases. HOX ncRNAs are spatially expressed along developmental axes and possess unique sequence motifs, and their expression demarcates broad chromosomal domains of differential histone methylation and RNA polymerase accessibility. We identified a 2.2 kilobase ncRNA residing in the HOXC locus, termed HOTAIR, which represses transcription in trans across 40 kilobases of the HOXD locus. HOTAIR interacts with Polycomb Repressive Complex 2 (PRC2) and is required for PRC2 occupancy and histone H3 lysine-27 trimethylation of HOXD locus. Thus, transcription of ncRNA may demarcate chromosomal domains of gene silencing at a distance; these results have broad implications for gene regulation in development and disease states.	Weizmann Inst Sci, Dept Comp Sci & Appl Math, IL-76100 Rehovot, Israel; Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Surg, Stanford, CA 94305 USA; Univ Calif Davis, Dept Pharmacol, Genome Ctr, Livermore, CA 95616 USA	Weizmann Institute of Science; Stanford University; Stanford University; University of California System; University of California Davis	Segal, E (corresponding author), Weizmann Inst Sci, Dept Comp Sci & Appl Math, IL-76100 Rehovot, Israel.	eran.segal@weizmann.ac.il; howchang@stanford.edu	Segal, Eran/AAF-4855-2019	Rinn, John/0000-0002-7231-7539; Segal, Eran/0000-0002-6859-1164; Helms, Jill/0000-0002-0463-396X; Wang, Jordon/0000-0003-1108-2534; Farnham, Peggy/0000-0003-4469-7914	NATIONAL CANCER INSTITUTE [R01CA119176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR050007] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA119176, R01 CA119176-02] Funding Source: Medline; NIAMS NIH HHS [K08 AR050007-03, K08 AR050007] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Albrecht U, 1997, MOL CELLULAR METHODS, P23; Bae E, 2002, P NATL ACAD SCI USA, V99, P16847, DOI 10.1073/pnas.222671299; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Bernstein E, 2006, MOL CELL BIOL, V26, P2560, DOI 10.1128/MCB.26.7.2560-2569.2006; Bernstein E, 2005, GENE DEV, V19, P1635, DOI 10.1101/gad.1324305; Bertone P, 2004, SCIENCE, V306, P2242, DOI 10.1126/science.1103388; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; CARROLL SB, 1995, NATURE, V376, P479, DOI 10.1038/376479a0; Chang HY, 2002, P NATL ACAD SCI USA, V99, P12877, DOI 10.1073/pnas.162488599; Chuong CM, 2003, J INVEST DERMATOL, V120, P9, DOI 10.1046/j.1523-1747.2003.00002.x; Denisenko O, 1998, MOL CELL BIOL, V18, P5634, DOI 10.1128/MCB.18.10.5634; Drewell RA, 2002, P NATL ACAD SCI USA, V99, P16853, DOI 10.1073/pnas.222671199; GOZANI O, 1994, EMBO J, V13, P3356, DOI 10.1002/j.1460-2075.1994.tb06638.x; Grimaud C, 2006, CELL, V124, P957, DOI 10.1016/j.cell.2006.01.036; Guenther MG, 2005, P NATL ACAD SCI USA, V102, P8603, DOI 10.1073/pnas.0503072102; Hall TMT, 2005, CURR OPIN STRUC BIOL, V15, P367, DOI 10.1016/j.sbi.2005.04.004; Kapranov P, 2005, GENOME RES, V15, P987, DOI 10.1101/gr.3455305; Kim DH, 2006, NAT STRUCT MOL BIOL, V13, P793, DOI 10.1038/nsmb1142; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Kmita M, 2000, NAT GENET, V26, P451, DOI 10.1038/82593; Kmita M, 2003, SCIENCE, V301, P331, DOI 10.1126/science.1085753; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lemons D, 2006, SCIENCE, V313, P1918, DOI 10.1126/science.1132040; Nelson CE, 1996, DEVELOPMENT, V122, P1449; OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076; Papp B, 2006, GENE DEV, V20, P2041, DOI 10.1101/gad.388706; Petruk S, 2006, CELL, V127, P1209, DOI 10.1016/j.cell.2006.10.039; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Ringrose L, 2007, DEVELOPMENT, V134, P223, DOI 10.1242/dev.02723; Rinn JL, 2004, DEV CELL, V6, P791, DOI 10.1016/j.devcel.2004.05.005; Rinn JL, 2003, GENE DEV, V17, P529, DOI 10.1101/gad.1055203; Rinn JL, 2006, PLOS GENET, V2, P1084, DOI 10.1371/journal.pgen.0020119; Sanchez-Elsner T, 2006, SCIENCE, V311, P1118, DOI 10.1126/science.1117705; Schmitt S, 2005, GENE DEV, V19, P697, DOI 10.1101/gad.326205; Segal E, 2003, BIOINFORMATICS, V19, pi273, DOI 10.1093/bioinformatics/btg1038; Sessa L, 2007, RNA, V13, P223, DOI 10.1261/rna.266707; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Squazzo SL, 2006, GENOME RES, V16, P890, DOI 10.1101/gr.5306606; Suemori H, 2000, DEV BIOL, V220, P333, DOI 10.1006/dbio.2000.9651; Sun Yinyan, 2005, RNA Biol, V2, P8, DOI 10.4161/rna.2.1.1465; Zakany J, 1997, P NATL ACAD SCI USA, V94, P13695, DOI 10.1073/pnas.94.25.13695; Zhang H, 2004, MOL CELL, V14, P841, DOI 10.1016/j.molcel.2004.06.001	45	3221	3462	15	325	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 29	2007	129	7					1311	1323		10.1016/j.cell.2007.05.022	http://dx.doi.org/10.1016/j.cell.2007.05.022			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188HQ	17604720	Bronze, Green Accepted			2022-12-28	WOS:000247911400017
J	Kaiser, SM; Malik, HS; Emerman, M				Kaiser, Shari M.; Malik, Harmit S.; Emerman, Michael			Restriction of an extinct retrovirus by the human TRIM5 alpha antiviral protein	SCIENCE			English	Article							OLD-WORLD; PRIMATE TRIM5-ALPHA; ADAPTIVE EVOLUTION; HIV-1 INFECTION; DOMAIN; SELECTION; VARIANTS; VIRUSES; CAPSIDS	Primate genomes contain a large number of endogenous retroviruses and encode evolutionarily dynamic proteins that provide intrinsic immunity to retroviral infections. We report here the resurrection of the core protein of a 4-million-year-old endogenous virus from the chimpanzee genome and show that the human variant of the intrinsic immune protein TRIM5 alpha can actively prevent infection by this virus. However, we suggest that selective changes that have occurred in the human lineage during the acquisition of resistance to this virus, and perhaps similar viruses, may have left our species more susceptible to infection by human immunodeficiency virus type 1 (HIV-1).	Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Emerman, M (corresponding author), Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA.	memerman@fhcrc.org	Malik, Harmit S/E-8519-2012; Liu, FL/D-1795-2009; Malik, Harmit S/I-5591-2019	Malik, Harmit S/0000-0001-6005-0016				Dewannieux M, 2006, GENOME RES, V16, P1548, DOI 10.1101/gr.5565706; Hatziioannou T, 2004, P NATL ACAD SCI USA, V101, P10774, DOI 10.1073/pnas.0402361101; Javanbakht H, 2006, VIROLOGY, V354, P15, DOI 10.1016/j.virol.2006.06.031; Keele BF, 2006, SCIENCE, V313, P523, DOI 10.1126/science.1126531; Lee SK, 2005, J VIROL, V79, P4159, DOI 10.1128/JVI.79.7.4159-4169.2005; Lee YN, 2007, PLOS PATHOG, V3, P119, DOI 10.1371/journal.ppat.0030010; Li Y, 2006, J VIROL, V80, P6738, DOI 10.1128/JVI.00270-06; Liu HF, 2005, GENE, V362, P109, DOI 10.1016/j.gene.2005.06.045; Mische CC, 2005, J VIROL, V79, P14446, DOI 10.1128/JVI.79.22.14446-14450.2005; Newman RM, 2006, P NATL ACAD SCI USA, V103, P19134, DOI 10.1073/pnas.0605838103; Perron MJ, 2004, P NATL ACAD SCI USA, V101, P11827, DOI 10.1073/pnas.0403364101; Sawyer SL, 2006, CURR BIOL, V16, P95, DOI 10.1016/j.cub.2005.11.045; Sawyer SL, 2005, P NATL ACAD SCI USA, V102, P2832, DOI 10.1073/pnas.0409853102; Sawyer SL, 2004, PLOS BIOL, V2, P1278, DOI 10.1371/journal.pbio.0020275; Song B, 2005, J VIROL, V79, P3930, DOI 10.1128/JVI.79.7.3930-3937.2005; Stremlau M, 2006, P NATL ACAD SCI USA, V103, P5514, DOI 10.1073/pnas.0509996103; Stremlau M, 2005, J VIROL, V79, P3139, DOI 10.1128/JVI.79.5.3139-3145.2005; Stremlau M, 2004, NATURE, V427, P848, DOI 10.1038/nature02343; Van Heuverswyn F, 2006, NATURE, V444, P164, DOI 10.1038/444164a; Wu XL, 2006, P NATL ACAD SCI USA, V103, P7465, DOI 10.1073/pnas.0510483103; Yap MW, 2005, CURR BIOL, V15, P73, DOI 10.1016/j.cub.2004.12.042; Yohn CT, 2005, PLOS BIOL, V3, P577, DOI 10.1371/journal.pbio.0030110	22	106	107	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 22	2007	316	5832					1756	1758		10.1126/science.1140579	http://dx.doi.org/10.1126/science.1140579			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180XE	17588933				2022-12-28	WOS:000247400500050
J	Stephens, BB; Gurney, KR; Tans, PP; Sweeney, C; Peters, W; Bruhwiler, L; Ciais, P; Ramonet, M; Bousquet, P; Nakazawa, T; Aoki, S; Machida, T; Inoue, G; Vinnichenko, N; Lloyd, J; Jordan, A; Heimann, M; Shibistova, O; Langenfelds, RL; Steele, LP; Francey, RJ; Denning, AS				Stephens, Britton B.; Gurney, Kevin R.; Tans, Pieter P.; Sweeney, Colm; Peters, Wouter; Bruhwiler, Lori; Ciais, Philippe; Ramonet, Michel; Bousquet, Philippe; Nakazawa, Takakiyo; Aoki, Shuji; Machida, Toshinobu; Inoue, Gen; Vinnichenko, Nikolay; Lloyd, Jon; Jordan, Armin; Heimann, Martin; Shibistova, Olga; Langenfelds, Ray L.; Steele, L. Paul; Francey, Roger J.; Denning, A. Scott			Weak northern and strong tropical land carbon uptake from vertical profiles of atmospheric CO2	SCIENCE			English	Article							LONG-TERM; TERRESTRIAL BIOSPHERE; PLANT-GROWTH; FORESTS; SEQUESTRATION; INVERSIONS; DIOXIDE; CLIMATE; BALANCE; FLUX	Measurements of midday vertical atmospheric CO2 distributions reveal annual-mean vertical CO2 gradients that are inconsistent with atmospheric models that estimate a large transfer of terrestrial carbon from tropical to northern latitudes. The three models that most closely reproduce the observed annual-mean vertical CO2 gradients estimate weaker northern uptake of -1.5 petagrams of carbon per year (Pg C year(-1)) and weaker tropical emission of +0.1 Pg C year(-1) compared with previous consensus estimates of -2.4 and +1.8 Pg C year(-1), respectively. This suggests that northern terrestrial uptake of industrial CO2 emissions plays a smaller role than previously thought and that, after subtracting land-use emissions, tropical ecosystems may currently be strong sinks for CO2.	Natl Ctr Atmospher Res, Boulder, CO 80305 USA; Purdue Univ, Dept Earth & Atmospher Sci, W Lafayette, IN 47907 USA; Natl Ocean & Atmospher Adm, Boulder, CO 80305 USA; Lab Sci Climat & Environm, F-91191 Gif Sur Yvette, France; Tohoku Univ, Ctr Atmospher & Ocean Studies, Sendai, Miyagi 9808578, Japan; Natl Inst Environm Studies, Tsukuba, Ibaraki 3058506, Japan; Nagoya Univ, Nagoya Univ, Grad Sch Environm Studies, Nagoya, Aichi 4648601, Japan; Cent Aerol Observ, Dolgoprudnyi 141700, Russia; Univ Leeds, Sch Geog, Leeds LS2 9JT, W Yorkshire, England; Max Planck Inst Biogeochem, D-07701 Jena, Germany; Sukachev Inst Forest, Krasnoyarsk 660036, Russia; CSIRO Marine & Atmospher Res, Aspendale, Vic 3195, Australia; Colorado State Univ, Dept Atmospher Sci, Ft Collins, CO 80523 USA	National Center Atmospheric Research (NCAR) - USA; Purdue University System; Purdue University; Purdue University West Lafayette Campus; National Oceanic Atmospheric Admin (NOAA) - USA; UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); Tohoku University; National Institute for Environmental Studies - Japan; Nagoya University; University of Leeds; Max Planck Society; Russian Academy of Sciences; Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Sciences; Sukachev Institute of Forest, Siberian Branch, Russian Academy of Sciences; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Colorado State University	Stephens, BB (corresponding author), Natl Ctr Atmospher Res, Boulder, CO 80305 USA.	stephens@ucar.edu	Ciais, Philippe/A-6840-2011; Shibistova, Olga/AAP-1594-2020; Denning, Scott/F-4974-2011; Francey, Roger J/A-2345-2012; Heimann, Martin/H-7807-2016; Langenfelds, Raymond L/B-5381-2012; Sweeney, Colm/AAE-9291-2019; Bruhwiler, Lori/AAQ-8502-2020; Machida, Toshinobu/H-6526-2018; Tans, Pieter/AAG-8273-2019; Steele, Paul/B-3185-2009; Stephens, Britton B/B-7962-2008; Lloyd, Jonathan J/F-8893-2010; Peters, Wouter/B-8305-2008	Ciais, Philippe/0000-0001-8560-4943; Denning, Scott/0000-0003-3032-7875; Heimann, Martin/0000-0001-6296-5113; Langenfelds, Raymond L/0000-0003-4890-2049; Bruhwiler, Lori/0000-0002-3554-9250; Machida, Toshinobu/0000-0003-3312-8775; Tans, Pieter/0000-0002-9883-0787; Steele, Paul/0000-0002-8234-3730; Stephens, Britton B/0000-0002-1966-6182; Lloyd, Jonathan J/0000-0002-5458-9960; Peters, Wouter/0000-0001-8166-2070; Sweeney, Colm/0000-0002-4517-0797; Bousquet, Philippe/0000-0002-4444-2703				Achard F, 2004, GLOBAL BIOGEOCHEM CY, V18, DOI 10.1029/2003GB002142; [Anonymous], 2006, GLOBALVIEW CO2 COOP; Baker DF, 2006, GLOBAL BIOGEOCHEM CY, V20, DOI 10.1029/2004GB002439; Barford CC, 2001, SCIENCE, V294, P1688, DOI 10.1126/science.1062962; CIAIS P, 1995, SCIENCE, V269, P1098, DOI 10.1126/science.269.5227.1098; De Vries W, 2006, GLOBAL CHANGE BIOL, V12, P1151, DOI 10.1111/j.1365-2486.2006.01151.x; DeFries RS, 2002, P NATL ACAD SCI USA, V99, P14256, DOI 10.1073/pnas.182560099; Denning AS, 1999, TELLUS B, V51, P249, DOI 10.1034/j.1600-0889.1999.t01-1-00010.x; DENNING AS, 1995, NATURE, V376, P240, DOI 10.1038/376240a0; DIXON RK, 1994, SCIENCE, V263, P185, DOI 10.1126/science.263.5144.185; Francey RJ, 1999, J ATMOS SCI, V56, P279, DOI 10.1175/1520-0469(1999)056<0279:HPLTMO>2.0.CO;2; FRIEDLINGSTEIN P, 1995, GLOBAL BIOGEOCHEM CY, V9, P541, DOI 10.1029/95GB02381; GRACE J, 1995, SCIENCE, V270, P778, DOI 10.1126/science.270.5237.778; Gurney KR, 2004, GLOBAL BIOGEOCHEM CY, V18, DOI 10.1029/2003GB002111; Gurney KR, 2002, NATURE, V415, P626, DOI 10.1038/415626a; Holmes KW, 2006, GLOBAL BIOGEOCHEM CY, V20, DOI 10.1029/2005GB002507; Houghton RA, 2003, TELLUS B, V55, P378, DOI 10.1034/j.1600-0889.2003.01450.x; Jacobson AR, 2007, GLOBAL BIOGEOCHEM CY, V21, DOI 10.1029/2006GB002703; Janssens IA, 2003, SCIENCE, V300, P1538, DOI 10.1126/science.1083592; Keeling RF, 1996, NATURE, V381, P218, DOI 10.1038/381218a0; Lewis SL, 2006, PHILOS T R SOC B, V361, P195, DOI 10.1098/rstb.2005.1711; Lloyd J, 1996, FUNCT ECOL, V10, P4, DOI 10.2307/2390258; McGuire AD, 2001, GLOBAL BIOGEOCHEM CY, V15, P183, DOI 10.1029/2000GB001298; Myneni RB, 1997, NATURE, V386, P698, DOI 10.1038/386698a0; Pacala SW, 2001, SCIENCE, V292, P2316, DOI 10.1126/science.1057320; Peylin P, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000857; Phillips OL, 1998, SCIENCE, V282, P439, DOI 10.1126/science.282.5388.439; Rodenbeck C, 2003, TELLUS B, V55, P488, DOI 10.1034/j.1600-0889.2003.00033.x; Saleska SR, 2003, SCIENCE, V302, P1554, DOI 10.1126/science.1091165; Schimel D, 2000, SCIENCE, V287, P2004, DOI 10.1126/science.287.5460.2004; TANAKA M, 1983, J GEOPHYS RES-OCEANS, V88, P1339, DOI 10.1029/JC088iC02p01339; TANS PP, 1990, SCIENCE, V247, P1431, DOI 10.1126/science.247.4949.1431	32	531	553	6	155	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 22	2007	316	5832					1732	1735		10.1126/science.1137004	http://dx.doi.org/10.1126/science.1137004			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180XE	17588927				2022-12-28	WOS:000247400500043
J	Merlin, R				Merlin, R.			Radiationless electromagnetic interference: Evanescent-field lenses and perfect focusing	SCIENCE			English	Article							NEGATIVE REFRACTIVE-INDEX; DIFFRACTION LIMIT; MICROSCOPY; SUPERLENS; LIMITATIONS; RESOLUTION	Diffraction restricts the ability of most electromagnetic devices to image or selectively target objects smaller than the wavelength. We describe planar subwavelength structures capable of focusing well beyond the diffraction limit, operating at arbitrary frequencies. The structure design, related to that of Fresnel plates, forces the input field to converge to a spot on the focal plane. However, unlike the diffraction-limited zone plates, for which focusing results from the interference of traveling waves, the subwavelength plates control the near field and, as such, their superlensing properties originate from a static form of interference. Practical implementations of these plates hold promise for near-field data storage, noncontact sensing, imaging, and nanolithography applications.	Univ Michigan, Dept Phys, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Merlin, R (corresponding author), Univ Michigan, Dept Phys, Ann Arbor, MI 48109 USA.	merlin@umich.edu		Merlin, Roberto/0000-0002-5584-0248				Abbe E., 1873, ARCH F MIKROSK ANAT, V9, P413, DOI [10.1007/bf02956173, DOI 10.1007/BF02956173, 10.1007/ BF02956173]; BETZIG E, 1992, SCIENCE, V257, P189, DOI 10.1126/science.257.5067.189; Clemmow P. C., 1966, PLANE WAVE SPECTRUM; DURNIN J, 1987, PHYS REV LETT, V58, P1499, DOI 10.1103/PhysRevLett.58.1499; Fang N, 2005, SCIENCE, V308, P534, DOI 10.1126/science.1108759; Grbic A, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.117403; Hecht E., 2002, OPTICS; Hillenbrand R, 2002, NATURE, V418, P159, DOI 10.1038/nature00899; Lerosey G, 2007, SCIENCE, V315, P1120, DOI 10.1126/science.1134824; MCLEOD JH, 1954, J OPT SOC AM, V44, P592, DOI 10.1364/JOSA.44.000592; Merlin R, 2004, APPL PHYS LETT, V84, P1290, DOI 10.1063/1.1650548; Milton GW, 2005, P ROY SOC A-MATH PHY, V461, P3999, DOI 10.1098/rspa.2005.1570; NICOROVICI NA, 1994, PHYS REV B, V49, P8479, DOI 10.1103/PhysRevB.49.8479; Pendry JB, 2000, PHYS REV LETT, V85, P3966, DOI 10.1103/PhysRevLett.85.3966; Planken PCM, 2004, OPT LETT, V29, P2306, DOI 10.1364/OL.29.002306; Shelby RA, 2001, SCIENCE, V292, P77, DOI 10.1126/science.1058847; Shvets G, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.035109; Smith DR, 2003, APPL PHYS LETT, V82, P1506, DOI 10.1063/1.1554779; Smith DR, 2004, SCIENCE, V305, P788, DOI 10.1126/science.1096796; Smith DR, 2005, SCIENCE, V308, P502, DOI 10.1126/science.1110900; Stockman MI, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.067402; Stratton J., 1941, ELECTROMAGNETIC THEO; Taubner T, 2006, SCIENCE, V313, P1595, DOI 10.1126/science.1131025; Tselev A, 2003, REV SCI INSTRUM, V74, P3167, DOI 10.1063/1.1571954; ZENHAUSERN F, 1995, SCIENCE, V269, P1083, DOI 10.1126/science.269.5227.1083	25	182	191	1	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 17	2007	317	5840					927	929		10.1126/science.1143884	http://dx.doi.org/10.1126/science.1143884			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200RJ	17626847	Green Submitted			2022-12-28	WOS:000248780200033
J	Korn, T; Bettelli, E; Gao, W; Awasthi, A; Jager, A; Strom, TB; Oukka, M; Kuchroo, VK				Korn, Thomas; Bettelli, Estelle; Gao, Wenda; Awasthi, Amit; Jaeger, Anneli; Strom, Terry B.; Oukka, Mohamed; Kuchroo, Vijay K.			IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells	NATURE			English	Article							MYELIN OLIGODENDROCYTE GLYCOPROTEIN; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; REGULATORY T-CELLS; IL-6-DEFICIENT MICE; CHRONIC INFLAMMATION; HELPER-CELLS; DIFFERENTIATION; ACTIVATION; CYTOKINE; BETA	On activation, naive T cells differentiate into effector T-cell subsets with specific cytokine phenotypes and specialized effector functions(1). Recently a subset of T cells, distinct from T helper (T-H) 1 and T(H)2 cells, producing interleukin (IL)-17 (T(H)17) was defined and seems to have a crucial role in mediating autoimmunity and inducing tissue inflammation(2-5). We and others have shown that transforming growth factor (TGF)-beta and IL-6 together induce the differentiation of T(H)17 cells, in which IL-6 has a pivotal function in dictating whether T cells differentiate into Foxp3(+) regulatory T cells (T-reg cells) or T(H)17 cells(6-9). Whereas TGF-beta induces Foxp3 and generates T-reg cells, IL-6 inhibits the generation of T-reg cells and induces the production of IL-17, suggesting a reciprocal developmental pathway for T(H)17 and T-reg cells. Here we show that IL-6-deficient (Il6(-/-)) mice do not develop a T(H)17 response and their peripheral repertoire is dominated by Foxp3(+) T-reg cells. However, deletion of T-reg cells leads to the reappearance of T(H)17 cells in Il6(-/-) mice, suggesting an additional pathway by which T(H)17 cells might be generated in vivo. We show that an IL-2 cytokine family member, IL-21, cooperates with TGF-beta to induce T(H)17 cells in naive Il6(-/-) T cells and that IL-21-receptor-deficient T cells are defective in generating a T(H)17 response.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Cambridge, MA 02139 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Transplant Res Ctr, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Oukka, M (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, 65 Landsdowne St, Cambridge, MA 02139 USA.	moukka@rics.bwh.harvard.edu; vkuchroo@rics.bwh.harvard.edu	Strom, Terry B./E-9268-2010; Korn, Thomas/AAE-6960-2019	Strom, Terry B./0000-0002-7570-0736; Korn, Thomas/0000-0002-3633-0955	NIAID NIH HHS [R01 AI073542, R01 AI073542-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI073542] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Batten M, 2006, NAT IMMUNOL, V7, P929, DOI 10.1038/ni1375; Bettelli E, 2003, J EXP MED, V197, P1073, DOI 10.1084/jem.20021603; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bettelli E, 2007, NAT IMMUNOL, V8, P345, DOI 10.1038/ni0407-345; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Eugster HP, 1998, EUR J IMMUNOL, V28, P2178, DOI 10.1002/(SICI)1521-4141(199807)28:07<2178::AID-IMMU2178>3.0.CO;2-D; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Kasaian MT, 2002, IMMUNITY, V16, P559, DOI 10.1016/S1074-7613(02)00295-9; Kleinschek MA, 2007, J EXP MED, V204, P161, DOI 10.1084/jem.20061738; Korn T, 2007, NAT MED, V13, P423, DOI 10.1038/nm1564; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Leonard WJ, 2005, NAT REV IMMUNOL, V5, P688, DOI 10.1038/nri1688; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Mendel I, 1998, EUR J IMMUNOL, V28, P1727, DOI 10.1002/(SICI)1521-4141(199805)28:05<1727::AID-IMMU1727>3.0.CO;2-#; Murphy E, 1996, J EXP MED, V183, P901, DOI 10.1084/jem.183.3.901; Nakamura T, 1997, J IMMUNOL, V158, P1085; Okuda Y, 1999, J NEUROIMMUNOL, V101, P188, DOI 10.1016/S0165-5728(99)00139-3; Okuda Y, 1998, INT IMMUNOL, V10, P703, DOI 10.1093/intimm/10.5.703; Reddy J, 2003, J IMMUNOL, V170, P870, DOI 10.4049/jimmunol.170.2.870; Samoilova EB, 1998, J IMMUNOL, V161, P6480; Steinman L, 2007, NAT MED, V13, P139, DOI 10.1038/nm1551; Stumhofer JS, 2006, NAT IMMUNOL, V7, P937, DOI 10.1038/ni1376; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Veldhoen M, 2006, NAT IMMUNOL, V7, P1151, DOI 10.1038/ni1391; Vollmer TL, 2005, J IMMUNOL, V174, P2696, DOI 10.4049/jimmunol.174.5.2696; Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557; Yamanouchi J, 2007, NAT GENET, V39, P329, DOI 10.1038/ng1958; Yang XXO, 2007, J BIOL CHEM, V282, P9358, DOI 10.1074/jbc.C600321200; Zeng R, 2007, BLOOD, V109, P4135, DOI 10.1182/blood-2006-10-054973	30	1432	1554	0	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 26	2007	448	7152					484	U9		10.1038/nature05970	http://dx.doi.org/10.1038/nature05970			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	193VG	17581588	Green Accepted			2022-12-28	WOS:000248302700049
J	Rutter, GM; Crain, JN; Guisinger, NP; Li, T; First, PN; Stroscio, JA				Rutter, G. M.; Crain, J. N.; Guisinger, N. P.; Li, T.; First, P. N.; Stroscio, J. A.			Scattering and interference in epitaxial graphene	SCIENCE			English	Article							CARBON NANOTUBES; BERRYS PHASE; GRAPHITE; STM; DEFECTS; GAS	A single sheet of carbon, graphene, exhibits unexpected electronic properties that arise from quantum state symmetries, which restrict the scattering of its charge carriers. Understanding the role of defects in the transport properties of graphene is central to realizing future electronics based on carbon. Scanning tunneling spectroscopy was used to measure quasiparticle interference patterns in epitaxial graphene grown on SiC( 0001). Energy-resolved maps of the local density of states reveal modulations on two different length scales, reflecting both intravalley and intervalley scattering. Although such scattering in graphene can be suppressed because of the symmetries of the Dirac quasiparticles, we show that, when its source is atomic-scale lattice defects, wave functions of different symmetries can mix.	Georgia Inst Technol, Sch Phys, Atlanta, GA 30332 USA; Natl Inst Stand & Technol, Ctr Nanoscale Sci & Technol, Gaithersburg, MD 20899 USA	University System of Georgia; Georgia Institute of Technology; National Institute of Standards & Technology (NIST) - USA	First, PN (corresponding author), Georgia Inst Technol, Sch Phys, Atlanta, GA 30332 USA.	first@physics.gatech.edu; joseph.stroscio@nist.gov	Li, jiayu/H-3827-2014	Li, jiayu/0000-0003-2639-213X				Ando T, 1998, J PHYS SOC JPN, V67, P2857, DOI 10.1143/JPSJ.67.2857; Berger C, 2004, J PHYS CHEM B, V108, P19912, DOI 10.1021/jp040650f; Berger C, 2006, SCIENCE, V312, P1191, DOI 10.1126/science.1125925; Geim AK, 2007, NAT MATER, V6, P183, DOI 10.1038/nmat1849; Hoffman JE, 2002, SCIENCE, V297, P1148, DOI 10.1126/science.1072640; Kelly KF, 1998, SURF SCI, V416, pL1085, DOI 10.1016/S0039-6028(98)00622-0; McCann E, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.146805; McCann E, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.086805; McEuen PL, 1999, PHYS REV LETT, V83, P5098, DOI 10.1103/PhysRevLett.83.5098; MIZES HA, 1989, SCIENCE, V244, P559, DOI 10.1126/science.244.4904.559; Novoselov KS, 2005, NATURE, V438, P197, DOI 10.1038/nature04233; Ohta T, 2006, SCIENCE, V313, P951, DOI 10.1126/science.1130681; Owman F, 1996, SURF SCI, V369, P126, DOI 10.1016/S0039-6028(96)00919-3; Pereira VM, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.036801; Petersen L, 2000, J ELECTRON SPECTROSC, V109, P97, DOI 10.1016/S0368-2048(00)00110-9; Rollings E, 2006, J PHYS CHEM SOLIDS, V67, P2172, DOI 10.1016/j.jpcs.2006.05.010; Ruffieux P, 2000, PHYS REV LETT, V84, P4910, DOI 10.1103/PhysRevLett.84.4910; Wehling TO, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.125425; Wu XS, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.136801; Zhang YB, 2005, NATURE, V438, P201, DOI 10.1038/nature04235	20	626	633	12	367	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 13	2007	317	5835					219	222		10.1126/science.1142882	http://dx.doi.org/10.1126/science.1142882			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189DC	17626878				2022-12-28	WOS:000247968600034
J	Trimble, WS; Grinstein, S				Trimble, William S.; Grinstein, Sergio			TB or not TB: Calcium regulation in mycobacterial survival	CELL			English	Editorial Material							PHAGOSOME-LYSOSOME FUSION; HUMAN MACROPHAGES; TUBERCULOSIS; CORONIN; CA2+		Univ Toronto, Hosp Sick Children, Program Cell Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Grinstein, S (corresponding author), Univ Toronto, Hosp Sick Children, Program Cell Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	sga@sickkids.ca						Czibener C, 2006, J CELL BIOL, V174, P997, DOI 10.1083/jcb.200605004; Ferrari G, 1999, CELL, V97, P435, DOI 10.1016/S0092-8674(00)80754-0; Foger N, 2006, SCIENCE, V313, P839, DOI 10.1126/science.1130563; Kusner DJ, 2001, J IMMUNOL, V167, P3308, DOI 10.4049/jimmunol.167.6.3308; Majeed M, 1998, MICROB PATHOGENESIS, V24, P309, DOI 10.1006/mpat.1997.0200; Malik ZA, 2000, J EXP MED, V191, P287, DOI 10.1084/jem.191.2.287; Schuller S, 2001, CELL MICROBIOL, V3, P785, DOI 10.1046/j.1462-5822.2001.00155.x; Solomon JM, 2003, INFECT IMMUN, V71, P3578, DOI 10.1128/IAI.71.6.3578-3586.2003; Stober CB, 2001, J IMMUNOL, V166, P6276, DOI 10.4049/jimmunol.166.10.6276; Vergne I, 2003, J EXP MED, V198, P653, DOI 10.1084/jem.20030527	10	31	34	1	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 13	2007	130	1					12	14		10.1016/j.cell.2007.06.039	http://dx.doi.org/10.1016/j.cell.2007.06.039			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	197WK	17632049	Bronze			2022-12-28	WOS:000248587000003
J	Vassylyev, DG; Vassylyeva, MN; Zhang, JW; Palangat, M; Artsimovitch, I; Landick, R				Vassylyev, Dmitry G.; Vassylyeva, Marina N.; Zhang, Jinwei; Palangat, Murali; Artsimovitch, Irina; Landick, Robert			Structural basis for substrate loading in bacterial RNA polymerase	NATURE			English	Article							3.3 ANGSTROM RESOLUTION; ELECTRON-DENSITY MAPS; II ELONGATION COMPLEX; ACTIVE-CENTER; CRYSTAL-STRUCTURE; TRANSCRIPTION ELONGATION; CATALYTIC RESIDUES; MECHANISM; NTP; DISCRIMINATION	The mechanism of substrate loading in multisubunit RNA polymerase is crucial for understanding the general principles of transcription yet remains hotly debated. Here we report the 3.0-angstrom resolution structures of the Thermus thermophilus elongation complex (EC) with a non-hydrolysable substrate analogue, adenosine-5'-[(alpha,beta)-methyleno]-triphosphate (AMPcPP), and with AMPcPP plus the inhibitor streptolydigin. In the EC/AMPcPP structure, the substrate binds to the active ('insertion') site closed through refolding of the trigger loop (TL) into two alpha-helices. In contrast, the EC/AMPcPP/streptolydigin structure reveals an inactive ('preinsertion') substrate configuration stabilized by streptolydigin-induced displacement of the TL. Our structural and biochemical data suggest that refolding of the TL is vital for catalysis and have three main implications. First, despite differences in the details, the two-step preinsertion/insertion mechanism of substrate loading may be universal for all RNA polymerases. Second, freezing of the preinsertion state is an attractive target for the design of novel antibiotics. Last, the TL emerges as a prominent target whose refolding can be modulated by regulatory factors.	Univ Alabama, Dept Biochem & Mol Genet, Sch Med, Birmingham, AL 35294 USA; Univ Alabama, Sch Dent, Birmingham, AL 35294 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53705 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University System of Ohio; Ohio State University	Vassylyev, DG (corresponding author), Univ Alabama, Dept Biochem & Mol Genet, Sch Med, 402B Kaul Genet Bldg,720 20th St S, Birmingham, AL 35294 USA.	dmitry@uab.edu	Zhang, Jinwei/AAU-9195-2020; Palangat, Murali/AAK-5445-2021; Zhang, Jinwei/D-8953-2012; Vassylyev, Dmitry/A-9005-2008; Artsimovitch, Irina/L-3467-2019	Zhang, Jinwei/0000-0002-2114-173X; Palangat, Murali/0000-0002-3327-3844				Abbondanzieri EA, 2005, NATURE, V438, P460, DOI 10.1038/nature04268; Artsimovitch I, 2004, CELL, V117, P299, DOI 10.1016/S0092-8674(04)00401-5; Artsimovitch I, 2003, J BIOL CHEM, V278, P12344, DOI 10.1074/jbc.M211214200; Bar-Nahum G, 2005, CELL, V120, P183, DOI 10.1016/j.cell.2004.11.045; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DIECI G, 1995, EMBO J, V14, P3766, DOI 10.1002/j.1460-2075.1995.tb00046.x; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Epshtein V, 2002, MOL CELL, V10, P623, DOI 10.1016/S1097-2765(02)00640-8; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Foster JE, 2001, CELL, V106, P243, DOI 10.1016/S0092-8674(01)00420-2; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Gong XQ, 2005, MOL CELL, V18, P461, DOI 10.1016/j.molcel.2005.04.011; Holmes SF, 2006, J BIOL CHEM, V281, P18677, DOI 10.1074/jbc.M600543200; Huang JB, 2000, BIOCHEMISTRY-US, V39, P11571, DOI 10.1021/bi000579d; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kashkina E, 2006, NUCLEIC ACIDS RES, V34, P4036, DOI 10.1093/nar/gkl559; Kettenberger H, 2004, MOL CELL, V16, P955, DOI 10.1016/j.molcel.2004.11.040; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Landick R, 2005, TRENDS BIOCHEM SCI, V30, P651, DOI 10.1016/j.tibs.2005.10.001; Langelier MF, 2005, NUCLEIC ACIDS RES, V33, P2629, DOI 10.1093/nar/gki570; Laptenko O, 2003, EMBO J, V22, P6322, DOI 10.1093/emboj/cdg610; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6018, DOI 10.1073/pnas.88.14.6018; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Nickels BE, 2004, CELL, V118, P281, DOI 10.1016/j.cell.2004.07.021; Sidorenkov I, 1998, MOL CELL, V2, P55, DOI 10.1016/S1097-2765(00)80113-6; Sosunov V, 2005, NUCLEIC ACIDS RES, V33, P4202, DOI 10.1093/nar/gki688; Sosunov V, 2003, EMBO J, V22, P2234, DOI 10.1093/emboj/cdg193; Sosunova E, 2003, P NATL ACAD SCI USA, V100, P15469, DOI 10.1073/pnas.2536698100; Svetlov V, 2004, J BIOL CHEM, V279, P38087, DOI 10.1074/jbc.C400316200; Temiakov D, 2005, MOL CELL, V19, P655, DOI 10.1016/j.molcel.2005.07.020; Temiakov D, 2004, CELL, V116, P381, DOI 10.1016/S0092-8674(04)00059-5; TOULOKHONOV I, IN PRESS MOL CELL; Tuske S, 2005, CELL, V122, P541, DOI 10.1016/j.cell.2005.07.017; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; Wang D, 2006, CELL, V127, P941, DOI 10.1016/j.cell.2006.11.023; Werner F, 2002, MOL CELL, V10, P635, DOI 10.1016/S1097-2765(02)00629-9; Westover KD, 2004, CELL, V119, P481, DOI 10.1016/j.cell.2004.10.016; Yin YW, 2004, CELL, V116, P393, DOI 10.1016/S0092-8674(04)00120-5; Zaychikov E, 1996, SCIENCE, V273, P107, DOI 10.1126/science.273.5271.107; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	41	275	285	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 12	2007	448	7150					163	U4		10.1038/nature05931	http://dx.doi.org/10.1038/nature05931			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	188QN	17581591				2022-12-28	WOS:000247934500035
J	Lovett, RA				Lovett, Richard A.			Olympic talent - Fit ... for nothing?	NATURE			English	Editorial Material																			0	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 5	2007	448	7149					104	104		10.1038/448104a	http://dx.doi.org/10.1038/448104a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185OS	17611543	Bronze			2022-12-28	WOS:000247720900045
J	Williams, DA				Williams, David A.			Clinical implications of basic research - A new mechanism of leukemia drug resistance?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ACUTE LYMPHOBLASTIC-LEUKEMIA; STEM-CELLS		Univ Cincinnati, Coll Med, Childrens Hosp Med Ctr, Div Expt Hematol, Cincinnati, OH 45221 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Williams, DA (corresponding author), Univ Cincinnati, Coll Med, Childrens Hosp Med Ctr, Div Expt Hematol, Cincinnati, OH 45221 USA.							DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; Iwamoto S, 2007, J CLIN INVEST, V117, P1049, DOI 10.1172/JCI30235; SCHOFIELD R, 1983, BIOMED PHARMACOTHER, V37, P375; Silverman LB, 2001, BLOOD, V97, P1211, DOI 10.1182/blood.V97.5.1211; Williams DA, 2006, NATURE, V444, P827, DOI 10.1038/444827a	5	12	15	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 5	2007	357	1					77	78		10.1056/NEJMcibr072412	http://dx.doi.org/10.1056/NEJMcibr072412			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185OR	17611211				2022-12-28	WOS:000247720800016
J	Wenger, NK; Lewis, SJ; Herrington, DM; Bittner, V; Welty, FK				Wenger, Nanette K.; Lewis, Sandra J.; Herrington, David M.; Bittner, Vera; Welty, Francine K.		Treating New Targets Study S C	Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease	ANNALS OF INTERNAL MEDICINE			English	Article							MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE; SECONDARY PREVENTION; CHOLESTEROL LEVELS; LOWERING THERAPY; VASCULAR-DISEASE; PRAVASTATIN; SIMVASTATIN; GUIDELINES; EVENTS	Background: Increased life expectancy is associated with an increase in the burden of chronic cardiovascular disease. Objective: To assess the efficacy and safety of high-dose atorvastatin in patients 65 years of a,e or older. Design: A prespecified secondary analysis of the Treating to New Targets study, a randomized, double-blind clinical trial. Setting: 256 sites in 14 countries participating in the Treating to New Targets study. Participants: 10001 patients (3809 patients 65 years of age) with coronary heart disease (CHD) and low-density lipoprotein cholesterol levels less than 3.4 mmol/L (< 130 mg/dL). Intervention: Patients were randomly assigned to receive atorvastatin, 10 or 80 mg/d. Measurements: The primary end point was the occurrence of a first major cardiovascular event (death from CHID, nonfatal nonprocedure-related myocardial infarction, resuscitated cardiac arrest, or fatal or nonfatal stroke). Results: In patients 65 years of age or older, absolute risk was reduced by 2.3% and relative risk by 19% for major cardiovascular events in favor of the high-dose atorvastatin group (hazard ratio, 0.81 [95% Cl, 0.67 to 0.98]; P = 0.032). Among the components of the composite outcome, the mortality rates from CHD, nonfatal non-procedure-related myocardial infarction, and fatal or nonfatal stroke (ischemic, embolic, hemorrhagic, or unknown origin) were all lower in older patients who received high-dose atorvastatin, although the difference was not statistically significant for each individual component. The improved clinical outcome in patients 65 years of age or older was not associated with persistent elevations in creatine kinase levels. Limitation: Because the study was a secondary analysis, the findings should be interpreted within the context of the main study results. Conclusions: The analysis suggests that additional clinical benefit can be achieved by treating older patients with CHID more aggressively to reduce low-density lipoprotein cholesterol levels to less than 2.6 mmol/L (< 100 mg/dL). The findings support the use of intensive low-density lipoprotein cholesterol-lowering therapy in high-risk older persons with established cardiovascular disease.	Emory Univ, Sch Med, Div Cardiol, Atlanta, GA 30303 USA; NW Cardiovasc Inst, Portland, OR USA; Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA; Univ Alabama Birmingham, Birmingham, AL USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA	Emory University; Wake Forest University; University of Alabama System; University of Alabama Birmingham; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Wenger, NK (corresponding author), Emory Univ, Sch Med, Div Cardiol, 49 Jesse Hill Jr Dr SE, Atlanta, GA 30303 USA.	nwenger@emory.edu		Bittner, Vera/0000-0001-9456-850X				American Heart Association, 2005, HEART DIS STROKE STA; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Bonow RO, 2002, CIRCULATION, V106, P1602, DOI 10.1161/01.CIR.0000035036.22612.2B; Byington RP, 2001, CIRCULATION, V103, P387; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Colhoun HM, 2004, LANCET, V364, P685, DOI 10.1016/S0140-6736(04)16895-5; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Deedwania P, 2007, CIRCULATION, V115, P700, DOI 10.1161/CIRCULATIONAHA.106.654756; Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E; LaRosa JC, 2005, NEW ENGL J MED, V352, P1425, DOI 10.1056/NEJMoa050461; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Lewis SJ, 1998, ANN INTERN MED, V129, P681, DOI 10.7326/0003-4819-129-9-199811010-00002; Miettinen TA, 1997, CIRCULATION, V96, P4211; Pedersen TR, 2005, JAMA-J AM MED ASSOC, V294, P2437, DOI 10.1001/jama.294.19.2437; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; Smith SC, 2006, CIRCULATION, V113, P2363, DOI 10.1161/CIRCULATIONAHA.106.174516; Waters DD, 2004, AM J CARDIOL, V93, P154, DOI 10.1016/j.amjcard.2003.09.031; 1998, N ENGL L MED, V339, P1349	19	96	104	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2007	147	1					1	9		10.7326/0003-4819-147-1-200707030-00002	http://dx.doi.org/10.7326/0003-4819-147-1-200707030-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186MN	17606955				2022-12-28	WOS:000247782900001
J	Kahn, JA; Burk, RD				Kahn, Jessica A.; Burk, Robert D.			Papillomavirus vaccines in perspective	LANCET			English	Editorial Material							CERVICAL INTRAEPITHELIAL NEOPLASIA; RANDOMIZED CLINICAL-TRIALS; PARTICLE VACCINE; QUADRIVALENT VACCINE; TYPE-18; EFFICACY; INFECTION; LESIONS; CANCER; WOMEN		Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45215 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45215 USA; Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Obstet Gynecol & Womens Hlth, Bronx, NY 10467 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Kahn, JA (corresponding author), Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45215 USA.	jessica.kahn@cchmc.org						Block SL, 2006, PEDIATRICS, V118, P2135, DOI 10.1542/peds.2006-0461; Bulk S, 2007, BRIT J CANCER, V96, P1234, DOI 10.1038/sj.bjc.6603693; ELLENBERG JH, 1994, STAT MED, V13, P557, DOI 10.1002/sim.4780130518; Freeman H, 2005, EXCESS CERVICAL CANC; Garland SM, 2007, NEW ENGL J MED, V356, P1928, DOI 10.1056/NEJMoa061760; Harper DM, 2006, LANCET, V367, P1247, DOI 10.1016/S0140-6736(06)68439-0; Joura EA, 2007, LANCET, V369, P1693, DOI 10.1016/S0140-6736(07)60777-6; KAHN JA, IN PRESS OBSTET GYNE; LORINCZ AT, 1992, OBSTET GYNECOL, V79, P328, DOI 10.1097/00006250-199203000-00002; Munoz N, 2004, INT J CANCER, V111, P278, DOI 10.1002/ijc.20244; Paavonen J, 2007, LANCET, V369, P2161, DOI 10.1016/S0140-6736(07)60946-5; Villa L, 2007, LANCET, V369, P1861, DOI 10.1016/S0140-6736(07)60852-6; Villa LL, 2007, NEW ENGL J MED, V356, P1915, DOI 10.1056/NEJMoa061741; *WHO UNFPA, 2006, PREP INTR HPV VACC P; Wise PH, 2003, ANNU REV PUBL HEALTH, V24, P341, DOI 10.1146/annurev.publhealth.24.100901.140816; Woodman CBJ, 2003, LANCET, V361, P40, DOI 10.1016/S0140-6736(03)12120-4; Yang BH, 2004, INT J CANCER, V109, P418, DOI 10.1002/ijc.11719	17	39	42	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 30	2007	369	9580					2135	2137		10.1016/S0140-6736(07)60947-7	http://dx.doi.org/10.1016/S0140-6736(07)60947-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LX	17602733				2022-12-28	WOS:000247644200004
J	Moskowitz, IPG; Kim, JB; Moore, ML; Wolf, CM; Peterson, MA; Shendure, J; Nobrega, MA; Yokota, Y; Berul, C; Izumo, S; Seidman, JG; Seidman, CE				Moskowitz, Ivan P. G.; Kim, Jae B.; Moore, Meredith L.; Wolf, Cordula M.; Peterson, Michael A.; Shendure, Jay; Nobrega, Marcelo A.; Yokota, Yoshifumi; Berul, Charles; Izumo, Seigo; Seidman, J. G.; Seidman, Christine E.			A molecular pathway including Id2, Tbx5, and Nkx2-5 required for cardiac conduction system development	CELL			English	Article							HOLT-ORAM-SYNDROME; TRANSCRIPTION FACTOR TBX5; P204 PROTEIN OVERCOMES; PURKINJE-FIBERS; HEART-DISEASE; DIFFERENTIATION; EXPRESSION; GENE; INHIBITION; MUTATIONS	The cardiac conduction system is an anatomically discrete segment of specialized myocardium that initiates and propagates electrical impulses to coordinate myocardial contraction. To define the molecular composition of the mouse ventricular conduction system we used microdissection and transcriptional profiling by serial analysis of gene expression (SAGE). Conduction-system-specific expression for Id2, a member of the Id gene family of transcriptional repressors, was identified. Analyses of Id2-deficient mice demonstrated structural and functional conduction system abnormalities, including left bundle branch block. A 1.2 kb fragment of the Id2 promoter proved sufficient for cooperative regulation by Nkx2-5 and Tbx5 in vitro and for conduction-system-specific gene expression in vivo. Furthermore, compound haploinsufficiency of Tbx5 and Nkx2-5 or Tbx5 and Id2 prevented embryonic specification of the ventricular conduction system. We conclude that a molecular pathway including Tbx5, Nkx2-5, and Id2 coordinates specification of ventricular myocytes into the ventricular conduction system lineage.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Childrens Hosp, Dept Pathol, Cardiac Registry, Boston, MA 02115 USA; Brigham & Womens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; Univ Fukui, Sch Med, Dept Mol Genet, Matsuoka, Fukui 9111193, Japan; Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA; Novartis Inst BioMed Res, Cambridge, MA 02139 USA; Univ Chicago, Inst Mol Pediat Sci, Dept Pediat & Pathol, Chicago, IL 60637 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; University of Chicago; University of Fukui; Harvard University; Boston Children's Hospital; Novartis; University of Chicago	Seidman, CE (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.	cseidman@genetics.med.harvard.edu	Shendure, Jay/AAU-3684-2021	Shendure, Jay/0000-0002-1516-1865				BASSON CT, 1994, NEW ENGL J MED, V330, P885, DOI 10.1056/NEJM199403313301302; Benson DW, 1999, J CLIN INVEST, V104, P1567, DOI 10.1172/JCI8154; Berul CI, 1996, CIRCULATION, V94, P2641, DOI 10.1161/01.CIR.94.10.2641; Bonaldo MF, 2004, GENOME RES, V14, P2053, DOI 10.1101/gr.2601304; Bruneau BG, 1999, DEV BIOL, V211, P100, DOI 10.1006/dbio.1999.9298; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; Cheng G, 1999, DEVELOPMENT, V126, P5041; DELORME B, 1995, DEV DYNAM, V204, P358, DOI 10.1002/aja.1002040403; Ding B, 2006, J BIOL CHEM, V281, P14893, DOI 10.1074/jbc.M511748200; Fraidenraich D, 2004, SCIENCE, V306, P247, DOI 10.1126/science.1102612; GOURDIE RG, 1995, DEVELOPMENT, V121, P1423; Harris BS, 2006, DEV DYNAM, V235, P38, DOI 10.1002/dvdy.20580; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; Jay PY, 2004, J CLIN INVEST, V113, P1130, DOI 10.1172/JCI200419846; Kondo RP, 2003, J CARDIOVASC ELECTR, V14, P383, DOI 10.1046/j.1540-8167.2003.02467.x; Kupershmidt S, 1999, CIRC RES, V84, P146, DOI 10.1161/01.RES.84.2.146; LEV M, 1973, ACTA ANAT, V85, P342; Li QY, 1997, NAT GENET, V15, P21; Liu CJ, 2002, MOL CELL BIOL, V22, P2893, DOI 10.1128/MCB.22.9.2893-2905.2002; Martinsen BJ, 1998, SCIENCE, V281, P988, DOI 10.1126/science.281.5379.988; Moorman AFM, 1998, CIRC RES, V82, P629, DOI 10.1161/01.RES.82.6.629; Morley GE, 2001, MICROSC RES TECHNIQ, V52, P241, DOI 10.1002/1097-0029(20010201)52:3<241::AID-JEMT1010>3.0.CO;2-3; Moskowitz IPG, 2004, DEVELOPMENT, V131, P4107, DOI 10.1242/dev.01265; Palaniswamy SK, 2005, BIOINFORMATICS, V21, P835, DOI 10.1093/bioinformatics/bti119; Pashmforoush M, 2004, CELL, V117, P373, DOI 10.1016/S0092-8674(04)00405-2; Prall OWJ, 2002, ANN MED, V34, P148; Rentschler S, 2001, DEVELOPMENT, V128, P1785; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; Sedmera D, 2003, AM J PHYSIOL-HEART C, V284, pH1152, DOI 10.1152/ajpheart.00870.2002; Sedmera D, 2003, ANAT REC PART A, V274A, P773, DOI 10.1002/ar.a.10085; St Croix B, 2000, SCIENCE, V289, P1197; TAWARA S, 1906, REIZLETIUNGSSYSTEM S; Thomas PS, 2001, ANAT RECORD, V263, P307, DOI 10.1002/ar.1106; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812; ZAHLER R, 1992, P NATL ACAD SCI USA, V89, P99, DOI 10.1073/pnas.89.1.99; ZELLER R, 1987, GENE DEV, V1, P693, DOI 10.1101/gad.1.7.693	37	192	196	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 29	2007	129	7					1365	1376		10.1016/j.cell.2007.04.036	http://dx.doi.org/10.1016/j.cell.2007.04.036			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188HQ	17604724	Bronze			2022-12-28	WOS:000247911400021
J	Quiros-Lopez, R; Garcia-Alegria, J				Quiros-Lopez, Raul; Garcia-Alegria, Javier			Images in clinical medicine - A medical mystery-high blood pressure	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Costa del Sol Hosp, Marbella 29600, Spain		Quiros-Lopez, R (corresponding author), Costa del Sol Hosp, Marbella 29600, Spain.	quiroslopez@hotmail.com	García-Alegría, Javier/AAA-7903-2019						0	2	3	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 21	2007	356	25					2630	2630		10.1056/NEJMicm061308	http://dx.doi.org/10.1056/NEJMicm061308			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180GN	17582073				2022-12-28	WOS:000247351200010
J	Renoux, C; Vukusic, S; Mikaeloff, Y; Edan, G; Clanet, M; Dubois, B; Debouverie, M; Brochet, B; Lebrun-Frenay, C; Pelletier, J; Moreau, T; Lubetzki, C; Vermersch, P; Roullet, E; Magy, L; Tardieu, M; Suissa, S; Confavreux, C; Brochet, H; Ouallet, JC; Couvreur, G; Fromont, A; Deryck, O; Ketelaer, P; Zephir, H; Ionescu-Achiti, I; Chabrol, B; Mancini, J; Malikova, I; Pittion-Vouyovitch, S; Fontaine, B; Lyon-Caen, O; Mrejen, S; Stankoff, B; Tourbah, A; Coustans, M; Le Page, E; Leray, E; Brassat, D; Lau, GKK				Renoux, Christel; Vukusic, Sandra; Mikaeloff, Yann; Edan, Gilles; Clanet, Michel; Dubois, Benedicte; Debouverie, Marc; Brochet, Bruno; Lebrun-Frenay, Christine; Pelletier, Jean; Moreau, Thibault; Lubetzki, Catherine; Vermersch, Patrick; Roullet, Etienne; Magy, Laurent; Tardieu, Marc; Suissa, Samy; Confavreux, Christian; Brochet, H.; Ouallet, J. C.; Couvreur, G.; Fromont, A.; Deryck, O.; Ketelaer, P.; Zephir, H.; Ionescu-Achiti, I.; Chabrol, B.; Mancini, J.; Malikova, I.; Pittion-Vouyovitch, S.; Fontaine, B.; Lyon-Caen, O.; Mrejen, S.; Stankoff, B.; Tourbah, A.; Coustans, M.; Le Page, E.; Leray, E.; Brassat, D.; Lau, G. K. K.		Adult Neurology Dept KIDMUS Study	Natural history of multiple sclerosis with childhood onset	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PARACLINICAL FEATURES; PROGNOSTIC-FACTORS; DISABILITY; CHILDREN; AGE; PROGRESSION; COHORT; MS	Background: The course and prognosis of childhood-onset multiple sclerosis have not been well described. Methods: We used data from 13 adult neurology departments affiliated with the European Database for Multiple Sclerosis (EDMUS) network to identify a cohort of 394 patients who had multiple sclerosis with an onset at 16 years of age or younger and a comparison group of 1775 patients who had multiple sclerosis with an onset after 16 years of age. We determined the initial clinical features, the dates of disease onset, and the occurrence of outcomes, including relapse, conversion to secondary progression, and irreversible disability as measured by scores of 4 (limited walking ability but ability to walk more than 500 m without aid or rest), 6 (ability to walk with unilateral support no more than 100 m without rest), and 7 (ability to walk no more than 10 m without rest while using a wall or furniture for support) on the Kurtzke Disability Status Scale (range, 0 to 10; higher scores indicate more severe disability). Results: For patients with childhood-onset multiple sclerosis, the estimated median time from onset to secondary progression was 28 years, and the median age at conversion to secondary progression was 41 years. The median times from onset to disability scores of 4, 6, and 7 were 20.0, 28.9, and 37.0 years, respectively, and the corresponding median ages were 34.6, 42.2, and 50.5 years. In comparison with patients with adult-onset disease, those with childhood-onset disease were more likely to be female than male (female:male ratio, 2.8 vs. 1.8), were more likely to have an exacerbating-remitting initial course (98% vs. 84%), took approximately 10 years longer to reach secondary progression and irreversible disability, and reached these landmarks at an age approximately 10 years younger (P<0.001 for all comparisons). Conclusions: Patients with childhood-onset multiple sclerosis take longer to reach states of irreversible disability but do so at a younger age than patients with adult-onset multiple sclerosis.	Hospices Civils Lyon, Hop Neurol Pierre Wertheimer, Serv Neurol A, F-69677 Lyon, France; Hop Neurol & Neurochirurg P Wertheimer, European Database Multiple Sclerosis Coordinating, F-69677 Lyon, France; INSERM, U842, F-69008 Lyon, France; Univ Lyon 1, F-69365 Lyon, France; Hop Bicetre, Paris, France; Hop Purpan, Toulouse, France; Hop St Julien, Nancy, France; Hop Pellegrin, F-33076 Bordeaux, France; Hop Louis Pasteur, F-06002 Nice, France; Hop Enfants La Timone, Marseille, France; Hop Gen, Dijon, France; Hop La Pitie Salpetriere, Paris, France; Ctr Hosp Reg & Univ Lille, Hop Roger Salengro, F-59037 Lille, France; Hop Tenon, F-75970 Paris, France; Ctr Hosp Univ Dupuytren, Limoges, France; Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium; McGill Univ, Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada	CHU Lyon; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; CHU de Toulouse; CHU de Nancy; CHU Bordeaux; CHU Nice; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite de Lille - ISITE; CHU Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Limoges; KU Leuven; University Hospital Leuven; McGill University; Royal Victoria Hospital	Confavreux, C (corresponding author), Hospices Civils Lyon, Hop Neurol Pierre Wertheimer, Serv Neurol A, 59 Blvd Pinel, F-69677 Lyon, France.	christian.confavreux@chu-lyon.fr	Edan, Gilles/AAI-5944-2020; lebrun-frenay, christine/AAP-9539-2021; LICEND, CEMND/F-1296-2015; Brassat, David/L-2173-2014; Deryck, Olivier/AAI-7367-2020; Leray, Emmanuelle/ABH-4374-2020; Zéphir, Helene/AAV-9407-2020; Dubois, Benedicte/A-4338-2019	lebrun-frenay, christine/0000-0002-3713-2416; Leray, Emmanuelle/0000-0001-8424-4499; Dubois, Benedicte/0000-0003-0604-8702; Magy, Laurent/0000-0003-1784-2901				Amato MP, 2004, J NEUROL, V251, P1472, DOI 10.1007/s00415-004-0567-0; Boiko A, 2002, NEUROLOGY, V59, P1006, DOI 10.1212/WNL.59.7.1006; BOUTIN B, 1988, NEUROPEDIATRICS, V19, P118, DOI 10.1055/s-2008-1052414; BYE AME, 1985, DEV MED CHILD NEUROL, V27, P215; COLE GF, 1995, DEV MED CHILD NEUROL, V37, P661; Compston A, 2002, LANCET, V360, P648; Compston A, 2002, LANCET, V359, P1221, DOI 10.1016/S0140-6736(02)08220-X; Confavreux C, 2006, BRAIN, V129, P606, DOI 10.1093/brain/awl007; Confavreux C, 2006, BRAIN, V129, P595, DOI 10.1093/brain/awh714; CONFAVREUX C, 1992, J NEUROL NEUROSUR PS, V55, P671, DOI 10.1136/jnnp.55.8.671; Confavreux C, 2000, NEW ENGL J MED, V343, P1430, DOI 10.1056/NEJM200011163432001; Confavreux C, 2003, BRAIN, V126, P770, DOI 10.1093/brain/awg081; CONFAVREUX C, 1980, BRAIN, V103, P281, DOI 10.1093/brain/103.2.281; Confavreux C, 2006, MCALPINES MULTIPLE S, P183; DUQUETTE P, 1987, J PEDIATR-US, V111, P359, DOI 10.1016/S0022-3476(87)80454-7; GALL JC, 1958, PEDIATRICS, V21, P703; Ghezzi A, 1997, MULT SCLER, V3, P43, DOI 10.1177/135245859700300105; Ghezzi A, 2002, MULT SCLER, V8, P115, DOI 10.1191/1352458502ms786oa; GUILHOTO LMDF, 1995, BRAIN DEV-JPN, V17, P9; HANEFELD F, 1991, BRAIN DEV-JPN, V13, P410, DOI 10.1016/S0387-7604(12)80038-6; KURTZKE JF, 1961, NEUROLOGY, V11, P686, DOI 10.1212/WNL.11.8.686; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; Mikaeloff M, 2004, J PEDIATR-US, V144, P246, DOI 10.1016/j.jpeds.2003.10.056; Mikaeloff Y, 2004, BRAIN, V127, P1942, DOI 10.1093/brain/awh218; Mikaeloff Y, 2006, PEDIATRICS, V118, P1133, DOI 10.1542/peds.2006-0655; MULLER R, 1951, AMA ARCH NEUROL PSY, V66, P561; Ozakbas S, 2003, BRAIN DEV-JPN, V25, P233, DOI 10.1016/S0387-7604(03)00034-2; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Ruggieri M, 1999, NEUROLOGY, V53, P478, DOI 10.1212/WNL.53.3.478; RUNMARKER B, 1993, BRAIN, V116, P117, DOI 10.1093/brain/116.1.117; SCHUMACHER GA, 1965, ANN NY ACAD SCI, V122, P552; Selcen D, 1996, EUR NEUROL, V36, P79, DOI 10.1159/000117213; Simone IL, 2002, NEUROLOGY, V59, P1922, DOI 10.1212/01.WNL.0000036907.37650.8E; SINDERN E, 1992, ACTA NEUROL SCAND, V86, P280, DOI 10.1111/j.1600-0404.1992.tb05086.x; WEINSHENKER BG, 1989, BRAIN, V112, P133, DOI 10.1093/brain/112.1.133; YUDKIN PL, 1991, LANCET, V338, P1051, DOI 10.1016/0140-6736(91)91909-E	37	388	397	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 21	2007	356	25					2603	2613		10.1056/NEJMoa067597	http://dx.doi.org/10.1056/NEJMoa067597			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180GN	17582070	Green Published			2022-12-28	WOS:000247351200007
J	Lartigue, C; Glass, JI; Alperovich, N; Pieper, R; Parmar, PP; Hutchison, CA; Smith, HO; Venter, JC				Lartigue, Carole; Glass, John I.; Alperovich, Nina; Pieper, Rembert; Parmar, Prashanth P.; Hutchison, Clyde A., III; Smith, Hamilton O.; Venter, J. Craig			Genome transplantation in bacteria: Changing one species to another	SCIENCE			English	Article							MYCOPLASMA-CAPRICOLUM; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; COMPETENT CELLS; DNA; TRANSFORMATION; PLASMIDS; CLONING	As a step toward propagation of synthetic genomes, we completely replaced the genome of a bacterial cell with one from another species by transplanting a whole genome as naked DNA. Intact genomic DNA from Mycoplasma mycoides large colony (LC), virtually free of protein, was transplanted into Mycoplasma capricolum cells by polyethylene glycol-mediated transformation. Cells selected for tetracycline resistance, carried by the M. mycoides LC chromosome, contain the complete donor genome and are free of detectable recipient genomic sequences. These cells that result from genome transplantation are phenotypically identical to the M. mycoides LC donor strain as judged by several criteria.	J Craig Venter Inst, Rockville, MD 20850 USA	J. Craig Venter Institute	Glass, JI (corresponding author), J Craig Venter Inst, Rockville, MD 20850 USA.	jglass@jcvi.org	Lartigue, Carole/GQP-4896-2022; lartigue, carole/I-1576-2013; Glass, John/A-6572-2015	Lartigue, Carole/0000-0001-5550-7579; Glass, John/0000-0002-3784-5301				Akamatsu T, 2001, BIOSCI BIOTECH BIOCH, V65, P823, DOI 10.1271/bbb.65.823; Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; BEVERLEY SM, 1988, NUCLEIC ACIDS RES, V16, P925, DOI 10.1093/nar/16.3.925; BRIGGS R, 1952, P NATL ACAD SCI USA, V38, P455, DOI 10.1073/pnas.38.5.455; Cho MK, 1999, SCIENCE, V286, P2087, DOI 10.1126/science.286.5447.2087; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; Garfinkel M. S., SYNTHETIC GENOMICS O; Gatlin CL, 2006, PROTEOMICS, V6, P1530, DOI 10.1002/pmic.200500253; *GENBANK, NC007633 GENBANK; Glass JI, 2006, P NATL ACAD SCI USA, V103, P425, DOI 10.1073/pnas.0510013103; Gurdon JB, 2003, P NATL ACAD SCI USA, V100, P8048, DOI 10.1073/pnas.1337135100; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Holt RA, 2007, BIOESSAYS, V29, P580, DOI 10.1002/bies.20585; Hutchison CA, 1999, SCIENCE, V286, P2165, DOI 10.1126/science.286.5447.2165; Itaya M, 2005, P NATL ACAD SCI USA, V102, P15971, DOI 10.1073/pnas.0503868102; Lartigue C, 2003, NUCLEIC ACIDS RES, V31, P6610, DOI 10.1093/nar/gkg848; Saito Y, 2006, J BIOSCI BIOENG, V101, P334, DOI 10.1263/jbb.101.334; Seto S, 1999, J BACTERIOL, V181, P6073, DOI 10.1128/JB.181.19.6073-6080.1999; Seto S, 1998, J BACTERIOL, V180, P256, DOI 10.1128/JB.180.2.256-264.1998; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; TARSHIS M, 1993, BIOPHYS J, V64, P709, DOI 10.1016/S0006-3495(93)81430-9; Teachman AM, 2002, J BACTERIOL, V184, P947, DOI 10.1128/jb.184.4.947-951.2002; TULLY JG, 1979, J INFECT DIS, V139, P478, DOI 10.1093/infdis/139.4.478; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	24	266	311	4	130	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 3	2007	317	5838					632	638		10.1126/science.1144622	http://dx.doi.org/10.1126/science.1144622			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	196PL	17600181				2022-12-28	WOS:000248494400037
J	Tombros, N; Jozsa, C; Popinciuc, M; Jonkman, HT; van Wees, BJ				Tombros, Nikolaos; Jozsa, Csaba; Popinciuc, Mihaita; Jonkman, Harry T.; van Wees, Bart J.			Electronic spin transport and spin precession in single graphene layers at room temperature	NATURE			English	Article							ELECTRICAL DETECTION; METAL	Electronic transport in single or a few layers of graphene is the subject of intense interest at present. The specific band structure of graphene, with its unique valley structure and Dirac neutrality point separating hole states from electron states, has led to the observation of new electronic transport phenomena such as anomalously quantized Hall effects, absence of weak localization and the existence of a minimum conductivity(1). In addition to dissipative transport, supercurrent transport has also been observed(2). Graphene might also be a promising material for spintronics and related applications, such as the realization of spin qubits, owing to the low intrinsic spin orbit interaction, as well as the low hyperfine interaction of the electron spins with the carbon nuclei(3,4). Here we report the observation of spin transport, as well as Larmor spin precession, over micrometre-scale distances in single graphene layers. The 'non-local' spin valve geometry was used in these experiments, employing four-terminal contact geometries with ferromagnetic cobalt electrodes making contact with the graphene sheet through a thin oxide layer. We observe clear bipolar (changing from positive to negative sign) spin signals that reflect the magnetization direction of all four electrodes, indicating that spin coherence extends underneath all of the contacts. No significant changes in the spin signals occur between 4.2 K, 77K and room temperature. We extract a spin relaxation length between 1.5 and 2 mm at room temperature, only weakly dependent on charge density. The spin polarization of the ferromagnetic contacts is calculated from the measurements to be around ten per cent.	Univ Groningen, Zernike Inst Adv Mat, NL-9747 AG Groningen, Netherlands	University of Groningen	Tombros, N (corresponding author), Univ Groningen, Zernike Inst Adv Mat, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	n.tombros@rug.nl	van, bart/U-1770-2017; Institute, Zernike/W-7033-2019					Ando T, 2006, J PHYS SOC JPN, V75, DOI 10.1143/JPSJ.75.074716; Costache MV, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.012412; Fert A, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.184420; Geim AK, 2007, NAT MATER, V6, P183, DOI 10.1038/nmat1849; Heersche HB, 2007, NATURE, V446, P56, DOI 10.1038/nature05555; Hill EW, 2006, IEEE T MAGN, V42, P2694, DOI 10.1109/TMAG.2006.878852; Huertas-Hernando D, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.155426; Jedema FJ, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.085319; Jedema FJ, 2002, NATURE, V416, P713, DOI 10.1038/416713a; JOHNSON M, 1988, PHYS REV B, V37, P5312, DOI 10.1103/PhysRevB.37.5312; Lou XH, 2007, NAT PHYS, V3, P197, DOI 10.1038/nphys543; Peres NMR, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.174406; Rashba EI, 2000, PHYS REV B, V62, pR16267, DOI 10.1103/PhysRevB.62.R16267; Schmidt G, 2000, PHYS REV B, V62, pR4790, DOI 10.1103/PhysRevB.62.R4790; Tombros N, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.233403; Zutic I, 2005, NAT PHYS, V1, P85, DOI 10.1038/nphys164	17	1943	1961	27	1043	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 2	2007	448	7153					571	U4		10.1038/nature06037	http://dx.doi.org/10.1038/nature06037			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	195XV	17632544	Green Submitted			2022-12-28	WOS:000248446700038
J	Nozue, K; Covington, MF; Duek, PD; Lorrain, S; Fankhauser, C; Harmer, SL; Maloof, JN				Nozue, Kazunari; Covington, Michael F.; Duek, Paula D.; Lorrain, Severine; Fankhauser, Christian; Harmer, Stacey L.; Maloof, Julin N.			Rhythmic growth explained by coincidence between internal and external cues	NATURE			English	Article							DISRUPTS CIRCADIAN-RHYTHMS; LIGHT-SIGNAL-TRANSDUCTION; STEM ELONGATION; TRANSCRIPTION FACTORS; FLOWERING TIME; TOMATO PLANTS; ARABIDOPSIS; DEGRADATION; EXPRESSION; PHOSPHORYLATION	Most organisms use circadian oscillators to coordinate physiological and developmental processes such as growth with predictable daily environmental changes like sunrise and sunset. The importance of such coordination is highlighted by studies showing that circadian dysfunction causes reduced fitness in bacteria(1) and plants(2), as well as sleep and psychological disorders in humans(3). Plant cell growth requires energy and water-factors that oscillate owing to diurnal environmental changes. Indeed, two important factors controlling stem growth are the internal circadian oscillator(4-6) and external light levels(7). However, most circadian studies have been performed in constant conditions, precluding mechanistic study of interactions between the clock and diurnal variation in the environment. Studies of stem elongation in diurnal conditions have revealed complex growth patterns, but no mechanism has been described(8-10). Here we show that the growth phase of Arabidopsis seedlings in diurnal light conditions is shifted 8-12 h relative to plants in continuous light, and we describe a mechanism underlying this environmental response. We find that the clock regulates transcript levels of two basic helix-loop-helix genes, phytochrome-interacting factor 4 (PIF4) and PIF5, whereas light regulates their protein abundance. These genes function as positive growth regulators; the coincidence of high transcript levels (by the clock) and protein accumulation (in the dark) allows them to promote plant growth at the end of the night. Thus, these two genes integrate clock and light signalling, and their coordinated regulation explains the observed diurnal growth rhythms. This interaction may serve as a paradigm for understanding how endogenous and environmental signals cooperate to control other processes.	Univ Calif Davis, Plant Biol Sect, Coll Biol Sci, Davis, CA 95616 USA; Univ Lausanne, Ctr Integrative Genom, CH-1015 Lausanne, Switzerland	University of California System; University of California Davis; University of Lausanne	Maloof, JN (corresponding author), Univ Calif Davis, Plant Biol Sect, Coll Biol Sci, 1 Shields Ave, Davis, CA 95616 USA.	jnmaloof@ucdavis.edu	Fankhauser, Christian/ABE-8757-2021; Covington, Michael/G-9208-2014; Duek, Paula/AAV-2308-2020; Fankhauser, Christian/C-4291-2018	Fankhauser, Christian/0000-0003-4719-5901; Covington, Michael/0000-0002-0555-6409; Fankhauser, Christian/0000-0003-4719-5901; Duek Roggli, Paula/0000-0002-0819-0473; Maloof, Julin/0000-0002-9623-2599; Harmer, Stacey/0000-0001-6813-6682	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069418] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM069418] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Al-Sady B, 2006, MOL CELL, V23, P439, DOI 10.1016/j.molcel.2006.06.011; BERTRAM L, 1994, SCI HORTIC-AMSTERDAM, V58, P139, DOI 10.1016/0304-4238(94)90134-1; Bertram L, 1997, PHOTOCHEM PHOTOBIOL, V66, P396, DOI 10.1111/j.1751-1097.1997.tb03164.x; Breitling R, 2004, FEBS LETT, V573, P83, DOI 10.1016/j.febslet.2004.07.055; Bunning E., 1936, BER DEUT BOT GES, V54, P590, DOI DOI 10.1038/424033A; Chen M, 2004, ANNU REV GENET, V38, P87, DOI 10.1146/annurev.genet.38.072902.092259; Covington MF, 2001, PLANT CELL, V13, P1305, DOI 10.1105/tpc.13.6.1305; Czechowski T, 2005, PLANT PHYSIOL, V139, P5, DOI 10.1104/pp.105.063743; Czechowski T, 2004, PLANT J, V38, P366, DOI 10.1111/j.1365-313X.2004.02051.x; Dodd AN, 2005, SCIENCE, V309, P630, DOI 10.1126/science.1115581; Dowson-Day MJ, 1999, PLANT J, V17, P63, DOI 10.1046/j.1365-313X.1999.00353.x; Doyle MR, 2002, NATURE, V419, P74, DOI 10.1038/nature00954; Duek PD, 2005, TRENDS PLANT SCI, V10, P51, DOI 10.1016/j.tplants.2004.12.005; Duek PD, 2004, CURR BIOL, V14, P2296, DOI 10.1016/j.cub.2004.12.026; DUNLAP JC, 2005, CHRONOBIOLOGY; Fujimori T, 2004, PLANT CELL PHYSIOL, V45, P1078, DOI 10.1093/pcp/pch124; Gardner MJ, 2006, BIOCHEM J, V397, P15, DOI 10.1042/BJ20060484; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; HSIAO TC, 1973, ANNU REV PLANT PHYS, V24, P519, DOI 10.1146/annurev.pp.24.060173.002511; Huq E, 2002, EMBO J, V21, P2441, DOI 10.1093/emboj/21.10.2441; IBRAHIM C A, 1981, Plant Physiology (Rockville), V67, P113; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Khanna R, 2004, PLANT CELL, V16, P3033, DOI 10.1105/tpc.104.025643; Kohchi T, 2001, PLANT CELL, V13, P425, DOI 10.1105/tpc.13.2.425; LECHARNY A, 1984, PHYSIOL PLANTARUM, V60, P437, DOI 10.1111/j.1399-3054.1984.tb06089.x; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McWatters HG, 2000, NATURE, V408, P716, DOI 10.1038/35047079; Mockler TC, 2004, P NATL ACAD SCI USA, V101, P12759, DOI 10.1073/pnas.0404552101; Osterlund MT, 2000, NATURE, V405, P462, DOI 10.1038/35013076; Park E, 2004, PLANT CELL PHYSIOL, V45, P968, DOI 10.1093/pcp/pch125; *R DEV COR TEAM, 2005, R LANG ENV STAT COMP; Schaffer R, 1998, CELL, V93, P1219, DOI 10.1016/S0092-8674(00)81465-8; Schmid M, 2005, NAT GENET, V37, P501, DOI 10.1038/ng1543; Shen H, 2005, PLANT J, V44, P1023, DOI 10.1111/j.1365-313X.2005.02606.x; Strayer C, 2000, SCIENCE, V289, P768, DOI 10.1126/science.289.5480.768; Thain SC, 2004, PLANT PHYSIOL, V136, P3751, DOI 10.1104/pp.104.042523; Tsuda M, 2000, J EXP BOT, V51, P823, DOI 10.1093/jexbot/51.345.823; TUTTY JR, 1994, J AM SOC HORTIC SCI, V119, P138, DOI 10.21273/JASHS.119.2.138; Wang ZY, 1998, CELL, V93, P1207, DOI 10.1016/S0092-8674(00)81464-6; Woelfle MA, 2004, CURR BIOL, V14, P1481, DOI 10.1016/j.cub.2004.08.023; Yamashino T, 2003, PLANT CELL PHYSIOL, V44, P619, DOI 10.1093/pcp/pcg078	41	498	520	0	146	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 19	2007	448	7151					358	U11		10.1038/nature05946	http://dx.doi.org/10.1038/nature05946			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	191GC	17589502				2022-12-28	WOS:000248118300059
J	Mallet, L; Spinewine, A; Huang, A				Mallet, Louise; Spinewine, Anne; Huang, Allen			Prescribing in elderly people 2 - The challenge of managing drug interactions in elderly people	LANCET			English	Article							INAPPROPRIATE MEDICATION USE; PHYSICIAN ORDER ENTRY; OLDER-ADULTS; DISEASE INTERACTIONS; CHOLINESTERASE-INHIBITORS; HOSPITAL-ADMISSIONS; CYTOCHROMES P450; CONSENSUS PANEL; MANAGEMENT; SOFTWARE	Drug therapy is essential when caring for elderly patients, but clearly it is a double-edged sword. Elderly patients are at high risk of having drug interactions, but the prevalence of these interactions is not well documented. Several types of interactions exist: drug-drug, drug-disease, drug-food, drug-alcohol, drug-herbal products, and drug-nutritional status. Factors such as age-related changes in pharmacokinetics and pharmacodynamics, frailty, interindividual variability, reduced homoeostatic mechanisms, and psychosocial issues need to be considered when drug interactions are assessed. Software can help clinicians to detect drug interactions, but many programmes have not been updated with the evolving knowledge of these interactions, and do not take into consideration important factors needed to optimise drug treatment in elderly patients. Any generated recommendations have to be tempered by a holistic, geriatric, multiprofessional approach that is team-based. This second paper in a series of two on prescribing in elderly people proposes an approach to categorise drug interactions, along with strategies to assist in their detection, management, and prevention.	Univ Montreal, Fac Pharm, Montreal, PQ, Canada; Univ Catholique Louvain, Ctr Clin Pharm, Sch Pharm, B-1200 Brussels, Belgium; McGill Univ, Ctr Hlth, Dept Pharm, Montreal, PQ, Canada; McGill Univ, Ctr Hlth, Div Geriatr Med, Montreal, PQ, Canada	Universite de Montreal; Universite Catholique Louvain; McGill University; McGill University	Spinewine, A (corresponding author), Univ Catholique Louvain, Ctr Clin Pharm, Sch Pharm, UCL 73-70 Ave E Mounier 73, B-1200 Brussels, Belgium.	anne.spinewine@facm.ucl.ac.be	mallet, louise/AAA-4088-2020	mallet, louise/0000-0002-3151-8991				Abarca Jacob, 2004, J Am Pharm Assoc (2003), V44, P136, DOI 10.1331/154434504773062582; Barrons R, 2004, AM J HEALTH-SYST PH, V61, P380, DOI 10.1093/ajhp/61.4.380; Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; Bates DW, 2000, BRIT MED J, V320, P788, DOI 10.1136/bmj.320.7237.788; Bjorkman IK, 2002, ANN PHARMACOTHER, V36, P1675, DOI 10.1345/aph.1A484; *CAN I HLTH INF, 2006, DRUG EXP CAN 1985 20; Canadian Institute for Health Information, 2005, NAT HLTH EXP TRENDS; Carnahan RM, 2004, J AM GERIATR SOC, V52, P2082, DOI 10.1111/j.1532-5415.2004.52563.x; Cavuto NJ, 1996, JAMA-J AM MED ASSOC, V275, P1086, DOI 10.1001/jama.275.14.1086; Christians Uwe, 2005, Expert Opin Drug Metab Toxicol, V1, P641, DOI 10.1517/17425255.1.4.641; Crotty Maria, 2004, Am J Geriatr Pharmacother, V2, P257, DOI 10.1016/j.amjopharm.2005.01.001; Cusack Barry J, 2004, Am J Geriatr Pharmacother, V2, P274, DOI 10.1016/j.amjopharm.2004.12.005; Davies SJC, 2004, BRIT J CLIN PHARMACO, V57, P464, DOI 10.1111/j.1365-2125.2003.02040.x; Delafuente JC, 2003, CRIT REV ONCOL HEMAT, V48, P133, DOI 10.1016/j.critrevonc.2003.04.004; Dergal JM, 2002, DRUG AGING, V19, P879, DOI 10.2165/00002512-200219110-00005; Doucet J, 1996, J AM GERIATR SOC, V44, P944, DOI 10.1111/j.1532-5415.1996.tb01865.x; DuBuske LM, 2005, DRUG SAFETY, V28, P789, DOI 10.2165/00002018-200528090-00004; Edwards KR, 2002, J AM GERIATR SOC, V50, P1165, DOI 10.1046/j.1532-5415.2002.50281.x; Fick DM, 2003, ARCH INTERN MED, V163, P2716, DOI 10.1001/archinte.163.22.2716; Frank C, 2001, CAN FAM PHYSICIAN, V47, P1198; Fugh-Berman A, 2000, LANCET, V355, P134, DOI 10.1016/S0140-6736(99)06457-0; Gaeta TJ, 2002, J EMERG MED, V22, P159, DOI 10.1016/S0736-4679(01)00471-1; Gill SS, 2005, ARCH INTERN MED, V165, P808, DOI 10.1001/archinte.165.7.808; Goldberg RM, 1996, AM J EMERG MED, V14, P447, DOI 10.1016/S0735-6757(96)90147-3; Grenier L., 2003, MANUEL SOINS PHARMAC, P131; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; Hanlon Joseph T, 2005, Am J Geriatr Pharmacother, V3, P61, DOI 10.1016/S1543-5946(05)00030-9; Hanlon JT, 2004, ANN PHARMACOTHER, V38, P9, DOI 10.1345/aph.1D313; HANSTEN PD, 2006, HANSTEN HORNS DRUG I; Hohl CM, 2001, ANN EMERG MED, V38, P666, DOI 10.1067/mem.2001.119456; *I MED, 2004, PAT SAF ACH NEW STAN; Institute of Medicine, 2001, CROSSING QUALITY CHA; Izzedine H, 2004, KIDNEY INT, V66, P532, DOI 10.1111/j.1523-1755.2004.00772.x; Juurlink DN, 2004, NEW ENGL J MED, V351, P543, DOI 10.1056/NEJMoa040135; Juurlink DN, 2003, JAMA-J AM MED ASSOC, V289, P1652, DOI 10.1001/jama.289.13.1652; KANE RL, 2003, ESSENTIALS CLIN GERI, P357; Knollmann BC, 2005, CLIN PHARMACOL THER, V78, P7, DOI 10.1016/j.clpt.2005.03.007; Kohler GI, 2000, INT J CLIN PHARM TH, V38, P504; *LEX COMP, DRUG INT HDB DRUG IN; Lindblad CI, 2006, CLIN THER, V28, P1133, DOI 10.1016/j.clinthera.2006.08.006; Lindblad CI, 2005, ANN PHARMACOTHER, V39, P412, DOI 10.1345/aph.1E467; LINDOW J, 1994, CHEST, V105, P602, DOI 10.1378/chest.105.2.602; Mallet L, 2005, ANN PHARMACOTHER, V39, P150, DOI 10.1345/aph.1E392; Malone Daniel C, 2004, J Am Pharm Assoc (2003), V44, P142, DOI 10.1331/154434504773062591; Manfredi R, 2002, DRUG AGING, V19, P647, DOI 10.2165/00002512-200219090-00003; Mangoni AA, 2004, BRIT J CLIN PHARMACO, V57, P6, DOI 10.1046/j.1365-2125.2003.02007.x; McLeod PJ, 1997, CAN MED ASSOC J, V156, P385; MILLER LG, 1989, ARCH INTERN MED, V149, P2486, DOI 10.1001/archinte.149.11.2486; Multidisciplinary Medication Management Project, TOP 10 DANG DRUG INT; Nebert DW, 2002, LANCET, V360, P1155, DOI 10.1016/S0140-6736(02)11203-7; Perkins NA, 2006, ANN PHARMACOTHER, V40, P850, DOI 10.1345/aph.1G603; Pringle KE, 2005, J AM GERIATR SOC, V53, P1930, DOI 10.1111/j.1532-5415.2005.00474.x; Raschetti R, 1999, EUR J CLIN PHARMACOL, V54, P959, DOI 10.1007/s002280050582; Roberge RJ, 2000, ANN EMERG MED, V36, P160, DOI 10.1067/mem.2000.108617; Robertson SM, 2005, EXPERT OPIN PHARMACO, V6, P233, DOI 10.1517/14656566.6.2.233; Rosenblatt M, 1997, NEW ENGL J MED, V336, P1108, DOI 10.1056/NEJM199704103361518; Sandson NB, 2005, PSYCHOSOMATICS, V46, P464, DOI 10.1176/appi.psy.46.5.464; Sikka R, 2005, ACAD EMERG MED, V12, P1227, DOI 10.1197/j.aem.2005.06.027; Spina E, 2002, DRUG AGING, V19, P299, DOI 10.2165/00002512-200219040-00004; Spinewine A, 2005, J AM GERIATR SOC, V53, P360, DOI 10.1111/j.1532-5415.2005.53126_10.x; Stockley IH, 2002, STOCKLEYS DRUG INTER; STUCK AE, 1993, LANCET, V342, P1032, DOI 10.1016/0140-6736(93)92884-V; Tamblyn R, 2006, J AM MED INFORM ASSN, V13, P148, DOI 10.1197/jamia.M1887; Tamblyn RM, 1996, CAN MED ASSOC J, V154, P1177; Teich JM, 2000, ARCH INTERN MED, V160, P2741, DOI 10.1001/archinte.160.18.2741; Thomas JA, 1998, DRUG AGING, V13, P199, DOI 10.2165/00002512-199813030-00003; Warrington Jill S, 2005, Expert Opin Drug Metab Toxicol, V1, P487, DOI 10.1517/17425255.1.3.487; Wenger NS, 2001, ANN INTERN MED, V135, P642, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00002	68	314	326	3	30	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 14	2007	370	9582					185	191		10.1016/S0140-6736(07)61092-7	http://dx.doi.org/10.1016/S0140-6736(07)61092-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	190WP	17630042				2022-12-28	WOS:000248091600033
J	Murray, CJL; Lopez, AD; Black, R; Mathers, CD; Shibuya, K; Ezzati, M; Salomon, JA; Michaud, CM; Walker, N; Vos, T				Murray, Christopher J. L.; Lopez, Alan D.; Black, Robert; Mathers, Colin D.; Shibuya, Kenji; Ezzati, Majid; Salomon, Joshua A.; Michaud, Catherine M.; Walker, Neff; Vos, Theo			Global Burden of Disease 2005: call for collaborators	LANCET			English	Editorial Material							RISK-FACTORS; REGIONAL BURDEN; HEALTH; DISABILITY; DEATH		Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98104 USA; Univ Queensland, Sch Populat Hlth, Brisbane, Qld, Australia; Johsn hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; WHO, Dept Measurement & Hlth Informat Syst, CH-1211 Geneva, Switzerland; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Institute for Health Metrics & Evaluation; University of Washington; University of Washington Seattle; University of Queensland; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; World Health Organization; Harvard University; Harvard T.H. Chan School of Public Health	Murray, CJL (corresponding author), Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98104 USA.	cjlm@u.washington.edu	Salomon, Joshua A/D-3898-2009; Lopez, Alan D/F-1487-2010; Lopez, Alan/AAA-2734-2022; Salomon, Joshua/S-1929-2019; Vos, Theo/F-3324-2010	Salomon, Joshua A/0000-0003-3929-5515; Lopez, Alan D/0000-0001-5818-6512; Salomon, Joshua/0000-0003-3929-5515; Mathers, Colin/0000-0002-0617-6731; Shibuya, Kenji/0000-0003-2528-7530; Black, Robert/0000-0001-9926-7984				[Anonymous], POPULATION STUDIES; Bowie C, 1997, J PUBLIC HEALTH MED, V19, P87, DOI 10.1093/oxfordjournals.pubmed.a024595; Chapman G, 2006, TROP MED INT HEALTH, V11, P660, DOI 10.1111/j.1365-3156.2006.01601.x; Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6; Ha BM, 2003, PUBLIC HEALTH, V117, P358, DOI 10.1016/S0033-3506(03)00142-2; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Mathers CD, 2000, MED J AUSTRALIA, V172, P592, DOI 10.5694/j.1326-5377.2000.tb124125.x; Michalski C, 2006, EJC SUPPL, V4, P11, DOI 10.1016/j.ejcsup.2006.04.022; Murray, 2002, SUMMARY MEASURES POP, P205; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740; Murray CJL, 1996, GLOBAL BURDEN DIS CO; Salomon JA, 2004, BMJ-BRIT MED J, V328, P258, DOI 10.1136/bmj.37963.691632.44; Salomon JA, 2002, POPUL DEV REV, V28, P205, DOI 10.1111/j.1728-4457.2002.00205.x; World Health Organization , 1999, WORLD HLTH REP 1999	15	109	112	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 14	2007	370	9582					109	110		10.1016/S0140-6736(07)61064-2	http://dx.doi.org/10.1016/S0140-6736(07)61064-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	190WP	17630021				2022-12-28	WOS:000248091600006
J	Seymour, MT; Maughan, TS; Ledermann, JA; Topham, C; James, R; Gwyther, SJ; Smith, DB; Shepherd, S; Maraveyas, A; Ferry, DR; Meade, AM; Thompson, L; Griffiths, GO; Parmar, MKB; Stephens, RJ				Seymour, Matthew T.; Maughan, Timothy S.; Ledermann, Jonathan A.; Topham, Clare; James, Roger; Gwyther, Stephen J.; Smith, David B.; Shepherd, Stephen; Maraveyas, Anthony; Ferry, David R.; Meade, Angela M.; Thompson, Lindsay; Griffiths, Gareth O.; Parmar, Mahesh K. B.; Stephens, Richard J.		FOCUS Trial Investigators; Nat Canc Res Inst Colorectal Clin	Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial	LANCET			English	Article							FLUOROURACIL-LEUCOVORIN; 1ST-LINE TREATMENT; CONTINUOUS-INFUSION; PLUS IRINOTECAN; FOLINIC ACID; PHASE-II; OXALIPLATIN; BOLUS; 5-FLUOROURACIL; SURVIVAL	Background In the non-curative setting, the sequence in which anticancer agents are used, singly or in combination, may be important if patients are to receive the maximum period of disease control with the minimum of adverse effects. We compared sequential and combination chemotherapy strategies in patients with unpretreated advanced or metastatic colorectal cancer, who were regarded as not potentially curable irrespective of response. Methods We studied patients with advanced colorectal cancer, starting treatment with non-curative intent. 2135 unpretreated patients were randomly assigned to three treatment strategies in the ratio 1:1:1. Strategy A (control group) was single-agent fluorouracil (given with levofolinate over 48 h every 2 weeks) until failure, then single-agent irinotecan. Strategy B was fluorouracil until failure, then combination chemotherapy. Strategy C was combination chemotherapy from the outset. Within strategies B and Q patients were randomly assigned to receive, as the combination regimen, fluorouracil plus irinotecan (groups B-ir and C-ir) or fluorouracil plus oxaliplatin (groups B-ox and C-ox). The primary endpoint was overall survival, analysed by intention to treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN 79877428. Results Median survival of patients allocated to control strategy A was 13.9 months. Median survival of each of the other groups was longer (B-ir 15.0, B-ox 15.2, C-ir 16.7, and C-ox 15.4 months). However, log-rank comparison of each group against control showed that only C-ir - the first-line combination strategy including irinotecan-satisfied the statistical test for superiority (p=0.01). Overall comparison of strategy B with strategy C was within the predetermined non-inferiority boundary of HR=1.18 or less (HR=1.06, 90% CI 0.97-1.17). Interpretation Our data challenge the assumption that, in this non-curative setting, maximum tolerable treatment must necessarily be used first-line. The staged approach of initial single-agent treatment upgraded to combination when required is not worse than first-line combination, and is an alternative option for discussion with patients.	Cookridge Hosp, Gastrointestinal Canc Res Unit, Leeds LS16 6QB, W Yorkshire, England; Velindre Hosp, Cardiff, S Glam, Wales; UCL Hosp, London, England; St Lukes Canc Ctr, Guildford, Surrey, England; Mid Kent Oncol Ctr, Maidstone, Kent, England; E Surrey Hosp, Redhill, Surrey, England; Clatterbridge Ctr Oncol, Wirral, Merseyside, England; Cheltenham Gen Hosp, Cheltenham, Glos, England; Princess Royal Hosp, Kingston Upon Hull, N Humberside, England; New Cross Hosp, Wolverhampton, W Midlands, England; MRC, Clin Trials Unit, London, England	Cookridge Hospital; Velindre Hospital; University College London Hospitals NHS Foundation Trust; University of London; University College London; East Surrey Hospital; Clatterbridge Cancer Centre; Gloucestershire Hospitals NHS Foundation Trust; Cheltenham General Hospital; New Cross Hospital; Medical Research Council Clinical Trials Unit	Seymour, MT (corresponding author), Cookridge Hosp, Gastrointestinal Canc Res Unit, Leeds LS16 6QB, W Yorkshire, England.	matt.seymour@leedsth.nhs.uk	Maughan, Tim/AAV-7636-2021; Maraveyas, Anthony/GXH-7747-2022	Seymour, Matthew/0000-0002-2441-9629; Griffiths, Gareth/0000-0002-9579-8021	MRC [MC_U122861325] Funding Source: UKRI; Medical Research Council [MC_U122861325] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; BRAUN MS, 2006, J CLIN ONCOL S, V24, P10009; Burge ME, 2006, BRIT J CANCER, V94, P1281, DOI 10.1038/sj.bjc.6603084; Cao SS, 2000, CANCER RES, V60, P3717; Cheeseman SL, 2002, BRIT J CANCER, V87, P393, DOI 10.1038/sj.bjc.6600467; Chester JD, 2000, ANN ONCOL, V11, P235, DOI 10.1023/A:1008356017611; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Cunningham D, 1998, LANCET, V352, P1413, DOI 10.1016/S0140-6736(98)02309-5; de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938; deGramont A, 1997, J CLIN ONCOL, V15, P808, DOI 10.1200/JCO.1997.15.2.808; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Fischel JL, 1998, CLIN CANCER RES, V4, P2529; Giacchetti S, 2000, J CLIN ONCOL, V18, P136, DOI 10.1200/JCO.2000.18.1.136; Giacchetti S, 1999, ANN ONCOL, V10, P663, DOI 10.1023/A:1008347829017; Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046; Grothey A, 2004, J CLIN ONCOL, V22, P1209, DOI 10.1200/JCO.2004.11.037; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Hurwitz HI, 2005, J CLIN ONCOL, V23, P3502, DOI 10.1200/JCO.2005.10.017; Leonard P, 2002, BRIT J CANCER, V87, P1216, DOI 10.1038/sj.bjc.6600641; Maughan TS, 2003, LANCET, V361, P457, DOI 10.1016/S0140-6736(03)12461-0; *MED RES COUNC, 2005, MRC GOOD RES PRACT; *NAT I CLIN EXC, 2002, 33 NAT I CLIN EXC; Organization W.H, 1979, WHO HDB REP RES CANC; PIEDBOIS P, 1992, J CLIN ONCOL, V10, P896; PLUZANSKA A, 2005, J CLIN ONCOL, V23, P3517; Rothenberg ML, 2003, J CLIN ONCOL, V21, P2059, DOI 10.1200/JCO.2003.11.126; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113; *WHO INT AG RES CA, GLOBOCAN 2002; Wolmark N, 1998, J CLIN ONCOL, V16, P301; 2007, LANCET, V370, P135	32	445	459	1	32	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 14	2007	370	9582					143	152		10.1016/S0140-6736(07)61087-3	http://dx.doi.org/10.1016/S0140-6736(07)61087-3			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	190WP	17630037				2022-12-28	WOS:000248091600028
J	Koster, DA; Palle, K; Bot, ESM; Bjornsti, MA; Dekker, NH				Koster, Daniel A.; Palle, Komaraiah; Bot, Elisa S. M.; Bjornsti, Mary-Ann; Dekker, Nynke H.			Antitumour drugs impede DNA uncoiling by topoisomerase I	NATURE			English	Article							CELL-DEATH; CAMPTOTHECIN; MECHANISM; RELAXATION; INHIBITORS; YEAST; REPLICATION; MUTATIONS; COMPLEXES; TOXICITY	Increasing the ability of chemotherapeutic drugs to kill cancer cells is often hampered by a limited understanding of their mechanism of action. Camptothecins, such as topotecan, induce cell death by poisoning DNA topoisomerase I, an enzyme capable of removing DNA supercoils(1-4). Topotecan is thought to stabilize a covalent topoisomerase-DNA complex(5-7), rendering it an obstacle to DNA replication forks(2,3,8,9). Here we use single-molecule nanomanipulation to monitor the dynamics of human topoisomerase I in the presence of topotecan. This allowed us to detect the binding and unbinding of an individual topotecan molecule in real time and to quantify the drug-induced trapping of topoisomerase on DNA. Unexpectedly, our findings also show that topotecan significantly hinders topoisomerase-mediated DNA uncoiling, with a more pronounced effect on the removal of positive (overwound) versus negative supercoils. In vivo experiments in the budding yeast verified the resulting prediction that positive supercoils would accumulate during transcription and replication as a consequence of camptothecin poisoning of topoisomerase I. Positive supercoils, however, were not induced by drug treatment of cells expressing a catalytically active, camptothecin-resistant topoisomerase I mutant. This combination of single-molecule and in vivo data suggests a cytotoxic mechanism for camptothecins, in which the accumulation of positive supercoils ahead of the replication machinery induces potentially lethal DNA lesions.	Delft Univ Technol, Fac Sci Appl, Kavli Inst Nanosci, NL-2628 CJ Delft, Netherlands; St Jude Childrens Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA	Delft University of Technology; St Jude Children's Research Hospital	Dekker, NH (corresponding author), Delft Univ Technol, Fac Sci Appl, Kavli Inst Nanosci, Lorentzweg 1, NL-2628 CJ Delft, Netherlands.	n.h.dekker@tudelft.nl		Dekker, Nynke/0000-0003-4029-0973				Bjornsti MA, 2002, CANCER CELL, V2, P267, DOI 10.1016/S1535-6108(02)00160-5; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; CHAMPOUX JJ, 1989, J BIOL CHEM, V264, P1010; Chrencik JE, 2004, J MOL BIOL, V339, P773, DOI 10.1016/j.jmb.2004.03.007; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; GOTO T, 1984, CELL, V36, P1073, DOI 10.1016/0092-8674(84)90057-6; Hann C, 1998, J BIOL CHEM, V273, P8425, DOI 10.1074/jbc.273.14.8425; HOLM C, 1989, CANCER RES, V49, P6365; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Koster DA, 2005, NATURE, V434, P671, DOI 10.1038/nature03395; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; Minsky Bruce D, 2004, Oncology (Williston Park), V18, P49; Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Rodriguez-Galindo C, 2000, MED PEDIATR ONCOL, V35, P385, DOI 10.1002/1096-911X(20001001)35:4<385::AID-MPO1>3.0.CO;2-E; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; Staker BL, 2002, P NATL ACAD SCI USA, V99, P15387, DOI 10.1073/pnas.242259599; Stewart DJ, 2004, ONCOLOGIST, V9, P33, DOI 10.1634/theoncologist.9-90006-33; Stewart L, 1999, J BIOL CHEM, V274, P32950, DOI 10.1074/jbc.274.46.32950; Stivers JT, 1997, BIOCHEMISTRY-US, V36, P5212, DOI 10.1021/bi962880t; Strick T, 2000, PROG BIOPHYS MOL BIO, V74, P115, DOI 10.1016/S0079-6107(00)00018-3; Strick TR, 1996, SCIENCE, V271, P1835, DOI 10.1126/science.271.5257.1835; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Woo MH, 2003, P NATL ACAD SCI USA, V100, P13767, DOI 10.1073/pnas.2235886100; Woo MH, 2002, J BIOL CHEM, V277, P3813, DOI 10.1074/jbc.M110484200	30	224	228	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 12	2007	448	7150					213	217		10.1038/nature05938	http://dx.doi.org/10.1038/nature05938			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	188QN	17589503				2022-12-28	WOS:000247934500047
J	McWilliams, JM; Meara, E; Zaslavsky, AM; Ayanian, JZ				McWilliams, J. Michael; Meara, Ellen; Zaslavsky, Alan M.; Ayanian, John Z.			Use of health services by previously uninsured medicare beneficiaries	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INSURANCE COVERAGE; CARE UTILIZATION; NATIONAL-HEALTH; VALIDITY; ADULTS; DECLINE; ACCESS; OLDER	BACKGROUND: Previously uninsured adults who enroll in the Medicare program at the age of 65 years may have greater morbidity, requiring more intensive and costlier care over subsequent years, than they would if they had been previously insured. METHODS: We used longitudinal data from the nationally representative Health and Retirement Study to assess self-reported health care use and expenditures from 1992 through 2004 among 5158 adults who were privately insured or uninsured before Medicare coverage began at the age of 65 years. We used propensity-score methods to compare health care use and expenditures for previously insured and uninsured beneficiaries who were similar across numerous characteristics at 59 to 60 years of age and adjusted for differences in supplemental and prescription-drug coverage after 65 years of age. RESULTS: Among 2951 adults with hypertension, diabetes, heart disease, or stroke diagnosed before 65 years of age, previously uninsured adults who acquired Medicare coverage at the age of 65 reported significantly greater increases in the numbers of doctor visits (P < 0.001) and hospitalizations (P=0.001) and in total medical expenditures (P=0.02) than did previously insured adults. Significant differential increases were not evident among the 2207 adults without these conditions (P > 0.12 for all comparisons). In analyses adjusted for supplemental and prescription-drug coverage, previously uninsured adults with these conditions reported more doctor visits (13% relative difference, P=0.04), more hospitalizations (20% relative difference, P=0.04), and higher total medical expenditures (51% relative difference, P=0.09) from ages 65 to 72 years than did previously insured adults. CONCLUSIONS: The costs of expanding health insurance coverage for uninsured adults before they reach the age of 65 years may be partially offset by subsequent reductions in health care use and spending for these adults after the age of 65, particularly if they have cardiovascular disease or diabetes before the age of 65 years.	Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Gen Med & Primary Care, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Natl Bur Econ Res, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; National Bureau of Economic Research	Ayanian, JZ (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.	ayanian@hcp.med.harvard.edu		Meara, Ellen/0000-0003-0211-1970	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [T32HS000020] Funding Source: NIH RePORTER	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AM COLL PHYS, 2006, DEV MED BUY PROGR PO; [Anonymous], 11609 NAT BUR EC RES; Ayanian JZ, 2000, JAMA-J AM MED ASSOC, V284, P2061, DOI 10.1001/jama.284.16.2061; Ayanian JZ, 2003, AM J PUBLIC HEALTH, V93, P2051, DOI 10.2105/AJPH.93.12.2051; Baker DW, 2006, J GEN INTERN MED, V21, P1144, DOI 10.1111/j.1525-1497.2006.00576.x; Baker DW, 2006, MED CARE, V44, P277, DOI 10.1097/01.mlr.0000199696.41480.45; Baker DW, 2005, ARCH INTERN MED, V165, P770, DOI 10.1001/archinte.165.7.770; Baker DW, 2001, NEW ENGL J MED, V345, P1106, DOI 10.1056/NEJMsa002887; Bhandari A, 2006, MED CARE RES REV, V63, P217, DOI 10.1177/1077558705285298; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Buntin MB, 2004, J HEALTH ECON, V23, P525, DOI 10.1016/j.jhealeco.2003.10.005; CARD D, 2004, 10365 NAT BUR EC RES; Chaturvedi N, 1997, LANCET, V349, P1787, DOI 10.1016/S0140-6736(96)10244-0; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; CLEARY PD, 1984, MED CARE, V22, P796, DOI 10.1097/00005650-198409000-00003; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Collins R, 2003, LANCET, V361, P2005; De Giorgio L, 2000, NEW ENGL J MED, V342, P1376; Dor A, 2006, HEALTH SERV RES, V41, P759, DOI 10.1111/j.1475-6773.2006.00513.x; Federman AD, 2001, JAMA-J AM MED ASSOC, V286, P1732, DOI 10.1001/jama.286.14.1732; FRIEDLAND RB, 2005, 789 COMM FUND; Hadley J, 2006, HEALTH SERV RES, V41, P429, DOI 10.1111/j.1475-6773.2005.00491.x; HADLEY J, 2003, HLTH AFF MILLWOOD S; Heeringa S.G., 1995, TECHNICAL DESCRIPTIO; *HLTH US, 2005, DHHS PUBL; *I MED, 2003, HIDD COSTS VAL LOST; JOHNSON RW, 2002, MEDICARE BUY NEAR EL; JOYCE GF, 2005, HLTH AFF MILLWOOD S2, V24; *KAIS FAM FDN HLTH, 2004, 097512 KAIS FAM FDN; Levine DA, 2007, ARCH NEUROL-CHICAGO, V64, P37, DOI 10.1001/archneur.64.1.noc60002; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; LONG SH, 1994, HEALTH AFFAIR, V13, P211, DOI 10.1377/hlthaff.13.2.211; Lubitz J, 2003, NEW ENGL J MED, V349, P1048, DOI 10.1056/NEJMsa020614; Marks Andrea S, 2003, Dis Manag, V6, P199, DOI 10.1089/109350703322682513; McWilliams JM, 2004, HEALTH AFFAIR, V23, P223, DOI 10.1377/hlthaff.23.4.223; McWilliams JM, 2003, JAMA-J AM MED ASSOC, V290, P757, DOI 10.1001/jama.290.6.757; Miller Edward, 2004, 04007 AG HEALTHC RES; MONHEIT AC, 2004, 31 EC RES IN UN; NORRISH A, 1994, AM J EPIDEMIOL, V140, P938, DOI 10.1093/oxfordjournals.aje.a117182; Reijneveld SA, 2001, INT J EPIDEMIOL, V30, P1407, DOI 10.1093/ije/30.6.1407; Ritter PL, 2001, J CLIN EPIDEMIOL, V54, P136, DOI 10.1016/S0895-4356(00)00261-4; Roberts RO, 1996, J CLIN EPIDEMIOL, V49, P989, DOI 10.1016/0895-4356(96)00143-6; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; Rubin D.B., 2002, STAT ANAL MISSING DA; Shea DG, 2001, HEALTH AFFAIR, V20, P219, DOI 10.1377/hlthaff.20.1.219; SHEILS J, 2001, 441 COMM FUND; Simantov E, 2001, HEALTH AFFAIR, V20, P139, DOI 10.1377/hlthaff.20.4.139; STCLAIR P, 2006, RAND HRS DATA DOCUME; STUART B, 2003, HLTH AFF MILLWOOD S; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; *U MICH, 2006, HLTH RET STUD 1992 2; Weissman JS, 1996, AIDS, V10, P775, DOI 10.1097/00002030-199606001-00013; Yusuf S, 2000, NEW ENGL J MED, V342, P145	55	158	159	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 12	2007	357	2					143	153		10.1056/NEJMsa067712	http://dx.doi.org/10.1056/NEJMsa067712			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	188NX	17625126				2022-12-28	WOS:000247927700008
J	Whates, I				Whates, Ian			A piratical sabbatical - It's just too good to be true.	NATURE			English	Editorial Material																			0	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 12	2007	448	7150					224	224		10.1038/448224a	http://dx.doi.org/10.1038/448224a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	188QN	17625567	Bronze			2022-12-28	WOS:000247934500048
J	Calmy, A; Hirschel, B; Cooper, DA; Carr, A				Calmy, Alexandra; Hirschel, Bernard; Cooper, David A.; Carr, Andrew			Clinical update: adverse effects of antiretroviral therapy	LANCET			English	Article							HIV-INFECTED PATIENTS; TENOFOVIR DF; ADULTS; ZIDOVUDINE; EFAVIRENZ; ABACAVIR; DISEASE; COHORT; TRIAL		St Vincents Hosp, Sydney, NSW 2010, Australia; Univ Geneva, Hop Cantonal, Serv Malad Infect, CH-1211 Geneva, Switzerland; Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia	St Vincents Hospital Sydney; University of Geneva; University of New South Wales Sydney; Kirby Institute	Calmy, A (corresponding author), St Vincents Hosp, Sydney, NSW 2010, Australia.	acalmy@gmail.com						Brar I, 2007, JAIDS-J ACQ IMM DEF, V45, P66, DOI 10.1097/QAI.0b013e318031d7e3; *DHSS, 2006, GUID US ANT AG HIV 1; Fitch KV, 2006, AIDS, V20, P1843, DOI 10.1097/01.aids.0000244203.95758.db; Gallant JE, 2006, NEW ENGL J MED, V354, P251, DOI 10.1056/NEJMoa051871; Gallant JE, 2005, CLIN INFECT DIS, V40, P1194, DOI 10.1086/428840; Grinspoon S, 2005, NEW ENGL J MED, V352, P48, DOI 10.1056/NEJMra041811; Kappelhoff BS, 2005, ANTIVIR THER, V10, P489; Law M, 2006, ANTIVIR THER, V11, P179; Mallet V, 2007, AIDS, V21, P187, DOI 10.1097/QAD.0b013e3280119e47; Mallon PWG, 2006, AIDS, V20, P1003, DOI 10.1097/01.aids.0000222072.37749.5a; MOCROFT A, 2006, 16 INT AIDS C; Moyle GJ, 2006, AIDS, V20, P2043, DOI 10.1097/01.aids.0000247574.33998.03; Rauch A, 2006, CLIN INFECT DIS, V43, P99, DOI 10.1086/504874; Ssali F, 2006, ANTIVIR THER, V11, P741; Stein JH, 2007, NEW ENGL J MED, V356, P1773, DOI 10.1056/NEJMe078037; SUTINEN J, 2005, 7 INT WORKSH ADV EV, P7	16	57	58	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 7	2007	370	9581					12	14		10.1016/S0140-6736(07)61027-7	http://dx.doi.org/10.1016/S0140-6736(07)61027-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187QE	17617255				2022-12-28	WOS:000247862300009
J	Grulich, AE; van Leeuwen, MT; Falster, M; Vajdic, CM				Grulich, Andrew E.; van Leeuwen, Marina T.; Falster, Michael; Vajdic, Claire M.			Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis	LANCET			English	Article							ANTIRETROVIRAL THERAPY; RISK; HIV; INFECTION; IMMUNODEFICIENCY; COHORT; AIDS; EPIDEMIOLOGY; HERPESVIRUS; SMOKING	Background Only a few types of cancer are recognised as being directly related to immune deficiency in people with HIV/AIDS. Large population-based studies in transplant recipients have shown that a wider range of cancers could be associated with immune deficiency. Our aim was to compare cancer incidence in population-based cohort studies of people with HIV/AIDS and people immunosuppressed after solid organ transplantation. Methods Two investigators independently identified eligible studies through searches of PubMed and reference lists. Random-effects meta-analyses of log standardised incidence ratios (SIRs) were calculated by type of cancer for both immune deficient populations. Findings Seven studies of people with HIV/AIDS (n = 444172) and five of transplant recipients (n = 31977) were included. For 20 of the 28 types of cancer examined, there was a significantly increased incidence in both populations. Most of these were cancers with a known infectious cause, including all three types of AIDS-defining cancer, all HPV-related cancers. as well as Hodgkin's lymphoma (HIV/AIDS meta-analysis SIR 11.03, 95% CI 8.43-14.4; transplant 3.89, 2.42-6.26), liver cancer (HIV/AIDS 5.22, 3.32-8.20; transplant 2.13, 1.16-3.91), and stomach cancer (HIV/AIDS 1.90, 1.53-2.36; transplant 2.04, 1.49-2.79). Most common epithelial cancers did not occur at increased rates. Interpretation The similarity of the pattern of increased risk of cancer in the two populations suggests that it is immune deficiency, rather than other risk factors for cancer, that is responsible for the increased risk. infection-related cancer will probably become an increasingly important complication of long-term HIV infection.	Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Darlinghurst, NSW 2010, Australia	University of New South Wales Sydney; Kirby Institute	Grulich, AE (corresponding author), Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Level 2-376 Victoria St, Darlinghurst, NSW 2010, Australia.	agrulich@nchecr.unsw.edu.au	van Leeuwen, Marina T/AAQ-5339-2021; Falster, Michael/X-7118-2019; Vajdic, Claire/AAP-5940-2020	van Leeuwen, Marina T/0000-0002-1570-2852; Falster, Michael/0000-0001-6444-7272; Vajdic, Claire/0000-0002-3612-8298				Adami J, 2003, BRIT J CANCER, V89, P1221, DOI 10.1038/sj.bjc.6601219; Allardice GM, 2003, BRIT J CANCER, V89, P505, DOI 10.1038/sj.bjc.6601139; Biggar RJ, 2006, BLOOD, V108, P3786, DOI 10.1182/blood-2006-05-024109; Birkeland SA, 2000, LANCET, V355, P1886, DOI 10.1016/S0140-6736(00)02298-4; BURNET FM, 1970, PROG EXP TUMOR RES, V13, P1; Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072; Cogliano V, 2005, LANCET ONCOL, V6, P204, DOI 10.1016/S1470-2045(05)70086-3; Cooksley CD, 1999, INT J STD AIDS, V10, P795, DOI 10.1258/0956462991913574; Deeks JJ, 2001, SYSTEMATIC REV HLTH, P285, DOI DOI 10.1002/9780470693926.CH15; Del Maso L, 2003, BRIT J CANCER, V89, P94, DOI 10.1038/sj.bjc.6601017; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Engels EA, 2006, AIDS, V20, P1645, DOI 10.1097/01.aids.0000238411.75324.59; Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993, DOI 10.1056/NEJMoa030218; Frisch M, 2000, JNCI-J NATL CANCER I, V92, P1500, DOI 10.1093/jnci/92.18.1500; Frisch M, 2001, JAMA-J AM MED ASSOC, V285, P1736, DOI 10.1001/jama.285.13.1736; Gillison Maura L, 2003, J Natl Cancer Inst Monogr, P57; Grulich AE, 1999, J ACQ IMMUN DEF SYND, V20, P387, DOI 10.1097/00042560-199904010-00010; Grulich AE, 2002, AIDS, V16, P1155, DOI 10.1097/00002030-200205240-00009; Harwood CA, 2004, BRIT J DERMATOL, V150, P949, DOI 10.1111/j.1365-2133.2004.05847.x; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Kasiske BL, 2000, J AM SOC NEPHROL, V11, P753, DOI 10.1681/ASN.V114753; Kinlen L, 2004, ONCOGENE, V23, P6341, DOI 10.1038/sj.onc.1207898; Kyllonen L, 2000, Transpl Int, V13 Suppl 1, pS394, DOI 10.1007/s001470050369; Moore PS, 1998, AM J EPIDEMIOL, V147, P217, DOI 10.1093/oxfordjournals.aje.a009440; Newnham A, 2005, BRIT J CANCER, V92, P194, DOI 10.1038/sj.bjc.6602273; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Vajdic CM, 2006, JAMA-J AM MED ASSOC, V296, P2823, DOI 10.1001/jama.296.23.2823; Villeneuve PJ, 2007, AM J TRANSPLANT, V7, P941, DOI 10.1111/j.1600-6143.2007.01736.x; Yeni P, 2006, LANCET, V368, P287, DOI 10.1016/S0140-6736(06)69074-0	30	1498	1535	0	90	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 7	2007	370	9581					59	67		10.1016/S0140-6736(07)61050-2	http://dx.doi.org/10.1016/S0140-6736(07)61050-2			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187QE	17617273				2022-12-28	WOS:000247862300031
J	Kamerow, D				Kamerow, Douglas			Retail health clinics - threat or promise?	BRITISH MEDICAL JOURNAL			English	Editorial Material												dkamerow@bmj.com		Kamerow, Douglas/0000-0001-7000-9957					0	3	3	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUL 7	2007	335	7609					21	21		10.1136/bmj.39265.426817.59	http://dx.doi.org/10.1136/bmj.39265.426817.59			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	191LY	17615219	Green Published			2022-12-28	WOS:000248133900028
J	Cruikshank, DP; Dalton, JB; Ore, CMD; Bauer, J; Stephan, K; Filacchione, G; Hendrix, AR; Hansen, CJ; Coradini, A; Cerroni, P; Tosi, F; Capaccioni, F; Jaumann, R; Buratti, BJ; Clark, RN; Brown, RH; Nelson, RM; McCord, TB; Baines, KH; Nicholson, PD; Sotin, C; Meyer, AW; Bellucci, G; Combes, M; Bibring, JP; Langevin, Y; Sicardy, B; Matson, DL; Formisano, V; Drossart, P; Mennella, V				Cruikshank, D. P.; Dalton, J. B.; Ore, C. M. Dalle; Bauer, J.; Stephan, K.; Filacchione, G.; Hendrix, A. R.; Hansen, C. J.; Coradini, A.; Cerroni, P.; Tosi, F.; Capaccioni, F.; Jaumann, R.; Buratti, B. J.; Clark, R. N.; Brown, R. H.; Nelson, R. M.; McCord, T. B.; Baines, K. H.; Nicholson, P. D.; Sotin, C.; Meyer, A. W.; Bellucci, G.; Combes, M.; Bibring, J.-P.; Langevin, Y.; Sicardy, B.; Matson, D. L.; Formisano, V.; Drossart, P.; Mennella, V.			Surface composition of Hyperion	NATURE			English	Article							PHOEBE; THOLINS; IAPETUS; CO2	Hyperion, Saturn's eighth largest icy satellite, is a body of irregular shape in a state of chaotic rotation(1,2). The surface is segregated into two distinct units. A spatially dominant high-albedo unit having the strong signature of H2O ice contrasts with a unit that is about a factor of four lower in albedo and is found mostly in the bottoms of cup-like craters. Here we report observations of Hyperion's surface in the ultraviolet and near-infrared spectral regions with two optical remote sensing instruments on the Cassini spacecraft at closest approach during a fly-by on 25 - 26 September 2005. The close fly-by afforded us the opportunity to obtain separate reflectance spectra of the high-and low-albedo surface components. The low-albedo material has spectral similarities and compositional signatures that link it with the surface of Phoebe and a hemisphere-wide superficial coating on Iapetus.	NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; NASA, Ames Res Ctr, USR SOFIA, Moffett Field, CA 94035 USA; SETI Inst, Mountain View, CA 94043 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; DLR, Inst Planetary Explorat, D-12489 Berlin, Germany; INAF IASF Ist Astrofis Spaziale & Fis Cosmica, I-00133 Rome, Italy; INAF IASF Ist Spazio Interplanetario, I-00133 Rome, Italy; Denver Fed Ctr, USGS, Lakewood, CO 80225 USA; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; Univ Arizona, Steward Observ, Tucson, AZ 85721 USA; Space Sci Inst NW, Winthrop, WA USA; Cornell Univ, Ithaca, NY 14853 USA; Univ Nantes, F-44072 Nantes, France; Observ Paris, Dept Rech Spatial, F-95129 Meudon, France; Univ Paris 11, Inst Astrophys Spatial, F-91405 Orsay, France; INAF OAC Osservat Astron Capodimonte, I-80131 Naples, Italy	National Aeronautics & Space Administration (NASA); NASA Ames Research Center; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Helmholtz Association; German Aerospace Centre (DLR); Istituto Nazionale Astrofisica (INAF); United States Department of the Interior; United States Geological Survey; University of Arizona; University of Arizona; Cornell University; Nantes Universite; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; UDICE-French Research Universities; Universite Paris Saclay; Istituto Nazionale Astrofisica (INAF)	Cruikshank, DP (corresponding author), NASA, Ames Res Ctr, MS 245-6, Moffett Field, CA 94035 USA.	Dale.P.Cruikshank@nasa.gov	Filacchione, Gianrico/S-2320-2017; Jaumann, Ralf/N-1001-2018; Bellucci, Giancarlo/ABA-9201-2020; Drossart, Pierre/H-8670-2013; Stephan, Katrin/U-2524-2018; Tosi, Federico/F-2321-2018	Filacchione, Gianrico/0000-0001-9567-0055; Jaumann, Ralf/0000-0002-9759-6597; Bellucci, Giancarlo/0000-0003-0867-8679; Tosi, Federico/0000-0003-4002-2434; Capaccioni, Fabrizio/0000-0003-1631-4314; Mennella, Vito/0000-0001-9525-895X; Cerroni, Priscilla/0000-0003-0239-2741				Bernstein MP, 1999, SCIENCE, V283, P1135, DOI 10.1126/science.283.5405.1135; Brown RH, 2006, SCIENCE, V311, P1425, DOI 10.1126/science.1121031; Buratti BJ, 2005, ASTROPHYS J, V622, pL149, DOI 10.1086/429800; Buratti BJ, 2002, ICARUS, V155, P375, DOI 10.1006/icar.2001.6730; Chaban GM, 2007, ICARUS, V187, P592, DOI 10.1016/j.icarus.2006.10.010; Clark RN, 2005, NATURE, V435, P66, DOI 10.1038/nature03558; CRUIKSHANK DP, 1982, ICARUS, V50, P82, DOI 10.1016/0019-1035(82)90100-2; CRUIKSHANK DP, IN PRESS ICARUS; HENDRIX AR, IN PRESS ICARUS; HIBBITTS CA, 2006, LUN PLAN SCI C, V37, P1753; Jarvis KS, 2000, ICARUS, V146, P125, DOI 10.1006/icar.2000.6311; KHARE BN, 1984, ICARUS, V60, P127, DOI 10.1016/0019-1035(84)90142-8; LEBOFSKY LA, 1975, ICARUS, V25, P205, DOI 10.1016/0019-1035(75)90020-2; McCord TB, 1998, J GEOPHYS RES-PLANET, V103, P8603, DOI 10.1029/98JE00788; MCDONALD GD, 1994, ICARUS, V108, P137, DOI 10.1006/icar.1994.1046; SANDFORD SA, 1990, ASTROPHYS J, V355, P357, DOI 10.1086/168770; THOMAS P, 1985, ICARUS, V64, P414, DOI 10.1016/0019-1035(85)90065-X; WISDOM J, 1984, ICARUS, V58, P137, DOI 10.1016/0019-1035(84)90032-0	18	40	40	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 5	2007	448	7149					54	56		10.1038/nature05948	http://dx.doi.org/10.1038/nature05948			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185OS	17611536				2022-12-28	WOS:000247720900035
J	Muhm, JM; Rock, PB; McMullin, DL; Jones, SP; Lu, IL; Eilers, KD; Space, DR; McMullen, A				Muhm, J. Michael; Rock, Paul B.; McMullin, Dianne L.; Jones, Stephen P.; Lu, I. L.; Eilers, Kyle D.; Space, David R.; McMullen, Aleksandra			Effect of aircraft-cabin altitude on passenger discomfort	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MOUNTAIN-SICKNESS; INTERMEDIATE ALTITUDE; COMFORT; HEALTH; SATURATION; SAFETY	BACKGROUND: Acute mountain sickness occurs in some unacclimatized persons who travel to terrestrial altitudes at which barometric pressures are the same as those in commercial aircraft during flight. Whether the effects are similar in air travelers is unknown. METHODS: We conducted a prospective, single-blind, controlled hypobaric-chamber study of adult volunteers to determine the effect of barometric pressures equivalent to terrestrial altitudes of 650, 4000, 6000, 7000, and 8000 ft (198, 1219, 1829, 2134, and 2438 m, respectively) above sea level on arterial oxygen saturation and the occurrence of acute mountain sickness and discomfort as measured by responses to the Environmental Symptoms Questionnaire IV during a 20-hour simulated flight. RESULTS: Among the 502 study participants, the mean oxygen saturation decreased with increasing altitude, with a maximum decrease of 4.4 percentage points (95% confidence interval, 3.9 to 4.9) at 8000 ft. Overall, acute mountain sickness occurred in 7.4% of the participants, but its frequency did not vary significantly among the altitudes studied. The frequency of reported discomfort increased with increasing altitude and decreasing oxygen saturation and was greater at 7000 to 8000 ft than at all the lower altitudes combined. Differences became apparent after 3 to 9 hours of exposure. Persons older than 60 years of age were less likely than younger persons and men were less likely than women to report discomfort. Four serious adverse events, 1 of which may have been related to the study exposures, and 15 adverse events, 9 of which were related to study exposures, were reported. CONCLUSIONS: Ascent from ground level to the conditions of 7000 to 8000 ft lowered oxygen saturation by approximately 4 percentage points. This level of hypoxemia was insufficient to affect the occurrence of acute mountain sickness but did contribute to the increased frequency of reports of discomfort in unacclimatized participants after 3 to 9 hours.	Boeing Co, Boeing Med, Seattle, WA 98124 USA; Boeing Co, Shared Serv Grp, Seattle, WA USA; Boeing Co, Boeing Commercial Airplane Co, Seattle, WA USA; Boeing Co, Phantom Works, Seattle, WA USA; Oklahoma State Univ, Hlth Sci Ctr, Ctr Aerosp & Hyperbar Med, Tulsa, OK USA	Boeing; Boeing; Boeing; Boeing; Oklahoma State University System; Oklahoma State University Center for Health Sciences	Muhm, JM (corresponding author), Boeing Co, Boeing Med, POB 3707 MC 7H-90, Seattle, WA 98124 USA.	mike.muhm@boeing.com						Agresti A., 1990, CATEGORICAL DATA ANA, pXV; *AIR TRANSP MED CO, 1997, AVIAT SPACE ENV MED, V68, P943; Banderet L.E., 2002, MED ASPECTS HARSH EN, P729; BISHOP YMM, 1982, DISCRETE MULTIVARIAT; Brown TP, 2001, J R SOC PROMO HEALTH, V121, P177, DOI 10.1177/146642400112100315; Brundrett G, 2001, J R SOC PROMO HEALTH, V121, P29, DOI 10.1177/146642400112100108; *COMM AIRL CAB AIR, 1986, AIRL CAB ENV AIR QUA; Committee on Air Quality in Passenger Cabins of Commercial Aircraft, 2002, AIRL CAB ENV HLTH PA; COTTRELL JJ, 1995, AVIAT SPACE ENVIR MD, V66, P126; COX DR, 1972, J R STAT SOC B, V34, P187; DEAN AG, 1990, J WILDERNESS MED, V1, P86, DOI 10.1580/0953-9859-1.2.86; Hackett PH, 2001, NEW ENGL J MED, V345, P107, DOI 10.1056/NEJM200107123450206; HONIGMAN B, 1993, ANN INTERN MED, V118, P587, DOI 10.7326/0003-4819-118-8-199304150-00003; HONIGMAN B, 1994, ANN INTERN MED, V120, P698, DOI 10.7326/0003-4819-120-8-199404150-00034; Houston C. S., 1985, AM ALPINE J, V27, P162; JOHNSON TS, 1988, NEW ENGL J MED, V319, P841, DOI 10.1056/NEJM198809293191306; Kelly PT, 2006, AVIAT SPACE ENVIR MD, V77, P1143; Lawless J.F, 1982, STAT MODELS METHODS; MCFARLAND RA, 1971, AEROSPACE MED, V42, P1303; MONTGOMERY AB, 1989, JAMA-J AM MED ASSOC, V261, P732, DOI 10.1001/jama.261.5.732; PIGMAN EC, 1990, AM J EMERG MED, V8, P7, DOI 10.1016/0735-6757(90)90285-8; Rayman RB, 1997, AVIAT SPACE ENVIR MD, V68, P432; Roach RC, 1998, AVIAT SPACE ENVIR MD, V69, P1182; ROACH RC, 1995, WESTERN J MED, V162, P32; Roach RC, 2000, J APPL PHYSIOL, V88, P581, DOI 10.1152/jappl.2000.88.2.581; SAMPSON JB, 1983, AVIAT SPACE ENVIR MD, V54, P1063; SAVOUREY G, 1995, AVIAT SPACE ENVIR MD, V66, P963; Schneider M, 2002, MED SCI SPORT EXER, V34, P1886, DOI 10.1097/00005768-200212000-00005; WAGNER PD, 1986, J APPL PHYSIOL, V61, P260, DOI 10.1152/jappl.1986.61.1.260; West JB, 2004, ANN INTERN MED, V141, P789, DOI 10.7326/0003-4819-141-10-200411160-00010	30	113	115	1	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 5	2007	357	1					18	27		10.1056/NEJMoa062770	http://dx.doi.org/10.1056/NEJMoa062770			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185OR	17611205				2022-12-28	WOS:000247720800005
J	Carlsten, C; Hunt, S				Carlsten, Chris; Hunt, Stephen			Stress, redeployed	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												carlsten@u.washington.edu							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 4	2007	298	1					18	19		10.1001/jama.298.1.18	http://dx.doi.org/10.1001/jama.298.1.18			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185OU	17609481				2022-12-28	WOS:000247721100001
J	Goldman, DP; Joyce, GF; Zheng, YH				Goldman, Dana P.; Joyce, Geoffrey F.; Zheng, Yuhui			Prescription drug cost sharing associations with medication and medical utilization and spending and health	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PROTON PUMP INHIBITORS; PRIOR-AUTHORIZATION REQUIREMENT; OBSTRUCTIVE PULMONARY-DISEASE; CONVERTING ENZYME-INHIBITORS; INCENTIVE-BASED FORMULARIES; TIME-SERIES ANALYSIS; CARE UTILIZATION; ECONOMIC CONSEQUENCES; RECEPTOR ANTAGONISTS; GENERIC SUBSTITUTION	Context Prescription drugs are instrumental to managing and preventing chronic disease. Recent changes in US prescription drug cost sharing could affect access to them. Objective To synthesize published evidence on the associations among cost-sharing features of prescription drug benefits and use of prescription drugs, use of non-pharmaceutical services, and health outcomes. Data Sources We searched PubMed for studies published in English between 1985 and 2006. Study Selection and Data Extraction Among 923 articles found in the search, we identified 132 articles examining the associations between prescription drug plan cost-containment measures, including co-payments, tiering, or coinsurance (n = 65), pharmacy benefit caps or monthly prescription limits (n = 11), formulary restrictions (n = 41), and reference pricing (n = 16), and salient outcomes, including pharmacy utilization and spending, medical care utilization and spending, and health outcomes. Results Increased cost sharing is associated with lower rates of drug treatment, worse adherence among existing users, and more frequent discontinuation of therapy. For each 10% increase in cost sharing, prescription drug spending decreases by 2% to 6%, depending on class of drug and condition of the patient. The reduction in use associated with a benefit cap, which limits either the coverage amount or the number of covered prescriptions, is consistent with other cost-sharing features. For some chronic conditions, higher cost sharing is associated with increased use of medical services, at least for patients with congestive heart failure, lipid disorders, diabetes, and schizophrenia. While low-income groups may be more sensitive to increased cost sharing, there is little evidence to support this contention. Conclusions Pharmacy benefit design represents an important public health tool for improving patient treatment and adherence. While increased cost sharing is highly correlated with reductions in pharmacy use, the long-term consequences of benefit changes on health are still uncertain.	RAND Corp, Hlth Econ Finance & Org, Santa Monica, CA 90407 USA; RAND Corp, Pardee RAND Grad Sch, Santa Monica, CA 90407 USA	RAND Corporation; RAND Corporation; Pardee RAND Graduate School	Goldman, DP (corresponding author), RAND Corp, Hlth Econ Finance & Org, 1776 Main St, Santa Monica, CA 90407 USA.	dgoldman@rand.org	Goldman, Dana P/E-7667-2013	Goldman, Dana P/0000-0001-8498-6396	NIA NIH HHS [P30 AG024968] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG024968] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abdelgawad T, 2006, PHARMACOECONOMICS, V24, P55, DOI 10.2165/00019053-200624003-00005; Ackman ML, 2006, CAN J CARDIOL, V22, P1205, DOI 10.1016/S0828-282X(06)70960-6; Andersson K, 2006, HEALTH POLICY, V79, P231, DOI 10.1016/j.healthpol.2006.01.007; Anis AH, 2005, CAN MED ASSOC J, V173, P1335, DOI 10.1503/cmaj.045146; Aronsson T, 2001, REV IND ORGAN, V19, P425; Artz MB, 2002, AM J PUBLIC HEALTH, V92, P1257, DOI 10.2105/AJPH.92.8.1257; Balkrishnan R, 2001, AM J MANAG CARE, V7, P1093; Berndt ER, 1997, AM J MANAG CARE, V3, P243; BIRCH S, 1986, J ROY COLL GEN PRACT, V36, P154; Blais L, 2003, HEALTH POLICY, V64, P163, DOI 10.1016/S0168-8510(02)00158-6; Blais L, 2001, J AM GERIATR SOC, V49, P410, DOI 10.1046/j.1532-5415.2001.49084.x; BLOOM BS, 1985, MED CARE, V23, P872, DOI 10.1097/00005650-198507000-00004; Briesacher B, 2004, ARCH INTERN MED, V164, P1679, DOI 10.1001/archinte.164.15.1679; Campbell CA, 2003, ANN PHARMACOTHER, V37, P787, DOI 10.1345/aph.1C196; Carroll NV, 2006, AM J MANAG CARE, V12, P501; CHRISTIANHERMAN J, HLTH AFF MILLWOO JUL; Cole JA, 2006, PHARMACOTHERAPY, V26, P1157, DOI 10.1592/phco.26.8.1157; Contoyannis P, 2005, HEALTH ECON, V14, P909, DOI 10.1002/hec.1041; COULSON NE, 1995, SOUTHERN ECON J, V61, P1146, DOI 10.2307/1060746; Cox Emily R, 2002, J Manag Care Pharm, V8, P360; Cox ER, 2001, MED CARE, V39, P296, DOI 10.1097/00005650-200103000-00009; Cromwell DM, 1999, HEALTH SERV RES, V33, P1593; Crown WH, 2004, NBER FR HLTH POL RES, P95; Cunningham Peter J, 2002, Issue Brief Cent Stud Health Syst Change, P1; Cunningham PJ, 2005, HEALTH AFFAIR, V24, P780, DOI 10.1377/hlthaff.24.3.780; Delate T, 2005, AM J MANAG CARE, V11, P29; Dormuth CR, 2006, CLIN THER, V28, P964, DOI 10.1016/j.clinthera.2006.06.007; Dunn JD, 2006, J MANAG CARE PHARM, V12, P294, DOI 10.18553/jmcp.2006.12.4.294; Ellis JJ, 2004, J GEN INTERN MED, V19, P638, DOI 10.1111/j.1525-1497.2004.30516.x; Fairman KA, 2003, CLIN THER, V25, P3147, DOI 10.1016/S0149-2918(03)90099-3; Fischer MA, 2004, NEW ENGL J MED, V351, P2187, DOI 10.1056/NEJMsa042770; Fortess EE, 2001, J AM GERIATR SOC, V49, P793, DOI 10.1046/j.1532-5415.2001.49158.x; FOXMAN B, 1987, J CHRON DIS, V40, P429, DOI 10.1016/0021-9681(87)90176-7; Gabel J, 2002, HEALTH AFFAIR, V21, P143, DOI 10.1377/hlthaff.21.5.143; Gibson TB, 2005, INQUIRY-J HEALTH CAR, V42, P293, DOI 10.5034/inquiryjrnl_42.3.293; Gibson TB, 2006, AM J MANAG CARE, V12, pSP11; Gibson TB, 2006, AM J MANAG CARE, V12, P509; Gleason PP, 2005, PHARMACOTHERAPY, V25, P924, DOI 10.1592/phco.2005.25.7.924; Goldman DP, 2006, HEALTH AFFAIR, V25, P1319, DOI 10.1377/hlthaff.25.5.1319; Goldman DP, 2004, JAMA-J AM MED ASSOC, V291, P2344, DOI 10.1001/jama.291.19.2344; Goldman DP, 2006, AM J MANAG CARE, V12, P21; Goldman DP, 2001, HEALTH SERV RES, V35, P1357; Grootendorst PV, 2005, HEALTH SERV RES, V40, P1297, DOI 10.1111/j.1475-6773.2005.00420.x; Grootendorst PV, 1997, MED CARE, V35, P386, DOI 10.1097/00005650-199704000-00008; Grootendorst PV, 2001, CAN MED ASSOC J, V165, P1011; Hansen RA, 2005, CLIN THER, V27, P1478, DOI 10.1016/j.clinthera.2005.09.006; HARRIS BL, 1990, MED CARE, V28, P907, DOI 10.1097/00005650-199010000-00005; Harris Brittany N, 2004, J Manag Care Pharm, V10, P449; Hartung DM, 2004, CLIN THER, V26, P1518, DOI 10.1016/j.clinthera.2004.09.013; Hazlet TK, 2002, MED CARE, V40, P640, DOI 10.1097/00005650-200208000-00003; Hillman AL, 1999, HEALTH AFFAIR, V18, P189, DOI 10.1377/hlthaff.18.2.189; Hong SH, 1996, CLIN THER, V18, P528, DOI 10.1016/S0149-2918(96)80035-X; Horn SD, 1998, AM J MANAG CARE, V4, P1105; Hsu J, 2006, NEW ENGL J MED, V354, P2349, DOI 10.1056/NEJMsa054436; HUGHES D, 1995, HEALTH ECON, V4, P213, DOI 10.1002/hec.4730040306; Huskamp HA, 2003, HEALTH AFFAIR, V22, P149, DOI 10.1377/hlthaff.22.3.149; Huskamp HA, 2005, ARCH GEN PSYCHIAT, V62, P435, DOI 10.1001/archpsyc.62.4.435; Huskamp HA, 2003, NEW ENGL J MED, V349, P2224, DOI 10.1056/NEJMsa030954; Johnson RE, 1997, HEALTH SERV RES, V32, P103; Johnson RE, 1997, MED CARE, V35, P1119, DOI 10.1097/00005650-199711000-00004; Jones DL, 1996, JAMA-J AM MED ASSOC, V275, P926, DOI 10.1001/jama.275.12.926; JONSSON B, 1994, PHARMACOECONOMICS, V6, P51; Joyce GF, 2002, JAMA-J AM MED ASSOC, V288, P1733, DOI 10.1001/jama.288.14.1733; Kahan NR, 2006, BRIT J CLIN PHARMACO, V61, P341, DOI 10.1111/j.1365-2125.2006.02577.x; *KAIS FAM FDN, 2006, PRESCR DRUG TRENDS, P3057; Kamal-Bahl S, 2004, HEALTH AFFAIR, V23, P227, DOI 10.1377/hlthaff.23.1.227; Kotzan JA, 1993, J RES PHARM ECON, V5, P43; Kotzan JA, 1993, J RES PHARM ECON, V5, P25; KOTZAN JA, 1996, J MANAGE CARE PHARM, V2, P651; KOZMA CM, 1990, MED CARE, V28, P963, DOI 10.1097/00005650-199010000-00010; Kozyrskyj AL, 2001, CAN MED ASSOC J, V165, P897; Kozyrskyj AL, 2001, ARCH PEDIAT ADOL MED, V155, P1219; KRELING DH, 1989, MED CARE, V27, P34, DOI 10.1097/00005650-198901000-00004; Landsman PB, 2005, AM J MANAG CARE, V11, P621; LAVERS RJ, 1989, APPL ECON, V21, P1043; LEIBOWITZ A, 1985, SOC SCI MED, V21, P1063, DOI 10.1016/0277-9536(85)90161-3; Li X, 2007, HEALTH POLICY, V82, P340, DOI 10.1016/j.healthpol.2006.11.002; Lichtenberg FR, 2005, AM J MANAG CARE, V11, pSP7; Lichtenberg FR, 2001, HEALTH AFFAIR, V20, P241, DOI 10.1377/hlthaff.20.5.241; LINGLE EW, 1987, INQUIRY-J HEALTH CAR, V24, P203; LINGLE EW, 1990, J RES PHARM EC, V2, P93; Liu SZ, 2004, HEALTH POLICY, V68, P277, DOI 10.1016/j.healthpol.2003.12.013; Liu SZ, 2003, MED CARE, V41, P1331, DOI 10.1097/01.MLR.0000100579.91550.C4; Lurk JT, 2004, AM J HEALTH-SYST PH, V61, P267, DOI 10.1093/ajhp/61.3.267; Mabasa VH, 2006, J MANAGE CARE PHARM, V12, P371, DOI 10.18553/jmcp.2006.12.5.371; Mahoney JJ, 2005, AM J MANAG CARE, V11, pS170; Marshall JK, 2002, CAN MED ASSOC J, V166, P1655; Martin BC, 1996, MED CARE, V34, P686, DOI 10.1097/00005650-199607000-00003; McCombs JS, 2002, CLIN THER, V24, P1939, DOI 10.1016/S0149-2918(02)80090-X; McDonald HP, 2002, JAMA-J AM MED ASSOC, V288, P2868, DOI 10.1001/jama.288.22.2868; McManus P, 1996, Pharmacoepidemiol Drug Saf, V5, P385, DOI 10.1002/(SICI)1099-1557(199611)5:6<385::AID-PDS246>3.0.CO;2-8; McManus P, 2001, PHARMACOEPIDEM DR S, V10, P295, DOI 10.1002/pds.603; Meissner Brian L, 2004, J Manag Care Pharm, V10, P226; MOORE WJ, 1993, J LAW ECON, V36, P71, DOI 10.1086/467265; Motheral B, 2001, MED CARE, V39, P1293, DOI 10.1097/00005650-200112000-00005; Motheral BR, 1999, INQUIRY-J HEALTH CAR, V36, P481; Motheral BR, 2004, AM J MANAG CARE, V10, P457; Motheral BR, 1999, AM J MANAG CARE, V5, P1383; Murawski MM, 2005, AM J MANAG CARE, V11, pSP35; Nair Kavita V, 2003, J Manag Care Pharm, V9, P123; Narine L, 1999, CAN MED ASSOC J, V161, P286; NARINE L, 2001, J RES PHARM EC, V11, P63; OBRIEN B, 1989, J HEALTH ECON, V8, P109, DOI 10.1016/0167-6296(89)90011-8; Ong M, 2003, CLIN THER, V25, P1262, DOI 10.1016/S0149-2918(03)80082-6; PHILLIPS CR, 1997, J MANAGE CARE PHARM, P699; Pilote L, 2002, CAN MED ASSOC J, V167, P246; Rector TS, 2000, JAMA-J AM MED ASSOC, V283, P2163, DOI 10.1001/jama.283.16.2163; Rector TS, 2003, MED CARE, V41, P398, DOI 10.1097/00005650-200303000-00008; REED M, 2005, UPDATE AM ACCESS PRE; REEDER CE, 1985, INQUIRY-J HEALTH CAR, V22, P396; Ridley DB, 2006, PHARMACOECONOMICS, V24, P65, DOI 10.2165/00019053-200624003-00006; Roblin DW, 2005, MED CARE, V43, P951, DOI 10.1097/01.mlr.0000178216.23514.b7; Roughead EE, 2006, MED CARE, V44, P378, DOI 10.1097/01.mlr.0000204056.31664.36; RYAN M, 1991, SOC SCI MED, V33, P681, DOI 10.1016/0277-9536(91)90022-5; Schneeweiss S, 2006, CLIN PHARMACOL THER, V79, P379, DOI 10.1016/j.clpt.2005.12.304; Schneeweiss S, 2004, MED CARE, V42, P653, DOI 10.1097/01.mlr.0000129497.10930.a2; Schneeweiss S, 2004, BRIT MED J, V328, P560, DOI 10.1136/bmj.38020.698194.F6; Schneeweiss S, 2003, CLIN PHARMACOL THER, V74, P388, DOI 10.1016/S0009-9236(03)00227-3; Schneeweiss S, 2002, NEW ENGL J MED, V346, P822, DOI 10.1056/NEJMsa003087; Schneeweiss S, 2002, CAN MED ASSOC J, V166, P737; SMALLEY WE, 1995, NEW ENGL J MED, V332, P1612, DOI 10.1056/NEJM199506153322406; Smith D G, 1992, Pharmacoeconomics, V2, P335, DOI 10.2165/00019053-199202040-00008; SMITH DG, 1993, INQUIRY-J HEALTH CAR, V30, P189; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; SOUMERAI SB, 1994, NEW ENGL J MED, V331, P650, DOI 10.1056/NEJM199409083311006; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; Spence MM, 2006, J MANAG CARE PHARM, V12, P377, DOI 10.18553/jmcp.2006.12.5.377; Streja DA, 1999, AM J MANAG CARE, V5, P1133; Stuart B, 1998, MED CARE, V36, P202, DOI 10.1097/00005650-199802000-00009; Stuart B, 1999, HEALTH AFFAIR, V18, P201, DOI 10.1377/hlthaff.18.2.201; Taira DA, 2006, AM J MANAG CARE, V12, P678; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; Thomas CP, 2001, HLTH AFF MILLWOOD S; Topol EJ, 2004, NEW ENGL J MED, V350, P1562, DOI 10.1056/NEJMe048061; Tseng CW, 2006, AM J MANAG CARE, V12, P525; Tseng CW, 2004, JAMA-J AM MED ASSOC, V292, P952, DOI 10.1001/jama.292.8.952; Tseng CW, 2003, JAMA-J AM MED ASSOC, V290, P222, DOI 10.1001/jama.290.2.222; Virabhak S, 2005, AM J MANAG CARE, V11, pSP14; Wang JL, 2006, MED CARE RES REV, V63, P742, DOI 10.1177/1077558706293638; Wang YR, 2003, AM J MANAG CARE, V9, P686; West DS, 2006, J MANAG CARE PHARM, V12, P25, DOI 10.18553/jmcp.2006.12.1.25; White AC, 1997, CLIN INFECT DIS, V25, P230; Wilson J, 2005, AM J MANAG CARE, V11, pSP27; Winkelmann R, 2004, HEALTH ECON, V13, P1081, DOI 10.1002/hec.868	144	578	583	2	64	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 4	2007	298	1					61	69		10.1001/jama.298.1.61	http://dx.doi.org/10.1001/jama.298.1.61			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	185OU	17609491	Green Accepted			2022-12-28	WOS:000247721100022
J	Norton, C; Thomas, L; Hill, J				Norton, Christine; Thomas, Louise; Hill, Jennifer			NICE guidelines - Management of faecal incontinence in adults: summary of NICE guidance	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE; COMMUNITY		Kings Coll London, Florence Nightingale Sch Nursing & Midwifery, London WC2R 2LS, England; Royal Coll Surgeons England, Natl Collaborating Ctr Acute Care, London WC2A 3PE, England	University of London; King's College London; Royal College of Surgeons of England	Norton, C (corresponding author), Kings Coll London, Florence Nightingale Sch Nursing & Midwifery, London WC2R 2LS, England.	christine.s.norton@kcl.ac.uk	Oliver, Kathryn/I-9905-2019	Oliver, Kathryn/0000-0002-4326-5258				British Geriatrics Society, 2007, CLOS DOORS DEL DIGN; Chelvanayagam S, 2000, Nurs Times, V96, P15; Johanson JF, 1996, AM J GASTROENTEROL, V91, P33; Macmillan AK, 2004, DIS COLON RECTUM, V47, P1341, DOI 10.1007/s10350-004-0593-0; *NAT I HLTH CLIN E, 2005, 27 NICE NAT I HLTH C; *NICE, 2007, FAEC INC MAN FAEC IN; Perry S, 2002, GUT, V50, P480, DOI 10.1136/gut.50.4.480	7	59	59	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 30	2007	334	7608					1370	1371		10.1136/bmj.39231.633275.AD	http://dx.doi.org/10.1136/bmj.39231.633275.AD			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185VX	17600027	Green Published, Green Accepted			2022-12-28	WOS:000247739600036
J	Haas, D; Hoffmann, GF				Haas, Dorothea; Hoffmann, Georg F.			Mevalonate kinase deficiency and autoinflammatory disorders	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SPECTRUM		Univ Hosp Pediat & Adolescent Med, Div Inborn Metab Dis, Dept Gen Pediat, Heidelberg, Germany	Ruprecht Karls University Heidelberg	Haas, D (corresponding author), Univ Hosp Pediat & Adolescent Med, Div Inborn Metab Dis, Dept Gen Pediat, Heidelberg, Germany.							HOFFMAN G, 1986, NEW ENGL J MED, V314, P1610, DOI 10.1056/NEJM198606193142504; Mandey SHL, 2006, HUM MUTAT, V27, P796, DOI 10.1002/humu.20361; Mantha AJ, 2005, CLIN CANCER RES, V11, P2398, DOI 10.1158/1078-0432.CCR-04-1951; MAYATEPEK E, 1994, J INHERIT METAB DIS, V17, P263, DOI 10.1007/BF00711803; Prietsch V, 2003, PEDIATRICS, V111, P258, DOI 10.1542/peds.111.2.258	5	20	21	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 28	2007	356	26					2671	2673		10.1056/NEJMp078083	http://dx.doi.org/10.1056/NEJMp078083			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	183HS	17596600				2022-12-28	WOS:000247564500003
J	Borra, EF; Seddiki, O; Angel, R; Eisenstein, D; Hickson, P; Seddon, KR; Worden, SP				Borra, Ermanno F.; Seddiki, Omar; Angel, Roger; Eisenstein, Daniel; Hickson, Paul; Seddon, Kenneth R.; Worden, Simon P.			Deposition of metal films on an ionic liquid as a basis for a lunar telescope	NATURE			English	Article							MIRROR; NANOPARTICLES; FRAGMENTATION	An optical/infrared telescope of 20 - 100 m aperture located on the Moon would be able to observe objects 100 to 1,000 times fainter than the proposed next generation of space telescopes(1). The infrared region of the spectrum is particularly important for observations of objects at redshifts z > 7. The apparent simplicity and low mass of a liquid mirror telescope, compared with a traditional pointable glass mirror, suggest that the concept should be considered further. A previously proposed liquid mirror telescope, based upon a spinning liquid metallic alloy(2), is not appropriate for infrared applications, which will require a liquid below 130 K. Here we report the successful coating of an ionic liquid with silver. The surface is smooth and the silver coating is stable on a timescale of months. The underlying ionic liquid does not evaporate in a vacuum and remains liquid down to a temperature of 175 K. Given that there are similar to 10(6) simple and similar to 10(18) ternary ionic liquids, it should be possible to synthesize liquids with even lower melting temperatures.	Univ Laval, Ctr Opt Photon & Laser, Dept Phys Genie Phys & Opt, Quebec City, PQ G1K 7P4, Canada; Univ Arizona, Steward Observ, Tucson, AZ USA; Univ British Columbia, Dept Phys & Astron, Vancouver, BC V6T 1Z1, Canada; Queens Univ Belfast, QUILL Ctr, Belfast BT9 5AG, Antrim, North Ireland; NASA, Ames Res Ctr, Off Director, Moffett Field, CA 94035 USA	Laval University; University of Arizona; University of British Columbia; Queens University Belfast; National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Borra, EF (corresponding author), Univ Laval, Ctr Opt Photon & Laser, Dept Phys Genie Phys & Opt, Quebec City, PQ G1K 7P4, Canada.	borra@phy.ulaval.ca			Engineering and Physical Sciences Research Council [EP/D029538/1] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Abel T, 2000, ASTROPHYS J, V540, P39, DOI 10.1086/309295; Barkana R, 2001, PHYS REP, V349, P126, DOI 10.1016/s0370-1573(01)00019-9; BORRA EF, 1991, ASTROPHYS J, V373, P317, DOI 10.1086/170053; Borra EF, 2004, ASTRON ASTROPHYS, V419, P777, DOI 10.1051/0004-6361:20034474; Bromm V, 1999, ASTROPHYS J, V527, pL5, DOI 10.1086/312385; Cabanac RA, 1998, ASTROPHYS J, V509, P309, DOI 10.1086/306488; Deetlefs M, 2006, CHIM OGGI, V24, P16; Earle MJ, 2006, NATURE, V439, P831, DOI 10.1038/nature04451; Fonseca GS, 2006, J COLLOID INTERF SCI, V301, P193, DOI 10.1016/j.jcis.2006.04.073; Gardner JP, 2006, SPACE SCI REV, V123, P485, DOI 10.1007/s11214-006-8315-7; Giavalisco M, 2002, ANNU REV ASTRON ASTR, V40, P579, DOI 10.1146/annurev.astro.40.121301.111837; Gingras J, 2006, COLLOID SURFACE A, V279, P79, DOI 10.1016/j.colsurfa.2005.12.043; Girard L, 1997, APPL OPTICS, V36, P6278, DOI 10.1364/AO.36.006278; Hickson P, 1998, ASTROPHYS J SUPPL S, V115, P35, DOI 10.1086/313080; Hickson P, 2003, P SOC PHOTO-OPT INS, V4840, P273, DOI 10.1117/12.459075; HICKSON P, 2004, P SOC PHOTO-OPT INS, V532, P115; Hickson P, 2007, PUBL ASTRON SOC PAC, V119, P456, DOI 10.1086/517619; Hickson P, 2007, PUBL ASTRON SOC PAC, V119, P444, DOI 10.1086/517621; Hickson P, 2006, APPL OPTICS, V45, P8052, DOI 10.1364/AO.45.008052; Holbrey JD, 2002, GREEN CHEM, V4, P407, DOI 10.1039/b204469b; Itoh H, 2004, J AM CHEM SOC, V126, P3026, DOI 10.1021/ja039895g; MacFarlane DR, 2007, AUST J CHEM, V60, P3, DOI 10.1071/CH06478; Ninane NM, 1996, APPL OPTICS, V35, P6131, DOI 10.1364/AO.35.006131; Seddon K. R, 1999, INT G PAP S P, P131; STARK A, 2007, KIRK OTHMER ENCY CHE, V26, P836, DOI DOI 10.1002/0471238961.IONISEDD.A01; Warren SC, 2006, J AM CHEM SOC, V128, P12074, DOI 10.1021/ja064469r; Wasserscheid P., 2003, IONIC LIQUIDS SYNTHE, DOI 10.1002/3527600701	27	186	197	3	122	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 21	2007	447	7147					979	981		10.1038/nature05909	http://dx.doi.org/10.1038/nature05909			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180NU	17581579				2022-12-28	WOS:000247373100041
J	Williams, JR; DiCarlo, L; Marcus, CM				Williams, J. R.; DiCarlo, L.; Marcus, C. M.			Quantum hall effect in a gate-controlled p-n junction of graphene	SCIENCE			English	Article							PHASE; GAS	The unique band structure of graphene allows reconfigurable electric-field control of carrier type and density, making graphene an ideal candidate for bipolar nanoelectronics. We report the realization of a single-layer graphene p-n junction in which carrier type and density in two adjacent regions are locally controlled by electrostatic gating. Transport measurements in the quantum Hall regime reveal new plateaus of two-terminal conductance across the junction at 1 and 3/2 times the quantum of conductance, e(2)/h, consistent with recent theory. Beyond enabling investigations in condensed-matter physics, the demonstrated local-gating technique sets the foundation for a future graphene-based bipolar technology.	Harvard Univ, Dept Phys, Cambridge, MA 02138 USA; Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA	Harvard University; Harvard University	Marcus, CM (corresponding author), Harvard Univ, Dept Phys, Cambridge, MA 02138 USA.	marcus@harvard.edu	DiCarlo, Leonardo/F-8714-2010; Marcus, Charles M./M-4526-2014	Marcus, Charles M./0000-0003-2420-4692; Williams, James/0000-0002-5196-2440				Abanin DA, 2007, SCIENCE, V317, P641, DOI 10.1126/science.1144672; Abanin DA, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.176803; Berger C, 2006, SCIENCE, V312, P1191, DOI 10.1126/science.1125925; Cheianov VV, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.041403; Cheianov VV, 2007, SCIENCE, V315, P1252, DOI 10.1126/science.1138020; Farmer DB, 2006, NANO LETT, V6, P699, DOI 10.1021/nl052453d; Geim AK, 2007, NAT MATER, V6, P183, DOI 10.1038/nmat1849; Gusynin VP, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.146801; HAUG RJ, 1988, PHYS REV LETT, V61, P2797, DOI 10.1103/PhysRevLett.61.2797; Heersche HB, 2007, NATURE, V446, P56, DOI 10.1038/nature05555; Huard B, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.236803; Hwang EH, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.186806; Katsnelson MI, 2006, NAT PHYS, V2, P620, DOI 10.1038/nphys384; Lemme MC, 2007, IEEE ELECTR DEVICE L, V28, P282, DOI 10.1109/LED.2007.891668; Novoselov KS, 2005, NATURE, V438, P197, DOI 10.1038/nature04233; Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896; Peres NMR, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.125411; Rycerz A, 2007, NAT PHYS, V3, P172, DOI 10.1038/nphys547; Smith DR, 2004, SCIENCE, V305, P788, DOI 10.1126/science.1096796; SYPHERS DA, 1985, PHYS REV B, V32, P6620, DOI 10.1103/PhysRevB.32.6620; WASHBURN S, 1988, PHYS REV LETT, V61, P2801, DOI 10.1103/PhysRevLett.61.2801; Zhang YB, 2005, NATURE, V438, P201, DOI 10.1038/nature04235	22	873	921	6	364	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 3	2007	317	5838					638	641		10.1126/science.1144657	http://dx.doi.org/10.1126/science.1144657			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	196PL	17600183				2022-12-28	WOS:000248494400038
J	Moglia, A; Menciassi, A; Dario, P; Cuschieri, A				Moglia, Andrea; Menciassi, Arianna; Dario, Paolo; Cuschieri, Alfted			Clinical update: endoscopy for small-bowel turnours	LANCET			English	Article							DOUBLE-BALLOON ENTEROSCOPY; WIRELESS CAPSULE ENDOSCOPY; INTRAOPERATIVE ENTEROSCOPY; TUMORS; LIMITATIONS; EXPERIENCE; DIAGNOSIS; YIELD		Scuola Super Sant Anna, I-56127 Pisa, Italy; Italian Inst Technol Network, Genoa, Italy	Scuola Superiore Sant'Anna; Istituto Italiano di Tecnologia - IIT	Moglia, A (corresponding author), Scuola Super Sant Anna, I-56127 Pisa, Italy.	andrea.moglia@crim.sssup.it	Moglia, Andrea/Y-5433-2018; Cuschieri, Alfred/A-7634-2013; Cuschieri, Alfred/O-4092-2019; Menciassi, Arianna/A-2664-2010	Moglia, Andrea/0000-0002-3365-580X; Cuschieri, Alfred/0000-0003-0764-5947; 				Bailey AA, 2006, AM J GASTROENTEROL, V101, P2237, DOI 10.1111/j.1572-0241.2006.00749.x; Chong AKH, 2006, GASTROINTEST ENDOSC, V64, P445, DOI 10.1016/j.gie.2006.04.007; Cobrin GM, 2006, CANCER-AM CANCER SOC, V107, P22, DOI 10.1002/cncr.21975; De Leusse A, 2007, GASTROENTEROLOGY, V132, P855, DOI 10.1053/j.gastro.2006.12.002; Flieger D, 2005, ENDOSCOPY, V37, P1174, DOI 10.1055/s-2005-921045; Hadithi M, 2006, AM J GASTROENTEROL, V101, P52, DOI 10.1111/j.1572-0241.2005.00346.x; Hartmann D, 2005, GASTROINTEST ENDOSC, V61, P826, DOI 10.1016/S0016-5107(05)00372-X; Hatzaras I, 2007, ARCH SURG-CHICAGO, V142, P229, DOI 10.1001/archsurg.142.3.229; HERBERT J, 2005, CANC PRINCIPLES PRAC, P1035; Hsu CM, 2007, DIGEST DIS SCI, V52, P162, DOI 10.1007/s10620-006-9554-x; Jakobs R, 2006, WORLD J GASTROENTERO, V12, P313, DOI 10.3748/wjg.v12.i2.313; Lepage C, 2006, AM J GASTROENTEROL, V101, P2826, DOI 10.1111/j.1572-0241.2006.00854.x; Matsumoto T, 2005, ENDOSCOPY, V37, P827, DOI 10.1055/s-2005-870207; May A, 2007, AM J GASTROENTEROL, V102, P527, DOI 10.1111/j.1572-0241.2007.01063.x; Mehdizadeh S, 2006, GASTROINTEST ENDOSC, V64, P740, DOI 10.1016/j.gie.2006.05.022; Moglia A, 2007, BIOMED MICRODEVICES, V9, P235, DOI 10.1007/s10544-006-9025-3; Rondonotti E, 2005, GASTROINTEST ENDOSC, V62, P712, DOI 10.1016/j.gie.2005.05.002; Suzuki T, 2007, DIGEST DIS SCI, V52, P1914, DOI 10.1007/s10620-007-9749-9; Triester SL, 2005, AM J GASTROENTEROL, V100, P2407, DOI 10.1111/j.1572-0241.2005.00274.x; Yamamoto H, 2004, CLIN GASTROENTEROL H, V2, P1010, DOI 10.1016/S1542-3565(04)00453-7	20	21	22	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 14	2007	370	9582					114	116		10.1016/S0140-6736(07)61066-6	http://dx.doi.org/10.1016/S0140-6736(07)61066-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	190WP	17630023				2022-12-28	WOS:000248091600009
J	Watrin, E; Peters, JM				Watrin, Erwan; Peters, Jan-Michael			Molecular biology - How and when the genome sticks together	SCIENCE			English	Editorial Material							DNA-REPLICATION; SISTER CHROMATIDS; COHESION; REPAIR		Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Watrin, E (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	peters@imp.univie.ac.at		watrin, erwan/0000-0002-4582-6493				Brands A, 2005, CURR BIOL, V15, pR50, DOI 10.1016/j.cub.2004.12.052; Haering CH, 2004, MOL CELL, V15, P951, DOI 10.1016/j.molcel.2004.08.030; Ivanov D, 2002, CURR BIOL, V12, P323, DOI 10.1016/S0960-9822(02)00681-4; Nasmyth K, 2005, ANNU REV BIOCHEM, V74, P595, DOI 10.1146/annurev.biochem.74.082803.133219; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; Strom L, 2007, SCIENCE, V317, P242, DOI 10.1126/science.1140649; Strom L, 2004, MOL CELL, V16, P1003, DOI 10.1016/j.molcel.2004.11.026; Strom L, 2005, CELL CYCLE, V4, P536, DOI 10.4161/cc.4.4.1613; Unal E, 2007, SCIENCE, V317, P245, DOI 10.1126/science.1140637; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; Unal E, 2004, MOL CELL, V16, P991, DOI 10.1016/j.molcel.2004.11.027; Watrin E, 2006, EXP CELL RES, V312, P2687, DOI 10.1016/j.yexcr.2006.06.024	13	5	6	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 13	2007	317	5835					209	210		10.1126/science.1146072	http://dx.doi.org/10.1126/science.1146072			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189DC	17626874				2022-12-28	WOS:000247968600029
J	Imrie, J; Elford, J; Kippax, S; Hart, GJ				Imrie, John; Elford, Jonathan; Kippax, Susan; Hart, Graham J.			Biomedical HIV prevention - and social science	LANCET			English	Editorial Material							SEXUAL RISK BEHAVIOR; MEN		Univ New S Wales, Natl Ctr HIV Social Res, Sydney, NSW, Australia; City Univ London, Inst Hlth Sci, London EC1V 0HB, England; UCL, Ctr Sexual Hlth & HIV Res, London, England	University of New South Wales Sydney; City University London; University of London; University College London	Imrie, J (corresponding author), Univ New S Wales, Natl Ctr HIV Social Res, Sydney, NSW, Australia.	j.imrie@unsw.edu.au		Hart, Graham/0000-0001-9676-6577				Aral SO, 1998, LANCET, V351, P33; AYODO H, 2007, E AFRICAN STAND 0331; Bailey RC, 2007, LANCET, V369, P643, DOI 10.1016/S0140-6736(07)60312-2; BANSA E, 2007, E AFRICAN STAND 0228; Cassell MM, 2006, BMJ-BRIT MED J, V332, P605, DOI 10.1136/bmj.332.7541.605; Crepaz N, 2004, JAMA-J AM MED ASSOC, V292, P224, DOI 10.1001/jama.292.2.224; Foss AM, 2003, AIDS, V17, P1227, DOI 10.1097/00002030-200305230-00015; *GLOB CAMP MICR, CELL SULF TRIALS CLO; Gray RH, 2007, LANCET, V369, P657, DOI 10.1016/S0140-6736(07)60313-4; PETERSON L, 2007, PLOS CLIN TRIALS MAY; Truong HHM, 2006, SEX TRANSM INFECT, V82, P461, DOI 10.1136/sti.2006.019950; UNAIDS & WHO, 2007, WHO UNAIDS ANN REC E	12	31	31	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 7	2007	370	9581					10	11		10.1016/S0140-6736(07)61026-5	http://dx.doi.org/10.1016/S0140-6736(07)61026-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	187QE	17617254				2022-12-28	WOS:000247862300008
J	Kowalski, MP; Dubouix-Bourandy, A; Bajmoczi, M; Golan, DE; Zaidi, T; Coutinho-Sledge, YS; Gygi, MP; Gygi, SP; Wiemer, EAC; Pier, GB				Kowalski, Michael P.; Dubouix-Bourandy, Anne; Bajmoczi, Milan; Golan, David E.; Zaidi, Tanweer; Coutinho-Sledge, Yamara S.; Gygi, Melanie P.; Gygi, Steven P.; Wiemer, Erik A. C.; Pier, Gerald B.			Host resistance to lung infection mediated by major vault protein in epithelial cells	SCIENCE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; PSEUDOMONAS-AERUGINOSA INFECTION; CYSTIC-FIBROSIS PATIENTS; DRUG-RESISTANCE; MUTANT CFTR; DEFENSE; DISEASE; LOCALIZATION; PHOSPHATASE; CLEARANCE	The airway epithelium plays an essential role in innate immunity to lung pathogens. Ribonucleoprotein particles primarily composed of major vault protein (MVP) are highly expressed in cells that encounter xenobiotics. However, a clear biologic function for MVP is not established. We report here that MVP is rapidly recruited to lipid rafts when human lung epithelial cells are infected with Pseudomonas aeruginosa, and maximal recruitment is dependent on bacterial binding to the cystic fibrosis transmembrane conductance regulator. MVP was also essential for optimal epithelial cell internalization and clearance of P. aeruginosa. These results suggest that MVP makes a substantial contribution to epithelial cell-mediated resistance to infection.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA; Novartis Inst Biomed Res, Cambridge, MA 02139 USA; Inst Federatif Biol Purpan, Lab Bacteriol Hyg, Toulouse, France; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Hematol, Boston, MA 02115 USA; Erasmus MC, Josephine Nefkens Inst, Dept Med Oncol, NL-3015 GE Rotterdam, Netherlands	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Novartis; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Erasmus University Rotterdam; Erasmus MC	Pier, GB (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA.	gpier@channing.harvard.edu	Pier, Gerald/AAO-2692-2021	Pier, Gerald/0000-0002-9112-2331; Wiemer, Erik/0000-0002-0673-7236	NHLBI NIH HHS [R01 HL058398, R37 HL032854, R01 HL 58398-08, R37 HL 32854-22] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058398, R37HL032854] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Boucher RC, 2004, EUR RESPIR J, V23, P146, DOI 10.1183/09031936.03.00057003; Cannon CL, 2003, AM J RESP CELL MOL, V29, P188, DOI 10.1165/rcmb.4898; Chung JH, 2005, CANCER RES, V65, P4108, DOI 10.1158/0008-5472.CAN-05-0124; Cortes G, 2002, INFECT IMMUN, V70, P1075, DOI 10.1128/IAI.70.3.1075-1080.2002; Drumm ML, 2005, NEW ENGL J MED, V353, P1443, DOI 10.1056/NEJMoa051469; Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823; Grassme H, 2000, SCIENCE, V290, P527, DOI 10.1126/science.290.5491.527; Herrmann C, 1999, J CELL BIOL, V144, P1163, DOI 10.1083/jcb.144.6.1163; Kerem B, 1996, EUR J HUM GENET, V4, P65; Kickhoefer VA, 1998, J BIOL CHEM, V273, P8971, DOI 10.1074/jbc.273.15.8971; Kolli S, 2004, J BIOL CHEM, V279, P29374, DOI 10.1074/jbc.M313955200; Kowalski MP, 2004, J IMMUNOL, V172, P418, DOI 10.4049/jimmunol.172.1.418; Mossink MH, 2003, ONCOGENE, V22, P7458, DOI 10.1038/sj.onc.1206947; Mossink MH, 2003, IMMUNOLOGY, V110, P58, DOI 10.1046/j.1365-2567.2003.01708.x; Mossink MH, 2002, CANCER RES, V62, P7298; Mulvey MA, 1998, SCIENCE, V282, P1494, DOI 10.1126/science.282.5393.1494; Pier GB, 1996, AM J RESP CRIT CARE, V154, pS175, DOI 10.1164/ajrccm/154.4_Pt_2.S175; Pier GB, 1997, P NATL ACAD SCI USA, V94, P12088, DOI 10.1073/pnas.94.22.12088; Pier GB, 1996, SCIENCE, V271, P64, DOI 10.1126/science.271.5245.64; Reiniger N, 2005, INFECT IMMUN, V73, P6822, DOI 10.1128/IAI.73.10.6822-6830.2005; SCHEFFER GL, 1995, NAT MED, V1, P578, DOI 10.1038/nm0695-578; Schrager HM, 1998, J CLIN INVEST, V101, P1708, DOI 10.1172/JCI2121; Schroeder TH, 2002, P NATL ACAD SCI USA, V99, P6907, DOI 10.1073/pnas.092160899; Schroeder TH, 2001, J IMMUNOL, V166, P7410, DOI 10.4049/jimmunol.166.12.7410; Steiner E, 2006, J CELL SCI, V119, P459, DOI 10.1242/jcs.02773; STGEME JW, 1992, J INFECT DIS, V165, pS117, DOI 10.1093/infdis/165-Supplement_1-S117; Worlitzsch D, 2002, J CLIN INVEST, V109, P317, DOI 10.1172/JCI0213870; Xiang ZM, 2006, BIOCHEM BIOPH RES CO, V347, P288, DOI 10.1016/j.bbrc.2006.06.076; Yi CL, 2005, CANCER RES, V65, P5835, DOI 10.1158/0008-5472.CAN-05-0423; Yu ZB, 2002, J BIOL CHEM, V277, P40247, DOI 10.1074/jbc.M207608200	30	93	96	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2007	317	5834					130	132		10.1126/science.1142311	http://dx.doi.org/10.1126/science.1142311			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186KD	17615361	Green Accepted			2022-12-28	WOS:000247776700069
J	Perkins, HS				Perkins, Henry S.			Controlling death: The false promise of advance directives	ANNALS OF INTERNAL MEDICINE			English	Article							OF-LIFE CARE; SELF-DETERMINATION ACT; DECISION-MAKING; HEALTH-CARE; PHYSICIAN ORDERS; END; COMPLETION; DISCUSSIONS; FACILITIES; ETHNICITY	Advance directives promise patients a say in their future care but actually have had little effect. Many experts blame problems with completion and implementation, but the advance directive concept itself may be fundamentally flawed. Advance directives simply presuppose more control over future care than is realistic. Medical crises cannot be predicted in detail, making most prior instructions difficult to adapt, irrelevant, or even misleading. Furthermore, many proxies either do not know patients' wishes or do not pursue those wishes effectively. Thus, unexpected problems arise often to defeat advance directives, as the case in this paper illustrates. Because advance directives offer only limited benefit, advance care planning should emphasize not the completion of directives but the emotional preparation of patients and families for future crises. The existentialist Albert Camus might suggest that physicians should warn patients and families that momentous, unforeseeable decisions lie ahead. Then, when the crisis hits, physicians should provide guidance; should help make decisions despite the inevitable uncertainties; should share responsibility for those decisions; and, above all, should courageously see patients and families through the fearsome experience of dying.	Univ Texas, Hlth Sci Ctr, Dept Med, Div Gen Med, San Antonio, TX 78229 USA; Ecumenical Ctr Relig & Hlth, San Antonio, TX USA	University of Texas System; University of Texas Health San Antonio	Perkins, HS (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Gen Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.							Annas GJ, 2005, NEW ENGL J MED, V352, P1710, DOI 10.1056/NEJMlim050643; Balaban RB, 2000, J GEN INTERN MED, V15, P195, DOI 10.1046/j.1525-1497.2000.07228.x; BECK RN, 1969, PERSPECTIVES PHILOS, P437; Bloche MG, 2005, NEW ENGL J MED, V352, P2371, DOI 10.1056/NEJMp058104; Bradley EH, 2001, AM J MED, V111, P218, DOI 10.1016/S0002-9343(01)00798-7; BRETT AS, 1991, JAMA-J AM MED ASSOC, V266, P825, DOI 10.1001/jama.266.6.825; BURT RA, 2005, HASTINGS CENT REP; CALLAHAN D, 2005, HASTINGS CENT REP; CAMUS A, 1972, PLAGUE, P286; CUGLIARI AM, 1995, ARCH INTERN MED, V155, P1893, DOI 10.1001/archinte.155.17.1893; Dresser R, 2005, HASTINGS CENT REP, V35, P20, DOI 10.1353/hcr.2005.0061; DUBLER NN, 2005, HASTINGS CENT REP; Eleazer GP, 1996, J AM GERIATR SOC, V44, P938, DOI 10.1111/j.1532-5415.1996.tb01864.x; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; Fagerlin A, 2004, HASTINGS CENT REP, V34, P30, DOI 10.2307/3527683; Fischer GS, 1998, J GEN INTERN MED, V13, P447, DOI 10.1046/j.1525-1497.1998.00133.x; FOLEY KM, 2005, HASTING CENT REP; Galambos CM, 1998, HEALTH SOC WORK, V23, P275, DOI 10.1093/hsw/23.4.275; Gordon NP, 1999, ARCH INTERN MED, V159, P701, DOI 10.1001/archinte.159.7.701; Gostin LO, 2005, JAMA-J AM MED ASSOC, V293, P2403, DOI 10.1001/jama.293.19.2403; Hammes BJ, 1998, ARCH INTERN MED, V158, P383, DOI 10.1001/archinte.158.4.383; Hanson LC, 1996, ARCH INTERN MED, V156, P1018, DOI 10.1001/archinte.156.9.1018; Hickman SE, 2004, J AM GERIATR SOC, V52, P1424, DOI 10.1111/j.1532-5415.2004.52402.x; HICKMAN SE, 2005, HASTING CENT REP; Hoffmann DE, 1996, J LAW MED ETHICS, V24, P5, DOI 10.1111/j.1748-720X.1996.tb01829.x; JENNINGS B, 2005, HASTINGS CENT REP; Kahana B, 2004, J AM GERIATR SOC, V52, P1163, DOI 10.1111/j.1532-5415.2004.52316.x; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KOENIG B, 2006, BIOETHICS EXAMINER, V9, P4; KOENIG B, 2006, BIOETHICS EXAMINER, V9, P1; Lee MA, 2000, J AM GERIATR SOC, V48, P1219, DOI 10.1111/j.1532-5415.2000.tb02594.x; LEVINE C, 2005, NY TIMES        1206, pD5; Lo B, 2004, ARCH INTERN MED, V164, P1501, DOI 10.1001/archinte.164.14.1501; LYNN J, 1993, HASTINGS CENT REP, V23, P20, DOI 10.2307/3562275; MacIntyre A., 1967, ENCYCL PHILOS, V3, P147; Molloy DW, 2000, JAMA-J AM MED ASSOC, V283, P1437, DOI 10.1001/jama.283.11.1437; Morrison RS, 2004, ARCH INTERN MED, V164, P2421, DOI 10.1001/archinte.164.22.2421; Morrison RS, 1998, J CLIN ETHIC, V9, P118; Murphy ST, 1996, J LAW MED ETHICS, V24, P108, DOI 10.1111/j.1748-720X.1996.tb01843.x; MURRAY TH, 2005, HASTINGS CENT REP; Palker N B, 1995, Nurse Pract, V20, P7; PALKER NB, 1995, NURSE PRACTITIONER, V20, P17; PALKER NB, 1995, NURSE PRACTITIONER, V20, P13; Patel RV, 2004, J CRIT CARE, V19, P1, DOI 10.1016/j.jcrc.2004.02.002; Pearlman RA, 2005, ARCH INTERN MED, V165, P667, DOI 10.1001/archinte.165.6.667; PEARLMAN RA, 2002, YOUR LIFE YOUR CHOIC; Perkins HS, 2002, J GEN INTERN MED, V17, P48, DOI 10.1046/j.1525-1497.2002.01032.x; Perkins HS, 2004, AM J MED SCI, V327, P25, DOI 10.1097/00000441-200401000-00006; PERKINS HS, 2008, IN PRESS; REILLY BM, 1995, ARCH INTERN MED, V155, P2317, DOI 10.1001/archinte.155.21.2317; Rosenfeld KE, 2000, J GEN INTERN MED, V15, P620, DOI 10.1046/j.1525-1497.2000.06289.x; RUBIN SM, 1994, JAMA-J AM MED ASSOC, V271, P209, DOI 10.1001/jama.271.3.209; Schwartz CE, 2002, ARCH INTERN MED, V162, P1611, DOI 10.1001/archinte.162.14.1611; Singer PA, 1997, J GEN INTERN MED, V12, P729, DOI 10.1046/j.1525-1497.1997.07157.x; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; SINGER PA, 1992, ARCH INTERN MED, V152, P22, DOI 10.1001/archinte.152.1.22; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; SUGARMAN J, 1992, ARCH INTERN MED, V152, P343, DOI 10.1001/archinte.152.2.343; Sulmasy DP, 1996, J GEN INTERN MED, V11, P657, DOI 10.1007/BF02600156; Teno JM, 1998, J GEN INTERN MED, V13, P439, DOI 10.1046/j.1525-1497.1998.00132.x; Thorevska N, 2005, J CRIT CARE, V20, P26, DOI 10.1016/j.jcrc.2004.11.002; Tierney WM, 2001, J GEN INTERN MED, V16, P32, DOI 10.1111/j.1525-1497.2001.00215.x; Tulsky JA, 2005, JAMA-J AM MED ASSOC, V294, P359, DOI 10.1001/jama.294.3.359; Volicer L, 2002, J AM GERIATR SOC, V50, P761, DOI 10.1046/j.1532-5415.2002.50175.x; Wolfson J, 2005, HASTINGS CENT REP, V35, P16, DOI 10.2307/3528798; 1978, LIVING WILL; MED ORDERS LIFE SUST	69	252	254	1	24	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2007	147	1					51	57		10.7326/0003-4819-147-1-200707030-00008	http://dx.doi.org/10.7326/0003-4819-147-1-200707030-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	186MN	17606961				2022-12-28	WOS:000247782900007
J	Dammann, O; O'Shea, TM				Dammann, Olaf; O'Shea, T. Michael			Happiness reconsidered in children with cerebral palsy	LANCET			English	Editorial Material							QUALITY-OF-LIFE		Tufts Univ New England Med Ctr, Dept Pediat, Boston, MA 02111 USA; Hannover Med Sch, Dept Pediat, Perinatal ID Epidemiol Unit, D-3000 Hannover, Germany; Hannover Med Sch, Dept Gynecol, D-3000 Hannover, Germany; Childrens Hosp, Neuroepidemiol Unit, Boston, MA 02115 USA; Wake Forest Univ, Sch Med, Dept Pediat, Winston Salem, NC 27109 USA	Tufts Medical Center; Hannover Medical School; Hannover Medical School; Harvard University; Boston Children's Hospital; Wake Forest University	Dammann, O (corresponding author), Tufts Univ New England Med Ctr, Dept Pediat, Boston, MA 02111 USA.	odammann@tufts-nemc.org						Dickinson HO, 2007, LANCET, V369, P2171, DOI 10.1016/S0140-6736(07)61013-7; Eiser C, 2007, ARCH DIS CHILD, V92, P348, DOI 10.1136/adc.2005.086405; Garratt AN, 2002, BMJ-BRIT MED J, V324, P1417, DOI 10.1136/bmj.324.7351.1417; Hack M, 1999, Pediatrics, V103, P319; Livingston MH, 2007, DEV MED CHILD NEUROL, V49, P225, DOI 10.1111/j.1469-8749.2007.00225.x; WOLKE D, 1994, EUR J PEDIATR, V153, P906, DOI 10.1007/s004310050239	7	2	2	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 30	2007	369	9580					2137	2138		10.1016/S0140-6736(07)60989-1	http://dx.doi.org/10.1016/S0140-6736(07)60989-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	184LX	17604780				2022-12-28	WOS:000247644200005
J	Boyd, R; Mathew, S				Boyd, Robert; Mathew, Sarah			Behavior - A narrow road to cooperation	SCIENCE			English	Editorial Material							HIWI		Univ Calif Los Angeles, Dept Anthropol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Boyd, R (corresponding author), Univ Calif Los Angeles, Dept Anthropol, Los Angeles, CA 90095 USA.	rboyd@anthro.ucla.edu						Alvard MS, 2003, HUM NATURE-INT BIOS, V14, P129, DOI 10.1007/s12110-003-1001-5; Alvard MS, 2002, CURR ANTHROPOL, V43, P533, DOI 10.1086/341653; Boyd R, 2003, P NATL ACAD SCI USA, V100, P3531, DOI 10.1073/pnas.0630443100; Fehr E, 2002, NATURE, V415, P137, DOI 10.1038/415137a; Gurerk O, 2006, SCIENCE, V312, P108, DOI 10.1126/science.1123633; Gurven M, 2004, BEHAV ECOL SOCIOBIOL, V56, P366, DOI 10.1007/s00265-004-0793-6; Gurven M, 2000, HUM ECOL, V28, P171, DOI 10.1023/A:1007067919982; Hauert C, 2002, SCIENCE, V296, P1129, DOI 10.1126/science.1070582; Hauert C, 2007, SCIENCE, V316, P1905, DOI 10.1126/science.1141588; Hawkes K, 2001, EVOL HUM BEHAV, V22, P113, DOI 10.1016/S1090-5138(00)00066-0; Henrich J, 2004, J ECON BEHAV ORGAN, V53, P3, DOI 10.1016/S0167-2681(03)00094-5; Henrich J, 2001, J THEOR BIOL, V208, P79, DOI 10.1006/jtbi.2000.2202; Marlowe FW, 2004, RES ECON ANTHROPOL, V23, P69, DOI 10.1016/S0190-1281(04)23003-7; McCabe J. Terrence, 2004, CATTLE BRING US OUR; Milinski M, 2002, NATURE, V415, P424, DOI 10.1038/415424a; Panchanathan K, 2004, NATURE, V432, P499, DOI 10.1038/nature02978	16	49	50	2	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 29	2007	316	5833					1858	1859		10.1126/science.1144339	http://dx.doi.org/10.1126/science.1144339			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	183WI	17600207				2022-12-28	WOS:000247602700027
J	Cunningham, MJ; Lin, DT; Curry, WT; Ebb, DH; Yock, TI; Curtin, HD; Faquin, WC				Cunningham, Michael J.; Lin, Derrick T.; Curry, William T., Jr.; Ebb, David H.; Yock, Torunn I.; Curtin, Hugh D.; Faquin, William C.			A boy with a calcified mass in the nose - Olfactory neuroblastoma, grade 1 of 4, with extensive calcification and invasion of bone.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SINONASAL TRACT; ESTHESIONEUROBLASTOMA; TUMORS; RESECTION; NASAL; RADIOTHERAPY; IRRADIATION; METASTASES; EXPERIENCE; SURGERY		Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA; Massachusetts Eye & Ear Infirm, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Radiat Oncol, Boston, MA USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA	Harvard University; Massachusetts Eye & Ear Infirmary; Harvard University; Massachusetts Eye & Ear Infirmary; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Cunningham, MJ (corresponding author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA.							Barnes L, 2005, WHO CLASSIFICATION T, V9; BEITLER JJ, 1991, HEAD NECK-J SCI SPEC, V13, P321, DOI 10.1002/hed.2880130409; Berger L, 1924, B ASS FRANC CANCER, V13, P410; Bockmuhl U, 2004, BRAIN PATHOL, V14, P158, DOI 10.1111/j.1750-3639.2004.tb00048.x; Broich G, 1997, ANTICANCER RES, V17, P2683; Casiano RR, 2001, AM J RHINOL, V15, P271, DOI 10.1177/194589240101500410; Chacko G, 1998, BRIT J NEUROSURG, V12, P264, DOI 10.1080/02688699845113; COTTON RT, 1995, NEW ENGL J MED, V332, P1285, DOI 10.1056/NEJM199505113321908; Devaiah AK, 2003, LARYNGOSCOPE, V113, P2086, DOI 10.1097/00005537-200312000-00005; Dias FL, 2003, ARCH OTOLARYNGOL, V129, P1186, DOI 10.1001/archotol.129.11.1186; Diaz EM, 2005, HEAD NECK-J SCI SPEC, V27, P138, DOI 10.1002/hed.20127; Dulguerov P, 2001, LANCET ONCOL, V2, P683, DOI 10.1016/S1470-2045(01)00558-7; Fitzek MM, 2002, CANCER-AM CANCER SOC, V94, P2623, DOI 10.1002/cncr.10537; Gruber GN, 2002, INT J RADIAT ONCOL, V54, P486, DOI 10.1016/S0360-3016(02)02941-3; Hyams VJ, 1988, ARMED FORCES I PATHO; KADISH S, 1976, CANCER, V37, P1571, DOI 10.1002/1097-0142(197603)37:3<1571::AID-CNCR2820370347>3.0.CO;2-L; KETCHAM AS, 1973, AM J SURG, V126, P469, DOI 10.1016/S0002-9610(73)80032-7; Knott PD, 2003, LARYNGOSCOPE, V113, P783, DOI 10.1097/00005537-200305000-00004; Kumar S, 1999, HUM PATHOL, V30, P1356, DOI 10.1016/S0046-8177(99)90068-0; Loy AH, 2006, ARCH OTOLARYNGOL, V132, P134, DOI 10.1001/archotol.132.2.134; MASHBERG A, 1960, Oral Surg Oral Med Oral Pathol, V13, P908, DOI 10.1016/0030-4220(60)90032-3; MCCORMACK LJ, 1955, JAMA-J AM MED ASSOC, V157, P318, DOI 10.1001/jama.1955.02950210014004; Mezzelani A, 1999, BRIT J CANCER, V81, P586, DOI 10.1038/sj.bjc.6690734; Monroe AT, 2003, HEAD NECK-J SCI SPEC, V25, P529, DOI 10.1002/hed.10247; Riaziamand SH, 2002, CANCER GENET CYTOGEN, V136, P53, DOI 10.1016/S0165-4608(01)00659-8; Rinaldo A, 2002, ACTA OTO-LARYNGOL, V122, P215, DOI 10.1080/00016480252814261; SCHALL LA, 1951, ANN OTO RHINOL LARYN, V60, P221, DOI 10.1177/000348945106000118; Theilgaard SA, 2003, ACTA OTO-LARYNGOL, V123, P433, DOI 10.1080/00016480310001295; Walton DS, 2006, NEW ENGL J MED, V354, P741, DOI 10.1056/NEJMcpc059041; Yock T, 2004, NEW ENGL J MED, V350, P494, DOI 10.1056/NEJMcpc030036; Yock TI, 2004, NAT CLIN PRACT ONCOL, V1, P97, DOI 10.1038/ncponc0090	31	5	5	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 28	2007	356	26					2721	2730		10.1056/NEJMcpc079014	http://dx.doi.org/10.1056/NEJMcpc079014			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	183HS	17596608				2022-12-28	WOS:000247564500013
J	Vergo, MT; Davis, BT; Harris, NL; Pasternack, MS				Vergo, Maxwell T.; Davis, Benjamin T.; Harris, Nancy Lee; Pasternack, Mark S.			Case 19-2007: A 19-year-old college student with fever and joint pain - Meningococcal arthritis. Infectious mononucleosis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DISSEMINATED GONOCOCCAL-INFECTION; NEISSERIA-GONORRHOEAE; SUSCEPTIBILITY		Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; Harvard Med Sch, Dept Med, Boston, MA USA; Harvard Med Sch, Dept Pediat, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Vergo, MT (corresponding author), Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.							Banerjee A, 2002, J EXP MED, V196, P147, DOI 10.1084/jem.20012022; BOHNHOFF M, 1986, J INFECT DIS, V154, P225, DOI 10.1093/infdis/154.2.225; BRUNHAM RC, 1985, J INFECT DIS, V152, P339, DOI 10.1093/infdis/152.2.339; Candy B, 2006, COCHRANE DB SYST REV, V3; CANNON JG, 1983, INFECT IMMUN, V40, P816, DOI 10.1128/IAI.40.2.816-819.1983; *CDCP, 2007, CDC CHANG REC GON TR; FINNE J, 1987, J IMMUNOL, V138, P4402; Gardner P, 2007, NEW ENGL J MED, V356, P536; Gardner P, 2006, NEW ENGL J MED, V355, P1466, DOI 10.1056/NEJMcp063561; HOLMES KH, 1971, ANN INTERN MED, V74, P979, DOI 10.7326/0003-4819-74-6-979; KNAPP JS, 1984, J INFECT DIS, V150, P44, DOI 10.1093/infdis/150.1.44; Laurenson I, 2001, NEW ENGL J MED, V345, P699, DOI 10.1056/NEJM200108303450914; Mast Eric E., 2005, Morbidity and Mortality Weekly Report, V54, P1; Mehraein Y, 2004, J CLIN VIROL, V31, P25, DOI 10.1016/j.jcv.2004.02.014; PETERSEN BH, 1979, ANN INTERN MED, V90, P917, DOI 10.7326/0003-4819-90-6-917; RAY CG, 1982, JAMA-J AM MED ASSOC, V248, P2990, DOI 10.1001/jama.248.22.2990; Ross JDC, 1996, GENITOURIN MED, V72, P404; SCHOOLNIK GK, 1976, J CLIN INVEST, V58, P1163, DOI 10.1172/JCI108569; TAPSALL JW, 1992, INT J STD AIDS, V3, P273, DOI 10.1177/095646249200300408; Weisfelt M, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-64; WISE CM, 1994, ARCH INTERN MED, V154, P2690, DOI 10.1001/archinte.1994.00420230077009	21	8	8	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 21	2007	356	25					2631	2637		10.1056/NEJMcpc079013	http://dx.doi.org/10.1056/NEJMcpc079013			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180GN	17582074				2022-12-28	WOS:000247351200011
J	Smith, KL; Robison, BH; Helly, JJ; Kaufmann, RS; Ruhl, HA; Shaw, TJ; Twining, BS; Vernet, M				Smith, Kenneth L., Jr.; Robison, Bruce H.; Helly, John J.; Kaufmann, Ronald S.; Ruhl, Henry A.; Shaw, Timothy J.; Twining, Benjamin S.; Vernet, Maria			Free-drifting icebergs: Hot spots of chemical and biological enrichment in the Weddell Sea	SCIENCE			English	Article							SOUTHERN-OCEAN; ANTARCTIC PENINSULA; MARINE MAMMALS; CLIMATE-CHANGE; IRON; ICE; PHYTOPLANKTON; DISSOLUTION; OXIDE	The proliferation of icebergs from Antarctica over the past decade has raised questions about their potential impact on the surrounding pelagic ecosystem. Two free-drifting icebergs, 0.1 and 30.8 square kilometers in aerial surface area, and the surrounding waters were sampled in the northwest Weddell Sea during austral spring 2005. There was substantial enrichment of terrigenous material, and there were high concentrations of chlorophyll, krill, and seabirds surrounding each iceberg, extending out to a radial distance of similar to 3.7 kilometers. Extrapolating these results to all icebergs in the same size range, with the use of iceberg population estimates from satellite surveys, indicates that they similarly affect 39% of the surface ocean in this region. These results suggest that free-drifting icebergs can substantially affect the pelagic ecosystem of the Southern Ocean and can serve as areas of enhanced production and sequestration of organic carbon to the deep sea.	Monterey Bay Aquarium Res Inst, Moss Landing, CA 95039 USA; Univ Calif San Diego, San Diego Supercomp Ctr, La Jolla, CA 92093 USA; Univ San Diego, Marine Sci & Environm Studies Dept, San Diego, CA 92110 USA; Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA; Univ Calif San Diego, Integrat Oceanog Div, Scripps Inst Oceanog, La Jolla, CA 92093 USA	Monterey Bay Aquarium Research Institute; University of California System; University of California San Diego; University of San Diego; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of California System; University of California San Diego; Scripps Institution of Oceanography	Smith, KL (corresponding author), Monterey Bay Aquarium Res Inst, 7700 Sandholdt Rd, Moss Landing, CA 95039 USA.	ksmith@mbari.org		Twining, Benjamin/0000-0002-1365-9192; Shaw, Timothy/0000-0002-0032-457X				Arrigo K.R., 2002, GEOPHYS RES LETT, V29; Boyd PW, 2007, SCIENCE, V315, P612, DOI 10.1126/science.1131669; Coale KH, 2004, SCIENCE, V304, P408, DOI 10.1126/science.1089778; Cook AJ, 2005, SCIENCE, V308, P541, DOI 10.1126/science.1104235; de Baar H.J.W., 2001, BIOGEO CHEM IRON SEA, P123; DEBAAR HJW, 1995, NATURE, V373, P412, DOI 10.1038/373412a0; FINDEN DAS, 1984, NATURE, V309, P783, DOI 10.1038/309783a0; JOIRIS CR, 1991, POLAR BIOL, V11, P415; Kaufmann RS, 1995, MAR BIOL, V124, P387, DOI 10.1007/BF00363912; Kraemer SM, 2005, REV MINERAL GEOCHEM, V59, P53, DOI 10.2138/rmg.2005.59.4; KRISTENSEN M, 1983, PROG PHYS GEOG, V7, P313, DOI 10.1177/030913338300700301; Loscher BM, 1997, DEEP-SEA RES PT II, V44, P143, DOI 10.1016/S0967-0645(96)00101-4; Marinov I, 2006, NATURE, V441, P964, DOI 10.1038/nature04883; Orheim O, 1988, ANN GLACIOL, V11, P205; Pakhomov EA, 2002, DEEP-SEA RES PT II, V49, P1881, DOI 10.1016/S0967-0645(02)00017-6; RIBIC CA, 1991, ANTARCT SCI, V3, P181, DOI 10.1017/S0954102091000214; RICH HW, 1990, LIMNOL OCEANOGR, V35, P652, DOI 10.4319/lo.1990.35.3.0652; Rignot E, 2002, SCIENCE, V296, P2020, DOI 10.1126/science.1070942; Scambos TA, 2000, J GLACIOL, V46, P516, DOI 10.3189/172756500781833043; SMITH WO, 1985, SCIENCE, V227, P163, DOI 10.1126/science.227.4683.163; STONE G, 2001, NAT GEOG MAG     DEC, P36; Sugihara G, 2003, P NATL ACAD SCI USA, V100, P5246, DOI 10.1073/pnas.0831096100; SUNDA WG, 1995, MAR CHEM, V50, P189, DOI 10.1016/0304-4203(95)00035-P; Thomas R, 2004, SCIENCE, V306, P255, DOI 10.1126/science.1099650; Thompson DWJ, 2002, SCIENCE, V296, P895, DOI 10.1126/science.1069270; Vaughan DG, 2001, SCIENCE, V293, P1777, DOI 10.1126/science.1065116; Velicogna I, 2006, SCIENCE, V311, P1754, DOI 10.1126/science.1123785; WAITE TD, 1984, J COLLOID INTERF SCI, V102, P121, DOI 10.1016/0021-9797(84)90206-6; WELLS ML, 1983, J MAR RES, V41, P731, DOI 10.1357/002224083788520478; Williams RN, 1999, INT J REMOTE SENS, V20, P3183, DOI 10.1080/014311699211697; [No title captured]	31	185	191	0	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 27	2007	317	5837					478	482		10.1126/science.1142834	http://dx.doi.org/10.1126/science.1142834			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194JD	17588896				2022-12-28	WOS:000248339800035
J	Wilk, T; Webster, SC; Kuhn, A; Rempe, G				Wilk, Tatjana; Webster, Simon C.; Kuhn, Axel; Rempe, Gerhard			Single-atom single-photon quantum interface	SCIENCE			English	Article							CAVITY; ENTANGLEMENT; STATE; GENERATION	A major challenge for a scalable quantum computing architecture is the faithful transfer of information from one node to another. We report on the realization of an atom-photon quantum interface based on an optical cavity, using it to entangle a single atom with a single photon and then to map the quantum state of the atom onto a second single photon. The latter step disentangles the atom from the light and produces an entangled photon pair. Our scheme is intrinsically deterministic and establishes the basic element required to realize a distributed quantum network with individual atoms at rest as quantum memories and single flying photons as quantum messengers.	Max Planck Inst Quantum Opt, D-85748 Garching, Germany; Univ Oxford, Clarendon Lab, Oxford OX1 3PU, England	Max Planck Society; University of Oxford	Rempe, G (corresponding author), Max Planck Inst Quantum Opt, Hans Kopfermann Str 1, D-85748 Garching, Germany.	gerhard.rempe@mpq.mpg.de	Kuhn, Axel/B-9402-2008; Wilk, Tatjana/D-9568-2011	Kuhn, Axel/0000-0002-5101-8732; Wilk, Tatjana/0000-0003-0600-6668				Altepeter JB, 2005, ADV ATOM MOL OPT PHY, V52, P105, DOI 10.1016/S1049-250X(05)52003-2; Blinov BB, 2004, NATURE, V428, P153, DOI 10.1038/nature02377; Bose S, 1999, PHYS REV LETT, V83, P5158, DOI 10.1103/PhysRevLett.83.5158; Briegel HJ, 1998, PHYS REV LETT, V81, P5932, DOI 10.1103/PhysRevLett.81.5932; Browne DE, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.067901; Cirac JI, 1997, PHYS REV LETT, V78, P3221, DOI 10.1103/PhysRevLett.78.3221; Darquie B, 2005, SCIENCE, V309, P454, DOI 10.1126/science.1113394; Duan LM, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.253601; Hennrich M, 2000, PHYS REV LETT, V85, P4872, DOI 10.1103/PhysRevLett.85.4872; Hennrich M, 2004, NEW J PHYS, V6, DOI 10.1088/1367-2630/6/1/086; Hijlkema M, 2007, NAT PHYS, V3, P253, DOI 10.1038/nphys569; James DFV, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.052312; Keller M, 2004, NATURE, V431, P1075, DOI 10.1038/nature02961; Knill E, 2001, NATURE, V409, P46, DOI 10.1038/35051009; Kuhn A, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.067901; Lim YL, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.030505; McKeever J, 2004, SCIENCE, V303, P1992, DOI 10.1126/science.1095232; Nussmann S, 2005, NAT PHYS, V1, P122, DOI 10.1038/nphys120; Raimond JM, 2001, REV MOD PHYS, V73, P565, DOI 10.1103/RevModPhys.73.565; Sackett CA, 2000, NATURE, V404, P256, DOI 10.1038/35005011; Schon C, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.110503; Serafini A, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.010503; Volz J, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.030404; Wilk T, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.063601	24	365	373	1	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 27	2007	317	5837					488	490		10.1126/science.1143835	http://dx.doi.org/10.1126/science.1143835			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194JD	17588899				2022-12-28	WOS:000248339800037
J	Farmer, A; Wade, A; Goyder, E; Yudkin, P; French, D; Craven, A; Holman, R; Kinmonth, AL; Neil, A				Farmer, Andrew; Wade, Alisha; Goyder, Elizabeth; Yudkin, Patricia; French, David; Craven, Anthea; Holman, Rury; Kinmonth, Ann-Louise; Neil, Andrew		Diabet Glycaemic Edu Monitoring Tr	Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BEHAVIOR-CHANGE; MELLITUS; METAANALYSIS	Objective To determine whether self monitoring, alone or with instruction in incorporating the results into self care, is more effective than usual care in improving glycaemic control in non-insulin treated patients with type 2 diabetes. Design Three arm, open, parallel group randomised trial. Setting 48 general practices in Oxfordshire and South Yorkshire. Participants 453 patients with non-insulin treated type 2 diabetes (mean age 65.7 years) for a median duration of three years and a mean haemoglobin A(1c) level of 7.5%. Interventions Standardised usual care with measurements of HbA(1c) every three months as the control group (n=152); blood glucose self monitoring with advice for patients to contact their doctor for interpretation of results, in addition to usual care (n=150); and blood glucose self monitoring with additional training of patients in interpretation and application of the results to enhance motivation and maintain adherence to a healthy lifestyle (n=151). Main outcome measure HbA(1c) level measured at 12 months. Results At 12 months the differences in HbA(1c) level between the three groups (adjusted for baseline HbA(1c), level) were not statistically significant (P=0.12). The difference in unadjusted mean change in HbA(1c) level from baseline to 12 months between the control and less intensive self monitoring groups was -0.14% (95% confidence interval -0.35% to 0.07%) and between the control and more intensive self monitoring groups was -0-17% (-0.37% to 0.03%). Conclusions Evidence is not convincing of an effect of self monitoring blood glucose, with or without instruction in incorporating findings into self care, in improving glycaemic control compared with usual care in reasonably welt controlled non-insulin treated patients with type 2 diabetes.	Univ Oxford, Dept Primary Hlth Care, Oxford OX2 7LF, England; Johns Hopkins Univ, Baltimore, MD USA; Univ Sheffield, Sch Hlth & Related Res, Sheffield S10 2TN, S Yorkshire, England; Coventry Univ, Appl Res Ctr Hlth & Lifestyle Intervent, Coventry, W Midlands, England; Univ Oxford, Diabet Trials Unit, Oxford OX1 2JD, England; Univ Cambridge, Inst Publ Hlth, Cambridge CB2 1TN, England; Univ Oxford, Div Publ Hlth & Primary Care, Oxford OX1 2JD, England	University of Oxford; Johns Hopkins University; University of Sheffield; Coventry University; University of Oxford; University of Cambridge; University of Oxford	Farmer, A (corresponding author), Univ Oxford, Dept Primary Hlth Care, Oxford OX2 7LF, England.	andrew.farmer@dphpc.ox.ac.uk	Goyder, Elizabeth E/A-2146-2010; Wade, Alisha/A-8180-2011; French, David P/K-7283-2012	Goyder, Elizabeth E/0000-0003-3691-1888; French, David P/0000-0002-7663-7804; Wade, Alisha/0000-0002-1158-2523				Am Diabetes Assoc, 2006, DIABETES CARE, V29, pS4; Amiel S, 2002, BRIT MED J, V325, P746, DOI 10.1136/bmj.325.7367.746; Bellg AJ, 2004, HEALTH PSYCHOL, V23, P443, DOI 10.1037/0278-6133.23.5.443; Bergenstal RM, 2005, AM J MED, V118, p1S, DOI 10.1016/j.amjmed.2005.07.055; Coster S, 2000, DIABETIC MED, V17, P755, DOI 10.1046/j.1464-5491.2000.00390.x; Davidson MB, 2005, DIABETES CARE, V28, P1531, DOI 10.2337/diacare.28.6.1531; Davidson MB, 2005, AM J MED, V118, P422, DOI 10.1016/j.amjmed.2004.12.006; EuroQol Group, 2001, HLTH POL, V16, P199; Farmer A, 2005, DIABETIC MED, V22, P511, DOI 10.1111/j.1464-5491.2005.01530.x; Farmer Andrew, 2005, BMC Fam Pract, V6, P25, DOI 10.1186/1471-2296-6-25; Franciosi M, 2005, DIABETIC MED, V22, P900, DOI 10.1111/j.1464-5491.2005.01546.x; Gerich JE, 2006, DIABETES EDUCATOR, V32, P513, DOI 10.1177/0145721706290832; Guerci B, 2003, DIABETES METAB, V29, P587, DOI 10.1016/S1262-3636(07)70073-3; Hardeman W, 2000, INT J OBESITY, V24, P131, DOI 10.1038/sj.ijo.0801100; Hardeman W, 2005, HEALTH EDUC RES, V20, P676, DOI 10.1093/her/cyh022; Karter AJ, 2006, DIABETES CARE, V29, P1757, DOI 10.2337/dc06-2073; Leventhal H., 1984, HDB PSYCHOL HLTH, V4, P219; Martin S, 2006, DIABETOLOGIA, V49, P271, DOI 10.1007/s00125-005-0083-5; Nathan DM, 2005, NEW ENGL J MED, V353, P2643, DOI 10.1056/nejmoa052187; *NNAT I CLIN EXC, 2002, MAN TYP 2 DIAB MAN B; Norris SL, 2002, DIABETES CARE, V25, P1159, DOI 10.2337/diacare.25.7.1159; OWENS DR, 2004, DIABETES PRIMARY CAR, V6, P398; Peel E, 2004, BRIT J GEN PRACT, V54, P183; Sarol JN, 2005, CURR MED RES OPIN, V21, P173, DOI 10.1185/030079904X20286; Schwedes U, 2002, DIABETES CARE, V25, P1928, DOI 10.2337/diacare.25.11.1928; STRECHER VJ, 1995, HEALTH EDUC QUART, V22, P190, DOI 10.1177/109019819502200207; Turner RC, 1999, JAMA-J AM MED ASSOC, V281, P2005, DOI 10.1001/jama.281.21.2005; Welschen LMC, 2005, DIABETES CARE, V28, P1510, DOI 10.2337/diacare.28.6.1510; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047	29	272	274	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 21	2007	335	7611					132	136		10.1136/bmj.39247.447431.BE	http://dx.doi.org/10.1136/bmj.39247.447431.BE			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195RA	17591623	Green Published, Green Submitted, Bronze, Green Accepted			2022-12-28	WOS:000248428100033
J	Jain, AK; Gaynon, M				Jain, Atul K.; Gaynon, Michael			Macular hemorrhage from bungee jumping	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Stanford Univ, Stanford, CA 94305 USA	Stanford University	Jain, AK (corresponding author), Stanford Univ, Stanford, CA 94305 USA.	atuljain@stanford.edu							0	7	7	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 19	2007	357	3					E3	E3		10.1056/NEJMicm064881	http://dx.doi.org/10.1056/NEJMicm064881			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191FH	17634454				2022-12-28	WOS:000248115100010
J	Gates, S; Brocklehurst, P				Gates, Simon; Brocklehurst, Peter			Decline in effectiveness of antenatal corticosteroids with time to birth: real or artefact?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							RESPIRATORY-DISTRESS-SYNDROME; PRETERM DELIVERY; WEEKLY COURSES; SINGLE		Univ Oxford, Natl Perinatal Epidemiol Unit, Oxford OX3 7LF, England	University of Oxford		s.gates@warwick.ac.uk	Brocklehurst, Peter/B-5804-2011					Brocklehurst P, 1999, BRIT J OBSTET GYNAEC, V106, P977, DOI 10.1111/j.1471-0528.1999.tb08440.x; CROWLEY P, 1990, BRIT J OBSTET GYNAEC, V97, P11, DOI 10.1111/j.1471-0528.1990.tb01711.x; Crowley P., 1989, EFFECTIVE CARE PREGN, P746; CROWLEY PA, 1995, AM J OBSTET GYNECOL, V173, P322, DOI 10.1016/0002-9378(95)90222-8; Crowther CA, 2006, LANCET, V367, P1913, DOI 10.1016/S0140-6736(06)68846-6; Crowther CA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003935.pub3; Deeks~ JJ, 2001, SYSTEMATIC REV HLTH; Gilstrap LC, 2001, OBSTET GYNECOL, V98, P144; Grier David G, 2004, Treat Respir Med, V3, P295, DOI 10.2165/00151829-200403050-00004; Guinn DA, 2001, JAMA-J AM MED ASSOC, V286, P1581, DOI 10.1001/jama.286.13.1581; Howie RN, 1977, PRE TERM LAB P 5 STU, p:281; Jobe A H, 2001, Semin Neonatol, V6, P331, DOI 10.1053/siny.2001.0068; LIGGINS GC, 1972, PEDIATRICS, V50, P515; Montan S, 2006, LANCET, V367, P1878, DOI 10.1016/S0140-6736(06)68820-X; Quinlivan JA, 1998, AUST NZ J OBSTET GYN, V38, P1, DOI 10.1111/j.1479-828X.1998.tb02947.x; Roberts D, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004454.pub2; Rochon J, 1999, DRUG INF J, V33, P1219, DOI 10.1177/009286159903300425; van Walraven C, 2004, J CLIN EPIDEMIOL, V57, P672, DOI 10.1016/j.jclinepi.2003.12.008; Wapner RJ, 2006, AM J OBSTET GYNECOL, V195, P633, DOI 10.1016/j.ajog.2006.03.087	19	12	13	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 14	2007	335	7610					77	79		10.1136/bmj.39225.677708.80	http://dx.doi.org/10.1136/bmj.39225.677708.80			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192JM	17626962	Green Published, Green Submitted			2022-12-28	WOS:000248197500032
J	Gregor, T; Tank, DW; Wieschaus, EF; Bialek, W				Gregor, Thomas; Tank, David W.; Wieschaus, Eric F.; Bialek, William			Probing the limits to positional information	CELL			English	Article							EARLY DROSOPHILA EMBRYO; GENE-EXPRESSION; BICOID PROTEIN; DNA-BINDING; FLUORESCENCE MICROSCOPY; MORPHOGEN GRADIENTS; PHYSICAL LIMITS; SINGLE-CELL; PATTERN; DOMAIN	The reproducibility and precision of biological patterning is limited by the accuracy with which concentration profiles of morphogen molecules can be established and read out by their targets. We consider four measures of precision for the Bicoid morphogen in the Drosophila embryo: the concentration differences that distinguish neighboring cells, the limits set by the random arrival of Bicoid molecules at their targets ( which depends on absolute concentration), the noise in readout of Bicoid by the activation of Hunchback, and the reproducibility of Bicoid concentration at corresponding positions in multiple embryos. We show, through a combination of different experiments, that all of these quantities are similar to 10%. This agreement among different measures of accuracy indicates that the embryo is not faced with noisy input signals and readout mechanisms; rather, the system exerts precise control over absolute concentrations and responds reliably to small concentration differences, approaching the limits set by basic physical principles.	Princeton Univ, Joseph Henry Labs Phys, Princeton, NJ 08544 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA; Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA	Princeton University; Princeton University; Princeton University; Howard Hughes Medical Institute; Princeton University	Gregor, T (corresponding author), Princeton Univ, Joseph Henry Labs Phys, Princeton, NJ 08544 USA.	tg2@princeton.edu		Gregor, Thomas/0000-0001-9460-139X	NIGMS NIH HHS [R01 GM077599, R01 GM077599-01, P50 GM071508-01, R01 GM077599-02, P50 GM071508] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM071508, R01GM077599] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arias AM, 2006, NAT REV GENET, V7, P34, DOI 10.1038/nrg1750; BARLOW HB, 1981, PROC R SOC SER B-BIO, V212, P1, DOI 10.1098/rspb.1981.0022; BERG HC, 1977, BIOPHYS J, V20, P193, DOI 10.1016/S0006-3495(77)85544-6; Bialek W, 2005, P NATL ACAD SCI USA, V102, P10040, DOI 10.1073/pnas.0504321102; BIALEK W, 1987, ANNU REV BIOPHYS BIO, V16, P455; BIALEK W, 2006, COOPERATIVITY SENSIT; BIALEK W, 2002, PHYS BIOMOLECULES CE, P485; Burz DS, 1998, EMBO J, V17, P5998, DOI 10.1093/emboj/17.20.5998; Crauk O, 2005, CURR BIOL, V15, P1888, DOI 10.1016/j.cub.2005.09.046; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; DEVRIES H, 1956, PROG BIOPHYS MOL BIO, V6, P208, DOI 10.1016/S0096-4174(18)30108-2; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; Eldar A, 2004, CURR OPIN GENET DEV, V14, P435, DOI 10.1016/j.gde.2004.06.009; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; Elowitz MB, 1999, J BACTERIOL, V181, P197, DOI 10.1128/JB.181.1.197-203.1999; Gao Q, 1998, DEVELOPMENT, V125, P4185; Gergen J. P., 1986, S SOC DEV BIOL, V43, P195; Goldman MS, 2001, J NEUROSCI, V21, P5229, DOI 10.1523/JNEUROSCI.21-14-05229.2001; Gregor T, 2005, P NATL ACAD SCI USA, V102, P18403, DOI 10.1073/pnas.0509483102; Holloway DM, 2006, DEV DYNAM, V235, P2949, DOI 10.1002/dvdy.20940; Houchmandzadeh B, 2002, NATURE, V415, P798, DOI 10.1038/415798a; Howard M, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.208103; Jaeger J, 2004, NATURE, V430, P368, DOI 10.1038/nature02678; Kosman D, 1998, DEV GENES EVOL, V208, P290, DOI 10.1007/s004270050184; Lawrence Peter A, 1993, MAKING FLY GENETICS, V6; LEMASSON G, 1993, SCIENCE, V259, P1915, DOI 10.1126/science.8456317; Ma XG, 1996, DEVELOPMENT, V122, P1195; MARGOLIS JS, 1995, DEVELOPMENT, V121, P3067; Patterson GH, 1997, BIOPHYS J, V73, P2782, DOI 10.1016/S0006-3495(97)78307-3; Pedone PV, 1996, P NATL ACAD SCI USA, V93, P2822, DOI 10.1073/pnas.93.7.2822; Pologruto TA, 2003, BIOMED ENG ONLINE, V2, DOI 10.1186/1475-925X-2-13; Ptashne M., 1992, A GENETIC SWITCH; Raser JM, 2004, SCIENCE, V304, P1811, DOI 10.1126/science.1098641; Rieke F, 1998, REV MOD PHYS, V70, P1027, DOI 10.1103/RevModPhys.70.1027; RIVERAPOMAR R, 1995, NATURE, V376, P253, DOI 10.1038/376253a0; Rosenfeld N, 2005, SCIENCE, V307, P1962, DOI 10.1126/science.1106914; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; SCHRODINGER E, 1944, WHAT LIFE; Slonim N, 2005, ESTIMATING MUTUAL IN; Spirov Alexander V., 2003, In Silico Biology, V3, P89; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; Svoboda K, 1997, NATURE, V385, P161, DOI 10.1038/385161a0; von Dassow G, 2000, NATURE, V406, P188, DOI 10.1038/35018085; Winston RL, 1999, BIOCHEMISTRY-US, V38, P5138, DOI 10.1021/bi982856a; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; Zhao C, 2002, DEVELOPMENT, V129, P1669	50	481	486	0	47	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 13	2007	130	1					153	164		10.1016/j.cell.2007.05.025	http://dx.doi.org/10.1016/j.cell.2007.05.025			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	197WK	17632062	Green Accepted, Green Submitted, Bronze			2022-12-28	WOS:000248587000018
J	Hector, A; Bagchi, R				Hector, Andy; Bagchi, Robert			Biodiversity and ecosystem multifunctionality	NATURE			English	Article							STATISTICAL INEVITABILITY; EUROPEAN GRASSLANDS; CURRENT KNOWLEDGE; DIVERSITY; STABILITY; PRODUCTIVITY; ECOLOGY; COMMUNITIES; SERVICES	Biodiversity loss can affect ecosystem functions and services(1-4). Individual ecosystem functions generally show a positive asymptotic relationship with increasing biodiversity, suggesting that some species are redundant(5-8). However, ecosystems are managed and conserved for multiple functions, which may require greater biodiversity. Here we present an analysis of published data from grassland biodiversity experiments(9-11), and show that ecosystem multifunctionality does require greater numbers of species. We analysed each ecosystem function alone to identify species with desirable effects. We then calculated the number of species with positive effects for all possible combinations of functions. Our results show appreciable differences in the sets of species influencing different ecosystem functions, with average proportional overlap of about 0.2 to 0.5. Consequently, as more ecosystem processes were included in our analysis, more species were found to affect overall functioning. Specifically, for all of the analysed experiments, there was a positive saturating relationship between the number of ecosystem processes considered and the number of species influencing overall functioning. We conclude that because different species often influence different functions, studies focusing on individual processes in isolation will underestimate levels of biodiversity required to maintain multifunctional ecosystems.	Univ Zurich, Inst Environm Sci, CH-8057 Zurich, Switzerland	University of Zurich	Hector, A (corresponding author), Univ Zurich, Inst Environm Sci, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	ahector@uwinst.uzh.ch	Bagchi, Robert/F-1732-2011; Hector, Andrew/H-4199-2011	Bagchi, Robert/0000-0003-4035-4105; Hector, Andrew/0000-0002-1309-7716				Balvanera P, 2006, ECOL LETT, V9, P1146, DOI 10.1111/j.1461-0248.2006.00963.x; Burnham K.P., 2002, MODEL SELECTION MULT, VSecond edition; Cardinale BJ, 2006, NATURE, V443, P989, DOI 10.1038/nature05202; CARLANDER KD, 1955, J FISH RES BOARD CAN, V12, P543, DOI 10.1139/f55-029; COMTET L, 1974, ADV COMBINATORICS AR, P176; Cottingham KL, 2001, ECOL LETT, V4, P72, DOI 10.1046/j.1461-0248.2001.00189.x; Darwin C., 1858, J P LINNEAN SOC LOND, V3, P45, DOI DOI 10.1111/J.1096-3642.1858.TB02500.X; Doak DF, 1998, AM NAT, V151, P264, DOI 10.1086/286117; Hector A, 1999, SCIENCE, V286, P1123, DOI 10.1126/science.286.5442.1123; Hector A, 2002, SCIENCE, V295, P639, DOI 10.1126/science.1064815; HECTOR A, 2005, ECOL ARCH, pS1; HECTOR A, IN PRESS FUNCT ECOL; Hooper DU, 2005, ECOL MONOGR, V75, P3, DOI 10.1890/04-0922; Kinzig A. P., 2002, FUNCTIONAL CONSEQUEN; Lehman CL, 2000, AM NAT, V156, P534, DOI 10.1086/303402; Loreau M, 2002, BIODIVERSITY AND ECOSYSTEM FUNCTIONING: SYNTHESIS AND PERSPECTIVES, P79; Loreau M, 2001, SCIENCE, V294, P804, DOI 10.1126/science.1064088; Loreau M., 2002, BIODIVERSITY ECOSYST, P294; McCann KS, 2000, NATURE, V405, P228, DOI 10.1038/35012234; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; *R DEV COR TEAM, 2007, LANG ENV STAT COMP; RIPLEY BD, 2004, METHODS MODELS STAT, P155; Sanderson MA, 2004, CROP SCI, V44, P1132, DOI 10.2135/cropsci2004.1132; Spehn EM, 2005, ECOL MONOGR, V75, P37, DOI 10.1890/03-4101; Srivastava DS, 2005, ANNU REV ECOL EVOL S, V36, P267, DOI 10.1146/annurev.ecolsys.36.102003.152636; Steiner CF, 2006, ECOLOGY, V87, P996, DOI 10.1890/0012-9658(2006)87[996:PACRIM]2.0.CO;2; TAPER ML, 2005, NATURE SCI EVIDENCE, P488; Tilman D, 1998, AM NAT, V151, P277, DOI 10.1086/286118; Tilman D, 2006, NATURE, V441, P629, DOI 10.1038/nature04742; Venables WN., 2002, MODERN APPL STAT S; Worm B, 2006, SCIENCE, V314, P787, DOI 10.1126/science.1132294; Yachi S, 1999, P NATL ACAD SCI USA, V96, P1463, DOI 10.1073/pnas.96.4.1463	32	715	810	87	949	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 12	2007	448	7150					188	U6		10.1038/nature05947	http://dx.doi.org/10.1038/nature05947			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	188QN	17625564				2022-12-28	WOS:000247934500041
J	Markowitz, AJ; Rabow, MW				Markowitz, Amy J.; Rabow, Michael W.			Palliative management of fatigue at the close of life: "It feels like my body is just worn out"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Markowitz, Amy/0000-0001-9314-2814				Yennurajalingam S, 2007, JAMA-J AM MED ASSOC, V297, P295, DOI 10.1001/jama.297.3.295	1	11	12	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2007	298	2					217	217		10.1001/jama.298.2.217	http://dx.doi.org/10.1001/jama.298.2.217			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188HI	17622603				2022-12-28	WOS:000247910600027
J	Wood, E; Kerr, T; Montaner, JSG				Wood, Evan; Kerr, Thomas; Montaner, Julio S. G.			HIV treatment, injection drug use, and illicit drug policies	LANCET			English	Editorial Material									St Pauls Hosp, Providence Hlth Care, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada; Univ British Columbia, Fac Med, Dept Med, Vancouver, BC V5Z 1M9, Canada	B.C. Centre for Excellence in HIV/AIDS; St. Paul's Hospital; University of Saskatchewan; University of British Columbia	Montaner, JSG (corresponding author), St Pauls Hosp, Providence Hlth Care, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada.	jmontaner@cfenet.ubc.ca	Montaner, Julio/K-7621-2012					Aceijas C, 2006, ADDICTION, V101, P1246, DOI 10.1111/j.1360-0443.2006.01509.x; Davis CS, 2005, AM J PUBLIC HEALTH, V95, P233, DOI 10.2105/AJPH.2003.031310; Des Jarlais DC, 1999, PUBLIC HEALTH, V113, P182; GRUND JPC, 1992, J PSYCHOACTIVE DRUGS, V24, P41, DOI 10.1080/02791072.1992.10471617; Kerr T, 2004, LANCET, V364, P1918, DOI 10.1016/S0140-6736(04)17490-4; Mattick RP, 2003, COCHRANE DB SYST REV, V2; Small Dan, 2007, Harm Reduct J, V4, P13, DOI 10.1186/1477-7517-4-13; Swan N, 1999, JAMA-J AM MED ASSOC, V281, P1782, DOI 10.1001/jama.281.19.1782; UNAIDS, 2006, REP GLOB AIDS EP; Wainberg MA, 2006, CAN MED ASSOC J, V175, P1395, DOI 10.1503/cmaj.061404; Wood E, 2005, LANCET, V366, P1834, DOI 10.1016/S0140-6736(05)67737-9; 2005, LANCET, V365, P629	12	16	16	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 7	2007	370	9581					8	10		10.1016/S0140-6736(07)61025-3	http://dx.doi.org/10.1016/S0140-6736(07)61025-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	187QE	17617253				2022-12-28	WOS:000247862300007
J	Iglehart, JK				Iglehart, John K.			Insuring all children - The new political imperative	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-INSURANCE PROGRAM; SCHIP; MEDICAID; COVERAGE; IMPACT; CARE											*AC HLTH, 2007, STAT STAT BUILD HOP; [Anonymous], 2004, CHILDRENS HLTH NATIO; Bansak C, 2007, J POLICY ANAL MANAG, V26, P149, DOI 10.1002/pam.20231; BELLUCK P, 2007, NY TIMES        0412, pA11; *C BUDG OFF, 2007, STAT CHILDR HLTH INS; CARASSO A, 2007, KIDS SHARE 2007 CHIL; Chang DI, 2007, HEALTH AFFAIR, V26, P466, DOI 10.1377/hlthaff.26.2.466; Cohen Ross D., 2007, RESUMING PATH HLTH C; Currie J, 2007, HEALTH AFFAIR, V26, P331, DOI 10.1377/hlthaff.26.2.331; Damiano PC, 2003, AMBUL PEDIATR, V3, P263, DOI 10.1367/1539-4409(2003)003<0263:TIOTIS>2.0.CO;2; Davidoff A, 2005, PEDIATRICS, V116, pE34, DOI 10.1542/peds.2004-2297; DENAVASWALT C, 2005, INCOME POVERTY HLTH; Dubay L, 2007, HEALTH AFFAIR, V26, P370, DOI 10.1377/hlthaff.26.2.370; FREUDENHEIM M, 2007, NY TIMES, pC1; Iglehart JK, 2007, NEW ENGL J MED, V356, P734, DOI 10.1056/NEJMhpr066650; Gruber Jonathan, 2007, 12858 NAT BUR EC RES; Halfon N, 2002, MILBANK Q, V80, P433, DOI 10.1111/1468-0009.00019; Halfon N, 2007, HEALTH AFFAIR, V26, P315, DOI 10.1377/hlthaff.26.2.315; HARWOOD J, 2007, WALL STREET J   0123, pA6; Heckman JJ, 2006, SCIENCE, V312, P1900, DOI 10.1126/science.1128898; HERZ EJ, 2007, STATE CHILDRENS HLTH; HOLAHAN J, 2005, HLTH AFF MILLW S JUL; HOLAHAN J, 2006, WHY DID NUMBER UNINS; Hudson JL, 2005, INQUIRY-J HEALTH CAR, V42, P232, DOI 10.5034/inquiryjrnl_42.3.232; Jacobson M, 2007, HEALTH AFFAIR, V26, P538, DOI 10.1377/hlthaff.26.2.538; KENNEY G, IN PRESS HLTH SERV R; KENNEY G, 2007, COVERAGE PATTERNS SC; Kenney G, 2007, HEALTH AFFAIR, V26, P356, DOI 10.1377/hlthaff.26.2.356; Lo Sasso AT, 2004, J HEALTH ECON, V23, P1059, DOI 10.1016/j.jhealeco.2004.03.006; NODINE TR, 2007, GOVERNORS SPEAK 2007; *OFF ASS SECR PLAN, 2005, CONGR MAND EV STAT C; PARK E, 2007, SCHIP REAUTHORIZATIO; PARK E, 2007, OPTIONS EXIST OFFSET; PEAR R, 2007, NY TIMES        0225, pA15; Reischauer RD, 2007, NEW ENGL J MED, V356, P1393, DOI 10.1056/NEJMp078034; ROGERS D, 2007, WALL STREET J   0503, pA6; ROSENBAUM S, 2007, SCHIP 10 BACKGROUND; Rosenbaum S, 2007, HEALTH AFFAIR, V26, P382, DOI 10.1377/hlthaff.26.2.382; Rosenbaum Sara, 2004, J HLTH BIOMEDICAL LA, V1, P1; Shone LP, 2005, PEDIATRICS, V115, pE697, DOI 10.1542/peds.2004-1726; Sommers A, 2007, HEALTH AFFAIR, V26, P529, DOI 10.1377/hlthaff.26.2.529; Szilagyi PG, 2004, PEDIATRICS, V113, pE395, DOI 10.1542/peds.113.5.e395; TONER R, 2007, NY TIMES        0302, pA1	43	5	5	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 5	2007	357	1					70	76		10.1056/NEJMhpr071840	http://dx.doi.org/10.1056/NEJMhpr071840			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	185OR	17611210				2022-12-28	WOS:000247720800015
J	White, DB; Curtis, JR; Wolf, LE; Prendergast, TJ; Taichman, DB; Kuniyoshi, G; Acerra, F; Lo, B; Luce, JM				White, Douglas B.; Curtis, J. Randall; Wolf, Leslie E.; Prendergast, Thomas J.; Taichman, Darren B.; Kuniyoshi, Gary; Acerra, Frank; Lo, Bernard; Luce, John M.			Life support for patients without a surrogate decision maker: Who decides?	ANNALS OF INTERNAL MEDICINE			English	Article							INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; TREATMENT PREFERENCES; SUSTAINING TREATMENT; ADVANCE DIRECTIVES; WITHDRAWAL; PHYSICIANS; FUTILITY; CAPACITY; POLICY	Background: Physicians in intensive care units have withdrawn life support in incapacitated patients who lack surrogate decision makers and advance directives, yet little is known about how often this occurs or under what circumstances. Objective: To determine the proportion of deaths in intensive care units that occur in patients who lack decision-making capacity and a surrogate and the process that physicians use to make these decisions. Design: Multicenter, prospective cohort study. Setting: Intensive care units of 7 medical centers in 2004 to 2005. Patients: 3011 consecutive critically ill adults. Measurements: Attending physicians completed a questionnaire about the decision-making process for each incapacitated patient without a surrogate or advance directive for whom they considered limiting life support. Results: Overall, 5.5% (25 of 451 patients) of deaths in intensive care units occurred in incapacitated patients who lacked a surrogate decision maker and an advance directive. This percentage ranged from 0% to 27% across the 7 centers. Physicians considered limiting life support in 37 such patients or would have considered it if a surrogate had been available. In 6 patients, there was prospective hospital review of the decision, and in 1 patient, there was court review. In the remaining 30 patients, the decision was made by the intensive care unit team alone or by the intensive care unit team plus another attending physician. The authors found wide variability in hospital policies, professional society guidelines, and state laws regarding who should make life-support decisions for this patient population. Thirty-six of 37 life-support decisions were made in a manner inconsistent with American College of Physicians guidelines for judicial review. Limitations: The results are based on physicians' self-reported practices and may not match actual practices. The number of incapacitated patients without surrogates in the study is small. Conclusions: Incapacitated patients without surrogates accounted for approximately 1 in 20 deaths in intensive care units. Most life-support decisions were made by physicians without institutional or judicial review.	Univ Calif San Francisco, Program Med Eth, San Francisco, CA 94143 USA; San Francisco Gen Hosp, San Francisco, CA 94110 USA; Univ Washington, Sch Med, Seattle, WA 98195 USA; Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA; Univ Penn, Philadelphia, PA 19104 USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA; Beth Israel Deaconess Med Ctr, New York, NY 10003 USA	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of Washington; University of Washington Seattle; Dartmouth College; University of Pennsylvania; Oregon Health & Science University; Harvard University; Beth Israel Deaconess Medical Center	White, DB (corresponding author), Univ Calif San Francisco, Program Med Eth, 521 Parnassus Ave,Suite C-126,Box 0903, San Francisco, CA 94143 USA.	dwhite@medicine.ucsf.edu		Wolf, Leslie/0000-0002-4660-8383	NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR024130] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL068593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NCRR NIH HHS [KL2 RR024130] Funding Source: Medline; NHLBI NIH HHS [K24 HL 68593] Funding Source: Medline; NIMH NIH HHS [MH 42459] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		American Medical Association, 2004, COD MED ETH CURR OP; Arnold RM, 2003, CRIT CARE MED, V31, pS347, DOI 10.1097/01.CCM.0000065123.23736.12; ASCH DA, 1995, AM J RESP CRIT CARE, V151, P288, DOI 10.1164/ajrccm.151.2.7842181; Beauchamp T L, 2012, PRINCIPLES BIOMEDICA; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; COHEN LM, 1993, ARCH INTERN MED, V153, P2481, DOI 10.1001/archinte.153.21.2481; Cohen S, 2005, INTENS CARE MED, V31, P1215, DOI 10.1007/s00134-005-2742-x; COOK DJ, 1995, JAMA-J AM MED ASSOC, V273, P703, DOI 10.1001/jama.273.9.703; Curtis JR, 2003, J CRIT CARE, V18, P22, DOI 10.1053/jcrc.2003.YJCRC5; FADER AM, 1989, J AM GERIATR SOC, V37, P544, DOI 10.1111/j.1532-5415.1989.tb05687.x; Fine RL, 2003, ANN INTERN MED, V138, P743, DOI 10.7326/0003-4819-138-9-200305060-00011; Fischer GS, 1998, J GEN INTERN MED, V13, P447, DOI 10.1046/j.1525-1497.1998.00133.x; Gillick Muriel R, 1995, J Ethics Law Aging, V1, P87; Halevy A, 1996, JAMA-J AM MED ASSOC, V276, P571, DOI 10.1001/jama.276.7.571; Hoffmann D, 2000, J LAW MED ETHICS, V28, P30, DOI 10.1111/j.1748-720X.2000.tb00314.x; Karp N., 2003, INCAPACITATED ALONE; KRUSE JA, 1988, JAMA-J AM MED ASSOC, V260, P1739, DOI 10.1001/jama.260.12.1739; Layde P M, 1995, Arch Fam Med, V4, P518, DOI 10.1001/archfami.4.6.518; *LEV CAR STUD INV, 2004, CRIT CARE MED, V32, P1149; LO B, 1987, NEW ENGL J MED, V317, P46, DOI 10.1056/NEJM198707023170110; Lo B, 2003, JAMA-J AM MED ASSOC, V290, P1208, DOI 10.1001/jama.290.9.1208; LO B, 1985, ARCH INTERN MED, V145, P1115, DOI 10.1001/archinte.145.6.1115; MARINER WK, 1984, J AM GERIATR SOC, V32, P739, DOI 10.1111/j.1532-5415.1984.tb04173.x; Norris WM, 2005, CHEST, V127, P2180, DOI 10.1378/chest.127.6.2180; PEARLMAN RA, 1982, ANN INTERN MED, V97, P420, DOI 10.7326/0003-4819-97-3-420; Prendergast TJ, 1998, AM J RESP CRIT CARE, V158, P1163, DOI 10.1164/ajrccm.158.4.9801108; Prendergast TJ, 1997, AM J RESP CRIT CARE, V155, P15, DOI 10.1164/ajrccm.155.1.9001282; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; Snyder L, 2005, ANN INTERN MED, V142, P560, DOI 10.7326/0003-4819-142-7-200504050-00014; Sprung CL, 2003, JAMA-J AM MED ASSOC, V290, P790, DOI 10.1001/jama.290.6.790; White DB, 2006, CRIT CARE MED, V34, P2053, DOI 10.1097/01.CCM.0000227654.38708.C1; Wolf Leslie E, 2004, IRB, V26, P14, DOI 10.2307/3563582; 1996, J AM GERIATR SOC, V44, P986	33	72	72	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2007	147	1					34	40		10.7326/0003-4819-147-1-200707030-00006	http://dx.doi.org/10.7326/0003-4819-147-1-200707030-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186MN	17606959				2022-12-28	WOS:000247782900005
J	Schattner, A; Zornitzki, T				Schattner, Ami; Zornitzki, Taiba			When the whole-body scan shows no abnormality	LANCET			English	Editorial Material									Kaplan Med Ctr, Dept Med, IL-76100 Rehovot, Israel; Kaplan Med Ctr, Endocrinol Unit, IL-76100 Rehovot, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91010 Jerusalem, Israel	Hebrew University of Jerusalem; Kaplan Medical Center; Hebrew University of Jerusalem; Kaplan Medical Center; Hebrew University of Jerusalem	Schattner, A (corresponding author), Kaplan Med Ctr, Dept Med, POB 1, IL-76100 Rehovot, Israel.	amiMD@cialit.org.il	Schattner, Ami/ABI-1894-2020	Schattner, Ami/0000-0002-1413-8858				Alibhai SMH, 2005, CAN MED ASSOC J, V172, P773, DOI 10.1503/cmaj.1031527; Andrioli Massimiliano, 2006, Pituitary, V9, P289, DOI 10.1007/s11102-006-0408-5; Lo Re V III, 2002, ANN INTERN MED, V136, P634, DOI 10.7326/0003-4819-136-8-200204160-00022; Stewart PM, 2003, WILLIAMS TXB ENDOCRI, P491; TOBIN MV, 1989, AM J GASTROENTEROL, V84, P1302	5	2	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 30	2007	369	9580					2214	2214		10.1016/S0140-6736(07)61018-6	http://dx.doi.org/10.1016/S0140-6736(07)61018-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LX	17604804				2022-12-28	WOS:000247644200033
J	Coppi, P				Coppi, Paolo			Astronomy - Inside a cosmic train wreck	SCIENCE			English	Editorial Material									Yale Univ, Dept Astron, New Haven, CT 06511 USA	Yale University	Coppi, P (corresponding author), Yale Univ, Dept Astron, New Haven, CT 06511 USA.	coppi@astro.yale.edu						Max CE, 2007, SCIENCE, V316, P1877, DOI 10.1126/science.1136205; Mayer L, 2007, SCIENCE, V316, P1874, DOI 10.1126/science.1141858; Primack JR, 2005, NEW ASTRON REV, V49, P25, DOI 10.1016/j.newar.2005.01.039	3	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 29	2007	316	5833					1852	1854		10.1126/science.1139057	http://dx.doi.org/10.1126/science.1139057			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183WI	17600203				2022-12-28	WOS:000247602700023
J	Solomon, SD; Janardhanan, R; Verma, A; Bourgoon, M; Daley, WL; Dos Purkayastha; Lacourciere, Y; Hippler, SE; Fields, H; Naqvi, TZ; Mulvagh, SL; Arnold, MO; Thomas, JD; Zile, MR; Aurigemma, GP				Solomon, Scott D.; Janardhanan, Rajesh; Verma, Anil; Bourgoon, Mikhail; Daley, William L.; Dos Purkayastha; Lacourciere, Yves; Hippler, Stephen E.; Fields, Harold; Naqvi, Tasneem Z.; Mulvagh, Sharon L.; Arnold, Malcolm O.; Thomas, James D.; Zile, Michael R.; Aurigemma, Gerard P.		VALIDD Investigators	Effect of angiotensin receptor blockade and anti hypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial	LANCET			English	Article							LEFT-VENTRICULAR HYPERTROPHY; CONGESTIVE-HEART-FAILURE; END-POINT REDUCTION; LOSARTAN INTERVENTION; MYOCARDIAL-INFARCTION; EJECTION FRACTION; VALSARTAN; DIAGNOSIS; LIFE; CARDIOMYOPATHY	Background Diastolic dysfunction might represent an important pathophysiological intermediate between hypertension and heart failure. Our aim was to determine whether inhibitors of the renin-angiotensin-aldosterone system, which can reduce ventricular hypertrophy and myocardial fibrosis, can improve diastolic function to a greater extent than can other antihypertensive agents. Methods Patients with hypertension and evidence of diastolic dysfunction were randomly assigned to receive either the angiotensin receptor blocker valsartan (titrated to 320 mg once daily) or matched placebo. Patients in both groups also received concomitant antihypertensive agents that did not inhibit the renin-angiotensin system to reach targets of under 135 mm Hg systolic blood pressure and under 80 mm Hg diastolic blood pressure. The primary endpoint was change in diastolic relaxation velocity between baseline and 38 weeks as determined by tissue doppler imaging. Analyses were done by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00170924. Findings 186 patients were randomly assigned to receive valsartan; 198 were randomly assigned to receive placebo. 43 patients were lost to follow-up or discontinued the assigned intervention. Over 38 weeks, there was a 12.8 (SD 17.2)/7.1 (9.9) mm, Hg reduction in blood pressure in the valsartan group and a 9.7 (17.0)/5.5 (10.2) mm Hg reduction in the placebo group. The difference in blood pressure reduction between the two groups was not significant. Diastolic relaxation velocity increased by 0.60 (SD 1.4) cm/s from baseline in the valsartan group (p < 0.0001) and 0.44 (1.4) cm/s from baseline in the placebo group (p < 0.0001) by week 38. However, there was no significant difference in the change in diastolic relaxation velocity between the groups (p=0.29). Interpretation Lowering blood pressure improves diastolic function irrespective of the type of antihypertensive agent used.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Univ Massachusetts, Med Ctr, Worcester, MA USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Mayo Clin, Rochester, MN USA; Med Univ S Carolina, Charleston, SC 29425 USA; Dept Vet Affairs Med Ctr, Charleston, SC USA; Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; London Hlth Sci Ctr, London, ON, Canada; Ctr Hosp Univ Laval, Ste Foy, PQ, Canada; Clin Res Ctr, OSF Med Grp, Peoria, IL USA; Village Family Practice Res, Houston, TX USA; Novartis Pharmaceut, E Hanover, NJ USA	Harvard University; Brigham & Women's Hospital; University of Massachusetts System; University of Massachusetts Worcester; Cleveland Clinic Foundation; Mayo Clinic; Medical University of South Carolina; Cedars Sinai Medical Center; London Health Sciences Centre; Laval University; Novartis	Solomon, SD (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.	ssolomon@rics.bwh.harvard.edu	Arnold, Malcolm/G-2869-2011; Solomon, Scott/I-5789-2013	Zile, Michael/0000-0001-7076-221X				Aeschbacher BC, 2001, AM J HYPERTENS, V14, P106, DOI 10.1016/S0895-7061(00)01245-0; Aronow WS, 1997, AM J CARDIOL, V80, P207, DOI 10.1016/S0002-9149(97)00320-2; Aurigemma GP, 2001, J AM COLL CARDIOL, V37, P1042, DOI 10.1016/S0735-1097(01)01110-X; Aurigemma GP, 2004, NEW ENGL J MED, V351, P1097, DOI 10.1056/NEJMcp022709; Brilla CG, 2000, CIRCULATION, V102, P1388, DOI 10.1161/01.CIR.102.12.1388; Cain BS, 1998, J AM COLL CARDIOL, V32, P458, DOI 10.1016/S0735-1097(98)00233-2; Cleland JGF, 2006, EUR HEART J, V27, P2338, DOI 10.1093/eurheartj/ehl250; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; DAHLOF B, 1992, AM J HYPERTENS, V5, P95, DOI 10.1093/ajh/5.2.95; Devereux RB, 2004, CIRCULATION, V110, P1456, DOI 10.1161/01.CIR.0000141573.44737.5A; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; FRIEDRICH SP, 1994, CIRCULATION, V90, P2761, DOI 10.1161/01.CIR.90.6.2761; Gaasch WH, 2004, ANNU REV MED, V55, P373, DOI 10.1146/annurev.med.55.091902.104417; Garcia MJ, 1998, J AM COLL CARDIOL, V32, P865, DOI 10.1016/S0735-1097(98)00345-3; Henein M, 2002, EUR HEART J, V23, P162, DOI 10.1053/euhj.2001.3032; Ho CY, 2006, CIRCULATION, V113, pE396, DOI 10.1161/CIRCULATIONAHA.105.579268; Ho CY, 2002, CIRCULATION, V105, P2992, DOI 10.1161/01.CIR.0000019070.70491.6D; Janardhanan R, 2006, AM HEART J, V152, P246, DOI 10.1016/j.ahj.2006.01.009; Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005; Levy D, 1996, JAMA-J AM MED ASSOC, V275, P1557, DOI 10.1001/jama.275.20.1557; Nagueh SF, 1997, J AM COLL CARDIOL, V30, P1527, DOI 10.1016/S0735-1097(97)00344-6; Nagueh SF, 2001, CIRCULATION, V104, P128, DOI 10.1161/01.CIR.104.2.128; Oki T, 1998, J AM SOC ECHOCARDIOG, V11, P1106, DOI 10.1016/S0894-7317(98)80005-9; Pfeffer MA, 2003, NEW ENGL J MED, V349, P1893, DOI 10.1056/NEJMoa032292; Pfeffer MA, 2003, LANCET, V362, P759, DOI 10.1016/S0140-6736(03)14282-1; Redfield MM, 2003, JAMA-J AM MED ASSOC, V289, P194, DOI 10.1001/jama.289.2.194; Schmieder RE, 1996, JAMA-J AM MED ASSOC, V275, P1507, DOI 10.1001/jama.275.19.1507; SETARO JF, 1990, AM J CARDIOL, V66, P981, DOI 10.1016/0002-9149(90)90937-V; Sohn DW, 1997, J AM COLL CARDIOL, V30, P474, DOI 10.1016/S0735-1097(97)88335-0; Vinereanu D, 2005, EUR J HEART FAIL, V7, P820, DOI 10.1016/j.ejheart.2005.02.003; Wachtell K, 2002, CIRCULATION, V105, P1071, DOI 10.1161/hc0902.104599; Wachtell K, 2000, AM J CARDIOL, V85, P466, DOI 10.1016/S0002-9149(99)00773-0; Williams B, 2006, CIRCULATION, V113, P1213, DOI 10.1161/CIRCULATIONAHA.105.595496; Yusuf S, 2003, LANCET, V362, P777, DOI 10.1016/S0140-6736(03)14285-7; Zile MR, 2004, NEW ENGL J MED, V350, P1953, DOI 10.1056/NEJMoa032566; ZILE MR, 1987, CIRC RES, V60, P815, DOI 10.1161/01.RES.60.6.815; ZILE MR, 1989, CIRC RES, V65, P406, DOI 10.1161/01.RES.65.2.406; Zile MR, 2002, CIRCULATION, V105, P1387, DOI 10.1161/hc1102.105289	38	249	258	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 23	2007	369	9579					2079	2087		10.1016/S0140-6736(07)60980-5	http://dx.doi.org/10.1016/S0140-6736(07)60980-5			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	182GM	17586303				2022-12-28	WOS:000247493100028
J	Sundararaman, T				Sundararaman, Thiagarajan			Community health-workers: scaling up programmes	LANCET			English	Editorial Material									State Hlth Resource Ctr, Raipur 492001, Madhya Pradesh, India		Sundararaman, T (corresponding author), State Hlth Resource Ctr, Raipur 492001, Madhya Pradesh, India.	sundararaman.t@gmail.com						GARG S, 2006, EC POLIT WKLY   0826, P3694; *GOV CHHATT DEP PU, 2003, ANN ADM REP 2002 200, P47; HAINES A, 2007, LANCET          0306, DOI DOI 10.1016/S0140-6736(07)60325-0; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; KOHLI K, 2006, INFOCHANGE FEATU MAY; Manandhar DS, 2004, LANCET, V364, P970, DOI 10.1016/S0140-6736(04)17021-9; *NAT FAM HLTH SURV, 2006, KEY FIND NFHS 3; *REG GEN IND, 2006, VIT STAT SAMPL REG S; *STAT HLTH RES CTR, 2003, MIT PROGR CONC ISS O; *UNICEF MOD SERV P, 2006, CONV EV SURV 2005 AL, P90; WALT G, 1989, SOC SCI MED, V29, P599, DOI 10.1016/0277-9536(89)90179-2; WERNER D, 1977, VILLAGE HLTH WORKER	12	25	25	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 23	2007	369	9579					2058	2059		10.1016/S0140-6736(07)60326-2	http://dx.doi.org/10.1016/S0140-6736(07)60326-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	182GM	17586287				2022-12-28	WOS:000247493100007
J	Lewis, MH; Gohagan, JK; Merenstein, DJ				Huckaby Lewis, Michelle; Gohagan, John K.; Merenstein, Daniel J.			The locality rule and the physician's dilemma - Local medical practices vs the national standard of care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Johns Hopkins Berman Inst Bioeth, Greenwall Fellowship Program Bioeth & Hlth Policy, Baltimore, MD 21201 USA; Johns Hopkins Sch Med, Robert Wood Johnson Clin Scholars Program, Baltimore, MD USA; Georgetown Univ, Dept Family Med, Washington, DC USA; NCI, Div Canc Prevent, US Natl Inst Hlth, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lewis, MH (corresponding author), Johns Hopkins Berman Inst Bioeth, Greenwall Fellowship Program Bioeth & Hlth Policy, 100 N Charles St,Suite 740, Baltimore, MD 21201 USA.	michellelewismd@yahoo.com						CRAMM T, 2002, WAKE FOREST LAW REV, V37, P699; Eddy DM, 2001, J HEALTH POLIT POLIC, V26, P387, DOI 10.1215/03616878-26-2-387; Garner B. A., 2004, BLACKS LAW DICT, V8th; GROSS SR, 1991, WISC LAW REV, P1113; Merenstein D, 2004, JAMA-J AM MED ASSOC, V291, P15, DOI 10.1001/jama.291.1.15; Peters Jr. Philip G., 2000, WASHINGTON LEE LAW R, V57, P163; Peters PG, 2002, IOWA LAW REV, V87, P909; SWARTZ LC, 2005, 3698 PBI; WALTZ JR, 1969, DEPAUL L REV, V18, P408; WENNBERG JE, 1987, LANCET, V1, P1185, DOI 10.1016/s0140-6736(87)92152-0	10	33	33	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 20	2007	297	23					2633	2637		10.1001/jama.297.23.2633	http://dx.doi.org/10.1001/jama.297.23.2633			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180HB	17579232				2022-12-28	WOS:000247352600027
J	South, D				South, Dwalia			A tissue diagnosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												rwbdsb@ripleycable.net							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 20	2007	297	23					2565	2566		10.1001/jama.297.23.2565	http://dx.doi.org/10.1001/jama.297.23.2565			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180HB	17579217				2022-12-28	WOS:000247352600001
J	Weitzel, JN; Lagos, VI; Cullinane, CA; Gambol, PJ; Culver, JO; Blazer, KR; Palomares, MR; Lowstuter, KJ; MacDonald, DJ				Weitzel, Jeffrey N.; Lagos, Veronica I.; Cullinane, Carey A.; Gambol, Patricia J.; Culver, Julie O.; Blazer, Kathleen R.; Palomares, Melanie R.; Lowstuter, Katrina J.; MacDonald, Deborah J.			Limited family structure and BRCA gene mutation status in single cases of breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTRALATERAL PROPHYLACTIC MASTECTOMY; ASHKENAZI JEWISH CARRIERS; OF-CLINICAL-ONCOLOGY; OVARIAN-CANCER; RISK-ASSESSMENT; SCORING SYSTEM; SUSCEPTIBILITY; WOMEN; STATEMENT; HISTORY	Context An autosomal dominant pattern of hereditary breast cancer may be masked by small family size or transmission through males given sex-limited expression. Objective To determine if BRCA gene mutations are more prevalent among single cases of early onset breast cancer in families with limited vs adequate family structure than would be predicted by currently available probability models. Design, Setting, and Participants A total of 1543 women seen at US high-risk clinics for genetic cancer risk assessment and BRCA gene testing were enrolled in a prospective registry study between April 1997 and February 2007. Three hundred six of these women had breast cancer before age 50 years and no first- or second-degree relatives with breast or ovarian cancers. Main Outcome Measure The main outcome measure was whether family structure, assessed from multigenerational pedigrees, predicts BRCA gene mutation status. Limited family structure was defined as fewer than 2 first- or second-degree female relatives surviving beyond age 45 years in either lineage. Family structure effect and mutation probability by the Couch, Myriad, and BRCAPRO models were assessed with stepwise multiple logistic regression. Model sensitivity and specificity were determined and receiver operating characteristic curves were generated. Results Family structure was limited in 153 cases (50%). BRCA gene mutations were detected in 13.7% of participants with limited vs 5.2% with adequate family structure. Family structure was a significant predictor of mutation status ( odds ratio, 2.8; 95% confidence interval, 1.19-6.73; P=.02). Although none of the models performed well, receiver operating characteristic analysis indicated that modification of BRCAPRO output by a corrective probability index accounting for family structure was the most accurate BRCA gene mutation status predictor ( area under the curve, 0.72; 95% confidence interval, 0.63- 0.81; P <. 001) for single cases of breast cancer. Conclusions Family structure can affect the accuracy of mutation probability models. Genetic testing guidelines may need to be more inclusive for single cases of breast cancer when the family structure is limited and probability models need to be recreated using limited family history as an actual variable.	City Hope Natl Med Ctr, Dept Clin Canc Genet, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Dept Gen Oncol Surg, Duarte, CA 91010 USA	City of Hope; City of Hope	Weitzel, JN (corresponding author), City Hope Natl Med Ctr, Dept Clin Canc Genet, 1500 E Duarte Rd, Duarte, CA 91010 USA.	jweitzel@coh.org	Blazer, Kathleen/ABC-8530-2021		NCI NIH HHS [R25 CA85771, R25 CA085771] Funding Source: Medline; NCRR NIH HHS [M01 RR00043, M01 RR000043] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R25CA085771] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000043] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		*AM COLL MED GEN, 1999, GEN SUSC BREAST OV C, P1; *AM SOC HUM GEN, 1994, AM J HUM GENET, V55, P22; Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Antoniou AC, 2002, BRIT J CANCER, V86, P76, DOI 10.1038/sj.bjc.6600008; Antoniou AC, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1365; Antoniou AC, 2004, BRIT J CANCER, V91, P1580, DOI 10.1038/sj.bjc.6602175; Barcenas CH, 2006, J CLIN ONCOL, V24, P354, DOI 10.1200/JCO.2005.02.2368; Berg AO, 2005, ANN INTERN MED, V143, P355, DOI 10.7326/0003-4819-143-5-200509060-00011; Bruinooge SS, 2003, J CLIN ONCOL, V21, P2397, DOI 10.1200/JCO.2003.03.189; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; Culver JO, 2005, ANN INTERN MED; Domchek SM, 2003, J CLIN ONCOL, V21, P593, DOI 10.1200/JCO.2003.07.007; Evans DGR, 2005, J MED GENET, V42, DOI 10.1136/jmg.2005.031989; Evans DGR, 2004, J MED GENET, V41, P474, DOI 10.1136/jmg.2003.017996; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Frank TS, 2002, J CLIN ONCOL, V20, P1480, DOI 10.1200/JCO.20.6.1480; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Herrinton LJ, 2005, J CLIN ONCOL, V23, P4275, DOI 10.1200/JCO.2005.10.080; James PA, 2006, J CLIN ONCOL, V24, P707, DOI 10.1200/JCO.2005.01.9737; KANDEL MJ, 2006, 42 ANN M AM SOC CLIN; KRIEGE M, 2003, AM SOC CLIN ONC 39 A; McDonnell SK, 2001, J CLIN ONCOL, V19, P3938, DOI 10.1200/JCO.2001.19.19.3938; Metcalfe K, 2004, J CLIN ONCOL, V22, P2328, DOI 10.1200/JCO.2004.04.033; Metcalfe KA, 2005, GYNECOL ONCOL, V96, P222, DOI 10.1016/j.ygyno.2004.09.039; National Comprehensive Cancer Network, 2007, NCCN CLIN PRACT GUID; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; Parmigiani G, 1998, AM J HUM GENET, V62, P145, DOI 10.1086/301670; Peralta EA, 2000, AM J SURG, V180, P439, DOI 10.1016/S0002-9610(00)00505-5; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; Rebbeck TR, 2004, J CLIN ONCOL, V22, P1055, DOI 10.1200/JCO.2004.04.188; Satagopan JM, 2002, CLIN CANCER RES, V8, P3776; Satagopan JM, 2001, CANCER EPIDEM BIOMAR, V10, P467; Schwartz MD, 2004, J CLIN ONCOL, V22, P1823, DOI 10.1200/JCO.2004.04.086; Shih HA, 2002, J CLIN ONCOL, V20, P994, DOI 10.1200/JCO.20.4.994; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; WAMER E, 2004, JAMA-J AM MED ASSOC, V292, P1317; Weitzel JN, 2003, ARCH SURG-CHICAGO, V138, P1323, DOI 10.1001/archsurg.138.12.1323; Weitzel JN, 1999, CANCER, V86, P2483, DOI 10.1002/(SICI)1097-0142(19991201)86:11+<2483::AID-CNCR5>3.3.CO;2-W; Weitzel JN, 2004, BREAST DIS YB Q, V14, P354; Yong MC, 2003, ONCOLOGY-BASEL, V64, P220, DOI 10.1159/000069309	40	139	141	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 20	2007	297	23					2587	2595		10.1001/jama.297.23.2587	http://dx.doi.org/10.1001/jama.297.23.2587			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180HB	17579227	Bronze			2022-12-28	WOS:000247352600021
J	Hakonarson, H; Grant, SFA; Bradfield, JP; Marchand, L; Kim, CE; Glessner, JT; Grabs, R; Casalunovo, T; Taback, SP; Frackelton, EC; Lawson, ML; Robinson, LJ; Skraban, R; Lu, Y; Chiavacci, RM; Stanley, CA; Kirsch, SE; Rappaport, EF; Orange, JS; Monos, DS; Devoto, M; Qu, HQ; Polychronakos, C				Hakonarson, Hakon; Grant, Struan F. A.; Bradfield, Jonathan P.; Marchand, Luc; Kim, Cecilia E.; Glessner, Joseph T.; Grabs, Rosemarie; Casalunovo, Tracy; Taback, Shayne P.; Frackelton, Edward C.; Lawson, Margaret L.; Robinson, Luke J.; Skraban, Robert; Lu, Yang; Chiavacci, Rosetta M.; Stanley, Charles A.; Kirsch, Susan E.; Rappaport, Eric F.; Orange, Jordan S.; Monos, Dimitri S.; Devoto, Marcella; Qu, Hui-Qi; Polychronakos, Constantin			A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene	NATURE			English	Article							LYMPHOID TYROSINE PHOSPHATASE; NATURAL-KILLER-CELLS; SUSCEPTIBILITY GENES; FUNCTIONAL VARIANT; INSULIN GENE; LOCUS; MELLITUS; AUTOIMMUNITY; MHC; POLYMORPHISMS	Type 1 diabetes (T1D) in children results from autoimmune destruction of pancreatic beta cells, leading to insufficient production of insulin(1). A number of genetic determinants of T1D have already been established through candidate gene studies, primarily within the major histocompatibility complex(2-4) but also within other loci(5-12). To identify new genetic factors that increase the risk of T1D, we performed a genome-wide association study in a large paediatric cohort of European descent. In addition to confirming previously identified loci(2-9), we found that T1D was significantly associated with variation within a 233-kb linkage disequilibrium block on chromosome 16p13. This region contains KIAA0350, the gene product of which is predicted to be a sugar-binding, C-type lectin. Three common non-coding variants of the gene (rs2903692, rs725613 and rs17673553) in strong linkage disequilibrium reached genome-wide significance for association with T1D. A subsequent transmission disequilibrium test replication study in an independent cohort confirmed the association. These results indicate that KIAA0350 might be involved in the pathogenesis of T1D and demonstrate the utility of the genome-wide association approach in the identification of previously unsuspected genetic determinants of complex traits.	Childrens Hosp Philadelphia, Ctr Appl Genom, Abramson Res Ctr, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Abramson Res Ctr, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Human Genet, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Endocrinol, Philadelphia, PA 19104 USA; McGill Univ, Dept Pediat, Montreal, PQ H3H 1P3, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3H 1P3, Canada; Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3E 0Z2, Canada; Univ Ottawa, Div Endocrinol, Childrens Hosp Eastern Ontario, Ottawa, ON K1H 8L1, Canada; Markham Stouffville Hosp, Markham, ON L3P 7P3, Canada; Childrens Hosp Philadelphia Nucleic Acid & Prot C, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; McGill University; McGill University; University of Manitoba; University of Ottawa; Children's Hospital of Eastern Ontario; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Hakonarson, H (corresponding author), Childrens Hosp Philadelphia, Ctr Appl Genom, Abramson Res Ctr, Philadelphia, PA 19104 USA.	hakonarson@chop.edu; constantin.polychronakos@mcgill.ca	Devoto, Marcella/AAP-7595-2021; Qu, Hui-Qi/B-4719-2009; Rappaport, Eric/GRO-4051-2022; Orange, Jordan S/D-5239-2009; Polychronakos, Constantin/B-8151-2008; Lawson, Margaret/M-6969-2015	Qu, Hui-Qi/0000-0001-9317-4488; orange, jordan/0000-0001-7117-7725; DEVOTO, MARCELLA/0000-0002-4431-5114; Glessner, Joseph/0000-0001-5131-2811; Lawson, Margaret/0000-0002-2370-9552; STANLEY, CHARLES/0000-0003-4881-9392; Polychronakos, Constantin/0000-0002-7624-6635; Grant, Struan/0000-0003-2025-5302				Anjos SM, 2004, J CLIN ENDOCR METAB, V89, P6257, DOI 10.1210/jc.2004-0881; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; BELL GI, 1984, DIABETES, V33, P176, DOI 10.2337/diabetes.33.2.176; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; Biason-Lauber A, 2005, DIABETOLOGIA, V48, P900, DOI 10.1007/s00125-005-1723-5; Bottini N, 2004, NAT GENET, V36, P337, DOI 10.1038/ng1323; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Cambi A, 2005, CURR OPIN IMMUNOL, V17, P345, DOI 10.1016/j.coi.2005.05.011; Concannon P, 1998, NAT GENET, V19, P292, DOI 10.1038/985; Cucca F, 1998, NAT GENET, V19, P301, DOI 10.1038/995; Cucca F, 2001, HUM MOL GENET, V10, P2025, DOI 10.1093/hmg/10.19.2025; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; de Bakker PIW, 2006, NAT GENET, V38, P1166, DOI 10.1038/ng1885; Devendra D, 2004, BMJ-BRIT MED J, V328, P750, DOI 10.1136/bmj.328.7442.750; Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149; Fisher R.A., 1958, STAT METHODS RES WOR; Gunderson KL, 2005, NAT GENET, V37, P549, DOI 10.1038/ng1547; Guo DH, 2004, NAT GENET, V36, P837, DOI 10.1038/ng1391; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; Kristiansen OP, 2000, GENES IMMUN, V1, P170, DOI 10.1038/sj.gene.6363655; Mein CA, 1998, NAT GENET, V19, P297, DOI 10.1038/991; Mirel DB, 2002, DIABETES, V51, P3336, DOI 10.2337/diabetes.51.11.3336; NERUP J, 1974, LANCET, V2, P864; Noble JA, 1996, AM J HUM GENET, V59, P1134; Poirot L, 2004, P NATL ACAD SCI USA, V101, P8102, DOI 10.1073/pnas.0402065101; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; PURCELL S, IN PRESS AM J HUM GE; Rodacki M, 2007, DIABETES, V56, P177, DOI 10.2337/db06-0493; Smyth D, 2004, DIABETES, V53, P3020, DOI 10.2337/diabetes.53.11.3020; Smyth DJ, 2006, NAT GENET, V38, P617, DOI 10.1038/ng1800; Steemers FJ, 2006, NAT METHODS, V3, P31, DOI 10.1038/NMETH842; TODD JA, 2007, NATURE GENET, DOI DOI 10.1038/NG2068; Ueda H, 2003, NATURE, V423, P506, DOI 10.1038/nature01621; Vafiadis P, 1997, NAT GENET, V15, P289, DOI 10.1038/ng0397-289; Vella A, 2005, AM J HUM GENET, V76, P773, DOI 10.1086/429843	35	412	431	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 2	2007	448	7153					591	U7		10.1038/nature06010	http://dx.doi.org/10.1038/nature06010			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	195XV	17632545				2022-12-28	WOS:000248446700043
J	Smith, R				Smith, Richard			Should medical journals carry drug advertising? Yes	BRITISH MEDICAL JOURNAL			English	Editorial Material									UnitedHlth Europe, London SW1P 1SB, England		Smith, R (corresponding author), UnitedHlth Europe, London SW1P 1SB, England.	richardswsmith@yahoo.co.uk							0	10	10	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUL 14	2007	335	7610					74	74		10.1136/bmj.39259.472998.AD	http://dx.doi.org/10.1136/bmj.39259.472998.AD			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	192JM	17626959	Green Published			2022-12-28	WOS:000248197500029
J	Detsky, AS; Laupacis, A				Detsky, Allan S.; Laupacis, Andreas			Relevance of cost-effectiveness analysis to clinicians and policy makers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LIFE EXPECTANCY; GUIDELINES		Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Hlth Policy, Toronto, ON, Canada; Univ Toronto, Dept Management, Toronto, ON, Canada; Univ Toronto, Dept Evaluat, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Hlth Network, Dept Med, Toronto, ON, Canada; St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON M5B 1W8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto	Detsky, AS (corresponding author), Mt Sinai Hosp, Dept Med, 600 Univ Ave,Room 427, Toronto, ON M5G 1X5, Canada.	allan.detsky@uhn.on.ca						ABT CC, 1977, COSTS RISKS BENEFITS, pCH3; Bell CM, 2006, BMJ-BRIT MED J, V332, P699, DOI 10.1136/bmj.38737.607558.80; BIRCH S, 1992, J HEALTH ECON, V11, P279, DOI 10.1016/0167-6296(92)90004-K; *CAN I HLTH INF, 2007, DRUG EXP CAN 1985 20; DETSKY AS, 1990, ANN INTERN MED, V113, P147, DOI 10.7326/0003-4819-113-2-147; DETSKY AS, 1994, PHARMACOECONOMICS, V6, P281; DRUMMOND M, 1993, SOC SCI MED, V37, P33, DOI 10.1016/0277-9536(93)90315-U; Gold MR, 1996, COST EFFECTIVENESS H; KASSIRER JP, 1994, NEW ENGL J MED, V331, P669, DOI 10.1056/NEJM199409083311009; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; NAIMARK D, 1994, J GEN INTERN MED, V9, P702, DOI 10.1007/BF02599016; OBRIEN B, 1994, MED DECIS MAKING, V14, P289, DOI 10.1177/0272989X9401400311; PLISKIN N, 1977, COSTS RISKS BENEFITS; Torrance GW, 1996, PHARMACOECONOMICS, V9, P535, DOI 10.2165/00019053-199609060-00008; Wright JC, 1998, NEW ENGL J MED, V339, P380, DOI 10.1056/NEJM199808063390606	15	70	72	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2007	298	2					221	224		10.1001/jama.298.2.221	http://dx.doi.org/10.1001/jama.298.2.221			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188HI	17622605				2022-12-28	WOS:000247910600029
J	Topol, EJ; Murray, SS; Frazer, KA				Topol, Eric J.; Murray, Sarah S.; Frazer, Kelly A.			The genomics gold rush	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							WIDE ASSOCIATION; RISK LOCI; VARIANT		Scripps Res Inst, La Jolla, CA 92037 USA; Scripps Genom Med, La Jolla, CA USA; Scripps Hlth, La Jolla, CA USA	Scripps Research Institute	Topol, EJ (corresponding author), Scripps Res Inst, 10550 N Torrey Pines Rd,MEM-275, La Jolla, CA 92037 USA.	etopol@scripps.edu		Topol, Eric/0000-0002-1478-4729; Frazer, Kelly/0000-0002-6060-8902				Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; CRICHTON M, 2007, NY TIMES A      0213; EASTON DF, 2007, NATURE          0527, DOI DOI 10.1038/NATURE05887; Frayling TM, 2007, SCIENCE, V316, P889, DOI 10.1126/science.1141634; Gudmundsson J, 2007, NAT GENET, V39, P631, DOI 10.1038/ng1999; Haiman CA, 2007, NAT GENET, V39, P638, DOI 10.1038/ng2015; Helgadottir A, 2007, SCIENCE, V316, P1491, DOI 10.1126/science.1142842; Hinds DA, 2005, SCIENCE, V307, P1072, DOI 10.1126/science.1105436; HUNTER DJ, 2007, NATURE          0527, DOI DOI 10.1038/NG2075; Kohane IS, 2006, JAMA-J AM MED ASSOC, V296, P212, DOI 10.1001/jama.296.2.212; McPherson R, 2007, SCIENCE, V316, P1488, DOI 10.1126/science.1142447; Nadeau JH, 2006, NAT GENET, V38, P1095, DOI 10.1038/ng1006-1095; Saxena R, 2007, SCIENCE, V316, P1331, DOI 10.1126/science.1142358; Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382; Sladek R, 2007, NATURE, V445, P881, DOI 10.1038/nature05616; STACEY SN, 2007, NATURE          0527, DOI DOI 10.1038/NG2064; Steinthorsdottir V, 2007, NAT GENET, V39, P770, DOI 10.1038/ng2043; Szatmari P, 2007, NAT GENET, V39, P319, DOI 10.1038/ng1985; Topol EJ, 2007, NAT GENET, V39, P439, DOI 10.1038/ng0407-439; Yeager M, 2007, NAT GENET, V39, P645, DOI 10.1038/ng2022; Zeggini E, 2007, SCIENCE, V316, P1336, DOI 10.1126/science.1142364	21	61	63	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2007	298	2					218	221		10.1001/jama.298.2.218	http://dx.doi.org/10.1001/jama.298.2.218			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188HI	17622604				2022-12-28	WOS:000247910600028
J	Mehl, MR; Vazire, S; Ramirez-Esparza, N; Slatcher, RB; Pennebaker, JW				Mehl, Matthias R.; Vazire, Simine; Ramirez-Esparza, Nairan; Slatcher, Richard B.; Pennebaker, James W.			Are women really more talkative than men?	SCIENCE			English	Article									Univ Arizona, Dept Psychol, Tucson, AZ 85721 USA; Washington Univ, Dept Psychol, St Louis, MO 63130 USA; Univ Texas, Dept Psychol, Austin, TX 78712 USA	University of Arizona; Washington University (WUSTL); University of Texas System; University of Texas Austin	Mehl, MR (corresponding author), Univ Arizona, Dept Psychol, Tucson, AZ 85721 USA.	mehl@email.arizona.edu	Pennebaker, James W/E-5997-2013; Pennebaker, James/GLR-6058-2022; Ramirez-Esparza, Nairan/Q-2854-2018	Pennebaker, James W/0000-0001-9091-214X; Vazire, Simine/0000-0002-3933-9752	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052391] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 52391] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Brizendine L., 2006, FEMALE BRAIN; James D., 1993, GENDER CONVERSATIONA, P281; LAKOFF R, 1975, LANGUAGE WORNANS PLA; LIBERMAN M, SEX LINKED LEXICAL B; Litosseliti L., 2006, GENDER LANGUAGE THEO; Mehl MR, 2001, BEHAV RES METH INS C, V33, P517, DOI 10.3758/BF03195410; Rayson Paul., 1997, INT J CORPUS LINGUIS, V2, P133, DOI DOI 10.1075/IJCL.2.1.07RAY	7	219	224	3	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2007	317	5834					82	82		10.1126/science.1139940	http://dx.doi.org/10.1126/science.1139940			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186KD	17615349				2022-12-28	WOS:000247776700054
J	Cross, M				Cross, Mchaell			Richard Granger's legacy - Computer says yes - and no - What is the future of the NHSIT programme now that its supremo has quit?	BRITISH MEDICAL JOURNAL			English	Editorial Material												michaelcross@fastmail.fm							0	5	5	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 30	2007	334	7608					1350	1351		10.1136/bmj.39259.445035.34	http://dx.doi.org/10.1136/bmj.39259.445035.34			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	185VX	17600022	Green Published			2022-12-28	WOS:000247739600029
J	McDonald, R; Harrison, S; Checkland, K; Campbell, SM; Roland, M				McDonald, Ruth; Harrison, Stephen; Checkland, Kath; Campbell, Stephen M.; Roland, Martin			Impact of financial incentives on clinical autonomy and internal motivation in primary care: ethnographic study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PAY-FOR-PERFORMANCE; GENERAL-PRACTICE; QUALITY; WORK	Objective To explore the impact of financial incentives for quality of care on practice organisation, clinical autonomy, and internal motivation of doctors and nurses working in primary care. Design Ethnographic case study. Setting Two English general practices. Participants 12 general practitioners, nine nurses, four healthcare assistants, and four administrative staff. Main outcome measure Observation of practices over a five month period after the introduction of financial incentives for quality of care introduced in the 2004 general practitioner contract. Results After the introduction of the quality and outcomes framework there was an increase in the use of templates to collect data on quality of care. New regimens of surveillance were adopted, with clinicians seen as "chasers" or the "chased," depending on their individual responsibility for delivering quality targets. Attitudes towards the contract were largely positive, although discontent was higher in the practice with a more intensive surveillance regimen. Nurses expressed more concern than doctors about changes to their clinical practice but also appreciated being given responsibility for delivering on targets in particular disease areas. Most doctors did not question the quality targets that existed at the time or the implications of the targets for their own clinical autonomy. Conclusions Implementation of financial incentives for quality of care did not seem to have damaged the internal motivation of the general practitioners studied, although more concern was expressed by nurses.	Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England	University of Manchester	McDonald, R (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England.	ruth.mcdonald@manchester.ac.uk	McDonald, Ruth/C-3547-2013; Checkland, Kath/G-8442-2014	Checkland, Kath/0000-0002-9961-5317; McDonald, Ruth/0000-0002-3488-4209; Campbell, Stephen/0000-0002-2328-4136	National Institute for Health Research [CL-2006-06-008] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR))		Campbell S, 2001, BRIT MED J, V322, P1580, DOI 10.1136/bmj.322.7302.1580; CAMPBELL S, IN PRESS N ENGL J ME; Campbell SM, 2005, BMJ-BRIT MED J, V331, P1121, DOI 10.1136/bmj.38632.611123.AE; Charles-Jones H, 2003, SOCIOL HEALTH ILL, V25, P71, DOI 10.1111/1467-9566.t01-1-00325; Christianson JB, 2006, J GEN INTERN MED, V21, pS9, DOI 10.1111/j.1525-1497.2006.00356.x; Committee on Redesigning Health Insurance Performance Measures PaPIP, 2007, REW PROV PERF AL INC; Deci E. L., 1985, INTRINSIC MOTIVATION; Deci EL, 1999, PSYCHOL BULL, V125, P627, DOI 10.1037/0033-2909.125.6.627; Doran T, 2006, NEW ENGL J MED, V355, P375, DOI 10.1056/NEJMsa055505; Gagne M, 2005, J ORGAN BEHAV, V26, P331, DOI 10.1002/job.322; Green J, 1999, BRIT MED J, V319, P421; Harrison S, 2002, J SOC POLICY, V31, P465, DOI 10.1017/S0047279402006694; Harrison S, 2002, SOCIOL HEALTH ILL, V24, P208, DOI 10.1111/1467-9566.00291; HOLMSTROM B, 1982, BELL J ECON, V13, P324, DOI 10.2307/3003457; Lanier DC, 2003, LANCET, V362, P1404, DOI 10.1016/S0140-6736(03)14638-7; Marshall M, 2005, QUAL SAF HEALTH CARE, V14, P4, DOI 10.1136/qshc.2004.013193; Mercer SW, 2007, BMJ-BRIT MED J, V334, P8, DOI 10.1136/bmj.39070.553924.3A; Newman Graeme R., 2005, NAT I JUST FOC GROUP; Roland M, 2004, NEW ENGL J MED, V351, P1448, DOI 10.1056/NEJMhpr041294; Roland M, 2006, PRIM HEALTH CARE RES, V7, P18, DOI DOI 10.1191/1463423606PC2720A; Sheaff R, 2003, SOCIOL HEALTH ILL, V25, P408, DOI 10.1111/1467-9566.00352; Sheaff R, 2002, SOC POLICY ADMIN, V36, P765, DOI 10.1111/1467-9515.00316; Spooner A, 2001, J Health Serv Res Policy, V6, P145, DOI 10.1258/1355819011927396	23	106	107	0	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 30	2007	334	7608					1357	1359		10.1136/bmj.39238.890810.BE	http://dx.doi.org/10.1136/bmj.39238.890810.BE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	185VX	17580318	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000247739600033
J	Ha, T				Ha, Taekjip			Need for speed: Mechanical regulation of a replicative helicase	CELL			English	Editorial Material							UNWINDING MECHANISM; HEXAMERIC HELICASE; DNA; TRANSLOCATION	There is much debate about how helicases unwind DNA during DNA replication and how their activity is regulated. In this issue, Johnson et al. (2007) shed light on this conundrum using a single molecule approach to dissect the behavior of the T7 DNA helicase.	Univ Illinois, Inst Genom Biol, Dept Phys, Urbana, IL 61801 USA; Univ Illinois, Inst Genom Biol, Dept Phys, Urbana, IL 61801 USA; Howard Hughes Med Inst, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Howard Hughes Medical Institute	Ha, T (corresponding author), Univ Illinois, Inst Genom Biol, Dept Phys, Urbana, IL 61801 USA.	tjha@uiuc.edu	Ha, Taekjip/B-9506-2009	Ha, Taekjip/0000-0003-2195-6258	NIGMS NIH HHS [R01 GM065367] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065367] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Dumont S, 2006, NATURE, V439, P105, DOI 10.1038/nature04331; Enemark EJ, 2006, NATURE, V442, P270, DOI 10.1038/nature04943; Galletto R, 2004, J MOL BIOL, V343, P101, DOI 10.1016/j.jmb.2004.07.056; Ha T, 2002, NATURE, V419, P638, DOI 10.1038/nature01083; Jeong YJ, 2004, P NATL ACAD SCI USA, V101, P7264, DOI 10.1073/pnas.0400372101; Lee JB, 2006, NATURE, V439, P621, DOI 10.1038/nature04317; Myong S, 2005, NATURE, V437, P1321, DOI 10.1038/nature04049; Skordalakes E, 2003, CELL, V114, P135, DOI 10.1016/S0092-8674(03)00512-9; Stano NM, 2005, NATURE, V435, P370, DOI 10.1038/nature03615	9	6	6	1	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 29	2007	129	7					1249	1250		10.1016/j.cell.2007.06.007	http://dx.doi.org/10.1016/j.cell.2007.06.007			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188HQ	17604712	Bronze			2022-12-28	WOS:000247911400008
J	Johnson, DS; Bai, L; Smith, BY; Patel, SS; Wang, MD				Johnson, Daniel S.; Bai, Lu; Smith, Benjamin Y.; Patel, Smita S.; Wang, Michelle D.			Single-molecule studies reveal dynamics of DNA unwinding by the ring-shaped T7 helicase	CELL			English	Article							STRANDED-DNA; CRYSTAL-STRUCTURE; HEXAMERIC HELICASE; BACTERIOPHAGE T7; RECBCD ENZYME; MACROMOLECULAR MACHINES; ACTIVE MECHANISM; GENE-4 PROTEIN; COLI UVRD; TRANSLOCATION	Helicases are molecular motors that separate DNA strands for efficient replication of genomes. We probed the kinetics of individual ring-shaped T7 helicase molecules as they unwound double-stranded DNA (dsDNA) or translocated on single-stranded DNA (ssDNA). A distinctive DNA sequence dependence was observed in the unwinding rate that correlated with the local DNA unzipping energy landscape. The unwinding rate increased similar to 10- fold (approaching the ssDNA translocation rate) when a destabilizing force on the DNA fork junction was increased from 5 to 11 pN. These observations reveal a fundamental difference between the mechanisms of ring-shaped and nonring-shaped helicases. The observed force-velocity and sequence dependence are not consistent with a simple passive unwinding model. However, an active unwinding model fully supports the data even though the helicase on its own does not unwind at its optimal rate. This work offers insights into possible ways helicase activity is enhanced by associated proteins.	Cornell Univ, Dept Phys, Atom & Solid State Phys Lab, Ithaca, NY 14853 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Cornell University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Wang, MD (corresponding author), Cornell Univ, Dept Phys, Atom & Solid State Phys Lab, Ithaca, NY 14853 USA.	mdw17@cornell.edu		Johnson, Daniel/0000-0001-8906-0509	NIGMS NIH HHS [R01 GM059849-05, R01 GM059849, R01 GM059849-04, R01 GM055310, R01 GM059849-07, R01 GM059849-09, GM55310, R01 GM059849-06A1, R01 GM059849-08] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059849, R01GM055310] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adelman K, 2002, P NATL ACAD SCI USA, V99, P13538, DOI 10.1073/pnas.212358999; Ahnert P, 1997, J BIOL CHEM, V272, P32267, DOI 10.1074/jbc.272.51.32267; AMARATUNGA M, 1993, BIOCHEMISTRY-US, V32, P6815, DOI 10.1021/bi00078a003; [Anonymous], 1992, INTERMOLECULAR SURFA; Bertram RD, 2002, BIOCHEMISTRY-US, V41, P7725, DOI 10.1021/bi025755s; BETTERDON MD, 2005, SOFT MATTER PHYS, V71; Betterton MD, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.258103; Bockelmann U, 1997, PHYS REV LETT, V79, P4489, DOI 10.1103/PhysRevLett.79.4489; Brendza KM, 2005, P NATL ACAD SCI USA, V102, P10076, DOI 10.1073/pnas.0502886102; CHEN YZ, 1992, J BIOMOL STRUCT DYN, V10, P415, DOI 10.1080/07391102.1992.10508656; Cheng W, 2002, P NATL ACAD SCI USA, V99, P16006, DOI 10.1073/pnas.242479399; Delagoutte E, 2002, Q REV BIOPHYS, V35, P431, DOI 10.1017/S0033583502003852; Delagoutte E, 2001, BIOCHEMISTRY-US, V40, P4459, DOI 10.1021/bi001306l; Dessinges MN, 2004, P NATL ACAD SCI USA, V101, P6439, DOI 10.1073/pnas.0306713101; Dillingham MS, 2003, NATURE, V423, P893, DOI 10.1038/nature01673; Dillingham MS, 2000, BIOCHEMISTRY-US, V39, P205, DOI 10.1021/bi992105o; Dohoney KM, 2001, NATURE, V409, P370, DOI 10.1038/35053124; Dumont S, 2006, NATURE, V439, P105, DOI 10.1038/nature04331; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; Enemark EJ, 2006, NATURE, V442, P270, DOI 10.1038/nature04943; Fischer CJ, 2004, J MOL BIOL, V344, P1287, DOI 10.1016/j.jmb.2004.10.005; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; Hacker KJ, 1997, BIOCHEMISTRY-US, V36, P14080, DOI 10.1021/bi971644v; Jeong YJ, 2004, P NATL ACAD SCI USA, V101, P7264, DOI 10.1073/pnas.0400372101; Johnson DS, 2004, BIOPHYS J, V86, p328A; Kaplan DL, 2004, MOL CELL, V15, P453, DOI 10.1016/j.molcel.2004.06.039; Kim DE, 2002, J MOL BIOL, V321, P807, DOI 10.1016/S0022-2836(02)00733-7; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Koch SJ, 2002, BIOPHYS J, V83, P1098, DOI 10.1016/S0006-3495(02)75233-8; Lee JY, 2006, CELL, V127, P1349, DOI 10.1016/j.cell.2006.10.049; Lee JB, 2006, NATURE, V439, P621, DOI 10.1038/nature04317; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Maluf NK, 2003, J MOL BIOL, V325, P913, DOI 10.1016/S0022-2836(02)01277-9; Markham NR, 2005, NUCLEIC ACIDS RES, V33, pW577, DOI 10.1093/nar/gki591; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; Myong S, 2005, NATURE, V437, P1321, DOI 10.1038/nature04049; PATEL SS, 1992, J BIOL CHEM, V267, P15013; PATEL SS, 1993, J BIOL CHEM, V268, P10668; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Perkins TT, 2004, BIOPHYS J, V86, P1640, DOI 10.1016/S0006-3495(04)74232-0; Peterman EJG, 2003, BIOPHYS J, V84, P1308, DOI 10.1016/S0006-3495(03)74946-7; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; Shundrovsky A, 2006, NAT STRUCT MOL BIOL, V13, P549, DOI 10.1038/nsmb1102; Singleton MR, 2004, NATURE, V432, P187, DOI 10.1038/nature02988; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Singleton MR, 2002, J BACTERIOL, V184, P1819, DOI 10.1128/JB.184.7.1819-1826.2002; Smith SB, 1996, SCIENCE, V271, P795, DOI 10.1126/science.271.5250.795; Soultanas P, 2001, TRENDS BIOCHEM SCI, V26, P47, DOI 10.1016/S0968-0004(00)01734-5; Soultanas P, 2000, EMBO J, V19, P3799, DOI 10.1093/emboj/19.14.3799; Spies M, 2003, CELL, V114, P647, DOI 10.1016/S0092-8674(03)00681-0; Stano NM, 2005, NATURE, V435, P370, DOI 10.1038/nature03615; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; Taylor AF, 2003, NATURE, V423, P889, DOI 10.1038/nature01674; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; von Hippel PH, 2001, CELL, V104, P177, DOI 10.1016/S0092-8674(01)00203-3; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350	58	186	190	0	35	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 29	2007	129	7					1299	1309		10.1016/j.cell.2007.04.038	http://dx.doi.org/10.1016/j.cell.2007.04.038			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188HQ	17604719	Bronze, Green Accepted			2022-12-28	WOS:000247911400016
J	Lansdorp, PM				Lansdorp, Peter M.			Immortal strands? Give me a break	CELL			English	Article							TEMPLATE DNA STRANDS; STEM-CELLS; SELECTIVE SEGREGATION; CANCER; GENOME; DIVISION; GENES	The "immortal strand" hypothesis proposes that asymmetrically dividing stem cells selectively retain chromosomes containing "old" DNA to prevent accumulation of mutations. As I describe in this Essay, such a possibility seems unlikely. An alternative explanation is that asymmetric cell divisions and cell fate are codirected by epigenetic differences between sister chromatids.	British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; Univ British Columbia, Dept Med, Div Hematol, Vancouver, BC V5Z 1L3, Canada	British Columbia Cancer Agency; University of British Columbia	Lansdorp, PM (corresponding author), British Columbia Canc Agcy, Terry Fox Lab, 601 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	plansdor@bccrc.ca		Lansdorp, Peter/0000-0001-7435-1071				Armakolas A, 2006, SCIENCE, V311, P1146, DOI 10.1126/science.1120519; Bailey SM, 2004, CYTOGENET GENOME RES, V107, P14, DOI 10.1159/000079565; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; Cairns J, 2002, P NATL ACAD SCI USA, V99, P10567, DOI 10.1073/pnas.162369899; Conboy MJ, 2007, PLOS BIOL, V5, P1120, DOI 10.1371/journal.pbio.0050102; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Hochedlinger K, 2004, GENE DEV, V18, P1875, DOI 10.1101/gad.1213504; Karpowicz P, 2005, J CELL BIOL, V170, P721, DOI 10.1083/jcb.200502073; Lansdorp P M, 1997, Biol Blood Marrow Transplant, V3, P171; Lansdorp PM, 2005, TRENDS BIOCHEM SCI, V30, P388, DOI 10.1016/j.tibs.2005.05.004; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; Morrison SJ, 2006, NATURE, V441, P1068, DOI 10.1038/nature04956; Potten CS, 2002, J CELL SCI, V115, P2381; Shinin V, 2006, NAT CELL BIOL, V8, P677, DOI 10.1038/ncb1425; Slotkin RK, 2007, NAT REV GENET, V8, P272, DOI 10.1038/nrg2072; Smith GH, 2005, DEVELOPMENT, V132, P681, DOI 10.1242/dev.01609; Spalding KL, 2005, CELL, V122, P133, DOI 10.1016/j.cell.2005.04.028; Veeramachaneni V, 2004, GENOME RES, V14, P280, DOI 10.1101/gr.1590904; WILMUT I, 1997, NATURE, V385, P813; Yamashita YM, 2007, SCIENCE, V315, P518, DOI 10.1126/science.1134910	22	145	149	1	13	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 29	2007	129	7					1244	1247		10.1016/j.cell.2007.06.017	http://dx.doi.org/10.1016/j.cell.2007.06.017			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188HQ	17604711	Bronze			2022-12-28	WOS:000247911400007
J	Pan, JM; Snell, W				Pan, Junmin; Snell, William			The primary cilium: Keeper of the key to cell division	CELL			English	Editorial Material							INTRAFLAGELLAR TRANSPORT; CHLAMYDOMONAS; FLAGELLA; CYCLE	Assembly of the nonmotile primary cilium of vertebrate cells requires one of the centrioles of the centrosome. A cluster of new studies, including one in this issue of Cell by Pugacheva et al. (2007), reveal that ciliary assembly proteins influence cell-cycle progression and that a centrosomal "mitotic kinase" promotes ciliary disassembly. The link between the cell cycle and the primary cilium may reflect a requirement for liberation of the ciliary centriole to allow the centrosome to form the mitotic spindle.	[Pan, Junmin] Tsinghua Univ, Dept Biol Sci & Technol, Beijing 100084, Peoples R China; [Snell, William] Univ Texas Southwestern Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	Tsinghua University; University of Texas System; University of Texas Southwestern Medical Center Dallas	Snell, W (corresponding author), Univ Texas Southwestern Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA.	william.snell@utsouthwestern.edu	Pan, Junmin/H-2673-2014					Pan JM, 2005, DEV CELL, V9, P431, DOI 10.1016/j.devcel.2005.07.010; Qin HM, 2007, CURR BIOL, V17, P193, DOI 10.1016/j.cub.2006.12.040; Quarmby LM, 2005, J CELL BIOL, V169, P707, DOI 10.1083/jcb.200503053; RIEDER CL, 1979, J ULTRA MOL STRUCT R, V68, P173, DOI 10.1016/S0022-5320(79)90152-7; Robert A, 2007, J CELL SCI, V120, P628, DOI 10.1242/jcs.03366; Scholey JM, 2006, CELL, V125, P439, DOI 10.1016/j.cell.2006.04.013; SLUDER G, 2004, CENTROSOMES DEV DIS, P167, DOI DOI 10.1002/3527603808.CH9; SOROKIN S, 1962, J CELL BIOL, V15, P363, DOI 10.1083/jcb.15.2.363; Tam LW, 2007, J CELL BIOL, V176, P819, DOI 10.1083/jcb.200610022; TUCKER RW, 1979, CELL, V17, P527, DOI 10.1016/0092-8674(79)90261-7	10	122	128	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 29	2007	129	7					1255	1257		10.1016/j.cell.2007.06.018	http://dx.doi.org/10.1016/j.cell.2007.06.018			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188HQ	17604715	Bronze			2022-12-28	WOS:000247911400011
J	Vega, FM; Ridley, AJ				Vega, Francisco M.; Ridley, Anne J.			SnapShot: Rho family GTPases	CELL			English	Editorial Material							PROTEINS; CANCER		Kings Coll London, Randall Div Cell & Mol Biophys, London, England	University of London; King's College London	Vega, FM (corresponding author), Kings Coll London, Randall Div Cell & Mol Biophys, London, England.		Vega, Francisco M./C-4678-2008	Vega, Francisco M./0000-0002-9015-864X				Aspenstrom P, 2004, BIOCHEM J, V377, P327, DOI 10.1042/BJ20031041; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Ridley AJ, 2004, BREAST CANCER RES TR, V84, P13, DOI 10.1023/B:BREA.0000018423.47497.c6; Ridley AJ, 2006, TRENDS CELL BIOL, V16, P522, DOI 10.1016/j.tcb.2006.08.006; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sorokina EM, 2005, J CELL BIOCHEM, V94, P225, DOI 10.1002/jcb.20327; Villalonga P, 2006, GROWTH FACTORS, V24, P159, DOI 10.1080/08977190600560651; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; Wheeler AP, 2004, EXP CELL RES, V301, P43, DOI 10.1016/j.yexcr.2004.08.012	9	50	56	3	18	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 29	2007	129	7					1430	U2		10.1016/j.cell.2007.06.021	http://dx.doi.org/10.1016/j.cell.2007.06.021			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	188HQ	17604728	Bronze			2022-12-28	WOS:000247911400027
J	Louik, C; Lin, AE; Werler, MM; Hernandez-Diaz, S; Mitchell, AA				Louik, Carol; Lin, Angela E.; Werler, Martha M.; Hernandez-Diaz, Sonia; Mitchell, Allen A.			First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MATERNAL OBESITY; PREGNANT-WOMEN; BENDECTIN USE; IN-UTERO; EXPOSURE; DEPRESSION; OUTCOMES; ANTIDEPRESSANTS; PREVALENCE; DRUGS	BACKGROUND: The risk of birth defects after antenatal exposure to selective serotonin-reuptake inhibitors (SSRIs) remains controversial. METHODS: We assessed associations between first-trimester maternal use of SSRIs and the risk of birth defects among 9849 infants with and 5860 infants without birth defects participating in the Slone Epidemiology Center Birth Defects Study. RESULTS: In analyses of defects previously associated with SSRI use (involving 42 comparisons), overall use of SSRIs was not associated with significantly increased risks of craniosynostosis (115 subjects, 2 exposed to SSRIs; odds ratio, 0.8; 95% confidence interval [CI], 0.2 to 3.5), omphalocele (127 subjects, 3 exposed; odds ratio, 1.4; 95% CI, 0.4 to 4.5), or heart defects overall (3724 subjects, 100 exposed; odds ratio, 1.2; 95% CI, 0.9 to 1.6). Analyses of the associations between individual SSRIs and specific defects showed significant associations between the use of sertraline and omphalocele (odds ratio, 5.7; 95% CI, 1.6 to 20.7; 3 exposed subjects) and septal defects (odds ratio, 2.0; 95% CI, 1.2 to 4.0; 13 exposed subjects) and between the use of paroxetine and right ventricular outflow tract obstruction defects (odds ratio, 3.3; 95% CI, 1.3 to 8.8; 6 exposed subjects). The risks were not appreciably or significantly increased for other defects or other SSRIs or non-SSRI antidepressants. Exploratory analyses involving 66 comparisons showed possible associations of paroxetine and sertraline with other specific defects. CONCLUSIONS: Our findings do not show that there are significantly increased risks of craniosynostosis, omphalocele, or heart defects associated with SSRI use overall. They suggest that individual SSRIs may confer increased risks for some specific defects, but it should be recognized that the specific defects implicated are rare and the absolute risks are small.	Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA; Massachusetts Gen Hosp Children, Genet Unit, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Boston University; Harvard University; Harvard T.H. Chan School of Public Health	Louik, C (corresponding author), Boston Univ, Slone Epidemiol Ctr, 1010 Commonwealth Ave, Boston, MA 02215 USA.	clouik@slone.bu.edu		Werler, Martha/0000-0003-3392-6814; Louik, Carol/0000-0001-5429-5084; Mitchell, Allen/0000-0003-0950-6799	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027697] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50763] Funding Source: Medline; NICHD NIH HHS [HD27697] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alwan S, 2005, Birth Defects Research, V73, P291; Alwan S, 2007, NEW ENGL J MED, V356, P2684, DOI 10.1056/NEJMoa066584; Anderson JL, 2005, EPIDEMIOLOGY, V16, P87, DOI 10.1097/01.ede.0000147122.97061.bb; Bennett HA, 2004, OBSTET GYNECOL, V103, P698, DOI 10.1097/01.AOG.0000116689.75396.5f; Bennett HA, 2004, OBSTET GYNECOL, V103, P1344; Chambers CD, 1996, NEW ENGL J MED, V335, P1010, DOI 10.1056/NEJM199610033351402; Cohen LS, 2000, BIOL PSYCHIAT, V48, P996, DOI 10.1016/S0006-3223(00)00877-5; COLE JA, 2006, PHARMACOEPIDEM DR S, V15, pS6; Ericson A, 1999, EUR J CLIN PHARMACOL, V55, P503, DOI 10.1007/s002280050664; Ferencz C., 1997, PERSPECTIVES PEDIAT; Garbis H, 2005, REPROD TOXICOL, V19, P453, DOI 10.1016/j.reprotox.2004.09.002; *GLAXOSMITHKLINE, 2005, EP STUD UPD PREL REP; Heinonen OP, 1977, BIRTH DEFECTS DRUGS; Hemeryck A, 2002, CURR DRUG METAB, V3, P13, DOI 10.2174/1389200023338017; Kallen B, 2006, REPROD TOXICOL, V21, P221, DOI 10.1016/j.reprotox.2005.11.006; KESSLER RC, 1993, J AFFECT DISORDERS, V29, P85, DOI 10.1016/0165-0327(93)90026-G; Kulin NA, 1998, JAMA-J AM MED ASSOC, V279, P609, DOI 10.1001/jama.279.8.609; Levison-Castiel R, 2006, ARCH PEDIAT ADOL MED, V160, P173, DOI 10.1001/archpedi.160.2.173; Llewellyn AM, 1997, J CLIN PSYCHIAT, V58, P26; Malm H, 2005, OBSTET GYNECOL, V106, P1289, DOI 10.1097/01.AOG.0000187302.61812.53; Mikhail LN, 2002, J NATL MED ASSOC, V94, P695; MITCHELL AA, 1981, JAMA-J AM MED ASSOC, V245, P2311; Mitchell AA, 2003, NEW ENGL J MED, V349, P2556, DOI 10.1056/NEJMsb031395; MITCHELL AA, 1986, AM J EPIDEMIOL, V123, P670, DOI 10.1093/oxfordjournals.aje.a114286; MITCHELL AA, 1983, AM J OBSTET GYNECOL, V147, P737, DOI 10.1016/0002-9378(83)90028-5; Mitchell AA, 2005, PHARMACOEPIDEMIOLOGY, 4TH EDITION, P501; Moore LL, 2000, EPIDEMIOLOGY, V11, P689, DOI 10.1097/00001648-200011000-00013; Nemeroff CB, 1996, AM J PSYCHIAT, V153, P311; Nulman I, 1997, NEW ENGL J MED, V336, P258, DOI 10.1056/NEJM199701233360404; PASTUSZAK A, 1993, JAMA-J AM MED ASSOC, V269, P2246, DOI 10.1001/jama.269.17.2246; Preskorn SH, 1997, CLIN PHARMACOKINET, V32, P1, DOI 10.2165/00003088-199700321-00003; Sanz EJ, 2005, LANCET, V365, P482, DOI 10.1016/S0140-6736(05)17865-9; Simon GE, 2002, AM J PSYCHIAT, V159, P2055, DOI 10.1176/appi.ajp.159.12.2055; Sivojelezova A, 2005, AM J OBSTET GYNECOL, V193, P2004, DOI 10.1016/j.ajog.2005.05.012; Ward RM, 2000, PEDIATRICS, V105, P880; Watkins ML, 2003, PEDIATRICS, V111, P1152; Werler MM, 1999, AM J EPIDEMIOL, V150, P675, DOI 10.1093/oxfordjournals.aje.a010070; Wogelius P, 2006, EPIDEMIOLOGY, V17, P701, DOI 10.1097/01.ede.0000239581.76793.ae	38	379	387	0	39	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 28	2007	356	26					2675	2683		10.1056/NEJMoa067407	http://dx.doi.org/10.1056/NEJMoa067407			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	183HS	17596601				2022-12-28	WOS:000247564500004
J	Feudtner, C; Feinstein, JA; Satchell, M; Zhao, HQ; Kang, TI				Feudtner, Chris; Feinstein, James A.; Satchell, Marlon; Zhao, Huaqing; Kang, Tammy I.			Shifting place of death among children with complex chronic conditions in the United States, 1989-2003	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-HEART-DISEASE; MULTIPLE IMPUTATION; ETHNIC-DIFFERENCES; WASHINGTON-STATE; PALLIATIVE CARE; CANCER-PATIENTS; HOME; HOSPICE; TRENDS; SITE	Context The place where children with complex chronic conditions are dying may be shifting toward residential homes due to the evolving epidemiology of life-threatening childhood conditions, advances in home-based medical technology, and changes in attitudes about pediatric palliative care and hospice services. Objectives To determine whether pediatric deaths attributed to complex chronic conditions are increasingly occurring in the home and to assess race and ethnicity disparities in the location of death. Design, Setting, and Participants Retrospective national-level case series drawn from the National Center for Health Statistics' Multiple Cause of Death Files spanning 1989-2003. Participants included all deceased individuals aged 19 years or younger with a complex chronic condition excluding injury and noncomplex chronic conditions ( as classified by International Classification of Diseases, Ninth Revision or International Classification of Diseases, Tenth Revision). Main Outcome Measure Place where death occurred. Results Among the 22.1% of deaths ( 198 160 of 896 509 total deaths) attributed to a complex chronic condition between 1989 and 2003, the percentage of individuals dying at home increased significantly ( P <. 001) over time for infants ( aged < 1 year) (4.9% in 1989 and 7.3% in 2003); 1- to 9-year-olds (17.9% and 30.7%); and for 10- to 19-year-olds (18.4% and 32.2%). Adjusting for decedent characteristics, the odds of dying at home increased significantly each year ( odds ratio, 1.04; 95% confidence interval, 1.03-1.04) and were reduced among both black and Hispanic decedents ( odds ratio, 0.50; 95% confidence interval, 0.48-0.52 and odds ratio, 0.52; 95% confidence interval, 0.50-0.54, respectively) compared with white decedents. Conclusions Children who die with underlying complex chronic conditions increasingly are dying at home. Racial and ethnic disparities regarding place of death may represent important limitations and opportunities for improvement in the current systems of pediatric chronic and palliative care.	Childrens Hosp Philadelphia, Pediat Adv Care Team, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Pediat Generalist Res Grp, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Biostat & Data Management Core, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Div Gen Pediat, Philadelphia, PA 19104 USA; Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Feudtner, C (corresponding author), Childrens Hosp Philadelphia, Pediat Adv Care Team, 3535 Market St,Room 1523,34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	feudtner@email.chop.edu	Feudtner, Chris/AAI-1126-2019; Feinstein, James Aaron/I-6373-2013	Feudtner, Chris/0000-0002-5879-0434; Feinstein, James Aaron/0000-0003-3074-8805	AHRQ HHS [K08 HS00002] Funding Source: Medline; NINR NIH HHS [R21-NR008614] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS000002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R21NR008614] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Burge F, 2003, CAN MED ASSOC J, V168, P265; Burge FI, 2005, J RURAL HEALTH, V21, P233, DOI 10.1111/j.1748-0361.2005.tb00088.x; Caveney AF, 2006, PUBLIC HEALTH REP, V121, P275, DOI 10.1177/003335490612100309; *CDCP, 1996, DOC PUBL US MULT CAU; *COMM PALL END OF, 2003, CHILDR DIE IMPR PALL; Davies E, 2006, BRIT J CANCER, V95, P593, DOI 10.1038/sj.bjc.6603305; Enguidanos S, 2005, J AM GERIATR SOC, V53, P1411, DOI 10.1111/j.1532-5415.2005.53410.x; Feudtner C, 2000, PEDIATRICS, V106, P205; Feudtner C, 2002, PEDIATRICS, V109, P656, DOI 10.1542/peds.109.4.656; Feudtner Chris, 2005, BMC Pediatr, V5, P8, DOI 10.1186/1471-2431-5-8; Flory J, 2004, HEALTH AFFAIR, V23, P194, DOI 10.1377/hlthaff.23.3.194; Fox CS, 2005, AM J CARDIOL, V95, P856, DOI 10.1016/j.amjcard.2004.12.011; GOLDMAN A, 1990, ARCH DIS CHILD, V65, P641, DOI 10.1136/adc.65.6.641; Gomes B, 2006, BMJ-BRIT MED J, V332, P515, DOI 10.1136/bmj.38740.614954.55; Guyer B, 2000, PEDIATRICS, V106, P1307, DOI 10.1542/peds.106.6.1307; Himelstein BP, 2004, NEW ENGL J MED, V350, P1752, DOI 10.1056/NEJMra030334; Iwashyna TJ, 2002, J AM GERIATR SOC, V50, P1113, DOI 10.1046/j.1532-5415.2002.50269.x; Johnson KS, 2005, J AM GERIATR SOC, V53, P2209, DOI 10.1111/j.1532-5415.2005.00502.x; KATZ BP, 1979, PUBLIC HEALTH REP, V94, P522; Kreicbergs U, 2005, J CLIN ONCOL, V23, P9162, DOI 10.1200/JCO.2005.08.557; LAUER ME, 1989, CANCER, V63, P988, DOI 10.1002/1097-0142(19890301)63:5<988::AID-CNCR2820630534>3.0.CO;2-Y; Leuthner Steven R, 2004, J Palliat Med, V7, P269, DOI 10.1089/109662104773709396; Lloyd-Jones DM, 1998, ANN INTERN MED, V129, P1020, DOI 10.7326/0003-4819-129-12-199812150-00005; MCCUSKER J, 1983, PUBLIC HEALTH REP, V98, P170; Meier DE, 2007, J PALLIAT MED, V10, P284, DOI 10.1089/jpm.2006.9985; MOINPOUR CM, 1989, AM J PUBLIC HEALTH, V79, P1549, DOI 10.2105/AJPH.79.11.1549; MOR V, 1983, J HEALTH SOC BEHAV, V24, P375, DOI 10.2307/2136403; Mor Vincent, 2005, J Palliat Med, V8, P58, DOI 10.1089/jpm.2005.8.58; MULHERN RK, 1983, PEDIATRICS, V71, P743; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; PALFREY JS, 1994, PUBLIC HEALTH REP, V109, P226; Polissar L, 1987, J Community Health, V12, P40, DOI 10.1007/BF01321396; Royston P, 2005, STATA J, V5, P188, DOI 10.1177/1536867X0500500204; Royston P, 2004, STATA J, V4, P227, DOI 10.1177/1536867X0400400301; Stuart G, 2002, HEART, V88, pI1; Surkan PJ, 2006, PALLIATIVE MED, V20, P161, DOI 10.1191/0269216306pm1139oa; Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care (full printed version), 2003, UN TREATM CONFR RAC; Vincer MJ, 2006, PEDIATRICS, V118, pE1621, DOI 10.1542/peds.2006-1522; Weitzen S, 2003, MED CARE, V41, P323, DOI 10.1097/00005650-200302000-00013; Wolfe J, 2000, JAMA-J AM MED ASSOC, V284, P2469, DOI 10.1001/jama.284.19.2469	40	159	163	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 27	2007	297	24					2725	2732		10.1001/jama.297.24.2725	http://dx.doi.org/10.1001/jama.297.24.2725			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	182UE	17595273	Bronze			2022-12-28	WOS:000247528700022
J	Yates, JRW; Sepp, T; Matharu, BK; Khan, JC; Thurlby, DA; Shahid, H; Clayton, DG; Hayward, C; Morgan, J; Wright, AF; Armbrecht, AM; Dhillon, B; Deary, IJ; Redmond, E; Bird, AC; Moore, AT				Yates, John R. W.; Sepp, Tiina; Matharu, Baljinder K.; Khan, Jane C.; Thurlby, Deborah A.; Shahid, Humma; Clayton, David G.; Hayward, Caroline; Morgan, Joanne; Wright, Alan F.; Armbrecht, Ana Maria; Dhillon, Baljean; Deary, Ian J.; Redmond, Elizabeth; Bird, Alan C.; Moore, Anthony T.		Genetic Factors AMD Study G	Complement C3 variant and the risk of age-related macular degeneration	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLOMERULONEPHRITIS TYPE-II; DENSE DEPOSIT DISEASE; FACTOR-H POLYMORPHISM; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; CHOROIDAL NEOVASCULARIZATION; GENETIC-POLYMORPHISM; MOLECULAR ANALYSIS; COMMON; CFH; SUSCEPTIBILITY	Background: Age-related macular degeneration is the most common cause of blindness in Western populations. Susceptibility is influenced by age and by genetic and environmental factors. Complement activation is implicated in the pathogenesis. Methods: We tested for an association between age-related macular degeneration and 13 single-nucleotide polymorphisms (SNPs) spanning the complement genes C3 and C5 in case subjects and control subjects from the southeastern region of England. All subjects were examined by an ophthalmologist and had independent grading of fundus photographs to confirm their disease status. To test for replication of the most significant findings, we genotyped a set of Scottish cases and controls. Results: The common functional polymorphism rs2230199 (Arg80Gly) in the C3 gene, corresponding to the electrophoretic variants C3S (slow) and C3F (fast), was strongly associated with age-related macular degeneration in both the English group (603 cases and 350 controls, P=5.9 x 10(sup -5)) and the Scottish group (244 cases and 351 controls, P=5.0 x 10(sup -5)). The odds ratio for age-related macular degeneration in C3 S/F heterozygotes as compared with S/S homozygotes was 1.7 (95% confidence interval [CI], 1.3 to 2.1); for F/F homozygotes, the odds ratio was 2.6 (95% CI, 1.6 to 4.1). The estimated population attributable risk for C3F was 22%. Conclusions: Complement C3 is important in the pathogenesis of age-related macular degeneration. This finding further underscores the influence of the complement pathway in the pathogenesis of this disease.	Univ Cambridge, Cambridge Inst Med Res, Wellcome Trust, Dept Med Genet,Addenbrookes Hosp, Cambridge CB2 0XY, England; Med Res Council Human Genet Unit, Edinburgh, Midlothian, Scotland; Univ Edinburgh, Edinburgh, Midlothian, Scotland; UCL, London, England; Moorfields Eye Hosp, London, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Wellcome Trust Sanger Institute; University of Edinburgh; University of London; University College London; University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust	Yates, JRW (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Wellcome Trust, Dept Med Genet,Addenbrookes Hosp, MRC Bldg,Box 139,, Cambridge CB2 0XY, England.	jrwy1@cam.ac.uk	Deary, Ian J/C-6297-2009; Hayward, Caroline/M-8818-2016	Deary, Ian J/0000-0002-1733-263X; Hayward, Caroline/0000-0002-9405-9550	Medical Research Council [G0000067, MC_U127584475] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [MC_U127584475, G0000067] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315; Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078; ARVILOMMI H, 1974, NATURE, V251, P740, DOI 10.1038/251740a0; AZEN EA, 1968, SCIENCE, V162, P905, DOI 10.1126/science.162.3856.905; BARTOK I, 1995, J IMMUNOL, V154, P5367; BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X; Bora PS, 2003, P NATL ACAD SCI USA, V100, P2679, DOI 10.1073/pnas.0438014100; BOTTO M, 1990, J EXP MED, V172, P1011, DOI 10.1084/jem.172.4.1011; Brown KM, 2006, NEW ENGL J MED, V354, P2014, DOI 10.1056/NEJMoa052825; Colville D, 2003, AM J KIDNEY DIS, V42, DOI 10.1016/S0272-6386(03)00665-6; de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326; Deary IJ, 2004, J PERS SOC PSYCHOL, V86, P130, DOI 10.1037/0022-3514.86.1.130; Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; FINN JE, 1993, CLIN EXP IMMUNOL, V91, P410; FINN JE, 1994, NEPHROL DIAL TRANSPL, V9, P1564; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750; Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001; Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; HOGASEN K, 1995, J CLIN INVEST, V95, P1054, DOI 10.1172/JCI117751; Hughes AE, 2007, NAT GENET, V39, P567, DOI 10.1038/ng0407-567c; Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890; Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437; Janssen BJC, 2006, NATURE, V444, P213, DOI 10.1038/nature05172; Jokiranta TS, 2006, EMBO J, V25, P1784, DOI 10.1038/sj.emboj.7601052; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; KOCH C, 1986, IMMUNOGENETICS, V23, P322, DOI 10.1007/BF00398796; Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871; Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873; MCLEAN RH, 1984, J PEDIATR-US, V105, P179, DOI 10.1016/S0022-3476(84)80110-9; Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142; Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835; Patel D, 2006, POSTGRAD MED J, V82, P774, DOI 10.1136/pgmj.2006.047001; Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912; RAMBAUSEK M, 1987, Nephrology Dialysis Transplantation, V2, P208; Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; WELCH TR, 1990, J PEDIATR-US, V116, pS92, DOI 10.1016/S0022-3476(05)82709-X; Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811	41	641	685	0	46	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 9	2007	357	6					553	561		10.1056/NEJMoa072618	http://dx.doi.org/10.1056/NEJMoa072618			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	197VP	17634448	Green Published, Bronze			2022-12-28	WOS:000248584900006
J	Abanin, DA; Levitov, LS				Abanin, D. A.; Levitov, L. S.			Quantized transport in graphene p-n junctions in a magnetic field	SCIENCE			English	Article							SHOT-NOISE; CHAOTIC CAVITIES; MATRIX THEORY; BACKSCATTERING; CONDUCTORS	Recent experimental work on locally gated graphene layers resulting in p-n junctions has revealed the quantum Hall effect in their transport behavior. We explain the observed conductance quantization, which is fractional in the bipolar regime and an integer in the unipolar regime, in terms of quantum Hall edge modes propagating along and across the p-n interface. In the bipolar regime, the electron and hole modes can mix at the p-n boundary, leading to current partition and quantized shot-noise plateaus similar to those of conductance, whereas in the unipolar regime transport is noiseless. These quantum Hall phenomena reflect the massless Dirac character of charge carriers in graphene, with particle/hole interplay manifest in mode mixing and noise in the bipolar regime.	MIT, Dept Phys, Ctr Mat Sci & Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Levitov, LS (corresponding author), MIT, Dept Phys, Ctr Mat Sci & Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	levitov@mit.edu	Abanin, Dmitry/ABD-6660-2021	Levitov, Leonid/0000-0002-4268-731X				Abanin DA, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.176803; Agam O, 2000, PHYS REV LETT, V85, P3153, DOI 10.1103/PhysRevLett.85.3153; BARANGER HU, 1994, PHYS REV LETT, V73, P142, DOI 10.1103/PhysRevLett.73.142; Beenakker CWJ, 1997, REV MOD PHYS, V69, P731, DOI 10.1103/RevModPhys.69.731; Blanter YM, 2000, PHYS REV LETT, V84, P1280, DOI 10.1103/PhysRevLett.84.1280; Blanter YM, 2000, PHYS REP, V336, P1, DOI 10.1016/S0370-1573(99)00123-4; BUTTIKER M, 1988, PHYS REV B, V38, P9375, DOI 10.1103/PhysRevB.38.9375; Cheianov VV, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.041403; Cheianov VV, 2007, SCIENCE, V315, P1252, DOI 10.1126/science.1138020; Geim AK, 2007, NAT MATER, V6, P183, DOI 10.1038/nmat1849; HAUG RJ, 1988, PHYS REV LETT, V61, P2797, DOI 10.1103/PhysRevLett.61.2797; Katsnelson MI, 2006, NAT PHYS, V2, P620, DOI 10.1038/nphys384; KHAETSKII AV, 1994, PHYS REV B, V50, P4571, DOI 10.1103/PhysRevB.50.4571; NAGAEV KE, 1992, PHYS LETT A, V169, P103, DOI 10.1016/0375-9601(92)90814-3; Novoselov KS, 2005, NATURE, V438, P197, DOI 10.1038/nature04233; Oberholzer S, 2001, PHYS REV LETT, V86, P2114, DOI 10.1103/PhysRevLett.86.2114; Ohta T, 2006, SCIENCE, V313, P951, DOI 10.1126/science.1130681; Peres NMR, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.125411; Rycerz A, 2007, NAT PHYS, V3, P172, DOI 10.1038/nphys547; Savin DV, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.081307; Silvestrov PG, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.016802; Son YW, 2006, NATURE, V444, P347, DOI 10.1038/nature05180; WASHBURN S, 1988, PHYS REV LETT, V61, P2801, DOI 10.1103/PhysRevLett.61.2801; Williams JR, 2007, SCIENCE, V317, P638, DOI 10.1126/science.1144657; Zhang YB, 2005, NATURE, V438, P201, DOI 10.1038/nature04235	25	248	252	3	129	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 3	2007	317	5838					641	643		10.1126/science.1144672	http://dx.doi.org/10.1126/science.1144672			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	196PL	17600182	Green Submitted			2022-12-28	WOS:000248494400039
J	McGregor, AP; Orgogozo, V; Delon, I; Zanet, J; Srinivasan, DG; Payre, F; Stern, DL				McGregor, Alistair P.; Orgogozo, Virginie; Delon, Isabelle; Zanet, Jennifer; Srinivasan, Dayalan G.; Payre, Francois; Stern, David L.			Morphological evolution through multiple cis-regulatory mutations at a single	NATURE			English	Article							DROSOPHILA-MELANOGASTER; EPIDERMIS DIFFERENTIATION; EXPRESSION; GENE; WINGLESS; MAIZE; OVO/SHAVENBABY; PARALLELISM; GERMLINE; PROTEINS	One central, and yet unsolved, question in evolutionary biology is the relationship between the genetic variants segregating within species and the causes of morphological differences between species. The classic neo-darwinian view postulates that species differences result from the accumulation of small-effect changes at multiple loci. However, many examples support the possible role of larger abrupt changes in the expression of developmental genes in morphological evolution(1-3). Although this evidence might be considered a challenge to a neo-darwinian micromutationist view of evolution, there are currently few examples of the actual genes causing morphological differences between species(4-10). Here we examine the genetic basis of a trichome pattern difference between Drosophila species, previously shown to result from the evolution of a single gene, shavenbaby (svb), probably through cis-regulatory changes(6). We first identified three distinct svb enhancers from D. melanogaster driving reporter gene expression in partly overlapping patterns that together recapitulate endogenous svb expression. All three homologous enhancers from D. sechellia drive expression in modified patterns, in a direction consistent with the evolved svb expression pattern. To test the influence of these enhancers on the actual phenotypic difference, we conducted interspecific genetic mapping at a resolution sufficient to recover multiple intragenic recombinants. This functional analysis revealed that independent genetic regions upstream of svb that overlap the three identified enhancers are collectively required to generate the D. sechellia trichome pattern. Our results demonstrate that the accumulation of multiple small-effect changes at a single locus underlies the evolution of a morphological difference between species. These data support the view that alleles of large effect that distinguish species may sometimes reflect the accumulation of multiple mutations of small effect at select genes.	Princeton Univ, Dept Ecol & Evolut Biol, Princeton, NJ 08544 USA; Ctr Dev Biol, F-31062 Toulouse 4, France	Princeton University	Stern, DL (corresponding author), Princeton Univ, Dept Ecol & Evolut Biol, Princeton, NJ 08544 USA.	dstern@princeton.edu		Courtier-Orgogozo, Virginie/0000-0002-9297-9230; McGregor, Alistair/0000-0002-2908-2420; Stern, David/0000-0002-1847-6483; PAYRE, Francois/0000-0002-8144-6711	NIGMS NIH HHS [R01 GM063622, R01 GM063622-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063622] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abzhanov A, 2004, SCIENCE, V305, P1462, DOI 10.1126/science.1098095; BLOCHLINGER K, 1990, GENE DEV, V4, P1322, DOI 10.1101/gad.4.8.1322; Bokor P, 1996, DEVELOPMENT, V122, P1083; Carroll S. B., 2001, DNA DIVERSITY MOL GE; Chanut-Delalande H, 2006, PLOS BIOL, V4, P1549, DOI 10.1371/journal.pbio.0040290; Clark RM, 2006, NAT GENET, V38, P594, DOI 10.1038/ng1784; Delon I, 2003, MECH DEVELOP, V120, P747, DOI 10.1016/S0925-4773(03)00081-9; DOEBLEY J, 1995, GENETICS, V141, P333; GLEASON JM, 2004, DROSOPHILA INFO SERV, V87, P107; Harr B, 1998, CURR BIOL, V8, P1183, DOI 10.1016/S0960-9822(07)00490-3; Hatini V, 2005, GENE DEV, V19, P709, DOI 10.1101/gad.1268005; Hay A, 2006, NAT GENET, V38, P942, DOI 10.1038/ng1835; Khila A, 2003, INSECT BIOCHEM MOLEC, V33, P691, DOI 10.1016/S0965-1748(03)00063-8; Marcellini S, 2006, PLOS BIOL, V4, P2252, DOI 10.1371/journal.pbio.0040386; MEVELNINIO M, 1995, MECH DEVELOP, V49, P83, DOI 10.1016/0925-4773(94)00305-7; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; Payre F, 1999, NATURE, V400, P271, DOI 10.1038/22330; Powell J. R., 1997, PROGR PROSPECTS EVOL; Prud'homme B, 2006, NATURE, V440, P1050, DOI 10.1038/nature04597; ROBERTSON HM, 1988, GENETICS, V118, P461; Roch F, 2003, J CELL SCI, V116, P1199, DOI 10.1242/jcs.00298; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sharma Y, 2002, GENESIS, V34, P115, DOI 10.1002/gene.10127; Stam LF, 1996, GENETICS, V144, P1559; Stern DL, 1998, NATURE, V396, P463, DOI 10.1038/24863; STERN DL, 2000, DROSOPHILA PROTOCOLS, P601; Sucena E, 2003, NATURE, V424, P935, DOI 10.1038/nature01768; Sucena E, 2000, P NATL ACAD SCI USA, V97, P4530, DOI 10.1073/pnas.97.9.4530; Tao H, 2006, PLOS GENET, V2, P848, DOI 10.1371/journal.pgen.0020093; Thummel CS, 1992, DROS INF SERV, V71, P150; True JR, 1996, GENETICS, V142, P507; Walters JW, 2005, DEV BIOL, V286, P415, DOI 10.1016/j.ydbio.2005.06.031; Wang H, 2005, NATURE, V436, P714, DOI 10.1038/nature03863; Wang XD, 2002, GENE DEV, V16, P2345, DOI 10.1101/gad.996302; Wiellette EL, 1999, DEVELOPMENT, V126, P1985; Yoon HS, 2004, P NATL ACAD SCI USA, V101, P6524, DOI 10.1073/pnas.0401824101	37	234	237	2	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 2	2007	448	7153					587	U6		10.1038/nature05988	http://dx.doi.org/10.1038/nature05988			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	195XV	17632547				2022-12-28	WOS:000248446700042
J	Fink, M; Taylor, MA				Fink, Max; Taylor, Michael Alan			Electroconvulsive therapy - Evidence and challenges	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CLINICAL-RESPONSE; ECT; CONSORTIUM; PHARMACOTHERAPY; STIMULATION; PREVENTION; DEPRESSION; RESISTANCE		SUNY Stony Brook, Dept Psychiat, Stony Brook, NY USA; SUNY Stony Brook, Dept Neurol, Stony Brook, NY USA; Rosalinf Franklin Univ Med & Sci, Dept Psychiat, N Chicago, IL USA; Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Rosalind Franklin University Medical & Science; University of Michigan System; University of Michigan	Fink, M (corresponding author), POB 457, St James, NY 11780 USA.	max.fink@sunysb.edu						Abrams R., 2002, ELECTROCONVULSIVE TH; DUKAKIS K, 2006, SHOCK; Eranti S, 2007, AM J PSYCHIAT, V164, P73, DOI 10.1176/appi.ajp.164.1.73; Fink M, 2000, AM SCI, V88, P162, DOI 10.1511/2000.19.893; Fink M, 2007, J ECT, V23, P3, DOI 10.1097/01.yct.0000263250.91173.08; Glass RM, 2001, JAMA-J AM MED ASSOC, V285, P1346, DOI 10.1001/jama.285.10.1346; Kellner CH, 2005, AM J PSYCHIAT, V162, P977, DOI 10.1176/appi.ajp.162.5.977; Kellner CH, 2006, ARCH GEN PSYCHIAT, V63, P1337, DOI 10.1001/archpsyc.63.12.1337; Lisanby Sarah H, 2004, BRAIN STIMULATION PS; McCall WV, 2000, ARCH GEN PSYCHIAT, V57, P438, DOI 10.1001/archpsyc.57.5.438; Mulsant BH, 1997, AM J PSYCHIAT, V154, P559; NULAND S, 2003, LOST AM; Petrides G, 2001, J ECT, V17, P244, DOI 10.1097/00124509-200112000-00003; Petrides G, 1996, CONVULSIVE THER, V12, P138; Prudic J, 2004, BIOL PSYCHIAT, V55, P301, DOI 10.1016/j.biopsych.2003.09.015; PRUDIC J, 1990, PSYCHIAT RES, V31, P287, DOI 10.1016/0165-1781(90)90098-P; Prudic J, 1996, AM J PSYCHIAT, V153, P985; Prudic J, 1999, J CLIN PSYCHIAT, V60, P104; Rasmussen KG, 2006, J ECT, V22, P116, DOI 10.1097/00124509-200606000-00008; RASMUSSEN KG, IN PRESS J CLIN PSYC; Rush AJ, 2006, NEW ENGL J MED, V354, P1231, DOI 10.1056/NEJMoa052963; Sackeim HA, 2001, JAMA-J AM MED ASSOC, V285, P1299, DOI 10.1001/jama.285.10.1299; Sackeim HA, 2000, ARCH GEN PSYCHIAT, V57, P425, DOI 10.1001/archpsyc.57.5.425; Taylor MA., 2006, MELANCHOLIA DIAGNOSI, DOI [10.1017/CBO9780511544330, DOI 10.1017/CBO9780511544330]; Vothknecht S, 2003, J ECT, V19, P151, DOI 10.1097/00124509-200309000-00007	25	86	87	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 18	2007	298	3					330	332		10.1001/jama.298.3.330	http://dx.doi.org/10.1001/jama.298.3.330			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	190US	17635894				2022-12-28	WOS:000248086700028
J	Jimenez-Guri, E; Philippe, H; Okamura, B; Holland, PWH				Jimenez-Guri, Eva; Philippe, Herve; Okamura, Beth; Holland, Peter W. H.			Buddenbrockia is a Cnidarian worm	SCIENCE			English	Article							BILATERAL SYMMETRY; ANIMAL PHYLOGENY; SEA-ANEMONE; MYXOZOA; ORIGIN; VERTEBRATES; EVOLUTION; PROTISTS	A major evolutionary divide occurs in the animal kingdom between the so-called radially symmetric animals, which includes the cnidarians, and the bilaterally symmetric animals, which includes all worm phyla. Buddenbrockia plumatellae is an active, muscular, parasitic worm that belongs to the phylum Myxozoa, a group of morphologically simplified microscopic endoparasites that has proved difficult to place phylogenetically. Phylogenetic analyses of multiple protein-coding genes demonstrate that Buddenbrockia is a cnidarian. This active muscular worm increases the known diversity in cnidarian body plans and demonstrates that a muscular, wormlike form can evolve in the absence of overt bilateral symmetry.	Univ Oxford, Dept Zool, Oxford OX1 3PS, England; Univ Montreal, Canadian Inst Adv Res, Ctr Robert Cedergren, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Univ Reading, Sch Biol Sci, Reading RG6 6BX, Berks, England; Nat Hist Museum, Dept Zool, London SW7 5BD, England	University of Oxford; Canadian Institute for Advanced Research (CIFAR); Universite de Montreal; University of Reading; Natural History Museum London	Holland, PWH (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.	peter.holland@zoo.ox.ac.uk		Holland, Peter/0000-0003-1533-9376; jimenez-guri, eva/0000-0002-9592-1077	Biotechnology and Biological Sciences Research Council [G19271] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Anderson CL, 1998, NATURE, V392, P346, DOI 10.1038/32801; Baurain D, 2007, MOL BIOL EVOL, V24, P6, DOI 10.1093/molbev/msl137; Canning EU, 2002, J EUKARYOT MICROBIOL, V49, P280, DOI 10.1111/j.1550-7408.2002.tb00371.x; Canning EU, 2004, ADV PARASIT, V56, P43, DOI 10.1016/S0065-308X(03)56002-X; Collins AG, 2006, BIOL LETT-UK, V2, P120, DOI 10.1098/rsbl.2005.0372; Delsuc F, 2006, NATURE, V439, P965, DOI 10.1038/nature04336; Finnerty JR, 2004, SCIENCE, V304, P1335, DOI 10.1126/science.1091946; Finnerty JR, 2005, BIOESSAYS, V27, P1174, DOI 10.1002/bies.20299; Halanych KM, 2004, ANNU REV ECOL EVOL S, V35, P229, DOI 10.1146/annurev.ecolsys.35.112202.130124; HYMAN LH, 1940, INVERTEBRATES PROTOZ; Lartillot N, 2004, MOL BIOL EVOL, V21, P1095, DOI 10.1093/molbev/msh112; Lartillot N, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-S1-S4; Lom J, 2006, FOLIA PARASIT, V53, P1, DOI 10.14411/fp.2006.001; Monteiro AS, 2002, MOL BIOL EVOL, V19, P968, DOI 10.1093/oxfordjournals.molbev.a004155; Okamura B, 2002, PARASITOLOGY, V124, P215, DOI 10.1017/S0031182001001184; Philippe H, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-50; Philippe H, 2005, ANNU REV ECOL EVOL S, V36, P541, DOI 10.1146/annurev.ecolsys.35.112202.130205; PICKENS PE, 1988, J EXP BIOL, V135, P133; Sanderson MJ, 2002, ANNU REV ECOL SYST, V33, P49, DOI 10.1146/annurev.ecolsys.33.010802.150509; Schroder O, 1910, Z WISS ZOOL ABT A, V96, P525; Seipel K, 2006, INT J DEV BIOL, V50, P589, DOI 10.1387/ijdb.062150ks; Shimodaira H, 2002, SYST BIOL, V51, P492, DOI 10.1080/10635150290069913; Siddall ME, 1995, J PARASITOL, V81, P961, DOI 10.2307/3284049; SMOTHERS JF, 1994, SCIENCE, V265, P1719, DOI 10.1126/science.8085160; Stolc A, 1899, B INT ACAD SCI BOHEM, V22, P1; WADA H, 1994, P NATL ACAD SCI USA, V91, P1801, DOI 10.1073/pnas.91.5.1801; Weill R, 1938, TRAVAUX STATION ZOOL, V13, P727; Westfall JA, 2004, HYDROBIOLOGIA, V530, P117, DOI 10.1007/s10750-004-2678-0; Zrzavy J, 2003, CLADISTICS, V19, P164, DOI 10.1016/S0748-3007(03)00007-0	29	117	122	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 6	2007	317	5834					116	118		10.1126/science.1142024	http://dx.doi.org/10.1126/science.1142024			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186KD	17615357				2022-12-28	WOS:000247776700064
J	Borg, NA; Wun, KS; Kjer-Nielsen, L; Wilce, MCJ; Pellicci, DG; Koh, R; Besra, GS; Bharadwaj, M; Godfrey, DI; McCluskey, J; Rossjohn, J				Borg, Natalie A.; Wun, Kwok S.; Kjer-Nielsen, Lars; Wilce, Matthew C. J.; Pellicci, Daniel G.; Koh, Ruide; Besra, Gurdyal S.; Bharadwaj, Mandvi; Godfrey, Dale I.; McCluskey, James; Rossjohn, Jamie			CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor	NATURE			English	Article							ALPHA-GALACTOSYLCERAMIDE; ANTIGEN PRESENTATION; STRUCTURAL BASIS; HIGH-AFFINITY; HUMAN CD1D; TCR; SELECTION; COMPLEX; BINDING; GLYCOSPHINGOLIPIDS	The CD1 family is a large cluster of non-polymorphic, major histocompatibility complex (MHC) class-I-like molecules that bind distinct lipid-based antigens that are recognized by T cells. The most studied group of T cells that interact with lipid antigens are natural killer T (NKT) cells, which characteristically express a semi-invariant T-cell receptor ( NKT TCR) that specifically recognizes the CD1 family member, CD1d. NKT-cell-mediated recognition of the CD1d - antigen complex has been implicated in microbial immunity, tumour immunity, autoimmunity and allergy. Here we describe the structure of a human NKT TCR in complex with CD1d bound to the potent NKT-cell agonist alpha-galactosylceramide, the archetypal CD1d-restricted glycolipid. In contrast to T-cell receptor - peptide- antigen - MHC complexes, the NKT TCR docked parallel to, and at the extreme end of the CD1d-binding cleft, which enables a lock-and-key type interaction with the lipid antigen. The structure provides a basis for the interaction between the highly conserved NKT TCR alpha-chain and the CD1d - antigen complex that is typified in innate immunity, and also indicates how variability of the NKT TCR beta-chain can impact on recognition of other CD1d - antigen complexes. These findings provide direct insight into how a T-cell receptor recognizes a lipid-antigen-presenting molecule of the immune system.	Monash Univ, Prot Crystallog Unit, ARC Ctr Excellence Struct & Funct Microbial Genom, Dept Biochem & Mol Biol,Sch Biomed Sci, Clayton, Vic 3800, Australia; Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	Monash University; University of Melbourne; University of Birmingham	Rossjohn, J (corresponding author), Monash Univ, Prot Crystallog Unit, ARC Ctr Excellence Struct & Funct Microbial Genom, Dept Biochem & Mol Biol,Sch Biomed Sci, Clayton, Vic 3800, Australia.	jamesm1@unimelb.edu.au; jamie.rossjohn@med.monash.edu.au	Rossjohn, Jamie/F-9032-2013; McCluskey, James/A-1291-2007; Pellicci, Daniel/AAX-8539-2020; Bharadwaj, Mandvi/C-4446-2014	Rossjohn, Jamie/0000-0002-2020-7522; McCluskey, James/0000-0002-8597-815X; Wun, Kwok/0000-0002-1908-4596; Godfrey, Dale/0000-0002-3009-5472; Besra, Gurdyal/0000-0002-5605-0395; Pellicci, Daniel/0000-0001-5305-2398; Borg, Natalie/0000-0002-8677-9056	MRC [G0400421] Funding Source: UKRI; Medical Research Council [G0400421] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Bendelac A, 2007, ANNU REV IMMUNOL, V25, P297, DOI 10.1146/annurev.immunol.25.022106.141711; Brigl M, 2004, ANNU REV IMMUNOL, V22, P817, DOI 10.1146/annurev.immunol.22.012703.104608; Burdin N, 2000, P NATL ACAD SCI USA, V97, P10156, DOI 10.1073/pnas.97.18.10156; Cantu C, 2003, J IMMUNOL, V170, P4673, DOI 10.4049/jimmunol.170.9.4673; Clements CS, 2006, CURR OPIN STRUC BIOL, V16, P787, DOI 10.1016/j.sbi.2006.09.004; Cui JQ, 1997, SCIENCE, V278, P1623, DOI 10.1126/science.278.5343.1623; DELLABONA P, 1994, J EXP MED, V180, P1171, DOI 10.1084/jem.180.3.1171; FISCHER B, 1985, FERTILITAT, V1, P101; Gadola SD, 2006, J EXP MED, V203, P699, DOI 10.1084/jem.20052369; Gadola SD, 2002, J IMMUNOL, V168, P5514, DOI 10.4049/jimmunol.168.11.5514; Godfrey DI, 2004, NAT REV IMMUNOL, V4, P231, DOI 10.1038/nri1309; Godfrey DI, 2005, NAT IMMUNOL, V6, P754, DOI 10.1038/ni0805-754; Godfrey DI, 2004, J CLIN INVEST, V114, P1379, DOI 10.1172/JCI200423594; Kamada N, 2001, INT IMMUNOL, V13, P853, DOI 10.1093/intimm/13.7.853; Kinjo Y, 2005, NATURE, V434, P520, DOI 10.1038/nature03407; Kinjo Y, 2006, NAT IMMUNOL, V7, P978, DOI 10.1038/ni1380; Kjer-Nielsen L, 2003, IMMUNITY, V18, P53, DOI 10.1016/S1074-7613(02)00513-7; Kjer-Nielsen L, 2006, J EXP MED, V203, P661, DOI 10.1084/jem.20051777; Koch M, 2005, NAT IMMUNOL, V6, P819, DOI 10.1038/ni1225; Mattner J, 2005, NATURE, V434, P525, DOI 10.1038/nature03408; PORCELLI S, 1993, J EXP MED, V178, P1, DOI 10.1084/jem.178.1.1; Pyz E, 2006, J IMMUNOL, V176, P7447, DOI 10.4049/jimmunol.176.12.7447; Rauch J, 2003, J BIOL CHEM, V278, P47508, DOI 10.1074/jbc.M308089200; Rudolph MG, 2006, ANNU REV IMMUNOL, V24, P419, DOI 10.1146/annurev.immunol.23.021704.115658; Schumann J, 2005, J IMMUNOL, V175, P7303, DOI 10.4049/jimmunol.175.11.7303; Schumann J, 2003, J IMMUNOL, V170, P5815, DOI 10.4049/jimmunol.170.12.5815; Sidobre S, 2002, J IMMUNOL, V169, P1340, DOI 10.4049/jimmunol.169.3.1340; Sidobre S, 2004, P NATL ACAD SCI USA, V101, P12254, DOI 10.1073/pnas.0404632101; Sriram V, 2005, EUR J IMMUNOL, V35, P1692, DOI 10.1002/eji.200526157; Tynan FE, 2005, NAT IMMUNOL, V6, P1114, DOI 10.1038/ni1257; Tynan FE, 2007, NAT IMMUNOL, V8, P268, DOI 10.1038/ni1432; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Wu DY, 2003, J EXP MED, V198, P173, DOI 10.1084/jem.20030446; Zajonc DM, 2005, NAT IMMUNOL, V6, P810, DOI 10.1038/ni1224; Zhou DP, 2004, SCIENCE, V306, P1786, DOI 10.1126/science.1103440; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	36	465	507	1	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 5	2007	448	7149					44	49		10.1038/nature05907	http://dx.doi.org/10.1038/nature05907			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185OS	17581592				2022-12-28	WOS:000247720900033
J	Katano, S; Kim, Y; Hori, M; Trenary, M; Kawai, M				Katano, Satoshi; Kim, Yousoo; Hori, Masafumi; Trenary, Michael; Kawai, Maki			Reversible control of hydrogenation of a single molecule	SCIENCE			English	Article							VIBRATIONAL-EXCITATION; MANIPULATION; CHEMISTRY; STM; MICROSCOPY; ADSORPTION; SURFACE; PT(111)	Low-temperature scanning tunneling microscopy was used to selectively break the N-H bond of a methylaminocarbyne (CNHCH3) molecule on a Pt(111) surface at 4.7 kelvin, leaving the C-H bonds intact, to form an adsorbed methylisocyanide molecule (CNCH3). The methylisocyanide product was identified through comparison of its vibrational spectrum with that of directly adsorbed methylisocyanide as measured with inelastic electron tunneling spectroscopy. The CNHCH3 could be regenerated in situ by exposure to hydrogen at room temperature. The combination of tip-induced dehydrogenation with thermodynamically driven hydrogenation allows a completely reversible chemical cycle to be established at the single-molecule level in this system. By tailoring the pulse conditions, irreversible dissociation entailing cleavage of both the C-H and N-H bonds can also be demonstrated.	RIKEN, Surface Chem Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Dept Adv Mat, Kashiwa, Chiba 2778651, Japan; Univ Illinois, Dept Chem, Chicago, IL 60607 USA	RIKEN; University of Tokyo; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kim, Y (corresponding author), RIKEN, Surface Chem Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	ykim@riken.jp; maki@riken.jp	Kawai, Maki/AAC-2345-2021; Kim, Yousoo/C-6383-2008; Trenary, Michael/D-4406-2015	Kawai, Maki/0000-0002-7963-6989; Kim, Yousoo/0000-0001-7730-0704; Trenary, Michael/0000-0003-1419-9252				AVERY NR, 1984, SURF SCI, V143, P110, DOI 10.1016/0039-6028(84)90413-8; Gaudioso J, 1999, J AM CHEM SOC, V121, P8479, DOI 10.1021/ja991218s; Gimzewski JK, 1999, SCIENCE, V283, P1683, DOI 10.1126/science.283.5408.1683; Ho W, 2002, J CHEM PHYS, V117, P11033, DOI 10.1063/1.1521153; Kang DH, 2001, J AM CHEM SOC, V123, P8432, DOI 10.1021/ja0162717; Kim Y, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.126104; Komeda T, 2005, PROG SURF SCI, V78, P41, DOI 10.1016/j.progsurf.2005.05.001; Lorente N, 2005, J PHYS-CONDENS MAT, V17, pS1049, DOI 10.1088/0953-8984/17/13/003; Moresco F, 2004, PHYS REP, V399, P175, DOI 10.1016/j.physrep.2004.08.001; SCHWEIZER E, 1989, SURF SCI, V213, P49, DOI 10.1016/0039-6028(89)90252-5; Seminario JM, 2001, J AM CHEM SOC, V123, P5616, DOI 10.1021/ja015661q; Stipe BC, 1998, SCIENCE, V280, P1732, DOI 10.1126/science.280.5370.1732; Ueba H, 2003, SURF REV LETT, V10, P771, DOI 10.1142/S0218625X03005578	13	64	64	2	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 29	2007	316	5833					1883	1886		10.1126/science.1141410	http://dx.doi.org/10.1126/science.1141410			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183WI	17600213				2022-12-28	WOS:000247602700035
J	Sarkar, I; Hauber, I; Hauber, J; Buchholz, F				Sarkar, Indrani; Hauber, Ilona; Hauber, Joachim; Buchholz, Frank			HIV-1 proviral DNA excision using an evolved recombinase	SCIENCE			English	Article							SITE-SPECIFIC RECOMBINATION; LONG TERMINAL REPEAT; CRE RECOMBINASE; ANTIRETROVIRAL THERAPY; INFECTION; EVOLUTION; REPLICATION; SPECIFICITY; RESISTANCE; INHIBITOR	HIV-1 integrates into the host chromosome and persists as a provirus flanked by long terminal repeats (LTRs). To date, treatment regimens primarily target the virus enzymes or virus-cell fusion, but not the integrated provirus. We report here the substrate-linked protein evolution of a tailored recombinase that recognizes an asymmetric sequence within an HIV-1 LTR. This evolved recombinase efficiently excised integrated HIV proviral DNA from the genome of infected cells. Although a long way from use in the clinic, we speculate that this type of technology might be adapted in future antiretroviral therapies, among other possible uses.	Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Max Planck Society; Heinrich Pette Institute	Hauber, J (corresponding author), Max Planck Inst Mol Cell Biol & Genet, Pfotenhauerstr 108, D-01307 Dresden, Germany.	joachim.hauber@hpi.uni-hamburg.de; buchholz@mpi-cbg.de	Buchholz, Frank/B-4700-2017	Buchholz, Frank/0000-0002-4577-3344				Akoplan A, 2005, ADV GENET, V55, P1, DOI 10.1016/S0065-2660(05)55001-6; Blackard JT, 1999, VIROLOGY, V254, P220, DOI 10.1006/viro.1998.9504; Bloom JD, 2005, CURR OPIN STRUC BIOL, V15, P447, DOI 10.1016/j.sbi.2005.06.004; Buchholz F, 2001, NAT BIOTECHNOL, V19, P1047, DOI 10.1038/nbt1101-1047; Chiu YL, 2005, NATURE, V435, P108, DOI 10.1038/nature03493; Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072; Emerman M, 1998, SCIENCE, V280, P1880, DOI 10.1126/science.280.5371.1880; Flowers CC, 1997, J VIROL, V71, P2685, DOI 10.1128/JVI.71.4.2685-2692.1997; Glaser S, 2005, NAT GENET, V37, P1187, DOI 10.1038/ng1668; Grindley NDF, 2006, ANNU REV BIOCHEM, V75, P567, DOI 10.1146/annurev.biochem.73.011303.073908; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hauber I, 2005, J CLIN INVEST, V115, P76, DOI 10.1172/JCI200521949; Hazuda DJ, 2004, SCIENCE, V305, P528, DOI 10.1126/science.1098632; Huthoff H, 2005, VIROLOGY, V334, P147, DOI 10.1016/j.virol.2005.01.038; Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026; Lee YS, 1998, BIOCHEM BIOPH RES CO, V253, P588, DOI 10.1006/bbrc.1998.9814; Lewandoski M, 2001, NAT REV GENET, V2, P743, DOI 10.1038/35093537; Little SJ, 2002, NEW ENGL J MED, V347, P385, DOI 10.1056/NEJMoa013552; Matsumura I, 2001, J MOL BIOL, V305, P331, DOI 10.1006/jmbi.2000.4259; Rufer AW, 2002, NUCLEIC ACIDS RES, V30, P2764, DOI 10.1093/nar/gkf399; Santoro SW, 2002, P NATL ACAD SCI USA, V99, P4185, DOI 10.1073/pnas.022039799; Saraf-Levy T, 2006, BIOORGAN MED CHEM, V14, P3081, DOI 10.1016/j.bmc.2005.12.016; Van Duyne GD, 2001, ANNU REV BIOPH BIOM, V30, P87, DOI 10.1146/annurev.biophys.30.1.87	23	147	161	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 29	2007	316	5833					1912	1915		10.1126/science.1141453	http://dx.doi.org/10.1126/science.1141453			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183WI	17600219				2022-12-28	WOS:000247602700044
J	Georg, RB; Halliday, AN; Schauble, EA; Reynolds, BC				Georg, R. Bastian; Halliday, Alex N.; Schauble, Edwin A.; Reynolds, Ben C.			Silicon in the Earth's core	NATURE			English	Article							FE ISOTOPE FRACTIONATION; LATTICE-DYNAMICS; OXYGEN ISOTOPES; METEORITES; MINERALS; MOON; ACCRETION; ELEMENTS; ROCKS	Small isotopic differences between the silicate minerals in planets may have developed as a result of processes associated with core formation, or from evaporative losses during accretion as the planets were built up. Basalts from the Earth and the Moon do indeed appear to have iron isotopic compositions that are slightly heavy relative to those from Mars, Vesta and primitive undifferentiated meteorites(1-4) (chondrites). Explanations for these differences have included evaporation during the 'giant impact' that created the Moon (when a Mars-sized body collided with the young Earth). However, lithium(5) and magnesium(6), lighter elements with comparable volatility(7-9), reveal no such differences, rendering evaporation unlikely as an explanation. Here we show that the silicon isotopic compositions of basaltic rocks from the Earth and the Moon are also distinctly heavy. A likely cause is that silicon is one of the light elements in the Earth's core. We show that both the direction and magnitude of the silicon isotopic effect are in accord with current theory(10) based on the stiffness of bonding in metal and silicate. The similar isotopic composition of the bulk silicate Earth and the Moon is consistent with the recent proposal(11) that there was large-scale isotopic equilibration during the giant impact. We conclude that Si was already incorporated as a light element in the Earth's core before the Moon formed.	Univ Oxford, Dept Earth Sci, Oxford OX1 3PR, England; Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; ETH Zentrum NW, Dept Earth Sci, CH-8092 Zurich, Switzerland	University of Oxford; University of California System; University of California Los Angeles; Swiss Federal Institutes of Technology Domain; ETH Zurich	Halliday, AN (corresponding author), Univ Oxford, Dept Earth Sci, S Parks Rd, Oxford OX1 3PR, England.	alexh@earth.ox.ac.uk	Schauble, Edwin A/E-7812-2012	Georg, Bastian/0000-0002-3109-1860	Science and Technology Facilities Council [PP/D001250/1] Funding Source: researchfish; STFC [PP/D001250/1] Funding Source: UKRI	Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))		ALLEGRE CJ, 1995, EARTH PLANET SC LETT, V134, P515, DOI 10.1016/0012-821X(95)00123-T; Baroni S, 2001, REV MOD PHYS, V73, P515, DOI 10.1103/RevModPhys.73.515; CLAYTON RN, 1993, ANNU REV EARTH PL SC, V21, P115, DOI 10.1146/annurev.earth.21.1.115; CLAYTON RN, 1988, PHILOS T R SOC A, V325, P483, DOI 10.1098/rsta.1988.0062; DOUTHITT CB, 1982, GEOCHIM COSMOCHIM AC, V46, P1449, DOI 10.1016/0016-7037(82)90278-2; EPSTEIN S, 1970, SCIENCE, V167, P533, DOI 10.1126/science.167.3918.533; Georg RB, 2006, CHEM GEOL, V235, P95, DOI 10.1016/j.chemgeo.2006.06.006; Gonze X, 2002, COMP MATER SCI, V25, P478, DOI 10.1016/S0927-0256(02)00325-7; KIEFFER SW, 1982, REV GEOPHYS, V20, P827, DOI 10.1029/RG020i004p00827; Lodders K, 2003, ASTROPHYS J, V591, P1220, DOI 10.1086/375492; Magna T, 2006, EARTH PLANET SC LETT, V243, P336, DOI 10.1016/j.epsl.2006.01.005; MOLINIVELSKO C, 1986, GEOCHIM COSMOCHIM AC, V50, P2719, DOI 10.1016/0016-7037(86)90221-8; Newsom H. E, 1990, ORIGIN EARTH, P273; PAHLEVAN K, 2005, LUNAR PLANET SCI, V36, P2382; Palme H., 2003, TREATISE GEOCHEMISTR, V2, P1, DOI DOI 10.1016/B978-0-08-095975-7.00201-1; Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865; Poitrasson F, 2004, EARTH PLANET SC LETT, V223, P253, DOI 10.1016/j.epsl.2004.04.032; RANDL OG, 1995, J PHYS-CONDENS MAT, V7, P5983, DOI 10.1088/0953-8984/7/30/005; Schauble EA, 2004, REV MINERAL GEOCHEM, V55, P65, DOI 10.2138/gsrmg.55.1.65; Schauble EA, 2006, GEOCHIM COSMOCHIM AC, V70, P2510, DOI 10.1016/j.gca.2006.02.011; Schoenberg R, 2006, EARTH PLANET SC LETT, V252, P342, DOI 10.1016/j.epsl.2006.09.045; Takafuji N, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL022773; TAYLOR HP, 1970, EARTH PLANET SC LETT, V9, P208, DOI 10.1016/0012-821X(70)90054-3; Wade J, 2005, EARTH PLANET SC LETT, V236, P78, DOI 10.1016/j.epsl.2005.05.017; Wang CX, 2002, BMC NEUROL, V2, DOI 10.1186/1471-2377-2-2; Weyer S, 2005, EARTH PLANET SC LETT, V240, P251, DOI 10.1016/j.epsl.2005.09.023; Wiechert U, 2001, SCIENCE, V294, P345, DOI 10.1126/science.1063037; Wiechert U, 2007, EARTH PLANET SC LETT, V256, P360, DOI 10.1016/j.epsl.2007.01.007; Williams HM, 2006, EARTH PLANET SC LETT, V250, P486, DOI 10.1016/j.epsl.2006.08.013; Williams HM, 2005, EARTH PLANET SC LETT, V235, P435, DOI 10.1016/j.epsl.2005.04.020	30	249	255	4	86	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 28	2007	447	7148					1102	1106		10.1038/nature05927	http://dx.doi.org/10.1038/nature05927			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183HT	17597757				2022-12-28	WOS:000247564600035
J	Neven, B; Valayannopoulos, V; Quartier, P; Blanche, S; Prieur, A; Debre, M; Rolland, MO; Rabier, D; Cuisset, L; Cavazzana-Calvo, M; de Lonlay, P; Fischer, A				Neven, Benedicte; Valayannopoulos, Vassili; Quartier, Pierre; Blanche, Stephane; Prieur, Anne-Marie; Debre, Marianne; Rolland, Marie-Odile; Rabier, Daniel; Cuisset, Laurence; Cavazzana-Calvo, Marina; de Lonlay, Pascale; Fischer, Alain			Allogeneic bone marrow transplantation in mevalonic aciduria	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERIODIC FEVER SYNDROME; HYPERIMMUNOGLOBULINEMIA-D; KINASE-DEFICIENCY; INBORN ERROR; HYPER-IGD; MUTATIONS; BIOSYNTHESIS; CHOLESTEROL; SPECTRUM; MVK	Mevalonic aciduria is a rare, inborn error of isoprene biosynthesis characterized by severe, periodic attacks of fever and inflammation, developmental delay, ataxia, and dysmorphic features. This autosomal recessive disease is caused by a mutation in the mevalonate kinase gene that severely reduces mevalonate kinase activity. A 3-year-old boy with mevalonic aciduria whose condition had failed to improve with antiinflammatory treatment underwent allogeneic bone marrow transplantation from an HLA-identical sister who was a heterozygous carrier of the mutant gene. We observed sustained remission of febrile attacks and inflammation during a 15-month follow-up period.	Hop Cochin, Inst Cochin, F-75674 Paris, France; Univ Paris 05, Hop Necker Enfants Malad, Assistance Publ Hop Paris, Unite Immunohematol & Rhumatol Pediat, Paris, France; Univ Paris 05, Hop Necker Enfants Malad, Assistance Publ Hop Paris, Unite Pediat & Malad Metab, Paris, France; Univ Paris 05, Hop Necker Enfants Malad, Assistance Publ Hop Paris, Biochim Lab, Paris, France; Univ Paris 05, Hop Necker Enfants Malad, Assistance Publ Hop Paris, Dept Biotherapie, Paris, France; INSERM, U768, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Fischer, A (corresponding author), Hop Necker Enfants Malad, Serv Immunohematol Pediat, 149 Rue Sevres, F-75015 Paris, France.	alain.fischer@nck.aphp.fr	Valayannopoulos, Vassili/AFR-8311-2022	Quartier, Pierre/0000-0002-1769-549X				BERGER R, 1985, CLIN CHIM ACTA, V152, P219, DOI 10.1016/0009-8981(85)90195-0; Cuisset L, 2001, EUR J HUM GENET, V9, P260, DOI 10.1038/sj.ejhg.5200614; DRENTH JPH, 1994, MEDICINE, V73, P133, DOI 10.1097/00005792-199405000-00002; Drenth JPH, 1999, NAT GENET, V22, P178, DOI 10.1038/9696; Frenkel J, 2002, ARTHRITIS RHEUM, V46, P2794, DOI 10.1002/art.10550; HOFFMAN G, 1986, NEW ENGL J MED, V314, P1610, DOI 10.1056/NEJM198606193142504; HOFFMANN GF, 1993, PEDIATRICS, V91, P915; Houten SM, 1999, NAT GENET, V22, P175, DOI 10.1038/9691; Houten SM, 2000, BBA-MOL CELL BIOL L, V1529, P19, DOI 10.1016/S1388-1981(00)00135-9; MANCINI J, 1993, PEDIATR NEUROL, V9, P243, DOI 10.1016/0887-8994(93)90095-T; Prietsch V, 2003, PEDIATRICS, V111, P258, DOI 10.1542/peds.111.2.258; SCHAFER BL, 1992, J BIOL CHEM, V267, P13229; Simon A, 2004, CLIN PHARMACOL THER, V75, P476, DOI 10.1016/j.clpt.2004.01.012; Simon A, 2004, NEUROLOGY, V62, P994, DOI 10.1212/01.WNL.0000115390.33405.F7; Takada K, 2003, ARTHRITIS RHEUM, V48, P2645, DOI 10.1002/art.11218	15	70	74	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 28	2007	356	26					2700	2703		10.1056/NEJMoa070715	http://dx.doi.org/10.1056/NEJMoa070715			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	183HS	17596604				2022-12-28	WOS:000247564500007
J	Maris, JM; Hogarty, MD; Bagatell, R; Cohn, SL				Maris, John M.; Hogarty, Michael D.; Bagatell, Rochelle; Cohn, Susan L.			Neuroblastoma	LANCET			English	Review							HIGH-RISK NEUROBLASTOMA; PHASE-I TRIAL; MYOCLONUS-ATAXIA SYNDROME; ANGIOGENESIS INHIBITOR TNP-470; MINIMAL RESIDUAL DISEASE; STAGE 4 NEUROBLASTOMA; N-MYC ONCOGENE; PEDIATRIC-ONCOLOGY; BONE-MARROW; NEURO-BLASTOMA	The clinical hallmark of neuroblastoma is heterogeneity, with the likelihood of cure varying widely according to age at diagnosis, extent of disease, and tumour biology. A subset of tumours will undergo spontaneous regression while others show relentless progression. Around half of all cases are currently classified as high-risk for disease relapse, with overall survival rates less than 40% despite intensive multimodal therapy. This Seminar focuses on recent advances in our understanding of the biology of this complex paediatric solid tumour. We outline plans for the development of a uniform international Neuroblastoma Risk Group (INRG) classification system, and summarise strategies for risk-based therapies. We also update readers on new discoveries related to the underlying molecular pathogenesis of this tumour, with special emphasis on advances that are translatable to the clinic. Finally, we discuss new approaches to treatment, including recently discovered molecular targets that might provide more effective treatment strategies with the potential for less toxicity.	Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Abramson Family Canc Res Inst, Philadelphia, PA USA; Univ Arizona, Hlth Sci Ctr, Tucson, AZ USA; Steele Childrens Res Ctr, Tucson, AZ USA; Comer Childrens Hosp, Chicago, IL USA; Univ Chicago, Chicago, IL 60637 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Arizona; University of Arizona Health Sciences; University of Chicago	Maris, JM (corresponding author), Childrens Hosp Philadelphia, Div Oncol, ARC 902A, Philadelphia, PA 19104 USA.	maris@chop.edu	Cohn, Susan/AAB-6010-2021	Cohn, Susan/0000-0001-5749-7650	NCI NIH HHS [P30CA60553, R01-CA87847, P01-CA97323, U10-CA98543, R01-CA78545] Funding Source: Medline; NINDS NIH HHS [R01-NS049814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA060553, R01CA078545, R01CA087847, P01CA097323, U10CA098543] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS049814] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adamson PC, 1997, J CLIN ONCOL, V15, P3330, DOI 10.1200/JCO.1997.15.11.3330; Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159; Alvarado CS, 2000, J PEDIAT HEMATOL ONC, V22, P197, DOI 10.1097/00043426-200005000-00003; Amiel J, 2003, NAT GENET, V33, P459, DOI 10.1038/ng1130; Antunes NL, 2000, J PEDIAT HEMATOL ONC, V22, P315, DOI 10.1097/00043426-200007000-00007; Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; Bagatell R, 2005, J CLIN ONCOL, V23, P8819, DOI 10.1200/JCO.2004.00.2931; Bagatell R, 2005, INT J CANCER, V113, P179, DOI 10.1002/ijc.20611; Beheshti B, 2003, NEOPLASIA, V5, P53, DOI 10.1016/S1476-5586(03)80017-9; Beppu K, 2004, JNCI-J NATL CANCER I, V96, P46, DOI 10.1093/jnci/djh004; BERTHOLD F, 1982, KLIN PADIATR, V194, P262, DOI 10.1055/s-2008-1033815; Berthold F, 2005, LANCET ONCOL, V6, P649, DOI 10.1016/S1470-2045(05)70291-6; BIEGEL JA, 1993, AM J HUM GENET, V52, P176; Bilke S, 2005, BIOINFORMATICS, V21, P1138, DOI 10.1093/bioinformatics/bti133; BOLANDE RP, 1974, HUM PATHOL, V5, P409, DOI 10.1016/S0046-8177(74)80021-3; Bolesta E, 2005, CANCER RES, V65, P3410, DOI 10.1158/0008-5472.CAN-04-2164; BorgnaPignatti C, 1996, J PEDIATR-US, V129, P179, DOI 10.1016/S0022-3476(96)70225-1; Borgstrom P, 1999, PEDIATR RES, V46, P328, DOI 10.1203/00006450-199909000-00014; BOWER RJ, 1980, CLIN PEDIATR, V19, P665, DOI 10.1177/000992288001901004; Bowman LC, 1997, J NATL CANCER I, V89, P373, DOI 10.1093/jnci/89.5.373; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; Brodeur G. M., 2006, PRINCIPLES PRACTICE, P933; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; BRODEUR GM, 1987, CANCER RES, V47, P4248; BRODEUR GM, 1986, CANCER GENET CYTOGEN, V19, P101, DOI 10.1016/0165-4608(86)90377-8; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Caron H, 1996, NEW ENGL J MED, V334, P225, DOI 10.1056/NEJM199601253340404; Carr J, 2006, CANCER RES, V66, P2138, DOI 10.1158/0008-5472.CAN-05-2623; Cecchetto G, 2005, J CLIN ONCOL, V23, P8483, DOI 10.1200/JCO.2005.02.4661; Chen QR, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-70; Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192; Cheung IY, 2001, CLIN CANCER RES, V7, P1698; Cheung NKV, 1998, INT J ONCOL, V12, P1299; Cheung NKV, 2001, MED PEDIATR ONCOL, V36, P227, DOI 10.1002/1096-911X(20010101)36:1<227::AID-MPO1055>3.0.CO;2-U; Chlenski A, 2002, CANCER RES, V62, P7357; Cho SY, 2004, J CLIN ONCOL, V22, p147S; Coffey DC, 2001, CANCER RES, V61, P3591; Cohn SL, 2000, J CLIN ONCOL, V18, P3604, DOI 10.1200/JCO.2000.18.21.3604; COHN SL, 1995, CANCER RES, V55, P721; Cooper R, 2001, MED PEDIATR ONCOL, V36, P623, DOI 10.1002/mpo.1139; CORVI R, 1995, ONCOGENE, V10, P1081; Dam V, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-177; DANGIO GJ, 1971, LANCET, V1, P1046; De Bernardi B, 2005, CANCER LETT, V228, P283, DOI 10.1016/j.canlet.2005.01.053; De Bernardi B, 2003, J CLIN ONCOL, V21, P1592, DOI 10.1200/JCO.2003.05.191; De Bernardi B, 2001, J CLIN ONCOL, V19, P183, DOI 10.1200/JCO.2001.19.1.183; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; DuBois SG, 2004, J CLIN ONCOL, V22, P2452, DOI 10.1200/jco.2004.08.058; Eggert A, 2000, CLIN CANCER RES, V6, P1900; Erdreich-Epstein A, 2000, CANCER RES, V60, P712; Evans AE, 1999, CLIN CANCER RES, V5, P3594; Evans AE, 1996, J CLIN ONCOL, V14, P2504, DOI 10.1200/JCO.1996.14.9.2504; Evans AE, 2001, MED PEDIATR ONCOL, V36, P181, DOI 10.1002/1096-911X(20010101)36:1<181::AID-MPO1043>3.3.CO;2-H; Fotsis T, 1999, EUR J BIOCHEM, V263, P757, DOI 10.1046/j.1432-1327.1999.00575.x; Frantz CN, 2004, J CLIN ONCOL, V22, p802S; Frappaz D, 2000, MED PEDIATR ONCOL, V34, P237, DOI 10.1002/(SICI)1096-911X(200004)34:4<237::AID-MPO1>3.0.CO;2-J; Fukuda M, 2001, J PEDIAT HEMATOL ONC, V23, P10, DOI 10.1097/00043426-200101000-00004; Garaventa A, 2003, CLIN CANCER RES, V9, P2032; Garaventa A, 1999, BRIT J CANCER, V81, P1378, DOI 10.1038/sj.bjc.6694223; GEATTI O, 1985, J NUCL MED, V26, P736; GEHRING M, 1995, CANCER RES, V55, P5366; George RE, 2005, J CLIN ONCOL, V23, P6466, DOI 10.1200/JCO.2005.05.582; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Godfried MB, 2002, ONCOGENE, V21, P2097, DOI 10.1038/sj.onc.1205259; Goldsmith KC, 2005, CANCER LETT, V228, P133, DOI 10.1016/j.canlet.2005.01.048; Gonzalez S, 2004, J GENE MED, V6, P704, DOI 10.1002/jgm.489; Guo C, 1999, ONCOGENE, V18, P4948, DOI 10.1038/sj.onc.1202887; Hayward K, 2001, J PEDIATR-US, V139, P552, DOI 10.1067/mpd.2001.118200; Ho R, 2005, CANCER RES, V65, P9868, DOI 10.1158/0008-5472.CAN-04-2426; Hoon DSB, 2001, AM J PATHOL, V159, P493, DOI 10.1016/S0002-9440(10)61721-X; Howard JP, 2005, PEDIATR BLOOD CANCER, V44, P232, DOI 10.1002/pbc.20240; Hsu LL, 1996, MED PEDIATR ONCOL, V27, P521, DOI 10.1002/(SICI)1096-911X(199612)27:6<521::AID-MPO3>3.0.CO;2-N; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Jaboin J, 2002, CANCER RES, V62, P6108; Kang TI, 2003, J PEDIAT HEMATOL ONC, V25, P769, DOI 10.1097/00043426-200310000-00005; KAPLAN SJ, 1980, AM J DIS CHILD, V134, P21, DOI 10.1001/archpedi.1980.02130130013005; Katzenstein HM, 1999, CLIN CANCER RES, V5, P4273; Katzenstein HM, 1998, J CLIN ONCOL, V16, P2007, DOI 10.1200/JCO.1998.16.6.2007; Katzenstein HM, 2001, J CLIN ONCOL, V19, P1047, DOI 10.1200/JCO.2001.19.4.1047; Keshelava N, 2001, CANCER RES, V61, P6185; King DM, 2004, J CLIN ONCOL, V22, P4463, DOI 10.1200/JCO.2004.11.035; Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829; KNUDSON AG, 1972, AM J HUM GENET, V24, P514; KNUDSON AG, 1976, JNCI-J NATL CANCER I, V57, P675, DOI 10.1093/jnci/57.3.675; KNUDSON AG, 1966, CANCER, V19, P1032, DOI 10.1002/1097-0142(196607)19:7<1032::AID-CNCR2820190719>3.0.CO;2-7; Kushner BH, 1996, J CLIN ONCOL, V14, P2174, DOI 10.1200/JCO.1996.14.7.2174; KUSHNER BH, 1985, J CLIN ONCOL, V3, P117, DOI 10.1200/JCO.1985.3.1.117; Kushner BH, 2003, J CLIN ONCOL, V21, P1082, DOI 10.1200/JCO.2003.07.142; Kushner BH, 1996, J CLIN ONCOL, V14, P373, DOI 10.1200/JCO.1996.14.2.373; Kushner BH, 2001, J CLIN ONCOL, V19, P3397, DOI 10.1200/JCO.2001.19.14.3397; Kushner BH, 2001, J CLIN ONCOL, V19, P4189, DOI 10.1200/JCO.2001.19.22.4189; KUSHNER BH, 1986, CANCER-AM CANCER SOC, V57, P1887, DOI 10.1002/1097-0142(19860501)57:9<1887::AID-CNCR2820570931>3.0.CO;2-7; Langler A, 2002, KLIN PADIATR, V214, P153, DOI 10.1055/s-2002-33175; Lode HN, 1999, P NATL ACAD SCI USA, V96, P1591, DOI 10.1073/pnas.96.4.1591; London WB, 2005, J CLIN ONCOL, V23, P6459, DOI 10.1200/JCO.2005.05.571; Mahoney NR, 2006, AM J OPHTHALMOL, V142, P651, DOI 10.1016/j.ajo.2006.05.047; Maris JM, 1997, EUR J CANCER, V33, P1923, DOI 10.1016/S0959-8049(97)00265-7; Maris JM, 2005, GENOME RES, V15, P1168, DOI 10.1101/gr.3865305; Maris JM, 2000, J CLIN ONCOL, V18, P1888, DOI 10.1200/JCO.2000.18.9.1888; Maris JM, 2005, PEDIAT ONCOL, P21; Maris JM, 2002, CANCER RES, V62, P6651; Maris JM, 2000, NEUROBLASTOMA, P125; Maris JM, 1997, MED PEDIATR ONCOL, V28, P1, DOI 10.1002/(SICI)1096-911X(199701)28:1<1::AID-MPO1>3.0.CO;2-P; MARTINSSON T, 1995, CANCER RES, V55, P5681; Matthay KK, 1998, J CLIN ONCOL, V16, P229, DOI 10.1200/JCO.1998.16.1.229; Matthay KK, 2005, CANCER LETT, V228, P275, DOI 10.1016/j.canlet.2005.01.051; MATTHAY KK, 1989, J CLIN ONCOL, V7, P236, DOI 10.1200/JCO.1989.7.2.236; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Matthay KK, 2003, J CLIN ONCOL, V21, P2486, DOI 10.1200/JCO.2003.09.122; Matthay KK, 1998, J CLIN ONCOL, V16, P1256, DOI 10.1200/JCO.1998.16.4.1256; Maurer BJ, 2000, JNCI-J NATL CANCER I, V92, P1897, DOI 10.1093/jnci/92.23.1897; Maurer BJ, 1999, JNCI-J NATL CANCER I, V91, P1138, DOI 10.1093/jnci/91.13.1138; Meitar D, 1996, J CLIN ONCOL, V14, P405, DOI 10.1200/JCO.1996.14.2.405; Messina JA, 2006, PEDIATR BLOOD CANCER, V47, P865, DOI 10.1002/pbc.20777; Mitchell WG, 2002, PEDIATRICS, V109, P86; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Mosse Y, 2003, LANCET ONCOL, V4, P769, DOI 10.1016/S1470-2045(03)01283-X; Mosse YP, 2005, GENE CHROMOSOME CANC, V43, P390, DOI 10.1002/gcc.20198; Mosse YP, 2005, CANCER LETT, V228, P83, DOI 10.1016/j.canlet.2005.02.052; Mosse YP, 2004, AM J HUM GENET, V75, P727, DOI 10.1086/424530; MUSARELLA MA, 1984, OPHTHALMOLOGY, V91, P936; Nagabuchi E, 1997, J PEDIATR SURG, V32, P287, DOI 10.1016/S0022-3468(97)90196-2; NAKAGAWARA A, 1990, CANCER, V65, P1960, DOI 10.1002/1097-0142(19900501)65:9<1960::AID-CNCR2820650914>3.0.CO;2-4; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; Nakagawara A, 2001, CANCER LETT, V169, P107, DOI 10.1016/S0304-3835(01)00530-4; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Neal ZC, 2004, CLIN CANCER RES, V10, P4839, DOI 10.1158/1078-0432.CCR-03-0799; Nickerson HJ, 2000, J CLIN ONCOL, V18, P477, DOI 10.1200/JCO.2000.18.3.477; Nilsson JA, 2005, CANCER CELL, V7, P433, DOI 10.1016/j.ccr.2005.03.036; NISHI M, 1987, CANCER, V60, P433, DOI 10.1002/1097-0142(19870801)60:3<433::AID-CNCR2820600326>3.0.CO;2-H; Nishihira H, 2000, J CLIN ONCOL, V18, P3012, DOI 10.1200/JCO.2000.18.16.3012; ODORISIO MS, 1994, SEMIN ONCOL, V21, P33; Oue T, 2005, J PEDIATR SURG, V40, P359, DOI 10.1016/j.jpedsurg.2004.10.062; PARK J, 2006, J CLIN ONCOL, V24, P9013; Perez CA, 2000, J CLIN ONCOL, V18, P18, DOI 10.1200/JCO.2000.18.1.18; PETRUZZI MJ, 1995, J PEDIATR-US, V127, P328, DOI 10.1016/S0022-3476(95)70322-5; Plantaz D, 2001, INT J CANCER, V91, P680, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1114>3.0.CO;2-R; Plantaz D, 1996, CANCER, V78, P311, DOI 10.1002/(SICI)1097-0142(19960715)78:2<311::AID-CNCR19>3.3.CO;2-O; Ponthan F, 2001, BRIT J CANCER, V85, P2004, DOI 10.1054/bjoc.2001.2186; Quinn J J, 1979, Am J Pediatr Hematol Oncol, V1, P201; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Reynolds C P, 2000, Curr Oncol Rep, V2, P511, DOI 10.1007/s11912-000-0104-y; Reynolds CP, 2003, CANCER LETT, V197, P185, DOI 10.1016/S0304-3835(03)00108-3; Reynolds CP, 2001, J PEDIAT HEMATOL ONC, V23, P150, DOI 10.1097/00043426-200103000-00005; Ricci-Vitiani L, 2004, J EXP MED, V200, P1257, DOI 10.1084/jem.20040921; Rossler J, 1999, INT J CANCER, V81, P113; Rousseau RF, 2003, BLOOD, V101, P1718, DOI 10.1182/blood-2002-08-2493; Rudnick E, 2001, MED PEDIATR ONCOL, V36, P612, DOI 10.1002/mpo.1138; Russo C, 1997, MED PEDIATR ONCOL, V28, P284, DOI 10.1002/(SICI)1096-911X(199704)28:4<284::AID-MPO7>3.0.CO;2-E; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Satge D, 2003, CANCER GENET CYTOGEN, V147, P89, DOI 10.1016/S0165-4608(03)00203-6; SAWADA T, 1984, CANCER, V53, P2731, DOI 10.1002/1097-0142(19840615)53:12<2731::AID-CNCR2820531232>3.0.CO;2-D; Saylors RL, 2001, J CLIN ONCOL, V19, P3463, DOI 10.1200/JCO.2001.19.15.3463; Scanga DR, 2004, CLIN NUCL MED, V29, P86, DOI 10.1097/01.rlu.0000109329.34975.9f; Schilling FH, 2002, NEW ENGL J MED, V346, P1047, DOI 10.1056/NEJMoa012277; Schleiermacher G, 2004, GENE CHROMOSOME CANC, V39, P143, DOI 10.1002/gcc.10313; Schmidt ML, 2005, J CLIN ONCOL, V23, P6474, DOI 10.1200/JCO.2005.05.183; Schramm A, 2005, ONCOGENE, V24, P7902, DOI 10.1038/sj.onc.1208936; SCHWAB M, 1993, HUMAN NEUROBLASTOMA; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Seeger RC, 2000, J CLIN ONCOL, V18, P4067, DOI 10.1200/JCO.2000.18.24.4067; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; Shimada H, 1999, CANCER, V86, P364, DOI 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.3.CO;2-Z; Shojaei-Brosseau T, 2004, PEDIATR BLOOD CANCER, V42, P99, DOI 10.1002/pbc.10381; Shusterman S, 2000, MED PEDIATR ONCOL, V35, P673, DOI 10.1002/1096-911X(20001201)35:6<673::AID-MPO41>3.0.CO;2-O; SIDELL N, 1982, J NATL CANCER I, V68, P589; Spitz R, 2003, CLIN CANCER RES, V9, P52; Spitz R, 2002, GENE CHROMOSOME CANC, V34, P299, DOI 10.1002/gcc.10070; STROTHER DR, 2006, PEDIAT BLOOD CANC, V47, P426; Suita S, 1996, J PEDIATR SURG, V31, P555, DOI 10.1016/S0022-3468(96)90495-9; Tacconelli A, 2004, CANCER CELL, V6, P347, DOI 10.1016/j.ccr.2004.09.011; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; TANAKA T, 1995, CANCER-AM CANCER SOC, V76, P1086, DOI 10.1002/1097-0142(19950915)76:6<1086::AID-CNCR2820760625>3.0.CO;2-8; Tang XX, 2006, CANCER RES, V66, P2826, DOI 10.1158/0008-5472.CAN-05-0854; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tepmongkol S, 1999, MED PEDIATR ONCOL, V32, P427, DOI 10.1002/(SICI)1096-911X(199906)32:6<427::AID-MPO6>3.0.CO;2-T; Thompson DR, 2001, IMECHE CONF TRANS, V2001, P61; Trochet D, 2004, AM J HUM GENET, V74, P761, DOI 10.1086/383253; Tweddle DA, 2001, CANCER RES, V61, P8; Valsesia-Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033; Vandesompele J, 2001, MED PEDIATR ONCOL, V36, P5, DOI 10.1002/1096-911X(20010101)36:1<5::AID-MPO1003>3.0.CO;2-E; Vassal G, 2003, J CLIN ONCOL, V21, P3844, DOI 10.1200/JCO.2003.08.175; Veneselli E, 1998, MED PEDIATR ONCOL, V30, P15, DOI 10.1002/(SICI)1096-911X(199801)30:1<15::AID-MPO6>3.0.CO;2-3; Villablanca JG, 2006, J CLIN ONCOL, V24, P3423, DOI 10.1200/JCO.2005.03.9271; Vitali R, 2003, INT J CANCER, V106, P147, DOI 10.1002/ijc.11187; Voute P A, 1985, Prog Clin Biol Res, V175, P389; Wagner LM, 2004, CLIN CANCER RES, V10, P840, DOI 10.1158/1078-0432.CCR-03-0175; Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618; Wassberg E, 1997, PEDIATR RES, V41, P327, DOI 10.1203/00006450-199703000-00004; Weese-Mayer DE, 2003, AM J MED GENET A, V123A, P267, DOI 10.1002/ajmg.a.20527; WEINBLATT ME, 1983, PEDIATRICS, V71, P947; Weiss WA, 2000, CANCER RES, V60, P2483; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; White PS, 2005, ONCOGENE, V24, P2684, DOI 10.1038/sj.onc.1208306; White PS, 2001, MED PEDIATR ONCOL, V36, P37, DOI 10.1002/1096-911X(20010101)36:1<37::AID-MPO1010>3.0.CO;2-L; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; WISEMAN GA, 1995, SEMIN NUCL MED, V25, P272, DOI 10.1016/S0001-2998(95)80016-6; Woods WG, 2002, NEW ENGL J MED, V346, P1041, DOI 10.1056/NEJMoa012387; Yaari S, 2005, CLIN CANCER RES, V11, P4321, DOI 10.1158/1078-0432.CCR-04-2071; Yamamoto K, 1998, J CLIN ONCOL, V16, P1265, DOI 10.1200/JCO.1998.16.4.1265; Yang ZF, 2005, CANCER RES, V65, P219; Yanik GA, 2002, J CLIN ONCOL, V20, P2142, DOI 10.1200/JCO.2002.08.124; YU A, 2004, ADV NEUROBLASTOMA RE, P75; Yu AL, 1998, J CLIN ONCOL, V16, P2169, DOI 10.1200/JCO.1998.16.6.2169; Zechner D, 2003, DEV BIOL, V258, P406, DOI 10.1016/S0012-1606(03)00123-4	208	1574	1649	3	162	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 23	2007	369	9579					2106	2120		10.1016/S0140-6736(07)60983-0	http://dx.doi.org/10.1016/S0140-6736(07)60983-0			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	182GM	17586306				2022-12-28	WOS:000247493100031
J	Sulloway, FJ				Sulloway, Frank J.			Birth order and intelligence	SCIENCE			English	Editorial Material							ACHIEVEMENT; PERSONALITY; TESTS; MODEL		Univ Calif Berkeley, Inst Personal & Social Res, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Sulloway, FJ (corresponding author), Univ Calif Berkeley, Inst Personal & Social Res, Berkeley, CA 94720 USA.	sulloway@berkeley.edu						BJERKEDAL T, INTELLIGENCE; Ernst C., 2012, BIRTH ORDER ITS INFL; Healey MD, 2007, EVOL HUM BEHAV, V28, P55, DOI 10.1016/j.evolhumbehav.2006.05.003; Hertwig R, 2002, PSYCHOL BULL, V128, P728, DOI 10.1037//0033-2909.128.5.728; Kristensen P, 2007, SCIENCE, V316, P1717, DOI 10.1126/science.1141493; Paulhus DL, 1999, PSYCHOL SCI, V10, P482, DOI 10.1111/1467-9280.00193; RETHERFORD RD, 1991, AM SOCIOL REV, V56, P141, DOI 10.2307/2095775; Rodgers JL, 2000, AM PSYCHOL, V55, P599, DOI 10.1037//0003-066X.55.6.599; SMITH TE, 1993, SOC PSYCHOL QUART, V56, P77, DOI 10.2307/2786647; Sulloway F. J., 2001, CONCEPTUAL CHALLENGE, V27, P39; ZAJONC RB, 1979, J PERS SOC PSYCHOL, V37, P1325; ZAJONC RB, PERS SOC PSYCHOL B	12	37	37	6	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 22	2007	316	5832					1711	1712		10.1126/science.1144749	http://dx.doi.org/10.1126/science.1144749			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	180XE	17588922				2022-12-28	WOS:000247400500036
J	[Anonymous]				[Anonymous]			Asia on the rise	NATURE			English	Editorial Material																			0	1	1	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 21	2007	447	7147					885	885		10.1038/447885a	http://dx.doi.org/10.1038/447885a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	180NU	17581541	Bronze			2022-12-28	WOS:000247373100001
J	Samani, NJ; Erdmann, J; Hall, AS; Hengstenberg, C; Mangino, M; Mayer, B; Dixon, RJ; Meitinger, T; Braund, P; Wichmann, HE; Barrett, JH; Konig, IR; Stevens, SE; Szymczak, S; Tregouet, D; Iles, MM; Pahlke, F; Pollard, H; Lieb, W; Cambien, F; Fischer, M; Ouwehand, W; Blankenberg, S; Balmforth, AJ; Baessler, A; Ball, SG; Strom, TM; Braenne, I; Gieger, C; Deloukas, P; Tobin, MD; Ziegler, A; Thompson, JR; Schunkert, H				Samani, Nilesh J.; Erdmann, Jeanette; Hall, Alistair S.; Hengstenberg, Christian; Mangino, Massimo; Mayer, Bjoern; Dixon, Richard J.; Meitinger, Thomas; Braund, Peter; Wichmann, H.-Erich; Barrett, Jennifer H.; Koenig, Inke R.; Stevens, Suzanne E.; Szymczak, Silke; Tregouet, David-Alexandre; Iles, Mark M.; Pahlke, Friedrich; Pollard, Helen; Lieb, Wolfgang; Cambien, Francois; Fischer, Marcus; Ouwehand, Willem; Blankenberg, Stefan; Balmforth, Anthony J.; Baessler, Andrea; Ball, Stephen G.; Strom, Tim M.; Braenne, Ingrid; Gieger, Christian; Deloukas, Panos; Tobin, Martin D.; Ziegler, Andreas; Thompson, John R.; Schunkert, Heribert		WTCCC; Cardiogenics Consortium	Genomewide association analysis of coronary artery disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WIDE ASSOCIATION; RISK-FACTORS; MYOCARDIAL-INFARCTION; GENE; SUSCEPTIBILITY; EXPRESSION; FAMILIES; LINKAGE; LOCI	Background Modern genotyping platforms permit a systematic search for inherited components of complex diseases. We performed a joint analysis of two genomewide association studies of coronary artery disease. Methods We first identified chromosomal loci that were strongly associated with coronary artery disease in the Wellcome Trust Case Control Consortium (WTCCC) study (which involved 1926 case subjects with coronary artery disease and 2938 controls) and looked for replication in the German MI [Myocardial Infarction] Family Study (which involved 875 case subjects with myocardial infarction and 1644 controls). Data on other single-nucleotide polymorphisms (SNPs) that were significantly associated with coronary artery disease in either study (P<0.001) were then combined to identify additional loci with a high probability of true association. Genotyping in both studies was performed with the use of the GeneChip Human Mapping 500K Array Set (Affymetrix). Results Of thousands of chromosomal loci studied, the same locus had the strongest association with coronary artery disease in both the WTCCC and the German studies: chromosome 9p21.3 (SNP, rs1333049) (P=1.80x10(-14) and P=3.40x10(-6), respectively). Overall, the WTCCC study revealed nine loci that were strongly associated with coronary artery disease (P<1.2x10(-5) and less than a 50% chance of being falsely positive). In addition to chromosome 9p21.3, two of these loci were successfully replicated (adjusted P<0.05) in the German study: chromosome 6q25.1 (rs6922269) and chromosome 2q36.3 (rs2943634). The combined analysis of the two studies identified four additional loci significantly associated with coronary artery disease (P<1.3x10(-6)) and a high probability(>80%) of a true association: chromosomes 1p13.3 (rs599839), 1q41 (rs17465637), 10q11.21 (rs501120), and 15q22.33 (rs17228212). Conclusions We identified several genetic loci that, individually and in aggregate, substantially affect the risk of development of coronary artery disease.	Univ Leicester, Glenfield Gen Hosp, Dept Cardiovasc Sci, Leicester LE3 9QP, Leics, England; Med Univ Lubeck, Med Klin 2, D-23538 Lubeck, Germany; Univ Leeds, Leeds, W Yorkshire, England; Univ Cambridge, Cambridge, England; Wellcome Trust Sanger Inst, Hinxton, England; Wellcome Trust Sanger Inst, Hinxton, England; Univ Regensburg, D-8400 Regensburg, Germany; GSF Forschungszentrum Umwelt & Gesundheit GMBH, Neuherberg, Germany; Tech Univ Munich, D-8000 Munich, Germany; Univ Munich, Munich, Germany; Johannes Gutenberg Univ Mainz, D-6500 Mainz, Germany; Univ Paris 06, INSERM, UMR S525, Paris, France	University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Lubeck; University of Leeds; University of Cambridge; Wellcome Trust Sanger Institute; Wellcome Trust Sanger Institute; University of Regensburg; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; University of Munich; Johannes Gutenberg University of Mainz; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Samani, NJ (corresponding author), Univ Leicester, Glenfield Gen Hosp, Dept Cardiovasc Sci, Leicester LE3 9QP, Leics, England.	njs@le.ac.uk; heribert.schunkert@innere2.uni-luebeck.de	Erdmann, Jeanette/P-7513-2014; Hall, Alistair/K-1953-2019; Szymczak, Silke/HGT-8202-2022; Hengstenberg, Christian/U-5485-2019; Mangino, Massimo/F-5134-2011; Deloukas, Panos/B-2922-2013; Cambien, Francois/AAP-9751-2020; Lieb, Wolfgang/AAC-7650-2022; Girelli, Domenico/B-1183-2008; Tregouet, David-Alexandre/E-3961-2016; Szymczak, Silke/C-6625-2013; Brown, Matthew A/E-5749-2010; Erdmann, Jeanette/A-4417-2009; Trégouët, David-Alexandre/P-9210-2019; Wichmann, Heinz Erich/AAA-5695-2022; Meitinger, Thomas/O-1318-2015; König, Inke R/A-4544-2009; Ziegler, Andreas/G-4246-2012	Erdmann, Jeanette/0000-0002-4486-6231; Mangino, Massimo/0000-0002-2167-7470; Deloukas, Panos/0000-0001-9251-070X; Girelli, Domenico/0000-0001-9684-1899; Brown, Matthew A/0000-0003-0538-8211; Trégouët, David-Alexandre/0000-0001-9084-7800; König, Inke R/0000-0003-0504-6465; Barrett, Jenny/0000-0002-1720-7724; Tobin, Martin/0000-0002-3596-7874; Gieger, Christian/0000-0001-6986-9554; Szymczak, Silke/0000-0002-8897-9035; Iles, Mark/0000-0002-2603-6509; Pahlke, Friedrich/0000-0003-2105-2582; Meitinger, Thomas/0000-0002-8838-8403; Ziegler, Andreas/0000-0002-8386-5397; Hall, Alistair/0000-0003-0306-7887; Morgan, Ann/0000-0003-1109-624X	MRC [G9806740, G0501942] Funding Source: UKRI; Medical Research Council [G9806740, G0501942] Funding Source: Medline; Wellcome Trust [077011, 076113] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		ALFAKIH K, IN PRESS ATHEROSCLER; Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Bosserhoff AK, 2002, HISTOL HISTOPATHOL, V17, P289, DOI 10.14670/HH-17.289; Broeckel U, 2002, NAT GENET, V30, P210, DOI 10.1038/ng827; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Christensen K, 2007, NEW ENGL J MED, V356, P1094, DOI 10.1056/NEJMp068126; Fischer M, 2005, CIRCULATION, V111, P855, DOI 10.1161/01.CIR.0000155611.41961.BB; Fruchart JC, 2004, CIRCULATION, V109, P15, DOI 10.1161/01.CIR.0000131513.33892.5b; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Helgadottir A, 2007, SCIENCE, V316, P1491, DOI 10.1126/science.1142842; Kalinina N, 2004, ARTERIOSCL THROM VAS, V24, P1391, DOI 10.1161/01.ATV.0000133605.89421.79; Libby P, 2005, CIRCULATION, V111, P3481, DOI 10.1161/CIRCULATIONAHA.105.537878; Lo PK, 1999, ONCOGENE, V18, P7765, DOI 10.1038/sj.onc.1203167; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; MARENBERG ME, 1994, NEW ENGL J MED, V330, P1041, DOI 10.1056/NEJM199404143301503; McPherson R, 2007, SCIENCE, V316, P1488, DOI 10.1126/science.1142447; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; Morgan TM, 2007, JAMA-J AM MED ASSOC, V297, P1551, DOI 10.1001/jama.297.14.1551; Prasannan P, 2003, J BIOL CHEM, V278, P43178, DOI 10.1074/jbc.M304319200; Qin BY, 2002, GENE DEV, V16, P1950, DOI 10.1101/gad.1002002; Randak C, 2000, J INHERIT METAB DIS, V23, P520, DOI 10.1023/A:1005667707355; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Samani NJ, 2005, AM J HUM GENET, V77, P1011; Saxena R, 2007, SCIENCE, V316, P1331, DOI 10.1126/science.1142358; Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382; Tiret L, 2005, CIRCULATION, V112, P643, DOI 10.1161/CIRCULATIONAHA.104.519702; Wacholder S, 2004, J NATL CANCER I, V96, P434, DOI 10.1093/jnci/djh075; Walkup AS, 2005, ARCH BIOCHEM BIOPHYS, V442, P196, DOI 10.1016/j.abb.2005.08.007; Wichmann HE, 2005, GESUNDHEITSWESEN, V67, pS26, DOI 10.1055/s-2005-858226; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9; Zeggini E, 2007, SCIENCE, V316, P1336, DOI 10.1126/science.1142364	32	1572	1646	1	101	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 2	2007	357	5					443	453		10.1056/NEJMoa072366	http://dx.doi.org/10.1056/NEJMoa072366			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195UB	17634449	Green Accepted, Green Published, Bronze, Green Submitted			2022-12-28	WOS:000248436300005
J	Klein, DF; O'Brien, CP				Klein, Donald F.; O'Brien, Charles P.			Improving detection of adverse effects of marketed drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ANTIDEPRESSANTS; RISK		Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA; Columbia Univ, Dept Psychiat, New York, NY USA	University of Pennsylvania; Columbia University	O'Brien, CP (corresponding author), Univ Penn, Dept Psychiat, 3900 Chestnut St, Philadelphia, PA 19104 USA.	obrien@mail.trc.upenn.edu						*I DRUG OUTR, 2007, PHARMA WEB SIT; Institute of Medicine, 2007, ADV DRUG EV REP ROL; Klein DF, 2006, NEUROPSYCHOPHARMACOL, V31, P689, DOI 10.1038/sj.npp.1300996; Libby AM, 2007, AM J PSYCHIAT, V164, P884, DOI 10.1176/appi.ajp.164.6.884; Lopez J, 2004, AM J HYPERTENS, V17, P1095, DOI 10.1016/j.amjhyper.2004.07.015; Meijer WEE, 2004, ARCH INTERN MED, V164, P2367, DOI 10.1001/archinte.164.21.2367; Tiihonen J, 2006, ARCH GEN PSYCHIAT, V63, P1358, DOI 10.1001/archpsyc.63.12.1358; Woo JJY, 2007, AM J CLIN NUTR, V85, p323S, DOI 10.1093/ajcn/85.1.323S	8	11	11	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 18	2007	298	3					333	334		10.1001/jama.298.3.333	http://dx.doi.org/10.1001/jama.298.3.333			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	190US	17635895				2022-12-28	WOS:000248086700029
J	Lunyak, VV; Prefontaine, GG; Nunez, E; Cramer, T; Ju, BG; Ohgi, KA; Hutt, K; Roy, R; Garcia-Diaz, A; Zhu, XY; Yung, Y; Montoliu, L; Glass, CK; Rosenfeld, MG				Lunyak, Victoria V.; Prefontaine, Gratien G.; Nunez, Esperanza; Cramer, Thorsten; Ju, Bong-Gun; Ohgi, Kenneth A.; Hutt, Kasey; Roy, Rosa; Garcia-Diaz, Angel; Zhu, Xiaoyan; Yung, Yun; Montoliu, Lluis; Glass, Christopher K.; Rosenfeld, Michael G.			Developmentally regulated activation of a SINE B2 repeat as a domain boundary in organogenesis	SCIENCE			English	Article							LOCUS-CONTROL REGION; BETA-GLOBIN INSULATOR; GROWTH-HORMONE GENE; RNA-POLYMERASE-II; NUCLEAR ARCHITECTURE; METHYLTRANSFERASES; HETEROCHROMATIN; ELEMENTS; CELLS; TRANSCRIPTION	The temporal and spatial regulation of gene expression in mammalian development is linked to the establishment of functional chromatin domains. Here, we report that tissue-specific transcription of a retrotransposon repeat in the murine growth hormone locus is required for gene activation. This repeat serves as a boundary to block the influence of repressive chromatin modifications. The repeat element is able to generate short, overlapping Pol II- and Pol III-driven transcripts, both of which are necessary and sufficient to enable a restructuring of the regulated locus into nuclear compartments. These data suggest that transcription of interspersed repetitive sequences may represent a developmental strategy for the establishment of functionally distinct domains within the mammalian genome to control gene activation.	Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Div Endocrinol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, Dept Med, Sch Med, La Jolla, CA 92093 USA; CSIC, CNB, Dept Mol & Cellular Biol, Madrid 28049, Spain; Charite Univ Med Berlin, Dept Gastroenterol & Hepatol, D-13353 Berlin, Germany	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Lunyak, VV (corresponding author), Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, 9500 Gilman Dr,Room 345, La Jolla, CA 92093 USA.	vlunyak@uscd.edu; mrosenfeld@ucsd.edu	Montoliu, Lluis/I-2039-2015; ROY, ROSA/AAA-9584-2019; Garcia-Diaz, Angel/AAT-9213-2020; Glass, Christopher/AAI-3933-2021; Cramer, Thorsten/S-2479-2016; lunyak, victoria/R-3765-2017	Montoliu, Lluis/0000-0003-3941-1176; Garcia-Diaz, Angel/0000-0001-6139-6764; Glass, Christopher/0000-0003-4344-3592; Cramer, Thorsten/0000-0002-6462-239X; Roy Barcelona, Rosa/0000-0003-0729-3849; lunyak, victoria/0000-0001-9093-2714				Allen TA, 2004, NAT STRUCT MOL BIOL, V11, P816, DOI 10.1038/nsmb813; Antes TJ, 2001, BIOCHEMISTRY-US, V40, P6731, DOI 10.1021/bi0100743; BACHVAROVA R, 1988, DEV BIOL, V130, P513, DOI 10.1016/0012-1606(88)90346-6; Bennani-Baiti IM, 1998, GENOMICS, V48, P258, DOI 10.1006/geno.1997.5171; Bennani-Baiti IM, 1998, P NATL ACAD SCI USA, V95, P10655, DOI 10.1073/pnas.95.18.10655; Biron VL, 2004, DEV BIOL, V276, P337, DOI 10.1016/j.ydbio.2004.08.038; Capelson M, 2004, BIOL CELL, V96, P617, DOI 10.1016/j.biolcel.2004.06.004; Chung JH, 1997, P NATL ACAD SCI USA, V94, P575, DOI 10.1073/pnas.94.2.575; CILIBERTO G, 1983, CELL, V32, P725, DOI 10.1016/0092-8674(83)90058-2; Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075; Espinoza CA, 2004, NAT STRUCT MOL BIOL, V11, P822, DOI 10.1038/nsmb812; Ferrigno O, 2001, NAT GENET, V28, P77, DOI 10.1038/ng0501-77; Gasser SM, 2002, SCIENCE, V296, P1412, DOI 10.1126/science.1067703; Giraldo P, 2003, NUCLEIC ACIDS RES, V31, P6290, DOI 10.1093/nar/gkg793; JONES BK, 1995, MOL CELL BIOL, V15, P7010; Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843; Noma KI, 2006, CELL, V125, P859, DOI 10.1016/j.cell.2006.04.028; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Recillas-Targa F, 1999, P NATL ACAD SCI USA, V96, P14354, DOI 10.1073/pnas.96.25.14354; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Rice JC, 2001, NATURE, V414, P258, DOI 10.1038/35104721; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Scully KM, 2000, SCIENCE, V290, P1127, DOI 10.1126/science.290.5494.1127; Shewchuk BM, 2001, NUCLEIC ACIDS RES, V29, P3356, DOI 10.1093/nar/29.16.3356; Treier M, 1998, GENE DEV, V12, P1691, DOI 10.1101/gad.12.11.1691; Valadez-Graham V, 2004, NUCLEIC ACIDS RES, V32, P1354, DOI 10.1093/nar/gkh301	27	196	209	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 13	2007	317	5835					248	251		10.1126/science.1140871	http://dx.doi.org/10.1126/science.1140871			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189DC	17626886				2022-12-28	WOS:000247968600044
J	Okamura, K; Hagen, JW; Duan, H; Tyler, DM; Lai, EC				Okamura, Katsutomo; Hagen, Joshua W.; Duan, Hong; Tyler, David M.; Lai, Eric C.			The mirtron pathway generates microRNA-class regulatory RNAs in Drosophila	CELL			English	Article							UTR SEQUENCE MOTIF; NUCLEAR EXPORT; C-ELEGANS; POSTTRANSCRIPTIONAL REGULATION; DISTINCT ROLES; K-BOX; GENES; IDENTIFICATION; INTERFERENCE; EXPRESSION	The canonical microRNA ( miRNA) pathway converts primary hairpin precursor transcripts into similar to 22 nucleotide regulatory RNAs via consecutive cleavages by two RNase III enzymes, Drosha and Dicer. In this study, we characterize Drosophila small RNAs that derive from short intronic hairpins termed `` mirtrons.'' Their nuclear biogenesis appears to bypass Drosha cleavage, which is essential for miRNA biogenesis. Instead, mirtron hairpins are defined by the action of the splicing machinery and lariat- debranching enzyme, which yield pre- miRNA- like hairpins. The mirtron pathway merges with the canonical miRNA pathway during hairpin export by Exportin- 5, and both types of hairpins are subsequently processed by Dicer- 1/ loqs. This generates small RNAs that can repress perfectly matched and seed- matched targets, and we provide evidence that they function, at least in part, via the RNA- induced silencing complex effector Ago1. These findings reveal that mirtrons are an alternate source of miRNA- type regulatory RNAs.	Mem Sloan Kettering Canc Ctr, Dept Dev Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Lai, EC (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Dev Biol, 1275 York Ave,Box 252, New York, NY 10021 USA.	laie@mskcc.org	Lai, Eric C/A-3412-2008; Lai, Eric/AAO-1143-2021	Lai, Eric/0000-0002-8432-5851	NIGMS NIH HHS [GM07739, R01 GM083300-01, R01 GM083300, T32 GM007739] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM083300, T32GM007739] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bohnsack MT, 2004, RNA, V10, P185, DOI 10.1261/rna.5167604; Borchert GM, 2006, NAT STRUCT MOL BIOL, V13, P1097, DOI 10.1038/nsmb1167; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Chen K, 2007, NAT REV GENET, V8, P93, DOI 10.1038/nrg1990; Conklin JF, 2005, METHODS, V37, P368, DOI 10.1016/j.ymeth.2005.08.002; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Du TT, 2005, DEVELOPMENT, V132, P4645, DOI 10.1242/dev.02070; Farh KKH, 2005, SCIENCE, V310, P1817, DOI 10.1126/science.1121158; Forstemann K, 2005, PLOS BIOL, V3, P1187, DOI 10.1371/journal.pbio.0030236; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Grun D, 2005, PLOS COMPUT BIOL, V1, P51, DOI 10.1371/journal.pcbi.0010013; Han JJ, 2006, CELL, V125, P887, DOI 10.1016/j.cell.2006.03.043; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Jiang F, 2005, GENE DEV, V19, P1674, DOI 10.1101/gad.1334005; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Kim YK, 2007, EMBO J, V26, P775, DOI 10.1038/sj.emboj.7601512; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lai EC, 1998, CELL, V93, P1103, DOI 10.1016/S0092-8674(00)81454-3; Lai EC, 1997, DEVELOPMENT, V124, P4847; Lai EC, 1998, DEVELOPMENT, V125, P4077; Lai EC, 2005, GENE DEV, V19, P1067, DOI 10.1101/gad.1291905; Lai EC, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-r42; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; Miyoshi K, 2005, GENE DEV, V19, P2837, DOI 10.1101/gad.1370605; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; Okamura K, 2004, GENE DEV, V18, P1655, DOI 10.1101/gad.1210204; Ooi SL, 1998, RNA, V4, P1096, DOI 10.1017/S1355838298980785; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Ruby JG, 2007, NATURE, V448, P83, DOI 10.1038/nature05983; Saito K, 2005, PLOS BIOL, V3, P1202, DOI 10.1371/journal.pbio.0030235; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Shibata S, 2006, NUCLEIC ACIDS RES, V34, P4711, DOI 10.1093/nar/gkl663; Stark A, 2005, CELL, V123, P1133, DOI 10.1016/j.cell.2005.11.023; Stark A, 2003, PLOS BIOL, V1, P397, DOI 10.1371/journal.pbio.0000060; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; Wang YM, 2007, NAT GENET, V39, P380, DOI 10.1038/ng1969; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Wu HJ, 2000, J BIOL CHEM, V275, P36957, DOI 10.1074/jbc.M005494200; Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803	50	688	735	2	50	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 13	2007	130	1					89	100		10.1016/j.cell.2007.06.028	http://dx.doi.org/10.1016/j.cell.2007.06.028			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	197WK	17599402	Green Accepted, Bronze			2022-12-28	WOS:000248587000013
J	Ma, JF; Yamaji, N; Mitani, N; Tamai, K; Konishi, S; Fujiwara, T; Katsuhara, M; Yano, M				Ma, Jian Feng; Yamaji, Naoki; Mitani, Namiki; Tamai, Kazunori; Konishi, Saeko; Fujiwara, Toru; Katsuhara, Maki; Yano, Masahiro			An efflux transporter of silicon in rice	NATURE			English	Article							PLANTS; ROOTS; RESISTANCE	Silicon is an important nutrient for the optimal growth and sustainable production of rice(1-4). Rice accumulates up to 10% silicon in the shoot, and this high accumulation is required to protect the plant from multiple abiotic and biotic stresses(1-5). A gene, Lsi1, that encodes a silicon influx transporter has been identified in rice(6). Here we describe a previously uncharacterized gene, low silicon rice 2 (Lsi2), which has no similarity to Lsi1. This gene is constitutively expressed in the roots. The protein encoded by this gene is localized, like Lsi1, on the plasma membrane of cells in both the exodermis and the endodermis, but in contrast to Lsi1, which is localized on the distal side, Lsi2 is localized on the proximal side of the same cells. Expression of Lsi2 in Xenopus oocytes did not result in influx transport activity for silicon, but preloading of the oocytes with silicon resulted in a release of silicon, indicating that Lsi2 is a silicon efflux transporter. The identification of this silicon transporter revealed a unique mechanism of nutrient transport in plants: having an influx transporter on one side and an efflux transporter on the other side of the cell to permit the effective transcellular transport of the nutrients.	Okayama Univ, Bioresources Res Inst, Kurashiki, Okayama 7100046, Japan; Inst Soc Technoinnovat Agr Forestry & Fisheries, Tsukuba, Ibaraki 3050854, Japan; Univ Tokyo, Biotechnol Res Ctr, Bunkyo Ku, Tokyo 1138657, Japan; Japan Sci & Technol Agcy, Solut Oriented Res Sci & Technol, Tokyo 1030027, Japan; Natl Inst Agrobiol Sci, QTL Genom Res Ctr, Tsukuba, Ibaraki 3058602, Japan	Okayama University; University of Tokyo; Japan Science & Technology Agency (JST); National Institute of Agrobiological Sciences - Japan	Ma, JF (corresponding author), Okayama Univ, Bioresources Res Inst, Chuo 2-20-1, Kurashiki, Okayama 7100046, Japan.	maj@rib.okayama-u.ac.jp	Feng, Jian/C-7213-2009; Yano, Masahiro/AAC-5441-2019; FUJIWARA, Toru/A-4119-2011; YAMAJI, Naoki/B-2524-2011; Ma, Jianfeng/GZB-0110-2022	Feng, Jian/0000-0003-3411-827X; YAMAJI, Naoki/0000-0002-7499-3004; Katsuhara, Maki/0000-0002-8264-3063; Yano, Masahiro/0000-0003-1510-4622				[Anonymous], 2005, MINERAL NUTR PLANTS; Epstein E, 1999, ANNU REV PLANT PHYS, V50, P641, DOI 10.1146/annurev.arplant.50.1.641; Fauteux F, 2005, FEMS MICROBIOL LETT, V249, P1, DOI 10.1016/j.femsle.2005.06.034; Fuse T., 2001, PLANT BIOTECHNOL, V18, P219, DOI DOI 10.5511/PLANTBI0TECHN0L0GY.18.219; Gong HJ, 2006, PLANT CELL ENVIRON, V29, P1970, DOI 10.1111/j.1365-3040.2006.01572.x; HIEI Y, 1994, PLANT J, V6, P271, DOI 10.1046/j.1365-313X.1994.6020271.x; HILDEBRAND M, 1993, GENE, V132, P213, DOI 10.1016/0378-1119(93)90198-C; Hildebrand M, 1997, NATURE, V385, P688, DOI 10.1038/385688b0; Hodson MJ, 2005, ANN BOT-LONDON, V96, P1027, DOI 10.1093/aob/mci255; Kawai M, 1998, PLANTA, V204, P277, DOI 10.1007/s004250050257; Ma JF, 2006, NATURE, V440, P688, DOI 10.1038/nature04590; Ma JF, 2004, SOIL SCI PLANT NUTR, V50, P11, DOI 10.1080/00380768.2004.10408447; Ma JF, 2003, PLANT SOIL, V249, P383, DOI 10.1023/A:1022842421926; Ma JF, 2002, PLANT PHYSIOL, V130, P2111, DOI 10.1104/pp.010348; Ma JF, 2001, PLANT PHYSIOL, V127, P1773, DOI 10.1104/pp.010271; Ma JF, 2006, TRENDS PLANT SCI, V11, P392, DOI 10.1016/j.tplants.2006.06.007; Ma JianFeng, 2002, Soil, fertilizer and plant silicon research in Japan, DOI 10.1016/B978-044451166-9/50007-5; Meng YL, 2004, J BIOL CHEM, V279, P18334, DOI 10.1074/jbc.M400037200; Rains DW, 2006, PLANT SOIL, V280, P223, DOI 10.1007/s11104-005-3082-x; Raven J.A., 2001, SILICON AGR, P41, DOI DOI 10.1016/S0928-3420(01)80007-0; Savant NK, 1997, ADV AGRON, V58, P151; Taiz L, 1998, PLANT PHYSIOL, P103; Takahashi E., 1976, Journal of the Science of Soil and Manure, Japan, V47, P191; Takahashi E., 1976, Journal of the Science of Soil and Manure, Japan, V47, P183; Takahashi E., 1990, Comments on Agricultural and Food Chemistry, V2, P99; Tallberg P, 2002, WATER RES, V36, P956, DOI 10.1016/S0043-1354(01)00312-8; Tamai K, 2003, NEW PHYTOL, V158, P431, DOI 10.1046/j.1469-8137.2003.00773.x; YOSHIDA SHOICHI, 1965, BULL NAT INST AGR SCI SER B [JAP], V15, P1	28	568	623	13	266	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 12	2007	448	7150					209	U12		10.1038/nature05964	http://dx.doi.org/10.1038/nature05964			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	188QN	17625566				2022-12-28	WOS:000247934500046
J	Wasko, MCM; Hubert, HB; Lingala, VB; Elliott, JR; Luggen, ME; Fries, JF; Ward, MM				Wasko, Mary Chester M.; Hubert, Helen B.; Lingala, Vijaya Bharathi; Elliott, Jennifer R.; Luggen, Michael E.; Fries, James F.; Ward, Michael M.			Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LIFE-STYLE INTERVENTION; RANDOMIZED-TRIAL; MELLITUS; PREVENTION; METFORMIN; WOMEN; CLASSIFICATION; DIAGNOSIS; ESTROGEN; RAMIPRIL	Context Hydroxychloroquine, a commonly used antirheumatic medication, has hypoglycemic effects and may reduce the risk of diabetes mellitus. Objective To determine the association between hydroxychloroquine use and the incidence of self-reported diabetes in a cohort of patients with rheumatoid arthritis. Design, Setting, and Patients A prospective, multicenter observational study of 4905 adults with rheumatoid arthritis ( 1808 had taken hydroxychloroquine and 3097 had never taken hydroxychloroquine) and no diagnosis or treatment for diabetes in outpatient university-based and community-based rheumatology practices with 21.5 years of follow-up ( January 1983 through July 2004). Main Outcome Measures Diabetes by self-report of diagnosis or hypoglycemic medication use. Results During the observation period, incident diabetes was reported by 54 patients who had taken hydroxychloroquine and by 171 patients who had never taken hydroxychloroquine, with incidence rates of 5.2 per 1000 patient-years of observation compared with 8.9 per 1000 patient-years of observation, respectively ( P <. 001). In time-varying multivariable analysis with adjustments for possible confounding factors, the hazard ratio for incident diabetes among patients who had taken hydroxychloroquine was 0.62 (95% confidence interval, 0.42-0.92) compared with those who had not taken hydroxychloroquine. In Poisson regression, the risk of incident diabetes was significantly reduced with increased duration of hydroxychloroquine use ( P <. 001 for trend); among those taking hydroxychloroquine for more than 4 years (n= 384), the adjusted relative risk of developing diabetes was 0.23 ( 95% confidence interval, 0.11-0.50; P <. 001), compared with those who had not taken hydroxychloroquine. Conclusion Among patients with rheumatoid arthritis, use of hydroxychloroquine is associated with a reduced risk of diabetes.	Univ Pittsburgh, Div Clin Immunol & Rheumatol, Pittsburgh, PA 15261 USA; Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA; Univ Cincinnati, Div Immunol, Cincinnati, OH USA; NIAMSD, Intramural Res Program, NIH, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Stanford University; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Wasko, MCM (corresponding author), Univ Pittsburgh, Div Clin Immunol & Rheumatol, 3500 Terrace St,BST 704 S, Pittsburgh, PA 15261 USA.	wasko@pitt.edu	Fries, James F/F-6271-2011		Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041153, Z01AR041153] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Bonds DE, 2006, DIABETOLOGIA, V49, P459, DOI 10.1007/s00125-005-0096-0; Booth GL, 2006, LANCET, V368, P29, DOI 10.1016/S0140-6736(06)68967-8; Bosch J, 2006, NEW ENGL J MED, V355, P1551; Chiasson JL, 2002, LANCET, V359, P2072, DOI 10.1016/S0140-6736(02)08905-5; Crandall J, 2006, J GERONTOL A-BIOL, V61, P1075; Emami J, 1999, CAN J PHYSIOL PHARM, V77, P118, DOI 10.1139/cjpp-77-2-118; Emami J, 1998, LIFE SCI, V64, P325, DOI 10.1016/S0024-3205(98)00568-2; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; Gabriel SE, 1999, J RHEUMATOL, V26, P2475; Gavin JR, 1997, DIABETES CARE, V20, P1183; Genuth S, 2003, DIABETES CARE, V26, P3160; Gerstein HC, 2006, LANCET, V368, P1096, DOI 10.1016/S0140-6736(06)69420-8; Gerstein HC, 2002, DIABETES RES CLIN PR, V55, P209, DOI 10.1016/S0168-8227(01)00325-4; Jones SK, 1999, BRIT J DERMATOL, V140, P3, DOI 10.1046/j.1365-2133.1999.02600.x; Kanaya AM, 2003, ANN INTERN MED, V138, P1, DOI 10.7326/0003-4819-138-1-200301070-00005; Kitabchi AE, 2005, DIABETES, V54, P2404, DOI 10.2337/diabetes.54.8.2404; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Krishnan E, 2004, ARTHRITIS RES THER, V6, pR505, DOI 10.1186/ar1220; Margolis KL, 2004, DIABETOLOGIA, V47, P1175, DOI 10.1007/s00125-004-1448-x; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; O'Dell JR, 2004, NEW ENGL J MED, V350, P2591, DOI 10.1056/NEJMra040226; ODell JR, 1996, NEW ENGL J MED, V334, P1287, DOI 10.1056/NEJM199605163342002; Peters Annette, 2006, Epidemiol Perspect Innov, V3, P10, DOI 10.1186/1742-5573-3-10; Petri M, 1996, LUPUS, V5, pS16, DOI 10.1177/096120339600500105; Petri M., 1994, Arthritis and Rheumatism, V37, pS323; POWRIE JK, 1991, AM J PHYSIOL, V260, pE897, DOI 10.1152/ajpendo.1991.260.6.E897; QUATRARO A, 1990, ANN INTERN MED, V112, P678, DOI 10.7326/0003-4819-112-9-678; Selzer F, 2001, HYPERTENSION, V37, P1075, DOI 10.1161/01.HYP.37.4.1075; Shojania K, 1999, J RHEUMATOL, V26, P195; Simard JF, 2007, J RHEUMATOL, V34, P469; Yusuf S, 2000, NEW ENGL J MED, V342, P145	32	186	195	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2007	298	2					187	193		10.1001/jama.298.2.187	http://dx.doi.org/10.1001/jama.298.2.187			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188HI	17622600	Bronze			2022-12-28	WOS:000247910600024
J	Willerslev, E; Cappellini, E; Boomsma, W; Nielsen, R; Hebsgaard, MB; Brand, TB; Hofreiter, M; Bunce, M; Poinar, HN; Dahl-Jensen, D; Johnsen, S; Steffensen, JP; Bennike, O; Schwenninger, JL; Nathan, R; Armitage, S; de Hoog, CJ; Alfimov, V; Christl, M; Beer, J; Muscheler, R; Barker, J; Sharp, M; Penkman, KEH; Haile, J; Taberlet, P; Gilbert, MTP; Casoli, A; Campani, E; Collins, MJ				Willerslev, Eske; Cappellini, Enrico; Boomsma, Wouter; Nielsen, Rasmus; Hebsgaard, Martin B.; Brand, Tina B.; Hofreiter, Michael; Bunce, Michael; Poinar, Hendrik N.; Dahl-Jensen, Dorthe; Johnsen, Sigfus; Steffensen, Jorgen Peder; Bennike, Ole; Schwenninger, Jean-Luc; Nathan, Roger; Armitage, Simon; de Hoog, Cees-Jan; Alfimov, Vasily; Christl, Marcus; Beer, Juerg; Muscheler, Raimund; Barker, Joel; Sharp, Martin; Penkman, Kirsty E. H.; Haile, James; Taberlet, Pierre; Gilbert, M. Thomas P.; Casoli, Antonella; Campani, Elisa; Collins, Matthew J.			Ancient biomolecules from deep ice cores reveal a forested Southern Greenland	SCIENCE			English	Article							ELLESMERE ISLAND; DNA; GLACIER; CLIMATE; POLLEN; INSTABILITY; CHRONOLOGY; SEDIMENTS; HOLOCENE; RECORD	It is difficult to obtain fossil data from the 10% of Earth's terrestrial surface that is covered by thick glaciers and ice sheets, and hence, knowledge of the paleoenvironments of these regions has remained limited. We show that DNA and amino acids from buried organisms can be recovered from the basal sections of deep ice cores, enabling reconstructions of past flora and fauna. We show that high-altitude southern Greenland, currently lying below more than 2 kilometers of ice, was inhabited by a diverse array of conifer trees and insects within the past million years. The results provide direct evidence in support of a forested southern Greenland and suggest that many deep ice cores may contain genetic records of paleoenvironments in their basal sections.	Univ Copenhagen, Ctr Ancient Genet, DK-1168 Copenhagen, Denmark; Univ York, Dept Biol, York YO10 5DD, N Yorkshire, England; Univ York, Dept Archaeol, York YO10 5DD, N Yorkshire, England; Univ Copenhagen, Bioinformat Ctr, DK-1168 Copenhagen, Denmark; Univ Copenhagen, Ctr Comparat Genom, DK-1168 Copenhagen, Denmark; Max Planck Inst Evolutionary Anthropol, Leipzig, Germany; Murdoch Univ, Ancient DNA Res Lab, Murdoch, WA 6150, Australia; McMaster Univ, McMaster Ancient DNA Ctr, Hamilton, ON L8S 4L8, Canada; Geol Survey Denmark & Greenland, Copenhagen, Denmark; Univ Oxford, Archaeol & Hist Art Res Lab, Oxford OX1 2JD, England; Univ London Royal Holloway & Bedford New Coll, Dept Geog, Egham TW20 0EX, Surrey, England; Univ Oxford, Dept Earth Sci, Oxford OX1 2JD, England; Swiss Fed Inst Technol, Paul Scherrer Inst, Lab Ion Beam Phys, Inst Particle Phys, Zurich, Switzerland; Swiss Fed Inst Aquat Sci & Technol EAWAG, Dubendorf, Switzerland; Lund Univ, Geobiosphere Sci Ctr, S-22100 Lund, Sweden; Univ Alberta, Dept Earth & Atmospher Sci, Edmonton, AB T6G 2M7, Canada; Univ Oxford, Ancient Biomol Ctr, Oxford OX1 2JD, England; Univ Grenoble 1, CNRS, Unite Mixte Rech 5553, Lab Ecol Alpine, F-38041 Grenoble 9, France; Univ Parma, Dipartimento Chim Gen & Inorgan, I-43100 Parma, Italy	University of Copenhagen; University of York - UK; University of York - UK; University of Copenhagen; University of Copenhagen; Max Planck Society; Murdoch University; McMaster University; Geological Survey Of Denmark & Greenland; University of Oxford; University of London; Royal Holloway University London; University of Oxford; Swiss Federal Institutes of Technology Domain; ETH Zurich; Paul Scherrer Institute; Swiss Federal Institutes of Technology Domain; Swiss Federal Institute of Aquatic Science & Technology (EAWAG); Lund University; University of Alberta; University of Oxford; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); Universite de Savoie; University of Parma	Willerslev, E (corresponding author), Univ Copenhagen, Ctr Ancient Genet, DK-1168 Copenhagen, Denmark.	ewillerslev@bi.ku.dk	Willerslev, Eske/AAA-5686-2019; Willerslev, Eske/A-9619-2011; Alfimov, Vasily/B-3629-2010; Dahl-Jensen, Dorthe/AAO-6951-2020; Hebsgaard, Martin B/C-8220-2009; Gilbert, Marcus TP/A-8936-2013; Penkman, Kirsty E/D-1952-2012; Dahl-Jensen, Dorthe/N-4401-2016; Bennike, Ole/G-7070-2018; Boomsma, Wouter/K-2903-2014; TABERLET, Pierre/D-1178-2010; Armitage, Simon/K-7471-2015; Hofreiter, Michael/A-3996-2017; Christl, Marcus/J-4769-2016; Nielsen, Rasmus/D-4405-2009; De Hoog, Jan/C-1354-2010; Cappellini, Enrico/F-9346-2013	Willerslev, Eske/0000-0002-7081-6748; Dahl-Jensen, Dorthe/0000-0002-1474-1948; Gilbert, Marcus TP/0000-0002-5805-7195; Penkman, Kirsty E/0000-0002-6226-9799; Dahl-Jensen, Dorthe/0000-0002-1474-1948; Bennike, Ole/0000-0002-5486-9946; Boomsma, Wouter/0000-0002-8257-3827; TABERLET, Pierre/0000-0002-3554-5954; Armitage, Simon/0000-0003-1480-9188; Steffensen, Jorgen Peder/0000-0002-5516-1093; Barker, Joel/0000-0003-1661-2709; Hofreiter, Michael/0000-0003-0441-4705; casoli, antonella/0000-0002-9212-9463; Christl, Marcus/0000-0002-3131-6652; Muscheler, Raimund/0000-0003-2772-3631; Nielsen, Rasmus/0000-0003-0513-6591; De Hoog, Jan/0000-0002-5930-3597; Bunce, Michael/0000-0002-0302-4206; Collins, Matthew/0000-0003-4226-5501; Cappellini, Enrico/0000-0001-7885-7811	NERC [NE/C511148/1] Funding Source: UKRI; Natural Environment Research Council [NE/C511148/1] Funding Source: researchfish; Wellcome Trust [076905] Funding Source: Medline	NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Bennike O, 2002, PALAEOGEOGR PALAEOCL, V186, P1, DOI 10.1016/S0031-0182(02)00439-X; Bennike O., 2000, GEOLOGICAL SURVEY B, V186, P29, DOI [10.34194/ggub.v186.5212, DOI 10.34194/GGUB.V186.5212]; BENNIKE O, 1990, MEDD GROENL GEOSCI, V23, P85; BERGSMA BM, 1984, ARCTIC, V37, P49; Binladen J, 2006, GENETICS, V172, P733, DOI 10.1534/genetics.105.049718; BLAKE W, 1989, RADIOCARBON, V31, P570; Bourgeois JC, 2001, J GEOPHYS RES-ATMOS, V106, P5255, DOI 10.1029/2000JD900708; BOURGEOIS JC, 1990, J GLACIOL, V36, P340, DOI 10.3189/002214390793701363; COLLINS MJ, 2000, PERSPECTIVES AMINO A, P142; Copland L, 2001, J GLACIOL, V47, P232, DOI 10.3189/172756501781832377; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; DANSGAARD W, 1982, SCIENCE, V218, P1273, DOI 10.1126/science.218.4579.1273; Francis JE, 1996, PALAIOS, V11, P389, DOI 10.2307/3515248; Funder S, 2001, B GEOL SOC DENMARK, V48, P117; Gudmundsson GH, 1997, J GLACIOL, V43, P80, DOI 10.3189/S0022143000002835; Haile J, 2007, MOL BIOL EVOL, V24, P982, DOI 10.1093/molbev/msm016; Hebsgaard MB, 2005, TRENDS MICROBIOL, V13, P212, DOI 10.1016/j.tim.2005.03.010; Hofreiter M, 2003, CURR BIOL, V13, pR693, DOI 10.1016/j.cub.2003.08.039; Hofreiter M, 2000, MOL ECOL, V9, P1975, DOI 10.1046/j.1365-294X.2000.01106.x; Otto-Bliesner BL, 2006, SCIENCE, V311, P1751, DOI 10.1126/science.1120808; Overpeck JT, 2006, SCIENCE, V311, P1747, DOI 10.1126/science.1115159; Parducci L, 2005, MOL ECOL, V14, P2873, DOI 10.1111/j.1365-294X.2005.02644.x; SHIYI H, 1997, ACTA BOT SIN, V39, P363; Souchez R, 1998, GEOPHYS RES LETT, V25, P1943, DOI 10.1029/98GL01411; von Wintzingerode F, 1997, FEMS MICROBIOL REV, V21, P213; Willerslev E, 2005, P ROY SOC B-BIOL SCI, V272, P3, DOI 10.1098/rspb.2004.2813; Willerslev E, 2004, TRENDS ECOL EVOL, V19, P141, DOI 10.1016/j.tree.2003.11.010; Willerslev E, 2003, SCIENCE, V300, P791, DOI 10.1126/science.1084114	28	301	317	4	128	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 6	2007	317	5834					111	114		10.1126/science.1141758	http://dx.doi.org/10.1126/science.1141758			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186KD	17615355	Green Accepted, Green Published			2022-12-28	WOS:000247776700062
J	Fazel, R; Froehlich, JB; Williams, DM; Saint, S; Nallamothu, BK				Fazel, Reza; Froehlich, James B.; Williams, David M.; Saint, Sanjay; Nallamothu, Brahmajee K.			Clinical problem-solving - A sinister development	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ILIAC VEIN COMPRESSION; DEEP VENOUS THROMBOSIS; ENDOVASCULAR MANAGEMENT; DIAGNOSIS		Emory Univ, Div Cardiol, Atlanta, GA 30322 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA; Ann Arbor Vet Affairs Med Ctr, Hlth Serv Res & Dev Ctr Excellence, Ann Arbor, MI USA	Emory University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System	Fazel, R (corresponding author), Emory Univ, Div Cardiol, 1639 Pierce Dr,Suite 319, Atlanta, GA 30322 USA.	rfazel@emory.edu	Saint, Sanjay/AAF-5126-2019	Fazel, Reza/0000-0002-9102-6155				Augustinos P, 2004, CIRCULATION, V110, pI27, DOI 10.1161/01.CIR.0000140900.64198.f4; Bates SM, 2004, NEW ENGL J MED, V351, P268, DOI 10.1056/NEJMcp031676; EVANS AJ, 1993, AM J ROENTGENOL, V161, P131, DOI 10.2214/ajr.161.1.8517292; Forauer AR, 2002, J VASC INTERV RADIOL, V13, P523, DOI 10.1016/S1051-0443(07)61535-8; Kearon C, 1998, ANN INTERN MED, V129, P425, DOI 10.7326/0003-4819-128-8-199804150-00011; Kearon C, 1998, ANN INTERN MED, V128, P663, DOI 10.7326/0003-4819-128-8-199804150-00011; Kibbe MR, 2004, J VASC SURG, V39, P937, DOI 10.1016/j.jvs.2003.12.032; MAY R., 1957, ANGIOLOGY, V8, P419, DOI 10.1177/000331975700800505; MESSINA LM, 1993, SURGERY, V114, P921; Mickley V, 1998, J VASC SURG, V28, P492, DOI 10.1016/S0741-5214(98)70135-1; O'Sullivan GJ, 2000, J VASC INTERV RADIOL, V11, P823, DOI 10.1016/S1051-0443(07)61796-5; Patel NH, 2000, J VASC INTERV RADIOL, V11, P1297, DOI 10.1016/S1051-0443(07)61304-9; VIRCHOW R, 1851, ARCH PATH ANAT, V3, P427, DOI DOI 10.1007/BF01960918	13	22	25	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 5	2007	357	1					53	59		10.1056/NEJMcps061337	http://dx.doi.org/10.1056/NEJMcps061337			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185OR	17611208				2022-12-28	WOS:000247720800010
J	Hudis, CA				Hudis, Clifford A.			Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							METASTATIC BREAST-CANCER; EPIDERMAL-GROWTH-FACTOR; PHASE-II TRIAL; MONOCLONAL-ANTIBODY; FACTOR RECEPTOR; IN-VIVO; ADJUVANT CHEMOTHERAPY; GENE AMPLIFICATION; 1ST-LINE TREATMENT; HER2		Mem Sloan Kettering Canc Ctr, Dept Med, Solid Tumor Div, Canc Med Serv, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Hudis, CA (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Solid Tumor Div, Canc Med Serv, 1275 York Ave,POB 206, New York, NY 10021 USA.	hudisc@mskcc.org	Mieszkowska, Magdalena/O-6753-2017; Hudis, Clifford/AAW-9482-2021	Hudis, Clifford/0000-0001-7144-8791				Agus DB, 2005, J CLIN ONCOL, V23, P2534, DOI 10.1200/JCO.2005.03.184; Albanell J, 1996, ANTICANCER RES, V16, P1027; Badache A, 2004, CANCER CELL, V5, P299, DOI 10.1016/S1535-6108(04)00088-1; Bangemann N, 2000, ANN ONCOL, V11, P143; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; Baselga J, 2005, J CLIN ONCOL, V23, P2162, DOI 10.1200/JCO.2005.01.014; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Berry DA, 2000, J CLIN ONCOL, V18, P3471, DOI 10.1200/JCO.2000.18.20.3471; Bianchi G, 2003, CLIN CANCER RES, V9, P5944; Brennan PJ, 2000, ONCOGENE, V19, P6093, DOI 10.1038/sj.onc.1203967; Burstein HJ, 2003, J CLIN ONCOL, V21, P2889, DOI 10.1200/JCO.2003.02.018; Buzdar AU, 2007, CLIN CANCER RES, V13, P228, DOI 10.1158/1078-0432.CCR-06-1345; Carlson Robert W, 2006, J Natl Compr Canc Netw, V4 Suppl 1, pS1; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Chia S, 2006, J CLIN ONCOL, V24, P2773, DOI 10.1200/JCO.2005.03.8331; Chien KR, 2006, NEW ENGL J MED, V354, P789, DOI 10.1056/NEJMp058315; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Colomer R, 2000, CLIN CANCER RES, V6, P2356; Crone SA, 2002, NAT MED, V8, P459, DOI 10.1038/nm0502-459; Dang CT, 2004, CLIN CANCER RES, V10, P4062, DOI 10.1158/1078-0432.CCR-03-0463; Disis ML, 2002, J CLIN ONCOL, V20, P2624, DOI 10.1200/JCO.2002.06.171; DOri S, 2002, J ORAL PATHOL MED, V31, P463, DOI 10.1034/j.1600-0714.2002.00017.x; Ellis MJ, 2001, J CLIN ONCOL, V19, P3808, DOI 10.1200/JCO.2001.19.18.3808; Esteva FJ, 2002, J CLIN ONCOL, V20, P1800, DOI 10.1200/JCO.2002.07.058; FENDLY BM, 1990, CANCER RES, V50, P1550; Garratt AN, 2003, TRENDS CARDIOVAS MED, V13, P80, DOI 10.1016/S1050-1738(02)00231-1; Gennari R, 2004, CLIN CANCER RES, V10, P5650, DOI 10.1158/1078-0432.CCR-04-0225; *GERM BREAST GROUP, 2006, GERM BREAST GROUP AN; Geyer CE, 2007, NEW ENGL J MED, V356, P1487; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Heinemann Volker, 2002, Clin Breast Cancer, V3 Suppl 1, P24; Jacobs TW, 1999, J CLIN ONCOL, V17, P1974, DOI 10.1200/JCO.1999.17.7.1974; Jacobs TW, 1999, J CLIN ONCOL, V17, P1983, DOI 10.1200/JCO.1999.17.7.1983; Jahanzeb M, 2002, ONCOLOGIST, V7, P410, DOI 10.1634/theoncologist.7-5-410; Joensuu H, 2006, NEW ENGL J MED, V354, P809, DOI 10.1056/NEJMoa053028; Kaufman B, 2006, ANN ONCOL, V17; Keefe DL, 2003, CANCER, V97, P1136, DOI 10.1002/cncr.11256; Klein PM, 2003, SEMIN ONCOL, V30, P49, DOI 10.1053/j.seminoncol.2003.08.007; Kumar R, 2001, SEMIN ONCOL, V28, P27, DOI 10.1016/S0093-7754(01)90279-9; Latif Z, 2004, EUR J CANCER, V40, P56, DOI 10.1016/j.ejca.2003.08.027; Latif Z, 2002, BJU INT, V89, P5, DOI 10.1046/j.1464-6.2001.01372.x; Lebeau A, 2001, J CLIN ONCOL, V19, P354, DOI 10.1200/JCO.2001.19.2.354; Leyland-Jones B, 2003, J CLIN ONCOL, V21, P3965, DOI 10.1200/JCO.2003.12.109; Livingston RB, 2001, ONCOLOGIST, V6, P315, DOI 10.1634/theoncologist.6-4-315; Marty M, 2005, J CLIN ONCOL, V23, P4265, DOI 10.1200/JCO.2005.04.173; Mass R, 2000, P AN M AM SOC CLIN, V19, p75a; MASS RD, 2001, P AN M AM SOC CLIN, V20, pA22; Menard S, 2001, J CLIN ONCOL, V19, P329, DOI 10.1200/JCO.2001.19.2.329; Milenic DE, 2004, CANCER BIOL THER, V3, P361, DOI 10.4161/cbt.3.4.790; Modi S, 2005, BREAST CANCER RES TR, V94, pS72; Molina MA, 2001, CANCER RES, V61, P4744; Morris MJ, 2002, CANCER-AM CANCER SOC, V94, P980, DOI 10.1002/cncr.10339; Negro A, 2004, RECENT PROG HORM RES, V59, P1, DOI 10.1210/rp.59.1.1; O'Shaughnessy Joyce, 2002, Clin Breast Cancer, V3 Suppl 1, P17; Onda M, 1996, CANCER-AM CANCER SOC, V77, P71, DOI 10.1002/(SICI)1097-0142(19960101)77:1<71::AID-CNCR13>3.3.CO;2-L; Ozcelik C, 2002, P NATL ACAD SCI USA, V99, P8880, DOI 10.1073/pnas.122249299; Park DI, 2006, DIGEST DIS SCI, V51, P1371, DOI 10.1007/s10620-005-9057-1; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; PEGRAM M, 2006, P 29 ANN SAN ANT BRE; Pegram MD, 1999, SEMIN ONCOL, V26, P89; Pegram MD, 2004, JNCI-J NATL CANCER I, V96, P759, DOI 10.1093/jnci/djh133; Pegram MD, 2002, SEMIN ONCOL, V29, P29, DOI 10.1053/sonc.2002.34053; Perez EA, 2004, J CLIN ONCOL, V22, P322, DOI 10.1200/JCO.2004.01.120; PEREZ EA, 2005, 45 ANN M AM SOC CLIN; Perez EA, 2006, J CLIN ONCOL, V24, P3032, DOI 10.1200/JCO.2005.03.4744; Petit AMV, 1997, AM J PATHOL, V151, P1523; Piccart MJ, 2001, ANN ONCOL, V12, P89, DOI 10.1023/A:1011133908093; Redana S, 2007, ANN ONCOL, V18, P43; Robert N, 2006, J CLIN ONCOL, V24, P2786, DOI 10.1200/JCO.2005.04.1764; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Safran H, 2001, AM J CLIN ONCOL-CANC, V24, P496, DOI 10.1097/00000421-200110000-00016; Safran H, 2002, AM J CLIN ONCOL-CANC, V25, P181; Santinelli A, 2002, ANAL QUANT CYTOL, V24, P54; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; Schneider JW, 2001, SEMIN ONCOL, V28, P18, DOI 10.1053/sonc.2001.28546; Seidman A, 2002, J CLIN ONCOL, V20, P1215, DOI 10.1200/JCO.20.5.1215; Seidman AD, 2001, J CLIN ONCOL, V19, P2587, DOI 10.1200/JCO.2001.19.10.2587; SEIDMAN AD, 2004, P AM SOC CLIN ONCO S, V23, pS512; SHEPARD HM, 1991, J CLIN IMMUNOL, V11, P117, DOI 10.1007/BF00918679; SLAMON D, 2006, P 29 ANN SAN ANT BRE; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sledge George W Jr, 2003, Oncology (Williston Park), V17, P33; Smith I, 2007, LANCET, V369, P29, DOI 10.1016/S0140-6736(07)60028-2; THEODOULOU M, 2002, P AN M AM SOC CLIN, V21, pA55; Viloria-Petit A, 2001, CANCER RES, V61, P5090; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Weiner LM, 2000, ONCOGENE, V19, P6144, DOI 10.1038/sj.onc.1204000; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; YARDLEY D, 2002, 38 ANN M AM SOC CLIN	95	1697	1787	8	284	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 5	2007	357	1					39	51		10.1056/NEJMra043186	http://dx.doi.org/10.1056/NEJMra043186			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185OR	17611206				2022-12-28	WOS:000247720800007
J	Kareiva, P; Watts, S; McDonald, R; Boucher, T				Kareiva, Peter; Watts, Sean; McDonald, Robert; Boucher, Tim			Domesticated nature: Shaping landscapes and ecosystems for human welfare	SCIENCE			English	Review							SPECIES-DIVERSITY; ECOLOGICAL FOOTPRINT; LAND-USE; URBAN; URBANIZATION; BIODIVERSITY; IMPACTS; FISH	Like all species, humans have exercised their impulse to perpetuate and propagate themselves. In doing so, we have domesticated landscapes and ecosystems in ways that enhance our food supplies, reduce exposure to predators and natural dangers, and promote commerce. On average, the net benefits to humankind of domesticated nature have been positive. We have, of course, made mistakes, causing unforeseen changes in ecosystem attributes, while leaving few, if any, truly wild places on Earth. Going into the future, scientists can help humanity to domesticate nature more wisely by quantifying the tradeoffs among ecosystem services, such as how increasing the provision of one service may decrease ecosystem resilience and the provision of other services.	Nature Conservancy, Arlington, VA 22203 USA; Santa Clara Univ, Inst Environm Studies, Santa Clara, CA 95053 USA; Harvard Univ, Grad Sch Design, Cambridge, MA 02138 USA	Nature Conservancy; Santa Clara University; Harvard University	Kareiva, P (corresponding author), Nature Conservancy, 4245 N Fairfax Dr,Suite 100, Arlington, VA 22203 USA.	pkareiva@tnc.org		McDonald, Robert/0000-0002-7273-6549				Airoldi L, 2007, OCEANOGR MAR BIOL, V45, P345; Angel S., 2005, DYNAMICS GLOBAL URBA; Blair RB, 1996, ECOL APPL, V6, P506, DOI 10.2307/2269387; Carpenter S, 2001, ECOSYSTEMS, V4, P765, DOI 10.1007/s10021-001-0045-9; CARTER D, 1996, INT J WILDERNESS, V3, P17; Chocholouskova Z, 2003, FLORA, V198, P366, DOI 10.1078/0367-2530-00109; DAY J, 2004, SCIENCE, V315, P1679; Donovan GH, 2007, FRONT ECOL ENVIRON, V5, P73, DOI 10.1890/1540-9295(2007)5[73:BCWYWF]2.0.CO;2; Galloway JN, 2003, BIOSCIENCE, V53, P341, DOI 10.1641/0006-3568(2003)053[0341:TNC]2.0.CO;2; Hare B, 2002, SCIENCE, V298, P1634, DOI 10.1126/science.1072702; IUCN, 2007, WORLD DAT PROT AR; Kenworthy JR, 1999, TRANSPORT RES A-POL, V33, P691, DOI 10.1016/S0965-8564(99)00006-3; Kuhn I, 2006, BIOL CONSERV, V127, P292, DOI 10.1016/j.biocon.2005.06.033; Lambin EF, 2003, ANNU REV ENV RESOUR, V28, P205, DOI 10.1146/annurev.energy.28.050302.105459; Levine JM, 2003, CONSERV BIOL, V17, P322, DOI 10.1046/j.1523-1739.2003.02038.x; Lynam CP, 2006, CURR BIOL, V16, pR492, DOI 10.1016/j.cub.2006.06.018; Lyons SK, 2004, EVOL ECOL RES, V6, P339; MA, 2005, ECOSYSTEMS HUMAN WEL; Marchetti MP, 2003, ENVIRON BIOL FISH, V66, P9, DOI 10.1023/A:1023269221678; McKinney ML, 2002, BIOSCIENCE, V52, P883, DOI 10.1641/0006-3568(2002)052[0883:UBAC]2.0.CO;2; Mennechez G, 2006, ACTA OECOL, V30, P182, DOI 10.1016/j.actao.2006.03.002; Naylor RL, 2000, NATURE, V405, P1017, DOI 10.1038/35016500; OESTERHELD M, 1992, NATURE, V356, P234, DOI 10.1038/356234a0; Oki T, 2006, SCIENCE, V313, P1068, DOI 10.1126/science.1128845; Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498; PIMENTEL D, 1976, Bulletin of the Entomological Society of America, V22, P20; Pysek P, 2004, J VEG SCI, V15, P781, DOI 10.1111/j.1654-1103.2004.tb02321.x; Ripple WJ, 2006, BIOL CONSERV, V133, P397, DOI 10.1016/j.biocon.2006.07.002; Sanderson EW, 2002, BIOSCIENCE, V52, P891, DOI 10.1641/0006-3568(2002)052[0891:THFATL]2.0.CO;2; Tilman D, 1999, P NATL ACAD SCI USA, V96, P5995, DOI 10.1073/pnas.96.11.5995; TOOPS C, 2007, NATL PARKS       WIN, P28; UNESCO, 2003, WAT PEOPL WAT LIF UN; UNPP, 2005, WORLD URB PROSP 2005; van Vuuren DP, 2005, ECOL ECON, V52, P43, DOI 10.1016/j.ecolecon.2004.06.009; Wackernagel M, 1999, ECOL ECON, V29, P375, DOI 10.1016/S0921-8009(98)90063-5; WHEELER E, P 2006 U COUNC WAT R; Willis KJ, 2004, SCIENCE, V304, P402, DOI 10.1126/science.1093991; Woodroffe R, 2000, ANIM CONSERV, V3, P165, DOI 10.1111/j.1469-1795.2000.tb00241.x; Woods AJ, 2003, FOREST CHRON, V79, P892, DOI 10.5558/tfc79892-5; Worm B, 2006, SCIENCE, V314, P787, DOI 10.1126/science.1132294; [No title captured]	41	560	610	18	502	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 29	2007	316	5833					1866	1869		10.1126/science.1140170	http://dx.doi.org/10.1126/science.1140170			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183WI	17600209				2022-12-28	WOS:000247602700029
J	Tauber, E; Zordan, M; Sandrelli, F; Pegoraro, M; Osterwalder, N; Breda, C; Daga, A; Selmin, A; Monger, K; Benna, C; Rosato, E; Kyriacou, CP; Costa, R				Tauber, Eran; Zordan, Mauro; Sandrelli, Federica; Pegoraro, Mirko; Osterwalder, Nicolo; Breda, Carlo; Daga, Andrea; Selmin, Alessandro; Monger, Karen; Benna, Clara; Rosato, Ezio; Kyriacou, Charalambos P.; Costa, Rodolfo			Natural selection favors a newly derived timeless allele in Drosophila melanogaster	SCIENCE			English	Article							CLOCK GENE; DIAPAUSE; MUTATIONS; REGION	Circadian and other natural clock-like endogenous rhythms may have evolved to anticipate regular temporal changes in the environment. We report that a mutation in the circadian clock gene timeless in Drosophila melanogaster has arisen and spread by natural selection relatively recently in Europe. We found that, when introduced into different genetic backgrounds, natural and artificial alleles of the timeless gene affect the incidence of diapause in response to changes in light and temperature. The natural mutant allele alters an important life history trait that may enhance the fly's adaptation to seasonal conditions.	Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England; Univ Padua, Dept Biol, I-35131 Padua, Italy	University of Leicester; University of Padua	Kyriacou, CP (corresponding author), Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England.	cpk@leicester.ac.uk	Tauber, Eran/F-9826-2011; Tauber, Eran/AAA-1562-2022; benna, clara/K-1083-2018; daga, andrea/J-1865-2018	Tauber, Eran/0000-0003-4018-6535; Tauber, Eran/0000-0003-4018-6535; daga, andrea/0000-0001-8935-5489; BENNA, CLARA/0000-0002-9077-2471; Pegoraro, Mirko/0000-0001-9381-5249; Breda, Carlo/0000-0002-6365-9828; SANDRELLI, FEDERICA/0000-0002-5631-7467; Rosato, Ezio/0000-0001-7297-4697	Natural Environment Research Council [NE/D012058/1] Funding Source: researchfish; NERC [NE/D012058/1] Funding Source: UKRI	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Bradshaw WE, 2003, AM NAT, V161, P735, DOI 10.1086/374344; COSTA R, 1992, P ROY SOC B-BIOL SCI, V250, P43, DOI 10.1098/rspb.1992.0128; Fitzpatrick MJ, 2005, TRENDS ECOL EVOL, V20, P96, DOI 10.1016/j.tree.2004.11.017; FU YX, 1993, GENETICS, V133, P693; Hall JC, 2003, ADV GENET, V48, P1, DOI 10.1016/S0065-2660(03)48000-0; Hoekstra HE, 2006, SCIENCE, V313, P101, DOI 10.1126/science.1126121; HUDSON RR, 1994, GENETICS, V136, P1329; HUDSON RR, 1987, GENETICS, V116, P153; LACHAISE D, 1988, EVOL BIOL, V22, P159; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; Ousley A, 1998, GENETICS, V148, P815; Rosato E, 1997, GENET RES, V69, P89, DOI 10.1017/S001667239700267X; Rosato E, 1997, NUCLEIC ACIDS RES, V25, P455, DOI 10.1093/nar/25.3.455; RUSSO CAM, 1995, MOL BIOL EVOL, V12, P391; Sandrelli F, 2007, SCIENCE, V316, P1898, DOI 10.1126/science.1138426; SAUNDERS DS, 1989, P NATL ACAD SCI USA, V86, P3748, DOI 10.1073/pnas.86.10.3748; Sawyer LA, 1997, SCIENCE, V278, P2117, DOI 10.1126/science.278.5346.2117; Schmidt PS, 2006, EVOLUTION, V60, P1602, DOI 10.1111/j.0014-3820.2006.tb00505.x; Schmidt PS, 2005, EVOLUTION, V59, P2616, DOI 10.1111/j.0014-3820.2005.tb00974.x; Schmidt PS, 2005, EVOLUTION, V59, P1721, DOI 10.1111/j.0014-3820.2005.tb01821.x; TAJIMA F, 1989, GENETICS, V123, P585; Williams KD, 2006, P NATL ACAD SCI USA, V103, P15911, DOI 10.1073/pnas.0604592103; WILLIAMS KD, 1993, HEREDITY, V71, P312, DOI 10.1038/hdy.1993.141	23	210	213	1	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 29	2007	316	5833					1895	1898		10.1126/science.1138412	http://dx.doi.org/10.1126/science.1138412			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183WI	17600215				2022-12-28	WOS:000247602700039
J	Kaplitt, MG; Feigin, A; Tang, C; Fitzsimons, HL; Mattis, P; Lawlor, PA; Bland, RJ; Young, D; Strybing, K; Eidelberg, D; During, MJ				Kaplitt, Michael G.; Feigin, Andrew; Tang, Chengke; Fitzsimons, Helen L.; Mattis, Paul; Lawlor, Patricia A.; Bland, Ross J.; Young, Deborah; Strybing, Kristin; Eidelberg, David; During, Matthew J.			Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial	LANCET			English	Article							DEEP-BRAIN-STIMULATION; SUBTHALAMIC NUCLEUS; MOVEMENT-DISORDERS; IMMUNE-RESPONSES; EXPRESSION; MODEL; MPTP	Background Dopaminergic neuronal loss in Parkinson's disease leads to changes in the circuitry of the basal ganglia, such as decreased inhibitory GABAergic input to the subthalamic nucleus. We aimed to measure the safety; tolerability, and potential efficacy of transfer of glutamic acid decarboxylase (GAD) gene with adeno-associated virus (AAV) into the subthalamic nucleus of patients with Parkinson's disease. Methods We did an open label, safety and tolerability trial of unilateral subthalamic viral vector (AAV-GAD) injection in 11 men and 1 woman with Parkinson's disease (mean age 58.2, SD=5.7 years). Four patients received low-dose, four medium-dose, and four high-dose AAV-GAD at New York Presbyterian Hospital. Inclusion criteria consisted of Hoehn and Yahr stage 3 or greater, motor fluctuations with substantial off time, and age 70 years or less. Patients were assessed clinically both off and on medication at baseline and after 1, 3, 6, and 12 months at North Shore Hospital. Efficacy measures included the Unified Parkinson!s Disease Rating Scale (UPDRS), scales of activities of daily living (ADL), neuropsychological testing, and PET imaging with F-18-fluorodeoxyglucose. The trial is registered with the ClinicalTrials.gov registry, number NCT00195143. Findings All patients who enrolled had surgery, and there were no dropouts or patients lost to follow-up. There were no adverse events related to gene therapy. Significant improvements in motor UPDRS scores (p=0.0015), predominantly on the side of the body that was contralateral to surgery, were seen 3 months after gene therapy and persisted up to 12 months. PET scans revealed a substantial reduction in thalamic metabolism that was restricted to the treated hemisphere, and a correlation between clinical motor scores and brain metabolism in the supplementary motor area. Interpretation AAV-GAD gene therapy of the subthalamic nucleus is safe and well tolerated by patients with advanced Parkinson's disease, suggesting that in-vivo gene therapy in the adult brain might be safe for various neurodegenerative diseases.	Cornell Univ, Weill Med Coll, Dept Neurol Surg, New York, NY USA; N Shore Long Isl Jewish Hlth Syst, Feinstein Inst Med Res, Ctr Neurosci, Manhasset, NY USA; NYU, Sch Med, Dept Neurol, New York, NY USA; NYU, Sch Med, Dept Med, New York, NY USA; Neurologix, Ft Lee, NJ USA; Univ Auckland, Dept Mol Med, Auckland 1, New Zealand	Cornell University; Northwell Health; New York University; New York University; University of Auckland	During, MJ (corresponding author), Ohio State Univ, Sch Med, 912 BRT,460 W 12th Ave, Columbus, OH 43210 USA.	During.l@osu.edu	During, Matthew/AAC-1388-2020; Eidelberg, David/F-5214-2011	Eidelberg, David/0000-0002-0854-864X; Young, Deborah/0000-0003-1085-2824; Fitzsimons, Helen/0000-0001-7825-3911				Asanuma K, 2006, BRAIN, V129, P2667, DOI 10.1093/brain/awl162; Chirmule N, 1999, GENE THER, V6, P1574, DOI 10.1038/sj.gt.3300994; Deuschl G, 2006, NEW ENGL J MED, V355, P896, DOI 10.1056/NEJMoa060281; Eidelberg D, 1997, BRAIN, V120, P1315, DOI 10.1093/brain/120.8.1315; Eidelberg D, 1996, ANN NEUROL, V39, P450, DOI 10.1002/ana.410390407; Emborg ME, 2007, J CEREBR BLOOD F MET, V27, P501, DOI 10.1038/sj.jcbfm.9600364; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; Fukuda M, 2001, BRAIN, V124, P1601, DOI 10.1093/brain/124.8.1601; Hamani C, 2004, BRAIN, V127, P4, DOI 10.1093/brain/awh029; Herzog RW, 1997, P NATL ACAD SCI USA, V94, P5804, DOI 10.1073/pnas.94.11.5804; Hobson DE, 2002, JAMA-J AM MED ASSOC, V287, P455, DOI 10.1001/jama.287.4.455; HOEHN MMM, 1992, NEUROL CLIN, V10, P331; KAPLITT MG, 1994, NAT GENET, V8, P148, DOI 10.1038/ng1094-148; Kleiner-Fisman G, 2006, MOVEMENT DISORD, V21, pS290, DOI 10.1002/mds.20962; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Lee B, 2005, GENE THER, V12, P1215, DOI 10.1038/sj.gt.3302520; Luo J, 2002, SCIENCE, V298, P425, DOI 10.1126/science.1074549; Manno CS, 2006, NAT MED, V12, P342, DOI 10.1038/nm1358; McPhee SWJ, 2006, J GENE MED, V8, P577, DOI 10.1002/jgm.885; Metman LV, 2004, MOVEMENT DISORD, V19, P1079, DOI 10.1002/mds.20101; Nutt JG, 2005, NEW ENGL J MED, V353, P1021, DOI 10.1056/NEJMcp043908; OBESO JA, 2000, NEUROLOGY S6, V55, P57; Oh MY, 2002, NEUROSURGERY, V50, P1268; PALOMBO E, 1990, J NEUROSCI, V10, P860; Pulkkanen KJ, 2005, MOL THER, V12, P585, DOI 10.1016/j.ymthe.2005.07.357; Schwab J., 1968, 3 S PARK DIS, P152; Simuni T, 2002, J NEUROSURG, V96, P666, DOI 10.3171/jns.2002.96.4.0666; Somia N, 2000, NAT REV GENET, V1, P91, DOI 10.1038/35038533; Su PC, 2001, ANN NEUROL, V50, P514, DOI 10.1002/ana.1232; Tuszynski MH, 2005, NAT MED, V11, P551, DOI 10.1038/nm1239; Wichmann T, 2003, ANN NY ACAD SCI, V991, P199, DOI 10.1111/j.1749-6632.2003.tb07477.x	31	733	816	0	128	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 23	2007	369	9579					2097	2105		10.1016/S0140-6736(07)60982-9	http://dx.doi.org/10.1016/S0140-6736(07)60982-9			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	182GM	17586305				2022-12-28	WOS:000247493100030
J	Hippisley-Cox, J; Coupland, C; Vinogradova, Y; Robson, J; May, M; Brindle, P				Hippisley-Cox, Julia; Coupland, Carol; Vinogradova, Yana; Robson, John; May, Margaret; Brindle, Peter			Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; MYOCARDIAL-INFARCTION; MORTALITY; ACCURACY; DRUGS	Objective To derive a new cardiovascular disease risk score (QRISK) for the United Kingdom and to validate its performance against the established Framingham cardiovascular disease algorithm and a newly developed Scottish score (ASSIGN). Design Prospective open cohort study using routinely collected data from general practice. Setting UK practices contributing to the QRESEARCH database. Participants The derivation cohort consisted of 1.28 million patients, aged 35-74 years, registered at 318 practices between 1 January 1995 and 1 April 2007 and who were free of diabetes and existing cardiovascular disease. The validation cohort consisted of 0.61 million patients from 160 practices. Main outcome measures First recorded diagnosis of cardiovascular disease (incident diagnosis between 1 January 1995 and 1 April 2007): myocardial infarction, coronary heart disease, stroke, and transient ischaemic attacks. Risk factors were age, sex, smoking status, systolic blood pressure, ratio of total serum cholesterol to high density lipoprotein, body mass index, family history of coronary heart disease in first degree relative aged less than 60, area measure of deprivation, and existing treatment with antihypertensive agent. Results A cardiovascular disease risk algorithm (QRISK) was developed in the derivation cohort. In the validation cohort the observed 10 year risk of a cardiovascular event was 6.60% (95% confidence interval 6.48% to 6.72%) in women and 9.28% (9.14% to 9.43%) in men. Overall the Framingham algorithm over-predicted cardiovascular disease risk at 10 years by 35%, ASSIGN by 36%, and QRISK by 0.4%. Measures of discrimination tended to be higher for QRISK than for the Framingham algorithm and it was better calibrated to the UK population than either the Framingham or ASSIGN models. With QRISK 8.5% of patients aged 35-74 are at high risk (>= 20% risk over 10 years) compared with 13% when using the Framingham algorithm and 14% when using ASSIGN. With QRISK 34% of women and 73% of men aged 64-75 would be at high risk compared with 24% and 86% according to the Framingham algorithm. UK estimates for 2005 based on QRISK give 3.2 million patients aged 35-74 at high risk, with the Framingham algorithm predicting 4.7 million and ASSIGN 5.1 million. Overall, 53 668 patients in the validation dataset (9% of the total) would be reclassified from high to low risk or vice versa using QRISK compared with the Framingham algorithm. Conclusion QRISK performed at least as well as the Framingham model for discrimination and was better calibrated to the UK population than either the Framingham model or ASSIGN. QRISK is likely to provide more appropriate risk estimates to help identify high risk patients on the basis of age, sex, and social deprivation. It is therefore likely to be a more equitable too[ to inform management decisions and help ensure treatments are directed towards those most likely to benefit. It includes additional variables which improve risk estimates for patients with a positive family history or those on antihypertensive treatment. However, since the validation was performed in a similar population to the population from which the algorithm was derived, it potentially has a "home advantage." Further validation in other populations is therefore required.	Barts & London Queen Marys Sch Med & Dent, Ctr Hlth Sci, London, England; Univ Bristol, Dept Social Med, Bristol BS8 1TH, Avon, England; Bristol Primary Care Trust, Avon Primary Care Res Collaborat, Bristol, Avon, England	University of London; Queen Mary University London; University of Bristol	Hippisley-Cox, J (corresponding author), Tower Bldg,Univ Pk, Nottingham NG2 2RD, England.	julia.hippisley-cox@nottingham.ac.uk	Robson, John/H-3904-2014; Hippisley-Cox, Julia/AAY-2788-2020; May, Margaret T/E-8099-2013	Robson, John/0000-0001-6889-0415; Hippisley-Cox, Julia/0000-0002-2479-7283; May, Margaret T/0000-0002-9733-1003; Coupland, Carol/0000-0002-2327-3306				ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; Barzi F, 2007, J EPIDEMIOL COMMUN H, V61, P115, DOI 10.1136/jech.2005.044842; Brindle P, 2006, HEART, V92, P1752, DOI 10.1136/hrt.2006.087932; Brindle P, 2003, BMJ-BRIT MED J, V327, P1267, DOI 10.1136/bmj.327.7426.1267; BRINDLE P, 2003, BRIT MED J, V327, P1; Brindle PM, 2005, BRIT J GEN PRACT, V55, P838; *BRIT HEART FDN, 2007, COR HEART DIS STAT; Clark TG, 2003, J CLIN EPIDEMIOL, V56, P28, DOI 10.1016/S0895-4356(02)00539-5; DAGOSTINO RB, 1994, STROKE, V25, P40, DOI 10.1161/01.STR.25.1.40; De Backer G, 2003, EUR HEART J, V24, P1601, DOI 10.1016/S0195-668X(03)00347-6; *DEP HLTH, 2003, TACKL HLTH IN PROGR, P83; *DEP HLTH, 2000, NAT SERV FRAM COR HE; Hippisley-Cox J, 2006, HEART, V92, P752, DOI 10.1136/hrt.2005.061523; Hippisley-Cox J, 2005, BMJ-BRIT MED J, V330, P1366, DOI 10.1136/bmj.330.7504.1366; Hippisley-Cox J, 2005, BMJ-BRIT MED J, V330, P1059, DOI 10.1136/bmj.330.7499.1059; HIPPISLEYCOX J, 2005, TRENDS VARIATIONS GM; HIPPISLEYCOX J, 2007, IN PRESS HEART; HIPPISLEYCOX J, 2005, COMPARISON KEY PRACT; Jick H, 1996, PHARMACOTHERAPY, V16, P321; Lloyd-Jones DM, 2004, JAMA-J AM MED ASSOC, V291, P2204, DOI 10.1001/jama.291.18.2204; MANN JI, 1993, NEW ZEAL MED J, V106, P133; *N ENGL HYP GUID D, 2004, ESS HP MAN AD PAT PR; National Institute for Health and Clinical Excellence, 2006, STAT PREV CARD EV PA; *NCEP EXP PAN, 2001, DET EV TREATM HIGH B, V3, P1; Nilsson PM, 2004, J INTERN MED, V255, P229, DOI 10.1046/j.1365-2796.2003.01287.x; Royston P, 2005, STATA J, V5, P279, DOI 10.1177/1536867X0500500212; Royston P, 2004, STAT MED, V23, P723, DOI 10.1002/sim.1621; Royston P, 1999, INT J EPIDEMIOL, V28, P964, DOI 10.1093/ije/28.5.964; Royston P, 2006, STATA J, V6, P83, DOI 10.1177/1536867X0600600105; Royston P, 2004, STATA J, V4, P227, DOI 10.1177/1536867X0400400301; Scottish Intercollegiate Guidelines Network, 2007, RISK EST PREV CARD D; Townsend P, 1982, THE BLACK REPORT; Tunstall-Pedoe H, 2006, HEART, V92, P307, DOI 10.1136/hrt.2005.077289; Victora CG, 2000, LANCET, V356, P1093, DOI 10.1016/S0140-6736(00)02741-0; Ward S, 2007, HEALTH TECHNOL ASSES, V11, P1, DOI 10.3310/hta11140; WHITE C, 2003, HLTH STAT Q, V20, P25; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; Wood D, 2005, HEART, V91, P1, DOI 10.1136/hrt.2005.079988; Woodward M, 2007, HEART, V93, P172, DOI 10.1136/hrt.2006.108167	39	593	614	2	53	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 21	2007	335	7611					136	141		10.1136/bmj.39261.471806.55	http://dx.doi.org/10.1136/bmj.39261.471806.55			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195RA	17615182	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000248428100034
J	Bartrip, P				Bartrip, Peter			A long way from Worcester	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Northampton, Northampton, England	University of Northampton	Bartrip, P (corresponding author), Univ Northampton, Northampton, England.	peter.bartrip@socio-legal-studies.oxford.ac							0	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 14	2007	335	7610					72	73		10.1136/bmj.39269.717454.59	http://dx.doi.org/10.1136/bmj.39269.717454.59			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192JM	17626958	Green Published			2022-12-28	WOS:000248197500028
J	Kim, JY; Lee, K; Coates, NE; Moses, D; Nguyen, TQ; Dante, M; Heeger, AJ				Kim, Jin Young; Lee, Kwanghee; Coates, Nelson E.; Moses, Daniel; Nguyen, Thuc-Quyen; Dante, Mark; Heeger, Alan J.			Efficient tandem polymer solar cells fabricated by all-solution processing	SCIENCE			English	Article							PHOTOVOLTAIC CELLS; HETEROJUNCTIONS; PERFORMANCE; NETWORK; BLENDS	Tandem solar cells, in which two solar cells with different absorption characteristics are linked to use a wider range of the solar spectrum, were fabricated with each layer processed from solution with the use of bulk heterojunction materials comprising semiconducting polymers and fullerene derivatives. A transparent titanium oxide ( TiOx) layer separates and connects the front cell and the back cell. The TiOx layer serves as an electron transport and collecting layer for the first cell and as a stable foundation that enables the fabrication of the second cell to complete the tandem cell architecture. We use an inverted structure with the low band-gap polymer-fullerene composite as the charge-separating layer in the front cell and the high band-gap polymer composite as that in the back cell. Power-conversion efficiencies of more than 6% were achieved at illuminations of 200 milliwatts per square centimeter.	Univ Calif Santa Barbara, Ctr Polymers & Organ Solids, Santa Barbara, CA 93106 USA; Gwangju Inst Sci & Technol, Dept Mat Sci & Engn, Kwangju 500712, South Korea	University of California System; University of California Santa Barbara; Gwangju Institute of Science & Technology (GIST)	Lee, K (corresponding author), Univ Calif Santa Barbara, Ctr Polymers & Organ Solids, Santa Barbara, CA 93106 USA.	klee@gist.ac.kr	Coates, Nelson E/F-8920-2011; Kim, Jin Young/E-6152-2010; chen, jia/F-8731-2011	Kim, Jin Young/0000-0002-6595-4468; 				Brabec CJ, 2004, SOL ENERG MAT SOL C, V83, P273, DOI 10.1016/j.solmat.2004.02.030; BURDICK J, 1986, SOL CELLS, V18, P301, DOI 10.1016/0379-6787(86)90129-8; Coakley KM, 2004, CHEM MATER, V16, P4533, DOI 10.1021/cm049654n; Dennler G, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2336593; Drechsel J, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1935771; Gilot J, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2719668; Hadipour A, 2006, ADV FUNCT MATER, V16, P1897, DOI 10.1002/adfm.200600138; HIRAMOTO M, 1990, CHEM LETT, P327, DOI 10.1246/cl.1990.327; Kawano K, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2177633; Kim JY, 2006, ADV MATER, V18, P572, DOI 10.1002/adma.200501825; Kim Y, 2006, NAT MATER, V5, P197, DOI 10.1038/nmat1574; Li G, 2005, NAT MATER, V4, P864, DOI 10.1038/nmat1500; Ma WL, 2005, ADV FUNCT MATER, V15, P1617, DOI 10.1002/adfm.200500211; Muhlbacher D, 2006, ADV MATER, V18, P2884, DOI 10.1002/adma.200600160; Reyes-Reyes M, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2006986; Riedel I, 2004, PHYS STATUS SOLIDI A, V201, P1332, DOI 10.1002/pssa.200404333; SARICIFTCI NS, 1992, SCIENCE, V258, P1474, DOI 10.1126/science.258.5087.1474; Shrotriya V, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2172741; WANLASS MW, 1989, SOL CELLS, V27, P191, DOI 10.1016/0379-6787(89)90028-8; Xue JG, 2004, APPL PHYS LETT, V85, P5757, DOI 10.1063/1.1829776; Yakimov A, 2002, APPL PHYS LETT, V80, P1667, DOI 10.1063/1.1457531; YU G, 1995, SCIENCE, V270, P1789, DOI 10.1126/science.270.5243.1789	22	3023	3121	11	1166	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 13	2007	317	5835					222	225		10.1126/science.1141711	http://dx.doi.org/10.1126/science.1141711			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189DC	17626879				2022-12-28	WOS:000247968600035
J	Lorincz, MC; Schubeler, D				Lorincz, Matthew C.; Schuebeler, Dirk			RNA polymerase II: Just stopping by	CELL			English	Editorial Material							METHYLATION; GENES		Univ British Columbia, Dept Med Genet, Vancouver, BC V6T 1Z3, Canada; Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland	University of British Columbia; Friedrich Miescher Institute for Biomedical Research	Lorincz, MC (corresponding author), Univ British Columbia, Dept Med Genet, 2222 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	mlorincz@interchange.ubc.ca; dirk@fmi.ch		Lorincz, Matthew/0000-0003-0885-0467				Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; Brandenberger Ralph, 2004, BMC Developmental Biology, V4, P1; Dellino GI, 2004, MOL CELL, V13, P887, DOI 10.1016/S1097-2765(04)00128-5; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; Sato N, 2003, DEV BIOL, V260, P404, DOI 10.1016/S0012-1606(03)00256-2; Saunders A, 2006, NAT REV MOL CELL BIO, V7, P557, DOI 10.1038/nrm1981; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990	10	10	10	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 13	2007	130	1					16	18		10.1016/j.cell.2007.06.040	http://dx.doi.org/10.1016/j.cell.2007.06.040			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	197WK	17632051	Bronze			2022-12-28	WOS:000248587000005
J	Sardar, Z				Sardar, Ziauddin			Beyond the troubled relationship	NATURE			English	Editorial Material																			0	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 12	2007	448	7150					131	133		10.1038/448131a	http://dx.doi.org/10.1038/448131a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	188QN	17625546				2022-12-28	WOS:000247934500021
J	Amori, RE; Lau, J; Pittas, AG				Amori, Renee E.; Lau, Joseph; Pittas, Anastassios G.			Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							DIPEPTIDYL PEPTIDASE-4 INHIBITOR; GLUCAGON-LIKE PEPTIDE-1; IMPROVES GLYCEMIC CONTROL; METFORMIN-TREATED PATIENTS; DRUG-NAIVE PATIENTS; DOUBLE-BLIND; EXENATIDE EXENDIN-4; GLUCOSE CONTROL; LIRAGLUTIDE NN2211; VILDAGLIPTIN	Context Pharmacotherapies that augment the incretin pathway have recently become available, but their role in the management of type 2 diabetes is not well defined. Objective To assess the efficacy and safety of incretin-based therapy in adults with type 2 diabetes based on randomized controlled trials published in peer-reviewed journals or as abstracts. Data Sources We searched MEDLINE ( 1966 - May 20, 2007) and the Cochrane Central Register of Controlled Trials ( second quarter, 2007) for English-language randomized controlled trials involving an incretin mimetic (glucagonlike peptide 1 [GLP-1] analogue) or enhancer ( dipeptidyl peptidase 4 [DPP4] inhibitor). We also searched prescribing information, relevant Web sites, reference lists and citation sections of recovered articles, and abstracts presented at recent conferences. Study Selection Randomized controlled trials were selected if they were at least 12 weeks in duration, compared incretin therapy with placebo or other diabetes medication, and reported hemoglobin A(1c) data in nonpregnant adults with type 2 diabetes. Data Extraction Two reviewers independently assessed trials for inclusion and extracted data. Differences were resolved by consensus. Meta-analyses were conducted for several efficacy and safety outcomes. Results Of 355 potentially relevant articles identified, 51 were retrieved for detailed evaluation and 29 met the inclusion criteria. Incretins lowered hemoglobin A1c compared with placebo ( weighted mean difference, - 0.97% [95% confidence interval {CI}, - 1.13% to - 0.81%] for GLP-1 analogues and - 0.74% [ 95% CI, - 0.85% to - 0.62%] for DPP4 inhibitors) and were noninferior to other hypoglycemic agents. Glucagon-like peptide 1 analogues resulted in weight loss (1.4 kg and 4.8 kg vs placebo and insulin, respectively) while DPP4 inhibitors were weight neutral. Glucagon-like peptide 1 analogues had more gastrointestinal side effects ( risk ratio, 2.9 [ 95% CI, 2.0-4.2] for nausea and 3.2 [ 95% CI, 2.5-4.4] for vomiting). Dipeptidyl peptidase 4 inhibitors had an increased risk of infection ( risk ratio, 1.2 [ 95% CI, 1.0-1.4] for nasopharyngitis and 1.5 [ 95% CI, 1.0-2.2] for urinary tract infection) and headache ( risk ratio, 1.4 [ 95% CI, 1.1-1.7]). All but 3 trials had a 30-week or shorter duration; thus, long-term efficacy and safety could not be evaluated. Conclusions Incretin therapy offers an alternative option to currently available hypoglycemic agents for nonpregnant adults with type 2 diabetes, with modest efficacy and a favorable weight-change profile. Careful postmarketing surveillance for adverse effects, especially among the DPP4 inhibitors, and continued evaluation in longer-term studies and in clinical practice are required to determine the role of this new class among current pharmacotherapies for type 2 diabetes.	Tufts Univ New England Med Ctr, Div Endocrinol Diabet & Metab, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA	Tufts Medical Center; Tufts Medical Center	Pittas, AG (corresponding author), Tufts Univ New England Med Ctr, Div Endocrinol Diabet & Metab, 750 Washington St,268, Boston, MA 02111 USA.	apittas@tufts-nemc.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K23DK061506] Funding Source: NIH RePORTER; NIDDK NIH HHS [K23 DK61506] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahren B, 2004, DIABETES CARE, V27, P2874, DOI 10.2337/diacare.27.12.2874; Aschner P, 2006, DIABETES CARE, V29, P2632, DOI 10.2337/dc06-0703; Bosi E, 2007, DIABETES CARE, V30, P890, DOI 10.2337/dc06-1732; Boyko EJ, 2002, DIABETES CARE, V25, P1778, DOI 10.2337/diacare.25.10.1778; Buse JB, 2004, DIABETES CARE, V27, P2628, DOI 10.2337/diacare.27.11.2628; Charbonnel B, 2006, DIABETES CARE, V29, P2638, DOI 10.2337/dc06-0706; DeFronzo RA, 2005, DIABETES CARE, V28, P1092, DOI 10.2337/diacare.28.5.1092; Dejager S, 2007, HORM METAB RES, V39, P218, DOI 10.1055/s-2007-970422; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Drucker DJ, 2006, LANCET, V368, P1696, DOI 10.1016/S0140-6736(06)69705-5; DRUCKER DJ, 1987, P NATL ACAD SCI USA, V84, P3434, DOI 10.1073/pnas.84.10.3434; ELRICK H, 1964, J CLIN ENDOCR METAB, V24, P1076, DOI 10.1210/jcem-24-10-1076; Feinglos MN, 2005, DIABETIC MED, V22, P1016, DOI 10.1111/j.1464-5491.2005.01567.x; Fineman MS, 2004, DIABETES-METAB RES, V20, P411, DOI 10.1002/dmrr.499; Fonseca V, 2007, DIABETOLOGIA, V50, P1148, DOI 10.1007/s00125-007-0633-0; Garber AJ, 2007, DIABETES OBES METAB, V9, P166, DOI 10.1111/j.1463-1326.2006.00684.x; Goldstein DE, 2004, DIABETES CARE, V27, P1761, DOI 10.2337/diacare.27.7.1761; Gutzwiller JP, 1999, AM J PHYSIOL-REG I, V276, pR1541, DOI 10.1152/ajpregu.1999.276.5.R1541; Habener J.F., 2000, DIABETES MELLITUS FU; Hanefeld M, 2005, DIABETOLOGIA, V48, pA287; Heine RJ, 2005, ANN INTERN MED, V143, P559, DOI 10.7326/0003-4819-143-8-200510180-00006; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Kendall DM, 2005, DIABETES CARE, V28, P1083, DOI 10.2337/diacare.28.5.1083; Kim D, 2007, DIABETES CARE, V30, P1487, DOI 10.2337/dc06-2375; Madsbad S, 2004, DIABETES CARE, V27, P1335, DOI 10.2337/diacare.27.6.1335; Mimori N, 2006, DIABETES, V55, pA125; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Naslund E, 1998, AM J CLIN NUTR, V68, P525; Nathan DM, 2007, NEW ENGL J MED, V356, P437, DOI 10.1056/NEJMp068294; Nauck MA, 2007, DIABETES OBES METAB, V9, P194, DOI 10.1111/j.1463-1326.2006.00704.x; Nauck MA, 2007, DIABETOLOGIA, V50, P259, DOI 10.1007/s00125-006-0510-2; NONAKA K, 2006, DIABETES S1, V55, pA129; Patterson JE, 1997, INFECT DIS CLIN N AM, V11, P735, DOI 10.1016/S0891-5520(05)70383-4; Pi-Sunyer FX, 2007, DIABETES RES CLIN PR, V76, P132, DOI 10.1016/j.diabres.2006.12.009; Pratley RE, 2006, HORM METAB RES, V38, P423, DOI 10.1055/s-2006-944546; Raz I, 2006, DIABETOLOGIA, V49, P2564, DOI 10.1007/s00125-006-0416-z; Resnick HE, 2006, DIABETES CARE, V29, P531, DOI 10.2337/diacare.29.03.06.dc05-1254; Ristic S, 2005, DIABETES OBES METAB, V7, P692, DOI 10.1111/j.1463-1326.2005.00539.x; Rosenstock J, 2007, DIABETES OBES METAB, V9, P175, DOI 10.1111/j.1463-1326.2006.00698.x; Rosenstock J, 2006, CLIN THER, V28, P1556, DOI 10.1016/j.clinthera.2006.10.007; Rosenstock J, 2007, DIABETES CARE, V30, P217, DOI 10.2337/dc06-1815; Schweizer A, 2007, DIABETIC MED, V24, P955, DOI 10.1111/j.1464-5491.2007.02191.x; Scott R, 2007, INT J CLIN PRACT, V61, P171, DOI 10.1111/j.1742-1241.2006.01246.x; Toft-Nielsen MB, 2001, J CLIN ENDOCR METAB, V86, P3717, DOI 10.1210/jc.86.8.3717; Turner RC, 1999, JAMA-J AM MED ASSOC, V281, P2005, DOI 10.1001/jama.281.21.2005; Zinman B, 2007, ANN INTERN MED, V146, P477, DOI 10.7326/0003-4819-146-7-200704030-00003	46	814	859	1	114	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2007	298	2					194	206		10.1001/jama.298.2.194	http://dx.doi.org/10.1001/jama.298.2.194			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188HI	17622601				2022-12-28	WOS:000247910600025
J	Patra, S; Kumar, A; Trivedi, SS; Puri, M; Sarin, SK				Patra, Sharda; Kumar, Ashish; Trivedi, Shubha Sagar; Puri, Manju; Sarin, Shiv Kumar			Maternal and fetal outcomes in pregnant women with acute hepatitis e virus infection	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE VIRAL-HEPATITIS; ACUTE LIVER-FAILURE; CLINICAL-COURSE; ETIOLOGY; TRANSMISSION; INDIA	Background: Hepatitis E virus (HEV) infection is known to cause severe liver disease in pregnant women. It is unclear whether obstetric and fetal outcomes are worse in pregnant women with HEV infection than in women with other forms of viral hepatitis. Objective: To compare maternal, obstetric, and fetal outcomes in pregnant women with acute viral hepatitis caused by HEV and other hepatitis viruses. Design: Observational cohort. Setting: Tertiary care hospital, New Delhi, India. Patients: 220 consecutive pregnant women presenting with jaundice caused by acute viral hepatitis. Measurements: Maternal mortality and medical complications, obstetric complications, deliveries, and fetal outcomes. Results: Infection with HEV caused acute viral hepatitis in 60% of included women. Fulminant hepatic failure was more common (relative risk, 2.7 [95% Cl, 1.7 to 4.2]; P = 0.001) and maternal mortality was greater (relative risk, 6.0 [Cl, 2.7 to 13.3]; P < 0.001) in HEV-infected women than in non-HEV-infected women. Women with HEV infection were more likely than those with other forms of viral hepatitis to have obstetric complications (relative risk, 4.1 [Cl, 1.7 to 10.2] for antepartum hemorrhage and 1.9 [Cl, 1.3 to 2.7] for intrauterine fetal death; P < 0.001 for both) and poor fetal outcomes (relative risk, 1.2 [Cl, 1.0 to 1.4] for preterm delivery [P = 0.0051 and 1.8 [Cl, 1.2 to 2.51 for stillbirth [P = 0.026]). Limitations: The findings may not apply to community settings, to women who are asymptomatic or have only minor symptoms, or in the setting of an HEV epidemic. Conclusions: Pregnant women with jaundice and acute viral hepatitis caused by HEV infection had a higher maternal mortality rate and worse obstetric and fetal outcomes than did pregnant women with jaundice and acute viral hepatitis caused by other types of viral hepatitis.	GB Pant Hosp, Dept Gastroenterol, New Delhi 110002, India; Lady Hardinge Med Coll & Hosp, New Delhi, India	Govind Ballabh Pant Institute of Postgraduate Medical Education & Research; Lady Hardinge Medical College & Hospital	Sarin, SK (corresponding author), GB Pant Hosp, Dept Gastroenterol, Room 201,Acad Block, New Delhi 110002, India.	sksarin@nda.vsnl.net.in	Kumar, Ashish/F-6737-2010; Kumar, Ashish/GRR-3470-2022	Kumar, Ashish/0000-0001-6680-7227; Kumar, Ashish/0000-0002-4476-3494				Acharya SK, 1996, HEPATOLOGY, V23, P1448, DOI 10.1053/jhep.1996.v23.pm0008675163; Arankalle V A, 2000, Indian J Gastroenterol, V19, P24; Aziz Aliya B., 1997, JPMA (Journal of the Pakistan Medical Association), V47, P198; Gelpi A P, 1978, Int J Gynaecol Obstet, V17, P73; Jaiswal SPB, 2001, INT J GYNECOL OBSTET, V72, P103, DOI 10.1016/S0020-7292(00)00264-2; KHUROO MS, 1981, AM J MED, V70, P252, DOI 10.1016/0002-9343(81)90758-0; Khuroo MS, 2003, J VIRAL HEPATITIS, V10, P224, DOI 10.1046/j.1365-2893.2003.00415.x; Khuroo MS, 2003, J VIRAL HEPATITIS, V10, P61, DOI 10.1046/j.1365-2893.2003.00398.x; KHUROO MS, 1980, AM J MED, V68, P818, DOI 10.1016/0002-9343(80)90200-4; Khuroo MS, 1997, HEPATOLOGY, V26, P244; KHUROO MS, 1995, LANCET, V345, P1025, DOI 10.1016/S0140-6736(95)90761-0; Krawczynski K, 2000, INFECT DIS CLIN N AM, V14, P669, DOI 10.1016/S0891-5520(05)70126-4; Kumar A, 2004, INT J GYNECOL OBSTET, V85, P240, DOI 10.1016/j.ijgo.2003.11.018; Kumar RM, 2001, EUR J OBSTET GYN R B, V100, P9, DOI 10.1016/S0301-2115(01)00448-1; MEDHAT A, 1993, INT J GYNECOL OBSTET, V40, P25, DOI 10.1016/0020-7292(93)90768-R; Mishra D, 2003, Indian J Pediatr, V70, P273, DOI 10.1007/BF02725598; NAYAK NC, 1989, J GASTROEN HEPATOL, V4, P345, DOI 10.1111/j.1440-1746.1989.tb00846.x; Pal R, 2005, J GASTROEN HEPATOL, V20, P1094, DOI 10.1111/j.1440-1746.2005.03875.x; SARIN SK, 2006, TXB LIVER DIS, P693; Schwartz E, 1999, CLIN INFECT DIS, V29, P1312, DOI 10.1086/313430; Singh Sarman, 2003, Indian Journal of Pediatrics, V70, P37, DOI 10.1007/BF02722743; Strand RT, 2003, SCAND J INFECT DIS, V35, P401, DOI 10.1080/00365540310010930; Trey C, 1970, Prog Liver Dis, V3, P282; TSEGA E, 1993, ETHIOPIAN MED J, V31, P173	24	270	275	3	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2007	147	1					28	33		10.7326/0003-4819-147-1-200707030-00005	http://dx.doi.org/10.7326/0003-4819-147-1-200707030-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186MN	17606958				2022-12-28	WOS:000247782900004
J	Burger, G				Buerger, Gerd			Comment on "The spatial extent of 20th-century warmth in the context of the past 1200 years"	SCIENCE			English	Editorial Material								Osborn and Briffa (Reports, 10 February 2006, p. 841) identified anomalous periods of warmth or cold in the Northern Hemisphere that were synchronous across 14 temperature-sensitive proxies. However, their finding that the spatial extent of 20th-century warming is exceptional ignores the effect of proxy screening on the corresponding significance levels. After appropriate correction, the significance of the 20th-century warming anomaly disappears.	Free Univ Berlin, Inst Meteorol, D-12165 Berlin, Germany	Free University of Berlin	Burger, G (corresponding author), Free Univ Berlin, Inst Meteorol, Carl Heinrich Weg 6-10, D-12165 Berlin, Germany.	gerd.buerger@met.fu-berlin.de	Bürger, Gerd/A-9714-2018	Bürger, Gerd/0000-0003-3539-2975				Esper J, 2002, SCIENCE, V295, P2250, DOI 10.1126/science.1066208; Jones PD, 2003, J CLIMATE, V16, P206, DOI 10.1175/1520-0442(2003)016<0206:HALSSA>2.0.CO;2; Livezey RE, 1995, ANALYSIS OF CLIMATE VARIABILITY, P159; Mann M. E., 2003, EOS, V84, P256, DOI DOI 10.1029/2003EO270003; Osborn TJ, 2006, SCIENCE, V311, P841, DOI 10.1126/science.1120514; Ribera P, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL015818	6	8	8	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 29	2007	316	5833					1844	+		10.1126/science.1140982	http://dx.doi.org/10.1126/science.1140982			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183WI	17600201				2022-12-28	WOS:000247602700018
J	Ahmed, A; Perry, GJ; Husain, A				Ahmed, Ali; Perry, Gilbert J.; Husain, Ahsan			VALIDD should not invalidate angiotensin-receptor blockers	LANCET			English	Editorial Material							DIASTOLIC HEART-FAILURE; LEFT-VENTRICULAR HYPERTROPHY; CARDIAC INTERSTITIUM; CONVERTING ENZYME; HYPERTENSION; FIBROSIS; REGRESSION; HUMANS; SYSTEM		Univ Alabama, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Physiol, Birmingham, AL 35294 USA; Univ Alabama, Dept Epidemiol, Birmingham, AL 35294 USA; Univ Alabama, Specialized Ctr Clin Oriented Res Heart Failure, Birmingham, AL 35294 USA; Univ Alabama, Ctr Heart Failure Res, Birmingham, AL 35294 USA; Vet Affairs Med Ctr, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Ahmed, A (corresponding author), Univ Alabama, Dept Med, Birmingham, AL 35294 USA.	aahmed@uab.edu	Husain, Ahsan/J-6861-2012; Ahmed, Ali/A-2934-2008	Husain, Ahsan/0000-0003-3426-3469; Ahmed, Ali/0000-0002-6832-6424				Ahmed Ali, 2006, ACP J Club, V145, P78; Ahmed A, 2006, AM HEART J, V152, P956, DOI 10.1016/j.ahj.2006.06.020; Brilla CG, 2000, CIRCULATION, V102, P1388, DOI 10.1161/01.CIR.102.12.1388; Devereux RB, 2001, CIRCULATION, V104, P1248, DOI 10.1161/hc3601.095927; Gottdiener JS, 2002, ANN INTERN MED, V137, P631, DOI 10.7326/0003-4819-137-8-200210150-00006; HUSAIN A, 1993, J HYPERTENS, V11, P1155; Kitzman DW, 2002, JAMA-J AM MED ASSOC, V288, P2144, DOI 10.1001/jama.288.17.2144; Levy D, 1996, JAMA-J AM MED ASSOC, V275, P1557, DOI 10.1001/jama.275.20.1557; Li M, 2004, J CLIN INVEST, V114, P112, DOI 10.1172/JCI200420805; Perry GJ, 2001, CIRCULATION, V103, P1012; Redfield MM, 2003, JAMA-J AM MED ASSOC, V289, P194, DOI 10.1001/jama.289.2.194; Rossi MA, 1998, J HYPERTENS, V16, P1031, DOI 10.1097/00004872-199816070-00018; Solomon SD, 2007, LANCET, V369, P2079, DOI 10.1016/S0140-6736(07)60980-5; Tallaj J, 2003, CIRCULATION, V108, P225, DOI 10.1161/01.CIR.0000079226.48637.5A; WEBER KT, 1991, CIRCULATION, V83, P1849, DOI 10.1161/01.CIR.83.6.1849; Zile MR, 2004, NEW ENGL J MED, V350, P1953, DOI 10.1056/NEJMoa032566	16	4	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 23	2007	369	9579					2053	2054		10.1016/S0140-6736(07)60955-6	http://dx.doi.org/10.1016/S0140-6736(07)60955-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	182GM	17586284				2022-12-28	WOS:000247493100004
J	Cheng, MH				Cheng, Margaret Harris			Health and housing after the Indian ocean tsunami	LANCET			English	Editorial Material								Over 2 years after the 2004 Indian Ocean tsunami caused massive devastation in southeast Asia, people are still living in temporary shelters. Reconstruction projects are struggling to ensure that new housing has clean water supplies and good sanitation. Margaret Harris Cheng reports.											0	6	6	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 23	2007	369	9579					2066	2068		10.1016/S0140-6736(07)60961-1	http://dx.doi.org/10.1016/S0140-6736(07)60961-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	182GM	17595703				2022-12-28	WOS:000247493100011
J	Persson, L; Amundsen, PA; De Roos, AM; Klemetsen, A; Knudsen, R; Primicerio, R				Persson, Lennart; Amundsen, Per-Arne; De Roos, Andre M.; Klemetsen, Anders; Knudsen, Rune; Primicerio, Raul			Culling prey promotes predator recovery - Alternative states in a whole-lake experiment	SCIENCE			English	Article							LIFE-HISTORY TRAITS; TROUT SALMO-TRUTTA; SALVELINUS-ALPINUS; ARCTIC CHARR; BROWN TROUT; STABLE EQUILIBRIA; FOOD-WEB; SIZE; POPULATIONS; GROWTH	Many top-predator fish stocks in both freshwater and marine systems have collapsed as a result of overharvesting. Consequently, some of these communities have shifted into seemingly irreversible new states. We showed, for predators feeding on prey that exhibit food-dependent growth, that culling of fish prey may promote predator recovery. We removed old stunted individuals of a prey-fish species in a large, low-productive lake, which caused an increase in the availability of small-sized prey and allowed the predator to recover. The shift in community state has been sustained for more than 15 years after the cull ended and represents an experimental demonstration of an alternative stable state in a large-scale field system. Because most animals exhibit food-dependent growth, shifts into alternative stable states resulting from overcompensating prey growth may be common in nature and may require counterintuitive management strategies.	Umea Univ, Dept Ecol & Environm Sci, S-90187 Umea, Sweden; Univ Tromso, Norwegian Coll Fishery Sci, Dept Aquat Biosci, N-9037 Tromso, Norway; Univ Amsterdam, Inst Biodivers & Ecosyst, NL-1090 GB Amsterdam, Netherlands	Umea University; UiT The Arctic University of Tromso; University of Amsterdam	Persson, L (corresponding author), Umea Univ, Dept Ecol & Environm Sci, S-90187 Umea, Sweden.	lennart.persson@emg.umu.se	De Roos, Andre M./A-1590-2008; Persson, Lennart/B-2885-2012	De Roos, Andre M./0000-0002-6944-2048; Amundsen, Per-Arne/0000-0002-2203-8216				Amundsen PA, 2007, J ANIM ECOL, V76, P149, DOI 10.1111/j.1365-2656.2006.01179.x; Chase JM, 1999, AM NAT, V154, P559, DOI 10.1086/303260; Chase JM, 2003, ECOL LETT, V6, P733, DOI 10.1046/j.1461-0248.2003.00482.x; CONNELL JH, 1983, AM NAT, V121, P789, DOI 10.1086/284105; De Roos AM, 2002, P NATL ACAD SCI USA, V99, P12907, DOI 10.1073/pnas.192174199; De Roos AM, 2003, ECOL LETT, V6, P473, DOI 10.1046/j.1461-0248.2003.00458.x; Duplisea DE, 2005, ICES J MAR SCI, V62, P412, DOI 10.1016/j.icesjms.2004.11.005; Edison TW, 2006, N AM J FISH MANAGE, V26, P800, DOI 10.1577/M04-020.1; Hutchings JA, 2005, CAN J FISH AQUAT SCI, V62, P824, DOI 10.1139/F05-081; Hutchings JA, 2000, NATURE, V406, P882, DOI 10.1038/35022565; Hyvarinen P, 2006, J FISH BIOL, V68, P87, DOI 10.1111/j.0022-1112.2006.00879.x; Jansen PA, 2002, CAN J FISH AQUAT SCI, V59, P6, DOI 10.1139/F01-184; Jansen PA, 2002, ENVIRON BIOL FISH, V64, P313, DOI 10.1023/A:1016009625754; JOHNSON L, 2002, IMPERFECT SYMMETRY T; Klemetsen A, 2002, ENVIRON BIOL FISH, V64, P39, DOI 10.1023/A:1016062421601; LABEELUND JH, 1992, J FISH BIOL, V41, P91, DOI 10.1111/j.1095-8649.1992.tb03172.x; Mora C, 2006, SCIENCE, V314, P758; PAINE RT, 1985, AM NAT, V125, P679, DOI 10.1086/284371; Persson L, 1996, ECOLOGY, V77, P900, DOI 10.2307/2265510; Post JR, 2002, FISHERIES, V27, P6, DOI 10.1577/1548-8446(2002)027&lt;0006:CRF&gt;2.0.CO;2; Scheffer M, 2001, NATURE, V413, P591, DOI 10.1038/35098000; Schmitz OJ, 2004, ECOL LETT, V7, P403, DOI 10.1111/j.1461-0248.2004.00592.x; Schroder A, 2005, OIKOS, V110, P3, DOI 10.1111/j.0030-1299.2005.13962.x; SEBENS KP, 1987, ANNU REV ECOL SYST, V18, P371, DOI 10.1146/annurev.es.18.110187.002103; TONN WM, 1992, ECOLOGY, V73, P951, DOI 10.2307/1940171; van Kooten T, 2005, J THEOR BIOL, V237, P67, DOI 10.1016/j.jtbi.2005.03.032; Walters C, 2001, CAN J FISH AQUAT SCI, V58, P39, DOI 10.1139/cjfas-58-1-39; Werner E.E., 1988, P60	28	146	151	2	84	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 22	2007	316	5832					1743	1746		10.1126/science.1141412	http://dx.doi.org/10.1126/science.1141412			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180XE	17588929				2022-12-28	WOS:000247400500046
J	Kyle, RA; Remstein, ED; Therneau, TM; Dispenzieri, A; Kurtin, PJ; Hodnefield, JM; Larson, DR; Plevak, MF; Jelinek, DF; Fonseca, R; Melton, LJI; Rajkumar, SV				Kyle, Robert A.; Remstein, Ellen D.; Therneau, Terry M.; Dispenzieri, Angela; Kurtin, Paul J.; Hodnefield, Janice M.; Larson, Dirk R.; Plevak, Matthew F.; Jelinek, Diane F.; Fonseca, Rafael; Melton, Lee Joseph, III; Rajkumar, S. Vincent			Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MONOCLONAL GAMMOPATHY; NATURAL-HISTORY	Background: Smoldering (asymptomatic) multiple myeloma is an asymptomatic plasma-cell proliferative disorder associated with a high risk of progression to symptomatic multiple myeloma or amyloidosis. Prognostic factors for the progression and outcome of this disease are unclear. Methods: We searched a computerized database and reviewed the medical records of all patients at Mayo Clinic who fulfilled the criteria of the International Myeloma Working Group for the diagnosis of smoldering multiple myeloma between 1970 and 1995. Bone marrow aspirate and biopsy specimens were studied, and patients were followed throughout the course of disease. Results: During the 26-year period, 276 patients fulfilled the criteria for smoldering multiple myeloma. During 2131 cumulative person-years of follow-up, symptomatic multiple myeloma or amyloidosis developed in 163 persons (59%). The overall risk of progression was 10% per year for the first 5 years, approximately 3% per year for the next 5 years, and 1% per year for the last 10 years; the cumulative probability of progression was 73% at 15 years. At diagnosis, significant risk factors for progression included the serum level and type of monoclonal protein, the presence of urinary light chain, the extent and pattern of bone marrow involvement, and the reduction in uninvolved immunoglobulins. The proportion of plasma cells in the bone marrow and the serum monoclonal protein level were combined to create a risk-stratification model with three distinct prognostic groups. Conclusions: The risk of progression from smoldering multiple myeloma to symptomatic disease is related to the proportion of bone marrow plasma cells and the serum monoclonal protein level at diagnosis.	Mayo Clin, Div Hematol, Rochester, MN 55905 USA; Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA; Mayo Clin, Div Biostat, Rochester, MN USA; Mayo Clin, Dept Immunol, Rochester, MN USA; Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Kyle, RA (corresponding author), Mayo Clin, Div Hematol, 200 1st St SW, Rochester, MN 55905 USA.	kyle.robert@mayo.edu	McPhail, Ellen D. Remstein/AAF-3474-2020; Rajkumar, S. Vincent/AAV-1834-2021	McPhail, Ellen D. Remstein/0000-0001-6918-3376; Rajkumar, S. Vincent/0000-0002-5862-1833; Fonseca, Rafael/0000-0002-5938-3769; Dispenzieri, Angela/0000-0001-8780-9512	NATIONAL CANCER INSTITUTE [P01CA062242, R01CA107476] Funding Source: NIH RePORTER; NCI NIH HHS [CA107476, CA62242] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANIAN R, 1988, ARCH INTERN MED, V148, P1963, DOI 10.1001/archinte.148.9.1963; BERRY G, 1983, BIOMETRICS, V39, P173, DOI 10.2307/2530817; Cesana C, 2002, J CLIN ONCOL, V20, P1625, DOI 10.1200/JCO.20.6.1625; COX DR, 1972, J R STAT SOC B, V34, P187; DIMOPOULOS MA, 1993, AM J MED, V94, P57, DOI 10.1016/0002-9343(93)90120-E; FACON T, 1995, AM J HEMATOL, V48, P71, DOI 10.1002/ajh.2830480201; Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kyle RA, 2003, BRIT J HAEMATOL, V121, P749; Kyle RA, 2003, MAYO CLIN PROC, V78, P21, DOI 10.4065/78.1.21; Kyle RA, 2002, NEW ENGL J MED, V346, P564, DOI 10.1056/NEJMoa01133202; KYLE RA, 1992, BLOOD, V79, P1817; KYLE RA, 1980, NEW ENGL J MED, V302, P1347, DOI 10.1056/NEJM198006123022405; KYLE RA, 2002, MANUAL CLIN LAB IMMU, P71; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; Rajkumar SV, 2003, LEUKEMIA, V17, P775, DOI 10.1038/sj.leu.2402866; Rajkumar SV, 2001, LEUKEMIA, V15, P1274, DOI 10.1038/sj.leu.2402183; Rosinol L, 2003, BRIT J HAEMATOL, V123, P631, DOI 10.1046/j.1365-2141.2003.04654.x; *SEER PROGR, 2005, SEER STAT DAT INC SE; SUKPANICHNANT S, 1994, HUM PATHOL, V25, P308, DOI 10.1016/0046-8177(94)90204-6; Weber DM, 1997, BRIT J HAEMATOL, V97, P810, DOI 10.1046/j.1365-2141.1997.1122939.x; WEBER DM, 2003, HEMATOL J, V4, pS31	23	549	574	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 21	2007	356	25					2582	2590		10.1056/NEJMoa070389	http://dx.doi.org/10.1056/NEJMoa070389			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180GN	17582068				2022-12-28	WOS:000247351200005
J	Padian, NS; van der Straten, A; Ramjee, G; Chipato, T; de Bruyn, G; Blanchard, K; Shiboski, S; Montgomery, ET; Fancher, H; Cheng, H; Rosenblum, M; van der Laan, M; Jewell, N; McIntyre, J				Padian, Nancy S.; van der Straten, Ariane; Ramjee, Gita; Chipato, Tsungai; de Bruyn, Guy; Blanchard, Kelly; Shiboski, Stephen; Montgomery, Elizabeth T.; Fancher, Heidi; Cheng, Helen; Rosenblum, Michael; van der Laan, Mark; Jewell, Nicholas; McIntyre, James		MIRA Team	Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial	LANCET			English	Article							SEXUALLY-TRANSMITTED-DISEASES; NONOXYNOL-9 VAGINAL GEL; FEMALE SEX WORKERS; MALE CIRCUMCISION; DEVELOPING-COUNTRIES; ZIMBABWEAN WOMEN; CLINICAL-TRIALS; ACCEPTABILITY; INFECTION; TRANSMISSION	Background Female-controlled methods of HIV prevention are urgently needed. We assessed the effect of provision of latex diaphragm, lubricant gel, and condoms (intervention), compared with condoms alone (control) on HIV seroincidence in women in South Africa and Zimbabwe. Methods We did an open-label, randomised controlled trial in HIV-negative, sexually active women recruited from clinics and community-based organisations, who were followed up quarterly for 12-24 months (median 21 months). All participants received an HIV prevention package consisting of pre-test and post-test counselling about HIV and sexually transmitted infections, testing, treatment of curable sexually transmitted infections, and intensive risk-reduction counselling. The primary outcome was incident HIV infection. This study is registered with ClinicalTrials.gov, number NCT00121459. Findings Overall HIV incidence was 4.0% per 100 woman-years: 4.1% in the intervention group (n=2472) and 3.9% in the control group (n=2476), corresponding to a relative hazard of 1.05 (95% CI 0.84-1.32, intention-to-treat analysis). The proportion of women using condoms was significantly lower in the intervention than in the control group (54% vs 85% of visits, p < 0.0001). The proportions of participants who reported adverse events (60% [1523] vs 61% [1529]) and serious adverse events (5% [130] vs 4% [101]) were similar between the two groups. Interpretation We observed no added protective benefit against HIV infection when the diaphragm and lubricant gel were provided in addition to condoms and a comprehensive HIV prevention package. Our observation that lower condom use in women provided with diaphragms did not result in increased infection merits further research. Although the intervention seemed safe, our findings do not support addition of the diaphragm to current HIV prevention strategies.	Univ Calif San Francisco, San Francisco, CA 94105 USA; MRC, HIV Prevent Res Unit, Durban, South Africa; Univ Zimbabwe, Harare, Zimbabwe; Univ Witwatersrand, Perinatal HIV Res Unit, Johannesburg, South Africa; Ibis Reprod Hlth, Cambridge, MA USA; Univ Calif Berkeley, Berkeley, CA 94720 USA	University of California System; University of California San Francisco; University of Zimbabwe; University of Witwatersrand; University of California System; University of California Berkeley	Padian, NS (corresponding author), Univ Calif San Francisco, San Francisco, CA 94105 USA.	npadian@globalhealth.ucsf.edu	de Bruyn, Guy/E-5574-2010; McIntyre, James/V-7115-2019	Montgomery, Elizabeth/0000-0002-5477-4445; de Bruyn, Guy/0000-0002-8028-4474; van der Straten, Ariane/0000-0001-8536-648X	NIAID NIH HHS [R01 AI070043, R01 AI070043-01A1, R01 AI074345, R01 AI074345-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI070043, R01AI074345] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abdool Q, 2001, J Am Med Womens Assoc (1972), V56, P193; ANDERSON J, 1998, ANN M AM STAT ASS; Auvert B, 2005, PLOS MED, V2, P1112, DOI 10.1371/journal.pmed.0020298; Bailey RC, 2007, LANCET, V369, P643, DOI 10.1016/S0140-6736(07)60312-2; Behets F, 2005, SEX TRANSM INFECT, V81, P472, DOI 10.1136/sti.2005.015107; BOUNDS W, 1995, J REPROD MED, V40, P764; Buck J, 2005, AIDS BEHAV, V9, P415, DOI 10.1007/s10461-005-9013-2; Bulut A, 2001, CONTRACEPTION, V63, P267, DOI 10.1016/S0010-7824(01)00204-9; CHECK E, 2007, NATURE, V446, P12; *CONRAD, 2007, PHAS III TRIALS CELL; dCruzGrote D, 1996, LANCET, V348, P1071, DOI 10.1016/S0140-6736(95)11031-3; DOLAGO TD, 1995, INT FAM PLAN PERSPEC, V21, P114, DOI 10.2307/2133185; *FHI, 2005, JOINT STAT SAVV PHAS; *FHI, 2006, PHAS 3 TRIAL NIG EV; Gallo MF, 2006, SEX TRANSM DIS, V33, P476, DOI 10.1097/01.olq.0000231960.92850.75; Gray RH, 2007, LANCET, V369, P657, DOI 10.1016/S0140-6736(07)60313-4; Green G, 2001, SOC SCI MED, V52, P585, DOI 10.1016/S0277-9536(00)00162-3; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; HEISE LL, 1995, SOC SCI MED, V40, P931, DOI 10.1016/0277-9536(94)00165-P; HUSSAIN LA, 1995, IMMUNOLOGY, V85, P475; Kang MS, 2007, AIDS BEHAV, V11, P443, DOI 10.1007/s10461-006-9190-7; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Levine WC, 1998, J INFECT DIS, V177, P167, DOI 10.1086/513820; Maguire RA, 2001, SEX TRANSM DIS, V28, P259, DOI 10.1097/00007435-200105000-00003; Mantell JE, 2005, SOC SCI MED, V60, P319, DOI 10.1016/j.socscimed.2004.05.011; MENSCH B, 2006, POP ASS AM ANN M; Minnis AM, 2007, CONTRACEPTION, V75, P59, DOI 10.1016/j.contraception.2006.07.002; Moench TR, 2001, AIDS, V15, P1595, DOI 10.1097/00002030-200109070-00001; Nguyen D, 2004, J BIOL REG HOMEOS AG, V18, P268; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Patterson BK, 1998, AM J PATHOL, V153, P481, DOI 10.1016/S0002-9440(10)65591-5; Posner SF, 2005, AIDS BEHAV, V9, P443, DOI 10.1007/s10461-005-9016-z; Pudney J, 2005, BIOL REPROD, V73, P1253, DOI 10.1095/biolreprod.105.043133; RAVINDRAN TK, 1995, STUDY USER PERSPECTI; Rohan LC, 2004, SEX TRANSM DIS, V31, P143, DOI 10.1097/01.OLQ.0000114655.79109.ED; TRUSSELL J, 2004, CONTRACEPTIVE TECHNO, P773; Turner CF, 1998, SCIENCE, V280, P867, DOI 10.1126/science.280.5365.867; ULIN PR, 1992, SOC SCI MED, V34, P63, DOI 10.1016/0277-9536(92)90068-2; *UNAIDS WHO, 2006, AIDS EP UPD; Van Damme L, 2000, AIDS, V14, P85, DOI 10.1097/00002030-200001070-00010; Van Damme L, 1998, AIDS, V12, P433, DOI 10.1097/00002030-199804000-00013; Van Damme L, 2002, LANCET, V360, P971, DOI 10.1016/S0140-6736(02)11079-8; van der Laak JAWM, 2002, J CLIN PATHOL, V55, P446, DOI 10.1136/jcp.55.6.446; van der Straten A, 2005, SEX TRANSM DIS, V32, P64, DOI 10.1097/01.olq.0000148301.90343.3a; VANDERSTRATEN A, 2005, 16 BIENN M INT SOC S; VANDERSTRATEN A, 2004, INT C AIDS; WASSERHEIT JN, 2007, 14 C RETR OPP INF; Wong EL, 2005, SEX TRANSM DIS, V32, P300, DOI 10.1097/01.olq.0000162362.98248.27; Zhang LQ, 1998, J VIROL, V72, P5035, DOI 10.1128/JVI.72.6.5035-5045.1998; [No title captured]; 2007, NATURE, V446, P1	51	253	260	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 21	2007	370	9583					251	261		10.1016/S0140-6736(07)60950-7	http://dx.doi.org/10.1016/S0140-6736(07)60950-7			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	194MG	17631387	Green Accepted			2022-12-28	WOS:000248347900029
J	Galan, JE				Galan, Jorge E.			SnapShot: Effector proteins of type III secretion systems	CELL			English	Editorial Material							HOST-CELLS; IMMUNE-RESPONSES; SHIGELLA; MIMICRY		Yale Univ, Sch Med, Clin Microbial Pathogenesis, New Haven, CT 06536 USA	Yale University	Galan, JE (corresponding author), Yale Univ, Sch Med, Clin Microbial Pathogenesis, 333 Cedar St, New Haven, CT 06536 USA.							Abrahams GL, 2006, CELL MICROBIOL, V8, P728, DOI 10.1111/j.1462-5822.2006.00706.x; Alto NM, 2006, CELL, V124, P133, DOI 10.1016/j.cell.2005.10.031; Caron E, 2006, CURR OPIN MICROBIOL, V9, P40, DOI 10.1016/j.mib.2005.12.008; Galan JE, 2001, ANNU REV CELL DEV BI, V17, P53, DOI 10.1146/annurev.cellbio.17.1.53; Galan JE, 2006, NATURE, V444, P567, DOI 10.1038/nature05272; Grant SR, 2006, ANNU REV MICROBIOL, V60, P425, DOI 10.1146/annurev.micro.60.080805.142251; Izard T, 2006, J CELL BIOL, V175, P465, DOI 10.1083/jcb.200605091; Kim DW, 2005, P NATL ACAD SCI USA, V102, P14046, DOI 10.1073/pnas.0504466102; Mukherjee S, 2007, TRENDS BIOCHEM SCI, V32, P210, DOI 10.1016/j.tibs.2007.03.007; Rohde JR, 2007, CELL HOST MICROBE, V1, P77, DOI 10.1016/j.chom.2007.02.002; Rytkonen A, 2007, P NATL ACAD SCI USA, V104, P3502, DOI 10.1073/pnas.0610095104; Tam VC, 2007, CELL HOST MICROBE, V1, P95, DOI 10.1016/j.chom.2007.03.005; Viboud GI, 2005, ANNU REV MICROBIOL, V59, P69, DOI 10.1146/annurev.micro.59.030804.121320; Worley MJ, 2006, P NATL ACAD SCI USA, V103, P17915, DOI 10.1073/pnas.0604054103; Yoshida S, 2006, SCIENCE, V314, P985, DOI 10.1126/science.1133174; Zhang L, 2006, MOL PHARMACEUT, V3, P62, DOI 10.1021/mp050095h	16	17	19	1	5	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 13	2007	130	1					192	U5	e1	10.1016/j.cell.2007.06.042	http://dx.doi.org/10.1016/j.cell.2007.06.042			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	197WK	17632065	Bronze			2022-12-28	WOS:000248587000021
J	Nakatogawa, H; Ichimura, Y; Ohsumi, Y				Nakatogawa, Hitoshi; Ichimura, Yoshinobu; Ohsumi, Yoshinori			Atg8, a ubiquitin-like protein required for autophagosome formation, mediates membrane tethering and hemifusion	CELL			English	Article							MAMMALIAN HOMOLOG; FUSION; YEAST; RECONSTITUTION; BINDING; STATE	Autophagy involves de novo formation of double membrane- bound structures called autophagosomes, which engulf material to be degraded in lytic compartments. Atg8 is a ubiquitinlike protein required for this process in Saccharomyces cerevisiae that can be conjugated to the lipid phosphatidylethanolamine by a ubiquitin- like system. Here, we show using an in vitro system that Atg8 mediates the tethering and hemifusion of membranes, which are evoked by the lipidation of the protein and reversibly modulated by the deconjugation enzyme Atg4. Mutational analyses suggest that membrane tethering and hemifusion observed in vitro represent an authentic function of Atg8 in autophagosome formation in vivo. In addition, electron microscopic analyses indicate that these functions of Atg8 are involved in the expansion of autophagosomal membranes. Our results provide further insights into the mechanisms underlying the unique membrane dynamics of autophagy and also indicate the functional versatility of ubiquitin- like proteins.	Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Ohsumi, Y (corresponding author), Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan.	yohsumi@nibb.ac.jp	Nakatogawa, Hitoshi/D-5155-2015; Ohsumi, Yoshinori/C-6449-2009	Nakatogawa, Hitoshi/0000-0002-5828-0741; Ohsumi, Yoshinori/0000-0003-2384-2166				Akiyama Y, 2003, J BIOL CHEM, V278, P18146, DOI 10.1074/jbc.M302152200; Amar N, 2006, EMBO REP, V7, P635, DOI 10.1038/sj.embor.7400698; BABA M, 1994, J CELL BIOL, V124, P903, DOI 10.1083/jcb.124.6.903; Chen XC, 2006, BIOPHYS J, V90, P2062, DOI 10.1529/biophysj.105.071415; Chernomordik LV, 2005, CELL, V123, P375, DOI 10.1016/j.cell.2005.10.015; Coyle JE, 2002, NEURON, V33, P63, DOI 10.1016/S0896-6273(01)00558-X; Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002; Hanada T, 2005, AUTOPHAGY, V1, P110, DOI 10.4161/auto.1.2.1858; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Ichimura Y, 2004, J BIOL CHEM, V279, P40584, DOI 10.1074/jbc.M405860200; Ishihara N, 2001, MOL BIOL CELL, V12, P3690, DOI 10.1091/mbc.12.11.3690; Jahn R, 2006, NAT REV MOL CELL BIO, V7, P631, DOI 10.1038/nrm2002; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Meers P, 2000, BBA-BIOMEMBRANES, V1467, P227, DOI 10.1016/S0005-2736(00)00224-8; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 2005, CELL DEATH DIFFER, V12, P1535, DOI 10.1038/sj.cdd.4401728; Paz Y, 2000, J BIOL CHEM, V275, P25445, DOI 10.1074/jbc.C000307200; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; Sugawara K, 2004, GENES CELLS, V9, P611, DOI 10.1111/j.1356-9597.2004.00750.x; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; Welchman RL, 2005, NAT REV MOL CELL BIO, V6, P599, DOI 10.1038/nrm1700; Xu YB, 2005, NAT STRUCT MOL BIOL, V12, P417, DOI 10.1038/nsmb921; Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765; Yoshimoto K, 2004, PLANT CELL, V16, P2967, DOI 10.1105/tpc.104.025395	28	844	881	3	102	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 13	2007	130	1					165	178		10.1016/j.cell.2007.05.021	http://dx.doi.org/10.1016/j.cell.2007.05.021			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	197WK	17632063	Bronze			2022-12-28	WOS:000248587000019
J	Tomita, K; Cooper, JP				Tomita, Kazunori; Cooper, Julia Promisel			The telomere bouquet controls the meiotic spindle	CELL			English	Article							OSCILLATORY NUCLEAR-MOVEMENT; YEAST SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; POLE BODY; CHROMOSOME SYNAPSIS; TAZ1 PROTEIN; MEIOSIS; RECOMBINATION; PROPHASE; MICROTUBULES	Bouquet formation, in which telomeres gather to a small region of the nuclear membrane in early meiosis, has been observed in diverse eukaryotes, but the function of the bouquet has remained a mystery. Here, we demonstrate that the telomere bouquet plays a crucial role in controlling the behavior of the fission yeast microtubule- organizing center ( known as the spindle pole body or SPB) and the meiotic spindle. Using mutations that specifically disrupt the bouquet, we analyze chromosome, SPB, and spindle dynamics throughout meiosis. If the bouquet fails to form, the SPB becomes fragmented at meiosis I, leading to monopolar, multiple, and mislocalized spindles. Correct SPB and spindle behavior require not only the SPB recruitment of telomere proteins but also that the proteins are properly bound to telomeric DNA. This discovery illuminates an unanticipated level of communication between chromosomes and the spindle apparatus that may be widely conserved among eukaryotes.	Canc Res UK, Telomere Biol Lab, London WC2A 3PX, England	Cancer Research UK	Cooper, JP (corresponding author), Canc Res UK, Telomere Biol Lab, London WC2A 3PX, England.	julie.cooper@cancer.org.uk	Tomita, Kazunori/P-6363-2019	Tomita, Kazunori/0000-0003-1096-6725; cooper, julia promisel/0000-0003-2171-2587				Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Bridge AJ, 1998, GENE DEV, V12, P927, DOI 10.1101/gad.12.7.927; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Chang L, 2000, P NATL ACAD SCI USA, V97, P5249, DOI 10.1073/pnas.97.10.5249; CHIKASHIGE Y, 1994, SCIENCE, V264, P270, DOI 10.1126/science.8146661; Chikashige Y, 2006, CELL, V125, P59, DOI 10.1016/j.cell.2006.01.048; Chikashige Y, 1997, EMBO J, V16, P193, DOI 10.1093/emboj/16.1.193; Chikashige Y, 2001, CURR BIOL, V11, P1618, DOI 10.1016/S0960-9822(01)00457-2; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Chua PR, 1997, GENE DEV, V11, P1786, DOI 10.1101/gad.11.14.1786; Conrad MN, 1997, SCIENCE, V276, P1252, DOI 10.1126/science.276.5316.1252; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; Cooper JP, 1998, NATURE, V392, P828, DOI 10.1038/33947; DEVEAUX LC, 1992, GENETICS, V130, P251; Ding DQ, 2004, DEV CELL, V6, P329, DOI 10.1016/S1534-5807(04)00059-0; Ding DQ, 1998, J CELL SCI, V111, P701; Ding R, 1997, MOL BIOL CELL, V8, P1461, DOI 10.1091/mbc.8.8.1461; Ferreira MG, 2001, MOL CELL, V7, P55, DOI 10.1016/S1097-2765(01)00154-X; Flory MR, 2002, CELL GROWTH DIFFER, V13, P47; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; Golubovskaya IN, 2002, GENETICS, V162, P1979; HAGAN I, 1995, J CELL BIOL, V129, P1033, DOI 10.1083/jcb.129.4.1033; Harper L, 2004, J CELL SCI, V117, P4025, DOI 10.1242/jcs.01363; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jin Y, 2005, DEV CELL, V9, P63, DOI 10.1016/j.devcel.2005.04.016; Kanoh J, 2001, CURR BIOL, V11, P1624, DOI 10.1016/S0960-9822(01)00503-6; Khodjakov A, 2000, CURR BIOL, V10, P59, DOI 10.1016/S0960-9822(99)00276-6; Kitajima TS, 2004, NATURE, V427, P510, DOI 10.1038/nature02312; Liebe B, 2004, MOL BIOL CELL, V15, P827, DOI 10.1091/mbc.E03-07-0524; Mahoney NM, 2006, CURR BIOL, V16, P564, DOI 10.1016/j.cub.2006.01.053; MARO B, 1985, J CELL BIOL, V101, P1665, DOI 10.1083/jcb.101.5.1665; Martin-Castellanos C, 2005, CURR BIOL, V15, P2056, DOI 10.1016/j.cub.2005.10.038; MESSINGER SM, 1991, J CELL SCI, V100, P289; Miki F, 2002, MOL BIOL CELL, V13, P930, DOI 10.1091/mbc.01-11-0543; Miller KM, 2006, NATURE, V440, P824, DOI 10.1038/nature04638; Niccoli T, 2004, J CELL SCI, V117, P5543, DOI 10.1242/jcs.01475; Nimmo ER, 1998, NATURE, V392, P825, DOI 10.1038/33941; Saito TT, 2006, J CELL BIOL, V173, P27, DOI 10.1083/jcb.200512129; Saito TT, 2005, J CELL SCI, V118, P447, DOI 10.1242/jcs.01629; Saitoh S, 1997, CELL, V90, P131, DOI 10.1016/S0092-8674(00)80320-7; Scherthan H, 2000, MOL BIOL CELL, V11, P4189, DOI 10.1091/mbc.11.12.4189; Shimanuki M, 1997, MOL GEN GENET, V254, P238, DOI 10.1007/s004380050412; Tanaka K, 2005, CURR BIOL, V15, P1479, DOI 10.1016/j.cub.2005.07.058; Tang X, 2006, J CELL BIOL, V173, P845, DOI 10.1083/jcb.200602152; Trelles-Sticken E, 2000, J CELL BIOL, V151, P95, DOI 10.1083/jcb.151.1.95; Tuzon CT, 2004, J CELL BIOL, V165, P759, DOI 10.1083/jcb.200312061; Watanabe Y, 1999, NATURE, V400, P461, DOI 10.1038/22774; West RR, 1998, MOL BIOL CELL, V9, P2839, DOI 10.1091/mbc.9.10.2839; Wu HY, 2006, MOL CELL BIOL, V26, P3683, DOI 10.1128/MCB.26.10.3683-3694.2006; Yamamoto A, 1999, J CELL BIOL, V145, P1233, DOI 10.1083/jcb.145.6.1233; Yamashita A, 2006, GENETICS, V173, P1187, DOI 10.1534/genetics.105.050062; Yokobayashi S, 2005, CELL, V123, P803, DOI 10.1016/j.cell.2005.09.013	55	83	83	0	12	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 13	2007	130	1					113	126		10.1016/j.cell.2007.05.024	http://dx.doi.org/10.1016/j.cell.2007.05.024			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	197WK	17632059	Bronze			2022-12-28	WOS:000248587000015
J	Gostin, LO				Gostin, Lawrence O.			Meeting the survival needs of the world's least healthy people - A proposed model for global health governance	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							POPULATION HEALTH; PUBLIC-HEALTH; FRAMEWORK; TARGETS		Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, Washington, DC 20001 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA	Georgetown University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.	gostin@law.georgetown.edu		Gostin, Lawrence/0000-0001-5286-4044				Aginam O, 2005, GLOBAL HLTH GOVERNAN; BATE R, 2007, HONESTY IS VIRTUE PR; Burci Gian Luca, 2004, WORLD HLTH ORG, P124; Burris S., 2004, TEMPLE LAW REV, V77, P335; Daniels N, 2006, HASTINGS CENT REP, V36, P22, DOI 10.1353/hcr.2006.0058; Fidler D., 1998, VANDERBILT J TRANS L, V31, P1079; Fidler DP, 2006, J LAW MED ETHICS, V34, P85, DOI 10.1111/j.1748-720X.2006.00011.x; Garrett L, 2007, FOREIGN AFF, V86, P14; Gostin LO, 2007, JAMA-J AM MED ASSOC, V298, P89, DOI 10.1001/jama.298.1.89; Gostin LO, 2006, HEALTH AFFAIR, V25, P1053, DOI 10.1377/hlthaff.25.4.1053; Labonte R, 2007, B WORLD HEALTH ORGAN, V85, P185, DOI 10.2471/BLT.06.037242; Miller JM, 2007, JAMA-J AM MED ASSOC, V297, P2241, DOI 10.1001/jama.297.20.2241; Molyneux DH, 2004, BMJ-BRIT MED J, V328, P1129, DOI 10.1136/bmj.328.7448.1129; Office of the High Commissioner for Human Rights United Nations, INT COV EC SOC CULT; Ram PK, 2007, AM J PUBLIC HEALTH, V97, P398, DOI 10.2105/AJPH.2005.073460; Roemer R, 2005, AM J PUBLIC HEALTH, V95, P936, DOI 10.2105/AJPH.2003.025908; Rose G., 1992, STRATEGY PREVENTIVE; SEPULVEDA J, 2007, PEPFAR IMPLEMENTATIO; TAYLOR AL, 1992, AM J LAW MED, V18, P301; Transparency International, 2006, GLOB CORR REP 2006 S; *UN, UN FRAM CONV CLIM CH; *UN ENV PROGR, VIENN CONV PROT OZ L; 2003, AFRICA MALARIA REPOR; UN MILLENNIUM DEV GO	24	32	33	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2007	298	2					225	228		10.1001/jama.298.2.225	http://dx.doi.org/10.1001/jama.298.2.225			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188HI	17622606				2022-12-28	WOS:000247910600030
J	Aveyard, P; West, R				Aveyard, Paul; West, Robert			Managing smoking cessation	BMJ-BRITISH MEDICAL JOURNAL			English	Review							NICOTINE; TOBACCO; ABSTINENCE; METABOLISM; MORTALITY; SMOKERS; TRIAL		Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England; UCL, Dept Epidemiol & Publ Hlth, Canc Res UK Hlth Behav Unit, London WC1E 6BT, England	University of Birmingham; University of London; University College London	Aveyard, P (corresponding author), Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England.	p.n.aveyard@bham.ac.uk	West, Robert/B-5414-2009; West, Robert/B-5414-2009	West, Robert/0000-0002-0291-5760; Aveyard, Paul/0000-0002-1802-4217; West, Robert/0000-0001-6398-0921				Ahluwalia JS, 2006, ADDICTION, V101, P883, DOI 10.1111/j.1360-0443.2006.01461.x; AVEYARD P, 2007, IN PRESS THORAX; Balfour DJK, 2004, NICOTINE TOB RES, V6, P899, DOI 10.1080/14622200412331324965; Barnes J, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001008.pub2; Cahill K, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006103.pub2; Dempsey D, 2002, J PHARMACOL EXP THER, V301, P594, DOI 10.1124/jpet.301.2.594; DiFranza JR, 2005, NICOTINE TOB RES, V7, P9, DOI 10.1080/14622200412331328538; Doll R, 2004, BMJ-BRIT MED J, V328, P1519, DOI 10.1136/bmj.38142.554479.AE; FRYSMITH A, 2006, CLIN COST EFFECTIVEN; Godtfredsen NS, 2002, AM J EPIDEMIOL, V156, P994, DOI 10.1093/aje/kwf150; Grimshaw GM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003289.pub4; Hajek P, 2001, ADDICTION, V96, P485, DOI 10.1046/j.1360-0443.2001.96348511.x; Hajek P, 2009, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003999.pub3, 10.1002/14651858.CD003999.pub4]; Hughes JR, 2007, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000031.pub4, 10.1002/14651858.CD000031.pub3]; Hughes JR, 2007, NICOTINE TOB RES, V9, P315, DOI 10.1080/14622200701188919; Hughes JR, 2007, NICOTINE TOB RES, V9, P329, DOI 10.1080/14622200701188927; Hughes JR, 2004, ADDICTION, V99, P29, DOI 10.1111/j.1360-0443.2004.00540.x; Hyland A, 2006, TOB CONTROL, V15, P83, DOI 10.1136/tc.2005.013516; Lancaster T, 2005, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001292.pub2, 10.1002/14651858.CD001292.pub3]; Lancaster T, 1999, BRIT J GEN PRACT, V49, P191; Lumley J., 2004, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD001055.PUB2; McEwen A, 2001, ADDICTION, V96, P997, DOI 10.1046/j.1360-0443.2001.9679978.x; McEwen A, 2006, ADDICT BEHAV, V31, P1650, DOI 10.1016/j.addbeh.2005.12.014; McRobbie H., 2007, RAPID REV NONNHS TRE; *NAT I HLTH CLIN E, 2007, FIN APPR DET VAR SMO; *OFF NAT STAT, 2007, STAT SMOK ENGL 2006; Perez-Stable EJ, 1998, JAMA-J AM MED ASSOC, V280, P152, DOI 10.1001/jama.280.2.152; Pisinger C, 2005, PREV MED, V40, P278, DOI 10.1016/j.ypmed.2004.06.011; Shiffman S, 2005, DRUG ALCOHOL DEPEN, V77, P311, DOI 10.1016/j.drugalcdep.2004.08.026; Stapleton J, 1998, Stat Methods Med Res, V7, P187, DOI 10.1191/096228098671391775; STEAD L, 2005, RAPID REV BRIEF INTE; Stead LF, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002850.pub2; Stead LF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000146.pub3; Stead LF, 2005, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001007.PUB2; Strecher VJ, 2005, ADDICTION, V100, P682, DOI 10.1111/j.1360-0443.2005.01093.x; Swartz LHG, 2006, TOB CONTROL, V15, P7, DOI 10.1136/tc.2003.006189; Taylor T, 2006, SMOKING RELATED BEHA; Tverdal A, 2006, TOB CONTROL, V15, P472, DOI 10.1136/tc.2006.016246; WANG D, 2007, IN PRESS HLTH TECHNO; WEST R, 2007, SMOKING CESSATION FA; WEST R, 2006, SMOKING SMOKING CESS; West R., 2006, UNDERSTANDING NICOTI, V275, P36, DOI DOI 10.1002/9780470029237.CH4; White AR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000009.pub2; Wu P, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-300	44	91	96	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 7	2007	335	7609					37	41		10.1136/bmj.39252.591806.47	http://dx.doi.org/10.1136/bmj.39252.591806.47			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	191LY	17615224	Green Published			2022-12-28	WOS:000248133900034
J	Doherty, R				Doherty, Roger			Robert W. Cahn (1924-2007) and David Turnbull (1915-2007)	SCIENCE			English	Biographical-Item									Drexel Univ, Dept Mat Engn, Philadelphia, PA 19104 USA	Drexel University	Doherty, R (corresponding author), Drexel Univ, Dept Mat Engn, Philadelphia, PA 19104 USA.	dohertrd@drexel.edu						CAHN RW, PUBLICATION LIST; TURNBULL D, PUBLICATION LIST	2	2	2	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2007	317	5834					56	57		10.1126/science.1145490	http://dx.doi.org/10.1126/science.1145490			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186KD	17615332				2022-12-28	WOS:000247776700037
J	Naugler, WE; Sakurai, T; Kim, S; Maeda, S; Kim, K; Elsharkawy, AM; Karin, M				Naugler, Willscott E.; Sakurai, Toshiharu; Kim, Sunhwa; Maeda, Shin; Kim, KyoungHyun; Elsharkawy, Ahmed M.; Karin, Michael			Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production	SCIENCE			English	Article							NF-KAPPA-B; HEPATOCELLULAR-CARCINOMA; CHEMICAL HEPATOCARCINOGENESIS; ESTROGEN-RECEPTOR; INNATE IMMUNITY; RISK-FACTORS; INFLAMMATION; MICE; REGENERATION; CIRRHOSIS	Hepatocellular carcinoma (HCC), the most common liver cancer, occurs mainly in men. Similar gender disparity is seen in mice given a chemical carcinogen, diethylnitrosamine ( DEN). DEN administration caused greater increases in serum interleukin-6 (IL-6) concentration in males than it did in females. Furthermore, ablation of IL-6 abolished the gender differences in hepatocarcinogenesis in mice. DEN exposure promoted production of IL-6 in Kupffer cells (KCs) in a manner dependent on the Toll-like receptor adaptor protein MyD88, ablation of which also protected male mice from DEN-induced hepatocarcinogenesis. Estrogen inhibited secretion of IL-6 from KCs exposed to necrotic hepatocytes and reduced circulating concentrations of IL-6 in DEN-treated male mice. We propose that estrogen-mediated inhibition of IL-6 production by KCs reduces liver cancer risk in females, and these findings may be used to prevent HCC in males.	Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Div Gastroenterol, San Diego, CA 93093 USA; Asahi Life Fdn, Inst Adult Dis, Div Gastroenterol, Chiyoda Ku, Tokyo 1000005, Japan; Univ Newcastle Upon Tyne, Liver Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Asahi Life Foundation; Newcastle University - UK	Karin, M (corresponding author), Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, 9500 Gilman Rd,Mail Code 0723, La Jolla, CA 92093 USA.	karinoffice@ucsd.edu		Kim, Kyounghyun/0000-0002-7240-2768; Elsharkawy, Ahmed Mohamed/0000-0001-5369-3734	NATIONAL CANCER INSTITUTE [R01CA118165, T32CA121938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004151, R01ES006376, R37ES004151] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA121938, R01 CA118165, CA118165] Funding Source: Medline; NIDDK NIH HHS [T32 DK007202, DK007202] Funding Source: Medline; NIEHS NIH HHS [R01 ES006376, ES004151, ES006376] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abiru S, 2006, LIVER INT, V26, P39, DOI 10.1111/j.1478-3231.2005.01191.x; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; Erikoglu M, 2005, SURG TODAY, V35, P467, DOI 10.1007/s00595-004-2958-3; Fattovich G, 2004, GASTROENTEROLOGY, V127, pS35, DOI 10.1053/j.gastro.2004.09.014; Ghebranious N, 1998, HEPATOLOGY, V27, P383, DOI 10.1002/hep.510270211; Karin M, 2006, CELL, V124, P823, DOI 10.1016/j.cell.2006.02.016; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; KOVALSZKY I, 1992, CARCINOGENESIS, V13, P773, DOI 10.1093/carcin/13.5.773; Lee JS, 2004, NAT GENET, V36, P1306, DOI 10.1038/ng1481; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Nakatani T, 2001, JPN J CANCER RES, V92, P249, DOI 10.1111/j.1349-7006.2001.tb01089.x; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Sakurai T, 2006, P NATL ACAD SCI USA, V103, P10544, DOI 10.1073/pnas.0603499103; Sherman M, 2005, SEMIN LIVER DIS, V25, P143, DOI 10.1055/s-2005-871194; Soresi M, 2006, WORLD J GASTROENTERO, V12, P2563, DOI 10.3748/wjg.v12.i16.2563; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Suzuki T, 2007, J APPL PHYSIOL, V102, P163, DOI 10.1152/japplphysiol.00964.2006; Taub R, 2004, NAT REV MOL CELL BIO, V5, P836, DOI 10.1038/nrm1489; Velayudham A, 2006, J HEPATOL, V45, P813, DOI 10.1016/j.jhep.2006.06.017; Verna L, 1996, PHARMACOL THERAPEUT, V71, P57, DOI 10.1016/0163-7258(96)00062-9; Weber LWD, 2003, CRIT REV TOXICOL, V33, P105, DOI 10.1080/713611034; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Zheng R, 2006, MOL MED, V12, P65, DOI 10.2119/2006-00030.Zheng	27	1390	1473	9	119	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2007	317	5834					121	124		10.1126/science.1140485	http://dx.doi.org/10.1126/science.1140485			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186KD	17615358				2022-12-28	WOS:000247776700066
J	Rakoff-Nahoum, S; Medzhitov, R				Rakoff-Nahoum, Seth; Medzhitov, Ruslan			Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88	SCIENCE			English	Article							NF-KAPPA-B; TOLL-LIKE RECEPTORS; SYSTEMIC INFLAMMATION; COLORECTAL-CANCER; KNOCKOUT MICE; MUTATION; INJURY; MOUSE; SUPPRESSION; INHIBITION	Inflammation is increasingly recognized as an important component of tumorigenesis, although the mechanisms and pathways involved are not well understood. Tumor development is regulated by products of several modifier genes, but instructions for their tumor-specific expression are currently unknown. We show that the signaling through the adaptor protein MyD88 has a critical role in spontaneous tumor development in mice with heterozygous mutation in the adenomatous polyposis coli (APC) gene. We found that MyD88-dependent signaling controls the expression of several key modifier genes of intestinal tumorigenesis and has a critical role in both spontaneous and carcinogen-induced tumor development. This study thus reveals the important role of an innate immune signaling pathway in intestinal tumorigenesis.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University; Yale University	Medzhitov, R (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, 333 Cedar St, New Haven, CT 06520 USA.	ruslan.medzhitov@yale.edu						Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Boivin GP, 2003, GASTROENTEROLOGY, V124, P762, DOI 10.1053/gast.2003.50094; Brown JR, 2005, J CLIN ONCOL, V23, P2840, DOI 10.1200/JCO.2005.09.051; Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849; CHO CH, 2002, FRONTIERS GASTROINTE, V25; Chulada PC, 2000, CANCER RES, V60, P4705; Clevers H, 2004, CELL, V118, P671, DOI 10.1016/j.cell.2004.09.005; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Dinarello CA, 2005, J EXP MED, V201, P1355, DOI 10.1084/jem.20050640; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; GUKATA M, 2005, AM J PHYSIOL-GASTR L, V288, pG1055; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hong KH, 2001, P NATL ACAD SCI USA, V98, P3935, DOI 10.1073/pnas.051635898; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kettunen HL, 2003, CANCER RES, V63, P5136; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pull SL, 2005, P NATL ACAD SCI USA, V102, P99, DOI 10.1073/pnas.0405979102; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Takaku K, 2000, J BIOL CHEM, V275, P34013, DOI 10.1074/jbc.C000586200; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402	28	461	480	4	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2007	317	5834					124	127		10.1126/science.1140488	http://dx.doi.org/10.1126/science.1140488			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186KD	17615359				2022-12-28	WOS:000247776700067
J	Yazawa, M; Ferrante, C; Feng, J; Mio, K; Ogura, T; Zhang, M; Lin, PH; Pan, Z; Komazaki, S; Kato, K; Nishi, M; Zhao, XL; Weisleder, N; Sato, C; Ma, JJ; Takeshima, H				Yazawa, Masayuki; Ferrante, Christopher; Feng, Jue; Mio, Kazuhiro; Ogura, Toshihiko; Zhang, Miao; Lin, Pei-Hui; Pan, Zui; Komazaki, Shinji; Kato, Kazuhiro; Nishi, Miyuki; Zhao, Xiaoli; Weisleder, Noah; Sato, Chikara; Ma, Jianjie; Takeshima, Hiroshi			TRIC channels are essential for Ca2+ handling in intracellular stores	NATURE			English	Article							SARCOPLASMIC-RETICULUM VESICLES; AUTOMATIC PARTICLE PICKUP; CALCIUM-RELEASE; RECEPTOR; ION; EXPRESSION; TOPOLOGY; NETWORK; FAMILY; BLOCK	Cell signalling requires efficient Ca2+ mobilization from intracellular stores through Ca2+ release channels, as well as predicted counter-movement of ions across the sarcoplasmic/endoplasmic reticulum membrane to balance the transient negative potential generated by Ca2+ release(1-7). Ca2+ release channels were cloned more than 15 years ago(8,9), whereas the molecular identity of putative counter- ion channels remains unknown. Here we report two TRIC ( trimeric intracellular cation) channel subtypes that are differentially expressed on intracellular stores in animal cell types. TRIC subtypes contain three proposed transmembrane segments, and form homo-trimers with a bullet-like structure. Electrophysiological measurements with purified TRIC preparations identify a monovalent cation-selective channel. In TRIC-knockout mice suffering embryonic cardiac failure, mutant cardiac myocytes show severe dysfunction in intracellular Ca2+ handling. The TRIC-deficient skeletal muscle sarcoplasmic reticulum shows reduced K+ permeability, as well as altered Ca2+ 'spark' signalling and voltage-induced Ca2+ release. Therefore, TRIC channels are likely to act as counter- ion channels that function in synchronization with Ca2+ release from intracellular stores.	Kyoto Univ, Dept Biol Chem, Grad Sch Pharmaceut Sci, Kyoto 6068501, Japan; Tohoku Univ, Dept Med Chem, Grad Sch Med, Miyagi 9808575, Japan; Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; [Ogura, Toshihiko; Sato, Chikara] Natl Inst Adv Ind Sci & Technol, Neurosci Res Inst, Ibaraki 3058568, Japan; Japan Sci & Technol Agcy, PRESTO, Saitama 3320012, Japan; Saitama Med Univ, Dept Anat, Saitama 3500495, Japan	Kyoto University; Tohoku University; Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institute of Advanced Industrial Science & Technology (AIST); Japan Science & Technology Agency (JST); Saitama Medical University	Takeshima, H (corresponding author), Kyoto Univ, Dept Biol Chem, Grad Sch Pharmaceut Sci, Kyoto 6068501, Japan.	takeshim@pharm.kyoto-u.ac.jp	Sato, Chikara/M-7183-2016; Mio, Kazuhiro/L-7488-2018; Weisleder, Noah L/A-7098-2013; Lin, Pei-Hui/I-3011-2015	Sato, Chikara/0000-0001-5543-4496; Mio, Kazuhiro/0000-0002-1655-8231; Weisleder, Noah L/0000-0002-2619-8022; Lin, Pei-Hui/0000-0002-3894-5099; Takeshima, Hiroshi/0000-0003-4525-3725; Weisleder, Noah/0000-0003-2710-3088; Pan, Zui/0000-0003-4105-901X				ANTOON FM, 2000, DEV BIOL, V223, P279; Berridge MJ, 2002, CELL CALCIUM, V32, P235, DOI 10.1016/S0143416002001823; Collet C, 1999, J PHYSIOL-LONDON, V520, P417, DOI 10.1111/j.1469-7793.1999.00417.x; CORONADO R, 1980, NATURE, V288, P495, DOI 10.1038/288495a0; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DANI JA, 1995, CURR OPIN NEUROBIOL, V5, P310, DOI 10.1016/0959-4388(95)80043-3; EBASHI S, 1976, ANNU REV PHYSIOL, V38, P293, DOI 10.1146/annurev.ph.38.030176.001453; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FAULK WP, 1971, IMMUNOCHEMISTRY, V8, P1081; Feramisco JD, 2004, J BIOL CHEM, V279, P8487, DOI 10.1074/jbc.M312623200; FERNANDEZ JL, 1980, BIOCHIM BIOPHYS ACTA, V599, P552, DOI 10.1016/0005-2736(80)90199-6; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; Fink RHA, 1996, ACTA PHYSIOL SCAND, V156, P387, DOI 10.1046/j.1365-201X.1996.212000.x; Frank J, 2006, 3 DIMENSIONAL ELECT; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HARAUZ G, 1986, OPTIK, V73, P146; Kourie JI, 1996, BIOPHYS J, V70, P202, DOI 10.1016/S0006-3495(96)79564-4; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIU QY, 1991, FEBS LETT, V291, P13, DOI 10.1016/0014-5793(91)81092-M; MA JJ, 1993, J GEN PHYSIOL, V102, P1031, DOI 10.1085/jgp.102.6.1031; MEISSNER G, 1983, MOL CELL BIOCHEM, V55, P65; MEISSNER G, 1980, J BIOL CHEM, V255, P6814; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Mio K, 2005, BIOCHEM BIOPH RES CO, V337, P998, DOI 10.1016/j.bbrc.2005.09.141; Ogura T, 2003, J STRUCT BIOL, V143, P185, DOI 10.1016/j.jsb.2003.08.005; Ogura T, 2004, J STRUCT BIOL, V145, P63, DOI 10.1016/S1047-8477(03)00139-4; Ogura T, 2004, J STRUCT BIOL, V146, P344, DOI 10.1016/j.jsb.2004.01.007; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SOMLYO AV, 1977, NATURE, V268, P556, DOI 10.1038/268556a0; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; Takeshima H, 2000, MOL CELL, V6, P11, DOI 10.1016/S1097-2765(00)00003-4; Takeshima H, 1998, EMBO J, V17, P3309, DOI 10.1093/emboj/17.12.3309; Takeshima H, 1998, BIOCHEM J, V331, P317, DOI 10.1042/bj3310317; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; van Heel M, 2000, Q REV BIOPHYS, V33, P307, DOI 10.1017/S0033583500003644; Wang X, 2005, NAT CELL BIOL, V7, P525, DOI 10.1038/ncb1254; Weisleder N, 2006, J CELL BIOL, V174, P639, DOI 10.1083/jcb.200604166; ZHANG M, IN PRESS CELL CALCIU	40	115	125	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 5	2007	448	7149					78	82		10.1038/nature05928	http://dx.doi.org/10.1038/nature05928			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185OS	17611541				2022-12-28	WOS:000247720900041
J	Dillehay, TD; Rossen, J; Andres, TC; Williams, DE				Dillehay, Tom D.; Rossen, Jack; Andres, Thomas C.; Williams, David E.			Preceramic adoption of peanut, squash, and cotton in northern Peru	SCIENCE			English	Article							CUCURBITA CUCURBITACEAE; ANDEAN CIVILIZATION; EARLY HOLOCENE; DOMESTICATION; ORIGIN; PLANT; AMERICA; ECUADOR; SITES; COAST	The early development of agriculture in the New World has been assumed to involve early farming in settlements in the Andes, but the record has been sparse. Peanut (Arachis sp.), squash (Cucurbita moschata), and cotton (Gossypium barbadense) macrofossils were excavated from archaeological sites on the western slopes of the northern Peruvian Andes. Direct radiocarbon dating indicated that these plants grew between 9240 and 5500 C-14 years before the present. These and other plants were recovered from multiple locations in a tropical dry forest valley, including household clusters, permanent architectural structures, garden plots, irrigation canals, hoes, and storage structures. These data provide evidence for early use of peanut and squash in the human diet and of cotton for industrial purposes and indicate that horticultural economies in parts of the Andes took root by about 10,000 years ago.	Vanderbilt Univ, Dept Anthropol, Nashville, TN 37221 USA; Ithaca Coll, Dept Anthropol, Ithaca, NY 14850 USA; Cucurbit Network, Bronx, NY 10458 USA; USDA, Washington, DC 20250 USA	Vanderbilt University; United States Department of Agriculture (USDA)	Dillehay, TD (corresponding author), Vanderbilt Univ, Dept Anthropol, Nashville, TN 37221 USA.	tom.dillehay@vanderbilt.edu						ACEITUNO FJ, 2005, BEFORE FARMING, V2, P2; ANDRES TC, 2004, P CUC 2004 8 EUCARPI, P13; Barker G., 2006, AGR REVOLUTION PREHI; BONAVIA D, 1993, REV HISTORIQUE, V47, P77; Bruno MC, 2003, LAT AM ANTIQ, V14, P339, DOI 10.2307/3557565; DAMP JE, 1994, ECON BOT, V48, P163, DOI 10.1007/BF02908209; Dillehay TD, 2005, P NATL ACAD SCI USA, V102, P17241, DOI 10.1073/pnas.0508583102; Dillehay TD, 1997, AM SCI, V85, P46; Dillehay TD, 2003, QUATERN INT, V109, P3, DOI 10.1016/S1040-6182(02)00198-2; DILLEHAY TD, 1989, AM ANTIQUITY, V54, P733, DOI 10.2307/280679; Erickson DL, 2005, P NATL ACAD SCI USA, V102, P18315, DOI 10.1073/pnas.0509279102; Ferguson ME, 2005, BIODIVERS CONSERV, V14, P1777, DOI 10.1007/s10531-004-0699-7; Haas J, 2006, CURR ANTHROPOL, V47, P745, DOI 10.1086/506281; JARVIS A, 2002, PLANT GENET RESOUR N, V131, P28; Kislev ME, 2006, SCIENCE, V312, P1372, DOI 10.1126/science.1125910; NEE M, 1990, ECON BOT, V44, P56, DOI 10.1007/BF02860475; NETHERLY PJ, 1983, ARCHAEO, V30, P22; Olsen KM, 2001, AM J BOT, V88, P131, DOI 10.2307/2657133; Piperno D.R., 1998, ORIGINS AGR LOWLAND; Piperno DR, 2000, NATURE, V407, P894, DOI 10.1038/35038055; Piperno DR, 2003, SCIENCE, V299, P1054, DOI 10.1126/science.1080365; Rossen J, 1996, J ARCHAEOL SCI, V23, P391, DOI 10.1006/jasc.1996.0035; ROSSEN J, 1991, THESIS U KENTUCKY; Sanjur OI, 2002, P NATL ACAD SCI USA, V99, P535, DOI 10.1073/pnas.012577299; Smith BD, 1997, SCIENCE, V276, P932, DOI 10.1126/science.276.5314.932; STEPHENS SG, 1974, AM ANTIQUITY, V39, P109, DOI 10.2307/279225; Wessel-Beaver L., 2000, Cucurbit Genetics Cooperative, P54; Westengen O, 2005, THEOR APPL GENET, V110, P392, DOI 10.1007/s00122-004-1850-2; Zohary D, 2000, DOMESTICATION PLANTS, DOI DOI 10.1006/ANBO.2001.1505	29	142	152	2	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 29	2007	316	5833					1890	1893		10.1126/science.1141395	http://dx.doi.org/10.1126/science.1141395			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183WI	17600214				2022-12-28	WOS:000247602700037
J	Engelman, A				Engelman, Alan			AIDS/HIV - A reversal of fortune in HIV-1 integration	SCIENCE			English	Editorial Material							IMMUNODEFICIENCY-VIRUS TYPE-1; SUBSTRATE; STRATEGY; CELLS; LOXP; SITE; CRE		Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute	Engelman, A (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.	alan_engelman@dfci.harvard.edu						Buchholz F, 2001, NAT BIOTECHNOL, V19, P1047, DOI 10.1038/nbt1101-1047; CRAIG NL, 2002, MOBILE DNA, V2; Han YF, 2007, NAT REV MICROBIOL, V5, P95, DOI 10.1038/nrmicro1580; Kim ST, 2001, J CELL BIOCHEM, V80, P321, DOI 10.1002/1097-4644(20010301)80:3<321::AID-JCB40>3.0.CO;2-C; LEAVITT AD, 1992, J VIROL, V66, P2359, DOI 10.1128/JVI.66.4.2359-2368.1992; Lee YS, 1998, BIOCHEM BIOPH RES CO, V253, P588, DOI 10.1006/bbrc.1998.9814; LOBEL LI, 1989, J VIROL, V63, P2629, DOI 10.1128/JVI.63.6.2629-2637.1989; Sarkar I, 2007, SCIENCE, V316, P1912, DOI 10.1126/science.1141453; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Siliciano Robert F, 2005, Top HIV Med, V13, P96; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; Strayer DS, 2006, MOL BIOTECHNOL, V34, P257, DOI 10.1385/MB:34:2:257; Swiggard WJ, 2005, J VIROL, V79, P14179, DOI 10.1128/JVI.79.22.14179-14188.2005	13	6	7	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 29	2007	316	5833					1855	1857		10.1126/science.1145015	http://dx.doi.org/10.1126/science.1145015			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183WI	17600205				2022-12-28	WOS:000247602700025
J	Logan, LK; Zheng, XTT; Dizikes, GS; Tan, TQ				Logan, Latania K.; Zheng, Xiaotian T.; Dizikes, George S.; Tan, Tina Q.			Failure to thrive in Chicago	LANCET			English	Editorial Material							CENTRAL-NERVOUS-SYSTEM; TUBERCULOUS MENINGITIS		Childrens Mem Hosp, Div Infect Dis, Chicago, IL 60614 USA; Childrens Mem Hosp, Dept Microbiol, Chicago, IL 60614 USA; Illinois Dept Publ Hlth, Chicago, IL USA; Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Logan, LK (corresponding author), Childrens Mem Hosp, Div Infect Dis, Chicago, IL 60614 USA.	liogan@childrensmemorial.org		Logan, Latania/0000-0002-3883-2043				BAGGA A, 1988, CLIN PEDIATR, V27, P487, DOI 10.1177/000992288802701004; Bernaerts A, 2003, EUR RADIOL, V13, P1876, DOI 10.1007/s00330-002-1608-7; Garcia-Monco JC, 1999, NEUROL CLIN, V17, P737, DOI 10.1016/S0733-8619(05)70164-X; Schoeman J, 2002, DEV MED CHILD NEUROL, V44, P522, DOI 10.1017/S0012162201002493; Tung YR, 2002, PEDIATR NEUROL, V27, P262, DOI 10.1016/S0887-8994(02)00431-9	5	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 23	2007	369	9579					2132	2132		10.1016/S0140-6736(07)60984-2	http://dx.doi.org/10.1016/S0140-6736(07)60984-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	182GM	17586308				2022-12-28	WOS:000247493100033
J	ter Kuile, FO; van Eijk, AM; Filler, SJ				ter Kuile, Feiko O.; van Eijk, Annemieke M.; Filler, Scott J.			Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy - A systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PLASMODIUM-FALCIPARUM MALARIA; UNCOMPLICATED MALARIA; RANDOMIZED-TRIAL; CHLOROQUINE; CHILDREN; WOMEN; ARTESUNATE; QUALITY; ANEMIA; AMODIAQUINE	Context In malaria-endemic regions, strategies to control malaria during pregnancy rely on case management of malaria illness and anemia, and preventive measures such as insecticide-treated nets and intermittent preventive therapy (IPT). Objective To determine the effect of increasing resistance to sulfadoxine-pyrimethamine on the efficacy of IPT during pregnancy in Africa. Data Sources and Study Selection The 6 databases of MEDLINE, EMBASE, SCOPUS, LILACS, Cochrane CENTRAL, and the trial register and bibliographic database of the Malaria in Pregnancy Library were searched for relevant studies regardless of language, published between 1966 and December 2006. The reference lists of all trials identified were searched and researchers were contacted about relevant data. Nine trials of IPT with sulfadoxine-pyrimethamine during pregnancy in Africa were identified and matched by year and location with treatment studies of sulfadoxine-pyrimethamine among symptomatic children. Data Extraction Data on the efficacy of IPT with sulfadoxine-pyrimethamine on placental and peripheral malaria, birth weight, and hemoglobin level/anemia were independently abstracted by 2 investigators. Sulfadoxine-pyrimethamine resistance was defined as the proportion of total treatment failures in symptomatic children by day 14. Data Synthesis Four trials compared 2-dose IPT with sulfadoxine-pyrimethamine to case management or placebo in women during their first or second pregnancy. The IPT reduced placental malaria ( relative risk [RR], 0.48; 95% CI, 0.35-0.68), low birth weight ( RR, 0.71; 95% CI, 0.55-0.92), and anemia ( RR, 0.90; 95% CI, 0.81-0.99). The effect did not vary by sulfadoxine-pyrimethamine resistance levels ( range, 19%-26%). Efficacy of IPT with sulfadoxine-pyrimethamine was lower among women using insecticide-treated nets. Three trials compared 2-dose with monthly IPT with sulfadoxine-pyrimethamine during pregnancy. Among HIV-positive women in their first or second pregnancy, monthly IPT resulted in less placental malaria ( RR, 0.34; 95% CI, 0.18-0.64) and higher birth weight ( mean difference, 112 g; 95% CI, 19-205 g) over the range of sulfadoxine-pyrimethamine resistance tested (8%-39%). Among HIV-negative women, there was no conclusive additional effect of monthly dosing ( 2 trials; 24% and 39% resistance). Conclusions In areas in which 1 of 4 treatments with sulfadoxine-pyrimethamine fail in children by day 14, the 2-dose IPT with sulfadoxine-pyrimethamine regimen continues to provide substantial benefit to HIV-negative semi-immune pregnant women. However, more frequent dosing is required in HIV-positive women not using cotrimoxazole prophylaxis for opportunistic infections.	Univ Liverpool, Liverpool Sch Trop Med, Child & Reprod Hlth Grp, Pembroke Pl, Liverpool L3 5QA, Merseyside, England; US Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis, Atlanta, GA USA; Univ Amsterdam, Acad Med Ctr, Dept Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands	Liverpool School of Tropical Medicine; University of Liverpool; Centers for Disease Control & Prevention - USA; University of Amsterdam; Academic Medical Center Amsterdam	ter Kuile, FO (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Child & Reprod Hlth Grp, Pembroke Pl, Liverpool L3 5QA, Merseyside, England.	terkuile@liv.ac.uk	van Eijk, Anna Maria/AAQ-9894-2021	van Eijk, Anna Maria/0000-0003-1635-1289; ter Kuile, Feiko/0000-0003-3663-5617				Abacassamo F, 2004, TROP MED INT HEALTH, V9, P200, DOI 10.1046/j.1365-3156.2003.01182.x; Adjuik M, 2004, LANCET, V363, P9, DOI 10.1016/S0140-6736(03)15162-8; Alker AP, 2005, ANTIMICROB AGENTS CH, V49, P3919, DOI 10.1128/AAC.49.9.3919-3921.2005; Amukoye E, 1997, ANTIMICROB AGENTS CH, V41, P2261, DOI 10.1128/AAC.41.10.2261; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Bloland PB, 1998, TROP MED INT HEALTH, V3, P543; Challis K, 2004, TROP MED INT HEALTH, V9, P1066, DOI 10.1111/j.1365-3156.2004.01307.x; DEEKS JJ, 2005, COCHRANE HDB SYSTEMA; Dunyo S, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010014; Farnert A, 2002, AM J TROP MED HYG, V66, P487; Filler SJ, 2006, J INFECT DIS, V194, P286, DOI 10.1086/505080; *GLOB FUND WEB SIT, FIGHT MAL; Hastings MD, 2002, T ROY SOC TROP MED H, V96, P674, DOI 10.1016/S0035-9203(02)90349-4; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Kalanda GC, 2006, TROP MED INT HEALTH, V11, P569, DOI 10.1111/j.1365-3156.2006.01608.x; Kayentao K, 2005, J INFECT DIS, V191, P109, DOI 10.1086/426400; Mbaye A, 2006, TROP MED INT HEALTH, V11, P992, DOI 10.1111/j.1365-3156.2006.01649.x; Menendez C, 2007, LANCET INFECT DIS, V7, P126, DOI 10.1016/S1473-3099(07)70024-5; Meshnick SR, 2006, J INFECT DIS, V194, P273, DOI 10.1086/505087; *NAT MAL CONTR CTR, 2002, PREL FIND IN VIV ANT; Njagi JK, 2003, T ROY SOC TROP MED H, V97, P277, DOI 10.1016/S0035-9203(03)90141-6; Njagi JK, 2002, THESIS U NAIROBI; Nwanyanwu OC, 1996, TROP MED INT HEALTH, V1, P231; Obonyo CO, 2003, T ROY SOC TROP MED H, V97, P585, DOI 10.1016/S0035-9203(03)80038-X; Omar SA, 2001, T ROY SOC TROP MED H, V95, P657, DOI 10.1016/S0035-9203(01)90107-5; Parise ME, 1998, AM J TROP MED HYG, V59, P813, DOI 10.4269/ajtmh.1998.59.813; Plowe CV, 2004, BRIT MED J, V328, P545, DOI 10.1136/bmj.37977.653750.EE; Plowe CV, 2001, AM J TROP MED HYG, V64, P242, DOI 10.4269/ajtmh.2001.64.242; SCHULTZ LJ, 1994, AM J TROP MED HYG, V51, P515, DOI 10.4269/ajtmh.1994.51.515; Shulman CE, 1999, LANCET, V353, P632, DOI 10.1016/S0140-6736(98)07318-8; Staedke SG, 2004, TROP MED INT HEALTH, V9, P624, DOI 10.1111/j.1365-3156.2004.01239.x; Ter Kuile FO, 2004, AM J TROP MED HYG, V71, P41, DOI 10.4269/ajtmh.2004.71.41; *UPD SOFTW WEB SIT, 2007, MAL PREGN LIB; *US AG INT DEV, PRES MAL IN; van Dillen J, 1999, T ROY SOC TROP MED H, V93, P185, DOI 10.1016/S0035-9203(99)90304-8; van Eijk AM, 2007, TROP MED INT HEALTH, V12, P342, DOI 10.1111/j.1365-3156.2006.01787.x; White NJ, 2005, PLOS MED, V2, P28, DOI 10.1371/journal.pmed.0020003; WHO, 2005, SUSC PLASM FALC ANT; WHO, 2004, STRAT FRAM MAL PREV; WHO, 2003, ASS MON ANT DRUG EFF; *WHO, 2005, REC US SULF PYR INT; *WHO REG OFF AFR, 1996, ASS THER EFF ANT DRU; *WORLD BANK, 2005, ROLL BANK MAL WORLD; Worrall E, 2007, LANCET INFECT DIS, V7, P156, DOI 10.1016/S1473-3099(07)70027-0; 2003, COCHRANE REV HDB 4 2	47	220	224	1	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 20	2007	297	23					2603	2616		10.1001/jama.297.23.2603	http://dx.doi.org/10.1001/jama.297.23.2603			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180HB	17579229				2022-12-28	WOS:000247352600023
J	Potter, S; Govindarajulu, S; Shere, M; Braddon, F; Curran, G; Greenwood, R; Sahu, AK; Cawthorn, SJ				Potter, Shelley; Govindarajulu, Sasi; Shere, Mike; Braddon, Fiona; Curran, Geoffrey; Greenwood, Rosemary; Sahu, Ajay K.; Cawthorn, Simon J.			Referral patterns, cancer diagnoses, and waiting times after introduction of two week wait rule for breast cancer: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SUSPECTED CANCER; 2-WEEK WAIT; IMPACT	Objective To investigate the long term impact of the two week wait rule for breast cancer on referral patterns, cancer diagnoses, and waiting times. Design Prospective cohort study. Setting A specialist breast clinic in a teaching hospital in Bristol. Participants All patients referred to breast clinic from primary care between 1999 and 2005. Main outcome measures Number, route, and outcome of referrals from primary care and waiting times for urgent and routine appointments. Results The annual number of referrals increased by 9% over the seven years from 3499 in 1999 to 3821 in 2005. Routine referrals decreased by 24% (from 1748 to 1331), but two week wait referrals increased by 42% (from 1751 to 2490) during this time. The percentage of patients diagnosed with cancer in the two week wait group decreased from 12.8% (224/1751) in 1999 to 7.7% (191/2490) in 2005 (P<0.001), while the number of cancers detected in the "routine" group increased from 2.5% (43/1748) to 5.3% (70/1331) (P<0.001) over the same period. About 27% (70/261) of people with cancer are currently referred in the non-urgent group. Waiting times for routine referrals have increased with time. Conclusion The two week wait rule for breast cancer is failing patients. The number of cancers detected in the two week wait population is decreasing, and an unacceptable proportion is now being referred via the routine route. If breast cancer services are to be improved, the two week wait rule should be reviewed urgently.	Frenchay Hosp, Breast Care Ctr, Bristol BS16 1JE, Avon, England; Southmead Hosp, Bristol, Avon, England; United Bristol Healthcare Trust, Res & Dev Unit, Bristol, Avon, England	Southmead Hospital	Cawthorn, SJ (corresponding author), Frenchay Hosp, Breast Care Ctr, Bristol BS16 1JE, Avon, England.	Simon.Cawthorn@nbt.nhs.uk	Potter, Shelley/C-5924-2012	Potter, Shelley/0000-0002-6977-312X				Bray F, 2002, EUR J CANCER, V38, P99, DOI 10.1016/S0959-8049(01)00350-1; Cant PJ, 2000, BRIT J SURG, V87, P1082, DOI 10.1046/j.1365-2168.2000.01551.x; Coates AS, 1999, LANCET, V353, P1112, DOI 10.1016/S0140-6736(99)00082-3; Dodds W, 2004, EUR J CANCER CARE, V13, P82, DOI 10.1111/j.1365-2354.2004.00447.x; Fentiman IS, 2005, INT J CLIN PRACT, V59, P1251, DOI 10.1111/j.1368-5031.2005.00728d.x; Ganz Patricia A., 2000, Breast J, V6, P324, DOI 10.1046/j.1524-4741.2000.20042.x; GRIFFITHS C, 2006, EUR J SURG ONCOL, V32, P1042; Hanna SJ, 2005, INT J CLIN PRACT, V59, P1334, DOI 10.1111/j.1368-5031.2005.00687.x; *HCS, 1998, 1998242 HCS; Jones R, 2001, BRIT MED J, V322, P1555, DOI 10.1136/bmj.322.7302.1555; Khawaja AR, 2000, EUR J SURG ONCOL, V26, P536, DOI 10.1053/ejso.2000.0942; *NAT I CLIN EXC, 2005, NICE GUID REF SUSP C; PAICE A, 2006, EUR J SURG ONCOL, V32, pA1036; PAICE A, 2006, EUR J SURG ONC, V32, P1036; Patel RS, 2000, EUR J SURG ONCOL, V26, P452, DOI 10.1053/ejso.1999.0920; Sauven P, 2001, BRIT MED J, V323, P864; Sauven P, 2002, BREAST, V11, P262, DOI 10.1054/brst.2001.0390	17	76	77	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 11	2007	335	7614					288	290A		10.1136/bmj.39258.688553.55	http://dx.doi.org/10.1136/bmj.39258.688553.55			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	203PV	17631514	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000248987400024
J	Merkle, FT; Mirzadeh, Z; Alvarez-Buylla, A				Merkle, Florian T.; Mirzadeh, Zaman; Alvarez-Buylla, Arturo			Mosaic organization of neural stem cells in the adult brain	SCIENCE			English	Article							OLFACTORY-BULB INTERNEURONS; RADIAL GLIA; NEURONS; GENERATION; FOREBRAIN; ZONE; SUBPOPULATIONS; NEUROGENESIS; PROGENITORS; ASTROCYTES	The in vivo potential of neural stem cells in the postnatal mouse brain is not known, but because they produce many different types of neurons, they must be either very versatile or very diverse. By specifically targeting stem cells and following their progeny in vivo, we showed that postnatal stem cells in different regions produce different types of neurons, even when heterotopically grafted or grown in culture. This suggests that rather than being plastic and homogeneous, neural stem cells are a restricted and diverse population of progenitors.	Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dev & Stem Cell Biol Program, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Alvarez-Buylla, A (corresponding author), Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA.	abuylla@stemcell.ucsf.edu	Merkle, Florian/A-2639-2011	Merkle, Florian/0000-0002-8513-2998; Alvarez-Buylla, Arturo/0000-0003-4426-8925				Anthony TE, 2004, NEURON, V41, P881, DOI 10.1016/S0896-6273(04)00140-0; Campbell K, 2003, CURR OPIN NEUROBIOL, V13, P50, DOI 10.1016/S0959-4388(03)00009-6; De Marchis S, 2007, J NEUROSCI, V27, P657, DOI 10.1523/JNEUROSCI.2870-06.2007; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Doetsch F, 1996, P NATL ACAD SCI USA, V93, P14895, DOI 10.1073/pnas.93.25.14895; Fukushima N, 2002, NEUROSCI RES, V44, P467, DOI 10.1016/S0168-0102(02)00173-6; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gritti A, 2002, J NEUROSCI, V22, P437, DOI 10.1523/JNEUROSCI.22-02-00437.2002; Guillemot F, 2005, CURR OPIN CELL BIOL, V17, P639, DOI 10.1016/j.ceb.2005.09.006; HACK MA, 2005, NAT NEUROSCI; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; Imura T, 2003, J NEUROSCI, V23, P2824; JACOBOWITZ DM, 1991, J COMP NEUROL, V304, P198, DOI 10.1002/cne.903040205; Kohwi M, 2005, J NEUROSCI, V25, P6997, DOI 10.1523/JNEUROSCI.1435-05.2005; KOSAKA K, 1995, NEUROSCI RES, V23, P73, DOI 10.1016/0168-0102(95)00930-R; Merkle FT, 2004, P NATL ACAD SCI USA, V101, P17528, DOI 10.1073/pnas.0407893101; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; Noctor SC, 2002, J NEUROSCI, V22, P3161, DOI 10.1523/JNEUROSCI.22-08-03161.2002; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; PRICE JL, 1970, J CELL SCI, V7, P125; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Rubenstein JLR, 1998, CURR OPIN NEUROBIOL, V8, P18, DOI 10.1016/S0959-4388(98)80004-4; Scheffler B, 2005, P NATL ACAD SCI USA, V102, P9353, DOI 10.1073/pnas.0503965102; Seri B, 2006, CEREB CORTEX, V16, pI103, DOI 10.1093/cercor/bhk027; SHEPHERD GM, 1998, SYNOPATIC ORG BRAIN; Shihabuddin LS, 2000, J NEUROSCI, V20, P8727; Suhonen JO, 1996, NATURE, V383, P624, DOI 10.1038/383624a0; Ventura RE, 2007, J NEUROSCI, V27, P4297, DOI 10.1523/JNEUROSCI.0399-07.2007; Waclaw RR, 2006, NEURON, V49, P503, DOI 10.1016/j.neuron.2006.01.018	29	612	630	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 20	2007	317	5836					381	384		10.1126/science.1144914	http://dx.doi.org/10.1126/science.1144914			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	191RR	17615304				2022-12-28	WOS:000248150200049
J	Atalar, K; Afzali, B; Lams, B; Tungekar, MF; Goldsmith, DJA				Atalar, Kerem; Afzali, Behdad; Lams, Boris; Tungekar, M. Fahim; Goldsmith, David J. A.			Falls, hypokalaemia, and a dry mouth	LANCET			English	Editorial Material							PRIMARY SJOGRENS-SYNDROME; RENAL INVOLVEMENT; REMISSION; THERAPY		Guys Hosp, Dept Nephrol & Transplantat, London SE1 9RT, England; Guys Hosp, Dept Med, London SE1 9RT, England; Guys Hosp, Dept Histopathol, London SE1 9RT, England; St Thomas Hosp, Dept Nephrol & Transplantat, London, England; St Thomas Hosp, Dept Med, London, England; St Thomas Hosp, Dept Histopathol, London, England	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust	Goldsmith, DJA (corresponding author), Guys Hosp, Dept Nephrol & Transplantat, 6th Floor New Guys House, London SE1 9RT, England.	david.goldsmith@gstt.nhs.uk	Afzali, Behdad/H-8565-2013; Goldsmith, David J.A./H-8500-2013	Afzali, Behdad/0000-0003-2968-1156; Atalar, Kerem/0000-0003-2338-8629	Medical Research Council [G0800413, G0500429] Funding Source: Medline; MRC [G0500429] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ELMALLAKH RS, 1985, AM J MED, V79, P509, DOI 10.1016/0002-9343(85)90040-3; Pertovaara M, 1999, RHEUMATOLOGY, V38, P1113, DOI 10.1093/rheumatology/38.11.1113; Ramos-Casals M, 2005, ANN RHEUM DIS, V64, P347, DOI 10.1136/ard.2004.025676; Saeki Y, 2001, CLIN RHEUMATOL, V20, P225, DOI 10.1007/PL00011200	4	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 14	2007	370	9582					192	192		10.1016/S0140-6736(07)61093-9	http://dx.doi.org/10.1016/S0140-6736(07)61093-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	190WP	17630043				2022-12-28	WOS:000248091600034
J	Hickson, M; D'Souza, AL; Muthu, N; Rogers, TR; Want, S; Rajkumar, C; Bulpitt, CJ				Hickson, Mary; D'Souza, Aloysius L.; Muthu, Nirmala; Rogers, Thomas R.; Want, Susan; Rajkumar, Chakravarthi; Bulpitt, Christopher J.			Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							METAANALYSIS; PROPHYLAXIS; CASEI	Objective To determine the efficacy of a probiotic drink containing Lactobacillus for the prevention of any diarrhoea associated with antibiotic use and that caused by Clostridium difficile. Design Randomised double blind placebo controlled study. Participants 135 hospital patients (mean age 74) taking antibiotics. Exclusions included diarrhoea on admission, bowel pathology that could result in diarrhoea, antibiotic use in the previous four weeks, severe illness, immunosuppression, bowel surgery, artificial heart valves, and history of rheumatic heart disease or infective endocarditis. Intervention Consumption of a 100 g (97 ml) drink containing Lactobacillus casei, L bulgaricus, and Streptococcus thermophilus twice a day during a course of antibiotics and for one week after the course finished. The placebo group received a longlife sterile milkshake. Main outcome measures Primary outcome: occurrence of antibiotic associated diarrhoea. Secondary outcome: presence of C difficile toxin and diarrhoea. Results 7/57 (12%) of the probiotic group developed diarrhoea associated with antibiotic use compared with 19/56 (34%) in the placebo group (P=0.007). Logistic regression to control for other factors gave an odds ratio 0.25 (95% confidence interval 0.07 to 0.85) for use of the probiotic, with low albumin and sodium also increasing the risk of diarrhoea. The absolute risk reduction was 21.6% (6.6% to 36.6%), and the number needed to treat was 5 (3 to 15). No one in the probiotic group and 9/53 (17%) in the placebo group had diarrhoea caused by C difficile (P=0.001). The absolute risk reduction was 17% (7% to 27%), and the number needed to treat was 6 (4 to 14). Conclusion Consumption of a probiotic drink containing L casei, L bulgaricus, and S thermophilus reduce the incidence of antibiotic associated diarrhoea and C difficile associated diarrhoea. This has the potential to decrease morbidity, healthcare costs, and mortality if used routinely in patients aged over 50.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Nutr & Dietet Res Grp, London W12 0HS, England; Hillingdon Hosp, Uxbridge, Middx, England; Imperial Coll Sch Med, Fac Med, Dept Infect Dis & Immun, London, England; Hammersmith Hosp NHS Trust, Dept Microbiol, London, England	Imperial College London; Imperial College London; Imperial College London	Hickson, M (corresponding author), Charing Cross Hosp, Dept Nutr & Dietet, London W6 8RF, England.	mhickson@hhnt.nhs.uk	Hickson, Mary/D-3672-2011	Hickson, Mary/0000-0001-7996-0095; Rogers, Thomas/0000-0003-4336-7729				Barbut F, 2001, CLIN MICROBIOL INFEC, V7, P405, DOI 10.1046/j.1198-743x.2001.00289.x; Bergogne-Berezin E, 2000, INT J ANTIMICROB AG, V16, P521, DOI 10.1016/S0924-8579(00)00293-4; Black FT, 1989, TRAVEL MED, V7, P333, DOI DOI 10.1007/978-3-642-73772-5_70; Boyle RJ, 2006, AM J CLIN NUTR, V83, P1256, DOI 10.1093/ajcn/83.6.1256; Cremonini F, 2002, ALIMENT PHARM THER, V16, P1461, DOI 10.1046/j.1365-2036.2002.01318.x; D'Souza AL, 2002, BRIT MED J, V324, P1361, DOI 10.1136/bmj.324.7350.1361; Dunne C, 2001, AM J CLIN NUTR, V73, p386S, DOI 10.1093/ajcn/73.2.386s; FAO/WHO Expert Consultation Group, 2007, HLTH NUTR PROP PROB; GOTZ V, 1979, AM J HOSP PHARM, V36, P754, DOI 10.1093/ajhp/36.6.754; Guarner F, 1998, INT J FOOD MICROBIOL, V39, P237, DOI 10.1016/S0168-1605(97)00136-0; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; Kelly CP, 1998, ANNU REV MED, V49, P375; Kyne L, 2002, CLIN INFECT DIS, V34, P346, DOI 10.1086/338260; LEPLINGARD A, 2003, 9 EUR NUTR C ROM FED; MAJAMAA H, 1995, J PEDIATR GASTR NUTR, V20, P333, DOI 10.1097/00005176-199504000-00012; McFarland LV, 2006, AM J GASTROENTEROL, V101, P812, DOI 10.1111/j.1572-0241.2006.00465.x; Pedone CA, 1999, INT J CLIN PRACT, V53, P179; Pedone CA, 2000, INT J CLIN PRACT, V54, P568; SAAVEDRA JM, 1994, LANCET, V344, P1046, DOI 10.1016/S0140-6736(94)91708-6; Sullivan A, 2005, J INTERN MED, V257, P78, DOI 10.1111/j.1365-2796.2004.01410.x; TANKANOW RM, 1990, DICP ANN PHARMAC, V24, P382, DOI 10.1177/106002809002400408; Wilcox MH, 1996, J HOSP INFECT, V34, P23, DOI 10.1016/S0195-6701(96)90122-X	22	368	399	1	61	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 14	2007	335	7610					80	83		10.1136/bmj.39231.599815.55	http://dx.doi.org/10.1136/bmj.39231.599815.55			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192JM	17604300	Green Submitted, Green Accepted, Green Published, Bronze			2022-12-28	WOS:000248197500033
J	Tesar, PJ; Chenoweth, JG; Brook, FA; Davies, TJ; Evans, EP; Mack, DL; Gardner, RL; McKay, RDG				Tesar, Paul J.; Chenoweth, Josh G.; Brook, Frances A.; Davies, Timothy J.; Evans, Edward P.; Mack, David L.; Gardner, Richard L.; McKay, Ronald D. G.			New cell lines from mouse epiblast share defining features with human embryonic stem cells	NATURE			English	Article							IN-VITRO; CLONAL ANALYSIS; SELF-RENEWAL; GERM-LINE; DIFFERENTIATION; PLURIPOTENCY; ORIGIN; GENOME; DERIVATION; NETWORK	The application of human embryonic stem (ES) cells in medicine and biology has an inherent reliance on understanding the starting cell population. Human ES cells differ from mouse ES cells and the specific embryonic origin of both cell types is unclear. Previous work suggested that mouse ES cells could only be obtained from the embryo before implantation in the uterus(1-5). Here we show that cell lines can be derived from the epiblast, a tissue of the post-implantation embryo that generates the embryo proper. These cells, which we refer to as EpiSCs (post-implantation epiblast-derived stem cells), express transcription factors known to regulate pluripotency, maintain their genomic integrity, and robustly differentiate into the major somatic cell types as well as primordial germ cells. The EpiSC lines are distinct from mouse ES cells in their epigenetic state and the signals controlling their differentiation. Furthermore, EpiSC and human ES cells share patterns of gene expression and signalling responses that normally function in the epiblast. These results show that epiblast cells can be maintained as stable cell lines and interrogated to understand how pluripotent cells generate distinct fates during early development.	NINDS, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Oxford, Dept Zool, Mammalian Dev Lab, Oxford OX1 3PS, England; NCI, Stem Cell Biol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Oxford; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	McKay, RDG (corresponding author), NINDS, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.	paultesar@ninds.nih.gov; mckayr@ninds.nih.gov	Mack, David/AAE-5437-2022; Tesar, Paul/GPK-5942-2022	Tesar, Paul/0000-0003-1532-3155	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002881, ZIANS002881] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wellcome Trust(Wellcome TrustEuropean Commission)		Androutsellis-Theotokis A, 2006, NATURE, V442, P823, DOI 10.1038/nature04940; Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403; BEDDINGTON RS, 1987, ISOLATION CULTURE MA; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Brook FA, 1997, P NATL ACAD SCI USA, V94, P5709, DOI 10.1073/pnas.94.11.5709; Cai JL, 2006, STEM CELLS, V24, P516, DOI 10.1634/stemcells.2005-0143; Camus A, 2006, DEV BIOL, V295, P743, DOI 10.1016/j.ydbio.2006.03.047; Chung Y, 2006, NATURE, V439, P216, DOI 10.1038/nature04277; Daheron L, 2004, STEM CELLS, V22, P770, DOI 10.1634/stemcells.22-5-770; DEOME KB, 1959, CANCER RES, V19, P515; Downs KM, 2006, METH MOLEC MED, V121, P241; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; GARDNER RL, 1985, J EMBRYOL EXP MORPH, V88, P349; GARDNER RL, 1983, INT REV EXP PATHOL, V24, P63; Hayashi K, 2007, SCIENCE, V316, P394, DOI 10.1126/science.1137545; Hirst CE, 2006, DEV BIOL, V293, P90, DOI 10.1016/j.ydbio.2006.01.023; James D, 2005, DEVELOPMENT, V132, P1273, DOI 10.1242/dev.01706; Keller G, 2005, GENE DEV, V19, P1129, DOI 10.1101/gad.1303605; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kubo A, 2004, DEVELOPMENT, V131, P1651, DOI 10.1242/dev.01044; LAWSON KA, 1991, DEVELOPMENT, V113, P891; Lawson KA, 1999, GENE DEV, V13, P424, DOI 10.1101/gad.13.4.424; Liu Y, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-20; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Nagy A., 2003, MANIPULATING MOUSE E; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Ogawa K, 2007, J CELL SCI, V120, P55, DOI 10.1242/jcs.03296; Pelton TA, 2002, J CELL SCI, V115, P329; Robertson E. J., 1987, TERATOCARCINOMAS EMB; Surani MA, 2007, CELL, V128, P747, DOI 10.1016/j.cell.2007.02.010; Tesar PJ, 2005, P NATL ACAD SCI USA, V102, P8239, DOI 10.1073/pnas.0503231102; Vallier L, 2004, DEV BIOL, V275, P403, DOI 10.1016/j.ydbio.2004.08.031; Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284; Yeom YI, 1996, DEVELOPMENT, V122, P881; Yu RN, 1998, NAT GENET, V20, P353, DOI 10.1038/3822; Zvetkova I, 2005, NAT GENET, V37, P1274, DOI 10.1038/ng1663	38	1566	1652	1	138	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 12	2007	448	7150					196	U10		10.1038/nature05972	http://dx.doi.org/10.1038/nature05972			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	188QN	17597760				2022-12-28	WOS:000247934500043
J	Madruga, JV; Berger, D; McMurchie, M; Suter, F; Banhegyi, D; Ruxrungtham, K; Norris, D; Lefebvre, E; de Bethune, MP; Tomaka, F; De Pauw, M; Vangeneugden, T; Spinoso-Guzman, S				Madruga, Jose Valdez; Berger, Daniel; McMurchie, Marilyn; Suter, Fredy; Banhegyi, Denes; Ruxrungtham, Kiat; Norris, Dorece; Lefebvre, Eric; de Bethune, Marie-Pierre; Tomaka, Frank; De Pauw, Martine; Vangeneugden, Tony; Spinoso-Guzman, Sabrina		TITAN Study Grp	Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial	LANCET			English	Article							LOPINAVIR/RITONAVIR; TMC114/RITONAVIR; INHIBITOR; POWER-1	Background The protease inhibitor darunavir has been shown to be efficacious in highly treatment-experienced patients with HIV infection, but needs to be assessed in patients with a broader range of treatment experience. We did a randomised, controlled, phase III trial (TITAN) to compare 48-week efficacy and safety of darunavir-ritonavir with that of lopinavir-ritonavir in treatment-experienced, lopinavir-naive patients. Methods Patients received optimised background regimen plus non-blinded treatment with darunavir-ritonavir 600/100 mg twice daily or lopinavir-ritonavir 400/100 mg twice daily. The primary endpoint was non-inferiority (95% Cl lower limit for the difference in treatment response -12% or greater) for HIV RNA of less than 400 copies per mL in plasma at week 48 (per-protocol analysis). TITAN (TMC114-C214) is registered with ClinicalTrials.gov, number NCT00110877. Findings Of 595 patients randomised and treated, 187 (31%) were protease inhibitor naive; 476 of 582 (82%) were susceptible to four or more protease inhibitors. At week 48, significantly more darunavir-ritonavir than lopinavir-ritonavir patients had HIV RNA of less than 400 copies per mL (77% [220 of 286] vs 68% [199 of 293]; estimated difference 9%, 95% Cl 2-16). Fewer virological failures treated with darunavir-ritonavir than with lopinavir-ritonavir developed primary protease inhibitor mutations (21% [n = 6] vs 36% [n = 20]) and nucleoside analogue-associated mutations (14% [n = 4] vs27% [n = 15]). Safety data were generally similar between the groups; grade 3 or 4 adverse events occurred in 80 (27%) darunavir-ritonavir and 89 (30%) lopinavir-ritonavir patients. Interpretation In lopinavir-naive, treatment-experienced patients, darunavir-ritonavir was non-inferior to lopinavir-ritonavir treatment in terms of our virological endpoint, and should therefore be considered as a treatment option for this population.	Ctr Referencia & Treinamento DST AIDS, Unidade Pesquisa 2, BR-02141000 Sao Paulo, Brazil; Northstar Med Ctr, Chicago, IL USA; Univ Sydney, Sydney, NSW 2006, Australia; Osped Riuniti Bergamo, I-24100 Bergamo, Italy; Szent Laslo Hosp, Budapest, Hungary; Thai Red Cross AIDS Res Ctr, HIVNAT, Bangkok, Thailand; Chulalongkorn Univ, Bangkok, Thailand; Comprehens Res Inst, Tampa, FL USA; Tibotec, Mechelen, Belgium; Tibotec, Yardley, PA USA	University of Sydney; Ospedali Riuniti di Bergamo; Thai Red Cross Society; Chulalongkorn University; Johnson & Johnson; Johnson & Johnson USA	Madruga, JV (corresponding author), Ctr Referencia & Treinamento DST AIDS, Unidade Pesquisa 2, R Santa Cruz,81 Vila Mariana, BR-02141000 Sao Paulo, Brazil.	vaidezmr@uol.com.br						*ABB LAB, 2005, KALETRA LOP RIT PRES; *ABB LAB, 2007, KALETRA LOP RIT PRES; *AIDS CLIN TRIALS, DIV AIDS TABL GRAD S; Benson CA, 2002, J INFECT DIS, V185, P599, DOI 10.1086/339014; Clotet B, 2007, LANCET, V369, P1169, DOI 10.1016/S0140-6736(07)60497-8; DEJESUS E, 2003, 10 C RETR OPP INF; DEMEYER S, 2006, 15 INT HIV DRUG RES; DEMEYER S, 2007, 4 IAS C HIV PATH TRE; ELSADR W, 2006, 16 INT AIDS C; *EUR MED AG, POINTS CONS SWITCH S; *EUR MED AG, INT C HARM TECHN REQ; Gazzard B, 2006, HIV MED, V7, P487, DOI 10.1111/j.1468-1293.2006.00424.x; Hammer SM, 2006, JAMA-J AM MED ASSOC, V296, P827, DOI 10.1001/jama.296.7.827; Haubrich R, 2007, AIDS, V21, pF11, DOI 10.1097/QAD.0b013e3280b07b47; Johnson M, 2005, AIDS, V19, P685, DOI 10.1097/01.aids.0000166091.39317.99; Johnson Victoria A, 2006, Top HIV Med, V14, P125; Katlama C, 2007, AIDS, V21, P395, DOI 10.1097/QAD.0b013e328013d9d7; Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026; Lepri AC, 1998, AIDS, V12, P1639, DOI 10.1097/00002030-199813000-00011; NIETOCISNEROS L, 2003, ANTIVIR THER S, V8, pS212; POLLARD RB, 2004, P 7 INT C DRUG THER; *US DEP HHS, 2006, GUID US ANT AG HIV 1; *US DEP HHS FDA CT, GUID IND ANT DRUGS U	23	256	272	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 7	2007	370	9581					49	58		10.1016/S0140-6736(07)61049-6	http://dx.doi.org/10.1016/S0140-6736(07)61049-6			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187QE	17617272				2022-12-28	WOS:000247862300030
J	Diaconescu, B; Pohl, K; Vattuone, L; Savio, L; Hofmann, P; Silkin, VM; Pitarke, JM; Chulkov, EV; Echenique, PM; Farias, D; Rocca, M				Diaconescu, Bogdan; Pohl, Karsten; Vattuone, Luca; Savio, Letizia; Hofmann, Philip; Silkin, Vyacheslav M.; Pitarke, Jose M.; Chulkov, Eugene V.; Echenique, Pedro M.; Farias, Daniel; Rocca, Mario			Low-energy acoustic plasmons at metal surfaces	NATURE			English	Article							2-DIMENSIONAL PLASMON; ELECTRONIC-STRUCTURE; BE(0001); SYSTEMS; STATE; LIGHT	Nearly two-dimensional (2D) metallic systems formed in charge inversion layers(1) and artificial layered materials(2,3) permit the existence of low-energy collective excitations(4,5), called 2D plasmons, which are not found in a three-dimensional (3D) metal. These excitations have caused considerable interest because their low energy allows them to participate in many dynamical processes involving electrons and phonons(3), and because they might mediate the formation of Cooper pairs in high-transition-temperature superconductors(6). Metals often support electronic states that are confined to the surface, forming a nearly 2D electron-density layer. However, it was argued that these systems could not support low-energy collective excitations because they would be screened out by the underlying bulk electrons(7). Rather, metallic surfaces should support only conventional surface plasmons(8) - higher-energy modes that depend only on the electron density. Surface plasmons have important applications in microscopy(9,10) and sub-wavelength optics(11-13), but have no relevance to the low-energy dynamics. Here we show that, in contrast to expectations, a low-energy collective excitation mode can be found on bare metal surfaces. The mode has an acoustic ( linear) dispersion, different to the q(parallel to)(1/2) dependence of a 2D plasmon, and was observed on Be( 0001) using angle-resolved electron energy loss spectroscopy. First-principles calculations show that it is caused by the coexistence of a partially occupied quasi-2D surface-state band with the underlying 3D bulk electron continuum and also that the non-local character of the dielectric function prevents it from being screened out by the 3D states. The acoustic plasmon reported here has a very general character and should be present on many metal surfaces. Furthermore, its acoustic dispersion allows the confinement of light on small surface areas and in a broad frequency range, which is relevant for nano-optics and photonics applications.	Univ New Hampshire, Dept Phys, Durham, NH 03824 USA; Univ New Hampshire, Mat Sci Program, Durham, NH 03824 USA; Univ Genoa, CNISM, I-16146 Genoa, Italy; Univ Genoa, Dipartimento Fis, I-16146 Genoa, Italy; Univ Aarhus, Inst Storage Ring Facil, DK-8000 Aarhus C, Denmark; Univ Aarhus, Interdisciplinary Nanosci Ctr iNANO, DK-8000 Aarhus C, Denmark; Univ Basque Country, Fac Ciencias Quim, DIPC, Dept Fis Mat, San Sebastian 20018, Spain; Univ Basque Country, Fac Ciencias Quim, Ctr Mixto, CSIC, San Sebastian 20018, Spain; Univ Basque Country, CIC Nanogune Consolider & Mat Kondentsatuaren Fis, E-2009 Donostia San Sebastian, Basque, Spain; Univ Autonoma Madrid, Dept Fis Mat Condensada, E-28049 Madrid, Spain; Univ Genoa, IMEM CNR, I-16146 Genoa, Italy; Univ Genoa, Dipartimento Fis, I-16146 Genoa, Italy	University System Of New Hampshire; University of New Hampshire; University System Of New Hampshire; University of New Hampshire; University of Genoa; University of Genoa; Aarhus University; Aarhus University; University of Basque Country; Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; University of Basque Country; Autonomous University of Madrid; Consiglio Nazionale delle Ricerche (CNR); Istituto dei Materiali per l'Elettronica ed il Magnetismo (IMEM-CNR); University of Genoa; University of Genoa	Pohl, K (corresponding author), Univ New Hampshire, Dept Phys, Durham, NH 03824 USA.	karsten.pohl@unh.edu	Bogdan, Diaconescu/C-8545-2009; Vattuone, Luca/M-1864-2015; Chulkov, Eugeni V./J-5015-2017; Savio, Letizia/B-8323-2015; Rocca, Mario A/J-1802-2016; Farias, Daniel/L-2435-2013; Pohl, Karsten/G-9817-2012; Echenique, Pedro Miguel/AAB-3348-2019; Silkin, Vyacheslav/G-5446-2011; Hofmann, Philip/B-5938-2008; Vattuone, Luca/HDM-5726-2022; Silkin, Vyacheslav M/T-8285-2019; Pitarke, Jose M/C-8602-2009	Vattuone, Luca/0000-0003-3718-6470; Savio, Letizia/0000-0001-7410-0715; Farias, Daniel/0000-0002-8537-8074; Pohl, Karsten/0000-0002-5050-734X; Silkin, Vyacheslav/0000-0002-7840-3868; Hofmann, Philip/0000-0002-7367-5821; Vattuone, Luca/0000-0003-3718-6470; Pitarke, Jose M/0000-0002-3398-8073; Rocca, Mario/0000-0002-5019-745X; nanoGUNE, CIC/0000-0001-7874-5254				Barnes WL, 2003, NATURE, V424, P824, DOI 10.1038/nature01937; BARTYNSKI RA, 1985, PHYS REV B, V32, P1921, DOI 10.1103/PhysRevB.32.1921; Chaplik A. V., 1972, Soviet Physics - JETP, V35, P395; CHULKOV EV, 1987, SURF SCI, V188, P287, DOI 10.1016/S0039-6028(87)80158-9; FLATGEN G, 1995, SCIENCE, V269, P668, DOI 10.1126/science.269.5224.668; HOCHST H, 1977, PHYS LETT A, V60, P69, DOI 10.1016/0375-9601(77)90324-3; KARLSSON UO, 1984, SOLID STATE COMMUN, V49, P711, DOI 10.1016/0038-1098(84)90226-6; Lezec HJ, 2002, SCIENCE, V297, P820, DOI 10.1126/science.1071895; Liebsch A., 1997, ELECT EXCITATIONS ME; March NH, 1995, ADV PHYS, V44, P299, DOI 10.1080/00018739500101546; Nagao T, 2001, PHYS REV LETT, V86, P5747, DOI 10.1103/PhysRevLett.86.5747; Pendry J, 1999, SCIENCE, V285, P1687, DOI 10.1126/science.285.5434.1687; PERSSON BNJ, 1985, PHYS REV B, V31, P1863, DOI 10.1103/PhysRevB.31.1863; Politano A, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.081401; RITCHIE RH, 1957, PHYS REV, V106, P874, DOI 10.1103/PhysRev.106.874; ROCCA M, 1995, SURF SCI REP, V22, P1, DOI 10.1016/0167-5729(95)00004-6; ROCCA M, 1991, REV SCI INSTRUM, V62, P2172, DOI 10.1063/1.1142335; RUVALDS J, 1987, NATURE, V328, P299, DOI 10.1038/328299a0; Sarma S. D., 1981, Physical Review B (Condensed Matter), V23, P805, DOI 10.1103/PhysRevB.23.805; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; Silkin VM, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.115435; Silkin VM, 2004, EUROPHYS LETT, V66, P260, DOI 10.1209/epl/i2003-10184-1; STERN F, 1967, PHYS REV LETT, V18, P546, DOI 10.1103/PhysRevLett.18.546	24	168	169	4	116	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 5	2007	448	7149					57	59		10.1038/nature05975	http://dx.doi.org/10.1038/nature05975			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185OS	17611537				2022-12-28	WOS:000247720900036
J	Gostin, LO				Gostin, Lawrence O.			Why rich countries should care about the world's least healthy people	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							GLOBAL HEALTH; PUBLIC-HEALTH		Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, Washington, DC 20001 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA	Georgetown University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.	gostin@law.georgetown.edu						[Anonymous], 1999, DEV FREEDOM; [Anonymous], BURDEN DIS GLOBAL PO; Bloom DE, 2000, SCIENCE, V287, P1207, DOI 10.1126/science.287.5456.1207; Daniels N, 2006, HASTINGS CENT REP, V36, P22, DOI 10.1353/hcr.2006.0058; Eberstadt N, 2002, FOREIGN AFF, V81, P22, DOI 10.2307/20033342; Esty D, 1998, STATE FAILURE TASK F; Fidler DP, 2002, J LAW MED ETHICS, V30, P150, DOI 10.1111/j.1748-720X.2002.tb00382.x; Fox DM, 2001, AM J PUBLIC HEALTH, V91, P1554, DOI 10.2105/AJPH.91.10.1554; Labonte R, 2007, B WORLD HEALTH ORGAN, V85, P185, DOI 10.2471/BLT.06.037242; Lee K, 2004, JAMA-J AM MED ASSOC, V291, P2636, DOI 10.1001/jama.291.21.2636; MASSEY SM, 2002, RUSSIAS MATERNAL CHI; McNabb SJN, 2002, EMERG INFECT DIS, V8, P1314, DOI 10.3201/eid0811.020402; Nagel T, 2005, PHILOS PUBLIC AFF, V33, P113, DOI 10.1111/j.1088-4963.2005.00027.x; *NEWS ONL BBC, 2000, US AIDS IS SEC THREA; Okie S, 2006, NEW ENGL J MED, V355, P1084, DOI 10.1056/NEJMp068186; Ruger JP, 2006, J EPIDEMIOL COMMUN H, V60, P928, DOI 10.1136/jech.2005.041954; SCHIEBER G, 2006, FINANCE DEV IMF  DEC, V43; Taylor AL, 2004, J LAW MED ETHICS, V32, P500, DOI 10.1111/j.1748-720X.2004.tb00163.x; *UN INT CHILDR EM, STAT WORLDS CHILDR; *UN MILL PROJ, 2005, OV REP PRACT PLAN AC; *WHO, SUBS AFR 2006 AIDS E; World Health Organization, 2006, WORLD HLTH STAT	22	33	33	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 4	2007	298	1					89	92		10.1001/jama.298.1.89	http://dx.doi.org/10.1001/jama.298.1.89			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185OU	17609495				2022-12-28	WOS:000247721100026
J	Karamouzis, MV; Grandis, JR; Argiris, A				Karamouzis, Michalis V.; Grandis, Jennifer R.; Argiris, Athanassios			Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS; PHASE-II TRIAL; GENE COPY NUMBER; SOUTHWEST-ONCOLOGY-GROUP; IN-SITU-HYBRIDIZATION; NECK-CANCER; ESOPHAGEAL CANCER; BRONCHIOLOALVEOLAR-CARCINOMA; GEFITINIB THERAPY	Context Malignancies arising from the aerodigestive epithelium, including lung, head and neck, and esophageal carcinomas, are the leading causes of cancer-related mortality worldwide. Given the biological importance of epidermal growth factor receptor (EGFR) in cancer development and progression, EGFR inhibitors have emerged as promising novel therapies. Objectives To summarize the current status of EGFR inhibitors in aerodigestive carcinomas (ADCs), highlight ongoing research designed to optimize their therapeutic effectiveness, and consider the future role of these agents. Evidence Acquisition Systematic MEDLINE search of English-language literature (1966-April 2007) performed using the terms EGFR, EGFR inhibitors, monoclonal antibodies, tyrosine kinase inhibitors, lung cancer, head and neck cancer, esophageal cancer, and EGFR predictive factors. Quality assessment of selected studies included clinical pertinence, with an emphasis on controlled study design, publication in peer-reviewed journals, adequate number of enrolled patients, objectivity of measurements, and techniques used to minimize bias. Evidence Synthesis The role of EGFR in ADC pathogenesis has been extensively studied, and multiple EGFR inhibition strategies are under evaluation. Erlotinib, an EGFR tyrosine kinase inhibitor used as a single agent, and cetuximab, an anti-EGFR monoclonal antibody used in combination with radiation, have conferred survival benefit in 1 trial of patients with advanced non-small cell lung cancer (median survival, 6.7 vs 4.7 months; hazard ratio, 0.70; 95% confidence interval, 0.58-0.87; P < .001) and in 1 trial of patients with locally advanced head and neck squamous cell carcinoma (median survival, 49 vs 29.3 months; hazard ratio, 0.74; 95% confidence interval, 0.57-0.97; P = .03), respectively. However, other trials have not shown these degrees of improvement. EGFR inhibitors toxicities include rash, diarrhea, and hypomagnesemia. Somatic mutations and other molecular tumoral characteristics offer opportunities for treatment individualization and optimal patient selection for anti-EGFR therapy. Conclusions EGFR is a promising therapeutic target in ADC. Further translational research is needed to optimize ways of inhibiting EGFR using single-agent or combination regimens and to identify patients who benefit the most from these therapies.	Univ Pittsburgh, Inst Canc, Dept Med, Div Hematol Oncol, Pittsburgh, PA 15232 USA; Univ Pittsburgh, Inst Canc, Dept Otolaryngol, Pittsburgh, PA 15232 USA; Univ Pittsburgh, Inst Canc, Head & Neck Canc Program, Pittsburgh, PA 15232 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Argiris, A (corresponding author), Univ Pittsburgh, Inst Canc, Dept Med, Div Hematol Oncol, UPMC Canc Pavil,5th Floor, Pittsburgh, PA 15232 USA.	argirisae@upmc.edu	Karamouzis, Michalis/AAD-2860-2020		NATIONAL CANCER INSTITUTE [P50CA090440, P50CA097190] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA90440-06, P50 CA097190-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABIDOYE OO, 2006, J CLIN ONCOL S, V24, P5568; Adjei AA, 2006, CLIN CANCER RES, V12, p4446S, DOI 10.1158/1078-0432.CCR-06-0623; Akita RW, 2003, SEMIN ONCOL, V30, P15, DOI 10.1016/S0093-7754(03)00187-8; Amador ML, 2004, CANCER RES, V64, P9139, DOI 10.1158/0008-5472.CAN-04-1036; Ang KK, 2002, CANCER RES, V62, P7350; Araujo A, 2007, ONCOLOGIST, V12, P201, DOI 10.1634/theoncologist.12-2-201; Asahina H, 2006, BRIT J CANCER, V95, P998, DOI 10.1038/sj.bjc.6603393; Aviel-Ronen S, 2006, CLIN LUNG CANCER, V8, P30, DOI 10.3816/CLC.2006.n.030; BAILEY LR, 2003, P AM ASSOC CANC RES, pA1362; Baselga J, 2005, J CLIN ONCOL, V23, P5568, DOI 10.1200/JCO.2005.07.119; Baselga J., 2006, J CLIN ONCOL, V24, P3006; Baselga J, 2006, SCIENCE, V312, P1175, DOI 10.1126/science.1125951; Bezjak A, 2006, J CLIN ONCOL, V24, P3831, DOI 10.1200/JCO.2006.05.8073; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Bozec A, 2006, CURR OPIN ONCOL, V18, P330, DOI 10.1097/01.cco.0000228737.78003.06; Brabender J, 2001, CLIN CANCER RES, V7, P1850; Burtness B, 2005, J CLIN ONCOL, V23, P8646, DOI 10.1200/JCO.2005.02.4646; Calvo E, 2007, ANN ONCOL, V18, P761, DOI 10.1093/annonc/mdl495; Calvo E, 2006, J CLIN ONCOL, V24, P2158, DOI 10.1200/JCO.2006.06.5961; Cappuzzo F, 2005, BRIT J CANCER, V93, P1334, DOI 10.1038/sj.bjc.6602865; Cappuzzo F, 2006, ANN ONCOL, V17, P1120, DOI 10.1093/annonc/mdl077; Cappuzzo F, 2005, J CLIN ONCOL, V23, P5007, DOI 10.1200/JCO.2005.09.111; Cappuzzo F, 2005, JNCI-J NATL CANCER I, V97, P643, DOI 10.1093/jnci/dji112; Cappuzzo F, 2004, JNCI-J NATL CANCER I, V96, P1133, DOI 10.1093/jnci/djh217; Carter TA, 2005, P NATL ACAD SCI USA, V102, P11011, DOI 10.1073/pnas.0504952102; Chung CH, 2006, J CLIN ONCOL, V24, P4170, DOI 10.1200/JCO.2006.07.2587; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Cohen EEW, 2003, J CLIN ONCOL, V21, P1980, DOI 10.1200/JCO.2003.10.051; Cohen EEW, 2005, CLIN CANCER RES, V11, P8418, DOI 10.1158/1078-0432.CCR-05-1247; Cohen EEW, 2006, J CLIN ONCOL, V24, P2659, DOI 10.1200/JCO.2005.05.4577; Coppelli FM, 2005, CURR PHARM DESIGN, V11, P2825, DOI 10.2174/1381612054546752; Dobelbower MC, 2006, ANTI-CANCER DRUG, V17, P95, DOI 10.1097/01.cad.0000185178.26862.4c; Dragovich T, 2006, J CLIN ONCOL, V24, P4922, DOI 10.1200/JCO.2006.07.1316; Dziadziuszko R, 2006, CLIN CANCER RES, V12, p4409S, DOI 10.1158/1078-0432.CCR-06-0087; Eberhard DA, 2005, J CLIN ONCOL, V23, P5900, DOI 10.1200/JCO.2005.02.857; FONTANINI G, 1995, EUR J CANCER, V31A, P178, DOI 10.1016/0959-8049(93)00421-M; Frey MR, 2006, EMBO J, V25, P5683, DOI 10.1038/sj.emboj.7601457; Fujino S, 1996, EUR J CANCER, V32A, P2070, DOI 10.1016/S0959-8049(96)00243-2; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Gandara DR, 2005, J CLIN ONCOL, V23, P5856, DOI 10.1200/JCO.2005.05.030; Gatzemeier U, 2007, J CLIN ONCOL, V25, P1545, DOI 10.1200/JCO.2005.05.1474; Giaccone G, 2005, J CLIN ONCOL, V23, P3235, DOI 10.1200/JCO.2005.08.409; Giaccone G, 2004, J CLIN ONCOL, V22, P777, DOI 10.1200/JCO.2004.08.001; Gibault L, 2005, BRIT J CANCER, V93, P107, DOI 10.1038/sj.bjc.6602625; Govindan SV, 2005, TECHNOL CANCER RES T, V4, P375, DOI 10.1177/153303460500400406; GRANDIS JR, 1993, CANCER RES, V53, P3579; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; Guo MZ, 2006, NEW ENGL J MED, V354, P2193, DOI 10.1056/NEJMc052698; Gururaj AE, 2006, CLIN CANCER RES, V12, p1001S, DOI 10.1158/1078-0432.CCR-05-2110; Han SW, 2005, J CLIN ONCOL, V23, P2493, DOI 10.1200/JCO.2005.01.388; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanawa M, 2006, INT J CANCER, V118, P1173, DOI 10.1002/ijc.21454; Hanna N, 2006, J CLIN ONCOL, V24, P5253, DOI 10.1200/JCO.2006.08.2263; Herbst RS, 2004, J CLIN ONCOL, V22, P785, DOI 10.1200/JCO.2004.07.215; Herbst RS, 2005, J CLIN ONCOL, V23, P5892, DOI 10.1200/JCO.2005.02.840; Herbst RS, 2005, J CLIN ONCOL, V23, P5578, DOI 10.1200/JCO.2005.07.120; Heymach JV, 2006, CLIN CANCER RES, V12, p4441S, DOI 10.1158/1078-0432.CCR-06-0286; Hirsch FR, 2005, J CLIN ONCOL, V23, P6838, DOI 10.1200/JCO.2005.01.2823; Hirsch FR, 2003, J CLIN ONCOL, V21, P3798, DOI 10.1200/JCO.2003.11.069; Hirsch FR, 2006, J CLIN ONCOL, V24, P5034, DOI 10.1200/JCO.2006.06.3958; Holmes RS, 2007, SEMIN RADIAT ONCOL, V17, P2, DOI 10.1016/j.semradonc.2006.09.003; Huang SM, 2004, CANCER RES, V64, P5355, DOI 10.1158/0008-5472.CAN-04-0562; Ichihara S, 2007, INT J CANCER, V120, P1239, DOI 10.1002/ijc.22513; Imai K, 2006, NAT REV CANCER, V6, P714, DOI 10.1038/nrc1913; Ingram JL, 2006, CURR MOL MED, V6, P409, DOI 10.2174/156652406777435426; Inoue A, 2006, J CLIN ONCOL, V24, P3340, DOI 10.1200/JCO.2005.05.4692; Isomura M, 2004, J CLIN ONCOL, V22, p200S; Janmaat ML, 2006, J CLIN ONCOL, V24, P1612, DOI 10.1200/JCO.2005.03.4900; Kalyankrishna S, 2006, J CLIN ONCOL, V24, P2666, DOI 10.1200/JCO.2005.04.8306; Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308; Karamouzis MV, 2006, TRENDS MOL MED, V12, P595, DOI 10.1016/j.molmed.2006.10.003; Kawaguchi Y, 2007, INT J CANCER, V120, P781, DOI 10.1002/ijc.22370; Kimura H, 2006, CANCER SCI, V97, P642, DOI 10.1111/j.1349-7006.2006.00216.x; Kirby AM, 2006, BRIT J CANCER, V94, P631, DOI 10.1038/sj.bjc.6602999; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Kulke MH, 2006, J CLIN ONCOL, V24, P401, DOI 10.1200/JCO.2005.03.6046; Kwak EL, 2006, CLIN CANCER RES, V12, P4283, DOI 10.1158/1078-0432.CCR-06-0189; Lacouture ME, 2006, NAT REV CANCER, V6, P803, DOI 10.1038/nrc1970; Leeman RJ, 2006, EXPERT OPIN BIOL TH, V6, P231, DOI 10.1517/14712598.6.3.231; Li J, 2006, JNCI-J NATL CANCER I, V98, P1714, DOI 10.1093/jnci/djj466; Li SQ, 2005, CANCER CELL, V7, P301, DOI 10.1016/j.ccr.2005.03.003; Liu WQ, 2003, CLIN CANCER RES, V9, P1009; Loeffler-Ragy J, 2006, EUR J CANCER, V42, P109, DOI 10.1016/j.ejca.2005.08.034; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Marshall J, 2006, CANCER-AM CANCER SOC, V107, P1207, DOI 10.1002/cncr.22133; Meert AP, 2002, EUR RESPIR J, V20, P975, DOI 10.1183/09031936.02.00296502; Mendelsohn J, 2006, SEMIN ONCOL, V33, P369, DOI 10.1053/j.seminoncol.2006.04.003; Miller VA, 2006, J CLIN ONCOL, V24, p364S; Mitsudomi T, 2005, J CLIN ONCOL, V23, P2513, DOI 10.1200/JCO.2005.00.992; Noro R, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-277; Oliveira S, 2006, EXPERT OPIN BIOL TH, V6, P605, DOI 10.1517/14712598.6.6.605; OZAWA S, 1989, CANCER, V63, P2169, DOI 10.1002/1097-0142(19890601)63:11<2169::AID-CNCR2820631117>3.0.CO;2-W; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, J CLIN ONCOL, V23, P2556, DOI 10.1200/JCO.2005.07.799; Pastorino U, 1997, J CLIN ONCOL, V15, P2858, DOI 10.1200/JCO.1997.15.8.2858; Patel JD, 2004, CRIT REV ONCOL HEMAT, V50, P175, DOI 10.1016/j.critrevonc.2004.02.004; Paz-Ares L, 2006, J CLIN ONCOL, V24, P7020, DOI DOI 10.1200/jco.2006.24.18_suppl.7020; Pedersen MW, 2005, BRIT J CANCER, V93, P915, DOI 10.1038/sj.bjc.6602793; Perez-Soler R, 2005, J CLIN ONCOL, V23, P5235, DOI 10.1200/JCO.2005.00.6916; Perez-Soler R, 2004, J CLIN ONCOL, V22, P3238, DOI 10.1200/JCO.2004.11.057; Pfeiffer P, 1996, BRIT J CANCER, V74, P86, DOI 10.1038/bjc.1996.320; Pfister DG, 2006, J CLIN ONCOL, V24, P1072, DOI 10.1200/JCO.2004.00.1792; Pham DK, 2006, J CLIN ONCOL, V24, P1700, DOI 10.1200/JCO.2005.04.3224; Raz DJ, 2006, CLIN CANCER RES, V12, P3698, DOI 10.1158/1078-0432.CCR-06-0457; RUSCH V, 1993, CANCER RES, V53, P2379; Rusch V, 1997, CLIN CANCER RES, V3, P515; Scagliotti GV, 2004, CLIN CANCER RES, V10, p4227S, DOI 10.1158/1078-0432.CCR-040007; Schrag D, 2005, J NATL CANCER I, V97, P1221, DOI 10.1093/jnci/dji242; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Shigematsu H, 2006, INT J CANCER, V118, P257, DOI 10.1002/ijc.21496; Sok JC, 2006, CLIN CANCER RES, V12, P5064, DOI 10.1158/1078-0432.CCR-06-0913; Solit DB, 2005, CLIN CANCER RES, V11, P1983, DOI 10.1158/1078-0432.CCR-04-1347; Soulieres D, 2004, J CLIN ONCOL, V22, P77, DOI 10.1200/JCO.2004.06.075; Sposto R, 2005, J CLIN ONCOL, V23, p584S; STEWART S, 2007, P AM ASSOC CANC RES, pA3522; Sudo T, 2007, EJSO-EUR J SURG ONC, V33, P44, DOI 10.1016/j.ejso.2006.10.034; Taron M, 2005, CLIN CANCER RES, V11, P5878, DOI 10.1158/1078-0432.CCR-04-2618; Tejpar S, 2007, LANCET ONCOL, V8, P387, DOI 10.1016/S1470-2045(07)70108-0; Thatcher N, 2005, LANCET, V366, P1527, DOI 10.1016/S0140-6736(05)67625-8; Thomas SM, 2003, CANCER RES, V63, P5629; Thomas SM, 2006, CANCER RES, V66, P11831, DOI 10.1158/0008-5472.CAN-06-2876; Toker A, 2006, CANCER RES, V66, P3963, DOI 10.1158/0008-5472.CAN-06-0743; Toschi L, 2007, ONCOLOGIST, V12, P211, DOI 10.1634/theoncologist.12-2-211; Toyooka S, 2006, CANCER RES, V66, P1371, DOI 10.1158/0008-5472.CAN-05-2625; Trigo J, 2004, J CLIN ONCOL, V22, p488S; Tsao M, 2006, J CLIN ONCOL, V24, p365S; Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736; Vermorken JB, 2006, J CLIN ONCOL, V24, P5537; Verreault M, 2006, CURR GENE THER, V6, P505, DOI 10.2174/156652306777934838; Viloria-Petit A, 2001, CANCER RES, V61, P5090; Volm M, 1998, BRIT J CANCER, V77, P663, DOI 10.1038/bjc.1998.106; Wang KL, 2007, CANCER-AM CANCER SOC, V109, P658, DOI 10.1002/cncr.22445; West HL, 2006, J CLIN ONCOL, V24, P1807, DOI 10.1200/JCO.2005.04.9890; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8; Willmore-Payne C, 2006, MODERN PATHOL, V19, P634, DOI 10.1038/modpathol.3800552; Wirth LJ, 2005, J CLIN ONCOL, V23, P6976, DOI 10.1200/JCO.2005.02.4182	138	134	141	1	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 4	2007	298	1					70	82		10.1001/jama.298.1.70	http://dx.doi.org/10.1001/jama.298.1.70			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185OU	17609492	Bronze			2022-12-28	WOS:000247721100023
J	Menon, V; Shlipak, MG; Wang, XL; Coresh, J; Greene, T; Stevens, L; Kusek, JW; Beck, GJ; Collins, AJ; Levey, AS; Sarnak, MJ				Menon, Vandana; Shlipak, Michael G.; Wang, Xuelei; Coresh, Josef; Greene, Tom; Stevens, Lesley; Kusek, John W.; Beck, Gerald J.; Collins, Allan J.; Levey, Andrew S.; Sarnak, Mark J.			Cystatin C as a risk factor for outcomes in chronic kidney disease	ANNALS OF INTERNAL MEDICINE			English	Article							GLOMERULAR-FILTRATION-RATE; CORONARY-HEART-DISEASE; CARDIOVASCULAR OUTCOMES; RENAL DYSFUNCTION; BIOLOGICAL VARIATION; SERUM CREATININE; MARKER; EVENTS; DEATH; INSUFFICIENCY	Background: No study has compared cystatin C level, serum creatinine concentration, and estimated glomerular filtration rate (GFR) as risk factors for outcomes in chronic kidney disease (CKD), and none has compared measured GFR with CKD in any population. Objective: To compare cystatin C level with serum creatinine concentration and iothalamate GFR as risk factors for death and kidney failure. Design: Observational study using serum cystatin C assayed from baseline samples of the Modificztion of Diet in Renal Disease Study (1989-1993). Setting: 15 clinical centers in the United States that participated in the Modification of Diet in Renal Disease Study. Participants: 825 trial participants with stage 3 or 4 nondiabetic CKD who had measurements of serum cystatin C. Measurements: All-cause mortality, cardiovascular (CVD) mortality, and kidney failure until December 2000. Results: Mean cystatin C level, creatinine concentration, and GFR were 2.2 mg/L (SD, 0.7), 212.16 mu mol/L (SD, 88.4) (2.4 mg/dL [SD, 1.0]), and 33 mL/min per 1.73 m(2) (SD, 12), respectively. Median follow-up was 10 years. Twenty-five percent of patients (n = 203) died of any cause, 15% (n = 123) died of CVD, and 66% (n = 548) reached kidney failure. In multivariate-adjusted models, 1-SD decreases in 1/creatinine, GFR, and 1/cystatin C were associated with increased risks for all-cause mortality of 1.27 (95% Cl, 1.06 to 1.49), 1.27 (Cl, 1.08 to 1.49), and 1.41 (Cl, 1.18 to 1.67), respectively. For CVD mortality, the increased risks were 1.32 (Cl, 1.05 to 1.64), 1.28 (Cl, 1.04 to 1.59), and 1.64 (Cl, 1.28 to 2.08), respectively. For kidney failure, the increased risks were 2.81 (Cl, 2.48 to 3.18), 2.41 (Cl, 2.15 to 2.70), and 2.36 (Cl, 2.10 to 2.66), respectively. Limitation: The Modification of Diet in Renal Disease Study cohort may not be representative of all patients with nondiabetic CKD because participants were more likely to reach kidney failure than death in follow-up. Conclusion: The association of cystatin C level with all-cause and CVD mortality was as strong as or perhaps stronger than that of iothalamate GFR with these outcomes in stage 3 or 4 CKD.	Tufts Univ, New England Med Ctr, Div Nephrol, Boston, MA 02111 USA; Vet Affairs Med Ctr, San Francisco, CA 94121 USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; NIH, Bethesda, MD 20892 USA; Univ Utah, Salt Lake City, UT USA; Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA	Tufts Medical Center; Tufts University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cleveland Clinic Foundation; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; National Institutes of Health (NIH) - USA; Utah System of Higher Education; University of Utah; Hennepin County Medical Center	Sarnak, MJ (corresponding author), Tufts Univ, New England Med Ctr, Div Nephrol, 750 Washington St,391, Boston, MA 02111 USA.	msarnak@tufts-nemc.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073208] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK053869, R01DK066488, R01DK053869, K23DK002904, K23DK067303, U01DK035073] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL073208-01] Funding Source: Medline; NIDDK NIH HHS [R01 DK066488-01, UO1 DK 35073, DK53869-05, K23 DK067303, K23 DK02904] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albert MA, 2001, VASC MED, V6, P145, DOI 10.1177/1358836X0100600304; Anavekar NS, 2004, NEW ENGL J MED, V351, P1285, DOI 10.1056/NEJMoa041365; Apperloo AJ, 1996, J AM SOC NEPHROL, V7, P567; Coll E, 2000, AM J KIDNEY DIS, V36, P29, DOI 10.1053/ajkd.2000.8237; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; Fliser D, 2001, AM J KIDNEY DIS, V37, P79, DOI 10.1053/ajkd.2001.20591; Fried LF, 2003, J AM COLL CARDIOL, V41, P1364, DOI 10.1016/S0735-1097(03)00163-3; Galteau MM, 2001, CLIN CHEM LAB MED, V39, P850, DOI 10.1515/CCLM.2001.141; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; GREENE T, 1993, J AM SOC NEPHROL, V4, P1221; Herget-Rosenthal S, 2000, AM J NEPHROL, V20, P97, DOI 10.1159/000013564; Hoek FJ, 2003, NEPHROL DIAL TRANSPL, V18, P2024, DOI 10.1093/ndt/gfg349; Hsu CY, 2002, KIDNEY INT, V61, P1567, DOI 10.1046/j.1523-1755.2002.00299.x; Jernberg T, 2004, CIRCULATION, V110, P2342, DOI 10.1161/01.CIR.0000145166.44942.E0; Keevil BG, 1998, CLIN CHEM, V44, P1535; Knight EL, 2004, KIDNEY INT, V65, P1416, DOI 10.1111/j.1523-1755.2004.00517.x; Koenig W, 2005, CLIN CHEM, V51, P321, DOI 10.1373/clinchem.2004.041889; KYHSEANDERSEN J, 1994, CLIN CHEM, V40, P1921; Larsson A, 2005, SCAND J CLIN LAB INV, V65, P301, DOI 10.1080/00365510510013839; LEVEY AS, 1993, J AM SOC NEPHROL, V4, P1159; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Lloyd-Jones DM, 2006, ANN INTERN MED, V145, P35, DOI 10.7326/0003-4819-145-1-200607040-00129; Luc G, 2006, ATHEROSCLEROSIS, V185, P375, DOI 10.1016/j.atherosclerosis.2005.06.017; Manjunath G, 2003, J AM COLL CARDIOL, V41, P47, DOI 10.1016/S0735-1097(02)02663-3; Muntner P, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133745; NEWMAN DJ, 1995, KIDNEY INT, V47, P312, DOI 10.1038/ki.1995.40; O'Hare AM, 2005, ARCH INTERN MED, V165, P2666, DOI 10.1001/archinte.165.22.2666; O'Riordan SE, 2003, ANN CLIN BIOCHEM, V40, P648, DOI 10.1258/000456303770367243; Oddoze C, 2001, AM J KIDNEY DIS, V38, P310, DOI 10.1053/ajkd.2001.26096; Perkins BA, 2005, J AM SOC NEPHROL, V16, P1404, DOI 10.1681/ASN.2004100854; Rahman M, 2006, ANN INTERN MED, V144, P172, DOI 10.7326/0003-4819-144-3-200602070-00005; Randers E, 1998, SCAND J CLIN LAB INV, V58, P585, DOI 10.1080/00365519850186210; Rule AD, 2006, KIDNEY INT, V69, P399, DOI 10.1038/sj.ki.5000073; SAMAK MJ, 2003, CIRCULATION, V108, P2154; Sarnak MJ, 2005, ANN INTERN MED, V142, P497, DOI 10.7326/0003-4819-142-7-200504050-00008; SHEMESH O, 1985, KIDNEY INT, V28, P830, DOI 10.1038/ki.1985.205; Shlipak MG, 2005, NEW ENGL J MED, V352, P2049, DOI 10.1056/NEJMoa043161; Shlipak Michael G, 2005, Am J Med, V118, P1416; Shlipak MG, 2006, ANN INTERN MED, V145, P237, DOI 10.7326/0003-4819-145-4-200608150-00003; Shlipak Michael G, 2004, Am J Geriatr Cardiol, V13, P81, DOI 10.1111/j.1076-7460.2004.02125.x; Shlipak MG, 2006, J AM SOC NEPHROL, V17, P254, DOI 10.1681/ASN.2005050545; Tan GD, 2002, DIABETES CARE, V25, P2004, DOI 10.2337/diacare.25.11.2004; Van Den Noortgate NJ, 2002, J AM GERIATR SOC, V50, P1278, DOI 10.1046/j.1532-5415.2002.50317.x	43	150	156	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2007	147	1					19	27		10.7326/0003-4819-147-1-200707030-00004	http://dx.doi.org/10.7326/0003-4819-147-1-200707030-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186MN	17606957				2022-12-28	WOS:000247782900003
J	Novara, G; Artibani, W				Novara, Giacomo; Artibani, Walter			Myoblasts and fibroblasts in stress urinary incontinence	LANCET			English	Editorial Material							WOMEN		Univ Padua, Urol Clin, Dept Oncol & Surg Sci, Padua, Italy; IRCCS Inst Oncol Veneto, I-35128 Padua, Italy	IRCCS Istituto Oncologico Veneto (IOV); University of Padua; IRCCS Istituto Oncologico Veneto (IOV)	Novara, G (corresponding author), Univ Padua, Urol Clin, Dept Oncol & Surg Sci, Padua, Italy.	giacomonovara@libero.it	Novara, Giacomo/A-5054-2018	Novara, Giacomo/0000-0003-4693-5058				Daneshgari F, 2006, BJU INT, V98, P8, DOI 10.1111/j.1464-410X.2006.06365.x; DELANCEY JOL, 1994, AM J OBSTET GYNECOL, V170, P1713, DOI 10.1016/S0002-9378(12)91840-2; Diokno AC, 2003, J UROLOGY, V170, P507, DOI 10.1097/01.ju.0000070404.24755.35; ENHORNING G, 1961, Acta Chir Scand Suppl, VSuppl 276, P1; Luber KM, 2001, AM J OBSTET GYNECOL, V184, P1496, DOI 10.1067/mob.2001.114868; MCGUIRE EJ, 1993, J UROLOGY, V150, P1452, DOI 10.1016/S0022-5347(17)35806-8; Petros PEP, 1990, ACTA OBSTET GYN SCAN, V69, P7, DOI 10.1111/j.1600-0412.1990.tb08027.x; Strasser H, 2007, LANCET, V369, P2179, DOI 10.1016/S0140-6736(07)61014-9; Ulmsten U, 1996, Int Urogynecol J Pelvic Floor Dysfunct, V7, P81, DOI 10.1007/BF01902378	9	9	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 30	2007	369	9580					2139	2140		10.1016/S0140-6736(07)60990-8	http://dx.doi.org/10.1016/S0140-6736(07)60990-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LX	17604781				2022-12-28	WOS:000247644200006
J	Spiegel, PB; Bennedsen, AR; Claass, J; Bruns, L; Patterson, N; Yiweza, D; Schilperoord, M				Spiegel, Paul B.; Rygaard Bennedsen, Anne; Claass, Johanna; Bruns, Laurie; Patterson, Njogu; Yiweza, Dieudonne; Schilperoord, Marian			Prevalence of HIV infection in conflict-affected and displaced people in seven sub-Saharan African countries: a systematic review	LANCET			English	Article							PREGNANT-WOMEN; POPULATIONS; PREVENTION; AIDS; WAR; SEROPOSITIVITY; SURVEILLANCE; TRANSMISSION; PROPHYLAXIS; ANTIBODIES	Background Violence and rape are believed to fuel the HIV epidemic in countries affected by conflict. We compared HIV prevalence in populations directly affected by conflict with that in those not directly affected and in refugees versus the nearest surrounding host communities in sub-Saharan African countries. Methods Seven countries affected by conflict (Democratic Republic of Congo, southern Sudan, Rwanda, Uganda, Sierra Leone, Somalia, and Burundi) were chosen since HIV prevalence surveys within the past 5 years had been done and data, including original antenatal-care sentinel surveillance data, were available. We did a systematic and comprehensive literature search using Medline and Embase. Only articles and reports that contained original data for prevalence of HIV infection were included. All survey reports were independently evaluated by two epidemiologists to assess internationally accepted guidelines for HIV sentinel surveillance and population-based surveys. Whenever possible, data from the nearest antenatal care and host country sentinel site of the neighbouring countries were presented. 95% CIs were provided when available. Findings Of the 295 articles that met our search criteria, 88 had original prevalence data and 65 had data from the seven selected countries. Data from these countries did not show an increase in prevalence of HIV infection during periods of conflict, irrespective of prevalence when conflict began. Prevalence in urban areas affected by conflict decreased in Burundi, Rwanda, and Uganda at similar rates to urban areas unaffected by conflict in their respective countries. Prevalence in conflict-affected rural areas remained low and fairly stable in these countries. Of the 12 sets of refugee camps, nine had a lower prevalence of HIV infection, two a similar prevalence, and one a higher prevalence than their respective host communities. Despite wide-scale rape in many countries, there are no data to show that rape increased prevalence of HIV infection at the population level. Interpretation We have shown that there is a need for mechanisms to provide time-sensitive information on the effect of conflict on incidence of HIV infection, since we found insufficient data to support the assertions that conflict, forced displacement, and wide-scale rape increase prevalence or that refugees spread HIV infection in host communities.	UN, CH-1202 Geneva, Switzerland; Univ Copenhagen, Copenhagen, Denmark	University of Copenhagen	Spiegel, PB (corresponding author), UN, 94 Rue Montbrillant, CH-1202 Geneva, Switzerland.	SPIEGEL@unhcr.org	Spiegel, Paul/AAL-3238-2021	Spiegel, Paul/0000-0002-6158-6661				ADEN O, 1987, AIDS, V1, P257; Allen T, 2006, J BIOSOC SCI, V38, P7, DOI 10.1017/S0021932005001008; *AMN INT, MASS RAP TIM REM; Amowitz LL, 2002, JAMA-J AM MED ASSOC, V287, P513, DOI 10.1001/jama.287.4.513; Asamoah-Odei E, 2004, LANCET, V364, P35, DOI 10.1016/S0140-6736(04)16587-2; *AVEGA, ASS GEN WID; Bamberger JD, 1999, AM J MED, V106, P323, DOI 10.1016/S0002-9343(99)00018-2; Boerma JT, 2003, LANCET, V362, P1929, DOI 10.1016/S0140-6736(03)14967-7; Brown T, 2006, SEX TRANSM INFECT, V82, pIII34, DOI 10.1136/sti.2006.020230; Buve A, 2002, LANCET, V359, P2011, DOI 10.1016/S0140-6736(02)08823-2; CARBALLO M, 2001, HIV AIDS CONFLICT RE; CIANTIA F, 2004, J MED PERSON, V2, P172; *CONS NAT LUTT SID, 2006, RWAND DEM HLTH SURV; Donovan P, 2002, LANCET, V360, pS17, DOI 10.1016/S0140-6736(02)11804-6; Fabiani M, 2006, T ROY SOC TROP MED H, V100, P586, DOI 10.1016/j.trstmh.2005.09.002; GHYS PD, 2006, SEX TRANSM INFECT S3, V82, P1; GOSTIN LO, 1994, JAMA-J AM MED ASSOC, V271, P1436, DOI 10.1001/jama.271.18.1436; Grassly NC, 2004, SEX TRANSM INFECT, V80, DOI 10.1136/sti.2004.010637; Hankins CA, 2002, AIDS, V16, P2245, DOI 10.1097/00002030-200211220-00003; Hierholzer M, 2002, AIDS RES HUM RETROV, V18, P1163, DOI 10.1089/088922202320567923; Holt BY, 2003, DISASTERS, V27, P1, DOI 10.1111/1467-7717.00216; Hooper Edward, 1999, RIVER JOURNEY SOURCE; Human Security Centre, 2005, HUM SEC REP 2005 WAR; *IRC CDC, 2002, KAK REF CAMP SENT SU; Joint United Nations Program on AIDS/ World Health Organization (UNAIDS/WHO), 2003, GUID COND HIV SENT S; Joint United Nations Programme on HIV/AIDS (UNAIDS), JOINT UN PROGR HIV A; Kaiser R, 2006, AIDS, V20, P942, DOI 10.1097/01.aids.0000218564.20521.51; KAISER R, 2002, HIV SEROPREVALENCE B; KAMBALE L, 2001, STUDY HIV AIDS PREVA; KAYIRANGWA E, 2003, SEX TRANSM INFECT S1, V82, P27; Lemey P, 2003, P NATL ACAD SCI USA, V100, P6588, DOI 10.1073/pnas.0936469100; LEROY V, 1995, LANCET, V346, P1488, DOI 10.1016/S0140-6736(95)92504-X; MCCARTHY MC, 1989, AM J TROP MED HYG, V41, P726, DOI 10.4269/ajtmh.1989.41.726; MCCARTHY MC, 1995, J MED VIROL, V46, P18, DOI 10.1002/jmv.1890460105; McGinn T., 2001, FORCED MIGRATION TRA; *MIN HLTH GUIN USA, 2001, NAT HIV SER STUD GOG; *MIN HLTH KEN, 2005, AIDS KEN TRENDS INT; *MIN HLTH RWAND, 2005, RWAND DEM HLTH SURV; *MIN HLTH SUD, 2005, ANN REP SUD NAT HIV; *MIN HLTH TANZ, HIV AIDS IND SURV 20; *MIN HLTH UG, 2004, HIV AIDSD SER SURV; *MIN HLTH UG, 2003, STD HIV AIDS SURV RE; Mock Nancy B, 2004, Emerg Themes Epidemiol, V1, P6, DOI 10.1186/1742-7622-1-6; *MOH SUD, 2002, SNAP SIT AN BEH EP S; Morris CN, 2006, SEX TRANSM INFECT, V82, P368, DOI 10.1136/sti.2006.020933; MUJAWAYO E, 1999, SIL EM SEM LOND LOND; Mulanga C, 2004, AIDS, V18, P832, DOI 10.1097/00002030-200403260-00024; Mulanga-Kabeya C, 1998, AIDS, V12, P905, DOI 10.1097/00002030-199808000-00013; *NAT AIDS CONTR PR, 1997, NAT POP BAS SER; *NAT HIV SECR MIN, 2005, NAT POP BAS HIV SER; Nur YA, 2000, EPIDEMIOL INFECT, V124, P137, DOI 10.1017/S0950268899003441; Poulsen AG, 2000, SCAND J INFECT DIS, V32, P169, DOI 10.1080/003655400750045286; *PROGR NAT LUTT VI, 2003, RAPP PASS SURV SENT; Rey JL, 1996, B SOC PATHOL EXOT, V89, P204; *RWAND HIV SER STU, 1989, LANCET, V333, P941; Salama P, 2001, AIDS, V15, pS4, DOI 10.1097/00002030-200104003-00002; *SAV CHILDR, 2002, HIV CONFL DOUBL EM; SCOTT DA, 1991, AM J TROP MED HYG, V45, P653, DOI 10.4269/ajtmh.1991.45.653; SMALLMANRAYNOR MR, 1991, EPIDEMIOL INFECT, V107, P69, DOI 10.1017/S095026880004869X; SMITH A, 2002, NETWORK HPN PAPER, V38, P1; SPIEGEL P, 2005, HIV AIDS INTERNALLY; Spiegel PB, 2004, DISASTERS, V28, P322, DOI 10.1111/j.0361-3666.2004.00261.x; Swiss S, 1998, JAMA-J AM MED ASSOC, V279, P625, DOI 10.1001/jama.279.8.625; TITTI F, 1986, AIDS RES HUM RETROV, V2, P161, DOI 10.1089/aid.1.1986.2.161; *TREATM RES AIDS C, 2002, HIV SENT SURV PREGN; *TROP DIS RES CTR, 2005, NAT SENT SURV HIV SY; *UNAIDS, AIDS AFR COUNTR COUN; *UNAIDS, 2004, AIDS CONFL GROW PROB, P175; *UNAIDS, 1998, AIDS EP UPD DEC 1998; *UNAIDS WHO, 2005, GUID MEAS NAT HIV PR; *UNAIDS WHO, 2004, AIDS EP UPD, P1; *UNHCR, 2003, W TANZ REF CAMPS HIV; UNHCR, 2003, NAT AIDS SEX TRANSM; *UNHCR, 2002, HIV SENT SURV REF CA; UNHCR, 2005, NAT AIDS SEX TRANSM; *UNHCR, 2006, HIV SENT SURV REP 2; *UNHCR AMREF, 2001, PROJ EXP HIV AIDS AC; *UNHCR UNAIDS, 2003, HIV AIDS STI PREV CA; *WHO ZON AUTH WORL, 2005, SOM 2004 1 NAT 2 GEN; World Health Organization, 2005, WHO MULT STUD WOM HL; 1998, AIDS ANAL AFR, V8, P13; [No title captured]	82	138	139	1	37	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 30	2007	369	9580					2187	2195		10.1016/S0140-6736(07)61015-0	http://dx.doi.org/10.1016/S0140-6736(07)61015-0			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184LX	17604801				2022-12-28	WOS:000247644200030
J	Griffin, BM; Schott, J; Schink, B				Griffin, Benjamin M.; Schott, Joachim; Schink, Bernhard			Nitrite, an electron donor for anoxygenic photosynthesis	SCIENCE			English	Article									Univ Konstanz, Dept Biol, D-78457 Constance, Germany	University of Konstanz	Griffin, BM (corresponding author), Univ Illinois, Inst Genom Biol, Urbana, IL 61801 USA.	griff113@uiuc.edu						CUSANOVI.MA, 1968, BIOCHIM BIOPHYS ACTA, V153, P397, DOI 10.1016/0005-2728(68)90083-2; Imhoff J.F., 1995, ANOXYGENIC PHOTOSYNT, P1, DOI DOI 10.1007/0-306-47954-0_1; IMHOFF JF, 2006, PROKARYOTES, V6, P846; OLSON JM, 1970, SCIENCE, V168, P438, DOI 10.1126/science.168.3930.438; Visscher P.T., 2003, BIOGEOCHEMISTRY, V8, P317, DOI DOI 10.1016/B0-08-043751-6/08132-9	5	62	71	5	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 29	2007	316	5833					1870	1870		10.1126/science.1139478	http://dx.doi.org/10.1126/science.1139478			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	183WI	17600210				2022-12-28	WOS:000247602700030
J	Chadee, DD; Kittayapong, P; Morrison, AC; Tabachnick, WJ				Chadee, Dave D.; Kittayapong, Pattamaporn; Morrison, Amy C.; Tabachnick, Walter J.			A breakthrough for global public health	SCIENCE			English	Editorial Material							GENOME SEQUENCE; ANOPHELES-GAMBIAE; MALARIA; MOSQUITOS		Univ W Indies, Dept Life Sci, St Augustine, Trinidad Tobago; Mahidol Univ, Fac Sci, Ctr Vectors & Vector Borne Dis, Bangkok 10400, Thailand; Mahidol Univ, Fac Sci, Dept Biol, Bangkok 10400, Thailand; Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA; Univ Florida, Inst Food & Agr Sci, Florida Med Entomol Lab, Dept Entomol & Nematol, Vero Beach, FL 32962 USA	University West Indies Mona Jamaica; University West Indies Saint Augustine; Mahidol University; Mahidol University; University of California System; University of California Davis; State University System of Florida; University of Florida	Chadee, DD (corresponding author), Univ W Indies, Dept Life Sci, St Augustine, Trinidad Tobago.	dchadee@fsa.uwi.tt; grpkt@mahidol.ac.th; amy.aegypti@gmail.com; wjt@ufl.edu	Morrison, Amy/AAU-6511-2020	Morrison, Amy/0000-0001-6224-5984				Bennett KE, 2005, GENETICS, V170, P185, DOI 10.1534/genetics.104.035634; Chadee DD, 2005, TROP MED INT HEALTH, V10, P748, DOI 10.1111/j.1365-3156.2005.01449.x; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; James AA, 2005, TRENDS PARASITOL, V21, P64, DOI 10.1016/j.pt.2004.11.004; Justice RW, 2003, BIOESSAYS, V25, P1011, DOI 10.1002/bies.10331; Morel CM, 2002, SCIENCE, V298, P79, DOI 10.1126/science.1078047; Nene V, 2007, SCIENCE, V316, P1718, DOI 10.1126/science.1138878; Riehle MM, 2006, SCIENCE, V312, P577, DOI 10.1126/science.1124153; Sinkins SP, 2004, INSECT BIOCHEM MOLEC, V34, P723, DOI 10.1016/j.ibmb.2004.03.025; TABACHNICK W J, 1991, American Entomologist, V37, P14; Tabachnick WJ, 2003, J MED ENTOMOL, V40, P597, DOI 10.1603/0022-2585-40.5.597; *WHO, 2002, FACT SHEET 117	12	3	4	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 22	2007	316	5832					1703	1704		10.1126/science.1138904	http://dx.doi.org/10.1126/science.1138904			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180XE	17588917				2022-12-28	WOS:000247400500030
J	Maherali, H; Klironomos, JN				Maherali, Hafiz; Klironomos, John N.			Influence of Phylogeny on fungal community assembly and ecosystem functioning	SCIENCE			English	Article							PLANT-COMMUNITIES; CURRENT KNOWLEDGE; BIODIVERSITY; NICHE; EVOLUTION; ECOLOGY; PRODUCTIVITY; CONSERVATISM; CONVERGENCE	Ecology seeks to explain species coexistence and its functional consequences, but experimental tests of mechanisms that simultaneously account for both processes are difficult. We used an experimental mycorrhizal plant system to test whether functional similarity among closely related species (phylogenetic conservatism) can drive community assembly and ecosystem functioning. Communities were constructed with the same number of fungal species, but after 1 year of growth, realized species richness was highest where the starting species were more distantly related to each other. Communities with high realized species richness also stimulated plant productivity more than those with low realized species richness. Our findings suggest that phylogenetic trait conservatism can promote coexistence because of reduced competition between distinct evolutionary lineages and enhance ecosystem function because of functional complementarity among those same lineages.	Univ Guelph, Dept Integrat Biol, Guelph, ON N1G 2W1, Canada	University of Guelph	Maherali, H (corresponding author), Univ Guelph, Dept Integrat Biol, Guelph, ON N1G 2W1, Canada.	maherali@uoguelph.ca; jklirono@uoguelph.ca						Ackerly DD, 2006, ECOLOGY, V87, pS50, DOI 10.1890/0012-9658(2006)87[50:NEAART]2.0.CO;2; Ackerly DD, 2004, AM NAT, V163, P654, DOI 10.1086/383062; Anderson TM, 2004, AM NAT, V164, P709, DOI 10.1086/425372; [Anonymous], 1861, ORIGIN SPECIES MEANS; Cavender-Bares J, 2004, AM NAT, V163, P823, DOI 10.1086/386375; ELTON C, 1946, J ANIM ECOL, V15, P54, DOI 10.2307/1625; Forest F, 2007, NATURE, V445, P757, DOI 10.1038/nature05587; Hart MM, 2002, NEW PHYTOL, V153, P335, DOI 10.1046/j.0028-646X.2001.00312.x; Hooper DU, 2005, ECOL MONOGR, V75, P3, DOI 10.1890/04-0922; Hubbell Stephen P., 2001, V32, pi; Huston MA, 1997, OECOLOGIA, V110, P449, DOI 10.1007/s004420050180; Lekberg Y, 2007, J ECOL, V95, P95, DOI 10.1111/j.1365-2745.2006.01193.x; Loreau M, 2001, NATURE, V412, P72, DOI 10.1038/35083573; Loreau M, 2001, SCIENCE, V294, P804, DOI 10.1126/science.1064088; Losos JB, 2003, NATURE, V424, P542, DOI 10.1038/nature01814; MACARTHUR R, 1967, AM NAT, V101, P377, DOI 10.1086/282505; NEWSHAM KK, 1995, TRENDS ECOL EVOL, V10, P407, DOI 10.1016/S0169-5347(00)89157-0; Peterson AT, 1999, SCIENCE, V285, P1265, DOI 10.1126/science.285.5431.1265; Pfisterer AB, 2004, BASIC APPL ECOL, V5, P5, DOI 10.1078/1439-1791-00215; Prinzing A, 2001, P ROY SOC B-BIOL SCI, V268, P2383, DOI 10.1098/rspb.2001.1801; Schmid B, 2002, MG POP BIOL, V33, P120; Schussler A, 2001, MYCOL RES, V105, P1413, DOI 10.1017/S0953756201005196; Silvertown J, 2006, P ROY SOC B-BIOL SCI, V273, P39, DOI 10.1098/rspb.2005.3288; Silvertown J, 2004, TRENDS ECOL EVOL, V19, P605, DOI 10.1016/j.tree.2004.09.003; Strauss SY, 2006, P NATL ACAD SCI USA, V103, P5841, DOI 10.1073/pnas.0508073103; Swenson NG, 2006, ECOLOGY, V87, P2418, DOI 10.1890/0012-9658(2006)87[2418:TPAPOS]2.0.CO;2; Tofts R, 2000, P ROY SOC B-BIOL SCI, V267, P363, DOI 10.1098/rspb.2000.1010; van der Heijden MGA, 2007, NEW PHYTOL, V174, P244, DOI 10.1111/j.1469-8137.2007.02041.x; van der Heijden MGA, 1998, NATURE, V396, P69, DOI 10.1038/23932; Wardle DA, 1999, OIKOS, V87, P403, DOI 10.2307/3546757; Webb CO, 2002, ANNU REV ECOL SYST, V33, P475, DOI 10.1146/annurev.ecolsys.33.010802.150448; Webb CO, 2000, AM NAT, V156, P145, DOI 10.1086/303378; WEIHER E, 1995, OIKOS, V73, P323, DOI 10.2307/3545956; Weiher E., 1999, ECOLOGICAL ASSEMBLY, DOI DOI 10.1017/CBO9780511542237; WINSTON MR, 1995, AM NAT, V145, P527, DOI 10.1086/285754; Zavaleta ES, 2004, SCIENCE, V306, P1175, DOI 10.1126/science.1102643	36	643	673	18	410	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 22	2007	316	5832					1746	1748		10.1126/science.1143082	http://dx.doi.org/10.1126/science.1143082			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180XE	17588930				2022-12-28	WOS:000247400500047
J	Waterhouse, RM; Kriventseva, EV; Meister, S; Xi, ZY; Alvarez, KS; Bartholomay, LC; Barillas-Mury, C; Bian, GW; Blandin, S; Christensen, BM; Dong, YM; Jiang, HB; Kanost, MR; Koutsos, AC; Levashina, EA; Li, JY; Ligoxygakis, P; MacCallum, RM; Mayhew, GF; Mendes, A; Michel, K; Osta, MA; Paskewitz, S; Shin, SW; Vlachou, D; Wang, LH; Wei, WQ; Zheng, LB; Zou, Z; Severson, DW; Raikhel, AS; Kafatos, FC; Dimopoulos, G; Zdobnov, EM; Christophides, GK				Waterhouse, Robert M.; Kriventseva, Evgenia V.; Meister, Stephan; Xi, Zhiyong; Alvarez, Kanwal S.; Bartholomay, Lyric C.; Barillas-Mury, Carolina; Bian, Guowu; Blandin, Stephanie; Christensen, Bruce M.; Dong, Yuemei; Jiang, Haobo; Kanost, Michael R.; Koutsos, Anastasios C.; Levashina, Elena A.; Li, Jianyong; Ligoxygakis, Petros; MacCallum, Robert M.; Mayhew, George F.; Mendes, Antonio; Michel, Kristin; Osta, Mike A.; Paskewitz, Susan; Shin, Sang Woon; Vlachou, Dina; Wang, Lihui; Wei, Weiqi; Zheng, Liangbiao; Zou, Zhen; Severson, David W.; Raikhel, Alexander S.; Kafatos, Fotis C.; Dimopoulos, George; Zdobnov, Evgeny M.; Christophides, George K.			Evolutionary dynamics of immune-related genes and pathways in disease-vector mosquitoes	SCIENCE			English	Article							ANOPHELES-GAMBIAE; DROSOPHILA-MELANOGASTER; SERINE PROTEASES; ANTIVIRAL RESPONSE; SEPHADEX BEADS; AEDES-AEGYPTI; PLASMODIUM; MELANIZATION; PHAGOCYTOSIS; RECOGNITION	Mosquitoes are vectors of parasitic and viral diseases of immense importance for public health. The acquisition of the genome sequence of the yellow fever and Dengue vector, Aedes aegypti (Aa), has enabled a comparative phylogenomic analysis of the insect immune repertoire: in Aa, the malaria vector Anopheles gambiae (Ag), and the fruit fly Drosophila melanogaster (Dm). Analysis of immune signaling pathways and response modules reveals both conservative and rapidly evolving features associated with different functional gene categories and particular aspects of immune reactions. These dynamics reflect in part continuous readjustment between accommodation and rejection of pathogens and suggest how innate immunity may have evolved.	Univ Geneva, Sch Med, Dept Struct Biol & Bioinformat, CH-1211 Geneva, Switzerland; Univ London Imperial Coll Sci Technol & Med, Fac Nat Sci, Div Cell & Mol Biol, London SW7 2AZ, England; Univ Geneva, Sch Med, Dept Genet Med & Dev, CH-1211 Geneva, Switzerland; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA; Univ Calif Riverside, Inst Integrat Genome Biol, Riverside, CA 92521 USA; Iowa State Univ, Dept Entomol, Ames, IA 50011 USA; NIAID, Lab Malaria & Vector Res, Twinbrook II Facil, NIH, Bethesda, MD 20892 USA; CNRS, Unite Propre Rech 9022, Avnir INSERM, Inst Mol & Cellulaire, Strasbourg, France; Univ Wisconsin, Dept Anim Hlth & Biomed Sci, Madison, WI 53706 USA; Oklahoma State Univ, Dept Entomol & Plant Pathol, Stillwater, OK 74078 USA; Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA; Virginia Tech, Dept Biochem, Blacksburg, VA 24061 USA; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ Wisconsin, Dept Entomol, Madison, WI 53706 USA; Yale Univ, Sch Med Epidemiol & Publ Hlth, New Haven, CT 06520 USA; Fujian Ctr Prevent & Control Occupat Dis & Chem P, Fuzhou, Fujian, Peoples R China; Inst Plant Physiol & Ecol, Shanghai, Peoples R China; Univ Notre Dame, Ctr Global Hlth & Infect Dis, Dept Biol Sci, Notre Dame, IN 46556 USA; Swiss Inst Bioinformat, CH-1211 Geneva, Switzerland	University of Geneva; Imperial College London; University of Geneva; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of California System; University of California Riverside; University of California System; University of California Riverside; Iowa State University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Wisconsin System; University of Wisconsin Madison; Oklahoma State University System; Oklahoma State University - Stillwater; Kansas State University; Virginia Polytechnic Institute & State University; University of Oxford; University of Wisconsin System; University of Wisconsin Madison; Yale University; Chinese Academy of Sciences; University of Notre Dame; Swiss Institute of Bioinformatics	Kafatos, FC (corresponding author), Univ Geneva, Sch Med, Dept Struct Biol & Bioinformat, CH-1211 Geneva, Switzerland.	f.kafatos@imperial.ac.uk; zdobnov@medecine.unige.ch; g.christophides@imperial.ac.uk	Michel, Kristin/F-3400-2011; Jiang, Haobo/A-6519-2008; Waterhouse, Robert M/A-1858-2010; Bian, Guowu/B-1572-2010; Meister, Stephan/M-6608-2014; Blandin, Stephanie/ABH-2267-2021; Alvarez, Kanwal/AAQ-6451-2020; Mayhew, George F/B-4042-2016; Blandin, Stephanie/I-2786-2016; zou, zhen/C-6134-2016; Zdobnov, Evgeny M/K-1133-2012; Zdobnov, Evgeny/AAB-2745-2022; Xi, Zhiyong/AAD-7936-2022	Waterhouse, Robert M/0000-0003-4199-9052; Meister, Stephan/0000-0003-2436-7037; Blandin, Stephanie/0000-0003-4566-1200; Mayhew, George F/0000-0003-0609-6018; Blandin, Stephanie/0000-0003-4566-1200; zou, zhen/0000-0003-3550-7656; Zdobnov, Evgeny/0000-0002-5178-1498; Xi, Zhiyong/0000-0001-7786-012X; Kanost, Michael/0000-0002-6827-0061; Dimopoulos, George/0000-0001-6755-8111; Jiang, Haobo/0000-0003-1357-1315; Levashina, Elena/0000-0003-4605-906X; Christophides, George/0000-0002-3323-1687; Shin, Sang Woon/0000-0001-9467-0803; Vlachou, Dina/0000-0002-8305-3014; Dong, Yuemei/0000-0002-7902-2899; MacCallum, Robert/0000-0001-5070-4493; M. Mendes, Antonio/0000-0001-6562-5325	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000947, R01AI037083, R01AI059492, R01AI061576, P01AI044220] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041247, R37GM041247, R01GM058634, R01GM041247] Funding Source: NIH RePORTER; MRC [G0300170] Funding Source: UKRI; Medical Research Council [G0300170] Funding Source: Medline; NIAID NIH HHS [1 R01 AI059492-01A1, 5 R01 AI61576-2, R01 AI037083, P01 AI044220-06A1] Funding Source: Medline; NIGMS NIH HHS [GM41247, R01 GM058634-09] Funding Source: Medline; Wellcome Trust [GR077229MA] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome Trust)		Bedoya RJU, 2005, INSECT MOL BIOL, V14, P89, DOI 10.1111/j.1365-2583.2004.00534.x; Bian G, 2005, P NATL ACAD SCI USA, V102, P13568, DOI 10.1073/pnas.0502815102; Bischoff V, 2006, PLOS PATHOG, V2, P139, DOI 10.1371/journal.ppat.0020014; Blandin S, 2004, MOL IMMUNOL, V40, P903, DOI 10.1016/j.molimm.2003.10.010; Christensen BM, 2005, TRENDS PARASITOL, V21, P192, DOI 10.1016/j.pt.2005.02.007; Christophides GK, 2002, SCIENCE, V298, P159, DOI 10.1126/science.1077136; Cohuet A, 2006, EMBO REP, V7, P1285, DOI 10.1038/sj.embor.7400831; DAFFRE S, 1994, MOL GEN GENET, V242, P152, DOI 10.1007/BF00391008; Dong YM, 2006, PLOS PATHOG, V2, P513, DOI 10.1371/journal.ppat.0020052; Dostert C, 2005, NAT IMMUNOL, V6, P946, DOI 10.1038/ni1237; Gottar M, 2006, CELL, V127, P1425, DOI 10.1016/j.cell.2006.10.046; Hillyer JF, 2003, J PARASITOL, V89, P62, DOI 10.1645/0022-3395(2003)089[0062:RPAMOB]2.0.CO;2; IMIER JL, 2004, J LEUKOCYTE BIOL, V75, P18; Jang IH, 2006, DEV CELL, V10, P45, DOI 10.1016/j.devcel.2005.11.013; Kambris Z, 2006, CURR BIOL, V16, P808, DOI 10.1016/j.cub.2006.03.020; Kumar S, 2003, P NATL ACAD SCI USA, V100, P14139, DOI 10.1073/pnas.2036262100; Kumar S, 2004, J BIOL CHEM, V279, P53475, DOI 10.1074/jbc.M409905200; Lazzaro BP, 2004, SCIENCE, V303, P1873, DOI 10.1126/science.1092447; Levashina EA, 2001, CELL, V104, P709, DOI 10.1016/S0092-8674(01)00267-7; Li B, 2005, GENE, V360, P131, DOI 10.1016/j.gene.2005.07.001; Li JS, 2005, INSECT BIOCHEM MOLEC, V35, P1269, DOI 10.1016/j.ibmb.2005.07.001; Meister S, 2005, P NATL ACAD SCI USA, V102, P11420, DOI 10.1073/pnas.0504950102; Michel K, 2005, EMBO REP, V6, P891, DOI 10.1038/sj.embor.7400478; Michel K, 2006, P NATL ACAD SCI USA, V103, P16858, DOI 10.1073/pnas.0608033103; Moita LF, 2005, IMMUNITY, V23, P65, DOI 10.1016/j.immuni.2005.05.006; Muller HM, 1999, J BIOL CHEM, V274, P11727, DOI 10.1074/jbc.274.17.11727; Nene V, 2007, SCIENCE, V316, P1718, DOI 10.1126/science.1138878; Ooi JY, 2002, EMBO REP, V3, P82, DOI 10.1093/embo-reports/kvf004; Osta MA, 2004, SCIENCE, V303, P2030, DOI 10.1126/science.1091789; Paskewitz SM, 2006, INSECT BIOCHEM MOLEC, V36, P701, DOI 10.1016/j.ibmb.2006.06.001; Riehle MM, 2006, SCIENCE, V312, P577, DOI 10.1126/science.1124153; Roxstrom-Lindquist K, 2004, EMBO REP, V5, P207, DOI 10.1038/sj.embor.7400073; Shin SW, 2003, P NATL ACAD SCI USA, V100, P2616, DOI 10.1073/pnas.0537347100; van Rij RP, 2006, GENE DEV, V20, P2985, DOI 10.1101/gad.1482006; Volz J, 2005, J BIOL CHEM, V280, P40161, DOI 10.1074/jbc.M506191200; Volz J, 2006, CELL MICROBIOL, V8, P1392, DOI 10.1111/j.1462-5822.2006.00718.x; Wang LH, 2006, IMMUNOBIOLOGY, V211, P251, DOI 10.1016/j.imbio.2006.01.001; Wang LH, 2006, EMBO J, V25, P5005, DOI 10.1038/sj.emboj.7601363; Warr E, 2006, INSECT BIOCHEM MOLEC, V36, P769, DOI 10.1016/j.ibmb.2006.07.006; Zaidman-Remy A, 2006, IMMUNITY, V24, P463, DOI 10.1016/j.immuni.2006.02.012; Zambon RA, 2005, P NATL ACAD SCI USA, V102, P7257, DOI 10.1073/pnas.0409181102	42	471	490	3	99	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 22	2007	316	5832					1738	1743		10.1126/science.1139862	http://dx.doi.org/10.1126/science.1139862			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180XE	17588928	Green Accepted, Green Submitted			2022-12-28	WOS:000247400500045
J	Ransohoff, RM				Ransohoff, Richard M.			Natalizumab for multiple sclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; EPSTEIN-BARR-VIRUS; CLINICALLY ISOLATED SYNDROMES; QUALITY-OF-LIFE; MRI CRITERIA; FOLLOW-UP; THERAPY; DISEASE; MECHANISMS; ANTIBODIES		Cleveland Clin Fdn, Neuroinflammat Res Ctr, Dept Neurosci, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Mellen Ctr Multiple Sclerosis Treatmen & Res, Neurol Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Ransohoff, RM (corresponding author), Cleveland Clin Fdn, Neuroinflammat Res Ctr, Dept Neurosci, Lerner Res Inst, NC30,9500 Euclid Ave, Cleveland, OH 44195 USA.	ransohr@ccf.org						Ascherio A, 2001, JAMA-J AM MED ASSOC, V286, P3083, DOI 10.1001/jama.286.24.3083; Bartt RE, 2006, CURR OPIN NEUROL, V19, P341, DOI 10.1097/01.wco.0000236612.66839.a2; CALABRESE LO, IN PRESS ARTHRITIS R; Cohen JA, 2007, MULTIPLE SCLEROSIS T, P3; Confavreux C, 2004, CLIN NEUROL NEUROSUR, V106, P263, DOI 10.1016/j.clineuro.2004.02.012; Dorsey ER, 2007, NEUROLOGY, V68, P1524, DOI 10.1212/01.wnl.0000260699.09720.ad; Engelhardt B, 2005, TRENDS IMMUNOL, V26, P485, DOI 10.1016/j.it.2005.07.004; Fox RJ, 2006, CLEV CLIN J MED, V73, P91, DOI 10.3949/ccjm.73.1.91; Frohman EM, 2006, NEW ENGL J MED, V354, P942, DOI 10.1056/NEJMra052130; Frohman EM, 2005, ARCH NEUROL-CHICAGO, V62, P1345, DOI 10.1001/archneur.62.9.1345; Haahr S, 2006, REV MED VIROL, V16, P297, DOI 10.1002/rmv.503; Hafler DA, 2004, J CLIN INVEST, V113, P788, DOI 10.1172/JCI200421357; Hauser SL, 2006, ANN NEUROL, V59, P731, DOI 10.1002/ana.20877; Hauser SL, 2006, NEURON, V52, P61, DOI 10.1016/j.neuron.2006.09.011; Jeffery DR, 2004, J NEUROL SCI, V223, P41, DOI 10.1016/j.jns.2004.04.018; Kappos L, 2007, LANCET NEUROL, V6, P431, DOI 10.1016/S1474-4422(07)70078-9; Kleinschmidt-DeMasters BK, 2005, NEW ENGL J MED, V353, P369, DOI 10.1056/NEJMoa051782; Kobelt G, 2006, J NEUROL NEUROSUR PS, V77, P918, DOI 10.1136/jnnp.2006.090365; Kobelt G, 2006, NEUROLOGY, V66, P1696, DOI 10.1212/01.wnl.0000218309.01322.5c; Koralnik IJ, 2006, ANN NEUROL, V60, P162, DOI 10.1002/ana.20933; Korteweg T, 2006, LANCET NEUROL, V5, P221, DOI 10.1016/S1474-4422(06)70353-2; Kutzelnigg A, 2005, BRAIN, V128, P2705, DOI 10.1093/brain/awh641; Langer-Gould A, 2006, LANCET, V367, P708, DOI 10.1016/S0140-6736(06)68279-2; Levin LI, 2005, JAMA-J AM MED ASSOC, V293, P2496, DOI 10.1001/jama.293.20.2496; Phillips JT, 2007, NEUROLOGY, V68, P473; Phillips JT, 2006, NEUROLOGY, V67, P1717, DOI 10.1212/01.wnl.0000242629.66372.33; Pittock SJ, 2006, ARCH NEUROL-CHICAGO, V63, P611, DOI 10.1001/archneur.63.4.611; Pohl D, 2006, NEUROLOGY, V67, P2063, DOI 10.1212/01.wnl.0000247665.94088.8d; Polman CH, 2006, NEW ENGL J MED, V354, P899, DOI 10.1056/NEJMoa044397; Ransohoff RM, 2005, NAT NEUROSCI, V8, P1275, DOI 10.1038/nn1005-1275; Rice GPA, 2005, NEUROLOGY, V64, P1336, DOI 10.1212/01.WNL.0000158329.30470.D0; Rizvi SA, 2004, NEUROLOGY, V63, pS8, DOI 10.1212/WNL.63.12_suppl_6.S8; Ropper AH, 2006, NEW ENGL J MED, V354, P965, DOI 10.1056/NEJMe068002; Rudick RA, 2006, NEW ENGL J MED, V354, P911, DOI 10.1056/NEJMoa044396; Rudick RA, 2004, ANN NEUROL, V56, P548, DOI 10.1002/ana.20224; RUDICK RA, 1986, ARCH NEUROL-CHICAGO, V43, P578, DOI 10.1001/archneur.1986.00520060042015; Sayao AL, 2007, NEUROLOGY, V68, P496, DOI 10.1212/01.wnl.0000253185.03943.66; Scott LM, 2003, MOL CELL BIOL, V23, P9349, DOI 10.1128/MCB.23.24.9349-9360.2003; Sloka JS, 2005, MULT SCLER J, V11, P425, DOI 10.1191/1352458505ms1190oa; Sorensen PS, 2006, NEUROLOGY, V67, P1681, DOI 10.1212/01.wnl.0000242884.76598.bb; Spence S, 2002, TERATOLOGY, V65, P26, DOI 10.1002/tera.1095; Steinman L, 2006, ANN NEUROL, V60, P12, DOI 10.1002/ana.20913; Stuve O, 2006, ANN NEUROL, V59, P743, DOI 10.1002/ana.20858; Stuve O, 2007, ARCH NEUROL-CHICAGO, V64, P169, DOI 10.1001/archneur.64.2.169; Stuve O, 2006, ARCH NEUROL-CHICAGO, V63, P1383, DOI 10.1001/archneur.63.10.1383; Swanton JK, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.073247; Traboulsee Anthony L, 2006, Adv Neurol, V98, P125; Van Assche G, 2005, NEW ENGL J MED, V353, P362, DOI 10.1056/NEJMoa051586; von Andrian UH, 2003, NEW ENGL J MED, V348, P68, DOI 10.1056/NEJMe020157; Yousry TA, 2006, NEW ENGL J MED, V354, P924, DOI 10.1056/NEJMoa054693	50	191	197	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 21	2007	356	25					2622	2629		10.1056/NEJMct071462	http://dx.doi.org/10.1056/NEJMct071462			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180GN	17582072				2022-12-28	WOS:000247351200009
J	Toffelmier, DA; Tyburczy, JA				Toffelmier, Daniel A.; Tyburczy, James A.			Electromagnetic detection of a 410-km-deep melt layer in the southwestern United States	NATURE			English	Article							ELECTRICAL-CONDUCTIVITY; TRANSITION-ZONE; MANTLE BENEATH; SILICATE MELT; WATER; DENSITY; PRESSURE; PERIDOTITE; STABILITY; BASE	A deep-seated melt or fluid layer on top of the 410-km-deep seismic discontinuity in Earth's upper mantle, as proposed in the transition-zone 'water filter' hypothesis(1), may have significant bearing on mantle dynamics and chemical differentiation. The geophysical detection of such a layer has, however, proved difficult. Magnetotelluric and geomagnetic depth sounding are geophysical methods sensitive to mantle melt. Here we use these methods to search for a distinct structure near 410-km depth. We calculate one-dimensional forward models of the response of electrical conductivity depth profiles, based on mineral physics studies of the effect of incorporating hydrogen in upper-mantle and transition-zone minerals. These models indicate that a melt layer at 410-km depth is consistent with regional magnetotelluric and geomagnetic depth sounding data from the southwestern United States (Tucson)(2). The 410-km-deep melt layer in this model has a conductance of 3.0 x 10(4) S and an estimated thickness of 5 - 30 km. This is the only regional data set that we have examined for which such a melt layer structure was found, consistent with regional seismic studies(3). We infer that the hypothesized transition-zone water filter(1) occurs regionally, but that such a layer is unlikely to be a global feature.	Arizona State Univ, Sch Earth & Space Explorat, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe	Tyburczy, JA (corresponding author), Arizona State Univ, Sch Earth & Space Explorat, Tempe, AZ 85287 USA.	jim.tyburczy@asu.edu						Bell DR, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB000679; Bercovici D, 2003, NATURE, V425, P39, DOI 10.1038/nature01918; BROWN JM, 1981, GEOPHYS J ROY ASTR S, V66, P579, DOI 10.1111/j.1365-246X.1981.tb04891.x; EGBERT GD, 1992, J GEOPHYS RES-SOL EA, V97, P15113, DOI 10.1029/92JB01252; Fisler D.K, 1995, MINERAL PHYS CRYSTAL, P185; Gaillard F, 2004, EARTH PLANET SC LETT, V218, P215, DOI 10.1016/S0012-821X(03)00639-3; Hirschmann MM, 2005, EARTH PLANET SC LETT, V236, P167, DOI 10.1016/j.epsl.2005.04.022; Huang XG, 2005, NATURE, V434, P746, DOI 10.1038/nature03426; Kohlstedt DL, 1996, CONTRIB MINERAL PETR, V123, P345, DOI 10.1007/s004100050161; LIZARRALDE D, 1995, J GEOPHYS RES-SOL EA, V100, P17837, DOI 10.1029/95JB01244; Matsukage KN, 2005, NATURE, V438, P488, DOI 10.1038/nature04241; MITCHELL AC, 1982, J CHEM PHYS, V76, P6273, DOI 10.1063/1.443030; OHTANI E, 1995, CHEM GEOL, V120, P207, DOI 10.1016/0009-2541(94)00139-Y; Ohtani E, 2001, EARTH PLANET SC LETT, V193, P69, DOI 10.1016/S0012-821X(01)00505-2; Olsen N, 1999, GEOPHYS J INT, V138, P179, DOI 10.1046/j.1365-246x.1999.00854.x; PARKER RL, 1980, J GEOPHYS RES, V85, P4421, DOI 10.1029/JB085iB08p04421; REVENAUGH J, 1994, NATURE, V369, P474, DOI 10.1038/369474a0; Sakamaki T, 2006, NATURE, V439, P192, DOI 10.1038/nature04352; SCHULTZ A, 1993, GEOPHYS RES LETT, V20, P2941, DOI 10.1029/93GL02833; Simpson F, 2001, NATURE, V412, P632, DOI 10.1038/35088051; Song TRA, 2004, NATURE, V427, P530, DOI 10.1038/nature02231; Suzuki A, 1998, PHYS EARTH PLANET IN, V107, P53, DOI 10.1016/S0031-9201(97)00123-4; Tarits P, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL019277; TYBURCZY JA, 1983, J GEOPHYS RES, V88, P2413, DOI 10.1029/JB088iB03p02413; vanderLee S, 1997, J GEOPHYS RES-SOL EA, V102, P22815, DOI 10.1029/97JB01168; Wang DJ, 2006, NATURE, V443, P977, DOI 10.1038/nature05256; Xu YS, 2000, J GEOPHYS RES-SOL EA, V105, P27865, DOI 10.1029/2000JB900299	27	67	73	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 21	2007	447	7147					991	994		10.1038/nature05922	http://dx.doi.org/10.1038/nature05922			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180NU	17581582				2022-12-28	WOS:000247373100044
J	Holick, MF				Holick, Michael F.			Vitamin D deficiency	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RANDOMIZED CONTROLLED-TRIAL; SERUM 25-HYDROXYVITAMIN D; BONE-MINERAL DENSITY; 3RD NATIONAL-HEALTH; D INSUFFICIENCY; HYPOVITAMINOSIS-D; CANCER-MORTALITY; ULTRAVIOLET-B; D INADEQUACY; D-RECEPTOR		Boston Univ, Sch Med, Med Ctr, Dept Med,Sect Endocrinol Nutr & Diabet, Boston, MA 02118 USA; Boston Univ, Sch Med, Med Ctr, Vitamin D Skin & Bone Res Lab, Boston, MA 02118 USA	Boston University; Boston University	Holick, MF (corresponding author), Boston Univ, Sch Med, Med Ctr, Dept Med,Sect Endocrinol Nutr & Diabet, 715 ALbany St,M-1013, Boston, MA 02118 USA.	mfholick@bu.edu		Holick, Michael/0000-0001-6023-9062	NCRR NIH HHS [M01RR00533] Funding Source: Medline; NIAMS NIH HHS [AR36963] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AARON JE, 1974, LANCET, V1, P229; Adams JS, 1997, ANN INTERN MED, V127, P203, DOI 10.7326/0003-4819-127-3-199708010-00004; adams Js, 2006, PRIMER METABOLIC BON, V6, P200; Ahonen MH, 2000, CANCER CAUSE CONTROL, V11, P847, DOI 10.1023/A:1008923802001; Apperly FL, 1941, CANCER RES, V1, P191; Aris RM, 2005, J CLIN ENDOCR METAB, V90, P1888, DOI 10.1210/jc.2004-1629; Armas LAG, 2004, J CLIN ENDOCR METAB, V89, P5387, DOI 10.1210/jc.2004-0360; Bakhtiyarova S, 2006, OSTEOPOROSIS INT, V17, P441, DOI 10.1007/s00198-005-0006-9; Berwick M, 2005, J NATL CANCER I, V97, P195, DOI 10.1093/jnci/dji019; Bischoff-Ferrari HA, 2006, AM J CLIN NUTR, V84, P1253; Bischoff-Ferrari HA, 2006, AM J CLIN NUTR, V84, P18, DOI 10.1093/ajcn/84.1.18; Black PN, 2005, CHEST, V128, P3792, DOI 10.1378/chest.128.6.3792; Bodnar LM, 2007, J NUTR, V137, P447, DOI 10.1093/jn/137.2.447; Boonen S, 2006, CALCIFIED TISSUE INT, V78, P257, DOI 10.1007/s00223-005-0009-8; Bouillon R, 2001, ENDOCRINOLOGY, P1009; Broe KE, 2007, J AM GERIATR SOC, V55, P234, DOI 10.1111/j.1532-5415.2007.01048.x; Brown AJ, 2001, AM J KIDNEY DIS, V38, pS3, DOI 10.1053/ajkd.2001.28111; Calvo MS, 2004, AM J CLIN NUTR, V80, p1710S, DOI 10.1093/ajcn/80.6.1710S; Camargo CA, 2007, AM J CLIN NUTR, V85, P788, DOI 10.1093/ajcn/85.3.788; Cantorna MT, 2004, AM J CLIN NUTR, V80, p1717S, DOI 10.1093/ajcn/80.6.1717S; Chang ET, 2005, J NATL CANCER I, V97, P1466, DOI 10.1093/jnci/dji293; Chapuy MC, 1997, OSTEOPOROSIS INT, V7, P439, DOI 10.1007/s001980050030; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; Chel VGM, 1998, J BONE MINER RES, V13, P1238, DOI 10.1359/jbmr.1998.13.8.1238; Chen H, 2003, P NATL ACAD SCI USA, V100, P6109, DOI 10.1073/pnas.1031395100; Chiu KC, 2004, AM J CLIN NUTR, V79, P820; Cooper C, 2005, J NUTR, V135, p2728S, DOI 10.1093/jn/135.11.2728S; Correa P, 2002, J CLIN ENDOCR METAB, V87, P5826, DOI 10.1210/jc.2002-021356; Dawson-Hughes B, 2005, OSTEOPOROSIS INT, V16, P713, DOI 10.1007/s00198-005-1867-7; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; de Nijs RNJ, 2004, OSTEOPOROSIS INT, V15, P589, DOI 10.1007/s00198-004-1614-5; DeLuca HF, 2004, AM J CLIN NUTR, V80, p1689S, DOI 10.1093/ajcn/80.6.1689S; Dusso AS, 2006, KIDNEY INT, V70, pS8, DOI 10.1038/sj.ki.5001595; Dusso AS, 2005, AM J PHYSIOL-RENAL, V289, pF8, DOI 10.1152/ajprenal.00336.2004; Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272-6386(03)00111-2; El-Hajj Fuleihan G, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.4.e53; Eyles DW, 2005, J CHEM NEUROANAT, V29, P21, DOI 10.1016/j.jchemneu.2004.08.006; Feskanich D, 2004, CANCER EPIDEM BIOMAR, V13, P1502; Garland CF, 2006, AM J PUBLIC HEALTH, V96, P252, DOI 10.2105/AJPH.2004.045260; Gascon-Barre M, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P47; Giovannucci E, 2006, JNCI-J NATL CANCER I, V98, P451, DOI 10.1093/jnci/djj101; Glerup H, 2000, J INTERN MED, V247, P260, DOI 10.1046/j.1365-2796.2000.00595.x; Gloth F M 3rd, 1999, J Nutr Health Aging, V3, P5; GLOTH FM, 1991, ARCH INTERN MED, V151, P1662, DOI 10.1001/archinte.151.8.1662; Gordon CM, 2004, ARCH PEDIAT ADOL MED, V158, P531, DOI 10.1001/archpedi.158.6.531; Gorham ED, 2005, J STEROID BIOCHEM, V97, P179, DOI 10.1016/j.jsbmb.2005.06.018; Grant AM, 2005, LANCET, V365, P1621, DOI 10.1016/S0140-6736(05)63013-9; Grant WB, 2002, CANCER-AM CANCER SOC, V94, P1867, DOI 10.1002/cncr.10427; Grey A, 2005, J CLIN ENDOCR METAB, V90, P2122, DOI 10.1210/jc.2004-1772; HANCHETTE CL, 1992, CANCER, V70, P2861, DOI 10.1002/1097-0142(19921215)70:12<2861::AID-CNCR2820701224>3.0.CO;2-G; Heaney RP, 2003, J AM COLL NUTR, V22, P142, DOI 10.1080/07315724.2003.10719287; Heaney RP, 2003, AM J CLIN NUTR, V78, P1047; Heaney RP, 2003, AM J CLIN NUTR, V77, P204, DOI 10.1093/ajcn/77.1.204; Holick EA, 2002, BIOLOGIC EFFECTS OF LIGHT 2001, P205; Holick M.F., 1998, RETINOIDS, V14, P12; Holick MF, 2006, MAYO CLIN PROC, V81, P353, DOI 10.4065/81.3.353; Holick MF, 2005, SEMIN DIALYSIS, V18, P266, DOI 10.1111/j.1525-139X.2005.18402.x; Holick MF, 2005, J CLIN ENDOCR METAB, V90, P3215, DOI 10.1210/jc.2004-2364; Holick MF, 2004, AM J CLIN NUTR, V79, P890; Holick MF, 2006, PRIMER METABOLIC BON, P129; Holick MF, 2006, J CLIN INVEST, V116, P2062, DOI 10.1172/JCI29449; Holick MF, 2006, NEW ENGL J MED, V354, P2287; Hollis BW, 2004, AM J CLIN NUTR, V80, p1752S, DOI 10.1093/ajcn/80.6.1752S; Hollis BW, 2004, AM J CLIN NUTR, V79, P717; HRUSKA KA, 2006, PRIMER METABOLIC BON, P233; Hypponen E, 2001, LANCET, V358, P1500, DOI 10.1016/S0140-6736(01)06580-1; Jackson RD, 2006, NEW ENGL J MED, V354, P1102; Jackson RD, 2006, NEW ENGL J MED, V354, P669, DOI 10.1056/NEJMoa055218; Jones G, 1998, J CLIN ENDOCR METAB, V83, P4274, DOI 10.1210/jc.83.12.4274; Kennedy C, 2003, J INVEST DERMATOL, V120, P1087, DOI 10.1046/j.1523-1747.2003.12246.x; Kitanaka S, 1998, NEW ENGL J MED, V338, P653, DOI 10.1056/NEJM199803053381004; Koutkia P, 2001, GASTROENTEROLOGY, V121, P1485, DOI 10.1053/gast.2001.29686; Koutkia P, 2001, NEW ENGL J MED, V345, P66, DOI 10.1056/NEJM200107053450115; Kragballe K, 1998, BRIT J DERMATOL, V139, P649; Krause R, 1998, LANCET, V352, P709, DOI 10.1016/S0140-6736(05)60827-6; Kreiter SR, 2000, J PEDIATR-US, V137, P153, DOI 10.1067/mpd.2000.109009; Lappe JM, 2007, AM J CLIN NUTR, V85, P1586, DOI 10.1093/ajcn/85.6.1586; Larsen ER, 2004, J BONE MINER RES, V19, P370, DOI 10.1359/JBMR.0301240; Lee JM, 2007, CLIN PEDIATR, V46, P42, DOI 10.1177/0009922806289311; Li YC, 2003, J CELL BIOCHEM, V88, P327, DOI 10.1002/jcb.10343; Lips P, 2006, J INTERN MED, V260, P245, DOI 10.1111/j.1365-2796.2006.01685.x; Lips P, 2001, ENDOCR REV, V22, P477, DOI 10.1210/er.22.4.477; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; LO CW, 1985, AM J CLIN NUTR, V42, P644, DOI 10.1093/ajcn/42.4.644; Luscombe CJ, 2001, LANCET, V358, P641, DOI 10.1016/S0140-6736(01)05788-9; Malabanan A, 1998, LANCET, V351, P805, DOI 10.1016/S0140-6736(05)78933-9; Malabanan AO, 1998, J CLIN DENSITOM, V1, P201, DOI 10.1385/JCD:1:2:201; Mantell DJ, 2000, CIRC RES, V87, P214, DOI 10.1161/01.RES.87.3.214; MARKESTAD T, 1984, ACTA PAEDIATR SCAND, V73, P225, DOI 10.1111/j.1651-2227.1984.tb09933.x; Marwaha RK, 2005, AM J CLIN NUTR, V82, P477, DOI 10.1093/ajcn/82.2.477; McAlindon TE, 1996, ANN INTERN MED, V125, P353, DOI 10.7326/0003-4819-125-5-199609010-00001; McGrath J, 2002, SCHIZOPHR RES, V54, P199, DOI 10.1016/S0920-9964(01)00259-6; McGrath JJ, 2001, MED J AUSTRALIA, V174, P150, DOI 10.5694/j.1326-5377.2001.tb143195.x; MCKENNA MJ, 1992, AM J MED, V93, P69, DOI 10.1016/0002-9343(92)90682-2; Merlino LA, 2004, ARTHRITIS RHEUM-US, V50, P72, DOI 10.1002/art.11434; Munger KL, 2006, JAMA-J AM MED ASSOC, V296, P2832, DOI 10.1001/jama.296.23.2832; Munger KL, 2004, NEUROLOGY, V62, P60, DOI 10.1212/01.WNL.0000101723.79681.38; Nagpal S, 2005, ENDOCR REV, V26, P662, DOI 10.1210/er.2004-0002; Nesby-O'Dell S, 2002, AM J CLIN NUTR, V76, P187, DOI 10.1093/ajcn/76.1.187; Penna G, 2005, BLOOD, V106, P3490, DOI 10.1182/blood-2005-05-2044; Pettifor JM, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P1065; Pittas AG, 2006, DIABETES CARE, V29, P650, DOI 10.2337/diacare.29.03.06.dc05-1961; Plotnikoff GA, 2003, MAYO CLIN PROC, V78, P1463, DOI 10.4065/78.12.1463; Ponsoby AL, 2002, TOXICOLOGY, V181, P71, DOI 10.1016/S0300-483X(02)00257-3; Porthouse J, 2005, BMJ-BRIT MED J, V330, P1003, DOI 10.1136/bmj.330.7498.1003; REID IR, 1986, AGE AGEING, V15, P35, DOI 10.1093/ageing/15.1.35; Ritter CS, 2006, KIDNEY INT, V70, P654, DOI 10.1038/sj.ki.5000394; Rostand SG, 1997, HYPERTENSION, V30, P150, DOI 10.1161/01.HYP.30.2.150; Sahota O, 2006, OSTEOPOROSIS INT, V17, P1825, DOI 10.1007/s00198-006-0219-6; Sahota O, 2006, OSTEOPOROSIS INT, V17, P1013, DOI 10.1007/s00198-006-0084-3; Sato Y, 2005, J BONE MINER RES, V20, P1327, DOI 10.1359/JBMR.050402; SEDRANI SH, 1984, ANN NUTR METAB, V28, P181, DOI 10.1159/000176801; SHAH BR, 1994, J PEDIATR-US, V125, P487, DOI 10.1016/S0022-3476(05)83303-7; Shimada T, 2004, J BONE MINER RES, V19, P429, DOI 10.1359/JBMR.0301264; Sullivan SS, 2005, J AM DIET ASSOC, V105, P971, DOI 10.1016/j.jada.2005.03.002; Tangpricha V, 2002, AM J MED, V112, P659, DOI 10.1016/S0002-9343(02)01091-4; Tangpricha V, 2004, AM J CLIN NUTR, V80, P1645, DOI 10.1093/ajcn/80.6.1645; Tangpricha V, 2003, AM J CLIN NUTR, V77, P1478, DOI 10.1093/ajcn/77.6.1478; Thacher TD, 1999, NEW ENGL J MED, V341, P563, DOI 10.1056/NEJM199908193410803; Trang HM, 1998, AM J CLIN NUTR, V68, P854, DOI 10.1093/ajcn/68.4.854; Trivedi DP, 2003, BMJ-BRIT MED J, V326, P469, DOI 10.1136/bmj.326.7387.469; VanAmerongen BM, 2004, EUR J CLIN NUTR, V58, P1095, DOI 10.1038/sj.ejcn.1601952; Vieth R, 2004, J STEROID BIOCHEM, V89-90, P575, DOI 10.1016/j.jsbmb.2004.03.038; Vitamin D., 1999, DIET REF INT CALC PH, P250; Ward LM, 2004, BONE, V34, P905, DOI 10.1016/j.bone.2003.12.025; Wolpowitz D, 2006, J AM ACAD DERMATOL, V54, P301, DOI 10.1016/j.jaad.2005.11.1057; Zhou CC, 2006, J CLIN INVEST, V116, P1703, DOI 10.1172/JCI27793; Zittermann A, 2003, J AM COLL CARDIOL, V41, P105, DOI 10.1016/S0735-1097(02)02624-4; Zittermann A, 2006, PROG BIOPHYS MOL BIO, V92, P39, DOI 10.1016/j.pbiomolbio.2006.02.001	130	9602	10160	74	1543	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 19	2007	357	3					266	281		10.1056/NEJMra070553	http://dx.doi.org/10.1056/NEJMra070553			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191FH	16821459				2022-12-28	WOS:000248115100008
